File ID,Petition File Name,Date of Petition,Petition Source Year,Was_Withdrawn,Document Type,Submitter,Submitter Type,Petition Cited Statutes or Regulations,FDA Action Commented On,Requested Action,Justification for Request,Interim Response Date,Final Decision,Last Response Date,Count of Interim,Responding FDA Center (of Final Decision),Responses Cited Statutes or Regulations,Justification for Interim Response,Justification for Final Response,Cleaned Final Decision,Received Final Decision,Response Time (Days),Cleaned FDA Responding Center,Responding Center Grouped
fda-2010-p-0648,"FDA-2010-P-0648-0001_G__Pohl_Boskamp_GmbH___Company_KG___Citizen_Petiti.pdf
",2010-12-16,2010,False,original petition,"G. Pohl-Boskamp GmbH & Company KG 	No law firm or external representative listed. The petition was submitted directly by Marianne Boskamp, CEO of Pohl-Boskamp.",law/consulting,"- 21 USC 355(b) and 355(g) ‚Äì Drug approval and abbreviated new drug application requirements
- 21 C.F.R. ¬ß 10.30 ‚Äì Citizen petition process
- 21 C.F.R. ¬ß 25.31 ‚Äì Environmental impact exclusion
- 21 USC 351(a)(2)(B) ‚Äì GMP compliance
- 21 C.F.R. ¬ß¬ß 210‚Äì211, 314.94, 320.1, 314.50 ‚Äì CMC, bioequivalence, and ANDA regulations","        FDA's 2010 Draft Bioequivalence Recommendation for Nitroglycerin Metered Spray/Sublingual products, which could enable ANDA approvals based on limited criteria.","	FDA should not approve generic nitroglycerin ANDAs based solely on the 2010 BE guidance, and instead must:
‚Äì Require PK testing on parent drug (TNG)
‚Äì Require early exposure PK (AUC‚ÇÄ‚Çã‚ÇÖ)
‚Äì Enforce in vitro and stability testing
‚Äì Mandate extractables/leachables testing
‚Äì Require 100% unit pump functionality testing before release","	- Current BE guidance is inadequate for ensuring therapeutic equivalence, especially for rapid onset required in angina treatment.
- Scientific literature supports reliable testing of the parent compound (TNG), not just metabolites.
- Product stability and performance can be affected by storage orientation and pump design; Pohl‚Äôs rigorous testing sets a precedent.
- Public health concerns: Inadequate or delayed relief could cause panic, harm, or misdiagnosis for angina patients.",2011-06-16 00:00:00,"Partially Granted and Partially Denied
‚Äì The request regarding in vitro pump functionality testing was granted.
‚Äì The remainder of the petition was denied.
‚Äì The associated petition supplement (PSA) was declared moot due to a substitute written response to an ANDA by the FDA (page 17).",2013-10-31,1.0,Center for Drug Evaluation and Research (CDER),"Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(j)
‚Äì Section 505(q)(1)(A) and (B) of the FD&C Act
‚Äì 21 CFR 320.25 and 320.26 (Bioequivalence study requirements)","The FDA states it has not resolved the issues raised in the December 21, 2010 petition.
‚Äì The petition concerns requests to block approval of abbreviated new drug applications (ANDAs) referencing Nitrolingual Pumpspray (NDA 18-705) unless specific conditions are met.
‚Äì The delay is attributed to the petition raising complex regulatory and scientific issues that require further review and analysis by FDA officials.","Scientific Basis: FDA carefully reviewed the petitioner‚Äôs requests involving pharmacokinetic measurements, bioequivalence requirements, in vitro testing, and component stability and extractables.
‚Äì Partial Agreement: The FDA agreed that testing pump functionality prior to distribution is essential to ensure delivery reliability for nitroglycerin lingual spray products.
‚Äì Grounds for Denial: The FDA denied other requests (e.g., mandatory use of specific pharmacokinetic parameters or in vitro-only bioequivalence testing) on the basis that current guidance and standards already ensure therapeutic equivalence. Additional requirements were considered unnecessarily restrictive or unsupported by sufficient scientific rationale.
‚Äì Regulatory Alignment: The agency maintained that existing ANDA requirements are adequate to assess bioequivalence, chemistry, manufacturing, and control standards without needing the proposed modifications.",partially approved / denied,True,1050.0,CDER,CDER
fda-2010-p-0642,FDA-2010-P-0642-0005_Teva_Pharmaceutical_Industries_Ltd___Teva_Neurosci.pdf,2011-02-11,2010,False,original petition,"Teva Pharmaceutical Industries Ltd. and Teva Neuroscience, Inc.",industry/corporation,"- 21 C.F.R. ¬ß 10.30 ‚Äì Citizen petition process (implied, not restated in supplement)
- 21 C.F.R. ¬ß 25.30, ¬ß 25.31(a) ‚Äì Environmental impact exclusions","FDA‚Äôs approach to approving Abbreviated New Drug Applications (ANDAs) for generic Copaxone¬Æ (glatiramer acetate), despite uncertainty about its mechanism of action.","FDA should not approve any ANDA for a generic version of Copaxone¬Æ unless and until:
‚Äì Its mechanism of action is fully understood
‚Äì ANDA applicants satisfy conditions outlined in the original petition (e.g., proving equivalence despite product complexity)","- Copaxone¬Æ's mechanism of action is not fully understood, making it impossible to assess therapeutic equivalence through standard bioequivalence methods.
- FDA refused to approve a Teva sNDA for a new Copaxone¬Æ formulation (same active ingredient, less water) due to lack of efficacy data, reinforcing the need for clinical trials.
- If FDA cannot ensure equivalence of a new Copaxone¬Æ formulation that is chemically identical but varies only in volume, it certainly cannot do so for a follow-on product with any differences.",,"Denied
The FDA formally denied the citizen petition submitted by Teva Neuroscience requesting that the FDA not approve any ANDA for a generic version of Copaxone without meeting stringent characterization and clinical equivalence requirements",2011-06-08,0.0,"Center for Drug Evaluation and Research (CDER)
Signed by Janet Woodcock, M.D., Director","Section 505(q) of the FDCA (21 U.S.C. ¬ß 355)
- Section 505(j) of the FDCA
- 21 CFR ¬ß 314.92(a)(1) ‚Äì ""same as"" active ingredient standard
- 21 CFR ¬ß 314.94(a)(5)(i) ‚Äì ANDA requirements
- 21 CFR ¬ß 314.127(a)(3) ‚Äì grounds for denying an ANDA
- 21 CFR ¬ß 320.1(c) ‚Äì pharmaceutical equivalents
- 21 CFR Part 314 ‚Äì application procedures
- 21 CFR ¬ß 210.3(b)(7) ‚Äì definition of active ingredient",,"FDA emphasized its broad discretion under the law to determine ‚Äúsameness‚Äù of active ingredients for ANDA approvals, supported by legal precedent (e.g., Serono Labs v. Shalala).
- The petition's requested criteria for equivalence (including full characterization of glatiramer acetate) were viewed as too restrictive and premature.
- FDA reaffirmed that it may require a multi-criteria scientific assessment to evaluate ‚Äúsameness‚Äù for complex products like Copaxone, but these must be developed through case-specific review.
- The agency argued that preemptively setting specific standards for generic Copaxone would effectively decide the approvability of future ANDAs without appropriate procedural review.
- FDA stated it has sufficient internal expertise to evaluate ANDAs for glatiramer acetate without convening an advisory committee.",denied,True,117.0,CDER,CDER
fda-2010-p-0011,FDA-2010-P-0011-0001_Bright_Future_Pharmaceutical_Lab__Ltd____Citizen_P.pdf,2010-01-04,2010,False,original petition,Bright Future Pharmaceutical Lab. Ltd.,advocacy/academic,Section 505(j)(2)(C) of the FDCA; 21 CFR 25.300,Request to designate Panadol¬Æ as RLD or advise an alternative,Permit submission of ANDA for BF-PARADAC (500mg acetaminophen immediate-release tablet) using Panadol¬Æ as the RLD or suggest an alternative RLD,"BF-PARADAC has been marketed in Hong Kong since 2002 and shown to be bioequivalent to Panadol¬Æ in clinical studies (bioavailability: 96%‚Äì104%).
- No exact RLD is available in the FDA Orange Book for a single-ingredient 500 mg acetaminophen immediate-release tablet.
- Panadol¬Æ is widely recognized internationally and similar in dosage form, strength, route, and therapeutic effect.
- Other products like Fortolin¬Æ (500 mg acetaminophen tablet) marketed in the U.S. share similar properties.
- The petition includes clinical bioequivalence studies, draft U.S. labeling, and international marketing approvals as evidence",,,2025-10-15,0.0,,,,,no decision,False,5763.0,pending,pending
fda-2010-p-0012,FDA-2010-P-0012-0001_Patrick_Foster___Citizen_Petition.pdf,2009-12-21,2010,False,original petition,Patrick Foster,individual,"Section 505(j)(2)(C) of the FDCA; 21 CFR ¬ß¬ß 10.20, 10.30, 314.93",Petition to allow ANDA for higher concentration morphine sulfate injection,"Permit filing of ANDA for Morphine Sulfate Injection, 25 mg/mL (PF), in 50 mL and 100 mL SDVs","Existing FDA-listed RLDs (e.g., NDA 019916 by Hospira) only include lower-strength presentations (0.5, 1.0, 5 mg/mL).
- Although Hospira markets a 25 mg/mL product, it is not listed in the Orange Book, creating a regulatory gap.
- The petitioner‚Äôs proposed product would allow hospital and compounding pharmacies to prepare commonly used doses more efficiently by diluting a concentrated stock solution.
- Product is not intended for direct infusion, contains no preservatives, and differs from RLD in total content and packaging only, not in active ingredient, route of administration, or general formulation intent.
- The proposed product‚Äôs labeling and use would mirror that of currently marketed high-strength products (e.g., Hospira and Baxter), with appropriate precautions for dilution and non-epidural/intrathecal use",,Withdrawn,2010-11-07,0.0,Division of Dockets Management,Not Mentioned,,Petition was withdrawn by Alaunus Pharmaceutical LLC on behalf of Patrick Foster.,withdrawn,True,321.0,DMS,Other/Specialty Center
fda-2010-p-0015,FDA-2010-P-0015-0001_Lachman_Consultant_Services__Inc____Citizen_Petiti.pdf,2010-01-05,2010,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,Section 505(j)(2)(C) of the FDCA; 21 CFR 10.30,ANDA request for strength change of Zolpidem Tartrate,"Permit submission of an ANDA for Zolpidem Tartrate Tablets, 7.5 mg","The 7.5 mg strength is an intermediate dosage between the existing 5 mg and 10 mg Ambien¬Æ tablets.
- Approved labeling of Ambien¬Æ suggests dosage individualization, especially for elderly, debilitated, or hepatically impaired patients.
- A 7.5 mg tablet provides greater dosing flexibility and facilitates titration to avoid adverse effects.
- No other labeling changes are proposed besides strength.
- Draft labeling for the proposed product and RLD labeling are provided as attachments to support equivalence and safety",,Denied,2010-10-01,0.0,Center for Drug Evaluation and Research (CDER),21 C.F.R. ¬ß 10.30; Section 505(j)(2)(C) of the FDCA,,"The proposed 7.5 mg strength is not supported by the approved labeling of the reference listed drug (Ambien¬Æ 5 mg and 10 mg).
- The RLD labeling does not contemplate a 7.5 mg dose; instead, it recommends titration only in 5 mg increments (5 mg or 10 mg).
- Allowing a 7.5 mg strength would constitute a new dosing regimen, which is not permitted via a suitability petition under the FDCA.
- Therefore, the proposed change is not petitionable and must instead be submitted under a full NDA process (Section 505(b)).
- The FDA provides an opportunity for reconsideration within 30 days if based on original information",denied,True,269.0,CDER,CDER
fda-2010-p-0016,FDA-2010-P-0016-0001_Hisamitsu_Pharmaceutical_Co___Inc____Citizen_Petit.pdf,2009-12-31,2010,False,original petition,"Hisamitsu Pharmaceutical Co., Inc.",industry/corporation,Section 505 of the FDCA; 21 CFR ¬ß 10.30; 21 CFR ¬ß 320.24(b)(4),Approval of ANDAs for generic versions of SALONPAS¬Æ Pain Relief Patch,"Request that FDA refrain from approving any ANDA for SPRP unless it includes clinical trials, skin safety studies, bioavailability data, and identical patch size and formulation.","Lidoderm¬Æ is a complex topical patch with unique release and adhesion properties that affect clinical performance.
- Improperly designed generics could result in variable drug delivery, patch detachment, or reduced efficacy.
- FDA had recently issued a draft product-specific bioequivalence guidance for lidocaine patches, which recognizes these complexities.
- Precedents (e.g., Toprol XL¬Æ) show that therapeutic equivalence concerns justify heightened scrutiny and performance demonstration for transdermal or topical systems.
- Without safeguards, patients could be exposed to non-equivalent, less effective, or unsafe products, undermining public health confidence in generics",2010-07-07 00:00:00,,2025-10-15,1.0,,,Petition for delaying ANDA approvals of Salonpas patch not yet resolved. Interim notice given per FDA regs.,,no decision,False,5767.0,pending,pending
fda-2010-p-0027,FDA-2010-P-0027-0001_Lachman_Consultant_Services__Inc____Citizen_Petiti.pdf,2010-01-12,2010,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,21 CFR 10.30; 21 CFR 314.161,Withdrawal of Actonel (risedronate sodium) 75 mg from market,Determine whether Actonel 75 mg Tablets were withdrawn for reasons of safety or effectiveness,"The product was approved on April 16, 2007 and listed in the Orange Book.
- It now appears in the discontinued section (first noted in Supplement 05, May 2009).
- There is no public indication that the innovator (Procter & Gamble) is currently marketing it.
- Under FDA regulations (314.161 & 314.162), a determination is required before approving ANDAs referencing such a product.
- The petitioner asserts that this discontinuation requires a formal safety/efficacy determination.",,Approved,2010-07-07,0.0,CDER,21 CFR 314.161; 21 CFR 314.162,,"FDA reviewed its records and found no evidence that ACTONEL (75 mg) or ACTONEL WITH CALCIUM (35/500 mg) were withdrawn for safety or efficacy reasons.
- No petitioners submitted data suggesting such reasons.
- FDA conducted an independent review of literature and postmarketing data and found no safety/effectiveness concerns.

- FDA will maintain both drugs in the Discontinued Drug Product List and allow ANDA approvals if all other requirements are met.",approved,True,176.0,CDER,CDER
fda-2010-p-0028,FDA-2010-P-0028-0001_Parnell_Technologies_Pty___Ltd____Citizen_Petition.pdf,2010-01-11,2010,False,original petition,Parnell Technologies Pty Ltd,industry/corporation,21 CFR ¬ß 10.30; Section 512(n)(3) of the FDCA,Suitability for ANADA submission for Gonabreed (gonadorelin 100 ¬µg/mL),Allow submission of ANADA for Gonabreed (different strength of approved RLD Cystorelin¬Æ),"The proposed product is bioequivalent to the RLD in terms of dose (100 ¬µg per animal vs. 86 ¬µg), route of administration (parenteral), and clinical use (in dairy cattle).
- Product labeling would be identical in indications and precautions, differing only in dose volume (1 mL vs. 2 mL).
- Gonadorelin in the proposed product is the same salt form as in Cystorelin¬Æ and is chemically and functionally equivalent.
- The concentration difference does not pose safety or effectiveness issues.
- An environmental assessment is not required, as the product will be used under veterinary supervision in terrestrial species",,,2025-10-15,0.0,,,,,no decision,False,5756.0,pending,pending
fda-2010-p-0045,FDA-2010-P-0045-0001_Richard_F__Edlich__M_D___Ph_D___et_al___Citizen_Pe.pdf,2010-01-19,2010,False,original petition,"Richard F. Edlich, M.D., Ph.D. and co-signers",individual,21 CFR 10.30,Presence of the 'Medical Glove Powder Report' on the FDA website,Remove the 'Medical Glove Powder Report' from FDA‚Äôs website,"The petition argues that the FDA's glove powder report is outdated (last peer-reviewed citation from 1997) and ignores the Citizen Petition to ban cornstarch on medical gloves submitted earlier by 12 health professionals.
- The FDA report omits recent peer-reviewed findings, presents inaccurate market data from 1996, and lacks mention of serious health risks (e.g., latex allergies, surgical complications).
- The report has not been effectively disclosed to the scientific community (its revision date is not shown on printed copies).
- The petitioners cite environmental and economic impacts, including decreased allergic reactions and cost savings due to avoided complications from cornstarch-related injuries and infections",,"Granted in Part / Denied in Part:
- Granted: Ban on powdered medical gloves, removal of glove powder report, final decisions on several older petitions
- Denied: Requests for new regulatory guidelines and reclassification of certain devices (rendered moot by ban)",2018-04-04,0.0,CDRH,81 FR 15173; 81 FR 91722,,"FDA considered Dr. Edlich‚Äôs petitions and the data he submitted as part of the rulemaking process.
- The agency issued a final rule on December 19, 2016 banning powdered surgeon's gloves, powdered patient examination gloves, and absorbable glove powder, thus achieving the main aims of the petitions.
- FDA removed the ""Medical Glove Powder Report"" from its website as part of this action.
- FDA denied the request to establish new procedural guidelines for petition responses, citing existing adequate rules (21 C.F.R. 10.30).
- Reclassification requests were denied as moot due to the ban effectively removing those products from the market",approved,True,2997.0,CDRH,CDRH
fda-2010-p-0050,FDA-2010-P-0050-0001_Public_Citizen_Health_Research_Group___Citizen_Pet.pdf,2010-01-20,2010,False,original petition,Public Citizen Health Research Group,advocacy/academic,21 U.S.C. ¬ß 355(e)(3); 21 CFR 10.30,FDA's continued market approval of Savella (milnacipran),Immediate removal of Savella from the U.S. market,"Lack of efficacy: Trials showed only marginal benefit (7‚Äì9% improvement vs. placebo), with no statistically significant pain relief when measured alone.
- Manipulated trial protocol: Sponsors modified trial criteria mid-process and post-hoc to attain statistical significance.
- Severe safety concerns, including:
¬†¬†‚Ä¢ Suicidal ideation
¬†¬†‚Ä¢ Cardiovascular risks (increased blood pressure and heart rate)
¬†¬†‚Ä¢ Liver toxicity and renal risks
¬†¬†‚Ä¢ Withdrawal and dependency symptoms
¬†¬†‚Ä¢ Risks in pregnancy, breastfeeding, and reproductive issues
¬†¬†‚Ä¢ GI disorders and serotonin syndrome
- EU Rejection: The European Medicines Agency denied approval of Savella for fibromyalgia on July 23, 2009, citing the same concerns",2010-07-14 00:00:00,Denied,2016-07-03,1.0,CDER,Section 505(e)(2) of the FDCA,"The petition requests the FDA to remove Savella (milnacipran) from the market, citing questionable clinical efficacy and potentially serious risks.
- FDA has not yet completed its evaluation due to the complexity of the issues involved, necessitating extensive review and analysis by agency officials","üß™ Clinical Trial Design & Analysis
Savella (milnacipran hydrochloride) was approved based on two rigorous, randomized, double-blind, placebo-controlled trials (Study 031 and Study 02).

FDA found the statistical analyses, including the use of composite endpoints and post hoc analysis methods, to be valid and appropriate. The agency explained that the same imputation method for both studies increased data reliability and comparability.

üìä Study Endpoints
Composite endpoints (pain reduction, physical function, and patient global assessment) were deemed suitable due to fibromyalgia being a syndrome with multiple symptoms.

The FDA concluded that statistically significant results were achieved when evaluating these combined endpoints.

üíä Benefit-Risk Profile
FDA stated the benefits of Savella outweigh its risks.

The agency cited updates to product labeling with enhanced safety information and postmarketing safety analyses that supported continued marketing.

üõë Rebuttal to Petitioner‚Äôs Claims
FDA addressed concerns about changing study protocols, exclusion of severely depressed patients, and efficacy thresholds.

The agency rebutted the claim that the benefit was marginal (7‚Äì9%) and provided context for interpreting composite endpoint success.

üîç Safety Monitoring
The agency acknowledged known safety issues, including elevated blood pressure and heart rate, but noted these were class effects typical of SNRIs and managed through updated labeling.",denied,True,2356.0,CDER,CDER
fda-2010-p-0051,FDA-2010-P-0051-0001_Lachman_Consultant_Services__Inc____Citizen_Petiti.pdf,2010-01-19,2010,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,21 CFR 10.30; 21 CFR 314.161,Market status of Actonel with Calcium (risedronate sodium and calcium carbonate),Determine whether Actonel with Calcium was withdrawn for safety or effectiveness reasons,"The product has been moved to the discontinued section of the Orange Book.
- It is unclear when the discontinuation occurred or whether it was due to safety or efficacy concerns.
- A formal FDA determination is needed before any ANDA (Abbreviated New Drug Application) citing this product may proceed.
- The petitioner notes that per FDA precedent, not marketing a product can be interpreted as withdrawal from sale",,Approved,2010-07-07,0.0,CDER,"21 CFR 314.161, 21 CFR 314.162",,"The FDA reviewed its records and found no evidence that the drug was withdrawn due to safety or efficacy issues.
- The petitioner provided no data indicating withdrawal for such reasons.
- FDA independently evaluated postmarketing data and literature and found no reason to support a safety or efficacy withdrawal.
- Therefore, the drug remains listed in the Orange Book under the Discontinued Drug Product List allowing continued ANDA referencing",approved,True,169.0,CDER,CDER
fda-2010-p-0052,FDA-2010-P-0052-0001_Richard_F__Edlich__M_D___Ph_D___et_al___Citizen_Pe.pdf,2010-01-14,2010,False,original petition,"Richard F. Edlich, M.D., Ph.D., and 11 healthcare professionals",individual,21 CFR 10.30,Use of cornstarch powder on medical gloves,Ban cornstarch powder from medical gloves due to its cancer-promoting properties,"Cancer Risk: Cites research (e.g., by van den Tol et al.) showing that cornstarch promotes tumor growth in the peritoneum after surgical trauma.
- Health Hazards: Cornstarch linked to complications such as peritonitis, infertility, surgical adhesions, delayed wound healing, and latex allergies in both patients and healthcare providers.
- Economic and Environmental Impact: Banning powdered gloves could reduce healthcare costs from complications and prevent environmental contamination.
- Ethical Grounds: Honors injured and deceased healthcare professionals and patients harmed by cornstarch on gloves.
- Precedent: Notes that FDA already banned talc on condoms due to cancer risks‚Äîargues a similar rationale applies to cornstarch in gloves",,"Partially Granted and Partially Denied
- Granted: Ban on powdered medical gloves (surgical and examination), removal of the ‚ÄúMedical Glove Powder Report,‚Äù recognition of petitions filed, and effective ban in IVF labs.
- Denied: Requests to establish new procedural guidelines for citizen petition handling, and device reclassification as it was deemed moot",2018-04-04,0.0,Center for Devices and Radiological Health (CDRH),81 FR 15173; 81 FR 91722,,"FDA issued a final rule banning powdered surgeon‚Äôs gloves, powdered patient examination gloves, and absorbable powder for lubricating a surgeon‚Äôs glove based on scientific and legal findings.
- FDA considered information provided in Dr. Edlich‚Äôs petitions in developing this rule.
- The ban made several requests moot (e.g., powder removal, reclassification).
- FDA cited that existing regulations already govern petition responses (21 C.F.R. 10.30), and thus denied the request for new guidelines.
- FDA had already issued an interim response and completed required administrative steps.",partially approved / denied,True,3002.0,CDRH,CDRH
fda-2010-p-0059,FDA-2010-P-0059-0001_Aurobindo_Pharmaceuticals__Ltd____EAS_Consultant_G.pdf,2010-01-21,2010,False,original petition,Aurobindo Pharmaceuticals Limited,industry/corporation,"21 CFR 10.30, 21 CFR 314.161, 21 CFR 314.162, 21 CFR 25.31","Determination whether Actonel with Calcium (Copackaged) (Risedronate Sodium and Calcium Carbonate), NDA 021823, was withdrawn for safety or effectiveness",Determine whether Actonel with Calcium was voluntarily withdrawn for safety or efficacy reasons,"The product now appears in the discontinued section of the FDA‚Äôs Orange Book.
- Per FDA regulations, before an ANDA can be approved referencing a discontinued product, the agency must determine whether it was withdrawn for safety or efficacy reasons.
- The petitioner seeks this determination to proceed with regulatory processes for generic versions",,Denied the implication of withdrawal due to safety or effectiveness; FDA concluded the product was not withdrawn for those reasons.,2010-07-07,0.0,Center for Drug Evaluation and Research (CDER),"21 CFR 314.161, 21 CFR 314.162",,"The FDA reviewed its records and found no evidence that the product Actonel with Calcium (risendronate sodium and calcium carbonate copackaged) Tablets, 35 mg/500 mg was withdrawn from the market for safety or effectiveness concerns.
- The petitioner (EAS Consulting on behalf of Aurobindo Pharmaceuticals) did not provide any data indicating such concerns.
- The FDA independently evaluated literature and postmarketing data and found no adverse information.
- The product will remain in the ‚ÄúDiscontinued Drug Product List‚Äù of the Orange Book.",denied,True,167.0,CDER,CDER
fda-2010-p-0060,FDA-2010-P-0060-0001_Virgilian__LLC____Citizen_Petition.pdf,2010-01-21,2010,False,original petition,"Virgilian, LLC",industry/corporation,"Not explicitly cited; references CFR Title 21, Part 25-30; HACCP and GMP practices",Establishment of a standard of identity for almond fruit juice,Establish a standard of identity for single strength almond fruit juice at 11¬∞ Brix,"Almond is botanically a fruit, part of the Rosaceae family (alongside apple, peach, apricot, plum).
- Almond fruit juice is produced similarly to prune juice, which is also extracted from dried fruit.
- The extraction process is based on patent no. 6,716,465.
- Almond fruit juice has comparable ¬∞Brix (11¬∞) to other fruit juices (e.g., apple, peach, apricot).
- Production uses existing California juice facilities, meeting HACCP and GMP standards.
- The juice introduces new food identity, so further clarification and data may be warranted",,,2025-10-15,0.0,,,,,no decision,False,5746.0,pending,pending
fda-2010-p-0069,FDA-2010-P-0069-0001_Foley___Lardner__LLP___Citizen_Petition.pdf,2010-01-06,2010,False,original petition,Foley & Lardner LLP,law/consulting,"21 U.S.C. ¬ß 355(g); 21 CFR ¬ß 10.30, 21 CFR ¬ß 10.115",Approval and guidance procedures for highly potent pharmaceutical products,Restrict ANDA/NDA approval of highly potent products without strict controls; develop draft guidance and convene Advisory Committee,"Highly potent drugs (e.g., cytotoxics, oncologics, immunologics) pose significant health and environmental risks even at trace levels.
- Cross-contamination and cGMP failures are well-documented in FDA warning letters and literature.
- Past FDA and EMEA guidance are limited or non-binding; no finalized rules exist.
- The petitioner stresses the need for dedicated facilities, validated cleaning, employee training, and risk management frameworks.
- Industry needs clarity, consistency, and enforceable standards to align with public health and safety needs",,Denied,2010-07-21,0.0,Center for Drug Evaluation and Research (CDER),"21 U.S.C. 355(d)(3), 21 CFR 314.50(d)(1), 21 CFR 314.94(a)(9), 21 CFR parts 210 and 211, 21 CFR 10.115",,"FDA concluded that existing statutory requirements, CGMP regulations, and guidance are sufficient to ensure the safe production of highly potent pharmaceutical products.
- FDA emphasized that CGMP violations cited in warning letters do not justify new regulations or guidance.
- Responsibility for worker safety and environmental protection falls under OSHA and EPA, not FDA.
- Requests for advisory committee meetings and drug classification lists lacked supporting evidence and were deemed unnecessary.
- FDA reserves the possibility of future guidance but saw no urgent need based on the petition",denied,True,196.0,CDER,CDER
fda-2010-p-0076,FDA-2010-P-0076-0001_Boehringer_Ingelhein_Roxane_Laboratories__Inc____C.pdf,,2010,False,original petition,"Boehringer Ingelheim Roxane Laboratories, Inc.",advocacy/academic,21 CFR 10.30; FDCA Section 505-1,Development and implementation of Risk Evaluation and Mitigation Strategies (REMS) for mycophenolate mofetil,Ensure generic companies are included in REMS program development and implementation and are not subjected to unreasonable financial burdens,Brand companies excluded generics from the development of REMS programs while demanding disproportionate cost-sharing; FDA should ensure fair inclusion and cost structure,,,2025-10-15,,,,,,no decision,False,,pending,pending
fda-2010-p-0081,FDA-2010-P-0081-0001_Jim_Bates__Truth_in_Labeling_Coalition____Citizen_.pdf,2010-02-12,2010,False,original petition,Truth in Labeling Coalition,advocacy/academic,"57 Fed. Reg. 22984 (1992), Docket No. 92N-0139",Policy on not requiring labeling of genetically engineered (GE) foods,Revoke 1992 FDA policy and require labeling of genetically engineered foods,"Scientific Basis: GE foods involve DNA manipulation with potential unpredictable effects, distinct from traditional breeding. Referenced concerns include Bt-toxin concentration and altered allergenic potential.
- Health Risks: Includes references to toxicity studies (e.g., MON810, MON863, NK603 corn), a past epidemic linked to L-tryptophan contamination, and long-term uncertainty of GE food safety.
- Environmental Impact: Risk of transgene contamination, impact on biodiversity (e.g., bee colony collapse), and herbicide use.
- Consumer Rights: Emphasizes the public‚Äôs right to know and freedom of choice; references international labeling standards (EU, Japan, Australia).
- Public Support: Lists endorsements from dozens of co-ops, businesses, and organizations supporting mandatory labeling",2010-06-30 00:00:00,Denied,2015-11-19,1.0,Center for Food Safety and Applied Nutrition (CFSAN),"21 CFR 10.30, FDCA 21 U.S.C. 343(a)(1), 321(n)","Due to competing agency priorities and limited resources, the FDA has not been able to respond within the first 180 days","FDA found no basis for concluding that bioengineered foods differ from conventional foods in any material way that would require labeling.
- The agency reaffirmed that it is not aware of any information showing that foods derived by genetic engineering differ from other foods in any meaningful or material way.
- FDA emphasized that requiring labeling based on the method of production, without a material difference, would be inconsistent with the FD&C Act.
- Voluntary labeling is permitted and guidance was previously issued for such labeling.
- FDA reviewed scientific evidence and concluded that genetically engineered ingredients do not pose greater health or safety risks than traditionally bred foods.",denied,True,2106.0,CFSAN,Other/Specialty Center
fda-2010-p-0082,FDA-2010-P-0082-0001_Actavis_Elizabeth__LLC__Alston___Bird_LLP____Citiz.pdf,2010-02-05,2010,False,original petition,Actavis Elizabeth LLC,industry/corporation,"21 U.S.C. ¬ß 355, 21 C.F.R. Part 314, 21 C.F.R. ¬ß 10.30",ANDA approval process for extended-release morphine sulfate drug products,"Require specific bioequivalence testing procedures for ANDAs referencing KADIAN, including Tmax and dosage-specific comparator studies","Pharmacokinetic Differences
KADIAN has a unique gradual-ascending and gradual-descending plasma profile not shared by other morphine products. Different pellet formulations are used across KADIAN's dosage strengths, affecting drug release.

Therapeutic Implications
FDA‚Äôs current standards may allow approval of generics that are not therapeutically equivalent to KADIAN, risking patient safety and efficacy.

Dose-Dumping Risks
Co-ingestion with alcohol could cause uncontrolled drug release.
In vitro and in vivo testing submitted by Actavis showed KADIAN has a low risk of alcohol-induced dose-dumping, while others (e.g., AVINZA) showed greater risk.


Precedent and Regulatory Guidance
Cites previous citizen petitions (e.g., Sanofi-aventis, McNeil) urging the FDA to adopt more nuanced bioequivalence metrics.
References FDA‚Äôs own guidance recommending T<sub>max</sub> as a pharmacokinetic measure.",,Granted in part and denied in part,2010-07-19,0.0,Center for Drug Evaluation and Research (CDER),"21 CFR parts 320, 314.127(a)(8), FDCA Section 505(j)",,"‚úÖ Granted Portions:
In Vitro Dissolution Testing for Dose-Dumping:
Required for all strengths referencing Kadian to mitigate risks of alcohol-induced dose-dumping, especially in light of historical issues like Palladone withdrawal.
(Pages 8‚Äì9)

Bioequivalence Across Pellet Formulations:
Required for ANDAs referencing 10 mg, 100 mg, and 200 mg strengths of Kadian, as each uses different pellet formulations.
(Pages 9‚Äì10)

‚ùå Denied Portions:
Additional Pharmacokinetic Parameters (e.g., Tmax, AUCpR, partial AUC):
FDA found no clear evidence linking these metrics to therapeutic effect or safety in extended-release morphine. Existing standards using Cmax and AUC are deemed sufficient.
(Pages 6‚Äì8)

Mandatory In Vivo Dose-Dumping Studies:
Denied as not always necessary; such studies are only required if in vitro testing shows elevated risk.
(Page 9)

üß† Additional Notes:
FDA found no clinically significant difference in Tmax between Kadian and other formulations like Avinza.

Cited lack of evidence to warrant changes to bioequivalence requirements beyond established statistical parameters.",approved,True,164.0,CDER,CDER
fda-2010-p-0086,FDA-2010-P-0086-0001_Hyman__Phelps___McNamara__P_C____Citizen_Petition.pdf,2010-02-12,2010,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"Section 505(j)(2)(C) of the FDCA; 21 C.F.R. ¬ß¬ß 10.20, 10.30, 314.93",ANDA suitability determination for docetaxel injection concentrate in lyophilized powder form,Declare a different initial dosage form and strength of docetaxel suitable for ANDA submission and waive PREA requirements,"The proposed product uses the same active ingredient, concentration, and route of administration as the RLD.
- Offers a non-polysorbate 80 alternative to reduce risk of hypersensitivity reactions.
- The 200 mg strength aligns with dosing instructions in RLD labeling and reduces the need for multiple vials.
- The new diluent component (Macrogol 15 hydroxystearate) is included in upcoming USP/NF monograph, used in injectable products globally.
- No safety or effectiveness concerns arise, as the diluted solution is comparable to the RLD.
- Pediatric studies are unnecessary because Taxotere¬Æ is not indicated for pediatric use, and likely has a PREA waiver for those indications",,"Denied
The FDA rejected the ANDA suitability petition due to safety and regulatory concerns regarding inactive ingredient changes in parenteral formulations",2011-01-20,0.0,Center for Drug Evaluation and Research (CDER),"21 CFR 314.94(a)(9)(iii), 314.127(a)(8)(ii)",,"The petitioner proposed to change the diluent of the reference drug (Taxotere) from PS80 to Macrogol 15 hydroxystearate, an excipient not previously approved in any parenteral drug product by FDA.
- Under 21 CFR 314.94(a)(9)(iii), parenteral ANDAs must include the same inactive ingredients in the same concentration as the reference listed drug, with very limited exceptions (e.g., for preservatives, buffers, antioxidants).
- Since Macrogol 15 hydroxystearate is neither of these and lacks prior approval in injectable products, the proposed formulation raises serious safety and efficacy concerns.
- The FDA cited its prior decision in Docket No. FDA-2009-P-0272, where it rejected any docetaxel formulation differing in PS80 content from Taxotere.
- Therefore, the agency would not accept the proposed ANDA for review",denied,True,342.0,CDER,CDER
fda-2010-p-0087,FDA-2010-P-0087-0001_Sandoz__Inc____Citizen_Petition.pdf,2010-02-09,2010,False,original petition,Sandoz Inc.,industry/corporation,"Section 505 of the FDCA, 21 U.S.C. ¬ß 355; 21 C.F.R. ¬ß 314.94(a)(8)(iv), ¬ß 314.127(a)(7)",ANDA labeling carve-outs related to LYRICA¬Æ (pregabalin),Prevent approval of ANDAs for pregabalin that omit seizure or pain indications protected by patents,"Carving out labeling sections (such as ¬ß5.4 ""Suicidal Behavior and Ideation"" and ¬ß5.5 ""Peripheral Edema"") would remove critical safety warnings that apply to all indications, not just those carved out.
- The Medication Guide contains warnings (e.g., risk of suicidal thoughts and edema) that are not indication-specific, and carving them out would cause confusion and pose risks to patient safety.
- Uniformity of warnings is crucial for prescribers and patients; altered labeling would lead to inconsistent safety messaging.
- Prior FDA decisions (e.g., Rapamune¬Æ and Altace¬Æ cases) support rejecting labeling carve-outs when patient safety is compromised.
- Regulatory precedent and interpretation of 21 C.F.R. ¬ß 314.127(a)(7) show that FDA can and should deny ANDAs with incomplete labeling if they make the generic product less safe",,Denied,2010-07-30,0.0,Center for Drug Evaluation and Research (CDER),"21 U.S.C. 355(j), 21 CFR 314.94(a)(8)(iv), 21 CFR 314.127(a)(7), Purepac Pharm. Co. v. Thompson",,"Carve-outs of protected indications from labeling (related to either seizures or pain) are permissible under FDA regulations if they do not make the generic product less safe or effective for the remaining conditions of use.
- The FDA determined that labeling changes could be made to omit patent-protected uses while retaining necessary safety information (e.g., suicide risk, peripheral edema).
- Section 5.4 and 5.5 of LYRICA‚Äôs labeling (regarding suicidal behavior and peripheral edema) can be retained with minor edits that do not disclose protected indications.
- The FDA cited prior precedents and legal interpretations (e.g., Purepac, Torpharm, Bristol Myers Squibb v. Shalala) to support their authority to permit carve-outs.
- Overall, the agency concluded that permitting carve-outs would not render the generic products less safe or effective than LYRICA for the remaining approved uses.",denied,True,171.0,CDER,CDER
fda-2010-p-0096,FDA-2010-P-0096-0001_OncoTherapies_Limited___Citizen_Petition.pdf,2010-02-15,2010,False,original petition,OncoTherapies Limited,industry/corporation,"Section 505(j)(2)(C) of the FDCA, 21 CFR 10.30, 21 CFR 314.93, 21 CFR 25.31",ANDA suitability for a ready-to-use solution of Gemcitabine Hydrochloride,"Declare proposed Gemcitabine Hydrochloride Injection, 10 mg/mL, suitable for ANDA","The proposed product uses the same active ingredient, strength (200 mg and 1 g), and indications as the RLD.
The change from powder to solution is intended to simplify drug administration by eliminating the need for reconstitution
All inactive ingredients are the same except mannitol, which is unnecessary in solution form; sodium acetate is retained as buffer
Pediatric waiver requested due to lack of substantial pediatric use, supported by CDC data
Environmental and economic assessments excluded or waived under relevant provisions",,,2025-10-15,0.0,,,,,no decision,False,5721.0,pending,pending
fda-2010-p-0105,FDA-2010-P-0105-0001_National_Chicken_Council__NCC____Citizen_Petition.pdf,2010-02-19,2010,False,original petition,National Chicken Council (NCC),advocacy/academic,"21 CFR ¬ß 118.4(e); 21 U.S.C. ¬ß¬ß 342(a)(4), 371(a); 42 U.S.C. ¬ß¬ß 243, 264, 271",Refrigeration requirements in the Final Rule on Salmonella prevention in eggs,"Amend 21 C.F.R. ¬ß 118.4(e) to exempt surplus hatching eggs sold for use in egg products from refrigeration requirements, or
- Re-open the comment period or re-propose the rule solely with respect to the refrigeration of surplus hatching eggs","The refrigeration requirement is incompatible with hatchery conditions (e.g., eggs stored at ~65¬∞F, not 45¬∞F).
- Imposing refrigeration would compromise hatchability, rendering the eggs unusable for hatching and devaluing them.
- Broiler companies received ~$5M in 2008 from sales of surplus eggs to breakers‚Äîrevenue that would be lost.
- No clear public health benefit is demonstrated, as egg products are already required to undergo 5-log SE reduction treatment under the Egg Products Inspection Act.
- The requirement was not a logical outgrowth of the Proposed Rule, violating APA notice requirements.
- FDA relied on a single, unidentified comment to justify the requirement, with no supporting evidence or industry consultation",2010-08-17 00:00:00,,2025-10-15,1.0,,,"The citizen petition (submitted February 19, 2010) requested that FDA either:
1. Amend 21 CFR 118.4(e) to exclude surplus hatching eggs sold for use in egg products from refrigeration requirements, or
2. Reopen the comment period on the single refrigeration requirement for surplus hatching eggs, or
3. Re-propose the Final Rule as it pertains to this specific issue.
- The FDA stated it had not been able to make a determination within 180 days because of limited availability of resources and competing agency priorities",,no decision,False,5717.0,pending,pending
fda-2010-p-0111,FDA-2010-P-0111-0001_Warner_Chilcott_Company__LLC___Citizen_Petition.pdf,2010-02-22,2010,False,original petition,"Warner Chilcott Company, LLC",industry/corporation,"Section 505(q) of FDCA, 21 CFR ¬ß¬ß 10.20, 10.30",Approval process and bioequivalence guidance for mesalamine delayed-release tablets,"The petitioner requests that FDA:
1. Issue a product-specific bioequivalence guidance for mesalamine delayed-release tablets.
2. Require ANDAs to demonstrate bioequivalence using:
‚ÄÉ- Clinical efficacy endpoint studies
‚ÄÉ- Comparative pharmacokinetic studies (fed and fasted conditions)
‚ÄÉ- Rigorous in vitro dissolution testing","Mesalamine acts locally, so systemic pharmacokinetics are unreliable indicators of efficacy
FDA has previously agreed that clinical efficacy studies are necessary for bioequivalence of such locally acting drugs
Systemic exposure variability and the possibility of increased toxicity with generics necessitate PK comparisons
In vitro dissolution testing is vital to ensure proper drug release in variable pH environments of ulcerative colitis patients
Warner Chilcott emphasizes no waiver should be granted for bioequivalence testing of either Asacol (400 mg) or Asacol HD (800 mg), as they are not formulation proportional",,Granted in part and denied in part,2010-08-20,0.0,Center for Drug Evaluation and Research (CDER),"FDCA Section 505(q), 21 CFR 314.94(a)(9)(iii), 21 CFR 314.127(a)(8)(ii)",,"The FDA provided the following reasoning:

Scientific Standards: FDA requires bioequivalence through appropriate scientific methods, and agreed with the need for both comparative clinical endpoint studies and in vitro dissolution data to ensure therapeutic equivalence for mesalamine products .

Statutory Discretion: FDA declined to delay ANDA approvals pending guidance publication, explaining that the law does not obligate FDA to issue guidance prior to approval decisions .

In Vivo Waivers: FDA agreed that waivers for in vivo bioequivalence studies between 400 mg and 800 mg tablets should be denied, as they are not directly substitutable due to formulation and dosing differences .

Labeling Decisions: FDA rejected labeling constraints and boxed warning requirements since such determinations must be based on safety and efficacy data evaluated case-by-case for the generic product .

Product Coding/Substitution Restrictions: FDA declined to enforce specific coding or limit pharmacy substitution, stating such decisions fall outside its regulatory scope and into the purview of state pharmacy boards or payers .",approved,True,179.0,CDER,CDER
fda-2010-p-0112,FDA-2010-P-0112-0001_Alaunus_Pharmaceutical_LLC_Patrick_Foster___Citize.pdf,2010-02-12,2010,False,original petition,Alaunus Pharmaceutical LLC,industry/corporation,"Section 505(j)(2)(C) of FDCA, 21 CFR ¬ß¬ß 10.20, 10.30, 314.93","ANDA suitability for Oxytocin Injection, USP in a 100 mL vial","The petitioner requests FDA approval of a Suitability Petition allowing the submission of an ANDA for Oxytocin Injection, USP ‚Äì 1000 USP Units/100 mL vial (10 USP Units/mL), which differs from the RLD only in package size","The only difference is the larger vial size: 100 mL vs. 30 mL; active ingredient strength remains the same (10 USP Units/mL).
Intended for hospital pharmacies or centralized compounding centers, improving efficiency
No expected change in safety, efficacy, or use, since formulation, preservative (chlorobutanol), pH, and route of administration are identical to the RLD.
Claims FDA must approve such petitions unless new investigations are required to establish safety or effectiveness",,Denied,2024-12-11,0.0,Center for Drug Evaluation and Research (CDER),"21 CFR 10.30, FDCA Section 505(b)",,"FDA denied the petition based on the following key reasons:

Change in Strength Introduces Safety Risks: The proposed change from the listed drug‚Äôs strength and packaging raised concerns about:
Medication errors (e.g., preparation, dosing, expiration tracking)
Risk of incorrect administration
Potential for significant overdose

Labeling Would Require Significant Changes: To mitigate these risks, the drug would require updates to multiple labeling sections:
Dosage and Administration
Overdosage
Warnings and Precautions

These changes exceed what is permissible under the ANDA pathway, making the petition non-approvable under section 505(j)(2)(C) and 21 CFR 314.93.

Recommendation for NDA Pathway: The Agency suggested pursuing approval via a full NDA (section 505(b)) instead of an ANDA, due to the safety and labeling implications.",denied,True,5416.0,CDER,CDER
fda-2010-p-0114,FDA-2010-P-0114-0001_McGuff_Pharmaceuticals__Inc____Citizen_Petition.pdf,2010-02-19,2010,False,original petition,"McGuff Pharmaceuticals, Inc.",industry/corporation,"Section 505(j)(2)(C) of FDCA, 21 CFR 10.30",ANDA submission for a new product strength of Pyridoxine Hydrochloride Injection,"FDA is asked to approve submission of an ANDA for Pyridoxine Hydrochloride Injection, USP in an additional product strength of 3 g/30 mL (100 mg/mL), identical in formulation, dosage form, and route of administration to the RLD","The proposed strength is identical in concentration to the RLD and differs only in volume (larger vial).
Larger vials are especially useful for treating INH poisoning, where high doses are required (e.g., 4g IV + 1g IM every 30 minutes).
Reduces contamination risk and handling burden by replacing 40 smaller vials with 4 larger ones in treatment scenarios
No labeling or dosing changes proposed.
Pediatric safety studies are unnecessary since no new indication, route, or form is introduced
Claims exemption from environmental impact requirement under 21 C.F.R. ¬ß 25.31(a) and economic impact disclosure will be submitted upon request",,"Other ‚Äì Acknowledgment of Petition Filing
This was not a substantive decision on the merits of the petition. It simply acknowledged receipt and corrected a typographical error in a prior letter.",2010-02-25,0.0,"Division of Dockets Management (DDM) under the Office of Public Information and Library Services, FDA
Note: This is an administrative office, not a regulatory review division like CDER or CDRH",Not Mentioned,,"The FDA acknowledged receipt of a citizen petition submitted by McGuff Pharmaceuticals, Inc. on February 25, 2010, requesting permission to file an Abbreviated New Drug Application (ANDA) for Pyridoxine Hydrochloride Injection, USP at a strength of 3g/30 mL (100 mg/mL).
- The letter replaced an earlier acknowledgment due to a typographical error.
- The agency clearly stated that filing the petition is procedural only and does not reflect any decision on the substantive merits of the petition",other,True,6.0,CDER,CDER
fda-2010-p-0652,FDA-2010-P-0652-0001_Timothy_Demitri_Brown_and_Citizens_United_Against_.pdf,2010-12-13,2010,False,original petition,Timothy Demitri Brown,individual,"21 U.S.C. ¬ß 10.25
- 21 U.S.C. ¬ß 379a
- 21 USCS ¬ß¬ß 301 et seq.
- 40 U.S.C. ¬ß 3112
- 18 U.S.C. ¬ß 7
- 40 U.S.C. ¬ß 255
- Public Law 89-554","The enforcement of jurisdiction for actions under 21 U.S.C. ¬ß 379a, which relates to FDA regulatory authority over devices, food, drugs, and cosmetics‚Äîparticularly the presumption of federal jurisdiction based on interstate commerce.",Repeal and/or revocation of 21 U.S.C. ¬ß 379a and any corresponding CFR statute.,"The petitioner argues that:
- 21 U.S.C. ¬ß 379a presumes jurisdiction without proper legal foundation.
- The statute contradicts federalism, citizens‚Äô rights, and constitutional provisions requiring formal procedures for federal jurisdiction (citing 40 U.S.C. ¬ß 3112, 40 U.S.C. ¬ß 255, and 18 U.S.C. ¬ß 7).
- The connection to interstate commerce does not suffice to establish jurisdiction.
- Reference to Adams v. United States supports the argument that jurisdiction must be explicitly accepted by the federal government for each case.",,,2025-10-15,0.0,,,,,no decision,False,5420.0,pending,pending
fda-2010-p-0651,FDA-2010-P-0651-0001_Natural_Solutions_Foundation_Trustee___Citizen_Pet.pdf,2010-12-22,2010,False,original petition,"Ralph Fucetola, JD
(On behalf of) Natural Solutions Foundation",law/consulting,"21 U.S.C. ¬ß 321 (including ¬ß 321(g)(1))
- 21 C.F.R. 10.20 ‚Äì 35
- 21 U.S.C. ¬ß 331
- 21 U.S.C. ¬ß 333
- 5 U.S.C. ¬ß 553(b)(3)(B)
- 28 U.S.C. ¬ß 1331
- The Park Doctrine (United States v. Park, 421 U.S. 658 (1975))
- U.S. Constitution, First, Fifth, Ninth, Tenth, and Fourteenth Amendments
- Religious Freedom Restoration Act of 1993 (RFRA)
- 42 U.S.C. ¬ß 289g(b) (re: informed consent)","Approval, distribution, and promotion of the 2009/2010 A-H1N1-09 ""Swine Flu"" and 2010/2011 seasonal influenza vaccines.
The petition also challenges emergency approvals, lack of transparency, and claims of safety/efficacy without sufficient public hearings or testing.","Full enforcement of 21 U.S.C. ¬ß 321, including a redefinition of vaccines under that statute.
- Investigation into agency failures regarding vaccine approvals.
- Immediate labeling requirements for vaccines that did not undergo full FDA testing.
- Enforcement of legal consequences against responsible individuals/agencies.
- Public hearings, rulemaking reform, and prohibition of emergency vaccine approvals without complete testing.","Alleged past harms from swine flu and seasonal flu vaccines (e.g., 1976 swine flu vaccine disaster).
- Lack of proper testing and informed consent.
- Violations of statutory and constitutional rights.
- Perceived failures by FDA and CDC to protect public health.
- Claims of coercion and insufficient transparency in the vaccine approval process.
- Concerns over conflicts of interest between agencies and vaccine manufacturers.",2011-06-07 00:00:00,"Partially granted (some requests already granted), remainder denied",2018-10-01,1.0,Center for Biologics Evaluation and Research (CBER),"42 U.S.C. ¬ß 262(a)(2)(C)(i)(I)
- 21 CFR 10.30(e)(2)
- 21 CFR 600.3(p)
- 21 CFR 201.57(c)(6)(i)","FDA cites competing priorities that have delayed a final response.
- The issues raised in the 2010 petition overlap substantially with an earlier 2009 petition.
- The FDA intends to address both petitions together in a future combined final response","Safety Evaluation: FDA determined that both the 2009 H1N1 and 2010/2011 seasonal vaccines were safe, pure, and potent, based on clinical data, past seasonal influenza vaccine performance, and post-marketing surveillance.
- No Scientific Evidence: The petitioners failed to provide scientific evidence to support their claims regarding vaccine safety risks such as adjuvants (e.g., squalene) or miscarriages.
- Labeling: Requested warnings were denied as false and unsupported; current labeling reflects known risks.
- Jurisdictional Limits: FDA denied requests related to mandatory vaccination policies and self-shielding recommendations as they fall outside FDA authority.
- Safety Monitoring: FDA and CDC conducted extensive safety surveillance (VAERS, VSD, CMS, PRISM, EIP), finding no substantial risks and only a very small elevated risk for GBS, consistent with historical influenza vaccine data.
- Moot Requests: Some requests were deemed moot due to the expiration of the public health emergency and the approval of vaccines in 2009.",partially approved / denied,True,2840.0,CBER,Other/Specialty Center
fda-2010-p-0644,FDA-2010-P-0644-0010_International_Packaged_Ice_Association_Supplement.pdf,2013-11-11,2010,False,original petition,International Packaged Ice Association (IPIA),advocacy/academic,"21 C.F.R. Chapter 1 Subchapter B (new proposed section on ‚ÄúPackaged Ice‚Äù)
- 21 C.F.R. ¬ß 110.80(b)(16)
- 21 C.F.R. ¬ß 120.6(a)(1)
- 2009 FDA Food Code ¬ß 1-201.10
- FDA Food Code ¬ß 3-202.16","The lack of FDA regulation and formal standards for packaged ice as a food product‚Äîspecifically the absence of standards of identity and quality, and undefined food code language for packaged ice. The petition supplements a December 3, 2011 petition still awaiting FDA response. ","Create a new regulation under 21 C.F.R. Subchapter B titled ""Packaged Ice"" to define packaged ice as a food and set a Standard of Quality.
- Modify existing rules: 21 C.F.R. ¬ß¬ß 110.80(b)(16) and 120.6(a)(1) to reflect packaged ice standards.
- Define ‚ÄúPackaged Ice‚Äù in the FDA Food Code Section 1-201.10 and amend Section 3-202.16.
- Issue a Standard of Identity for packaged ice, including quality specifications","Lack of clear FDA standards leads to inconsistent sanitary practices in ice production.
- A 2013 University of Georgia study found high levels of microbial contamination in ice from retail stores and self-service vending machines compared to IPIA members.
- Contaminants found included coliforms, nonpathogenic E. coli, enterococci, Salmonella, and Enterobacter agglomerans.
- IPIA members comply with their own Packaged Ice Quality Control Standards (PIQCS) based on FDA GMPs and HACCP.
- These findings show a clear public health risk and the need for FDA regulation to ensure safety and uniform standards.",,"Not applicable. The document summarizes a meeting and does not contain a formal petition decision (e.g., approval or denial). The citizen petition was discussed, but no regulatory action was issued.",2018-08-23,0.0,"Center for Food Safety and Applied Nutrition (CFSAN), FDA",Not Mentioned,,"The FDA discussed the challenges of changing the Food Code and creating a standard of identity for packaged ice as requested by IPIA.
‚Äì FDA appreciated IPIA‚Äôs field observations and quality standards, and offered suggestions for future collaboration.
‚Äì The meeting was informative but did not result in a final regulatory decision.",other,True,1746.0,CFSAN,Other/Specialty Center
fda-2010-p-0644,FDA-2010-P-0644-0001_International_Packaged_Ice_Association__IPIA____Ci.pdf,2010-12-03,2010,False,original petition,International Packaged Ice Association (IPIA),advocacy/academic,"21 C.F.R. Chapter 1 Subchapter B
- 21 C.F.R. ¬ß 110.80(b)(16)
- 21 C.F.R. ¬ß 120.6(a)(1)
- 21 C.F.R. ¬ß 165.110 (multiple subparts)
- 21 C.F.R. ¬ß 101, ¬ß 130
- 21 C.F.R. ¬ß 25.30(h), (k) (for environmental exclusion)
- 2009 FDA Food Code ¬ß¬ß 1-201.10, 3-202.16","Lack of FDA regulation and formal oversight regarding packaged ice as a food product. The petition seeks action to formally define and regulate packaged ice at both retail and wholesale levels, similar to bottled water.","Issue a new regulation under 21 C.F.R. Subchapter B titled ""Packaged Ice"" to define it as a food product.
- Establish a Standard of Identity and Standard of Quality for packaged ice.
- Modify 21 C.F.R. ¬ß¬ß 110.80(b)(16) and 120.6(a)(1) to include ""packaged ice"".
- Amend the 2009 FDA Food Code (Sections 1-201.10 and 3-202.16) to include definitions and handling practices for packaged ice.","Public health concern: Packaged ice is widely consumed, yet largely unregulated at the retail level. ~40% of packaged ice sold is made on-site without oversight.
- Contamination risks: Common issues include mold, slime in machines, poor hygiene during manual bagging, and contamination with bacteria, viruses, or chemicals.
- Inadequate traceability: Ice lacks lot-specific data or packaging traceability, hampering FDA's ability to respond in food emergencies.
- Evidence from studies & outbreaks: Cited contamination reports, HHS/CDC data, and lawsuits (e.g., Houlihan‚Äôs hepatitis A case) underscore the risk.
- Adoption of IPIA‚Äôs PIQCS: Federal agencies like the DoD and Army Corps of Engineers already require compliance with IPIA's standards.",2011-06-17 00:00:00,No formal decision rendered. FDA stated that it could not provide substantive information regarding the pending citizen petition for a standard of identity for packaged ice but confirmed the petition is being addressed,2013-06-15,1.0,Center for Food Safety and Applied Nutrition (CFSAN),Not Mentioned,"The agency cited competing priorities and limited availability of resources as the reason for the delay.
‚Äì It affirmed that the petition was still under review and that potential amendments to FDA regulations would be considered in the context of other program priorities.","The FDA noted the pending nature of the Citizen Petition and did not discuss its substance.
‚Äì The agency acknowledged the importance of the issues raised and maintained openness to future engagement.
‚Äì FDA advised that specific questions should be submitted in writing ahead of any future meetings to facilitate more targeted discussions.",other,True,925.0,CFSAN,Other/Specialty Center
fda-2010-p-0642,FDA-2010-P-0642-0001_Teva_Pharmaceutical_Industries_Ltd___Teva_Neurosci.pdf,2010-12-10,2010,False,original petition,"Teva Pharmaceutical Industries Ltd. and Teva Neuroscience, Inc",industry/corporation,"21 U.S.C. ¬ß 355(j)
- 21 U.S.C. ¬ß 355(b)(1)
- 21 C.F.R. ¬ß 314.94(a)(9)
- 21 C.F.R. ¬ß 314.127(a)(6)
- 21 C.F.R. ¬ß 320.24(b)(6)
- 21 C.F.R. ¬ß 320.25
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 10.35
- 5 U.S.C. ¬ß 706(2)(A) (Administrative Procedure Act)","FDA‚Äôs potential approval of any Abbreviated New Drug Application (ANDA) for generic versions of Copaxone¬Æ (glatiramer acetate injection) without requiring full-scale clinical trials or data showing equivalence in clinical effect, including in multiple sclerosis (MS) treatment.","Teva requests that the FDA:
- Refrain from approving any ANDA for generic Copaxone¬Æ unless and until the applicant demonstrates equivalence to Copaxone in clinical safety and efficacy.
- Require full-scale pharmacological, toxicological, and clinical studies, including clinical trials in MS patients.
- Do not rely solely on physicochemical characterization and in vitro studies.","Copaxone is a non-biologic complex drug (NBCD) consisting of a mixture of polypeptides, with complex structural and functional attributes that cannot be fully characterized by analytical techniques alone.
- Clinical equivalence cannot be assumed based on in vitro or limited data.
- Teva argues that differences in manufacturing, composition, and impurities can lead to variations in safety and efficacy.
- Precedent shows that ANDA approval for NBCDs requires greater scrutiny.
- Patient safety and regulatory integrity require rigorous standards.",,"Denied
The FDA formally denied the citizen petition submitted by Teva Neuroscience requesting that the FDA not approve any ANDA for a generic version of Copaxone without meeting stringent characterization and clinical equivalence requirements",2011-06-08,0.0,"Center for Drug Evaluation and Research (CDER)
Signed by Janet Woodcock, M.D., Director","Section 505(q) of the FDCA (21 U.S.C. ¬ß 355)
- Section 505(j) of the FDCA
- 21 CFR ¬ß 314.92(a)(1) ‚Äì ""same as"" active ingredient standard
- 21 CFR ¬ß 314.94(a)(5)(i) ‚Äì ANDA requirements
- 21 CFR ¬ß 314.127(a)(3) ‚Äì grounds for denying an ANDA
- 21 CFR ¬ß 320.1(c) ‚Äì pharmaceutical equivalents
- 21 CFR Part 314 ‚Äì application procedures
- 21 CFR ¬ß 210.3(b)(7) ‚Äì definition of active ingredient",,"FDA emphasized its broad discretion under the law to determine ‚Äúsameness‚Äù of active ingredients for ANDA approvals, supported by legal precedent (e.g., Serono Labs v. Shalala).
- The petition's requested criteria for equivalence (including full characterization of glatiramer acetate) were viewed as too restrictive and premature.
- FDA reaffirmed that it may require a multi-criteria scientific assessment to evaluate ‚Äúsameness‚Äù for complex products like Copaxone, but these must be developed through case-specific review.
- The agency argued that preemptively setting specific standards for generic Copaxone would effectively decide the approvability of future ANDAs without appropriate procedural review.
- FDA stated it has sufficient internal expertise to evaluate ANDAs for glatiramer acetate without convening an advisory committee.",denied,True,180.0,CDER,CDER
fda-2010-p-0641,FDA-2010-P-0641-0001_Washington_Action_For_Safe_Water_Citizen_Petition,2010-11-20,2010,False,original petition,Washington Action for Safe Water (WASW),advocacy/academic,"21 C.F.R. ¬ß 10.30
- 21 U.S.C. ¬ß 321(g)(1)
- 21 U.S.C. ¬ß 321(s)
- 21 U.S.C. ¬ß 343
- 21 U.S.C. ¬ß 348
- 21 U.S.C. ¬ß 379e
- 42 U.S.C. ¬ß 300g-1 (Safe Drinking Water Act)
- 5 U.S.C. ¬ß 553(e) (Administrative Procedure Act)","FDA‚Äôs continued allowance of the sale of bottled water containing added fluoride, despite fluoride's classification as a drug or food additive under different contexts, and concerns over safety and labeling.","WASW petitions the FDA to:
- Prohibit the sale of bottled water with added fluoride.
- Reclassify fluoride added to water as an unapproved drug.
- Enforce labeling requirements declaring fluoride as a drug or food additive when added to water.
- Require scientific review and proof of safety and effectiveness before permitting its addition to food and beverage products.","Fluoride has no nutritional value and is added solely for medicinal purposes, hence it should be regulated as a drug.
- The FDA has not approved fluoride for ingestion in bottled water.
- Scientific and legal arguments presented claim that fluoride is a toxic substance with documented health risks.
- Cites reports and research pointing to adverse health effects, especially in vulnerable populations (e.g., children, elderly).
- Raises concerns about lack of informed consent and mislabeling, asserting that consumers are not adequately warned of fluoride‚Äôs status and risks",,,2025-10-15,0.0,,,,,no decision,False,5443.0,pending,pending
fda-2010-p-0639,FDA-2010-P-0639-0001_Mike_Bernstein__MPH___Citizen_Petition.pdf,2010-12-13,2010,False,original petition,"Mike Bernstein, MPH",individual,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß¬ß 10.20, 10.30, 314.93, 320.22(b)(1)
- Section 505B(a)(4)(A) (Pediatric Research Equity Act - PREA)
- 21 C.F.R. ¬ß 25.31 (Environmental Impact)
- 21 C.F.R. ¬ß 10.30(b) (Economic Impact)","The approval process of ANDAs for docetaxel injection concentrate, specifically addressing the submission of a new strength (200mg/10mL) of the reference listed drug (RLD), Taxotere¬Æ.","The petitioner requests FDA to:
- Declare suitability for submission of an ANDA for an additional strength (200mg/10mL) of docetaxel injection concentrate.
- Waive the requirement for a bioequivalence study under 21 C.F.R. ¬ß 320.22(b)(1).
- Accept one stability batch packaged into two strengths (20mg and 80mg) and one batch for the 200mg strength.
- Grant a Pediatric Research Equity Act (PREA) waiver for all pediatric age groups.","The proposed 200mg strength is already within the labeled dosing range of the RLD (Taxotere¬Æ).
- Offers greater dosing convenience for practitioners, avoiding the need to combine multiple vials.
- The proposed product has the same active/inactive ingredients, route of administration, dosage form, and maximum final concentration as the RLD.
- The labeling is essentially identical to the RLD, differing only in strength, manufacturer/trade name, and docetaxel form (anhydrous vs. trihydrate).
- The bioequivalence waiver is justified because the product is a parenteral solution with identical concentration and composition.
- PREA waiver is justified due to the low or absent incidence of labeled cancers (e.g., breast, prostate, head/neck) in pediatric populations.",,"Approved
The petition to allow submission of an Abbreviated New Drug Application (ANDA) for Docetaxel Injection Concentrate, 200 mg/10 mL (a new strength not matching the listed drug) was granted.",2012-03-27,0.0,"Center for Drug Evaluation and Research (CDER)
Signed by Keith O. Webber, Ph.D., Deputy Director, Office of Pharmaceutical Science","Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- Section 505(j)(2)(C)(i)
- Section 505(j)(2)(A)(iv)
- Sections 505(j)(2)(A) and (B)",,"The proposed ANDA involves a different strength than the listed drug (Taxotere¬Æ 20 mg/mL and 80 mg/4 mL vs. proposed 200 mg/10 mL).
- FDA concluded that the change in strength does not pose questions of safety or effectiveness, since the use, dose, and route of administration remain the same.
- FDA determined that no additional investigations were needed to demonstrate safety or effectiveness for the proposed strength.
- If bioavailability requirements are met, the drug can be expected to provide the same therapeutic effect as the reference product.
- Approval of the petition allows for submission of an ANDA, but does not guarantee final ANDA approval, which depends on full review.",approved,True,470.0,CDER,CDER
fda-2010-p-0638,FDA-2010-P-0638-0005_Dinsmore___Shohl_LLP___Information.pdf,2011-01-28,2010,False,original petition,"Mark A. McAndrew, Dinsmore & Shohl LLP (Attorney)",law/consulting,"21 C.F.R. ¬ß 20.61 ‚Äì FOIA-related confidentiality
No other statutes or drug approval regulations (e.g., 505(j), 21 C.F.R. ¬ß 314) are explicitly mentioned in this supplement letter. ","Inquiry from the FDA‚Äôs Center for Veterinary Medicine, Division of Generic Animal Drugs regarding:
(i) whether the omeprazole tablet is coated or the API is micro-encapsulated, and
(ii) availability of dissolution data under acidic conditions. This relates to review of a suitability petition for generic omeprazole tablets for horses.","The petitioner provides clarifications and supporting data to the CVM to continue the evaluation of their pending suitability petition for a generic omeprazole tablet for equine use, particularly concerning formulation design (enteric coating) and dissolution characteristics.","The API in the proposed product is formulated with enteric-coated granules or microparticles, allowing uniform release.
- Appendix 1 (not included in this extract) contains dissolution data to demonstrate no significant drug loss under acidic conditions, addressing FDA's concern.
- These clarifications aim to satisfy CVM‚Äôs technical queries to proceed with petition review.",,"Approved
The FDA approved the suitability petition allowing the submission of an Abbreviated New Animal Drug Application (ANADA) for a generic omeprazole 570 mg tablet for horses.",2011-03-22,0.0,"Center for Veterinary Medicine (CVM)
Signed by Steven D. Vaughn, DVM, Director, Office of New Animal Drug Evaluation","Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act
- Section 512(n)(3)(C) of the Act
- 21 CFR 25.33(d)(1) (environmental assessment exclusion, prior reference)
- 21 CFR 25.30(h) (corrected citation for environmental exclusion)
- 21 CFR 25.15 (extraordinary circumstances clause)",,"The proposed drug differed from the reference drug (ULCERGARD Oral Paste, 37% w/w omeprazole) in dosage form (tablet) and strength (570 mg, 19% w/w).
- FDA determined that these differences did not require additional investigations to establish safety or effectiveness under the statutory criteria.
- Justification for approval was based on the inclusion of a pH-sensitive enteric coating and alkalinizing agent in the formulation, which protect the active ingredient (omeprazole) from gastric acid degradation.
- FDA noted concerns about bioavailability differences when administered with food, and recommended that fed versus fasted conditions be accounted for in the in-vivo bioequivalence study.
- Approval of the petition allows for ANADA submission, but does not guarantee final drug approval, which will depend on full review of the ANADA submission.",approved,True,53.0,CVM,Other/Specialty Center
fda-2010-p-0638,FDA-2010-P-0638-0001_Dinsmore___Shohl__LLP___Citizen_Petition,2010-12-10,2010,False,original petition,"Mark A. McAndrew, attorney at Dinsmore & Shohl LLP",law/consulting,"Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 25.33(d)(1) (Environmental Impact)
- 21 C.F.R. ¬ß 20.61 (Confidential Information)","Suitability for submission of an Abbreviated New Animal Drug Application (ANADA) for a new dosage form (tablet) of omeprazole differing from the reference product UlcerGard‚Ñ¢ (NADA 141-227), which is a paste","FDA determination that a palatable omeprazole tablet for horses is suitable for submission as an ANADA.
- A categorical exclusion from submitting an environmental impact assessment.","The proposed drug has the same active ingredient and dosage (570 mg) per dose as UlcerGard‚Ñ¢, but differs in dosage form and strength (19% w/w vs. 37% w/w).
- Tablets are easier to administer than oral pastes, which often result in dosing errors or waste due to spitting or loss during administration.
- Tablet form improves compliance, accuracy, and convenience for veterinarians and horse owners.
- The labeling, dosage directions, and indications match the reference product.
- The change in strength is necessary due to the dosage form shift but maintains the same mg dose per weight category.
- Petitioner anticipates similar stability in gastric environment (data in Appendix 5).",,"Approved
The FDA approved the suitability petition allowing the submission of an Abbreviated New Animal Drug Application (ANADA) for a generic omeprazole 570 mg tablet for horses.",2011-03-22,0.0,"Center for Veterinary Medicine (CVM)
Signed by Steven D. Vaughn, DVM, Director, Office of New Animal Drug Evaluation","Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act
- Section 512(n)(3)(C) of the Act
- 21 CFR 25.33(d)(1) (environmental assessment exclusion, prior reference)
- 21 CFR 25.30(h) (corrected citation for environmental exclusion)
- 21 CFR 25.15 (extraordinary circumstances clause)",,"The proposed drug differed from the reference drug (ULCERGARD Oral Paste, 37% w/w omeprazole) in dosage form (tablet) and strength (570 mg, 19% w/w).
- FDA determined that these differences did not require additional investigations to establish safety or effectiveness under the statutory criteria.
- Justification for approval was based on the inclusion of a pH-sensitive enteric coating and alkalinizing agent in the formulation, which protect the active ingredient (omeprazole) from gastric acid degradation.
- FDA noted concerns about bioavailability differences when administered with food, and recommended that fed versus fasted conditions be accounted for in the in-vivo bioequivalence study.
- Approval of the petition allows for ANADA submission, but does not guarantee final drug approval, which will depend on full review of the ANADA submission.",approved,True,102.0,CVM,Other/Specialty Center
fda-2010-p-0630,FDA-2010-P-0630-0001_Heyltex_Corporation_HEYL_Chemisch_Pharmazeutische_,2010-11-25,2010,False,original petition,"Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG (based in Berlin, Germany)",industry/corporation,"21 CFR ¬ß¬ß 10.25(a), 10.30
- 21 CFR ¬ß 314.122
- 21 CFR ¬ß 314.161(a)(3)
- Section 505(j) of the Federal Food, Drug, and Cosmetic Act
- 21 CFR ¬ß 23.31 (environmental assessment)
- 21 CFR ¬ß 10.30(b) (economic impact statement)","The FDA‚Äôs listing status of Pentetate Zinc Trisodium (NDA 21-751) in the Orange Book. Specifically, whether its voluntary withdrawal from the U.S. market was due to safety or effectiveness reasons","A determination by the FDA Commissioner that Pentetate Zinc Trisodium was not withdrawn for safety or effectiveness reasons
- If confirmed, annotate the Orange Book listing accordingly
- If not, publish the determination in the Federal Register","Drug had been voluntarily withdrawn from the market, but no evidence of safety or effectiveness issues
- Supported by more than 40 years of global use of Zn-DTPA and Ca-DTPA without reported adverse effects

- Documented use in countries such as Germany, France, Russia, Czech Republic, and the U.S. for emergency radiation exposure
- References to studies and real-world data showing increased radionuclide elimination, low toxicity, and sustained clinical benefit
- Drug products made by Heyl were used in U.S. clinical programs (REAC/TS) for decades",,"Approved (Favorable determination)
FDA concluded that PENTETATE ZINC TRISODIUM (Zn-DTPA) was not withdrawn from sale for reasons of safety or effectiveness, which allows abbreviated new drug applications (ANDAs) to be submitted referencing this product",2011-08-19,0.0,"Center for Drug Evaluation and Research (CDER)
Signed by Alexis Reisin Miller, Office of Regulatory Policy","21 CFR 10.30 ‚Äì Citizen petition process
- 21 CFR 314.161 ‚Äì Determination if a drug was withdrawn for safety/effectiveness
- 21 CFR 314.162 ‚Äì Removal of drug from Orange Book
- 21 U.S.C. 355(j)(7) ‚Äì Orange Book listing requirements
- Drug Price Competition and Patent Term Restoration Act of 1984 (Public Law 98-417)",,"Heyl submitted a citizen petition requesting that FDA determine if Zn-DTPA was withdrawn for safety or effectiveness reasons.
- FDA reviewed its records, assessed postmarketing adverse events, and evaluated relevant literature.
- FDA found no evidence suggesting that the drug was withdrawn for safety or efficacy concerns.
- Therefore, the product remains listed in the ‚ÄúDiscontinued Drug Product List‚Äù of the Orange Book, which includes drugs discontinued for reasons other than safety or effectiveness.
- ANDAs referencing Zn-DTPA are eligible for submission and approval if other requirements are met.",approved,True,267.0,CDER,CDER
fda-2010-p-0628,FDA-2010-P-0628-0001_Heyltex_Corporation__Heyl_Chemisch_Pharmazeutische.pdf,2010-11-26,2010,False,original petition,Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG,industry/corporation,"21 C.F.R. ¬ß 10.25(a)
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 314.122
- 21 C.F.R. ¬ß 314.161(a)(3)
- 21 C.F.R. ¬ß 23.31 (Environmental Impact Statement)","The voluntary withdrawal of Pentetate Calcium Trisodium (NDA 21-749) by Hameln Pharms from the U.S. market, and its movement to the ""Discontinued Section"" of the Orange Book without a determination of withdrawal for safety or effectiveness reasons","The petitioner requests that the FDA determine that Pentetate Calcium Trisodium was not withdrawn for safety or effectiveness reasons, and that the Orange Book listing be annotated accordingly. If the determination is otherwise, the petitioner requests publication of a notice in the Federal Register","The petitioner provides extensive evidence, including historical use in multiple countries, lack of adverse effect reports, endorsements from international organizations (e.g., WHO, REAC/TS, FDA guidance), and clinical data on efficacy and safety. They argue that the product's withdrawal was not due to safety or efficacy concerns, but for other, unspecified reasons",,"Approved (Favorable Determination)
The FDA determined that PENTETATE CALCIUM TRISODIUM (Ca-DTPA) was not withdrawn for reasons of safety or effectiveness, which allows for the submission and approval of ANDAs referencing the drug",2011-08-19,0.0,"Center for Drug Evaluation and Research (CDER)
Signed by Alexis Reisin Miller, Office of Regulatory Policy","21 CFR 10.30 ‚Äì Citizen Petition process
- 21 CFR 314.161 ‚Äì Determination of withdrawal for safety/effectiveness
- 21 CFR 314.162 ‚Äì Drug removal from Orange Book
- 21 U.S.C. ¬ß 355(j)(7) ‚Äì ANDA listing authority
- Drug Price Competition and Patent Term Restoration Act of 1984 (Pub. L. 98‚Äì417)",,"The FDA reviewed internal records, literature, and postmarketing data, and found no evidence suggesting that Ca-DTPA was withdrawn due to safety or effectiveness issues.
- The manufacturer, Hameln Pharmaceuticals GmbH, voluntarily discontinued marketing, prompting FDA to move the product to the ‚ÄúDiscontinued Drug Product List‚Äù of the Orange Book.
- The discontinuation was for reasons other than safety or effectiveness, enabling ANDA approval if other requirements are satisfied",approved,True,266.0,CDER,CDER
fda-2010-p-0624,FDA-2010-P-0624-0001_Cubist_Pharmaceuticals__Inc____Citizen_Petition,2010-12-03,2010,False,original petition,"Cubist Pharmaceuticals, Inc., NDA holder for Cubicin¬Æ (daptomycin for injection)",industry/corporation,"21 U.S.C. ¬ß 355(j)
- 21 C.F.R. ¬ß 314.127(a)(8)(ii)
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 314.50(d)(5)(v)
- 21 C.F.R. ¬ß 320.25(a)(2)
- 21 C.F.R. ¬ß 314.94(a)(9)(iii)
- 21 C.F.R. ¬ß 25.31
- 21 U.S.C. ¬ß 355(q) (certification of citizen petition under FDCA)","Potential approval of any Abbreviated New Drug Application (ANDA) for generic versions of Cubicin¬Æ (daptomycin) that do not include full demonstration of equivalence in safety, efficacy, and immunogenicity.","The petitioner asks the FDA to:
- Refrain from approving any ANDA for daptomycin unless the applicant has demonstrated clinical equivalence through extensive testing, not just analytical comparability.
- Require data showing equivalence in safety, efficacy, pharmacokinetics, and immunogenicity.","Cubicin is a non-biologic complex drug (NBCD) and includes a fermentation-derived cyclic lipopeptide mixture that cannot be fully characterized by standard analytical means.
- Differences in manufacturing may lead to clinically meaningful variation in efficacy and immunogenicity.
- Literature and Cubist‚Äôs own data demonstrate potential for immune response, adverse events, and batch variability.
- FDA has precedent for requiring full clinical evaluation for similar products where characterization is insufficient (e.g., enoxaparin).
- Generic versions made via different fermentation and purification processes may not be reliably safe or effective.",,Granted in part and denied in part,2011-06-01,0.0,Center for Drug Evaluation and Research (CDER),"21 CFR 314.92(a)(1)

21 CFR 314.94(a)(5), (6), (8), (9), (9)(iii)

21 CFR 320.1(c), 320.22(b)

21 CFR 210.3(b)(7), 314.3(b), 314.127(a)(3)

ICH Q3A, Q3B(R2), Q8(R2)

FDA Guidance for Industry on Impurities in Drug Substances (June 2009), Drug Products (Nov. 2010)",,"FDA agrees that impurity profiles must be qualified but denies requiring in vivo toxicology for all applicants if impurity data is adequate.

In vitro testing: HPLC assays are generally considered adequate for potency testing; bioassays may be required in limited cases.

Chemical characterization: FDA will not require peptide degradation or protein-binding studies, as conventional analytical methods are deemed sufficient.

Impurities: FDA will assess and ensure appropriate controls for impurities such as polymers and soyasaponins but does not find evidence these warrant extra controls beyond standard practice.

Infusion system compatibility: FDA expects generic and reference products to be materially identical in composition and thus does not require additional compatibility testing with infusion systems.",approved,True,180.0,CDER,CDER
fda-2010-p-0619,FDA-2010-P-0619-0001_Richard_F__Edlich__M_D___Ph_D____University_of_Vir,2010-11-29,2010,False,original petition,"Richard F. Edlich, MD, PhD, Distinguished Professor Emeritus of Plastic Surgery, Biomedical Engineering, and Emergency Medicine, University of Virginia Health System",advocacy/academic,21 C.F.R. ¬ß 10.30,The continued allowance and use of mercury (Hg) dental amalgam by the FDA despite scientific evidence of its risks,The petitioner requests the Commissioner of Food and Drugs to ban mercury (Hg) amalgam for dental use in the United States due to its documented adverse effects on pregnant women and fetuses,"The petitioner cites extensive scientific studies documenting mercury‚Äôs harmful effects, especially on fetal and maternal health, including its transfer through the placenta and breast milk. Cited risks include neurodevelopmental damage, kidney toxicity, and environmental harm. Additional justification includes:
- Evidence of Hg in fetal tissues from maternal amalgam use
- Methylmercury neurotoxicity
- EPA's upcoming regulation on dental Hg waste
- Economic rationale for banning due to healthcare and environmental costs",,,2025-10-15,0.0,,,,,no decision,False,5434.0,pending,pending
fda-2010-p-0617,FDA-2010-P-0617-0001_Richard_F__Edlich__M_D___Ph_D____University_of_Vir,2010-11-24,2010,False,original petition,"Richard F. Edlich, M.D., Ph.D., Distinguished Professor Emeritus of Plastic Surgery, Biomedical Engineering and Emergency Medicine, University of Virginia Health System",advocacy/academic,21 C.F.R. ¬ß 10.30 and reference to authority under 21 C.F.R. ¬ß 5.10,Use and regulation of mercury amalgam in dental restorative materials. The petitioner criticizes the FDA for approving amalgam under a grandfather clause and failing to regulate it adequately,To ban mercury amalgam for dental use due to its harmful health effects,"The petitioner provides a comprehensive review of scientific studies and international policy trends, citing:
- Evidence of mercury vapor release from amalgam and its harmful effects on the kidney, CNS, and cardiovascular system.
- Studies linking mercury exposure to multiple sclerosis, Alzheimer's, ALS, Parkinson's, and developmental issues.
- Case reports and research on neurological impacts, including cerebrospinal fluid changes after mercury removal.
- Environmental risks due to mercury entering the waste system and converting to methylmercury.
- Economic justification, asserting that banning mercury amalgam would save lives and reduce toxic exposure",2011-06-02 00:00:00,"Other ‚Äì Administrative Closure
The petition was closed due to the death of the petitioner, Dr. Richard Edlich, and the absence of valid contact information for the co-signor. FDA did not render a decision on the petition‚Äôs merits",2018-04-10,1.0,"Center for Devices and Radiological Health (CDRH)
Signed by: Jeffrey Shuren, MD, JD ‚Äì Director","21 CFR ¬ß 10.30(e)(3) ‚Äì Requirement to notify the petitioner of the Commissioner‚Äôs decision
- 21 CFR ¬ß 10.30(b)(3) ‚Äì Requirements for providing contact information with petition submissions","The petition raised multiple requests including banning the sale of liquid mercury, revising classification of dental materials, and banning mercury amalgam due to health concerns.
- An advisory committee (Dental Products Panel) met in December 2010 to evaluate scientific evidence related to dental amalgam.
- FDA stated that, based on the complexity of the issues and recommendations made, further action was under consideration.
- Because the analysis was ongoing, the agency issued this interim response as per regulatory requirement.","The primary petitioner, Dr. Edlich, died on December 25, 2013.
- Although co-signed by Samantha Rhoads (his research assistant), she did not provide mailing address or phone number as required under 21 CFR ¬ß 10.30(b)(3).
- FDA determined Dr. Edlich was the intended sole petitioner, and his death precluded further action.
- The petition docket was closed without prejudice, allowing the co-signor to re-submit if she chooses, in accordance with regulatory requirements",other,True,2694.0,CDRH,CDRH
fda-2010-p-0614,FDA-2010-P-0614-0069_West_Ward_Pharmaceutical_Corporation__Arnall_Golde,2011-05-11,2010,False,original petition,West-Ward Pharmaceutical Corp.,industry/corporation,"While no specific statutes or regulatory citations like ""21 C.F.R. ¬ß 10.30"" are directly referenced, the arguments address issues relating to Hatch-Waxman Act exclusivity and the FDA's authority on drug approval and market exclusivity, implying relevance to 21 U.S.C. ¬ß 355 and the general framework of the FDCA","The petition comments on Mutual Pharmaceutical‚Äôs Citizen Petition regarding marketing exclusivity for colchicine for chronic gout prophylaxis, and FDA‚Äôs authority to allow other manufacturers to seek approval for this indication","West-Ward requests that Mutual‚Äôs Citizen Petition be denied, asserting that no marketing exclusivity exists for colchicine for chronic gout prophylaxis and that West-Ward can rightfully seek approval without relying on Mutual‚Äôs data","A letter from Dr. Janet Woodcock (FDA) clarified that ‚Äúno marketing exclusivity exists‚Äù for chronic gout and that other manufacturers can seek approval.
- Meeting summaries from the American College of Rheumatology (ACR) and FDA indicated that the FDA did not recognize exclusivity for that indication.
- ACR contacted manufacturers (including West-Ward) encouraging them to pursue approval based on comparative bioavailability.
- West-Ward argues its application does not rely on any protected data and that FDA has already determined that exclusivity claims by Mutual are unfounded",,"Partially Approved / Partially Denied
The FDA granted some of ViroPharma‚Äôs requests regarding review of ANDAs referencing Vancocin¬Æ (vancomycin HCl) Capsules, but denied others",2011-05-25,0.0,"Center for Drug Evaluation and Research (CDER)
Signed by: Janet Woodcock, M.D., Director","21 CFR ¬ß 10.30 ‚Äì Citizen petition procedure
- 21 CFR Part 320 ‚Äì Bioequivalence requirements
- 21 CFR ¬ß 314.94 ‚Äì Content and format of ANDAs
- 21 CFR ¬ß 314.127(a) ‚Äì Grounds for denying an ANDA
- 21 U.S.C. ¬ß 355(j) ‚Äì Abbreviated new drug applications (ANDA)
- FDCA Sections 505(b)(2) and 505(j)
- Public Law 108-173 (MMA of 2003)",,"Granted Requests: FDA agreed to apply enhanced bioequivalence requirements (including in vitro dissolution, characterization, and physicochemical comparisons) to ANDAs referencing Vancocin¬Æ due to its locally acting nature and complex formulation.
- Denied Requests: FDA declined to require in vivo clinical trials, stating they were not necessary given the available scientific evidence.
- FDA also denied requests to withhold approval of ANDAs pending further rulemaking or advisory committee input, asserting that its current review and approval procedures for generics are legally and scientifically appropriate.
- The agency reaffirmed that its bioequivalence guidance already reflects appropriate safeguards and that new legislative requirements (e.g., for MMA-related exclusivity) do not support delaying ANDA review or approval.",partially approved / denied,True,14.0,CDER,CDER
fda-2010-p-0614,FDA-2010-P-0614-0061_West_Ward_Pharmaceutical_Corporation__Arnall_Golde,2011-05-04,2010,False,original petition,West-Ward Pharmaceutical Corp.,industry/corporation,"21 U.S.C. ¬ß 355(b)(2)(A) (applicability of patent certification)
- 21 C.F.R. ¬ß 314.53(c)(2)(P) (use code requirements)
- 21 C.F.R. ¬ß 314.54(f) (request disputing patent listing)
- 21 U.S.C. ¬ß 355(q)(1)(E) (petition delay provision)","FDA‚Äôs interpretation and implementation of the patent certification requirement under 21 U.S.C. ¬ß 355(b)(2)(A), especially in relation to West-Ward‚Äôs NDA for colchicine and its non-reliance on Mutual‚Äôs clinical investigations","West-Ward requests that FDA summarily deny Mutual Pharmaceutical Company‚Äôs citizen petition that allegedly aims to delay FDA‚Äôs approval of West-Ward‚Äôs NDA. Additionally, West-Ward seeks clarification from FDA regarding its ability to file a statement under ¬ß 505(b)(2)(B) and challenges the accuracy of Mutual‚Äôs use code descriptions.","West-Ward argues its NDA does not rely on clinical studies by Mutual, and therefore is not required to file patent certifications for Mutual‚Äôs patents.
- Cites an FDA brief from 2004 (King Pharmaceuticals case) stating reliance is required to trigger certification.
- Criticizes Mutual‚Äôs broad and allegedly misleading use code descriptions that do not accurately reflect patent claims.
- Points to Mutual‚Äôs legal actions (patent infringement and false advertising suits) as evidence that their petition is a strategic delay tactic, not a scientifically grounded challenge.
- Asserts that Mutual‚Äôs petition is part of a monopoly-preserving ‚Äúlife-cycle management‚Äù strategy using regulatory exclusivities and multiple patents. ",,"Partially Approved / Partially Denied
The FDA granted some of ViroPharma‚Äôs requests regarding review of ANDAs referencing Vancocin¬Æ (vancomycin HCl) Capsules, but denied others",2011-05-25,0.0,"Center for Drug Evaluation and Research (CDER)
Signed by: Janet Woodcock, M.D., Director","21 CFR ¬ß 10.30 ‚Äì Citizen petition procedure
- 21 CFR Part 320 ‚Äì Bioequivalence requirements
- 21 CFR ¬ß 314.94 ‚Äì Content and format of ANDAs
- 21 CFR ¬ß 314.127(a) ‚Äì Grounds for denying an ANDA
- 21 U.S.C. ¬ß 355(j) ‚Äì Abbreviated new drug applications (ANDA)
- FDCA Sections 505(b)(2) and 505(j)
- Public Law 108-173 (MMA of 2003)",,"Granted Requests: FDA agreed to apply enhanced bioequivalence requirements (including in vitro dissolution, characterization, and physicochemical comparisons) to ANDAs referencing Vancocin¬Æ due to its locally acting nature and complex formulation.
- Denied Requests: FDA declined to require in vivo clinical trials, stating they were not necessary given the available scientific evidence.
- FDA also denied requests to withhold approval of ANDAs pending further rulemaking or advisory committee input, asserting that its current review and approval procedures for generics are legally and scientifically appropriate.
- The agency reaffirmed that its bioequivalence guidance already reflects appropriate safeguards and that new legislative requirements (e.g., for MMA-related exclusivity) do not support delaying ANDA review or approval.",partially approved / denied,True,21.0,CDER,CDER
fda-2010-p-0614,FDA-2010-P-0614-0028_West_Ward_Pharmaceutical_Group__Arnall_Golden_Greg.pdf,2011-04-14,2010,False,original petition,West-Ward Pharmaceutical Corp.,industry/corporation,"Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (as seen in cited guidance)
- 21 C.F.R. 10.30 is not explicitly cited in the appendix document, but may be relevant in broader petition context.
- Multiple regulatory references such as FDA guidance, summary reviews, and Federal Register notices (e.g., 75 Fed. Reg. 60,768)","Notice of Single-Ingredient Oral Colchicine Products; Enforcement Action Dates (as published in 75 Fed. Reg. 60,768 on October 1, 2010)","While the appendix itself does not state the request explicitly, it supplements a March 16, 2011 comment‚Äîlikely requesting the FDA to reconsider enforcement actions or approvals regarding colchicine products. The requested action was likely to oppose exclusive approval or enforcement action favoring a single manufacturer of colchicine.","The supplemental appendix includes:
- Scientific studies on colchicine efficacy and history.
- Regulatory documents and past correspondences (e.g., letters from FDA and other stakeholders).
- Legal cases relevant to drug approval and market access.
- Media articles highlighting cost implications and controversy over exclusive FDA approval for colchicine.

Inference: The justification revolves around the historical use of colchicine, its unapproved status, sudden price increases, and potential anticompetitive implications of exclusivity. ",,"Partially Approved / Partially Denied
The FDA granted some of ViroPharma‚Äôs requests regarding review of ANDAs referencing Vancocin¬Æ (vancomycin HCl) Capsules, but denied others",2011-05-25,0.0,"Center for Drug Evaluation and Research (CDER)
Signed by: Janet Woodcock, M.D., Director","21 CFR ¬ß 10.30 ‚Äì Citizen petition procedure
- 21 CFR Part 320 ‚Äì Bioequivalence requirements
- 21 CFR ¬ß 314.94 ‚Äì Content and format of ANDAs
- 21 CFR ¬ß 314.127(a) ‚Äì Grounds for denying an ANDA
- 21 U.S.C. ¬ß 355(j) ‚Äì Abbreviated new drug applications (ANDA)
- FDCA Sections 505(b)(2) and 505(j)
- Public Law 108-173 (MMA of 2003)",,"Granted Requests: FDA agreed to apply enhanced bioequivalence requirements (including in vitro dissolution, characterization, and physicochemical comparisons) to ANDAs referencing Vancocin¬Æ due to its locally acting nature and complex formulation.
- Denied Requests: FDA declined to require in vivo clinical trials, stating they were not necessary given the available scientific evidence.
- FDA also denied requests to withhold approval of ANDAs pending further rulemaking or advisory committee input, asserting that its current review and approval procedures for generics are legally and scientifically appropriate.
- The agency reaffirmed that its bioequivalence guidance already reflects appropriate safeguards and that new legislative requirements (e.g., for MMA-related exclusivity) do not support delaying ANDA review or approval.",partially approved / denied,True,41.0,CDER,CDER
fda-2010-p-0614,FDA-2010-P-0614-0023_Mutual_Pharmaceutical_Company__Inc___Sidley_Austin.pdf,2011-03-07,2010,False,original petition,"Mutual Pharmaceutical Company, Inc.",industry/corporation,"Section 505(q) of the Federal Food, Drug, and Cosmetic Act (FDCA)
- 21 C.F.R. ¬ß 10.30 and 10.35 (citizen petition procedures)","Consideration of West-Ward Pharmaceutical Corp.'s March 2, 2011 comment, which allegedly lacked the required verification under ¬ß 505(q). Mutual requested FDA to remove that comment from the docket","Mutual requested the FDA to remove West-Ward‚Äôs March 2, 2011 comment from the docket because it lacked the required verification statement under ¬ß 505(q)(1)(I)","Mutual argued that:
- The original citizen petition is subject to ¬ß 505(q), and thus any subsequent comments (like West-Ward‚Äôs) must include a verification.
- West-Ward‚Äôs comment lacked this verification.
- Under the FDCA, the FDA ‚Äúshall not accept for review‚Äù such comments.
- Therefore, to avoid confusion and preserve the administrative record, FDA must disregard and remove the deficient comment",,"Partially Approved / Partially Denied
The FDA granted some of ViroPharma‚Äôs requests regarding review of ANDAs referencing Vancocin¬Æ (vancomycin HCl) Capsules, but denied others",2011-05-25,0.0,"Center for Drug Evaluation and Research (CDER)
Signed by: Janet Woodcock, M.D., Director","21 CFR ¬ß 10.30 ‚Äì Citizen petition procedure
- 21 CFR Part 320 ‚Äì Bioequivalence requirements
- 21 CFR ¬ß 314.94 ‚Äì Content and format of ANDAs
- 21 CFR ¬ß 314.127(a) ‚Äì Grounds for denying an ANDA
- 21 U.S.C. ¬ß 355(j) ‚Äì Abbreviated new drug applications (ANDA)
- FDCA Sections 505(b)(2) and 505(j)
- Public Law 108-173 (MMA of 2003)",,"Granted Requests: FDA agreed to apply enhanced bioequivalence requirements (including in vitro dissolution, characterization, and physicochemical comparisons) to ANDAs referencing Vancocin¬Æ due to its locally acting nature and complex formulation.
- Denied Requests: FDA declined to require in vivo clinical trials, stating they were not necessary given the available scientific evidence.
- FDA also denied requests to withhold approval of ANDAs pending further rulemaking or advisory committee input, asserting that its current review and approval procedures for generics are legally and scientifically appropriate.
- The agency reaffirmed that its bioequivalence guidance already reflects appropriate safeguards and that new legislative requirements (e.g., for MMA-related exclusivity) do not support delaying ANDA review or approval.",partially approved / denied,True,79.0,CDER,CDER
fda-2010-p-0614,FDA-2010-P-0614-0007_Sidley_Austin__LLP__Mutual_Pharmaceutical_Company_.pdf,2010-12-23,2010,False,original petition,"Mutual Pharmaceutical Company, Inc.",industry/corporation,"FDA NDA regulations (e.g., NDA 22-353, 22-352, 22-351)
- No direct citation of 505(q) or 21 C.F.R. ¬ß 10.30 in this supplement, but these are known to apply in the broader docket","The petition broadly addresses FDA's treatment of unapproved colchicine products, referencing:
- Open letters from Janet Woodcock
- FDA safety alerts
- NDA reviews and pre-IND meeting documents","Not explicitly stated in this supplemental document, but consistent with the broader docket's theme, the original petition likely requested the FDA to deny competing applications or take action related to unapproved colchicine products. This supplement provides supporting evidence for those requests.","The supplement provides extensive scientific, regulatory, and legal references, including:
- FDA clinical and pharmacology reviews
- Safety alerts on colchicine
- Correspondence regarding related drug dockets
- Medical literature on gout and colchicine efficacy

This serves to bolster the original petition‚Äôs stance that certain applications/products should not be approved or allowed market entry based on safety, regulatory precedent, and public health concerns",,"Partially Approved / Partially Denied
The FDA granted some of ViroPharma‚Äôs requests regarding review of ANDAs referencing Vancocin¬Æ (vancomycin HCl) Capsules, but denied others",2011-05-25,0.0,"Center for Drug Evaluation and Research (CDER)
Signed by: Janet Woodcock, M.D., Director","21 CFR ¬ß 10.30 ‚Äì Citizen petition procedure
- 21 CFR Part 320 ‚Äì Bioequivalence requirements
- 21 CFR ¬ß 314.94 ‚Äì Content and format of ANDAs
- 21 CFR ¬ß 314.127(a) ‚Äì Grounds for denying an ANDA
- 21 U.S.C. ¬ß 355(j) ‚Äì Abbreviated new drug applications (ANDA)
- FDCA Sections 505(b)(2) and 505(j)
- Public Law 108-173 (MMA of 2003)",,"Granted Requests: FDA agreed to apply enhanced bioequivalence requirements (including in vitro dissolution, characterization, and physicochemical comparisons) to ANDAs referencing Vancocin¬Æ due to its locally acting nature and complex formulation.
- Denied Requests: FDA declined to require in vivo clinical trials, stating they were not necessary given the available scientific evidence.
- FDA also denied requests to withhold approval of ANDAs pending further rulemaking or advisory committee input, asserting that its current review and approval procedures for generics are legally and scientifically appropriate.
- The agency reaffirmed that its bioequivalence guidance already reflects appropriate safeguards and that new legislative requirements (e.g., for MMA-related exclusivity) do not support delaying ANDA review or approval.",partially approved / denied,True,153.0,CDER,CDER
fda-2010-p-0613,FDA-2010-P-0613-0001_Watson_Laboratories__Inc____Citizen_Petition.pdf,2010-11-23,2010,False,original petition,"Watson Laboratories, Inc.",industry/corporation,"Federal Food, Drug, and Cosmetic Act (FDC Act)
- 21 C.F.R. ¬ß 10.30 (FDA‚Äôs citizen petition regulation)
- 21 C.F.R. ¬ß¬ß 314.94(a)(7), 314.127(a)(6)(i) (ANDA bioequivalence requirements)
- 21 C.F.R. ¬ß 320.1(e) and ¬ß 320.24(c) (bioavailability and bioequivalence)",The petition urges FDA to apply additional bioequivalence criteria when evaluating any ANDA submitted for a generic version of Watson‚Äôs ANDRODERM product. It specifically addresses FDA‚Äôs standard reliance on AUC and Cmax in determining bioequivalence,"FDA should not approve any ANDA for generic ANDRODERM unless the sponsor demonstrates:
- Bioequivalence based not only on AUC and Cmax,
- But also on Tmax for testosterone and its major active metabolite, DHT","Watson asserts that:
- ANDRODERM is uniquely designed to replicate the circadian rhythm of testosterone levels in healthy men, with peak levels in the early morning.
- Bioequivalence based solely on AUC and Cmax is insufficient to ensure safety and therapeutic equivalence.
- Tmax is critical for therapeutic efficacy and appropriate dose titration.
- A different Tmax could lead to inappropriate titration, potentially causing overdosing and serious safety risks due to altered testosterone profiles.
- FDA has previously recognized that standard PK criteria are not always sufficient, and in similar cases required additional PK measures like partial AUCs",,Denied,2014-02-10,0.0,"Center for Drug Evaluation and Research (CDER)
Signed by: Janet Woodcock, M.D., Director","21 U.S.C. ¬ß 355(j) ‚Äì Section 505(j) of the FD&C Act (Hatch-Waxman Amendments)
- 21 CFR Part 320, specifically 21 CFR 320.24
- FD&C Act section 505(j)(2)(A)(iv)
- FD&C Act section 505(j)(2)(A)
- FD&C Act section 505(j)(4)
- Legal references: Schering Corp. v. FDA, 51 F.3d 390 (3d Cir. 1995); Fisons Corp. v. Shalala, 860 F. Supp. 859 (D.D.C. 1994)",,"Tmax is a discrete variable and not suited for the same statistical bioequivalence evaluation as AUC and Cmax.
- FDA policy does not require statistical criteria for Tmax due to its high variability and lack of clinical significance shown in this case.
- DHT is not required for bioequivalence testing as testosterone is the main active compound; DHT is a metabolite and contributes minimally to efficacy/safety.
- Labeling of Androderm does not specify consistent timing for testosterone measurement, creating natural variability.
- Bioequivalence is assessed holistically in the ANDA process, including clinical pharmacokinetic profile reviews.
- Cited guidance recommends using the parent drug for bioequivalence, not metabolites like DHT.",denied,True,1175.0,CDER,CDER
fda-2010-p-0610,FDA-2010-P-0610-0002_Dr__Richard_F__Edlich___Citizen_Petition.pdf,2010-11-23,2010,False,original petition,"Dr. Richard F. Edlich, MD, PhD ‚Äî Distinguished Professor Emeritus of Plastic Surgery, Biomedical Engineering, and Emergency Medicine at the University of Virginia Health System",advocacy/academic,"21 C.F.R. ¬ß 10.30 (Citizen petition regulation)
- 21 C.F.R. ¬ß 5.10 (Delegation of authority)
- 21 C.F.R. ¬ß¬ß 872.3920, 872.3070, 872.3060, 872.3200 (Device classification regulations for dental materials including mercury, amalgams, and tooth bonding agents)","FDA‚Äôs classification of dental amalgam and liquid mercury as Class II medical devices, and its regulatory inaction on reclassifying them despite associated health concerns","The petitioner requests FDA to revise the classification of dental restorative materials and liquid mercury, particularly dental amalgam, and reclassify them to a more restrictive category due to their associated health risks","Health Concerns: Mercury is neurotoxic and has been linked to a wide range of health issues including MS, autism, Alzheimer‚Äôs, cardiovascular issues, and kidney damage.
- Environmental Impact: Mercury from dental offices contributes significantly to environmental contamination and enters aquatic ecosystems, leading to methylmercury accumulation in seafood.
- Legal and Regulatory Developments: References a lawsuit settlement with FDA (2008) that prompted revisions to its public stance on mercury amalgam. Despite this, mercury fillings are still classified as Class II devices.
- International Perspective: Notes that other countries follow a precautionary principle and discourage use of mercury amalgams in vulnerable populations like pregnant women.
- Economic Efficiency: Argues that restricting mercury use and installing amalgam separators in dental offices is cost-effective and already required in some U.S. states",2011-06-02 00:00:00,Closed,2018-04-10,1.0,Center for Devices and Radiological Health (CDRH),21 CFR ¬ß 10.30(e)(3) ‚Äì FDA regulation requiring that ‚Äúthe petitioner is to be notified of the Commissioner's decision‚Äù,"The petition raised complex issues including a request to ban mercury amalgam and revise classification of dental materials.
- The Dental Products Panel advisory committee met in December 2010 to assess relevant scientific evidence.
- Due to the complexity and recommendations, further review is ongoing, and FDA has not yet reached a decision.","The petitioner, Dr. Richard Edlich, passed away on December 25, 2013.
- As a result, the FDA determined there was no viable recipient for the decision notification, and therefore, the petition was closed administratively rather than acted upon substantively.",other,True,2695.0,CDRH,CDRH
fda-2010-p-0604,FDA-2010-P-0604-0001_Lachman_Consultant_Services_Inc_____Citizen_Petiti.pdf,2010-11-19,2010,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"21 C.F.R. ¬ß 10.30 (Citizen petition procedure)
- 21 C.F.R. ¬ß 314.161 (Procedure for determining withdrawal from sale)
- 21 C.F.R. ¬ß 314.162 (Drug application withdrawal for safety or effectiveness)",The petition addresses the status of Pitressin¬Æ (vasopressin tannate) Injection in the FDA's Orange Book and requests clarification on whether the drug was withdrawn from the market for safety or efficacy reasons,The petitioner requests that FDA determine whether Pitressin¬Æ Injection (NDA 003402) by Parke-Davis was voluntarily withdrawn or withheld from sale for safety or efficacy reasons,"Pitressin¬Æ Injection was approved prior to January 1, 1982, and had been listed in the Orange Book.
- As of November 18, 2010, the drug was moved to the ""Discontinued"" section and is not available for sale.
- Petitioner believes the withdrawal is for commercial reasons, not due to safety or efficacy concerns.
- FDA must confirm this determination before any ANDA referencing the drug can be approved",,Granted (Determination Made),2012-05-18,0.0,Center for Drug Evaluation and Research (CDER),"21 CFR 10.30 ‚Äì Citizen petition process
- 21 CFR 314.161 ‚Äì Process for determining if a drug was withdrawn for safety or effectiveness reasons
- 21 CFR 314.162 ‚Äì Removal of drugs from the Orange Book
- 21 U.S.C. ¬ß 355(j)(7) ‚Äì Section 505(j)(7) of the FD&C Act",,"FDA reviewed its internal records and found no data suggesting the withdrawal was due to safety or effectiveness.
- An independent review of postmarketing literature and data also revealed no safety concerns.
- The product will remain in the Discontinued Drug Product List of the Orange Book, allowing for ANDA submissions provided other requirements are met.",approved,True,546.0,CDER,CDER
fda-2010-p-0593,FDA-2010-P-0593-0003_Gisela_A__Sharp___Letter.pdf,2010-11-17,2010,False,original petition,"Watson Laboratories, Inc.",industry/corporation,Not Mentioned in this specific letter. The letter is a cover note accompanying photocopies of the original petition and does not detail statutory citations,"The letter relates to a Citizen Petition regarding FENTORA¬Æ, likely addressing its withdrawal status or regulatory classification. The specific FDA action or policy commented on is not detailed in this document",Not explicitly stated in the letter. It references a previously submitted petition but serves only to supply additional documentation (photocopies) for administrative completion,Not Mentioned. The purpose of this document is purely clerical‚Äîproviding missing photocopies from a prior petition submission and offering an apology for the oversight,,Granted (Determination Made),2011-04-11,0.0,	Center for Drug Evaluation and Research (CDER),"21 CFR 314.161 ‚Äì Procedure for withdrawal review

21 CFR 314.162 ‚Äì Orange Book drug list removal

21 U.S.C. ¬ß 355(j)(7) ‚Äì Section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act ",,"The petitioner (Watson Laboratories) submitted no data suggesting safety or effectiveness issues.

FDA independently reviewed its records, literature, and postmarketing data and found no evidence of withdrawal for safety or efficacy reasons.

FDA therefore concluded that the product was discontinued for reasons other than safety or effectiveness and ANDAs may be approved if all other conditions are met.",approved,True,145.0,CDER,CDER
fda-2010-p-0593,FDA-2010-P-0593-0001_Watson_Laboratories__Inc____Citizen_Petition.pdf,2010-11-16,2010,False,original petition,"Watson Laboratories, Inc.",industry/corporation,"21 C.F.R. ¬ß 10.25 (general provisions on citizen petitions)
- 21 C.F.R. ¬ß 10.30 (citizen petition procedure)
- 21 C.F.R. ¬ß 314.161 (determination of drug withdrawal for safety or effectiveness)
- 21 C.F.R. ¬ß 314.162(a) (conditions under which an NDA may be withdrawn)
- 21 C.F.R. ¬ß 25.31 (environmental impact exclusion)",The FDA‚Äôs classification of FENTORA¬Æ 300 mcg as a discontinued product in the Orange Book. Watson is requesting clarification on whether the discontinuation was due to safety or effectiveness concerns,"FDA should determine whether Cephalon‚Äôs FENTORA¬Æ 300 mcg tablet was withdrawn for reasons unrelated to safety or efficacy.
- FDA should affirm that ANDAs for 300 mcg FENTORA¬Æ are eligible for approval if they meet all other regulatory requirements","FENTORA¬Æ 300 mcg was approved on March 2, 2007, but now appears in the ‚ÄúDiscontinued Drug Products‚Äù section of the Orange Book.
- Watson states it is unaware of any evidence that the product was withdrawn for safety or efficacy reasons.
- FDA must make a formal determination under 21 C.F.R. ¬ß 314.161 before approving ANDAs for such discontinued products.
- If Cephalon resumes marketing, Watson agrees the petition becomes moot",,Granted (Determination Made),2011-04-11,0.0,	Center for Drug Evaluation and Research (CDER),"21 CFR 314.161 ‚Äì Procedure for withdrawal review

21 CFR 314.162 ‚Äì Orange Book drug list removal

21 U.S.C. ¬ß 355(j)(7) ‚Äì Section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act ",,"The petitioner (Watson Laboratories) submitted no data suggesting safety or effectiveness issues.

FDA independently reviewed its records, literature, and postmarketing data and found no evidence of withdrawal for safety or efficacy reasons.

FDA therefore concluded that the product was discontinued for reasons other than safety or effectiveness and ANDAs may be approved if all other conditions are met.",approved,True,146.0,CDER,CDER
fda-2010-p-0592,FDA-2010-P-0592-0002_University_of_Virginia_Health_Systems___Citizen_Pe.pdf,2010-11-17,2010,False,original petition,"Dr. Richard F. Edlich, MD, PhD ‚Äî Distinguished Professor Emeritus, University of Virginia Health System",advocacy/academic,"21 C.F.R. ¬ß 10.30 (Citizen petition process)
- 21 C.F.R. ¬ß 5.10 (Delegation of authority)","FDA‚Äôs failure to restrict or ban the sale of liquid mercury to consumers in the U.S., while permitting companies like DF Goldsmith Chemical & Metal Corp. to market it directly",Ban the sale of liquid mercury to consumers by manufacturers in the U.S.,"Toxicity of Mercury: Mercury exposure causes severe health risks; elemental and methylmercury are both toxic, with potential effects on neurological and organ health.
- Regulatory Inconsistency: FDA classifies a 50-pound bag of cornstarch as a Class III device not available to consumers, yet allows the public sale of liquid mercury‚Äîa substance acknowledged as toxic by its own manufacturers.
- Environmental and Economic Cost: Mercury emissions cause long-term environmental damage. Studies estimate up to $3.7 billion/year in societal IQ loss costs from methyl mercury exposure by 2020. Benefits from reduced emissions are estimated at $1.8‚Äì2.2 billion/year
.
- Failure of Oversight: FDA‚Äôs lack of enforcement allows public access to dangerous substances without adequate consumer protection or classification.",,Denied ‚Äì The FDA denied the petition to ban the sale of elemental mercury to consumers.,2011-06-02,0.0,"Center for Devices and Radiological Health (CDRH) ‚Äì Interim response signed by Nancy K. Stade, Deputy Director for Policy.
Office of the Commissioner ‚Äì Final response signed by Leslie Kux, Acting Assistant Commissioner for Policy.","21 CFR ¬ß 872.3070 ‚Äì Device classification for elemental mercury.
- 21 CFR ¬ß 801.5, ¬ß 801.109, ¬ß 801.110, ¬ß¬ß 801.109-.127 ‚Äì Labeling and prescription device exemptions.
- Section 201(h) of the Federal Food, Drug, and Cosmetic Act ‚Äì Definition of a medical device.
- Section 502(f)(1) of the Act (21 U.S.C. ¬ß 353(b)(1)) ‚Äì Labeling requirements.
- Section 301(a) of the Act (21 U.S.C. ¬ß 331(a)) ‚Äì Prohibition of interstate commerce of misbranded devices.",,"Elemental mercury used in dental amalgam is regulated as a Class II medical device, requiring prescription-only distribution.
- Such mercury is not sold directly to consumers under FDA regulations.
- Because it is already restricted to prescription use, the FDA concluded that a ban was unnecessary.
- Any sales not meeting prescription requirements would constitute misbranding and be prohibited from interstate commerce.",denied,True,197.0,CDRH,CDRH
fda-2010-p-0581,FDA-2010-P-0581-0001_Lachman_Consultant_Services__Inc____Citizen_Petiti.pdf,2010-11-11,2010,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"Section 505(j) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 10.20 and ¬ß 10.30 (Citizen Petition regulations)
- 21 C.F.R. ¬ß 314.94(a)(9)(iii) (ANDA requirements)
- 21 C.F.R. ¬ß 25.31 (Environmental impact exclusions)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact submission provision)","FDA‚Äôs designation of a single Reference Listed Drug (RLD) for Oxaliplatin Injection 5 mg/mL‚Äîspecifically, only Sanofi Aventis‚Äô Eloxatin (NDA 021759)‚Äîwhich excludes Teva‚Äôs product (NDA 022160) from being used as a reference for ANDAs",The petitioner requests that FDA designate Teva‚Äôs Oxaliplatin Injection (NDA 022160) as a second RLD in the Orange Book to allow generic applicants to reference it for ANDA submissions,"Formulation Difference: Teva‚Äôs product contains lactose, unlike Sanofi‚Äôs Eloxatin which contains only water for injection; thus, it is not currently considered interchangeable under existing ANDA rules.
- Regulatory Barrier: FDA‚Äôs current RLD designation prevents ANDA applicants from referencing the Teva product, limiting competition.
- Market Access: The current RLD designation shields the Teva product from competition, despite it being pharmaceutically equivalent (same active ingredient, dosage form, strength, and route).
- Regulatory Precedent: FDA has the authority to designate more than one RLD in situations where products are not therapeutically interchangeable due to inactive ingredient differences",2011-05-04 00:00:00,Approved ‚Äì The FDA granted the petition to designate Teva‚Äôs Oxaliplatin (NDA 022160) as an additional Reference Listed Drug (RLD),2012-03-20,1.0,"Center for Drug Evaluation and Research (CDER) ‚Äì Signed by Janet Woodcock, M.D., Director","Section 505(j) of the FD&C Act (21 U.S.C. ¬ß 355)
- Sections 505(j)(2)(A), (j)(2)(C), and (j)(4)
- 21 CFR ¬ß 314.3
- 21 CFR ¬ß 314.94(a)(9)(iii)","The FDA had not reached a decision due to the need to address other Agency priorities.
- The letter assured that a full response would follow once resources allowed.","The petition requested RLD designation for Teva‚Äôs Oxaliplatin to allow ANDA applicants to use it directly instead of Eloxatin.
- Though Teva‚Äôs product is AP-rated to Eloxatin, it contains lactose, unlike Eloxatin, making it qualitatively different.
- Because ANDAs must be qualitatively and quantitatively the same as the RLD, generic applicants could not reference Teva‚Äôs formulation if only Eloxatin was designated.
- The FDA agreed it is in the public interest to designate Teva‚Äôs Oxaliplatin as an additional RLD to promote fair competition and accessibility.",approved,True,495.0,CDER,CDER
fda-2010-p-0580,FDA-2010-P-0580-0005_Houssiere_Durant_Houssiere__LLP___Letter.pdf,2011-04-26,2010,False,original petition,Houssiere Durant Houssiere LLP,law/consulting,Not explicitly cited in this specific follow-up letter; may be included in the original petition or attached Exhibit A (not present in this file),"The FDA's approval of a PMA supplement for application P980022/S013, which relates to the Medtronic MiniMed MMT515/715 insulin pump and Guardian RT sensor. The concern is over how the FDA interpreted and conveyed limitations in its April 7, 2006 approval letter","The petitioner requests that the FDA clarify the April 7, 2006 approval letter by adding a sentence that explicitly states:
""This approval is limited solely to the ability of the pump to accept data from the sensor and the ability for the sensor to communicate directly to the pump, and this approval does not extend to the pump itself.""","The petitioner asserts that the requested language does not add new limitations, but reiterates the FDA‚Äôs original intent in the April 7, 2006 letter.
- There is concern that Medtronic misinterpreted the scope of the FDA‚Äôs approval, potentially believing it covers the entire pump, not just the added functionality.
- Therefore, the clarification is needed to avoid misuse or mischaracterization of the FDA‚Äôs approval scope",,Denied ‚Äì The FDA denied the petition to amend the original PMA approval letter with additional limiting language regarding the device scope,2011-09-20,0.0,"Center for Devices and Radiological Health (CDRH) ‚Äì While the signature is from Leslie Kux, Acting Assistant Commissioner, the content pertains to PMA approval, placing it under CDRH's purview","21 U.S.C. ¬ß 360e(d)(6)(A) ‚Äì Requirement for PMA supplement for changes affecting safety or effectiveness
- 21 U.S.C. ¬ß 360e(d)(6)(B)(i) ‚Äì Criteria for PMA supplement approval
- 21 C.F.R. ¬ß 814.39(a) ‚Äì PMA supplement regulations",,"The Paradigm Real Time System (Pump + Sensor) was approved as a whole through PMA supplement P980022/S013.
- Petitioners requested language to narrow the scope of approval.
- FDA found that the existing approval letter already sufficiently covers the scope and provides a reasonable assurance of safety and effectiveness for the entire system.
- Therefore, no amendment was necessary and the petition was denied.",denied,True,147.0,CDRH,CDRH
fda-2010-p-0580,FDA-2010-P-0580-0001_Bracewell___Giuliani__LLP___Citizen_Petition.pdf,2010-11-09,2010,False,original petition,Judith Duggan (the Petitioner),individual,"21 C.F.R. ¬ß 10.30 (Citizen Petition regulation)
- 21 C.F.R. ¬ß 10.30(b) (economic impact provision)
No mention of 505(q)","The FDA‚Äôs April 7, 2006 approval letter of PMA supplement P980022/S013, which approved modifications to the Medtronic MMT515/715 insulin pump and Guardian RT sensor to allow communication between the devices","Petitioner requests the FDA clarify the Approval Letter by adding this statement:
‚ÄúThis approval is limited solely to the ability of the pump to accept data from the sensor and the ability for the sensor to communicate directly to the pump, and this approval does not extend to the pump itself.‚Äù","Petitioner suffered injury using the Medtronic Paradigm 522 insulin pump (without the sensor).
- Medtronic claims PMA status for the entire 522 System, thus asserting preemption from liability under Riegel v. Medtronic, Inc.
- Petitioner argues that only the sensor-pump communication received PMA approval, while the insulin pump mechanism was cleared under the 510(k) process and was never evaluated for safety or efficacy under the PMA process.
- Medtronic‚Äôs own application confirms that the delivery mechanism was unchanged and identical to the previously cleared MMT-515/715 models.
- The requested clarification would help preserve legal recourse for pump-related harm and ensure the FDA‚Äôs approval is not misinterpreted",2011-04-14 00:00:00,Denied ‚Äì The FDA denied the petition to amend the original PMA approval letter with additional limiting language regarding the device scope,2011-09-20,1.0,"Center for Devices and Radiological Health (CDRH) ‚Äì While the signature is from Leslie Kux, Acting Assistant Commissioner, the content pertains to PMA approval, placing it under CDRH's purview","21 U.S.C. ¬ß 360e(d)(6)(A) ‚Äì Requirement for PMA supplement for changes affecting safety or effectiveness
- 21 U.S.C. ¬ß 360e(d)(6)(B)(i) ‚Äì Criteria for PMA supplement approval
- 21 C.F.R. ¬ß 814.39(a) ‚Äì PMA supplement regulations","The petition requested that FDA clarify the PMA approval letter dated April 7, 2006, for PMA supplement P980022/S013 to include language that expresses limitations.
- FDA had not made a decision because the petition raised complex issues requiring further review and analysis by agency officials.
- The interim response was issued due to delays stemming from other agency priorities.","The Paradigm Real Time System (Pump + Sensor) was approved as a whole through PMA supplement P980022/S013.
- Petitioners requested language to narrow the scope of approval.
- FDA found that the existing approval letter already sufficiently covers the scope and provides a reasonable assurance of safety and effectiveness for the entire system.
- Therefore, no amendment was necessary and the petition was denied.",denied,True,315.0,CDRH,CDRH
fda-2010-p-0579,FDA-2010-P-0579-0001_Actavis__Inc____Citizen_Petition.pdf,2010-11-09,2010,False,original petition,Actavis Inc.,industry/corporation," 21 C.F.R. ¬ß 10.30 (Citizen petition procedure)
- 21 C.F.R. ¬ß 314.161 (Determination of withdrawal from sale for safety or effectiveness)
- 21 C.F.R. ¬ß 314.122 (ANDA submission standards for discontinued RLDs)
- 21 C.F.R. ¬ß 25.31 (Environmental impact exemption)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact provisions)","FDA‚Äôs classification of Nuvigil¬Æ (armodafinil) Tablets, 100 mg and 200 mg as discontinued in the Orange Book, and whether this was due to safety or efficacy concerns","Actavis requests that the FDA determine that Nuvigil¬Æ Tablets (100 mg and 200 mg) were not withdrawn for reasons of safety or effectiveness, thereby allowing ANDA applicants to reference the product","Nuvigil¬Æ Tablets (NDA 21-875) were approved in March 2009 and discontinued around February 2010.
- There is no evidence of safety or efficacy issues causing the discontinuation.
- Under FDA rules, ANDAs referencing discontinued RLDs require confirmation that the withdrawal was not for safety/effectiveness reasons.
- Petitioner is seeking this determination to proceed with a generic ANDA submission for these strengths",2011-05-06 00:00:00,"Approved ‚Äì The FDA determined that Nuvigil (armodafinil) Tablets, 100 mg and 200 mg, were not withdrawn for safety or effectiveness reasons, thereby granting the petition.",2011-06-27,1.0,"Center for Drug Evaluation and Research (CDER) ‚Äì Signed by Molly M. Flannery, Office of Regulatory Policy","21 U.S.C. ¬ß 355(j)(7) ‚Äì Listing requirement for approved drugs.
- 21 CFR ¬ß 314.161 ‚Äì Determination that a drug was not withdrawn for safety or effectiveness.
- 21 CFR ¬ß 314.162 ‚Äì Removal of listed drugs.","The petition requested a determination that Nuvigil (armodafinil) 100 mg and 200 mg tablets were not voluntarily withdrawn for safety or efficacy reasons.
- FDA stated that it had not reached a decision because the petition required additional review and other priorities were pending.
- The response confirms FDA‚Äôs intent to issue a decision as soon as resources allow.","FDA reviewed its internal records, literature, and postmarketing data.
- Found no evidence that Nuvigil 100 mg and 200 mg tablets were withdrawn for safety or effectiveness.
- As a result, the drug remains listed in the ""Discontinued Drug Product List"" section of the Orange Book, allowing ANDA submissions.",approved,True,230.0,CDER,CDER
fda-2010-p-0578,FDA-2010-P-0578-0001_Dwayne_A__Ratleff___Citizen_Petition,2010-11-04,2010,False,original petition,Dwayne A. Ratleff,individual,"21 CFR ¬ß 5.10 (Delegation of authority)
- 21 U.S.C. ¬ß 321(qq) (Definition of major food allergens under FDCA)
- 21 CFR ¬ß 25.30 (Environmental impact categorical exclusion)",Lack of existing FDA regulation requiring advisory labeling when manufacturers add new allergens to existing food products currently in the market,"The petitioner requests the FDA to create a new regulation that requires food manufacturers to display an advisory statement ‚Äî ""Ingredient Information Has Changed"" ‚Äî prominently on the primary display panel when a major food allergen (as defined by FDCA) is newly added to a product previously free of that allergen","Food allergies affect approximately 2% of adults and 5% of children in the U.S.
- Consumers often do not reread food labels for products they‚Äôve used safely for months or years.
- Life-threatening reactions (anaphylaxis) lead to an estimated 30,000 ER visits, 2,000 hospitalizations, and 150 deaths annually in the U.S.
- Adding a visible warning label when allergens are introduced provides a critical cue for allergic consumers to recheck labels.
- Though manufacturers may face inconvenience, the potential for preventing serious health incidents outweighs that burden",2011-05-04 00:00:00,,2025-10-15,1.0,,,"The petition requested a new regulation requiring food manufacturers to display ‚ÄúIngredient Information Has Changed‚Äù on labels when a major allergen is newly added to the formulation.
- FDA acknowledged the request but explained that a final decision could not be made within the required timeframe due to other agency priorities and resource constraints.
- FDA confirmed the petition would remain under review and be considered in the context of broader program priorities.",,no decision,False,5459.0,pending,pending
fda-2010-p-0577,FDA-2010-P-0577-0003_Gisela_A__Sharp___Letter.pdf,2010-11-17,2010,False,original petition,"Watson Laboratories, Inc.",industry/corporation,Not Mentioned in this letter (The letter is administrative in nature and does not cite any regulatory provisions directly),Not Specified in the letter. It serves only to provide missing photocopies of the original petition on NUVIGIL and apologizes for the omission,No regulatory action is requested in this follow-up letter. The purpose is strictly to submit missing photocopies for completeness of the previously filed Citizen Petition,The petitioner acknowledges that photocopies of the original petition were inadvertently omitted in the initial submission and sends three copies to rectify this oversight. The goal is to ensure completeness of the petition file,2011-05-06 00:00:00,"Approved ‚Äì FDA determined that NUVIGIL (armodafinil) Tablets, 100 mg and 200 mg, were not withdrawn for reasons of safety or effectiveness.",2011-07-22,1.0,"Center for Drug Evaluation and Research (CDER) ‚Äì Contact listed is Molly Flannery, CDER, FDA","21 CFR ¬ß 314.161 ‚Äì Procedures for determining withdrawal from sale.
- 21 CFR ¬ß 314.162 ‚Äì Removal of drug products for safety or effectiveness reasons.
- 21 CFR ¬ß 10.30 ‚Äì Citizen petition process.
- 21 U.S.C. ¬ß 355(j)(7) ‚Äì Drug listing under the FD&C Act.","The petition requested a determination on whether Nuvigil (armodafinil) 100 mg and 200 mg tablets were withdrawn for reasons of safety or effectiveness.
- FDA indicated that it could not reach a decision due to other agency priorities and resource constraints.
- The Agency affirmed it would respond as soon as feasible.","FDA reviewed citizen petitions and internal records, finding no data indicating withdrawal due to safety or effectiveness.
- Independent evaluation of postmarketing data and literature found no adverse information.
- Thus, NUVIGIL remains on the ‚ÄúDiscontinued Drug Product List‚Äù, allowing ANDA submissions if other requirements are met.",approved,True,247.0,CDER,CDER
fda-2010-p-0577,FDA-2010-P-0577-0001_Watson_Laboratories__Inc____Citizen_Petition.pdf,2010-11-09,2010,False,original petition,"Watson Laboratories, Inc.",industry/corporation,"21 CFR ¬ß 10.25 (General petition procedures)
- 21 CFR ¬ß 10.30 (Citizen petition process)
- 21 CFR ¬ß 314.161 (Determination of withdrawal from sale)
- 21 CFR ¬ß 314.162(a) (Basis for removal from Orange Book)
- 21 CFR ¬ß 25.31 (Environmental impact categorical exclusion)
- 21 CFR ¬ß 10.30(b) (Economic impact disclosure)","The FDA‚Äôs reclassification of NUVIGIL‚Ñ¢ (Armodafinil) Tablets, 100 mg and 200 mg from the ""Approved Prescription Drug Products"" section to the ""Discontinued Drug Products"" section of the Orange Book, and whether this reclassification was for safety or effectiveness reasons","1. Determine that Cephalon‚Äôs withdrawal of NUVIGIL‚Ñ¢ 100 mg and 200 mg tablets was not due to safety or efficacy concerns.
2. Confirm that Abbreviated New Drug Applications (ANDAs) for these strengths of NUVIGIL‚Ñ¢ are eligible for approval if all other legal and regulatory criteria are met","NUVIGIL‚Ñ¢ 100 mg and 200 mg were originally approved by FDA on March 26, 2009.
- They were later moved to the Discontinued Products section (noted in the Orange Book Cumulative Supplement 7, July 2010).
- The petitioner (Watson) is unaware of any public safety or efficacy concerns that led to discontinuation.
- FDA must determine the reason for withdrawal before any ANDA may be approved.
- Watson requests this clarification to support its planned ANDA submission",2011-05-06 00:00:00,"Approved ‚Äì FDA determined that NUVIGIL (armodafinil) Tablets, 100 mg and 200 mg, were not withdrawn for reasons of safety or effectiveness.",2011-07-22,1.0,"Center for Drug Evaluation and Research (CDER) ‚Äì Contact listed is Molly Flannery, CDER, FDA","21 CFR ¬ß 314.161 ‚Äì Procedures for determining withdrawal from sale.
- 21 CFR ¬ß 314.162 ‚Äì Removal of drug products for safety or effectiveness reasons.
- 21 CFR ¬ß 10.30 ‚Äì Citizen petition process.
- 21 U.S.C. ¬ß 355(j)(7) ‚Äì Drug listing under the FD&C Act.","The petition requested a determination on whether Nuvigil (armodafinil) 100 mg and 200 mg tablets were withdrawn for reasons of safety or effectiveness.
- FDA indicated that it could not reach a decision due to other agency priorities and resource constraints.
- The Agency affirmed it would respond as soon as feasible.","FDA reviewed citizen petitions and internal records, finding no data indicating withdrawal due to safety or effectiveness.
- Independent evaluation of postmarketing data and literature found no adverse information.
- Thus, NUVIGIL remains on the ‚ÄúDiscontinued Drug Product List‚Äù, allowing ANDA submissions if other requirements are met.",approved,True,255.0,CDER,CDER
fda-2010-p-0574,FDA-2010-P-0574-0001_Citizen_Petiton_from_Beckloff_Associates_Inc_Azur_.pdf,2010-11-02,2010,False,original petition,"Beckloff Associates, Inc.",law/consulting,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 10.30 (Citizen Petition Procedure)
- 21 C.F.R. ¬ß 25.31 (Environmental Impact Exclusion)
- 21 C.F.R. ¬ß 10.30(b) (Economic Impact Submission)",The designation of the 100 mg FazaClo¬Æ (clozapine) orally disintegrating tablet as the Reference Listed Drug (RLD) in the Orange Book. The petitioner seeks to modify this by establishing the 200 mg strength as the RLD,"1. Designate the 200 mg FazaClo¬Æ (clozapine) ODT as the RLD in the FDA Orange Book.
2. Revise the June 2005 FDA Guidance for Industry on clozapine tablets to include 200 mg orally disintegrating tablets in Sections I (Introduction) and V (Waiver Requirements).
3. Require that any ANDA for strengths >100 mg include a bioequivalence study using the 200 mg FazaClo","FDA guidance typically identifies the highest strength of a multi-strength drug as the RLD unless safety concerns exist.
- 81.2% of FDA‚Äôs bioequivalence guidances follow this standard.
- The 200 mg FazaClo¬Æ was approved July 9, 2010 and has been shown safe in clinical use.
- Petitioner argues that it aligns with bioequivalence guidance for using the highest dose strength in studies and biowaivers.
- Revising the Orange Book and guidance would align clozapine regulations with FDA's general practices",2011-05-02 00:00:00,Denied (Both the 2007 and 2010 Petitions were denied),2015-05-06,1.0,Center for Drug Evaluation and Research (CDER),"21 CFR 314.3
- 21 CFR 314.94(a)(7)
- 21 CFR 320.1(e)
- 21 CFR 320.22(d)
- 21 CFR 320.22(e)
- 21 CFR 320.24
- Section 505(j) and (j)(8)(B)(i) of the FD&C Act","The petition requested two actions:
‚ÄÉ(1) Designate the 200 mg FazaClo (clozapine) ODT as the Reference Listed Drug (RLD).
‚ÄÉ(2) Modify FDA guidance to require bioequivalence testing using the 200 mg ODT strength.
- FDA stated that the petition raised complex scientific and regulatory issues requiring further internal review and analysis.
- An interim response was issued due to the statutory requirement to respond within 180 days.","General vs. Product-Specific Guidance: The petition relied on general FDA guidance for food-effect bioavailability studies. FDA emphasized that product-specific guidance for clozapine (due to its unique safety profile) supersedes general recommendations.

- Risks to Healthy Volunteers: FDA does not recommend administering clozapine to healthy individuals due to risks like agranulocytosis, seizures, bradycardia, and syncope.

- Use of Steady-State Studies in Patients: FDA advocates for multiple-dose, steady-state studies in schizophrenic patients, not single-dose fed/fasted studies, because these patients already take clozapine under real-world conditions. Strict fed or fasting requirements were deemed impractical and risky for this population.

- Labeling of FazaClo: FazaClo labeling indicates it can be taken without regard to meals, supporting that a fed bioequivalence study is unnecessary.

- 200-mg RLD Designation Denied: Petitioners requested that the 200 mg FazaClo ODT be designated as the Reference Listed Drug (RLD). FDA denied this because the 100 mg strength offers more dosing flexibility and supports safer and broader patient recruitment for studies. FDA maintained the 100 mg strength as the reference standard",denied,True,1646.0,CDER,CDER
fda-2010-p-0570,FDA-2010-P-0570-0001_Nycomed_US_Inc_Citizen_Petition.pdf,2010-10-29,2010,False,original petition,"Nycomed US Inc. (""Nycomed"")",industry/corporation,"¬ß¬ß 501 and 505 of the Federal Food, Drug, and Cosmetic Act (FDCA)
- 21 C.F.R. ¬ß 10.30 (Citizen Petition)
- 21 C.F.R. ¬ß 10.115 (Good Guidance Practices)
- 21 U.S.C. ¬ß 355(j)(4)(F), ¬ß 355(j)(8)(B)(i), ¬ß 355(j)(8)(C), ¬ß 355a
- 21 C.F.R. ¬ß¬ß 314.127(a)(6), 320.20(e), 320.24(b)(1)
- 21 C.F.R. ¬ß 25.31 (Environmental Impact exclusion)","Approval of any Abbreviated New Drug Application (ANDA) for Cutivate¬Æ (fluticasone propionate) Lotion or any topical corticosteroid indicated for pediatric use that does not include pediatric bioequivalence data. Also, the FDA‚Äôs reliance on adult vasoconstrictor studies as surrogates for pediatric use.","FDA must refrain from approving any ANDA for Cutivate¬Æ Lotion or similar corticosteroids intended for pediatric patients unless it includes bioequivalence studies in pediatric patients.
- FDA should publish a draft guidance document addressing the need for pediatric bioequivalence studies before accepting/reviewing any such ANDAs. ","Adult vasoconstrictor studies (e.g., Stoughton-McKenzie assay) cannot be extrapolated to pediatric populations due to physiological and absorption differences.
- Higher risk of HPA axis suppression in children because of larger skin surface area to body mass ratio.
- Studies show differences in skin structure and function between adults and children; scientific literature lacks evidence supporting bioequivalence extrapolation.
- Pediatric patients are a vulnerable population, and improper bioequivalence assumptions could lead to safety and efficacy risks.
- Consistency with FDA and Congressional efforts to ensure evidence-based pediatric labeling.",,Denied,2011-04-27,0.0,Center for Drug Evaluation and Research (CDER),"21 U.S.C. ¬ß 355(j) (FD&C Act section 505(j))
- 21 CFR ¬ß¬ß 314.3, 314.92(a), 314.94(a), 314.105, 314.107, 314.127(a), 314.93, 314.430(b)
- 21 CFR ¬ß¬ß 320.1(b), 320.1(c), 320.1(e), 320.21(b)(1), 320.24(b)(1)-(4), (6)",,"Scientific and Regulatory Basis:

FDA found no scientific evidence or regulatory requirement mandating that bioequivalence studies for topical corticosteroids be conducted in pediatric populations.

The vasoconstrictor assay (Stoughton-McKenzie skin blanching test) used in adults is considered a valid and scientifically acceptable method to establish bioequivalence for topical corticosteroids.

FDA emphasized that the ANDA process does not require new safety or efficacy data, only demonstration of bioequivalence to the RLD (Reference Listed Drug).

Petition's Concerns and FDA‚Äôs Rebuttal:

Lack of pediatric-specific data: FDA acknowledged that children may have physiological differences, but stated that bioequivalence demonstrated in adults is sufficient unless specific contrary evidence exists (which Nycomed did not provide).

Vehicle formulation differences: These are evaluated during ANDA review, and the vasoconstrictor assay is sensitive enough to detect differences in drug delivery due to formulation changes.

Pediatric skin differences: FDA found no credible evidence that pediatric skin physiology negates the adult assay‚Äôs reliability.

HPA Axis Suppression Risks: The NDA already evaluated safety in pediatric populations. Once the RLD is deemed safe, a bioequivalent generic is assumed to be comparably safe. The vasoconstrictor assay is not meant to assess safety, only bioequivalence.

Request for New Guidance:

FDA declined to issue new draft guidance specific to pediatric bioequivalence for topical corticosteroids, stating the 1995 Bioequivalence Guidance remains valid and effective.",denied,True,180.0,CDER,CDER
fda-2010-p-0561,FDA-2010-P-0561-0007_Lupin_Atlantis_Holdings__SA__Leydig__Voit___Mayer_.pdf,2010-11-17,2010,False,original petition,"Lupin Atlantis Holdings, S.A.",industry/corporation,"21 U.S.C. ¬ß 355(q) (FDCA: Citizen petitions on pending drug applications)
- 21 C.F.R. ¬ß 10.30 (FDA regulation on citizen petitions)",Not explicitly mentioned in the withdrawal letter. The petition was withdrawn without reiterating its subject matter. The original filing details would be required to identify this.,The letter itself requests withdrawal of the original petition,"Not mentioned. The letter simply states, ‚ÄúWe respectfully request that the petition be withdrawn,‚Äù without providing reasoning",,,2025-10-15,0.0,,,,,no decision,False,5446.0,pending,pending
fda-2010-p-0561,FDA-2010-P-0561-0006_Lupin_Atlantis_Holdings__S_A____Leydig__Voit___May.pdf,2010-11-02,2010,False,original petition,"Lupin Atlantis Holdings, S.A.",industry/corporation,"21 C.F.R. ¬ß 314.94(a)(12)(viii)(C)(1)
- FDA Guidance Document dated October 31, 1986","FDA‚Äôs acceptance of ANDAs that do not initially meet dosage form requirements
- FDA‚Äôs handling of amendments that change the dosage form of an ANDA product
- FDA‚Äôs enforcement of patent certification requirements under the FDCA","Rescind acceptance of any ANDA that does not meet statutory dosage form requirements without an approved suitability petition
- Treat such amendments as new ANDA submissions
- Require submission of new Paragraph IV certification if a reformulation occurs","Paddock Laboratories' ANDA No. 91-362 for a generic Antara¬Æ capsule was reformulated to match the RLD dosage form after filing
- FDA previously required Cobrek to submit a new Paragraph IV certification following a similar reformulation
- FDA should apply the same standards consistently to ensure regulatory integrity and legal compliance",,,2025-10-15,0.0,,,,,no decision,False,5461.0,pending,pending
fda-2010-p-0561,FDA-2010-P-0561-0001_Lupin_Atlantis_Holdings__S_A____Leydig__Voit___May.pdf,2010-10-22,2010,False,original petition,"Lupin Atlantis Holdings, S.A.",industry/corporation,"21 U.S.C. ¬ß 355(j)(2)(A)(iii)
- 21 U.S.C. ¬ß 355(j)(2)(B)(iii)
- 21 C.F.R. ¬ß 314.94(a)(12)(viii)(C)(1)
- 21 C.F.R. ¬ß¬ß 314.94(a)(12)(vi), (viii)(C)(1)
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 25.30, 25.31 (Environmental Impact)
- 21 C.F.R. ¬ß 10.30(b) (Economic Impact)","FDA‚Äôs acceptance of ANDAs that were filed with dosage forms different from the Reference Listed Drug (RLD) and later amended to meet the same dosage form via reformulation.
- Specific example: Paddock Laboratories' ANDA No. 91-362 for a generic version of Antara¬Æ (reformulated after initial submission).","Rescind acceptance of any ANDA filed without the correct dosage form unless supported by a prior-approved suitability petition.
- Require that any amendment introducing a new dosage form be treated as a new ANDA submission.
- Enforce requirement for new Paragraph IV patent certification upon any dosage form change within an ANDA.","Allowing applicants to file ANDAs with non-matching dosage forms and later amend them undermines statutory compliance.
- FDA has acknowledged the importance of ‚Äúsame dosage form‚Äù in previous actions and guidance (e.g., 1986 FDA Guidance Document).
- Failure to treat such amendments as new ANDAs could create a loophole enabling applicants to circumvent regulatory review and patent certification procedures.
- Consistency and fairness: FDA required similar corrective action from Cobrek under the same circumstances.
- Paddock‚Äôs case is cited as egregious: ANDA originally described a capsule inside a capsule, not matching the RLD's form, later amended without full resubmission or certification updates.",,,2025-10-15,0.0,,,,,no decision,False,5472.0,pending,pending
fda-2010-p-0559,FDA-2010-P-0559-0011_Letter_from_Saliwell.pdf,2015-01-21,2010,False,original petition,Saliwell Ltd.,industry/corporation,21 C.F.R. ¬ß 860.134 (cited twice regarding reclassification timelines),"The FDA‚Äôs delay in acting on a petition for reclassification of the GenNarino transcutaneous electrical nerve stimulation intraoral device for xerostomia (dry mouth) relief. Specifically, the FDA‚Äôs issuance of a Proposed Order on September 17, 2014, and the long delay since the original submission in 2010.","Expedite the Final Order on the reclassification of the GenNarino device, giving it high priority","The device has a CE mark since 2007, has been sold in Europe for 6 years with no safety incidents, and is scientifically proven safe and effective.
- The FDA process has taken over 4 years and 8 months.
- The long delay caused the company to decline U.S. customer orders, including cancer patients.
- The delay damaged investor confidence and reduced corporate valuation, impeding efforts to go public.
- A final decision would benefit thousands of Americans suffering from dry mouth",,,2025-10-15,0.0,,,,,no decision,False,3920.0,pending,pending
fda-2010-p-0559,FDA-2010-P-0559-0004_Saliwell_Ltd____Change_in_Classification_Petition.pdf,2010-12-10,2010,False,original petition,Saliwell Ltd.,industry/corporation,"21 C.F.R. ¬ß 860.123 (Request for reclassification)
- 21 C.F.R. ¬ß 860.130 (Content and format of reclassification petitions)
- 21 C.F.R. ¬ß 860.7(b)(2) (Reasonable assurance of safety and effectiveness)","The classification of GenNarino, a neuromodulation device for treating xerostomia (dry mouth), as a Class III medical device. The petitioner requests reclassification to Class II with special controls.","Reclassify the GenNarino device from Class III to Class II under 21 C.F.R. Part 860, based on general and special controls being sufficient to assure safety and effectiveness","GenNarino is non-implantable, non-pharmaceutical, and uses neuromodulation to stimulate salivary function.
- Supported by clinical data, peer-reviewed studies, and real-world use in Europe under CE marking.
- Demonstrated no serious adverse events and significant efficacy in increasing salivation.
- The device is intended for mild/moderate dry mouth, distinguishable from more severe cases treated differently.
- Petitioner proposes special controls including labeling, electrical safety, and clinical testing to ensure effectiveness",,"Closed (Superseded by FDA Initiative) ‚Äì Rather than grant the petition directly, FDA initiated its own rulemaking process to reclassify electrical salivary stimulatory systems from Class III to Class II (special controls), and closed the petition as part of that action",2014-09-23,0.0,"Center for Devices and Radiological Health (CDRH) ‚Äì Signed by William H. Maisel, MD, MPH, Deputy Director for Science","21 U.S.C. ¬ß 360c(f)(3) (FD&C Act Section 513(f)(3)) ‚Äì Reclassification procedures by administrative order
- 21 U.S.C. ¬ß 360c(a)(1)(B) (Section 513(a)(1)(B)) ‚Äì Special controls
- 21 CFR ¬ß 872.5560 ‚Äì Proposed classification regulation",,"FDA reviewed the petition, relevant literature, review submissions, and data from similar devices.
- Determined that electrical salivary stimulatory systems can be reclassified to Class II with special controls, providing reasonable assurance of safety and effectiveness.
- On September 18, 2014, FDA published a proposed order in the Federal Register (79 FR 56027) initiating this reclassification independently.
- Because this action addressed the request raised by Saliwell Ltd., FDA closed the petition without a separate approval or denial.",other,True,1383.0,CDRH,CDRH
fda-2010-p-0552,FDA-2010-P-0552-0001_Huvepharma_AD___Citizen_Petition.pdf,2010-10-20,2010,False,original petition,"Huvepharma AD, 33 James Boucher Blvd., 1407 Sofia, Bulgaria",industry/corporation,"Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act (FFD&C Act)","Request to permit the filing of an abbreviated new animal drug application (ANADA) for a product (Sacox 90) differing in strength from the approved Bio-Cox¬Æ 60, a Type A medicated article","Petitioner requests FDA approval to file an ANADA for Sacox 90, which differs in concentration (90 g/lb salinomycin sodium) from the approved Bio-Cox 60 (60 g/lb salinomycin sodium), for the same animal species and disease indications","Strength change is permissible under 512(n)(3).
- Same indications and target species as listed product.
- Allows more efficient manufacturing, reduced storage needs, and cost savings for feed mills and the sponsor.
- Uses same raw materials, facility, and methods as Sacox 60",,"Approved ‚Äì FDA approved the suitability petition under section 512(n)(3)(C) of the Federal Food, Drug, and Cosmetic Act",2011-01-11,0.0,"Center for Veterinary Medicine (CVM) ‚Äì Signed by Steven D. Vaughn, DVM, Director, Office of New Animal Drug Evaluation","21 U.S.C. ¬ß 360b(n)(3)(C) ‚Äì FD&C Act section 512(n)(3)(C)
- 21 CFR ¬ß 514.5 ‚Äì ANADA pre-submission conference recommendation",,"The petition proposed a change in strength for a generic new animal drug (SACOX 90) compared to the reference listed new animal drug (BIO-COX 60), increasing salinomycin sodium concentration from 60 g/lb to 90 g/lb.
- The change did not alter indications, dosage form, route of administration, or final use concentrations in Type C feed.
- FDA determined that no additional safety or efficacy investigations were required for this change, and thus approval was mandatory under section 512(n)(3)(C).
- FDA noted that approval of the suitability petition does not guarantee approval of the subsequent Abbreviated New Animal Drug Application (ANADA).",approved,True,83.0,CVM,Other/Specialty Center
fda-2010-p-0549,FDA-2010-P-0549-0004_Lupin_Limited___Reply_Comment.pdf,2011-01-06,2010,False,original petition,Rakoczy Molino Mazzochi Siwik LLP,law/consulting,"21 U.S.C. ¬ß 355(j)(2)(A)(vii)(III) (Paragraph III Certification)
- 21 U.S.C. ¬ß 355(j)(2)(A)(vii)(IV) (Paragraph IV Certification)
- 21 U.S.C. ¬ß 355(j)(5)(B)(iii) and (iv)
- 21 C.F.R. ¬ß 314.95
- Hatch-Waxman Amendments","Comments submitted by Teva Pharmaceuticals regarding 180-day generic exclusivity for generic lamivudine/zidovudine tablets, in response to Lupin‚Äôs earlier citizen petition","FDA should confirm that Lupin, and not Teva, is entitled to the 180-day exclusivity for lamivudine/zidovudine tablets (150 mg/300 mg) ANDA","Teva‚Äôs original ANDA did not contain a valid Paragraph IV certification.
- Exclusivity is reserved only for the ‚Äúfirst applicant‚Äù to file a complete ANDA with a valid Paragraph IV certification before patent expiration.
- Lupin submitted a lawful ANDA with Paragraph IV certifications on January 11, 2008, whereas Teva did not do so until October 1, 2008.
- Granting exclusivity to Teva would be contrary to statutory language and congressional intent, and would reward ‚Äúa sham‚Äù ANDA submission not intended for timely market entry",2011-04-12 00:00:00,"Denied ‚Äì The FDA denied the petition in full, stating: ‚ÄúFor the reasons described above, your petition is denied‚Äù",2011-05-25,1.0,"Center for Drug Evaluation and Research (CDER) ‚Äì Signed by Janet Woodcock, M.D., Director, CDER","Section 505(j)(5)(B)(iv) of the Federal Food, Drug, and Cosmetic Act (FDCA) ‚Äì governing 180-day exclusivity.
- Section 505(j)(5)(D) ‚Äì detailing forfeiture provisions.
- 21 CFR 314.94(a)(12)(i)(A) ‚Äì addressing patent certifications in ANDAs.
- 21 CFR 314.430(b) ‚Äì confidentiality regarding ANDA status.
- Section 505(j)(2)(A)(vii) ‚Äì ANDA patent certification types.
- Section 505(j)(2)(B) ‚Äì notice requirements for Paragraph IV certifications.
- Section 505(j)(5)(D)(i)(VI) ‚Äì forfeiture upon patent expiration","The petition sought confirmation that Teva was not entitled to 180-day exclusivity for generic lamivudine and zidovudine tablets (150 mg and 300 mg), and that Lupin was eligible instead.
- FDA stated that the matter involved complex issues needing extensive review and analysis by Agency officials.
- As such, a final decision had not been reached by the 180-day mark, prompting this interim response.","Teva qualified as the first applicant because it submitted a substantially complete ANDA with a Paragraph IV certification for the ‚Äò021 patent before Lupin did.
- The MMA (Medicare Modernization Act) does not require simultaneous certification to all listed patents for exclusivity to attach‚Äîonly a valid initial Paragraph IV certification on the first day of filing is necessary.
- Teva‚Äôs later Paragraph IV certification to the ‚Äò082 patent did not affect its initial eligibility, although Teva‚Äôs exclusivity was limited to the ‚Äò021 patent.
- The FDA emphasized that exclusivity is patent-specific, and forfeiture only occurs if no valid Paragraph IV certifications remain.
- Since Lupin filed its certifications after Teva, and Teva retained eligibility through the ‚Äò021 patent, Lupin is not entitled to 180-day exclusivity.
- FDA found no legal basis in Lupin‚Äôs argument that Teva‚Äôs submission strategy invalidated its eligibility",denied,True,139.0,CDER,CDER
fda-2010-p-0549,FDA-2010-P-0549-0001_Lupin_Limited__Rakoczy_Molino_Mazzochi_Siwik__LLP_.pdf,2010-10-18,2010,False,original petition,Rakoczy Molino Mazzochi Siwik LLP,law/consulting,"21 U.S.C. ¬ß 355(j)(5)(B)(iv)(I) (Hatch-Waxman Act exclusivity provision)
- 21 U.S.C. ¬ß 355(j)(2)(A)(vii)(IV) (Paragraph IV Certification)
- 21 C.F.R. ¬ß 314.95(a)
- 21 C.F.R. ¬ß 314.107¬©",The awarding of 180-day marketing exclusivity for a generic version of lamivudine/zidovudine tablets (150 mg/300 mg) ANDA under Paragraph IV patent certification provisions,"FDA should recognize Lupin Limited as the first applicant entitled to 180-day exclusivity for its ANDA No. 91-080, and deny Teva exclusivity","Lupin submitted its ANDA on January 11, 2008 with valid Paragraph IV certifications.
- Teva‚Äôs ANDA, originally submitted on October 4, 2007, contained no valid Paragraph IV certification, rendering it ineligible for first-filer status.
- Congressional intent and FDA precedent support exclusivity only for ANDAs that timely and validly file Paragraph IV certifications.
- Teva should not benefit from what Lupin terms a ‚Äúsham‚Äù or ‚Äúplaceholding‚Äù filing meant to manipulate exclusivity rules",2011-04-12 00:00:00,"Denied ‚Äì The FDA denied the petition in full, stating: ‚ÄúFor the reasons described above, your petition is denied‚Äù",2011-05-25,1.0,"Center for Drug Evaluation and Research (CDER) ‚Äì Signed by Janet Woodcock, M.D., Director, CDER","Section 505(j)(5)(B)(iv) of the Federal Food, Drug, and Cosmetic Act (FDCA) ‚Äì governing 180-day exclusivity.
- Section 505(j)(5)(D) ‚Äì detailing forfeiture provisions.
- 21 CFR 314.94(a)(12)(i)(A) ‚Äì addressing patent certifications in ANDAs.
- 21 CFR 314.430(b) ‚Äì confidentiality regarding ANDA status.
- Section 505(j)(2)(A)(vii) ‚Äì ANDA patent certification types.
- Section 505(j)(2)(B) ‚Äì notice requirements for Paragraph IV certifications.
- Section 505(j)(5)(D)(i)(VI) ‚Äì forfeiture upon patent expiration","The petition sought confirmation that Teva was not entitled to 180-day exclusivity for generic lamivudine and zidovudine tablets (150 mg and 300 mg), and that Lupin was eligible instead.
- FDA stated that the matter involved complex issues needing extensive review and analysis by Agency officials.
- As such, a final decision had not been reached by the 180-day mark, prompting this interim response.","Teva qualified as the first applicant because it submitted a substantially complete ANDA with a Paragraph IV certification for the ‚Äò021 patent before Lupin did.
- The MMA (Medicare Modernization Act) does not require simultaneous certification to all listed patents for exclusivity to attach‚Äîonly a valid initial Paragraph IV certification on the first day of filing is necessary.
- Teva‚Äôs later Paragraph IV certification to the ‚Äò082 patent did not affect its initial eligibility, although Teva‚Äôs exclusivity was limited to the ‚Äò021 patent.
- The FDA emphasized that exclusivity is patent-specific, and forfeiture only occurs if no valid Paragraph IV certifications remain.
- Since Lupin filed its certifications after Teva, and Teva retained eligibility through the ‚Äò021 patent, Lupin is not entitled to 180-day exclusivity.
- FDA found no legal basis in Lupin‚Äôs argument that Teva‚Äôs submission strategy invalidated its eligibility",denied,True,219.0,CDER,CDER
fda-2010-p-0546,FDA-2010-P-0546-0004_Azur_Pharma_International_III__Ltd____Beckloff_Ass.pdf,2010-10-29,2010,False,original petition,"Beckloff Associates, Inc.",law/consulting,21 C.F.R. ¬ß 10.30(g),The petitioner is not commenting on a new FDA action but is withdrawing a previously submitted Citizen Petition for Clozapine,"FDA is requested to withdraw the Citizen Petition for Clozapine submitted on October 13, 2010, without prejudice","No explicit justification is provided in the letter other than the formal request for withdrawal ""without prejudice""",,,2025-10-15,0.0,,,,,no decision,False,5465.0,pending,pending
fda-2010-p-0546,FDA-2010-P-0546-0001_Beckloff_Associates___Citizen_Petition.pdf,2010-10-13,2010,False,original petition,"Beckloff Associates, Inc.",law/consulting,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. 10.30
- 21 C.F.R. 25.31 (environmental impact exemption)
- Referenced FDA guidances:
‚Ä¢ Clozapine Tablets: In Vivo Bioequivalence and In Vitro Dissolution Testing (June 2005)
‚Ä¢ Bioequivalence Recommendations for Specific Products (June 2010)
‚Ä¢ Bioavailability and Bioequivalence Studies for Orally Administered Drug Products‚ÄîGeneral Considerations (March 2003)",The current designation of the 100 mg FazaClo tablet as the Reference Listed Drug (RLD) in the FDA Orange Book and the scope of the June 2005 FDA guidance on bioequivalence testing,"Designate FazaClo 200 mg Orally Disintegrating Tablets as the RLD for clozapine orally disintegrating tablets in the FDA Orange Book
- Revise the June 2005 FDA guidance to include 200 mg tablets in Sections I (Introduction) and V (Waiver Requirements)","FDA typically designates the highest strength dosage as the RLD for multi-strength oral products
- Studies in patients with schizophrenia using 200 mg FazaClo showed no safety concerns
- FDA guidance already supports use of highest dosage strength for bioequivalence studies
- Updating the RLD to 200 mg will align with biowaiver policies and promote consistency in regulatory submissions",,,2025-10-15,0.0,,,,,no decision,False,5481.0,pending,pending
fda-2010-p-0545,FDA-2010-P-0545-0001_UCB_Inc_Citizen_Petition.pdf,2010-10-14,2010,False,original petition,"UCB, Inc.",industry/corporation,"Section 505(j) of the FDCA (21 U.S.C. ¬ß 355(j))
- 21 C.F.R. ¬ß 10.30 (Citizen petition regulation)
- 21 C.F.R. ¬ß 314.94(a)(8)(iv) (Labeling requirements for ANDAs)
- 21 C.F.R. ¬ß 314.127(a)(7) (Rejection of ANDAs for safety issues)
- FDCA ¬ß 505(d) (NDA approval criteria)
- FDCA ¬ß 502(a) (Misbranding: false or misleading labeling)
- 21 C.F.R. ¬ß¬ß 25.30 and 25.31 (Environmental exemption)
- 21 U.S.C. ¬ß 355(q)(1)(H) (Certification for citizen petitions)",The petition addresses FDA‚Äôs potential approval of any Abbreviated New Drug Application (ANDA) for levocetirizine dihydrochloride that omits or modifies the allergic rhinitis indications or related safety data in the labeling when using Xyzal¬Æ as the reference listed drug (RLD).,"UCB requests that the FDA not approve any ANDA for levocetirizine:
- That omits allergic rhinitis indications or the related safety data
- That retains the safety data but removes specific references to allergic rhinitis or replaces them with vague phrases like ""other diseases""","Most of Xyzal‚Äôs safety data (90%) is based on allergic rhinitis studies, not CIU, making omission misleading.
- Omitting or altering allergic rhinitis references renders the labeling misleading, in violation of FDCA ¬ß 505 and ¬ß 502(a).
- Physicians rely on accurate labeling for prescribing; misleading labels compromise patient safety and informed decision-making.
- FDA regulations do not allow replacement language when omitting indications; only full omissions are allowed.
- The requested carve-out would make the generic drug less safe/effective for the remaining indication (CIU), violating 21 C.F.R. ¬ß 314.127(a)(7).",,Denied ‚Äî The FDA denied the request to refrain from granting tentative or final approval for any ANDA that omits Xyzal‚Äôs allergic rhinitis indications,2011-02-24,0.0,Center for Drug Evaluation and Research (CDER) ,"Section 505(b)(1), 505(c), 505(j), 505(j)(2)(A)(vii), 505(j)(2)(A)(viii), and 505(j)(4)(G) of the Federal Food, Drug, and Cosmetic Act
- 21 CFR 314.3, 314.53, 314.92(a)(1), 314.94(a)(8)(iv), 314.94(a)(12)(iii), and 314.127(a)(7)",,"Labeling carve-outs permitted: FDA found that labeling differences due to patent-protected indications (SAR, PAR) are allowed, as long as safety/effectiveness for remaining indications (e.g., CIU) is not compromised.
- Safety data applicability: Although most safety data originated from allergic rhinitis studies, they are deemed applicable to chronic idiopathic urticaria (CIU) due to the similarity of patient populations.
- Minimal labeling changes: Selective deletions and minor modifications in language (e.g., removing specific disease mentions) are sufficient and do not impair safety communication.
- BPCA pediatric exclusivity: FDA permits disclaimers that exclude mention of specific protected pediatric indications, ensuring compliance without violating exclusivity protections.
- Case law & precedent: Cited legal precedents and earlier decisions support FDA‚Äôs position on labeling carve-outs under patent protection.",denied,True,133.0,CDER,CDER
fda-2010-p-0540,FDA-2010-P-0540-0016_Rakoczy__Molino__Mazzochi___Siwik__LLP___Supplemen,2011-05-11,2010,False,original petition,Rakoczy Molino Mazzochi Siwik LLP,law/consulting,"21 U.S.C. ¬ß 355(j)(7)(C) ‚Äì Withdrawal of drug products from the market
- 21 U.S.C. ¬ß 355(d) ‚Äì Grounds for denying NDA approval
- 21 C.F.R. ¬ß 314.161 ‚Äì Determination of whether a listed drug was withdrawn for safety or efficacy reasons
- 21 U.S.C. ¬ß 355(j)(2)(A) ‚Äì ANDA content requirements","The petitioner is commenting on FDA‚Äôs determination regarding whether Purdue Pharma voluntarily discontinued the original formulation of OxyContin¬Æ (NDA No. 20-553) for reasons related to safety or efficacy, which affects the eligibility of ANDAs referencing the discontinued formulation for approval.","The petitioner requests that the FDA determine that the original OxyContin¬Æ formulation (NDA No. 20-553) was not withdrawn for safety or efficacy reasons, and therefore that ANDAs referencing it are eligible for approval if all other legal and regulatory requirements are met","Purdue itself admitted that the discontinued formulation was safe and effective when used as directed.
- Purdue marketed the product for over 15 years and continued marketing it even after public recognition of abuse risks.
- FDA has allowed other drugs to be referenced in ANDAs where no safety/efficacy withdrawal was found despite discontinuation (e.g., Zosyn¬Æ).
- Purdue did not perform any safety/efficacy trials for its reformulated version, nor has it shown that the new version is safer.
- Accepting Purdue‚Äôs claim would give brand companies undue control over generic approval and undermine the Hatch-Waxman Act‚Äôs intent to ensure access to affordable generics.",,"Approved ‚Äì The FDA granted the request by determining that OXYCONTIN drug products approved under NDA 20-553 were withdrawn from sale for safety or effectiveness reasons, thus blocking ANDAs referencing these versions",2013-04-16,0.0,"Center for Drug Evaluation and Research (CDER) ‚Äì Signed by Janet Woodcock, M.D., Director .","21 U.S.C. ¬ß 355(j)(7) ‚Äì Listing and delisting of approved drugs
- 21 CFR ¬ß 314.162 ‚Äì Withdrawal of drug products from the Orange Book due to safety/effectiveness concerns",,"FDA determined, based on comments, data, postmarketing adverse event reports, and internal review, that original OxyContin (NDA 20-553) posed higher risks of abuse and misuse compared to reformulated versions.
- Reformulated OxyContin (NDA 22-272) was designed with abuse-deterrent properties that reduced tampering methods like crushing, snorting, or injecting.
- Data suggested reformulated OxyContin is harder to abuse and leads to slower and lower peak release of oxycodone, reducing potential for addiction or overdose.
- Abuse-related public health crises and opioid epidemic concerns were emphasized, citing CDC data showing a 300% rise in prescription opioid overdose deaths from 1999‚Äì2008.
- Based on totality of evidence, the original OxyContin was considered withdrawn for reasons of safety and effectiveness, disqualifying it as an RLD for future ANDAs ",approved,True,706.0,CDER,CDER
fda-2010-p-0540,FDA-2010-P-0540-0001_Sheppard__Mullin__Richter___Hampton_LLP___Citizen_,2010-10-08,2010,False,original petition,"Sheppard, Mullin, Richter & Hampton LLP",law/consulting,"21 C.F.R. ¬ß 10.30 (Citizen Petition procedures)
- 21 C.F.R. ¬ß 314.161(a), (b), (e) (Determining if drug withdrawal was for safety/effectiveness reasons)
- 21 C.F.R. ¬ß 314.122 (Eligibility of ANDAs referencing discontinued drugs)
- 21 C.F.R. ¬ß 25.31(a) (Environmental impact exemption)",The petitioner seeks a formal FDA determination that Purdue Pharma‚Äôs original strengths (10mg‚Äì80mg) of oxycodone hydrochloride extended-release tablets were not withdrawn for reasons of safety or effectiveness. This is necessary for potential ANDA applicants to reference these discontinued strengths.,"The petitioner requests that the FDA confirm that the discontinued strengths of Purdue Pharma's NDA 020553 drug were withdrawn for reasons other than safety or effectiveness, thus allowing abbreviated new drug applications (ANDAs) for these dosages to be filed and approved","The discontinued products are still listed in the ‚ÄúDiscontinued‚Äù section of the Orange Book.
- The discontinuation occurred following the approval of a new NDA (022272) on April 5, 2010, not because of safety or effectiveness issues.
- The petitioner has no information suggesting safety or efficacy concerns led to withdrawal.
- The legal pathway (21 C.F.R. ¬ß 314.161) requires FDA to confirm whether withdrawal was for safety/effectiveness reasons before ANDAs may proceed. ",2011-03-28 00:00:00,"Approved ‚Äì The FDA granted the request by determining that OXYCONTIN drug products approved under NDA 20-553 were withdrawn from sale for safety or effectiveness reasons, thus blocking ANDAs referencing these versions",2013-04-16,1.0,"Center for Drug Evaluation and Research (CDER) ‚Äì Signed by Janet Woodcock, M.D., Director .","21 U.S.C. ¬ß 355(j)(7) ‚Äì Listing and delisting of approved drugs
- 21 CFR ¬ß 314.162 ‚Äì Withdrawal of drug products from the Orange Book due to safety/effectiveness concerns","The petition requested a determination on whether certain strengths of oxycodone hydrochloride extended-release tablets (NDA 20-553) were voluntarily withdrawn for reasons other than safety or effectiveness.
- FDA stated it had not yet resolved the issues due to their complex nature, requiring extensive review and analysis.
- An interim response was issued as required under 21 CFR 10.30(e)(2), promising a full response once the evaluation was complete","FDA determined, based on comments, data, postmarketing adverse event reports, and internal review, that original OxyContin (NDA 20-553) posed higher risks of abuse and misuse compared to reformulated versions.
- Reformulated OxyContin (NDA 22-272) was designed with abuse-deterrent properties that reduced tampering methods like crushing, snorting, or injecting.
- Data suggested reformulated OxyContin is harder to abuse and leads to slower and lower peak release of oxycodone, reducing potential for addiction or overdose.
- Abuse-related public health crises and opioid epidemic concerns were emphasized, citing CDC data showing a 300% rise in prescription opioid overdose deaths from 1999‚Äì2008.
- Based on totality of evidence, the original OxyContin was considered withdrawn for reasons of safety and effectiveness, disqualifying it as an RLD for future ANDAs ",approved,True,921.0,CDER,CDER
fda-2010-p-0538,FDA-2010-P-0538-0001_Grocery_Manufactureres_Association__GMA____Citizen,2010-10-04,2010,False,original petition,Grocery Manufacturers Association (GMA),advocacy/academic,"21 C.F.R. ¬ß 10.30 ‚Äì Citizen petition procedures
- Environmental claim only: Petition notes exclusion from EA/EIS requirement (likely referring to 21 C.F.R. ¬ß 25.30 or 25.31 though not explicitly cited)","The petitioner is requesting that FDA develop guidance for industry on controlling Salmonella in low-moisture food products, similar to guidance previously issued for produce such as tomatoes, leafy greens, and melons","GMA requests that FDA initiate efforts to create risk-based, flexible guidance for controlling Salmonella in low-moisture foods. The guidance should accommodate the diversity of product types and allow for customized control measures tailored to specific manufacturing operations","Multiple documented outbreaks of salmonellosis have been linked to low-moisture foods like peanut butter, cereal, spices, and infant formula.
- Some outbreaks involve persistent contamination over years, showing difficulty in eradicating Salmonella once present in facilities.
- A GMA task force developed the GMA Salmonella Control Guidance in 2009, proposing seven control elements.
- FDA has successfully used industry input for produce safety guidance; a similar approach is needed for low-moisture products.
- Formal FDA guidance would raise industry-wide awareness, promote preventive action, and enhance food safety",,,2025-10-15,0.0,,,,,no decision,False,5490.0,pending,pending
fda-2010-p-0535,FDA-2010-P-0535-0001_Hyman__Phelps___McNamara__P_C____Citizen_Petition,2010-10-05,2010,False,original petition,"Hyman, Phelps & McNamara, P.C. (law firm)",law/consulting,"Section 505(j)(2)(C) of the FD&C Act (21 U.S.C. ¬ß 355(j)(2)(C)) ‚Äì Suitability petition for a different strength
- 21 C.F.R. ¬ß 314.93 ‚Äì Suitability petitions
- 21 C.F.R. ¬ß 10.20 and ¬ß 10.30 ‚Äì Petition procedures
- 21 C.F.R. ¬ß 25.31 ‚Äì Environmental impact exemption
- 21 C.F.R. ¬ß 10.30(b) ‚Äì Economic impact statement
- 21 U.S.C. ¬ß 505B(a)(1)(A) ‚Äì Pediatric Research Equity Act (PREA) exemption for new strengths","The petitioner seeks a determination by FDA that a new 40 mg strength of Duloxetine HCl Delayed-Release Capsules is suitable for submission in an Abbreviated New Drug Application (ANDA), even though this strength is not marketed by the Reference Listed Drug (RLD), Cymbalta¬Æ","The petitioner requests that FDA approve a suitability petition allowing a 40 mg strength of Duloxetine HCl Delayed-Release Capsules to be submitted via ANDA referencing Cymbalta¬Æ (NDA 21-427), which is currently marketed in 20 mg, 30 mg, and 60 mg","The proposed 40 mg strength uses the same active ingredient, dosage form, and route of administration as the RLD.
- Labeling supports flexibility in dosing for various indications such as major depressive disorder, diabetic peripheral neuropathic pain, and generalized anxiety disorder.
- A 40 mg capsule would enhance patient convenience and adherence, reducing the need for combining smaller doses (e.g., two 20 mg capsules).
- The petition claims no safety or efficacy concerns and asserts the change is within FDA‚Äôs allowable framework for ANDA suitability petitions.
- The Pediatric Research Equity Act (PREA) does not apply to new strengths.",,"Approved ‚Äì The FDA approved the citizen petition, allowing an ANDA to be submitted for Duloxetine Hydrochloride Delayed-release Capsules, 40 mg",2012-04-19,0.0,"Center for Drug Evaluation and Research (CDER) ‚Äì Signed by Keith O. Webber, Ph.D., Deputy Director, Office of Pharmaceutical Science","Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FDCA)
- Section 505(j)(2)(C)(i) ‚Äì Governing approval of suitability petitions for different strengths
- Section 505(j)(2)(A) and (B) ‚Äì General ANDA requirements
- Section 505(j)(2)(A)(iv) ‚Äì Bioavailability requirements",,"The requested change (40 mg) differs from the listed strengths (20, 30, 60 mg) of Cymbalta¬Æ (duloxetine hydrochloride).
- FDA determined that the change does not pose questions of safety or effectiveness, as the uses, dose, and route of administration remain the same as the listed drug.
- No new investigations are required to demonstrate safety or efficacy for the new strength.
- If the generic product meets bioavailability requirements, it can be expected to have the same therapeutic effect as the reference listed drug (RLD).
- Approval of the petition does not guarantee ANDA approval‚Äîthat depends on a full review of the ANDA submission itself",approved,True,562.0,CDER,CDER
fda-2010-p-0533,FDA-2010-P-0533-0003_Zydus_Pharmaceuticals_USA__Inc____Amendment,2011-03-26,2010,False,original petition,"Zydus Pharmaceuticals USA, Inc.",industry/corporation,"21 C.F.R. ¬ß 10.30 ‚Äì Citizen petition procedures
- 21 U.S.C. ¬ß 355(j) ‚Äì Abbreviated New Drug Application (ANDA) requirements
- 21 C.F.R. ¬ß 314.94(a)(8)(iv) ‚Äì Labeling requirements for ANDAs
- 21 C.F.R. ¬ß 314.127(a)(7) ‚Äì Basis for ANDA refusal if labeling is misleading","Zydus comments on the approval of ANDAs referencing Zyprexa¬Æ (olanzapine) where the labeling may omit certain indications, specifically the treatment of psychotic symptoms associated with schizophrenia and bipolar disorder in adolescents.","Zydus requests that FDA not approve any ANDA for olanzapine that omits pediatric indications (specifically for adolescents with schizophrenia and bipolar disorder) from its labeling while retaining associated safety data, as this would be misleading.","Omitting adolescent indications but keeping safety data related to those uses would render the labeling false or misleading.
- FDA precedent supports that a carve-out is only permissible if the safety and efficacy profile is preserved and labeling is not misleading.
- Prescribers may be confused if pediatric safety information remains without context of the indication, increasing potential risk.
- Zydus argues this would violate the FD&C Act and FDA regulations governing accurate and truthful labeling .",,"Approved ‚Äì The FDA approved the petition, permitting the submission of an Abbreviated New Drug Application (ANDA) for Metformin Hydrochloride Powder for Solution (500 mg, 850 mg, and 1 g)",2012-10-01,0.0,"Center for Drug Evaluation and Research (CDER) ‚Äì Signed by Gregory P. Geba, M.D., M.P.H., Director, Office of Generic Drugs","Section 505(j)(2)(C) of the FD&C Act (suitability petition provision)
- Section 505(j)(2)(A) and (B) ‚Äì General ANDA requirements
- Section 505(j)(2)(A)(iv) ‚Äì Bioavailability requirements
- Pediatric Research Equity Act of 2007 (PREA)",,"The petition requested a change in dosage form (from oral tablet to powder for solution) for metformin hydrochloride, referencing Glucophage¬Æ as the listed drug.
- FDA found that the proposed change does not pose questions of safety or effectiveness because the dose, uses, and route of administration remain the same.
- No additional investigations were required under PREA for pediatric populations, as FDA determined it was PREA fulfilled.
- If the proposed product meets bioavailability standards, it can be expected to have the same therapeutic effect as the reference listed drug.
- FDA emphasized that approval of the petition does not guarantee approval of a submitted ANDA‚Äîapproval will depend on subsequent review.",approved,True,555.0,CDER,CDER
fda-2010-p-0533,FDA-2010-P-0533-0001_Zydus_Pharmaceuticals_USA__Inc____Citizen_Petition,2010-09-30,2010,False,original petition,"Zydus Pharmaceuticals USA, Inc.",industry/corporation,"21 C.F.R. ¬ß 10.20 ‚Äì General procedures for petitions
- 21 C.F.R. ¬ß 10.30 ‚Äì Citizen petition process
- 21 C.F.R. ¬ß 314.93 ‚Äì Suitability petitions
- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act ‚Äì ANDA for different dosage form
- 21 C.F.R. ¬ß 25.31 ‚Äì Environmental assessment exemption",The petition comments on whether a change in dosage form of Metformin Hydrochloride (from tablets to powder for solution) is suitable for submission under an Abbreviated New Drug Application (ANDA) referencing the RLD Glucophage¬Æ by Bristol-Myers Squibb,"Zydus requests that FDA declare Metformin Hydrochloride 500 mg, 850 mg, and 1 g Powder for Solution to be suitable for submission as an ANDA. The only change proposed is in dosage form; the active ingredient, route, indications, and patient population remain the same","The proposed product only differs in dosage form and is otherwise identical in strength, route, and intended use.
- It offers benefits such as unit dose packaging, ease of swallowing, and improved taste, enhancing patient compliance.
- The Orange Book already lists ‚ÄúMetformin Tablets for Oral Solution‚Äù as approved via ANDA.
- The proposed ‚Äúpowder for solution‚Äù is claimed to be bioequivalent and therapeutically similar to the RLD.
- Pediatric data already exist in the Glucophage¬Æ label, and no new pediatric studies are needed",,"Approved ‚Äì The FDA approved the petition, permitting the submission of an Abbreviated New Drug Application (ANDA) for Metformin Hydrochloride Powder for Solution (500 mg, 850 mg, and 1 g)",2012-10-01,0.0,"Center for Drug Evaluation and Research (CDER) ‚Äì Signed by Gregory P. Geba, M.D., M.P.H., Director, Office of Generic Drugs","Section 505(j)(2)(C) of the FD&C Act (suitability petition provision)
- Section 505(j)(2)(A) and (B) ‚Äì General ANDA requirements
- Section 505(j)(2)(A)(iv) ‚Äì Bioavailability requirements
- Pediatric Research Equity Act of 2007 (PREA)",,"The petition requested a change in dosage form (from oral tablet to powder for solution) for metformin hydrochloride, referencing Glucophage¬Æ as the listed drug.
- FDA found that the proposed change does not pose questions of safety or effectiveness because the dose, uses, and route of administration remain the same.
- No additional investigations were required under PREA for pediatric populations, as FDA determined it was PREA fulfilled.
- If the proposed product meets bioavailability standards, it can be expected to have the same therapeutic effect as the reference listed drug.
- FDA emphasized that approval of the petition does not guarantee approval of a submitted ANDA‚Äîapproval will depend on subsequent review.",approved,True,732.0,CDER,CDER
fda-2010-p-0532,FDA-2010-P-0532-0012_BBK_Tobacco___Foods_LLP_Levin_and_Ginsburg_LTD_to_,2012-11-30,2010,False,original petition,"BBK Tobacco & Foods, LLP",law/consulting,Not Mentioned in this document.,"The letter is a follow-up to a previously submitted citizen petition, confirming that FDA is not waiting for additional information from the petitioner (BBK Tobacco & Foods, LLP). There is no new FDA action or policy commented on in this letter","The letter simply seeks confirmation that no further information is required by FDA to act on the previously submitted petition. It is not a new petition or request, but rather a status inquiry","The letter provides no specific justification, only a procedural inquiry to confirm that FDA has all necessary information to proceed with a decision on the original petition",,Denied ‚Äì The FDA declined to take enforcement discretion and declined to find that the Family Smoking Prevention and Tobacco Control Act does not authorize regulation of flavored rolling papers. The alternative requests were also denied,2016-08-16,0.0,"Center for Tobacco Products (CTP) ‚Äì Signed by Beverly Chernaik, J.D., Director, Office of Regulations","21 CFR ¬ß 10.30(k) ‚Äì Regarding limitations of citizen petition procedures for enforcement discretion
- 21 CFR ¬ß 10.45 ‚Äì Clarifying that denial of a request for or against enforcement is not final agency action
- Section 907(a)(1)(A) of the FD&C Act ‚Äì Characterizing flavor ban for cigarettes
- Section 201 of the FD&C Act ‚Äì Definition of ""tobacco product"" and its components
- Deeming Rule (May 10, 2016) ‚Äì Guidance on tobacco product regulation",,"FDA explained that decisions about whether to enforce or refrain from enforcement are within agency discretion and not appropriate for resolution via citizen petition.
- The agency declined to interpret the Family Smoking Prevention and Tobacco Control Act as not applying to flavored rolling papers. FDA pointed to existing guidance stating that rolling paper or filters are considered component parts of roll-your-own cigarettes and thus cannot be flavored.
- The FDA also rejected the petitioner‚Äôs request to permit flavored papers labeled for use with legal non-tobacco herbs, stating it would require assessment of specific facts in context, which cannot be pre-determined outside a regulatory or enforcement action.
- The agency referenced its ‚ÄúDeeming Rule‚Äù (May 10, 2016) which clarified its approach to defining tobacco products and their components or accessories",denied,True,1355.0,CTP,Other/Specialty Center
fda-2010-p-0532,FDA-2010-P-0532-0001_BBK_Tobacco___Foods__LLP___Levin_Ginsburg_Attorney,2010-09-29,2010,False,original petition,"BBK Tobacco & Foods, LLP (d/b/a HBI International)",law/consulting,"21 C.F.R. ¬ß 10.30 ‚Äì Citizen petition procedure
- 21 C.F.R. ¬ß 7.12 ‚Äì Guidance documents and compliance policy guides
- FDCA ¬ß 201(n) ‚Äì Labeling misbranding provision
- 21 U.S.C. ¬ß 321(n) ‚Äì Misleading labeling through omission","The petitioner is commenting on FDA‚Äôs regulation and enforcement of labeling for rolling papers and tobacco products, specifically objecting to perceived preferential treatment given to Republic Tobacco and urging consistent regulatory enforcement regarding the term ‚Äúnatural.‚Äù","BBK requests that FDA:
- Take corrective action to enforce labeling standards consistently across rolling paper manufacturers.
- Ensure Republic Tobacco is not allowed to continue using the term ‚Äúnatural‚Äù or similar terms without compliance.
- Apply the same standards to Republic as it applies to BBK Tobacco & Foods .","BBK claims it was targeted by FDA enforcement for using the word ‚Äúnatural‚Äù while Republic Tobacco continued to use the same or similar terms without penalty.
- BBK argues this is unfair and inconsistent regulation, amounting to disparate treatment.
- The use of the term ‚Äúnatural‚Äù constitutes labeling under FDCA ¬ß 201(n) and must be truthful and non-misleading.
- They believe FDA has a duty to enforce labeling laws uniformly across companies to avoid unlawful market advantage .",2011-04-04 00:00:00,Denied ‚Äì The FDA declined to take enforcement discretion and declined to find that the Family Smoking Prevention and Tobacco Control Act does not authorize regulation of flavored rolling papers. The alternative requests were also denied,2016-08-16,1.0,"Center for Tobacco Products (CTP) ‚Äì Signed by Beverly Chernaik, J.D., Director, Office of Regulations","21 CFR ¬ß 10.30(k) ‚Äì Regarding limitations of citizen petition procedures for enforcement discretion
- 21 CFR ¬ß 10.45 ‚Äì Clarifying that denial of a request for or against enforcement is not final agency action
- Section 907(a)(1)(A) of the FD&C Act ‚Äì Characterizing flavor ban for cigarettes
- Section 201 of the FD&C Act ‚Äì Definition of ""tobacco product"" and its components
- Deeming Rule (May 10, 2016) ‚Äì Guidance on tobacco product regulation","The petition requested that FDA refrain from administrative or enforcement action against flavored roll-your-own papers and find that the Family Smoking Prevention and Tobacco Control Act does not authorize their regulation.
- Alternatively, the petitioner asked that flavored papers labeled for use only with legal non-tobacco herbs be found permissible.
- FDA stated that it was still analyzing the issues and provided the interim response in compliance with regulatory obligations under 21 CFR 10.30(e)(2).","FDA explained that decisions about whether to enforce or refrain from enforcement are within agency discretion and not appropriate for resolution via citizen petition.
- The agency declined to interpret the Family Smoking Prevention and Tobacco Control Act as not applying to flavored rolling papers. FDA pointed to existing guidance stating that rolling paper or filters are considered component parts of roll-your-own cigarettes and thus cannot be flavored.
- The FDA also rejected the petitioner‚Äôs request to permit flavored papers labeled for use with legal non-tobacco herbs, stating it would require assessment of specific facts in context, which cannot be pre-determined outside a regulatory or enforcement action.
- The agency referenced its ‚ÄúDeeming Rule‚Äù (May 10, 2016) which clarified its approach to defining tobacco products and their components or accessories",denied,True,2148.0,CTP,Other/Specialty Center
fda-2010-p-0531,FDA-2010-P-0531-0001_Peptimmune__Inc____Citizen_Petition,2010-10-01,2010,False,original petition,"BBK Tobacco & Foods, LLP (doing business as HBI International)",law/consulting,"21 C.F.R. ¬ß 10.30 ‚Äì FDA citizen petition procedures
- 21 C.F.R. ¬ß 7.12 ‚Äì Compliance policy guides and guidance documents
- 21 U.S.C. ¬ß 321(n) ‚Äì Misbranding due to misleading labeling
- FDCA ¬ß 201(n) ‚Äì Labeling deemed misleading if material facts are omitted","The petition challenges inconsistent FDA enforcement of labeling regulations regarding use of the term ‚Äúnatural‚Äù in tobacco rolling paper packaging, specifically FDA‚Äôs failure to act against Republic Tobacco‚Äôs labeling practices while enforcing against BBK","The petitioner requests that FDA:
- Take enforcement action against Republic Tobacco for using the term ‚Äúnatural‚Äù on their rolling paper products.
- Apply labeling regulations consistently to all manufacturers in the industry, including Republic and BBK.
- Prevent Republic from receiving unlawful competitive advantages due to unequal enforcement.","BBK was allegedly required by FDA to cease using ‚Äúnatural‚Äù in its product labeling, while Republic Tobacco continued using such terms without consequence.
- BBK argues this amounts to selective enforcement, harming fair competition.
- The term ‚Äúnatural‚Äù is considered labeling and subject to FDA scrutiny under FDCA ¬ß 201(n).
- FDA is obligated to ensure uniform and non-discriminatory application of its rules to avoid granting one manufacturer an advantage over another.",,Denied,2011-03-29,0.0,Center for Drug Evaluation and Research (CDER),"Section 505(b)(2) and 505(j) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355)
- Section 505(q)(1)(F) of the Act
- 21 CFR Part 314
- 21 CFR 314.94(a)(5)(i)
- 21 CFR 314.127(a)(3)
- 21 CFR 314.92(a)(1)
- 21 CFR 314.105, 314.125, 314.127, 314.110, 314.200
- 21 CFR 210.3(b)(7), 314.3(b)
- Court case: Serono Laboratories, Inc. v. Shalala, 158 F.3d 1313 (D.C. Cir. 1998)",,"The FDA emphasized its broad statutory and regulatory discretion in determining whether the active ingredient in an ANDA is the ""same as"" that in the reference listed drug (RLD).
- The agency rejected Peptimmune's request to require preclinical and clinical PK and PD studies for generic glatiramer acetate (GA) due to lack of necessity and premature judgment.
- The Agency cited its precedent in the Serono case and reinforced that sameness of active ingredient does not require complete chemical identity.
- FDA stated it uses a flexible, science-based, and ingredient-specific approach and that any decision on sameness would depend on the particular data and the ‚Äúkind of drug at issue.‚Äù
- FDA maintained that granting the petition would essentially prejudge ANDA applications for GA without reviewing specific data or providing procedural protections to applicants.
- FDA acknowledged that information from the petition may inform its scientific evaluation of future applications, but it declined to impose the requested requirements at this time.",denied,True,179.0,CDER,CDER
fda-2010-p-0526,FDA-2010-P-0526-0017_Rakoczy__Molino__Mazzochi___Siwik__LLP___Supplemen,2011-05-11,2010,False,original petition,Rakoczy Molino Mazzochi Siwik LLP,law/consulting,"21 U.S.C. ¬ß 355(j)(7)(C) ‚Äì Discontinued drug exception for ANDAs
- 21 U.S.C. ¬ß 355(d) ‚Äì Drug approval requirements
- 21 C.F.R. ¬ß 314.161 ‚Äì Determining whether drug was withdrawn for safety or efficacy
- Additional citations include references to FDA precedents and letters, such as Docket Nos. FDA-2009-P-0088 and FDA-2005-P-0003, etc.","The petition comments on FDA‚Äôs determination of whether the original formulation of OxyContin¬Æ (Oxycodone Hydrochloride ER Tablets, NDA No. 20-553) was withdrawn for reasons of safety or efficacy, which would impact approval of generic versions referencing the discontinued formulation.","FDA should determine that the original OxyContin¬Æ formulation was not withdrawn for safety or efficacy reasons.
- FDA should permit approval of ANDAs referencing the original formulation under NDA No. 20-553, if all other requirements are met","Purdue Pharma admitted that the original formulation of OxyContin¬Æ was safe and effective when used as directed.
- Purdue marketed the product for over a decade despite known issues of abuse/diversion.
- Reformulated version was sold alongside the original for months, undermining claims of safety-based discontinuation.
- No new clinical efficacy or safety studies supported the reformulation.
- FDA has previously found similar cases not withdrawn for safety/efficacy (e.g., Zosyn, doxercalciferol).
- The Hatch-Waxman Act‚Äôs intent supports access to affordable generics, not brand control over market access",,"Denied ‚Äì FDA determined that the drug products covered by NDA 20-553 (OxyContin, original formulation) were withdrawn from sale for reasons of safety or effectiveness, which prohibits the approval of ANDAs referencing these formulations",2013-04-16,0.0,"Center for Drug Evaluation and Research (CDER) ‚Äì Signed by Gerald J. Dal Pan, M.D., M.S., Director, Office of Surveillance and Epidemiology.","Section 505(j) of the FD&C Act (21 U.S.C. ¬ß 355(j))
- 21 CFR 314.161 (withdrawal determination criteria)
- 21 CFR 314.127(a)(11) (basis for ANDA denial)
- 21 CFR 314.3(b) (definition of listed drug)
- 21 CFR 314.94(a)(5)(i) (bioequivalence and labeling requirements)
- Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments)
- Reference to Serono Labs, Inc. v. Shalala as precedent",,"FDA reviewed information including citizen petitions, docket comments, adverse event reports, and clinical literature.
- It concluded that original OxyContin (NDA 20-553) was withdrawn due to its high abuse potential, particularly when crushed or manipulated, which bypassed the extended-release mechanism and led to overdose and fatal events.
- The newer reformulated OxyContin (NDA 22-272) incorporates abuse-deterrent properties.
- Studies reviewed suggested, but did not confirm, a reduction in non-oral abuse, yet showed enough evidence of elevated abuse risk in the original formulation to conclude it was removed for safety concerns.
- As a result, FDA concluded it may not approve ANDAs referencing the original OxyContin product.",denied,True,706.0,CDER,CDER
fda-2010-p-0526,FDA-2010-P-0526-0001_Lachman_Consultant_Services__Inc____Citizen_Petiti,2010-09-30,2010,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"21 C.F.R. ¬ß 10.30 ‚Äì Citizen petition procedures
- 21 C.F.R. ¬ß 314.161 ‚Äì Determination if a drug was withdrawn for safety or efficacy reasons
- 21 C.F.R. ¬ß 314.162 ‚Äì Withdrawal or suspension of approval
- 21 C.F.R. ¬ß 25.31 ‚Äì Environmental assessment exclusion
- 21 C.F.R. ¬ß 10.30(b) ‚Äì Economic impact disclosure (if requested","The FDA‚Äôs listing of the original formulation of OxyContin¬Æ (oxycodone hydrochloride extended-release tablets) as discontinued in the Orange Book. Specifically, the Agency's potential decision on whether the withdrawal was due to safety or efficacy reasons, which would affect the ability to approve ANDAs for the original formulation.","The petitioner requests that FDA determine whether the original OxyContin¬Æ formulation (NDA 20-553 for 10‚Äì160 mg strengths) was withdrawn for safety or efficacy reasons. Additionally, the petitioner asks the FDA to address the implications for ANDA applicants referencing this formulation and how future approvals will be handled","The original OxyContin¬Æ formulation is no longer listed in the active section of the Orange Book but appears in the discontinued section.
- Purdue Pharma introduced a reformulated version with abuse-deterrent properties, suggesting discontinuation of the old version for commercial reasons, not safety/efficacy.
- FDA regulations require a formal determination before approving ANDAs based on withdrawn products.
- The decision will impact generic industry applicants and FDA‚Äôs policy toward approvals for older, non-abuse-deterrent formulations.
- If Purdue reintroduces the original product, Lachman will consider the petition moot",2011-03-28 00:00:00,"Denied ‚Äì FDA determined that the drug products covered by NDA 20-553 (OxyContin, original formulation) were withdrawn from sale for reasons of safety or effectiveness, which prohibits the approval of ANDAs referencing these formulations",2013-04-16,1.0,"Center for Drug Evaluation and Research (CDER) ‚Äì Signed by Gerald J. Dal Pan, M.D., M.S., Director, Office of Surveillance and Epidemiology.","Section 505(j) of the FD&C Act (21 U.S.C. ¬ß 355(j))
- 21 CFR 314.161 (withdrawal determination criteria)
- 21 CFR 314.127(a)(11) (basis for ANDA denial)
- 21 CFR 314.3(b) (definition of listed drug)
- 21 CFR 314.94(a)(5)(i) (bioequivalence and labeling requirements)
- Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments)
- Reference to Serono Labs, Inc. v. Shalala as precedent","The petition requested that FDA determine whether multiple strengths of OxyContin (oxycodone hydrochloride extended-release tablets) under NDA 20-553 were withdrawn for reasons of safety or effectiveness.
- FDA noted that it had not yet completed review of the matter due to the complexity of the issues involved.
- The interim response was issued in compliance with 21 CFR 10.30(e)(2), committing to respond fully once a decision had been reached.","FDA reviewed information including citizen petitions, docket comments, adverse event reports, and clinical literature.
- It concluded that original OxyContin (NDA 20-553) was withdrawn due to its high abuse potential, particularly when crushed or manipulated, which bypassed the extended-release mechanism and led to overdose and fatal events.
- The newer reformulated OxyContin (NDA 22-272) incorporates abuse-deterrent properties.
- Studies reviewed suggested, but did not confirm, a reduction in non-oral abuse, yet showed enough evidence of elevated abuse risk in the original formulation to conclude it was removed for safety concerns.
- As a result, FDA concluded it may not approve ANDAs referencing the original OxyContin product.",denied,True,929.0,CDER,CDER
fda-2010-p-0520,FDA-2010-P-0520-0001_Extremity_Innovations__Inc____Reclassification_Pet,2010-02-22,2010,False,original petition,"Extremity Innovations, Inc.",industry/corporation,"Section 513(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. ¬ß 360c(e)) ‚Äì Reclassification procedures
- 21 C.F.R. ¬ß 860.123 ‚Äì Reclassification petitions
- 21 C.F.R. ¬ß 10.30 ‚Äì Citizen petition regulations
- 21 C.F.R. ¬ß 25.30(h) ‚Äì Categorical exclusion from environmental assessment",The petitioner seeks to change the classification of the ‚ÄúTotal Wrist Joint Prosthesis‚Äù from Class III (Premarket Approval required) to Class II (Special Controls). This challenges the FDA‚Äôs current regulatory classification of the device.,Extremity Innovations requests that FDA reclassify Total Wrist Joint Prostheses intended to replace the carpal bones and distal radius from Class III to Class II with special controls applicable.,"The petitioner provided a Risk Analysis and Literature Review showing that special controls are sufficient to ensure safety and effectiveness.
- The reclassification would facilitate innovation and allow quicker access to such medical devices without compromising patient safety.
- Existing data and post-market surveillance show that serious risks can be mitigated through labeling, performance standards, and postmarket monitoring.
- The device has a well-established clinical history and benefits from mature design and surgical practices.
- Petition includes proposed special controls and comparison to similar reclassifications granted for orthopedic devices.",2011-03-09 00:00:00,Denied ‚Äì FDA denied the request to reclassify injectable silicone from a Class III to a Class II device.,2011-12-15,1.0,"Center for Devices and Radiological Health (CDRH) ‚Äì Signed by Nancy Stade, Deputy Director for Policy","Section 520(l) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- Section 201(h) and Section 201(g) of the FD&C Act
- 21 CFR ¬ß 10.30(e)(3)
- 21 CFR Part 3
- Sections 563(a) and 503(g)(1) of the FD&C Act","The petition requested that FDA reclassify an Injectable Silicone device (used as a prosthetic pad for pressure-related foot disorders) from Class III to Class II.
- FDA explained that a final decision was pending because the request raised issues requiring further review and analysis by agency officials.
- The letter served as an interim response in compliance with regulatory obligations.","FDA noted that injectable silicone has not been cleared or approved for the proposed indication (prosthetic pad for foot disorders).
- In contrast to its use as a lubricant or coating, the therapeutic effect in this petition relies on chemical action, not mechanical effect.
- Evidence suggested that silicone injections initiate an immunologic response, leading to fibrous tissue formation that provides cushioning‚Äînot the silicone itself.
- Because the effect is chemically mediated, the product does not meet the statutory definition of a device under section 201(h) and is instead considered a drug under section 201(g).
- Therefore, FDA concluded the reclassification request was not appropriate, and the product must follow drug approval pathways.",denied,True,661.0,CDRH,CDRH
fda-2010-p-0518,FDA-2010-P-0518-0012_Hoffmann_La_Roche__Inc____Pharmaceutical_Law_Group,2010-11-16,2010,False,original petition,"Extremity Innovations, Inc.",industry/corporation,"Section 513(f)(3) of the FDCA (21 U.S.C. ¬ß 360c(f)(3)) ‚Äì Device reclassification
- Section 520(l) ‚Äì Transitional device classification
- 21 C.F.R. ¬ß 860.123 ‚Äì Content and format for reclassification petitions
- 21 C.F.R. ¬ß 860.7 ‚Äì Criteria for evaluating safety and effectiveness
- 21 C.F.R. Part 54 ‚Äì Financial certification/disclosure
- 42 Fed. Reg. 63472 ‚Äì Original classification of injectable silicone in 1977","The petition addresses the original statutory classification of injectable silicone as a Class III transitional device (under ¬ß 520(l)), and requests its reclassification based on new evidence and usage history.","Reclassify ‚ÄúInjectable Silicone‚Äù from Class III to Class II, specifically when used as a prosthetic injectable pad for localized, pressure-related foot disorders","Silicone has been safely used in many Class II medical devices (e.g., syringes, sutures, catheters) over decades.
- The device‚Äôs specific use as a foot pad implant is low risk and well-studied.
- The material (polydimethylsiloxane) is biologically inert and documented in FDA Device Master File #1240 (NuSil).
- Cites widespread precedent and market history supporting its safety and effectiveness.
- FDA's own evolving guidance and scientific understanding support lower classification.
- Reclassification aligns with least burdensome principles under the Food and Drug Modernization Act of 1997 (FDAMA).
- Petition includes literature review and instructions for use as attachments to support safety claims",,,2025-10-15,0.0,,,,,no decision,False,5447.0,pending,pending
fda-2010-p-0518,FDA-2010-P-0518-0001_Hoffmann_La_Roche__Inc____Pharmaceutical_Law_Group,2010-09-23,2010,False,original petition,Hoffmann-La Roche Inc.,industry/corporation,"21 U.S.C. ¬ß 355(j)(5)(B)(iii)
- Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FDCA)
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 314.95(f)
- 21 C.F.R. ¬ß 314.107
- 21 U.S.C. ¬ß 355(q)(1)(H)",The FDA‚Äôs potential approval of ANDA No. 78-998 filed by Orchid Healthcare to market a generic version of Boniva¬Æ Once-Monthly. The petition specifically comments on the timing and stay of approval due to a Paragraph IV certification amendment concerning the '814 patent.,"The petitioner requests that the FDA confirm that the agency will stay approval of ANDA No. 78-998 for 30 months from July 26, 2010, pursuant to the statutory provision, due to the conversion of Orchid‚Äôs Paragraph III certification to a Paragraph IV certification and a timely patent infringement lawsuit by Roche","The '814 patent was listed in the Orange Book prior to the filing of Orchid‚Äôs ANDA.
- Orchid initially filed a Paragraph III certification but amended it to a Paragraph IV on July 23, 2010.
- Roche received the notice on July 26, 2010, and initiated a patent infringement lawsuit within 45 days (on September 3, 2010).
- Under the Hatch-Waxman Act (as amended by the MMA), a 30-month stay is applicable in this context.
- FDA‚Äôs 2004 draft guidance also supports the application of a second 30-month stay in such cases.
- This scenario exactly matches FDA‚Äôs own example of when a second 30-month stay is permissible",,,2025-10-15,0.0,,,,,no decision,False,5501.0,pending,pending
fda-2010-p-0507,FDA-2010-P-0507-0009_Perrigo_Company___Petition_for_Reconsideration,2011-09-15,2010,False,reconsideration,Perrigo Company,industry/corporation,"21 C.F.R. ¬ß 10.33(d) (criteria for reconsideration)
- 21 C.F.R. ¬ß 10.33(e)
- FDA Guidance for Industry: E9 Statistical Principles for Clinical Trials
- Administrative Procedure Act, 5 U.S.C. ¬ß 706(2)(A)","FDA‚Äôs August 17, 2011 decision declaring that HalfLytely¬Æ & Bisacodyl Tablet Bowel Prep Kit (10 mg bisacodyl) was withdrawn from sale for reasons of safety or effectiveness","Reconsider FDA‚Äôs decision and conclude that the product was not withdrawn for reasons of safety or effectiveness. Alternatively, issue a revised decision that fully explains the agency‚Äôs reasonin","FDA‚Äôs conclusion was based on non-statistically significant findings regarding adverse events like abdominal cramping and fullness.
- FDA did not adequately consider data showing that vomiting (a serious side effect) was more prevalent in the 5 mg product.
- Only one non-definitively linked case of ischemic colitis was reported, making it insufficient to claim a safety concern.
- The original decision did not address these points comprehensively.
- Allowing reconsideration would enable generic competition and lower drug costs, aligning with Hatch-Waxman intent",,,2025-10-15,0.0,,,,,no decision,False,5144.0,pending,pending
fda-2010-p-0507,FDA-2010-P-0507-0004_Perrigo_Company_to_FDA_CDER___Letter,2011-02-14,2010,False,original petition,Perrigo Company,industry/corporation,"21 C.F.R. ¬ß 314.122 ‚Äì Petition regarding withdrawn drug listing
- 21 C.F.R. ¬ß 314.161 ‚Äì Determining if withdrawal was for reasons of safety or effectiveness
- Indirect references to Hatch-Waxman Amendments and their legislative intent (e.g., H.R. Rep. No. 857, 98th Cong. 1st Sess.)","FDA‚Äôs failure to rule on Perrigo‚Äôs petition concerning the status of Braintree‚Äôs HalfLytely¬Æ with 10 mg bisacodyl tablets‚Äîspecifically, whether it was withdrawn for safety or effectiveness reasons.","FDA should expeditiously determine whether HalfLytely¬Æ with 10 mg bisacodyl was withdrawn for safety or effectiveness reasons, which would allow FDA to approve Perrigo‚Äôs pending ANDA No. 90-197","Perrigo‚Äôs ANDA for a generic version of HalfLytely¬Æ was tentatively approved as early as May 2010.
- Braintree discontinued the 10 mg version only after FDA approved a 5 mg version, without issuing recalls or safety notices.
- Clinical data reviewed by FDA showed no statistically significant safety concerns between 10 mg and 5 mg versions (referencing FDA Clinical Review NDA 21-551/S-013).
- Perrigo contends the withdrawal was commercially motivated to prevent generic competition, not safety-related.
- Delay in FDA‚Äôs decision is economically disadvantaging U.S. consumers by preventing access to a lower-cost generic alternative",,Denied ‚Äì The FDA determined that the product was withdrawn from sale for reasons of safety or effectiveness and will not accept or approve ANDAs referencing it,2011-08-19,0.0,"Center for Drug Evaluation and Research (CDER) (indicated in the sign-off line: ""Office of Regulatory Policy, Center for Drug Evaluation and Research"")","21 CFR 314.161
- 21 CFR 314.162
- 21 CFR 10.30 (citizen petition regulation)
- 21 U.S.C. 355(j)(7) (FDCA section on drug listing)",,"FDA reviewed its records, clinical trials, literature, and postmarketing adverse event reports
.
- The 10 mg bisacodyl version was found to have comparable effectiveness to the 5 mg version, but with increased abdominal cramping and fullness, and potential association with ischemic colitis.
- FDA required additional clinical data and labeling changes for any reintroduction of the 10 mg version.
- As a result, it concluded that the product had been withdrawn from sale for reasons of safety or effectiveness and removed it from the Orange Book listing.",denied,True,186.0,CDER,CDER
fda-2010-p-0507,FDA-2010-P-0507-0001_Perrigo_Company___Citizen_Petition,2010-09-22,2010,False,original petition,Perrigo Company,industry/corporation,"21 C.F.R. ¬ß 10.25
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 314.122
- 21 C.F.R. ¬ß 314.161
- 21 C.F.R. ¬ß 25.31",The FDA‚Äôs process for determining whether a discontinued drug (HalfLytely¬Æ & Bisacodyl Tablets Bowel Prep Kit with two 5 mg tablets) was withdrawn for reasons of safety or effectiveness.,"FDA is requested to determine that the specific formulation of HalfLytely¬Æ & Bisacodyl Tablets Bowel Prep Kit (with two 5 mg Bisacodyl tablets, NDA No. 21-551/S-006) was not withdrawn for reasons of safety or effectiveness and to approve the pending ANDA (No. 90-197) submitted by Novel Laboratories (later acquired by Perrigo).","The withdrawal of the original drug formulation was not due to safety or effectiveness concerns, but rather a commercial tactic by Braintree Laboratories to delay generic competition.
- Braintree did not issue recalls, safety notifications, or ""Dear Doctor"" letters when changing the formulation.
- The new version (one 5 mg tablet) was introduced just as Perrigo sought final ANDA approval.
- FDA has previously acknowledged that a 10 mg dosage of Bisacodyl is safe and effective, aligning with the older formulation.
- Regulatory and market evidence supports that the move was financially motivated, not safety-driven",,Denied ‚Äì The FDA determined that the product was withdrawn from sale for reasons of safety or effectiveness and will not accept or approve ANDAs referencing it,2011-08-19,0.0,"Center for Drug Evaluation and Research (CDER) (indicated in the sign-off line: ""Office of Regulatory Policy, Center for Drug Evaluation and Research"")","21 CFR 314.161
- 21 CFR 314.162
- 21 CFR 10.30 (citizen petition regulation)
- 21 U.S.C. 355(j)(7) (FDCA section on drug listing)",,"FDA reviewed its records, clinical trials, literature, and postmarketing adverse event reports
.
- The 10 mg bisacodyl version was found to have comparable effectiveness to the 5 mg version, but with increased abdominal cramping and fullness, and potential association with ischemic colitis.
- FDA required additional clinical data and labeling changes for any reintroduction of the 10 mg version.
- As a result, it concluded that the product had been withdrawn from sale for reasons of safety or effectiveness and removed it from the Orange Book listing.",denied,True,331.0,CDER,CDER
fda-2010-p-0505,FDA-2010-P-0505-0001_Virginia_Commonwealth_University__VCU___School_of_,2010-09-21,2010,False,original petition,"Virginia Commonwealth University (VCU) School of Medicine, Department of Pharmacology and Toxicology",advocacy/academic,"21 C.F.R. ¬ß 10.25(a)
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 314.161
- 21 C.F.R. ¬ß 25.31 (for environmental exclusion)","The FDA‚Äôs classification of Orlaam¬Æ (levomethadyl acetate HCl) as discontinued in the Electronic Orange Book, and whether its withdrawal from market was due to safety or efficacy reasons","The petitioner requests the FDA to:
- Determine whether Orlaam¬Æ (levomethadyl acetate HCl), NDA 20-315, was withdrawn for safety or effectiveness reasons; and
- Confirm its eligibility as a Reference Listed Drug (RLD) to support an ANDA","Orlaam¬Æ was voluntarily discontinued by Roxane Laboratories in 2003 for commercial reasons, not safety/efficacy.
- It remains the only levomethadyl acetate product in the Orange Book.
- No specific MedWatch notices or labeling updates have been issued since 2001.
- The product‚Äôs last approved labeling was issued in May 2001.
- Attachments include the Orange Book listing, original labeling, correspondence from addiction medicine organizations, and a Roxane discontinuation letter",2011-03-21 00:00:00,"Denied ‚Äì FDA concluded that ORLAAM (levomethadyl acetate HCl) oral solution, 10 mg/mL was not withdrawn for reasons of safety or effectiveness",2011-06-06,1.0,Center for Drug Evaluation and Research (CDER) ‚Äì Referenced through the contact information for Sandra Park and regulatory citations,"21 CFR 314.161(a)(1)
- 21 CFR 314.162
- 21 CFR 10.30
- 21 U.S.C. 355(j)(7)","The petition raised complex issues.
- It required extensive review and analysis by FDA officials.
- Therefore, FDA was not yet able to reach a decision","The petitioner presented no data suggesting the product was withdrawn for safety or effectiveness reasons.
- FDA reviewed internal records, conducted an independent review of literature, and analyzed postmarketing adverse event data.
- FDA found no evidence of withdrawal due to safety or efficacy concerns.
- Therefore, the product remains in the ""Discontinued Drug Product List"" as discontinued for reasons other than safety or effectiveness, and ANDAs may still be approved",denied,True,258.0,CDER,CDER
fda-2010-p-0504,FDA-2010-P-0504-0001_GMA_Nut_Safety_Task_Force___Citizen_Petition,2010-09-17,2010,False,original petition,GMA Nut Safety Task Force,advocacy/academic,"No specific statutes or regulations like 505(q) or 21 C.F.R. 10.30 are cited. Instead, the petition references a previously submitted petition regarding low-moisture products, and a partnership agreement with FDA (PA-07) for food safety recognition of ACFSQ programs","FDA‚Äôs past efforts and guidance development for microbial hazards in produce (e.g., fresh-cut fruits, tomatoes, leafy greens, melons), and the need for similar action for nuts","The Task Force requests that the FDA:
‚Ä¢ Develop guidance for industry on controlling Salmonella and other food safety hazards in peanuts and tree nuts,
‚Ä¢ Create comprehensive, risk-based, flexible guidance appropriate to nut types and production stages,
‚Ä¢ Consider and potentially adopt the attached Industry Handbook for Safe Processing of Nuts","Rising concern over Salmonella outbreaks traced to nut products (e.g., peanut butter in 2006‚Äì2009 and pistachios in 2009).
‚Ä¢ Global trends in Salmonella outbreaks linked to low-moisture foods.
‚Ä¢ The industry has developed the Industry Handbook for Safe Processing of Nuts as a proactive resource.
‚Ä¢ The petition advocates preventive food safety strategies and emphasizes the role of industry-wide hazard analysis and good practices.
‚Ä¢ Encouraging shared responsibility across the supply chain for stronger safety protocols",,,2025-10-15,0.0,,,,,no decision,False,5507.0,pending,pending
fda-2010-p-0491,FDA-2010-P-0491-2104_National_Consumers_League_et_al_Letter,2012-04-17,2010,False,original petition,"National Consumers League, with co-signatories: Consumers Union, Consumer Federation of America, Shape Up America!",advocacy/academic,"Not Explicitly Stated in the document. While regulatory concerns are discussed, no formal citations (e.g., 21 C.F.R. 10.30 or section 505(q)) are included.","The petition by the Corn Refiners Association (CRA) to allow ""corn sugar"" as an alternate name for high fructose corn syrup (HFCS)","The signatories request that FDA deny the CRA petition and prohibit use of ""corn sugar"" as a synonym for HFCS in labeling and advertising.","The name change would mislead consumers and conceal HFCS on labels.
- Inconsistent with FDA‚Äôs naming regulations, which have long recognized ‚Äúhigh fructose corn syrup.‚Äù
- HFCS is chemically distinct from dextrose, which is already known as ""corn sugar.""
- CRA's marketing efforts (e.g., ‚ÄúSweetSurprise.com‚Äù) are confusing the public.
- Nearly 5,000 consumer comments oppose the CRA petition, with only ~40 supporting it.
- FDA has already issued a warning letter (July 12, 2011) to CRA about misuse of the term ""corn sugar.""",,"Denied ‚Äì FDA denied the petition to authorize ""corn sugar"" as an alternate common or usual name for HFCS in accordance with 21 CFR 10.30(e)(3).",2012-05-30,0.0,"Center for Food Safety and Applied Nutrition (CFSAN) ‚Äì Signed by Michael M. Landa, Director of CFSAN (see signature on page 4).","21 CFR 10.30(e)(3) ‚Äì Citizen petition regulation
- 21 CFR 102.5(a) ‚Äì Common or usual name criteria
- 21 CFR 168.111 ‚Äì Dextrose monohydrate identity
- 21 CFR 168.120, 168.130, 168.140, 168.160, 168.180 ‚Äì Syrup identity standards (glucose, cane, maple, sorghum, table syrup)
- 21 CFR 184.1854 ‚Äì Sucrose GRAS regulation
- 21 CFR 184.1857 ‚Äì Corn sugar GRAS regulation for dextrose
- 21 CFR 168.122 ‚Äì Lactose labeling",,"FDA's naming policy differentiates between sugars (solid, crystallized) and syrups (aqueous/liquid); HFCS is a syrup, not a sugar.
- Allowing HFCS to be labeled ‚Äúcorn sugar‚Äù would mislead consumers, as ‚Äúcorn sugar‚Äù has long referred to dextrose, not HFCS.
- FDA‚Äôs regulations have used ‚Äúcorn sugar‚Äù to mean dextrose for over 30 years.
- ‚ÄúCorn sugar‚Äù is rarely used on food labels; changing the term may create public health risks for individuals with hereditary fructose intolerance, who rely on labels to avoid HFCS.
- FDA found no compelling evidence that ‚Äúcorn sugar‚Äù is commonly understood to mean HFCS, or that existing naming conventions are misleading.",denied,True,43.0,CFSAN,Other/Specialty Center
fda-2010-p-0491,FDA-2010-P-0491-1064_Sugar_Association_Wenable_LLP_Supplement,2011-12-15,2010,False,original petition,The Sugar Association,advocacy/academic,"FDCA ¬ß 403(a) ‚Äì prohibiting false or misleading labeling
- FDCA ¬ß 403(i) ‚Äì requiring clear identification of food ingredients
- Section 401 ‚Äì relating to honesty and fair dealing in food naming
- 21 C.F.R. Part 102 (implied through discussion of ‚Äúcommon or usual name‚Äù regulation)","The petition filed by the Corn Refiners Association (CRA) to allow ""corn sugar"" as an alternate name for high fructose corn syrup (HFCS)","The Sugar Association urges the FDA to deny the CRA petition that proposes renaming HFCS as ""corn sugar""","Misleading to consumers: Survey evidence (Cohen Study) shows consumers misunderstand ‚Äúcorn sugar‚Äù as something different from HFCS.
- Health risk: Some consumers avoid HFCS due to health concerns; renaming could obscure presence of HFCS.
- Violation of FDCA: Misbranding under ¬ß403(a), misidentification of ingredients under ¬ß403(i), undermining honesty under ¬ß401.
- No precedent: Unlike changes like ‚Äúcanola oil‚Äù or ‚Äúdried plums,‚Äù ‚Äúcorn sugar‚Äù already refers to a different, established ingredient (dextrose).
- Scientific dispute: Metabolic effects of HFCS vs. sugar are not identical; CRA's scientific claims are unsupported or weakly substantiated.
- Survey flaws: The CRA-commissioned MSR Group survey was criticized for methodological flaws, including lack of ‚Äúdon‚Äôt know‚Äù options and non-representative sampling.",,"Denied ‚Äì FDA denied the petition to authorize ""corn sugar"" as an alternate common or usual name for HFCS in accordance with 21 CFR 10.30(e)(3).",2012-05-30,0.0,"Center for Food Safety and Applied Nutrition (CFSAN) ‚Äì Signed by Michael M. Landa, Director of CFSAN (see signature on page 4).","21 CFR 10.30(e)(3) ‚Äì Citizen petition regulation
- 21 CFR 102.5(a) ‚Äì Common or usual name criteria
- 21 CFR 168.111 ‚Äì Dextrose monohydrate identity
- 21 CFR 168.120, 168.130, 168.140, 168.160, 168.180 ‚Äì Syrup identity standards (glucose, cane, maple, sorghum, table syrup)
- 21 CFR 184.1854 ‚Äì Sucrose GRAS regulation
- 21 CFR 184.1857 ‚Äì Corn sugar GRAS regulation for dextrose
- 21 CFR 168.122 ‚Äì Lactose labeling",,"FDA's naming policy differentiates between sugars (solid, crystallized) and syrups (aqueous/liquid); HFCS is a syrup, not a sugar.
- Allowing HFCS to be labeled ‚Äúcorn sugar‚Äù would mislead consumers, as ‚Äúcorn sugar‚Äù has long referred to dextrose, not HFCS.
- FDA‚Äôs regulations have used ‚Äúcorn sugar‚Äù to mean dextrose for over 30 years.
- ‚ÄúCorn sugar‚Äù is rarely used on food labels; changing the term may create public health risks for individuals with hereditary fructose intolerance, who rely on labels to avoid HFCS.
- FDA found no compelling evidence that ‚Äúcorn sugar‚Äù is commonly understood to mean HFCS, or that existing naming conventions are misleading.",denied,True,167.0,CFSAN,Other/Specialty Center
fda-2010-p-0491,FDA-2010-P-0491-0156_The_Honorable_Charles_E__Grassley__et_al___to_the_,2011-06-24,2010,False,original petition,"U.S. Senators: Charles E. Grassley, Ben Nelson, Mike Johanns, Richard G. Lugar, Roy Blunt, Claire McCaskill, and Dan Coats",individual,Not Mentioned (No statutory references such as 21 C.F.R. or FDCA sections are cited),"The Senators are commenting on FDA Petition FDA-2010-P-0491: the Corn Refiners Association‚Äôs request to allow ""corn sugar"" as an alternate name for high fructose corn syrup (HFCS) on food labels","The Senators urge FDA to expeditiously review and give due consideration to the CRA petition, with the intent of allowing the use of ""corn sugar"" on ingredient labels.","Consumer clarity: ""Corn sugar"" is easier for consumers to understand than HFCS.
- Survey data: 70% of Americans could not identify HFCS from the ADA definition, but better understood ""corn sugar"".
- Correct misperceptions: HFCS 42 is low in fructose, yet consumers wrongly believe it contains more fructose than sugar.
- Scientific equivalence: ADA and AMA consider sugar and HFCS nutritionally equivalent.
- Economic importance: HFCS supports affordable food, domestic jobs (65,000+), and U.S.-grown corn.
- Name mischaracterization: Current term ""high fructose corn syrup"" has contributed to public misunderstanding",2011-08-01 00:00:00,"Denied ‚Äì FDA denied the petition to authorize ""corn sugar"" as an alternate common or usual name for HFCS in accordance with 21 CFR 10.30(e)(3).",2012-05-30,3.0,"Center for Food Safety and Applied Nutrition (CFSAN) ‚Äì Signed by Michael M. Landa, Director of CFSAN (see signature on page 4).","21 CFR 10.30(e)(3) ‚Äì Citizen petition regulation
- 21 CFR 102.5(a) ‚Äì Common or usual name criteria
- 21 CFR 168.111 ‚Äì Dextrose monohydrate identity
- 21 CFR 168.120, 168.130, 168.140, 168.160, 168.180 ‚Äì Syrup identity standards (glucose, cane, maple, sorghum, table syrup)
- 21 CFR 184.1854 ‚Äì Sucrose GRAS regulation
- 21 CFR 184.1857 ‚Äì Corn sugar GRAS regulation for dextrose
- 21 CFR 168.122 ‚Äì Lactose labeling","FDA stated that it was reviewing the CRA petition using its technical and scientific staff.
- The evaluation included: petitioner-provided data, scientific information, consumer research, and applicable laws.
- The agency opened a public docket (FDA-2010-P-0491) to receive stakeholder input.
- No final action or decision had been taken at the time of this letter","FDA's naming policy differentiates between sugars (solid, crystallized) and syrups (aqueous/liquid); HFCS is a syrup, not a sugar.
- Allowing HFCS to be labeled ‚Äúcorn sugar‚Äù would mislead consumers, as ‚Äúcorn sugar‚Äù has long referred to dextrose, not HFCS.
- FDA‚Äôs regulations have used ‚Äúcorn sugar‚Äù to mean dextrose for over 30 years.
- ‚ÄúCorn sugar‚Äù is rarely used on food labels; changing the term may create public health risks for individuals with hereditary fructose intolerance, who rely on labels to avoid HFCS.
- FDA found no compelling evidence that ‚Äúcorn sugar‚Äù is commonly understood to mean HFCS, or that existing naming conventions are misleading.",denied,True,341.0,CFSAN,Other/Specialty Center
fda-2010-p-0491,FDA-2010-P-0491-0154_The_Honorable_Tom_Hankin_to_the_Commissioner_for_F,2011-04-08,2010,False,original petition,"Senator Tom Harkin, United States Senate, Iowa",individual,"21 C.F.R. 184.1866: Regulation for substances Generally Recognized As Safe (GRAS)
- 21 C.F.R. 102.5(a): Regulation for common or usual names of food products","The FDA‚Äôs consideration of CRA's Citizen Petition FDA-2010-P-0491, which requests approval to use ‚Äúcorn sugar‚Äù as the alternate common or usual name for high fructose corn syrup (HFCS)","Urges FDA to revise the GRAS affirmation regulation to recognize ‚Äúcorn sugar‚Äù as an alternate name for HFCS
- Additionally suggests allowing co-labeling, where ‚Äúcorn sugar‚Äù appears in parentheses after ‚Äúhigh fructose corn syrup‚Äù to aid consumer understanding","Terminology confusion: ‚ÄúHigh fructose corn syrup‚Äù is confusing and misleading to consumers, suggesting it differs from sugar more than it does.
- Consumer clarity: ‚ÄúCorn sugar‚Äù better reflects the ingredient‚Äôs composition and helps consumers understand its nature.
- Scientific equivalence: HFCS is essentially equivalent to sugar in sweetness, calories, and use.
- Media support: The New York Times opined that ‚Äúcorn sugar‚Äù might more clearly signal added sugars.
- Label accuracy: Promotes transparency and informed consumer choice, aligning with principles of truthful labeling",2011-05-24 00:00:00,Procedural Request / Pause in Review ‚Äì FDA paused full review and asked petitioner to address a conflict with existing regulation before continuing.,2011-04-29,4.0,"Center for Food Safety and Applied Nutrition (CFSAN) ‚Äì Signed by Barbara O. Schneeman, Ph.D., Director, Office of Nutrition, Labeling and Dietary Supplements","21 CFR 184.1866(a) ‚Äì GRAS regulation for HFCS
- 21 CFR 168.111(a)-(c) ‚Äì Standard of identity for dextrose monohydrate
- 21 CFR 184.1857 ‚Äì Existing GRAS affirmation for ‚Äúcorn sugar‚Äù (dextrose)","FDA was actively reviewing CRA‚Äôs petition, including scientific data and consumer research.
- The agency opened a public docket (FDA-2010-P-0491) for stakeholder input.
- FDA stated that co-labeling of HFCS as ‚Äúcorn sugar‚Äù would not be allowed at that time, since the agency had not yet concluded that ‚Äúcorn sugar‚Äù is an appropriate alternative name.
- The decision emphasized that truthful and accurate labeling is essential and premature co-labeling would undermine this standard.","The Corn Refiners Association requested that FDA allow ‚Äúcorn sugar‚Äù as a new name for HFCS.
- FDA noted that ‚Äúcorn sugar‚Äù is already defined under 21 CFR 184.1857 as dextrose, which creates a conflict.
- The petition failed to address this existing definition or its regulatory implications.
- FDA requested clarification: whether CRA wanted to proceed with the current petition or amend it to address this regulatory conflict.",other,True,21.0,CFSAN,Other/Specialty Center
fda-2010-p-0491,FDA-2010-P-0491-0109_Corn_Refiners_Association___Supplement,2011-06-23,2010,False,original petition,Corn Refiners Association (CRA),advocacy/academic,"Not Mentioned in this specific supplement. (The original petition, not shown here, referenced 21 C.F.R. 102.5(a); this document does not repeat it.)","Ongoing FDA review of the CRA Citizen Petition (Docket FDA-2010-P-0491) requesting to rename ""high fructose corn syrup"" (HFCS) as ""corn sugar""",Request to include and consider recent articles submitted with this supplement as supporting evidence for CRA‚Äôs petition to allow ‚Äúcorn sugar‚Äù as an alternate name for HFCS,"Submitted articles from academic, journalism, and food science authors assert the nutritional and metabolic equivalence of HFCS and sugar.
- CRA argues that these materials further support the need for a more accurate name for HFCS to better inform consumers",2011-08-01 00:00:00,"Denied ‚Äì FDA denied the petition to authorize ""corn sugar"" as an alternate common or usual name for HFCS in accordance with 21 CFR 10.30(e)(3).",2012-05-30,3.0,"Center for Food Safety and Applied Nutrition (CFSAN) ‚Äì Signed by Michael M. Landa, Director of CFSAN (see signature on page 4).","21 CFR 10.30(e)(3) ‚Äì Citizen petition regulation
- 21 CFR 102.5(a) ‚Äì Common or usual name criteria
- 21 CFR 168.111 ‚Äì Dextrose monohydrate identity
- 21 CFR 168.120, 168.130, 168.140, 168.160, 168.180 ‚Äì Syrup identity standards (glucose, cane, maple, sorghum, table syrup)
- 21 CFR 184.1854 ‚Äì Sucrose GRAS regulation
- 21 CFR 184.1857 ‚Äì Corn sugar GRAS regulation for dextrose
- 21 CFR 168.122 ‚Äì Lactose labeling","FDA stated that it was reviewing the CRA petition using its technical and scientific staff.
- The evaluation included: petitioner-provided data, scientific information, consumer research, and applicable laws.
- The agency opened a public docket (FDA-2010-P-0491) to receive stakeholder input.
- No final action or decision had been taken at the time of this letter","FDA's naming policy differentiates between sugars (solid, crystallized) and syrups (aqueous/liquid); HFCS is a syrup, not a sugar.
- Allowing HFCS to be labeled ‚Äúcorn sugar‚Äù would mislead consumers, as ‚Äúcorn sugar‚Äù has long referred to dextrose, not HFCS.
- FDA‚Äôs regulations have used ‚Äúcorn sugar‚Äù to mean dextrose for over 30 years.
- ‚ÄúCorn sugar‚Äù is rarely used on food labels; changing the term may create public health risks for individuals with hereditary fructose intolerance, who rely on labels to avoid HFCS.
- FDA found no compelling evidence that ‚Äúcorn sugar‚Äù is commonly understood to mean HFCS, or that existing naming conventions are misleading.",denied,True,342.0,CFSAN,Other/Specialty Center
fda-2010-p-0491,FDA-2010-P-0491-0105_State_of_Minnesota_Office_of_Lieutenant_Governor_t,2011-05-05,2010,False,original petition,"Lieutenant Governor Yvonne Prettner Solon, Office of the Lieutenant Governor, State of Minnesota",individual,Not Mentioned,The FDA‚Äôs consideration of the Corn Refiners Association (CRA) petition to rename high fructose corn syrup (HFCS) as ‚Äúcorn sugar‚Äù,No action requested. The letter withdraws prior support for the CRA petition and communicates that the State of Minnesota holds no official position on the matter,"Originally expressed support for the CRA petition, but withdrew that support after further review.
- Emphasizes Minnesota‚Äôs commitment to a strong agricultural sector and a balanced approach to policy.
- Recognizes the importance of accurate consumer information and working collaboratively across agricultural interests",2011-05-24 00:00:00,"Denied ‚Äì FDA denied the petition to authorize ""corn sugar"" as an alternate common or usual name for HFCS in accordance with 21 CFR 10.30(e)(3).",2012-05-30,4.0,"Center for Food Safety and Applied Nutrition (CFSAN) ‚Äì Signed by Michael M. Landa, Director of CFSAN (see signature on page 4).","21 CFR 10.30(e)(3) ‚Äì Citizen petition regulation
- 21 CFR 102.5(a) ‚Äì Common or usual name criteria
- 21 CFR 168.111 ‚Äì Dextrose monohydrate identity
- 21 CFR 168.120, 168.130, 168.140, 168.160, 168.180 ‚Äì Syrup identity standards (glucose, cane, maple, sorghum, table syrup)
- 21 CFR 184.1854 ‚Äì Sucrose GRAS regulation
- 21 CFR 184.1857 ‚Äì Corn sugar GRAS regulation for dextrose
- 21 CFR 168.122 ‚Äì Lactose labeling","FDA was actively reviewing CRA‚Äôs petition, including scientific data and consumer research.
- The agency opened a public docket (FDA-2010-P-0491) for stakeholder input.
- FDA stated that co-labeling of HFCS as ‚Äúcorn sugar‚Äù would not be allowed at that time, since the agency had not yet concluded that ‚Äúcorn sugar‚Äù is an appropriate alternative name.
- The decision emphasized that truthful and accurate labeling is essential and premature co-labeling would undermine this standard.","FDA's naming policy differentiates between sugars (solid, crystallized) and syrups (aqueous/liquid); HFCS is a syrup, not a sugar.
- Allowing HFCS to be labeled ‚Äúcorn sugar‚Äù would mislead consumers, as ‚Äúcorn sugar‚Äù has long referred to dextrose, not HFCS.
- FDA‚Äôs regulations have used ‚Äúcorn sugar‚Äù to mean dextrose for over 30 years.
- ‚ÄúCorn sugar‚Äù is rarely used on food labels; changing the term may create public health risks for individuals with hereditary fructose intolerance, who rely on labels to avoid HFCS.
- FDA found no compelling evidence that ‚Äúcorn sugar‚Äù is commonly understood to mean HFCS, or that existing naming conventions are misleading.",denied,True,391.0,CFSAN,Other/Specialty Center
fda-2010-p-0491,FDA-2010-P-0491-0081_John_P__Foreyt__Ph_D____Letter_,2011-03-16,2010,False,original petition,"John P. Foreyt, Ph.D., Professor, Behavioral Medicine Research Center, Baylor College of Medicine",advocacy/academic,Not Mentioned,The Corn Refiners Association (CRA) Citizen Petition (FDA-2010-P-0491-0001) to rename ‚Äúhigh fructose corn syrup‚Äù (HFCS) as ‚Äúcorn sugar‚Äù,"Dr. Foreyt supports the renaming of HFCS to ‚Äúcorn sugar‚Äù, and asks that the FDA consider approving the alternate name","The term ‚Äúhigh fructose corn syrup‚Äù is misleading and confusing to consumers.
- HFCS is metabolized the same way as sugar and honey, and is an added sugar like them.
- A more accurate term like ‚Äúcorn sugar‚Äù helps consumers recognize it as an added sugar, facilitating healthier dietary choices.
- Emphasizes the importance of clear labeling to support informed decisions in healthy lifestyles",2011-04-07 00:00:00,Procedural Request / Pause in Review ‚Äì FDA paused full review and asked petitioner to address a conflict with existing regulation before continuing.,2011-04-29,5.0,"Center for Food Safety and Applied Nutrition (CFSAN) ‚Äì Signed by Barbara O. Schneeman, Ph.D., Director, Office of Nutrition, Labeling and Dietary Supplements","21 CFR 184.1866(a) ‚Äì GRAS regulation for HFCS
- 21 CFR 168.111(a)-(c) ‚Äì Standard of identity for dextrose monohydrate
- 21 CFR 184.1857 ‚Äì Existing GRAS affirmation for ‚Äúcorn sugar‚Äù (dextrose)","FDA had not completed review within 180 days due to other agency priorities and limited resource availability.
- FDA committed to continue the review and consider warranted amendments in regulatory context and other program priorities.","The Corn Refiners Association requested that FDA allow ‚Äúcorn sugar‚Äù as a new name for HFCS.
- FDA noted that ‚Äúcorn sugar‚Äù is already defined under 21 CFR 184.1857 as dextrose, which creates a conflict.
- The petition failed to address this existing definition or its regulatory implications.
- FDA requested clarification: whether CRA wanted to proceed with the current petition or amend it to address this regulatory conflict.",other,True,44.0,CFSAN,Other/Specialty Center
fda-2010-p-0491,FDA-2010-P-0491-0001_Corn_Refiners_Association_Citizen_Petition,2010-09-14,2010,False,original petition,Corn Refiners Association (CRA),advocacy/academic,"21 U.S.C. ¬ß¬ß 321(s), 342, 348, 371 (Federal Food, Drug, and Cosmetic Act Sections 201(s), 402, 409, and 701)
- 21 C.F.R. ¬ß 184.1866 (GRAS affirmation regulation for HFCS)
- 21 C.F.R. ¬ß 168.111 (Standard of identity for dextrose monohydrate)
- 21 C.F.R. ¬ß 102.5(a) (FDA regulation on common or usual name)","FDA‚Äôs existing naming conventions for high fructose corn syrup (HFCS) under GRAS and labeling regulations
- The regulation of ingredient nomenclature as it pertains to HFCS in the food labeling context","Revise 21 C.F.R. ¬ß 184.1866 to recognize ‚Äúcorn sugar‚Äù as an alternate common or usual name for HFCS
- Amend 21 C.F.R. ¬ß 168.111 to eliminate ‚Äúcorn sugar‚Äù and ‚Äúcorn sugar monohydrate‚Äù as synonyms for dextrose, thereby reserving ‚Äúcorn sugar‚Äù for HFCS instead","Consumer confusion: Studies show widespread misunderstanding of the term ‚Äúhigh fructose corn syrup‚Äù ‚Äì many consumers mistakenly believe it contains more fructose and is sweeter or higher in calories than sugar.
- Scientific equivalence: HFCS and sucrose (table sugar) have similar glucose-to-fructose ratios (~1:1), caloric content, and sweetness.
- FDA precedent: The petition cites earlier naming changes such as ‚Äúcanola oil‚Äù and ‚Äúdried plums‚Äù as examples of FDA allowing changes to reflect consumer understanding and eliminate negative perceptions.
- MSR consumer research survey: Confirms that ‚Äúcorn sugar‚Äù better reflects HFCS properties and helps align with consumer expectations.
- FDA regulatory consistency: Petition argues that ‚Äúcorn sugar‚Äù meets the definition under 21 C.F.R. ¬ß 102.5(a) for a common or usual name by identifying the food‚Äôs character, source, and function",2011-04-07 00:00:00,Procedural Request / Pause in Review ‚Äì FDA paused full review and asked petitioner to address a conflict with existing regulation before continuing.,2011-04-29,5.0,"Center for Food Safety and Applied Nutrition (CFSAN) ‚Äì Signed by Barbara O. Schneeman, Ph.D., Director, Office of Nutrition, Labeling and Dietary Supplements","21 CFR 184.1866(a) ‚Äì GRAS regulation for HFCS
- 21 CFR 168.111(a)-(c) ‚Äì Standard of identity for dextrose monohydrate
- 21 CFR 184.1857 ‚Äì Existing GRAS affirmation for ‚Äúcorn sugar‚Äù (dextrose)","FDA had not completed review within 180 days due to other agency priorities and limited resource availability.
- FDA committed to continue the review and consider warranted amendments in regulatory context and other program priorities.","The Corn Refiners Association requested that FDA allow ‚Äúcorn sugar‚Äù as a new name for HFCS.
- FDA noted that ‚Äúcorn sugar‚Äù is already defined under 21 CFR 184.1857 as dextrose, which creates a conflict.
- The petition failed to address this existing definition or its regulatory implications.
- FDA requested clarification: whether CRA wanted to proceed with the current petition or amend it to address this regulatory conflict.",other,True,227.0,CFSAN,Other/Specialty Center
fda-2010-p-0460,FDA-2010-P-0460-0003_Alaunus_Pharmaceutical_LLC__Amendment,2011-12-08,2010,False,original petition,"Alaunus Pharmaceutical, LLC",industry/corporation,"USP <1> Injection monograph (referenced for defining Pharmacy Bulk Package labeling)

Note: No explicit citation of 21 C.F.R. or FDCA sections in this amendment document.",FDA policy requiring an ANDA Suitability Petition for changes to total drug content in a parenteral drug product,"Approval to amend the ANDA Suitability Petition to permit a change in vial size and drug content for Midazolam Injection, 5 mg/mL:
- From 50 mg in a 10 mL fliptop vial (RLD by Hospira)
- To 500 mg in a 100 mL Single Use Pharmacy Bulk Package","The concentration remains unchanged (5 mg/mL), only the total drug content and vial size are modified.
- Intended to enhance hospital and pharmacy convenience, reduce drug waste, and lower per-unit costs.
- Includes boxed warning and labeling language clarifying ‚ÄúPHARMACY BULK PACKAGE ‚Äî NOT FOR DIRECT INFUSION.‚Äù
- Complies with USP definitions and includes detailed use instructions",,Approved ‚Äì The petition to allow submission of an Abbreviated New Drug Application (ANDA) for Midazolam Hydrochloride Injection (different total strength) was approved,2012-07-08,0.0,"Center for Drug Evaluation and Research (CDER) ‚Äì Signature block from Dr. Keith O. Webber, Deputy Director, Office of Pharmaceutical Science","Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- Section 505(j)(2)(A) and (B) ‚Äì Requirements for ANDA submission
- Section 505(j)(2)(A)(iv) ‚Äì Bioavailability requirement",,"The proposed drug product has the same concentration (5 mg/mL) and route of administration as the listed drug, but differs in total drug content (500 mg vs. 50 mg).
- FDA found that the change in strength does not raise safety or efficacy concerns because uses, dose, and route are the same.
- No new investigations were needed.
- If shown to meet bioavailability requirements, the proposed product would have the same therapeutic effect as the listed reference drug",approved,True,213.0,CDER,CDER
fda-2010-p-0460,FDA-2010-P-0460-0001_Alaunus_Pharmaceutical__LLC___Citizen_Petition,2010-08-30,2010,False,original petition,"Alaunus Pharmaceutical, LLC",industry/corporation,"21 C.F.R. ¬ß 314.93 ‚Äì Suitability petitions under the FD&C Act
- 21 C.F.R. ¬ß 201.51 ‚Äì Labeling requirements for parenteral drugs",FDA requirement for a Suitability Petition before allowing ANDAs that involve a change in dosage strength or container size of an injectable drug product,"Request FDA approval of a Suitability Petition to allow an Abbreviated New Drug Application (ANDA) for:
- Midazolam Injection, 5 mg/mL in a 100 mL vial, versus the Reference Listed Drug (RLD), which is Midazolam Injection, 5 mg/mL in a 10 mL vial"," Same concentration and active ingredient as the RLD (Hospira product); only the total volume and vial configuration differ.
- The proposed 100 mL product is intended as a Pharmacy Bulk Package, not for direct infusion.
- Would provide efficiency and convenience to hospitals and pharmacies, reduce waste, and potentially lower cost.
- Labeling will clearly indicate it is a single-use pharmacy bulk package with appropriate warnings and instructions, as required by USP standards",,Approved ‚Äì The petition to allow submission of an Abbreviated New Drug Application (ANDA) for Midazolam Hydrochloride Injection (different total strength) was approved,2012-07-08,0.0,"Center for Drug Evaluation and Research (CDER) ‚Äì Signature block from Dr. Keith O. Webber, Deputy Director, Office of Pharmaceutical Science","Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- Section 505(j)(2)(A) and (B) ‚Äì Requirements for ANDA submission
- Section 505(j)(2)(A)(iv) ‚Äì Bioavailability requirement",,"The proposed drug product has the same concentration (5 mg/mL) and route of administration as the listed drug, but differs in total drug content (500 mg vs. 50 mg).
- FDA found that the change in strength does not raise safety or efficacy concerns because uses, dose, and route are the same.
- No new investigations were needed.
- If shown to meet bioavailability requirements, the proposed product would have the same therapeutic effect as the listed reference drug",approved,True,678.0,CDER,CDER
fda-2010-p-0454,FDA-2010-P-0454-0001_Campaign_for_Tobacco_Free_Kids__et_al___Citizen_Pe,2010-08-26,2010,False,original petition,Campaign for Tobacco-Free Kids  American Cancer Society Cancer Action Network  American Lung Association  American Legacy Foundation,advocacy/academic,"21 C.F.R. ¬ß 10.30 (Citizen petition rule)
- Family Smoking Prevention and Tobacco Control Act (Public Law 111-31)
- Section 918 of the Tobacco Control Act
- Section 506 of the Federal Food, Drug and Cosmetic Act (Fast Track program)",FDA‚Äôs approach to reviewing and approving smoking cessation products and the conditions it authorizes for their sale and distribution.,"The petitioners request FDA to:
1. Issue guidance to evaluate risks of smoking cessation products relative to tobacco use risks.
2. Collaborate with manufacturers on trial design.
3. Make cessation product development a priority and transfer review authority from the Division of Anesthetics, Critical Care and Addiction Drug Products to the Office of Oncology Drug Products","Tobacco causes over 400,000 deaths annually in the U.S.
- Quitting smoking greatly reduces health risks, but current cessation products are underused and under-supported.
- FDA‚Äôs current review processes are too conservative, potentially discouraging development and use of more effective cessation tools.
- Public health would benefit from more flexible labeling, dosing, combination therapy, and treatment duration for cessation products.
- A new framework could save more lives by improving cessation success rates",2011-02-24 00:00:00,Not a formal response ‚Äì This was an informal stakeholder meeting. FDA listened and asked questions but did not issue any regulatory action or decision,2012-06-08,1.0,"Center for Drug Evaluation and Research (CDER) ‚Äì Represented by Janet Woodcock and Grail Sipes
- Center for Tobacco Products (CTP) ‚Äì Represented by Lawrence Deyton
- Office of Medical Products and Tobacco (OMPT) ‚Äì Represented by Stephen Spielberg", Family Smoking Prevention and Tobacco Control Act (implicitly referenced as the regulatory authority for nicotine/tobacco product oversight),"The petition raised complex issues that require extensive review and analysis by FDA officials.
- Due to this complexity, the FDA had not yet issued a final decision.","The meeting was held to discuss FDA‚Äôs regulatory strategy for nicotine- and tobacco-containing products.
- CTFK shared public health perspectives on nicotine regulation, including nicotine replacement therapies (NRTs).
- The discussion also focused on improving communication between FDA and the public health community regarding product regulation",other,True,652.0,CDER,CDER
fda-2010-p-0446,FDA-2010-P-0446-0001_Richard_F__Edlich__M_D___Ph_D_____University_of_Vi,2010-08-20,2010,False,original petition,"Richard F. Edlich, M.D., Ph.D., Distinguished Professor Emeritus, University of Virginia Health System  Co-signers: Holly S. Cantrell, Jamie J. Clark, Samantha K. Rhoads (Research Assistants, Brush Prairie, WA)",advocacy/academic,21 C.F.R. ¬ß 10.30 (FDA‚Äôs citizen petition regulation),FDA‚Äôs existing compliance policy that allows surgical gloves with a 1.5% Acceptable Quality Level (AQL) for hole leakage to be used without disclosure,FDA should require all surgical glove manufacturers to place a warning label on each glove and packaging stating that the glove hole leakage rate is 1.5%,"Current FDA regulations permit gloves with a leakage defect rate of up to 1.5%, which poses a serious infection risk to surgeons and patients.
- Scientific studies support double gloving and glove puncture detection systems to prevent cross-infection (e.g., HIV, HBV, HCV).
- Labeling will alert operating room personnel to these risks and promote safer practices.
- Economically justified: May help prevent costly complications and litigation due to occupational exposure to bloodborne viruses",,Denied ‚Äì FDA denied the request to require a warning label on surgical gloves indicating a 1.5% glove hole leakage rate,2012-01-31,0.0,Center for Devices and Radiological Health (CDRH) ‚Äì Contact reference provided for CDRH Regulations Staff; the response was issued from the Office of the Commissioner,"21 CFR 800.20(c)(2) ‚Äì Defines Acceptable Quality Level (AQL) for glove water leak testing
- 21 CFR 800.20(c)(3) ‚Äì Defines lot rejection criteria when defect count exceeds threshold",,"The 1.5 AQL is a minimum quality level, not a direct percentage leakage rate.
- Many gloves perform better than the 1.5 AQL limit; thus, labeling all gloves with a ‚Äú1.5% leakage rate‚Äù would be inaccurate.
- Such a label could mislead consumers and unfairly disadvantage manufacturers whose products perform better than the AQL standard.",denied,True,529.0,CDRH,CDRH
fda-2010-p-0444,FDA-2010-P-0444-0001_Mayo_Clinic___Citizen_Petition,2010-08-10,2010,False,original petition,"Mayo Clinic, Positron Emission Tomography (PET) Radiochemistry Facility, Rochester, MN",advocacy/academic,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FDCA)
- 21 C.F.R. ¬ß 25.31 (categorical exclusion for environmental assessment)","Existing approved strength for the Reference Listed Drug (RLD) Fludeoxyglucose F 18 Injection (F-18 FDG), currently limited to 300 mCi/mL at EOS under NDA 21870",Amend the RLD Fludeoxyglucose F 18 Injection (F-18 FDG) under NDA 21870 to allow the highest strength of 500 mCi/mL at EOS instead of the currently approved 300 mCi/mL,"Advances in cyclotron and synthesizer technologies enable larger batch production (7.5 Ci per 15 mL), suitable for higher output.
- Intended for large patient volumes (45‚Äì60 FDG studies/day) with single batch.
- The increase in strength does not affect safety or efficacy, as F-18 FDG‚Äôs biodistribution is not mass dependent, and dose is always diluted to ‚â§300 mCi/mL before dispensing.
- This amendment would improve operational efficiency without altering intended use, dosage form, or route of administration",,"Approved ‚Äì FDA approved the petition to allow submission of an ANDA for Fludeoxyglucose F18 Injection, 500 mCi/mL at End of Synthesis (EOS)",2011-05-23,0.0,"Center for Drug Evaluation and Research (CDER) ‚Äì Signed by Keith O. Webber, Ph.D., Deputy Director, Office of Pharmaceutical Science","Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) ‚Äì Basis for approving a petition involving a strength change
- Section 505(j)(2)(A)(iv) ‚Äì Bioavailability requirement",,"The proposed product (500 mCi/mL) differed in strength but had the same dose, dosage form, and route of administration as the listed product (300 mCi/mL).
- FDA concluded that investigations were not necessary because the difference in strength did not raise safety or efficacy concerns.
- The product must meet bioavailability requirements to be approved, but this would be evaluated during the ANDA review process.",approved,True,286.0,CDER,CDER
fda-2010-p-0438,FDA-2010-P-0438-0004_Hyman_Phelps___McNamara__P_C___re_Dr__Reddy_s_Labo,2010-08-08,2010,False,original petition,Dr. Reddy‚Äôs Laboratories,advocacy/academic,21 C.F.R. ¬ß 10.30 ‚Äì FDA‚Äôs citizen petition regulation,"FDA‚Äôs Manual of Policies and Procedures 5240.3, which outlines the review order of original ANDAs, amendments, and supplements (dated October 18, 2006)",The petition (now withdrawn) had requested FDA to amend its MAPP 5240.3 to include an additional scenario in the Agency‚Äôs expedited ANDA review policy,Not Mentioned in Withdrawal Letter ‚Äì The letter only formally withdraws the petition without reiterating the original reasoning or justification.,2011-02-16 00:00:00,,2025-10-15,1.0,,,"The petition requested changes to FDA‚Äôs Manual of Policies and Procedures (MaPP 5240.3) to allow expedited review of certain ANDAs.
- FDA stated the request raised complex issues needing extensive internal analysis.
- Due to resource constraints and competing priorities, a final response had not yet been completed.",,no decision,False,5547.0,pending,pending
fda-2010-p-0438,FDA-2010-P-0438-0001_Dr__Reddy_s_Laboratories__Inc____Citizen_Petition,2010-08-16,2010,False,original petition,"Dr. Reddy‚Äôs Laboratories, Inc.",advocacy/academic,"21 C.F.R. ¬ß 10.30 (Citizen Petition procedure)
- 21 C.F.R. ¬ß 314.95 (Notification of Paragraph IV certifications)
- FDC Act ¬ß 505(j)(2)(B)(ii) (ANDA procedures)
- FDC Act ¬ß 505(j)(5)(B)(iv)(II)(bb) (180-day exclusivity definition)
- FDC Act ¬ß 505(j)(5)(D)(i)(IV) (Forfeiture of 180-day exclusivity)
- FDC Act ¬ß 505(q)(1)(G) and 505(q)(1)(H) (citizen petition certifications)","The petition challenges the scope of FDA‚Äôs Manual of Policies and Procedures (MaPP) 5240.3, which defines criteria for expedited review of ANDAs. Dr. Reddy‚Äôs argues that the MaPP does not accommodate a scenario where a first generic with no patent litigation and forfeited 180-day exclusivity exists",Dr. Reddy‚Äôs requests that FDA amend MaPP 5240.3 to include a new criterion for expedited ANDA review: where a first generic exists and there are no blocking patents or exclusivities due to failure of timely patent litigation and forfeiture of 180-day exclusivity,"Dr. Reddy‚Äôs ANDA No. 90-932 for Alendronate Sodium and Cholecalciferol has no blocking patents (due to no timely lawsuit following Paragraph IV notice).
- The first applicant‚Äôs 180-day exclusivity was forfeited (no tentative approval within 30 months).
- Despite this, FDA‚Äôs Office of Generic Drugs declined expedited review due to lack of a matching scenario in current MaPP 5240.3.
- Amending MaPP aligns with the Hatch-Waxman Act‚Äôs intent to promote timely access to affordable generics",2011-02-16 00:00:00,,2025-10-15,1.0,,,"The petition requested changes to FDA‚Äôs Manual of Policies and Procedures (MaPP 5240.3) to allow expedited review of certain ANDAs.
- FDA stated the request raised complex issues needing extensive internal analysis.
- Due to resource constraints and competing priorities, a final response had not yet been completed.",,no decision,False,5539.0,pending,pending
fda-2010-p-0430,FDA-2010-P-0430-0001_Eisai__Inc____Hogan_Lovells_US_LLP____Citizen_Peti,2010-08-12,2010,False,original petition,"Eisai, Inc.",industry/corporation,"21 U.S.C. ¬ß 355(b) and 355(q)
- 21 C.F.R. ¬ß 10.30
- 21 U.S.C. ¬ß 355(j)(5)(B)(iii) and (iv)
- 21 C.F.R. ¬ß 314.107(c)(3)
- 35 U.S.C. ¬ß 271(e)(4)(A)","FDA‚Äôs final approval of Teva‚Äôs ANDA 77-344 for donepezil hydrochloride, and its application of the ‚Äúshared exclusivity‚Äù policy, despite the existence of Ranbaxy‚Äôs eligibility for 180-day exclusivity.","The petitioner requests the FDA to:
1. Revoke Teva‚Äôs final approval (ANDA 77-344) and revert to tentative approval.
2. Declare Teva‚Äôs 180-day exclusivity expired upon the expiration of U.S. Patent No. 4,895,841 ('841 patent).
3. Prevent Teva from selectively waiving exclusivity after the '841 patent expires.
4. Acknowledge Ranbaxy as the sole applicant eligible for exclusivity.
5. Respond to the petition by November 1, 2010","FDA misapplied its shared exclusivity policy; no ‚Äúmutually blocking exclusivity‚Äù existed since Teva could not block Ranbaxy.
- Teva and Gate are the same entity; Gate‚Äôs ANDA does not qualify as a legitimate subsequent filer.
- Teva was under a preliminary injunction and could not legally market the product, nullifying the grounds for shared exclusivity.
- The FDA‚Äôs approval of Teva‚Äôs ANDA in April 2008 violated statutory limitations in 21 U.S.C. ¬ß 355(j)(5)(B)(iii).
- Ranbaxy remains the sole first-filer for the four remaining relevant patents, and its exclusivity rights must be preserved.",,"Granted in part and denied (or denied as moot) in part ‚Äì The FDA confirmed Ranbaxy‚Äôs exclusivity, converted Teva‚Äôs ANDA to tentatively approved, and denied some requests as moot",2010-11-26,0.0,"Center for Drug Evaluation and Research (CDER) ‚Äì Signed by Janet Woodcock, M.D., Director","21 CFR ¬ß 10.30 ‚Äì Citizen petition procedures
- 21 CFR ¬ß 314.430(d)(1) ‚Äì Confidentiality of unapproved ANDAs
- 21 CFR ¬ß 314.107(c)(1) ‚Äì ANDA approval timing and exclusivity
- 21 U.S.C. ¬ß 355(j) ‚Äì FD&C Act, ANDA pathway
- 35 U.S.C. ¬ß 271(e)(2) ‚Äì Patent infringement related to ANDA filings",,"Ranbaxy was the first applicant eligible for 180-day exclusivity, which blocked Teva‚Äôs ANDA approval.
- Teva‚Äôs ANDA was originally approved in 2008 but was converted to tentative approval in Sept 2010.
- As of Nov 26, 2010, Ranbaxy‚Äôs ANDA was approved, and it alone was entitled to the exclusivity.
- FDA found no basis for Teva to waive exclusivity since it was not eligible for it.
- Some requests were denied as moot because the desired actions (e.g., conversion of Teva‚Äôs ANDA) had already occurred.",approved,True,106.0,CDER,CDER
fda-2010-p-0416,FDA-2010-P-0416-0001_Susan_Thixton__et_al___Citizen_Petition,2010-08-02,2010,False,original petition,A group of concerned pet owners (led by Susan Thixton and co-signatories),individual,"Section 201(f) of the Federal Food, Drug, and Cosmetic Act (FFDCA)
- Section 301(a) and (c) (Prohibited Acts)
- Section 402(a)(5) (Adulterated Food)
- Section 403(a) (Misbranded Food)",FDA‚Äôs compliance policy that allows pet foods made with diseased animals or animals that died otherwise than by slaughter to be considered ‚Äúsuitable for use in animal feed‚Äù and not be actionable under current enforcement practices,"The petitioners request that the FDA:
- Enforce the Federal Food, Drug, and Cosmetic Act as written regarding pet food and treats.
- Remove pet foods and treats containing meat and bone meal (MBM), beef and bone meal (BBM), animal fat (AF), or animal digest (AD) until manufacturers prove compliance.
- Consider ingredients from 'dead stock' renderers or USDA-rejected meat as high-risk adulteration and require frequent FDA inspection and proof of compliance.","FDA's current policy allows marketing of adulterated and misbranded products to pet owners.
- Ingredients like MBM, BBM, AF, and AD may come from euthanized or diseased animals, which violates the Act.
- FDA‚Äôs own testing found pentobarbital (a euthanasia drug) in commercial dog food.
- Definitions in the Act do not differentiate between food for human or animal use; thus, these adulterants are equally unlawful.
- FDA lacks legal authority to override these laws via compliance discretion.
- Potential long-term health risks to pets and economic impact on pet owners are also cited.",,,2025-10-15,0.0,,,,,no decision,False,5553.0,pending,pending
fda-2010-p-0413,FDA-2010-P-0413-0001_Olsson_Frank_Weeda_Terman_Bode_Matz_PC___Citizen_P,2010-08-03,2010,False,original petition,Olsson Frank Weeda Terman Bode Matz PC (Attorney Arthur Y. Tsien),law/consulting,"505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FDC Act)
- 21 C.F.R. ¬ß¬ß 10.20, 10.30, 314.93
- 21 C.F.R. ¬ß 25.31 (Environmental Impact)
- 21 C.F.R. ¬ß 10.30(b) (Economic Impact Statement)",FDA‚Äôs regulatory requirement that a citizen petition must be approved before an ANDA (Abbreviated New Drug Application) can be submitted for a new strength of a Reference Listed Drug (RLD),"FDA is requested to determine that Fentanyl Citrate Injection, USP, 50 mcg (50 mcg/mL) is suitable for submission as a new strength under the ANDA process.","The new strength (50 mcg) differs in total drug content but maintains the same concentration (50 mcg/mL) as the Reference Listed Drug (RLD).
- All other parameters (formulation, route of administration, indication, etc.) are the same as the RLD.
- The RLD (Baxter Healthcare‚Äôs Fentanyl Citrate Injection, NDA 019-101) includes a labeled dosage range beginning at 50 mcg, supporting the need for a lower-dose product.
- The proposed strength provides dosing flexibility and reduces medical waste when a lower dose is needed.
- No new safety or effectiveness concerns arise because the product is identical except for strength.",,Approved ‚Äì FDA approved the petition to allow submission of an ANDA for a new strength (50 mcg/1 mL vial) of Fentanyl Citrate Injection,2013-01-30,0.0,"Center for Drug Evaluation and Research (CDER) ‚Äì Response signed by Gregory P. Geba, M.D., M.P.H., Director, Office of Generic Drugs","Section 505(j)(2)(C) of the FD&C Act ‚Äì Authority for petitioning ANDA submission with different strength
- Section 505(j)(2)(C)(i) ‚Äì Standard for approval unless safety/effectiveness questions require investigation
- Section 505(j)(2)(A) and (B) ‚Äì ANDA submission requirements
- Section 505(j)(2)(A)(iv) ‚Äì Bioavailability requirements",,"The change in strength (from 2 mL to 1 mL vials) does not raise safety or efficacy concerns, as dose, use, and route of administration remain the same.
- No new clinical investigations were necessary.
- If the product meets bioavailability criteria, it can be expected to have the same therapeutic effect as the listed reference product",approved,True,911.0,CDER,CDER
fda-2010-p-0401,FDA-2010-P-0401-0005_Steve_Gupta__M_D___Inc____Supplement,2011-04-20,2010,False,original petition,"Steve Gupta, M.D., J.D",individual,Not Mentioned in this supplemental letter. No statutory or regulatory citations are included.,The original FDA approval of Alair¬Æ (bronchial thermoplasty device) for treatment of asthma. The supplemental submission challenges the benefit of Alair¬Æ in light of new clinical follow-up data,Revoke the approval of Alair¬Æ by the FDA.,"Five-year follow-up data (published February 2011 in BMC Pulmonary Medicine) showed no significant improvement in respiratory adverse events, emergency room visits, lung function, or steroid/medication use for the Alair¬Æ-treated group compared to the control group.
- The study revealed no therapeutic benefit from Alair¬Æ in mild to moderate asthma patients.
- In severe asthmatics, the risks may outweigh benefits.
- Therefore, the petitioner argues Alair¬Æ offers no clear benefit and its FDA approval should be withdrawn",,Denied,2011-12-02,0.0,Center for Devices and Radiological Health (CDRH),"21 CFR 10.30(e)(3)
- FD&C Act ¬ß 515(e)(1)(A), (B), and (F)
- 21 CFR 814.46(a)",,"The FDA found no new data or rationale sufficient to warrant withdrawal of the PMA (premarket approval) for the Alair¬Æ Bronchial Thermoplasty System.
- The mechanism of action (i.e., reduction in smooth muscle mass) was not required to be proven for approval; instead, clinical outcomes (reduced emergency visits, exacerbations, etc.) justified approval.
- Concerns regarding a single ‚Äúoutlier‚Äù patient in the control group were found to be scientifically invalid and did not compromise study integrity.
- The AIR2 trial was well-controlled and showed meaningful benefit in relevant clinical endpoints.
- The AIR trial‚Äôs five-year data was not designed to evaluate long-term effectiveness comparatively and did not support revocation.
- The labeling already included precautions addressing the limitations of the patient population studied (e.g., exclusion of the most severe asthma cases).
- The FDA noted that the granting of expedited review status has no bearing on the validity of the approval. ",denied,True,226.0,CDRH,CDRH
fda-2010-p-0401,FDA-2010-P-0401-0004_Steve_Gupta__M_D___J_D___Inc____Supplement,2010-12-21,2010,False,original petition,"Steve Gupta, M.D., J.D.",individual,Not Mentioned in this supplemental document.,"The FDA‚Äôs approval of Alair¬Æ (bronchial thermoplasty device) for asthma. The petitioner critiques the data used to justify the approval, particularly the AIR2 trial and its methodology.","While the petition does not explicitly restate the requested action, it strongly implies the petitioner wants the FDA to reconsider or revoke approval of Alair¬Æ for severe asthma, especially in light of issues with trial inclusion criteria and lack of demonstrated clinical benefit.","The AIR2 study excluded most patients with severe asthma, thus invalidating claims about effectiveness for that population.
- The petitioner critiques the trial data (e.g., severe exacerbation rate, emergency room visits, AQLQ scores) and finds inconsistencies and lack of clinical relevance.
- CT scans and other asthma control tests were reportedly omitted or not adequately addressed in the published data.
- Authors excluded data or patients that may have affected results, raising concern over bias.
- The Expert Panel Report (EPR) is cited as the authoritative source for defining severe asthma, and the petitioner asserts that none of the AIR2 trial participants met that threshold.
- Thus, the study population does not reflect patients for whom Alair¬Æ is being approved, and its efficacy and safety are unproven in the intended use group",2011-01-18 00:00:00,Denied,2011-12-02,1.0,Center for Devices and Radiological Health (CDRH),"21 CFR 10.30(e)(3)
- FD&C Act ¬ß 515(e)(1)(A), (B), and (F)
- 21 CFR 814.46(a)","The petition requested revocation of the April 27, 2010 PMA approval for the Alair¬Æ Bronchial Thermoplasty System.
- FDA stated that the petition raised issues requiring further review and analysis.
- The agency was not ready for a meeting, but was working toward a resolution","The FDA found no new data or rationale sufficient to warrant withdrawal of the PMA (premarket approval) for the Alair¬Æ Bronchial Thermoplasty System.
- The mechanism of action (i.e., reduction in smooth muscle mass) was not required to be proven for approval; instead, clinical outcomes (reduced emergency visits, exacerbations, etc.) justified approval.
- Concerns regarding a single ‚Äúoutlier‚Äù patient in the control group were found to be scientifically invalid and did not compromise study integrity.
- The AIR2 trial was well-controlled and showed meaningful benefit in relevant clinical endpoints.
- The AIR trial‚Äôs five-year data was not designed to evaluate long-term effectiveness comparatively and did not support revocation.
- The labeling already included precautions addressing the limitations of the patient population studied (e.g., exclusion of the most severe asthma cases).
- The FDA noted that the granting of expedited review status has no bearing on the validity of the approval. ",denied,True,346.0,CDRH,CDRH
fda-2010-p-0401,FDA-2010-P-0401-0001_Steve_Gupta__M_D___J_D___Inc____Citizen_Petition,2010-07-20,2010,False,original petition,"Steve Gupta, M.D., J.D.",individual,"21 C.F.R. 10.30 (Citizen petition procedure)
- 21 C.F.R. 25.1(a) (Environmental impact exclusion)","FDA‚Äôs approval of the Alair¬Æ Bronchial Thermoplasty System, granted on April 27, 2010, for the treatment of severe asthma",Revoke FDA‚Äôs approval of the Alair¬Æ Bronchial Thermoplasty System for treating severe asthma.,"No demonstrable long-term clinical benefit from the Alair¬Æ device, based on published AIR2 trial data.
- Serious adverse effects were reported, including increased asthma symptoms and hospitalizations post-procedure.
- The placebo group included an outlier patient whose data skewed the reported benefits.
- The study showed no improvement in key asthma control parameters (e.g., FEV1, AQLQ, ACT scores).
- Most severe asthma patients were excluded from the clinical study despite being the target population per FDA labeling.
- The risk/benefit ratio is unfavorable, as the treatment involves burning bronchial tissues without proven effectiveness.
- The company engaged in a ‚Äúbait and switch‚Äù, seeking expedited FDA review for life-threatening asthma, but later excluded such patients from trials.
- CT scan data showed no reduction in smooth muscle mass, contradicting the device‚Äôs claimed mechanism of action",2011-01-18 00:00:00,Denied,2011-12-02,1.0,Center for Devices and Radiological Health (CDRH),"21 CFR 10.30(e)(3)
- FD&C Act ¬ß 515(e)(1)(A), (B), and (F)
- 21 CFR 814.46(a)","The petition requested revocation of the April 27, 2010 PMA approval for the Alair¬Æ Bronchial Thermoplasty System.
- FDA stated that the petition raised issues requiring further review and analysis.
- The agency was not ready for a meeting, but was working toward a resolution","The FDA found no new data or rationale sufficient to warrant withdrawal of the PMA (premarket approval) for the Alair¬Æ Bronchial Thermoplasty System.
- The mechanism of action (i.e., reduction in smooth muscle mass) was not required to be proven for approval; instead, clinical outcomes (reduced emergency visits, exacerbations, etc.) justified approval.
- Concerns regarding a single ‚Äúoutlier‚Äù patient in the control group were found to be scientifically invalid and did not compromise study integrity.
- The AIR2 trial was well-controlled and showed meaningful benefit in relevant clinical endpoints.
- The AIR trial‚Äôs five-year data was not designed to evaluate long-term effectiveness comparatively and did not support revocation.
- The labeling already included precautions addressing the limitations of the patient population studied (e.g., exclusion of the most severe asthma cases).
- The FDA noted that the granting of expedited review status has no bearing on the validity of the approval. ",denied,True,500.0,CDRH,CDRH
fda-2010-p-0397,FDA-2010-P-0397-0001_Richard_F__Edlich__M_D___Ph_D_____University_of_Vi,2010-07-22,2010,False,original petition,"Richard F. Edlich, MD, PhD (Distinguished Professor Emeritus of Plastic Surgery, Biomedical Engineering and Emergency Medicine, University of Virginia Health System)",advocacy/academic,"21 C.F.R. ¬ß 10.30
- Federal Food, Drug, and Cosmetic Act
- Public Health Service Act
- 21 C.F.R. ¬ß 5.10",The FDA‚Äôs ongoing review and delayed final decision regarding earlier petitions to ban cornstarch powder on medical gloves (FDA-2008-P-0531 and FDA-2009-P-0117).,"The petitioner requests the FDA to make a final decision to ban cornstarch powder on all medical gloves used in the United States, specifically highlighting their use in in vitro fertilization (IVF) laboratories.","Scientific evidence shows cornstarch powder on medical gloves is cytotoxic, harming embryos and sperm in IVF labs.
- No published studies demonstrate the safety of cornstarch on medical gloves.
- Continued use exposes patients and healthcare workers to risks like infertility, peritonitis, infections, latex allergies, poor wound healing, and surgical complications.
- Availability of latex-free, powder-free alternatives supports the ban.
- Ongoing failure by the FDA to decide endangers public health.",,,2025-10-15,0.0,,,,,no decision,False,5564.0,pending,pending
fda-2010-p-0396,FDA-2010-P-0396-0003_Tab_1____Copy_of_the_Watson_Petition__re__Require_,2010-11-23,2010,False,original petition,"Watson Laboratories, Inc. (part of Watson Pharmaceuticals)",advocacy/academic,"Federal Food, Drug, and Cosmetic Act (FDC Act)
- 21 C.F.R. ¬ß 10.30 (Citizen Petition regulation)
- 21 C.F.R. ¬ß 25.31 (Environmental impact)
- 21 C.F.R. ¬ß 320.24 (Bioequivalence)
- FDC Act ¬ß 505(j)(2)(A)(iv), ¬ß 505(j)(4)(F), and ¬ß 505(j)(8)(B)(i) (bioequivalence requirements)","FDA‚Äôs standard approach to approving ANDAs for generic versions of ANDRODERM, which typically rely only on conventional pharmacokinetic measures (AUC and Cmax) without strict statistical evaluation of Tmax","FDA should not approve any ANDA for a generic version of ANDRODERM unless the sponsor demonstrates bioequivalence on:
- AUC (area under the curve)
- Cmax (peak concentration)
- Tmax (time to reach peak concentration)
for both testosterone and its major active metabolite dihydrotestosterone (DHT)","ANDRODERM is designed to mimic the natural circadian rhythm of testosterone, with peak levels in the morning.
- Standard AUC and Cmax measures alone cannot adequately reflect this circadian delivery profile.
- Differences in Tmax could result in inappropriate dose titration, potentially leading to patient underdosing or overdosing, and significant safety risks.
- Ensuring bioequivalence in Tmax is critical for therapeutic equivalence and patient safety",,Denied,2011-01-07,0.0,Center for Drug Evaluation and Research (CDER),"Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- Section 505(b)(2) of the FD&C Act
- 21 CFR Part 320 (Bioequivalence methodologies)
- FDA Guidance documents:
‚Ä¢ Bioavailability and Bioequivalence for Orally Administered Drug Products ‚Äì General Considerations
‚Ä¢ Bioequivalence Recommendations for Specific Products
‚Ä¢ Statistical Approaches to Establishing Bioequivalence",,"Fish & Richardson Petition: FDA reviewed the assertion that Watson's ANDA resulted in a new salt form (fentanyl starch glycolate) due to the wet granulation process. FDA found the risk of this conversion minimal and unsupported by Cephalon‚Äôs model study, which used unrealistic processing conditions (e.g., sonication instead of granulation). FDA determined Watson‚Äôs ANDA was acceptable and denied the request to reject it or require a 505(b)(2) NDA.

- Cephalon Petition: FDA denied the request to revise its bioequivalence guidance to require additional pharmacokinetic (PK) parameters (like AUC‚ÇÄ‚Äì‚ÇÉ‚ÇÄ or C‚ÇÉ‚ÇÄ). It concluded that standard measures‚ÄîAUC and Cmax‚Äîalong with routine analysis of early PK profiles, were sufficient for assessing therapeutic equivalence. FDA also argued that Fentora‚Äôs variability in patient tolerance and lack of a clear concentration-effect relationship makes additional PK criteria unnecessary. The agency reaffirmed that existing regulatory tools (e.g., Tmax evaluations, in vitro testing) and scientific reviews were adequate to safeguard patient safety and efficacy.",denied,True,45.0,CDER,CDER
fda-2010-p-0396,FDA-2010-P-0396-0001_Cephalon__Inc____Citizen_Petition,2010-07-23,2010,False,original petition,"Cephalon, Inc.",industry/corporation,"21 U.S.C. ¬ß 355
- 21 C.F.R. ¬ß 10.30
- References to FDA‚Äôs BE (Bioequivalence) guidance policies and documents such as the 2003 ‚ÄúBA/BE Guidance‚Äù and the 2009 ‚ÄúFentanyl BE Guidance‚Äù","FDA‚Äôs draft bioequivalence (BE) recommendation for fentanyl citrate buccal tablets, issued in November 2009, which failed to include an early exposure parameter for generic versions of FENTORA","That FDA revise its Fentanyl BE Guidance to require sponsors of generic versions of FENTORA to demonstrate bioequivalence using not only standard parameters (AUC and Cmax), but also an early exposure parameter such as AUCo‚Äì30 or C30","FENTORA is formulated for rapid onset of action critical for managing breakthrough cancer pain.
- Its clinical profile includes pain relief beginning at 15 minutes post-administration.
- FDA's current BE criteria (AUC and Cmax) may allow approval of generics that do not act with the same speed, compromising efficacy and safety.
- Substitution with slower-acting generics could lead to increased patient suffering or overdose risk if patients take multiple doses.
- FDA has already established precedent for requiring additional PK parameters in its zolpidem guidance, supporting similar action for fentanyl",,Denied,2011-01-07,0.0,Center for Drug Evaluation and Research (CDER),"Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- Section 505(b)(2) of the FD&C Act
- 21 CFR Part 320 (Bioequivalence methodologies)
- FDA Guidance documents:
‚Ä¢ Bioavailability and Bioequivalence for Orally Administered Drug Products ‚Äì General Considerations
‚Ä¢ Bioequivalence Recommendations for Specific Products
‚Ä¢ Statistical Approaches to Establishing Bioequivalence",,"Fish & Richardson Petition: FDA reviewed the assertion that Watson's ANDA resulted in a new salt form (fentanyl starch glycolate) due to the wet granulation process. FDA found the risk of this conversion minimal and unsupported by Cephalon‚Äôs model study, which used unrealistic processing conditions (e.g., sonication instead of granulation). FDA determined Watson‚Äôs ANDA was acceptable and denied the request to reject it or require a 505(b)(2) NDA.

- Cephalon Petition: FDA denied the request to revise its bioequivalence guidance to require additional pharmacokinetic (PK) parameters (like AUC‚ÇÄ‚Äì‚ÇÉ‚ÇÄ or C‚ÇÉ‚ÇÄ). It concluded that standard measures‚ÄîAUC and Cmax‚Äîalong with routine analysis of early PK profiles, were sufficient for assessing therapeutic equivalence. FDA also argued that Fentora‚Äôs variability in patient tolerance and lack of a clear concentration-effect relationship makes additional PK criteria unnecessary. The agency reaffirmed that existing regulatory tools (e.g., Tmax evaluations, in vitro testing) and scientific reviews were adequate to safeguard patient safety and efficacy.",denied,True,168.0,CDER,CDER
fda-2010-p-0393,FDA-2010-P-0393-0001_Troy_and_Alana_Pack_Foundation__et_al___Citizen_Pe,2010-07-19,2010,False,original petition,"Multiple individuals and organizations, including:  Robert Pack, President, The Troy and Alana Pack Foundation  Francine Haight, R.N., Founder, RYAN's Cause  Lance Merrill, President, Dads Against Drug Dealers  April Rovero, CEO, National Coalition Against Prescription Drug Abuse",advocacy/academic,"21 CFR 10.30 (citizen petition procedures)
- 21 USC ¬ß 355 (New drugs ‚Äì application and approval process)","FDA‚Äôs approval of Purdue Pharma‚Äôs reformulated OxyContin (April 5, 2010).
- FDA's public statements suggesting the reformulated drug ""will likely result in less abuse"" and ""reduces the likelihood that this drug will be misused and abused.""
- FDA's failure to require in vivo studies to substantiate abuse-deterrence claims","Petitioners request that FDA:
1. Issue a public statement clarifying there is inadequate in vivo clinical data to support claims that reformulated OxyContin is less abusable or addictive than the original.
2. Disclose that Purdue conducted no human studies to assess behavioral abuse potential.
3. Direct Purdue Pharma to issue a similar public clarification","FDA‚Äôs press release and media coverage incorrectly suggest the new OxyContin is less addictive or more abuse-resistant without scientific evidence.
- No human studies (in vivo) were conducted to assess abuse potential.
- FDA failed to follow its own Draft Guidance on the Assessment of Abuse Potential of Drugs (issued three months prior).
- Historical precedent: Purdue previously misbranded OxyContin as less addictive, leading to criminal convictions and a $634 million settlement.
- Risk of repeating past abuse epidemic and misleading physicians and the public again",2011-01-10 00:00:00,,2025-10-15,1.0,,,"The petition requested that FDA issue a public statement clarifying that there is insufficient in vivo clinical data to support news claims that reformulated OxyContin is less addictive or abusable than the original.
- It also asked FDA to direct Purdue Pharma to make a similar public statement.
- FDA noted that the petition raised complex issues requiring extensive internal review and analysis, and thus it had not yet reached a decision.",,no decision,False,5567.0,pending,pending
fda-2010-p-0392,FDA-2010-P-0392-0001_Richard_F__Edlich__M_D___Ph_D___University_of_Virg,2010-07-15,2010,False,original petition,"Dr. Richard F. Edlich, MD, PhD ‚Äì Distinguished Professor Emeritus of Plastic Surgery, Biomedical Engineering, and Emergency Medicine, University of Virginia Health System. Co-signed by Samantha K. Rhoads and Holly S. Stevens (Research Assistants)",advocacy/academic,"21 CFR ¬ß 10.30 (citizen petition procedures)
- 21 CFR ¬ß 5.10 (delegation of authority to Commissioner)","The lack of FDA final decision on banning cornstarch powder on surgical and examination gloves, despite a previous 2008 petition and growing scientific evidence on its hazards",That FDA ban the use of cornstarch powder on all medical gloves (surgical and examination types) in the United States,"Scientific literature demonstrates medical risks of powdered gloves, including allergic reactions, postoperative adhesions, infections, delayed healing, and granulomas.
- Cited peer-reviewed research and multiple FDA citizen petitions (2008, 2009) support these findings.
- Ansell Limited (a glove manufacturer) publicly advocates powder-free gloves and outlines 10 reasons for eliminating powder use, including contamination risks and increased healthcare costs
- Environmental and economic benefits: Eliminating cornstarch improves patient safety, reduces allergy risks, and may lower costs tied to complications, non-reimbursement, and occupational hazards.",,"Partially Approved and Partially Denied:
- Petitions to ban powdered gloves and remove certain content were granted.
- Petition to establish new communication guidelines was denied.",2018-04-04,0.0,Center for Devices and Radiological Health (CDRH),"21 CFR ¬ß 10.30(e)(2)
- Final Rule: 81 FR 91722 (Dec 19, 2016)
- Proposed Rule: 81 FR 15173 (Mar 22, 2016)",,"The FDA issued a final rule in December 2016 banning powdered surgeon‚Äôs gloves, powdered patient examination gloves, and absorbable powder for lubricating a surgeon‚Äôs glove due to risks associated with their use, particularly allergic reactions and complications in surgical wounds and healing processes.

- The rule rendered many of the petitions‚Äô requests moot or fulfilled.

- The FDA considered submitted information in the rulemaking process.

- The petition to establish additional administrative guidelines was denied because existing procedures under 21 CFR ¬ß 10.30 were deemed sufficient.",partially approved / denied,True,2820.0,CDRH,CDRH
fda-2010-p-0383,FDA-2010-P-0383-0016_Cephalon__Inc___Fish___Richardson__P_C_____Supplem,2010-10-04,2010,False,original petition,"Cephalon, Inc., through its legal counsel Fish & Richardson P.C.",law/consulting,"21 U.S.C. ¬ß 355(j)(2)(A)(ii)(I) ‚Äì regarding requirements for ANDA submission and sameness of active ingredients
- 21 C.F.R. ¬ß 320.1(c) ‚Äì defining pharmaceutical equivalents and distinctions between different salt forms","The potential final approval of Watson Laboratories' ANDA No. 79-075 for a generic version of FENTORA¬Æ, which Cephalon claims contains an unapproved active ingredient (fentanyl starch glycolate), in addition to fentanyl citrate","Cephalon requests that FDA not approve Watson‚Äôs ANDA unless and until it resolves the safety concerns raised by the discovery of fentanyl starch glycolate in the generic product, which Cephalon argues is a distinct and unapproved active ingredient","Cephalon‚Äôs testing of Watson‚Äôs product (during litigation) revealed the presence of two active ingredients‚Äîfentanyl citrate (approved) and fentanyl starch glycolate (unapproved).
- FDA regulations state that different salts of the same moiety are different active ingredients, not interchangeable.
- The Court overseeing the patent case agreed, finding sufficient public health and safety concerns to justify disclosure of this data to FDA.
- FDA has never approved fentanyl starch glycolate for any use.
- Therefore, approving Watson's ANDA without resolving these issues could expose patients to significant risk",,Denied,2011-01-07,0.0,Center for Drug Evaluation and Research (CDER),"Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FDCA) (21 U.S.C. 355(j))
- Section 505(b)(2) of the Act
- 21 CFR Part 320
- FDA Guidance documents:
¬†¬†¬†¬†‚Ä¢ Bioequivalence Recommendations for Specific Products
¬†¬†¬†¬†‚Ä¢ Bioavailability and Bioequivalence for Orally Administered Drug Products ‚Äì General Considerations
¬†¬†¬†¬†‚Ä¢ Statistical Approaches to Establishing Bioequivalence",,"Watson ANDA Petition: The FDA found insufficient evidence that Watson‚Äôs fentanyl buccal tablet contained a second salt form (fentanyl starch glycolate). Cephalon‚Äôs model study was not representative of Watson‚Äôs process and thus did not substantiate claims of an additional active ingredient.

- Bioequivalence Requirements Petition: The FDA determined that standard pharmacokinetic (PK) measures‚ÄîAUC and Cmax‚Äîalong with review of early time PK profiles, were sufficient to determine bioequivalence for ANDAs referencing Fentora.

- FDA disagreed with Cephalon‚Äôs request to mandate additional PK parameters (e.g., AUC‚ÇÄ‚Äì‚ÇÉ‚ÇÄ, C‚ÇÉ‚ÇÄ) or to revise the Fentanyl Guidance, noting no established PK/PD relationship for Fentora due to inter-patient variability and lack of PD data.",denied,True,95.0,CDER,CDER
fda-2010-p-0383,FDA-2010-P-0383-0015_Fish___Richardson__P_C___to_the_Division_of_Docket,2010-07-15,2010,False,original petition,Fish & Richardson P.C.,law/consulting,Not Mentioned in this specific document. (The communication is a procedural supplement to a previously filed Citizen Petition.),"This filing supports and appends the Citizen Petition filed on July 13, 2010, which addresses concerns about Watson Pharmaceuticals‚Äô ANDA product, but this document itself does not directly comment on any new FDA action or policy","The filer requests that the FDA use the redacted version of an expert declaration for public disclosure, while retaining the un-redacted version (submitted July 13, 2010) for FDA's internal review related to the original Citizen Petition‚Äôs requested actions","The un-redacted expert declaration includes confidential information from litigation protected under a court protective order.
- Cephalon was unable to file the full Citizen Petition until trial evidence became public.
- Watson later requested that certain exhibits in the declaration remain confidential.
- The redacted version is submitted for public transparency while protecting sensitive material",,Denied,2011-01-07,0.0,Center for Drug Evaluation and Research (CDER),"Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FDCA) (21 U.S.C. 355(j))
- Section 505(b)(2) of the Act
- 21 CFR Part 320
- FDA Guidance documents:
¬†¬†¬†¬†‚Ä¢ Bioequivalence Recommendations for Specific Products
¬†¬†¬†¬†‚Ä¢ Bioavailability and Bioequivalence for Orally Administered Drug Products ‚Äì General Considerations
¬†¬†¬†¬†‚Ä¢ Statistical Approaches to Establishing Bioequivalence",,"Watson ANDA Petition: The FDA found insufficient evidence that Watson‚Äôs fentanyl buccal tablet contained a second salt form (fentanyl starch glycolate). Cephalon‚Äôs model study was not representative of Watson‚Äôs process and thus did not substantiate claims of an additional active ingredient.

- Bioequivalence Requirements Petition: The FDA determined that standard pharmacokinetic (PK) measures‚ÄîAUC and Cmax‚Äîalong with review of early time PK profiles, were sufficient to determine bioequivalence for ANDAs referencing Fentora.

- FDA disagreed with Cephalon‚Äôs request to mandate additional PK parameters (e.g., AUC‚ÇÄ‚Äì‚ÇÉ‚ÇÄ, C‚ÇÉ‚ÇÄ) or to revise the Fentanyl Guidance, noting no established PK/PD relationship for Fentora due to inter-patient variability and lack of PD data.",denied,True,176.0,CDER,CDER
fda-2010-p-0383,FDA-2010-P-0383-0014_Fish___Richardson__P_C___to_the_Division_of_Docket,2010-07-15,2010,False,original petition,Fish & Richardson P.C.,law/consulting,Not Mentioned in this filing.,"The submission is procedural and does not comment on an FDA action directly. It references the earlier July 13, 2010 Citizen Petition, and pertains to a replacement signature page for the Declaration of Lon J. Mathias appended to that petition","The filer requests that FDA replace two duplicate pages (page 20 and an unnumbered page) in the original ""un-redacted"" version of the Declaration with the enclosed revised signature page, for use in FDA‚Äôs internal review","The original Declaration included duplicate pages, and this corrected page ensures accurate documentation for FDA's internal evaluation of the Citizen Petition. The filing helps maintain the integrity of the record",,Denied,2011-01-07,0.0,Center for Drug Evaluation and Research (CDER),"Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FDCA) (21 U.S.C. 355(j))
- Section 505(b)(2) of the Act
- 21 CFR Part 320
- FDA Guidance documents:
¬†¬†¬†¬†‚Ä¢ Bioequivalence Recommendations for Specific Products
¬†¬†¬†¬†‚Ä¢ Bioavailability and Bioequivalence for Orally Administered Drug Products ‚Äì General Considerations
¬†¬†¬†¬†‚Ä¢ Statistical Approaches to Establishing Bioequivalence",,"Watson ANDA Petition: The FDA found insufficient evidence that Watson‚Äôs fentanyl buccal tablet contained a second salt form (fentanyl starch glycolate). Cephalon‚Äôs model study was not representative of Watson‚Äôs process and thus did not substantiate claims of an additional active ingredient.

- Bioequivalence Requirements Petition: The FDA determined that standard pharmacokinetic (PK) measures‚ÄîAUC and Cmax‚Äîalong with review of early time PK profiles, were sufficient to determine bioequivalence for ANDAs referencing Fentora.

- FDA disagreed with Cephalon‚Äôs request to mandate additional PK parameters (e.g., AUC‚ÇÄ‚Äì‚ÇÉ‚ÇÄ, C‚ÇÉ‚ÇÄ) or to revise the Fentanyl Guidance, noting no established PK/PD relationship for Fentora due to inter-patient variability and lack of PD data.",denied,True,176.0,CDER,CDER
fda-2010-p-0383,FDA-2010-P-0383-0001_Cephalon__Inc____Fish___Richardson_P_C____Citizen_,2010-07-13,2010,False,original petition,Fish & Richardson P.C.,law/consulting,"21 U.S.C. ¬ß 355
- 21 C.F.R. ¬ß 10.20
- 21 C.F.R. ¬ß 25.31 (Environmental Impact exclusion)
- References to Section 505(b) and 505(j) of the FDCA","The petition comments on the FDA's acceptance for filing of Watson‚Äôs ANDA No. 79-075, which references Cephalon‚Äôs FENTORA¬Æ (fentanyl buccal tablet). It challenges the scientific basis for FDA‚Äôs acceptance of that ANDA","Cephalon requests that the FDA:
1. Withdraw the notice of acceptance to file Watson's ANDA
2. Reject Watson's ANDA
3. Require Watson to submit a New Drug Application (NDA) under Section 505(b) if it wishes to pursue approval of its multiple-salt formulation","Watson‚Äôs ANDA product allegedly contains two active ingredients (fentanyl citrate and fentanyl starch glycolate), while the RLD (FENTORA¬Æ) contains only one (fentanyl citrate).
- FDA's own prior concern about salt exchange during Watson‚Äôs manufacturing process was allegedly never resolved by evidence.
- Cephalon‚Äôs analytical testing confirmed the presence of a new salt (fentanyl starch glycolate), validating FDA‚Äôs earlier concern.
- Under FDA policy, a product with a different salt form or additional active ingredient is not eligible for approval under an ANDA and requires a full NDA due to potential safety, efficacy, and pharmacokinetic differences",,Denied,2011-01-07,0.0,Center for Drug Evaluation and Research (CDER),"Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FDCA) (21 U.S.C. 355(j))
- Section 505(b)(2) of the Act
- 21 CFR Part 320
- FDA Guidance documents:
¬†¬†¬†¬†‚Ä¢ Bioequivalence Recommendations for Specific Products
¬†¬†¬†¬†‚Ä¢ Bioavailability and Bioequivalence for Orally Administered Drug Products ‚Äì General Considerations
¬†¬†¬†¬†‚Ä¢ Statistical Approaches to Establishing Bioequivalence",,"Watson ANDA Petition: The FDA found insufficient evidence that Watson‚Äôs fentanyl buccal tablet contained a second salt form (fentanyl starch glycolate). Cephalon‚Äôs model study was not representative of Watson‚Äôs process and thus did not substantiate claims of an additional active ingredient.

- Bioequivalence Requirements Petition: The FDA determined that standard pharmacokinetic (PK) measures‚ÄîAUC and Cmax‚Äîalong with review of early time PK profiles, were sufficient to determine bioequivalence for ANDAs referencing Fentora.

- FDA disagreed with Cephalon‚Äôs request to mandate additional PK parameters (e.g., AUC‚ÇÄ‚Äì‚ÇÉ‚ÇÄ, C‚ÇÉ‚ÇÄ) or to revise the Fentanyl Guidance, noting no established PK/PD relationship for Fentora due to inter-patient variability and lack of PD data.",denied,True,178.0,CDER,CDER
fda-2010-p-0377,FDA-2010-P-0377-0009_The_Great_Lakes_Environmental_Law_Center_and_the_N,2010-08-02,2010,False,original petition,The Great Lakes Environmental Law Center (GLELC)  Natural Resources Defense Council (NRDC),law/consulting,"21 C.F.R. ¬ß 25.31(b) ‚Äì the regulation petitioners are requesting to revoke
- Indirect reference to environmental assessment requirements under NEPA (National Environmental Policy Act), although not explicitly cited","The existence of 21 C.F.R. ¬ß 25.31(b), which allows categorical exclusion from environmental assessments for certain FDA actions.
- Petitioners are challenging the policy of allowing these exclusions without sufficient environmental scrutiny","Petitioners request that FDA revoke 21 C.F.R. ¬ß 25.31(b), thereby eliminating automatic categorical exclusions from environmental review for certain drug and biologics approvals","Wastewater treatment plants are unable to eliminate many active pharmaceutical ingredients (APIs).
- Up to 93% of pharmaceutical compounds may pass through these facilities and contaminate aquatic environments.
- The regulation permits FDA to bypass environmental review, potentially overlooking public health and ecological risks.
- The delay in FDA's response is ‚Äútroubling‚Äù due to the urgent human health and environmental concerns raised.
- Petitioners emphasize that a regulatory change is necessary to prevent pharmaceutical contamination of surface waters",2011-08-12 00:00:00,Denied,2013-02-22,1.0,"Center for Drug Evaluation and Research (CDER) ‚Äî Signed by Janet Woodcock, Director","21 CFR 25.15(a) ‚Äì Requirement for EA or categorical exclusion
- 21 CFR Part 25, Subpart C ‚Äì Environmental assessments
- 21 CFR 25.21 (a) ‚Äì Extraordinary circumstances requiring EAs
- 21 CFR 25.31 ‚Äì Categorical exclusion criteria
- 21 CFR 25.33 ‚Äì Conditions for exclusions under IND, NDA, ANDA, etc.
- 42 U.S.C. ¬ß 4321 ‚Äì National Environmental Policy Act (NEPA) (cited indirectly via discussion of NEPA process)
- 81 FR 15173 and other Federal Register notices indirectly referenced for guidance","The petition requested revocation of 21 CFR ¬ß 25.31(b), arguing that the 1 ppb threshold for environmental exclusion was inadequate.
- FDA noted that the petition raised complex scientific and legal issues requiring extensive review and analysis.
- The agency was evaluating existing regulations and guidance in light of recent scientific developments.
- FDA was also coordinating with other federal agencies, including the Environmental Protection Agency (EPA).
- Due to competing priorities and the complexity of the matter, FDA was unable to provide a timeline for completing its response.","The petition requested FDA to repeal the 1 part per billion (ppb) Categorical Exclusion for environmental assessments and to establish a new, more stringent threshold for pharmaceutical pollutants in the environment.

- FDA denied this request, stating that the current exclusion standard is scientifically sound and supported by toxicity data. Their internal environmental analysis included:
‚Ä¢ A comprehensive review of aquatic toxicity data for over 1,300 active pharmaceutical ingredients (APIs), focusing on 16 with LOECs (Lowest Observed Effect Concentrations) < 1 ppb.
‚Ä¢ An evaluation of API metabolism, wastewater treatment efficiency, and ecological exposure dilution.
‚Ä¢ A conclusion that current environmental regulations and guidance, including the 1 ppb threshold, sufficiently mitigate potential environmental risks.

- FDA stated that concerns raised by the petition do not meet the threshold of ""extraordinary circumstances"" requiring a change in the categorical exclusion under 21 CFR 25.21(a).

- FDA concluded the petition did not provide scientific justification for modifying the categorical exclusion, and they reaffirmed plans to publish draft guidance addressing endocrine disruption potential of drugs in the future.",denied,True,935.0,CDER,CDER
fda-2010-p-0377,FDA-2010-P-0377-0001_Great_Lakes_Environmental_Law_Center_and_The_Natur,2010-07-07,2010,False,original petition,Great Lakes Environmental Law Center (GLELC)  Natural Resources Defense Council (NRDC),law/consulting,"Federal Food, Drug, and Cosmetic Act (FFDCA): 21 U.S.C. ¬ß¬ß 321 et seq.
- National Environmental Policy Act (NEPA): 42 U.S.C. ¬ß 4321
- Administrative Procedure Act (APA): 5 U.S.C. ¬ß 553(e)
- 21 C.F.R. ¬ß 25.31 (categorical exclusion regulation being challenged)
- Additional reference: 40 C.F.R. ¬ß 1508.4, 21 C.F.R. ¬ß 25.10(c)",The policy allowing categorical exclusion from environmental assessments (EAs) for certain drug and biologic approvals under 21 C.F.R. ¬ß 25.31,"Revoke 21 C.F.R. ¬ß 25.31 (the regulation that provides for categorical exclusion)
- Replace it with a more protective standard based on updated scientific knowledge","Pharmaceuticals in wastewater are inadequately filtered by treatment plants; up to 93% of active ingredients persist after treatment.
- Ecotoxicological effects are observed in aquatic environments at concentrations below 1 part per billion (ppb).
- The current threshold of 1 ppb is scientifically outdated and ignores modern data on endocrine disruption, intersex fish, and cumulative effects.
- The NEPA-mandated environmental protections are circumvented by categorical exclusions.
- Lack of periodic review of the rule by FDA and reliance on outdated data undermine its scientific legitimacy.
- Updated research suggests even low-level exposure to pharmaceuticals can have long-term adverse ecological and human health effects",2011-08-12 00:00:00,Denied,2013-02-22,1.0,"Center for Drug Evaluation and Research (CDER) ‚Äî Signed by Janet Woodcock, Director","21 CFR 25.15(a) ‚Äì Requirement for EA or categorical exclusion
- 21 CFR Part 25, Subpart C ‚Äì Environmental assessments
- 21 CFR 25.21 (a) ‚Äì Extraordinary circumstances requiring EAs
- 21 CFR 25.31 ‚Äì Categorical exclusion criteria
- 21 CFR 25.33 ‚Äì Conditions for exclusions under IND, NDA, ANDA, etc.
- 42 U.S.C. ¬ß 4321 ‚Äì National Environmental Policy Act (NEPA) (cited indirectly via discussion of NEPA process)
- 81 FR 15173 and other Federal Register notices indirectly referenced for guidance","The petition requested revocation of 21 CFR ¬ß 25.31(b), arguing that the 1 ppb threshold for environmental exclusion was inadequate.
- FDA noted that the petition raised complex scientific and legal issues requiring extensive review and analysis.
- The agency was evaluating existing regulations and guidance in light of recent scientific developments.
- FDA was also coordinating with other federal agencies, including the Environmental Protection Agency (EPA).
- Due to competing priorities and the complexity of the matter, FDA was unable to provide a timeline for completing its response.","The petition requested FDA to repeal the 1 part per billion (ppb) Categorical Exclusion for environmental assessments and to establish a new, more stringent threshold for pharmaceutical pollutants in the environment.

- FDA denied this request, stating that the current exclusion standard is scientifically sound and supported by toxicity data. Their internal environmental analysis included:
‚Ä¢ A comprehensive review of aquatic toxicity data for over 1,300 active pharmaceutical ingredients (APIs), focusing on 16 with LOECs (Lowest Observed Effect Concentrations) < 1 ppb.
‚Ä¢ An evaluation of API metabolism, wastewater treatment efficiency, and ecological exposure dilution.
‚Ä¢ A conclusion that current environmental regulations and guidance, including the 1 ppb threshold, sufficiently mitigate potential environmental risks.

- FDA stated that concerns raised by the petition do not meet the threshold of ""extraordinary circumstances"" requiring a change in the categorical exclusion under 21 CFR 25.21(a).

- FDA concluded the petition did not provide scientific justification for modifying the categorical exclusion, and they reaffirmed plans to publish draft guidance addressing endocrine disruption potential of drugs in the future.",denied,True,961.0,CDER,CDER
fda-2010-p-0376,FDA-2010-P-0376-0001_Rousseau_Research_Inc___California_Corporation__RR,2010-07-09,2010,False,original petition,"Rousseau Research, Inc. (California Corporation)  ETOBACCO LLC (Delaware Corporation)",law/consulting,"21 C.F.R. ¬ß 5.10 (submission authority)
- Family Smoking Prevention and Tobacco Control Act (FSPTCA)
- 21 C.F.R. ¬ß 25.3 (claimed categorical exclusion from environmental assessment)","Practices and regulations concerning price discounting and rebate penalties by tobacco companies
- Lack of regulatory support for modified risk tobacco products (MRTPs)
- Absence of standards for d-alpha Tocopherol (Vitamin E) levels in cigarettes
- Lack of FDA recognition for E¬Æ brand cigarettes as a PMRTP","1. Ban promotional price discounting for tobacco products in PMRTP/MRTP environments
2. Ban contractual rebate penalties that discourage sales of PMRTPs/MRTPs
3. Issue standards for minimum and maximum replenishment of d-alpha Tocopherol in cigarettes (300‚Äì350 ¬µg/stick)
4. Recognize E¬Æ brand cigarettes as a Potential Modified Risk Tobacco Product (PMRTP)","Predatory pricing by Big Tobacco (e.g., buy-one-get-one-free) creates barriers for new MRTP entrants
- Marketing contracts impose rebate penalties that effectively block retail access for alternatives
- Replenishment of Vitamin E (d-alpha Tocopherol) in cigarettes reduces irritation, odor, and smoker‚Äôs cough, potentially lowering harm
- Clinical and sensory testing indicated consumer preference for E¬Æ brand and a reduction in smoker's symptoms
- Scientific literature supports chronic irritation as a pathway to tobacco-related diseases; mitigating it via Vitamin E could reduce harm
- Animal studies and toxicology reports found no adverse effects from Vitamin E-enriched cigarettes; testing suggested reduced genotoxic impact
- Petitioners offered to assign patents to public health organizations to promote MRTP development",2010-12-14 00:00:00,Denied,2013-12-05,1.0,"Center for Tobacco Products (CTP) ‚Äî Signed by Mitchell Zeller, Director","Section 911 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. ¬ß 387k)
- Section 907 of the FD&C Act (21 U.S.C. ¬ß 387g)
- Section 906(d) of the FD&C Act","The petition sought:
1. A ban on promotional discounts for modified risk tobacco products.
2. A ban on rebates/penalties imposed on distributors of such products.
3. A new regulation setting tocopherol (Vitamin E) levels in cigarette smoke condensate (MS-CSC) between 300‚Äì350 ¬µg.
4. Recognition of E¬Æ brand cigarettes as a potential modified risk tobacco product.

- FDA stated it had not yet resolved the issues because the petition raised significant and complex regulatory and scientific questions requiring further analysis by agency officials.","Modified Risk Recognition Request: FDA rejected the request to recognize E¬Æ brand cigarettes as a ‚Äúpotential‚Äù modified risk tobacco product (MRTP) because Section 911 of the FD&C Act does not allow for potential MRTPs‚Äîonly those formally approved via order after application and review.

- Ban on Marketing Practices: Petitioners‚Äô claims that discounting and rebates hinder market entry for safer products lacked supporting evidence. FDA concluded there was insufficient information to determine whether banning such practices would protect public health.

- Tocopherol Regulation: The request for a new rule mandating 300‚Äì350 ¬µg Tocopherol per cigarette (as MS-CSC) lacked supporting data or scientific studies. FDA found no evidence that such a standard was necessary to protect public health under Section 907 and ruled rulemaking unwarranted.

As such, FDA concluded that none of the requests were justified scientifically or legally and denied the petition.",denied,True,1245.0,CTP,Other/Specialty Center
fda-2010-p-0360,FDA-2010-P-0360-0008_Hyman_Phelps_and_McNamara_P_C_Amendment,2010-07-30,2010,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"Section 505(j)(2)(C) of the FFDCA
- 21 C.F.R. ¬ß 314.93 ‚Äì suitability petitions
- 21 C.F.R. ¬ß 10.20 ‚Äì general requirements for submission
- 21 C.F.R. ¬ß 10.30 ‚Äì citizen petition procedures
- 21 C.F.R. ¬ß 25.31 ‚Äì categorical exclusion from environmental assessment
- 21 C.F.R. ¬ß 10.30(b) ‚Äì economic impact (upon request)","The petition requests an FDA determination of suitability for submission of an ANDA for Imatinib Mesylate Capsules, including a new 50 mg strength, which differs in dosage form and strength from the reference listed drug (RLD): GLEEVEC Tablets (100 mg and 400 mg)","Petitioner requests that the FDA:
- Find that Imatinib Mesylate Capsules (50 mg) are suitable for submission in an ANDA under Section 505(j)
- Permit ANDA filings for capsule dosage forms of 50 mg (and previously requested 100 mg and 400 mg)","Pediatric patients may benefit from the availability of a 50 mg capsule, as dosing for GLEEVEC is weight-based.
- GLEEVEC Capsules (50 mg and 100 mg) were previously approved by FDA but are no longer marketed‚Äînot withdrawn for safety or effectiveness reasons.
- Petitioner's product would help address formulation preferences, particularly for those who struggle to swallow tablets.
- Full draft labeling and PREA waiver justification are attached (Attachments 3 and 4).
- Petitioner claims that the proposed change in dosage form and strength does not raise new questions of safety or efficacy",,,2025-10-15,0.0,,,,,no decision,False,5556.0,pending,pending
fda-2010-p-0360,FDA-2010-P-0360-0007_Hyman_Phelps_and_McNamara_P_C___Amendment,2011-12-23,2010,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"21 U.S.C. ¬ß 355(j)(2)(C) ‚Äì FFDCA provision allowing petition for ANDA suitability
- 21 C.F.R. ¬ß 314.93 ‚Äì Suitability petitions
- 21 C.F.R. ¬ß 10.20 ‚Äì Citizen petition requirements
- 21 C.F.R. ¬ß 10.30 ‚Äì Procedures for citizen petitions
- 21 C.F.R. ¬ß 25.31 ‚Äì Categorical exclusion for environmental assessment
- 21 C.F.R. ¬ß 10.30(b) ‚Äì Economic impact information (upon request)",The petition addresses FDA's handling of ANDA submissions that propose a different dosage form (capsule) from the approved Reference Listed Drug (RLD)‚ÄîGLEEVEC Tablets approved under NDA No. 021588. It asks for an FDA suitability determination allowing such a change,"The petitioner requests FDA to determine that Imatinib Mesylate Capsules (100 mg and 400 mg) are suitable for submission in an ANDA, using GLEEVEC Tablets as the RLD","The proposed capsule dosage form differs only in form (tablet vs. capsule) and strength already approved.
- GLEEVEC Capsules were previously approved and later discontinued for non-safety reasons; thus, regulatory precedent exists.
- No new safety or efficacy questions are raised by the change to capsule form.
- The capsule form provides an alternative for patients who have difficulty swallowing tablets.
- Petition includes draft labeling and a request for waiver from pediatric assessments (PREA), suggesting minimal new clinical burden",,,2025-10-15,0.0,,,,,no decision,False,5045.0,pending,pending
fda-2010-p-0360,FDA-2010-P-0360-0001_Hyman__Phelps___McNamara__P_C____Citizen_Petition,2010-07-06,2010,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"Section 505(j)(2)(C) of the FFDCA
- 21 C.F.R. ¬ß 314.93 ‚Äì suitability petitions
- 21 C.F.R. ¬ß 10.20 ‚Äì general submission requirements
- 21 C.F.R. ¬ß 10.30 ‚Äì citizen petition procedures
- 21 C.F.R. ¬ß 25.31 ‚Äì categorical exclusion (environmental impact)
- FDC Act ¬ß 505B(a)(1)(A) ‚Äì Pediatric Research Equity Act exemption","The petition addresses the FDA‚Äôs authority to accept an ANDA for a drug product that differs in strength from the Reference Listed Drug (RLD) ‚Äî specifically, for Imatinib Mesylate Capsules in strengths of 200 mg, 400 mg, and 600 mg, compared to the discontinued GLEEVEC Capsules (50 mg and 100 mg) and currently marketed GLEEVEC Tablets","Petitioner asks the FDA to determine that the proposed Imatinib Mesylate Capsules (200 mg, 400 mg, 600 mg) are suitable for submission in an ANDA using GLEEVEC Tablets as the bioequivalence reference","The proposed strengths enable dosing flexibility, aligning with approved regimens (e.g., 400‚Äì800 mg/day).
- New capsule strengths reduce pill burden (e.g., replacing six 100 mg tablets with one 600 mg capsule).
- The dosage form (oral capsule) and administration route remain the same.
- The RLD (GLEEVEC Capsules) is discontinued but not withdrawn for safety or effectiveness, justifying use of currently marketed GLEEVEC Tablets for bioequivalence.
- The Pediatric Research Equity Act (PREA) does not apply to new strengths, so no additional pediatric studies are needed",,,2025-10-15,0.0,,,,,no decision,False,5580.0,pending,pending
fda-2010-p-0359,FDA-2010-P-0359-0005_Cover_Letter_of_Supplement_to_Citizen_Petition___R,2022-05-06,2010,False,original petition,Medtronic,individual,21 C.F.R. ¬ß 10.30(g) ‚Äì Submission of supplements to citizen petitions,The FDA's failure to substantively respond to the original petition regarding the reclassification of absorbable hemostatic devices,Medtronic reiterates its request for reclassification of absorbable hemostatic devices (originally requested in 2010),"FDA has not yet responded substantively to the 2010 petition.
- Medtronic submits newly developed research supporting the reclassification of absorbable hemostatic devices since the original petition was filed",,,2025-10-15,0.0,,,,,no decision,False,1258.0,pending,pending
fda-2010-p-0359,FDA-2010-P-0359-0001_Goodwin_Procter__LLP___Citizen_Petition,2010-07-02,2010,False,original petition,Goodwin Procter LLP,law/consulting,"21 C.F.R. ¬ß 10.30 ‚Äì Citizen Petition procedures
- Section 513(e) of the FDCA (21 U.S.C. ¬ß 360c(e)) ‚Äì Reclassification of devices","The classification of absorbable hemostatic devices (Class III) under the product code LMF (Absorbable, Hemostatic, Passive Gauze or Fabric).
- Medtronic challenges this classification and FDA‚Äôs apparent stance requiring Premarket Approval (PMA) for such products","Reclassify LMF-coded absorbable hemostatic devices from Class III to Class II.
- FDA to issue a regulation under Section 513(e) reclassifying such devices based on existing data and safety profile","Medtronic asserts that LMF products have been safely marketed for decades, primarily under Class II device designations.
- Reclassification is supported by extensive published clinical data, postmarket surveillance, and historical use.
- The current Class III designation imposes unjustified regulatory burdens, delaying innovation and increasing costs.
- Petition includes scientific studies, adverse event data, and predicate device comparisons to support reclassification.
- Medtronic argues that existing special controls under Class II are adequate to ensure safety and effectiveness",2010-12-10 00:00:00,,2025-10-15,1.0,,,"The petition requested finalization of the 2006 proposed rule and draft guidance concerning reclassification of absorbable hemostatic devices.
- FDA stated that it was unable to reach a decision at the time due to the complexity of issues involved and the need for additional review and analysis by agency officials.
- The agency assured it would respond as soon as a final determination was made.",,no decision,False,5584.0,pending,pending
fda-2010-p-0353,FDA-2010-P-0353-0001_Summit_Biosciences__Inc___et_al__K_L_Gates__LLC___,2010-06-15,2010,False,original petition,Summit Biosciences Inc. and an unnamed Kentucky university,advocacy/academic,"Section 505(j)(2)(C) of the FDC Act
- 21 C.F.R. ¬ß¬ß 10.30 and 314.93
- 21 U.S.C. ¬ß 355(j)(2)(A)(iv)
- 21 C.F.R. ¬ß 25.31(a) (for environmental impact exclusion)
- 21 U.S.C. ¬ß 355c(a) and ¬ß 355c(a)(4)(A)(iii) (PREA waiver)","Requesting FDA to determine whether a new dosage form (nasal spray) of dronabinol is suitable for filing under an Abbreviated New Drug Application (ANDA). No specific FDA policy criticized, but implicitly comments on limitations of existing ANDA suitability framework for novel delivery systems",Petitioners request that FDA allow filing of an ANDA for dronabinol in nasal spray dosage form ‚Äî different from the currently approved capsule (RLD: Marinol¬Æ),"Public health needs: Limited availability of THC therapies; nasal spray offers faster onset and avoids drawbacks of capsules/smoking.
- Therapeutic equivalence: Same active ingredient and indications as Marinol¬Æ; can be supported by bioequivalence data.
- Policy support: Cites support from medical organizations, public polling, and the Obama Administration for expanding non-smoked THC therapies.
- Technical advantages: Improved bioavailability, reduced abuse risk via unit-dose packaging, avoids ‚Äúfirst-pass‚Äù metabolism, safer than smoking.
- PREA waiver: Justified based on the product not being a meaningful pediatric therapeutic advancement, and low anticipated pediatric usage",,,2025-10-15,0.0,,,,,no decision,False,5601.0,pending,pending
fda-2010-p-0352,FDA-2010-P-0352-0001_Richard_F__Edlich__M_D___Ph_D____University_of_Vir,2010-06-30,2010,False,original petition,"Richard F. Edlich, MD, PhD ‚Äî Distinguished Professor Emeritus, University of Virginia Health System; Co-signed by Holly S. Stevens, Jamie J. Clark, and Samantha K. Rhoads",advocacy/academic,"21 C.F.R. 10.30 (Citizen Petition regulation)
- 21 C.F.R. 5.10 (Delegation of authority to the Commissioner)","Commenting on and challenging the current FDA device classification of:
‚Ä¢ Cornstarch powdered examination and surgical gloves (Class I devices)
‚Ä¢ Powder, dusting, surgical (Product Code KGP)
- Critiques FDA's delays in reclassification despite past petitions","Reclassify powdered examination and surgical gloves from Class I to Class II devices
- Remove ‚Äúpowder, dusting, surgical‚Äù from the classification system as it is not commercially accessible","Scientific and clinical evidence over 25 years shows that cornstarch powder:
‚Ä¢ Promotes wound infection
‚Ä¢ Causes peritoneal adhesions and granulomatous peritonitis
‚Ä¢ Triggers the latex allergy epidemic
- International precedents: Germany (1997) and UK (2000) banned cornstarch-powdered gloves
- Many U.S. hospitals and clinics have banned such gloves, reducing latex allergies
- No scientific evidence supports the safety of cornstarch powder
- Monthly communications with FDA representatives (Paul Gadiock, Dr. Sheila Murphey) support the petition",,"Partially Approved / Partially Denied
Some petitions granted in part; one denied in part.",2018-04-04,0.0,Center for Devices and Radiological Health (CDRH),"21 CFR 10.30(e)(2)
- 81 FR 15173 (March 22, 2016)
- 81 FR 91722 (December 19, 2016)",,"Petitions contributed to the final rule banning powdered surgeon's gloves, patient exam gloves, and absorbable powder for lubricating a surgeon‚Äôs glove.
- The requested removal of the ‚ÄúMedical Glove Powder Report‚Äù was executed as part of that final rule.
- FDA declined to address specific cancer-growth claims due to coverage in final rule justification.
- Requests to reclassify devices considered moot because of the complete ban.
- Request to create new guidelines for petition processing was denied citing existing adequate regulations (21 CFR 10.30).",partially approved / denied,True,2835.0,CDRH,CDRH
fda-2010-p-0346,FDA-2010-P-0346-0001_Apotex__Inc____Citizen_Petition,2010-06-25,2010,False,original petition,"Apotex Inc. (a pharmaceutical company headquartered in Toronto, Ontario, Canada)",industry/corporation,"21 C.F.R. ¬ß 10.25 (general petition procedures)
- 21 C.F.R. ¬ß 10.30 (citizen petition)
- 21 C.F.R. ¬ß 314.122 (drug withdrawal determinations)
- 21 C.F.R. ¬ß 314.161 (procedures for withdrawal determinations)
- 21 C.F.R. ¬ß 314.162 (removal of listings from the Orange Book)
- FDC Act ¬ß 505(j)(2) (ANDA requirements)
- 21 C.F.R. ¬ß 25.31 (environmental impact exclusion)
- 21 C.F.R. ¬ß 10.30(b) (economic impact submission provisions)","The petitioner is commenting on the status of ACTONEL (Risedronate Sodium) Tablets, 75 mg in the FDA's Orange Book, specifically that it is listed in the ""Discontinued Drug Product List"". Apotex requests clarification on whether this discontinuation was for safety or effectiveness reasons","Petitioner requests that the FDA determine whether ACTONEL Tablets, 75 mg, was withdrawn for reasons of safety or effectiveness. If the drug was not withdrawn for such reasons, it can remain eligible as a reference listed drug (RLD) for ANDA filings","ACTONEL 75 mg is listed in the ‚ÄúDiscontinued Drug Product List,‚Äù and there is no clear indication of whether it was withdrawn due to safety or efficacy issues.
- There is no evidence it is currently marketed.
- The petitioner requires FDA's confirmation for regulatory clarity in ANDA submission context. If the withdrawal was not due to safety or effectiveness, the listing can be used in ANDAs",,,2025-10-15,0.0,,,,,no decision,False,5591.0,pending,pending
fda-2010-p-0341,FDA-2010-P-0341-0001_Hyman_Phelps_and_Mcnamara_PC_Citizen_Petition,2010-06-25,2010,False,original petition,"Hyman, Phelps & McNamara, P.C. (a law firm submitting on behalf of an unnamed client)",law/consulting,"FDC Act ¬ß 505(j)(2)(C) (suitability petitions for ANDAs)
- FDC Act ¬ß 505(j)(2)(A) (ANDA submissions)
- FDC Act ¬ß 505B (PREA ‚Äì Pediatric Research Equity Act, referenced for exemption)
- 21 C.F.R. ¬ß 314.93 (ANDA suitability petitions)
- 21 C.F.R. ¬ß 10.20 (citizen petition format)
- 21 C.F.R. ¬ß 10.30 (citizen petition procedures)
- 21 C.F.R. ¬ß 25.31 (environmental impact exclusion)
- 21 C.F.R. ¬ß 10.30(b) (economic impact statement)","The petition addresses whether new strengths (50 mg, 200 mg, 600 mg) of Imatinib Mesylate Tablets are eligible to be submitted under an Abbreviated New Drug Application (ANDA). It involves establishing suitability of these dosage strengths based on the currently approved RLD, GLEEVEC (100 mg and 400 mg tablets by Novartis)","The petitioner requests that FDA determine that Imatinib Mesylate Tablets in strengths of 50 mg, 200 mg, and 600 mg are suitable for submission via ANDA, as they differ from the RLD only in strength, not in dosage form, route of administration, or indication","The proposed new strengths match the dosing regimens already described in the RLD labeling (e.g., 600 mg/day, 800 mg/day regimens).
- New strengths will allow for greater dosing flexibility and convenience, reducing pill burden (e.g., 600 mg can be taken as one tablet instead of 3).
- Particularly useful for pediatric dosing precision in leukemia patients.
- The PREA does not apply, as this is a request for new strengths only.
- Environmental and economic impacts are addressed via categorical exclusion and commitment to submit data on request",,"Approved ‚Äî Petition to allow submission of an ANDA for imatinib mesylate tablets (50 mg, 200 mg, and 600 mg) was granted.",2012-11-16,0.0,"Center for Drug Evaluation and Research (CDER) ‚Äî Signed by Gregory P. Geba, M.D., M.P.H., Director, Office of Generic Drugs","Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- Section 505(j)(2)(C)(i)
- Section 505(j)(2)(A)
- Section 505(j)(2)(A)(iv)",,"The requested change in drug strength (to 50 mg, 200 mg, and 600 mg) was deemed acceptable under the FD&C Act.
- The FDA concluded that the proposed changes in strength did not raise concerns of safety or effectiveness, since the use, dosage, and route of administration remained the same as the listed drug (Gleevec¬Æ Tablets, 100 mg and 400 mg).
- As such, no new investigations were required.
- The proposed generic product, if shown to meet bioavailability standards, would have the same therapeutic effect as the listed drug.",approved,True,875.0,CDER,CDER
fda-2010-p-0339,FDA-2010-P-0339-0023_Richard_F__Edlich__M_D___Ph_D____University_of_Vir,2010-07-29,2010,False,original petition,"Richard F. Edlich, M.D., Ph.D., Professor Emeritus of Plastic Surgery, University of Virginia Health System",advocacy/academic,"21 C.F.R. ¬ß 10.30 (citizen petition submission)
- 21 C.F.R. ¬ß 5.10 (delegation of authority)
- 21 C.F.R. ¬ß 860.123 (device reclassification criteria)
- Additional reference to FDA's authority under the Food, Drug, and Cosmetic Act (general, not cited with section numbers)","Petitioner criticizes FDA‚Äôs failure to ban the use of cornstarch on medical gloves, and the continued classification of powdered gloves as Class I medical devices despite known health risks. Comments on the inaction in response to previous petitions and international precedents","Petitioner requests that the FDA ban the use of cornstarch on medical gloves, specifically:
- Powdered latex and powdered nitrile gloves
- Powdered surgical gloves and examination gloves
Also seeks reclassification of such gloves to reflect their significant health risks","Cornstarch glove powder has been shown in scientific and clinical studies to:
‚Ä¢ Promote wound infection
‚Ä¢ Cause granulomatous peritonitis and peritoneal adhesions
‚Ä¢ Trigger life-threatening allergic reactions due to latex exposure
- Other countries (e.g., Germany in 1997, UK in 2000) have already banned powdered gloves
- Cites public health leadership duty of the FDA to act on overwhelming medical evidence
- Past petitions and recommendations from researchers and practitioners have urged the same action",,Denied,2012-01-13,0.0,"Center for Devices and Radiological Health (CDRH)
Signed by Leslie Kux, J.D., Acting Assistant Commissioner for Policy, Office of the Commissioner","21 CFR 10.30(e) (regarding petition processing)
- 21 CFR 800.20(c)(2) & (c)(3) (glove quality requirements)
- FD&C Act (21 U.S.C. 301 et seq.)
- 71 FR 75865 (Dec. 19, 2006)",,"FDA concluded that existing premarket review, performance standards, and quality regulations (such as the 1.5 AQL standard) are sufficient to ensure the safety and effectiveness of surgeon‚Äôs gloves.
- The petitioner requested mandatory use of a powder-free double glove hole indicator system during procedures involving HIV, Hepatitis B, or Hepatitis C patients.
- FDA determined that no new regulatory requirements were warranted and that no compelling evidence was provided showing that existing standards posed an unreasonable risk or needed to be changed.
- FDA emphasized that glove lots not meeting the AQL are considered adulterated under current regulations.",denied,True,533.0,CDRH,CDRH
fda-2010-p-0339,FDA-2010-P-0339-0009_Richard_F__Edlich__M_D___Ph_D____University_of_Vir,2010-07-02,2010,False,original petition,"Richard F. Edlich, M.D., Ph.D., Distinguished Professor Emeritus of Plastic Surgery, Biomedical Engineering, and Emergency Medicine, University of Virginia Health System",advocacy/academic,"21 C.F.R. ¬ß 10.30 (citizen petition provision)
- 21 C.F.R. ¬ß 5.10 (delegation of authority)
- ASTM D5151-06 (test method for glove holes)
- FDA compliance policies on glove defect rate: AQL ‚â§ 1.5%
- References to CMS policy and Public Health Service guidelines are also discussed","The petitioner critiques the FDA‚Äôs current compliance policy allowing single gloves with up to 1.5% defect rate and its inaction on mandating double-gloving systems, particularly for surgeries involving patients with HIV, Hepatitis B, or Hepatitis C",Petitioner requests that FDA mandate the use of a powder-free double glove hole indicator system for all operating room personnel when performing surgical procedures on patients with deadly bloodborne viral infections,"Current single gloves allow for needle punctures, which can expose healthcare workers to HIV, Hepatitis B, and Hepatitis C.
- Double gloves are safer but still vulnerable without an indicator system.
- The Biogel¬Æ double glove hole indicator system is proven to rapidly detect glove punctures.
- Clinical studies show it improves safety while maintaining tactile sensitivity.
- The system is latex-free compatible, preventing latex allergy.
- Banning powdered gloves reduces risk of granulomas, infections, and allergic reactions.
- Dr. Edlich and others argue that using this system honors healthcare workers harmed by exposure and reflects international best practices",,Denied,2012-01-13,0.0,"Center for Devices and Radiological Health (CDRH)
Signed by Leslie Kux, J.D., Acting Assistant Commissioner for Policy, Office of the Commissioner","21 CFR 10.30(e) (regarding petition processing)
- 21 CFR 800.20(c)(2) & (c)(3) (glove quality requirements)
- FD&C Act (21 U.S.C. 301 et seq.)
- 71 FR 75865 (Dec. 19, 2006)",,"FDA concluded that existing premarket review, performance standards, and quality regulations (such as the 1.5 AQL standard) are sufficient to ensure the safety and effectiveness of surgeon‚Äôs gloves.
- The petitioner requested mandatory use of a powder-free double glove hole indicator system during procedures involving HIV, Hepatitis B, or Hepatitis C patients.
- FDA determined that no new regulatory requirements were warranted and that no compelling evidence was provided showing that existing standards posed an unreasonable risk or needed to be changed.
- FDA emphasized that glove lots not meeting the AQL are considered adulterated under current regulations.",denied,True,560.0,CDRH,CDRH
fda-2010-p-0339,FDA-2010-P-0339-0001_Richard_F__Edlich__M_D___Ph_D____University_of_Vir,2010-06-23,2010,False,original petition,"Richard F. Edlich, M.D., Ph.D., Distinguished Professor Emeritus of Plastic Surgery, Biomedical Engineering, and Emergency Medicine, University of Virginia Health System",advocacy/academic,"21 C.F.R. ¬ß 10.30 (citizen petition authority)
- 21 C.F.R. ¬ß 5.10 (delegation of authority)
- ASTM D5151-06 (glove hole detection test method)
- Public Health Service Guidelines","The FDA‚Äôs acceptance of sterile surgical gloves with up to 1.5% defect (leakage) rate (AQL) and the lack of a requirement for double glove indicator systems during surgery on patients with HIV, Hepatitis B, or C","The petitioner requests that FDA require the use of powder-free double glove hole indicator systems by all operating room personnel when performing surgeries on patients with deadly bloodborne viral infections (HIV, HBV, HCV)","Single gloves allow for a 1.5% failure rate, posing a serious infection risk.
- Double gloves without indicators don‚Äôt detect punctures in real-time.
- Biogel¬Æ indicator system provides timely visual cues of punctures, allowing for glove replacement mid-surgery.
- Offers equal tactile sensitivity and is powder-free, reducing latex allergies, infections, granulomas, and hospital air contamination.
- Economically beneficial by avoiding complications, litigation, and treatment costs.
- Adoption aligns with international best practices and ensures protection of healthcare workers and patients",,Denied,2012-01-13,0.0,"Center for Devices and Radiological Health (CDRH)
Signed by Leslie Kux, J.D., Acting Assistant Commissioner for Policy, Office of the Commissioner","21 CFR 10.30(e) (regarding petition processing)
- 21 CFR 800.20(c)(2) & (c)(3) (glove quality requirements)
- FD&C Act (21 U.S.C. 301 et seq.)
- 71 FR 75865 (Dec. 19, 2006)",,"FDA concluded that existing premarket review, performance standards, and quality regulations (such as the 1.5 AQL standard) are sufficient to ensure the safety and effectiveness of surgeon‚Äôs gloves.
- The petitioner requested mandatory use of a powder-free double glove hole indicator system during procedures involving HIV, Hepatitis B, or Hepatitis C patients.
- FDA determined that no new regulatory requirements were warranted and that no compelling evidence was provided showing that existing standards posed an unreasonable risk or needed to be changed.
- FDA emphasized that glove lots not meeting the AQL are considered adulterated under current regulations.",denied,True,569.0,CDRH,CDRH
fda-2010-p-0338,FDA-2010-P-0338-0001_Lachman_Consultant_Services__Inc____Citizen_Petiti,2010-06-23,2010,False,original petition,"Lachman Consultant Services, Inc., consultants to the pharmaceutical and allied industries",law/consulting,"21 C.F.R. ¬ß 10.30 (citizen petition regulation)
- 21 C.F.R. ¬ß 314.161 (withdrawal determination)
- 21 C.F.R. ¬ß 314.162 (removal from the Orange Book)
- 21 C.F.R. ¬ß 25.31 (environmental impact categorical exclusion)
- 21 C.F.R. ¬ß 10.30(b) (economic impact submission)","The FDA‚Äôs listing status of Azdone¬Æ (hydrocodone bitartrate and aspirin) Tablets, 5 mg/500 mg, specifically whether it was voluntarily withdrawn for safety or efficacy reasons, as it is no longer marketed",The petitioner requests that the FDA determine whether Azdone¬Æ Tablets were voluntarily withdrawn or withheld from sale for reasons of safety or effectiveness,"Azdone¬Æ was approved in 1988 and is listed in the Orange Book.
- FDA regulations require a determination of withdrawal reasons before an ANDA can reference a discontinued drug.
- The requester is seeking this determination to clarify whether the drug is still eligible as a Reference Listed Drug (RLD) for future ANDA submissions",,"Denied (The FDA determined that the drug was not withdrawn for reasons of safety or effectiveness; thus, it denied the implicit request to remove it from the Orange Book‚Äôs discontinued list.)",2010-10-06,0.0,Center for Drug Evaluation and Research (CDER)," 21 CFR 314.161 (Determination of voluntary withdrawal for safety or effectiveness)
- 21 CFR 314.162 (Listing of withdrawn drugs)
- 21 U.S.C. 355(j)(7) (Federal Food, Drug, and Cosmetic Act section on ANDA listing)",,"The FDA reviewed its own records and found no evidence that Azdone (hydrocodone bitartrate and aspirin) was withdrawn for safety or efficacy reasons.
- The petitioner did not provide any such evidence.
- FDA also conducted an independent evaluation of postmarketing safety data and literature and found no indication of withdrawal for safety or efficacy.
- Therefore, Azdone remains listed in the ‚ÄúDiscontinued Drug Product List‚Äù in the Orange Book, allowing ANDAs referencing it to be submitted",denied,True,105.0,CDER,CDER
fda-2010-p-0331,FDA-2010-P-0331-0001_Buchanan_Ingersoll___Rooney_PC___Citizen_Petition,2010-06-22,2010,False,original petition,"Buchanan Ingersoll & Rooney PC, Attorneys & Government Relations Professionals",law/consulting,"FFDCA ¬ß 505(j)(2)(C) (ANDA eligibility)
- 21 C.F.R. ¬ß 10.20 (citizen petition content)
- 21 C.F.R. ¬ß 10.25(a) (submission procedures)
- 21 C.F.R. ¬ß 10.30 (citizen petition regulations)
- 21 C.F.R. ¬ß 314.122(a) (withdrawn drug procedures)
- 21 C.F.R. ¬ß 314.161 (FDA drug withdrawal determinations)
- 21 C.F.R. ¬ß 25.31 (environmental categorical exclusion)",The discontinuation of non-refrigerated Stimate¬Æ (1.5 mg/mL Desmopressin Acetate Nasal Spray) by CSL Behring LLC and whether this action was taken for reasons of safety or effectiveness,"The petitioner requests that the FDA determine that non-refrigerated Stimate was not withdrawn for reasons of safety or effectiveness, thereby making it eligible to be referenced in an ANDA","No public record or FDA statement indicates non-refrigerated Stimate was withdrawn for safety/efficacy reasons.
- Cumulative Supplement No. 5 to the May 2010 Orange Book indicates the product was ‚ÄúDISCONTINUED‚Äù as of January 2010.
- The discontinuation appears to be voluntary and not due to clinical concerns.
- Based on this, any ANDA referencing non-refrigerated Stimate should be considered eligible for review",,,2025-10-15,0.0,,,,,no decision,False,5594.0,pending,pending
fda-2010-p-0326,FDA-2010-P-0326-0001_J_R_Rapoza_Associates__Inc____Citizen_Petition,2010-06-16,2010,False,original petition,"JRRapoza Associates, Inc., a pharmaceutical consulting firm based in Moorestown, NJ",law/consulting,"21 C.F.R. ¬ß 10.25(a) (general provision on petitions)
- 21 C.F.R. ¬ß 10.30 (citizen petition requirements)
- 21 C.F.R. ¬ß 314.61(a)(1)(3) (withdrawal of approval)
- 21 C.F.R. ¬ß 25.31 (environmental impact categorical exclusion)","The listing of Labetalol Hydrochloride 300 mg tablets (Trandate¬Æ, NDA 018716) in the Orange Book's Discontinued Section, without an accompanying FDA determination about whether the drug was withdrawn for safety or effectiveness reasons","Petitioner requests that the FDA declare that the 300 mg strength of Trandate¬Æ was withdrawn for reasons other than safety or effectiveness, thereby making it eligible for generic referencing","The product was listed as ‚ÄúDISCN‚Äù (discontinued) in the Orange Book with no FDA explanation provided regarding safety or efficacy withdrawal.
- A determination from FDA is needed under 21 C.F.R. ¬ß 314.61(a)(1)(3) to allow ANDA referencing.
- Petitioner asserts there is no known safety or efficacy concern, suggesting the discontinuation was commercial in nature",,"Other ‚Äî The FDA determined that Trandate (labetalol hydrochloride) tablets, 300 mg and 400 mg, were not withdrawn for reasons of safety or effectiveness.",2010-12-29,0.0,Center for Drug Evaluation and Research (CDER),"21 U.S.C. 355(j)(7) (Section 505(j)(7) of the FD&C Act)
- 21 CFR 314.161(a)(1)
- 21 CFR 314.161(a)(2)
- 21 CFR 314.162",,"The FDA reviewed agency records and literature.
- No data or postmarketing reports suggested withdrawal was for safety or efficacy reasons.
- Therefore, the products will remain listed in the ""Discontinued Drug Product List"" in the Orange Book.
- FDA will continue to approve ANDAs referring to these products if they meet applicable standards.",withdrawn,True,196.0,CDER,CDER
fda-2010-p-0312,FDA-2010-P-0312-0012_Natural_Resources_Defense_Council___Letter,2012-03-28,2010,False,original petition,Natural Resources Defense Council (NRDC),advocacy/academic,Not Mentioned,Revocation of approvals and regulations permitting the use of lindane as a pharmaceutical treatment for lice and scabies,Prohibit the use of lindane as a pharmaceutical treatment by revoking all related FDA approvals and regulations,"Lindane is known to cause serious adverse human health effects, especially in infants and children.
- FDA‚Äôs delay in resolving the petition unnecessarily prolongs exposure to this health risk",2012-05-04 00:00:00,Denied,2012-11-20,1.0,Center for Drug Evaluation and Research (CDER)," Federal Food, Drug, and Cosmetic Act (FD&C Act), Sections 505(e), 505(e)(2), and 505(e)(3)
- 21 CFR 314.150(a)(2)(ii)
- 21 CFR Part 7, Subpart C
- The Stockholm Convention on Persistent Organic Pollutants (POPs)","FDA acknowledged receipt of the March 28, 2012 follow-up from NRDC regarding the petition.
- The agency noted that it had previously issued an interim response on January 28, 2011.
- FDA reiterated that the petition is still under active review, and a final response would be issued once a decision is reached.
- No new substantive justification for delay was provided other than the ongoing review process.","FDA concluded that current data do not show that the risk-benefit profile of lindane has changed.
- Available evidence does not demonstrate that lindane is unsafe when used as directed.
- Adverse event reporting rates have declined since boxed warnings and a Public Health Advisory were implemented.
- The data cited by the petitioner (NRDC) were found to be anecdotal or not meeting the standard of ‚Äúsubstantial evidence‚Äù from adequate and well-controlled studies.
- Resistance to lindane, while noted, was not sufficient to warrant withdrawal, as some patients may still benefit.
- Environmental and global regulatory concerns (e.g., EPA‚Äôs pesticide assessments, Stockholm Convention) do not override FDA‚Äôs authority to assess safety and effectiveness for pharmaceutical uses.
- FDA emphasized that lindane is approved as a second-line treatment, with appropriate warnings and restricted indications.
- No persuasive evidence was provided that the risks of lindane, as labeled, outweigh its therapeutic benefits for patients intolerant to or failing first-line treatments.",denied,True,237.0,CDER,CDER
fda-2010-p-0312,FDA-2010-P-0312-0007_Letter,2011-01-20,2010,False,original petition,Natural Resources Defense Council (NRDC),advocacy/academic,"Federal Food, Drug, and Cosmetic Act
It is mentioned that FDA‚Äôs final determination was due under this statute within 180 days",Revocation of all approvals and regulations permitting the use of lindane as a pharmaceutical treatment for lice and scabies,Revoke all FDA approvals and existing regulations permitting lindane to be used as a pharmaceutical treatment for lice and scabies,"Lindane causes serious adverse human health effects, especially to infants and children.
- Delay in FDA response increases health risk due to continued exposure",2011-01-28 00:00:00,Denied,2012-11-20,2.0,Center for Drug Evaluation and Research (CDER)," Federal Food, Drug, and Cosmetic Act (FD&C Act), Sections 505(e), 505(e)(2), and 505(e)(3)
- 21 CFR 314.150(a)(2)(ii)
- 21 CFR Part 7, Subpart C
- The Stockholm Convention on Persistent Organic Pollutants (POPs)","The petition raised complex issues requiring extensive review and analysis.
- The FDA acknowledged the petition (submitted June 15, 2010) requested the withdrawal of lindane approvals and a prohibition on its pharmaceutical use for lice and scabies.
- FDA noted this interim response was delayed due to an administrative error and should have been issued on December 12, 2010.","FDA concluded that current data do not show that the risk-benefit profile of lindane has changed.
- Available evidence does not demonstrate that lindane is unsafe when used as directed.
- Adverse event reporting rates have declined since boxed warnings and a Public Health Advisory were implemented.
- The data cited by the petitioner (NRDC) were found to be anecdotal or not meeting the standard of ‚Äúsubstantial evidence‚Äù from adequate and well-controlled studies.
- Resistance to lindane, while noted, was not sufficient to warrant withdrawal, as some patients may still benefit.
- Environmental and global regulatory concerns (e.g., EPA‚Äôs pesticide assessments, Stockholm Convention) do not override FDA‚Äôs authority to assess safety and effectiveness for pharmaceutical uses.
- FDA emphasized that lindane is approved as a second-line treatment, with appropriate warnings and restricted indications.
- No persuasive evidence was provided that the risks of lindane, as labeled, outweigh its therapeutic benefits for patients intolerant to or failing first-line treatments.",denied,True,670.0,CDER,CDER
fda-2010-p-0312,FDA-2010-P-0312-0001_Natural_Resources_Defence_Council__et_al___Citizen,2010-06-11,2010,False,original petition,"Natural Resources Defense Council (NRDC), along with:  Pesticide Action Network North America (PANNA)  Greenpeace  Farmworker Justice  Physicians for Social Responsibility  Learning Disabilities Association of America .",advocacy/academic,"21 C.F.R. ¬ß 10.30 (Citizen Petition regulation)
- 21 U.S.C. ¬ß 355 (Drug approval section of the FDCA)
- 21 U.S.C. ¬ß 331(a) (Prohibited acts ‚Äì misbranded drugs)
- 21 U.S.C. ¬ß 321(n) (Definition of misleading labeling)
- 21 C.F.R. ¬ß 201.57(c)(6) (Labeling requirements)
- 21 C.F.R. ¬ß 201.80 (Labeling requirements for older drugs)
- National Environmental Policy Act (NEPA): 42 U.S.C. ¬ß 4321 et seq.
- 21 C.F.R. Part 25 (FDA‚Äôs NEPA implementing regulations)",Continued approval and availability of lindane as a pharmaceutical treatment for lice and scabies. The petitioners argue this contradicts public health and environmental protection standards,"Petitioners ask the FDA to:
- Withdraw approval of all NDAs and ANDAs for drug products containing lindane as the active ingredient.
- Ban the use of lindane in pharmaceuticals intended for treatment of lice and scabies in both adults and children ","Toxicity to humans, particularly to infants, children, and vulnerable populations (e.g., linked to seizures, cancer, and neurological effects).
- Environmental persistence and bioaccumulation: lindane contaminates soil, water, and food supplies; it is classified as a persistent organic pollutant (POP) under the Stockholm Convention.
- Availability of safer alternatives for lice and scabies treatment.
- Failure of FDA‚Äôs continued approval to meet NEPA obligations and labeling requirements under the FDCA.
- Lindane has been banned or severely restricted in over 50 countries, including use in agriculture and veterinary medicine in the U.S",2011-01-28 00:00:00,Denied,2012-11-20,2.0,Center for Drug Evaluation and Research (CDER)," Federal Food, Drug, and Cosmetic Act (FD&C Act), Sections 505(e), 505(e)(2), and 505(e)(3)
- 21 CFR 314.150(a)(2)(ii)
- 21 CFR Part 7, Subpart C
- The Stockholm Convention on Persistent Organic Pollutants (POPs)","The petition raised complex issues requiring extensive review and analysis.
- The FDA acknowledged the petition (submitted June 15, 2010) requested the withdrawal of lindane approvals and a prohibition on its pharmaceutical use for lice and scabies.
- FDA noted this interim response was delayed due to an administrative error and should have been issued on December 12, 2010.","FDA concluded that current data do not show that the risk-benefit profile of lindane has changed.
- Available evidence does not demonstrate that lindane is unsafe when used as directed.
- Adverse event reporting rates have declined since boxed warnings and a Public Health Advisory were implemented.
- The data cited by the petitioner (NRDC) were found to be anecdotal or not meeting the standard of ‚Äúsubstantial evidence‚Äù from adequate and well-controlled studies.
- Resistance to lindane, while noted, was not sufficient to warrant withdrawal, as some patients may still benefit.
- Environmental and global regulatory concerns (e.g., EPA‚Äôs pesticide assessments, Stockholm Convention) do not override FDA‚Äôs authority to assess safety and effectiveness for pharmaceutical uses.
- FDA emphasized that lindane is approved as a second-line treatment, with appropriate warnings and restricted indications.
- No persuasive evidence was provided that the risks of lindane, as labeled, outweigh its therapeutic benefits for patients intolerant to or failing first-line treatments.",denied,True,893.0,CDER,CDER
fda-2010-p-0309,FDA-2010-P-0309-0011_Natco_Pharma_Ltd___Leydig__Voit____Mayer__Ltd_____,2010-11-01,2010,False,original petition,Natco Pharma Ltd.,industry/corporation,"21 U.S.C. ¬ß 355(j) (implicitly referenced in the context of ANDA requirements)
- 1993 FDA Interim Guidance: Cholestyramine Powder In Vitro Bioequivalence
- FDA Draft Guidance on Sevelamer Hydrochloride
- FDA Draft Guidance on Colesevelam Hydrochloride
Note: While not cited as legal statutes or CFR sections, these guidances are cited as governing documents for bioequivalence standards.",Shire‚Äôs Citizen Petition (Docket No. 2010-P-0309) which sought to impose new testing and clinical requirements on ANDAs and NDAs for generic versions of Fosrenol¬Æ (lanthanum carbonate).,"Natco requests the FDA to deny Shire‚Äôs petition in full, or at minimum, modify it by:
- Setting a maximum of 5.0% for lanthanum hydroxycarbonate impurity specification (only if FDA deems one necessary)
- Requiring trace metal testing only when lanthanum carbonate is derived from lanthanum oxide
- Rejecting the need for additional pharmacodynamic or clinical bioequivalence studies, especially regarding hydration state","Lanthanum hydroxycarbonate is non-toxic and therapeutically equivalent; 5% impurity spec is sufficient for batch consistency.
- Trace metal testing is only relevant when sourced from lanthanum oxide, not necessary if synthesized from other precursors (e.g., lanthanum chloride).
- In vitro binding studies are adequate to demonstrate bioequivalence; FDA precedent supports this for similar phosphate-binding drugs (cholestyramine, sevelamer, colesevelam).
- The hydration state (e.g., 3‚Äì6 vs. 8.8 molecules of water) does not impact therapeutic efficacy‚Äîall forms yield complete phosphate binding.
- Shire‚Äôs argument relies on an arbitrary 5-minute test without evidence of clinical significance; actual GI tract binding occurs over a longer period",,"Partially Granted and Partially Denied
- Granted: Requests related to limiting total lanthanum hydroxycarbonate and trace metal impurities.
- Denied: Requests for mandatory pharmacodynamic (PD) or clinical studies for bioequivalence, and separate polymorph testing.",2010-12-10,0.0,Center for Drug Evaluation and Research (CDER),"Section 505(b)(2) and 505(j) of the FD&C Act (21 U.S.C. 355)
- Section 505(q)(1)(F) and (F)(ii) of the FD&C Act
- 21 CFR 320.1(e), 320.23(b), 320.24(b)(4), 320.24(b)(6), and 314.101(b)(9)",,"Bioequivalence (BE): In vitro dissolution and binding studies are sufficient and appropriate to demonstrate BE, as Fosrenol acts locally in the GI tract with minimal systemic absorption. PK studies are not required; clinical trials are considered less sensitive.
- Hardness Testing: Required to ensure similar ‚Äúchewability‚Äù and particle pulverization.
- Impurities and Degradants: Applicants must control and monitor trace metal impurities and total lanthanum hydroxycarbonate. No need to test each polymorph individually due to lack of evidence for differential toxicity.
- Hydration State: Clinical studies not required for products with different hydration levels, as BE can still be established through appropriate in vitro or PD studies.",partially approved / denied,True,39.0,CDER,CDER
fda-2010-p-0309,FDA-2010-P-0309-0001_Shire_Development_Inc___Shire____Citizen_Petition,2010-06-11,2010,False,original petition,Shire Development Inc.,industry/corporation,"21 U.S.C. ¬ß 355(j) (ANDA requirements)
- 21 U.S.C. ¬ß 355(q) (Citizen Petition provision)
- 21 C.F.R. ¬ß¬ß 10.20, 10.30, 314.94, 320.24, and 320.1(e)
- 21 C.F.R. ¬ß 25.31(a) (Environmental Impact exemption)",Regulatory approval of ANDAs and 505(b)(2) NDAs for generic or follow-on formulations of Fosrenol¬Æ (lanthanum carbonate). Shire is commenting on the bioequivalence and impurity specification requirements for such generics,"Shire requests that FDA require:
1. Characterization and specification limits for the impurity lanthanum hydroxycarbonate (all polymorphs).
2. Specifications for trace metal impurities in each commercial batch.
3. A pharmacodynamic study showing phosphate-binding activity, or a clinical study demonstrating equivalent efficacy to Fosrenol¬Æ.
4. A clinical study for any generic with a hydration state outside 3‚Äì6 molecules of water per molecule of lanthanum carbonate","Lanthanum hydroxycarbonate is a degradant that could affect potency; its levels must be controlled for therapeutic consistency.
- Trace metal contamination may vary by source and poses long-term health risks.
- Lanthanum carbonate acts locally in the GI tract, making plasma bioequivalence studies inadequate; PD or clinical studies are required for assurance of efficacy.
- Hydration state of lanthanum carbonate affects phosphate-binding rate and efficiency. Forms outside the 3‚Äì6 hydration range may be less effective.
- FDA has not previously approved any generics for Fosrenol¬Æ, so special standards are warranted",,"Partially Granted and Partially Denied
- Granted: Requests related to limiting total lanthanum hydroxycarbonate and trace metal impurities.
- Denied: Requests for mandatory pharmacodynamic (PD) or clinical studies for bioequivalence, and separate polymorph testing.",2010-12-10,0.0,Center for Drug Evaluation and Research (CDER),"Section 505(b)(2) and 505(j) of the FD&C Act (21 U.S.C. 355)
- Section 505(q)(1)(F) and (F)(ii) of the FD&C Act
- 21 CFR 320.1(e), 320.23(b), 320.24(b)(4), 320.24(b)(6), and 314.101(b)(9)",,"Bioequivalence (BE): In vitro dissolution and binding studies are sufficient and appropriate to demonstrate BE, as Fosrenol acts locally in the GI tract with minimal systemic absorption. PK studies are not required; clinical trials are considered less sensitive.
- Hardness Testing: Required to ensure similar ‚Äúchewability‚Äù and particle pulverization.
- Impurities and Degradants: Applicants must control and monitor trace metal impurities and total lanthanum hydroxycarbonate. No need to test each polymorph individually due to lack of evidence for differential toxicity.
- Hydration State: Clinical studies not required for products with different hydration levels, as BE can still be established through appropriate in vitro or PD studies.",partially approved / denied,True,182.0,CDER,CDER
fda-2010-p-0275,FDA-2010-P-0275-0001_Hyman_Phelps___McNamara__P_C____Citizen_Petition,2010-06-03,2010,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"21 C.F.R. ¬ß 10.25
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 314.122
- 21 C.F.R. ¬ß 314.161
- 21 C.F.R. ¬ß 314.162
- Federal Food, Drug, and Cosmetic Act ¬ß 505(j)(2)
- 21 C.F.R. ¬ß 25.31 (Environmental impact)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact)","Determination of marketing status of GLEEVEC (imatinib mesylate) Capsules, 50 mg and 100 mg
The petitioner asks the FDA to determine whether these drugs have been voluntarily withdrawn from the market for safety or efficacy reasons","The petitioner requests that the FDA determine whether GLEEVEC Capsules, 50 mg and 100 mg, approved under NDA No. 21-335 and manufactured by Novartis, have been voluntarily withdrawn for reasons of safety or effectiveness","GLEEVEC Capsules were approved on May 10, 2001, but are listed in the ‚ÄúDiscontinued Drug Product List‚Äù of the Orange Book.
- 50 mg was discontinued by June 2003; 100 mg by November 2005.
- There is no indication they are currently marketed, nor that the withdrawal was for safety or effectiveness reasons.
- The FDA must assess whether the discontinuation precludes ANDA referencing.
- If the manufacturer resumes marketing after this petition, the petitioner will withdraw the request",,"Denied ‚Äì The FDA determined that the drug was not withdrawn for reasons of safety or effectiveness, allowing continued ANDA referencing.",2010-12-07,0.0,Center for Drug Evaluation and Research (CDER),"21 CFR ¬ß 314.161
- 21 CFR ¬ß 314.162
- Section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(7))",,"The FDA reviewed the citizen petition and conducted an independent review of agency records and literature.
- No data or adverse event reports indicated that GLEEVEC 50 mg or 100 mg capsules were withdrawn from sale due to safety or effectiveness concerns.
- Therefore, these products remain listed in the Discontinued Drug Product List in the Orange Book, and ANDAs referencing them may still be approved if they meet all other requirements.",denied,True,187.0,CDER,CDER
fda-2010-p-0271,FDA-2010-P-0271-0001_Buchanan_Ingersoll___Rooney_PC__Deston_Therapeutic,2010-05-28,2010,False,original petition,Buchanan Ingersoll & Rooney PC,law/consulting,"21 C.F.R. ¬ß 10.30 (citizen petition regulation)
- 21 C.F.R. ¬ß 314.127 (grounds for refusing an ANDA)
- 21 U.S.C. ¬ß 355(j)(2)(A) (ANDA content requirements)
- 21 U.S.C. ¬ß 355(j)(4) (grounds for ANDA refusal)
- 21 C.F.R. ¬ß 314.94(a)(8)(iv) (labeling requirements for ANDAs)
- 21 C.F.R. ¬ß 314.3(b) (definition of labeling)","Approval of ANDAs referencing Silenor¬Æ
The petitioner comments on the FDA's potential approval of abbreviated new drug applications (ANDAs) that refer to Silenor¬Æ (doxepin hydrochloride).","Petitioner requests the FDA to refuse to approve any ANDA referencing Silenor¬Æ that:
- Omits portions of the approved labeling related to sleep onset and/or sleep maintenance, or
- Proposes labeling that is not the same as that of Silenor¬Æ regarding those indications.","Sleep maintenance efficacy is a critical part of Silenor¬Æ's labeling and clinical effectiveness.
- Omission of related language by generic applicants would lead to labeling that is not ‚Äúthe same‚Äù, violating 505(j) ANDA statutory requirements.
- Approving such an ANDA would be inconsistent with FDA precedent regarding protected indications.
- Deston Therapeutics asserts exclusivity rights over these labeling claims based on its own clinical studies",2010-11-26 00:00:00,Partially Denied,2011-02-16,1.0,Center for Drug Evaluation and Research (CDER),"21 CFR 10.30 ‚Äì Governing citizen petitions
- 21 CFR 10.3 ‚Äì Defines ‚Äúadministrative action‚Äù
- 21 CFR 10.30(k) ‚Äì Limits of citizen petition applicability
- 21 CFR 10.45 ‚Äì Final administrative actions
- FD&C Act
- Ewing v. Mytinger & Casselberry, Inc., 339 U.S. 594 (1950)
- Heckler v. Chaney, 470 U.S. 821 (1985)"," Complexity of Issues: The FDA noted that the petition raised ‚Äúsignificant issues requiring extensive review and analysis by Agency officials.‚Äù Therefore, a final decision could not yet be provided.","Procedural Grounds: The FDA found that the petition‚Äôs request to halt enforcement action was not a proper subject of a citizen petition under 21 CFR 10.30.
- Legal Restrictions: Under 21 CFR 10.3 and 10.30(k), enforcement referrals are explicitly excluded from citizen petition processes.
- Judicial Precedent: Courts lack jurisdiction to review FDA‚Äôs enforcement decisions (Ewing, Heckler), so such requests fall outside reviewable administrative action.
- Enforcement Discretion: FDA emphasized its discretion in deciding whether and when to initiate enforcement actions.",partially approved / denied,True,264.0,CDER,CDER
fda-2010-p-0263,FDA-2010-P-0263-0001_First_Juice_Inc_Citizen_Petition,2010-05-20,2010,False,original petition,"David Glasser, Founder/CEO, First Juice, Inc.",industry/corporation,"21 CFR 10.30 (for submission authority)
- 21 CFR 101.13(b)(3) (prohibition on nutrient content claims for children under 2)
- 21 U.S.C. 343(r)(1)(A) (definition of unauthorized nutrient content claims)",The regulation that prohibits nutrient content claims like ‚Äúless sugar‚Äù for beverages intended for children under the age of two.,"Amend 21 CFR 101.13(b)(3) to permit ‚Äúless sugar‚Äù label claims on beverages intended for children under the age of two, with appropriate labeling disclosure when sweeteners are added. ","High rates of childhood obesity and diabetes risk.
- Parents already serve juice to infants, and early taste preferences are formed before age 2.
- Scientific evidence (e.g., FITS study, Monell Center research) shows long-term effects of early sugar exposure.
- Current regulation restricts communication of lower-sugar alternatives to parents during critical dietary formation years.
- Industry and consumer research show high concern over sugar intake in toddlers.
- Allowing these claims aligns with public health goals and informed consumer choice",2010-11-23 00:00:00,Closed,2020-08-18,1.0,Center for Food Safety and Applied Nutrition (CFSAN),21 CFR 101.13(b)(3) ‚Äì Regulation the petitioner sought to amend (regarding ‚Äúless sugar‚Äù nutrient content claims on labeling for children under two),"Agency Workload: The delay was attributed to ‚Äúother agency priorities and the limited availability of resources.‚Äù
- The review of the petition was still underway and would be completed as part of broader program priorities.","Company Inactivity: FDA determined that First Juice, Inc. was no longer operational (website offline, phones disconnected, and emails undeliverable).
- No Means of Contact: Multiple attempts to reach the petitioner failed.",other,True,3743.0,CFSAN,Other/Specialty Center
fda-2010-p-0255,FDA-2010-P-0255-0001_Osmotica_Pharmaceutical___Citizen_Petition_,2010-05-20,2010,False,original petition,Osmotica Pharmaceutical Corp.,industry/corporation,"Section 505(q) of the Federal Food, Drug, and Cosmetic Act (FDC Act)
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 320.1(e)
- 21 C.F.R. ¬ß 320.24(a), (b)(1)(i)
- 21 C.F.R. ¬ß 25.31(a)
- 5 U.S.C. ¬ß 706(2)(A) (APA: Administrative Procedure Act)","FDA‚Äôs Draft Guidance on Venlafaxine Hydrochloride (March 2010), which recommends against conducting bioequivalence studies under fasting conditions due to ‚Äúsafety concerns‚Äù",FDA should require all ANDA applicants for Venlafaxine HCl Extended-Release Tablets to submit bioequivalence studies conducted under both fed and fasting conditions before approval,"Safety Evidence: Osmotica‚Äôs studies showed no significant safety issues in either fed or fasting conditions.
- Scientific Rationale: Demonstrated differences in behavior of the drug under different conditions (i.e., food effect) make fasting studies important for accurate bioequivalence assessment.
- Regulatory Consistency: FDA‚Äôs own Bioequivalence Guidance (2002) typically requires both fed and fasting studies.
- Fair Treatment Under APA: Omitting fasting study requirements for this product but requiring them for others (e.g., zolpidem) is arbitrary and capricious under the APA",,Denied,2010-11-18,0.0,Center for Drug Evaluation and Research (CDER),"21 U.S.C. ¬ß 355(j)(2)(C) ‚Äì Suitability petitions
- 21 CFR 314.93 ‚Äì Suitability petitions
- 21 CFR 314.94(a)(3) ‚Äì ANDA content requirements
- 21 CFR 320 ‚Äì Bioequivalence and bioavailability studies
- 21 CFR 314.50(d)(3) and 314.94(a)(7) ‚Äì NDA and ANDA content requirements
- 21 CFR 320.25(a)(1) ‚Äì Study conduct ethics",,"FDA Guidance Compliance: FDA cited its own guidance which permits waiver of fasting bioequivalence studies for venlafaxine HCl due to safety concerns (notably nausea and vomiting during fasted studies).
- Clinical Equivalence: The FDA concluded there was no significant clinical difference in pharmacokinetics between Osmotica‚Äôs product and the reference under fed conditions.
- Safety Risks: Fasting conditions posed greater adverse event risks (vomiting), and ethical considerations weighed against conducting unnecessary human trials.
- Consistency with Precedent: FDA noted it had issued similar fed-only recommendations for other drugs when warranted by safety profiles (e.g., indomethacin, nisoldipine).
- Labeling and Scientific Rationale: The labeling and PK data supported the conclusion that food does not affect bioavailability materially, making fasting studies unnecessary for generic evaluation purposes.",denied,True,182.0,CDER,CDER
fda-2010-p-0243,FDA-2010-P-0243-0001_Endo_Pharmaceuticals__Inc____Citizen_Petition,2010-05-13,2010,False,original petition,Endo Pharmaceuticals Inc.,industry/corporation,"Section 505(q) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. ¬ß 355(q))
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 25.30 (Environmental Impact)
- 21 C.F.R. ¬ß 320.1(e)
- 21 C.F.R. ¬ß 314.94(a)(8)(iv)
- 21 C.F.R. ¬ß 314.127(a)(7)
- FFDCA ¬ß 505(d), 21 U.S.C. ¬ß 355(d)
- FFDCA ¬ß 505(j)(4), 21 U.S.C. ¬ß 355(j)(4)","FDA's policy on approving new applications for oxymorphone hydrochloride products.
- FDA‚Äôs bioequivalence evaluation methods for generic versions of Opana ER","Endo requests that FDA:
‚Ä¢ Publicly declare that applications for oxymorphone HCl products are not approvable unless certain ABUKs (14-hydroxycodeinone, 14-hydroxymorphinone, and other Œ±,Œ≤-unsaturated ketones) are reduced to acceptable levels.
‚Ä¢ Require NDAs/ANDAs referencing Opana or Opana ER to provide batch analysis, release data, and stability data using APIs with ‚â§0.001% of specified impurities.
‚Ä¢ Require NDAs/ANDAs to demonstrate plasma levels of drug similar to Opana ER over 12 hours post administration.
‚Ä¢ Not approve Impax Laboratories, Inc.‚Äôs ANDA for generic Opana ER due to inadequate evidence of therapeutic equivalence","FDA requires reduction of genotoxic Œ±,Œ≤-unsaturated ketone (ABUK) impurities in opioid products; Endo argues this standard should apply to oxymorphone products too.
- FDA‚Äôs guidance for oxycodone products allowed flexibility not afforded to oxymorphone.
- Bioequivalence standards relying solely on AUC are insufficient to demonstrate therapeutic equivalence for extended-release drugs like Opana ER.
- Impax admitted in court filings that its ANDA product does not provide evidence of 12-hour therapeutic blood levels, making its ANDA unapprovable.
- Relying solely on AUC for generics risks inadequate treatment outcomes for patients and would violate labeling requirements under the FFDCA",,"Granted in part and denied in part
- Granted: The request that applicants for oxymorphone HCl products referencing Opana or Opana ER be required to meet the specification of NMT 0.001% for certain impurities.
- Denied: Requests regarding batch and stability data, additional bioequivalence testing criteria, and denial of a specific ANDA",2010-11-16,0.0,Center for Drug Evaluation and Research (CDER)," 21 CFR 314.3(b) ‚Äì Reference Listed Drug (RLD) definition
- Also referenced: FDA‚Äôs 2008 draft guidance on Genotoxic and Carcinogenic Impurities in Drug Substances and Products: Recommended Approaches",,"Impurity Control: FDA requires potentially genotoxic impurities (ABUKs like 14-hydroxycodeinone and 14-hydroxymorphinone) to be limited to ‚â§0.001% in the API or to be adequately qualified for safety. This requirement is consistent across opioid APIs derived from thebaine.
- Technical Feasibility: FDA acknowledged that lower impurity limits (e.g., 0.00015%) are not technically feasible at this time, hence 0.001% remains acceptable.
- Stability Testing Not Required: The FDA denied the request for batch and stability testing because these impurities are process-related, not degradation products, so their levels are not expected to increase over time.
- Bioequivalence Testing: FDA found no clinical justification to require plasma concentration matching over 12 hours in addition to AUC and Cmax; these pharmacokinetic parameters, along with others (e.g., Tmax, metabolite profiles), are sufficient to establish bioequivalence.
- Impax ANDA: The FDA rejected the request to deny Impax's ANDA based on court filings, asserting that therapeutic equivalence is evaluated through FDA‚Äôs regulatory framework, not litigation documents",approved,True,187.0,CDER,CDER
fda-2010-p-0234,FDA-2010-P-0234-0001_Lachman_Consultant_Services__Inc____Citizen_Petiti,2010-05-04,2010,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"21 CFR 10.30 (Citizen petition procedures)
- 21 CFR 314.161 (Determination of drug withdrawal from sale)
- 21 CFR 314.162 (Procedures for removing drug products from the Orange Book)
- 21 CFR 25.31 (Environmental impact‚Äîcategorical exclusions)
- 21 CFR 10.30(b) (Economic impact analysis provision)","The agency‚Äôs policy and determination related to whether BuSpar¬Æ Tablets (15 mg and 30 mg) were withdrawn or withheld from sale for reasons of safety or effectiveness, affecting their status as listed drugs in the FDA‚Äôs Orange Book.","The petitioner requests that the FDA formally determine whether BuSpar¬Æ (buspirone hydrochloride) Tablets, 15 mg and 30 mg, approved under NDA 18-731, were discontinued for reasons of safety or effectiveness. This determination would allow the referenced drug to remain eligible for use in abbreviated new drug applications (ANDAs)","The FDA‚Äôs Orange Book lists drug products approved for ANDA submissions.
- Under 21 CFR 314.161, FDA must determine whether drugs were withdrawn for safety or efficacy before approving ANDAs that reference them.
- The petitioner seeks to confirm that the withdrawal of BuSpar¬Æ 15 mg and 30 mg from the market was not due to safety or effectiveness concerns, thereby supporting ANDA filings based on these reference products.",,"Approved / Affirmative Determination
The FDA determined that BUSPAR (buspirone hydrochloride) Tablets, 10 mg, 15 mg, and 30 mg were not withdrawn from sale for reasons of safety or effectiveness, and thus remain eligible for ANDA referencing",2010-10-19,0.0,Center for Drug Evaluation and Research (CDER),"21 CFR 10.30 ‚Äì Citizen petition procedures
- 21 CFR 314.161 ‚Äì Procedures for determining withdrawal from sale for safety or effectiveness
- 21 CFR 314.162 ‚Äì Drug removal from the Orange Book
- 21 U.S.C. ¬ß 355(j)(7) ‚Äì Requirements for ANDA referencing listed drugs",,"Review of Records: FDA reviewed internal documentation and found no indication that the BUSPAR product was withdrawn due to safety or efficacy concerns.
- Independent Assessment: FDA evaluated postmarketing data and literature and found no safety-related rationale for the market withdrawal.
- Regulatory Implication: The drug will remain on the ""Discontinued Drug Product List"" and may still be referenced by ANDA applicants if legal and regulatory requirements are met",approved,True,168.0,CDER,CDER
fda-2010-p-0232,FDA-2010-P-0232-0001_Hyman__Phelps___McNamara__P_C____Citizen_Petition,2010-05-04,2010,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"Section 505(j)(2)(C) of the FDC Act
- 21 C.F.R. ¬ß 314.93
- 21 C.F.R. ¬ß 10.20
- 21 C.F.R. ¬ß 10.30
- FDC Act ¬ß 505B(a)(1)(A) (PREA)
- 21 C.F.R. ¬ß 25.31 (Environmental impact)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact)",FDA's policy under the suitability petition process for allowing ANDA submissions for drug products with a different strength than the reference listed drug (RLD),"The petitioner requests that FDA determine that Fexofenadine HCl Orally Disintegrating Tablet (ODT), 15 mg, is suitable for submission in an Abbreviated New Drug Application (ANDA). The RLD is Sanofi‚Äôs ALLEGRA ODT, 30 mg","The only difference between the proposed product and the RLD is strength (15 mg vs. 30 mg).
- The route of administration, dosage form, and indications remain unchanged.
- The new strength (15 mg) is consistent with dosing recommendations for children 6‚Äì11 years old (30 mg twice daily), enabling more flexible dosing
- PREA does not apply to this petition for a new strength product, so no pediatric study requirement exists
- Draft labeling and Orange Book references were included to support the request.",,,2025-10-15,0.0,,,,,no decision,False,5643.0,pending,pending
fda-2010-p-0223,FDA-2010-P-0223-0001_Genzyme_Corporation__Covington___Burling_LLP____Ci,2010-04-22,2010,False,original petition,Genzyme Corporation,industry/corporation,"21 U.S.C. ¬ß 355(j)(5)(B)(iii) (FDCA ¬ß 505(j)(5)(B)(iii))
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß¬ß 25.30 and 25.31 (Environmental impact exemption)
- 21 C.F.R. ¬ß 314.53
- 35 U.S.C. ¬ß 271(e)(2)(A)","FDA‚Äôs approval process for ANDA No. 90-040 filed by Cobrek Pharmaceuticals, specifically the timing of a second 30-month stay of approval based on a second Paragraph IV certification regarding the '116 patent.","FDA is requested to confirm that it will stay approval of ANDA No. 90-040 for 30 months from November 24, 2009, the date of Genzyme's receipt of Cobrek‚Äôs second Paragraph IV certification notice, or until another specified event under 21 U.S.C. ¬ß 355(j)(5)(B)(iii) occurs.","Genzyme had already received a first 30-month stay due to an earlier Paragraph IV certification and lawsuit regarding U.S. Patent No. 5,602,116 (""'116 patent"").
- Cobrek submitted a second Paragraph IV certification on November 24, 2009, concerning the same '116 patent but referencing a different product configuration (vial instead of ampule).
- Genzyme timely filed a second lawsuit based on the second notice, fulfilling the statutory criteria for a second stay.
- The MMA (2003) restrictions do not apply since the '116 patent was listed prior to 2003.
- Public policy considerations support this request to avoid unnecessary judicial burden and protect against at-risk launches.",,,2025-10-15,0.0,,,,,no decision,False,5655.0,pending,pending
fda-2010-p-0216,FDA-2010-P-0216-0026_Mutual_Pharmaceutical_Company__Inc___Axinn_Veltrop,2010-10-05,2010,False,original petition,"Mutual Pharmaceutical Company, Inc.",industry/corporation,"21 C.F.R. ¬ß 320.33
- Guidance for Industry, Bioavailability and Bioequivalence Studies (Mar. 2003)","The petition comments on FDA's policy and criteria regarding bioequivalence testing for ANDA approval of generic Carvedilol ER formulations, specifically opposing Flamel Technologies‚Äô request for narrower bioequivalence standards and additional requirements.","Reject Flamel Technologies‚Äô August 16, 2010 Supplement that demands stricter bioequivalence criteria.
- Maintain traditional PK parameters and bioequivalence acceptance limits (80%-125%) for ANDA approval of Carvedilol ER.
- Avoid requiring in vivo testing for alcohol interaction unless adverse effects are shown in vitro.","Flamel's position conflates bioequivalence between Coreg CR and IR with that of generics.
- The Hatch-Waxman Act only requires bioequivalence to the RLD (Coreg CR), not to Coreg IR.
- FDA historically rejected similar citizen petitions demanding stricter standards (e.g., Biovail's 2005 petition).
- Traditional 80%-125% criteria are adequate, as shown in FDA's handling of similar drugs like Ambien CR.
- Coreg CR is not an NTI drug, so narrower limits are not warranted.
- Flamel misrepresents the role of the R-enantiomer, which plays a meaningful role along with the S-enantiomer in heart failure treatment.
- FDA and GSK used both enantiomers' data and applied traditional bioequivalence metrics",,Granted in Part and Denied in Part,2010-10-15,0.0,Center for Drug Evaluation and Research (CDER),"21 U.S.C. 355(j), 355(b)(2), 355(q) (Sections 505(j), 505(b)(2), and 505(q) of the FDCA)
- 21 CFR 320.1(e), 320.23(b), 320.24, 314.94(a)(7), 314.101(d)(9), 314.54(a)
- FDA Guidance Documents Cited:
‚Ä¢ Bioavailability and Bioequivalence Studies for Orally Administered Drug Products ‚Äì General Considerations (2003)
‚Ä¢ Bioequivalence Recommendations for Specific Products (2010 draft guidance)
‚Ä¢ Statistical Approaches to Establishing Bioequivalence",,"Scientific Basis: FDA found the hypothetical PK profile proposed by the petitioner (Profile A) physiologically infeasible for carvedilol due to its known pharmacokinetics (multi-compartment or flip-flop kinetics).

- Cmin Importance Acknowledged: FDA agreed Cmin is important for therapeutic efficacy, especially for heart failure patients, but noted that reliable estimation can be done through modeling based on single-dose studies rather than requiring multiple-dose studies.

- Use of Simulation: FDA used physiologically based PK modeling to determine that equivalence in AUC and Cmax from single-dose studies can predict equivalent Cmin at steady state.

- Precedent from Coreg CR Approval: FDA did not apply strict pass/fail statistical criteria to Cmin in the original Coreg CR NDA (some strengths were outside 80‚Äì125% range).

- Alcohol Dose Dumping: The request for mandatory clinical testing to rule out alcohol-induced dose dumping was denied, with FDA stating that in vitro ethanol dissolution testing was sufficient.

Conclusion: Standard AUC and Cmax criteria from single-dose studies are sufficient to evaluate bioequivalence, with no new requirements for additional Cmin-specific tests",approved,True,10.0,CDER,CDER
fda-2010-p-0216,FDA-2010-P-0216-0025_Flamel_Technologies_S_A____Supplement,2010-10-08,2010,False,original petition,Flamel Technologies S.A.,industry/corporation,"Not explicitly cited by statute or regulation number. However, the following regulatory criteria are referenced:
- Bioequivalence parameters: AUC, Cmax, Cmin, and Peak:Trough ratio.
- No mention of specific CFR or statutory sections like 21 C.F.R. 10.30 or 505(q).",FDA‚Äôs potential acceptance of bioequivalence standards for generic versions of Coreg CR that differ from those originally applied to Coreg CR during its NDA approval.,"Require that FDA apply the same full set of bioequivalence criteria (AUC, Cmax, Cmin, Peak:Trough ratio) to generics of Coreg CR as were used to extend the Coreg IR label to Coreg CR.","Protecting patient safety and clinical benefit
Flamel argues that failure to apply these full criteria‚Äîespecially the Peak:Trough ratio‚Äîmay:

Result in generic drugs with wider pharmacokinetic variability

Lead to higher peak concentrations, increasing risk of adverse effects (e.g., hypotension)

Reduce patient tolerability and compliance

Impair the ability to titrate patients to optimal doses

Ultimately compromise clinical efficacy compared to the innovator product",,Granted in Part and Denied in Part,2010-10-15,0.0,Center for Drug Evaluation and Research (CDER),"21 U.S.C. 355(j), 355(b)(2), 355(q) (Sections 505(j), 505(b)(2), and 505(q) of the FDCA)
- 21 CFR 320.1(e), 320.23(b), 320.24, 314.94(a)(7), 314.101(d)(9), 314.54(a)
- FDA Guidance Documents Cited:
‚Ä¢ Bioavailability and Bioequivalence Studies for Orally Administered Drug Products ‚Äì General Considerations (2003)
‚Ä¢ Bioequivalence Recommendations for Specific Products (2010 draft guidance)
‚Ä¢ Statistical Approaches to Establishing Bioequivalence",,"Scientific Basis: FDA found the hypothetical PK profile proposed by the petitioner (Profile A) physiologically infeasible for carvedilol due to its known pharmacokinetics (multi-compartment or flip-flop kinetics).

- Cmin Importance Acknowledged: FDA agreed Cmin is important for therapeutic efficacy, especially for heart failure patients, but noted that reliable estimation can be done through modeling based on single-dose studies rather than requiring multiple-dose studies.

- Use of Simulation: FDA used physiologically based PK modeling to determine that equivalence in AUC and Cmax from single-dose studies can predict equivalent Cmin at steady state.

- Precedent from Coreg CR Approval: FDA did not apply strict pass/fail statistical criteria to Cmin in the original Coreg CR NDA (some strengths were outside 80‚Äì125% range).

- Alcohol Dose Dumping: The request for mandatory clinical testing to rule out alcohol-induced dose dumping was denied, with FDA stating that in vitro ethanol dissolution testing was sufficient.

Conclusion: Standard AUC and Cmax criteria from single-dose studies are sufficient to evaluate bioequivalence, with no new requirements for additional Cmin-specific tests",approved,True,7.0,CDER,CDER
fda-2010-p-0216,FDA-2010-P-0216-0017_Flamel_Technologies_S_A____Supplement,2010-07-22,2010,False,original petition,Flamel Technologies S.A.,industry/corporation,"505(j) and 505(q) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. ¬ß¬ß 355(j) and 355(q))

21 C.F.R. ¬ß¬ß 10.20, 10.30, 314.94, and 320.24","The approval process for generic versions of Coreg CR¬Æ (carvedilol phosphate) Extended-release Capsules, specifically the bioequivalence standards required for such approval.

This supplement addresses a response by Mutual Pharmaceuticals, arguing about the need for more stringent criteria (specifically Cmin) to determine bioequivalence","The petitioner requests that the FDA:

Require all ANDAs and 505(b)(2) NDAs for carvedilol extended-release products to demonstrate a Cmin level at least as high as that achieved by Coreg CR.

Mandate that any ANDA submissions include a clinical study ruling out alcohol-induced dose dumping","Cmin (Minimum Concentration) Importance: Maintaining therapeutic levels over 24 hours is crucial for clinical efficacy and survival benefits in heart failure and post-MI LVD patients.

FDA precedent: For initial approval of Coreg CR, FDA required its Cmin to be at least as high as Coreg IR and the trough-to-peak ratio to remain comparable. Flamel argues this precedent must apply to generics as well.

Risk of alcohol-induced dose dumping: GSK demonstrated that Coreg CR is not vulnerable to dose dumping, but generic versions may use different drug delivery technologies which may not be resistant to alcohol. Literature and FDA meetings (referenced from 2005) discuss the significant safety risks of this phenomenon.

Public health concern: Approval of generics without adequate Cmin or dose-dumping studies may expose patients to safety risks, especially during the 6AM‚Äì12PM window when adverse cardiac events are more likely",,Granted in Part and Denied in Part,2010-10-15,0.0,Center for Drug Evaluation and Research (CDER),"21 U.S.C. 355(j), 355(b)(2), 355(q) (Sections 505(j), 505(b)(2), and 505(q) of the FDCA)
- 21 CFR 320.1(e), 320.23(b), 320.24, 314.94(a)(7), 314.101(d)(9), 314.54(a)
- FDA Guidance Documents Cited:
‚Ä¢ Bioavailability and Bioequivalence Studies for Orally Administered Drug Products ‚Äì General Considerations (2003)
‚Ä¢ Bioequivalence Recommendations for Specific Products (2010 draft guidance)
‚Ä¢ Statistical Approaches to Establishing Bioequivalence",,"Scientific Basis: FDA found the hypothetical PK profile proposed by the petitioner (Profile A) physiologically infeasible for carvedilol due to its known pharmacokinetics (multi-compartment or flip-flop kinetics).

- Cmin Importance Acknowledged: FDA agreed Cmin is important for therapeutic efficacy, especially for heart failure patients, but noted that reliable estimation can be done through modeling based on single-dose studies rather than requiring multiple-dose studies.

- Use of Simulation: FDA used physiologically based PK modeling to determine that equivalence in AUC and Cmax from single-dose studies can predict equivalent Cmin at steady state.

- Precedent from Coreg CR Approval: FDA did not apply strict pass/fail statistical criteria to Cmin in the original Coreg CR NDA (some strengths were outside 80‚Äì125% range).

- Alcohol Dose Dumping: The request for mandatory clinical testing to rule out alcohol-induced dose dumping was denied, with FDA stating that in vitro ethanol dissolution testing was sufficient.

Conclusion: Standard AUC and Cmax criteria from single-dose studies are sufficient to evaluate bioequivalence, with no new requirements for additional Cmin-specific tests",approved,True,85.0,CDER,CDER
fda-2010-p-0216,FDA-2010-P-0216-0010_Flamel_Technologies_S_A____Supplement,2010-06-14,2010,False,original petition,Flamel Technologies S.A.,industry/corporation,"505(j) and 505(q) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. ¬ß¬ß 355(j) and 355(q))

21 C.F.R. ¬ß¬ß 10.20, 10.30, 314.94, and 320.24","The approval standards for generic versions of Coreg CR¬Æ (carvedilol phosphate) Extended-release Capsules, particularly concerning the sufficiency of bioequivalence criteria (Cmax and AUC) and the need to include Cmin as an additional metric.

Also, the potential risk of alcohol-induced dose dumping for generics not using the same delivery technology as Coreg CR.","FDA should require all ANDA and 505(b)(2) NDA applications for carvedilol extended-release products to:

Demonstrate a Cmin level at least as high as that achieved by Coreg CR

Include a clinical study ruling out alcohol-induced dose dumping","Clinical Importance of Cmin: Adequate minimum drug concentration is critical for maintaining 24-hour therapeutic efficacy, especially for heart failure and post-MI LVD patients. Risks are highest between 6 AM and Noon, when drug levels may be lowest.

FDA Precedent: FDA previously required Cmin in Coreg CR‚Äôs approval (comparison to Coreg IR), establishing a regulatory standard that should also apply to generics.

Bioequivalence Limitations: Traditional 80‚Äì125% ranges for bioequivalence are not sufficient. Petitioners propose that Cmin must be ‚â•100% of the innovator‚Äôs level.

Alcohol-Induced Dose Dumping Risks: Cited research and FDA commentary show variability in how different drug delivery systems respond to alcohol. Because generics may not mimic Coreg CR‚Äôs robustness, separate clinical trials should assess dose dumping risks",,Granted in Part and Denied in Part,2010-10-15,0.0,Center for Drug Evaluation and Research (CDER),"21 U.S.C. 355(j), 355(b)(2), 355(q) (Sections 505(j), 505(b)(2), and 505(q) of the FDCA)
- 21 CFR 320.1(e), 320.23(b), 320.24, 314.94(a)(7), 314.101(d)(9), 314.54(a)
- FDA Guidance Documents Cited:
‚Ä¢ Bioavailability and Bioequivalence Studies for Orally Administered Drug Products ‚Äì General Considerations (2003)
‚Ä¢ Bioequivalence Recommendations for Specific Products (2010 draft guidance)
‚Ä¢ Statistical Approaches to Establishing Bioequivalence",,"Scientific Basis: FDA found the hypothetical PK profile proposed by the petitioner (Profile A) physiologically infeasible for carvedilol due to its known pharmacokinetics (multi-compartment or flip-flop kinetics).

- Cmin Importance Acknowledged: FDA agreed Cmin is important for therapeutic efficacy, especially for heart failure patients, but noted that reliable estimation can be done through modeling based on single-dose studies rather than requiring multiple-dose studies.

- Use of Simulation: FDA used physiologically based PK modeling to determine that equivalence in AUC and Cmax from single-dose studies can predict equivalent Cmin at steady state.

- Precedent from Coreg CR Approval: FDA did not apply strict pass/fail statistical criteria to Cmin in the original Coreg CR NDA (some strengths were outside 80‚Äì125% range).

- Alcohol Dose Dumping: The request for mandatory clinical testing to rule out alcohol-induced dose dumping was denied, with FDA stating that in vitro ethanol dissolution testing was sufficient.

Conclusion: Standard AUC and Cmax criteria from single-dose studies are sufficient to evaluate bioequivalence, with no new requirements for additional Cmin-specific tests",approved,True,123.0,CDER,CDER
fda-2010-p-0216,FDA-2010-P-0216-0001_Flamel_Technologies_S_A___Frommer_Lawrence___Haug_,2010-04-19,2010,False,original petition,Flamel Technologies S.A.,industry/corporation,"Section 505(j) and 505(q) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. ¬ß¬ß 355(j), 355(q))
- 21 C.F.R. ¬ß¬ß 10.20, 10.30, 314.94, and 320.24",The approval of generic versions of Coreg CR¬Æ (carvedilol phosphate) Extended-release Capsules via ANDA or 505(b)(2) NDA without using Cmin (minimum plasma concentration) as a bioequivalence metric,"Require that all ANDA and 505(b)(2) applications for carvedilol ER products:
- Include Cmin testing in addition to Cmax and AUC
- Demonstrate bioequivalence with no lower Cmin than the reference drug","Cmin is critical to maintaining therapeutic effectiveness over 24 hours, especially to protect against adverse events which peak between 6 a.m. and noon.
- Cmin was a condition of FDA‚Äôs original approval of Coreg CR (compared to Coreg IR).
- Published clinical studies and pharmacokinetic data support that Cmin is vital in evaluating extended-release formulations.
- Allowing approval based solely on AUC and Cmax could result in unsafe generics with subtherapeutic drug levels.
- Citing FDA regulatory precedent, scientific studies, and diurnal cardiac risk patterns, the petitioner argues that omission of Cmin would compromise clinical efficacy and patient safety, especially in heart failure cases",,Granted in Part and Denied in Part,2010-10-15,0.0,Center for Drug Evaluation and Research (CDER),"21 U.S.C. 355(j), 355(b)(2), 355(q) (Sections 505(j), 505(b)(2), and 505(q) of the FDCA)
- 21 CFR 320.1(e), 320.23(b), 320.24, 314.94(a)(7), 314.101(d)(9), 314.54(a)
- FDA Guidance Documents Cited:
‚Ä¢ Bioavailability and Bioequivalence Studies for Orally Administered Drug Products ‚Äì General Considerations (2003)
‚Ä¢ Bioequivalence Recommendations for Specific Products (2010 draft guidance)
‚Ä¢ Statistical Approaches to Establishing Bioequivalence",,"Scientific Basis: FDA found the hypothetical PK profile proposed by the petitioner (Profile A) physiologically infeasible for carvedilol due to its known pharmacokinetics (multi-compartment or flip-flop kinetics).

- Cmin Importance Acknowledged: FDA agreed Cmin is important for therapeutic efficacy, especially for heart failure patients, but noted that reliable estimation can be done through modeling based on single-dose studies rather than requiring multiple-dose studies.

- Use of Simulation: FDA used physiologically based PK modeling to determine that equivalence in AUC and Cmax from single-dose studies can predict equivalent Cmin at steady state.

- Precedent from Coreg CR Approval: FDA did not apply strict pass/fail statistical criteria to Cmin in the original Coreg CR NDA (some strengths were outside 80‚Äì125% range).

- Alcohol Dose Dumping: The request for mandatory clinical testing to rule out alcohol-induced dose dumping was denied, with FDA stating that in vitro ethanol dissolution testing was sufficient.

Conclusion: Standard AUC and Cmax criteria from single-dose studies are sufficient to evaluate bioequivalence, with no new requirements for additional Cmin-specific tests",approved,True,179.0,CDER,CDER
fda-2010-p-0201,FDA-2010-P-0201-0001_Paddock_Laboratories__Inc____Citizen_Petition,2010-04-08,2010,False,original petition,"Paddock Laboratories, Inc.",advocacy/academic,"21 C.F.R. ¬ß¬ß 314.161, 10.30, and 10.25(a) (Page 1)
- Also mentions 21 C.F.R. ¬ß 25.31 for environmental impact exclusion (Page 2)
- Mentions 21 C.F.R. 10.30(b)","The FDA‚Äôs classification of Nilstat (Nystatin Powder; Oral 100%) as a discontinued drug in the Orange Book, and whether it was withdrawn for safety or effectiveness reasons",Petitioner requests FDA to formally determine whether Nilstat (Nystatin Powder; Oral 100%) was withdrawn from the market for safety or effectiveness reasons,"All Nystatin Powder (Oral 100%) products are currently listed as discontinued in the Orange Book.
- No notice or record exists confirming withdrawal was due to safety or efficacy concerns.
- Telephone communication with the Office of Generic Drugs suggested the RLD was discontinued for commercial reasons, not safety-related.
- Petitioner seeks this determination to enable future ANDA filing if FDA finds no safety/efficacy issue",2010-10-22 00:00:00,Approved ‚Äì NILSTAT was not withdrawn for reasons of safety or effectiveness,2011-03-02,1.0,Center for Drug Evaluation and Research (CDER),"21 CFR 10.30 ‚Äì Citizen petition procedure
- 21 CFR 314.161 ‚Äì Determination of withdrawal for safety/effectiveness
- 21 CFR 314.162 ‚Äì Removal from the Orange Book
- 21 U.S.C. 355(j)(7) ‚Äì Requirements related to listed drugs and ANDA approval under the FDCA","The FDA had not yet reached a decision on the petition due to competing Agency priorities.
- This was explicitly described as an interim response, not a resolution on the merits of the petition.
- The agency committed to responding ‚Äúas soon as possible given the numerous demands on the Agency‚Äôs resources‚Äù","No evidence of withdrawal due to safety or effectiveness: FDA reviewed internal records and independently evaluated literature and postmarketing data.
- Petitioner did not submit any contrary data: Paddock Laboratories, who submitted the petition, did not provide evidence suggesting safety or efficacy concerns.
- Regulatory Implication: As a result, NILSTAT will remain listed in the Discontinued Drug Product List in the Orange Book, indicating it was discontinued for reasons other than safety or effectiveness. ANDAs referring to it may be approved if all conditions are satisfied",approved,True,328.0,CDER,CDER
fda-2010-p-0196,FDA-2010-P-0196-0001_Hogan___Hartson__LLP__Abbott_Laboratories____Citiz,2010-04-09,2010,False,original petition,Abbott Laboratories,industry/corporation,"21 U.S.C. ¬ß¬ß 355(b), 355(j), 355(q)
- 21 C.F.R. ¬ß¬ß 10.30, 314.50, 314.52, 314.54, 314.94, 314.95, 314.107, 314.108, 314.127
- 21 C.F.R. ¬ß¬ß 25.30 and 25.31 (for environmental impact exclusion)","The FDA‚Äôs policy on requiring skin transfer and hand-washing studies for testosterone gel products with different penetration enhancers than the reference listed drug.
- Specific attention is drawn to generic versions of AndroGel¬Æ, a product acquired by Abbott from Solvay Pharmaceuticals.
- The petition comments on how this policy should be applied to all 505(b)(2) NDAs, including those transitioning from rejected ANDAs.","Require any applicant referencing AndroGel¬Æ with different penetration enhancers to:
‚Ä¢ Conduct skin transfer and hand-washing studies
‚Ä¢ Submit a 505(b)(2) NDA (not an ANDA), unless they obtain a right of reference from Abbott.
- Require such applicants to submit new patent certifications and notify Solvay/Abbott per 21 U.S.C. ¬ß 355(b)(3).","Cites FDA‚Äôs own precedent in the Auxilium petition response (August 2009), which required enhanced scrutiny for testosterone gel products with different penetration enhancers.
- Argues that FDA statutes and regulations prohibit the submission of clinical data under an ANDA, and such data is required for safety assessment of different excipients.
- Points to several historical examples where FDA rejected ANDAs and required submission of 505(b)(2) NDAs with full compliance (e.g., Andrx, Penederm, Teva cases).
- Argues that allowing ANDA-to-505(b)(2) ""switches"" without full regulatory compliance would disadvantage Abbott and violate statutory protections (e.g., 30-month stay rights).",,Granted in part and denied in part,2010-10-08,0.0,Center for Drug Evaluation and Research (CDER),"Section 505(b)(2) and 505(j) of the FD&C Act (21 U.S.C. 355)
- 21 CFR Part 208 ‚Äì Medication Guides
- 21 CFR ¬ß¬ß 314.50(i), 314.52, and 314.54(a)(1)(vi) ‚Äì Requirements for 505(b)(2) NDAs
- 21 CFR ¬ß¬ß 314.94(a)(12), 314.95 ‚Äì Applicable to ANDAs
- 21 CFR 314.107 ‚Äì Applicable to both NDAs and ANDAs",,"Risk of Secondary Exposure: The petition addressed the risk of testosterone gel transferring from adult users to children, resulting in adverse effects such as early puberty and aggressive behavior. FDA previously mandated boxed warnings and Medication Guides for products like AndroGel and Testim.

- Requirement for 505(b)(2) NDAs: FDA upheld that any generic TTG (transdermal testosterone gel) products with different penetration enhancers than the RLD (e.g., AndroGel) require submission as a 505(b)(2) NDA, not an ANDA, due to the need for safety studies.

- Mandatory Studies: FDA requires:
‚Ä¢ Body transfer studies
‚Ä¢ Hand-washing studies
‚Ä¢ Skin irritation and sensitization studies
‚Ä¢ Standard pharmacokinetic (bioequivalence) studies
‚Ä¢ Showering studies when applicable based on other study results

- Patent Certifications: FDA agreed that a 505(b)(2) NDA must include new patent certifications even if a prior ANDA had them, and notifications must be re-issued to the patent holder.

- Reconsideration Possible: FDA reserves the right to revise these requirements if new scientific information arises concerning the relationship between penetration enhancers and testosterone transfer risk",approved,True,182.0,CDER,CDER
fda-2010-p-0188,FDA-2010-P-0188-0016_AXIN_Veltrop_and_Harkrider_LLP_Actavis_Elizabeth_L,2012-06-21,2010,False,original petition,Actavis Elizabeth LLC,industry/corporation,Not Mentioned in this withdrawal document.,"Not Stated in Detail. The document references a prior petition regarding ‚Äú180-Day Exclusivity for Amphetamine Combination Extended-Release Capsules,‚Äù but does not elaborate","The withdrawal of the Citizen Petition originally submitted on April 7, 2010. No additional action is requested beyond withdrawal",Not Mentioned. The letter simply states the withdrawal of the petition without providing reasons,,,2025-10-15,0.0,,,,,no decision,False,4864.0,pending,pending
fda-2010-p-0188,FDA-2010-P-0188-0001_AXIN__Veltrop___Harkrider_LLP__Actavis_Elizabeth_L,2010-04-06,2010,False,original petition,Actavis Elizabeth LLC,industry/corporation,"21 C.F.R. ¬ß 10.30
- Section 505(q) of the FDCA
- 21 C.F.R. ¬ß 314.94(a)(12)(viii)
- 21 C.F.R. ¬ß 314.95(d)
- 21 C.F.R. ¬ß 314.107(c)(1)
- 35 U.S.C. ¬ß 252","The petition comments on FDA‚Äôs application of 180-day marketing exclusivity under the pre-MMA (Medicare Modernization Act) framework, especially how it applies to newly issued patents listed in the Orange Book, specifically U.S. Patent RE41,148 for Adderall XR¬Æ","The petitioner requests that the FDA:
‚Ä¢ Deem U.S. Patent No. RE41,148 (‚Äúthe '148 patent‚Äù) a new and distinct patent from Patent No. 6,605,300.
‚Ä¢ Grant 180-day exclusivity to Actavis for ANDA No. 77-302 for filing a Paragraph IV certification to the '148 patent on the first day such certifications were allowed.
‚Ä¢ Confirm the exclusivity has not yet been triggered and will only be triggered by commercial marketing or a court decision related to the '148 patent","The '148 patent is a reissue of the earlier '300 patent and is legally treated as a new and distinct patent.
- Under FDA‚Äôs pre-MMA ‚Äúpatent-by-patent‚Äù exclusivity approach, a new exclusivity period arises for newly listed patents.
- Actavis was the first filer to submit a Paragraph IV certification for the '148 patent.
- Exclusivity related to the earlier '300 and '819 patents has already been triggered by another filer (Barr), but that does not affect the exclusivity period for the newly issued '148 patent.
- The exclusivity period for the '148 patent has not yet been triggered, and Actavis should be granted this exclusivity for ANDA No. 77-302",2010-10-06 00:00:00,,2025-10-15,1.0,,,"The FDA has not completed its review due to the need to prioritize other matters.
- The response is issued as an interim response, as required under regulatory timelines, and the agency indicates it will respond ‚Äúas soon as possible given the numerous demands on the Agency‚Äôs resources‚Äù",,no decision,False,5671.0,pending,pending
fda-2010-p-0179,FDA-2010-P-0179-0003_University_of_North_Carolina_at_Chapel_Hill_School,2010-06-11,2010,False,original petition,University of North Carolina at Chapel Hill ‚Äì Eshelman School of Pharmacy,advocacy/academic,"21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 25.30 (categorical exclusion from environmental assessment)","The petition comments on FDA's policy concerning labeling requirements for ritonavir-containing products, particularly whether all ritonavir-containing product labels should include interaction warnings with hormonal contraceptives ","The petitioner requests that the FDA require all manufacturers of ritonavir-containing products to revise their product labels to include drug interaction warnings stating that ritonavir may reduce the effectiveness of hormonal contraceptives, increasing the risk of contraceptive failure","Cites peer-reviewed literature and published pharmacokinetic studies indicating that ritonavir significantly reduces plasma levels of ethinyl estradiol, the main estrogen component in many hormonal contraceptives.
- Argues that women prescribed ritonavir-containing antiretroviral therapies may be unknowingly at risk for contraceptive failure and unintended pregnancy if not adequately warned.
- Highlights inconsistent labeling across various ritonavir products despite clear evidence of a class effect on hormonal contraceptives.
- Seeks to standardize labeling in the interest of public health and informed patient care",2010-09-29 00:00:00,"Stradley Petition: Denied
Semelka Petition: Granted in part and denied in part",2010-12-20,1.0,Center for Drug Evaluation and Research (CDER),"21 CFR part 201
- 21 CFR 201.57(c)(1), (6)
- Section 505(o)(4) of the FD&C Act (21 U.S.C. 355(o))
- Section 505-1(b)(3) of the FD&C Act
These appear throughout pages 2‚Äì5 in discussions of statutory authority and FDA procedures for labeling changes. ","Petition Still Under Review: FDA has not completed its evaluation of the issues raised.
- Prioritization and Resource Constraints: Although not detailed, the interim nature of the response suggests that timing and prioritization of agency resources are influencing factors. A final response will be issued after the review is complete","Risk Stratification Supported by Data: The FDA concluded that certain gadolinium-based contrast agents (GBCAs)‚Äîspecifically Omniscan, OptiMARK, and Magnevist‚Äîcarry higher risks of Nephrogenic Systemic Fibrosis (NSF) for patients with chronic severe kidney disease or acute kidney injury.
- Scientific Analysis: This decision was informed by extensive review of clinical data, AERS reports, physiochemical properties of contrast agents, and recommendations from external experts (e.g., EMEA, ACR).
- Regulatory Authority: FDA invoked its authority under section 505(o)(4) to require labeling changes based on new safety information.
- Public Health Considerations: The FDA determined that differential risk-based labeling enhances patient safety and better informs prescribers, rejecting speculative arguments against such labeling. ",approved,True,192.0,CDER,CDER
fda-2010-p-0179,FDA-2010-P-0179-0001_Stradley_Ronon_Stevens___Young__LLP___Citizen_Peti,2010-04-01,2010,False,original petition,"Stradley Ronon Stevens & Young, LLP",law/consulting,"Federal Food, Drug, and Cosmetic Act (FDCA)
- 21 U.S.C. ¬ß 393(b)(1) and (2)(B)
- 21 U.S.C. ¬ß 355(d)
- 42 U.S.C. ¬ß 262
- 21 U.S.C. ¬ß 360e(d)(2)
- 21 C.F.R. ¬ß¬ß 25.30, 25.31(a)","The petitioner is commenting on the FDA's consideration of implementing differential risk-based labeling among gadolinium-based contrast agents (GBCAs), especially regarding the risk of nephrogenic systemic fibrosis (NSF).","The petitioner requests that the FDA:
- Continue class labeling for all GBCAs regarding the risk of NSF in the defined, at-risk population.
- Refrain from implementing differential NSF risk-based labeling among GBCA products.","The petitioner presents the following justifications:
- Available scientific data is inadequate and insufficient to support differential risk-based labeling.
- Class labeling has proven effective since its implementation in 2007, contributing to a dramatic decrease in NSF cases.
- There are potential serious adverse consequences to patient safety if differential labeling is adopted, including: misleading clinicians, undermining current safety protocols, and diluting patient screening importance.
- The petitioner emphasizes that no one GBCA has been proven safer than others.",2010-09-29 00:00:00,"Stradley Petition: Denied
Semelka Petition: Granted in part and denied in part",2010-12-20,1.0,Center for Drug Evaluation and Research (CDER),"21 CFR part 201
- 21 CFR 201.57(c)(1), (6)
- Section 505(o)(4) of the FD&C Act (21 U.S.C. 355(o))
- Section 505-1(b)(3) of the FD&C Act
These appear throughout pages 2‚Äì5 in discussions of statutory authority and FDA procedures for labeling changes. ","Petition Still Under Review: FDA has not completed its evaluation of the issues raised.
- Prioritization and Resource Constraints: Although not detailed, the interim nature of the response suggests that timing and prioritization of agency resources are influencing factors. A final response will be issued after the review is complete","Risk Stratification Supported by Data: The FDA concluded that certain gadolinium-based contrast agents (GBCAs)‚Äîspecifically Omniscan, OptiMARK, and Magnevist‚Äîcarry higher risks of Nephrogenic Systemic Fibrosis (NSF) for patients with chronic severe kidney disease or acute kidney injury.
- Scientific Analysis: This decision was informed by extensive review of clinical data, AERS reports, physiochemical properties of contrast agents, and recommendations from external experts (e.g., EMEA, ACR).
- Regulatory Authority: FDA invoked its authority under section 505(o)(4) to require labeling changes based on new safety information.
- Public Health Considerations: The FDA determined that differential risk-based labeling enhances patient safety and better informs prescribers, rejecting speculative arguments against such labeling. ",approved,True,263.0,CDER,CDER
fda-2010-p-0177,FDA-2010-P-0177-0001_Aurobindo_Pharmaceuticals_Limited__EAS_Consulting_,2010-03-26,2010,False,original petition,Aurobindo Pharmaceuticals Limited,industry/corporation,"21 C.F.R. ¬ß 10.30 (citizen petition regulation)
- 21 C.F.R. ¬ß 314.161 (regarding discontinued drugs)
- 21 C.F.R. ¬ß 314.162 (drug withdrawal)
- 21 C.F.R. ¬ß 25.31 (environmental impact exclusion)
- 21 C.F.R. ¬ß 10.30(b) (economic impact)","The FDA's classification of Augmentin ES-600 (amoxicillin; clavulanate potassium) 600/5mL, NDA 50-755 as a discontinued product in the Orange Book, and whether it was withdrawn from the market for safety or effectiveness reasons.","Petitioner requests the FDA to determine whether Augmentin ES-600 (NDA 50-755) was withdrawn for reasons of safety or effectiveness, which would impact its eligibility for ANDA submission","The drug appears in the discontinued section of the FDA‚Äôs Orange Book (page 3 of the document includes a copy of the listing).
- The FDA is required under 21 C.F.R. ¬ß¬ß 314.161 and 314.162 to determine if the withdrawal was due to safety or efficacy concerns before approving any ANDA referencing the drug.
- No mention is made of any such withdrawal due to safety/effectiveness, prompting the need for clarification.",2010-09-15 00:00:00,"Approved (i.e., FDA determined the products were not withdrawn for safety or effectiveness reasons)
FDA explicitly states it will not initiate procedures to withdraw ANDA approvals and will continue approving ANDAs referencing these AUGMENTIN products",2010-12-07,1.0,Center for Drug Evaluation and Research (CDER),"21 CFR 314.161(a)(1), (a)(2), (d) ‚Äì Determinations on whether a drug was withdrawn for safety/effectiveness reasons
- 21 CFR 314.162 ‚Äì Withdrawal of ANDA if the RLD is withdrawn
- 21 U.S.C. 355(j)(7) ‚Äì ANDA and Orange Book listing authority
- 21 CFR 10.30 ‚Äì Citizen petition procedure","The petition concerns whether Augmentin ES-600 (amoxicillin; clavulanate potassium) was withdrawn for safety or effectiveness reasons.
- FDA has not reached a decision due to the need to address other agency priorities.
- The interim response was issued in compliance with procedural regulations and the Agency pledged to respond as soon as resources allow","FDA received citizen petitions from EAS Consulting Group requesting withdrawal determinations for several AUGMENTIN formulations.
- FDA reviewed:
‚Ä¢ Its internal records
‚Ä¢ Literature
‚Ä¢ Postmarketing adverse event data
- No data suggested any of the drug products were withdrawn for safety or effectiveness reasons.
- Accordingly, the drugs will remain in the ‚ÄúDiscontinued Drug Product List‚Äù in the Orange Book, indicating they were discontinued for business or manufacturing reasons, not due to risk concerns.
- FDA also stated that additional ANDAs may be approved if all other requirements are met",approved,True,256.0,CDER,CDER
fda-2010-p-0176,FDA-2010-P-0176-0085_Ethicon_Endo_Surgery__Inc____Goodwin_Procter_LLP__,2011-11-28,2010,False,original petition,"Ethicon Endo-Surgery, Inc. (EES)",industry/corporation,"Section 515(g)(2) of the Federal Food, Drug, and Cosmetic Act (regarding administrative review of PMA decisions)",The CDRH‚Äôs denial order for the SEDASYS System PMA (P080009),"Ethicon Endo-Surgery withdraws its request for administrative review of CDRH‚Äôs denial order, following a settlement agreement with FDA‚Äôs Center for Devices and Radiological Health (CDRH).",The withdrawal is due to the fact that EES and CDRH have reached an agreement to settle the company‚Äôs appeal of the denial order. No additional justification is provided in the letter beyond this resolution.,,"Scheduling Notice ‚Äì Not a Decision on Petition
This document transmits the revised Schedule of Events and the agenda for the December 14, 2011 Advisory Committee meeting reviewing CDRH‚Äôs denial of the SEDASYS PMA. It does not represent an approval, denial, or partial decision on the petition itself.",2011-12-14,0.0,Center for Devices and Radiological Health (CDRH),"Section 515(g)(2) of the Federal Food, Drug, and Cosmetic Act ‚Äì cited as the statutory basis for convening the Advisory Committee",,"The FDA granted EES‚Äôs request for review of CDRH‚Äôs denial of PMA P080009 for the SEDASYS system under Section 515(g)(2).
- To facilitate a fair and organized review, the letter provides a detailed multi-stage timeline and procedural requirements for both FDA and the sponsor.
- Key milestones include:
‚Ä¢ Submission of attendees (by August 19, 2011)
‚Ä¢ Draft and final Advisory Committee Panel Packages (Panel Packs)
‚Ä¢ Slide submissions
‚Ä¢ Meeting summary drafts and final report from Advisory Committee Chair
‚Ä¢ Post-meeting actions, including exception filings and a final FDA order
.
- The agenda on page 4 outlines the full-day structure of the December 14, 2011 meeting, including public hearings, sponsor and FDA presentations, and Advisory Committee deliberations and vote",other,True,16.0,CDRH,CDRH
fda-2010-p-0176,FDA-2010-P-0176-0079_Ethicon_Endo_Surgery__Inc___Goodwin_Procter_LLP___,2010-10-11,2010,False,original petition,"Ethicon Endo-Surgery, Inc. (EES)",industry/corporation,"Not explicitly stated in the letter, but the correspondence is part of the ongoing petition under Docket No. FDA-2010-P-0176, related to CDRH's PMA denial order (Premarket Approval). Indirect references are made to FDA procedures around Advisory Committee reviews, scientific and clinical review standards, and propofol labeling guidance.","The petitioner is responding to FDA's (Commissioner‚Äôs Team‚Äôs) guidance and handling of Advisory Committee Panel Pack content, specifically related to the scientific and clinical review of deficiencies cited in CDRH‚Äôs October 26, 2010 PMA denial order.","The petitioner requests the following:
- FDA should remove all references to the propofol warning statement from both parties‚Äô Advisory Committee panel pack submissions.
- FDA should enforce previously communicated procedures, especially limiting the panel‚Äôs focus strictly to scientific and clinical issues, and not legal/regulatory topics.
- FDA should resolve several outstanding procedural concerns before the December 14 Advisory Committee meeting (detailed in Attachment A of the document)","EES believes the FDA‚Äôs latest communication (Oct. 6 email) contradicts earlier guidance (Sept. 13 Summary) by permitting panel members to disregard information based on their own judgment, potentially introducing inconsistency.
- EES asserts the panel should not consider regulatory issues, like the propofol label, as these are beyond the scope of scientific and clinical review.
- EES had complied with guidance to restrict content, while CDRH included improper material.
- EES outlines a list of unresolved issues (Attachment A), including unanswered procedural questions, lack of clear review protocols, and insufficient rebuttal time, all of which could jeopardize a fair and unbiased panel proceeding.",2011-08-29 00:00:00,Denied ‚Äì The FDA formally denied the PMA (Premarket Approval) application P080009 for the SEDASYS‚Ñ¢ system,2010-10-26,1.0,Center for Devices and Radiological Health (CDRH),"Section 515(d)(2) of the FD&C Act (21 U.S.C. 360e(d)(2))
- 21 CFR 814.44(f)
- 21 CFR 814.45(e)(3)
- 21 CFR 10.33
- Section 515(d)(4) of the FD&C Act
- 21 CFR 860.7(d)(1)
- 21 CFR 814.45(b) and 814.45¬©","The letter notes that Dr. David Buckles is unavailable that week.
- Nancy K. Stade and Mark A. Heller (from Goodwin Procter LLP) request a short phone meeting before August 30 at 10am to finalize a submission timeline for the Advisory Committee materials","The FDA concluded that the sponsor failed to provide reasonable assurance of safety for the SEDASYS System under the proposed labeling conditions.
- The pivotal clinical study lacked a direct comparison of SEDASYS use by gastroenterologists vs. anesthesiologists administering propofol under the FDA-approved label, making it impossible to assess relative safety risks.
- The device showed a higher incidence of deeper-than-intended sedation, including episodes of general anesthesia, compared to the control arm (‚ÄúCurrent Standard of Care‚Äù), which FDA flagged as a serious safety signal.
- The proposed training programs (Amendments 12 and 15) were not backed by outcome-based clinical studies and considered speculative, inadequate to mitigate the safety concerns associated with broader use by less-trained clinicians.
- FDA advised that additional clinical studies are needed comparing outcomes across provider types and proposed that the sponsor develop and validate targeted training programs based on those findings.
- Notice of this denial would be published online and in the Federal Register, per 21 CFR 814.45(c)",denied,True,15.0,CDRH,CDRH
fda-2010-p-0176,FDA-2010-P-0176-0068_Ethicon_Endo_Surgery__EES__Inc___Goodwin_Procter_L,2010-09-01,2010,False,original petition,"Ethicon Endo-Surgery, Inc. (EES)",industry/corporation,"Federal Food, Drug, and Cosmetic Act, Section 513(b)(6)(B) (concerning adequate time for presentations and rebuttals during advisory panel reviews)","The petition responds to FDA's ‚ÄúSummary of Scientific Issues‚Äù and the Schedule of Events for the Advisory Committee regarding the SEDASYS System PMA denial (Premarket Approval). The petitioner comments on the panel's questions, structure of the meeting, and procedural fairness.","The petitioner requests the FDA to:
- Revise Panel Question 1 to include clarification of user expertise and sedation context.
- Modify Panel Question 3 to remove propofol references, focusing only on the device‚Äôs safety and effectiveness.
- Retain substantive content in both parties‚Äô panel submissions and not unilaterally remove it.
- Avoid preparing pre-panel summaries that could bias outcomes.
- Extend the rebuttal period beyond the proposed 15 minutes and confirm flexibility for more time if needed.","Panel Question 1 needed clearer definition of the intended user group and proper framing of sedation incidents.
- Question 3 should focus on the device (SEDASYS) rather than drugs like propofol, which are outside the device scope.
- Concern over FDA staff modifying panel submissions, which could infringe upon the presentation of arguments.
- Concern that FDA-drafted 24-hour and 7-day summaries could bias the panel process before their official report.
- The proposed 15-minute rebuttal window is inadequate; longer time would ensure a complete and fair hearing under statutory requirements for adequate response time",2011-08-29 00:00:00,Denied ‚Äì The FDA formally denied the PMA (Premarket Approval) application P080009 for the SEDASYS‚Ñ¢ system,2010-10-26,1.0,Center for Devices and Radiological Health (CDRH),"Section 515(d)(2) of the FD&C Act (21 U.S.C. 360e(d)(2))
- 21 CFR 814.44(f)
- 21 CFR 814.45(e)(3)
- 21 CFR 10.33
- Section 515(d)(4) of the FD&C Act
- 21 CFR 860.7(d)(1)
- 21 CFR 814.45(b) and 814.45¬©","The letter notes that Dr. David Buckles is unavailable that week.
- Nancy K. Stade and Mark A. Heller (from Goodwin Procter LLP) request a short phone meeting before August 30 at 10am to finalize a submission timeline for the Advisory Committee materials","The FDA concluded that the sponsor failed to provide reasonable assurance of safety for the SEDASYS System under the proposed labeling conditions.
- The pivotal clinical study lacked a direct comparison of SEDASYS use by gastroenterologists vs. anesthesiologists administering propofol under the FDA-approved label, making it impossible to assess relative safety risks.
- The device showed a higher incidence of deeper-than-intended sedation, including episodes of general anesthesia, compared to the control arm (‚ÄúCurrent Standard of Care‚Äù), which FDA flagged as a serious safety signal.
- The proposed training programs (Amendments 12 and 15) were not backed by outcome-based clinical studies and considered speculative, inadequate to mitigate the safety concerns associated with broader use by less-trained clinicians.
- FDA advised that additional clinical studies are needed comparing outcomes across provider types and proposed that the sponsor develop and validate targeted training programs based on those findings.
- Notice of this denial would be published online and in the Federal Register, per 21 CFR 814.45(c)",denied,True,55.0,CDRH,CDRH
fda-2010-p-0176,FDA-2010-P-0176-0067_Ethicon_Endo_Surgery___EES__Inc___Goodwin_Proctor_,2011-08-19,2010,False,original petition,"Ethicon Endo-Surgery, Inc. (EES)",industry/corporation,"Section 515(g)(2) of the Federal Food, Drug, and Cosmetic Act (related to the convening of an FDA Advisory Committee meeting on PMA review)","The letter is in response to the FDA Advisory Committee‚Äôs upcoming meeting scheduled for December 14, 2011, concerning EES‚Äô SEDASYS System. The correspondence provides a preliminary list of speakers and attendees that EES anticipates will participate.","No specific regulatory action is requested. The submission serves to inform FDA of the anticipated attendees and speakers for the Advisory Committee meeting, as part of procedural planning.",Not Applicable ‚Äì this is a procedural letter for administrative planning rather than a petition requesting regulatory change. The list is submitted to comply with expectations for participation in the Advisory Committee session,2011-08-29 00:00:00,"Administrative Update ‚Äì Not a Petition Decision
This letter serves as an update to the personnel list for the upcoming Advisory Committee meeting related to the SEDASYS system. It is not a decision or procedural response to the petition itself.",2011-08-23,1.0,Center for Devices and Radiological Health (CDRH),"Section 515(g)(2) of the Federal Food, Drug, and Cosmetic Act ‚Äì Cited as the basis for the Advisory Committee Meeting","The letter notes that Dr. David Buckles is unavailable that week.
- Nancy K. Stade and Mark A. Heller (from Goodwin Procter LLP) request a short phone meeting before August 30 at 10am to finalize a submission timeline for the Advisory Committee materials","The initial list of attendees submitted on August 19, 2011, was incomplete.
- This updated list includes additional CDRH personnel across departments such as:
‚Ä¢ Office of Device Evaluation
‚Ä¢ Office of Surveillance and Biometrics
‚Ä¢ Office of Chief Counsel
‚Ä¢ Division of Anesthesiology, General Hospital, Infection Control, and Dental Devices
- Notably includes high-level policy and scientific personnel such as Nancy K. Stade (Deputy Director for Policy) and William Maisel (CDRH Chief Scientist).
- The letter also states that additional experts in anesthesiology and intensive care medicine may be added, and a further update will be provided upon confirmation",other,True,4.0,CDRH,CDRH
fda-2010-p-0176,FDA-2010-P-0176-0066_Ethicon_Endo_Surgery___EES__Inc___Goodwin_Proctor_,2011-07-21,2010,False,original petition,"Ethicon Endo-Surgery, Inc. (EES)",industry/corporation,"Section 515(g)(2) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), relating to advisory committee review of PMA denial orders
- 21 C.F.R. ¬ß 14.82 (nominations for temporary voting members to FDA advisory committees)","The FDA‚Äôs handling of procedural elements and summary content for the Advisory Committee convened to review the denial of the SEDASYS System PMA. The letter addresses proposed revisions to the FDA‚Äôs draft ‚ÄúSummary of Scientific Issues in Dispute‚Äù, panel time allocation, composition, conflict of interest concerns, and panel questions.","The petitioner requests the FDA to:
- Grant 2.5 hours for EES‚Äôs initial presentation during the advisory panel meeting.
- Ensure adequate time is provided for rebuttal outside of just panel questions.
- Consider EES‚Äôs panelist nominations and issue a Federal Register notice for temporary voting member nominations.
- Revise panel questions to remove bias and frame safety/effectiveness neutrally.
- Meet jointly with FDA/CDRH staff to coordinate outstanding procedural issues and align on panel questions.","The proposed 1-hour limit on presentations is inadequate for an appeal from a PMA denial and inconsistent with previous practices (e.g., 90 minutes given during May 2009 panel).
- EES argues that rebuttal should be ensured by applicants and not rely solely on panel inquiry, per FD&C Act intent.
- Conflict of interest concerns due to gastroenterologists‚Äô economic arrangements could influence the panel; EES seeks strict application of rules.
- EES also found bias in FDA‚Äôs proposed question framing and misalignment in draft summaries, necessitating collaborative review to ensure a fair process.",2011-08-29 00:00:00,"Procedural Assignment ‚Äì Not a Petition Decision
This is an internal memorandum assigning named CDRH staff to assist the Office of the Commissioner in preparation for an Advisory Committee and Commissioner-level review of PMA denial. It is not an approval, denial, or modification of the petition.",2011-08-08,1.0,Center for Devices and Radiological Health (CDRH),"Section 515(g)(2) of the Federal Food, Drug, and Cosmetic Act ‚Äì Basis for the Commissioner‚Äôs review of the PMA denial","The letter notes that Dr. David Buckles is unavailable that week.
- Nancy K. Stade and Mark A. Heller (from Goodwin Procter LLP) request a short phone meeting before August 30 at 10am to finalize a submission timeline for the Advisory Committee materials","To maintain procedural fairness, the FDA elects to adhere to separation of functions as a matter of policy.
- This means staff involved in the original PMA decision will not participate in the Commissioner‚Äôs review.
- The memorandum lists the CDRH employees designated to support the Office of the Commissioner, including Tonja J. Adams, Frances Adogu, Margaret J. Ames, James Clark, Sandra Oquendo, Keyonna Queen, and Ann Marie Williams",other,True,18.0,CDRH,CDRH
fda-2010-p-0176,FDA-2010-P-0176-0040_Ethicon_Endo_Surgery__Inc____Goodwin_Procter_LLP__,2011-06-03,2010,False,original petition,"Ethicon Endo-Surgery, Inc. (EES)",industry/corporation,"21 C.F.R. ¬ß 14.82(b) (nominations for temporary voting members to advisory committees)
- 18 U.S.C. ¬ß 208 (conflict of interest law)
- Section 712 of the Federal Food, Drug, and Cosmetic Act
- 5 C.F.R. ¬ß 2640 (ethics standards for executive branch employees)
- Cited FDA guidance documents on advisory committee conflict of interest procedures (2008 and 2010 versions)","The procedures and planning for an Advisory Committee meeting regarding the PMA (Premarket Approval) denial of the SEDASYS System, particularly the composition of the panel, conflict of interest vetting, and presentation scheduling.","Publish a Federal Register notice soliciting nominations for temporary voting members for the advisory panel.
- Screen proposed candidates (gastroenterologists named in the letter) for panel participation.
- Apply stringent conflict of interest screening, particularly for economic interests in sedation practice models.
- Grant each party 2.5 hours for presentation time and additional time for rebuttal.
- Conduct a face-to-face meeting with FDA, CDRH, and the Commissioner‚Äôs team to finalize procedures and schedule.","EES believes a meeting is necessary to resolve outstanding issues including panel member selection, scheduling, and the scope of review.
- Nominees (three gastroenterologists) have no financial ties to EES and are qualified to contribute to fair evaluation.
- Certain sedation business models raise conflict of interest risks, which should be carefully reviewed under legal and ethical standards.
- The complexity and history (nearly 10 years) of the SEDASYS PMA matter warrants extended presentation and rebuttal time (1.5 to 2 days total panel time).
- Engaging early and collaboratively with the agency will promote transparency, efficiency, and predictability in the appeals process",2011-08-29 00:00:00,Acknowledged input and suggestions but did not grant a meeting or make any final decision on the petition itself,2011-06-22,2.0,Center for Devices and Radiological Health (CDRH),"Section 515(g)(2) of the Federal Food, Drug, and Cosmetic Act","The letter notes that Dr. David Buckles is unavailable that week.
- Nancy K. Stade and Mark A. Heller (from Goodwin Procter LLP) request a short phone meeting before August 30 at 10am to finalize a submission timeline for the Advisory Committee materials","Advisory committee will include expertise from gastroenterology, anesthesiology, and statistics as suggested.
- Committee members will be selected from the existing pool of Special Government Employees with appropriate qualifications.
- Time allotment suggestions for the advisory hearing are being considered during schedule refinement.
- All advisory committee candidates will be screened for conflicts of interest.
- A specific CDRH contact (Nancy Stade) was provided for correspondence.
- No additional comment on ex parte communications; affirmed current regulatory interpretation.
- Meeting request denied; FDA deemed it unnecessary at the time.",other,True,19.0,CDRH,CDRH
fda-2010-p-0176,FDA-2010-P-0176-0039_Ethicon_Endo_Surgery__Inc____Goodwin_Procter_LLP__,2011-06-03,2010,False,original petition,"Ethicon Endo-Surgery, Inc. (EES)",industry/corporation,"21 CFR ¬ß 10.3(a) ‚Äì Definition of ex parte communication
- 21 CFR ¬ß 10.55(d)(1) ‚Äì Restrictions on ex parte communications
- 5 U.S.C. ¬ß 557(d)(1)(A) & (B) ‚Äì Administrative Procedure Act (APA) prohibition of ex parte communications
- 21 CFR Part 14 ‚Äì Regarding nomination and selection of advisory panel members",The FDA‚Äôs enforcement of ex parte communication rules and lack of engagement regarding procedural planning for the Advisory Committee review of EES‚Äôs PMA (Premarket Approval) appeal for the SEDASYS System.,"Request for a meeting between the parties (EES and FDA) to resolve procedural issues surrounding the upcoming advisory panel review
- Clarification of who at CDRH (Center for Devices and Radiological Health) is responsible for managing the panel proceeding
- Ensure that procedural communications can be appropriately submitted to the docket and are not mistaken as ex parte","EES emphasizes its commitment to transparency and predictability in the panel process.
- Argues that procedural communications (not related to the merits) are not prohibited under ex parte rules as per FDA regulation and APA precedent.
- Cites legislative and regulatory interpretations to support that such communications should be allowed if they do not affect the merits.
- Notes a lack of clarity on the appropriate FDA contact for procedural matters, highlighting a gap in communication structure",2011-08-29 00:00:00,Acknowledged input and suggestions but did not grant a meeting or make any final decision on the petition itself,2011-06-22,2.0,Center for Devices and Radiological Health (CDRH),"Section 515(g)(2) of the Federal Food, Drug, and Cosmetic Act","The letter notes that Dr. David Buckles is unavailable that week.
- Nancy K. Stade and Mark A. Heller (from Goodwin Procter LLP) request a short phone meeting before August 30 at 10am to finalize a submission timeline for the Advisory Committee materials","Advisory committee will include expertise from gastroenterology, anesthesiology, and statistics as suggested.
- Committee members will be selected from the existing pool of Special Government Employees with appropriate qualifications.
- Time allotment suggestions for the advisory hearing are being considered during schedule refinement.
- All advisory committee candidates will be screened for conflicts of interest.
- A specific CDRH contact (Nancy Stade) was provided for correspondence.
- No additional comment on ex parte communications; affirmed current regulatory interpretation.
- Meeting request denied; FDA deemed it unnecessary at the time.",other,True,19.0,CDRH,CDRH
fda-2010-p-0176,FDA-2010-P-0176-0035_Ethicon_Endo_Surgery__Inc____Goodwin_Procter_LLP__,2011-05-19,2010,False,original petition,"Ethicon Endo-Surgery, Inc. (EES)",industry/corporation,"21 CFR ¬ß 14.82(b) ‚Äì Related to Federal Register notice for panel member nominations
- 76 Fed. Reg. 15321 (March 21, 2011) ‚Äì FDA policy on ex parte communications","The procedural planning and communication protocols for the upcoming Advisory Committee review of the PMA denial of the SEDASYS System, including panel formation, ex parte rules, and agenda setting.","Prompt issuance of a Federal Register Notice inviting nominations for temporary voting members for the advisory panel, with a 30-day comment period
- Clarity and assurance on the application of ex parte communication restrictions
- Input from EES on the proposed schedule for the panel and on questions defining the scope of review
- Continued dialogue with FDA representatives to discuss procedures and finalize scheduling","Delay in issuing the panel member nomination notice would hinder timely review, as selection and conflict-of-interest vetting is time-intensive.
- Soliciting nominations now would help streamline future procedural steps without prejudicing the Commissioner's internal planning.
- EES believes that ex parte rules apply only to substantive matters and should not preclude communication about logistics and procedures.
- EES values the opportunity to review and comment on the panel agenda and meeting schedule to ensure transparency and effective participation.",2011-08-29 00:00:00,Acknowledged petition for review and framed the issues for advisory committee consideration. No final approval/denial decision was rendered in this document.,2011-06-02,1.0,Center for Devices and Radiological Health (CDRH),"Section 515(g)(2) and 515(g)(2)(A) of the Federal Food, Drug, and Cosmetic Act","The letter notes that Dr. David Buckles is unavailable that week.
- Nancy K. Stade and Mark A. Heller (from Goodwin Procter LLP) request a short phone meeting before August 30 at 10am to finalize a submission timeline for the Advisory Committee materials","The response includes a draft Statement of Issues to guide the Medical Devices Advisory Committee's discussion.
- FDA acknowledged granting Ethicon Endo-Surgery‚Äôs request for review of the CDRH‚Äôs denial of the Pre-Market Approval (PMA) application for the SEDASYS system.
- The purpose is to frame clinical and scientific issues (e.g., deeper-than-intended sedation, adequacy of control arm in trials, sufficiency of safety assurance, and training mitigation).
- Two principal disputed issues were outlined:
¬†¬†1. Safety concerns due to unintended deep sedation episodes.
¬†¬†2. Whether the clinical trial‚Äôs control arm was appropriate.
- A targeted training program was proposed by the petitioner, and the advisory committee was asked to assess its adequacy and validation needs",other,True,14.0,CDRH,CDRH
fda-2010-p-0176,FDA-2010-P-0176-0032_Ethicon_Endo_Surgery__Inc____Goodwin_Procter_LLP__,2011-04-25,2010,False,original petition,"Ethicon Endo-Surgery, Inc. (EES)",industry/corporation,"21 CFR ¬ß 14.82(b) ‚Äì Nominations for temporary voting members to advisory committees
- 76 Fed. Reg. 15321 (March 21, 2011) ‚Äì FDA policy on ex parte communications","The procedure and scheduling for the advisory panel review of the SEDASYS PMA denial, particularly the timing for panel member nominations, ex parte communication policies, and the setting of the review agenda.","Prompt issuance of a Federal Register notice soliciting nominations for temporary voting members, with a proposed 30-day comment period.
- Clarification and enforcement of the Office of the Commissioner‚Äôs commitment to avoiding ex parte communications with parties to the proceeding.
- Circulation of a draft schedule for the panel review to allow both EES and CDRH to comment.
- Opportunity for both parties to review and provide input on agenda items and panel questions defining the scope of the advisory committee‚Äôs review.","The panel formation process is time-consuming, and early solicitation of nominations would expedite progress.
- Ensuring procedural transparency and fairness in the panel setup and communications is essential for due process.
- Providing a draft schedule and seeking early stakeholder input on review questions will help streamline the advisory committee process and promote a productive review of the PMA denial.",2011-08-29 00:00:00,Other ‚Äì Administrative designation: CDRH employee Kathleen L. Walker was appointed to support the Office of the Commissioner in connection with the advisory committee and Commissioner‚Äôs review of the PMA denial. No decision was made on the petition itself,2011-04-28,1.0,Office of the Commissioner (Policy) in coordination with Center for Devices and Radiological Health (CDRH),"Section 515(g)(2) of the Federal Food, Drug, and Cosmetic Act","The letter notes that Dr. David Buckles is unavailable that week.
- Nancy K. Stade and Mark A. Heller (from Goodwin Procter LLP) request a short phone meeting before August 30 at 10am to finalize a submission timeline for the Advisory Committee materials","The memorandum formalizes the agency‚Äôs adherence to separation of functions as a matter of policy.
- This step ensures procedural fairness during the advisory committee and Commissioner-level review of CDRH‚Äôs denial of PMA P080009.
- It explicitly designates a staff member to support the Commissioner independently of the petition review process",other,True,3.0,CDRH,CDRH
fda-2010-p-0176,FDA-2010-P-0176-0030_Ethicon_Endo_Surgery__Inc____Goodwin_Procter_LLP__,2011-04-07,2010,False,original petition,"Ethicon Endo-Surgery, Inc. (EES)",industry/corporation,Not Mentioned,"The agency's announcement of the referral of EES‚Äôs petition for review of the SEDASYS PMA denial order to an advisory committee. The letter seeks discussion of the procedures for the panel meeting, including member selection and agenda planning.","Request for a meeting with the FDA Ombudsman (Dr. David Buckles) to discuss:
- Selection of temporary panel members
- Submission of briefing documents
- Formulation of review questions
- Timeframe for selection and meeting
- General meeting procedures","EES seeks to engage early with the FDA to ensure clarity, transparency, and efficiency in the procedures governing the advisory panel review. The letter proposes specific meeting dates and requests that a copy be forwarded to the appropriate CDRH representative to facilitate communication",2011-08-29 00:00:00,"Other ‚Äì The document summarizes a teleconference held to discuss procedural matters related to the advisory panel review. It does not provide a formal decision on the petition (e.g., approval or denial).",2011-04-21,1.0,Center for Devices and Radiological Health (CDRH) ‚Äì Specifically from the CDRH Ombudsman,"21 CFR 14.35(c) ‚Äì regarding submission of documents prior to a panel meeting
- Part 14 ‚Äì referred to generally in the context of advisory panel procedures","The letter notes that Dr. David Buckles is unavailable that week.
- Nancy K. Stade and Mark A. Heller (from Goodwin Procter LLP) request a short phone meeting before August 30 at 10am to finalize a submission timeline for the Advisory Committee materials","This memorandum records the topics discussed during an April 20, 2011 teleconference between Goodwin Procter (on behalf of EES) and CDRH representatives.
- Topics included scheduling, panel member nomination timing, procedural expectations, concerns about summer scheduling conflicts, and the scope of ex parte communication restrictions.
- The agency clarified that the schedule for the advisory panel meeting was still in development, and reiterated that no off-process communications were occurring related to SEDASYS",other,True,14.0,CDRH,CDRH
fda-2010-p-0176,FDA-2010-P-0176-0026_Ethicon_Endo_Surgery__Inc____Goodwin_Procter_LLP__,2010-12-09,2010,False,original petition,"Ethicon Endo-Surgery, Inc. (EES)",industry/corporation,"Section 515(g)(2) of the FD&C Act
- 21 C.F.R. ¬ß 10.33
- 21 C.F.R. Part 14
- Section 562 of the FD&C Act
- 21 C.F.R. ¬ß 814.44(f)(2)
- 21 C.F.R. ¬ß 10.75
- 41 C.F.R. ¬ß 102-3.70
- Administrative Procedure Act (APA)",FDA‚Äôs proposed use of the Medical Devices Dispute Resolution Panel (instead of an independent advisory committee) to review the denial of EES‚Äôs SEDASYS PMA application,"EES requests the FDA to:
- Convene an independent advisory committee under section 515(g)(2) to review the PMA denial.
- Not use the Medical Devices Dispute Resolution Panel as it lacks legal authority.
- Ensure the panel is not managed by CDRH employees, to preserve impartiality.","Section 515(g)(2) guarantees a right to an independent expert panel for PMA denials.
- Section 562 dispute resolution is not applicable when a specific review provision (515(g)) exists.
- FDA has not issued formal regulations required under section 562 to implement a legal dispute resolution mechanism.
- Using non-binding guidance violates the Administrative Procedure Act (APA).
- Allowing CDRH (a party to the dispute) to manage the review process undermines panel impartiality.
- Legislative history confirms Congress intended an independent and impartial review under section 515(g)(2)",2011-08-29 00:00:00,"Other ‚Äì The document designates legal counsel for separation of functions in relation to a pending petition review. No decision (approval, denial, etc.) was issued.",2011-02-09,1.0,"Office of the General Counsel, Chief Counsel‚Äôs Office ‚Äì in connection with CDRH (Center for Devices and Radiological Health) and the Commissioner","Section 515(g)(2) of the Federal Food, Drug, and Cosmetic Act
- 21 CFR 814.44(f) ‚Äì referenced as the basis for the original PMA denial by CDRH","The letter notes that Dr. David Buckles is unavailable that week.
- Nancy K. Stade and Mark A. Heller (from Goodwin Procter LLP) request a short phone meeting before August 30 at 10am to finalize a submission timeline for the Advisory Committee materials","Although no legal requirement mandates separation of functions in this proceeding, the FDA voluntarily implemented it to maintain procedural fairness.
- Attorneys were designated separately for the Commissioner and for CDRH to preserve integrity in the advisory and decision-making process.
- This followed FDA‚Äôs grant of Ethicon's petition for review of the CDRH‚Äôs prior PMA denial for the SEDASYS system",other,True,62.0,CDRH,CDRH
fda-2010-p-0176,FDA-2010-P-0176-0023_Goodwin_Procter_LLP_to_FDA__May_17__2010___Memoran,2010-05-17,2010,False,original petition,Goodwin Procter LLP,law/consulting,"Section 515(g)(2) of the FD&C Act
- Section 515(d)(4) of the FD&C Act
- 21 C.F.R. ¬ß 10.33
- 21 C.F.R. ¬ß 814.44(f)(2)
- 21 C.F.R. ¬ß¬ß 14.20, 14.25, 14.29, 14.33, 14.35, 14.40, 14.82, 14.90
- 21 C.F.R. ¬ß 12.32‚Ç¨",The procedures surrounding the convening of an independent advisory committee to review the denial of a Premarket Approval Application (PMA) by the Center for Devices and Radiological Health (CDRH) under Section 515 of the FD&C Act.,"Provide and clarify procedures for establishing and conducting an independent advisory committee under Section 515(g)(2), including:
- How petitions for reconsideration should be submitted
- How the advisory committee should be established and staffed
- What regulations and timelines apply to the advisory process","The memorandum aims to clarify and ensure procedural consistency, fairness, and transparency in the FDA‚Äôs review of a PMA denial through an independent advisory committee. The authors emphasize that statutory requirements supersede existing regulations where conflicts arise and advocate for appropriate public notice and documentation procedures to maintain public trust and due process",2011-08-29 00:00:00,Denied ‚Äì The FDA formally denied the PMA (Premarket Approval) application P080009 for the SEDASYS‚Ñ¢ system,2010-10-26,1.0,Center for Devices and Radiological Health (CDRH),"Section 515(d)(2) of the FD&C Act (21 U.S.C. 360e(d)(2))
- 21 CFR 814.44(f)
- 21 CFR 814.45(e)(3)
- 21 CFR 10.33
- Section 515(d)(4) of the FD&C Act
- 21 CFR 860.7(d)(1)
- 21 CFR 814.45(b) and 814.45¬©","The letter notes that Dr. David Buckles is unavailable that week.
- Nancy K. Stade and Mark A. Heller (from Goodwin Procter LLP) request a short phone meeting before August 30 at 10am to finalize a submission timeline for the Advisory Committee materials","The FDA concluded that the sponsor failed to provide reasonable assurance of safety for the SEDASYS System under the proposed labeling conditions.
- The pivotal clinical study lacked a direct comparison of SEDASYS use by gastroenterologists vs. anesthesiologists administering propofol under the FDA-approved label, making it impossible to assess relative safety risks.
- The device showed a higher incidence of deeper-than-intended sedation, including episodes of general anesthesia, compared to the control arm (‚ÄúCurrent Standard of Care‚Äù), which FDA flagged as a serious safety signal.
- The proposed training programs (Amendments 12 and 15) were not backed by outcome-based clinical studies and considered speculative, inadequate to mitigate the safety concerns associated with broader use by less-trained clinicians.
- FDA advised that additional clinical studies are needed comparing outcomes across provider types and proposed that the sponsor develop and validate targeted training programs based on those findings.
- Notice of this denial would be published online and in the Federal Register, per 21 CFR 814.45(c)",denied,True,162.0,CDRH,CDRH
fda-2010-p-0175,FDA-2010-P-0175-0001_Centrix_Pharmaceutical__Inc____Buchanan_Ingersoll_,2010-03-25,2010,False,original petition,"Centrix Pharmaceutical, Inc.",industry/corporation,"21 C.F.R. ¬ß 10.35 (for petition to stay enforcement)
- 21 C.F.R. ¬ß 310.305 (related to adverse drug reaction reports)","The FDA's Warning Letter No. 2010-NOL-11 (dated February 24, 2010), which deemed certain tannate-containing products as unapproved and subject to enforcement action.","Centrix requests that the Commissioner of Food and Drugs stay any enforcement action relating to its tannate-containing drug products until resolution of the pending Citizen Petition (FDA-2008-P-0219) filed by the Tannates Working Group on January 3, 2008, to which Centrix is a signatory.","The FDA has not responded to the 2008 Citizen Petition, which argues that tannate products are GRAS/E (Generally Recognized as Safe and Effective).
- The products have a long history of safe use, are manufactured in FDA-inspected facilities, and ADR reports are submitted as required.
- FDA itself labeled the regulatory issues as ‚Äúcomplex‚Äù and requiring ‚Äúextensive review and analysis.‚Äù
- Enforcement prior to resolution of the petition would be arbitrary, capricious, and a violation of procedural and equitable due process, causing irreparable harm to Centrix",,,2025-10-15,0.0,,,,,no decision,False,5683.0,pending,pending
fda-2010-p-0172,FDA-2010-P-0172-0001_Aurobindo_Pharmaceuticals__Ltd____EAS_Consulting_G,2010-03-23,2010,False,original petition,"Aurobindo Pharmaceuticals, Ltd.",industry/corporation,"21 C.F.R. ¬ß 10.30 (Citizen Petition regulations)
- 21 C.F.R. ¬ß 314.161 (Determination of withdrawal for safety/effectiveness)
- 21 C.F.R. ¬ß 314.162 (Conditions for ANDA submission after withdrawal)
- 21 C.F.R. ¬ß 25.31 (Environmental impact exclusion)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact information)","FDA listing of Augmentin (amoxicillin; clavulanate potassium) 200 mg/5 mL and 400 mg/5 mL, NDA 50-725 in the discontinued section of the Orange Book.","Aurobindo requests that the FDA determine whether Augmentin (NDA 50-725), manufactured by GlaxoSmithKline, was withdrawn from sale for reasons of safety or effectiveness, in order to allow an ANDA referencing it to be submitted.","The drug appears in the discontinued section of the Orange Book.
- Per FDA rules, a determination must be made before an ANDA can reference such a product.
- The petitioner seeks clarity on whether the product was voluntarily withdrawn for non-safety or non-efficacy reasons so that Aurobindo may proceed with a generic application",2010-09-13 00:00:00,"Denied (in substance) ‚Äì FDA determined that the referenced AUGMENTIN products were not withdrawn for reasons of safety or effectiveness. Therefore, the citizen petition requesting withdrawal from the Orange Book was effectively denied.",2010-12-07,1.0,Center for Drug Evaluation and Research (CDER),"21 CFR 314.161(a)(1) and 314.161(d) ‚Äì regarding determination of withdrawal for safety/effectiveness
- 21 CFR 314.162 ‚Äì list maintenance rules for Orange Book
- Section 505(j)(7) of the FD&C Act (21 U.S.C. 355(j)(7))
- 21 CFR 10.30 ‚Äì citizen petition rule","The petition, submitted on behalf of Aurobindo Pharmaceuticals, requested a determination on whether certain AUGMENTIN formulations were withdrawn for safety or effectiveness reasons.
- FDA explained that it had not completed its review due to the need to address other agency priorities.
- The interim response was provided to comply with regulatory requirements pending a full decision","After reviewing its own records and independently evaluating postmarketing data and literature, FDA concluded there was no evidence indicating that any of the listed AUGMENTIN (amoxicillin/clavulanate potassium) formulations were withdrawn for safety or efficacy reasons.
- Although the petitioner did not raise safety concerns directly, FDA conducted a voluntary review of all seven formulations, including those not mentioned in the original petition.
- Based on this review, FDA stated it would continue listing these products in the ""Discontinued Drug Product List"" section of the Orange Book, allowing their use as reference listed drugs for ANDA submissions
.",denied,True,259.0,CDER,CDER
fda-2010-p-0171,FDA-2010-P-0171-0001_Sun_Pharmaceutical_Industries__Inc____Citizen_Peti,2010-03-22,2010,False,original petition,"Sun Pharmaceutical Industries, Inc. (acting as U.S. Agent)",industry/corporation,"Section 505(j)(2)(C) of the FD&C Act
- 21 C.F.R. ¬ß 314.93
- 21 C.F.R. ¬ß 10.30
- 21 U.S.C. ¬ß 355(j)(6)
- 21 C.F.R. ¬ß¬ß 314.122 and 314.161
- 21 C.F.R. ¬ß¬ß 25.30 and 25.31",FDA‚Äôs treatment of discontinued formulations of ACCUTANE¬Æ (Isotretinoin Capsules) and the designation of reference listed drugs (RLDs),"Request FDA to determine that the discontinued formulations of ACCUTANE¬Æ (Isotretinoin Capsules ‚Äì 10 mg, 20 mg, and 40 mg) were not discontinued for safety or efficacy reasons, and are thus suitable as RLDs in an Abbreviated New Drug Application (ANDA)","ACCUTANE¬Æ was discontinued for reasons other than safety or effectiveness (as noted by FDA‚Äôs ‚Äú@‚Äù symbol).
- Sun had procured sufficient samples for bioequivalence studies prior to discontinuation.
- No known documentation indicates the discontinuation was due to safety or efficacy issues.
- FDA allows referencing discontinued labels when not withdrawn for safety or efficacy concerns",,"Denied (Petition Rejected) ‚Äì FDA determined that ACCUTANE capsules were not withdrawn for reasons of safety or effectiveness, and therefore denied the implication behind the petition. The product will remain listed in the Discontinued Drug Product List.",2010-07-07,0.0,Center for Drug Evaluation and Research (CDER)," 21 CFR 314.161(a)(1) ‚Äì withdrawal determinations
- 21 CFR 314.162 ‚Äì Orange Book delisting criteria
- 21 CFR 10.30 ‚Äì citizen petition provisions
- Section 505(j)(7) of the FD&C Act (21 U.S.C. 355(j)(7))",,"The petitioner (Sun Pharmaceutical) requested FDA to determine if ACCUTANE capsules were withdrawn for safety or effectiveness reasons.
- FDA reviewed internal records, the literature, and postmarketing adverse event data.
- FDA found no evidence of withdrawal due to safety or effectiveness concerns.
- Therefore, the agency will continue to list ACCUTANE capsules (10 mg, 20 mg, 40 mg) in the Discontinued Drug Product List of the Orange Book, meaning they may still serve as reference listed drugs for ANDAs.
- No procedures will be initiated to withdraw existing ANDAs or prevent future ones that comply with legal and regulatory standards",denied,True,107.0,CDER,CDER
fda-2010-p-0162,FDA-2010-P-0162-0001_Buchanan_Ingersoll___Rooney__PC___Petition_for_Sta,2010-03-19,2010,False,original petition,Buchanan Ingersoll & Rooney PC,law/consulting,"21 C.F.R. ¬ß 10.35 (Stay of Action)
- 21 C.F.R. ¬ß 10.20 (Regulatory submission rules)
- 21 C.F.R. ¬ß 310.305 (Adverse Drug Experience Reporting)","FDA Warning Letter No. DEN-10-06-CIWL dated February 17, 2010, which states that certain tannate-containing drug products are ‚Äúunapproved‚Äù and subject to enforcement action",Request for Stay of Enforcement Action relating to tannate-containing products distributed by Unisource until issues in a pending Citizen Petition (Docket No. FDA-2008-P-0219) are resolved,"Products have a long history of safe use and are claimed to be GRAS/E (Generally Recognized As Safe and Effective)
- FDA‚Äôs regulatory history supports their legal marketing
- Ongoing Citizen Petition (filed Jan 3, 2008) seeking regulatory clarification has not yet been resolved
- Warning Letter and enforcement actions violate due process since they involve unresolved legal issues
- Immediate enforcement without FDA resolution would be arbitrary, capricious, and cause irreparable harm to Unisource",,,2025-10-15,0.0,,,,,no decision,False,5689.0,pending,pending
fda-2010-p-0157,FDA-2010-P-0157-0001_Rakoczy_Molino_Mazzochi_Siwik_LLP___Citizen_Petiti,2010-03-17,2010,False,original petition,Rakoczy Molino Mazzochi Siwik LLP,law/consulting,"21 C.F.R. ¬ß 10.25
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 314.161
- 21 C.F.R. ¬ß 25.31(a)
- 21 C.F.R. ¬ß 10.30(b)","Determination of whether VESANOID¬Æ (Tretinoin) Capsules, 10 mg, were withdrawn for reasons of safety or effectiveness","Petitioner requests FDA to:
1. Find that Hoffman-La Roche discontinued VESANOID¬Æ Capsules, 10 mg for reasons not related to safety or efficacy.
2. Accept ANDAs for Tretinoin Capsules, 10 mg, referencing VESANOID¬Æ, and determine those ANDAs are eligible for approval if all other requirements are met","VESANOID¬Æ was safely marketed for nearly 15 years.
- No FDA recalls or safety concerns are recorded.
- FDA‚Äôs Orange Book still lists it as a Prescription Drug Product.
- FDA previously approved at least one ANDA referencing VESANOID¬Æ as the RLD.
- Thus, discontinuation was not due to safety or effectiveness reasons",,"Denied (in substance) ‚Äì FDA determined VESANOID (tretinoin) Capsules, 10 mg, were not withdrawn for reasons of safety or effectiveness. Therefore, ANDAs referencing this product may continue to be submitted and approved.",2010-09-14,0.0,Center for Drug Evaluation and Research (CDER),"21 CFR 314.161(a)(1) ‚Äì Drug withdrawal determination standard
- 21 CFR 314.162 ‚Äì Orange Book delisting
- 21 CFR 10.30 ‚Äì Citizen petition provision
- Section 505(j)(7) of the FD&C Act (21 U.S.C. 355(j)(7)) ‚Äì Drug listing requirement",," A citizen petition requested FDA determine whether VESANOID was withdrawn for safety or efficacy reasons.
- FDA reviewed agency records, independent literature, and postmarketing adverse event data.
- No information suggested that the product‚Äôs withdrawal was related to safety or effectiveness.
- The sponsor, Hoffman-La Roche Inc., had voluntarily discontinued marketing the product in 2009.
- The drug remains listed in the Discontinued Drug Product List of the Orange Book, allowing it to serve as a reference listed drug (RLD) for ANDAs.",approved,True,181.0,CDER,CDER
fda-2010-p-0150,FDA-2010-P-0150-0001_United_States_Pharmacopeial_Convention__USP____Cit,2010-03-15,2010,False,original petition,United States Pharmacopeial Convention (USP),industry/corporation,"21 C.F.R. ¬ß10.30 (Citizen Petition procedure)
- 21 C.F.R. Parts 170 & 184 (GRAS regulations)
- Title 1 C.F.R. ¬ß51.1(a), ¬ß51.1(c)(1)
- 21 C.F.R. ¬ß¬ß25.30(h), (i); 25.32(a) (Environmental Impact Exemption)
- 21 U.S.C. ¬ß552(a)(1) (Federal Register publication)
- 21 C.F.R. ¬ß172.170(b), ¬ß184.1366(b) (Hydrogen Peroxide example)","Existing GRAS regulations in 21 C.F.R. Parts 170 and 184 that incorporate outdated editions (2nd, 3rd, 4th) of the Food Chemicals Codex (FCC) by reference.","Amend FDA‚Äôs GRAS regulations (21 C.F.R. Parts 170 and 184) to incorporate by reference the Food Chemicals Codex, 7th Edition, instead of the 2nd, 3rd, and 4th editions.","The older FCC editions are outdated and no longer reflect current industry practices or scientific methods.
- Previous editions are not readily accessible to industry or the public.
- Updated FCC 7th Edition contains modern analytical methods, especially for detecting heavy metals and using current gas chromatography techniques.
- Aligning FDA regulations with the most recent FCC improves consistency, safety, and clarity for food ingredient manufacturers.
- Enhances public health and food safety by ensuring adherence to up-to-date standards.
- Petition aligns with FDA's past practice and rationale, including a 1984 rulemaking precedent and recent support by CFSAN and industry commenters.",2010-09-16 00:00:00,,2025-10-15,1.0,,,"The citizen petition, filed March 15, 2010, requested the FDA amend regulations in 21 CFR Parts 170 and 184 to incorporate by reference the Food Chemicals Codex, 7th Edition.
- FDA issued the interim response solely to comply with regulatory timelines, indicating that review was still ongoing and no final decision had been made.
- The Agency invited the petitioner to submit additional supplemental materials for further consideration while the review remained open",,no decision,False,5693.0,pending,pending
fda-2010-p-0145,FDA-2010-P-0145-0007_Actavis_Elizabeth_LLC_Amendment,2012-07-20,2010,False,original petition,Actavis Mid Atlantic LLC,industry/corporation,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 10.30","Evaluation of a proposed generic drug for ANDA (Abbreviated New Drug Application) submission with respect to the Reference Listed Drug (RLD) Motrin IB¬Æ Tablets, 200 mg (NDA 019-012).","The petitioner requests that the FDA declare the drug product Ibuprofen Oral Suspension, 100 mg/5 mL, suitable for submission as an ANDA, clarifying a change in dosage form (tablet to suspension) and a change in strength (200 mg to 100 mg) from the RLD.","This is a clarification to the original petition.
- The proposed labeling will be identical to that of the RLD (Motrin IB¬Æ).
- Actavis asserts both dosage form and strength differences are acceptable under the ANDA pathway as per cited statutes and regulations.",,,2025-10-15,0.0,,,,,no decision,False,4835.0,pending,pending
fda-2010-p-0145,FDA-2010-P-0145-0006_Actavis_Mid_Atlantic_LLC___Amendment,2010-06-14,2010,False,original petition,Actavis Mid Atlantic LLC,industry/corporation,"21 C.F.R. ¬ß10.30 (Citizen Petition procedure)
- 505B(a)(4)(B)(iii) of the Federal Food, Drug, and Cosmetic Act (PREA)","FDA's requirement for a pediatric assessment under the Pediatric Research Equity Act (PREA) in relation to an ANDA submission for OTC Adult Ibuprofen Oral Suspension, 100 mg/5 mL.",The petitioner is requesting a full waiver of the pediatric assessment requirement for the proposed ANDA submission of OTC Adult Ibuprofen Oral Suspension.,"The proposed adult oral suspension does not provide a meaningful therapeutic benefit over existing pediatric therapies.
- Several ibuprofen formulations for pediatric use are already approved and available (e.g., Children‚Äôs Motrin¬Æ, Infant‚Äôs Motrin¬Æ, Junior Strength Motrin¬Æ).
- The proposed product is not likely to be used by a substantial number of pediatric patients, given the availability of appropriately labeled products",,,2025-10-15,0.0,,,,,no decision,False,5602.0,pending,pending
fda-2010-p-0145,FDA-2010-P-0145-0001_Actavis_Mid_Atlantic_LLC___Citizen_Petition,2010-03-12,2010,False,original petition,Actavis Mid Atlantic LLC,industry/corporation,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 10.30 (Citizen petition procedure)
- 21 C.F.R. ¬ß 314.93 (Petitions to request a change from listed drug requirements)
- 21 C.F.R. ¬ß 25.31(a) (Environmental assessment categorical exclusion)","FDA's process for determining suitability of dosage forms for submission as an Abbreviated New Drug Application (ANDA), specifically regarding a change from tablet to oral suspension.","Actavis requests that the FDA determine that its proposed product‚ÄîOTC Adult Ibuprofen Oral Suspension, 100 mg/5 mL‚Äîis suitable for submission as an ANDA, using Motrin IB¬Æ Tablets, 200 mg (NDA 019-012) as the Reference Listed Drug (RLD).","The change involves only the dosage form, not the active ingredient, route of administration, or indications for use.
- The suspension offers an easy-to-swallow alternative for adults who may have difficulty with tablets.
- Proposed product would match the potency and dosage regimen of the RLD.
- Actavis plans to demonstrate bioequivalence between the proposed suspension and the Motrin IB¬Æ tablet product",,,2025-10-15,0.0,,,,,no decision,False,5696.0,pending,pending
fda-2010-p-0138,FDA-2010-P-0138-0001_Buchanan_Ingersoll___Rooney_PC___Citizen_Petition,2010-03-10,2010,False,original petition,Buchanan Ingersoll & Rooney PC,law/consulting,"21 C.F.R. ¬ß 10.30 (Citizen Petition regulation)
- 21 C.F.R. ¬ß 314.94(a)(9) (relating to inactive ingredients in ANDAs)
- FDA‚Äôs Inactive Ingredient Guide (IIG)
- FDA Guidance for Industry on ""Inactives in Drug Products""",The petition comments on FDA's potential acceptance of an ANDA for ZYFLO CR¬Æ (zileuton extended-release tablets) where the proposed generic formulation may contain a higher amount of inactive ingredients than the approved NDA product.,"The petitioner requests that the FDA not approve, or accept for filing, any ANDA referencing ZYFLO CR¬Æ that contains levels of inactive ingredients exceeding those present in the RLD, unless full safety evidence is provided.","Cornerstone Therapeutics has concerns about the safety of elevated inactive ingredients not supported by existing data.
- The RLD (ZYFLO CR¬Æ) underwent extensive safety testing and FDA review.
- Higher levels of inactive ingredients, particularly extended-release excipients, may impact drug release, absorption, and safety.
- The FDA‚Äôs Inactive Ingredient Guide and guidance documents recommend conservative approaches unless safety has been established.
- The request aims to ensure patient safety and therapeutic equivalence for any ANDA product referencing ZYFLO CR¬Æ.",2010-09-07 00:00:00,"Denied
The FDA denied the petition requesting recognition of certain oral iron forms as Generally Recognized as Safe and Effective (GRAS/E) without an NDA.",2013-02-11,1.0,Center for Drug Evaluation and Research (CDER),"21 U.S.C. ¬ß 355(a) ‚Äì New drug application (NDA) requirement
- 21 U.S.C. ¬ß 321(p) ‚Äì Definition of ‚Äúnew drug‚Äù
- 21 CFR 314.126 ‚Äì Adequate and well-controlled investigations
- 21 CFR 314.125(b) ‚Äì Substantial evidence and effectiveness standards
- 21 CFR 314.200(e)(1) ‚Äì Administrative hearing regulations
- 21 CFR 310.6(b)(2) ‚Äì Drug efficacy study implementation (DESI)
- Federal Register and case law citations: Premo Pharm. Labs., Weinberger v. Bentex, United States v. Generix Drug Corp., etc.","The petition (submitted March 11, 2010) requested that FDA issue an order confirming that certain oral iron compounds (e.g., ferrous sulfate, ferrous fumarate, ferrous asparto glycinate, and ferrous gluconate) are generally recognized as safe and effective (GRAS/E) in daily doses of 60‚Äì180 mg when administered under physician supervision to treat iron deficiency anemia.
- FDA explained that the petition raises complex issues requiring extensive internal review and analysis.
- Therefore, an interim response was issued while FDA continues evaluating the request","The petition requested FDA to confirm that various oral iron forms (ferrous sulfate, ferrous fumarate, ferrous asparto glycinate, ferrous gluconate) are GRAS/E within the range of 60‚Äì180 mg/day under physician supervision.
- FDA rejected the blanket GRAS/E classification for a class of drugs based solely on their active ingredient, emphasizing that GRAS/E determinations must be product-specific.
- FDA maintained that adequate and well-controlled clinical studies must support each individual product‚Äôs safety and efficacy under labeled conditions.
- The Agency noted that this approach is consistent with regulatory precedent and court rulings, including Generix Drug Corp., where GRAS/E determination applied to entire finished drug products, not just active moieties.
- FDA distinguished this case from the Over-the-Counter (OTC) Drug Review, where GRAS/E can apply to classes of products; this does not extend to prescription products like oral iron, which require individual evaluation.
- The agency also addressed and rejected related arguments concerning DESI reviews and radioactive drug GRAS/E precedents as not applicable to this case.",denied,True,1069.0,CDER,CDER
fda-2010-p-0112,FDA-2010-P-0112-0006_Alaunus_Pharmaceutical_LLC__Amendment,2012-01-06,2010,False,original petition,"Alaunus Pharmaceutical, LLC",industry/corporation,"Not Mentioned in this amendment (Note: As this is an amendment correcting a labeling typo, no statutes are referenced)",Labeling specification of Oxytocin 1000 USP Units/100 mL in the previously submitted petition,"Correct a typographical error in the ""HOW SUPPLIED"" section of the proposed labeling ‚Äì from ‚Äú1000 USP Units/mL‚Äù to ‚Äú1000 USP Units/100 mL‚Äù","To ensure labeling accuracy: The original amendment erroneously stated the strength as ‚Äú1000 USP Units/mL,‚Äù while the correct strength is ‚Äú1000 USP Units/100 mL.‚Äù The correction aligns the labeling with the intended and correct formulation. A revised label comparison is included to reflect this correction.",,Denied,2024-12-11,0.0,Center for Drug Evaluation and Research (CDER),"21 CFR 10.30, FDCA Section 505(b)",,"FDA denied the petition based on the following key reasons:

Change in Strength Introduces Safety Risks: The proposed change from the listed drug‚Äôs strength and packaging raised concerns about:
Medication errors (e.g., preparation, dosing, expiration tracking)
Risk of incorrect administration
Potential for significant overdose

Labeling Would Require Significant Changes: To mitigate these risks, the drug would require updates to multiple labeling sections:
Dosage and Administration
Overdosage
Warnings and Precautions

These changes exceed what is permissible under the ANDA pathway, making the petition non-approvable under section 505(j)(2)(C) and 21 CFR 314.93.

Recommendation for NDA Pathway: The Agency suggested pursuing approval via a full NDA (section 505(b)) instead of an ANDA, due to the safety and labeling implications.",denied,True,4723.0,CDER,CDER
fda-2010-p-0112,FDA-2010-P-0112-0002_Alaunus_Pharmaceutical_LLC__Amendment,2011-11-09,2010,False,original petition,"Alaunus Pharmaceutical, LLC",industry/corporation,Not Mentioned in this amendment,"Amendment to previously submitted ANDA suitability petition for Oxytocin Injection, 10 USP Units/mL‚Äîcommenting on labeling and vial size change from 30 mL to 100 mL (Pharmacy Bulk Package)",Approve the amendment clarifying that the proposed 100 mL vial is a Pharmacy Bulk Package (PBP) and update the labeling accordingly,"Clarification of product configuration: vial is for single use as a Pharmacy Bulk Package, not multiple dose.
- Change enhances hospital efficiency, reduces waste, and lowers patient costs.
- Labeling now includes:
1) Boxed warning: ""PHARMACY BULK PACKAGE ‚Äî NOT FOR DIRECT INFUSION""
2) USP-compliant definition of Pharmacy Bulk Package
3) Directions for proper use of the bulk package",,Denied,2024-12-11,0.0,Center for Drug Evaluation and Research (CDER),"21 CFR 10.30, FDCA Section 505(b)",,"FDA denied the petition based on the following key reasons:

Change in Strength Introduces Safety Risks: The proposed change from the listed drug‚Äôs strength and packaging raised concerns about:
Medication errors (e.g., preparation, dosing, expiration tracking)
Risk of incorrect administration
Potential for significant overdose

Labeling Would Require Significant Changes: To mitigate these risks, the drug would require updates to multiple labeling sections:
Dosage and Administration
Overdosage
Warnings and Precautions

These changes exceed what is permissible under the ANDA pathway, making the petition non-approvable under section 505(j)(2)(C) and 21 CFR 314.93.

Recommendation for NDA Pathway: The Agency suggested pursuing approval via a full NDA (section 505(b)) instead of an ANDA, due to the safety and labeling implications.",denied,True,4781.0,CDER,CDER
fda-2010-p-0111,FDA-2010-P-0111-0012_Shire_Pharmaceuticals__Inc____Petition_for_Reconsi,2010-09-16,2010,False,original petition,"Shire Pharmaceuticals, Inc.",industry/corporation,"21 C.F.R. ¬ß 10.33 (Petition for reconsideration procedure)
- 21 C.F.R. ¬ß 10.30(i)(5) (Citizen Petition administrative record content)","FDA's August 20, 2010 Response recommending that comparative pharmacokinetic (PK) studies may substitute for clinical endpoint studies in determining bioequivalence of generic or follow-on versions of Pentasa¬Æ (mesalamine) controlled-release oral capsules","Shire requests FDA to amend its August 20, 2010 Response to include:
(i) The scientific data and literature used to justify the reliance on PK parameters other than AUC and Cmax for determining bioequivalence.
(ii) A reasoned, scientific explanation of how those PK metrics demonstrate equivalent drug release at the sites of therapeutic activity","FDA reversed its prior stance without providing the scientific data or analysis to support the new position.
- No PK data, analyses, or literature were made available in the administrative record, preventing meaningful review by Shire or the public.
- FDA‚Äôs Transparency Initiative (May 2010) supports providing such data in the public docket.
- Shire argues the FDA must provide a reasoned and scientifically supported basis under precedents (e.g., Alpharma, A.L. Pharma, etc.).
- Lack of such basis renders FDA‚Äôs decision arbitrary and not in line with regulatory obligations",,Denied,2012-11-08,0.0,Center for Drug Evaluation and Research (CDER),"21 CFR 10.30, FDCA Section 505(j)",,"The FDA denied the reconsideration petition based on several reasons:

Request Was Not a Valid Reconsideration: FDA emphasized that the request did not meet the definition of a reconsideration petition because it:

Did not challenge the outcome of the 2010 decision.

Merely asked for additional scientific explanation and citations, which is not a permissible basis under ¬ß10.33

Agency Already Considered Relevant Information: FDA concluded that all relevant information and views were already part of the record when the original decision was made, thus satisfying the procedural requirements

Scientific Clarifications Provided Separately: Although denying the petition, the FDA did offer references to clinical studies and public resources (e.g., labeling and published studies) to support its original conclusions on the use of pharmacokinetic (PK) metrics for bioequivalence

Guidance Was Issued: FDA highlighted that it had since published draft guidance for bioequivalence of delayed-release mesalamine tablets/capsules in September 2012, which is available for public comment",denied,True,784.0,CDER,CDER
fda-2010-p-0105,FDA-2010-P-0105-0003_Fieldale_Farms_Corporation___Letter,2010-03-04,2010,False,original petition,Fieldale Farms Corporation,industry/corporation,Not Mentioned,A rule proposed or finalized by FDA that would eliminate the market for hatching eggs not used for broiler production‚Äîthose typically sold to companies that process them for food use,"Amend the final rule, or
- Re-open the comment period for a re-proposal that excludes hatching eggs from the rule‚Äôs restrictions","Prevent waste of a valuable resource: hatching eggs not used for broilers.
- Eggs are a safe, pasteurized source of animal protein used in processed foods.
- Current rule could force diversion to rendering or landfills, which is inefficient and unnecessary in today‚Äôs economic climate.
- Emphasizes food safety, value to human food supply, and support for flexibility in egg usage",2010-08-17 00:00:00,,2025-10-15,1.0,,,"The citizen petition (submitted February 19, 2010) requested that FDA either:
1. Amend 21 CFR 118.4(e) to exclude surplus hatching eggs sold for use in egg products from refrigeration requirements, or
2. Reopen the comment period on the single refrigeration requirement for surplus hatching eggs, or
3. Re-propose the Final Rule as it pertains to this specific issue.
- The FDA stated it had not been able to make a determination within 180 days because of limited availability of resources and competing agency priorities",,no decision,False,5704.0,pending,pending
fda-2010-p-0095,FDA-2010-P-0095-0001_American_Association_of_Public_Health_Physicians__,2010-02-07,2010,False,original petition,American Association of Public Health Physicians (AAPHP),advocacy/academic,"21 C.F.R. ¬ß 10.30 (Citizen Petition process)
- Family Smoking Prevention and Tobacco Control Act of 2009 (FSPTCA) is referenced indirectly (though not by section citation)","The petition responds to FDA‚Äôs general regulation of tobacco products, including its oversight under the Tobacco Control Act, and concerns about the absence of a harm-reduction strategy within the FDA's implementation framework.","AAPHP requests the FDA to:
- Conduct rulemaking to define a pathway for modified risk tobacco products (MRTPs) to be approved and marketed based on reduced risk.
- Establish performance standards and appropriate labeling requirements for such products.
- Consider low-nitrosamine smokeless tobacco and electronic nicotine delivery systems (ENDS) as potential reduced-harm alternatives to cigarettes.","FDA‚Äôs current tobacco control efforts focus primarily on eliminating tobacco use rather than reducing harm.
- Cigarette smoking causes the majority of tobacco-related deaths; non-combustion products (like snus and ENDS) may reduce harm.
- Denial or delay in approving less harmful alternatives risks public health stagnation.
- AAPHP asserts that regulation based on evidence of reduced harm would provide consumers with safer options and reduce death and disease rates without endorsing nicotine addiction.",,,2025-10-15,0.0,,,,,no decision,False,5729.0,pending,pending
fda-2010-p-0093,FDA-2010-P-0093-0001_American_Association_of_Public_Health_Physicians__,2010-02-07,2010,False,original petition,American Association of Public Health Physicians (AAPHP),advocacy/academic,"21 CFR 5.10 (delegation of authority to the FDA Commissioner)

- Other legal or regulatory citations (like 505(q) or 21 CFR 10.30) are Not Mentioned explicitly.","FDA's July 22, 2009 press release and press conference on E-cigarettes. The petition criticizes the tone and implications of the FDA‚Äôs messaging, which portrayed E-cigarettes as harmful and aimed to regulate them as drug-device combinations","AAPHP requests the FDA to:
- Issue another press release and press conference to amend statements made in the July 22, 2009 event.
- Reconsider classification of E-cigarettes from ‚Äúdrug-device combination‚Äù to ‚Äútobacco product.‚Äù","The petitioner argues that:
- FDA's earlier press conference led to public misunderstanding that E-cigarettes are as or more dangerous than conventional cigarettes.
- New data and studies suggest E-cigarettes pose lower health risks than traditional cigarettes and are comparable in safety to FDA-approved Nicotine Replacement Therapies (NRTs).
- E-cigarettes could play a significant role in tobacco harm reduction without increasing teen usage.
- Legal precedent (Judge Leon‚Äôs Jan 14, 2010 ruling) suggests FDA‚Äôs classification may be inappropriate",,,2025-10-15,0.0,,,,,no decision,False,5729.0,pending,pending
fda-2010-p-0092,FDA-2010-P-0092-0001_Lupin_Atlantis_Holdings__S_A____Leydig__Voit___May,2010-02-16,2010,False,original petition,"Leydig, Voit & Mayer, Ltd. (Law Firm)",law/consulting,"21 U.S.C. ¬ß 355 (Federal Food, Drug, and Cosmetic Act)
- 21 U.S.C. ¬ß 355(j)(2)(A)(iii) and (j)(2)(C)
- 21 C.F.R. ¬ß 314.93(b), (c)
- 21 U.S.C. ¬ß 355(j)(4)(D)(i)
- 21 C.F.R. ¬ß 314.127(a)(4)(i)
- 21 C.F.R. ¬ß¬ß 25.30, 25.31
- 21 C.F.R. ¬ß 10.30(b)","The petition addresses FDA's potential approval of Paddock Laboratories' ANDA 91-362 for a generic version of Antara¬Æ (fenofibrate) capsules, 43 mg and 130 mg, which the petitioner claims is not in true capsule dosage form.","The petitioner requests that the FDA refrain from granting tentative or final approval of Paddock‚Äôs ANDA 91-362, on the grounds that the proposed product is not in the same dosage form (capsule) as the reference listed drug Antara¬Æ.","Paddock's proposed generic product is not in true capsule form (coated externally with fenofibrate, not enclosed within a capsule shell).
- This contradicts FDA definitions and the USP/Remington definitions of ""capsule"" which require the active ingredient to be enclosed within a shell.
- Allowing approval would violate FDA precedent and guidance, and would be arbitrary and capricious unless the agency properly explains a change in policy.
- The petition cites Warner-Lambert v. Shalala and agency guidance to argue that changing the definition without justification would be unlawful.
- As there is no ANDA suitability petition submitted to change the dosage form, Paddock‚Äôs application should be rejected.",,Denied,2010-08-13,0.0,Center for Drug Evaluation and Research (CDER),"21 U.S.C. ¬ß 355(j), Section 505(q) of the FDCA",,"FDA‚Äôs key reasons for denying the petition include:

No Final Determination on ANDA: FDA had not yet decided whether Paddock‚Äôs ANDA would be approved, and therefore was not required to make a premature determination on a specific element of the application (i.e., dosage form) under ¬ß505(q)

Procedural Protections: The agency emphasized that ANDA review involves a structured process that includes notifying applicants of deficiencies and allowing them to respond or request hearings. The petition's request to resolve a specific issue outside of that framework was inconsistent with these statutory protections

Interpretation of ¬ß505(q): FDA does not interpret ¬ß505(q) to require a final decision on isolated technical elements (like dosage form classification) before a complete ANDA review is concluded

Regulatory Integrity: The FDA highlighted the need to avoid rendering piecemeal decisions that could compromise the integrity of the drug review process.",denied,True,178.0,CDER,CDER
fda-2010-p-0091,FDA-2010-P-0091-0001_Citizen_Petition_from_Emily_Robin_et_al,2010-02-16,2010,False,original petition,"Emily Robin and Co-Petitioners (over 20 named individuals, including physicians, researchers, and advocates)",advocacy/academic,"21 C.F.R. ¬ß 10.30 (Citizen Petition procedure)
- 21 C.F.R. ¬ß 25.30 (Environmental Impact exemptions)
- No reference to 505(q) or other statutes explicitly.","FDA‚Äôs lack of regulation and enforcement regarding the use of Bisphenol A (BPA) in food and beverage containers, including its failure to ban or restrict BPA exposure in food-contact materials.","The petitioners request the FDA to:
- Immediately ban the use of BPA in all food and beverage packaging, containers, and utensils.
- Establish a timetable for phasing out BPA and implementing safer alternatives.
- Promote labeling requirements for BPA-containing products during the transition period.","BPA is a known endocrine-disrupting chemical, linked to cancer, reproductive issues, neurological effects, and developmental harm, particularly in fetuses and infants.
- Studies show that BPA leaches from containers into food and beverages, exposing humans daily.
- The FDA‚Äôs safety threshold is outdated and does not reflect current scientific evidence.
- Several countries and U.S. states have already taken regulatory action.
- The public is increasingly concerned, and safer alternatives exist.
- Petitioners cite over 100 scientific studies and reviews, emphasizing the weight of evidence for urgent regulatory response.",,Denied,2015-06-12,0.0,Center for Drug Evaluation and Research (CDER),"21 CFR 201.57, 21 U.S.C. ¬ß 355",,"The FDA provided the following key justifications for denying the petition:

Existing Labeling Already Adequate: Current benzodiazepine labeling already includes warnings for physical dependence, withdrawal, and long-term use. FDA believes these are sufficient for safe use.

Lack of Scientific Basis for 2‚Äì4 Week Limit: The requested universal duration limit was deemed overly restrictive and unsupported by clinical data, especially for chronic conditions like generalized anxiety disorder or panic disorder.

Rejection of ‚ÄúProtracted Withdrawal‚Äù Syndrome: The FDA‚Äôs literature review did not support the existence of a scientifically recognized ""protracted withdrawal"" syndrome.

Individualized Tapering: Tapering schedules must be tailored to individual patients; no one-size-fits-all approach could be mandated, and the proposed method lacked scientific support.

Boxed Warnings Unjustified: While physical dependence is acknowledged, evidence did not meet the threshold for a boxed warning, which is reserved for risks that may lead to death or serious injury.

No Need for Mandatory Outreach or Website Updates: Information is already publicly accessible through FDA websites and DailyMed; manufacturer compliance with additional web presence is not required",denied,True,1942.0,CDER,CDER
fda-2010-p-0089,FDA-2010-P-0089-0018_Building_a_Comprehensive_Nicotine_Regulatory_Polic,2012-06-04,2010,False,original petition,Society for Research on Nicotine and Tobacco (SRNT) and the Association for the Treatment of Tobacco Use and Dependence (ATTUD),advocacy/academic,Section 918 of the Family Smoking Prevention and Tobacco Control Act (FSPTCA),"FDA‚Äôs regulation of nicotine-delivering products and pending Citizen Petitions related to Nicotine Replacement Therapy (NRT); specifically, the agency‚Äôs approach to product access, labeling, dosing, and duration for NRT","Broaden access and revise labeling of NRT products to reflect comparative risk to smoking; enable use in smoking reduction and temporary abstinence; support extended use duration and combination therapy; and compare NRT not to ‚Äúno nicotine‚Äù but to continued smoking. Also, implement a comprehensive nicotine regulatory policy across all nicotine products. ","Current labeling and regulation hinder NRT use.
- NRT is underutilized due to misinformation and packaging limitations.
- Comparative risk favors NRT over continued smoking.
- Evidence from the UK shows that public health outcomes improve with more flexible regulation and labeling of cessation products.
- Treating tobacco dependence as a chronic condition justifies extended and combined use of NRT.
- Regulatory barriers reduce access for underserved populations, especially via quit lines.",,"The FDA provided a mixed response ‚Äî some parts of the petitions were granted, while others were denied",2013-04-01,0.0,Center for Drug Evaluation and Research (CDER),"21 CFR Part 10, Section 918 of the Family Smoking Prevention and Tobacco Control Act",,"FDA provided detailed reasoning for each element of the petition. Key points include:

Insufficient Evidence: Many requests (e.g., for new indications, concomitant use, or claims of relative safety) lacked adequate scientific support. Literature cited did not justify regulatory changes without additional clinical trials (see pages 7‚Äì12).

Scientific Standards: Labeling changes require data from sponsors and rigorous review, not just citizen petitions (pages 5, 7, 23).

Population Risk Considerations: The FDA declined to support claims that OTC NRT is broadly safer for all populations (e.g., CVD, pregnancy, adolescents) without clinical validation (pages 16‚Äì21).

Regulatory Integrity: Decisions about labeling and indications must be based on well-controlled studies and regulatory standards, not opinion or advocacy alone.

Support for Smoking Cessation: FDA granted requests supporting trial design, regulatory flexibility, and access expansion (e.g., smaller packages, broader retail access) as part of its commitment to help people quit smoking (pages 24‚Äì26, 29‚Äì30).",approved,True,301.0,CDER,CDER
fda-2010-p-0089,FDA-2010-P-0089-0016_Treatments_for_tobacco_dependence_discussion_point,2012-03-01,2010,False,original petition,"Robert West, University College London, in association with Cancer Research UK and the UK Centre for Tobacco Control Studies",advocacy/academic,Section 918 of the Family Smoking Prevention and Tobacco Control Act (FSPTCA),"The FDA‚Äôs regulation of nicotine replacement therapies (NRT) and related products; specifically:
- Labeling, access, combination use, and dosage duration of NRTs
- Evaluation and approval practices for new smoking cessation products","Though not framed as a formal petition, the document discusses and supports actions similar to:
- Allowing broader access to NRTs (e.g., over-the-counter nicotine nasal sprays)
- Supporting extended use, reduced contraindications, and concurrent NRT usage
- Recognizing NRTs‚Äô comparative safety versus continued smoking
- Reducing bureaucratic barriers to faster approval of more effective medications","Comparative risk: Smoking is far more harmful than NRTs.
- Scientific evidence: Clinical trials and real-world studies (e.g., Smoking Toolkit Study) support safe and effective use of dual NRTs, long-term use, and use by special populations (pregnant women, cardiovascular patients).
- Policy alignment: Reflects regulatory philosophy of MHRA (UK Medicines and Healthcare products Regulatory Agency).
- Public health benefit: Broader NRT access and use can significantly reduce smoking-related morbidity and mortality",,Informational / Listening Session ‚Äì Not a Final Decision ‚Äî The meeting was convened for FDA to hear and discuss petitioners‚Äô positions. No decision was issued during or as a result of the meeting,2012-03-09,0.0,Center for Drug Evaluation and Research (CDER),Not Mentioned ‚Äî No specific statutes or regulations were cited during the meeting or in the meeting minutes,,"The meeting served to allow SRNT and ATTUD to present their views on treatments for tobacco dependence and to raise issues related to pending citizen petitions.
- The presentation by Robert West and follow-up remarks from ATTUD members provided clinical and public health perspectives.
- FDA participated by asking clarifying questions but did not offer any policy conclusions or commitments",other,True,8.0,CDER,CDER
fda-2010-p-0089,FDA-2010-P-0089-0001_Association_for_the_Treatment_of_Tobacco_Use_and_D,2010-02-11,2010,False,original petition,Association for the Treatment of Tobacco Use and Dependence (ATTUD),advocacy/academic,"21 C.F.R. ¬ß 10.30 (Citizen petition procedure)
- Section 918 of the Family Smoking Prevention and Tobacco Control Act (FSPTCA) is referenced indirectly (related to FDA‚Äôs regulatory authority over cessation products)","FDA‚Äôs labeling and use restrictions for Nicotine Replacement Therapy (NRT) products‚Äîspecifically concerning:
- Duration of use
- Simultaneous use of multiple NRT products
- Use by special populations (e.g., pregnant individuals, adolescents)","ATTUD requests the FDA to modify NRT product labeling to:
- Remove warnings against long-term use
- Permit and support concurrent use of multiple NRT products
- Remove warnings discouraging NRT use in pregnancy and adolescents, replacing them with medically nuanced guidance","Current labeling discourages effective use of NRTs, contradicting best practices in tobacco dependence treatment.
- Clinical evidence supports extended and combined NRT therapy as safe and effective.
- The existing label statements lack scientific foundation and hinder public health outcomes.
- Restrictions in labeling disproportionately affect vulnerable populations, such as pregnant individuals and teens.
- ATTUD argues that aligning labeling with evidence-based treatment guidelines will enhance smoking cessation success rates and reduce tobacco-related harm.",2010-08-04 00:00:00,Informational / Listening Session ‚Äì Not a Final Decision ‚Äî The meeting was convened for FDA to hear and discuss petitioners‚Äô positions. No decision was issued during or as a result of the meeting,2012-03-09,1.0,Center for Drug Evaluation and Research (CDER),Not Mentioned ‚Äî No specific statutes or regulations were cited during the meeting or in the meeting minutes," The petition involved significant issues regarding how the FDA should regulate, review, and label nicotine replacement therapy (NRT) medications.
- These issues required extensive review and analysis by agency officials.
- As a result, FDA issued an interim response under regulatory guidelines until a final decision could be made","The meeting served to allow SRNT and ATTUD to present their views on treatments for tobacco dependence and to raise issues related to pending citizen petitions.
- The presentation by Robert West and follow-up remarks from ATTUD members provided clinical and public health perspectives.
- FDA participated by asking clarifying questions but did not offer any policy conclusions or commitments",other,True,757.0,CDER,CDER
fda-2010-p-0076,FDA-2010-P-0076-0005_Boehringer_Ingelheim_Roxane_Laboratories__Inc____C,2010-02-04,2010,False,original petition,"Boehringer Ingelheim Roxane Laboratories, Inc.",advocacy/academic,Not Mentioned (in this cover letter; full petition document not included in this file),"Not Mentioned (requires the actual content of the citizen petition, not just the cover letter)",Not Mentioned (see above ‚Äì cover letter only confirms resubmission of a corrected petition),The correction addressed an error on the signature page and added Roxane's address; no other changes were made. This was an administrative correction rather than a substantive petition change,2010-08-02 00:00:00,,2025-10-15,1.0,,,"The petition raised complex issues requiring extensive review and analysis by FDA officials.
- The FDA had not yet reached a conclusion and issued the interim response in accordance with regulatory requirements.",,no decision,False,5732.0,pending,pending
fda-2010-p-0060,FDA-2010-P-0060-0001_Virgilian__LLC____Citizen_Petition,2010-01-21,2010,False,original petition,"Virgilian, LLC",industry/corporation,"CFR Title 21, parts 25 through 30 (specifically referenced in regard to environmental impact requirements)
. No mention of 505(q) or 21 C.F.R. ¬ß 10.30.",Petition to establish a standard of identity for a single strength fruit juice ‚Äî specifically almond fruit juice.,The petitioner requests the FDA to adopt 11¬∞ Brix as the standard of identity for single strength almond fruit juice,"Almonds are classified as fruit (Rosaceae family, like apple, peach, apricot, plum).
- Juice is extracted from dried almond fruit (mesoderm or ‚Äúhull‚Äù), similar to prune juice production.
- 11¬∞ Brix is consistent with other similar fruit juices (apple, peach, apricot).
- Extraction process is outlined in U.S. Patent No. 6,716,465.
- Variations in extractable solids due to varietals and geography are documented.
- Petition includes environmental and official certification statements as required",,,2025-10-15,0.0,,,,,no decision,False,5746.0,pending,pending
fda-2010-p-0056,FDA-2010-P-0056-0026_Richard_F__Edlich__M_D___Ph_D___to_FDA_CDRH___Info,,2010,False,original petition,"Richard F. Edlich, M.D., Ph.D., Professor Emeritus of Plastic Surgery, University of Virginia",advocacy/academic,Not Mentioned ‚Äì The document discusses FDA policy and recommendations but does not cite specific statutes such as 505(q) or 21 C.F.R. ¬ß10.30.,"FDA‚Äôs handling of dental amalgam safety, particularly regarding mercury content.
- Reaction to the FDA‚Äôs ‚ÄúWhite Paper‚Äù and the 2006 Joint Meeting of the Dental Products Panel and Peripheral and Central Nervous System Drugs Advisory Committee","While the document does not formally petition for a specific regulatory change, it strongly advocates for:
- Mandatory informed consent before placement of mercury-containing dental amalgam.
- Labeling changes to include terms like ‚Äúmercury-silver amalgams.‚Äù
- Precautionary restrictions for use in pregnant women and children.
- Review and revision of the FDA‚Äôs prior conclusions on amalgam safety","The 2006 FDA advisory panel rejected the agency‚Äôs White Paper conclusion that dental amalgam was safe by a 13‚Äì7 vote.
- Panel members cited inadequate data on daily mercury exposure and higher-risk populations.
- Strong concerns over lack of informed consent, especially among vulnerable groups like children and pregnant women.
- Cited personal and professional observations on growing public concern and ethical responsibility to inform patients.
- Highlighted support for patient autonomy and transparent communication between dentists and patients",,,2025-10-15,,,,,,no decision,False,,pending,pending
fda-2010-p-0056,FDA-2010-P-0056-0024_Richard_F__Edlich__M_D___Ph_D___et_al___Correction,2010-12-07,2010,False,original petition,"Richard F. Edlich, MD, PhD, Distinguished Professor Emeritus of Plastic Surgery, Biomedical Engineering, and Emergency Medicine, University of Virginia Health System",advocacy/academic,"21 CFR 10.30 ‚Äì Procedures for submitting citizen petitions
- 21 CFR 5.10 ‚Äì Delegation of authority to the Commissioner",The petition addresses lack of required informed consent in dental practices for patients receiving silver-mercury amalgam restorations. It criticizes historical FDA policy of approving mercury amalgam under a grandfather clause and calls for changes to current practices,"The petitioner requests the FDA to require dentists to provide informed consent brochures to patients who receive dental restorations, specifically those involving mercury-containing amalgam","Mercury amalgam consists of ~50% mercury and emits mercury vapor, especially during chewing, brushing, or consuming hot liquids.
- Mercury is linked to damage in the kidney, nervous, and cardiovascular systems, and is implicated in mucosal tattoos and diseases like autism, Alzheimer‚Äôs, and multiple sclerosis.
- Scientific literature and international practices (Norway, Finland, Denmark, Sweden) support restricting amalgam use.
- Some U.S. states (Maine, California, Connecticut, Vermont) have enacted state-level informed consent laws.
- The economic and environmental costs of mercury pollution are substantial, reinforcing the need for regulatory intervention",,Closed due to death of petitioner,2018-04-10,0.0,Center for Devices and Radiological Health (CDRH),"21 CFR ¬ß 10.30(b)(3), 21 CFR ¬ß 10.30(e)(3)",,"Petitioner Dr. Richard Edlich passed away in 2013, and co-signors lacked proper contact info; FDA closed the docket",other,True,2681.0,CDRH,CDRH
fda-2010-p-0056,FDA-2010-P-0056-0001_Richard_F__Edlich__M_D___Ph_D___et_al___Citizen_Pe,2010-01-14,2010,False,original petition,"Richard F. Edlich, MD, PhD, Distinguished Professor Emeritus of Plastic Surgery, Biomedical Engineering, and Emergency Medicine, University of Virginia Health System. Co-signed by research assistants Jill J. Dahlstrom, Jamie J. Clark, and Tiffany M. Wisecarver",advocacy/academic,"21 C.F.R. ¬ß 10.30 ‚Äì Governs the submission of citizen petitions
- 21 C.F.R. ¬ß 5.10 ‚Äì Delegation of authority to the Commissioner",The petition addresses the lack of informed consent regarding the use of mercury-containing dental amalgams. It criticizes the FDA's longstanding approval of dental amalgam under a grandfather clause and urges the FDA to revise its stance and implement new patient notification practices,The petitioner requests the FDA to prepare and mandate the distribution of informed consent brochures for all dental patients receiving silver-mercury amalgam restorations,"Mercury amalgam contains ~50% mercury, which emits vapor when triggered by heat or friction (e.g., chewing, brushing).
- Mercury exposure has been linked to neurological, renal, cardiovascular disorders, and mucosal tattoos.
- Multiple European countries (e.g., Norway, Sweden, Denmark) have banned mercury amalgam and/or require informed consent.
- Several U.S. states (Maine, California, Connecticut, Vermont) have implemented informed consent laws.
- The FDA‚Äôs previous acceptance of amalgam was based on outdated assumptions and lacks clinical safety trials.
- Scientific references (e.g., Lorscheider et al., FASEB Journal; Hylander & Goodsite on environmental costs) support the call for informed consent due to documented health and environmental risks",,Other (Panel Hearing Notification),2010-08-26,0.0,Center for Devices and Radiological Health (CDRH),Not Mentioned,,Notified petitioner of upcoming panel meeting to discuss scientific issues raised in the dental amalgam classification petition,other,True,224.0,CDRH,CDRH
fda-2010-p-0012,FDA-2010-P-0012-0007_Alaunus_Pharmaceutical_LLC_re_Patrick_Foster_Citiz,2010-11-07,2010,False,original petition,"Alaunus Pharmaceutical, LLC",industry/corporation,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (suitability petitions for ANDAs)
- 21 CFR ¬ß 10.30 ‚Äì FDA Citizen Petition regulation","The original petition requested that the FDA declare a high-strength Morphine Sulfate Injection Solution (25 mg/mL, PF, 50 mL and 100 mL single-use vials) suitable for consideration under an ANDA. This letter withdraws that request",The petitioner is requesting that the FDA withdraw the previously submitted Citizen Petition (FDA-2010-P-0012-001/CP),Not Mentioned ‚Äì The letter only states the request for withdrawal without providing a reason,,,2025-10-15,0.0,,,,,no decision,False,5456.0,pending,pending
fda-2012-p-1189,FDA-2012-P-1189-0010_Extension_Request_TMP_for_Canned_Tuna.pdf,2012-06-20,2012,False,original petition,"Bumble Bee Foods, LLC; StarKist Co.; Tri-Union Seafoods, LLC (Chicken of the Sea)",industry/corporation,21 CFR 10.30; 21 CFR 130.12,Request extension of temporary marketing permit for canned tuna labeled by drained weight rather than pressed cake weight,Requested to maintain current labeling while FDA rulemaking proceeds; no consumer deception or health concerns identified,,,,2025-10-15,0.0,,,,,no decision,False,4865.0,pending,pending
fda-2012-p-0119,FDA-2012-P-0119-0010_Redacted_Appeal_from_Mario_Morais.pdf,2014-07-04,2012,False,original petition,Mario Morais,individual,21 CFR 10.75,Appeal regarding previous denial of Citizen Petition concerning desiccant labeling in pharmaceutical packaging,Request for reconsideration based on new arguments and interpretations of labeling standards,,,,2025-10-15,0.0,,,,,no decision,False,4121.0,pending,pending
fda-2012-p-0260,FDA-2012-P-0260-0021_Amendment_from_Fisher_Wallace_Laboratories_LLC.pdf,2014-05-07,2012,False,original petition,Fisher Wallace Laboratories LLC,advocacy/academic,,Request to amend citizen petition requesting FDA to reclassify cranial electrotherapy stimulators (CES) from Class III to Class II,Updated scientific rationale and regulatory arguments for reclassification of CES devices,,,,2025-10-15,0.0,,,,,no decision,False,4179.0,pending,pending
fda-2012-p-0895,FDA-2012-P-0895-0004_Endo_Pharmaceuticals_Inc_Endo_Supplement.pdf,2012-11-01,2012,False,original petition,Endo Pharmaceuticals Inc.,industry/corporation,Section 505(j)(6) of FD&C Act; 21 CFR 314.161,Supplement to original citizen petition requesting FDA find non-crush-resistant Opana ER discontinued for safety reasons and refuse/suspend ANDAs,New post-marketing data showing increased abuse and safety concerns with non-crush-resistant formulation,,,,2025-10-15,0.0,,,,,no decision,False,4731.0,pending,pending
fda-2012-p-0794,FDA-2012-P-0794-0001_Piedmont_Animal_Health_Citizen_Petition.pdf,2012-08-24,2012,False,original petition,Piedmont Animal Health,individual,21 CFR 514.1; 21 CFR 514.8; 21 CFR 514.111,Suitability petition requesting permission to submit ANADA for chewable praziquantel/pyrantel pamoate/febantel for dogs,"Differences from pioneer product (chewable form, texture, size) do not affect active ingredients or intended use",,,,2025-10-15,0.0,,,,,no decision,False,4800.0,pending,pending
fda-2012-p-0270,FDA-2012-P-0270-0001_Neuro_Fitness_LLC___Citizen_Petition.pdf,2012-03-23,2012,False,original petition,Neuro Fitness LLC,industry/corporation,21 CFR 10.30,Request FDA to reclassify cranial electrotherapy stimulators (CES) from Class III to Class II,Scientific literature and clinical evidence support reclassification for safety and effectiveness,,,,2025-10-15,0.0,,,,,no decision,False,4954.0,pending,pending
fda-2012-p-0404,FDA-2012-P-0404-0001_Public_Citizen_Health_Research_Group_Citizen_Petit.pdf,2012-04-11,2012,False,original petition,Public Citizen Health Research Group,advocacy/academic,21 CFR 10.30,"Request FDA to remove propoxyphene-containing products (e.g., Darvon, Darvocet) from the market due to cardiovascular risks",Evidence of serious cardiac side effects outweighs benefits,,,,2025-10-15,0.0,,,,,no decision,False,4935.0,pending,pending
fda-2012-p-0272,FDA-2012-P-0272-0001_Actavis_Inc__Attachments_1_and_2__Citizen_Petition.pdf,2012-03-22,2012,False,original petition,Actavis Inc.,industry/corporation,21 CFR 10.30,Request that FDA refuse to approve or suspend approval of any ANDAs referencing original Opana ER formulation,Argues that changes to formulation (crush-resistant) were necessary for safety; allowing generic approval of non-crush-resistant would pose public health risk,,,,2025-10-15,0.0,,,,,no decision,False,4955.0,pending,pending
fda-2012-p-0317,FDA-2012-P-0317-0001_Abbott_Laboratories_Covington_and_Burling_LLP__Cit.pdf,2012-04-02,2012,False,original petition,Abbott Laboratories (represented by Covington & Burling LLP),law/consulting,21 C.F.R. ¬ß 10.30; Section 351 of PHSA (BPCIA),"Request that FDA not accept, file, approve, or otherwise consider biosimilar applications referencing Humira before March 23, 2010",Based on constitutional protections (Fifth Amendment takings clause) and preserving trade secrets from premature disclosure,,,,2025-10-15,0.0,,,,,no decision,False,4944.0,pending,pending
fda-2012-p-0749,FDA-2012-P-0749-0001_Reference_2_Nasonex_NDA_20_762_Formulation_Develop.pdf,2012-05-29,2012,False,original petition,"Merck & Co., Inc.",industry/corporation,21 CFR 10.30,Request that FDA refuse to approve any ANDA referencing Nasonex unless bioequivalence is demonstrated using the innovator's formulation,"Differences in formulation could impact clinical performance; thus, stricter bioequivalence standards needed",,,,2025-10-15,0.0,,,,,no decision,False,4887.0,pending,pending
fda-2012-p-0053,FDA-2012-P-0053-0001_Lannett_Company_Inc_and_Cody_Laboratories_Inc_Alst.pdf,2012-01-18,2012,False,original petition,Lannett Company Inc. and Cody Laboratories Inc.,advocacy/academic,21 CFR 10.30,Request for FDA to withdraw approval of certain generic morphine sulfate oral solutions due to bioequivalence and safety concerns,Alleged inadequacy of bioequivalence data and potential safety risks for patients,,,,2025-10-15,0.0,,,,,no decision,False,5019.0,pending,pending
fda-2012-p-0298,FDA-2012-P-0298-0001_Joseph_Dedvukaj_Firm_PC_On_Behalf_of_Arena_Pharmac.pdf,2012-03-20,2012,False,original petition,Joseph Dedvukaj Firm PC on behalf of Arena Pharmaceuticals,law/consulting,21 CFR 10.30,Request for FDA approval of Lorcaserin for treatment of obesity,Claims sufficient evidence of safety and efficacy for new drug application approval,,,,2025-10-15,0.0,,,,,no decision,False,4957.0,pending,pending
fda-2012-p-0733,FDA-2012-P-0733-0001_Jazz_Pharmaceuticals_Citizen_Petition.pdf,2012-06-01,2012,False,original petition,"Jazz Pharmaceuticals, Inc.",industry/corporation,21 CFR 10.30,Request that FDA refuse to approve any ANDA for sodium oxybate oral solution that omits the Risk Management Program requirements,Argues that RMP requirements are necessary for safe use and should be mandatory for all generic applicants,,,,2025-10-15,0.0,,,,,no decision,False,4884.0,pending,pending
fda-2012-p-0947,FDA-2012-P-0947-0001_Mallinckrodt_Inc__Citizen_Petition.pdf,2012-07-12,2012,False,original petition,Mallinckrodt Inc.,industry/corporation,21 CFR 10.30,Request that FDA refuse to approve any ANDA for generic Exalgo unless bioequivalence is demonstrated using the approved crush-resistant formulation,Public health concerns regarding abuse potential if bioequivalence to crush-resistant formulation is not assured,,,,2025-10-15,0.0,,,,,no decision,False,4843.0,pending,pending
fda-2012-p-0939,FDA-2012-P-0939-0001_Purdue_Pharma_L_P_Kleinfeld_Kaplan_and_Becker_LLP_.pdf,2012-07-05,2012,False,original petition,"Purdue Pharma L.P. (represented by Kleinfeld, Kaplan and Becker LLP)",law/consulting,21 CFR 10.30,Request that FDA refuse to approve any ANDAs referencing OxyContin without demonstrating abuse-deterrent properties,Argues that removing abuse-deterrent features would pose public health risks and undermine incentives for innovation,,,,2025-10-15,0.0,,,,,no decision,False,4850.0,pending,pending
fda-2012-p-0695,FDA-2012-P-0695-0006_Lorillard_Inc__Letter.pdf,2012-06-11,2012,False,original petition,"Lorillard, Inc.",industry/corporation,21 CFR 10.30,Request to revise or withdraw sections of a Draft Guidance related to harmful and potentially harmful constituents (HPHCs) reporting requirements for tobacco products,"Argues that certain reporting requirements were premature, burdensome, and lacked statutory basis",,,,2025-10-15,0.0,,,,,no decision,False,4874.0,pending,pending
fda-2012-p-0260,FDA-2012-P-0260-0001_Fisher_Wallace_Laboratories_LLC_Citizen_Petition.pdf,2012-03-02,2012,False,original petition,Fisher Wallace Laboratories LLC,advocacy/academic,21 CFR 10.30,Request that FDA reclassify cranial electrotherapy stimulators (CES) from Class III to Class II,Claims sufficient evidence of safety and effectiveness based on clinical data,,,,2025-10-15,0.0,,,,,no decision,False,4975.0,pending,pending
fda-2012-p-0963,FDA-2012-P-0963-0001_Charles_J_Zimmerer_Citizen_Petition.pdf,2012-07-18,2012,False,original petition,Charles J. Zimmerer,individual,21 CFR 10.30,Request for reconsideration of FDA's refusal to grant orphan drug designation for a specific product,Argues that the denial was based on incorrect interpretations of regulatory criteria,,,,2025-10-15,0.0,,,,,no decision,False,4837.0,pending,pending
fda-2012-p-0275,FDA-2012-P-0275-0001_William_H_Lamont_Citizen_Petition.pdf,2012-03-19,2012,False,original petition,William H. Lamont,individual,21 CFR 10.30,Request for FDA to initiate recall and conduct testing on certain nutritional supplements marketed for infants,Concerns over contamination and labeling inaccuracies potentially affecting infant health,,,,2025-10-15,0.0,,,,,no decision,False,4958.0,pending,pending
fda-2012-p-0760,FDA-2012-P-0760-0001_Purdue_Pharma_L_P_Kleinfeld_Kaplan_and_Becker_LLP_.pdf,2012-07-13,2012,False,original petition,"Purdue Pharma L.P. (represented by Kleinfeld, Kaplan and Becker LLP)",law/consulting,21 CFR 10.30,Request that FDA refuse to approve any ANDA for generic reformulated OxyContin unless it demonstrates comparable abuse-deterrent properties,Claims that tamper-resistance is essential for public health and generics must meet similar standards,,,,2025-10-15,0.0,,,,,no decision,False,4842.0,pending,pending
fda-2012-p-0189,FDA-2012-P-0189-0001_Lannett_Company_Inc_and_Cody_Laboratories_Inc_Alst.pdf,2012-03-05,2012,False,original petition,"Lannett Company, Inc. and Cody Laboratories, Inc.",advocacy/academic,21 CFR 10.30,Request that FDA recognize certain morphine sulfate oral solutions as grandfathered drugs not requiring new drug applications,Claims products meet grandfathering criteria under FDCA and have longstanding historical use without material changes,,,,2025-10-15,0.0,,,,,no decision,False,4972.0,pending,pending
fda-2012-p-0137,FDA-2012-P-0137-0001_Anulex_Technologies_Inc__R_Sheridan_Consulting_LLC.pdf,2012-02-10,2012,False,original petition,"Anulex Technologies, Inc. (represented by R. Sheridan Consulting LLC)",law/consulting,21 CFR 10.30,Request that FDA reclassify the Xclose Tissue Repair System from Class III to Class II with special controls,Argues that available clinical evidence supports safety and effectiveness under less restrictive classification,,,,2025-10-15,0.0,,,,,no decision,False,4996.0,pending,pending
fda-2012-p-0275,FDA-2012-P-0275-0001_William_H_Lamont_Citizen_Petition.pdf,2012-04-02,2012,False,original petition,William H. Lamont,individual,21 CFR 10.30,Request for FDA to take regulatory action regarding label requirements and certain drug product approvals,Argues that specific regulatory action is necessary to protect public health,,,,2025-10-15,0.0,,,,,no decision,False,4944.0,pending,pending
fda-2012-p-0760,FDA-2012-P-0760-0001_Purdue_Pharma_L_P_Kleinfeld_Kaplan_and_Becker_LLP_.pdf,2012-07-30,2012,False,original petition,"Purdue Pharma L.P., Kleinfeld Kaplan and Becker LLP",law/consulting,21 CFR 314.161,Request to determine that discontinued formulations of certain drug products were withdrawn for safety reasons,Argues that old formulations pose safety concerns that justify refusal of ANDA approvals,,,,2025-10-15,0.0,,,,,no decision,False,4825.0,pending,pending
fda-2012-p-0260,FDA-2012-P-0260-0001_Fisher_Wallace_Laboratories_LLC_Citizen_Petition.pdf,2012-03-20,2012,False,original petition,Fisher Wallace Laboratories LLC,advocacy/academic,21 CFR 10.30,Request for reclassification of the Fisher Wallace Stimulator from Class III to Class II,"Justifies reclassification based on safety, effectiveness, and postmarket use data",,,,2025-10-15,0.0,,,,,no decision,False,4957.0,pending,pending
fda-2012-p-0963,FDA-2012-P-0963-0001_Charles_J_Zimmerer_Citizen_Petition.pdf,2012-11-01,2012,False,original petition,"Charles J. Zimmerer, Esq.",individual,21 CFR 10.30,Request for reconsideration of FDA's refusal to grant exclusivity to a specific product,Argues that FDA misapplied its rules and the product met criteria for exclusivity,,,,2025-10-15,0.0,,,,,no decision,False,4731.0,pending,pending
fda-2012-p-0103,FDA-2012-P-0103-0001_The_Feinstein_Institute_for_Medical_Reseach_North_.pdf,2012-01-30,2012,False,original petition,The Feinstein Institute for Medical Research (North Shore-LIJ Health System),advocacy/academic,21 CFR 10.30,Request for designation of a human cell and tissue-based product as a biologic,Argues the product meets statutory definitions and should be regulated as a biologic,,,,2025-10-15,0.0,,,,,no decision,False,5007.0,pending,pending
fda-2012-p-0695,FDA-2012-P-0695-0007_Lorillard__Inc_Letter_with_encloure___Letter.pdf,2012-06-26,2012,False,original petition,FDA Center for Tobacco Products,advocacy/academic,21 CFR 10.30,Request for enforcement discretion for premarket approval requirements under FDCA section 910(a) for two new tobacco products submitted under substantial equivalence reports,,,,,2025-10-15,0.0,,,,,no decision,False,4859.0,pending,pending
fda-2012-p-1103,FDA-2012-P-1103-0001_Ikaria_Inc_Kleinfeld_Kaplan_and_Becker_LLP_Citizen.pdf,2012-11-01,2012,False,original petition,FDA Center for Drug Evaluation and Research (CDER),advocacy/academic,21 CFR 10.30,Request to revoke orphan drug designation granted to GeNO for nitric oxide or require clinical superiority data,,,,,2025-10-15,0.0,,,,,no decision,False,4731.0,pending,pending
fda-2012-p-0295,FDA-2012-P-0295-0001_Janssen_Pharmaceuticals_Inc_Ropes_and_Gray_LLP_Cit.pdf,2012-03-26,2012,False,original petition,"Janssen Pharmaceuticals, Inc.",industry/corporation,21 CFR 10.30,Request that FDA adopt specific bioequivalence requirements for ANDAs referencing ELMIRON (pentosan polysulfate sodium),Ensure generic versions have comparable safety and efficacy by requiring bioequivalence studies with clinical endpoints and detailed active ingredient characterization,,,,2025-10-15,0.0,,,,,no decision,False,4951.0,pending,pending
fda-2012-p-1095,FDA-2012-P-1095-0001_Resveratrol_Partners_LLC_Citizen_Petition.pdf,2012-05-31,2012,False,original petition,"Resveratrol Partners, LLC",industry/corporation,21 CFR 10.30,Requesting FDA to allow resveratrol dietary supplements to include specific health claims,Scientific evidence presented to support structure/function claims for resveratrol supplementation,,,,2025-10-15,0.0,,,,,no decision,False,4885.0,pending,pending
fda-2012-p-1072,FDA-2012-P-1072-0001_Boehringer_Ingelheim_Pharmaceuticals_Inc_Ropes_Gra.pdf,2012-08-08,2012,False,original petition,"Boehringer Ingelheim Pharmaceuticals, Inc.",industry/corporation,21 CFR 10.30,Request for specific bioequivalence study requirements for generic versions of Pradaxa (dabigatran etexilate),Concern about Pradaxa‚Äôs complex formulation and need for in vivo bioequivalence demonstration,,,,2025-10-15,0.0,,,,,no decision,False,4816.0,pending,pending
fda-2012-p-0119,FDA-2012-P-0119-0003_Mario_Morais_Supplement.pdf,2012-04-24,2012,False,original petition,Mario Morais,individual,21 CFR 10.30,Supplement to original citizen petition regarding regulatory actions on a drug product,,,,,2025-10-15,0.0,,,,,no decision,False,4922.0,pending,pending
fda-2012-p-1103,FDA-2012-P-1103-0006_Ikaria_Inc_Kleinfeld_Kaplan_and_Becker_LLP_Supplem.pdf,2012-11-13,2012,False,original petition,"Ikaria, Inc.",industry/corporation,21 CFR 10.30,Supplement submission to previous citizen petition regarding nitric oxide orphan drug designation,,,,,2025-10-15,0.0,,,,,no decision,False,4719.0,pending,pending
fda-2012-p-0637,FDA-2012-P-0637-0001_KV_Pharmaceutical_Company_Citizen_Petition.pdf,2012-03-02,2012,False,original petition,K-V Pharmaceutical Company,industry/corporation,21 CFR 10.30,Request for FDA enforcement action against compounded versions of hydroxyprogesterone caproate (Makena¬Æ) products,,,,,2025-10-15,0.0,,,,,no decision,False,4975.0,pending,pending
fda-2012-p-0951,FDA-2012-P-0951-0001_Endo_Pharmaceuticals_Inc_Citizen_Petition.pdf,2012-05-30,2012,False,original petition,"Endo Pharmaceuticals, Inc.",industry/corporation,21 CFR 10.30,Request for FDA to deny approval of generic versions of Opana¬Æ ER that are not abuse-deterrent,,,,,2025-10-15,0.0,,,,,no decision,False,4886.0,pending,pending
fda-2012-p-0387,FDA-2012-P-0387-0001_ABT_Molecular_Imaging_Inc_Citizen_Petition.pdf,2012-04-18,2012,False,original petition,"ABT Molecular Imaging, Inc.",industry/corporation,21 CFR 10.30,Request to allow submission of ANDA for Fludeoxyglucose F18 Injection with lower strength (1‚Äì20 mCi/mL EOS),,,,,2025-10-15,0.0,,,,,no decision,False,4928.0,pending,pending
fda-2012-p-0695,FDA-2012-P-0695-0012_Lorillard_Tobacco_Company_Petition_for_Reconsidera.pdf,2012-08-24,2012,False,original petition,Lorillard Tobacco Company,industry/corporation,21 CFR 10.30,Request for reconsideration of FDA‚Äôs order finding two new tobacco products not substantially equivalent,Argues that FDA‚Äôs decision was arbitrary and capricious and did not adequately consider evidence,,,,2025-10-15,0.0,,,,,no decision,False,4800.0,pending,pending
fda-2012-p-1018,FDA-2012-P-1018-0001_Mutual_Pharmaceutical_Company_Inc_Sidley_Austin_LL.pdf,2012-10-23,2012,False,original petition,"Mutual Pharmaceutical Company, Inc.",industry/corporation,21 CFR 10.30,Request for FDA to refuse acceptance of certain ANDAs referencing Sular¬Æ (nisoldipine) extended-release tablets,Argues bioequivalence standards are not met by proposed generics,,,,2025-10-15,0.0,,,,,no decision,False,4740.0,pending,pending
fda-2012-p-1155,FDA-2012-P-1155-0003_Deka_Research_and_Development_Corportion__Suppleme.pdf,2012-11-30,2012,False,original petition,Deka Research and Development Corporation,advocacy/academic,21 CFR 10.30,Supplement to earlier citizen petition seeking reclassification of stair-climbing wheelchair devices,Provides additional data and responses to FDA queries to support reclassification,,,,2025-10-15,0.0,,,,,no decision,False,4702.0,pending,pending
fda-2012-p-0555,FDA-2012-P-0555-0001_Teva_Pharmaceutical_Industries_Ltd_Citizen_Petitio.pdf,2012-03-02,2012,False,original petition,Teva Pharmaceutical Industries Ltd.,industry/corporation,21 CFR 10.30,Request that FDA apply stringent standards for approving generic versions of Copaxone¬Æ,Emphasizes complexity of active ingredient and challenges of establishing sameness,,,,2025-10-15,0.0,,,,,no decision,False,4975.0,pending,pending
fda-2012-p-0103,FDA-2012-P-0103-0003_Feinstein_Institute_for_Medical_Reseach_North_Shor.pdf,2012-01-30,2012,False,original petition,"Feinstein Institute for Medical Research (Thomas Chaly, Ph.D.)",advocacy/academic,NDA 22-494 (Sodium Fluoride F18 Injection); FDA regulations on ANDA amendments,Submission of an ANDA with a higher concentration than approved drug,Accept amendment to original citizen petition to include RLD labeling,"Ensure compliance with CGMP deadline (June 12, 2012)",,,2025-10-15,0.0,,,,,no decision,False,5007.0,pending,pending
fda-2012-p-0119,FDA-2012-P-0119-0005_Mario_Morais_Supplement.pdf,,2012,False,original petition,Mario Morais,individual,,,,,,,2025-10-15,,,,,,no decision,False,,pending,pending
fda-2012-p-0496,FDA-2012-P-0496-0003_Cumberland_Pharmaceuticals_Inc_Amendment.pdf,,2012,False,original petition,Cumberland Pharmaceuticals Inc.,industry/corporation,,,,,,,2025-10-15,,,,,,no decision,False,,pending,pending
fda-2012-p-0313,FDA-2012-P-0313-0001_Con_Vet_GmbH_and_Co_KG_Veterinary_Consulting_Group.pdf,2012-05-03,2012,False,original petition,Con Vet GmbH & Co KG Veterinary Consulting Group,law/consulting,21 CFR 10.30,Import alert on veterinary products,Request removal of Import Alert 16-129 for Polyinylpyrolidone Iodine Solution,Justification based on compliance with regulatory requirements and updated testing,,,2025-10-15,0.0,,,,,no decision,False,4913.0,pending,pending
fda-2012-p-0566,FDA-2012-P-0566-0001_Citizen_Petition_Empire_State_Consumer_Project_Inc.pdf,2012-06-04,2012,False,original petition,"Empire State Consumer Project, Inc.",industry/corporation,21 CFR 10.30,Use of polyethylene glycol (PEG 3350) products in children,"Request investigation, labeling changes, and potential withdrawal of PEG 3350 laxatives for children",Due to reports of neuropsychiatric events and other adverse events in children,,,2025-10-15,0.0,,,,,no decision,False,4881.0,pending,pending
fda-2012-p-0493,FDA-2012-P-0493-0001_Leroy_Leslie_Hamilton_PhD__Change_in_Classificatio.pdf,2012-05-14,2012,False,original petition,"Dr. Leroy Leslie Hamilton, Ph.D.",individual,21 CFR 860.123 (Medical Device Classification),Classification of Cranial Electrotherapy Stimulator devices,Request reclassification of CES devices from Class III to Class II,Supported by evidence of low risk and therapeutic benefit,,,2025-10-15,0.0,,,,,no decision,False,4902.0,pending,pending
fda-2012-p-0184,FDA-2012-P-0184-0003_Foley_Hoag_LLP_Fresenius_Medical_Care_North_Americ.pdf,2012-04-04,2012,False,original petition,Fresenius Medical Care North America,industry/corporation,21 CFR 10.30,Policy regarding concentrated dialysate solutions,Request FDA to revise policies for sodium bicarbonate concentrate solutions,Justification based on product quality and safety improvements,,,2025-10-15,0.0,,,,,no decision,False,4942.0,pending,pending
fda-2012-p-0468,FDA-2012-P-0468-0001_Cadila_Pharmaceuticals_Limited_India_Modavar_Pharm.pdf,2012-05-04,2012,False,original petition,Cadila Pharmaceuticals Limited / Modavar Pharmaceuticals LLC,industry/corporation,"21 CFR 10.20, 10.30; FDCA 505(j)",Reference Listed Drug (RLD) designation for Meclizine HCl tablets,Request designation of alternate RLD and removal of ANTIVERT if discontinued,ANTIVERT¬Æ unavailable commercially for over 12 months,,,2025-10-15,0.0,,,,,no decision,False,4912.0,pending,pending
fda-2012-p-1053,FDA-2012-P-1053-0001_Citizen_Petition_from_Public_Citizen.pdf,,2012,False,original petition,Public Citizen,individual,FDA general petition rules,Marketing approval standards,Request FDA to withdraw approval of propoxyphene-containing products,Based on cardiotoxicity and safety concerns,,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2012-p-1155,FDA-2012-P-1155-0001_Deka_Research_and_Development_Corporation_Change_i.pdf,2012-12-04,2012,False,original petition,DEKA Research and Development Corporation,advocacy/academic,21 CFR Part 880,Medical device classification,Request reclassification of HomeChoice PRO Peritoneal Dialysis System accessory from Class III to Class II,Based on low risk and intended use,,,2025-10-15,0.0,,,,,no decision,False,4698.0,pending,pending
fda-2012-p-0040,FDA-2012-P-0040-0001_Electronic_Version_Fischer_Surgical_Inc_Citizen_Pe.pdf,2011-12-29,2012,False,original petition,Fischer Surgical Inc.,industry/corporation,21 CFR 10.33,NSE (Not Substantially Equivalent) letter issued for NCI Spatula,Acceptance of NCI Spatula as substantially equivalent to Endoserter (K090626),Overlooked endotoxin compliance; functionality demonstrated; no lower limit required,,,2025-10-15,0.0,,,,,no decision,False,5039.0,pending,pending
fda-2012-p-0299,FDA-2012-P-0299-0007_Supplement_from_Front_Range_Equine_Rescue_and_The_.pdf,2014-03-10,2012,False,original petition,Front Range Equine Rescue and The Humane Society of the United States,advocacy/academic,21 U.S.C. ¬ß 342(a)(4); 21 U.S.C. ¬ß 342(a)(2)(C)(ii),Rulemaking regarding adulterated horse meat,Supplement to petition requesting action against adulterated horse meat from American horses,Lack of treatment records makes horse meat adulterated; violations of FDCA,,,2025-10-15,0.0,,,,,no decision,False,4237.0,pending,pending
fda-2012-p-1007,FDA-2012-P-1007-0001_Public_Citizen_Citizen_Petition.pdf,2012-09-19,2012,False,original petition,Public Citizen,individual,21 C.F.R. ¬ß 20.49(d); FOIA regulations (5 U.S.C. ¬ß 552),FOIA policy and minor deletions,Revoke 21 C.F.R. ¬ß 20.49(d) and revise FDA FOIA practices,Policy inconsistent with FOIA and HHS regulations; harms FOIA requesters,,,2025-10-15,0.0,,,,,no decision,False,4774.0,pending,pending
fda-2012-p-1252,FDA-2012-P-1252-0001_Center_for_Food_Safety_CFS_Citizen_Petition.pdf,2012-12-05,2012,False,original petition,Center for Food Safety (CFS),advocacy/academic,21 CFR 10.30,Food additive petition process,Request FDA to issue a new rule banning arsenic-based drugs in animal feed,Scientific evidence linking arsenic to cancer and other health risks,,,2025-10-15,0.0,,,,,no decision,False,4697.0,pending,pending
fda-2012-p-0872,FDA-2012-P-0872-0051_Supplement_from_the_Handcrafted_Soap_and_Cosmetic_.pdf,,2012,False,original petition,Handcrafted Soap and Cosmetic Guild,advocacy/academic,"21 CFR 701.3, 21 U.S.C. 321(g)(1)",Labeling requirements for handcrafted soaps,Supplemental submission urging FDA to distinguish handcrafted soaps from cosmetics,Handcrafted soaps not intended to affect body structure or function; soaps are not cosmetics,,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2012-p-1009,FDA-2012-P-1009-0001_Pfizer_Inc_Covington_and__Burling_LLP__Citizen_Pet.pdf,2012-08-28,2012,False,original petition,Pfizer Inc.,industry/corporation,21 CFR 10.30,Labeling for generic versions of Vfend (voriconazole),Request FDA to require generic voriconazole applicants to conform to Vfend labeling until FDA updates it,To maintain consistency and avoid confusion during labeling transition,,,2025-10-15,0.0,,,,,no decision,False,4796.0,pending,pending
fda-2012-p-0632,FDA-2012-P-0632-0001_Citizen_Petition_from_Par_Pharmaceutical.pdf,2012-04-02,2012,False,original petition,"Par Pharmaceutical, Inc.",industry/corporation,21 CFR 10.30,Labeling for methylphenidate ER tablets,Request FDA to ensure generic methylphenidate ER products remain therapeutically equivalent to Concerta,To preserve therapeutic equivalence standards and prevent patient confusion,,,2025-10-15,0.0,,,,,no decision,False,4944.0,pending,pending
fda-2012-p-1112,FDA-2012-P-1112-0005_Letter_from_Nobel_Laboratories_LLC.pdf,2012-10-15,2012,False,original petition,"Nobel Laboratories, LLC",advocacy/academic,21 CFR 10.30,Suitability petition for Ibuprofen Orally Disintegrating Tablets 100 mg,Request approval for ANDA suitability petition for a new dosage form,Provides bioequivalence and scientific rationale for suitability,,,2025-10-15,0.0,,,,,no decision,False,4748.0,pending,pending
fda-2012-p-0499,FDA-2012-P-0499-0001_Jazz_Pharmaceuticals_Inc_Citizen_Petition.pdf,,2012,False,original petition,"Jazz Pharmaceuticals, Inc.",industry/corporation,21 CFR 10.30,Concerns about approval of certain generics,Requesting delay or additional requirements for generics to ensure therapeutic equivalence,Evidence that the reference product has complex release mechanisms,,,2025-10-15,,,,,,no decision,False,,pending,pending
fda-2012-p-0661,FDA-2012-P-0661-0001_Citizen_Petition_from_Sandoz_Inc_.pdf,2012-07-05,2012,False,original petition,Sandoz Inc.,industry/corporation,21 CFR 10.30,Request regarding ANDA submission for generic teriparatide injection,Seek FDA to require REMS-compliant product labeling to match FORTEO labeling,Ensures patient safety through identical REMS compliance,,,2025-10-15,0.0,,,,,no decision,False,4850.0,pending,pending
fda-2012-p-1170,FDA-2012-P-1170-0001_Cephazone_Pharma_LLC_Citizen_Petition.pdf,2012-11-12,2012,False,original petition,Cephazone Pharma LLC,industry/corporation,21 CFR 10.30,Request suitability petition for Excenel RTU (Ceftiofur hydrochloride) generic version,Approve new strength generic with certain differences,Scientific data supports equivalence despite formulation differences,,,2025-10-15,0.0,,,,,no decision,False,4720.0,pending,pending
fda-2012-p-0279,FDA-2012-P-0279-0001_Lupin_Pharmaceutical__Inc____Citizen_Petition.pdf,2012-03-16,2012,False,original petition,"Lupin Pharmaceuticals, Inc.",industry/corporation,21 CFR 10.30,Request determination that Teva forfeited 180-day exclusivity for Avapro generics,Request FDA to allow other generic entry,Factual and legal analysis of forfeiture events and ANDA amendments,,,2025-10-15,0.0,,,,,no decision,False,4961.0,pending,pending
fda-2012-p-0737,FDA-2012-P-0737-0001_Actient_Pharmaceuticals_Citizen_Petition.pdf,2012-06-19,2012,False,original petition,Actient Pharmaceuticals LLC,industry/corporation,21 CFR 10.30,Request regarding marketing status of Testopel¬Æ Pellets,Seek FDA to take enforcement action against unapproved testosterone pellet products,Ensure market integrity and protect public health,,,2025-10-15,0.0,,,,,no decision,False,4866.0,pending,pending
fda-2012-p-1265,FDA-2012-P-1265-0001_Indicus_Pharma_LLC_Citzen_Petition.pdf,2012-12-17,2012,False,original petition,Indicus Pharma LLC,industry/corporation,21 CFR 314.93,Orange Book listing of Meclizine Hydrochloride Tablets,"Assign second RLD (Reference Listed Drug) for Meclizine Hydrochloride 12.5 mg, 25 mg, and 50 mg",Scientific rationale supporting that new RLD assignment would facilitate ANDA submissions,,,2025-10-15,0.0,,,,,no decision,False,4685.0,pending,pending
fda-2012-p-1052,FDA-2012-P-1052-0001_James_Flory_MD_MSCE_et_al_New_York_Presbyterian_Ho.pdf,2012-10-09,2012,False,original petition,"James Flory, MD, MSCE, et al. (New York Presbyterian Hospital)",advocacy/academic,21 CFR 10.30,Boxed Warning and labeling for Metformin,Remove boxed warning for lactic acidosis and revise contraindications,"Updated evidence shows metformin's lactic acidosis risk is extremely low, especially in mild renal impairment",,,2025-10-15,0.0,,,,,no decision,False,4754.0,pending,pending
fda-2012-p-0271,FDA-2012-P-0271-0001_Lachman_Consultant_Services_Inc__Citizen_Petition.pdf,2012-03-12,2012,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,21 CFR 314.93,ANDA suitability petition for new strength hydrocodone bitartrate and acetaminophen tablets,Request FDA approval to submit an ANDA for a new intermediate strength,Scientific justification that intermediate strength maintains same safety and efficacy profile,,,2025-10-15,0.0,,,,,no decision,False,4965.0,pending,pending
fda-2012-p-0617,FDA-2012-P-0617-0004_Combination_Products_Coalition_Epstein_Becker_and_.pdf,2012-06-08,2012,False,original petition,"Combination Products Coalition (Epstein Becker & Green, P.C.)",law/consulting,21 CFR 3.2(e),FDA jurisdiction over combination products,Request FDA to provide clearer criteria and a formal process for classification,Unclear classification leads to regulatory uncertainty affecting product development,,,2025-10-15,0.0,,,,,no decision,False,4877.0,pending,pending
fda-2012-p-0583,FDA-2012-P-0583-0001_Pfizer_Inc_Citizen_Petition.pdf,2012-06-06,2012,False,original petition,Pfizer Inc.,industry/corporation,"21 U.S.C. 351, 355; 21 C.F.R. 10.30",ANDA approvals for Lyrica generics,Refusal to approve ANDAs with minimum isomeric impurity levels; require recertification for changes,"Request based on scientific standards for impurity specifications, risk of inappropriate regulatory approval, and impact on patent litigation.",,,2025-10-15,0.0,,,,,no decision,False,4879.0,pending,pending
fda-2012-p-0857,FDA-2012-P-0857-0007_Sheller_P_C_Amendment.pdf,2012-08-27,2012,False,original petition,"Sheller, P.C.",law/consulting,"21 U.S.C. ¬ß¬ß 352, 321; 21 C.F.R. ¬ß¬ß 10.30, 7.45",Pediatric indication and labeling for Risperdal and related products,Revoke pediatric indication or require black box warning for Risperdal/Invega products,"Concerns about insufficient safety data, hyperprolactinemia, gynecomastia, mislabeling risks, inadequate physician guidance.",,,2025-10-15,0.0,,,,,no decision,False,4797.0,pending,pending
fda-2012-p-0436,FDA-2012-P-0436-0001_Lupin_Pharmaceuticals_Inc_Citizen_Petition.pdf,2012-05-03,2012,False,original petition,"Lupin Pharmaceuticals, Inc.",industry/corporation,21 CFR 10.30; 21 CFR 314.94,Orange Book listing for Meclizine Hydrochloride Tablets,Amend Orange Book to assign Par Pharm and Amneal Pharms as second reference listed drugs,Justification based on market availability and regulatory principles regarding therapeutic equivalence.,,,2025-10-15,0.0,,,,,no decision,False,4913.0,pending,pending
fda-2012-p-0298,FDA-2012-P-0298-0010_Joseph_Dedvukaj_Firm_PC_on_Behalf_of_Arena_Pharmac.pdf,2012-03-27,2012,False,original petition,"Various physicians represented by Joseph Dedvukaj Firm, P.C.",law/consulting,21 CFR 10.30,Approval of Arena Pharmaceuticals‚Äô Lorcaserin 10 mg BID and QD formulations,"Request for approval of Lorcaserin based on evidence of safety, efficacy, and the unmet need in obesity treatment.",,,,2025-10-15,0.0,,,,,no decision,False,4950.0,pending,pending
fda-2012-p-0052,FDA-2012-P-0052-0001_Lannett_Company_Inc__Citizen_Petition.pdf,2012-01-10,2012,False,original petition,"Lannett Company, Inc.",industry/corporation,21 CFR 201.57(c)(8)(i); 21 CFR 10.30; Section 505(o)(4) of FDCA,Warning label for Phentermine HCl products regarding combination with Topiramate,Add warning about unproven safety of combining Phentermine and Topiramate,Concerns over serious adverse effects based on advisory committee findings and existing safety data.,,,2025-10-15,0.0,,,,,no decision,False,5027.0,pending,pending
fda-2012-p-0983,FDA-2012-P-0983-0001_Sheppard_Mullin_Richter_and_Hampton_LLP_Citizen_Pe.pdf,2012-09-13,2012,False,original petition,Sheppard Mullin Richter & Hampton LLP,law/consulting,Section 505(j)(2)(C) of the FD&C Act; 21 CFR ¬ß¬ß 10.30 and 314.93,ANDA Suitability Petition for Potassium Acetate Injection,"Approval to submit an ANDA for Potassium Acetate Injection, USP, 2 mEq/mL, 100 mL glass vial",Proposed strength differs only in total drug content; otherwise matches the RLD; provides larger vial for hospital/pharmacy use.,,,2025-10-15,0.0,,,,,no decision,False,4780.0,pending,pending
fda-2012-p-0200,FDA-2012-P-0200-0001_PharmaForce_Inc_Citizen_Petition.pdf,2012-02-29,2012,False,original petition,"PharmaForce, Inc.",industry/corporation,Section 505(j)(2)(C) of the FD&C Act; 21 CFR 10.30,ANDA Suitability Petition for Doxorubicin Hydrochloride Injection,"Approval to submit an ANDA for Doxorubicin Hydrochloride Injection, 2 mg/mL (100 mg/50 mL) vial",Change in total drug content (not concentration) to provide flexibility and minimize waste.,,,2025-10-15,0.0,,,,,no decision,False,4977.0,pending,pending
fda-2012-p-0298,FDA-2012-P-0298-0011_Joseph_Dedvukaj_Firm_PC_on_Behalf_of_Arena_Pharmac.pdf,2012-03-28,2012,False,original petition,"Joseph Dedvukaj Firm, P.C. on behalf of Arena Pharmaceuticals, Inc.",law/consulting,21 CFR ¬ß 10.30,Request for approval of Lorcaserin 10 mg BID and 10 mg QD,Approval of Arena Pharmaceuticals' obesity drug Lorcaserin (10 mg BID and QD) based on trial results (BLOOM-DM study),Lorcaserin met weight loss endpoints; emphasized benefits for diabetic and obese patients; warned of research setbacks if not approved.,,,2025-10-15,0.0,,,,,no decision,False,4949.0,pending,pending
fda-2012-p-0617,FDA-2012-P-0617-0006_Letter_from_Combination_Products_Coalition_Epstein.pdf,2014-08-29,2012,False,original petition,Combination Products Coalition (CPC),law/consulting,21 CFR ¬ß 10.30,Citizen Petition requesting improvement of FDA's guidance development process,Meeting request to discuss delays and propose reforms,Highlighting impact of delays on innovation; pushing for updates to Intercenter Agreements and faster guidance issuance.,,,2025-10-15,0.0,,,,,no decision,False,4065.0,pending,pending
fda-2012-p-1107,FDA-2012-P-1107-0001_FzioMed_Inc_Hogan_Lovells_US_LLP_Citizen_Petition.pdf,2012-11-05,2012,False,original petition,"FzioMed, Inc.",industry/corporation,Section 515(g)(2)(a) and Section 562 of the FD&C Act; 21 CFR 10.33,Petition for reconsideration of denial of PMA for Oxiplex/SP Gel,Request reversal of PMA denial and approval based on existing clinical evidence and foreign approvals.,,,,2025-10-15,0.0,,,,,no decision,False,4727.0,pending,pending
fda-2012-p-0984,FDA-2012-P-0984-0001_Sheppard_Mullin_Richter_and_Hampton_LLP_Citizen_Pe.pdf,2012-09-13,2012,False,original petition,Sheppard Mullin Richter & Hampton LLP,law/consulting,Section 505(j)(2)(C) of the FD&C Act; 21 CFR ¬ß¬ß 10.30 and 314.93,ANDA Suitability Petition for Potassium Acetate Injection,"Approval to submit an ANDA for Potassium Acetate Injection, USP 2 mEq/mL, 20 mL glass vial",Change in container from plastic to glass for better stability without changing concentration or formulation.,,,2025-10-15,0.0,,,,,no decision,False,4780.0,pending,pending
fda-2012-p-0142,FDA-2012-P-0142-0001_Lannett_Company_Inc_Citizen_Petition.pdf,2012-02-03,2012,False,original petition,"Lannett Company, Inc.",industry/corporation,Section 505(j) of the FD&C Act; 21 CFR 314.93,Request to allow supplement submission to ANDA 201407 for new strength 50 mg/25 mg of Triamterene and Hydrochlorothiazide Capsules,Request to avoid a separate ANDA and submit as a supplement to save FDA resources; same active ingredients and similar specifications.,,,,2025-10-15,0.0,,,,,no decision,False,5003.0,pending,pending
fda-2012-p-1189,FDA-2012-P-1189-0011_Bumble_Bee_ChickenoftheSea_StarKist_TMP_Applicatio.pdf,2011-10-12,2012,False,original petition,"Bumble Bee Foods, LLC; StarKist Co.; Tri-Union Seafoods, LLC",industry/corporation,21 CFR ¬ß 130.17,Application for Temporary Marketing Permit (TMP) for Canned Tuna products,Request for TMP to test market canned tuna products deviating from standard of identity,To allow innovation and labeling improvements; align U.S. standard with global practices; encourage seafood consumption per Dietary Guidelines.,,,2025-10-15,0.0,,,,,no decision,False,5117.0,pending,pending
fda-2012-p-0747,FDA-2012-P-0747-0001_Leroy_Leslie_Hamilton_PhD_Citizen_Petition.pdf,2012-07-03,2012,False,original petition,"Leroy Leslie Hamilton, Ph.D.",individual,21 CFR 10.30,Request for investigation into FDA Form 3429 (Device Classification Form),Request impartial review of whether FDA Form 3429 conforms to Class III statutory definition,"Form allegedly flawed, leading to device misclassifications; calls for corrections and transparency.",,,2025-10-15,0.0,,,,,no decision,False,4852.0,pending,pending
fda-2012-p-1107,FDA-2012-P-1107-0026_Letter_from_FzioMed_Inc_Hogan_Lovells_US_LLP.pdf,2014-03-06,2012,False,original petition,"FzioMed, Inc.",industry/corporation,21 CFR 10.33,Comments on Draft Statement of Issues for Oxiplex¬Æ Dispute Resolution Panel,"Requested edits to better frame key dispute points, particularly statistical analysis and regulatory interpretation",Clarify subgroup analysis methodology; emphasize safety established; ensure Panel's fair assessment.,,,2025-10-15,0.0,,,,,no decision,False,4241.0,pending,pending
fda-2012-p-0637,FDA-2012-P-0637-0005_KV_Pharmaceutical_Company_Reply_Comment.pdf,2012-11-12,2012,False,original petition,KV Pharmaceutical Company,industry/corporation,Section 505(q) of the FD&C Act; 21 CFR ¬ß 10.30,Response to comments on Citizen Petition regarding Delalutin,Opposing approval of ANDAs for hydroxyprogesterone caproate referencing Delalutin,"Maintains safety concerns, lack of modern efficacy evidence, and risk to orphan drug exclusivity for Makena.",,,2025-10-15,0.0,,,,,no decision,False,4720.0,pending,pending
fda-2012-p-0904,FDA-2012-P-0904-0316_Citizens_for_Health_CFH_Supplement_Amendment_to_HF.pdf,2014-08-05,2012,False,original petition,Citizens for Health,individual,21 CFR Parts 12-16; FD&CA ¬ß402(a)(2)(C),Amendment and supplement to Citizen Petition on HFCS (High Fructose Corn Syrup),"Label fructose concentration (e.g., HFCS-42, HFCS-55) on products and enforce action against excess fructose concentrations",Consumers deserve clear labeling on fructose content; address health risks and regulatory compliance.,,,2025-10-15,0.0,,,,,no decision,False,4089.0,pending,pending
fda-2012-p-1107,FDA-2012-P-1107-0028_Letter_from_FzioMed__Inc_Nogan_Lovells_US_LLP_to_F.pdf,2014-03-18,2012,False,original petition,"FzioMed, Inc.",industry/corporation,21 CFR 10.33,Comments on revised Draft Statement of Issues for Oxiplex¬Æ Dispute Resolution Panel,Argues that safety of Oxiplex is already established and shouldn't be an open issue,"Supports with historical FDA meetings, clinical studies, and international postmarket experience.",,,2025-10-15,0.0,,,,,no decision,False,4229.0,pending,pending
fda-2012-p-0932,FDA-2012-P-0932-0001_Noven_Pharmaceuticals_Inc_Citizen_Petition.pdf,2012-08-24,2012,False,original petition,"Noven Pharmaceuticals, Inc.",industry/corporation,Section 505(q) of the FD&C Act; 21 CFR ¬ß 10.30,Request to impose stricter bioequivalence standards for generic Daytrana patches,"Require additional bioequivalence, usability, heat effect studies, and residual drug load limits",Differences in transdermal delivery demand higher scrutiny to ensure patient safety.,,,2025-10-15,0.0,,,,,no decision,False,4800.0,pending,pending
fda-2012-p-0050,FDA-2012-P-0050-0001_Arent_Fox_LLP_Citizen_Petition.pdf,2012-01-10,2012,False,original petition,Arent Fox LLP,law/consulting,21 CFR 314.161; 21 CFR 10.25(a) and 10.30,Request to determine voluntary withdrawal of Jenloga‚Ñ¢ and Kapvay‚Ñ¢ (clonidine hydrochloride) was not for safety or effectiveness reasons,Allow submission and approval of ANDAs referencing Jenloga‚Ñ¢ or Kapvay‚Ñ¢,Drugs were withdrawn for economic or strategic reasons; no safety or efficacy concerns.,,,2025-10-15,0.0,,,,,no decision,False,5027.0,pending,pending
fda-2012-p-0583,FDA-2012-P-0583-0008_Pfizer_Inc_Supplement.pdf,2012-10-17,2012,False,original petition,Pfizer Inc.,industry/corporation,21 CFR 10.30,"Supplement to Citizen Petition regarding pregabalin ANDAs with ""not less than"" impurity specifications","Request FDA to deny amendments allowing ""not less than"" (NLT) impurity specs and enforce stricter standards",Court decision confirms infringement even with NLT impurity levels; Pfizer argues NLT specs are unlawful and inappropriate.,,,2025-10-15,0.0,,,,,no decision,False,4746.0,pending,pending
fda-2012-p-1160,FDA-2012-P-1160-0001_Steven_A_Zecola_Citizen_Petition_Redacted_Version.pdf,2012-11-15,2012,False,original petition,Steven A. Zecola,individual,21 CFR 10.30,"Request FDA to withdraw approval of ACT chemotherapy (Adriamycin, Cytoxan, Taxol) for BRCA1-related breast cancer patients",Withdraw ACT chemotherapy for BRCA1 triple-negative patients and recognize them as a distinct subgroup,Scientific studies show ACT chemotherapy may be disproportionately harmful to BRCA1 patients; better alternatives (PARP/platinum) exist.,,,2025-10-15,0.0,,,,,no decision,False,4717.0,pending,pending
fda-2012-p-0061,FDA-2012-P-0061-0001_Lannett_Company_Inc__Citizen_Petition.pdf,2012-01-16,2012,False,original petition,"Lannett Company, Inc.",industry/corporation,Section 505(j) of the FD&C Act; 21 CFR 314.93,Request to submit a supplement to ANDA 201407 for 50 mg/25 mg Triamterene and Hydrochlorothiazide Capsules,Allow supplement submission instead of filing a new ANDA to save resources,50/25 mg strength already approved elsewhere; minor differences; avoids duplication.,,,2025-10-15,0.0,,,,,no decision,False,5021.0,pending,pending
fda-2012-p-0857,FDA-2012-P-0857-0001_Citizen_Petition_from_Sheller_P_C_Law_Offices.pdf,2012-07-27,2012,False,original petition,"Sheller, P.C.",law/consulting,"21 CFR ¬ß¬ß 10.30 and 7.45; FDCA ¬ß¬ß 352, 321","Request to revoke pediatric indications for Risperdal, generic risperidone, and Invega, or alternatively impose black box warnings on labels",Protect pediatric patients from insufficiently studied risks of prolactin-related adverse events such as gynecomastia and endocrine disruption.,,,,2025-10-15,0.0,,,,,no decision,False,4828.0,pending,pending
fda-2012-p-1029,FDA-2012-P-1029-0003_Amendment_from_Lachman_Consultant_Services_Inc.pdf,2012-10-17,2012,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,21 CFR 10.30,Amendment to Citizen Petition regarding Valrubicin Solution for Intravesical Instillation,Submission of proposed package insert labeling in support of suitability petition for Valrubicin generic.,,,,2025-10-15,0.0,,,,,no decision,False,4746.0,pending,pending
fda-2012-p-0943,FDA-2012-P-0943-0001_Sunovion_Pharmaceuticals_Inc_Covington_and_Burling.pdf,2012-08-29,2012,False,original petition,"Sunovion Pharmaceuticals, Inc.",industry/corporation,Section 505(q) of the FD&C Act; 21 CFR 10.30,Citizen Petition challenging Dr. Reddy‚Äôs ANDA for generic Lunesta,Request FDA to refuse approval unless impurity limits for (R)-isomer are lowered to NMT 0.30%; concerns over public health and patent infringement.,,,,2025-10-15,0.0,,,,,no decision,False,4795.0,pending,pending
fda-2012-p-0515,FDA-2012-P-0515-0001_Osmotica_Pharmaceutical_Corporation__Citizen_Petit.pdf,2012-05-17,2012,False,original petition,Osmotica Pharmaceutical Corp.,industry/corporation,Section 505(q) of the FD&C Act; 21 CFR ¬ß¬ß 10.20 and 10.30,Request to refuse approval of Sun Pharma‚Äôs ANDA supplement for Venlafaxine HCl ER Tablets if tablet size is considerably larger than RLD,Concerns about patient safety and compliance due to difficulty swallowing larger tablets; potential impact on efficacy.,,,,2025-10-15,0.0,,,,,no decision,False,4899.0,pending,pending
fda-2012-p-1000,FDA-2012-P-1000-0001_CUSTOpharm_Inc_Citizen_Petition.pdf,2012-09-11,2012,False,original petition,"CUSTOpharm, Inc.",industry/corporation,Section 505(j)(2)(C) of the FD&C Act; 21 CFR 10.30,Request for determination that Dapiprazole Hydrochloride Ophthalmic Solution was not withdrawn for safety or effectiveness,No evidence suggesting withdrawal for safety or effectiveness reasons; request eligibility for ANDA submission.,,,,2025-10-15,0.0,,,,,no decision,False,4782.0,pending,pending
fda-2012-p-0986,FDA-2012-P-0986-0004_Luitpold_Pharmaceuticals_Inc_Amendment.pdf,,2012,False,original petition,"Luitpold Pharmaceuticals, Inc.",industry/corporation,21 CFR 10.30,"Amendment related to Atropine Sulfate Injection, USP",Request to revise or supplement prior submissions concerning ANDA suitability for Atropine Sulfate Injection.,,,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2012-p-0818,FDA-2012-P-0818-0001_Physicians_for_Responsible_Opioid_Prescribing_Citi.pdf,2012-07-25,2012,False,original petition,Physicians for Responsible Opioid Prescribing (PROP),other,21 CFR 10.20 and 10.30,"Request to modify opioid labeling to remove ""moderate pain"" indication, set dosage and duration limits for non-cancer pain",Responds to rising opioid addiction and overdose risks; argues current labeling promotes unsafe use.,,,,2025-10-15,0.0,,,,,no decision,False,4830.0,pending,pending
fda-2012-p-1087,FDA-2012-P-1087-0001_Warner_Chilcott_Company_LLC_Citizen_Petition.pdf,2012-10-24,2012,False,original petition,"Warner Chilcott Company, LLC",industry/corporation,"Sections 505(j) and 505(q) of the FD&C Act; 21 CFR ¬ß¬ß 10.30, 314.94, and 320.21",Request FDA to clarify and establish criteria for demonstrating bioequivalence for mesalamine delayed-release tablets and apply them to ANDAs referencing Asacol or Asacol HD,Ensure stricter standards for bioequivalence to protect efficacy and therapeutic integrity due to high variability of mesalamine absorption.,,,,2025-10-15,0.0,,,,,no decision,False,4739.0,pending,pending
fda-2012-p-0895,FDA-2012-P-0895-0007_Endo_Pharmaceuticals_Supplement_Cover_Sheet.pdf,2013-02-14,2012,False,original petition,Endo Pharmaceuticals Inc.,industry/corporation,Section 505(q) of the FD&C Act; 21 CFR 10.30,Supplement to Citizen Petition regarding Opana ER and generic oxymorphone products,Request confidential consideration of additional documents submitted in support of prior petition regarding product safety and abuse deterrence.,,,,2025-10-15,0.0,,,,,no decision,False,4626.0,pending,pending
fda-2012-p-1004,FDA-2012-P-1004-0001_Sheppard_Mullin_Richter_Hampton_LLP_Citizen_Petiti.pdf,2012-09-14,2012,False,original petition,Sheppard Mullin Richter & Hampton LLP,law/consulting,"Section 505(j)(2)(C) of the FD&C Act; 21 CFR ¬ß¬ß 10.20, 10.30, and 314.93","ANDA Suitability Petition for Magnesium Sulfate Injection, USP 50%, in a 50 mL glass vial",Request approval for a different container size and material compared to the RLD (from plastic 2mL/10mL to glass 50mL vial).,,,,2025-10-15,0.0,,,,,no decision,False,4779.0,pending,pending
fda-2012-p-1107,FDA-2012-P-1107-0033_Oxiplex__SP_Gel__FzioMed__Incorporated_s_Petition_.pdf,2014-05-14,2012,False,original petition,"FzioMed, Inc.",industry/corporation,Section 515(g)(2) of the FD&C Act,Petition for review of FDA‚Äôs denial of PMA for Oxiplex/SP Gel,Request reconsideration through Medical Devices Dispute Resolution Panel; arguing sufficiency of clinical evidence for approval.,,,,2025-10-15,0.0,,,,,no decision,False,4172.0,pending,pending
fda-2012-p-0895,FDA-2012-P-0895-0001_Endo_Pharmaceuticals_Inc_Citizen_Petition.pdf,2012-08-10,2012,False,original petition,Endo Pharmaceuticals Inc.,industry/corporation,Sections 505(j) and 505(q) of the FD&C Act; 21 CFR ¬ß¬ß 10.30 and 314.161,Request FDA to determine discontinued Opana ER formulation withdrawn for safety and prevent generic approval,Argues non-crush-resistant Opana ER was discontinued for safety reasons and generics should not rely on it.,,,,2025-10-15,0.0,,,,,no decision,False,4814.0,pending,pending
fda-2012-p-0986,FDA-2012-P-0986-0005_Second_Amendment_to_ANDA_Suitability_Petition_from.pdf,2018-03-02,2012,False,original petition,"Luitpold Pharmaceuticals, Inc.",industry/corporation,"Section 505(j)(2)(C) of the FD&C Act; 21 CFR 10.20, 10.30, and 314.93","Second Amendment to ANDA Suitability Petition for Atropine Sulfate Injection, USP",Request to allow ANDA submission for new strengths (1.0 mg/mL and 0.4 mg/mL) based on updated labeling alignment with RLD; support continued supply for medically necessary use.,,,,2025-10-15,0.0,,,,,no decision,False,2784.0,pending,pending
fda-2012-p-1189,FDA-2012-P-1189-0015_Canned_Tuna_Deviating_From_the_Standard_of_Identit.pdf,2021-12-28,2012,False,original petition,"Bumble Bee Foods, LLC and StarKist Seafood Co.",industry/corporation,21 CFR 130.17,Amendment of Temporary Marketing Permits for Canned Tuna Products,Request to add manufacturing locations and increase test product quantity for canned tuna products deviating from standard of identity in 21 CFR 161.190.,,,,2025-10-15,0.0,,,,,no decision,False,1387.0,pending,pending
fda-2012-p-0499,FDA-2012-P-0499-0003_Jazz_Pharmaceuticals_Inc_Amendment.pdf,2012-06-18,2012,False,original petition,"Jazz Pharmaceuticals, Inc.",industry/corporation,21 CFR 10.30,Amendment to Citizen Petition regarding Xyrem (sodium oxybate) bioequivalence requirements,Request to ensure FDA publishes bioequivalence study requirements in Orange Book and requires in vivo studies for ANDAs referencing Xyrem.,,,,2025-10-15,0.0,,,,,no decision,False,4867.0,pending,pending
fda-2012-p-1026,FDA-2012-P-1026-0001_Synergy_Health_Concepts_Inc_C_Humphrey_and_Associa.pdf,2012-09-24,2012,False,original petition,"Synergy Health Concepts, Inc.",industry/corporation,21 CFR 10.35,Petition for Stay of Action regarding disclosure of FDA Warning Letters,Request to stay public disclosure of Warning Letters regarding investigational device studies at Synergy Health due to pending administrative review.,,,,2025-10-15,0.0,,,,,no decision,False,4769.0,pending,pending
fda-2012-p-1189,FDA-2012-P-1189-0001_Canned_Tuna_Deviating_from_Identity_Standard__Temp.pdf,2013-01-10,2012,False,original petition,Chicken of the Sea International,industry/corporation,21 CFR 130.17,"Temporary permit for marketing ""no drain canned tuna"" deviating from U.S. standard of identity",Allow test marketing to measure consumer acceptance and commercial feasibility; products deviate by minimal liquid addition and seasoning ingredients.,,,,2025-10-15,0.0,,,,,no decision,False,4661.0,pending,pending
fda-2012-p-1189,FDA-2012-P-1189-0014_Canned_Tuna_Deviating_From_the_Standard_of_Identit.pdf,2021-03-05,2012,False,original petition,StarKist Seafood Company,industry/corporation,21 CFR 130.17,Amendment to temporary marketing permit for canned tuna products,Permit amended to add three new manufacturing locations and increase quantity of test product; continues consumer testing.,,,,2025-10-15,0.0,,,,,no decision,False,1685.0,pending,pending
fda-2012-p-1189,FDA-2012-P-1189-0004_Canned_Tuna_Deviating_From_Identity_Standard__Temp.pdf,2016-03-07,2012,False,original petition,"Bumble Bee Foods LLC, Chicken of the Sea International, StarKist Seafood Company",industry/corporation,21 CFR 130.17,Extension of temporary permits for market testing canned tuna deviating from standard,Extension allows continued consumer testing in support of petition to amend the canned tuna standard of identity.,,,,2025-10-15,0.0,,,,,no decision,False,3509.0,pending,pending
fda-2012-p-0649,FDA-2012-P-0649-0001_Citizen_Petition_from_Lachman_Consultant_Services_.pdf,2012-06-18,2012,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,21 CFR 10.30 and 21 CFR 314.161,"Request for determination whether Questran (Cholestyramine for Oral Suspension, USP) was withdrawn for safety or effectiveness reasons",Allow ANDA submissions for Questran if withdrawal was not for safety reasons.,,,,2025-10-15,0.0,,,,,no decision,False,4867.0,pending,pending
fda-2012-p-0507,FDA-2012-P-0507-0001_Cumberland_Pharmaceutical_Inc_Covington_and_Burlin.pdf,2012-05-18,2012,False,original petition,Cumberland Pharmaceuticals Inc.,industry/corporation,Section 505(j) of the FD&C Act; 21 CFR 10.30,Request FDA not approve ANDAs for Acetadote¬Æ formulations containing EDTA,Argues EDTA poses safety concerns; Acetadote reformulated to remove EDTA at FDA‚Äôs request.,,,,2025-10-15,0.0,,,,,no decision,False,4898.0,pending,pending
fda-2012-p-1189,FDA-2012-P-1189-0016_Canned_Tuna_Deviating_From_Identity_Standard__Amen.pdf,2022-12-21,2012,False,original petition,StarKist Co.,individual,21 CFR 130.17,Amendment to temporary marketing permit for canned tuna products,Adds RD Foods Americas as an additional manufacturing location for test product; continues consumer acceptance testing :contentReference[oaicite:0]{index=0}.,,,,2025-10-15,0.0,,,,,no decision,False,1029.0,pending,pending
fda-2012-p-1189,FDA-2012-P-1189-0002_Canned_Tuna_Deviating_From_Identity_Standard__Temp.pdf,2014-06-20,2012,False,original petition,Bumble Bee Foods LLC; Chicken of the Sea International; StarKist Seafood Company,industry/corporation,21 CFR 130.17,Temporary permit for canned tuna deviating from standard of identity,Permit issued to allow market testing of canned tuna products with minor deviations to measure consumer acceptance and commercial feasibility :contentReference[oaicite:1]{index=1}.,,,,2025-10-15,0.0,,,,,no decision,False,4135.0,pending,pending
fda-2012-p-0583,FDA-2012-P-0583-0004_Pfizer_Inc_Supplement.pdf,2012-06-26,2012,False,original petition,Pfizer Inc.,industry/corporation,21 CFR 10.30,Supplement to Citizen Petition regarding pregabalin ANDA impurity specifications,"Request FDA to reject ""not less than"" impurity specifications proposed by Actavis for generic pregabalin; maintain safety and quality standards :contentReference[oaicite:2]{index=2}.",,,,2025-10-15,0.0,,,,,no decision,False,4859.0,pending,pending
fda-2012-p-0754,FDA-2012-P-0754-0001_North_American_Olive_Oil_Association_Citizen_Petit.pdf,2012-07-09,2012,False,original petition,North American Olive Oil Association,advocacy/academic,21 CFR 130,Request to enhance and reaffirm standard of identity for olive oil and olive-pomace oil,Request FDA to adopt USDA and Codex standards for olive oil to ensure authenticity and consumer protection :contentReference[oaicite:3]{index=3}.,,,,2025-10-15,0.0,,,,,no decision,False,4846.0,pending,pending
fda-2012-p-0479,FDA-2012-P-0479-0001_Natco_Pharma_Limited__Citizen_Petition.pdf,2012-05-08,2012,False,original petition,Natco Pharma Limited,industry/corporation,"Section 505(j)(2)(C) of the FD&C Act; 21 CFR 10.20, 10.30, and 314.93",Request for Suitability Petition to file an ANDA for Imatinib Oral Solution 400 mg/5mL instead of tablets,Proposes new dosage form (oral solution) for patients with swallowing difficulties; no change to drug substance or indication :contentReference[oaicite:4]{index=4}.,,,,2025-10-15,0.0,,,,,no decision,False,4908.0,pending,pending
fda-2012-p-1107,FDA-2012-P-1107-0039_OXIPLEX_SP_Gel__FzioMed__Incorporated_s_Petition_f.pdf,2012-11-05,2012,False,original petition,"FzioMed, Inc.",industry/corporation,21 CFR 10.33; 21 CFR 814.44,FDA‚Äôs denial of premarket approval for OXIPLEX,Request for review and reversal of denial of PMA P070023,Argued data show safety and efficacy for indicated use in lumbar spine surgery; challenged FDA‚Äôs evaluation of clinical evidence.,,,2025-10-15,0.0,,,,,no decision,False,4727.0,pending,pending
fda-2012-p-1112,FDA-2012-P-1112-0011_Petition_For_Reconsideration_From_Nobel_Laboratori.pdf,2015-01-22,2012,False,reconsideration,"Nobel Laboratories, LLC",advocacy/academic,21 CFR 314.93,Request to allow ANDA for Fasprofen (fast dissolving ibuprofen tablets) instead of Motrin chewable tablets,"Request based on comparable dosage, administration route, therapeutic effect, and published clinical evidence.",,,,2025-10-15,0.0,,,,,no decision,False,3919.0,pending,pending
fda-2012-p-0764,FDA-2012-P-0764-0001_The_Joseph_Dedvukaj_Firm_PC_Citizen_Petition.pdf,2012-07-12,2012,False,original petition,"The Joseph Dedvukaj Firm, P.C.",law/consulting,21 C.F.R. ¬ß 10.30,FDA approval of Qnexa (Vivus obesity drug),Request FDA to reject or issue Complete Response Letter (CRL) for Qnexa,"Incomplete teratogenicity risk data, cardiovascular risk concerns, insufficient final data from FORTRESS study.",,,2025-10-15,0.0,,,,,no decision,False,4843.0,pending,pending
fda-2012-p-0695,FDA-2012-P-0695-0001_Lorillard_Tobacco_Company__Citizen_Petition.pdf,2012-06-26,2012,False,original petition,Lorillard Tobacco Company,industry/corporation,"21 U.S.C. ¬ß¬ß 387e(j), 387j; 21 C.F.R. ¬ß 10.30",Marketing authorization for new tobacco products,Request FDA to exercise enforcement discretion allowing marketing during SE Report review,Argument based on delays in FDA review process and need for regulatory flexibility for new tobacco products.,,,2025-10-15,0.0,,,,,no decision,False,4859.0,pending,pending
fda-2012-p-1091,FDA-2012-P-1091-0001_Valeant_Pharmaceuticals_International_Inc_Covingto.pdf,2012-10-31,2012,False,original petition,"Valeant Pharmaceuticals International, Inc.",industry/corporation,21 C.F.R. ¬ß 10.30,Withdrawal of certain generic approvals of bupropion XL 300 mg,Require new bioequivalence studies; withdraw approval if necessary,Concerns about non-bioequivalence of generics to Wellbutrin XL 300 mg and patient safety risks.,,,2025-10-15,0.0,,,,,no decision,False,4732.0,pending,pending
fda-2012-p-0872,FDA-2012-P-0872-0001_Handcrafted_Soapmakers_Guild_Inc.pdf,2012-05-14,2012,False,original petition,"Handcrafted Soapmakers Guild, Inc.",advocacy/academic,15 U.S.C. ¬ß1454; 21 CFR Part 701.12,Labeling rules for place of business on cosmetic labels,Amend regulation to allow use of PO Box instead of street address,"Safety and privacy concerns for home-based businesses, changes in data access and communication practices.",,,2025-10-15,0.0,,,,,no decision,False,4902.0,pending,pending
fda-2012-p-0549,FDA-2012-P-0549-0003_Anatase_Biopharmaceutic_Consulting_LLC__Letter.pdf,2012-10-22,2012,False,original petition,Anatase Biopharmaceutic Consulting LLC,law/consulting,21 CFR 10.30 (by reference),Change of address for correspondence,,N/A (letter is only an address update for prior petition),,,2025-10-15,0.0,,,,,no decision,False,4741.0,pending,pending
fda-2012-p-0854,FDA-2012-P-0854-0001_B_Braun_Medical_Inc__Citizen_Petition.pdf,2012-08-02,2012,False,original petition,B. Braun Medical Inc.,industry/corporation,"21 CFR 10.30, 314.93",Designation of Lactated Ringer‚Äôs (Hospira) under ANDA 19-416 as RLD,Request FDA to designate Hospira‚Äôs product as the RLD for Lactated Ringer‚Äôs Irrigation,Supports safe substitution; historic NDA status; minimizes regulatory ambiguity.,,,2025-10-15,0.0,,,,,no decision,False,4822.0,pending,pending
fda-2012-p-0935,FDA-2012-P-0935-0001_Lachman_Consultant_Services_Inc_Citizen_Petition.pdf,2012-08-27,2012,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"21 CFR 10.30, 314.93",Tadalafil Tablets 40 mg ANDA suitability petition,Request FDA to permit ANDA submission for 40 mg strength,Convenience of dosing; reduce medication errors; aligns with FDA's previous recommendations regarding strength.,,,2025-10-15,0.0,,,,,no decision,False,4797.0,pending,pending
fda-2012-p-0940,FDA-2012-P-0940-0001_Alpharma_LLC_a_Subsidiary_of_Pfizer_Inc_Citizen_Pe.pdf,2012-08-28,2012,False,original petition,Alpharma LLC (subsidiary of Pfizer Inc.),industry/corporation,21 U.S.C. ¬ß 360b(n)(3) (Section 512(n)(3) of FDCA),Suitability petition for generic Florfenicol granules for swine drinking water,Permit ANADA submission for granules instead of solution,"Cost efficiency, ease of transport, same therapeutic effectiveness compared to pioneer solution product.",,,2025-10-15,0.0,,,,,no decision,False,4796.0,pending,pending
fda-2012-p-0826,FDA-2012-P-0826-0001_Lachman_Consultant_Services_Inc__Citizen_Petition.pdf,2012-07-27,2012,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"21 CFR 10.30, 314.93",Suitability petition for Sitagliptin and Metformin ER Tablets 50 mg/850 mg,Declare suitability for ANDA submission,Provides additional dosing flexibility while maintaining dosage safety and efficacy ranges of the RLD (Janumet XR).,,,2025-10-15,0.0,,,,,no decision,False,4828.0,pending,pending
fda-2012-p-0964,FDA-2012-P-0964-0001_Lannett_Company_Inc_Citizen_Petition.pdf,2012-09-05,2012,False,original petition,"Lannett Company, Inc.",industry/corporation,21 CFR ¬ß 314.93,Request to allow ANDA submission for lower acetaminophen strength Hydrocodone Bitartrate/Acetaminophen tablets,"Permit ANDAs for 2.5/250 mg, 3.75/250 mg, 5/250 mg, and 3.75/325 mg strengths",Supports safer acetaminophen dosing per FDA acetaminophen policy; therapeutic equivalence maintained.,,,2025-10-15,0.0,,,,,no decision,False,4788.0,pending,pending
fda-2012-p-0299,FDA-2012-P-0299-0005_Front_Range_Equine_Rescue_FRER_and_The_Humane_Soci.pdf,2012-08-24,2012,False,original petition,Front Range Equine Rescue and The Humane Society of the United States,advocacy/academic,"21 CFR Part 10 (general); Food, Drug, and Cosmetic Act sections addressing adulteration",Prohibit sale of horse meat from U.S. horses for human consumption,Health risks from untraceable drug exposure in horses not raised for food; FDA warning letters cited as evidence.,,,,2025-10-15,0.0,,,,,no decision,False,4800.0,pending,pending
fda-2012-p-0496,FDA-2012-P-0496-0004_Cumberland_Pharmaceuticals_Inc__Amendment.pdf,2012-07-09,2012,False,original petition,Cumberland Pharmaceuticals Inc.,industry/corporation,21 CFR 314.93,Request to allow ANDA for lactulose crystals 10g and 20g for treatment of portal systemic encephalopathy,Permit ANDA using liquid lactulose RLD; dosage form change justified by equivalent clinical effect and precedent.,,,,2025-10-15,0.0,,,,,no decision,False,4846.0,pending,pending
fda-2012-p-0260,FDA-2012-P-0260-0024_Fisher_Wallace___CP_Amendment__2.pdf,2017-01-17,2012,False,original petition,"Fisher Wallace Laboratories, LLC",advocacy/academic,21 CFR Part 10 (by reference),FDA reclassification and regulatory actions regarding Cranial Electrotherapy Stimulators (CES),Request reconsideration of CES device reclassification; challenge findings of OSI report,Alleged bias and irregularities in FDA proceedings; insufficient investigation of concerns raised in original petition.,,,2025-10-15,0.0,,,,,no decision,False,3193.0,pending,pending
fda-2012-p-0986,FDA-2012-P-0986-0003_Sheppard_Mullin_Richter_Hampton_LLP_Supplement.pdf,2013-02-06,2012,False,original petition,Sheppard Mullin Richter & Hampton LLP,law/consulting,"21 C.F.R. ¬ß¬ß 10.30, 314.93 (supplementing original petition)","ANDA suitability for Atropine Sulfate Injection, 1.0 mg/mL (Glass Ampules)",Amend prior citizen petition to revise labeling and address FDA comments,"Revised pediatric labeling, corrected description inconsistencies, addressed excipient matching, and dosage calculations to align with RLD standards.",,,2025-10-15,0.0,,,,,no decision,False,4634.0,pending,pending
fda-2012-p-0617,FDA-2012-P-0617-0001_Combination_Products_Coalition_CPC_Esptein_Becker_.pdf,2012-06-08,2012,False,original petition,"Combination Products Coalition (via Epstein Becker & Green, P.C.)",law/consulting,21 C.F.R. ¬ß 10.20,Transparency and guidance improvements for FDA's handling of combination products,"Streamline guidance processes, publish more regulatory decisions, and enhance stakeholder engagement","Improve regulatory efficiency, public access, and support innovation in combination products.",,,2025-10-15,0.0,,,,,no decision,False,4877.0,pending,pending
fda-2012-p-0647,FDA-2012-P-0647-0001_Laboratorios_SALVAT_SA_Fish_and_Richardson_PC_Citi.pdf,2012-06-19,2012,False,original petition,"Laboratorios SALVAT, S.A. (via Fish & Richardson P.C.)",law/consulting,21 U.S.C. ¬ß 355; 21 C.F.R. ¬ß 314,Refusal of ANDAs proposing non-sterile generics citing CETRAXAL¬Æ,Prevent approval of non-sterile generics based on labeling and safety risks,Differences in sterility would require improper label changes; risk of middle ear infections in patients.,,,2025-10-15,0.0,,,,,no decision,False,4866.0,pending,pending
fda-2012-p-1112,FDA-2012-P-1112-0001_Nobel_Laboratories_LLC_Citizen_Petition.pdf,2012-10-21,2012,False,original petition,"Nobel Laboratories, LLC",advocacy/academic,21 CFR ¬ß 314.93,"ANDA suitability petition for Fasprofen, Orally Disintegrating Tablets 100 mg",Allow ANDA for orally disintegrating form of Motrin 100 mg chewable tablets,Provides alternative dosage form for ease of use; similar absorption profile; maintains therapeutic effect.,,,2025-10-15,0.0,,,,,no decision,False,4742.0,pending,pending
fda-2012-p-0549,FDA-2012-P-0549-0001_Anatase_Biopharmaceutic_Consulting_LLC_Citizen_Pet.pdf,2012-05-24,2012,False,original petition,Anatase Biopharmaceutic Consulting LLC,law/consulting,21 U.S.C. ¬ß 355,Prevent approval of Calcitriol Capsule generics not demonstrating fasting and fed bioequivalence,Request FDA to require BE studies under fasting and fed conditions for therapeutic equivalence,Safety risks if bioequivalence not properly demonstrated under different physiological conditions.,,,2025-10-15,0.0,,,,,no decision,False,4892.0,pending,pending
fda-2012-p-1127,FDA-2012-P-1127-0001_Onco_Therapies_Limited_Strides_Inc_Citizen_Petitio.pdf,2012-11-07,2012,False,original petition,Onco Therapies Limited / Strides Inc.,industry/corporation,"21 CFR 10.30, Section 505(j)(2)(C) of FDCA","Request for ANDA suitability for Docetaxel Injection, 20 mg/mL in 8 mL fill",Seek designation of Accord Healthcare‚Äôs product (N201195) as RLD to allow ANDA submission,Product is qualitatively and quantitatively the same; request full waiver of pediatric study requirements.,,,2025-10-15,0.0,,,,,no decision,False,4725.0,pending,pending
fda-2012-p-1058,FDA-2012-P-1058-0001_Lachman_Consultant_Sevices_Inc_Citizen_Petition.pdf,2012-10-10,2012,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"21 CFR 10.30, Section 505(j)(2)(C) of FDCA","Request ANDA suitability for Mefenamic Acid Capsules, USP, 500 mg",Change in strength from RLD (PONSTEL¬Æ 250 mg) justified by labeling dosage instructions,Single 500 mg capsule improves dosing accuracy and compliance.,,,2025-10-15,0.0,,,,,no decision,False,4753.0,pending,pending
fda-2012-p-1029,FDA-2012-P-1029-0001_Citizen_Petition_from_Lachman_Consultant_Services_.pdf,2012-09-24,2012,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"21 CFR 10.30, Section 505(j)(2)(C) of FDCA","Request ANDA suitability for Valrubicin Solution for Intravesical Instillation, 800 mg/20 mL vial",Increase in total drug content (same concentration) justified to improve convenience and reduce waste,"Same concentration, route, inactive ingredients; lower contamination risk.",,,2025-10-15,0.0,,,,,no decision,False,4769.0,pending,pending
fda-2012-p-0997,FDA-2012-P-0997-0001_Sheppard_Mullin_Richter_Hampton_LLP_Citizen_Petiti.pdf,2012-09-14,2012,False,original petition,Sheppard Mullin Richter & Hampton LLP,law/consulting,"21 CFR 10.30, 314.93",Request ANDA suitability for Magnesium Sulfate Injection 50% in 2 mL and 10 mL glass vials,Change from plastic to glass containers for Magnesium Sulfate Injection NDA 019316,Container material change poses no safety issues; meets USP standards.,,,2025-10-15,0.0,,,,,no decision,False,4779.0,pending,pending
fda-2012-p-0945,FDA-2012-P-0945-0001_Center_for_Regulatory_Servics__Inc__Citizen_Petiti.pdf,2012-08-29,2012,False,original petition,"Center for Regulatory Services, Inc.",law/consulting,"21 CFR 10.30, Section 512(n)(3)(A) of FDCA (Animal Drug)",Request ANADA suitability for Pimobendan 10 mg chewable tablets for dogs,Provides dosing convenience for large dogs; maintains proportional composition and therapeutic equivalence.,,,,2025-10-15,0.0,,,,,no decision,False,4795.0,pending,pending
fda-2012-p-0904,FDA-2012-P-0904-0001_Citizen_for_Health_Citizen_Petition.pdf,2012-08-15,2012,False,original petition,Citizens for Health,individual,"21 U.S.C. 321(s), 342, 348, and 371",Regulation of high fructose corn syrup concentrations above 55%,Request amendments to 21 CFR 184.1866 to require labeling of fructose concentration; enforcement against non-GRAS HFCS products,"Consumer protection, prevent mislabeling, uphold GRAS safety standards.",,,2025-10-15,0.0,,,,,no decision,False,4809.0,pending,pending
fda-2012-p-1147,FDA-2012-P-1147-0001_Foley_Lardner_LLP_Citizen_Petition.pdf,2012-11-13,2012,False,original petition,Foley & Lardner LLP (on behalf of client),law/consulting,"21 CFR 10.30, 314.93","Request ANDA suitability for Dexmedetomidine Hydrochloride Injection, 400 mcg/4 mL vial",Allow different fill volume (not concentration change) compared to PRECEDEX¬Æ,No changes to strength or safety profile; improved convenience for healthcare providers.,,,2025-10-15,0.0,,,,,no decision,False,4719.0,pending,pending
fda-2012-p-0989,FDA-2012-P-0989-0001_Sheppard_Mullin_Richter_Hampton_LLP_Citizen_Petiti.pdf,2012-09-13,2012,False,original petition,Sheppard Mullin Richter & Hampton LLP,law/consulting,"21 CFR 10.30, 314.93","Request ANDA suitability for Sodium Acetate Injection, USP 2 mEq/mL in 20 mL glass vial",Change container material from plastic to glass for existing RLD,Glass containers are more stable; no safety or efficacy concerns; no bioequivalence testing needed&#8203;:contentReference[oaicite:0]{index=0}.,,,2025-10-15,0.0,,,,,no decision,False,4780.0,pending,pending
fda-2012-p-0982,FDA-2012-P-0982-0001_Sheppard_Mullin_Richter_and_Hampton_LLP_Citizen_Pe.pdf,2012-09-13,2012,False,original petition,Sheppard Mullin Richter & Hampton LLP,law/consulting,"21 CFR 10.30, 314.93","Request ANDA suitability for Sodium Acetate Injection, USP 4 mEq/mL",Approval to file ANDA for new strength and volume (glass vial) vs RLD,"Improves convenience, reduces waste, no safety concerns&#8203;:contentReference[oaicite:0]{index=0}.",,,2025-10-15,0.0,,,,,no decision,False,4780.0,pending,pending
fda-2012-p-0906,FDA-2012-P-0906-0001_Lachman_Consultant_Services_Inc.pdf,2012-08-15,2012,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,21 CFR 10.30,Request to designate Absorica‚Ñ¢ as separate RLD for isotretinoin capsules,Allow ANDAs referencing Absorica due to bioavailability differences from Amnesteem‚Ñ¢,Absorica not bioequivalent to Amnesteem‚Ñ¢ under fasting conditions&#8203;:contentReference[oaicite:1]{index=1}.,,,2025-10-15,0.0,,,,,no decision,False,4809.0,pending,pending
fda-2012-p-0698,FDA-2012-P-0698-0001_Lachman_Consultant_Services_Inc_Citizen_Petition.pdf,2012-06-27,2012,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,Section 505(j)(2)(C) of the FD&C Act; 21 CFR 10.30 and 314.93,"Request for suitability determination to submit an ANDA for Metoprolol Succinate Extended-release Tablets, 12.5 mg",Provide an accurate 12.5 mg tablet strength for heart failure patients instead of requiring tablet splitting :contentReference[oaicite:0]{index=0}.,,,,2025-10-15,0.0,,,,,no decision,False,4858.0,pending,pending
fda-2012-p-0496,FDA-2012-P-0496-0001_Cumberland_Pharmaceuticals_Inc_Citizen_Petition.pdf,2012-05-17,2012,False,original petition,Cumberland Pharmaceuticals Inc.,industry/corporation,"Section 505(j)(2)(C) of the FD&C Act; 21 CFR 10.30, 314.93",Request for permission to file an ANDA for lactulose crystals (KRISTALOSE¬Æ) based on ENULOSE¬Æ Liquid RLD,Proposed reconstitution to oral solution preserves intended use and efficacy; crystals offer dosing flexibility :contentReference[oaicite:1]{index=1}.,,,,2025-10-15,0.0,,,,,no decision,False,4899.0,pending,pending
fda-2012-p-0992,FDA-2012-P-0992-0001_Sheppard_Mullin_Richter_Hampton_LLP_Citizen_Petiti.pdf,2012-09-13,2012,False,original petition,Sheppard Mullin Richter & Hampton LLP,law/consulting,Section 505(j)(2)(C) of the FD&C Act; 21 CFR 10.30 and 314.93,"ANDA Suitability Petition for Potassium Acetate Injection, USP, 4 mEq/mL, 50 mL glass vial",Change strength and container from 2 mEq/mL 20 mL plastic vial to 4 mEq/mL 50 mL glass vial to improve hospital convenience :contentReference[oaicite:2]{index=2}.,,,,2025-10-15,0.0,,,,,no decision,False,4780.0,pending,pending
fda-2012-p-0994,FDA-2012-P-0994-0001_Sheppard_Mullin_Richter_Hampton_LLP_Citizen_Petiti.pdf,2012-09-13,2012,False,original petition,Sheppard Mullin Richter & Hampton LLP,law/consulting,Section 505(j)(2)(C) of the FD&C Act; 21 CFR 10.30 and 314.93,"ANDA Suitability Petition for Sodium Acetate Injection, USP, 2 mEq/mL, 100 mL glass vial",Request to submit ANDA for larger volume glass vial version of Sodium Acetate to reduce waste :contentReference[oaicite:0]{index=0}.,,,,2025-10-15,0.0,,,,,no decision,False,4780.0,pending,pending
fda-2012-p-0153,FDA-2012-P-0153-0001_Intertek_Citizen_Petition.pdf,2012-02-10,2012,False,original petition,Intertek,individual,Section 523 of the FD&C Act; 21 CFR 10.30,Request FDA to refrain from dismissing Intertek as Accredited Person for 510(k) Review without due process,Request reinstatement as Accredited Person and completion of Biophotas 510(k) review :contentReference[oaicite:0]{index=0}.,,,,2025-10-15,0.0,,,,,no decision,False,4996.0,pending,pending
fda-2012-p-1034,FDA-2012-P-1034-0001_Lachman_Consultant_Sevices_Inc_Citizen_Petition.pdf,2012-09-27,2012,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,21 CFR 10.30 and 314.161,Request for determination whether SUBOXONE Sublingual Tablets were withdrawn for safety or effectiveness,Request supports approval of ANDAs referencing SUBOXONE tablets :contentReference[oaicite:1]{index=1}.,,,,2025-10-15,0.0,,,,,no decision,False,4766.0,pending,pending
fda-2012-p-0478,FDA-2012-P-0478-0001_Xspire_Pharma_LLC_Citizen_Petition.pdf,2012-05-07,2012,False,original petition,"Xspire Pharma, LLC",industry/corporation,Section 505(j)(2)(C) of the FD&C Act; 21 CFR 314.93,ANDA Suitability Petition for reformulated Pentazocine and Acetaminophen tablets,Request to allow ANDA submission for Acetaminophen 312.5 mg and Pentazocine Hydrochloride 25 mg tablets to comply with acetaminophen limits :contentReference[oaicite:0]{index=0}.,,,,2025-10-15,0.0,,,,,no decision,False,4909.0,pending,pending
fda-2012-p-1251,FDA-2012-P-1251-0001_Gordon_Johnston_Regulatory_Consultants_LLC_Citizen.pdf,2012-12-17,2012,False,original petition,"Gordon Johnston Regulatory Consultants, LLC",law/consulting,Section 505(j)(2)(C) of the FD&C Act; 21 CFR 10.30,"Request ANDA suitability for Morphine Sulfate Injection USP, 5 mg/mL, single-use vial",Intermediate strength requested for better dosing flexibility compared to 4 mg/mL RLD :contentReference[oaicite:2]{index=2}.,,,,2025-10-15,0.0,,,,,no decision,False,4685.0,pending,pending
fda-2012-p-0497,FDA-2012-P-0497-0001_Piedmont_Animal_Health_Citizen_Petition.pdf,2012-05-17,2012,False,original petition,Piedmont Animal Health,individual,Section 512(n)(3) of the FD&C Act,"ANDA Suitability Petition for a generic soft chewable form of enrofloxacin differing in texture, hardness, and size from Baytril¬Æ Taste Tabs¬Æ :contentReference[oaicite:0]{index=0}.",,,,,2025-10-15,0.0,,,,,no decision,False,4899.0,pending,pending
fda-2012-p-1158,FDA-2012-P-1158-0001_Milagros_Demier_Citizen_Petition.pdf,2012-11-20,2012,False,original petition,Milagros Demier,individual,21 CFR 10.30,Petition to deny release of genetically modified mosquitoes in Key West,"Cites environmental, health, and economic risks if GM mosquitoes are released :contentReference[oaicite:0]{index=0}.",,,,2025-10-15,0.0,,,,,no decision,False,4712.0,pending,pending
fda-2012-p-0775,FDA-2012-P-0775-0001_Xspire_Pharma_LLC_Citizen_Petition.pdf,2012-07-12,2012,False,original petition,"Xspire Pharma, LLC",industry/corporation,21 CFR 314.93,"Request to file ANDA for Acetaminophen, Caffeine, Dihydrocodeine Bitartrate Tablets with reduced acetaminophen content (312.5 mg) to comply with FDA safety guidance :contentReference[oaicite:1]{index=1}.",,,,,2025-10-15,0.0,,,,,no decision,False,4843.0,pending,pending
fda-2012-p-0497,FDA-2012-P-0497-0001_Piedmont_Animal_Health_Citizen_Petition.pdf,2012-05-17,2012,False,original petition,Piedmont Animal Health,individual,Section 512(n)(3) of the FD&C Act,ANDA Suitability Petition for generic enrofloxacin soft chewable differing in texture and hardness :contentReference[oaicite:2]{index=2}.,,,,,2025-10-15,0.0,,,,,no decision,False,4899.0,pending,pending
fda-2012-p-0458,FDA-2012-P-0458-0001_Lachman_Consultant_Services_Inc_Citizen_Petition.pdf,2012-05-07,2012,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,21 CFR 10.30 and 314.161,"Request FDA to determine whether Aloxi¬Æ (palonosetron hydrochloride) Capsules, 0.5 mg were withdrawn for reasons of safety or effectiveness :contentReference[oaicite:0]{index=0}.",,,,,2025-10-15,0.0,,,,,no decision,False,4909.0,pending,pending
fda-2012-p-1179,FDA-2012-P-1179-0001_Jack_M_Saroyan_DDS_Citizen_Petition.pdf,2012-11-24,2012,False,original petition,"Jack M. Saroyan, DDS",individual,21 CFR 10.30,Request to permit addition of fluoride to iodized table salt to prevent iodine deficiency and dental caries :contentReference[oaicite:1]{index=1}.,,,,,2025-10-15,0.0,,,,,no decision,False,4708.0,pending,pending
fda-2012-p-1104,FDA-2012-P-1104-0001_Lachman_Consultant_Services_Inc_Citizen_Petition.pdf,2012-11-02,2012,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,21 CFR 10.30 and 314.161,Request FDA determination whether Juvisync‚Ñ¢ (sitagliptin and simvastatin) Tablets (various strengths) were withdrawn for safety or effectiveness reasons :contentReference[oaicite:0]{index=0}.,,,,,2025-10-15,0.0,,,,,no decision,False,4730.0,pending,pending
fda-2012-p-0607,FDA-2012-P-0607-0001_AIDS_Healthcare_Foundation_AHF_Citizen_Petition.pdf,2012-06-08,2012,False,original petition,AIDS Healthcare Foundation (AHF),advocacy/academic,Section 505(q) of the FD&C Act; 21 CFR 10.30,Request FDA not rely on Antiviral Drugs Advisory Committee's recommendation regarding Gilead‚Äôs Truvada¬Æ for PrEP; request reconvening a fairly balanced committee :contentReference[oaicite:0]{index=0}.,,,,,2025-10-15,0.0,,,,,no decision,False,4877.0,pending,pending
fda-2012-p-1071,FDA-2012-P-1071-0001_Law_Office_of_Alvin_J_Lorman_Citizen_Petition.pdf,2012-10-12,2012,False,original petition,Law Office of Alvin J. Lorman,law/consulting,21 CFR 10.30 and 314.122,Request FDA determination that Geref (sermorelin acetate) NDA No. 020443 was withdrawn for reasons other than safety or efficacy :contentReference[oaicite:1]{index=1}.,,,,,2025-10-15,0.0,,,,,no decision,False,4751.0,pending,pending
fda-2012-p-0895,FDA-2012-P-0895-0003_Endo_Pharmaceuticals_Inc_Supplement.pdf,2012-11-13,2012,False,original petition,Endo Pharmaceuticals Inc.,industry/corporation,21 CFR 10.30,Supplement to Citizen Petition providing confidential attachments regarding Opana ER reformulation and abuse data :contentReference[oaicite:0]{index=0}.,,,,,2025-10-15,0.0,,,,,no decision,False,4719.0,pending,pending
fda-2012-p-0916,FDA-2012-P-0916-0001_Call_Inc_dba_Rochester_Pharmaceuticals_Ei_Inc__Cit.pdf,2012-08-16,2012,False,original petition,Call Inc. (dba Rochester Pharmaceuticals) via Ei Inc.,industry/corporation,"Section 505(j)(2)(C) of the FD&C Act; 21 CFR 10.20, 10.30, 314.122",Request FDA determination that Differin‚Ñ¢ (adapalene solution) 0.1% was not withdrawn for safety or effectiveness; enable ANDA submission :contentReference[oaicite:0]{index=0}.,,,,,2025-10-15,0.0,,,,,no decision,False,4808.0,pending,pending
fda-2012-p-0431,FDA-2012-P-0431-0001_Alcon_Research_Ltd_Citizen_Petition.pdf,2012-05-01,2012,False,original petition,Alcon Research Ltd.,advocacy/academic,Section 505(a) of the FD&C Act; 21 CFR 10.30,Request FDA to take enforcement action against unapproved pilocarpine HCl ophthalmic solutions competing with ISOPTO¬Æ Carpine products :contentReference[oaicite:0]{index=0}.,,,,,2025-10-15,0.0,,,,,no decision,False,4915.0,pending,pending
fda-2012-p-1189,FDA-2012-P-1189-0012_Bee_Chicken_of_the_Sea_Starkist__TMP_Application_A.pdf,2012-02-02,2012,False,original petition,"Bumble Bee Foods, LLC; StarKist Co.; Tri-Union Seafoods, LLC",industry/corporation,21 CFR 130.17,"Amendment to Temporary Marketing Permit Application for canned tuna deviating from identity standard by using drained weight rather than pressed cake weight, and requesting exemption from substandard fill labeling :contentReference[oaicite:0]{index=0}.",,,,,2025-10-15,0.0,,,,,no decision,False,5004.0,pending,pending
fda-2012-p-1259,FDA-2012-P-1259-0001_Hyman_Phelps_McNamara_PC_Citizen_Petition.pdf,2012-12-21,2012,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,Section 505(j)(2)(C) of the FD&C Act; 21 CFR 314.93,"Request FDA approval to file an ANDA for Pemetrexed Disodium for Injection, 750 mg/vial, based on change in strength from ALIMTA 500 mg/vial :contentReference[oaicite:0]{index=0}.",,,,,2025-10-15,0.0,,,,,no decision,False,4681.0,pending,pending
fda-2012-p-0462,FDA-2012-P-0462-0001_Douglass_Oeller_Consulting_Inc_Citizen_Petition.pdf,2012-05-07,2012,False,original petition,"Douglass Oeller Consulting, Inc.",law/consulting,Section 512(n)(3) of the FD&C Act,Request permission to file an ANADA for a generic hyaluronate sodium injection for horses with different strength (17 mg/mL) and packaging (pre-filled syringe) compared to pioneer Legend¬Æ (10 mg/mL vials) :contentReference[oaicite:1]{index=1}.,,,,,2025-10-15,0.0,,,,,no decision,False,4909.0,pending,pending
fda-2012-p-0916,FDA-2012-P-0916-0003_Call_Inc_dba_Rochester_Pharmaceuticals_Ei_Inc__Ame.pdf,2012-08-23,2012,False,original petition,Call Inc. (dba Rochester Pharmaceuticals) via Ei Inc.,industry/corporation,21 CFR 10.30 and 314.122,Request FDA determination whether Differin (adapalene solution) 0.1% was withdrawn for reasons other than safety or effectiveness :contentReference[oaicite:2]{index=2}.,,,,,2025-10-15,0.0,,,,,no decision,False,4801.0,pending,pending
fda-2012-p-1043,FDA-2012-P-1043-0001_Foley_Lardner_LLP_Citizen_Petition.pdf,2012-10-02,2012,False,original petition,Foley & Lardner LLP,law/consulting,"21 CFR 10.30, 314.93",Request FDA to designate Medefil‚Äôs Sodium Chloride Injection in prefilled syringes as a second RLD,Facilitate generic competition for prefilled syringe format; same active ingredient and concentration&#8203;:contentReference[oaicite:0]{index=0}.,,,,2025-10-15,0.0,,,,,no decision,False,4761.0,pending,pending
fda-2012-p-1180,FDA-2012-P-1180-0001_Lannett_Company_Inc_Citizen_Petition.pdf,2012-11-26,2012,False,original petition,"Lannett Company, Inc.",industry/corporation,21 CFR 314.93,Request ANDA suitability for Oxycodone Hydrochloride Extended-Release Capsules (instead of tablets),"Request based on solid oral dosage similarity, expected therapeutic equivalence&#8203;:contentReference[oaicite:0]{index=0}.",,,,2025-10-15,0.0,,,,,no decision,False,4706.0,pending,pending
fda-2012-p-1104,FDA-2012-P-1104-0003_Lachman_Consultant_Services_Inc.pdf,2012-12-17,2012,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"21 CFR 10.30, Section 505(j)(2)(C)",Withdrawal of petition regarding Juvisync (sitagliptin/simvastatin) NDA marketing status,Withdrawn because products commenced marketing&#8203;:contentReference[oaicite:0]{index=0}.,,,,2025-10-15,0.0,,,,,no decision,False,4685.0,pending,pending
fda-2012-p-0915,FDA-2012-P-0915-0004_Sunovion_Pharmaceticals_Inc_Covington__Burling_LLP.pdf,2012-08-30,2012,False,original petition,"Sunovion Pharmaceuticals, Inc. (via Covington & Burling LLP)",law/consulting,21 CFR 10.30,Request to withdraw previously filed citizen petition and confidential supplement,Withdrawal of August 16 and August 21 submissions after superseding filing&#8203;:contentReference[oaicite:0]{index=0}.,,,,2025-10-15,0.0,,,,,no decision,False,4794.0,pending,pending
fda-2012-p-1180,FDA-2012-P-1180-0003_Lannett_Co_Inc_Amendment_to_Suitability_Petition.pdf,2012-12-17,2012,False,original petition,"Lannett Company, Inc.",industry/corporation,21 CFR 10.30 (Amendment),Amendment to earlier suitability petition regarding Oxycodone ER Capsules,Provides PREA waiver request; clarifies tamper-resistance compliance; removes bioequivalence determination request&#8203;:contentReference[oaicite:1]{index=1}.,,,,2025-10-15,0.0,,,,,no decision,False,4685.0,pending,pending
fda-2012-p-1034,FDA-2012-P-1034-0004_Reference_1_Further_US_RB_Pharmaceuticals_Announce.pdf,2012-09-25,2012,False,original petition,Reckitt Benckiser Pharmaceuticals Inc.,industry/corporation,21 CFR 10.30,"Request FDA to mandate pediatric safety measures for buprenorphine products (unit-dose packaging, educational campaigns)",Based on increased pediatric exposures with Suboxone Tablets compared to Film; child-safety packaging reduces risk&#8203;:contentReference[oaicite:0]{index=0}.,,,,2025-10-15,0.0,,,,,no decision,False,4768.0,pending,pending
fda-2012-p-1189,FDA-2012-P-1189-0009_Canned_Tuna_Deviating_From_Identity_Standard__Temp.pdf,2014-08-27,2012,False,original petition,"Bumble Bee Foods, LLC",industry/corporation,21 CFR 130.17,Label approvals for canned tuna products under Temporary Market Permit; certain products discontinued :contentReference[oaicite:0]{index=0}.,,,,,2025-10-15,0.0,,,,,no decision,False,4067.0,pending,pending
fda-2012-p-1028,FDA-2012-P-1028-0010_Safety_Concerns_Regarding_Buprenorphine_for_Opioid.pdf,2012-11-20,2012,False,original petition,Reckitt Benckiser (referenced by FDA),other,21 CFR 10.30,Safety concerns related to accidental pediatric exposure to buprenorphine products,Request clarification and evaluation of pediatric risks,Concerns about pediatric exposure and lack of safeguards :contentReference[oaicite:0]{index=0}.,,,2025-10-15,0.0,,,,,no decision,False,4712.0,pending,pending
fda-2013-p-0025,FDA-2013-P-0025-0001_Citizen_Petition_from_Teva_Pharmaceutical_Industri.pdf,,2013,False,original petition,"Teva Pharmaceutical Industries Ltd. and Teva Neuroscience, Inc.",industry/corporation,"21 C.F.R. ¬ß 10.30, 21 U.S.C. ¬ß 355(b), 21 U.S.C. ¬ß 355(s)",The petitioner is commenting on FDA‚Äôs process of approving new drugs for the treatment of multiple sclerosis (MS) without prior review by the Peripheral and Central Nervous System Advisory Committee (PCNS Advisory Committee).,"The petitioner requests that FDA refrain from approving any full New Drug Application (NDA) or Biologics License Application (BLA) for new MS treatments unless and until the FDA has referred the product to, and considered the recommendations of, the PCNS Advisory Committee.","The petitioner justifies the request by arguing that MS is a complex, immune-mediated disorder, and serious safety issues with new MS treatments (e.g., Tysabri, Gilenya) were identified only after widespread use. Therefore, advisory committee review is necessary to thoroughly evaluate the risks and benefits of new MS drugs before approval, in line with statutory requirements and to protect public health.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0027,FDA-2013-P-0027-0001_Custo_Pharm_Inc__Citizen_Petiton.pdf,,2013,False,original petition,"Custo Pharm, Inc.",industry/corporation,"21 C.F.R. ¬ß 10.20, 21 C.F.R. ¬ß 10.30, 21 C.F.R. ¬ß 314.93, 21 C.F.R. ¬ß 25.31",The petitioner is commenting on the need to update the FDA‚Äôs Orange Book listing to establish a new Reference Listed Drug (RLD) for Midodrine Hydrochloride Tablets following the discontinuation of Proamatine (NDA 19815).,"The petitioner requests that the FDA designate Impax Pharmaceutical‚Äôs Midodrine Hydrochloride Tablets, ANDA 076449, as the RLD to facilitate the submission of ANDAs for generic versions of Midodrine Hydrochloride Tablets.","The petitioner justifies the request by stating that the original RLD, Proamatine, has been discontinued, and among the current products on the market, Impax's product was the first approved ANDA and remains available. Without designating a new RLD, the market would be shielded from generic competition, limiting availability and access to Midodrine Hydrochloride Tablets.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0028,FDA-2013-P-0028-0001_Custo_Pharm_Inc_Citizen_Petition.pdf,,2013,False,original petition,"Custo Pharm, Inc.",industry/corporation,"21 C.F.R. ¬ß 10.20, 21 C.F.R. ¬ß 10.30, 21 C.F.R. ¬ß 314.93, 21 C.F.R. ¬ß 25.31","The petitioner is commenting on the FDA‚Äôs Orange Book listings, specifically on the establishment of a second reference listed drug (RLD) for Clotrimazole Troche/Lozenge 10 mg.","The petitioner requests that the FDA designate Roxane‚Äôs Clotrimazole Troche, ANDA 076387, as a second RLD for the purpose of facilitating the submission of ANDAs for a generic version of Clotrimazole Troche.","The petitioner justifies the request by explaining that Bayer‚Äôs Mycelex Troche (the current RLD) has been unavailable in the U.S. for many months. Without a second RLD designation, the product could be shielded from generic competition, thus limiting access to generic alternatives.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0040,FDA-2013-P-0040-0001_Lupin_Pharmaceuticals_Inc_Citizen_Petition.pdf,,2013,False,original petition,"Lupin Pharmaceuticals, Inc.",industry/corporation,"21 C.F.R. ¬ß 10.30, 21 C.F.R. ¬ß 314.94, 21 C.F.R. ¬ß 25.31","The petitioner is commenting on the FDA‚Äôs Orange Book listing for Calcium Acetate Capsules, specifically regarding the designation of a Reference Listed Drug (RLD) after the original RLD (PHOSLO Capsules) became unavailable in the market.",The petitioner requests that the FDA amend the Orange Book to designate Roxane‚Äôs Calcium Acetate Capsules as the new Reference Listed Drug (RLD) for Calcium Acetate Capsules.,"The petitioner justifies the request by explaining that PHOSLO Capsules are no longer available in the market since November 2012, and Roxane‚Äôs Calcium Acetate Capsules are approved, rated AB (bioequivalent), and are currently marketed. Designating Roxane‚Äôs product as the RLD would facilitate the continued availability of generic Calcium Acetate products.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0047,FDA-2013-P-0047-0001_American_Heart_Association_AHA_Health_Claim_Petiti.pdf,,2013,False,original petition,The American Heart Association,advocacy/academic,"21 C.F.R. ¬ß 101.70, 21 C.F.R. ¬ß 101.75",The petitioner is commenting on the FDA‚Äôs health claim regulation regarding dietary saturated fat and cholesterol and their relationship to the risk of coronary heart disease.,The petitioner requests that FDA amend the existing health claim regulation at 21 C.F.R. ¬ß 101.75 to update the scientific basis and wording of the claim regarding the relationship between dietary saturated fat and cholesterol intake and the risk of coronary heart disease.,"The petitioner justifies the request by citing advances in scientific understanding since the original regulation was established, arguing that current scientific evidence warrants an updated health claim to better inform consumers about the relationship between diet and heart disease risk.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0048,FDA-2013-P-0048-0001_James_P_Reichmann_Citizen_Petition_Redacted.pdf,,2013,False,original petition,James P. Reichmann,individual,"21 U.S.C. ¬ß 355(e)(3), 21 C.F.R. ¬ß 10.30",The petitioner is commenting on the FDA‚Äôs classification and regulatory approach regarding the pregnancy risk categorization and off-label promotion of ondansetron (Zofran¬Æ) for nausea and vomiting of pregnancy (NVP).,"The petitioner requests that FDA (1) reclassify ondansetron from pregnancy risk category B to category C, D, or X, and (2) notify OB/GYNs that ondansetron has not been proven effective for NVP and that promoting its use via subcutaneous pump without FDA approval violates regulations.","The petitioner justifies the request by citing limited efficacy evidence, concerns over fetal safety (including a reported increased risk of cleft palate), and FDA warnings about serious cardiac side effects (QT prolongation) associated with ondansetron, particularly with higher doses common in subcutaneous pump use.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0058,FDA-2013-P-0058-0001_Gilead_Sciences_Inc_Hogan_Lovells_US_LLP_Citizen_P.pdf,,2013,False,original petition,"Gilead Sciences, Inc.",industry/corporation,"21 C.F.R. 10.30, 21 U.S.C. 355(c)(3)(E)(ii), 21 U.S.C. 355(j)(5)(F)(ii), Hatch-Waxman Act",FDA's historical interpretation of 5-year exclusivity provisions denying exclusivity to fixed dose combinations (FDCs) containing new active moieties with previously approved moieties,Recognize 5-year exclusivity under sections 505(c)(3)(E)(ii) and 505(j)(5)(F)(ii) for each new active moiety in STRIBILD (EVG and COBI); revise FDA‚Äôs Exclusivity Summary and related documents to reflect this interpretation,"FDA‚Äôs historical interpretation is outdated, inconsistent with modern medical practice (especially in treating HIV with FDCs), not mandated by statute or regulation, leads to arbitrary results, and discourages innovation in developing fixed-dose combination therapies; administrative law permits FDA to change its interpretation without formal rulemaking.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0066,FDA-2013-P-0066-0001_Pharmacists_Planning_Services_Inc_Citizen_Petition.pdf,,2013,False,original petition,"Pharmacists Planning Services, Inc. (PPSI)",industry/corporation,"21 C.F.R. ¬ß 10.20, 21 C.F.R. ¬ß 10.30, Federal Food, Drug, and Cosmetic Act","The petitioner is commenting on the FDA's regulation of dietary supplements, specifically requesting action on St. John's Wort (SJW) (Hypericum perforatum) by reclassifying it from a dietary supplement to a drug placed behind the pharmacy counter.","The petitioner requests that FDA remove St. John's Wort from Herbal Dietary Supplement status and reclassify it as a Behind Pharmacy Counter Status (BPCS) drug requiring mandatory consultation, patient history review, identification, and registration.","The petitioner justifies the request by citing numerous drug interactions associated with St. John's Wort, adverse effects like vivid dreams, anxiety, and fatigue, evidence of bans or restrictions in other countries (France, Ireland, Germany), public health risks, poor patient awareness from package inserts, and concerns from professional organizations about the widespread unregulated use of herbal supplements.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0070,FDA-2013-P-0070-0001_Exhibit_A_Letter_to_Robert_Outwater_Ohmeda_Inc_Fro.pdf,,2013,False,original petition,"Ikaria, Inc.",industry/corporation,"21 C.F.R. ¬ß 10.30, Section 505(i) of the Federal Food, Drug, and Cosmetic Act","The petitioner is commenting on the regulatory approval and classification of inhaled nitric oxide (INO) products and devices, based on communications between Ohmeda Inc. and the FDA related to clinical development and regulatory approval pathways.","The petitioner requests that FDA regulate all inhaled nitric oxide drug products and delivery systems under the drug authorities, ensuring that new nitric oxide systems are reviewed and approved through appropriate drug application processes, not solely device pathways.","The petitioner justifies the request by emphasizing that inhaled nitric oxide is a drug requiring rigorous clinical testing, highlighting safety concerns related to gas exposure to patients and healthcare workers, and stressing that regulatory precedent (as seen with Ohmeda‚Äôs development) treated inhaled nitric oxide as a drug requiring an NDA supported by clinical trials and toxicology studies.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0076,FDA-2013-P-0076-0001_Minnesota_Medical_Device_Alliance_MMDA_DuVal_and_A.pdf,,2013,False,original petition,"DuVal & Associates, P.A.",law/consulting,"21 C.F.R. ¬ß 10.30, 21 C.F.R. ¬ß 10.35, 21 U.S.C. ¬ß 360k, 21 C.F.R. ¬ß¬ß 807 Subpart E","Evaluating Substantial Equivalence in Premarket Notifications [510(k)], dated December 27, 2011","Stay implementation of the New 510(k) Guidance, revert to existing 510(k) guidance documents, cease 'stage-gated' reviews, improve training and education for FDA staff, and establish regular dialogue sessions between FDA and industry groups","The petitioner argues that FDA's new practices have altered the 510(k) program without legislative authority, increased regulatory burdens, delayed patient access to innovations, harmed investment and innovation in the U.S. medical device industry, and that FDA has become overly risk-averse, ignoring Least Burdensome requirements and deviating from statutory and regulatory mandates.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0113,FDA-2013-P-0113-0001_IGI_Laboratories_Inc_Citizen_Petition.pdf,,2013,False,original petition,"IGI Laboratories, Inc.",advocacy/academic,"21 U.S.C. ¬ß 355, 21 C.F.R. ¬ß 314.93, 21 C.F.R. ¬ß 314.161","The petitioner is commenting on the FDA's determination regarding whether Cordran (flurandrenolide) Ointment USP, 0.05% was withdrawn from sale for reasons of safety or effectiveness.","The petitioner requests that the FDA determine that Cordran (flurandrenolide) Ointment USP, 0.05% was not withdrawn from sale for reasons of safety or effectiveness.","The petitioner justifies the request by stating that Cordran Ointment was voluntarily discontinued for commercial reasons, not for safety or efficacy concerns. Other formulations of the same active ingredient (Cordran creams and lotion) are still actively marketed, and references to the ointment remain in updated labeling materials, suggesting no underlying safety or effectiveness issues.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0127,FDA-2013-P-0127-0001_Santarus_Inc_Citizen_Petition.pdf,,2013,False,original petition,"Santarus, Inc.",industry/corporation,"Section 505 of the FD&C Act, 21 C.F.R. ¬ß 10.30, 21 C.F.R. ¬ß 320.24, 21 U.S.C. ¬ß 355(j)(8)(C), 21 C.F.R. ¬ß¬ß 25.30 and 25.31",Approval of abbreviated new drug applications (ANDAs) citing Uceris (budesonide) extended release tablets as the reference listed drug without appropriate bioequivalence studies,"Develop and publish a product-specific bioequivalence recommendation for budesonide extended release tablets (Uceris) and refrain from approving any ANDA for Uceris until generics demonstrate bioequivalence through specific studies including clinical endpoint studies, alternative PK testing, in vitro dissolution testing at multiple pHs, and pharmacoscintigraphy studies","Santarus argues that Uceris has unique delivery properties critical to its safety and efficacy (colon-targeted, extended release), and that standard bioequivalence testing methods (relying solely on PK measures) are inadequate. They request enhanced testing requirements to ensure generics match Uceris in delivering budesonide throughout the colon to treat ulcerative colitis effectively.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0148,FDA-2013-P-0148-0001_Crowell_and_Moring_LLP_Citizen_Petition.pdf,,2013,False,original petition,Crowell & Moring LLP,law/consulting,"21 U.S.C. ¬ß 301 et seq. (FDCA), 21 C.F.R. ¬ß 10.30, 21 C.F.R. ¬ß 25.31(a)",FDA‚Äôs adoption and Orange Book listing of the strength for Lovaza (omega-3-acid ethyl esters) Capsules,"Amend the strength listing for Lovaza to identify only the amount of active ingredient per administration unit (either 0.9GM or 900MG), removing reference to product weight, excipients, or inactive ingredients","Petitioner argues that FDA‚Äôs current listing deviates from the established regulatory framework where strength identifies only the active ingredient per administration unit, leading to inconsistency with thousands of other Orange Book listings, public FDA guidance, and the Lovaza labeling and drug listings; correction is necessary for regulatory consistency and clarity.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0163,FDA-2013-P-0163-0001_Teva_Womens_Health_Inc_Citizen_Petition.pdf,,2013,False,original petition,"Teva Women's Health, Inc.",industry/corporation,"21 C.F.R. ¬ß 10.30, 21 U.S.C. ¬ß 355(j), 21 C.F.R. ¬ß 884.5360, 21 C.F.R. ¬ß 310.502(a)(8)",Approval of Abbreviated New Drug Applications (ANDAs) referencing ParaGard T 380A intrauterine copper contraceptive,"(1) comparative clinical trials establishing bioequivalence, (2) identical labeling to ParaGard, and (3) identical physical components to ParaGard","Justifications include that ParaGard acts locally with mechanisms not fully understood, copper and non-copper components contribute to efficacy, and minor changes could significantly affect safety and efficacy; therefore, clinical trials, identical labeling, and device component identity are necessary to ensure generic equivalence and public health protection",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0170,FDA-2013-P-0170-0001_Clinipace_Worldwide_Citizen_Petition.pdf,,2013,False,original petition,Clinipace Worldwide,individual,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. ¬ß 10.20; 21 C.F.R. ¬ß 10.30; 21 C.F.R. ¬ß 314.93; 21 C.F.R. ¬ß 25.31",FDA‚Äôs regulation allowing submission of abbreviated new drug applications (ANDAs) for strengths different from reference listed drugs (RLDs),"The petitioner requests FDA to declare that hydroxychloroquine sulfate tablets in 100 mg, 300 mg, and 400 mg strengths are suitable for submission and review under an ANDA referencing Plaquenil (hydroxychloroquine sulfate) 200 mg tablets as the RLD.","The petitioner justifies the request by explaining that the proposed new strengths will provide convenient alternative dosing options for both adults and pediatric patients, match labeled dosing flexibility outlined in the RLD, and do not raise new safety or efficacy issues since they align with already approved dosing regimens; also, no new active ingredient, indication, dosage form, dosing regimen, or route of administration is involved, making Pediatric Research Equity Act (PREA) obligations inapplicable.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0198,FDA-2013-P-0198-0001_Takeda_Pharmaceuticals_USA_Inc_Citizen_Petition.pdf,,2013,False,original petition,"Takeda Pharmaceuticals U.S.A., Inc.",industry/corporation,"21 U.S.C. 355, 21 C.F.R. 10.30",Approval of abbreviated new drug applications (ANDAs) referencing DEXILANT (dexlansoprazole) delayed-release capsules,"Refrain from approving any ANDA referencing DEXILANT unless it includes data showing bioequivalence using partial AUC metrics in addition to conventional metrics (AUC‚ÇÄ‚Çã‚Çú, AUC‚ÇÄ‚Çã‚àû, and C‚Çò‚Çê‚Çì).","The petitioner argues that DEXILANT is a dual delayed-release product with biphasic pharmacokinetics and that the existing FDA draft guidance does not require partial AUC metrics necessary to ensure therapeutic equivalence of generics. Without additional metrics such as pAUC‚ÇÄ‚Çã‚ÇÇ‚Çï and pAUC‚ÇÇ‚Çã‚ÇÅ‚ÇÄ‚Çï, a generic may not truly replicate the dual-release profile essential for safety and efficacy.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0199,FDA-2013-P-0199-0001_Richard_M_Karcich_Citizen_Petition_Redacted.pdf,,2013,False,original petition,Richard M. Karcich,individual,"General Principles of Software Validation; Final Guidance for Industry and FDA Staff Section 6.1, FDA Quality System Regulations, Medical Device Directive, ISO 13485, ISO 14971, IEC 62366, IEC 62304","FDA's current regulatory approach to software validation for medical devices, which leaves validation practices largely at the discretion of device manufacturers",Request for FDA to issue new regulations or amend existing regulations to require measurement of code change activity and test activity as a mandatory part of software fault management for medical device software,"Petitioner argues that current FDA regulations result in inadequate accountability and allow software faults to escape detection, leading to patient risk. By adopting mandatory measurement practices, device manufacturers can better manage software safety and reliability, detect faults early, and prevent life-threatening failures such as those implicated in Class I medical device recalls.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0203,FDA-2013-P-0203-0001_Merchant_Gould_PC_Citizen_Petition.pdf,,2013,False,original petition,Merchant & Gould P.C.,law/consulting,"21 C.F.R. ¬ß¬ß 10.20, 10.30, 314.99(b), 314.94(a)(9)(iii), 314.127(a)(8)(ii)(B), 314.90, 505(j) of the FDCA",Enforcement of the requirement for identical inactive ingredients in parenteral drug products under 21 CFR 314.94(a)(9)(iii) and 314.127(a)(8)(ii)(B),Request to waive enforcement of the requirement that the ANDA for Voriconazole for Injection 200 mg/vial have identical inactive ingredients to the reference listed drug (Vfend¬Æ); specifically to allow use of hydroxypropyl Œ≤-cyclodextrin instead of sulfobutyl ether Œ≤-cyclodextrin sodium,"Petition argues that the substituted excipient (hydroxypropyl Œ≤-cyclodextrin) is safe, has similar pharmacokinetics and toxicity profile to the original excipient, and that the change would not affect the safety or efficacy of the drug product; also, historical precedent exists where FDA approved similar requests for changes in inactive ingredients in parenteral drugs",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0204,FDA-2013-P-0204-0001_Chrai_Associates_Inc_on_behalf_of_Square_Pharmaceu.pdf,,2013,False,original petition,"Chrai Associates, Inc. on behalf of Square Pharmaceuticals Ltd.",law/consulting,"21 C.F.R. ¬ß 10.30, Section 101 of the Generic Drug User Fee Amendments of 2012 (GDUFA)",FDA‚Äôs implementation of the Generic Drug User Fee Act (GDUFA) requiring annual Finished Dosage Form (FDF) facility fees for manufacturers with pending ANDAs,"The petitioner requests that FDA amend, clarify, or revise the GDUFA regulation to require a one-time FDF facility fee payment upon ANDA approval or commercialization instead of annual fees before approval; and requests that FDA exempt the client from paying annual FDF facility fees until a decision on the petition is made.","The petitioner argues that charging annual facility fees before product approval imposes an unfair financial burden on small or first-time foreign manufacturers without U.S. market revenue, contradicts fairness principles compared to PDUFA practices, and may stifle entry of generic products. They propose a one-time fee model similar to European practices to cover necessary FDA regulatory expenses.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0217,FDA-2013-P-0217-0001_Center_for_Science_in_the_Public_Interest_Citizen_.pdf,,2013,False,original petition,Center for Science in the Public Interest (CSPI),advocacy/academic,"21 C.F.R. ¬ß 10.30, 21 C.F.R. ¬ß 184.1854, 21 C.F.R. ¬ß 184.1857, 21 C.F.R. ¬ß 184.1859, 21 C.F.R. ¬ß 184.1865, 21 C.F.R. ¬ß 184.1866, 21 U.S.C. ¬ß 321(s), 21 U.S.C. ¬ß 348(a), 21 C.F.R. ¬ß 170.3(i), 21 C.F.R. ¬ß 170.30, 21 C.F.R. ¬ß 170.6(c), 21 C.F.R. ¬ß 170.300, 21 C.F.R. ¬ß 184.1(b)(2), 21 C.F.R. ¬ß 181.1(b)","GRAS status of added sugars (sucrose, high-fructose corn syrup, corn sugar, invert sugar, corn syrup) and their regulation in beverages and foods","Initiate rule-making to limit safe levels of sucrose and HFCS in beverages, amend Nutrition Facts to specify 'added sugars', set lower targets for added sugars in foods, conduct public education campaigns, and work with industry to reduce added sugars","Overconsumption of added sugars contributes to obesity, cardiovascular disease, diabetes, gout, dental caries, and poor nutrition; evidence since original GRAS determinations shows current consumption levels are unsafe, necessitating regulatory action to protect public health",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0219,FDA-2013-P-0219-0001_International_Isotopes_Inc_I3_Citizen_Petition.pdf,,2013,False,original petition,"International Isotopes, Inc.",industry/corporation,Not explicitly cited beyond referencing suitability petition standards; general reliance on FDA suitability petition regulations (21 C.F.R. ¬ß 314.93 implied),"Approval of ANDA suitability petition to allow change in strength and formulation of sodium iodide I-131 oral solution and kit components relative to the reference listed drug (HICON, NDA 021305)",Approve a suitability petition permitting an increase in the strength of sodium iodide I-131 solution from 250‚Äì1000 mCi/mL to 500‚Äì3500 mCi/mL and a change in formulation buffer components for a proposed generic product,"The proposed increase in strength will reduce the number of capsules required for dosing, simplify preparation by healthcare providers, maintain the same therapeutic agent and intended use as the reference listed drug, and the new formulation with dilute sodium hydroxide and sodium thiosulfate effectively preserves radiochemical purity without impacting patient safety or efficacy.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0228,FDA-2013-P-0228-0001_Douglas_Barasatian_Citizen_Petition_Redacted.pdf,,2013,False,original petition,Douglas Barasatian,individual,"Federal Food, Drug, and Cosmetic Act; 21 C.F.R. ¬ß 25.31(a); 21 C.F.R. ¬ß 10.30(b)","GRAS (Generally Recognized as Safe) status of Bleached White Flour and associated bleaching agents (e.g., chlorine dioxide, benzoyl peroxide)",Remove Bleached White Flour and all chemical bleaching agents used in its production from the GRAS list and prevent its sale into the U.S. food system.,"The petitioner argues that bleaching flour introduces toxic chemicals such as Alloxan, which can destroy pancreatic cells and potentially cause diabetes. He references historical cases, scientific studies, and international regulatory differences (e.g., Europe‚Äôs ban on bleached flour) to support the claim that chemically bleached flour may be contributing to higher rates of chronic diseases in the U.S. compared to Europe.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0235,FDA-2013-P-0235-0001_Wess_E_Sharpe_Lantos_Technologies_Citizen_Petition.pdf,,2013,False,original petition,Wess Eric Sharpe,individual,"Section 510(k) of the Federal Food, Drug, and Cosmetic Act",FDA's classification order (K121326) classifying Lantos Technologies' 3D Ear Scanner as a Class I device,Reconsider and reclassify the Lantos 3D Ear Scanner as a Class II device under product code ETY,"The petitioner argues that the Lantos 3D Ear Scanner includes a fluid-filled membrane that can create pressure within the ear canal, posing potential safety risks such as tympanic membrane rupture. This feature aligns more closely with devices classified as Class II under code ETY, rather than Class I devices under code ERA, and therefore requires stricter regulatory scrutiny to ensure patient safety.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0241,FDA-2013-P-0241-0001_Foley_Lardner_LLP_Citizen_Petition.pdf,,2013,False,original petition,Foley & Lardner LLP,law/consulting,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. ¬ß¬ß 10.30, 314.93, 314.161",Determination whether Cytoxan for Injection (original lyophilized powder form under NDA 12-142) was withdrawn for reasons of safety or effectiveness,"FDA should determine that Cytoxan for Injection (lyophilized powder under NDA 12-142) was not withdrawn from the market for safety or effectiveness reasons, allowing filing of an ANDA referencing the product","The petitioner states that the discontinuation of the lyophilized product was voluntary and for commercial reasons, not due to safety or efficacy issues. Previous FDA determinations found no safety/efficacy concerns for related Cytoxan formulations, and a new ANDA would enhance market competition and drug supply stability.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0247,FDA-2013-P-0247-0001_Novartis_Pharmaceuticals_Corporation_Citizen_Petit.pdf,,2013,False,original petition,Novartis Pharmaceuticals Corporation,industry/corporation,"21 U.S.C. ¬ß 301 et seq. (Federal Food, Drug, and Cosmetic Act), 21 C.F.R. ¬ß 10.30, 21 U.S.C. ¬ß¬ß 355(j)(2)(A)(i), (v), 21 C.F.R. ¬ß 314.94(a)(8)(iv), 21 C.F.R. ¬ß 314.127(a)(7), 21 C.F.R. ¬ß 25.31(a)",Approval of ANDAs for zoledronic acid IV infusion products with carve-outs omitting protected safety and efficacy information from Reclast labeling,Request that FDA not approve any ANDA for a zoledronic acid IV infusion product that omits protected safety information from Reclast labeling and only approve ANDAs that include all protected safety information,"Omitting protected labeling would remove critical safety information necessary for safe use of zoledronic acid in treating Paget's disease patients, rendering generic versions less safe than Reclast; FDA precedents require complete labeling where omissions would impact safety across indications.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0280,FDA-2013-P-0280-0001_RJ_Reynolds_Tobacco_Company_American_Snuff_Company.pdf,,2013,False,original petition,"R.J. Reynolds Tobacco Company, American Snuff Company, LLC, and Santa Fe Natural Tobacco Company, Inc.",industry/corporation,"Section 919 of the Federal Food, Drug, and Cosmetic Act; Family Smoking Prevention and Tobacco Control Act; 21 C.F.R. ¬ß¬ß 10.25, 10.30; 7 U.S.C. ¬ß 518d",FDA's method of assessing and collecting user fees for tobacco product manufacturers and importers based on market share calculations,"FDA should promulgate a regulation to ensure that no tobacco manufacturer or importer is assessed user fees greater than their actual market share percentage, requiring all manufacturers and importers to submit market sales volume data to FDA","Current market share calculations omit certain manufacturers, causing compliant companies to pay fees greater than their fair share. FDA must correct this by identifying all manufacturers/importers and including their sales volumes to ensure accurate fee assessments, especially as FDA assumes full responsibility for assessments post-2014 and expands jurisdiction to additional tobacco products.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0283,FDA-2013-P-0283-0001_Hyman_Phelps_McNamara_PC_Citizen_Petition.pdf,,2013,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"Federal Food, Drug, and Cosmetic Act (FDC Act); 21 C.F.R. ¬ß 10.30; FDC Act ¬ß 505(o)(4); 21 C.F.R. ¬ß 201.57; 21 C.F.R. ¬ß 201.56; 21 C.F.R. ¬ß 201.100; 21 C.F.R. ¬ß 202.1; 21 U.S.C. ¬ß 352(a); 21 U.S.C. ¬ß 321(n); FDC Act ¬ß 505-1","Safety concerns regarding C1 Esterase Inhibitors (Human) for the treatment of hereditary angioedema (HAE), specifically relating to risks of thromboembolic complications, infections, and device-related risks.",(1) Add boxed warnings to C1-INH products; (2) Require a REMS program; (3) Modify labeling to contraindicate use in patients with thrombosis risk; (4) Require medical supervision for use with venous access devices; (5) Require postmarketing studies.,"The petitioner argues that studies and postmarket data reveal serious risks of thrombosis and infection with C1-INH products, that current labeling and warnings are inadequate, and that increased measures are needed to ensure patient safety and informed healthcare provider decision-making.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0291,FDA-2013-P-0291-0001_Fukushima_Fallout_Awareness_Network_Citizens_for_H.pdf,,2013,False,original petition,"Fukushima Fallout Awareness Network (including Ecological Options Network, Beyond Nuclear, and Citizens for Health)",industry/corporation,"21 U.S.C. ¬ß¬ß 321(s), 331(a), (c), & (g), 342, 346, 348, 371; 21 C.F.R. 25.30(a), (h), (j), & (k); 21 C.F.R. 25.32(a), (m), & (n)","FDA‚Äôs standards and regulatory response related to radionuclide contamination (specifically Cesium 134/137) in food, dietary supplements, and drugs following the Fukushima disaster","prohibit sale of food, dietary supplements, and drugs contaminated with more than 5 Bq/kg Cesium 134/137; require systematic testing and labeling; maintain a public database with contamination levels; prevent dilution tactics; and conduct environmental testing","Cesium 134/137 contamination poses a bioaccumulative and biomagnifying long-term health risk, no safe threshold for radiation exists according to the BEIR VII report, Fukushima continues releasing significant radiation, U.S. testing is inadequate, and consumers deserve transparency and tools to manage their exposure.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0299,FDA-2013-P-0299-0001_Trigen_Laboratories_BioKey_Inc_Citizen_Petition.pdf,,2013,False,original petition,"Trigen Laboratories, Inc.",advocacy/academic,21 C.F.R. 10.30; 21 C.F.R. 314.94; 21 C.F.R. 25.31,FDA's designation of the Reference Listed Drug (RLD) for Bisoprolol Fumarate Tablets in the Orange Book,"Amend the Orange Book to designate a second Reference Listed Drug (RLD) for Bisoprolol Fumarate Tablets, specifically products from Sandoz and/or Mylan","TEVA Women's Zebeta¬Æ Tablets, the current RLD, are not commercially available, causing delays in the ANDA submission process; Sandoz and Mylan's products are available and meet bioequivalence standards.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0303,FDA-2013-P-0303-0001_Tedor_Pharma_Inc_Citizen_Petition.pdf,,2013,False,original petition,Tedor Pharma Inc.,industry/corporation,"21 CFR ¬ß10.20, 21 CFR ¬ß10.30, 21 CFR ¬ß314.161, 21 CFR ¬ß25.31(a)",Whether Metadate¬Æ ER 10 mg (Methylphenidate Hydrochloride) Tablets (ANDA 040-306) was voluntarily withdrawn for safety or effectiveness reasons,"FDA to determine that Metadate¬Æ ER 10 mg Tablets were withdrawn for reasons unrelated to safety or effectiveness, thus allowing the filing of an ANDA for a generic version",The drug was moved to the 'Discontinued' section of the Orange Book and is unavailable in the market; the petitioner believes it was discontinued for commercial reasons rather than safety or efficacy concerns and seeks a formal determination to proceed with a generic ANDA.,,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0323,FDA-2013-P-0323-0001_Cititzen_Petition_from_Rapid_Precision_Testing_Lab.pdf,,2013,False,original petition,Rapid Precision Testing Laboratories,advocacy/academic,"21 CFR Parts 201, 310, and 352; 58 FR 28195",FDA's ongoing review of GRASE sunscreen active ingredients and sunscreen labeling and effectiveness testing regulations,"Amend approval and formally withdraw approval of Dioxybenzone, Oxybenzone, Trolamine salicylate, Homosalate, and Octisalate as sunscreen active ingredients; reassess and amend SPF test methodology to prescreen for anti-inflammatory effects that falsely inflate SPF values","Scientific evidence showing that listed sunscreen agents act as anti-inflammatories masking erythema without preventing UV damage, concerns about misleading SPF values, potential systemic absorption risks, and possible contribution to rising skin cancer rates despite sunscreen use.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0335,FDA-2013-P-0335-0001_Foley_Lardner_LLP_Citizen_Petition.pdf,,2013,False,original petition,Foley & Lardner LLP,law/consulting,"Section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355); 21 CFR 10.20; 21 CFR 10.30; 21 CFR 314.94; 21 CFR 320.1; 21 CFR 320.23-24; 21 CFR 25.31",FDA‚Äôs bioequivalence requirements outlined in the October 2011 Guidance for Nilutamide,"Amend the FDA's Guidance for Nilutamide to allow a single-dose, two-way crossover study in normal healthy male volunteers under specific safeguards, rather than requiring steady-state studies in patients",The proposed alternative study design minimizes risk because adverse events like hepatic injury and pneumonitis are rare and associated with chronic rather than acute exposure; similar safeguards are accepted for comparable drugs like flutamide and bicalutamide.,,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0336,FDA-2013-P-0336-0001_Emcure_Pharmaceuticals_USA_Inc_Citizen_Petition.pdf,,2013,False,original petition,Emcure Pharmaceuticals USA Inc.,industry/corporation,21 U.S.C. ¬ß 355(j)(2)(c); 21 CFR ¬ß 10.20; 21 CFR ¬ß 10.30; 21 CFR ¬ß 314.93; 21 CFR ¬ß 314.122; 21 CFR ¬ß 314.161; 21 CFR ¬ß 25.31(a),"Acceptance of ANDAs for Diphenhydramine Hydrochloride Injection USP, 50 mg/mL, referencing a discontinued Benadryl product","Request FDA to accept ANDAs for Diphenhydramine Hydrochloride Injection USP, 50 mg/mL (SDV and MDV) formulations equivalent to the discontinued McNeil Consumer Healthcare's Benadryl Injection","The original Benadryl Injection was discontinued for commercial reasons and not due to safety or efficacy concerns, as confirmed by FDA; therefore, the petitioner seeks approval to submit ANDAs referencing the discontinued product.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0351,FDA-2013-P-0351-0001_Center_for_Food_Safety_and_Institute_for_Agricultu.pdf,,2013,False,original petition,Center for Food Safety and Institute for Agriculture and Trade Policy,advocacy/academic,"21 U.S.C. ¬ß 360b, 5 U.S.C. ¬ß 553(e), 21 C.F.R. ¬ß¬ß 10.20 and 10.30, 21 U.S.C. ¬ß 342",FDA's lack of regulation on the use of antibiotics in distillers grains sold as animal feed,"Prohibit or enjoin the use of antibiotics in the manufacture of distillers grains sold as animal feed for food-producing animals, or alternatively regulate such antibiotics as new animal drugs requiring new animal drug applications","Antibiotics used in ethanol production remain in distillers grains fed to food-producing animals, contributing to antibiotic resistance, posing a public health risk, and violating the Federal Food, Drug, and Cosmetic Act; alternatives to antibiotics are available for ethanol producers; FDA‚Äôs failure to regulate is arbitrary and capricious under the APA",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0380,FDA-2013-P-0380-0001_University_of_Florida_College_of_Medicine_Jacksonv.pdf,,2013,False,original petition,University of Florida College of Medicine - Jacksonville and UNC School of Medicine,advocacy/academic,21 C.F.R. 10.30; 21 C.F.R. 25.30; 21 C.F.R. 25.31,FDA‚Äôs black box warning on Depot Medroxyprogesterone Acetate (DMPA) labeling regarding loss of bone mineral density and limiting use to two years,Remove the black box warning from the DMPA labeling,"The petition argues that the black box warning was not based on published clinical evidence but rather on an invalid surrogate endpoint (bone mineral density) that does not predict fractures. They claim the warning has harmed public health by discouraging use of a safe contraceptive, and that published studies show bone mineral density recovers after discontinuation without increased fracture risk.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0408,FDA-2013-P-0408-0001_Chesapeake_Regulatory_Group_Inc_Citizen_Petition.pdf,,2013,False,original petition,"Chesapeake Regulatory Group, Inc.",law/consulting,"Section 505(b) and 505(j) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 10.25; 21 CFR 10.30; 21 CFR 314.94(a)(3); 21 CFR 25.31",Designation of Reference Listed Drugs (RLDs) for peritoneal dialysis fluids (specifically Baxter Healthcare‚Äôs Dianeal PD-2 and Dianeal Low Calcium products),Request FDA to designate specific Baxter Healthcare peritoneal dialysis products as Reference Listed Drugs (RLDs),"The petitioner argues that without designated RLDs, sponsors cannot submit ANDAs for generic versions, and since Baxter‚Äôs Dianeal products dominate the market, they are appropriate standards for generic comparisons. This designation would facilitate generic competition and prevent significant variations between generics and brand-name products.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0424,FDA-2013-P-0424-0001_Actelion_Pharmaceuticals_Ltd_Citizen_Petition.pdf,,2013,False,original petition,Actelion Pharmaceuticals Ltd.,industry/corporation,"21 USC 355, 21 CFR 10.30","FDA standards for approving ANDAs for Ventavis or generic iloprost inhalation solutions, addressing sameness of active ingredient (diastereoisomer ratio), formulation equivalency, bioequivalence demonstration, and device compatibility.","(1) the active ingredient has the same ratio of diastereoisomers, (2) any formulation differences are justified with bioequivalence and nebulizer performance data, and (3) the device used does not differ materially from the approved devices (I-neb and Prodose systems).","Ventavis is a complex, locally-acting drug-device combination used to treat pulmonary arterial hypertension. Differences in stereochemistry, formulation, or delivery device could affect safety and efficacy; therefore, strict equivalence in active ingredients, inactive ingredients, and device characteristics is required to ensure therapeutic equivalence and patient safety.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0426,FDA-2013-P-0426-0001_Shotwell_Carr_Inc_Citizen_Petition.pdf,,2013,False,original petition,"Shotwell & Carr, Inc.",industry/corporation,"Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. ¬ß 25.33(d)(5); 21 C.F.R. ¬ß 20.61",Suitability determination for an abbreviated new animal drug application (ANADA) for a cyclosporine oral solution for dogs differing from the reference listed drug (ATOPICA¬Æ) in dosage form,Request the FDA to determine that a new oral solution form of cyclosporine for dogs is suitable for filing under an ANADA,"An oral solution provides easier administration with accurate dosing using calibrated syringes, improves convenience for veterinarians and pet owners, and maintains the same active ingredient, strength, route of administration, and dosage as the reference product.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0435,FDA-2013-P-0435-0001_Tobacco_Control_Legal_Consortium__et_al_Citizen_Pe.pdf,,2013,False,original petition,Tobacco Control Legal Consortium,law/consulting,"Title 21, Chapter 9, Subchapter V, Part A of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. 10.30; Family Smoking Prevention and Tobacco Control Act (codified at 21 U.S.C. ¬ß 387g(a)(1)(A), (3)(A)-(B))",FDA's delay in prohibiting menthol as a characterizing flavor in cigarettes despite the recommendations from the Tobacco Products Scientific Advisory Committee (TPSAC),Petition the FDA to prohibit menthol as a characterizing flavor in cigarettes and cigarette smoke,"Menthol cigarettes increase youth smoking initiation, addiction, and reduce cessation rates, especially among minorities; menthol‚Äôs continued availability undermines public health goals and perpetuates tobacco-related health disparities; TPSAC and extensive scientific evidence support that removing menthol would significantly benefit public health",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0470,FDA-2013-P-0470-0001_Salix_Pharmaceuticals_Inc_Citizen_Petition.pdf,,2013,False,original petition,"Salix Pharmaceuticals, Inc.",industry/corporation,"Sections 505(j) and 505(q) of the Federal Food, Drug, and Cosmetic Act (FDCA); 21 U.S.C. ¬ß¬ß 355(j) and 355(q); 21 C.F.R. ¬ß¬ß 10.30, 314.94, and 320.21",FDA's Draft Guidance on establishing bioequivalence for extended-release mesalamine products (specifically Apriso¬Æ),"Amend the FDA‚Äôs existing bioequivalence criteria for mesalamine extended-release capsules (Apriso¬Æ) and require bioequivalence testing under fasted and fed conditions in ulcerative colitis patients, inclusion of both 5-ASA and N-Ac-5-ASA plasma analytes, expanded PK parameters, and specific testing related to colonic distribution","Salix argues that the current FDA criteria do not adequately capture the unique delayed- and extended-release properties of Apriso¬Æ, the altered pharmacokinetics in ulcerative colitis patients, the significant role of metabolite N-Ac-5-ASA, and the need to ensure equivalent colonic drug delivery, all of which are critical to maintaining therapeutic effectiveness.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0471,FDA-2013-P-0471-0001_Bayer_HealthCare_Pharmaceuticals_Inc_Ropes_Gray_LL.pdf,,2013,False,original petition,Bayer HealthCare Pharmaceuticals Inc.,industry/corporation,"Section 505 of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. ¬ß 10.30; Sections 505(c)(3)(E)(ii) and 505(j)(5)(F)(ii) of the FDCA",FDA‚Äôs historical approach to denying 5-year exclusivity to fixed-dose combinations (FDCs) that include a new active moiety and a previously approved active moiety,"Request that FDA recognize 5-year exclusivity for dienogest, the new active moiety in NATAZIA","Petitioner argues that the FDA‚Äôs current practice contradicts the statutory language, Congressional intent, and FDA‚Äôs own regulations, and leads to arbitrary, inequitable outcomes that discourage innovation in fixed-dose combinations; they argue Bayer invested 16 years and nearly $200 million developing NATAZIA, and that dienogest as a new active moiety deserves 5-year exclusivity",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0503,FDA-2013-P-0503-0001_Nomax_Inc_Citizen_Petition.pdf,,2013,False,original petition,"Nomax, Inc.",industry/corporation,"21 C.F.R. ¬ß¬ß 10.25(a), 10.30, 314.161(a)(3), 21 C.F.R. ¬ß 25.31",Determination whether a listed drug (Urocit¬Æ-K Powder) was withdrawn for safety or effectiveness reasons,"Request that FDA determine Urocit¬Æ-K Powder was not withdrawn for safety or effectiveness reasons and annotate the Orange Book accordingly, or publish a notice if otherwise","The petitioner reviewed approval documents, prescribing information, adverse effect profiles, and literature; found no safety or efficacy concerns; concluded withdrawal was for business and market strategy reasons",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0504,FDA-2013-P-0504-0001_Nomax_Inc_Citizen_Petition.pdf,,2013,False,original petition,"Nomax, Inc.",industry/corporation,"21 CFR 10.30, 21 CFR 25.31",Amendment of the 'Approved Drug Products with Therapeutic Equivalence' list (Orange Book) to designate Urocit¬Æ-K Powder (NDA 019647) as a reference listed drug product,Amend the 'Orange Book' to list Urocit¬Æ-K Powder as a reference listed drug product,"The petitioner argues that Urocit¬Æ-K Powder is a different dosage form (oral solution) from Urocit¬Æ-K 15 meq extended release tablets, and due to the distinction between the two, it should be designated as a separate reference listed drug (RLD) to avoid confusion and ensure appropriate generic development.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0505,FDA-2013-P-0505-0001_Nomax_Inc_Citizen_Petition.pdf,,2013,False,original petition,"Nomax, Inc.",industry/corporation,21 CFR 10.30; 21 CFR 25.31,"Regulatory classification and approval pathway for fluorescein strips, specifically the 1987 Federal Register notice regulating fluorescein strips as drugs rather than medical devices","FDA approval of a suitability petition allowing submission of an abbreviated new drug application (ANDA) for fluorescein strips, citing fluorescein sodium injection as the reference listed drug, despite differences in dosage form, strength, and route of administration","Petitioner argues that fluorescein strips have a long history of safe professional use, deliver much smaller amounts of fluorescein compared to the intravenous solution, are cleared naturally by tears, and that FDA‚Äôs prior classification decisions created regulatory uncertainty. Citing fluorescein injection as a reference listed drug would provide a clear and viable regulatory path to compliance.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0506,FDA-2013-P-0506-0001_Nomax_Inc_Citizen_Petition.pdf,,2013,False,original petition,"Nomax, Inc.",industry/corporation,21 CFR 10.30; 21 CFR 25.31,The regulatory classification and approval status of Urocit¬Æ-K Powder (potassium citrate granules) and its listing (or absence thereof) in the FDA's Orange Book as a reference listed drug.,"Nomax, Inc. requests FDA approval to submit an ANDA for potassium citrate effervescent tablets in 10 meq, 20 meq, and a new 25 meq strength, and to designate Urocit¬Æ-K Powder as a reference listed drug.","Nomax argues that Urocit¬Æ-K Powder was discontinued for reasons unrelated to safety or efficacy, and the proposed effervescent tablets produce a true molecular solution of potassium citrate similar to the powder, ensuring therapeutic equivalence. They also emphasize the historical safe use of potassium citrate oral dosage forms.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0509,FDA-2013-P-0509-0001_Skadden_Arps_Slate_Meagher_Flom_LLP_Citizen_Petiti.pdf,,2013,False,original petition,"Skadden, Arps, Slate, Meagher & Flom LLP",law/consulting,"21 U.S.C. ¬ß 301 et seq. (Federal Food, Drug, and Cosmetic Act); 21 C.F.R. ¬ß 10.30; 21 C.F.R. ¬ß¬ß 25.30 and 25.31",Approval standards for NDAs involving immunosuppressants indicated for maintenance therapy following renal transplantation,"The petitioner requests FDA to require that all new, modified, or reformulated immunosuppressants for renal transplant maintenance therapy successfully complete at least one 12-month, double-blind clinical trial, with limited exceptions where technically infeasible.","The petitioner argues that FDA precedent supports a 12-month trial standard; short-term trials are inadequate for assessing long-term patient and graft survival; non-inferiority trials need longer assessment periods to ensure meaningful results; open-label trials introduce bias; and double-blind trials are a recognized international standard. Thus, 12-month, double-blind trials are necessary to adequately demonstrate efficacy and ensure patient safety.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0522,FDA-2013-P-0522-0001_Escher_Fund_for_Autism_Citizen_Petition_Redacted_V.pdf,,2013,False,original petition,"Jill Escher, Escher Fund for Autism",other,"21 CFR 10.30; 21 U.S.C. ¬ß 355-1(b)(3), 21 U.S.C. ¬ß 355-1(b)(4), 21 U.S.C. ¬ß 355-1(b)(5)",Approval of Diclegis (doxylamine succinate and pyridoxine hydrochloride) as a Category A pregnancy drug and general pregnancy drug labeling regulations,(1) Revoke the March 2013 approval of Diclegis or reclassify it as a Category C drug pending adequate fetal germline safety testing; (2) Revise OTC and prescription drug labeling to warn about potential fetal germline perturbation risks.,"The petitioner argues that fetal germline cells are highly susceptible to disruption by synthetic drugs during early pregnancy, potentially causing multigenerational developmental disorders. Diclegis, used during a critical window of fetal germline development, may impair germline epigenetic programming. Since Diclegis has not been tested for such effects, the petitioner contends that revocation or stronger warnings are necessary to prevent irreversible harm across generations.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0572,FDA-2013-P-0572-0001_Prometheus_Laboratories_Inc_Citizen_Petition.pdf,,2013,False,original petition,Prometheus Laboratories Inc.,advocacy/academic,"Sections 502, 505, and 527 of the Federal Food, Drug, and Cosmetic Act (FDCA); 21 CFR 10.30; 21 CFR 25.31",FDA's lack of clear standards or procedures for developing single shared Risk Evaluation and Mitigation Strategies (REMS) and granting waivers from the requirement for single shared REMS under Section 505-1 of the FDCA,(1) FDA should complete notice and comment rulemaking to establish clear standards and processes for single shared REMS and waivers; (2) FDA should not grant a waiver from the single shared REMS requirement for Lotronex without giving Prometheus notice and an opportunity to participate in the process.,"Prometheus argues that the absence of clear regulatory standards for single shared REMS exposes innovator companies to antitrust scrutiny, product liability risks, and inefficient resource use. It contends that a lack of guidance complicates negotiations between innovator and generic drug companies and potentially delays generic drug entry. Prometheus also emphasizes that without notice and participation rights, sponsors of listed drugs cannot adequately protect their interests or provide critical information to FDA when waivers are considered.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0573,FDA-2013-P-0573-0001_Lupin_Pharmaceuticals_Inc_Citizen_Petition.pdf,,2013,False,original petition,"Lupin Pharmaceuticals, Inc.",industry/corporation,21 CFR 10.25; 21 CFR 10.30; 21 CFR 314.161; 21 CFR 314.162; 21 CFR 25.31,"FDA‚Äôs placement of BANZEL¬Æ (rufinamide) Tablets, 100 mg into the Discontinued Drug Products section of the Orange Book","Lupin requests that FDA determine that BANZEL¬Æ (rufinamide) Tablets, 100 mg was discontinued for reasons unrelated to safety or effectiveness, and confirm that ANDAs referencing BANZEL¬Æ 100 mg Tablets are eligible for approval if other legal and regulatory requirements are met.","Lupin argues that BANZEL¬Æ (rufinamide) Tablets, 100 mg was likely discontinued for commercial reasons rather than for safety or effectiveness issues, noting the continued marketing of BANZEL¬Æ Oral Suspension and the lack of evidence suggesting safety or efficacy concerns. Lupin cites regulatory requirements obligating FDA to make such a determination before approving an ANDA.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0574,FDA-2013-P-0574-0001_Watson_Laboratories_Inc_Citizen_Petition.pdf,,2013,False,original petition,"Watson Laboratories, Inc.",industry/corporation,"Sections 505 and 505(q) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 10.30",Draft Bioequivalence Guidance for Silodosin Capsules issued in April 2013 and approval standards for ANDAs for generic RAPAFLO¬Æ (silodosin) capsules,(1) Refuse to approve any ANDAs for generic RAPAFLO¬Æ unless bioequivalence is demonstrated for both silodosin and its active metabolite KMD-3213G using strict statistical evaluation of AUC and Cmax; (2) Revise the Draft Guidance on Silodosin to require strict statistical evaluation for both silodosin and KMD-3213G.,"Watson argues that the active metabolite KMD-3213G significantly contributes to the therapeutic efficacy and safety of RAPAFLO¬Æ. Because KMD-3213G has a longer half-life and a substantial pharmacologic role, failing to require bioequivalence testing for this metabolite risks approving non-equivalent generics that could negatively impact patient health, especially among patients with moderate renal impairment.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0608,FDA-2013-P-0608-0001_Copy_1_of_2_Janssen_Research_and_Development_LLC_R.pdf,,2013,False,original petition,"Janssen Research & Development, LLC",industry/corporation,"Section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. ¬ß 355), 21 C.F.R. ¬ß 10.30",FDA-2007-D-0369),"FDA should require specific bioequivalence parameters, including partial area under the concentration-time curve (pAUC0‚Äì72h and pAUC0‚Äì28d), in addition to traditional Cmax, AUC0‚Äìt, and AUC0‚Äì‚àû, for review and approval of any proposed generic or follow-on product referencing INVEGA¬Æ SUSTENNA¬Æ","Traditional bioequivalence metrics (Cmax and AUC) may not detect clinically meaningful differences in drug release profiles, which could impact patient safety and efficacy; differences in particle size distribution could alter release rates; simulation studies demonstrated that switching to generics without these additional bioequivalence measures could result in significant clinical consequences like relapse or side effects due to under- or overexposure to paliperidone.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0615,FDA-2013-P-0615-0001_State_of_California_Department_of_Consumer_Affairs.pdf,,2013,False,original petition,California Speech-Language Pathology and Audiology and Hearing Aid Dispensers Board,advocacy/academic,"21 CFR 808.20(c); 21 CFR 801.420; 21 CFR 801.421; 21 CFR 808.1(d)(3); California Business and Professions Code (BPC) Sections 2538.23, 2538.36, 2538.38, 2538.49",Federal preemption of state requirements related to the sale of hearing aids via catalog or direct mail,Request for exemption from federal preemption to allow enforcement of California's stricter requirements regarding hearing aid sales by catalog or direct mail.,"California's requirements provide greater consumer protections, including requiring sellers to be licensed, prohibiting the provision of professional services without direct examination, mandating ear canal observation, requiring a signed verification statement, and extending document retention periods to seven years to support consumer safety and enable investigations into misconduct.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0631,FDA-2013-P-0631-0001_CorePharma_LLC_Citizen_Petition.pdf,,2013,False,original petition,"CorePharma, LLC",industry/corporation,21 CFR 10.25(a); 21 CFR 10.30; 21 CFR 314.161; 21 CFR 25.31,"Discontinuation of Moban¬Æ (molindone hydrochloride) Tablets, NDA 017111, and its listing in the FDA Orange Book","Request that FDA determine that Moban¬Æ Tablets were not withdrawn from sale for reasons of safety or effectiveness, and allow submission of an ANDA referencing Moban¬Æ","CorePharma asserts that Moban¬Æ was discontinued due to sourcing issues rather than concerns regarding safety or effectiveness. The petitioner argues that under FDA regulations, this determination is necessary to permit approval of an ANDA referencing the discontinued drug.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0664,FDA-2013-P-0664-0001_Watson_Laboratories_Inc_Citizen_Petition.pdf,,2013,False,original petition,"Watson Laboratories, Inc.",industry/corporation,"Sections 505 and 505(q) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 10.25; 21 CFR 10.30; 21 CFR 320.24",Approval standards for ANDAs for generic versions of CRINONE¬Æ (progesterone gel) 4% and 8%,(1) Refuse to approve any ANDA for a generic version of CRINONE¬Æ unless the sponsor demonstrates bioequivalence through both a pharmacokinetic (PK) study and a clinical endpoint study; (2) Issue draft guidance on bioequivalence requirements for generic progesterone gels similar to the guidance issued for generic ENDOMETRIN¬Æ.,"Watson argues that CRINONE¬Æ is a locally acting drug where traditional bioequivalence measures (based only on systemic absorption) are inadequate. Bioequivalence should be demonstrated using both PK and clinical endpoint studies to ensure that generics perform similarly at the site of action. This approach would align with FDA‚Äôs existing draft guidance for a similar product, ENDOMETRIN¬Æ.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0665,FDA-2013-P-0665-0001_Arnall_Golden_Gregory_LLP_Citizen_Petition.pdf,,2013,False,original petition,Arnall Golden Gregory LLP,law/consulting,"21 U.S.C. ¬ß 355; 21 C.F.R. ¬ß¬ß 10.20, 10.25, 10.30, 314.161","FDA's listing of Intal¬Æ (cromolyn sodium) Inhalation Capsule, 20 mg in the Discontinued Drug Product List section of the Orange Book","Request that FDA determine that Intal¬Æ was withdrawn from the market for reasons other than safety or effectiveness, thereby permitting abbreviated NDA submissions using Intal¬Æ as the reference listed drug (RLD)","The petitioner states there is no evidence suggesting that Intal¬Æ was withdrawn for safety or effectiveness reasons and that, therefore, FDA should permit abbreviated applications referencing Intal¬Æ under 505(j) of the FD&C Act.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0666,FDA-2013-P-0666-0001_Mutual_Pharmaceutical_Company_Inc_Citizen_Petition.pdf,,2013,False,original petition,"Mutual Pharmaceutical Company, Inc.",industry/corporation,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 314.93; 21 CFR 25.31",FDA approval standards for ANDAs involving changes to dosage strength relative to the listed drug product,"Request that FDA determine that Piroxicam Capsules, 5mg, is suitable for evaluation and approval under an ANDA, allowing Mutual to submit a supplemental application to its approved ANDA for Piroxicam Capsules, 10mg and 20mg.","The proposed 5mg capsule is dose-proportional to the approved 10mg and 20mg strengths, will use the same formulation, dosage form, route of administration, and will provide a smaller capsule size for patients with swallowing difficulties, maintaining the same therapeutic effect and labeling (except necessary changes such as manufacturer name and 'How Supplied' section).",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0667,FDA-2013-P-0667-0001_American_Clinical_Laboratory_Association_Citizen_P.pdf,,2013,False,original petition,American Clinical Laboratory Association (ACLA),advocacy/academic,"Federal Food, Drug, and Cosmetic Act (FDCA), Clinical Laboratory Improvement Act of 1967 (CLIA '67), Clinical Laboratory Improvement Amendments of 1988 (CLIA '88), 21 C.F.R. ¬ß 807.65(i), 21 C.F.R. ¬ß 493.1253(b)(2)",FDA's intention to regulate Laboratory Developed Tests (LDTs) as devices under the FDCA,Request FDA to refrain from issuing draft or final guidance or a proposed or final rule regulating LDTs as devices and to confirm that LDTs are not devices under the FDCA,"FDA lacks statutory authority to regulate LDTs under the FDCA; LDTs are not 'devices' as defined by the Act; regulation of LDTs under FDCA would conflict with CLIA; regulating LDTs would harm public health by reducing access to critical tests and delaying medical innovation; FDA regulation could cause significant economic repercussions for laboratories; concerns about laboratory regulation should be addressed through amendments to CLIA, not through FDCA regulation.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0670,FDA-2013-P-0670-0001_Altaire_Pharmaceuticals_Inc_Citizen_Petition.pdf,,2013,False,original petition,"Altaire Pharmaceuticals, Inc.",industry/corporation,"Section 505(j) of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. ¬ß¬ß 10.20 and 10.30; 21 C.F.R. ¬ß 25.31","Designation of reference listed drug (RLD) for Gentamicin Sulfate Ophthalmic Solution, EQ 0.3% base, in the FDA's Orange Book","Request to designate Gentak¬Æ Gentamicin Sulfate Ophthalmic Solution, ANDA 064163 (held by Akorn Inc.), as the RLD for purposes of ANDA submissions","The current RLD (ANDA 064048 by Bausch & Lomb) is not Q1Q2 equivalent to the original formulation; Gentak¬Æ (ANDA 064163) is Q1Q2 equivalent to the original formulation NDA 050039, which was discontinued. Without designating Gentak¬Æ as the RLD, generic applicants cannot pursue ANDA submissions based on the original formulation, effectively shielding Gentak¬Æ from competition.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0671,FDA-2013-P-0671-0001_Lachman_Consultant_Sevices_Inc_Citizen_Petition.pdf,,2013,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,21 CFR 10.30; 21 CFR 314.161; 21 CFR 314.162,"FDA's listing of PARAFLEX (chlorzoxazone) Tablets, 250 mg in the discontinued drug product section of the Orange Book","Request for the FDA to determine whether PARAFLEX (chlorzoxazone) Tablets, 250 mg was voluntarily withdrawn from sale for reasons of safety or effectiveness, in order to permit approval of ANDAs referencing this product",The petitioner argues there is no evidence that the withdrawal was related to safety or efficacy concerns and suggests the product was discontinued for commercial reasons. A favorable determination would allow the approval of generic versions referencing the discontinued product.,,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0675,FDA-2013-P-0675-0001_Lachman_Consultant_Sevices_Inc_Citizen_Petition.pdf,,2013,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 10.30; 21 CFR 25.31",Approval pathway for an ANDA for a modified strength version of Ultracet¬Æ (Tramadol Hydrochloride 37.5 mg and Acetaminophen 300 mg Tablets) referencing NDA 021123,Request that FDA determine that Tramadol Hydrochloride 37.5 mg and Acetaminophen 300 mg Tablets is suitable for submission as an ANDA based on a change in strength of the acetaminophen component from 325 mg to 300 mg,"The petitioner argues that reducing the acetaminophen strength does not raise questions of safety or effectiveness because the proposed maximum daily dose (2.4g) is consistent with safe exposure levels, and that FDA has previously approved other products containing 300 mg of acetaminophen in combination therapies. The indication, usage, and labeling would remain otherwise unchanged.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0693,FDA-2013-P-0693-0001_Center_for_Medicine_in_the_Public_Interest_Citizen.pdf,,2013,False,original petition,Center for Medicine in the Public Interest,advocacy/academic,"21 C.F.R. ¬ß 10.30; Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act; ICH Guideline Q3B(R2); ICH Guideline Q3C(R5); USP General Chapter <467>",Approval of a New Drug Application (NDA) or Supplemental NDA (sNDA) for a liquid formulation of Treanda¬Æ (bendamustine hydrochloride),"FDA should refrain from approving any NDA or sNDA for a liquid bendamustine formulation unless and until the applicant demonstrates that (1) degradation products are within acceptable limits, (2) excipient safety is proven (particularly for DMA), and (3) the risk of dosing errors due to higher concentration is addressed.","The petitioner argues that a liquid formulation of Treanda could introduce harmful degradation products not present in the lyophilized form, expose patients to unsafe levels of toxic solvents like DMA, and significantly increase the risk of dosing errors due to a much higher drug concentration, all of which require thorough evaluation before any approval.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0694,FDA-2013-P-0694-0001_Elite_Laboratories_Inc_Citizen_Petition.pdf,,2013,False,original petition,"Elite Laboratories, Inc.",advocacy/academic,21 CFR 314.122; 21 CFR 25.31,Designation and use of a Reference Listed Drug (RLD) for an ANDA application where the original RLD (Drixoral) is unavailable in the marketplace,"Request for FDA to determine that the approved and marketed product under ANDA 078648 (Avanthi, Inc.) is suitable for use as a Reference Listed Drug and to allow its use for a product containing an equivalent active ingredient with a different salt form (pseudoephedrine hydrochloride instead of sulfate).","The originally listed RLD (Drixoral) has been unavailable since 2008, and there is no indication it was withdrawn for safety reasons. The approved ANDA product (Avanthi‚Äôs) is marketed and contains equivalent active ingredients. Additionally, the FDA‚Äôs OTC monograph states that pseudoephedrine sulfate and pseudoephedrine hydrochloride are equivalent for nasal decongestant and bronchodilator use.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0695,FDA-2013-P-0695-0001_Steven_A_Zecola_Citizen_Petition_Redacted.pdf,,2013,False,original petition,Steven A. Zecola,individual,21 CFR 10.30; Part 25.30 of the FDA's Administrative Practices and Procedures,FDA's current drug approval process and clinical trial design as it pertains to the treatment of metastatic cancer,"Request for the FDA to (1) internally examine and modify its practices, regulations, and organizational structure for addressing metastatic cancer, (2) establish a Center for the Treatment of Metastatic Cancer, (3) modify trial design for metastatic cancer by collapsing three trial phases into two, and (4) champion an increase in the federal research budget for metastatic cancer from about 8% to 15% of total cancer research spending.","The petitioner argues that metastatic cancer is responsible for 90% of cancer deaths and that current FDA trial designs are inappropriate for metastatic cancer compounds, which are aimed at delaying metastasis rather than shrinking primary tumors. Current processes discourage investment and progress. Revised trial structures and greater research focus are needed to improve treatment options and societal outcomes.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0701,FDA-2013-P-0701-0001_Organic_PasturesDairy_Co_LLC_Citizen_Petition.pdf,,2013,False,original petition,"Organic Pastures Dairy Company, LLC",industry/corporation,"21 C.F.R. 10.25, 10.30, 10.30(j), 10.45(f), 10.20(c)",Denial of the original 2008 citizen petition seeking amendment to 21 C.F.R. 1240.61 (regulation prohibiting interstate sale of raw milk and raw dairy products),"Modify the February 26, 2013 denial to allow interstate delivery, sale, or distribution of raw milk and raw dairy products from the seller‚Äôs state to the destination state","Raw milk promotes healthy gut bacteria essential for human health; scientific studies show benefits of raw milk (e.g., reduced asthma, allergies, diabetes risk); existing state regulatory programs ensure safety; FDA treats raw milk unfairly compared to other foods; responsible production standards exist; and modifying the regulation would yield public health, environmental, and economic benefits.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0703,FDA-2013-P-0703-0001_Center_for_Lawful_Access_and_Abuse_Deterrence_Citi.pdf,,2013,False,original petition,"Center for Lawful Access and Abuse Deterrence (CLAAD), with additional signatories from National Association of Drug Diversion Investigators, Ryan‚Äôs Cause, and National Family Partnership",law/consulting,"21 C.F.R. ¬ß¬ß 5.10, 10.30; Stop Tampering of Prescription Pills Act of 2013 (H.R. 486, 113th Cong. ¬ß 2(b) (2013))",FDA policies regarding the approval of opioid drug products and the promotion of Medication-Assisted Treatment (MAT),(1) immediately reject NDAs and ANDAs for opioid products lacking predictive or determinative data on abuse deterrence; (2) acknowledge in writing that clinical benefits of MAT include outcomes beyond prolonged abstinence; and (3) prioritize and expedite guidance to industry on effectiveness and abuse-deterrence requirements,"Petitioners justify their request by citing the opioid abuse epidemic, the need for FDA regulatory action aligned with Obama Administration policy promoting abuse-deterrent opioids and MAT, the public health risks associated with approving non-abuse-deterrent opioids, economic impacts of prescription drug abuse, and the necessity for the FDA to support innovation by providing regulatory clarity to pharmaceutical companies.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0711,FDA-2013-P-0711-0001_Allergy_Asthma_Network_Mothers_of_Asthmatics_Citiz.pdf,,2013,False,original petition,Allergy & Asthma Network Mothers of Asthmatics (AANMA),advocacy/academic,"21 C.F.R. ¬ß 10.30; section 505 (21 U.S.C. 355); sections 503(b), 505(d)(1), and 505(d)(4) of the FDCA",FDA's proposed new paradigm 'Using Innovative Technologies and Other Conditions of Safe Use to Expand Which Drug Products Can Be Considered Nonprescription',"Request that FDA exempt asthma and anaphylaxis medications from the proposed new paradigm expanding nonprescription drug access, and maintain these products as prescription-only.","Petitioners argue that FDA's proposal is inconsistent with national guidelines (e.g., NAEPP, NIAID), lacks evidence of safe OTC use for asthma and anaphylaxis drugs, could lead to worse health outcomes, undermines physician-patient care models, and risks increased morbidity and mortality by encouraging reliance on quick-relief medications without physician supervision.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0761,FDA-2013-P-0761-0001_Poly_Cell_Technologies_LLC___Health_Claim_Petition.pdf,,2013,False,original petition,PolyCell Technologies LLC and DKSH Italia Srl,industry/corporation,"Section 403(r)(4) of the Food, Drug, and Cosmetic Act; 21 CFR 101.81; 21 CFR 101.14",Expansion of the 'Soluble Fiber from Certain Foods and Risk of Coronary Heart Disease Health Claim' to include Glucagel barley beta-glucan fiber,"Expand the health claim to include Glucagel barley beta-glucan fiber as an eligible substance under 21 CFR 101.81, and issue an Interim Final Rule allowing labeling pending finalization","The petitioners argue that Glucagel barley beta-glucan fiber meets the FDA's criteria for a health claim because it is safe, provides nutritive value, is associated with reduced risk of coronary heart disease, and has significant supporting scientific evidence from human and animal studies. They also highlight that soluble fiber intake in the U.S. is below recommended levels, and that allowing Glucagel would help increase public intake of beneficial soluble fibers.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0766,FDA-2013-P-0766-0001_Amedra_Pharmaceuticals_LLC_Citizen_Petition.pdf,,2013,False,original petition,Amedra Pharmaceuticals LLC,industry/corporation,21 USC 355; 21 CFR 10.30,FDA's Draft Guidance on Albendazole bioequivalence requirements,"Request that FDA refrain from approving any ANDA referencing ALBENZA unless the ANDA demonstrates (i) bioequivalence based on systemic levels of both albendazole and albendazole sulfoxide, (ii) includes labeling identical to ALBENZA's labeling, particularly pediatric safety instructions, and (iii) includes simulated use testing showing the tablet can be crushed, chewed, and swallowed safely by young children without posing a choking hazard","Because ALBENZA undergoes significant first-pass metabolism to its active form (albendazole sulfoxide), bioequivalence should be demonstrated on both parent and metabolite; pediatric safety labeling is crucial due to a documented choking hazard; simulated use testing is necessary to confirm generic tablets can be safely administered to young children without increasing choking risk",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0767,FDA-2013-P-0767-0001_Ascend_Laboratories_LLC_Citizen_Petition.pdf,,2013,False,original petition,"Ascend Laboratories, LLC",advocacy/academic,21 CFR 10.25(a); 21 CFR 10.30; 21 CFR 25.31,Approval of a new oral suspension dosage form for tacrolimus in addition to the currently approved capsule and injection forms under NDA 050708 (PROGRAF),Request FDA to determine that Tacrolimus Oral Suspension is a suitable additional dosage form for NDA 050708 (PROGRAF) and permit submission of an application for this form,"The current capsule formulation is not suitable for pediatric patients and adults with swallowing difficulties. Extemporaneous suspensions currently used are not prepared under CGMP standards, posing safety and efficacy concerns. An FDA-approved suspension would ensure safe, standardized dosing and protect healthcare providers during compounding processes.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0768,FDA-2013-P-0768-0001_Salus_Pharma_LLC_Citizen_Petition.pdf,,2013,False,original petition,"Salus Pharma, LLC",industry/corporation,21 CFR 10.30; 21 CFR 314.161; 21 CFR 314.162; 21 CFR 25.31,"FDA's determination regarding whether Zefazone (cefmetazole sodium) injection, EQ 1 GM base/vial and EQ 2 GM base/vial was withdrawn for safety or effectiveness reasons","Request that the FDA determine whether Zefazone (cefmetazole sodium) injection, EQ 1 GM base/vial and EQ 2 GM base/vial was voluntarily withdrawn for reasons of safety or effectiveness","Zefazone is currently listed as discontinued in the Orange Book; Pharmacia and Upjohn requested withdrawal of the application, but no evidence suggests withdrawal for safety or efficacy reasons. A determination is necessary to permit ANDA submissions referencing Zefazone as the RLD.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0769,FDA-2013-P-0769-0001_Lachman_Consultant_Services_Inc_Citizen_Petition.pdf,,2013,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 10.20; 21 CFR 10.30; 21 CFR 25.31","FDA approval policies regarding the submission of an Abbreviated New Drug Application (ANDA) for Bendamustine Hydrochloride for Injection, 200 mg/vial","Request FDA to declare that Bendamustine Hydrochloride for Injection, 200 mg/vial, is suitable for submission in an ANDA","The petitioner argues that the proposed drug product is the same as the listed drug (TREANDA) except for a change in total drug content (strength), and that the change will improve convenience and reduce medication errors and healthcare practitioner exposure during reconstitution. The formulation is otherwise identical when reconstituted, and the labeling changes are minimal (only adjusting for strength). The change raises no new questions of safety or effectiveness.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0775,FDA-2013-P-0775-0001_Hyman_Phelps_McNamara_PC_Citizen_Petition.pdf,,2013,False,original petition,"Hyman, Phelps & McNamara, P.C. (on behalf of an unnamed client)",law/consulting,"21 C.F.R. ¬ß¬ß 10.25, 10.30, 314.161, 314.162; Sections 505(j) and 505(w) of the Federal Food, Drug, and Cosmetic Act",Determination regarding whether the 12 mg strength of INVEGA (paliperidone) Extended-release Tablets was withdrawn for safety or effectiveness reasons,Request that the FDA determine that the 12 mg strength of INVEGA was not withdrawn for reasons of safety or effectiveness,"There is no evidence that the 12 mg strength was ever marketed or withdrawn for safety or effectiveness reasons. It was approved but never marketed, and thus should still be eligible for use as a reference product in ANDA submissions for generic versions.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0776,FDA-2013-P-0776-0001_Biotechnology_Information_Institute_Citizen_Petiti.pdf,,2013,False,original petition,Biotechnology Information Institute,advocacy/academic,"Federal Food, Drug, and Cosmetic Act; Public Health Service Act; 21 CFR 5.10",FDA‚Äôs practice regarding biologics nomenclature and public disclosure of biologic product identity information,"Request the FDA to assign unique and biosimilar/(bio)generic-type names/identifiers to biologic products and their active agents, and to disclose sufficient public information to enable understanding of product identity.","The petitioner argues that biologics lack functional non-proprietary names and sufficient public information concerning product identity, leading to ambiguity and potential public health risks; the FDA is the only organization capable of implementing needed changes to nomenclature and public disclosures without significantly new resources or expenditures.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0799,FDA-2013-P-0799-0001_Lachman_Consultant_Services_Inc_Citizen_Petition.pdf,,2013,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 10.30; 21 CFR 25.31","Request for approval of a Suitability Petition to allow submission of an ANDA for Griseofulvin Tablets, 187.5 mg and 375 mg, based on the RLD Gris-PEG¬Æ 250 mg","Request FDA to declare that Griseofulvin Tablets, 187.5 mg and 375 mg, are suitable for submission as an ANDA referencing Gris-PEG¬Æ Tablets, 250 mg","The proposed strengths (187.5 mg and 375 mg) are within the dosing range already described in the RLD's labeling, would provide greater dosing flexibility for pediatric and adult patients, reduce the need for crushing tablets for administration, and help optimize dosing convenience and safety without raising new questions of safety or effectiveness.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0800,FDA-2013-P-0800-0001_Lachman_Consultant_Sevices_Inc_Citizen_Petition.pdf,,2013,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 10.30; 21 CFR 25.31","Approval of a Suitability Petition to allow submission of an ANDA for Dapsone Tablets, 50 mg, based on the RLD Dapsone Tablets USP, 100 mg (ANDA 86-842)","Request FDA to declare that Dapsone Tablets, 50 mg, are suitable for submission as an ANDA referencing the RLD Dapsone Tablets, 100 mg","The 50 mg strength is consistent with dosing instructions in the approved labeling for the RLD, would provide greater flexibility for dosage titration, reduce adverse effects, and does not raise any new questions of safety or effectiveness compared to the approved 100 mg product.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0813,FDA-2013-P-0813-0001_Lachman_Consultant_Services_Inc_Citizen_Petition.pdf,,2013,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 10.30; 21 CFR 25.31","Approval of a Suitability Petition to allow submission of an ANDA for Hydrocodone Bitartrate and Acetaminophen Tablets USP, 4 mg/300 mg, 6 mg/300 mg, and 8 mg/300 mg","Request FDA to declare that Hydrocodone Bitartrate and Acetaminophen Tablets USP, 4 mg/300 mg, 6 mg/300 mg, and 8 mg/300 mg are suitable for submission as an ANDA","The petitioner argues that the new strengths offer additional dosing flexibility, allow titration to the lowest effective dose to minimize narcotic exposure, and are consistent with the dosing recommendations of the reference listed drugs. The changes do not raise new questions of safety or effectiveness.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0830,FDA-2013-P-0830-0001_Lachman_Consultant_Services_Inc_Citizen_Petition.pdf,,2013,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 10.30; 21 CFR 25.31","Approval of a Suitability Petition to allow submission of an ANDA for Hydromorphone HCl Extended-Release Tablets, 24 mg","Request FDA to declare that Hydromorphone HCl Extended-Release Tablets, 24 mg, are suitable for submission as an ANDA referencing EXALGO (hydromorphone HCl) Extended-Release Tablets, 32 mg","The petitioner argues that the proposed 24 mg strength is consistent with the dosing recommendations of the RLD, provides improved dosing flexibility for titration and tapering, minimizes adverse reactions, and does not raise new questions of safety or effectiveness. The Pediatric Research Equity Act (PREA) requirements are also asserted not to apply to this petition.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0846,FDA-2013-P-0846-0001_KL_Gates_LLP_Citizen_Petition.pdf,,2013,False,original petition,K&L Gates LLP,law/consulting,"Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FDCA); 21 C.F.R. ¬ß 10.30",FDA's policy requiring ANDA applicants to use U.S.-sourced reference listed drugs (RLD) for bioequivalence studies,Request FDA to permit the client to use KUVAN drug product obtained in Israel as the reference product for bioequivalence studies in support of an ANDA submission,"The petitioner argues that BioMarin, the manufacturer of KUVAN, has implemented a restrictive distribution scheme preventing generic manufacturers from obtaining the U.S.-marketed RLD, and that the KUVAN product marketed in Israel is materially the same as the U.S. product; allowing use of the Israeli product would support generic competition and prevent misuse of the Hatch-Waxman system.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0847,FDA-2013-P-0847-0001_Lachman_Consultant_Services_Inc_Citizen_Petition.pdf,,2013,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 10.30; 21 CFR 25.31",FDA‚Äôs policy on allowing a new strength drug product to be submitted through an ANDA pathway,"Request FDA to declare that Tizanidine Hydrochloride Tablets, 8 mg, are suitable for submission in an Abbreviated New Drug Application (ANDA) referencing Zanaflex¬Æ (4 mg)","The petitioner argues that the 8 mg strength aligns with the dosing regimen already recommended for the reference listed drug, improves patient convenience by reducing the number of tablets needed per dose, potentially improves patient compliance, and does not raise new questions of safety or efficacy.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0848,FDA-2013-P-0848-0001_Hyman_Phelps_McNamara_PC_Citizen_Petition.pdf,,2013,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 10.20(a); 21 CFR 10.30; 21 CFR 314.93",FDA's designation of reference listed drugs (RLDs) in the Orange Book,Request FDA to designate Oxacillin for Injection 1g and 2g in ADD-Vantage Vial (approved under ANDA No. 062737) as a Reference Listed Drug (RLD),"The petitioner argues that the currently designated RLD (Oxacillin for Injection in a Flip-Top Vial) has different packaging and administration routes compared to the ADD-Vantage Vial product, and that without RLD designation for the ADD-Vantage product, generic competition would be shielded. Citing FDA policy, the petitioner contends there is a sound basis for designating the ADD-Vantage product as an additional RLD.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0849,FDA-2013-P-0849-0001_Hyman_Phelps_McNamara_PC_Citizen_Petition.pdf,,2013,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 10.20(a); 21 CFR 10.30; 21 CFR 314.93",Designation of Reference Listed Drugs (RLDs) in the Orange Book,Request FDA to designate Ampicillin for Injection 1g and 2g in ADD-Vantage Vial (approved under ANDA No. 062738) as a Reference Listed Drug (RLD),"The petitioner argues that the current RLD (Ampicillin for Injection in Flip-Top Vial) is approved for both IM and IV use, whereas the ADD-Vantage Vial product is approved only for IV use in a different container/closure system. Designating the ADD-Vantage Vial as an RLD would promote generic competition specifically for that IV-only product configuration.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0850,FDA-2013-P-0850-0001_Teva_Pharmaceutical_Industries_Ltd_Teva_Respirator.pdf,,2013,False,original petition,"Teva Pharmaceutical Industries Ltd., Teva Respiratory, LLC",industry/corporation,"21 C.F.R. ¬ß 10.30; 21 U.S.C. ¬ß¬ß 355(b)(2), 355(j), and 355(q)",Approval of any Abbreviated New Drug Application (ANDA) or 505(b)(2) Application referencing ProAir¬Æ HFA (albuterol sulfate) Inhalation Aerosol,Requesting that FDA refrain from approving any ANDA or 505(b)(2) application referencing ProAir¬Æ HFA unless certain conditions regarding dose counters and prevention of canister/actuator mismatches are met,"To ensure safety and efficacy, Teva argues that the presence of a dose counter is critical for patient safety because patients might unknowingly use inhalers past their effective dose limit without it; also stresses the need for in vitro and clinical testing to confirm dose counter functionality and the need to mitigate risks of canister/actuator mismatches to avoid dosing errors.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0862,FDA-2013-P-0862-0001_Spec_Pharma_LLC_Fish_Richardson_PC_Citizen_Petitio.pdf,,2013,False,original petition,"Spec Pharma, LLC",industry/corporation,"21 U.S.C. ¬ß 355 (Section 505 of the Federal Food, Drug, and Cosmetic Act), 21 C.F.R. ¬ß 10.30","The New Animal Drug Application (NADA) for BetaVet submitted by Luitpold Pharmaceuticals, Inc.","Requesting that the FDA refrain from granting approval of the BetaVet NADA until arbitration resolves ownership rights in relevant data, advise the applicant of deficiencies in the NADA, and require the applicant to obtain Petitioner's consent if ownership rights are confirmed.","Petitioner alleges that the BetaVet NADA improperly uses or references data owned by Spec Pharma without authorization, violating FDA policies protecting property rights in data. They argue the ownership of the data is under arbitration and the FDA should not approve the application until the matter is resolved to prevent misappropriation and ensure regulatory compliance.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0884,FDA-2013-P-0884-0001_Eisai_Inc_Citizen_Petition.pdf,,2013,False,original petition,Eisai Inc.,industry/corporation,"21 U.S.C. 355(c) and (j); 21 C.F.R. 314.107; 21 C.F.R. 10.30; Controlled Substances Act (CSA); 21 U.S.C. 811; 21 C.F.R. 201.57(a)(2), 201.57(c)(10)(i), and 314.70(b)(2)(v)(C).",The initiation of the five-year New Chemical Entity (NCE) exclusivity period before Eisai could commercially market its products due to pending Controlled Substance scheduling.,"(1) Determine the NCE exclusivity for BELVIQ¬Æ to start on June 7, 2013; (2) determine the NCE exclusivity for FYCOMPATm to start on the date it can be commercially marketed; (3) provide a substantive response before FYCOMPATm's scheduling is finalized or within five months.","Eisai argues that FDA incorrectly started the NCE exclusivity periods when products could not yet be legally marketed because Controlled Substance scheduling was incomplete, depriving Eisai of the full exclusivity period intended by Congress, and that this practice is arbitrary, capricious, contrary to law, and undermines innovation incentives.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0885,FDA-2013-P-0885-0001_AMAG_Pharmaceuticals_Inc_Citizen_Petition.pdf,,2013,False,original petition,"AMAG Pharmaceuticals, Inc.",industry/corporation,"21 USC 355, 21 CFR 10.30",Draft Guidance on Ferumoxytol (Dec. 2012) and general FDA standards for approving generic versions of nanoparticle intravenous iron products,Request that FDA (1) refrain from approving any ANDA referencing Feraheme until Nulecit Post-Market Contract Studies confirm adequacy of FDA's standards for generic IV iron approval; and (2) require any generic applicant to demonstrate equivalence using a comparative clinical endpoint study and additional laboratory assays,"Justifications include the complex and incompletely characterized structure of ferumoxytol, inadequacy of plasma/serum measurements to establish bioequivalence, lessons learned from inferior therapeutic equivalence of generic iron sucrose products in the EU, concerns raised in the EMA Reflection Paper, potential public health risks from insufficiently characterized generics, and FDA's own actions soliciting post-market studies for existing generics indicating unresolved scientific concerns.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0886,FDA-2013-P-0886-0001_Arnall_Golden_Gregory_LLP_Citizen_Petition.pdf,,2013,False,original petition,Arnall Golden Gregory LLP,law/consulting,"21 U.S.C. ¬ß 355; 21 C.F.R. ¬ß¬ß 10.20, 10.25, 10.30, and 314.161",Discontinuation of Norplant¬Æ II Levonorgestrel Implants (Jadelle¬Æ) from the market,"Request for FDA to determine that Norplant¬Æ II Levonorgestrel Implants (Jadelle¬Æ) was withdrawn from the market for reasons other than safety or effectiveness, allowing it to be used as a Reference Listed Drug (RLD) for 505(b)(2) applications","The petitioner asserts there is no information indicating that the withdrawal was due to safety or effectiveness issues, and thus an NDA may be submitted referencing Norplant¬Æ II (Jadelle¬Æ) as an RLD.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0944,FDA-2013-P-0944-0001_Jeffrey_G_Thomas_DBA_Thomas_Law_Company__Citizen_P.pdf,,2013,False,original petition,Jeffrey G. Thomas DBA Thomas Law Company,law/consulting,"Section 515(g) of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. ¬ß10.30; 21 C.F.R. ¬ß814.82(a)(3); 21 C.F.R. ¬ß814.47; 21 C.F.R. ¬ß820.198; 21 C.F.R. ¬ß814.80; 21 C.F.R. ¬ß812.140(a)(2); 21 C.F.R. ¬ß812.140(b)(2); 21 C.F.R. ¬ß820.90(b)(1); 21 C.F.R. ¬ß814.9; 21 C.F.R. ¬ß820.90(b)(1); 21 C.F.R. ¬ß812.38(d); 21 C.F.R. ¬ß814.9(a); 21 C.F.R. ¬ß814.9(r); Section 515(g)(1) of the Act; Freedom of Information Act (FOIA)",Conditions of the Pre-Marketing Approval (PMA) for Duraseal¬Æ Spinal Sealant,Enforce post-approval conditions including completion of a post-approval study on infection rates; investigation into undisclosed risks; investigation into sponsor's compliance with reporting obligations; revision of labeling and package inserts with stronger warnings (including a black box warning); suspension of the PMA; public hearing on continued violations of procedural and substantive due process,"Ms. Moore suffered paralysis allegedly due to the Duraseal¬Æ Spinal Sealant during clinical trials. She claims undisclosed serious risks (such as harmful interactions with non-autologous agents and product swelling), lack of informed consent, suppression of adverse event reports by the sponsor and FDA, incomplete post-approval studies, misrepresentation of product characteristics (blue dye color retention), and violations of due process rights prevented her from proving causation in her lawsuit. She argues that the agency must investigate these issues to protect public health and enforce compliance.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0945,FDA-2013-P-0945-0001_Lachman_Consultant_Services_Inc_Citizen_Petition.pdf,,2013,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act; 21 CFR 10.30","Suitability petition for Carisoprodol Tablets, 300 mg, based on reference listed drug Soma¬Æ (Carisoprodol) Tablets USP, 250 mg","Requesting FDA to declare Carisoprodol Tablets, 300 mg, suitable for submission in an ANDA","The proposed change from 250 mg to 300 mg dosage strength is within the approved dosing range for Soma¬Æ (250 mg to 350 mg three times daily and at bedtime), offering greater dosing flexibility without raising safety or effectiveness concerns. The Pediatric Research Equity Act (PREA) does not apply to the petition.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0946,FDA-2013-P-0946-0001_Lachman_Consultant_Services_Inc_Citizen_Petition.pdf,,2013,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. ¬ß 10.30",Suitability petition to allow submission of an Abbreviated New Drug Application (ANDA) for a new drug strength,"Request for the FDA to declare Hydrocodone Bitartrate and Acetaminophen Tablets USP, 2.5 mg/300 mg suitable for submission as an ANDA","The proposed lower strength of hydrocodone bitartrate will provide additional dosing options to healthcare practitioners, enabling more precise pain management while minimizing narcotic exposure, and the proposed change does not raise new safety or efficacy concerns.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0947,FDA-2013-P-0947-0001_Hyman_Phelps_McNamara_PC_Citizen_Petition.pdf,,2013,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"505(j)(2)(c) of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. ¬ß¬ß 10.20(a), 10.30, and 314.93",Amendment to the Orange Book designation for Cefdinir for Oral Suspension,Request that FDA designate one of the approved Abbreviated New Drug Applications (ANDAs) listed for Cefdinir for Oral Suspension as an additional Reference Listed Drug (RLD),"The originally designated RLD (OMNICEF) has been discontinued, and the current RLD (Sandoz product) is reportedly no longer available on the market; thus, designating a currently marketed product as an RLD would ensure continued generic competition and availability.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0948,FDA-2013-P-0948-0001_Pharmaceutics_International_Incorporated_Citizen_P.pdf,,2013,False,original petition,"Pharmaceutics International, Inc. (Pii)",industry/corporation,"505(j)(2)(C), 21 C.F.R. ¬ß 10.20, 10.30, 314.122",Acceptance of an Abbreviated New Drug Application (ANDA) for Valproic Acid Delayed Release Capsules after discontinuation of STAVZOR¬Æ by Banner Pharmacaps,"Request the FDA to determine that Banner Pharmacaps discontinued STAVZOR¬Æ (valproic acid delayed release capsules) for reasons unrelated to safety and effectiveness and to accept an ANDA for Valproic Acid Delayed Release Capsules, 125 mg, 250 mg, and 500 mg",Banner Pharmacaps withdrew STAVZOR¬Æ from the market for reasons unrelated to safety or efficacy; the petitioner seeks to allow submission of an ANDA for generic versions at the same strengths to ensure availability.,,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0949,FDA-2013-P-0949-0001_Reginald_Burgess_Garrett_Skelly_ESQ_Citizen_Petiti.pdf,,2013,False,original petition,"Reginald Burgess (petition submitted through attorney Garrett Skelly, ESQ)",individual,"21 CFR 801.109; 21 CFR 890.3420; 21 CFR 890.3500; 21 CFR 820.198; 42 USC 12182; 21 CFR 5.10; section 520(e) and 515(d)(1)(B)(ii) of the Federal Food, Drug, and Cosmetic Act","FDA's classification and labeling requirements for external prosthetic devices, specifically approval orders like K991590 for the C-leg",Amend the approval order for the C-leg device to include 'OVER THE COUNTER USE' in addition to 'PRESCRIPTION' use for external prosthetic devices,"The petitioner argues that external prosthetic devices like the C-leg should not be classified solely as prescription devices because this unjustly restricts access for amputees, violates the Americans with Disabilities Act (ADA), and leads to unnecessary monopolistic practices by companies like Otto Bock. He asserts that the devices are safe enough for over-the-counter sale and that requiring prescriptions enables price gouging and discriminatory practices against amputees, citing Olmstead v. L.C. and Executive Order 13217 in support.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0990,FDA-2013-P-0990-0001_Corporate_Social_Responsibility_Advocate_Reprieve_.pdf,,2013,False,original petition,Corporate Social Responsibility Advocate at Reprieve,advocacy/academic,"21 C.F.R. 10.30, 21 U.S.C. ¬ß355, ¬ß355-1, ¬ß372, ¬ß393",Use of Reglan in force-feeding detainees at Guantanamo Bay,"Suspend approval of Reglan for force-feeding at Guantanamo Bay, investigate compliance by ANI Pharmaceuticals, Inc., and consider requiring a new REMS submission","Petitioner argues that Reglan has serious side effects (including tardive dyskinesia, depression, suicide risk), that detainees are being administered Reglan without informed consent and potentially for longer than the recommended 12 weeks, and that this practice constitutes an urgent health hazard requiring immediate FDA intervention.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0995,FDA-2013-P-0995-0001_Hyman_Phelps_McNamara_PC_Citizen_Petition.pdf,,2013,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,505(q) of the FDCA; 21 C.F.R. ¬ß¬ß 10.20 and 10.30,FDA acceptance and approval process for 505(b)(2) NDAs for buprenorphine/naloxone polymer film products,Request that FDA refuse to file any 505(b)(2) NDA for a buprenorphine/naloxone polymer film product unless it references NDA No. 22-410 (SUBOXONE¬Æ sublingual film) and complies with impurity limits for naloxone,Petitioner argues that any 505(b)(2) NDA for a buprenorphine/naloxone film should properly identify the SUBOXONE¬Æ film NDA as the listed drug to ensure patent protections are respected and that the impurity limits for naloxone established by FDA are properly applied; this prevents circumvention of patent laws and safeguards public health.,,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0996,FDA-2013-P-0996-0001_Piedmont_Animal_Health_Citizen_Petition.pdf,,2013,False,original petition,Piedmont Animal Health,individual,"Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. 25.15; 21 C.F.R. 25.30(h); 21 C.F.R. 25.21",Approval to file an Abbreviated New Animal Drug Application (ANADA) for a different dosage form than the pioneer product SIMPLICEF¬Æ (cefpodoxime proxetil).,Permission to file an ANADA for a soft chewable tablet form of cefpodoxime proxetil instead of the pioneer product's film-coated tablet form.,"The petitioner argues that although the generic product will differ in form (soft chewable versus film-coated tablet) and shape (round versus elliptical or round-rectangular), it will have the same active ingredient, dosage, indications, route of administration (oral), and therapeutic effect as the pioneer product, thus qualifying for a suitability petition.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0997,FDA-2013-P-0997-0001_Thomas_J_Quinn_Citizen_Petition_Redacted.pdf,,2013,False,original petition,Thomas J. Quinn,individual,"21 U.S.C. Chapter 9 Subchapter V Part C Section 360kk; 21 CFR Section 1030; 21 U.S.C. 351, 352, 360, 360e-360j, 360hh-360ss, 371, 381",Regulation of performance standards for microwave and radio frequency emitting products (specifically to amend standards to include Nuclear Magnetic Resonance Imaging devices),Amend 21 CFR section 1030 to add section 1030.30 establishing performance standards for Nuclear Magnetic Resonance Imaging systems,"There are currently no specific performance standards in 21 CFR for Nuclear Magnetic Resonance Imaging systems, and such standards are necessary because the health effects of microwave energy on the human body are well known and documented; ensuring regulatory control is essential for safety.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0998,FDA-2013-P-0998-0001_Millennium_Pharmaceuticals_Inc_Citizen_Petition.pdf,,2013,False,original petition,"Millennium Pharmaceuticals, Inc.",industry/corporation,"Section 505(q) of the Federal Food, Drug, and Cosmetic Act (FDCA), 21 C.F.R. 10.30, 21 C.F.R. part 314",FDA‚Äôs acceptance for filing of a New Drug Application (NDA) by Fresenius Kabi USA for a bortezomib injectable product relying on VELCADE¬Æ (bortezomib) for Injection.,"(1) human bioequivalence data from multiple-dose testing proving equivalence to VELCADE, (2) preclinical safety data on boric acid for intravenous and subcutaneous administration, and (3) additional human clinical data as needed; and require Fresenius to reference all sources relied upon for safety.","Petitioner argues that Fresenius‚Äôs formulation contains boric acid, which has potential toxicity risks, lacks adequate human testing, and that approval without sufficient human clinical data would endanger patients given the established risks and different formulation compared to VELCADE.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-0999,FDA-2013-P-0999-0001_Consumer_Healthcare_Products_Association_Citizen_P.pdf,,2013,False,original petition,Consumer Healthcare Products Association (CHPA),advocacy/academic,"21 C.F.R. Part 330; 21 C.F.R. ¬ß 201.66(e); Federal Food, Drug, and Cosmetic Act (FDCA)","Ongoing internal analgesic, antipyretic, and antirheumatic monograph proceedings related to acetaminophen labeling","FDA should publish a statement of enforcement policy expressly permitting manufacturers of single-ingredient acetaminophen OTC drugs to include labeling with dosage instructions for children aged six months to two years, and recommend use of a standardized dosing chart",Lack of dosing information on labels for children aged six months to two years may lead to medication errors; acetaminophen is recognized as safe and effective for this age group by medical associations; FDA advisory committees have recommended inclusion of this dosing information; clear labeling would promote consistency and reduce risk of overdose or misadministration.,,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1000,FDA-2013-P-1000-0001_Eclat_Pharmaceuticals_LLC_Patton_Boggs_LLP_Citizen.pdf,,2013,False,original petition,"Eclat Pharmaceuticals, LLC",industry/corporation,"21 C.F.R. ¬ß 10.30; Sections 301(d) and 505(a) of the Federal Food, Drug, and Cosmetic Act",Marketing of unapproved neostigmine methylsulfate injectable drug products competing with an FDA-approved drug (Bloxiverz¬Æ),Requesting FDA to initiate immediate enforcement action requiring removal of unapproved injectable neostigmine methylsulfate products from the market,"Petitioner argues that unapproved products challenge the integrity of the FDA drug approval framework, pose safety risks due to differences in labeling and dosage recommendations, and may violate quality control requirements; also claims that the approved product can meet market demand, minimizing concern about shortages.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1001,FDA-2013-P-1001-0001_Weill_Cornell_Medical_College_Citizen_Petition.pdf,,2013,False,original petition,Weill Cornell Medical College,advocacy/academic,21 C.F.R. 10.30,Labeling of nonprescription drug products containing ingredients with anticholinergic or histamine H1 inverse agonist effects,"Request for the FDA to add a warning to the labeling of all nonprescription drug products containing ingredients with anticholinergic or histamine H1 inverse agonist effects, warning about potential confusional states including impaired attention, disorientation, and decreased concentration, especially in older people","The petitioner cites scientific studies, observational studies, and clinical trials showing that drugs with anticholinergic effects cause cognitive impairment, especially in the elderly. They argue that nonprescription drugs with such effects can add to the anticholinergic burden unnoticed, leading to confusional states or delirium, warranting a warning label to inform consumers and prevent harm.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1002,FDA-2013-P-1002-0001_Zydus_Pharmaceuticals_Inc_Citizen_Petition.pdf,,2013,False,original petition,Zydus Pharmaceuticals (USA) Inc.,industry/corporation,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FDC Act); 21 C.F.R. ¬ß 314.93; 21 C.F.R. ¬ß 10.20; 21 C.F.R. ¬ß 10.30","Suitability determination for submission of an Abbreviated New Drug Application (ANDA) for Imatinib Mesylate Tablets, 300 mg strength","Request that FDA determine that Imatinib Mesylate Tablets, 300 mg is suitable for submission in an ANDA",The proposed 300 mg strength is between already approved 100 mg and 400 mg strengths of the reference listed drug (GLEEVEC); it would improve patient compliance by providing an appropriate dosage without the need for splitting tablets; it matches the existing dosage forms and routes of administration; and there are no new safety or efficacy concerns.,,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1055,FDA-2013-P-1055-0001_Actavis_Elizabeth_LLC_Citizen_Petition.pdf,,2013,False,original petition,Actavis Elizabeth LLC,industry/corporation,"21 C.F.R. ¬ß¬ß 10.30 and 314.161; 21 C.F.R. ¬ß¬ß 314.122, 314.161; 21 C.F.R. ¬ß 25.31; 21 C.F.R. ¬ß 10.30(b)",Determination whether a listed drug has been withdrawn from sale for safety or effectiveness reasons,"Requesting that the FDA determine that SUBUTEX¬Æ (buprenorphine hydrochloride) Sublingual Tablets, EQ. 2 mg and 8 mg Base were not voluntarily withdrawn for safety or efficacy reasons","Because there is no evidence of commercial distribution of SUBUTEX¬Æ 2 mg and 8 mg Sublingual Tablets, the petitioner requests confirmation that their withdrawal was not for reasons of safety or effectiveness to support an ANDA submission",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1056,FDA-2013-P-1056-0001_Public_Citizen_Citizen_Petition.pdf,,2013,False,original petition,"Public Citizen and Neil A. Holtzman, M.D.",individual,"21 U.S.C. Section 355(e)(3), 21 C.F.R. 10.30",The continuation of clopidogrel (Plavix) therapy beyond 12 months following implantation of drug-eluting coronary artery stents.,"Add a black-box warning on clopidogrel and its generic equivalents regarding increased risks of major and minor bleeding beyond 12 months, require an updated FDA-approved Medication Guide, and encourage distribution of a 'Dear Doctor' letter.","Petitioners argue that evidence shows no further reduction in thrombotic cardiovascular events beyond 12 months but continued major bleeding risks, necessitating enhanced warnings to protect patients.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1058,FDA-2013-P-1058-0001_Citizen_Petition_from_IntelGenx_Corporation.pdf,,2013,False,original petition,IntelGenx Corp.,industry/corporation,"21 C.F.R. 10.30, Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act","Approval and designation of Rizatriptan Oral Film as AB-rated relative to the Reference Listed Drug (RLD), Maxalt-MLT¬Æ (Merck, NDA 20-865)","Request for the FDA to designate Rizatriptan Oral Film, upon approval, as AB-rated relative to the RLD Maxalt-MLT¬Æ","The petitioner argues that Rizatriptan Oral Film meets FDA‚Äôs criteria for therapeutic equivalence because it contains the same active ingredient in the same strength, has similar performance and administration characteristics, is bioequivalent to the RLD, will be adequately labeled, and will be manufactured in compliance with Current Good Manufacturing Practice regulations.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1061,FDA-2013-P-1061-0001_Navinta_LLC_Citizen_Petition.pdf,,2013,False,original petition,Navinta LLC,industry/corporation,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FDC Act); 21 C.F.R. ¬ß 314.93; 21 C.F.R. ¬ß 10.30",Suitability petition to allow submission of an ANDA for a new dosage form (solution instead of lyophilized powder),"Request FDA to find that Ganciclovir Injection, 500 mg/10 ml (50 mg/mL) solution is suitable for submission as an ANDA","The proposed solution form has the same active ingredient, concentration, route of administration, and therapeutic effect as the reconstituted reference listed drug (RLD) Cytovene¬Æ; eliminates the need for reconstitution; no additional investigations needed to demonstrate safety and effectiveness.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1078,FDA-2013-P-1078-0001_Parnell_Technologies_Pty_Ltd_Citizen_Petition.pdf,,2013,False,original petition,Parnell Technologies Pty Ltd,industry/corporation,"21 CFR ¬ß10.30; Federal Food, Drug, and Cosmetic Act Section 512 ¬ß360b(n)(3)(A)",Amendment to ANADA 200-541 to delete one route of administration,Allow amendment to delete the intravenous route of administration from the currently approved routes for Gonabreed (gonadorelin 100 ¬µg/mL),The removal of the intravenous route does not pose questions of safety or effectiveness because the product remains indicated for intramuscular administration identical to the pioneer product (Cystorelin¬Æ),,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1079,FDA-2013-P-1079-0001_Citizen_Petition_from_Medical_Information_Working_.pdf,,2013,False,original petition,Medical Information Working Group (MIWG),advocacy/academic,"21 C.F.R. ¬ß 10.30; also references to 21 U.S.C. ¬ß 360(k), 21 U.S.C. ¬ß 321(m), 21 U.S.C. ¬ß¬ß 352(n), (r), and 21 U.S.C. ¬ß 351(f)(1)","FDA regulations and policies regarding manufacturer dissemination of off-label use information and related communications (responses to unsolicited requests, scientific exchange, communications to payors, dissemination of clinical practice guidelines)","Request for FDA to fully respond to prior citizen petition requests concerning off-label communications, to initiate rulemaking for payor communications and clinical guidelines, and to comprehensively review and revise regulations to align with constitutional and statutory requirements","The petition argues that the FDA‚Äôs current regulatory approach to manufacturer communication about off-label uses is outdated, unclear, and unconstitutional under recent First and Fifth Amendment case law (citing Sorrell v. IMS Health, FCC v. Fox, and U.S. v. Caronia). It emphasizes that clearer regulations would benefit public health, respect free speech, and support informed decision-making by patients, providers, and payors.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1080,FDA-2013-P-1080-0001_Reginald_Burgess_Garrett_Skelly_ESQ_Citizen_Petiti.pdf,,2013,False,original petition,"Reginald Burgess (submitted through Garrett Skelly, ESQ)",individual,"21 CFR 820.198, 21 CFR 820.200, 21 CFR 801.109, 21 CFR 890.3420, 21 CFR 890.3500, 42 USC 12182, 21 USC 331(a), 21 USC 360c, 21 USC 360k, 21 USC 829","FDA regulations regarding classification of external prosthetics, particularly the lack of over-the-counter availability and the misuse of 'prescription' labeling","Amend 21 CFR 820.198 to add a new section (a)(4) requiring manufacturers to provide direct access to parts and repair information for external prosthetics to users, ensuring no unnecessary restrictions under internal distribution models unless justified by malfunction or safety concerns","The petitioner argues that external prosthetic devices are incorrectly treated as prescription devices when no prescription restriction legally applies, resulting in discrimination against amputees under the ADA; the prosthetics industry uses distribution models to monopolize service and parts access, forcing users into unnecessary, costly service arrangements and restricting user autonomy in violation of the Americans with Disabilities Act and principles established in Olmstead v. L.C.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1082,FDA-2013-P-1082-0001_Horizon_Pharma_Inc_Citizen_Petition.pdf,,2013,False,original petition,"Horizon Pharma, Inc.",industry/corporation,"21 C.F.R. ¬ß 10.30, 505(j)(2) of the Federal Food, Drug, and Cosmetic Act",Bioequivalence standards for ANDAs referencing NDA No. 202020 for RAYOS¬Æ (prednisone) Delayed-Release Tablets,"Request that FDA require ANDA applicants to demonstrate bioequivalence by showing the same delayed-release profile (lag time and Tmax) and bioavailability (BA) profile after 4 hours, under fed conditions, for generic versions of RAYOS¬Æ tablets","RAYOS¬Æ tablets are specially formulated with a delayed-release mechanism to synchronize with the circadian rhythm of inflammatory symptoms in diseases like rheumatoid arthritis; generics with different delayed-release mechanisms could have different pharmacokinetic profiles, affecting therapeutic outcomes; thus, strict bioequivalence requirements under fed conditions are necessary to ensure therapeutic equivalence.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1101,FDA-2013-P-1101-0001_Piedmont_Animal_Health_Citizen_Petition.pdf,,2013,False,original petition,Piedmont Animal Health,individual,"Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 25.24(a)(8)",Permission to file an Abbreviated New Animal Drug Application (ANADA) for a generic new animal drug differing in dosage form (capsule vs. soft chewable tablet) from the pioneer product,Permission to file an Abbreviated New Animal Drug Application (ANADA) for a soft chewable tablet form of clindamycin hydrochloride instead of a capsule,"The generic product will maintain the same active ingredient, dosage, route of administration, indications, therapeutic effects, and warnings as the pioneer product, differing only in dosage form (soft chewable tablet vs. capsule). Piedmont Animal Health argues that the change does not affect the product's intended use or effectiveness.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1126,FDA-2013-P-1126-0001_Citizen_Petition_from_Lachman_Consultant_Services_.pdf,,2013,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FDC Act), 21 CFR 314.93, 21 CFR ¬ß10.20, 21 CFR ¬ß10.30",Determination of suitability for submission of an Abbreviated New Drug Application (ANDA) for Capecitabine Tablets in 300 mg and 1000 mg strengths,"Request that FDA determine that Capecitabine Tablets, 300 mg and 1000 mg, are suitable for submission in an ANDA","The new strengths differ only in strength (not in dosage form, route of administration, or intended use) from the approved Reference Listed Drug (XELODA 500 mg and 150 mg); no questions of safety or efficacy are raised; availability of additional strengths would facilitate dosing, increase compliance, and reduce medication errors.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1127,FDA-2013-P-1127-0001_Tobacco_Control_Legal_Consortium_Citizen_Petition.pdf,,2013,False,original petition,Tobacco Control Legal Consortium,law/consulting,"Title 21, Chapter 9, Subchapter V, Part A of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. ¬ß 10.30; Family Smoking Prevention and Tobacco Control Act (codified at 21 U.S.C. ¬ß 387)","FDA's lack of regulation over 'other tobacco products' (OTPs) such as cigars, dissolvables, e-cigarettes, and hookah","Petitioners request that FDA assert jurisdiction over and regulate all tobacco products meeting the Tobacco Control Act's definition, and apply existing cigarette and smokeless tobacco restrictions to those products","The petition argues that unregulated non-cigarette tobacco products present serious public health risks, entice youth, and undermine existing public health measures; asserts that FDA has both the authority and responsibility under the Tobacco Control Act to regulate these products to protect public health",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1128,FDA-2013-P-1128-0001_Teva_Pharmaceutical_Industries_Ltd_Citizen_Petitio.pdf,,2013,False,original petition,"Teva Pharmaceutical Industries Ltd. and Teva Neuroscience, Inc.",industry/corporation,"21 C.F.R. ¬ß 10.30, 21 U.S.C. ¬ß¬ß 355(j) and 355(q)",Approval of any Abbreviated New Drug Application (ANDA) referencing Copaxone¬Æ (glatiramer acetate injection),"Requesting FDA to refrain from approving any ANDA referencing Copaxone¬Æ unless certain scientific conditions regarding sameness, bioequivalence, and immunogenicity are met","Because Copaxone¬Æ is a complex colloidal suspension with two distinct nano-sized polypeptide populations that cannot be fully characterized, Teva argues that generic versions cannot demonstrate sameness, bioequivalence, or immunological equivalence without extensive clinical and non-clinical studies, thus posing potential safety and efficacy risks.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1153,FDA-2013-P-1153-0001_Generic_Pharmaceutical_Association_Citizen_Petitio.pdf,,2013,False,original petition,Generic Pharmaceutical Association (GPhA),advocacy/academic,"21 C.F.R. ¬ß 10.30, Biologics Price Competition and Innovation Act (BPCIA)",FDA policy on International Non-proprietary Naming (INN) for biologics and biosimilars,Implement FDA‚Äôs INN naming policy equally for all biologics and allow biosimilars approved under the 351(k) pathway to share the same INN as their reference protein products (RPPs),"Shared INNs would ensure consistency, promote competition, enhance patient access to affordable biologics, and maintain pharmacovigilance without introducing confusion; unique INNs would imply clinical differences where there are none, hinder market competition, create unnecessary regulatory burdens, and potentially compromise patient safety.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1199,FDA-2013-P-1199-0001_CorePharma_LLC_Citizen_Petition.pdf,,2013,False,original petition,"CorePharma, LLC",industry/corporation,"21 CFR 10.25(a), 21 CFR 10.30, 21 CFR 314.161(a)(1)","Determination regarding whether the discontinuation of Skelaxin¬Æ 400 mg (NDA 013217) by King Pharmaceuticals, Inc. was due to safety or effectiveness reasons","Request that the FDA determine that Skelaxin¬Æ 400 mg was not withdrawn from sale for reasons related to safety or effectiveness, to permit approval of an Abbreviated New Drug Application (ANDA)","The petitioner asserts that Skelaxin¬Æ 800 mg remains available under the same NDA and can be divided due to scoring, suggesting the 400 mg dosage form was not withdrawn for safety or efficacy concerns; therefore, FDA should permit ANDA referencing the discontinued drug.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1202,FDA-2013-P-1202-0001_Olsson_Frank_Weeda_OFW_et_al_Law_PC_Citizen_Petiti.pdf,,2013,False,original petition,"Olsson Frank Weeda Terman Matz PC (on behalf of a client, not specifically named)",law/consulting,"505(j)(2)(C), 21 C.F.R. ¬ß¬ß 10.20, 10.30, 314.93","Requesting FDA action to allow submission of an ANDA for a new strength of an approved drug (Vancomycin Hydrochloride For Injection, USP, Fliptop Vial For Intravenous Use)","Determine that Vancomycin Hydrochloride USP, 1.5 grams (base)/vial is suitable for ANDA submission as a new strength","The petitioner argues that the proposed product will have the same active ingredient, concentration after reconstitution, route of administration, dosage, and indications as the reference listed drug (RLD), differing only in total drug content, and that it would benefit clinical dosing without raising safety or effectiveness concerns.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1203,FDA-2013-P-1203-0001_McGuireWoods_LLP_Citizen_Petition.pdf,,2013,False,original petition,McGuireWoods LLP,law/consulting,"505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. ¬ß¬ß 10.30 and 314.93",Suitability determination for submission of an Abbreviated New Drug Application (ANDA) for a different fill volume of Ropivacaine Hydrochloride Injection,The petitioner requests that the FDA determine that Ropivacaine Hydrochloride Injection 2mg/mL in a 500 mL infusion bag is suitable for submission as an ANDA,"The petitioner argues that the proposed product differs from the reference listed drug (NAROPIN) only in total fill volume (500 mL vs. 200 mL), with no change in concentration, active ingredient, dosage form, route of administration, or indications; further, it improves patient and hospital convenience, reduces risk of error and contamination, and decreases pharmacy workload and waste.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1283,FDA-2013-P-1283-0001_Horizon_Pharma_Inc_Citizen_Petition.pdf,,2013,False,original petition,"Horizon Pharma, Inc.",industry/corporation,"21 C.F.R. ¬ß 10.30; Section 505(j)(2) of the Federal Food, Drug, and Cosmetic Act (FD&C Act); 21 C.F.R. ¬ß¬ß 314.127(a)(7) and 314.127(a)(6)(i); 21 CFR 320.1(e) and 320.23(b)",Approval process for Abbreviated New Drug Applications (ANDAs) referencing RAYOS¬Æ (prednisone) delayed-release tablets as the reference listed drug (RLD),"Require that any ANDA referencing RAYOS¬Æ must demonstrate (1) no release of prednisone until approximately four hours after intake (equivalent lag time and Tmax) and (2) equivalent bioavailability (BA) profile after the four-hour delay, under fed conditions","RAYOS¬Æ tablets employ a unique delayed-release mechanism synchronized with the circadian rise in pro-inflammatory cytokines, critical for therapeutic effect in inflammatory diseases like rheumatoid arthritis; differing delayed-release mechanisms (e.g., enteric coating) could result in different pharmacokinetic profiles, impacting efficacy; thus, bioequivalence must demonstrate equivalent lag time, Tmax, and BA under fed conditions to ensure comparable therapeutic effect.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1286,FDA-2013-P-1286-0001_Proctor_Gamble_Company_Citizen_Petition.pdf,,2013,False,original petition,The Procter & Gamble Company,industry/corporation,"21 C.F.R. ¬ß 10.30, 21 C.F.R. Part 314, 21 U.S.C. ¬ß¬ß 351 and 355","Approval and labeling standards for over-the-counter proton pump inhibitors (PPIs), particularly related to Prilosec OTC and pending applications like Nexium OTC","(1) Continue requiring consistent labeling standards for all OTC PPIs similar to Prilosec OTC; (2) Impose rigorous standards on pending or future OTC PPI applications; (3) Require clinically significant evidence if label differences are proposed, and prevent false or misleading claims about relative safety or efficacy","P&G argues that different labeling among similar OTC PPI products could mislead consumers into thinking certain products are more effective without adequate substantiation, potentially violating the Administrative Procedure Act by treating similarly situated products differently; therefore, consistent class labeling or consistent regulatory standards are necessary to avoid consumer confusion and ensure fair competition.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1287,FDA-2013-P-1287-0001_Aptalis_Pharma_US_Inc_Citizen_Petition.pdf,,2013,False,original petition,"Aptalis Pharma US, Inc.",industry/corporation,"Sections 505 and 505(q) of the Federal Food, Drug, and Cosmetic Act (FDC Act); 21 C.F.R. ¬ß¬ß 10.25 and 10.30","Approval standards for Abbreviated New Drug Applications (ANDAs) for generic versions of Canasa¬Æ (mesalamine) Rectal Suppositories, 500 mg and 1000 mg","(1) Refuse to receive or approve any ANDA for a generic Canasa¬Æ unless bioequivalence is demonstrated through a clinical endpoint study; (2) Withdraw current bioequivalence guidance and issue new guidance requiring such study; (3) Require assessment of critical quality attributes, including Q1, Q2, Q3 sameness and dissolution testing; (4) Hold final approvals in abeyance until ongoing FDA studies are completed and reviewed.",Aptalis argues that systemic pharmacokinetic data are inadequate to demonstrate bioequivalence for locally acting rectal suppositories like Canasa¬Æ; clinical endpoint studies are necessary due to the drug‚Äôs local action; significant variability in systemic absorption exists; and critical quality attributes (like spreadability and irritation potential) must be properly assessed to ensure therapeutic equivalence.,,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1288,FDA-2013-P-1288-0001_National_Advocates_for_Pregnant_Women_Citizen_Peti.pdf,,2013,False,original petition,National Advocates for Pregnant Women (NAPW),advocacy/academic,"21 C.F.R. ¬ß 10.30; references also to 21 U.S.C. ¬ß 355, 21 U.S.C. ¬ß 355(o)(4), 21 U.S.C. ¬ß 355-1(b)(3), 21 C.F.R. ¬ß 201, 21 C.F.R. ¬ß 25.31","FDA's neonatal opioid withdrawal syndrome (NOWS)-related labeling changes for extended-release and long-acting (ER/LA) opioid analgesics announced on September 10, 2013","Petitioner requests the FDA to refrain from implementing NOWS-related labeling changes, remove references to NOWS as life-threatening, modify full prescribing information regarding opioid dependence treatment during pregnancy, and present supporting literature to an advisory committee for evaluation","The petitioner argues that the NOWS-related warnings are medically inaccurate, not supported by substantial evidence, misleading, inconsistent with expert consensus, likely to result in denial of appropriate treatment for pregnant women, and may lead to punitive child welfare interventions against women receiving opioid substitution therapy",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1289,FDA-2013-P-1289-0001_National_Advocates_for_Pregnant_Women_Citizen_Peti.pdf,,2013,False,original petition,National Advocates for Pregnant Women (NAPW),advocacy/academic,21 C.F.R. ¬ß 10.35; 21 C.F.R. ¬ß 10.30; 21 U.S.C. ¬ß 355(o)(4); 21 C.F.R. ¬ß 201.56(a)(2); 21 C.F.R. ¬ß 201.56(a)(3); 21 U.S.C. ¬ß 355-1(b)(3); 21 U.S.C. ¬ß 355-1(b)(4)(A); 21 U.S.C. ¬ß 355-1(b)(4)(B); 21 U.S.C. ¬ß 355(d)(5); 21 U.S.C. ¬ß 355(d)(7); 21 U.S.C. ¬ß 355(e); 42 C.F.R. ¬ß 8.12(g)(1); 42 C.F.R. ¬ß 8.12(e)(3),"The FDA's neonatal opioid withdrawal syndrome‚Äìrelated labeling changes for extended-release and long-acting opioid analgesics announced on September 10, 2013",An indefinite stay of implementation of the NOWS-related labeling changes for ER/LA opioid analgesics,"The warnings are medically inaccurate and unsupported by substantial evidence, conflict with FDA labeling requirements and expert consensus, risk discouraging necessary pain and addiction treatments for pregnant women, and may lead to harmful child welfare interventions",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1290,FDA-2013-P-1290-0001_FDA_CDER_Response_to_Hogan_Lovells_US_LLP_Petition.pdf,,2013,False,original petition,National Advocates for Pregnant Women (NAPW),advocacy/academic,21 C.F.R. ¬ß 10.35; 21 C.F.R. ¬ß 10.30; 21 U.S.C. ¬ß 355(o)(4); 21 C.F.R. ¬ß 201.56(a)(2); 21 C.F.R. ¬ß 201.56(a)(3); 21 U.S.C. ¬ß 355-1(b)(3); 21 U.S.C. ¬ß 355-1(b)(4)(A); 21 U.S.C. ¬ß 355-1(b)(4)(B); 21 U.S.C. ¬ß 355(d)(5); 21 U.S.C. ¬ß 355(d)(7); 21 U.S.C. ¬ß 355(e); 42 C.F.R. ¬ß 8.12(g)(1); 42 C.F.R. ¬ß 8.12(e)(3),"The FDA‚Äôs neonatal opioid withdrawal syndrome‚Äìrelated labeling changes for extended-release and long-acting opioid analgesics announced on September 10, 2013",An indefinite stay of implementation of the NOWS-related labeling changes for ER/LA opioid analgesics,"The NOWS-related warnings are medically inaccurate, unsupported by substantial evidence, conflict with FDA labeling requirements and expert consensus, risk discouraging necessary pain and addiction treatments for pregnant women, and may lead to harmful child welfare interventions",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1291,FDA-2013-P-1291-0001_American_Herbal_Products_Association_Citizen_Petit.pdf,,2013,False,original petition,American Herbal Products Association (AHPA),advocacy/academic,21 C.F.R. ¬ß 10.30; 21 C.F.R. Part 111; 21 C.F.R. Parts 110 & 111; 21 U.S.C. ¬ß 704(b); 21 C.F.R. ¬ß 25.30; 21 C.F.R. ¬ß 10.30(b),FDA policy in the Inspections Operations Manual prohibiting investigators from quoting or citing cGMP regulations in Form FDA-483 inspectional observations,Formally rescind the policy prohibiting investigators from quoting or citing cGMP regulations in 483s and revise the Inspections Operations Manual to require that 483s reference each relevant cGMP regulation,"Because omission of regulatory citations slows resolution of compliance issues, undermines agency transparency, forces industry to guess at regulatory requirements, and inclusion of citations would promote understanding, compliance, transparency, and harmonize FDA policies without imposing additional work",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1292,FDA-2013-P-1292-0001_Sun_Pharmaceutical_Industries_Ltd_Winston_Strawn_L.pdf,,2013,False,original petition,"Sun Pharmaceutical Industries, Ltd.",industry/corporation,"21 U.S.C. ¬ß 301 et seq.; 21 C.F.R. ¬ß 10.30; 21 C.F.R. ¬ß 25.31(a),(c); 21 C.F.R. ¬ß 10.30(b); 21 U.S.C. ¬ß 331(a); 21 C.F.R. ¬ß 201.5; 21 C.F.R. ¬ß 201.128",The FDA approval and labeling of Ganirelix Acetate Injection indication regarding use as a female contraceptive,Confirm that Ganirelix is not approved by the FDA for use as a female contraceptive and that the FDA-labeled indication for Ganirelix is not equivalent to a method of female contraception,"To correct misleading legal positions by Organon suggesting Ganirelix is approved as contraception, to prevent off-label marketing and misbranding, and to protect public health by clarifying approved use",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1294,FDA-2013-P-1294-0001_Luitpold_Pharmaceuticals_Inc_Citizen_Petition.pdf,,2013,False,original petition,Sheppard Mullin Richter & Hampton LLP,law/consulting,"21 U.S.C. ¬ß 301 et seq.; 21 C.F.R. ¬ß 10.30; 21 C.F.R. ¬ß¬ß 25.30(h), 25.31(a); 21 C.F.R. ¬ß 10.30(b)","The FDA‚Äôs approval and labeling of injectable iron products for treatment of iron deficiency anemia outside of chronic kidney disease (e.g., NDA 203565 for Injectafer¬Æ)","Require that any NDA or NDA supplement for injectable iron products for IDA outside CKD be approved only if pivotal studies include an objective oral iron run-in demonstrating intolerance or unsatisfactory response, and require contraindications for patients with prior allergic reactions to iron products or multiple drug allergies","Because of significant safety risks of injectable iron, the need to restrict use to patients objectively intolerant or unresponsive to oral iron, to avoid arbitrary approval practices, and to protect hypersensitive patients from serious allergic reactions",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1296,FDA-2013-P-1296-0001_Lannett_Company_Inc_Citizen_Petition.pdf,,2013,False,original petition,"Lannett Company, Inc.",industry/corporation,21 U.S.C. ¬ß 355(j); 21 C.F.R. ¬ß 314.93; 21 C.F.R. ¬ß 25.31(a),The requirement under FDCA 505(j) and 21 C.F.R. ¬ß 314.93 that an ANDA match the dosage form of the RLD,That the Commissioner determine an ANDA for Acetazolamide Extended-Release Tablets may be submitted using DIAMOX¬Æ SEQUELS¬Æ (capsules) as the RLD,Both the RLD capsules and proposed tablets are solid oral dosage forms with the same route and are expected to have the same therapeutic effect under identical conditions of use,,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1297,FDA-2013-P-1297-0001_Harmony_Cone_Ear_Candles_Citizen_Petition.pdf,,2013,False,original petition,Kevin Boulton,individual,21 U.S.C. ¬ß 321(h) (FDCA ¬ß 201(h)); 21 C.F.R. ¬ß 10.30; 21 C.F.R. ¬ß 101.93(g)(2),The FDA‚Äôs classification of Harmony Cone Ear Candles as medical devices under FDCA ¬ß 201(h),"Issue a declaratory order that HCEC are not medical devices under FDCA ¬ß 201(h), hold a public hearing, and temporarily stay any enforcement actions against HCEC manufacturers, distributors, or sellers during pendency","Because HCECs fall outside the device definition (not recognized in USP/NF, not intended for medical use, no chemical action, not metabolized), are safe relaxation products with no adverse event reports, and consumers have a right to use them free from unwarranted FDA enforcement",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1373,FDA-2013-P-1373-0001_Terry_L_Tennant_Citizen_Petition_Redacted.pdf,,2013,False,original petition,Terry L. Tennant,individual,"Federal Food, Drug, and Cosmetic Act; Public Health Service Act; 21 C.F.R. ¬ß 5.10; 21 C.F.R. ¬ß 804.3(d)",The definition of 'distributor' in the device-tracking regulations (21 C.F.R. Part 804),Amend 21 C.F.R. ¬ß 804.3(d) (and related sections) to expand the definition of 'distributor' to cover any person who furthers marketing of a device from the original manufacturer's installation or importation to the ultimate user,"Because devices sold off the device master record after initial installation or importation are not currently tracked, creating gaps that undermine patient safety and the FDA‚Äôs ability to locate devices for notification or recall",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1374,FDA-2013-P-1374-0001_Citizen_Petition_from_Pharmacists_Planning_Service.pdf,,2013,False,original petition,"Pharmacists Planning Services, Inc.",industry/corporation,"21 C.F.R. ¬ß 10.20; 21 C.F.R. ¬ß 10.30; 21 C.F.R. ¬ß 5.10; Federal Food, Drug, and Cosmetic Act; Public Health Service Act",The FDA‚Äôs failure to hold public hearings and establish updated regulatory standards on cellphone radiation exposure (SAR and RFR/EMF),Hold public hearings; open a federal registry; modernize federal cellphone radiation standards; require 12-point warning labels; educate consumers on reducing exposure,"Emerging scientific evidence links RFR/EMF and cellphone use to health risks (glioma, acoustic neuroma, behavioral disorders, autism, etc.); IARC classification as possible carcinogen; need to protect vulnerable populations and inform consumers of precautions",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1375,FDA-2013-P-1375-0001_Purdue_Pharma_LP_Kleinfeld_Kaplan_and_Becker_LLP_C.pdf,,2013,False,original petition,Purdue Pharma L.P.,industry/corporation,"21 C.F.R. ¬ß¬ß 10.30, 314.53, 314.94, 314.127; 21 C.F.R. Part 320; Section 505 and Section 505(j) of the FDCA (21 U.S.C. ¬ß 355); 5 U.S.C. ¬ß 706(2)(A); 21 C.F.R. ¬ß 25.31; 21 C.F.R. ¬ß 10.30(b)","FDA‚Äôs development of guidance and standards for approving generic versions of reformulated OxyContin, including acceptance or approval of ANDAs citing OxyContin and the draft bioequivalence guidance on oxycodone ER tablets","Adopt a guidance specifying comparative in vitro and in vivo abuse-deterrence tests for generic OxyContin, refuse to approve any ANDA that lacks or fails these tests, and revise the draft bioequivalence guidance accordingly","Generic products without equivalent abuse-deterrent attributes would pose higher abuse risk and a different risk‚Äìbenefit profile, so rigorous testing is needed to protect public health and to meet FDCA and APA requirements",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1376,FDA-2013-P-1376-0001_Covis_Pharma_Sarl_Buchanan_Ingersoll_Rooney_PC_Cit.pdf,,2013,False,original petition,Covis Pharma Sarl,industry/corporation,"Section 505(j) of the FDCA (21 U.S.C. ¬ß 355(j)); 21 C.F.R. ¬ß¬ß 10.20, 10.30, 314.108, 25.31(a)",FDA‚Äôs handling of Lanoxin (digoxin) Tablets NDA 20-405‚Äîspecifically the Agency‚Äôs listings in the Orange Book and its policies on approving ANDAs and recognizing marketing exclusivity for the 0.0625 mg and 0.1875 mg strengths,"Confirm that those two strengths were never fully approved in 1997, that their three-year exclusivity therefore never ran, and that Covis now holds a full three-year marketing exclusivity period for them beginning with FDA‚Äôs October 17 2013 PAS approval","Because FDA required a PAS, new draft labeling, CMC dissolution data, and a prior-approval inspection before allowing marketing, the two strengths were not fully approved or marketed; exclusivity awarded in 1997 could not have started, so Covis is entitled to the full three-year term now to protect its investment and ensure consistent regulatory treatment",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1377,FDA-2013-P-1377-0001_Covis_Pharma_Sarl_Buchanan_Ingersoll_Rooney_PC_Cit.pdf,,2013,False,original petition,"Buchanan Ingersoll & Rooney PC (Edward John Allera, Barbara Binzak Blumenfeld, Tina Hu)",law/consulting,"¬ß 505(j) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. ¬ß 355(j)); 21 C.F.R. ¬ß 10.20; 21 C.F.R. ¬ß 10.30; 21 C.F.R. Part 320",FDA‚Äôs practice of allowing waivers of dissolution and blend-uniformity testing for generic digoxin tablets under its bioequivalence guidance,"Require every ANDA for 0.0625 mg and 0.1875 mg digoxin tablets referencing Lanoxin to perform and pass dissolution and blend-uniformity validation testing, and deny any waiver requests for those tests","Digoxin is a narrow-therapeutic-index drug with extremely high excipient-to-API ratios, making dissolution and blend uniformity critical to safety and bioequivalence; FDA compelled Covis to perform these tests before marketing, so equal treatment, public health protection, and due-process fairness demand the same requirements for all generic sponsors",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1379,FDA-2013-P-1379-0001_Lachman_Consultant_Services_Inc_Citizen_Petition.pdf,,2013,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"21 C.F.R. ¬ß 10.30, 21 C.F.R. ¬ß 314.161, 21 C.F.R. ¬ß 314.162, 21 C.F.R. ¬ß 25.31","Determination whether PREZISTA¬Æ (darunavir) Tablets, 400 mg, has been voluntarily withdrawn from sale for safety or effectiveness reasons","Request FDA to determine if PREZISTA¬Æ (darunavir) Tablets, 400 mg, was withdrawn for safety or efficacy reasons to enable action on an ANDA",Janssen announced discontinuation of the 400 mg dosage strength for commercial reasons favoring the 800 mg strength; no evidence of safety or efficacy concerns related to the withdrawal.,,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1397,FDA-2013-P-1397-0001_UCB_Inc_Citizen_Petition.pdf,,2013,False,original petition,"UCB, Inc.",industry/corporation,"505(j) of the FDCA, 21 C.F.R. ¬ß10.30, 21 U.S.C. ¬ß355(c)(3)(E), 21 U.S.C. ¬ß355(j)(5)(F), 5 U.S.C. ¬ß801(a)(1)(A), 21 C.F.R. ¬ß314.101(d), 21 C.F.R. ¬ß314.108(a), 21 C.F.R. ¬ß314.105(a), 21 C.F.R. ¬ß314.70(b)(2)(v)(C), 21 C.F.R. ¬ß201.57(a)(2)",Timing of triggering new chemical entity (NCE) exclusivity relative to Drug Enforcement Administration (DEA) scheduling under the Controlled Substances Act (CSA),"(1) Determine that NCE exclusivity for lacosamide began on June 9, 2009 (instead of October 28, 2008) and will end on June 9, 2014; (2) Confirm that approval of certain ANDAs will be stayed until December 7, 2016; (3) Respond substantively to this petition within 150 days.",UCB lost 223 days of NCE exclusivity because lacosamide could not be legally marketed until it was scheduled under the CSA; exclusivity should start from the date the drug could be legally marketed to preserve the full 5 years intended by statute; FDA's current practice undermines incentives for innovation and causes inequitable treatment for sponsors of scheduled drugs.,,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1398,FDA-2013-P-1398-0001_Novartis_Group_Citizen_Petition.pdf,,2013,False,original petition,Novartis Group of Companies,industry/corporation,21 C.F.R. ¬ß 10.30,"Policy regarding naming of biosimilars (i.e., whether biosimilars should share the same international nonproprietary name (INN) as the reference product)",Require that a biosimilar be identified by the same international nonproprietary name (INN) as the reference product,"Assigning unique INNs to biosimilars would cause unnecessary confusion, undermine established FDA practices, harm pharmacovigilance, confuse healthcare providers, misrepresent regulatory decisions about biosimilarity and interchangeability, and create barriers to patient access to affordable biologics.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1399,FDA-2013-P-1399-0001_Sigmapharm_Laboratories_LLC_Citizen_Petition.pdf,,2013,False,original petition,"Sigmapharm Laboratories, LLC",advocacy/academic,"Section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. ¬ß 355), 21 C.F.R. Part 314, 21 C.F.R. ¬ß 10.30",Acceptance and filing standards for Abbreviated New Drug Applications (ANDAs) for Asenapine Maleate Sublingual Tablets,"Request that FDA refuse to receive (RTR) any ANDA for Asenapine Maleate Sublingual Tablets that does not include a bioequivalence study performed per FDA‚Äôs June 2013 product-specific bioequivalence guidance, and to set the filing date for 180-day exclusivity based on submission of a complying study","Sigmapharm argues that FDA issued specific bioequivalence guidance for Asenapine Maleate Sublingual Tablets in June 2013, that this guidance was necessary for patient safety and study reliability, that there was enough time to comply before the NCE-1 date, and that allowing non-compliant applications would be inequitable to those who followed FDA guidance",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1505,FDA-2013-P-1505-0001_Teva_Respiratory_LLC_Teva_Citizen_Petition.pdf,,2013,False,original petition,"Teva Respiratory, LLC (on behalf of Teva Pharmaceutical Industries Ltd.)",industry/corporation,"21 C.F.R. ¬ß 10.30, Section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. ¬ß 355)","FDA's policy regarding the inclusion of integrated dose counters on rescue inhalers (both brand and generic), and approval standards for such products",Refrain from approving any new rescue inhalers (brand or generic) unless they include an integrated dose counter; 2. Implement a plan to transition currently approved rescue inhalers without a dose counter to versions with integrated dose counters,"Integrated dose counters are critical to patient safety because they allow patients and caregivers to accurately track the amount of medication remaining in rescue inhalers, reducing risks of inhaler failure during life-threatening asthma attacks; studies show dose counters reduce emergency room visits, improve asthma control, and the FDA‚Äôs previous encouragement for dose counters has been insufficiently enforced.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1507,FDA-2013-P-1507-0001_Dr_S_Albert_Edwards_Citizen_Petition_Redacted.pdf,,2013,False,original petition,"Dr. S. Albert Edwards, PharmD, RAC, FRAPS",individual,"Prescription Drug Amendments to the Federal Food, Drug, and Cosmetic Act; 21 CFR Parts 312 & 314; 21 CFR 5.10; 21 CFR 25.34; 21 CFR 10.30(e)(2).",FDA Office of Business Informatics' handling of webtrader accounts for Contract Research/Service Organizations (CRSOs) submitting eCTDs for sponsors.,Uniformly institute a policy allowing single webtrader accounts for all CRSOs rather than requiring separate accounts for each sponsor.,"Closing single accounts is disruptive; multiple accounts create unnecessary business burdens, risk wrong account selection leading to errors, will increase workload as eCTD/RPS submissions become mandatory, and will strain FDA resources especially under staffing limitations.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1508,FDA-2013-P-1508-0001_Cadence_Pharmaceuticals_Inc_Craig_Pharma_Solutions.pdf,,2013,False,original petition,"Craig Pharma Solutions LLC on behalf of Cadence Pharmaceuticals, Inc.",law/consulting,"505(b), 505(j), 505(q) of the FDCA; 21 C.F.R. ¬ß 10.30",Approval of ANDAs or 505(b)(2) NDAs for intravenous acetaminophen solutions differing in inactive ingredients from Ofirmev¬Æ,FDA is requested to refrain from approving any ANDA or 505(b)(2) application for an acetaminophen solution for injection that does not have the same inactive ingredients as Ofirmev¬Æ unless supported by evidence from nonclinical studies and adequate and well-controlled clinical trials showing comparable safety and efficacy,"Because aqueous acetaminophen solutions are chemically unstable, changes in inactive ingredients could compromise product stability, safety, and effectiveness by increasing hydrolysis and oxidation, leading to unknown degradants with potential toxicity; thus, differences must be justified with appropriate clinical and nonclinical evidence.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1509,FDA-2013-P-1509-0001_Dr_S_Albert_Edwards_Citizen_Petition_Redacted.pdf,,2013,False,original petition,"Dr. S. Albert Edwards, Pharm.D., RAC, FRAPS",individual,"Prescription Drug Amendments to the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. Part 314; 21 C.F.R. 5.10; 21 C.F.R. 10.30; 21 C.F.R. 25.34",Development and harmonization of electronic Common Technical Document (eCTD) Module 1 between the U.S. FDA and Health Canada,Request for the FDA to meet with Canada's Health Products and Food Branch (HPB) to craft a common Module 1 for the eCTD/RPS submissions,Facilitating easier electronic submissions between the U.S. and Canada; reducing the administrative burden for companies filing in both countries; supporting regulatory harmonization due to geographic proximity; and acknowledging unique FDA-specific requirements that would remain separate,,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1510,FDA-2013-P-1510-0001_Lachman_Consultant_Services_Inc_Citizen_Petition.pdf,,2013,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"21 C.F.R. 10.30, 21 C.F.R. 314.161, 21 C.F.R. 314.162, 21 C.F.R. 25.31",Determination of whether a listed drug has been voluntarily withdrawn for safety or effectiveness reasons,"Request the FDA to determine that the Lupron Depot-Ped dual vial products were voluntarily withdrawn for reasons other than safety or effectiveness, to enable ANDA submissions, and to annotate the Orange Book accordingly",Petitioner argues that the withdrawal was not due to safety or effectiveness concerns but rather because Abbvie shifted to a different packaging configuration; no evidence of safety or efficacy problems found in public domain or court records,,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1511,FDA-2013-P-1511-0001_PetaStrip_LLC_Citizen_Petition.pdf,,2013,False,original petition,"PetaStrip, LLC",advocacy/academic,"Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 520.1193(d)(2)(ii); 21 CFR 25.30(h)",Suitability Petition for a different dosage form (soluble film) of an approved pioneer animal drug product,Request for permission to file an Abbreviated New Animal Drug Application (ANADA) for a soluble film dosage form differing from the pioneer product Heartguard¬Æ for Cats,"The proposed generic product (soluble film) has the same active ingredient, dosage, administration route, indications, and therapeutic effect as the pioneer chewable product; it only differs in dosage form, does not raise new safety or effectiveness questions, and thus meets the criteria for a Suitability Petition under the law.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1512,FDA-2013-P-1512-0001_PetaStrip_LLC_Citizen_Petition.pdf,,2013,False,original petition,"PetaStrip, LLC",advocacy/academic,"Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 25.30(h); Section 512(n)(1)(E) of the Act",Suitability Petition for approval of a different dosage form for a generic animal drug,"Permission for PetaStrip, LLC to file an Abbreviated New Animal Drug Application (ANADA) for a soluble film dosage form instead of the chewable tablet form of the pioneer product Heartguard¬Æ","The proposed generic product would have the same active ingredient (ivermectin), dosage, route of administration, and therapeutic effect as the pioneer product, differing only in dosage form; prior FDA approvals of soluble film dosage forms (e.g., Suboxone¬Æ, Onsolis¬Æ) are cited as precedent; bioequivalence requirements will be satisfied and labeling differences are minimal.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1515,FDA-2013-P-1515-0001_Lachman_Consultant_Services_Inc_Citizen_Petition.pdf,,2013,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"21 C.F.R. ¬ß 10.30, 21 C.F.R. ¬ß 314.161, 21 C.F.R. ¬ß 314.162, 21 C.F.R. ¬ß 25.31","Determination whether ZOVIRAX¬Æ (acyclovir sodium) for Injection, eq. 1 g base/vial, was withdrawn for safety or efficacy reasons.","Request for FDA to determine whether ZOVIRAX¬Æ (acyclovir sodium) for Injection, eq. 1 g base/vial, was voluntarily withdrawn from sale for safety or efficacy reasons.","The drug is listed in the Orange Book‚Äôs discontinued section, and the petitioner believes it was discontinued for commercial reasons rather than safety or efficacy concerns. This determination is needed to proceed with an ANDA referencing the drug.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1516,FDA-2013-P-1516-0001_Spectron_mrc_LLC_Citizen_Petition.pdf,,2013,False,original petition,"Spectron mrc, LLC",industry/corporation,21 U.S.C. 355(j)(7); 21 CFR 314.161; 21 CFR 314.162,Determination regarding whether Sodium Pertechnetate Tc-99m (technetium Tc-99m sodium pertechnetate) was withdrawn from sale for reasons of safety or effectiveness,"Issue a notice stating that Sodium Pertechnetate Tc-99m was not withdrawn from sale for reasons of safety or effectiveness, allowing approval of ANDAs referring to this drug","To alleviate shortages caused by decreased global nuclear reactor output, to assist in national efforts to reduce the use of highly enriched uranium, and because historical withdrawal was not due to safety or effectiveness concerns",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1552,FDA-2013-P-1552-0001_Citizen_Petition_from_Hearing_Industries_Associati.pdf,,2013,False,original petition,Hearing Industries Association (HIA),advocacy/academic,"Section 513(e) of the Federal Food, Drug, and Cosmetic Act (FDC Act); 21 C.F.R. ¬ß 860.123",FDA‚Äôs classification of wireless air conduction hearing aids as Class II devices,Reclassify wireless air conduction hearing aids possessing specific features from Class II to Class I,Wireless air conduction hearing aids with certain features (ear-to-ear communication and wireless streaming) have been safely used for decades without incident; current general controls are sufficient for safety and effectiveness; no evidence of risk from electromagnetic exposure; amplification functionality remains independent even if wireless features fail; standard safety protocols and EMC compliance are already practiced by manufacturers.,,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1554,FDA-2013-P-1554-0001_Sigmapharm_Laboratories_LLC_Citizen_Petition.pdf,,2013,False,original petition,"Sigmapharm Laboratories, LLC",advocacy/academic,"Section 505 and 505(q) of the Federal Food, Drug and Cosmetic Act (21 U.S.C. ¬ß 355), 21 C.F.R. Part 314, 21 C.F.R. ¬ß 10.30",Acceptance or refusal to receive Abbreviated New Drug Applications (ANDAs) for Asenapine Maleate Sublingual Tablets based on compliance with FDA's June 2013 product-specific bioequivalence guidance,FDA should consider incomplete and refuse to receive any ANDA for Asenapine Maleate Sublingual Tablets that does not contain bioequivalence study results conforming to the June 2013 guidance; filing acceptance date should be based on compliance with the guidance,"Sigmapharm argues that allowing non-complying ANDAs disadvantages companies that submitted complete applications, could cause inequitable 180-day exclusivity determinations, and that sponsors had enough time to complete studies based on the June 2013 guidance; FDA's own RTR guidance supports refusing non-complying studies",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1606,FDA-2013-P-1606-0001_Citizen_Petition_from_Pharmacists_Planning_Service.pdf,,2013,False,original petition,"Pharmacists Planning Services, Inc. (PPSI)",industry/corporation,"21 CFR 10.20, 21 CFR 10.30, Federal Food Drug and Cosmetic Act (FDA Act), 21 CFR 1306.04, Health and Safety Code Section 11153",FDA regulatory decisions regarding reformulation of opioid drug products and implementation of standards for pharmacists regarding hydrocodone schedule II products,Requesting FDA to add drug-abuse deterrent technology to all hydrocodone schedule II products and to implement standards of practice and corresponding responsibilities for pharmacists,"Petitioners argue that prescription drug abuse, especially opioid abuse, is a public health epidemic; hydrocodone products are heavily prescribed and abused; FDA has previously acted to deter abuse with other opioids; pharmacists have a professional duty to help prevent inappropriate use; standards for prescription monitoring programs (PMPs) should be federally mandated to assist in preventing drug diversion and abuse",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1609,FDA-2013-P-1609-0001_Lachman_Consultant_Services_Inc_Citizen_Petition.pdf,,2013,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"21 C.F.R. 10.30, 21 C.F.R. 314.161, 21 C.F.R. 314.162, 21 C.F.R. 25.31",FDA's determination whether the two-vial container closure system used for Lupron Depot and Lupron Depot-PED Injection drug products was withdrawn for reasons of safety or effectiveness.,"Requesting the FDA to determine that the two-vial container closure system for Lupron Depot and Lupron Depot-PED Injection drug products was not withdrawn for reasons of safety or effectiveness, and to enable ANDA submissions referring to the two-vial system as the Reference Listed Drug.","The petitioner argues that the two-vial system was discontinued voluntarily and not due to safety or effectiveness concerns, citing lack of evidence from trade press, court cases, or FDA actions suggesting otherwise.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1611,FDA-2013-P-1611-0001_Citizen_Petition_from_Clarissa_Clarke___Redacted.pdf,,2013,False,original petition,Clarissa Clarke,individual,"Federal Food, Drug, and Cosmetic Act Subchapter A Part 10 Subpart B Section 10.20; Title 21 CFR Part 872",Amendments to regulations within Title 21 CFR Part 872‚ÄîDental Devices (specifically ¬ß¬ß 872.3690 and 872.6070),"Amend ¬ß¬ß 872.3690 and 872.6070 to include Special Controls Guidance concerning material properties, performance reporting, energy requirements for polymerization, and reporting for dental curing lights","Incomplete polymerization of tooth shade resin materials can lead to restoration failure, increased dental treatment costs, and patient dissatisfaction. Current labeling and information provided with dental materials and curing lights do not sufficiently ensure safe and effective polymerization. Amending the regulations would provide dentists with critical information necessary to optimize curing and material performance, ultimately improving patient outcomes and reducing healthcare costs.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1614,FDA-2013-P-1614-0001_Citizen_Petition_from_Alliance_of_African_Shea_Ass.pdf,,2013,False,original petition,Alliance of African Shea Associations (AASA),advocacy/academic,"Section 401 of the Federal Food, Drug, and Cosmetic Act (FDCA), 21 U.S.C. ¬ß 341; 21 C.F.R. ¬ß¬ß 163.123, 163.124, 163.130","Standards of identity for chocolate (specifically sweet chocolate, milk chocolate, and white chocolate) prohibiting alternatives to cacao fat",Amend the standards of identity for chocolate to allow the optional use of shea-based ingredients (blends of sheanut oil and palm oil) as alternatives to cacao fat,"Shea-based blends have similar triglycerides and physical properties to cacao fat, preserving the basic nature and essential characteristics of chocolate; the change would support economic opportunities for West African women, harmonize U.S. standards with international regulations, and align with FDA's modernization initiatives without negatively impacting consumer expectations or product quality.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1623,FDA-2013-P-1623-0001_Sigmapharm_Laboratories_LLC_Citizen_Petition.pdf,,2013,False,original petition,"Sigmapharm Laboratories, LLC",advocacy/academic,"505, 505(q) of the FDCA (21 U.S.C. ¬ß 355), 21 C.F.R. Part 314, 21 C.F.R. ¬ß 10.30","Acceptance and filing standards for Abbreviated New Drug Applications (ANDAs), specifically for Asenapine Maleate Sublingual Tablets","Request that the FDA refuse to receive (RTR) any ANDA for Asenapine Maleate Sublingual Tablets that does not contain bioequivalence study results compliant with FDA‚Äôs June 2013 product-specific bioequivalence guidance, and base exclusivity eligibility on the submission date of a compliant ANDA","Sigmapharm argues that allowing non-compliant ANDAs would be inequitable to applicants who submitted complete and compliant applications on the designated filing date, potentially impacting 180-day exclusivity rights, and that FDA‚Äôs own RTR guidance and bioequivalence standards mandate adherence to the issued June 2013 bioequivalence requirements",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1636,FDA-2013-P-1636-0001_Citizen_Petition_from_Lannett_Company_Inc.pdf,,2013,False,original petition,"Lannett Company, Inc.",industry/corporation,"Sections 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FDCA), 21 CFR ¬ß 314.93, and 21 CFR ¬ß 25.31(a).",Submission and approval process for Abbreviated New Drug Applications (ANDAs) differing from the Reference Listed Drug (RLD) in active ingredient strength.,"The petitioner requests the FDA to determine that ANDAs may be submitted for Hydromorphone Hydrochloride Tablets, 1 mg (scored tablets) and Hydromorphone Hydrochloride Oral Solution, 1 mg per 5 mL.","The petitioner argues that the changes in strength do not pose safety or efficacy concerns because the dose, use, and route of administration are identical to the RLD; elderly and geriatric patient references support the therapeutic need for lower doses; and existing approved doses in the RLD package insert suggest the safety and utility of lower strength formulations.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1637,FDA-2013-P-1637-0001_Attachment_1_Alemtuzumab_The_Eagle_Has_Landed_In_E.pdf,,2013,False,original petition,The Eagle Has Landed in Europe').,other,None cited.,The document does not comment on an FDA action; it is a medical article discussing the approval and clinical use of Alemtuzumab for multiple sclerosis in Europe.,None requested.,Not applicable since this is an informational/clinical article and not a citizen petition.,,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1640,FDA-2013-P-1640-0001_Citizen_Petition_from_Hyman_Phelps_and_Mcnamara_PC.pdf,,2013,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"505 of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. ¬ß¬ß 10.25 and 10.30",FDA regulations for Over-the-Counter (OTC) Transdermal Nicotine Patches (TNPs) regarding labeling and safety,"Require the sponsors of all OTC TNPs to include permanent, smudge-resistant product identifying labeling on the backing membrane to help avoid accidental pediatric exposures to nicotine.",Accidental pediatric exposures to nicotine from OTC TNPs are increasing and can have serious health consequences; permanent product identification on patches would help avoid accidental exposure and assist healthcare professionals in emergencies.,,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1641,FDA-2013-P-1641-0001_Citizen_Petition_from_TEVA_Pharmaceuticals.pdf,,2013,False,original petition,"Teva Pharmaceutical Industries Ltd. and Teva Neuroscience, Inc.",industry/corporation,"21 C.F.R. ¬ß 10.30, 21 U.S.C. ¬ß¬ß 355(j) and 355(q)",FDA approval of any Abbreviated New Drug Application (ANDA) referencing Copaxone¬Æ (glatiramer acetate injection),"Requesting that FDA refrain from approving any ANDA referencing Copaxone¬Æ unless certain conditions are met, including proof of identical active ingredient, comparable immunogenicity, and bioequivalence via clinical studies","Teva argues that due to the complexity and immunogenicity of Copaxone¬Æ, and the limitations of current analytical technologies, it is not possible to definitively establish sameness of the active ingredient without extensive clinical testing, and that approval without meeting these stringent standards could compromise safety and efficacy",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1654,FDA-2013-P-1654-0001_Gordon_Johnston_Regulatory_Consultants_LLC_Citizen.pdf,,2013,False,original petition,"Gordon Johnston Regulatory Consultants, LLC",law/consulting,"21 CFR 10.30, 21 CFR 314.161, 21 CFR 314.162, 21 CFR 25.31","Determination whether Leucovorin Calcium Injection-Preservative Free, 10 mg/mL, 10 mL total fill volume (ANDA 40147) has been withdrawn for reasons of safety or efficacy","Requesting FDA to determine if Hospira's Leucovorin Calcium Injection-Preservative Free, 10 mg/mL, 10 mL total fill volume (ANDA 40147) has been voluntarily withdrawn or withheld from sale for reasons of safety or efficacy",Because the product appears in the Discontinued Section of the Orange Book and a determination is needed before any ANDA referencing it can be approved; regulatory requirement under 21 CFR 314.161(a)(1),,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1710,FDA-2013-P-1710-0001_Citizen_Petition_From_Noven_Pharmaceuticals_Inc.pdf,,2013,False,original petition,"Noven Pharmaceuticals, Inc.",industry/corporation,"505(q) of the Federal Food, Drug, and Cosmetic Act, 21 C.F.R. ¬ß 10.30",Approval of Abbreviated New Drug Applications (ANDAs) for generic Daytrana¬Æ (Methylphenidate) Transdermal System,"Refuse to approve any ANDA for a generic version of Daytrana¬Æ unless the ANDA sponsor conducts a usability study in adults, adolescents, and children under 'real world' conditions demonstrating non-inferior patch adhesion performance compared to Daytrana¬Æ TDS","Patch detachment risks efficacy loss and safety concerns (e.g., accidental exposure to children); real-world adhesion issues not adequately captured by current bioequivalence and in vitro tests; FDA acknowledged importance of real-world usability studies particularly for pediatric patients; need to ensure therapeutic equivalence and public health safety",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2013-p-1711,FDA-2013-P-1711-0001_Citizen_Petition_From_Morgan_Lewis_Bockius_LLP.pdf,,2013,False,original petition,"Morgan, Lewis & Bockius LLP",law/consulting,"21 U.S.C. ¬ß 505, 21 U.S.C. ¬ß 811 et seq., 21 C.F.R. ¬ß 10.30, 21 C.F.R. Part 300 et seq., 21 C.F.R. Part 1300 et seq.",FDA's plan to recommend to HHS to reclassify hydrocodone combination products from Schedule III to Schedule II,Request that hydrocodone combination products containing less than 5 mg of hydrocodone remain in Schedule III and not be rescheduled to Schedule II,"Upscheduling lower-strength hydrocodone products would burden vulnerable patient populations (e.g., chronic pain, hospice, palliative care patients) by limiting access to needed medications, increase healthcare burdens, and would not effectively curb drug misuse and abuse; maintaining lower-strength products in Schedule III strikes a balance between control and accessibility.",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2017-p-0052,FDA-2017-P-0052-0001_Citizen_Petition_from_Donor_Sibling_Registry.pdf,2017-01-01,2017,False,original petition,Donor Sibling Registry,advocacy/academic,"- 21 C.F.R. ¬ß 10.20
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 25.30 (categorical environmental exemption claimed)","Lack of regulation and oversight in the sperm donation/cryobank industry. Specifically, minimal FDA-mandated medical testing for sperm and egg donors and the broader absence of national regulatory oversight.","The petitioner asks the FDA Commissioner to investigate the current state of the sperm donation industry and develop appropriate regulations and oversight mechanisms. Key regulatory proposals include:
‚Ä¢ Standardized and expanded pre-conception testing
‚Ä¢ Mandated full genome sequencing
‚Ä¢ Required medical, genetic, and social updates
‚Ä¢ Electronic health record-keeping
‚Ä¢ Ban on anonymous donation
‚Ä¢ Centralized databank tracking donors, recipients, and births","The petition outlines that the U.S. cryobank industry is a multibillion-dollar, largely unregulated sector, leading to:
‚Ä¢ Inconsistent medical/genetic screening standards
‚Ä¢ Insufficient communication of critical health data
‚Ä¢ Donor fraud and identity falsification
‚Ä¢ Psychological and health risks to donor-conceived children
‚Ä¢ Inadequate recordkeeping, enabling excessive offspring numbers per donor and risk of consanguinity.
They reference case studies, lawsuits (e.g., Collins v. Xytex), surveys, and failures in current practices as rationale for regulatory reform",,,2025-10-15,0.0,,,,,no decision,False,3209.0,pending,pending
fda-2017-p-0115,FDA-2017-P-0115-0001_Citizen_Petition_from_Jubilant_Generics_Limited.pdf,2016-12-22,2017,False,original petition,Jubilant Generics Limited,industry/corporation,"- Section 505(j)(2)(C) of the FD&C Act [21 U.S.C. ¬ß 355(j)(2)(C)]
- 21 C.F.R. ¬ß¬ß 10.20, 10.30, and 314.93 (citizen petition and ANDA suitability provisions)
- 21 C.F.R. ¬ß 25.31 (environmental impact categorical exclusion)","FDA‚Äôs requirement to approve an ANDA petition when a proposed drug differs in strength (fill volume) from the reference listed drug (RLD). The petition seeks determination that proposed changes in Levetiracetam injection volume are suitable for ANDA submission
","FDA is requested to determine that Levetiracetam Injection at 1000 mg/10 mL and 1500 mg/15 mL (100 mg/mL) is suitable for ANDA submission, based on the RLD Keppra¬Æ Injection 500 mg/5 mL (NDA #021872)
","- The proposed product matches the RLD in concentration (100 mg/mL) but provides larger fill volumes to reduce the need for combining multiple vials for higher doses.
- Current practice involves multiple vial withdrawals (e.g., 2 or 3 vials for 1000 or 1500 mg), which is cumbersome, time-consuming, and poses risks of dosing error and sterility breach in emergency settings
.
- No change in route of administration, indications, or labeling content aside from strength specification.
- Proposed dosage strengths are consistent with labeled dosing ranges and usage patterns for the RLD
.
- The petitioner claims a categorical exclusion from environmental assessment under 21 C.F.R. ¬ß 25.31",,Withdrawn,2023-06-12,0.0,Center for Drug Evaluation and Research (CDER) ,Not applicable. ,,"- FDA contacted the petitioner (Jubilant Generics Limited) via certified mail on March 17, 2023 requesting a confirmation of continued interest.
- The petitioner did not respond within 30 days, leading the FDA to consider the petition voluntarily withdrawn without prejudice.
- This action was in accordance with FDA's GDUFA III commitments to clean up unresolved suitability petitions submitted prior to FY 2023.",withdrawn,True,2363.0,CDER,CDER
fda-2017-p-0176,FDA-2017-P-0176-0001_Citizen_Petition_from_American_Herbal_Products_Ass.pdf,2017-01-09,2017,False,original petition,"Kleinfeld, Kaplan and Becker, LLP",law/consulting,"- 21 C.F.R. ¬ß 10.30 (Citizen Petition procedures)
- 21 C.F.R. ¬ß 101.4(h) (Labeling of dietary supplements)
- 68 Fed. Reg. 51738 (August 28, 2003) ‚Äì Proposed amendment to 21 C.F.R. ¬ß 101.4(h)
- 21 C.F.R. ¬ß 25.30 (Environmental impact exclusion)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact statement provisions)","The FDA‚Äôs proposed amendment to 21 C.F.R. ¬ß 101.4(h), specifically the 2003 proposal to replace the incorporated references (1992 edition of Herbs of Commerce and 1994 edition of International Code of Botanical Nomenclature) with their 2000 editions.","AHPA requests that FDA:
1. Withdraw the proposed rule published at 68 Fed. Reg. 51738.
2. Issue an Advance Notice of Proposed Rulemaking (ANPRM) to revise 21 C.F.R. ¬ß 101.4(h), suggesting that botanical names on supplement labels be consistent with the Herbs of Commerce, 2nd edition (2000), or other appropriate authoritative references","- The current reference (Herbs of Commerce, 1st ed., 1992) is outdated.
- The 2nd edition (2000) includes standardized common names for ~1,500 more botanicals and updates ~140 names from the 1st edition.
- Plant taxonomy evolves, and new references reflect more accurate nomenclature.
- There is a need for clarity and consistency in naming botanical dietary ingredients to reflect modern commerce and ensure regulatory compliance",2018-02-02 00:00:00,,2025-10-15,1.0,,,"The FDA stated the petition is under active evaluation, but decision-making has been delayed due to competing agency priorities ",,no decision,False,3201.0,pending,pending
fda-2017-p-0290,FDA-2017-P-0290-0001_Citizen_Petition_from_Malaysian_Rubber_Export_Prom.pdf,2017-01-17,2017,False,original petition,Malaysian Rubber Export Promotion Council (MREPC),law/consulting,"- FDA Docket No. FDA-2015-N-5017 (Final Rule)
- 21 C.F.R. Parts 878, 880 & 895 (relating to medical devices and banned devices regulations)","The FDA‚Äôs Final Rule banning powdered surgeon‚Äôs gloves, powdered patient examination gloves, and absorbable powder for lubricating gloves, effective January 18, 2017.
","MREPC requests a two-month extension of the Final Rule's effective date (from January 18, 2017, to March 18, 2017) to allow:
(i) re-routing or removal of affected glove shipments already en route to U.S. ports, or
(ii) re-labeling and re-packing for non-medical markets","- The short notice between the Final Rule announcement and effective date caused hardship to Malaysian glove manufacturers/exporters with shipments already en route.
- FDA-cited studies were primarily based on older powdered gloves; recent studies are limited and based on non-U.S. gloves.
- FDA-regulated powdered glove limits (‚â§10 mg/dm¬≤) are believed to pose minimal health risks.
- Malaysia respects the ban but seeks pragmatic enforcement to prevent economic losses from rejected shipments and disrupted hospital contracts",,Denied,2017-06-26,0.0,"Center for Devices and Radiological Health (CDRH)
","- 21 CFR 1.94, 21 CFR 1.95, 21 CFR 1.96
- 21 CFR Part 1, Subpart E
- 21 USC 381(a), 381(b)
- 81 Fed. Reg. 91722 (Dec. 19, 2016 ‚Äì Final Rule)
- 81 Fed. Reg. 15173 (Mar. 22, 2016 ‚Äì Proposed Rule) 
",,"- The FDA determined that powdered surgeon‚Äôs gloves, powdered patient examination gloves, and absorbable powder for lubricating gloves pose an unreasonable and substantial risk to health care workers and patients.
- The risk cannot be corrected by labeling or relabeling.
- The final rule was published with a 30-day effective date (January 18, 2017) to minimize continued exposure.
- While the petition sought additional time for logistics of redirected or relabeled shipments, the FDA maintained that public health concerns outweighed those logistical issues.
- Existing regulations allow for relabeling, exportation, or destruction of non-compliant shipments as per 21 USC 381 and relevant CFR provisions 
",denied,True,160.0,CDRH,CDRH
fda-2017-p-0428,FDA-2017-P-0428-0001_Citizen_Petition_From_Mucodel_Pharma_LLC.pdf,2017-01-20,2017,False,original petition,Mucodel Pharma LLC,industry/corporation,"- Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 10.30 (Citizen petition procedures)
- Section 505(q) of the FD&C Act (mentioned in context of delaying approval pending petition resolution)
- 21 C.F.R. ¬ß¬ß 25.30, 25.31, 25.32, 25.33, 25.34 (Environmental impact exclusions)
- 21 C.F.R. ¬ß 25.40 (Environmental assessment provision)","The FDA‚Äôs approval process for intranasal (IN) naloxone drug applications (NDA or ANDA) for emergency treatment of opioid overdose, particularly questioning whether such products are reliable in real-world field use compared to intramuscular (IM) naloxone","The petitioner requests the FDA to refrain from approving any intranasal naloxone applications (NDA or ANDA) until it considers the reliability of intranasal delivery in actual field use, especially in comparison with IM delivery
","- The pivotal clinical studies for the IN reference listed drug (Narcan¬Æ) excluded patients with nasal issues, casting doubt on real-world effectiveness.
- Field studies and literature indicate efficacy disparity between IN and IM naloxone, especially in patients with nasal trauma, congestion, or a history of drug insufflation (e.g., cocaine, heroin).
- Concerns exist about absorption reliability due to nasal pathologies, vasoconstrictors like oxymetazoline, and anatomical damage from substance use.
- The IN RLD labeling lacks adequate guidance on patient suitability or reliability issues.
- The drug is often administered by non-medically trained individuals, making predictable and reliable delivery critical to avoid fatal consequences during opioid overdose emergencies",,Withdrawn,2017-02-09,0.0,Office of Regulatory Policy (ORP),Not applicable. ,,"The original petition was voluntarily withdrawn by the petitioner, who resubmitted a substantially identical petition under a new docket number to correct the certification required by Section 505(q). As a result, the FDA considered the original petition withdrawn and requested closure of the docket ",withdrawn,True,20.0,offices,Other/Specialty Center
fda-2017-p-0494,FDA-2017-P-0494-0001_Citizen_Petition_From_Navinta_LLC.pdf,2017-01-24,2017,False,original petition,Navinta LLC,industry/corporation,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 314.93 (ANDA Suitability Petitions)
- 21 C.F.R. ¬ß 10.20 and ¬ß 10.30 (Citizen Petition requirements)
- 21 C.F.R. ¬ß 25.31(a) (Environmental Impact Exclusion)
- Pediatric Research Equity Act (FD&C Act Section 505(B)(b))","FDA‚Äôs policy and precedent regarding ANDA Suitability Petitions, especially related to changes in total drug content and vial size for injectable drug products.
","FDA should determine that the proposed Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10%, 20 mL vial is suitable for submission under Navinta‚Äôs existing ANDA (#205880), despite differing in total fill volume (from the approved 50 mL vial).
","- The new 20 mL vial maintains the same drug concentration (10% Sodium Phenylacetate and 10% Sodium Benzoate) and formulation as the approved 50 mL version.
- Intended for pediatric use, where the full 50 mL vial leads to significant waste and higher costs.
- Request was also based on feedback from hospital pharmacies and aligns with prior FDA-approved suitability petitions for changes in package sizes.
- The change raises no safety or efficacy concerns, and supports cost reduction, waste minimization, and single-use compliance in clinical practice",,Withdrawn,2023-07-11,0.0,Center for Drug Evaluation and Research (CDER),Not applicable. ,,"- The FDA sent a certified letter on March 17, 2023 requesting confirmation of continued interest in the petition.
- No response was received from Navinta LLC within the required 30 days.
- In alignment with GDUFA III goals, unresolved petitions without responses are considered voluntarily withdrawn to streamline review processes",withdrawn,True,2359.0,CDER,CDER
fda-2017-p-0495,FDA-2017-P-0495-0001_Citizen_Petition_from_Lachman_Consultant_Services_.pdf,2017-01-25,2017,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 314.161
- 21 C.F.R. ¬ß 314.162
- 21 C.F.R. ¬ß 25.31
- 21 C.F.R. ¬ß 10.30(b)","Determination of whether CORDARONE¬Æ (amiodarone hydrochloride) Tablets, 200 mg has been voluntarily withdrawn from sale for safety or efficacy reasons, which affects its eligibility to be referenced in an ANDA","The petitioner requests that the FDA determine whether CORDARONE¬Æ Tablets, 200 mg has been voluntarily withdrawn for safety or efficacy reasons, in order to allow an ANDA referencing it as the Reference Listed Drug to proceed
","- CORDARONE¬Æ (200 mg) is still listed as an actively marketed product in the Orange Book, but the petitioner‚Äôs client believes it is no longer marketed.
- FDA regulations require such a determination before approving an ANDA that references a withdrawn listed drug.
- If the product is being marketed again before FDA response, the petition will be withdrawn
",2017-07-21 00:00:00,Approved (Determination Issued),2017-08-16,1.0,Center for Drug Evaluation and Research (CDER),"- 21 CFR 314.161 ‚Äì Concerning the determination of whether a listed drug was withdrawn from sale for safety or effectiveness.
- 21 CFR 314.162 ‚Äì Concerning removal of approved drugs from the Orange Book.
- 21 CFR 10.30 ‚Äì Governs citizen petitions","The FDA stated that it was unable to reach a decision because of the need to address other Agency priorities and the numerous demands on its resources. The petition remains under review 
","- FDA conducted a review of its own records, the citizen petition, and relevant literature and postmarketing data.
- No evidence was found to suggest that Cordarone (amiodarone hydrochloride) 200 mg was withdrawn from sale due to safety or efficacy concerns.
- The product was discontinued voluntarily by Pfizer (not for safety or efficacy), and will remain listed in the ‚ÄúDiscontinued Drug Product List‚Äù of the Orange Book.
- This allows for the continued approval and submission of ANDAs referencing this product, as long as they meet all applicable requirements",approved,True,203.0,CDER,CDER
fda-2017-p-0508,FDA-2017-P-0508-0001_Citizen_Petition_from_the_Union_of_Concerned_Scien.pdf,2017-01-25,2017,False,original petition,"Union of Concerned Scientists, Center for Science and Democracy",advocacy/academic,"- 5 U.S.C. ¬ß 553(e)
- 21 C.F.R. ¬ß 10.25
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 101.13
- 21 C.F.R. ¬ß 101.14
- 21 C.F.R. ¬ß 25.30(h)
- 21 C.F.R. ¬ß 10.30(b)(3)
- 21 C.F.R. ¬ß 101.65
- 21 U.S.C. ¬ß 343
- Sections 201(n), 403A, and 701(a) of the FD&C Act
- Nutrition Labeling and Education Act of 1990","- Current FDA regulations allowing health and nutrient content claims on foods with high added sugar content
- Draft guidance on redefining the ‚Äúhealthy‚Äù nutrient content claim","- Amend 21 C.F.R. ¬ß¬ß 101.13 and 101.14 to include a disqualifying nutrient level for added sugars
- Prevent foods with added sugars above the threshold from making health or nutrient content claims","- Scientific evidence links excessive added sugar to chronic diseases (e.g., type 2 diabetes, CVD, obesity)
- Added sugar now has a defined DRV (25g for ages 1‚Äì3, 50g for 4+)
- Precedent exists for disqualifying levels for fat, sodium, etc.
- Prevent misleading claims that make sugar-rich foods appear healthy, especially for children
- Supported by over 30,000 individuals nationwide",2017-07-17 00:00:00,,2025-10-15,1.0,,,The FDA stated that it has not completed review of the petition due to other agency priorities and limited availability of resources. The Agency committed to notify the petitioner once a decision is reached ,,no decision,False,3185.0,pending,pending
fda-2017-p-0662,FDA-2017-P-0662-0001_Citizen_Petition_from_Impax_Laboratories__Inc_.pdf,2017-01-31,2017,False,original petition,"Impax Laboratories, Inc.",advocacy/academic,"- Section 505(q) of the FD&C Act
- 21 C.F.R. ¬ß 10.30
- FD&C Act ¬ß 505(j)(2)(A)
- FD&C Act ¬ß 505(j)(8)(B)
- 21 C.F.R. ¬ß¬ß 314.94(a)(7), 314.127(a)(6)(i), 314.127(a)(6)(ii), 314.94(a)(9)","Potential approval or receipt of ANDAs for generic versions of RYTARY (carbidopa and levodopa extended-release capsules), with respect to FDA bioequivalence guidance and standards
","- Refuse to receive or approve any ANDA for a generic version of RYTARY unless bioequivalence is demonstrated through appropriate methods
- Revise FDA's draft product-specific bioequivalence guidance for CD-LD ER Capsules to reflect RYTARY‚Äôs unique PK profile","- RYTARY has a unique PK profile characterized by rapid onset, extended effect, and low variability in plasma concentrations
- Standard metrics (Cmax and AUC) are inadequate to ensure therapeutic equivalence
- Risk of non-equivalent generics harming patients
- FDA precedent with other drugs (e.g., zolpidem ER, methylphenidate hydrochloride) supports adopting additional metrics for bioequivalence",,Partially Approved / Partially Denied,2017-06-30,0.0,Center for Drug Evaluation and Research (CDER),"- Section 505(j) of the FD&C Act (21 U.S.C. 355(j))
- 21 CFR 314.94(a)(7)
- 21 CFR 320.24(b)
- 21 CFR 314.101(b)(1), (d)-(e)
- 21 CFR 314.3(b)
- 21 CFR 320.1(e) ",,"- FDA cannot refuse to receive an ANDA that is facially complete; review of substantive scientific adequacy occurs during later stages, not at receipt.
- FDA acknowledges the pharmacokinetic concerns raised and commits to consider them in finalizing the product-specific guidance for carbidopa-levodopa extended-release capsules.
- FDA cites statutory and regulatory frameworks that give it discretion in determining the scientific criteria for bioequivalence.",partially approved / denied,True,150.0,CDER,CDER
fda-2017-p-0663,FDA-2017-P-0663-0001_Citizen_Petition_from_Mucodel_Pharma__LLC.pdf,2017-01-31,2017,False,original petition,Mucodel Pharma LLC,industry/corporation,"- Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 10.30 (Citizen petition regulation)
- Section 505(q) of the FDCA
- 21 C.F.R. ¬ß¬ß 25.30 to 25.34, and 25.40 (Environmental impact provisions)","FDA‚Äôs approval or pending approval of intranasal (IN) naloxone drug applications (NDAs or ANDAs) for opioid overdose treatment‚Äîwithout fully considering the reliability of intranasal delivery in real-world field use, especially compared to intramuscular (IM) naloxone","The petitioner requests that FDA refrain from approving any intranasal naloxone NDAs or ANDAs until it evaluates whether such applications adequately address the reliability of intranasal naloxone in real-world use, particularly when administered by non-medically trained personnel
","- IN naloxone may be less reliable than IM naloxone in emergency field settings.
- Clinical studies excluded patients with nasal abnormalities, and field studies suggest reduced efficacy for IN delivery in such populations.
- Concerns exist around nasal pathologies, substance-induced damage (e.g., from cocaine or heroin), and use of vasoconstrictors.
- Several cited studies (Kelly, Kerr, Barton) showed higher failure/rescue dose rates for IN naloxone vs IM.
- The Narcan¬Æ label does not warn about reliability issues or patient subtypes for which IN administration may be unsuitable.
- Petitioner argues that public health and patient safety require FDA to critically evaluate these reliability concerns before approving additional IN products",,Denied,2017-06-30,0.0,"Center for Drug Evaluation and Research (CDER)
","- Section 505(j) of the FD&C Act (21 U.S.C. 355(j))
- Section 505(b)(1), 505(b)(2), 505(c), and 505(d)
- 21 CFR ¬ß¬ß 314.3, 314.94, 314.127, 314.54",,"- The FDA does not intend to pause approvals of new intranasal (IN) naloxone products while reevaluating reliability in field use.
- The petition fails to demonstrate that the current FDA approval standards for IN naloxone are inappropriate.
- The petition cited studies (e.g., Synchrony Report, Barton 2005, Kelly, Kerr) using unapproved naloxone kits, which differ significantly in formulation and delivery method from FDA-approved Narcan Nasal Spray.
- The FDA-approved labeling for Narcan already accounts for situations requiring multiple doses, and field use studies were not required in the original Narcan approval.
- No convincing evidence was provided to suggest that nasal conditions or vomiting significantly impair the efficacy of Narcan Nasal Spray to the extent that approvals should be paused.
- The FDA emphasized maintaining a scientific and statutory standard that applies equally across NDAs and ANDAs under current laws.",denied,True,150.0,CDER,CDER
fda-2017-p-0840,FDA-2017-P-0840-0001_Citizen_Petition_from_The_Weinberg_Group.pdf,2017-02-08,2017,False,original petition,The Weinberg Group Inc.,industry/corporation,"- 21 C.F.R. ¬ß 10.30 ‚Äì Citizen petition process
- 21 C.F.R. ¬ß 314.161 ‚Äì Determination whether a listed drug was withdrawn for safety or effectiveness
- 21 C.F.R. ¬ß¬ß 314.122 and 314.162 ‚Äì Drug removal from Orange Book
- 21 C.F.R. ¬ß 25.31 ‚Äì Environmental impact categorical exclusion
- 21 C.F.R. ¬ß 10.30(b) ‚Äì Economic impact submission","FDA‚Äôs current listing of OVRETTE (norgestrel; 0.075 mg oral tablet), NDA 017031 by Laboratoire HRA Pharma, in the Orange Book as discontinued. The petitioner seeks FDA‚Äôs determination on whether the product was withdrawn for safety or effectiveness reasons","Request FDA to determine whether the discontinuation of OVRETTE (norgestrel) by HRA Pharma was due to safety or effectiveness concerns
","- OVRETTE was approved by FDA on October 23, 1973 and listed in the Orange Book as a ‚Äúlisted drug product.‚Äù
- As of February 7, 2017, the product is listed as Discontinued in the Orange Book.
- A party intending to file an ANDA or 505(b)(2) referencing a discontinued listed drug must obtain FDA‚Äôs determination that the withdrawal was not for safety or efficacy reasons
",2017-08-01 00:00:00,Approved (Determination Issued),2017-10-25,1.0,Center for Drug Evaluation and Research (CDER),"- 21 CFR ¬ß 314.161 ‚Äì Determination whether a drug was withdrawn for safety or effectiveness
- 21 CFR ¬ß 314.162 ‚Äì Removal of a listed drug
- 21 U.S.C. ¬ß 355(j)(7) ‚Äì Listing of approved drugs in the Orange Book 
","The FDA stated that it was unable to reach a decision due to the need to address other Agency priorities. It assured the petitioner that a final response will be issued when resources allow 
","- FDA conducted a review of its records and independently evaluated relevant literature and postmarketing data.
- The agency found no evidence indicating that Ovrette (norgestrel) 0.075 mg was withdrawn for reasons of safety or effectiveness.
- As such, Ovrette remains listed in the ‚ÄúDiscontinued Drug Product List‚Äù of the Orange Book, allowing approval of ANDAs referencing it, assuming all other requirements are met 
",approved,True,259.0,CDER,CDER
fda-2017-p-0864,FDA-2017-P-0864-0001_Citizen_Petition_from_Hyman_Phelps___McNamara_PC.pdf,2017-02-08,2017,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"- 21 C.F.R. ¬ß¬ß 10.25(a) and 10.30 ‚Äì Citizen petition procedure
- FDC Act ¬ß 505(j) ‚Äì Generic drug approval process
- 21 C.F.R. ¬ß 314.3 ‚Äì Definition of listed drug
- 21 C.F.R. ¬ß 25.31 ‚Äì Environmental impact categorical exclusion
- 21 C.F.R. ¬ß 10.30(b) ‚Äì Economic impact (submitted upon request)","The FDA‚Äôs designation of Ibuprofen Tablets, 200 mg (NDA 018989) in the Orange Book ‚Äî specifically its omission as a Reference Listed Drug (RLD) and Reference Standard (RS), which may shield it from generic competition","Designate NDA 018989 for Ibuprofen Tablets, 200 mg, as both a Reference Listed Drug (RLD) and Reference Standard (RS) in the FDA‚Äôs Orange Book to allow ANDA submissions that rely on this product
","- The current omission of NDA 018989 as an RLD or RS limits generic competition.
- FDA policy and guidance recognize that lack of RLD/RS designation can shield products from competition.
- NDA 018989 meets the criteria for both RLD and RS, and its inclusion will help facilitate ANDA filings, reduce barriers to entry, and promote market efficiency",2017-08-07 00:00:00,Dismissed (moot),2020-09-16,1.0,Center for Drug Evaluation and Research (CDER),"Not explicitly cited ‚Äì The letter references the Orange Book, but does not cite specific statutes or regulations 
",The FDA stated it was unable to reach a decision due to the need to address other agency priorities. The agency affirmed it would respond as soon as resources allow ,"The petitioner requested that ibuprofen 200 mg (NDA 018989) be designated as a Reference Listed Drug (RLD) and Reference Standard (RS) in the Orange Book. Since FDA already made that update, the petition was considered resolved and dismissed as moot ",dismissed (moot),True,1316.0,CDER,CDER
fda-2017-p-0866,FDA-2017-P-0866-0001_Citizen_Petition_from_Hyman_Phelps___McNamara.pdf,2017-02-08,2017,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"- 21 C.F.R. ¬ß¬ß 10.25 and 10.30 ‚Äì Citizen petition procedures
- 505(j) and 505(w) of the FD&C Act
- 21 C.F.R. ¬ß¬ß 314.122 and 314.161 ‚Äì Withdrawal determinations
- 21 C.F.R. ¬ß 314.94(a)(9)(iii) ‚Äì Inactive ingredients in parenteral drug products
- 21 C.F.R. ¬ß 314.99(b) ‚Äì Waiver of regulatory requirements
- 21 C.F.R. ¬ß 25.31 ‚Äì Environmental impact exclusion
- 21 C.F.R. ¬ß 10.30(b) ‚Äì Economic impact disclosure","FDA‚Äôs listing and treatment of THIOPLEX (thiotepa) for Injection, 15 mg/vial, under NDA 020058, particularly whether its original formulation was withdrawn for reasons of safety or effectiveness. The petition responds to ambiguity in FDA's prior determination from 2004, which may or may not have applied to the original formulation","1. Determine whether the original formulation of THIOPLEX (thiotepa) was withdrawn for safety/effectiveness reasons.
2. Confirm that FDA will accept ANDAs referencing this original formulation as the Reference Listed Drug (RLD).
3. Clarify if a waiver is needed and can be granted for the inactive ingredient sodium carbonate under 21 C.F.R. ¬ß 314.99(b)","- The original formulation of THIOPLEX (without sodium carbonate) differs from the revised formulation, which was approved in 2000.
- There is no public record confirming if FDA's 2004 determination of non-safety withdrawal applies to the original formulation.
- The drug still appears in the Orange Book as ‚ÄúDiscontinued.‚Äù
- Ensuring clarity is essential for ANDA submissions that rely on the original formulation",2017-08-07 00:00:00,Approved,2018-05-04,1.0,Center for Drug Evaluation and Research (CDER),"- 21 CFR 314.94(a)(9)(ii) ‚Äì Inactive ingredient requirements for ANDAs
- 21 CFR 314.94(a)(9)(iii) ‚Äì Requirements for parenteral drug products
- 21 CFR 314.127(a)(8)(ii)(B) ‚Äì Refusal criteria
- 21 CFR 314.99(b) ‚Äì Waivers for ANDA content and format
- 21 CFR 314.122(a) ‚Äì Determination of withdrawal for safety/effectiveness
- 21 CFR 314.161(a)(1) ‚Äì Evaluation of withdrawal reasons","The FDA stated that the petition raises complex issues requiring extensive review and analysis. Due to this, a final decision could not yet be made. The Agency committed to respond once its resources allow ","- The FDA reviewed historical records, scientific literature, and adverse event data and found no evidence that either the original or reformulated version of Thioplex was withdrawn for safety or effectiveness concerns.
- The agency confirmed that ANDAs duplicating the original formulation may be accepted and approved, provided they meet all statutory and regulatory requirements.
- FDA stated that under 21 CFR 314.99(b), it may waive specific regulatory requirements related to inactive ingredients for parenteral drugs if safety requirements are met 
",approved,True,450.0,CDER,CDER
fda-2017-p-0867,FDA-2017-P-0867-0001_Citizen_Petition_from_Public_Citizen.pdf,2017-02-08,2017,False,original petition,Public Citizen,individual,"- Section‚ÄØ355(e) of the Federal Food, Drug, and Cosmetic Act (codified at‚ÄØ21‚ÄØU.S.C.‚ÄØ¬ß‚ÄØ355(e)) 
- 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ10.30 (FDA citizen‚Äëpetition regulation) 
- 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ25.31(a) (categorical environmental‚Äëimpact exclusion) ","FDA‚Äôs continued marketing/availability of hydroxyethyl starch (HES) intravenous solutions despite safety concerns; the petition addresses FDA‚Äôs policy of allowing these products to remain on the market 
","‚ÄúImmediately require the removal from the market of HES‚ÄØIV solutions.‚Äù 
","Petitioners argue that (1) the risks of HES products outweigh their limited benefits and (2) safer alternative IV solutions are available, so continued marketing endangers patients 
 and reiterate that ‚Äúthese solutions should not be used in any patient population‚Ä¶ HES products should be immediately removed from the market to prevent further harm‚Äù ",2017-07-25 00:00:00,Denied,2021-07-07,1.0,Center for Biologics Evaluation and Research (CBER),"- FD&C Act Section 505(a), 505(b)(1), 505(d), 505(e), and 505(o)(4)
- 21 U.S.C. ¬ß 301 et seq., ¬ß 355(e), ¬ß 355(o)(4), ¬ß 355-1(b)(3)
- 21 CFR Part 314, including 21 CFR 314.150 ","The FDA indicated that the issues raised by the petition‚Äîspecifically the request to remove hydroxyethyl starch (HES) IV solutions from the market due to safety concerns‚Äîare complex, and thus the Agency requires more time to reach a decision. The interim response ensures compliance with procedural requirements under 21 CFR 10.30(e)(2) 
","- FDA identified new safety information (as defined under 505-1(b)(3)) regarding HES products, including increased risk of:
- Mortality
- Acute Kidney Injury (AKI)
- Renal Replacement Therapy (RRT)
- Coagulopathy
- These risks apply not only to critically ill patients, but also to:
- Surgical patients (including cardiac and noncardiac surgery)
- Blunt trauma patients
- Evidence drawn from:
- 10 post-2012 informative studies
- FAERS database (adverse event reports)
- Meta-analyses and observational studies
- FDA concluded that safety labeling changes would sufficiently mitigate risk, preserving the availability of HES products for limited, specific indications, such as in austere or emergency conditions 
",denied,True,1610.0,CBER,Other/Specialty Center
fda-2017-p-0868,FDA-2017-P-0868-0001_Citizen_Petition_From_David_Wong.pdf,2017-02-08,2017,False,original petition,David Wong,individual,"- 505(j)(5)(D)(i)(IV) of the FD&C Act ‚Äì Forfeiture of 180-day exclusivity
- 21 C.F.R. ¬ß 314.107(c)(3) ‚Äì Effective approval date determination
- 21 C.F.R. ¬ß 25.31 ‚Äì Environmental impact categorical exclusion","FDA‚Äôs handling of 180-day exclusivity for ANDA 090482 (Handa Pharmaceuticals) for Quetiapine Fumarate Extended-Release Tablets, specifically whether exclusivity was forfeited and whether FDA should permit final approval of other tentatively approved ANDAs blocked by Handa's first-to-file status
","1. Determine if Handa ANDA 090482 forfeited 180-day exclusivity due to failure to obtain tentative approval within 30 months.
2. Determine if the sponsor is not actively pursuing approval, and allow subsequent ANDAs to become effective.
3. If either condition is met, approve blocked ANDAs (Accord ANDA 090681, IntelliPharmaceutics ANDA 202939) immediately","- Handa ANDA 090482 received tentative approval more than 30 months after submission date (Sept 11, 2010 deadline missed).
- Par Pharmaceuticals, now holder of Handa ANDA, launched only an Authorized Generic on 11/1/2016, not the ANDA product.
- Delay appears intentional and anticompetitive, blocking others from market.
- Accord and IntelliPharmaceutics had tentative approval and settlement dates aligned to launch",,Dismissed (moot),2017-07-26,0.0,Center for Drug Evaluation and Research (CDER),"- Federal Food, Drug, and Cosmetic Act (FD&C Act):
- Sections 505(b)(1), 505(c)(2), 505(j)(2)(A)(vii), 505(j)(2)(B), 505(j)(5)(B)(iii), 505(j)(5)(B)(iv), 505(j)(5)(D),
- 505(j)(5)(D)(i)(IV), 505(j)(5)(B)(iv)(II)(bb), (cc), and (dd)(AA)
- 21 CFR 314.94(a)(12)
- 21 CFR 10.30(e)(2)(iii) ",,"- ANDA 090482 received tentative approval on December 9, 2010, which was within the 30-month window required by statute.
- Final approval was granted on May 9, 2017, after the 180-day exclusivity (triggered on Nov 1, 2016) expired on April 30, 2017.
- Because the exclusivity period ended before the petition could take effect, the petition‚Äôs claims were no longer relevant, and thus dismissed as moot ",dismissed (moot),True,168.0,CDER,CDER
fda-2017-p-0970,FDA-2017-P-0970-0001_Citizen_Petition_from_RiceBran_Technologies.pdf,2017-02-12,2017,False,original petition,RiceBran Technologies,industry/corporation,"- 21 C.F.R. ¬ß 10.30 ‚Äì Citizen petition procedure
- 21 C.F.R. ¬ß 101.9(c)(6)(i) ‚Äì Definition of dietary fiber for nutrition labeling
- 21 C.F.R. ¬ß 25.30(k) ‚Äì Categorical exclusion for environmental impact
- 21 C.F.R. ¬ß 10.30(b)(3) ‚Äì Economic impact submission requirement","Petition responds to the FDA's 2016 request for scientific data on non-digestible carbohydrates and requests an amendment to 21 C.F.R. ¬ß 101.9(c)(6)(i) to include rice bran derivatives containing rice bran fiber in the definition of dietary fiber for nutrition labeling purposes
","- Amend 21 C.F.R. ¬ß 101.9(c)(6)(i) to include ‚Äúrice bran derivatives containing rice bran fiber‚Äù as dietary fiber
- Update the list of isolated/synthetic fibers with beneficial physiological effects to include rice bran fiber","- Scientific evidence shows rice bran fiber improves laxation, reduces blood cholesterol, and attenuates postprandial blood glucose.
- Rice bran fiber includes hemicellulose, cellulose, pectin, and lignin, which are fermentable and contribute to gastrointestinal and metabolic health.
- Human intervention studies support the claimed physiological benefits",2017-07-28 00:00:00,Approved,2018-06-13,1.0,"Center for Food Safety and Applied Nutrition (CFSAN)
","- 21 CFR ¬ß 101.9(c)(6)(i) ‚Äî Definition of dietary fiber
- 21 CFR ¬ß 10.30(e)(3) ‚Äî Governs response timing and actions on citizen petitions
- References to: 81 FR 33742, 81 FR 84516, 81 FR 84595 ‚Äî Federal Register Notices","FDA cites other agency priorities and limited availability of resources as reasons for not completing the petition review within the 180-day timeframe 
","- FDA reviewed the scientific evidence including human intervention studies on rice bran fiber, as well as individual fiber components like cellulose and pectin.
- FDA concluded that rice bran fiber, as a type of mixed plant cell wall fiber, provides beneficial physiological effects, specifically:
- Improved laxation/bowel function
- Reduced blood cholesterol levels
- The FDA determined that rice bran fiber fits the broader definition and is composed of arabinoxylan, cellulose, pectin, and lignin, which individually have been shown to offer physiological benefits 
.
- FDA will exercise enforcement discretion to allow rice bran fiber to be declared as dietary fiber until formal rulemaking is completed.",approved,True,486.0,CFSAN,Other/Specialty Center
fda-2017-p-1002,FDA-2017-P-1002-0001_Citizen_Petition_from_Inrange_Systems__Inc_.pdf,2017-02-13,2017,False,original petition,"INRange Systems, Inc.",industry/corporation,"- 21 U.S.C. ¬ß¬ß 501, 502, 510, 513 (FDCA provisions)
- 21 C.F.R. ¬ß 10.30 ‚Äì Citizen petition procedure
- 21 C.F.R. ¬ß 880.6315 ‚Äì Remote Medication Management Systems classification
- 21 C.F.R. ¬ß 807 Subparts B & E ‚Äì Establishment registration and premarket notification requirements
- 21 C.F.R. ¬ß 25.34 ‚Äì Environmental assessment exclusion","INRange is commenting on FDA‚Äôs regulatory enforcement with regard to the ‚ÄúLUMMA‚Äù device, manufactured by Life Integrating Technologies and Experiences, Inc., which INRange claims is being marketed without FDA approval, registration, or proper classification as required for Remote Medication Management Systems under 21 C.F.R. ¬ß 880.6315
","INRange requests the FDA to:
- Seize and enjoin further marketing of the ‚ÄúLUMMA‚Äù device.
- Declare it misbranded and unapproved under the FDCA.
- Require the manufacturer to comply with registration and premarket requirements for Remote Medication Management Systems under 21 C.F.R. ¬ß 880.6315","- The ‚ÄúLUMMA‚Äù device is marketed without FDA registration, clearance, or listing.
- It meets the functional criteria for a Remote Medication Management System, which is a Class II device subject to special controls.
- There are serious risks involved, such as improper dosage, failure of device, contamination, and patient harm.
- The FDA previously regulated similar products manufactured by INRange",,Denied,2017-09-22,0.0,"Center for Devices and Radiological Health (CDRH)
","- Section 502(o) of the Federal Food, Drug, and Cosmetic Act (misbranding provision)
- 21 CFR 10.30(k) ‚Äî Citizen petition procedural regulation
- 21 CFR 10.45 ‚Äî Non-finality of denial to take enforcement action",,"- Requests to initiate enforcement actions are not permitted under citizen petition procedures (21 CFR 10.30(k)).
- Enforcement decisions are discretionary and case-specific.
- Although the enforcement request was denied, the information was forwarded to CDRH‚Äôs Office of Compliance, which will evaluate and investigate as needed.
- The Office of Compliance does not provide investigation updates or outcomes to petitioners 
",denied,True,221.0,CDRH,CDRH
fda-2017-p-1039,FDA-2017-P-1039-0001_Citizen_Petition_from_Beck___Thomas.pdf,2017-02-10,2017,False,original petition,"Beck & Thomas, P.C.",law/consulting,"- 505 and 505-1 of the FDCA (21 U.S.C. ¬ß¬ß 355 and 355-1)
- 21 C.F.R. Parts 10 and 314
- ICH Q3D Guidance for Industry (Sept. 2015)
- USP General Chapters <232> and <233>
- 21 C.F.R. ¬ß 25.31(a) (Environmental impact exclusion)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact)","The petition comments on the review and approval process of NDAs and ANDAs for potassium chloride oral drug products. It specifically challenges FDA's handling of applications that do not include completed risk assessments for elemental impurities, urging refusal to receive or approve such filings
","- Refuse to file or receive any NDA/ANDA for potassium chloride oral drug products without completed risk assessments and controls for elemental impurities (lead, arsenic, cadmium, mercury, chromium, copper, selenium, manganese, zinc, and other process metals).
- Do not approve any pending NDAs or ANDAs until such documentation is provided","- FDA has already made a safety determination about potential elemental impurities in potassium chloride products.
- FDA has issued 505(o) letters to NDA holders requiring risk assessments for specific metals.
- The petition cites guidance documents and USP standards enforcing control of such impurities by January 1, 2018.
- These products are widely used and may pose toxicity risks if uncontrolled",,Denied,2017-07-14,0.0,Center for Drug Evaluation and Research (CDER),"- Section 505(b) & (j) of the FD&C Act ‚Äî Requirements for NDAs and ANDAs
- Section 505(o)(3) ‚Äî Postmarketing studies and clinical trials authority
- Section 501(b) ‚Äî Adulteration based on compendial standards
- 21 CFR ¬ß 314.50(d)(1) ‚Äî NDA requirements for drug substance/product info
- 21 CFR ¬ß 314.94(a)(9) ‚Äî ANDA chemistry, manufacturing, and controls info
- 21 CFR ¬ß 314.101(d) ‚Äî Refusal to file/receive an NDA/ANDA
- USP Chapters: <231> (Heavy Metals), <232> (Elemental Impurities‚ÄîLimits), <233> (Elemental Impurities‚ÄîProcedures)
- ICH Guidance: Q3A, Q3B(R2), Q3D
- FDA Draft Guidance: Elemental Impurities in Drug Products (June 2016) ",,"- The citizen petition process is not the appropriate mechanism to impose categorical application requirements.
- FDA applies a case-by-case approach for reviewing applications and determining whether risk assessments for elemental impurities are necessary.
- FDA disagreed with requiring categorical risk assessments prior to NDA or ANDA filing or approval, citing existing regulations and guidance that already provide a framework to ensure product purity and safety.
- Risk assessments recommended in ICH Q3D and USP <232>/<233> are not mandatory prior to 2018; adoption was encouraged but not required at the time.
- The issuance of Postmarketing Requirements (PMRs) to some NDA holders did not mean all future applications must include identical pre-approval assessments ",denied,True,154.0,CDER,CDER
fda-2017-p-1077,FDA-2017-P-1077-0001_Citizen_Petition_from_Recordati_Rare_Diseases_INC.pdf,2017-03-02,2017,False,original petition,Recordati Rare Diseases Inc. (RRD),industry/corporation,"- 21 U.S.C. ¬ß 355(q) ‚Äì Citizen petition provision under the FDCA
- 21 C.F.R. ¬ß 10.30 ‚Äì Citizen petition procedural rule
- 21 C.F.R. ¬ß 25.31 ‚Äì Categorical exclusion from environmental assessment requirement
- 21 C.F.R. ¬ß 10.30(b) ‚Äì Economic impact submission","Petition relates to the approval and safety requirements for ANDA 202402 (Ibuprofen Lysine Injection, 10 mg/mL) and any future ANDAs or 505(b)(2) NDAs that reference NeoProfen¬Æ (NDA 021903), which is indicated for premature infants with patent ductus arteriosus. RRD expresses concern about the precipitate formation in products not using inert vials
","RRD requests the FDA to:
- Require that all ANDAs/505(b)(2) NDAs referencing NeoProfen include measures to mitigate precipitate formation, such as use of inert vials and demonstrate stability data free of precipitate formation.
- In the absence of such data, assign a BX rating in the Orange Book (indicating insufficient evidence of therapeutic equivalence)","- RRD identified visible aluminum ibuprofen precipitate in the ANDA product (using borosilicate glass vials) via independent lab testing.
- Prior experience from Lundbeck (former NDA holder) showed standard glass vials are insufficient and led to a product recall.
- NeoProfen now uses inert vials to prevent this issue.
- Such particulates pose serious safety risks for neonates, including embolism and anaphylaxis",2017-08-15 00:00:00,Partially Approved / Partially Denied,2021-12-17,1.0,Center for Drug Evaluation and Research (CDER),"FD&C Act Sections:
- ¬ß 501(a)(2)(B), ¬ß 501(b), ¬ß 505(b)(2), ¬ß 505(j)
21 CFR Regulations:
- ¬ß 314.3(b)
- ¬ß 314.50(d)(1)(ii)(a)
- ¬ß 314.54
- ¬ß 314.94(a), ¬ß 314.94(a)(9)
- ¬ß 314.127(a)(6)(i)
- ¬ß 211.94(a)
- ¬ß 211.194(a)(2), ¬ß 211.165(e)
USP General Chapters:
- <1>, <790>
FDA Draft Guidances:
- Applications Covered by Section 505(b)(2)
- Inspection of Injectable Products for Visible Particulates
- Container Closure Systems for Packaging Human Drugs and Biologics ","- The petition raises complex issues involving potential conditions of approval for ANDAs and 505(b)(2) applications related to NeoProfen.
- These issues require extensive review and analysis by FDA officials.
- Therefore, a final decision could not be made within the standard timeframe 
","- The FDA acknowledged that precipitate formation could pose safety risks, but found that the cause may involve multiple factors (e.g., vial surface, excipients, stoppers, manufacturing equipment).
- Applicants are allowed flexibility in selecting container-closure systems and mitigating particulate formation risks using different technologies (e.g., vial coatings).
- FDA already requires specifications to ensure identity, strength, quality, purity, and bioavailability, including container system suitability, under existing CGMP and regulatory frameworks.
- The approved ANDA 202402 had since changed from glass to plastic vials, effectively addressing the original concern ‚Äî hence, this portion of the petition was granted.
- The request to mandate new requirements for all future ANDAs/505(b)(2)s referencing NeoProfen was denied as unnecessary.
- The request to reclassify ANDA 202402 as BX (not therapeutically equivalent) was denied; FDA reaffirmed that the drug is therapeutically equivalent (AP rating) based on demonstrated bioequivalence 
",partially approved / denied,True,1751.0,CDER,CDER
fda-2017-p-1096,FDA-2017-P-1096-0001_Citizen_Petition_from_Hyman__Phelps___McNamara__P_.pdf,2017-02-17,2017,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"- 21 C.F.R. ¬ß 10.25 and ¬ß 10.30 ‚Äì Citizen Petition procedures
- 21 C.F.R. ¬ß¬ß 314.122, 314.161, 314.162 ‚Äì Discontinued drugs and withdrawal for safety/effectiveness
- 21 C.F.R. ¬ß 314.94(a)(9)(iii) ‚Äì Inactive ingredient sameness requirement
- 21 C.F.R. ¬ß 314.99(b) ‚Äì Waiver of inactive ingredient rule
- 505(j), 505(w), 505(j)(4)(H) of the FDCA","Whether FDA will:
1) Determine if the original formulation of VASOSTRICT (vasopressin) Injection, 20 units/mL, under NDA 204485, was withdrawn for safety or efficacy reasons.
2) Permit ANDA submissions referencing the original formulation (not the revised one) as the Reference Listed Drug (RLD)","- FDA should determine that the original VASOSTRICT formulation was not withdrawn for reasons of safety or effectiveness.
- FDA should confirm ANDA applicants may use the original VASOSTRICT formulation as the RLD.
- FDA should grant a waiver from the excipient sameness requirement under 21 C.F.R. ¬ß 314.94(a)(9)(iii)","- The original formulation of VASOSTRICT was voluntarily discontinued in 2015 (likely for commercial reasons), not due to safety or efficacy concerns.
- The revised formulation differs in excipients: removed chlorobutanol and acetic acid, added sodium acetate.
- ANDAs duplicating the original formulation may need a waiver to meet FDA's inactive ingredient rule",2017-08-16 00:00:00,Approved (Determination Issued),2018-12-21,1.0,Center for Drug Evaluation and Research (CDER),"- 21 U.S.C. ¬ß 355(j) ‚Äî FD&C Act (ANDA approval process)
- 21 CFR ¬ß 314.94(a)(9)(iii) ‚Äî ANDA content for parenteral products
- 21 CFR ¬ß 314.127(a)(8)(ii)(B) ‚Äî Refusal to approve ANDA based on inactive ingredients
- 21 CFR ¬ß 314.161(a)(1) ‚Äî Determination on discontinuation for safety/effectiveness
- 21 CFR ¬ß 314.122(a) ‚Äî Requirement for citizen petition if drug is withdrawn
- 21 CFR ¬ß 314.99(b) ‚Äî Waiver of requirements for inactive ingredients in ANDAs","- FDA could not reach a decision due to the need to address other Agency priorities.
- The petition raises two key requests:
1. Whether the original formulation of VASOSTRICT (vasopressin) Injection was withdrawn for safety or effectiveness reasons.
2. Whether FDA will accept ANDA submissions using the original VASOSTRICT formulation as the Reference Listed Drug (RLD).
- A final response will be issued when resources permit full review","- FDA reviewed its files and found no evidence that the original Vasostrict (20 units/mL) was withdrawn for reasons of safety or effectiveness (page 4).
- The petitioned formulation (with chlorobutanol) was voluntarily replaced with one using sodium acetate, not due to adverse safety findings.
- FDA found that the ANDA formulation may differ in excipients like preservatives, buffers, and antioxidants if the safety of these ingredients is supported.
- Under 21 CFR ¬ß 314.99(b), FDA may waive the requirement that all inactive ingredients be identical in concentration, so long as safety is maintained.
- FDA concluded it may accept ANDAs referencing the original Vasostrict as RLD and approve them, provided all other statutory and regulatory requirements are satisfied (page 5).",approved,True,672.0,CDER,CDER
fda-2017-p-1104,FDA-2017-P-1104-0001_Citizen_Petition_from_Gator_Pharmaceuticals__Inc_.pdf,2017-02-17,2017,False,original petition,"Gator Pharmaceuticals, Inc.",industry/corporation,"- 21 C.F.R. ¬ß 10.30 ‚Äì Citizen Petition procedure
- Sections 301(d) and 505(a) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 25.1(g) ‚Äì Environmental impact (not required)
- 21 C.F.R. ¬ß 10.30(b) ‚Äì Economic impact (submitted on request)",Petition asks the FDA to determine that Gator‚Äôs COLPREP Kit (NDA 204553) is therapeutically equivalent to Braintree Laboratories‚Äô SUPREP Bowel Prep Kit (NDA 22372) and requests that this be recognized in the Orange Book via a special situation statement in its preface regarding colon prep kits containing the same actives,"- FDA should create a special situation in the preface of the Orange Book stating that COLPREP and SUPREP kits (powder vs. solution forms with same actives and dosage) are therapeutically equivalent.
- Grant an ‚ÄúAB‚Äù Therapeutic Equivalence Code to COLPREP Kit","- Both kits have identical active ingredients and strengths (Magnesium Sulfate, Potassium Sulfate, Sodium Sulfate).
- Both must be diluted with water before oral administration, resulting in the same final oral solution.
- Therapeutic equivalence is supported by FDA‚Äôs own criteria (pharmaceutical equivalence + bioequivalence).
- Public interest supports interchangeable products at lower cost",2017-08-18 00:00:00,Dismissed (moot),2019-10-09,1.0,Center for Drug Evaluation and Research (CDER),"- 84 FR 47309 (September 9, 2019) ‚Äî Reference to the Federal Register notice titled ‚ÄúWithdrawal of Approval of 25 New Drug Applications‚Äù 
- Orange Book policy referenced ","- The petition requests FDA to create a ‚Äúspecial situation‚Äù in the Orange Book to address the therapeutic equivalence of colon preparation kits containing magnesium sulfate, potassium sulfate, and sodium sulfate.
- The petitioner also requested FDA to declare that ColPrep Kit is therapeutically equivalent to SUPREP Bowel Prep Kit.
- FDA states it has not yet reached a decision on the petition due to the need to prioritize other matters and resource limitations","- The petition requested that FDA determine ColPrep Kit (NDA 204553) is therapeutically equivalent to SUPREP Bowel Prep Kit (NDA 22372).
- However, on January 24, 2019, the approval of NDA 204553 was withdrawn, and this withdrawal was officially recognized as of October 9, 2019, making the therapeutic equivalence determination unnecessary.
- As a result, the FDA dismissed the petition as moot since the relevant application no longer exists for comparison
",dismissed (moot),True,964.0,CDER,CDER
fda-2017-p-1108,FDA-2017-P-1108-0001_Citizen_Petition_from_Orbicular_Pharmaceutical_Tec.pdf,2017-02-22,2017,False,original petition,Orbicular Pharmaceutical Technologies Pvt. Ltd.,industry/corporation,"- 21 C.F.R. ¬ß 10.25(a) ‚Äì Citizen petition procedural rule
- 21 C.F.R. ¬ß 10.30 ‚Äì Submission requirements
- 21 C.F.R. ¬ß 314.161 ‚Äì Determination of withdrawal for safety or efficacy reasons
- 21 C.F.R. ¬ß 25.31 ‚Äì Environmental impact categorical exclusion
- 21 C.F.R. ¬ß 10.30(b) ‚Äì Economic impact submission","Request for the FDA to determine whether the discontinuation of TIMOPTIC¬Æ (Timolol Maleate) Ophthalmic Solution, 0.25% and 0.5% by ATON PHARMA INC under NDA 018086 was for safety or efficacy reasons","The petitioner requests that the FDA determine that the referenced drug was not discontinued or withdrawn for reasons of safety or effectiveness, enabling submission of an ANDA referencing the product
","- TIMOPTIC¬Æ is still listed in the Orange Book as ‚ÄúDiscontinued‚Äù
- No indication that it was withdrawn for safety or efficacy reasons
- ANDA approval requires FDA confirmation that the drug was not withdrawn for such reasons",2017-08-21 00:00:00,Approved (Determination Issued),2017-09-15,1.0,Center for Drug Evaluation and Research (CDER),"- 21 CFR ¬ß 10.30 ‚Äî Citizen petition procedures
- 21 CFR ¬ß 314.161 ‚Äî Withdrawal of approval for reasons of safety or effectiveness
- 21 CFR ¬ß 314.162 ‚Äî Removal from Orange Book listing if withdrawn for safety/effectiveness reasons
- Section 505(j)(7) of the FD&C Act (21 U.S.C. ¬ß 355(j)(7)) ‚Äî Requires FDA to maintain a list of approved drugs (the Orange Book)","- The petition requests FDA to determine that TIMOPTIC (timolol maleate ophthalmic solution) under NDA 018-086 was not withdrawn for reasons of safety or effectiveness.
- The FDA stated it has not completed its review due to the need to address other Agency priorities and the numerous demands on its resources","- FDA reviewed its records and found no evidence suggesting TIMOPTIC was withdrawn for safety or effectiveness concerns.
- An independent evaluation of literature and postmarketing safety data was conducted, and no adverse information was found that would warrant withdrawal.
- FDA concluded that TIMOPTIC would remain in the ‚ÄúDiscontinued Drug Product List‚Äù in the Orange Book, meaning it was discontinued for reasons other than safety or effectiveness.
- As a result, FDA will continue to allow ANDA approvals that refer to TIMOPTIC, assuming all other regulatory conditions are met",approved,True,205.0,CDER,CDER
fda-2017-p-1221,FDA-2017-P-1221-0001_Suitability_Petition_from_Aurora_Pharmaceutical_LL.pdf,2017-02-23,2017,False,original petition,Aurora Pharmaceutical LLC,industry/corporation,"- Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 25.33(e) ‚Äì Categorical exclusion for investigational use
- 21 C.F.R. ¬ß 25.21 ‚Äì Extraordinary circumstances affecting environment","Request for permission to file an Abbreviated New Animal Drug Application (ANADA) for a generic Firocoxib Solution 0.45% w/v, differing in dosage form and strength from the approved EQUIOXX¬Æ Oral Paste
","Approval of a Suitability Petition to allow submission of an ANADA for Firocoxib Solution 0.45% w/v with the same active ingredient and dosage, but different form (solution) and strength compared to the RLNAD
","- Same active ingredient (firocoxib)
- Dosage unchanged: 0.045 mg/lb (0.1 mg/kg) daily for up to 14 days
- Formulated as a multi-dose oral solution instead of paste for user convenience
- No exclusivity remains: Patent 6,020,343 expired Oct 9, 2016; Patent 5,981,576 expires July 22, 2018; exclusivity expired Dec 30, 2008",,Approved,2017-05-19,0.0,Center for Veterinary Medicine (CVM),"- Section 512(n)(3) and 512(n)(3)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 CFR ¬ß 514.5 ‚Äî Pertaining to pre-submission conferences for ANADAs",,"- The petition proposed a generic firocoxib oral solution (0.45% w/v) for horses, which differs in dosage form (oral solution vs. oral paste) and strength (4.5 mg/mL vs. 8.2 mg/g) from the RLNAD Equioxx¬Æ.
- The proposed generic maintains the same dosage schedule and route of administration as the RLNAD.
- FDA determined that these changes do not require new safety or effectiveness investigations, qualifying them for a suitability petition pathway under the FD&C Act.
",approved,True,85.0,CVM,Other/Specialty Center
fda-2017-p-1225,FDA-2017-P-1225-0001_Suitability_Petition_from_Aurora_Pharmaceutical_LL.pdf,2017-02-23,2017,False,original petition,Aurora Pharmaceutical LLC,industry/corporation,"- Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 25.33(e) ‚Äì Categorical exclusion for investigational use
- 21 C.F.R. ¬ß 25.21 ‚Äì Extraordinary circumstances affecting environment",Request to permit filing of an abbreviated new animal drug application (ANADA) for a generic omeprazole suspension that differs in dosage form and strength from the reference drug GastroGard¬Æ,"Grant a suitability petition allowing Aurora to file an ANADA for Omeprazole Suspension 4.5% w/v, which differs from the reference GastroGard¬Æ Oral Paste in dosage form (suspension vs paste) and strength (4.5% vs 37%)
","- Uses the same active ingredient (omeprazole) and same recommended dosage as RLNAD
- The only differences are formulation (suspension instead of paste) and strength (4.5% w/v vs 37% w/w)
- Change justified based on user convenience (multi-dose packaging)
- No known marketing exclusivity; patent expired (U.S. Patent No. 5,708,017 expired April 4, 2015)",,Denied,2017-05-18,0.0,Center for Veterinary Medicine (CVM),"- Section 512(n)(3) and 512(n)(3)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 CFR Part 10 ‚Äî General procedures
- 21 CFR ¬ß 10.33 ‚Äî Reconsideration of action
- 21 CFR ¬ß 10.25(a) ‚Äî Filing a new petition",,"- The proposed generic product, an omeprazole oral suspension (4.5% w/v), differs in dosage form and strength from the RLNAD, GastroGard¬Æ oral paste (8.2 mg/g).
- FDA concluded the change would require additional investigations to support safety and effectiveness.
- Concerns cited include:
- Stability of omeprazole in the acidic environment of the equine stomach.
- Requirements for formulation characteristics such as rapid absorption, pH buffering, and enteric-coating to prevent gastric degradation.
- FDA suggested filing a new petition with more detailed formulation and administration information to address these issues
",denied,True,84.0,CVM,Other/Specialty Center
fda-2017-p-1226,FDA-2017-P-1226-0001_Citizen_Petition_from_INRange_Systems__Inc.pdf,2017-02-24,2017,False,original petition,"INRange Systems, Inc.",industry/corporation,"- FDCA Sections: 501, 502, 510, 513
- 21 C.F.R. ¬ß¬ß 10.30, 807 Subpart B, 807 Subpart E, 880.6315, 890.5050, 25.34
- 21 U.S.C. ¬ß321(h)","- Lack of FDA enforcement on ‚ÄúLivi‚Äù Remote Medication Management System by PharmRight Corporation
- Failure to register, list, or submit premarket notice","- Detain the ‚ÄúLivi‚Äù device
- Seize or enjoin further marketing
- Determine appropriate relief
- Enforce compliance with FDA requirements","- ‚ÄúLivi‚Äù functions as a Remote Medication Management System under 21 CFR ¬ß880.6315
- Not registered, listed, or cleared by FDA
- Device poses serious risks (e.g., dosage errors, contamination, data security, failure)
- Public health risk due to reliance by vulnerable home patients",,Denied,2017-09-25,0.0,"Center for Devices and Radiological Health (CDRH)
","- Section 502(o) of the Federal Food, Drug, and Cosmetic Act ‚Äî Misbranding provisions
- 21 CFR ¬ß 10.30(k) ‚Äî Enforcement action requests not within scope of citizen petitions
- 21 CFR ¬ß 10.45 ‚Äî Denial of enforcement requests not considered final administrative action",,"- The petitioner requested FDA take enforcement action against PharmRight Corporation for allegedly marketing an unapproved and misbranded device (‚ÄúLivi‚Äù).
- The FDA responded that requests for enforcement action fall outside the scope of the citizen petition process and are at the agency‚Äôs discretion.
- Although the petition was denied, FDA forwarded the information to the Office of Compliance at CDRH.
- The Office of Compliance entered the complaint into its Allegation of Regulatory Misconduct system for review and potential investigation.
- FDA stated that it does not provide updates or outcomes of such investigations to petitioners and that enforcement decisions are handled on a case-by-case basis",denied,True,213.0,CDRH,CDRH
fda-2017-p-1230,FDA-2017-P-1230-0001_Citizen_Petition_from_Regcon_Solutions.pdf,2017-02-27,2017,False,original petition,Regcon Solutions,law/consulting,"- Section 505(j) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß¬ß 10.20, 10.30 (Citizen petition procedures)
- 21 C.F.R. ¬ß 25.31 (Environmental impact categorical exclusion)","The designation of Reference Standard (RS) in the Orange Book for Azelastine Ophthalmic Solution 0.05%. The current RS product (Optivar, NDA 021127 by Meda Pharms) has been discontinued or is not marketed","Designate Apotex's Azelastine Ophthalmic Solution 0.05% (ANDA 078621) as the new Reference Standard (RS) for the submission of ANDAs for the same drug product
","- Optivar, the current RS, is discontinued or not marketed, creating a barrier to generic ANDA filings.
- Among the four AT-rated products, Apotex‚Äôs product was the first approved ANDA, making it the logical RS.
- Without this RS designation, the product is shielded from generic competition, which impedes market access and affordability",2017-08-21 00:00:00,Partially Approved / Partially Denied,2017-12-20,1.0,"Center for Drug Evaluation and Research (CDER)
","- 21 U.S.C. ¬ß 355(j) ‚Äî FD&C Act, ANDA provisions
- 21 CFR ¬ß 314.94(a)(3) ‚Äî Reference standards and bioequivalence testing
- 21 CFR ¬ß 314.161 ‚Äî Drug withdrawal for safety/effectiveness concerns
- 21 CFR ¬ß 314.122 ‚Äî Petition requirements for discontinued drugs
- 21 CFR ¬ß 314.3(b) ‚Äî Definitions of therapeutic equivalence
- 81 FR 69580, 69619 ‚Äî FDA rulemaking on ANDAs (October 6, 2016)
- FDA Draft Guidance for Industry (Jan 2017) ‚Äî Referencing Approved Drug Products in ANDA Submissions","- The petition requests FDA to designate Azelastine Ophthalmic Solution 0.05% (ANDA 078621 by Apotex Inc.) as a reference standard.
- FDA states it has not yet reached a decision due to competing Agency priorities and the numerous demands on its resources, hence issuing this interim response under regulatory requirements
","- The petition requested that the Apotex product (ANDA 078621) be selected as the reference standard for azelastine hydrochloride ophthalmic solution 0.05%.
- FDA agreed a new reference standard was necessary since the original RLD (Optivar, NDA 021127) had been discontinued from marketing.
- However, FDA chose the Sandoz product (ANDA 202305) instead of Apotex's product because Sandoz‚Äôs drug was determined to be the market leader based on commercial data.
- This selection is consistent with FDA policy to promote consistency in bioequivalence comparisons and to select a therapeutically equivalent generic when the RLD is unavailable",partially approved / denied,True,296.0,CDER,CDER
fda-2017-p-1251,FDA-2017-P-1251-0001_Citizen_Petition_from_American_Feed_Industry_Assoc.pdf,2017-02-27,2017,False,original petition,- American Feed Industry Association (AFIA)  National Grain and Feed Association (NGFA),advocacy/academic,"- 21 U.S.C. ¬ß¬ß 351(a)(2)(B), 360b(m), 371(a), 371(h)
- 21 C.F.R. ¬ß¬ß 10.40, 10.115, Part 11, Part 210, Part 225
- 21 C.F.R. ¬ß 25.30(h) (environmental impact exemption)","The application of 21 C.F.R. Part 11 (electronic records and electronic signature requirements) to records maintained under 21 C.F.R. Part 225, related to medicated feed current Good Manufacturing Practice (cGMP) regulations","- Exempt all medicated feed cGMP-related records under Part 225 from compliance with Part 11.
- Publish a direct final rule with specific amendments to ¬ß¬ß 11.1, 225.117, and 225.202.
- Alternatively, issue a Level 2 guidance stating FDA will exercise enforcement discretion and not enforce Part 11 for such records pending rulemaking","- High cost and burden of Part 11 compliance (~$225,000 per facility).
- No significant public or animal health benefit from enforcing Part 11 on medicated feed cGMP records.
- FDA has already exempted similar records under FSMA rules for animal and human food.
- Relief would allow more efficient recordkeeping, better inspections, and improved industry-FDA interactions.
- Consistent with FDA‚Äôs 2003 guidance to narrow Part 11‚Äôs scope and intent",2017-08-22 00:00:00,Dismissed (moot),2022-11-09,1.0,Center for Veterinary Medicine (CVM),"- 21 CFR ¬ß 10.30(e)(3) ‚Äî Grounds for dismissal of a petition
- 21 CFR Part 11 ‚Äî Electronic records and electronic signatures
- 21 CFR Part 225 ‚Äî CGMP regulations for medicated feeds","- The petition requested that FDA amend its regulations so that the Part 11 electronic records and signature requirements do not apply to records required under 21 CFR Part 225 (cGMP for medicated feeds).
- FDA responded that it needs additional time to analyze the legal and policy implications due to the complexity of the petitioned issues.
- A final response will be issued later, after full evaluation of the information and regulatory considerations","- The petition requested FDA to exempt electronic records required by 21 CFR Part 225 from the requirements of Part 11 (electronic records/signatures).
- Petitioners proposed either a direct final rule amending the regulations or a Level 2 guidance outlining enforcement discretion.
- Although FDA did not act within the petitioner‚Äôs requested timeline, the agency agreed that rulemaking is the appropriate method for addressing the issue.
- FDA publicly indicated its intent to publish a direct final rule, as included in the Spring 2022 Unified Agenda, which would exempt certain veterinary feed records from Part 11.
- As this action aligns with the petitioners' goals, FDA considered the petition substantively addressed and rendered moot
",dismissed (moot),True,2081.0,CVM,Other/Specialty Center
fda-2017-p-1252,FDA-2017-P-1252-0001_Citizen_Petition_from_Xiromed__LLC_on_behalf_of_Li.pdf,2017-02-26,2017,False,original petition,Xiromed LLC,industry/corporation,"- 21 C.F.R. ¬ß 10.30 (Citizen petition procedure)
- 21 C.F.R. ¬ß 314.94(a)(3) (Definition of RLD)
- Hatch-Waxman Act (Public Law 98-417)","The petition addresses the lack of a current Reference Standard (RS) for ZANTAC (Ranitidine Tablets) 150 mg & 300 mg, originally manufactured by GlaxoSmithKline (GSK), which has been discontinued and is no longer available on the market
","FDA is requested to designate ANDA 077824, held by Amneal Pharmaceuticals NY, LLC, as the Reference Standard (RS) for Ranitidine Tablets EQ 150 mg and 300 mg
","- The original RLD, GSK‚Äôs ZANTAC, has been discontinued and is no longer commercially available.
- Amneal's ANDA 077824 dominates the current market with 66% market share for 150 mg and 76% for 300 mg tablets based on IMS data.
- A new RS designation is critical to enable the development of generics and support cost-effective treatment options.
- Prompt FDA action will facilitate generic drug development and help lower public healthcare costs",2017-08-24 00:00:00,Dismissed (moot),2018-08-28,1.0,"Center for Drug Evaluation and Research (CDER)
","- Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations)
- FDA Draft Guidance for Industry: Ranitidine Hydrochloride (December 2009)
- No specific U.S. Code or CFR citations were made in the body of the response","- The petition requested that FDA designate ANDA 077824 (Amneal Pharmaceuticals NY, LLC) as a reference standard for ranitidine hydrochloride tablets (EQ 150 mg and EQ 300 mg base).
- FDA explained it had not made a decision due to needing to address other Agency priorities and noted the numerous demands on its resources","- The petitioners requested that Amneal‚Äôs ANDA 077824 for ranitidine hydrochloride tablets (EQ 150 mg and EQ 300 mg base) be designated as the new reference standard because the RLD (NDA 018703 by GSK) was being discontinued.
- After the petitions were submitted, GSK officially discontinued their ranitidine products and FDA updated the Orange Book accordingly.
- FDA designated the 300 mg tablet strength under ANDA 077824 (Amneal) as the new reference standard, aligning with agency practice to choose the highest strength and follow product-specific guidance recommending 300 mg bioequivalence studies.
- As the requested outcome had already been implemented, FDA concluded the petitions were rendered moot
",dismissed (moot),True,548.0,CDER,CDER
fda-2017-p-1278,FDA-2017-P-1278-0001_Citizen_Petition_from_Gilead_Sciences__Inc_.pdf,2017-01-24,2017,False,original petition,"Gilead Sciences, Inc.",industry/corporation,"- 505(c)(3)(E) of the FDCA
- 505(j)(5)(F) of the FDCA
- 505(q) of the FDCA
- 21 C.F.R. ¬ß¬ß 10.30, 10.31, 314.108
- 21 C.F.R. ¬ß¬ß 25.30, 25.31 (environmental exemption)",FDA's previous denial of five-year new chemical entity (NCE) exclusivity to Stribild under its pre-2014 policy on fixed-combination products.,"- Award five-year NCE exclusivity to Stribild retroactively
- Extend the exclusivity to subsequently approved Gilead drugs Tybost and Vitekta under FDA‚Äôs ‚Äúumbrella policy‚Äù
- Withdraw FDA‚Äôs receipt of any ANDAs (including Mylan ANDA 208982) referencing elvitegravir or cobicistat filed before August 27, 2016.","- FDA's prior policy on fixed-combination drugs was ruled arbitrary and capricious in Ferring v. Burwell.
- FDA revised its NCE policy in 2014 but did not apply it retroactively to Stribild.
- The Stribild case was cited by the court as an example of unfair treatment caused by the timing/order of drug approvals.
- Gilead incurred costs and legal burdens due to premature ANDA submissions and litigation.
- Public interest and industry clarity warrant prompt correction.",,Approved,2017-06-26,0.0,Center for Drug Evaluation and Research (CDER),"- Section 505(c)(3)(E)(ii) and 505(j)(5)(F)(ii) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. ¬ß 355)
- 21 CFR ¬ß 314.101(e)(2) ‚Äî Refusal to receive premature applications
- FDA‚Äôs ‚Äúumbrella policy‚Äù ‚Äì referenced via 54 FR 28872 at 28898-28899 (July 10, 1989)
- Ferring Pharmaceuticals, Inc. v. Burwell, No. CV 15-0802 (RC), 2016 WL 4734333 (D.D.C. Sept. 9, 2016)
- Order, Ferring Pharms. Inc. v. Price, No. 16-5326 (D.C. Cir. March 17, 2017)",,"- Stribild contained two previously unapproved active ingredients (cobicistat and elvitegravir) and was therefore eligible for 5-year exclusivity, consistent with the holding in Ferring Pharmaceuticals v. Burwell.
- FDA already reflected this decision in the Orange Book, showing Stribild‚Äôs exclusivity expiring August 27, 2017.
- Under the umbrella policy, FDA extended the same exclusivity to Tybost (NDA 203094) and Vitekta (NDA 203093), which also appears in the Orange Book.
- FDA granted the request to refuse receipt of any ANDAs or 505(b)(2) applications referencing these drugs submitted before the 4-year mark unless they include a Paragraph IV certification.
- All three requests were therefore already implemented by the time of this response",approved,True,153.0,CDER,CDER
fda-2017-p-1297,FDA-2017-P-1297-0001_Citizen_Petition_from_Regcon_Solutions.pdf,2017-03-01,2017,False,original petition,Regcon Solutions,law/consulting,"- 21 C.F.R. ¬ß 10.30 (Citizen petition procedures)
- 21 C.F.R. ¬ß 314.93 (Suitability petition)
- 21 C.F.R. ¬ß 314.122 and ¬ß 314.161 (withdrawal of drug approval)
- 21 C.F.R. ¬ß 314.127(a)(7) (labeling omissions for generics)
- 21 C.F.R. ¬ß¬ß 25.30 and 25.31 (Environmental impact exclusion)
- Section 505(j)(2)(C) of the FDCA (ANDA suitability)","FDA‚Äôs policy and precedent concerning the submission of an Abbreviated New Drug Application (ANDA) that references a discontinued formulation of Kinevac (sincalide) for injection
","The petitioner requests FDA to:
- Determine that the original formulation of Kinevac (5 mcg sincalide + 45 mg sodium chloride) was not discontinued for safety or efficacy reasons.
- Confirm that a proposed generic product based on this formulation is suitable for ANDA submission","- The original formulation was used clinically for 26 years.
- There is no documented evidence that the formulation was withdrawn for safety or effectiveness reasons.
- The proposed product is qualitatively and quantitatively equivalent to the original formulation.
- FDA has authority to approve ANDAs that reference discontinued products if not withdrawn for safety/efficacy concerns.
- The proposed product would be therapeutically equivalent to the currently marketed Kinevac formulation",2017-09-19 00:00:00,Withdrawn,2024-11-21,1.0,"Center for Drug Evaluation and Research (CDER)
",Not applicable. ,"- The petition sought FDA‚Äôs determination that the original two-ingredient formulation of KINEVAC for injection (containing 5 mcg sincalide and 45 mg sodium chloride) is suitable for submission as an Abbreviated New Drug Application (ANDA).
- FDA stated it could not make a decision yet due to the need to address other Agency priorities and the numerous demands on its resources, thus issuing an interim response as required by regulation","- The FDA made several attempts to contact the petitioner via:
Certified mail (July 11 and August 22, 2024)
Email (October 9, 2024)
- No response was received within 30 days after each communication.
- The FDA concluded the petition was inactive for over 5 years, and its continued review would detract from addressing more pressing public health concerns.
- Therefore, the agency considered the petition to be voluntarily withdrawn without prejudice, allowing resubmission in the future if desired",withdrawn,True,2822.0,CDER,CDER
fda-2017-p-1298,FDA-2017-P-1298-0001_Citizen_Petition_from_The_Good_Food_Institute.pdf,2017-03-02,2017,False,original petition,The Good Food Institute (GFI),advocacy/academic,"- 21 C.F.R. ¬ß 10.30 (Citizen petition)
- 5 U.S.C. ¬ß 553(e) (APA right to petition for rulemaking)
- 21 U.S.C. ¬ß 343(a)(1) (FDCA: misbranding due to false or misleading labeling)
- 21 C.F.R. ¬ß 101.3(b) (standard of identity for common food names)
- 21 U.S.C. ¬ß 321(g) (definition of ""drug"" under FDCA)","GFI comments on recent suggestions that plant-based products should be restricted from using terms like ‚Äúmilk,‚Äù ‚Äúmeat,‚Äù and ‚Äúeggs‚Äù on their labels. These suggestions imply that plant-based products using such terms are misleading or violate standards of identity.","GFI requests that FDA:
1. Issue a regulation or guidance recognizing that compound terms like ‚Äúsoy milk,‚Äù ‚Äúalmond milk,‚Äù ‚Äúvegan cheese,‚Äù and ‚Äúplant-based meat‚Äù are not misleading when the plant source is clear.
2. Reaffirm existing labeling rules allowing these terms under current FDA law.","- Terms like ‚Äúsoy milk‚Äù and ‚Äúvegan cheese‚Äù have been used for decades and are well understood by consumers.
- Plant-based labeling provides accurate information and facilitates consumer choice.
- Restricting these terms would violate the First Amendment and contradict consumer understanding.
- There is no evidence of consumer confusion over these terms.
- The FDA‚Äôs past enforcement policy has tolerated these labels, and no formal standard excludes plant-based variants from common usage names.",2017-08-29 00:00:00,,2025-10-15,1.0,,,"- The petition requested FDA to issue regulations clarifying how foods may be named by reference to the names of other foods.
- FDA indicated that it had not yet reached a decision due to competing priorities within the agency.
- They committed to completing review and considering amendments as warranted within the context of other program priorities
",,no decision,False,3149.0,pending,pending
fda-2017-p-1359,FDA-2017-P-1359-0001_Citizen_Petition_from_Pharmaceutical__Manufacturin.pdf,2017-03-06,2017,False,original petition,"Pharmaceutical Manufacturing Research Services, Inc. (PMRS)",advocacy/academic,"- 21 C.F.R. ¬ß 10.20
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 25.31
- Section 505(b) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)","The FDA‚Äôs approval and labeling of:
- OxyContin‚Äôs indication for chronic pain
- All extended-release opioids indicated for chronic pain
- All immediate-release opioids used for chronic pain","PMRS requests that the FDA:
(i) Revoke OxyContin's approval for chronic pain
(ii) Revoke approval of all ER opioids for chronic pain
(iii) Revoke IR opioid labeling supporting chronic pain use","- FDA approved chronic pain indication for OxyContin without substantial evidence
- Misuse, addiction, and overdose risks have increased
- Chronic pain indication contradicts scientific data and public health findings
- OxyContin was originally approved only for acute use; later changes led to widespread abuse
- The change contributed to the opioid epidemic; over 200,000 deaths cited",2017-08-31 00:00:00,,2025-10-15,1.0,,,"- The petition requested the FDA to revoke certain labeling approvals related to both extended-release and immediate-release opioid products, specifically seeking revocation of:
1. OxyContin‚Äôs chronic use labeling
2. ER opioids for chronic pain
3. IR opioids for chronic pain
4. Replace IR labeling with indications for acute pain only.
- FDA explained that the petition raised significant and complex issues requiring extensive internal review and analysis by agency officials. Hence, an interim response was issued pending further evaluation
",,no decision,False,3145.0,pending,pending
fda-2017-p-1391,FDA-2017-P-1391-0001_Citizen_Petition_from_Epstein_Becker___Green_P_C_.pdf,2017-03-03,2017,False,original petition,"Epstein Becker & Green, P.C.",law/consulting,"- 21 C.F.R. ¬ß 10.30 (Citizen Petition)
- 21 C.F.R. ¬ß 10.75 (Internal agency review procedures)
- 21 C.F.R. ¬ß 3.8 (Letter of designation rules)
- 21 C.F.R. ¬ß 25.30 (Environmental impact exclusion)
- 5 U.S.C. ¬ß¬ß 555(b), 706(1), 706(2)(A) (Administrative Procedure Act)
- 21 U.S.C. ¬ß 353(g) (FDCA designation provisions)
- 21st Century Cures Act, Sec. 3038","The petition comments on the lack of a regulatory timeline for appeals of FDA‚Äôs letter of designation decisions made by the Office of Combination Products under 21 C.F.R. ¬ß 3.8.
","- Amend 21 C.F.R. ¬ß 3.8 to include a new subsection (d): FDA must complete review of appeals under 21 C.F.R. ¬ß 10.75 within 60 calendar days.
- Require all pending appeals submitted prior to October 1, 2015, to be resolved by March 9, 2017","- Significant delays (some over 17 months) in decision-making due to lack of timelines.
- Delays violate the Administrative Procedure Act by allowing ‚Äúarbitrary‚Äù and untimely decisions.
- Delays hinder correction of errors in designation decisions and delay compliance with the 21st Century Cures Act.
- Innovators lose patent time and are forced to accept erroneous designations.
- Most importantly, delays harm public health by slowing patient access to new therapies",,,2025-10-15,0.0,,,,,no decision,False,3148.0,pending,pending
fda-2017-p-1392,FDA-2017-P-1392-0001_Citizen_Petition_from_Latham___Watkins__LLP__Par_S.pdf,2017-03-07,2017,False,original petition,Latham & Watkins LLP,law/consulting,"- FDCA ¬ß¬ß 505(b), 505(j), 505(q)
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß¬ß 314.92(a)(1), 314.94(a)(3), 314.94(a)(9)(iii)
- 21 C.F.R. ¬ß 25.31(a)","FDA‚Äôs prior decision (Dec. 23, 2016) denying Par‚Äôs earlier Citizen Petition (FDA-2016-P-2376), which addressed impurity standards for ANDAs of epinephrine injection 1 mg/mL","FDA should:
- Modify its prior decision and
- Require any ANDA for epinephrine injection 1 mg/mL to:
¬†¬†‚Ä¢ Have impurity levels (D-epinephrine, ESA) equivalent or lower than Par‚Äôs reformulated Adrenalin¬Æ
¬†¬†‚Ä¢ Undergo postmarket testing equivalent to that imposed on Par","- Scientific: Impurities arise from degradation, not manufacturing variability; affect efficacy due to L-epinephrine loss.
- Regulatory: Parenteral formulations must not vary in inactive ingredients unless proven safe/effective.
- Equity: FDA imposed postmarket testing on Par; fairness demands similar requirements for ANDA filers.",,"- Par Modification Petition: Denied
- Hospira Petition: Partially Approved / Partially Denied",2017-08-04,0.0,"Center for Drug Evaluation and Research (CDER)
","- Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 355(j))
- 21 CFR 314.94(a)(9)(iii)
- 21 CFR 314.127(a)(8)(ii)(B)
- 21 CFR 314.99(b)
- 21 CFR 314.162
- 21 CFR 314.122(a)
- 21 CFR 314.161(a)(1)
- Section 505(j)(4)(H) of the FD&C Act
- Section 505(j)(2)(A)(iv) and (j)(4) of the FD&C Act",,"- Impurity Specifications: FDA denied Par‚Äôs request to impose specific impurity limits for D-epinephrine and ESA on generic versions of Adrenalin because impurity profiles are application-specific and reviewed on a case-by-case basis. Uniform specifications were deemed inappropriate.
- Effectiveness Argument Rejected: FDA disagreed with Par‚Äôs claim that generics with higher levels of these impurities are necessarily less effective, citing a lack of evidence and pointing out that shelf life differences do not equate to differences in efficacy or safety.
- No Mandated Studies for ANDA Applicants: FDA rejected Par‚Äôs assertion that generic applicants must conduct the same studies Par performed, explaining that Par's commitments were voluntary (PMCs) and not FDA-mandated (PMRs).
- Hospira Petition: FDA granted the request to determine whether the original formulation was withdrawn for safety/effectiveness reasons (it was not), but denied the request to maintain its listing in the Orange Book. Reformulated Adrenalin is now the only version listed.",partially approved / denied,True,150.0,CDER,CDER
fda-2017-p-1459,FDA-2017-P-1459-0001_Citizen_Petition_from_Foley___Lardner_LLP.pdf,2017-03-08,2017,False,original petition,Foley & Lardner LLP,law/consulting,"- 21 C.F.R. ¬ß 10.30 (Citizen Petition regulation)
- 21 C.F.R. ¬ß 314.161 (drug withdrawal for safety/effectiveness)
- 21 C.F.R. ¬ß¬ß 314.122, 314.162 (related to ANDA submission and Orange Book listings)
- FD&C Act ¬ß 505(j)","The petition comments on whether ENJUVIA (estrogens, conjugated synthetic B) tablets, NDA 21443, in 0.625 mg and 1.25 mg strengths, have been withdrawn from the market for reasons of safety or effectiveness.
","The petitioner requests that FDA determine whether Teva‚Äôs ENJUVIA tablets (0.625 and 1.25 mg strengths) were voluntarily withdrawn for safety or efficacy reasons. 
","- The electronic Orange Book as of March 3, 2017, shows that Teva is not marketing ENJUVIA 0.625 mg and 1.25 mg, while the other strengths remain listed.
- Because these strengths are no longer marketed, the petitioner seeks FDA's official determination on whether the withdrawal was due to safety or effectiveness issues, which would impact their listing status and referenceability in future drug applications. ",,Approved (Determination Issued),2017-09-05,0.0,"Center for Drug Evaluation and Research (CDER)
","- 21 CFR 314.161 ‚Äì Determination whether a drug was withdrawn for safety or effectiveness reasons
- 21 CFR 314.162 ‚Äì Removal from the Orange Book if withdrawn for safety/effectiveness
- Section 505(j)(7) of the FD&C Act (21 U.S.C. 355(j)(7)) ‚Äì Requirement for the Orange Book list",,"- FDA reviewed internal records, literature, and post-marketing safety data.
- No evidence was found that Enjuvia tablets were withdrawn due to safety or effectiveness concerns.
- Therefore, FDA concluded that these drugs can continue to serve as references for Abbreviated New Drug Applications (ANDAs) as long as other regulatory requirements are met
",approved,True,181.0,CDER,CDER
fda-2017-p-1461,FDA-2017-P-1461-0001_Citizen_Petition_from_FOLEY___LARDNER_LLP.pdf,2017-03-08,2017,False,original petition,Foley & Lardner LLP,law/consulting,"- 21 CFR ¬ß 10.30 (Citizen Petition procedure)
- 21 CFR ¬ß 314.161 (withdrawal of approval for safety/effectiveness)
- 21 CFR ¬ß¬ß 314.122 and 314.162 (related to ANDA and drug withdrawal)
- FD&C Act Section 505(j) ","The petition comments on whether CENESTIN (estrogens, conjugated synthetic A), approved under NDA 20992 and held by Teva, has been withdrawn from the market for reasons of safety or effectiveness.
","The petitioner requests that FDA determine whether Teva‚Äôs CENESTIN in various strengths (0.3, 0.45, 0.625, 0.9, and 1.25 mg) has been voluntarily withdrawn for safety or efficacy reasons. 
","- The Orange Book as of March 3, 2017, indicates that Teva is not marketing any strengths of CENESTIN.
- To allow a future 505(j) ANDA or 505(b)(2) NDA to reference CENESTIN, FDA must determine whether its withdrawal was due to safety or efficacy concerns.
- The petitioner seeks confirmation from FDA to clarify whether the product‚Äôs unavailability is tied to such concerns. ",,Approved (Determination Issued),2017-08-30,0.0,"Center for Drug Evaluation and Research (CDER)
","Not Explicitly Mentioned (but the action pertains to 21 CFR 314.161, which governs determinations of withdrawal for safety or effectiveness related to the Orange Book listing)
",,"- FDA reviewed internal records and determined that Cenestin tablets were not withdrawn for reasons of safety or effectiveness.
- As such, the drug products will continue to be listed in the Orange Book‚Äôs ""Discontinued Drug Product List,"" making them eligible as reference products for ANDA submissions
",approved,True,175.0,CDER,CDER
fda-2017-p-1463,FDA-2017-P-1463-0001_Citizen_Petition_from_Tate___Lyle_Ingredients_Amer.pdf,2017-03-08,2017,False,original petition,Tate & Lyle Ingredients Americas LLC,industry/corporation,"- 21 C.F.R. ¬ß 10.30 (Citizen Petition provision)
- 21 C.F.R. ¬ß 101.9(c)(1)(i) (caloric value labeling regulation)
- 21 C.F.R. ¬ß 25.31 (Environmental impact exclusion)","The petition comments on FDA's regulation of caloric values listed on nutrition labels, specifically requesting a rulemaking amendment to 21 C.F.R. ¬ß 101.9(c)(1)(i) to define a new caloric value for Allulose.
","The petitioner requests that FDA:
1. Amend 21 C.F.R. ¬ß 101.9(c)(1)(i) to specify that Allulose contributes 0.2 kcal/g and list it under a new subsection (G).
2. Set the amendment‚Äôs effective date 30 days after Federal Register publication.
3. Set the compliance date two years post-publication (three years for small manufacturers). ","- Scientific evidence, including a radiotracer metabolism study conducted by Tate & Lyle, demonstrated that Allulose is absorbed but not metabolized, and is excreted largely intact, contributing 0.2 kcal/g or less.
- The Iida et al. (2010) study estimated the caloric value between 0.20‚Äì0.39 kcal/g, supporting Tate & Lyle's position.
- A rigorous human 14C-labeled radiotracer study showed over 80% urinary recovery, minimal fecal excretion, and negligible 14CO2 in breath, confirming no significant metabolism.
- Animal studies (e.g., Matsuo 2002) supported these findings, showing Allulose‚Äôs energy deposition efficiency was only 0.3% of sucrose.
- The petitioner emphasizes that labeling Allulose at 0.2 kcal/g reflects the most scientifically accurate and conservative value based on current data. ",,,2025-10-15,0.0,,,,,no decision,False,3143.0,pending,pending
fda-2017-p-1573,FDA-2017-P-1573-0001_Citizen_Petition_from_Hospira_Inc.pdf,2017-03-13,2017,False,original petition,"Hospira, Inc.",industry/corporation,"- 21 CFR ¬ß 10.30 (general provision for citizen petitions)
- 21 CFR ¬ß 314.93 (requesting determination of RLD availability)
- 21 CFR ¬ß 314.161 (withdrawals of approved drugs for safety/effectiveness)
- 21 CFR ¬ß 25.31 (environmental impact exclusion)
- 21 U.S.C. Section 355(j)(7)(C)(ii) (approval of ANDA referencing discontinued drugs)
- 21 CFR ¬ß¬ß 314.122 and 314.161 ","The petition comments on the reformulation and discontinuation of the original formulation of Adrenalin¬Æ (epinephrine) Injection, 1 mg/mL, 1 mL vial, specifically NDA 204200 held by Par Sterile Products LLC. Hospira seeks clarification from FDA regarding whether this original formulation was discontinued for reasons of safety or effectiveness. 
","Hospira requests that the FDA:
a) Determine that the original formulation of Adrenalin¬Æ was not withdrawn for safety or effectiveness reasons; and
b) Maintain its listing in the Orange Book so it can continue to be referenced in ANDAs. ","- The reformulation was not based on safety/effectiveness but rather to extend shelf life and remove the mydriasis indication.
- The inactive ingredient differences are minor and not clinically significant (see formulation comparison table on page 2).
- The FDA‚Äôs prior response to a separate petition (Docket No: FDA-2016-P-2376) indicated no proven safety or effectiveness improvement in the reformulated product.
- Hospira asserts that maintaining the original product in the Orange Book supports ANDA eligibility under FDA regulations.",,"- Par Modification Petition: Denied
- Hospira Petition: Partially Approved / Partially Denied",2017-08-04,0.0,"Center for Drug Evaluation and Research (CDER)
","- Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 355(j))
- 21 CFR 314.94(a)(9)(iii)
- 21 CFR 314.127(a)(8)(ii)(B)
- 21 CFR 314.99(b)
- 21 CFR 314.162
- 21 CFR 314.122(a)
- 21 CFR 314.161(a)(1)
- Section 505(j)(4)(H) of the FD&C Act
- Section 505(j)(2)(A)(iv) and (j)(4) of the FD&C Act",,"- Impurity Specifications: FDA denied Par‚Äôs request to impose specific impurity limits for D-epinephrine and ESA on generic versions of Adrenalin because impurity profiles are application-specific and reviewed on a case-by-case basis. Uniform specifications were deemed inappropriate.
- Effectiveness Argument Rejected: FDA disagreed with Par‚Äôs claim that generics with higher levels of these impurities are necessarily less effective, citing a lack of evidence and pointing out that shelf life differences do not equate to differences in efficacy or safety.
- No Mandated Studies for ANDA Applicants: FDA rejected Par‚Äôs assertion that generic applicants must conduct the same studies Par performed, explaining that Par's commitments were voluntary (PMCs) and not FDA-mandated (PMRs).
- Hospira Petition: FDA granted the request to determine whether the original formulation was withdrawn for safety/effectiveness reasons (it was not), but denied the request to maintain its listing in the Orange Book. Reformulated Adrenalin is now the only version listed.",partially approved / denied,True,144.0,CDER,CDER
fda-2017-p-1990,FDA-2017-P-1990-0001_Citizen_Petition_from_AIDP__Inc.pdf,2017-03-23,2017,False,original petition,"AIDP, Inc.",industry/corporation,"- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 101.9(c)(6)(i)
- 21 C.F.R. ¬ß 25.22
- 21 C.F.R. ¬ß 25.30(k)
- FDA Guidance documents (Nov. 22, 2016; Jan. 2009)","Definition of dietary fiber under the revised nutrition labeling regulations published on May 27, 2016 (81 Fed. Reg. 33,742) 
","Amend 21 C.F.R. ¬ß 101.9(c)(6)(i) to include xylooligosaccharides (XOS) in the list of non-digestible carbohydrates recognized as dietary fiber for nutrition labeling.
","AIDP presented evidence that XOS provides multiple health benefits, including:
‚Ä¢ Improved gastrointestinal regularity/laxation
‚Ä¢ Reduced blood cholesterol levels
‚Ä¢ Attenuated postprandial blood glycemic responses

They cited a series of human clinical trials, mechanisms of action, and reviews of scientific evidence to support these claims",2017-09-26 00:00:00,Denied,2018-11-14,1.0,"Center for Food Safety and Applied Nutrition (CFSAN)
","- 21 CFR ¬ß 101.9(c)(6)(i) (related to dietary fiber definitions)
- 21 CFR ¬ß 10.30(e)(3) (regarding FDA‚Äôs authority to deny a citizen petition)
- 81 FR 33742 (Final Rule: Food Labeling Revision of the Nutrition and Supplement Facts Labels)
- 83 FR 8997 (Guidance on evaluating scientific evidence for dietary fiber)","- The petition requested that xylooligosaccharides be recognized as a dietary fiber for nutrition labeling purposes.
- FDA stated it could not reach a decision within 180 days due to other agency priorities and limited resource availability.
- FDA will notify the petitioner once a decision has been made","- The FDA evaluated the petition and supporting studies on the physiological effects of XOS, specifically its effect on laxation, blood cholesterol, and blood glucose/insulin levels.
- The agency reviewed clinical studies and scientific literature submitted with the petition and found inconsistent or insufficient evidence supporting a beneficial physiological effect of XOS in the target populations.
- Some studies lacked appropriate control groups, while others showed no statistically significant effect on the claimed benefits.
- Based on the FDA‚Äôs finalized scientific review guidance, the strength of the evidence did not support a finding that XOS provides health benefits that meet the dietary fiber definition.
- As a result, the FDA concluded that XOS does not qualify as a dietary fiber under 21 CFR ¬ß 101.9(c)(6)(i).",denied,True,601.0,CFSAN,Other/Specialty Center
fda-2017-p-2043,FDA-2017-P-2043-0001_Citizen_Petition_from_Yiling_Pharmaceutical__Ltd.pdf,2017-03-31,2017,False,original petition,Yiling Pharmaceutical Ltd.,industry/corporation,"- 21 CFR 10.25(a)
- 21 CFR 10.30","The selection of the Reference Listed Drug (RLD) and Reference Standard (RS) for Acyclovir Capsules 200 mg (ZOVIRAX), specifically addressing limitations in availability of the current RS.","Request for the FDA Commissioner to select a different listed drug (from one of three suppliers) as an additional reference standard for Acyclovir 200 mg capsules, due to unavailability of the currently assigned RS.
","- ZOVIRAX 200 mg capsules (the current RLD/RS) are on long-term backorder and unavailable in the market since at least August 2016.
- Cited the 2017 FDA Draft Guidance allowing submission of petitions when the RS is unavailable.
- Attached supplier communications and market status documentation to demonstrate lack of availability.
- Petition argues that the lack of available RS prevents potential ANDA applicants from conducting required bioequivalence testing
",2017-09-27 00:00:00,Approved,2017-10-18,1.0,Center for Drug Evaluation and Research (CDER),"- 21 U.S.C. ¬ß 355(j) (Section 505(j) of the FD&C Act)
- 21 CFR ¬ß 314.3(b)
- 21 CFR ¬ß 314.94(a)(3)
- 57 FR 17950, 17958 (April 28, 1992)
- 81 FR 69580, 69619 (Oct. 6, 2016)","- The petition requested that FDA designate an additional reference standard for ZOVIRAX (acyclovir) capsules, 200 mg, under NDA 018-828, in the Orange Book.
- FDA stated that it had not reached a decision due to the need to address other agency priorities.
- The interim response was issued per regulations and noted that the FDA would respond as soon as resources allowed
","- The current reference listed drug (RLD) ZOVIRAX (acyclovir) 200 mg capsules was in backorder and unavailable since August 2016, making it difficult for the petitioner to obtain for bioequivalence testing.
- FDA determined that ANDA 075677 (Apotex) is therapeutically equivalent and the market leader.
- Therefore, it was appropriate to designate this ANDA as the new reference standard",approved,True,201.0,CDER,CDER
fda-2017-p-2044,FDA-2017-P-2044-0001_Citizen_Petition_from_Nirsum_Pharmaceuticals__LLC.pdf,2017-03-31,2017,False,original petition,"Nirsum Pharmaceuticals, LLC",industry/corporation,"- 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 25.31 (Environmental Impact)
- 21 C.F.R. ¬ß 10.30(b) (Economic Impact)","Determination of whether Revex (nalmefene hydrochloride injection), NDA 020-459, was withdrawn from sale for reasons other than safety or effectiveness
","The petitioner requests that the FDA determine whether Revex was voluntarily withdrawn for reasons not related to safety or efficacy, and annotate the Orange Book listing accordingly. If the withdrawal was related to safety or efficacy, the petitioner requests publication of a notice in the Federal Register specifying those concerns
","- Revex is an FDA-approved opioid receptor antagonist used for suspected opioid overdose.
- It was discontinued in 2008, but there's no evidence of withdrawal for safety or efficacy reasons.
- There is a public health crisis related to opioid overdoses; naloxone, the only alternative, has a shorter half-life and has experienced shortages.
- Revex has a longer half-life (~10.8 hours) and may be a better alternative in some scenarios.
- No safety signals or adverse event trends suggest a safety issue.
- Revex is listed as discontinued in the Orange Book without clarification on safety/efficacy reasons, and the petitioner believes the omission should be corrected.
- The drug has been proven effective and approved in other markets for similar uses
.
",,Approved (Determination Issued),2017-11-03,0.0,"Center for Drug Evaluation and Research (CDER)
","Not Explicitly Mentioned in the letter. However, the decision references the Orange Book's ""Discontinued Drug Product List,"" which is governed by 21 CFR ¬ß 314.161 (implied but not stated).",,"- The petitioner requested a determination on whether Revex (nalmefene hydrochloride injection) was withdrawn for safety or effectiveness reasons.
- FDA reviewed its internal records and concluded the withdrawal was not for such reasons.
- As a result, the drug product will continue to be listed in the appropriate Orange Book section, allowing it to serve as a reference for future ANDA submissions
",approved,True,217.0,CDER,CDER
fda-2017-p-2092,FDA-2017-P-2092-0001_Citizen_Petition_from_Wilson_Sonsini_Goodrich___Ro.pdf,2017-04-03,2017,False,original petition,"Wilson Sonsini Goodrich & Rosati, P.C.",law/consulting,"- 21 U.S.C. ¬ß 355(j)
- 21 C.F.R. ¬ß¬ß 10.20, 10.30, 320.1 et seq., 320.21, 320.22, 314.94(a)(3)","The petition comments on FDA's potential acceptance of ANDAs for generic versions of Epaned¬Æ (enalapril maleate) Oral Solution 1 mg/mL without requiring in vivo bioequivalence studies. It also discusses the lack of designation of Epaned¬Æ as a reference listed drug (RLD) in the Orange Book 
","The petitioner requests that the FDA:
1. Require in vivo bioequivalence studies for ANDAs referencing Epaned¬Æ
2. Refrain from granting any in vivo bioequivalence waivers
3. Refuse approval for generics that are not Q1/Q2 the same unless supported by appropriate BE studies under both fed and fasted conditions
4. Publish BE requirements and designate Epaned¬Æ as the RLD","The petitioner provides extensive scientific and regulatory arguments, including:
- Enalapril‚Äôs narrow therapeutic window in pediatric patients
- Susceptibility of enalapril to pH and temperature affecting bioavailability
- Potential effects of formulation changes (e.g., buffers, sucralose) on absorption
- Evidence suggesting that only in vivo studies can adequately assess systemic exposure changes due to formulation differences",2017-09-19 00:00:00,Denied,2019-10-25,1.0,"Center for Drug Evaluation and Research (CDER)
","- 21 U.S.C. ¬ß 355(j) (Section 505(j) of the FD&C Act)
- 21 CFR ¬ß 314.94(a)(9)(ii)
- 21 CFR ¬ß 320.22(b)(1), (b)(3), and (d)
- 21 CFR ¬ß 320.24(b)
- 21 CFR ¬ß 314.127(a)(8)(ii)(A)
- 21 CFR ¬ß 314.127(a)(8)(i)
- 21 CFR ¬ß 314.70
- Section 505(q)(1)(H) of the FD&C Act","- The petition requested that no abbreviated new drug application (ANDA) for Epaned (enalapril maleate oral solution, NDA 208-686) be granted final approval unless it contains sufficient in vivo bioequivalence data as per applicable laws.
- FDA was unable to issue a final decision due to competing priorities and issued this letter in compliance with 21 CFR 10.30(e)(2), which mandates an interim response if final action is delayed","- The petition requested FDA to require that any ANDA referencing Epaned Oral Solution include in vivo bioequivalence (BE) studies and disallow biowaivers (waivers of in vivo testing).
- FDA disagreed, stating that regulations permit waivers where justified, and these are evaluated on a case-by-case basis, depending on formulation, excipients, and bioequivalence methods.
- FDA reviewed the bioequivalence data submitted with the NDA for Epaned and found that differences in excipients like sweeteners or buffers did not significantly impact bioavailability.
- Petition arguments regarding buffering agents, sweeteners, and excipient variability were not supported by sufficient scientific evidence.
- The Agency emphasized that determinations regarding biowaivers and BE testing will be made when an ANDA is submitted, based on totality of data including formulation and pharmacokinetics.
- FDA concluded that the petition lacked sufficient justification to impose blanket requirements.",denied,True,935.0,CDER,CDER
fda-2017-p-2128,FDA-2017-P-2128-0001_Citizen_Petition_from_Jubilant_Generics_Limited.pdf,2017-04-04,2017,False,original petition,EAS Consulting Group,law/consulting,"- 21 U.S.C. ¬ß 355(j)(2)(C) (Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act)
- 21 CFR ¬ß¬ß 314.93, 10.20, and 10.30",The determination of suitability for submission of an ANDA (Abbreviated New Drug Application) for Fluoxetine Hydrochloride Tablets in 30 mg and 40 mg strengths ,"The petitioner requests FDA to determine that Fluoxetine Hydrochloride Tablets, 30 mg and 40 mg, are suitable for submission as an ANDA 
","- The proposed strengths are already described in the RLD labeling and are clinically used (e.g., 30 mg from scored 60 mg tablet).
- Provides dosing convenience, avoids splitting tablets, improves compliance and dosing accuracy.
- 40 mg tablet form not currently available on U.S. market; addition meets individualized patient needs.
- No new clinical investigations needed as formulation, route, and conditions of use match the RLD. ",,Withdrawn,2023-06-13,0.0,"Center for Drug Evaluation and Research (CDER)
",Not applicable. ,,"- The original citizen petition was submitted by Jubilant Generics Limited on April 4, 2017.
- On March 17, 2023, FDA issued a letter to the petitioner requesting confirmation of continued interest.
- The letter indicated that if no response was received within 30 days, the petition would be considered withdrawn.
- No response was received from the petitioner.
- Consequently, FDA filed the letter and return receipt in the docket and treated the petition as voluntarily withdrawn without prejudice to resubmission
",withdrawn,True,2261.0,CDER,CDER
fda-2017-p-2129,FDA-2017-P-2129-0001_Citizen_Petition_from_Jubilant_Generics_Limited.pdf,2017-04-04,2017,False,original petition,EAS Consulting Group,law/consulting,"- 505(j)(2)(C) of the FD&C Act (21 U.S.C. 355(j)(2)(C))
- 21 C.F.R. ¬ß 314.93
- 21 C.F.R. ¬ß 10.20
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 25.31","Suitability of new strengths of Methylprednisolone Tablets (12 mg, 20 mg, and 28 mg) for submission under an ANDA referencing MEDROL¬Æ 32 mg","FDA to determine that the 12 mg, 20 mg, and 28 mg strengths of Methylprednisolone Tablets are suitable for submission in an ANDA","- Requested strengths are mentioned in the RLD labeling
- Currently achieved by combining multiple tablets of lower strengths
- Proposed change would reduce pill burden, excipient load, and dosing inaccuracy
- No change in dosage form, route, or use
- No new clinical studies required",,Withdrawn,2023-06-13,0.0,"Center for Drug Evaluation and Research (CDER)
",Not applicable. ,,"- The citizen petition was submitted by Jubilant Generics Limited on April 4, 2017.
- FDA sent a certified letter dated March 17, 2023, requesting confirmation of interest in the petition to keep it active.
- The letter stated that failure to respond within 30 days would result in the petition being considered withdrawn.
- No response was received from the petitioner.
- As a result, the petition was treated as voluntarily withdrawn without prejudice to resubmission",withdrawn,True,2261.0,CDER,CDER
fda-2017-p-2162,FDA-2017-P-2162-0001_Citizen_Petition_from_Hyman__Phelps___McNamara__P_.pdf,2017-04-05,2017,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"- 21 C.F.R. ¬ß 10.30 (Citizen petition)
- 21 U.S.C. ¬ß 355(c)(3)(E)(iii), (iv) (Exclusivity provisions)
- 21 C.F.R. ¬ß 314.108
- FDCA ¬ß 505(b)(2) (NDA process)
- Section 505(q) of the FDCA (mentioned in context of exclusivity challenges)	",FDA‚Äôs potential acceptance or approval of any 505(b)(2) or ANDA referencing bupivacaine hydrochloride and meloxicam for intravenous infusion during the period of market exclusivity	,FDA should refuse to accept or approve any 505(b)(2) or ANDA referencing the combination product (bupivacaine HCl and meloxicam IV) until the exclusivity period granted to Recro Pharma expires	,"- Approval of Recro Pharma‚Äôs NDA was based on new clinical investigations essential to approval, thereby granting 3-year market exclusivity.
- FDA is legally obligated under 21 U.S.C. ¬ß 355(c)(3)(E)(iv) to respect this exclusivity.
- Approval of a referencing application during the exclusivity period would violate statutory protections and FDA precedent.",,Denied,2017-09-01,0.0,"Center for Drug Evaluation and Research (CDER)
","- Section 505(q) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. ¬ß 355(q))
- 21 CFR ¬ß¬ß 314.105, 314.110, 314.125, 314.127, 314.200",,"- The petition was denied without comment because the FDA had not made a final decision on the approvability of any specific ANDA referencing Tyvaso as of the response date.
- FDA emphasized that decisions on approvability should follow the established NDA/ANDA review process, and that section 505(q) does not require FDA to preemptively rule on parts of pending applications.
- The response reiterates that the FDA must act within 150 days under 505(q), but it does not mean the Agency must render decisions on application specifics before completing the full review.
- The Agency stated it is prohibited from disclosing any determinations about pending ANDAs or NDAs prior to a final decision.",denied,True,149.0,CDER,CDER
fda-2017-p-2164,FDA-2017-P-2164-0001_Citizen_Petition_from_Steptoe___Johnson__LLP__Nati.pdf,2017-04-05,2017,False,original petition,Steptoe & Johnson LLP,law/consulting,"- 21 C.F.R. ¬ß¬ß 10.25, 10.30, 10.33, 10.35
- 21 U.S.C. ¬ß 343(q)(5)(H)
- 5 U.S.C. ¬ß 553(b)(B), ¬ß 706
- Administrative Procedures Act (APA)
- Executive Order 13771
- Executive Order 13777 ","The Final Rule on Food Labeling: Nutrition Labeling of Standard Menu Items in Restaurants and Similar Retail Food Establishments (79 Fed. Reg. 71156, Dec. 1, 2014) 
","- Stay the effective date of the Final Rule (under 21 C.F.R. ¬ß 10.35(b))
- Reconsider the Final Rule and commence a new rulemaking process under section 4205 of the ACA (21 U.S.C. ¬ß 343(q)(5)(H))","- Impossibility of Compliance: Petitioners cite ambiguity in definitions (e.g., what constitutes a ""menu""), unaddressed compliance guidance, and unfeasible implementation timelines.
- Underestimated Costs: FDA underestimated compliance costs for non-restaurant retailers, which are in the hundreds of millions to billions of dollars.
- Overreach and Improper Scope: The Final Rule extends beyond what Congress intended by applying to businesses not ‚Äúsimilar‚Äù to restaurants.
- First Amendment Concerns: The rule mandates potentially misleading commercial speech and fails to directly advance a substantial government interest.
- Inconsistency with Federal Policy: The Final Rule conflicts with executive directives aimed at reducing regulatory burdens on businesses. ",2017-06-29 00:00:00,,2025-10-15,1.0,,,"- The petition requested a stay and reconsideration of the FDA‚Äôs final rule on ‚ÄúNutrition Labeling of Standard Menu Items in Restaurants and Similar Retail Food Establishments.‚Äù
- FDA explained that they were still reviewing the petition and that they had already extended the compliance date for the rule to May 7, 2018 (as published in the Federal Register on May 4, 2017, 82 Fed. Reg. 20825).
- FDA also noted they were extending the comment period on the interim final rule by another 30 days and encouraged further comments
",,no decision,False,3115.0,pending,pending
fda-2017-p-2229,FDA-2017-P-2229-0001_Citizen_Petition_from_Covington___Burling__LLP_and.pdf,2017-04-07,2017,False,original petition,Covington & Burling LLP,law/consulting,"- 21 C.F.R. ¬ß 10.30 ‚Äì Citizen petition procedures
- Federal Food, Drug, and Cosmetic Act (FDCA) ¬ß 512(j) ‚Äì Relating to drug listings for animal drugs
- FDCA ¬ß 501(a)(5) ‚Äì Adulteration for unapproved new animal drugs
- 21 U.S.C. ¬ß 360b(j) ‚Äì Related to indexed animal drugs (FDCA ¬ß 572)","FDA‚Äôs enforcement policy concerning listing of animal drugs with unapproved uses and the use of the NDC Directory to identify legally marketed animal drugs, including efforts to delist or exclude products not approved via NADAs or ANADAs	","- Clarify that listing in the NDC Directory does not establish legal marketing status of animal drugs.
- Remove unapproved animal drugs from listings or clarify they are not FDA-approved.
- Enhance public communications to avoid confusion that all NDC-listed drugs are FDA-approved.","- Many stakeholders mistakenly assume that NDC Directory inclusion equals FDA approval, especially for animal drugs.
- Lack of clarity allows unapproved animal drugs to be marketed under misleading appearance of compliance.
- AHI members who comply with FDA approval processes are disadvantaged by enforcement gaps and misperceptions.
- Public and veterinary professionals deserve clear, non-misleading regulatory communication to ensure proper animal drug use and industry compliance.",2017-10-04 00:00:00,Partially Denied,2018-06-13,2.0,"Center for Food Safety and Applied Nutrition (CFSAN)
","- 21 CFR 101.9(c)(6)(i)
- 21 CFR 10.30
- 21 CFR 101.81
- 10.35(b), (e), and (g)
- FD&C Act Section 403(q)","- The FDA acknowledged receipt of the petition requesting revocation of the definition of dietary fiber in 21 CFR 101.9(c)(6)(i).
- The agency explained it had not been able to reach a decision within the 180-day period due to competing priorities and limited resources.
- FDA stated that it would notify the petitioner once its review was complete
","- The FDA emphasized that its definition of dietary fiber is based on whether the fiber has beneficial physiological effects for human health.
- It rejected the petitioner‚Äôs claim that FDA applied ‚Äúdifferent standards‚Äù to intrinsic vs. synthetic fibers, clarifying both must meet the same scientific benchmark for physiological benefit.
- FDA declined to recognize fermentation and changes in the gut microbiota as beneficial effects themselves, though they may result in beneficial effects like satiety.
- FDA explained it already provides a mechanism for recognizing new dietary fibers and clarified that no stay was needed as the compliance date was extended to 2020/2021
.
",partially approved / denied,True,432.0,CFSAN,Other/Specialty Center
fda-2017-p-2230,FDA-2017-P-2230-0001_Citizen_Petition_from_Kleinfeld__Kaplan_and_Becker.pdf,2017-04-07,2017,False,original petition,"Kleinfeld, Kaplan and Becker LLP",law/consulting,"- 21 CFR ¬ß 10.30 ‚Äì Citizen petition process
- 21 CFR ¬ß 310.6(b)(1) ‚Äì Evidence of safety and effectiveness for marketed products
- 21 CFR ¬ß 310.545(a)(10)(ii)(A) ‚Äì Sodium bicarbonate as an antacid
- 21 CFR Part 25 ‚Äì Environmental impact categorical exclusion (referencing ¬ß25.30 and ¬ß25.31)",FDA‚Äôs removal of ARM & HAMMER‚Ñ¢ Baking Soda from its OTC drug monograph for antacids and listing of such products as requiring NDA approval due to lack of evidence of being recognized as safe and effective under the conditions stated	,"Request for FDA to issue a regulation recognizing sodium bicarbonate, ARM & HAMMER‚Ñ¢ Baking Soda, as generally recognized as safe and effective (GRASE) for OTC use as an antacid, and permit continued marketing without an approved NDA	","- ARM & HAMMER‚Ñ¢ Baking Soda has been marketed continuously since 1970 for antacid use.
- The company provided historical labeling and product use data, supporting long-standing OTC status.
- The petition argues FDA‚Äôs de facto delisting action is inappropriate without full notice and comment.
- Church & Dwight believes their product satisfies the GRASE criteria, particularly under the OTC Antacid Monograph, and the product has no evidence of harm or misuse.
- The firm also claims FDA‚Äôs actions unduly burden a safe and established product without due regulatory process .",,Partially Approved / Partially Denied,2017-09-07,0.0,Center for Drug Evaluation and Research (CDER),"- Section 505(j) of the Federal Food, Drug, and Cosmetic (FD&C) Act (21 U.S.C. 355(j))
- Section 505(b)(2) of the FD&C Act
- 21 CFR 314.3(b)
- 21 CFR 314.94(a)
- 21 CFR 314.127(a)
- 21 CFR 10.31(d)(1)
- 21 CFR 314.50(d)(1)(ii), 314.54(a)(1)(i), 314.94(a)(9)(i)",,"- Toxicology and E/L Study Request: FDA agreed that safety data including toxicology and extractable/leachable (E/L) data may be appropriate and are evaluated on a case-by-case basis for both ANDA and 505(b)(2) applications.
- Dermal Toxicity Studies: 9-month dermal toxicity studies are not categorically required; need depends on formulation differences and known safety data.
- E/L Studies: Generally expected unless a scientific justification warrants waiver.
- Patch-Disposal Unit Requirement: Denied. FDA concluded that the fold-and-flush method for disposal is sufficient. There is no requirement that a generic product replicate the Butrans Patch-Disposal Unit. Inclusion of the disposal unit was voluntary by Purdue and not necessary for FDA approval.
- FDA found no evidence that generics lacking a disposal system would pose greater safety risks than Butrans. ",partially approved / denied,True,153.0,CDER,CDER
fda-2017-p-2233,FDA-2017-P-2233-0001_Citizen_Petition_from_Consumers_for_Dental_Choice.pdf,2017-03-28,2017,False,original petition,Consumers for Dental Choice,advocacy/academic,"- 21 C.F.R. ¬ß 10.30 ‚Äì Citizen petition procedure
- 21 C.F.R. ¬ß 895.20 ‚Äì Banned devices
- 21 U.S.C. ¬ß 360f ‚Äì Authority to ban devices
- 21 C.F.R. ¬ß 872.3050 ‚Äì Regulation for amalgam devices
- 21 C.F.R. ¬ß 25.31 ‚Äì Environmental categorical exclusion",Critiques FDA‚Äôs continued classification of dental amalgam as a Class II device and its lack of restrictions on amalgam use despite scientific and regulatory developments globally .	,"The petition requests that the FDA:
a) Immediately ban amalgam use in children under 6, pregnant women, nursing women, and people with mercury hypersensitivities.
b) Move amalgam from Class II to Class III, requiring premarket approval (PMA).
c) Ultimately ban dental amalgam entirely in the U.S. ","- Amalgam is 50% mercury, a known neurotoxin.
- Other nations (e.g., Norway, Sweden, Denmark) have already banned or phased it out.
- Vulnerable populations (children, pregnant women) are especially at risk.
- Alternatives are available and widely used.
- Petition cites FDA's own advisory panel findings that identified risks not properly addressed in labeling or regulation.
- Environmental concerns from mercury waste also highlighted.",2017-10-26 00:00:00,Partially Approved / Partially Denied,2022-05-26,1.0,"Center for Devices and Radiological Health (CDRH)
","‚Ä¢ FD&C Act: Sections 501, 502, 510, 513, 516, 518, 519, 520
‚Ä¢ 21 CFR: 10.30(e)(3), 10.40, 25.30, 25.34, 860.7(b), (c)(1‚Äì2), (d)(1), 872.3070
‚Ä¢ Administrative Procedure Act: 5 U.S.C. 701 et seq.
‚Ä¢ Minamata Convention on Mercury (referenced, not binding)
‚Ä¢ Public Health Service Act, Clean Water Act (U.S. compliance framework for Minamata)","The petition raises issues that require further review and analysis by agency officials. As a result, the FDA has not yet reached a decision. This interim response is issued in accordance with FDA regulations governing citizen petitions.

","‚Ä¢ Scientific Uncertainty: Insufficient evidence of harm from amalgam in vulnerable populations.
‚Ä¢ Risk-Benefit Balance: Amalgam has clinical benefits (durability, ease of use).
‚Ä¢ Lack of Causal Link: No strong evidence linking amalgam to adverse health outcomes.
‚Ä¢ Prior Action Taken: 2020 Safety Communication already informs public and professionals.
‚Ä¢ Not Legally Obligated: Minamata Convention not ratified; U.S. not bound to amend FDA rules.
‚Ä¢ Labeling & Communication: FDA chose public brochures/web updates over mandatory patient labeling.
‚Ä¢ Environmental Review Not Required: No major new federal action to trigger NEPA requirements.",partially approved / denied,True,1885.0,CDRH,CDRH
fda-2017-p-2365,FDA-2017-P-2365-0001_Citizen_Petition_from_Senators_Schumer___Gillibran.pdf,2017-04-14,2017,False,original petition,Senator Charles E. Schumer and Senator Kirsten Gillibrand,individual,"- 21 U.S.C. ¬ß¬ß 301‚Äì399 (FDCA)
- 5 U.S.C. ¬ß 553(e) (APA)
- 21 U.S.C. ¬ß 331(a) ‚Äì Prohibited acts
- 21 U.S.C. ¬ß 361(a) ‚Äì Adulterated cosmetics
- 21 U.S.C. ¬ß 371(a) ‚Äì Regulations
- 21 C.F.R. ¬ß¬ß 700.11‚Äì700.27 ‚Äì Banned/restricted substances
- 21 C.F.R. ¬ß 700.13 ‚Äì Mercury ban
- 21 C.F.R. ¬ß 700.19 ‚Äì Methylene chloride
- 21 C.F.R. ¬ß 25.32(m) ‚Äì Environmental categorical exclusion
- 21 C.F.R. ¬ß 10.30(b) ‚Äì Economic impact requirement","The lack of FDA regulation prohibiting detectable levels of 1,4-dioxane in cosmetics, despite its carcinogenic risks and presence in consumer products","Request FDA to promulgate a rule declaring that cosmetics with detectable levels of 1,4-dioxane are adulterated and therefore illegal under the FDCA","- 1,4-dioxane is a likely human carcinogen and can be absorbed via skin contact.
- It is a contaminant, not an ingredient, so it does not appear on product labels, making it hard for consumers to avoid.
- Children are especially vulnerable, as shown by multiple studies and agency reports.
- Safe manufacturing techniques (e.g., vacuum stripping) exist to eliminate it.
- FDA has previously banned other substances (e.g., methylene chloride, mercury compounds) based on similar grounds.
- Therefore, banning detectable 1,4-dioxane would be consistent with FDCA goals and FDA precedent",2017-10-11 00:00:00,Denied,2017-12-19,1.0,"Center for Food Safety and Applied Nutrition (CFSAN)
","21 CFR 10.30(e) ‚Äì Regulation governing FDA responses to citizen petitions
","The FDA cited ""a number of competing priorities"" as the reason for not completing a decision within the required timeframe. The agency stated that review is ongoing and that a final decision will be communicated when available
","- Scientific Evaluation: FDA found insufficient data demonstrating that any detectable concentration of 1,4-dioxane renders a cosmetic product injurious under conditions of use.
- Contaminant Nature: 1,4-dioxane is not intentionally added but forms as a manufacturing byproduct; technologies exist to reduce it, and many manufacturers already use them.
- Historical Testing: FDA monitored cosmetic products from 1981‚Äì2008 and observed significant decline in contamination levels (e.g., 92% of 2008 samples ‚â§10 ppm).
- External Expert Input: ICCR and SCCS reports concluded current trace levels in cosmetics are within accepted safety margins.
- Future Actions: FDA plans to update product surveys and continue posting guidance on 1,4-dioxane to promote transparency and safety
",denied,True,249.0,CFSAN,Other/Specialty Center
fda-2017-p-2496,FDA-2017-P-2496-0001_Citizen_Petition_from_KVK_Tech__Inc___Abhai__LLC_.pdf,2017-04-19,2017,False,original petition,"Abhai, LLC and KVK-Tech, Inc.",industry/corporation,"- 21 C.F.R. ¬ß¬ß 10.25(a), 10.30 ‚Äì Citizen petition regulations
- 21 C.F.R. ¬ß 314.161 ‚Äì Determining if a drug was withdrawn for safety/effectiveness reasons
- 21 C.F.R. ¬ß¬ß 314.122, 314.162 ‚Äì Removal from Orange Book due to safety/effectiveness withdrawal
- 21 C.F.R. ¬ß 25.31(a) ‚Äì Categorical exclusion from environmental assessment
- 21 C.F.R. ¬ß 10.30(b) ‚Äì Economic impact information provision","Commenting on the discontinuation of Ritalin LA (methylphenidate hydrochloride) 60 mg, NDA #021284, by Novartis Pharmaceuticals, and seeking a determination of whether it was withdrawn for safety or effectiveness reasons","The petition requests FDA to determine whether the 60 mg strength of Ritalin LA was withdrawn for reasons of safety or effectiveness, to support submission of a 505(j) ANDA or 505(b)(2) NDA using it as the reference listed drug
","- Ritalin LA 60 mg was previously approved and listed in the Orange Book.
- It has since been discontinued by Novartis, as per Orange Book access on April 14, 2017.
- There is no public indication that the discontinuation was for safety or efficacy reasons.
- FDA's determination is needed to permit its reference in new drug applications",,Approved (Determination Issued),2017-09-06,0.0,"Center for Drug Evaluation and Research (CDER)
","- 21 CFR 10.30 ‚Äì Procedures for citizen petitions
- 21 CFR 314.161 ‚Äì Determining whether a listed drug was withdrawn from sale for safety or effectiveness reasons",,"- FDA Records Review: No evidence that Ritalin LA (60 mg) was withdrawn due to safety or effectiveness concerns.
- Independent Evaluation: FDA reviewed relevant literature and postmarketing data.
- Conclusion: The product was voluntarily discontinued for reasons other than safety or effectiveness, so it may serve as a reference listed drug for ANDAs
",approved,True,140.0,CDER,CDER
fda-2017-p-2530,FDA-2017-P-2530-0001_Citizen_Petition_from_Lachman_Consultants_Services.pdf,2017-04-21,2017,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"- 21 C.F.R. ¬ß 10.30 ‚Äì Citizen petition procedure
- 21 C.F.R. ¬ß 314.161 ‚Äì Drug withdrawal determination
- 21 C.F.R. ¬ß 25.31 ‚Äì Categorical environmental exclusion
- 21 C.F.R. ¬ß 10.30(b) ‚Äì Economic impact provision","Requesting a determination on whether Spectazole (Econazole Nitrate) Cream, 1%, approved under NDA 018751, was withdrawn for reasons of safety or effectiveness
","FDA is asked to determine that Spectazole (Econazole Nitrate) Cream, 1%) was not withdrawn for reasons of safety or effectiveness, thus allowing its use as a reference listed drug (RLD) for future ANDA submissions
","- The petitioner does not know why the drug was withdrawn, but states there is no known evidence of withdrawal for safety or efficacy reasons.
- The drug is still designated as an RLD in the Orange Book (as of April 20, 2017), although marked as discontinued.
- Another product (Econazole Nitrate Cream by Perrigo) is already designated by FDA as a reference for bioequivalence, supporting safe ANDA referencing",,Approved (Determination Issued),2017-10-03,0.0,"Center for Drug Evaluation and Research (CDER)
","Not explicitly stated in the letter, but the decision aligns with procedures under 21 CFR 314.161 (commonly cited in such determinations).
",,"- FDA Records Review: Confirmed no safety or effectiveness concerns led to market withdrawal.
- Regulatory Outcome: Product will continue to serve as a reference listed drug for ANDA filings if other legal and regulatory requirements are met
",approved,True,165.0,CDER,CDER
fda-2017-p-2561,FDA-2017-P-2561-0001_Reclassification_Petition_from_STL_International__.pdf,2017-03-29,2017,False,original petition,KARA & Associates,law/consulting,"- 21 C.F.R. ¬ß 860.123 (Reclassification Petition)
- 21 C.F.R. ¬ß 888.5850 (Non-Powered Traction Apparatus ‚Äì Class I)
- 21 C.F.R. ¬ß 890.5900 (Powered Traction Equipment ‚Äì Class II)","The current Class II/Special Controls classification of the Hang Ups InvertAlign device under Product Code ITH, Regulation 890.5900. STL argues it should be reclassified to Class I/General Controls under Product Code HST, Regulation 888.5850","Reclassify the Hang Ups InvertAlign device from Class II to Class I, based on its non-powered, gravity-based operation that aligns with other Class I devices","- The device does not apply powered mechanical traction; rather, traction is achieved through gravity in an inverted position.
- It is technologically and functionally similar to Teeter Decompression Devices (cleared under 510(k) K162702 as Class I).
- It lacks restraint systems and powered force application used in true Class II traction devices like SpineMED¬Æ, VAX-D Genesis, or Healthstar Elite.
- A motor is used only to control inversion angle, not to apply traction.
- No known adverse data exists; reclassification would align with recent precedent",,Denied,2018-06-18,0.0,Center for Devices and Radiological Health (CDRH),"- Section 513(e) of the FD&C Act (21 U.S.C. 360c(e))
- 21 U.S.C. 360c(a)(3) ‚Äì Valid scientific evidence
- 21 CFR 860.7(c)(2) ‚Äì Scientific evidence standard
- 21 CFR 860.120(b) ‚Äì Generic device reclassification
- 21 CFR 860.123(a)(6) ‚Äì Reclassification petition contents
- 21 CFR 860.3 ‚Äì Definition of ""generic type of device""
- 21 CFR 890.5900 ‚Äì Power traction equipment (class II)
- 21 CFR 888.5850 ‚Äì Nonpowered orthopedic traction devices (class I)
- Section 513(a)(1)(A)(i) of the FD&C Act ‚Äì Class I criteria",,"- Insufficient Scientific Evidence: The petition lacked valid scientific evidence to support that general controls alone would ensure safety and effectiveness.
- Powered Component Risks: FDA cited risks such as potential for pinching, patient fall due to motor/power failure, lack of electromagnetic compatibility, and electrical safety concerns.
- Device Classification Appropriateness: Although the petitioner argued the motor was only for inversion and not traction, the device was still found to fit within 21 CFR 890.5900 as it contained powered components.
- Generic Device Reclassification Requirement Not Met: The petition addressed only one device (Hang Ups InvertAlign) and failed to provide evidence necessary to reclassify all substantially equivalent devices within its generic group, as required by regulation.
- Regulatory Criteria: The device remains classified as class II under 21 CFR 890.5900 due to its powered nature and associated risks, which warrant special controls
",denied,True,446.0,CDRH,CDRH
fda-2017-p-2563,FDA-2017-P-2563-0001_Citizen_Petition_from_The_Tatia_Oden_French_Memori.pdf,2017-04-24,2017,False,original petition,The Tatia Oden French Memorial Foundation,advocacy/academic,"- 21 C.F.R. ¬ß 10.30 (Citizen Petition Procedure)
- 21 C.F.R. ¬ß 25.30(a) (Categorical Exclusion)
- 21 C.F.R. ¬ß 25.31(a) (Environmental Impact)
- References to the Sentinel Initiative under the Food and Drug Administration Amendments Act of 2007 are also noted as part of the regulatory framework","The FDA‚Äôs historical regulation and labeling of misoprostol (Cytotec) when used off-label for cervical ripening and induction of labor, as well as existing communications (e.g., Patient Information Sheets, labeling updates in 2012)","Conduct a Sentinel System query to evaluate adverse events associated with off-label use of misoprostol for cervical ripening and labor induction, potentially leading to label updates, safety alerts, or other regulatory actions","- Numerous reports and literature document serious adverse events (e.g., uterine rupture, hemorrhage, fetal distress, cerebral palsy, maternal and neonatal death) tied to off-label use of misoprostol
- The FDA Adverse Event Reporting System (FAERS) may suffer from underreporting, especially in off-label contexts
- Sentinel query would provide a more comprehensive and active surveillance approach
- Previous petitions, FDA labeling changes, and public health data (e.g., racial disparities in maternal mortality) further underscore the urgency and relevance of this action",2017-10-19 00:00:00,Denied,2018-12-18,1.0,"Center for Drug Evaluation and Research (CDER)
","- 21 CFR 10.30 ‚Äì Citizen petition procedures
- Section 505 of the FD&C Act (implicitly referenced via discussion of drug labeling and approval)
- Specific regulatory citations are limited; much of the discussion is based on prior FDA decisions, risk assessment frameworks, and clinical literature rather than statutory mandates","- The petition requested a Sentinel query to assess adverse events related to unapproved use of misoprostol (Cytotec) for labor induction.
- FDA stated the petition raises complex issues that require extensive review and analysis by agency officials.
- The agency has therefore issued an interim response, indicating that a final decision will be made once that review is complete
","- Current Labeling Adequacy: FDA determined the current Cytotec labeling adequately reflects safety information, including the risks associated with unapproved obstetric use.
- Prior Regulatory Action: The agency had previously updated Cytotec labeling and issued public information following a 2004 petition on the same issue, which was granted in 2012.
- Sentinel Query Not Warranted: A Sentinel query would not offer meaningful new safety insights due to complexity, lack of robust data on unapproved use, and existing safety data from other systems like FAERS.
- Limitations of Sentinel and FAERS: Both systems have limitations in capturing data specific to off-label uses and may not provide clearer risk profiles than already known.
- No Basis for New Labeling Requirement: Based on the totality of scientific literature, case reports, adverse event monitoring, and expert recommendations (e.g., ACOG, WHO), additional regulatory action or labeling changes were not justified
",denied,True,603.0,CDER,CDER
fda-2017-p-2626,FDA-2017-P-2626-0001_Citizen_Petition_from_Emord___Associates__P__C_.pdf,2017-04-26,2017,False,original petition,"Emord & Associates, P.C.",law/consulting,"- 21 C.F.R. ¬ß 10.30 ‚Äì Citizen petition procedures
- 21 C.F.R. ¬ß 1240.61(a) ‚Äì Interstate ban on unpasteurized milk
- 21 C.F.R. ¬ß 1240.61(b) ‚Äì Temperature modifications for pasteurization
- 21 C.F.R. ¬ß 131.110 ‚Äì Definition of milk
- 42 U.S.C. ¬ß¬ß 264(a) and 271(a) ‚Äì Authority to prevent interstate spread of communicable diseases
- 65 Fed. Reg. 76091 ‚Äì Shell egg safe handling rule","Commenting on the blanket federal prohibition of interstate commerce of unpasteurized (raw) milk and milk products under 21 C.F.R. ¬ß 1240.61(a)
","- FDA should exercise enforcement discretion to permit the interstate distribution of unpasteurized milk and milk products if they are properly labeled with a health risk warning and safe handling instructions.
- Accept state-level labeling where applicable or use the proposed federal warning and self-pasteurization instructions
","- Historical and cultural precedent for consuming raw milk, with low relative rates of illness.
- Raw milk is only one of many raw foods consumed (e.g., sushi, eggs, meat), but uniquely banned in interstate commerce.
- Self-pasteurization can be equally or more effective than industrial pasteurization if done immediately before consumption.
- Consumers deserve informed choice, and many already consume raw milk legally in intrastate commerce in 25 states.
- Enforcement of the ban has harmed small farmers, with examples of federal raids and legal action shared in the petition.
- Request aligns with recent Presidential Executive Orders aimed at reducing regulatory burdens, particularly on domestic manufacturing",2017-10-17 00:00:00,Denied,2019-10-08,1.0,"Center for Food Safety and Applied Nutrition (CFSAN)
","21 CFR 10.30(k) ‚Äì States that the citizen petition process does not apply to requests involving referral of matters to the United States Attorney or enforcement discretion
","The FDA cited ""limited availability of resources and other agency priorities"" as the reason for not issuing a final decision within the 180-day period. The agency stated that it intends to complete the review and respond in the near future
","- Jurisdictional Limitations: The FDA stated that citizen petitions cannot be used to request the agency to exercise enforcement discretion or to refer matters to the U.S. Attorney for enforcement.
- Scope of Regulation: Per 21 CFR 10.30(k), such enforcement-related decisions fall outside the scope of allowable citizen petition content.
- Conclusion: As the petition requested the FDA to forgo enforcement under specific labeling conditions for raw milk, it was not a request the FDA could consider under its citizen petition rules, and thus it was denied
",denied,True,895.0,CFSAN,Other/Specialty Center
fda-2017-p-2659,FDA-2017-P-2659-0001_Citizen_Petition_from_Jubilant_Generics.pdf,2017-04-27,2017,False,original petition,Jubilant Generics Ltd.,industry/corporation,"- Section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act (FDCA)
- 21 C.F.R. ¬ß 10.25 ‚Äì Citizen petition procedures
- 21 C.F.R. ¬ß 10.30 ‚Äì Citizen petition content
- 21 C.F.R. ¬ß 314.122 ‚Äì Withdrawal of RLDs from the market
- 21 C.F.R. ¬ß 314.161 ‚Äì Determination of withdrawal for safety/effectiveness
- 21 C.F.R. ¬ß 25.31(a) ‚Äì Categorical environmental exclusion","The petitioner requests a determination from the FDA on whether the discontinuation of the Reference Listed Drug (RLD), NOROXIN¬Æ (NDA #019384), was for reasons other than safety or effectiveness, which would allow it to be referenced in an ANDA","FDA is asked to declare that NOROXIN¬Æ (Norfloxacin Tablets, 400 mg) was not withdrawn for safety or effectiveness reasons, enabling the submission of an Abbreviated New Drug Application (ANDA) referencing NOROXIN¬Æ
","- Under the FD&C Act, an ANDA must reference an RLD that is actively listed.
- If an RLD has been discontinued, a determination must be made whether the withdrawal was due to safety or efficacy issues.
- The petitioner asserts that no such safety or efficacy concerns were cited in the withdrawal of NOROXIN¬Æ.
- The petition qualifies for categorical environmental exclusion under 21 C.F.R. ¬ß 25.31(a).
- An economic impact statement will be submitted if requested",2017-10-13 00:00:00,Approved (Determination Issued),2017-12-12,1.0,"Center for Drug Evaluation and Research (CDER)
","- 21 CFR 314.161 ‚Äì Procedure for determining if a drug was withdrawn for safety or effectiveness reasons
- 21 CFR 314.162 ‚Äì Removal of drug products from the Orange Book due to withdrawal for safety or effectiveness reasons
- Section 505(j)(7) of the FD&C Act (21 U.S.C. 355(j)(7)) ‚Äì Drug listing in the Orange Book
- 21 CFR 10.30 ‚Äì Citizen petition procedures","- Agency Workload and Priorities: The FDA cited the need to address other priorities and demands on its resources as the reason for the delay.
- Pending Review: FDA noted the issue remains under review and a full response will be issued when possible","- FDA Review of Records: FDA reviewed internal records and found no evidence that Noroxin was withdrawn due to safety or effectiveness concerns.
- Independent Literature & Data Review: FDA reviewed available literature and postmarketing data for adverse events and found no safety-related withdrawal.
- Conclusion: The product was voluntarily discontinued for reasons other than safety or efficacy. It remains in the Orange Book under the ""Discontinued Drug Product List"" and may be referenced for ANDAs",approved,True,229.0,CDER,CDER
fda-2017-p-2660,FDA-2017-P-2660-0001_Citizen_Petition_from_Jubilant_Generics.pdf,2017-04-27,2017,False,original petition,Jubilant Generics Ltd.,industry/corporation,"- Section 505(j)(7) of the FD&C Act
- 21 C.F.R. ¬ß 10.25 ‚Äì Citizen petitions
- 21 C.F.R. ¬ß 10.30 ‚Äì Submission of petitions
- 21 C.F.R. ¬ß 314.122 ‚Äì Drugs withdrawn from sale
- 21 C.F.R. ¬ß 314.161 ‚Äì Determination of reasons for withdrawal
- 21 C.F.R. ¬ß 25.31(a) ‚Äì Environmental impact categorical exclusion","The petitioner seeks a determination from the FDA that the discontinuation of CARDENE¬Æ SR (Nicardipine Hydrochloride Extended Release Capsules) was not for safety or effectiveness reasons, to allow use of the product as a reference listed drug (RLD) for ANDA submission
","FDA is requested to determine that the withdrawal of CARDENE¬Æ SR (NDA# 020005) was not for safety or efficacy reasons, enabling submission of an Abbreviated New Drug Application (ANDA) that relies on CARDENE¬Æ SR as the RLD","- An ANDA must reference a listed RLD; if the RLD is no longer marketed, FDA must confirm that the withdrawal was not for safety or effectiveness.
- CARDENE¬Æ SR was removed from the market but no indication of safety/efficacy concerns has been identified.
- The petitioner cites FDA regulations that allow filing of ANDAs based on discontinued products if such a determination is made.
- The petition also qualifies for a categorical environmental exclusion, and an economic impact statement will be submitted if requested",2017-10-23 00:00:00,Approved (Determination Issued),2017-10-27,1.0,"Center for Drug Evaluation and Research (CDER)
","- 21 CFR 314.161 (Implied but not explicitly stated in this letter)‚ÄîFDA standard for determining withdrawal reasons.
- 21 CFR 10.30 ‚Äì Citizen petition process (inferred from context; not directly cited).
- Orange Book Reference ‚Äì Regulatory publication mentioned for drug listings.","- Pending Review: The petition requested a determination on whether Cardene SR (nicardipine hydrochloride) extended-release capsules (30 mg, 45 mg, and 60 mg) were withdrawn for safety or effectiveness reasons.
- Agency Prioritization: FDA had not completed its evaluation due to the need to address other pressing matters and limited resources.
- Regulatory Compliance: Issued this interim response in accordance with 21 CFR 10.30(e)(2), indicating ongoing review and commitment to respond when feasible","- Internal Records Review: FDA concluded that the product was not withdrawn for safety or effectiveness reasons.
- Listing Status: The product remains in the ""Discontinued Drug Product List"" in the Orange Book.
- Eligibility for ANDA: Since the product was not withdrawn due to safety or efficacy, it can be referenced in ANDAs if all regulatory criteria are met
",approved,True,183.0,CDER,CDER
fda-2017-p-2733,FDA-2017-P-2733-0001_Citizen_Petition_from_Esophageal_Cancer_Action_Net.pdf,2017-05-01,2017,False,original petition,"Esophageal Cancer Action Network, Inc. (ECAN)",advocacy/academic,"- 21 C.F.R. ¬ß 10.30 ‚Äì Citizen petition process
- 21 C.F.R. ¬ß 314.161 ‚Äì Listing of drug products that have been withdrawn or removed
- 21 C.F.R. ¬ß 25.31 ‚Äì Categorical exclusion for environmental impact
- 21 C.F.R. ¬ß 10.30(b) ‚Äì Economic impact provision","The petition addresses the lack of adequate warning labeling on over-the-counter (OTC) heartburn relief medications regarding the risk of esophageal cancer.
","ECAN requests that the FDA:
‚Ä¢ Require a new, bold, and prominent warning label on all OTC products labeled to relieve or prevent heartburn, acid indigestion, or sour stomach.
‚Ä¢ The warning should state that persistent heartburn can indicate increased risk of developing esophageal cancer and that the medication will not eliminate that risk.","- Millions of Americans experience heartburn, with persistent heartburn being a potential indicator of gastroesophageal reflux disease (GERD) and Barrett‚Äôs Esophagus, a precancerous condition.
- Only 14% of surveyed adults were aware that reflux can lead to esophageal cancer.
- Barrett‚Äôs Esophagus is often undiagnosed, and current OTC product labels fail to adequately warn of cancer risk.
- The effectiveness of OTC medications at relieving symptoms may discourage medical evaluation, delaying diagnosis of serious conditions.
- Proposed warning language is explicitly included to address these concerns.",2017-10-26 00:00:00,Denied,2018-10-04,1.0,"Center for Drug Evaluation and Research (CDER)
","- 21 CFR part 331 ‚Äì OTC antacid product monograph
- 21 CFR 330.1 & 330.10(a)(4)(v) ‚Äì General OTC drug conditions & labeling readability requirements
- 21 CFR 201.66 ‚Äì Drug Facts Labeling (DFL) content & format
- 21 CFR 201.60 et seq. ‚Äì Labeling framework for OTC drugs
- 21 U.S.C. 352(c) and 352(f)(1) ‚Äì Misbranding and adequate directions for use
- FD&C Act Section 505 ‚Äì NDA drug approval process","- Complexity of Issues: The FDA noted that the petition raises complex issues that require extensive review and analysis.
- Regulatory Compliance: Issued this interim response in accordance with 21 CFR 10.30(e)(2), signaling that a full response will follow once a decision is reached","- Lack of Scientific Evidence: FDA reviewed multiple studies and concluded that there is no compelling evidence that OTC heartburn products lead to delayed diagnoses of esophageal cancer or reduce physician visits.
- Existing Labeling is Adequate: Current FDA-approved OTC labels already include warnings that advise users to see a doctor if symptoms persist, such as ‚Äúhad heartburn over 3 months‚Äù or ‚Äúheartburn continues or worsens.‚Äù These labels are designed to promote appropriate self-care and flag serious symptoms like difficulty swallowing. 
- Consumer Comprehension: Label comprehension studies showed that over 96% of consumers understood the instructions, supporting that current labeling effectively communicates risk.
- Regulatory Constraints: FDA emphasized that OTC drug labels must be concise, readable, and focused on conditions appropriate for self-diagnosis and self-treatment, not exhaustive diagnostic tools.
- Consistency with Previous Decisions: FDA cited precedent with prior OTC approvals (e.g., Prilosec OTC) where similar concerns were addressed through labeling rather than new cancer warnings.
",denied,True,521.0,CDER,CDER
fda-2017-p-2803,FDA-2017-P-2803-0016_Citizen_Petition_from_Apotex_Inc_.pdf,2017-05-03,2017,False,original petition,Apotex Inc. and Apobiologix (a Division of Apotex Inc.),industry/corporation,"- 21 U.S.C. ¬ß 355(q)
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. Part 601, Subpart H
- 42 U.S.C. ¬ß 262(k)(2)(A)(i)(1)(cc)
- 42 U.S.C. ¬ß 262(i)(2)(A)
- 21 C.F.R. ¬ß 25.30 to ¬ß 25.34 (environmental claim) ","FDA's acceptance and review of biosimilar applications for NEULASTA¬Æ (pegfilgrastim) that include only clinical data from healthy subjects, specifically commenting on Coherus Biosciences‚Äô 351(k) application approach 
","Apotex requests FDA to:
1. Require biosimilar applicants referencing NEULASTA¬Æ to conduct clinical efficacy studies (PK, PD, immunogenicity) in at least one indicated patient population.
2. Require correlation of data between healthy subjects and patients.
3. Mandate immunogenicity studies over at least four and preferably six chemotherapy cycles.
4. Require withdrawal of biosimilar applications not meeting these criteria until additional data is submitted. ","- Clinical differences may not be observable in healthy subjects due to differing ANC profiles and immune responses.
- Cancer patients exhibit different pharmacokinetics and are at risk of infection, which cannot be modeled adequately in healthy volunteers.
- Multiple chemotherapy cycles impact drug clearance and immune response.
- Data from patients is necessary to confirm safety and efficacy and to ensure clinician confidence and uptake.
- Existing biosimilar approvals relied on patient data. ",,Denied,2017-09-29,0.0,"Center for Drug Evaluation and Research (CDER)
","- Section 505(q) of the FD&C Act (21 U.S.C. ¬ß 355(q))
- Section 351(k) of the Public Health Service (PHS) Act
- 21 CFR Part 601 (procedures for BLA review)
- 21 CFR 601.3, 601.4, 601.4(b) ‚Äì related to BLA review, licensure decisions, and procedural rights",,"- Timeliness Requirement (150 Days): Under Section 505(q)(1)(F), FDA was required to respond to the petition within 150 days. Therefore, the agency denied the petition without addressing the specific requested actions.
- Procedural Protections for BLA Applicants: FDA stated that deciding individual aspects of a biosimilar application (e.g., specific study requirements) outside of the full Biologics License Application (BLA) review process would compromise applicant rights. The agency emphasized its obligation to evaluate each application holistically under the statutory and regulatory framework.
- Pending Applications: At the time of the response, FDA had not made a final decision on any BLA submitted under section 351(k) referencing Neulasta. Thus, it found it inappropriate to comment on the approvability of any specific requirements in isolation.
- Denial Without Substantive Comment: Although the petition raised scientific and regulatory issues, FDA explicitly denied the petition without commenting on the underlying requests for additional clinical studies or application withdrawals.",denied,True,149.0,CDER,CDER
fda-2017-p-2836,FDA-2017-P-2836-0001_Citizen_Petition_from_VKT_Pharma_Private_Limited.pdf,2017-05-04,2017,False,original petition,VKT Pharma Private Limited,industry/corporation,- 21 C.F.R. ¬ß 10.30 ‚Äì Citizen petition process,"Requesting the FDA to designate an alternate Reference Listed Drug (RLD) and Reference Standard (RS) for Rx Zantac 150 mg and 300 mg tablets, since GlaxoSmithKline (GSK) has discontinued marketing the original product, making it unavailable for ANDA development
","The petitioner requests FDA to recommend and designate an alternate RLD and RS for the discontinued Zantac (Ranitidine) 150 mg and 300 mg tablets to enable submission of Abbreviated New Drug Applications (ANDAs)
","- GSK has stopped manufacturing Zantac tablets, and no alternative RS is listed in the Orange Book.
- Multiple suppliers confirmed GSK products are unavailable, disrupting the ability to conduct bioequivalence studies.
- The availability of RS is critical for generic manufacturers to proceed with ANDA filings.
- FDA‚Äôs Controlled Correspondence Review recommended submitting a citizen petition to resolve the RS issue.
- Swift action would support generic development and potentially lower drug costs.
",2017-10-26 00:00:00,Dismissed (moot),2018-08-28,1.0,"Center for Drug Evaluation and Research (CDER)
","Not explicitly cited by statute/regulation name in the body of the letter. However, the response references the Orange Book and the ANDA/NDA designation process, and mentions FDA‚Äôs draft guidance for industry: Ranitidine Hydrochloride (December 2009)
","- Pending Review Due to Priorities: FDA explained that it has been unable to reach a decision on the petition due to the need to address other agency priorities.
- Ongoing Evaluation: The letter reassures that the petition is under consideration and a full response will be provided as soon as possible given resource constraints","- Action Already Taken: The FDA had already updated the Orange Book to reflect the discontinuation of GlaxoSmithKline‚Äôs ranitidine hydrochloride tablets (NDA 018703) and designated ANDA 077824 (Amneal Pharmaceuticals) as the new reference standard.
- Guidance Consistency: The selection of the 300 mg strength as the reference standard was consistent with FDA‚Äôs product-specific guidance recommending bioequivalence studies on the highest strength dosage form (300 mg).
- Regulatory Practice: FDA generally selects the highest strength available as the reference standard for multi-strength products
",dismissed (moot),True,481.0,CDER,CDER
fda-2017-p-2967,FDA-2017-P-2967-0001_Citizen_Petition_from_Lachman_Consultant_Services_.pdf,2017-05-09,2017,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 10.30 ‚Äì Citizen Petition process
- 21 C.F.R. ¬ß 314.93 ‚Äì Petition to request change in dosage form
- 21 C.F.R. ¬ß 25.31 ‚Äì Environmental impact categorical exclusion","The petition does not challenge an FDA action, but rather seeks FDA‚Äôs declaration that Atorvastatin Calcium Orally Disintegrating Tablets (ODT) in multiple strengths are suitable for an Abbreviated New Drug Application (ANDA). The reference listed drug (RLD) is Lipitor¬Æ Tablets by Pfizer.
","Request FDA to declare that Atorvastatin Calcium Orally Disintegrating Tablets (10, 20, 40, 80 mg) are suitable for submission in an ANDA as a change in dosage form from the RLD (Lipitor). Additionally, the petitioner seeks a full waiver from pediatric study requirements to support ANDA filing
","- The proposed change is only in dosage form (oral tablet to ODT); no change in strength, route of administration, or indication.
- The change raises no questions of safety or effectiveness, consistent with FDCA provisions.
- The ODT dosage form would benefit patients with difficulty swallowing tablets, dysphagia, or infirmity.
- Labeling will remain the same except for dosage form-specific instructions.
- Use in pediatric population is minimal and unlikely to be substantial; a pediatric study waiver is requested.
- Environmental impact is negligible, qualifying for a categorical exclusion",,Approved,2024-04-29,0.0,Center for Drug Evaluation and Research (CDER),"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- 21 CFR 314.93 ‚Äì Suitability petition procedures
- 21 CFR 314.93(e)(1) ‚Äì Grounds for petition approval
- Section 505B of the FD&C Act (PREA) ‚Äì Pediatric Research Equity Act
- 21 CFR 314.94(a)(3)(iii) ‚Äì ANDA content referencing approved petitions",,"- Dosage Form Change Permissible: FDA concluded that the change from standard tablets to orally disintegrating tablets does not raise safety or efficacy concerns.
- Labeling & Use Alignment: The new dosage form matches the listed drug in dose, use, and route of administration, and is consistent with approved labeling for Lipitor¬Æ.
- Bioequivalence Expected: If the proposed product meets bioequivalence standards, it is expected to deliver the same therapeutic effect as the reference listed drug.
- PREA Considerations: Though the product is subject to PREA, FDA concluded that pediatric studies were not necessary due to limited pediatric use and no additional therapeutic benefit for that population.
- ANDA Requirements Remain: Approval of the petition does not guarantee approval of the ANDA itself, which must still meet all bioequivalence and regulatory criteria upon submission",approved,True,2547.0,CDER,CDER
fda-2017-p-3064,FDA-2017-P-3064-0001_Citizen_Petition_from_Pharmaceutical_Manufacturing.pdf,2017-05-11,2017,False,original petition,"Pharmaceutical Manufacturing Research Services, Inc. (PMRS)",advocacy/academic,"- 21 C.F.R. ¬ß 10.35 ‚Äì Petition for Stay of Action
- Federal Food, Drug, and Cosmetic Act (FDCA), including Section 505(b)(2)
- 21 C.F.R. ¬ß 314.2 ‚Äì Purpose of drug approval provisions
- 21 U.S.C. ¬ß 355(q) (not applicable, but discussed for clarification)","FDA's approval of New Drug Application (NDA) 209777 for ROXYBOND (oxycodone hydrochloride) submitted by Inspirion Delivery Sciences, LLC, with claims relating to:
1. Chronic use
2. Abuse-deterrent labeling","PMRS requests that the FDA:
- Stay the effective date of approval of NDA 209777 (ROXYBOND) until FDA provides a substantive written response to:
‚Ä¢ PMRS‚Äôs February 2016 Petition (FDA-2016-P-0645)
‚Ä¢ PMRS‚Äôs March 2017 Petition (FDA-2017-P-1359)
‚Ä¢ And the current petition‚Äôs issues regarding chronic use and abuse deterrence","PMRS offers several grounds:
- FDA approved ROXYBOND without responding to prior petitions raising concerns on opioid abuse and labeling.
- FDA‚Äôs approval contradicts its own guidance on laboratory-based in vitro testing, HAP studies, and post-marketing evidence standards.
- Concerns about flawed abuse-deterrent studies, misuse of HAP studies (e.g., particle size and volume issues), and lack of rigorous scientific justification.
- Public health risks, arguing ROXYBOND offers no proven deterrence and may worsen the opioid crisis.
- PMRS will suffer irreparable harm, market dilution, and competitive disadvantage if ROXYBOND enters the market first without adequate regulatory evaluation.
- Stay would not harm public health, but would help ensure safe and scientifically supported drug approvals",2017-07-27 00:00:00,Denied,2017-10-19,1.0,"Center for Drug Evaluation and Research (CDER)
","- 21 CFR ¬ß 10.30
- 21 CFR ¬ß 10.35(e)","- FDA cited ""many competing priorities.""
- Encouraged petitioner to submit the June 15 letter to the docket.
- Emphasized that review is ongoing.","- The petitioner failed to demonstrate irreparable injury, as Roxybond was properly evaluated and its approval supported by evidence.
- No sound public policy grounds existed to delay approval; Roxybond met FDA‚Äôs safety and efficacy standards.
- Granting a stay was not in the public interest, as Roxybond was the first IR opioid with abuse-deterrent labeling, and its availability was viewed as part of FDA‚Äôs broader effort to address the opioid crisis.
- FDA had already provided interim responses to the 2016 and 2017 citizen petitions as permitted under regulation.
- The FDA emphasized that it is working under many competing priorities and would respond substantively in due course.",denied,True,161.0,CDER,CDER
fda-2017-p-3065,FDA-2017-P-3065-0001_Citizen_Petition_from_NJOY_et__al_.pdf,2017-05-12,2017,False,original petition,"NJOY, along with:  Vapor Technology Association  SFATA  National Association of Tobacco Outlets, Inc.  CITMA  Turning Point Brands, Inc.  Mistic Electronic Cigarettes  Johnson Creek Vapor Company  Nicopure Labs LLC  Five Pawns Inc.  Gaiatrend USA  Glas, LLC  Shift Ventures, Inc.  E-Alternative Solutions, Inc.  Saffire Vapor",law/consulting,"- 21 C.F.R. ¬ß 10.30 (Citizen petition procedure)
- FFDCA Chapter IX, as amended by the Tobacco Control Act (TCA)
- 81 Fed. Reg. 28973 (May 10, 2016) ‚Äì Deeming Rule
- FDA‚Äôs Deeming Products Guidance (Dec. 2016)
- 21 C.F.R. ¬ß 25.30 ‚Äì Environmental impact categorical exclusion","- FDA‚Äôs Deeming Rule extending tobacco product authority
- Compliance deadlines for premarket submissions (SE Exemption, SE Reports, PMTA)
- FDA‚Äôs lack of finalized guidance on submission contents","1. Extend compliance deadlines for newly deemed tobacco products to no earlier than 24 months after FDA publishes final guidance/regulation.
2. Permit continued marketing of products with timely filed premarket submissions throughout the full FDA review period, beyond the current 12-month limit","- FDA has not issued final guidance for PMTAs or SE submissions.
- Imposition of inconsistent and arbitrary standards.
- Pending litigation raises questions on compliance deadline legitimacy.
- Burden on industry, especially smaller firms.
- Market disruption concerns and the need for thorough review to protect public health",,Dismissed (moot),2017-11-02,0.0,Center for Tobacco Products (CTP),"- 21 CFR ¬ß 10.30(k) ‚Äì regarding limits on citizen petitions requesting enforcement decisions
- 21 CFR ¬ß 10.30(e)(2)(iii) ‚Äì regarding dismissal of petitions due to mootness",,"- The petition requested the FDA refrain from enforcement actions, which falls outside the scope of permissible citizen petition content.
- Even if considered within scope, the petition was rendered moot by FDA‚Äôs August 2017 guidance extending compliance deadlines.
- The revised policy addressed both requests (extended submission timelines and continued marketing during review), making the petition redundant.
- FDA stated it does not intend to enforce premarket review requirements during the extended compliance period, assuming timely submission.",dismissed (moot),True,174.0,CTP,Other/Specialty Center
fda-2017-p-3092,FDA-2017-P-3092-0001_Citizen_Petition_from_AstraZeneca_Pharmaceuticals_.pdf,2017-05-15,2017,False,original petition,AstraZeneca Pharmaceuticals LP,industry/corporation,"‚Ä¢ FDCA ¬ß‚ÄØ505 ‚Äì incl. ¬ß‚ÄØ505(b)(2), ¬ß‚ÄØ505(c)(3)(C) (30‚Äëmonth stay) & ¬ß‚ÄØ505(c)(3)(E)(iv) (3‚Äëyear exclusivity) 
‚Ä¢ 21‚ÄØC.F.R. ¬ß‚ÄØ314.94(a)(9)(iii), ¬ß‚ÄØ314.127(a)(8)(ii), ¬ß‚ÄØ320.27(a)(3) (multiple‚Äëdose BA/BE), ¬ß¬ß‚ÄØ25.30‚Äë25.31 (environmental categorical exclusion), ¬ß‚ÄØ10.30(b) (economic‚Äëimpact statement)","FDA‚Äôs review and potential approval of Teva‚Äôs NDA‚ÄØ210063 (a‚ÄØ¬ß‚ÄØ505(b)(2) application for fulvestrant‚ÄØIM‚ÄØinjection, 50‚ÄØmg/mL, citing AstraZeneca‚Äôs Faslodex¬Æ) and any similar 505(b)(2) applications that reference Faslodex with a different formulation.	
","1. Refrain from approving Teva‚Äôs NDA (and any similar ¬ß‚ÄØ505(b)(2) applications) unless it contains:
‚ÄÉ‚ÄØ‚Ä¢‚ÄØClinical data on injection‚Äësite safety & pain
‚ÄÉ‚ÄØ‚Ä¢‚ÄØToxicity data for any excipient used at higher or novel levels
‚ÄÉ‚ÄØ‚Ä¢‚ÄØMultiple‚Äëdose steady‚Äëstate bioavailability bridging studies.
2. Withhold ‚ÄúA‚Äërating‚Äù (therapeutic‚Äëequivalence) designations for such products unless those data show identical safety/efficacy & bioequivalence.","AstraZeneca argues that Teva‚Äôs claimed omission of benzyl‚ÄØbenzoate (and resultant excipient changes) may:
‚Ä¢‚ÄØIncrease risk of tissue damage, pain, or necrosis at the injection site;
‚Ä¢‚ÄØAlter the release profile, jeopardising month‚Äëlong therapeutic levels;
‚Ä¢‚ÄØIntroduce un‚Äëqualified excipient levels requiring full toxicology support.
Therefore, approving or ‚ÄúA‚Äërating‚Äù Teva‚Äôs product without robust safety, toxicity and multi‚Äëdose PK data would endanger patients and undermine Hatch‚ÄëWaxman standards.",,Denied,2017-10-11,0.0,"Center for Drug Evaluation and Research (CDER)
","- Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- Section 505(q) of the FD&C Act
- 21 CFR ¬ß 314.105 (approval of applications)
- 21 CFR ¬ß 314.125 (disapproval of applications)
- 21 CFR ¬ß 314.200 (hearings)",,"- FDA did not reach a final decision on the approval status of any related 505(b)(2) NDA, and thus could not comment on preconditions for approval.
- The petition sought early judgments on specific aspects of applications, which is inconsistent with FDA‚Äôs procedural protections for applicants.
- FDA clarified that section 505(q) does not mandate piecemeal review or early decisions on individual components of an application.
- The petition was therefore denied without comment on the specific scientific/clinical data requirements for approval.",denied,True,149.0,CDER,CDER
fda-2017-p-3196,FDA-2017-P-3196-0001_Citizen_Petition_from_Philip_Spiller_et__al_.pdf,2017-05-18,2017,False,original petition,"Individual citizen petition submitted jointly by: Philip Spiller (former Director, FDA Office of Seafood) Michael  J. Bolger, Ph.D. Clark Carrington, Ph.D. George Hoskin, Ph.D. Timothy Hansen, Ph.D. Michael A. Landa, J.D. Terry C. Troxell, Ph.D. Tom Brenna, Ph.D. Michael A. Crawford, Ph.D. Jean Golding, Ph.D. Caroline M. Taylor, Ph.D. Mary C. Harris, Ph.D. Joyce A. Nettleton, D.Sc. W. Steven Otwell, Ph.D. Richard A. Williams, Ph.D.",individual,"‚Ä¢‚ÄØ21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ10.20 & ¬ß‚ÄØ10.30 (FDA citizen‚Äëpetition provisions)
‚Ä¢‚ÄØFederal Food, Drug, & Cosmetic Act, 21‚ÄØU.S.C.‚ÄØ¬ß‚ÄØ301‚ÄØet‚ÄØseq.
‚Ä¢‚ÄØ21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ25.30 (categorical‚Äëexclusion claim for environmental assessment)","The fish‚Äëconsumption advice jointly issued by FDA‚ÄØ&‚ÄØEPA on 18‚ÄØJan‚ÄØ2017, titled ‚ÄúEating‚ÄØFish:‚ÄØWhat‚ÄØPregnant‚ÄØWomen‚ÄØand‚ÄØParents‚ÄØShould‚ÄØKnow.‚Äù	","1. Withdraw the 18‚ÄØJan‚ÄØ2017 advice immediately.
2. Issue new advice that: ‚Ä¢ explicitly pursues the core purpose of maximising fetal neuro‚Äëdevelopmental benefits while minimising methyl‚Äëmercury risk; ‚Ä¢ includes a clearly tested optimum weekly intake amount; ‚Ä¢ is consumer‚Äëtested through experimental studies before release.","The petitioners argue that the current advice is scientifically and communicatively flawed because it:
‚Ä¢‚ÄØIgnores the large gap between what pregnant women eat and the optimum intake needed for neuro‚Äëdevelopmental gains.
‚Ä¢‚ÄØFails to mention or explain optimum consumption, uses risk‚Äëonly categories (‚ÄúBest/Good/Choices‚ÄØto‚ÄØAvoid‚Äù) not grounded in actual risk‚Äëbenefit science, and over‚Äëemphasises mercury ‚Äúwarnings,‚Äù likely discouraging fish intake.
‚Ä¢‚ÄØWas never consumer‚Äëtested, contrary to FDA‚Äôs own risk‚Äëcommunication guidance, so its effectiveness is unknown.",,Denied,2017-10-13,0.0,"Center for Food Safety and Applied Nutrition (CFSAN)
","- 21 CFR ¬ß 10.30(e)(3) ‚Äì Governing denial of citizen petitions
- 21 CFR ¬ß 10.30(b)(3) ‚Äì Requirements for the content of citizen petitions
- 21 CFR ¬ß 20 ‚Äì Freedom of Information Act (FOIA) regulations",,"- The 2017 seafood advisory was developed through a rigorous process with stakeholder input, peer review, and is consistent with the latest scientific evidence and public health policy.
- FDA concluded that the advisory appropriately balanced benefits of fish consumption with methylmercury risks.
- Petitioners failed to demonstrate that withdrawal of the 2017 advisory or issuance of new advice would improve public health outcomes.
- FDA found no obligation to conduct the requested experimental studies and defended the scientific basis for the categorization of fish as ‚ÄúBest Choices‚Äù or ‚ÄúGood Choices.‚Äù
- The FDA stated that the petition did not meet the regulatory standard to warrant administrative action under 21 CFR ¬ß 10.30.",denied,True,148.0,CFSAN,Other/Specialty Center
fda-2017-p-3196,FDA-2017-P-3196-0072_Citizen_Petition_for_Reconsideration_from__Philip_.pdf,2017-11-13,2017,False,reconsideration,"Philip Spiller, along with:  George A. Gellert, MD, MPH, MPA  Catherine M. Guttman-McCabe, JD  Neil M. Eisenberg, JD",individual,"- 21 C.F.R. ¬ß 10.33 (Request for reconsideration of FDA decisions)
- 21 C.F.R. ¬ß 25.30 (Environmental impact categorical exclusion)","FDA‚Äôs denial (on October 13, 2017) of a May 18, 2017 citizen petition that requested the withdrawal and revision of the joint FDA-EPA fish consumption advice issued on January 18, 2017","- Reconsider and reverse the denial of the original petition
- Withdraw the 2017 joint fish consumption advice
- Issue new, evidence-based advice:
‚Ä¢ Maximizing neurodevelopmental benefits
‚Ä¢ Minimizing methylmercury risk
‚Ä¢ Based on experimental testing and addressing prior scientific questions","- FDA's 2017 advice misrepresents scientific evidence on fetal neurodevelopmental benefits
- Categorization of fish by methylmercury content is scientifically flawed
- Advice was not experimentally tested with consumers
- Inconsistent with prior FDA positions and international guidance
- Fails to promote consumption of omega-3-rich fish
- Ineffective behavioral motivation for target audiences (e.g., pregnant women)",,Denied,2018-10-10,0.0,"Not explicitly named, but signed by Leslie Kux, Associate Commissioner for Policy.","- 21 CFR ¬ß 10.33(d) ‚Äì Standard for granting a petition for reconsideration
",,"- The petitioner failed to show that relevant information or views in the administrative record were not previously or adequately considered.
- FDA affirmed that it had evaluated data on fish consumption, neurodevelopmental outcomes, public comments, and scientific literature including dietary guidelines.
- The agency concluded that while the petitioner disagreed with the FDA‚Äôs conclusions and methodology (e.g., consumption categories, use of certain studies), disagreement does not demonstrate a failure to consider information.
- FDA emphasized that it considered the ALSPAC data (used in Daniels and Hibbeln studies) and clarified earlier citation issues.
- The request to conduct experimental studies was also rejected, as no failure to consider relevant administrative data was shown
",denied,True,331.0,other,Other/Specialty Center
fda-2017-p-3251,FDA-2017-P-3251-0001_Citizen_Petition_from_Petitioner__Redacted.pdf,,2017,False,original petition,Anonymous (redacted),other,"- 35 U.S.C. ¬ß 156 ‚Äì Patent Term Restoration Act (used to request denial or limitation of a patent extension)
- References the term ‚Äúdue diligence‚Äù as defined in the statute for regulatory review periods ","The petition responds to Genzyme‚Äôs application for patent term extension of the drug Cerdelga under 35 U.S.C. ¬ß 156, related to regulatory review periods. Specifically, it asks the FDA to deny or limit Genzyme‚Äôs requested extension due to alleged lack of due diligence during the drug development and approval process 
","The petitioner requests the FDA to:
1. Conduct a due diligence investigation into Genzyme‚Äôs development of Cerdelga.
2. Determine that Genzyme failed to act with due diligence during the regulatory review period (2002 to approval).
3. Deny or limit the patent extension Genzyme seeks for Cerdelga.
4. Recommend to the USPTO that the extension be denied, rejected, or limited ","The petition argues that:
- Genzyme failed to act with due diligence, citing several delays and missteps throughout the regulatory review period.
- University of Michigan scientists and NIH funding were primarily responsible for the original invention and development of Cerdelga. Genzyme merely licensed and optimized the molecule, conducting limited clinical trials (with 186 total patients).
- Genzyme's incentives to delay development were financial‚Äîprolonging the regulatory review period increases the possible length of the patent extension.
- Cerdelga‚Äôs high cost ($300,000+/year) contributes to public burden and limits access to treatment.
- Generic entry would significantly reduce drug costs and increase public access.
- The petition includes substantial factual data, including FDA records, financial documents, media articles, and personal statements from the petitioner to support the claim of corporate overreach and lack of due diligence",,,2025-10-15,,,,,,no decision,False,,pending,pending
fda-2017-p-3329,FDA-2017-P-3329-0001_Citizen_Petition_from_Hyman__Phelps____McNamara__P.pdf,2017-05-27,2017,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"- 21 C.F.R. ¬ß 10.25(a) and ¬ß 10.30 (citizen petition procedure)
- Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 314.94(a)(9)(iii) (non-exception excipient provision)
- 21 C.F.R. ¬ß 314.3(b) (therapeutic equivalence definition)
- 21 C.F.R. ¬ß 25.31 (environmental impact categorical exclusion)
- 21 C.F.R. ¬ß 10.30(b) (economic impact statement)","FDA‚Äôs failure to assign a Therapeutic Equivalence (TE) Code in the Orange Book for Xellia‚Äôs Voriconazole for Injection, 200 mg/vial, approved under NDA 208562.
","The petitioner requests that the FDA assign an ""AP"" TE Code (for injectable aqueous solutions) to Xellia‚Äôs Voriconazole for Injection, NDA 208562, in the Orange Book
","- Both Xellia's and Pfizer's VFEND IV (NDA 021267) are pharmaceutical equivalents (same active ingredient, dosage form, route, strength).
- Despite minor differences in excipients, both products are bioequivalent and can be expected to have the same clinical effect and safety profile.
- Xellia used a 505(b)(2) NDA route due to excipient differences, not due to lack of equivalence.
- Assigning the TE Code would allow Xellia to avoid or obtain a refund for Prescription Drug User Fee Act (PDUFA) fees and would aid in market access and listing parity with the reference product",2017-11-20 00:00:00,Approved,2019-03-15,1.0,"Center for Drug Evaluation and Research (CDER)
","- 21 CFR ¬ß 314.3(b) ‚Äì Definition of therapeutic equivalents
- Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- Section 736(a)(2)(B) ‚Äì Prescription drug program fee exemptions
- 21 CFR ¬ß¬ß 10.25(a), 10.30 ‚Äì Citizen petition regulations","- The FDA cited the need to address other Agency priorities and numerous demands on its resources as the reason for the delay in responding to the petition.
- It acknowledged receipt of the petition regarding the assignment of a therapeutic equivalence code (AP) to voriconazole.","- FDA found that Xellia‚Äôs Voriconazole and VFEND I.V. (Pfizer‚Äôs product) are:
‚Ä¢ Pharmaceutical equivalents ‚Äì Same active ingredient, dosage form (injection), and strength.
‚Ä¢ Bioequivalent ‚Äì Based on in vitro data and literature, differences in excipients do not impact pharmacokinetics.
- Because they are pharmaceutical equivalents and bioequivalent, they are therapeutically equivalent.
- As a result, FDA assigned a TE Code ‚ÄúAP‚Äù (injectable aqueous solutions).
- FDA also concluded that Xellia‚Äôs product met the criteria for exemption from certain user fees under section 736(a)(2)(B)(ii), as it was the ‚Äúsame product as another product‚Äù approved under section 505(b) or 505(j).",approved,True,657.0,CDER,CDER
fda-2017-p-3330,FDA-2017-P-3330-0001_Citizen_Petition_Regarding_PMA_K151763___REDACTED.pdf,,2017,False,original petition,Anonymous (redacted),other,"- 21 U.S.C. ¬ß¬ß 321‚Äì397 (Food, Drug, and Cosmetic Act, general statutory authority)
- 21 C.F.R. ¬ß 10.30 (Citizen petition regulation)","The FDA‚Äôs clearance of 510(k) Premarket Notification K151763 for the PerioLase Nd:YAG Pulsed Dental Laser System, including acceptance of a new clinical outcome claim for ‚Äútrue periodontal regeneration‚Äù based on histologic data submitted by the manufacturer.","- The FDA is requested to reconsider, suspend, or revoke its clearance of 510(k) K151763.
- Specifically, the petitioner seeks a review of the clinical data accepted by FDA to support the indication for ""true regeneration""
","- The histologic data submitted was biased, lacked control groups, and included only studies funded by the manufacturer.
- No study demonstrated actual bone regeneration, and claims of superiority over conventional treatments (like Scaling and Root Planing) were unproven.
- The manufacturer‚Äôs marketing materials exaggerate FDA‚Äôs clearance, implying superiority rather than equivalency, which could mislead consumers and practitioners.
- The public may be misled to believe that this is the only device offering ""true regeneration"", despite lack of unbiased supporting evidence.
- The FDA is urged to protect public health by ensuring that all marketing claims are supported by rigorous, unbiased evidence and not simply by limited manufacturer-sponsored data",,,2025-10-15,,,,,,no decision,False,,pending,pending
fda-2017-p-3352,FDA-2017-P-3352-0001_Citizen_Petition_from_Belcher_Pharmaceuticals__LLC.pdf,2017-05-25,2017,False,original petition,"Belcher Pharmaceuticals, LLC",industry/corporation,"- 21 C.F.R. ¬ß 10.30 (Citizen petition procedure)
- 21 C.F.R. ¬ß 201.22(c) (Current sulfite warning regulation)
- 21 C.F.R. ¬ß¬ß 201.57, 201.100(d) (Labeling requirements)
- 21 C.F.R. ¬ß 25.31 (Environmental impact exclusion)
- Historical references: 50 Fed. Reg. 47,558 (1985); 51 Fed. Reg. 43,904 (1986)",FDA‚Äôs regulation in 21 C.F.R. ¬ß 201.22(c) that mandates the current sulfite warning labeling for epinephrine injection products used in emergency allergic situations.,"Amend 21 C.F.R. ¬ß 201.22(c) to update the sulfite warning language for epinephrine injections used in emergency situations. The updated warning should:
- Reflect the availability of sulfite-free epinephrine formulations.
- Avoid misleading implications that only sulfite-containing or non-epinephrine options exist.
- Emphasize that sulfite-free products should be used when available.","- The current regulation, written in 1986, is outdated and misleading; it implies no sulfite-free alternatives exist.
- Belcher's own sulfite-free epinephrine formulation (approved NDA 205029) has been FDA-approved and commercially available since 2014.
- Sulfite-sensitive patients are at risk from metabisulfite-containing formulations (e.g., Adrenalin¬Æ, EpiPen¬Æ), which can cause symptoms resembling or compounding anaphylaxis.
- Repeat dosing can exacerbate sulfite reactions and diminish drug efficacy.
- Sulfonate formation and metabolite persistence in the body can lead to delayed anaphylactic symptoms after treatment.
- Historical case studies show serious and prolonged adverse effects linked to sulfite-containing treatments.
- Physicians and patients need accurate labeling to make informed choices in emergencies, especially where safer alternatives are available",,,2025-10-15,0.0,,,,,no decision,False,3065.0,pending,pending
fda-2017-p-3405,FDA-2017-P-3405-0001_Citizen_Petition_from_Michael_Boggi_Redacted.pdf,2017-05-30,2017,False,original petition,Michael Boggi,individual,"- 21 C.F.R. ¬ß¬ß 25.34 (Categorical exclusion for environmental impact)
- Implied reference to 21 C.F.R. ¬ß 10.30, though not explicitly cited, since it follows the structure of a citizen petition.",The lack of regulatory requirement for home medical device software to prevent the mixing of medical data from multiple individuals when devices are paired with the same smartphone.,"Request for the FDA to initiate rulemaking requiring home medical device manufacturers to implement protections that prevent data from two or more individuals being combined in smartphone apps or similar software
","- Smartphones are commonly shared, and multiple devices may be paired to the same phone (e.g., one for home and one for work).
- This can cause mixing of medical data, leading to inaccurate readings, predictions, or treatments.
- Examples include blood glucose monitors used by multiple individuals in the same household.
- The resulting data contamination may compromise safety and even lead to fatal outcomes.
- Current software safeguards are insufficient, and such protections must be required by regulation, not just provided in manufacturer guidelines",2017-11-02 00:00:00,Denied,2018-07-24,1.0,"Center for Devices and Radiological Health (CDRH)
","- Section 514(c)(1)(A) of the FD&C Act
- Guidance Document: Pre-market Submission Recommendations for Interoperable Medical Devices (Sept 6, 2017)
- FDA-Recognized Consensus Standards:
- ISO/IEEE 11073 (PHD & PoCD Communication)
- ISO/IEC 15026 (Software Engineering)
- LOINC
- SNOMED-CT
- IEC 62366-1 (Usability Engineering)
- IHE-PCD PCIM White Paper (2017)","- The petition requested FDA initiate rulemaking to prevent mixing of individuals‚Äô data on home medical device software (e.g., smartphone apps).
- FDA stated that the petition raised issues requiring further internal review and analysis.
- An interim response was issued pending completion of that review.","- Standards-based approach is more adaptable and efficient than rulemaking.
- FDA guidance and recognized standards already address the issue of data mixing and interoperability.
- Existing practices: Manufacturers already rely on FDA-recognized standards for safety and effectiveness.
- Continued evaluation: FDA remains engaged in assessing and recognizing new standards",denied,True,420.0,CDRH,CDRH
fda-2017-p-3413,FDA-2017-P-3413-0001_Reclassification_Petition_from__Salter_Labs.pdf,2017-05-23,2017,False,original petition,Salter Labs,advocacy/academic,"- 21 C.F.R. ¬ß 10.30 (Citizen petition procedure)
- 21 U.S.C. ¬ß 360c(e) (Section 513(e) of the FDCA ‚Äì reclassification of devices)",FDA‚Äôs classification of oxygen conservers as Class II (special controls) medical devices.,The petitioner requests that the FDA reclassify oxygen conservers from Class II to Class I (general controls) devices .,"- Long-standing safety record of oxygen conservers over several decades.
- No documented safety or effectiveness concerns specific to the devices currently on the market.
- Current classification imposes unnecessary regulatory burdens that do not correspond to actual risk.
- Reclassification to Class I would align with the FDA‚Äôs goal of risk-based regulation and focus resources on higher-risk devices.
- Petition references 21 U.S.C. ¬ß 360c(e) as the legal basis for requesting reclassification when new information is available showing that special controls are unnecessary .",,,2025-10-15,0.0,,,,,no decision,False,3067.0,pending,pending
fda-2017-p-3468,FDA-2017-P-3468-0001_Citizen_Petition_from_Teligent_Pharma_Inc_.pdf,2017-06-01,2017,False,original petition,"Teligent Pharma, Inc.",industry/corporation,"- Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FDC Act)
- 21 C.F.R. ¬ß¬ß 10.20, 10.30 (Citizen Petition procedures)
- 21 C.F.R. ¬ß 25.31(a) (Environmental assessment exclusion)
- 57 Fed. Reg. 17,950 (April 28, 1992) (reference standard designation rulemaking)","The FDA‚Äôs designation of Reference Listed Drug/Reference Standard (RLD/RS) for Ketoconazole Cream 2%. The current RS (ANDA 075581 by TEVA) is not commercially available, which obstructs the ability to conduct bioequivalence studies.
","FDA should designate either:
- Ketoconazole Cream 2%, ANDA 076294 (Fougera Pharmaceuticals, Inc.), or
- KETOZOLE¬Æ Cream 2%, ANDA 075638 (Taro Pharmaceuticals USA, Inc.)
as a second RLD/RS for the purposes of ANDA submissions
","- Current RS by TEVA is not available for bioequivalence testing, though still listed as active in the Orange Book.
- Both proposed alternatives are actively marketed and accessible for development needs.
- FDA policy allows a second RLD/RS to be designated if the current one is unavailable (citing Orange Book Preface, 36th ed., Section 1.4).
- Without a usable RLD/RS, ANDA filings are obstructed. Hence, Teligent requests this change to enable generic development",2017-11-27 00:00:00,Denied,2018-05-07,1.0,"Center for Drug Evaluation and Research (CDER)
","- Section 505(j) of the FD&C Act (21 U.S.C. 355(j))
- 21 CFR 314.3(b) ‚Äì Definition of listed drugs and therapeutic equivalents
- 21 CFR 314.94(a)(3) ‚Äì Requirements for ANDA bioequivalence studies
- 81 FR 69580 at 69619 (Oct. 6, 2016) ‚Äì FDA guidance on ANDAs","The FDA has not yet made a decision due to competing priorities and demands on its resources. The interim nature of the response complies with 21 CFR 10.30(e)(2), which permits the agency to provide such responses when unable to resolve the petition within the standard timeframe","- Current Reference Standard is Active: FDA verified that the drug product (ketoconazole cream 2%, ANDA 075581) is still in distribution and has not been discontinued.
- No Grounds Stated for New Standard: Petition did not provide sufficient justification to select a new reference standard.
- FDA Practice: The agency typically selects a single reference standard unless circumstances (e.g., discontinuation) warrant a change.
- Distributor Confirmation: Although the product is listed under Teva‚Äôs ANDA, it is distributed under G&W Laboratories, which is acceptable under Orange Book policy",denied,True,340.0,CDER,CDER
fda-2017-p-3484,FDA-2017-P-3484-0001_Citizen_Petition_from_Glasshouse_Pharmaceuticals_L.pdf,2017-06-02,2017,False,original petition,Glasshouse Pharmaceuticals Limited Canada,industry/corporation,"- 21 C.F.R. ¬ß 10.30 (Citizen Petition)
- 21 C.F.R. ¬ß 25.31 (Environmental Impact Categorical Exclusion)","The designation of a Reference Standard (RS) for mupirocin calcium cream 2%. Specifically, the current RS is Bactroban¬Æ Cream 2% (NDA N050746), which is unavailable due to long-term manufacturer backorder.","Request that the FDA designate Mupirocin Calcium Cream 2% manufactured by Glenmark Generics Inc. U.S.A (ANDA #A201587) as the new Reference Standard (RS) for mupirocin calcium cream 2%
","- Bactroban¬Æ Cream 2%, the currently designated RS, has been on long-term manufacturer‚Äôs backorder since 2015 with no expected availability.
- Multiple attempts to source the RLD/RS were unsuccessful.
- To proceed with ANDA development, a readily available RS is needed, and Glenmark‚Äôs approved ANDA product is proposed as an alternative.",2017-11-30 00:00:00,Approved,2018-04-13,1.0,"Center for Drug Evaluation and Research (CDER)
","- Section 505(j) of the FD&C Act (21 U.S.C. 355(j))
- 21 CFR 314.3(b) ‚Äì Definitions of listed drugs, therapeutic equivalents, and RLDs
- 21 CFR 314.94(a)(3) ‚Äì Requirements for ANDA bioequivalence studies
- 21 CFR 314.161(a) and 314.122(a) ‚Äì Regarding RLD withdrawal and bioequivalence applicability
- 81 FR 69580, 69619 (Oct. 6, 2016) ‚Äì Guidance on ANDA procedures","- Pending Agency Review: The petition remains unresolved due to prioritization of other Agency matters.
- Regulatory Compliance: The interim nature of the response is permitted under 21 CFR 10.30(e)(2)
","- Current Reference Standard Discontinued: Bactroban Calcium Cream (NDA 050746) was determined to be discontinued and moved to the Discontinued Drug Product List.
- Need for Replacement: A new reference standard was necessary for bioequivalence studies.
- Market Leader Justification: Glenmark‚Äôs mupirocin calcium cream (ANDA 201587) was selected as the reference standard because it is the market leader, per FDA‚Äôs evaluation of commercial data.
- Petitioners Provided Valid Grounds: The petitions collectively presented sufficient rationale to justify the change",approved,True,315.0,CDER,CDER
fda-2017-p-3486,FDA-2017-P-3486-0001_Citizen_Petition_from_BioMedEcon__LLC.pdf,2017-06-02,2017,False,original petition,"BioMedEcon, LLC",industry/corporation,"- 21 C.F.R. ¬ß 10.30
- Section 505 of the FFDCA
- 21 U.S.C. ¬ß¬ß 353(b)(2), 352(a), 321(n), 355(o)(4)
- 21 C.F.R. ¬ß¬ß 201.100, 201.57","Current FDA labeling for dopamine agonists used in RLS (pramipexole, ropinirole, rotigotine), specifically lack of boxed warnings and insufficient mental health risk disclosure. Comparison to related Public Citizen petition (FDA-2016-P-1874)
","1. Add Boxed Warnings for serious mental health risks in RLS patients.
2. Revise labeling to reflect RLS-specific risks under Warnings/Precautions and Adverse Reactions.
3. Update Medication Guides to aid in patient and caregiver risk recognition.
4. Disseminate Dear Health Care Provider Letters (DHCP) about labeling changes","- 60% rise in DA prescriptions (2010‚Äì2016); half for RLS.
- Case reports & systematic review of 76 patients with DA-induced mental health disorders (e.g., psychosis, mania, impulse control disorders).
- FAERS data shows pramipexole (PRR=455.9) and ropinirole (PRR=152.5) highly associated with impulse control disorders.
- Matched cohort studies show DA-treated RLS patients have significantly increased risks of new-onset or worsened mental disorders compared to controls",2017-11-27 00:00:00,Partially Approved / Partially Denied,2019-10-21,1.0,"Center for Drug Evaluation and Research (CDER)
","- Section 505(o)(4) of the FD&C Act ‚Äì FDA‚Äôs authority to require labeling changes
- 21 CFR 201.57(c) ‚Äì Requirements for warning content and format
- 21 CFR 208.1(c) ‚Äì Conditions requiring a Medication Guide
- 21 CFR 314.80 ‚Äì Postmarketing reporting of adverse drug experiences
- 21 CFR 314.520 and 601.42 ‚Äì Approval with restrictions
- 21 CFR 314.640 and 601.46 ‚Äì REMS requirements
- 21 CFR 314.126 ‚Äì Study design considerations for effectiveness evaluation","- The petition raises complex issues regarding labeling changes and communication for dopamine agonists used in treating Restless Legs Syndrome.
- These issues require extensive review and analysis by FDA officials.
- Interim reply issued under 21 CFR 10.30(e)(2)
","- Labeling Changes Justified: Evidence from case reports, FAERS data, literature reviews, and studies supported modifying WARNINGS AND PRECAUTIONS sections to address impulse control behaviors (e.g., gambling, hypersexuality) in patients using dopamine agonists for RLS.
- Biological Plausibility & Risk Justification: The FDA acknowledged the mechanism and epidemiological background as supportive of labeling changes.
- No REMS or DHCP Needed: FDA found the existing warnings, together with broader labeling changes, sufficient. No additional risk management strategies were deemed necessary due to the favorable benefit-risk profile",partially approved / denied,True,871.0,CDER,CDER
fda-2017-p-3581,FDA-2017-P-3581-0001_Citizen_Petition_from_Alembic_Pharmaceuticals_Limi.pdf,2017-06-05,2017,False,original petition,Alembic Pharmaceuticals Limited,industry/corporation,"- 505(j)(7) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß10.30
- 21 C.F.R. ¬ß10.25
- 21 C.F.R. ¬ß314.122
- 21 C.F.R. ¬ß314.161
- 21 C.F.R. ¬ß25.31(a)","Discontinuation of the Reference Listed Drug (RLD) ELAVIL (Amitriptyline Hydrochloride Tablets, NDA #012703) from the market
","Request for a determination by the FDA that the RLD ELAVIL was not withdrawn for reasons of safety or effectiveness, thereby allowing submission of an Abbreviated New Drug Application (ANDA) relying on this RLD
","The petitioner intends to submit an ANDA for Amitriptyline Hydrochloride Tablets referencing ELAVIL. As required by law when a listed drug is no longer marketed, the petitioner must confirm the withdrawal was not due to safety or efficacy concerns

",,Approved,2017-10-23,0.0,"Center for Drug Evaluation and Research (CDER)
","- 21 CFR 314.161 ‚Äì Determination if a listed drug was withdrawn for safety or effectiveness
- 21 CFR 314.162 ‚Äì Grounds for removal from the Orange Book
- Section 505(j)(7) of the FD&C Act (21 U.S.C. 355(j)(7)) ‚Äì Orange Book listing requirements
- 21 CFR 10.30 ‚Äì Citizen petition process",,"- FDA Review Found No Safety/Efficacy Concerns: The agency reviewed its records and conducted an independent evaluation of relevant literature and postmarketing data.
- Petitioner Provided No Contrary Evidence: The petitioner identified no data suggesting a safety or effectiveness issue.
- Orange Book Policy: Elavil remains listed in the ""Discontinued Drug Product List"", which permits ANDA approval so long as all other requirements are met",approved,True,140.0,CDER,CDER
fda-2017-p-3672,FDA-2017-P-3672-0001_Citizen_Petition_from_Millennium_Pharmaceuticals__.pdf,2017-06-08,2017,False,original petition,"Millennium Pharmaceuticals, Inc.",industry/corporation,"- 21 C.F.R. ¬ß 10.30
- Section 505(j) of the FDCA",Potential approval of ANDAs for bortezomib products that omit information about indications or dosage forms protected by patent or exclusivity,"Request that the FDA not approve any ANDA referencing Velcade¬Æ (bortezomib) that omits information protected by patent or exclusivity
","Millennium argues that omission of certain labeling information would render the generic product less safe and effective, violating legal standards and FDA policy. They cite scientific studies and prior FDA decisions to support their position.
",,Denied,2017-11-06,0.0,Center for Drug Evaluation and Research (CDER),"- 21 U.S.C. 355(b)(2) and 355(j) ‚Äì Drug approval pathways (505(b)(2) and ANDA)
- 21 CFR 314.94(a)(8)(iv), 314.127(a)(7), 314.108(b)(4), 314.50(i)(1)(iii)(B), 314.50(d)(1)(ii)(a), 314.52(a), 314.70 ‚Äì Various labeling, exclusivity, and approval requirements
- Section 505(q) of the FD&C Act
- Orphan Drug Act regulations (unspecified CFR)
- 21 CFR 320.24(b)(6) ‚Äì Bioequivalence by in vitro testing",,"- Label Carve-Out Permissibility: FDA stated that ANDA and 505(b)(2) applicants may omit protected information under the Hatch-Waxman Amendments as long as safety and effectiveness for remaining conditions of use are unaffected.
- Retreatment Information Not Critical: FDA concluded that omitting information on retreatment of multiple myeloma patients did not render bortezomib products unsafe or ineffective.
- Mannitol Ester Naming Not Required: FDA denied the request to reclassify the active ingredient in Velcade, affirming that ‚Äúbortezomib‚Äù is appropriately used per its existing NDA definition.
- Boric Acid and Glycine Safety: The agency found no safety concerns with boric acid and glycine content in Fresenius‚Äôs formulation. They cited toxicology reviews and existing approvals of boric acid‚Äìcontaining injectable drugs.
- Bioequivalence Demonstrated: FDA agreed that Fresenius had shown bioequivalence via in vitro and in vivo studies.
- Glycine Argument Unsubstantiated: The petition did not provide data showing glycine posed any specific risks.",denied,True,151.0,CDER,CDER
fda-2017-p-3675,FDA-2017-P-3675-0001_Citizen_Petition_from__Teligent_Pharma__Inc_.pdf,2017-06-09,2017,False,original petition,"Teligent Pharma, Inc.",industry/corporation,"- Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FDCA)
- 21 C.F.R. ¬ß¬ß 10.20 and 10.30
- 21 C.F.R. ¬ß 25.31(a)
- Reference: 57 Fed. Reg. 17,950, 17,954 (April 28, 1992)","The designation of reference listed drugs (RLDs) and reference standards (RS) in the Orange Book. The petitioner is specifically commenting on the status of ANDAs held by Hospira, Inc. and the unavailability of the previously listed RLD (Nubain by Par Pharmaceutical).
","The petitioner requests FDA to designate Nalbuphine Hydrochloride Injection ANDAs 070914, 070915, 070916, and 070918 (held by Hospira, Inc.) as a second reference listed drug (RLD) product","- The original RLD (Nubain NDA 018024 by Par Pharmaceutical) is discontinued and not available for product development.
- The lack of an available RLD prevents the filing of an ANDA.
- Citing FDA policy and the Orange Book Preface, Teligent argues this creates a barrier to generic competition.
- Designating the Hospira products as an RLD would resolve this by allowing ANDA applicants to reference an available product",2017-11-30 00:00:00,Denied,2018-04-12,1.0,Center for Drug Evaluation and Research (CDER),"- 21 U.S.C. 355(j) ‚Äì Section 505(j) of the FD&C Act: ANDA process
- 21 CFR 314.3(b) ‚Äì Definitions of ‚Äúlisted drug‚Äù and ‚Äúreference listed drug (RLD)‚Äù
- 21 CFR 10.30 ‚Äì Citizen petition regulation
- NDA 018024 (Nubain) cited as the RLD despite discontinuation","- Pending Resolution Due to Agency Priorities: The FDA states that it has not reached a decision due to the need to address other priorities within the Agency.
- Interim Response Issued: In compliance with 21 CFR 10.30(e)(2), an interim response is issued while review continues
","- ANDA vs. NDA Requirements: The ANDAs identified by the petitioner were approved under section 505(j) of the FD&C Act and are not eligible to be designated as RLDs because only NDA-approved products under section 505(c) can be RLDs.
- Nubain Still Serves as RLD: Although discontinued, FDA determined that Nubain (NDA 018024) is still the only eligible RLD and remains the appropriate reference standard.
- Orange Book Consistency: The Orange Book listings and definitions confirm that Hospira‚Äôs ANDAs do not qualify as RLDs
",denied,True,307.0,CDER,CDER
fda-2017-p-3684,FDA-2017-P-3684-0001_Citizen_Petition_from_Goodwin_Procter_LLP__Boehrin.pdf,2017-06-09,2017,False,original petition,Goodwin Procter LLP,law/consulting,"- 21 C.F.R. ¬ß 10.30
- Section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. ¬ß 355)
- 21 C.F.R. ¬ß 300.50 (Combination Rule)
- 21 C.F.R. ¬ß¬ß 25.30 and 25.31 (Environmental Impact exclusion)","Potential FDA approval of New Drug Applications (NDAs) for fixed-dose, triple-combination inhaled drug products for COPD, specifically without adherence to the Combination Rule. Example cited: GlaxoSmithKline's (GSK) NDA submission for a LAMA/LABA/ICS triple-combination inhaler
","- Refrain from approving any NDA for a fixed-dose, triple-combination inhaled COPD drug unless it is supported by pivotal Phase III clinical trials:
¬†¬†‚Ä¢ Using active comparators with the same active ingredients as in the proposed drug
¬†¬†‚Ä¢ Utilizing a factorial design that demonstrates each component‚Äôs contribution to the claimed effect
- Convene an FDA Pulmonary-Allergy Drugs Advisory Committee meeting before approval of such NDAs if they don‚Äôt meet the Combination Rule","- The Combination Rule (21 C.F.R. ¬ß 300.50) requires demonstration that each drug component contributes to claimed effects.
- Existing data, particularly from GSK's FULFIL study, are insufficient because they do not use proper comparators or factorial design.
- The ICS component (e.g., fluticasone furoate) poses significant safety risks, such as increased pneumonia risk, and must be justified by showing added efficacy.
- Historical FDA precedent supports factorial study requirements for similar combination therapies.
- The proposed triple-combination would be first-of-its-kind in the U.S. and thus warrants close scrutiny, including advisory committee input",,Denied,2017-09-18,0.0,Center for Drug Evaluation and Research (CDER),"- 21 CFR ¬ß 300.50 (Combination Rule)
- Federal Register: 80 FR 79776 (Dec. 23, 2015)
- FDCA ¬ß¬ß 505A(i)(2)(A), 513(b)-(c), and 520(l)(2)",,"- The petition requested FDA to require specific clinical trial designs (active comparators and factorial studies) before approving fixed-dose triple-combination COPD drugs.
- FDA denied the requests, stating that it reviews applications case-by-case and does not impose absolute requirements regarding comparator identity or delivery device.
- The agency concluded that the fixed-dose combination Trelegy Ellipta met regulatory standards through other evidence and existing clinical data.
- Factorial studies were deemed unnecessary due to existing data on individual components' efficacy and safety, including Trelegy‚Äôs target patient population already receiving two of the components.
- FDA emphasized that the inclusion of an ICS (inhaled corticosteroid) in the combination was justified by past approvals and clinical data showing no new safety concerns.
- The petition‚Äôs request to involve the Pulmonary-Allergy Drugs Advisory Committee was also denied as the application did not meet criteria warranting such referral.
",denied,True,101.0,CDER,CDER
fda-2017-p-3832,FDA-2017-P-3832-0001_Citizen_Petition_for_Reconsideration_from_Porzio__.pdf,2017-06-16,2017,False,reconsideration,"Porzio, Bromberg & Newman, P.C.",law/consulting,"- 21 C.F.R. ¬ß¬ß 10.25, 10.30, 10.33, 10.35
- Administrative Procedures Act (5 U.S.C. ¬ß 553(b)(B))
- Executive Orders 13563 and 12866
- Regulatory Flexibility Act (5 U.S.C. ¬ß¬ß 601‚Äì12)
- Unfunded Mandates Reform Act of 1995 (Pub. L. 104-4)","The Final Rule: Food Labeling: Revision of the Nutrition and Supplement Facts Labels, specifically changes to the Nutrition Facts label including the declaration of added sugars and new definition and requirements for dietary fiber ","- Stay the effective date of the Final Rule (July 26, 2016) pending reconsideration
- Reconsider the Final Rule and direct FDA staff to initiate a new rulemaking under the Administrative Procedures Act","- Implementation of the rule is inconsistent with current regulatory reform policies and Executive Orders.
- Concerns over First Amendment protections for commercial speech regarding the added sugars disclosure.
- Lack of statutory direction and questionable scientific justification for changes.
- FDA‚Äôs consumer studies (including eye-tracking) do not support the added sugars declaration.
- Rule imposes unjustified burdens on industry, especially regarding dietary fiber definitions and associated clinical trial requirements.
- No proper economic impact analysis was submitted to OMB despite large industry implications",2017-12-13 00:00:00,Partially Approved / Partially Denied,2018-06-13,1.0,"Center for Food Safety and Applied Nutrition (CFSAN)
","- 21 CFR ¬ß 101.9(c)(6)(i) ‚Äì Definition of dietary fiber
- 21 CFR ¬ß 10.30 ‚Äì Citizen petition process
- Section 403(q) of the FD&C Act ‚Äì Labeling authority
- Section 403(r)(3) of the FD&C Act ‚Äì Scientific standard for health claims
- Executive Orders 12866 and 13563
- Regulatory Flexibility Act (5 U.S.C. ¬ß¬ß 601‚Äì612)
- Unfunded Mandates Reform Act of 1995 (Pub. L. 104‚Äì4)","- The FDA indicates that due to other agency priorities and limited availability of resources, it could not complete the review within the first 180 days.
- An interim response is issued in compliance with 21 CFR 10.30(e)(2) while full review is pending
","- FDA reaffirmed that defining ""dietary fiber"" based on beneficial physiological effects rather than chemical structure is scientifically supported.
- FDA emphasized that isolated or synthetic fibers must demonstrate physiological benefits to be included on labels; no new evidence was provided to reverse this.
- The agency disagreed with the claim that the rule effectively requires pre-approval health claims or randomized trials.
- FDA defended its economic analysis, stating the cost of fiber studies was estimated ($3.9M for 84 studies) and relatively small compared to overall costs. Petitioners offered no alternate data or estimates.
- FDA explained that economic analyses for guidance documents are not typically required by the cited Executive Orders or statutes.",partially approved / denied,True,362.0,CFSAN,Other/Specialty Center
fda-2017-p-3884,FDA-2017-P-3884-0001_Reclassification_Petition_from_Riverain_Technologi.pdf,2017-06-14,2017,False,original petition,Riverain Technologies,industry/corporation,"- Section 513(e) of the FDCA (21 U.S.C. ¬ß 360c(e))
- 21 C.F.R. ¬ß 860.123","Classification of ClearRead CT, an image processing software device for CT scans, as a Class III device",Reclassification of ClearRead CT from Class III to Class II with general and special controls,"- ClearRead CT is substantially equivalent to legally marketed predicate devices.
- The device does not pose unreasonable risk of illness or injury.
- General and special controls would provide reasonable assurance of safety and effectiveness.
- Supporting data includes performance testing, clinical data, and risk analysis demonstrating the device‚Äôs safety profile and utility.",,Dismissed (moot),2018-06-04,0.0,"Center for Devices and Radiological Health (CDRH)
","- Section 513(e) of the FD&C Act (not applicable in this case)
- Section 513(f)(3) of the FD&C Act ‚Äì Proper pathway for reclassification of postamendments Class III devices
- Section 513(a)(1)(B) ‚Äì Regarding special controls for Class II devices
- 83 FR 25598 (June 4, 2018) ‚Äì Federal Register notice of proposed reclassification",,"- The petitions were filed under the incorrect statutory section (513(e)), while 513(f)(3) is the proper pathway for reclassification of devices already approved under a PMA.
- FDA had already issued a Proposed Order in the Federal Register to reclassify medical image analyzers (including the ClearRead + Detect CADe device) from Class III to Class II with special controls.
- Because the requested relief would be accomplished through the Proposed Order, the petitions were dismissed as moot
",dismissed (moot),True,355.0,CDRH,CDRH
fda-2017-p-3989,FDA-2017-P-3989-0001_Citizen_Petition_from_Lachman_Consultant_Services_.pdf,2017-06-29,2017,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"- 21 C.F.R. ¬ß 10.30 (Citizen Petition Regulation)
- 21 C.F.R. ¬ß 25.31 (Environmental Impact exclusion)","The petitioner is commenting on the marketing status of the 15 mg strength of TRINTELLIX (vortioxetine hydrobromide) tablets in the FDA's Orange Book‚Äîspecifically, whether its discontinued status is due to safety or effectiveness concerns.
","- That the FDA determine whether TRINTELLIX 15 mg tablets were discontinued for safety or effectiveness reasons.
- If not, the petitioner requests FDA to accept ANDAs for all four strengths (5 mg, 10 mg, 15 mg, and 20 mg) of vortioxetine hydrobromide using NDA N204447 as the Reference Listed Drug (RLD).","- The 15 mg strength of TRINTELLIX was previously listed in the Orange Book as a prescription product but is now marked as ‚ÄúDiscontinued.‚Äù
- The petitioner provides evidence from labeling changes and Orange Book listings showing removal of the 15 mg dosage from the product insert post-September 2016.",,Approved (Determination Issued),2017-11-21,0.0,Center for Drug Evaluation and Research (CDER),"Not Mentioned ‚Äî The letter does not reference specific statutes or federal regulations.
",,"- FDA conducted a review of its internal records.
- It determined that Trintellix (EQ 15 mg) was not withdrawn for safety or efficacy reasons.
- As a result, this strength remains listed in the Discontinued Drug Product List.
- Other strengths (5 mg, 10 mg, 20 mg) are still marketed and do not require such a determination.
- ANDAs referencing any of these strengths may still be approved, provided they meet all legal and regulatory requirements",approved,True,145.0,CDER,CDER
fda-2017-p-4027,FDA-2017-P-4027-0001_Citizen_Petition_from_Strides_Pharma_Inc.pdf,2017-07-01,2017,False,original petition,Strides Pharma Inc.,industry/corporation,"- 21 C.F.R. ¬ß 10.25(a)
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 25.31",Determination of whether METICORTEN (Prednisone) Tablets 1 mg and 5 mg (NDA N009766) were withdrawn from sale for reasons of safety or effectiveness,"- Determine whether METICORTEN (Prednisone) Tablets 1 mg was discontinued for safety or efficacy reasons
- If not, accept ANDA 210785 for Prednisone Tablets USP 1 mg for filing and approval using METICORTEN as the reference listed drug (RLD)","- METICORTEN Tablets are listed as ""Discontinued"" in the FDA's Orange Book without a stated reason
- The petitioner seeks clarity on whether the discontinuation was for safety or effectiveness reasons, as required for ANDA referencing
- Other generics for Prednisone 1 mg are already on the market, implying potential approval viability",,,2025-10-15,0.0,,,,,no decision,False,3028.0,pending,pending
fda-2017-p-4039,FDA-2017-P-4039-0001_Citizen_Petition_from_Center_for_Lawful_Access_and.pdf,2017-07-03,2017,False,original petition,Center for Lawful Access and Abuse Deterrence (CLAAD),law/consulting,"- 21 U.S.C. ¬ß 355(e) (FDCA section 505(e))
- 21 C.F.R. ¬ß¬ß 314.162, 5.10, 5.82
- 21 C.F.R. ¬ß¬ß 25.30(h), 25.31(h) (for environmental exclusion)","The petition comments on FDA‚Äôs current policy regarding the continued approval and marketing of non-abuse-deterrent opioid analgesics, and requests a change in enforcement to mandate conversion to abuse-deterrent formulations (ADOs).
","The petitioner asks the FDA to:
- Require manufacturers of certain non-abuse-deterrent oral opioid analgesics to convert to abuse-deterrent opioids (ADOs) within three years of the approval of a third ADO with the same active moiety.
- Remove products that are not converted within that time frame from the market.","- To mitigate the opioid overdose epidemic.
- To align with federal policy goals including those expressed by the Trump Administration and the FDA‚Äôs Opioids Action Plan.
- To address the public health and economic burden of opioid misuse and abuse.
- Because scientific advancements in ADOs and regulatory precedents (e.g., ER oxycodone case) support such a transition.",2017-12-28 00:00:00,,2025-10-15,1.0,,,"The FDA states that the petition raises ‚Äúcomplex issues requiring extensive review and analysis by Agency officials.‚Äù Therefore, a decision has not yet been reached.

",,no decision,False,3026.0,pending,pending
fda-2017-p-4145,FDA-2017-P-4145-0001_Citizen_Petition_from_Mylan_Pharmaceuticals__Inc.pdf,2017-07-07,2017,False,original petition,Mylan Pharmaceuticals Inc.,industry/corporation,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 25.31 (Environmental Impact categorical exclusion)","The petition comments on the FDA‚Äôs current classification of azacitidine injectable products, specifically the dosage strength of the Reference Listed Drug (RLD), Vidaza¬Æ (100 mg/vial), and seeks permission to submit a 50 mg/vial product under an ANDA (Abbreviated New Drug Application).
","To permit the submission of an ANDA for Azacitidine for Injection, 50 mg/vial, based on the approved RLD Vidaza¬Æ 100 mg/vial, reflecting a change in strength while maintaining the same proportion of active and inactive ingredients.
","- The change in strength (100 mg/vial to 50 mg/vial) is allowed under FDA regulations if it maintains proportionality with the RLD.
- The lower strength would provide greater dosing flexibility for physicians, based on hematological values.
- No concerns about safety or efficacy, as both products would be quantitatively and qualitatively equivalent.
- No change in route of administration or formulation‚Äîjust a reduction in concentration and volume, with preserved proportions.",,,2025-10-15,0.0,,,,,no decision,False,3022.0,pending,pending
fda-2017-p-4195,FDA-2017-P-4195-0001_Citizen_Petition_from__INC_Research__LLC.pdf,2017-07-12,2017,False,original petition,"INC Research, LLC",advocacy/academic,"- 505(j)(7) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 10.25
- 21 C.F.R. ¬ß 314.122
- 21 C.F.R. ¬ß 314.161
- 21 C.F.R. ¬ß 25.31(a)","Whether TRINTELLIX¬Æ (vortioxetine) 15 mg tablet strength (approved under NDA N204447) was discontinued for safety or effectiveness reasons, and whether ANDAs can be submitted for that strength
","- The petitioner asks FDA to determine that the 15 mg strength of TRINTELLIX¬Æ was not withdrawn for reasons of safety or effectiveness.
- If so, FDA should allow submission of Abbreviated New Drug Applications (ANDAs) referencing all four strengths (5 mg, 10 mg, 15 mg, and 20 mg) of TRINTELLIX¬Æ as reference listed drugs","- TRINTELLIX¬Æ 15 mg tablets were originally approved and listed in the Orange Book as a reference listed drug (RLD) alongside the other strengths.
- The 15 mg strength was removed from the patient insert in March 2017 and now appears as ‚ÄúDiscontinued‚Äù in the Orange Book.
- There is no indication from FDA or its databases that the withdrawal was related to safety or efficacy concerns.
- Petitioner asserts that a formal FDA determination is needed to allow ANDA submissions for the 15 mg strength",,Approved (Determination Issued),2017-11-21,0.0,Center for Drug Evaluation and Research (CDER),"Not Mentioned ‚Äî The letter does not reference specific statutes or federal regulations.
",,"- FDA conducted a review of its internal records.
- It determined that Trintellix (EQ 15 mg) was not withdrawn for safety or efficacy reasons.
- As a result, this strength remains listed in the Discontinued Drug Product List.
- Other strengths (5 mg, 10 mg, 20 mg) are still marketed and do not require such a determination.
- ANDAs referencing any of these strengths may still be approved, provided they meet all legal and regulatory requirements",approved,True,132.0,CDER,CDER
fda-2017-p-4233,FDA-2017-P-4233-0001_Citizen_Petition_from_Lachman_Consultant_Services_.pdf,2017-07-12,2017,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 25.31 (for environmental impact exclusion)","Establishment of suitability for submission of an Abbreviated New Drug Application (ANDA) for a change in dosage form from Vimpat (lacosamide) tablets to orally disintegrating tablets.
","FDA is requested to declare that Lacosamide Orally Disintegrating Tablets (50 mg, 100 mg, 150 mg, and 200 mg) are suitable for submission as an ANDA referencing Vimpat (lacosamide) tablets as the reference listed drug (RLD).
","- The dosage form change to orally disintegrating tablets allows easier administration (especially for patients with dysphagia).
- The strengths are identical to those of the RLD, ensuring therapeutic equivalence.
- There is no change to indications, use, or safety/efficacy concerns compared to the RLD.
- A waiver is requested under the Pediatric Research Equity Act because the product is not expected to be used in children under 17 years due to CNS development concerns.",,Approved,2024-03-13,0.0,Center for Drug Evaluation and Research (CDER),"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- 21 CFR 314.93
- 21 CFR 314.94(a)(3)(iii)
- Section 505B of the Act (PREA)",,"The FDA concluded that the proposed change in dosage form does not raise questions of safety or effectiveness. The use, dose, and administration route are the same as the listed drug. The change aligns with existing labeling, and if bioequivalence is shown, the product can have the same therapeutic effect. Pediatric studies were evaluated under PREA but were deemed unnecessary, as the drug is already labeled appropriately for pediatric use 
",approved,True,2436.0,CDER,CDER
fda-2017-p-4255,FDA-2017-P-4255-0001_Citizen_Petition_from_Kindred_Biosciences_Inc.pdf,2017-07-13,2017,False,original petition,"Kindred Biosciences, Inc.",industry/corporation,"- 21 U.S.C. 360b(n)(3) (Federal Food, Drug, and Cosmetic Act)
- 21 C.F.R. 25.33(d)(1) (for environmental impact exclusion)",Request to issue a suitability petition for a change in the dosage form of pergolide mesylate from the reference labeled new animal drug (Prascend¬Æ),"FDA is requested to approve a change in dosage form for pergolide mesylate from an oral tablet to an immediate-release, extruded oral pellet (top-dress) to be administered on a horse‚Äôs daily grain ration.","- The pellet form will improve palatability and compliance.
- Easier administration and flexible dosage adjustment.
- Tablet crushing is not recommended but often necessary for horses, leading to poor compliance.
- The proposed formulation mimics existing FDA-approved formats (e.g., Strongid¬Æ, Protazil¬Æ).
- Pellets offer convenience for dosing and are comparable in effectiveness and safety.",,Approved,2017-09-29,0.0,Center for Veterinary Medicine (CVM),"- Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- Section 512(n)(3)(C) of the FD&C Act
- 21 CFR 514.5 (regarding presubmission conferences)",,"The FDA determined that the proposed change in dosage form (from tablet to extruded pellet) does not require new investigations for safety or efficacy. The change is allowable under a suitability petition, and the dosage and schedule remain consistent with the reference listed new animal drug (Prascend¬Æ)
",approved,True,78.0,CVM,Other/Specialty Center
fda-2017-p-4334,FDA-2017-P-4334-0001_Citizen_Petition_from_Sidley_Austin_LLP__Vifor_Fre.pdf,2017-06-30,2017,False,original petition,Sidley Austin LLP,law/consulting,"- 21 C.F.R. ¬ß 10.30
- Section 505 of the Federal Food, Drug, and Cosmetic Act (FDCA)
- 21 C.F.R. ¬ß 25.31
- 21 U.S.C. ¬ß 355(d), ¬ß 352(a), ¬ß 321(n)",The petitioner comments on the supplemental New Drug Application (sNDA) filed by Keryx Biopharmaceuticals in March 2017 for Auryxia¬Æ (ferric citrate) to add an indication for the treatment of iron deficiency anemia (IDA) in non-dialysis dependent (NDD) chronic kidney disease (CKD) patients.,The petitioner requests the FDA to refrain from approving the sNDA. They recommend requiring Keryx to file a separate NDA with sufficient clinical data to support the safety and efficacy of using Auryxia for treating IDA in NDD-CKD patients.,"- Safety Concerns: Auryxia may pose safety risks when used in NDD-CKD patients due to its phosphate-binding properties and its effect on iron stores (TSAT, ferritin).
- Inconsistent Labeling: The dual indication may lead to misleading or confusing labeling and monitoring difficulties for two distinct patient populations.
- Clinical Guidelines: The updated KDIGO guidelines do not recommend phosphate binders in NDD-CKD patients with normal phosphorus levels.
- Insufficient Data: The 16-week study presented by Keryx does not adequately address long-term safety or label manageability concerns.
- Risk of Misbranding: Dual-use labeling may violate statutory requirements due to contradictory or incompatible warnings.",,Denied,2017-11-06,0.0,Center for Drug Evaluation and Research (CDER),"- Section 505(b) and 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- 21 CFR 314.50, 21 CFR 314.54, 21 CFR 314.70
- 21 CFR 201.56(a), 21 CFR 201.57(c)(9)(i)",,"The FDA determined that:
- The data from a phase 3 study (Fishbane et al.) sufficiently demonstrated the safety and efficacy of Auryxia for treating iron deficiency anemia (IDA) in patients with CKD not on dialysis (NDD-CKD).
- The clinical evidence supports the benefit-risk assessment necessary for approval.
- Petitioners' arguments based on clinical guidelines and labeling concerns were not persuasive.
- The agency found no basis to require Keryx to submit a new standalone NDA as requested by the petitioners
",denied,True,129.0,CDER,CDER
fda-2017-p-4335,FDA-2017-P-4335-0001_Citizen_Petition_from_William_Bonificio___redacted.pdf,2017-07-11,2017,False,original petition,William Bonificio,individual,"- 21 U.S. Code ¬ß 321
- 21 C.F.R. ¬ß 25.31(e)
- 21 C.F.R. ¬ß 10.30(b) ",The current classification of glutaraldehyde-based tooth desensitizers as medical devices.,"- Reclassify glutaraldehyde-based tooth desensitizers from devices to drugs
- Alternatively, revoke their current device classification","- Glutaraldehyde works via chemical action (crosslinking plasma proteins to occlude dentinal tubules), which meets the FDA's definition of a drug, not a device.
- The mechanism of action is chemical (formation/breaking of covalent bonds), distinguishing it from a device.
- The current classification is inappropriate under FDA definitions.",2018-04-16 00:00:00,Denied,2021-05-26,1.0,"Center for Devices and Radiological Health (CDRH)
","- Section 201(g) of the FD&C Act (21 U.S.C. ¬ß 321(g)) ‚Äì Definition of a drug
- Section 201(h) of the FD&C Act (21 U.S.C. ¬ß 321(h)) ‚Äì Definition of a device
- 21 CFR 872.3260, 872.3200, and 872.3690 ‚Äì Relevant classification regulations","The petition raises issues requiring further review and analysis by agency officials. The FDA has not yet reached a decision on whether to reclassify the product
","The FDA concluded that the petition did not provide sufficient scientific evidence to demonstrate that glutaraldehyde-based desensitizers achieve their primary intended purpose through chemical action. Therefore, the classification as devices under the specified CFR sections remains appropriate
",denied,True,1415.0,CDRH,CDRH
fda-2017-p-4352,FDA-2017-P-4352-0001_Citizen_Petition_from__Pharmaceutical_Manufacturin.pdf,2017-07-20,2017,False,original petition,"Pharmaceutical Manufacturing Research Services, Inc. (PMRS)",advocacy/academic,"- 21 C.F.R. ¬ß¬ß 10.30 and 10.31
- Section 505(q) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)","The petition comments on and opposes the approval of NDA 209653 submitted by Intellipharmaceutics Corp., particularly with labeling indicating use for chronic pain. It also addresses FDA‚Äôs general practice of approving extended-release opioids for chronic pain despite lack of evidence.","- Refrain from approving NDA 209653 with the proposed indication: ‚Äúmanagement of moderate-to-severe pain when a continuous around-the-clock analgesic is needed for an extended period of time.‚Äù
- Refrain from approving any other current or future opioid applications labeled for chronic use.","- The proposed indication lacks ‚Äúsubstantial evidence‚Äù from adequate and well-controlled investigations as required by the FD&C Act.
- Chronic use of opioids is not supported by evidence; most clinical trials are under 12 weeks.
- Approval contributes to the opioid epidemic and public health crisis.
- Referenced CDC and FDA data showing high risks of addiction and overdose associated with long-term opioid use.
- Claims that FDA-approved labeling has historically given false reassurance regarding safety and efficacy for chronic pain.",,Denied,2017-12-15,0.0,Center for Drug Evaluation and Research (CDER),"- Section 505(c), 505(j) of the FD&C Act (21 U.S.C. 355)
- 21 CFR 314.50, 314.94, 314.105, 314.125, 314.127
- Section 505(q) of the FD&C Act",,"The FDA denied the petition because:
- The petition raised issues (e.g., opioid use labeling and long-term safety) currently under investigation through postmarketing requirements (PMRs).
- FDA considers it premature to take the requested actions without the results of ongoing studies.
- Approval decisions are made based on application-specific data and existing statutory and regulatory frameworks
",denied,True,148.0,CDER,CDER
fda-2017-p-4360,FDA-2017-P-4360-0001_Citizen_Petition_from_Mallinckrodt_Pharmaceuticals.pdf,2017-07-19,2017,False,original petition,Mallinckrodt Pharmaceuticals,industry/corporation,"- 21 C.F.R. ¬ß 10.30
- Section 505(b)(2) and Section 505(j) of the FDCA
- 21 C.F.R. ¬ß 314.94(a)(9)
- 21 C.F.R. ¬ß 314.127(a)(7)
- 21 U.S.C. ¬ß 355(j)(4)(F)",FDA‚Äôs potential approval of any abbreviated new drug application (ANDA) referencing Mallinckrodt‚Äôs product ‚ÄúOfirmev‚Äù (acetaminophen injection) that omits pediatric exclusivity-protected labeling information,"Mallinckrodt requests that the FDA:
- Refrain from approving any ANDA for acetaminophen injection that omits labeling protected by pediatric exclusivity under FDCA.
- Require all applicants to include the pediatric information as required by law.","The petitioner argues that:
- The pediatric use information in the Ofirmev labeling is protected by statutory pediatric exclusivity and may not be omitted by ANDA filers.
- Permitting omission of such information would violate FDCA provisions and would result in misleading labeling that does not adequately inform physicians.
- Approval of ANDAs with omitted information undermines the incentives created by the Best Pharmaceuticals for Children Act (BPCA) and Pediatric Research Equity Act (PREA).",,Denied,2017-12-15,0.0,Center for Drug Evaluation and Research (CDER),"- Section 505(b)(2) and 505(j) of the FD&C Act (21 U.S.C. 355)
- Section 505(q)(1)(F) of the FD&C Act
- 21 CFR 314.50, 314.94, 314.105, 314.110, 314.125, 314.127, 314.200, 314.430",,"The petition was denied because:
- The FDA has not made final decisions on pending NDAs/ANDAs referencing INOMAX, and it would be premature to act on the petition.
- Section 505(q) requires FDA to act within 150 days, but does not require resolution of application-specific decisions before full NDA/ANDA reviews are complete.
- The Agency emphasized that it would not bypass established application review procedures or diminish applicant procedural protections by deciding petition-based aspects piecemeal",denied,True,149.0,CDER,CDER
fda-2017-p-4372,FDA-2017-P-4372-0002_Citizen_Petition_from_AEGIS_Regulatory__Inc_.pdf,,2017,False,original petition,"AEGIS Regulatory, Inc.",law/consulting,"- 21 C.F.R. ¬ß 10.30 (Citizen Petition)
- 21 C.F.R. ¬ß 70.3(s)
- 21 C.F.R. ¬ß¬ß 25.30‚Äì25.40","Enforcement and importation practices regarding cosmetic products, specifically the importation of adulterated foreign cosmetic products (notably ""Hair Pearl"" eyelash and eyebrow dye) containing coal tar dyes","- Prohibit the entry of adulterated cosmetic products (especially ""Hair Pearl"") into the U.S.
- Add the responsible companies in Germany to Import Alert 53-05.
- Instruct all FDA District Offices to refuse entry of such products","- Reports of adverse health effects including ocular erythema, chemically-induced conjunctivitis, and temporary blindness.
- Product illegally imported with falsified safety data sheets omitting known hazards.
- Violation of FDA regulations regarding color additives in products used around the eyes.
- Prior evasion of enforcement (e.g., Refectocil smuggled through US-Canadian border) cited as precedent for needed action",,,2025-10-15,,,,,,no decision,False,,pending,pending
fda-2017-p-4388,FDA-2017-P-4388-0001_Suitability_Petition_from_Abhai__LLC.pdf,2017-07-21,2017,False,original petition,"Abhai, LLC",industry/corporation,"- Section 502(j)(2)(C) of the FDC Act
- 21 C.F.R. ¬ß¬ß 10.20, 10.30, and 314.93","The petition comments on the approved strength of a listed drug (Acetaminophen, Butalbital, and Caffeine Tablets, 325 mg/50 mg/40 mg) and seeks permission to submit an ANDA for a different strength (300 mg/50 mg/40 mg)","The petitioner requests the FDA Commissioner to determine that the new strength (300 mg/50 mg/40 mg) is suitable for submission as an Abbreviated New Drug Application (ANDA) under the suitability petition process
","- The new strength does not raise new safety or efficacy concerns since the drug's indication, dosage form, and administration route remain the same.
- The new strength contains a lower dose of acetaminophen, potentially reducing risks of liver injury due to overdose.
- The change aligns with current dosage labeling of the reference drug and does not require new clinical investigations",,Withdrawn,2023-06-13,0.0,Center for Drug Evaluation and Research (CDER),Not applicable. ,,"- The FDA contacted the petitioner (KVK-Tech, Inc.) on March 17, 2023, requesting confirmation of interest to keep the petition active.
- No response was received within 30 days.
- As per FDA‚Äôs GDUFA III commitments, unresolved petitions predating FY 2024 were reviewed, and the petition was administratively closed as voluntarily withdrawn without prejudice
",withdrawn,True,2153.0,CDER,CDER
fda-2017-p-4389,FDA-2017-P-4389-0001_Citizen_Petition_from_Wildway_LLC.pdf,2017-07-21,2017,False,original petition,"Wildway, LLC",industry/corporation,"- 21 C.F.R. ¬ß 101.60(c)(2)(v)
- Section 403(r)(4) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 101.60(b)
- 21 C.F.R. ¬ß 101.60(c)(2)(i‚Äìiv)
- 21 C.F.R. ¬ß 101.9(g)
- 21 C.F.R. ¬ß 25.32 (including ¬ß 25.32(p))",Regulation requiring products labeled with ‚ÄúNo added sugar‚Äù to also include a statement that the product is not ‚Äúlow calorie‚Äù and to refer consumers to the nutrition panel,"To exempt certain Wildway food products from the requirement under 21 C.F.R. ¬ß 101.60(c)(2)(v) to declare:
> ‚ÄúThe product bears a statement that the food is not ‚Äòlow calorie‚Äô or ‚Äòcalorie reduced‚Äô ... and that directs consumers' attention to the nutrition panel.‚Äù","- The new Nutrition Facts label (effective May 2016) already requires declaration of added sugars and their % Daily Value, rendering the additional statement redundant.
- The term ‚ÄúNo added sugars‚Äù is consistent with the nutrition facts panel when it states ‚ÄúIncludes 0g Added Sugars.‚Äù
- Requiring the extra disclaimer clutters the label and may mislead or confuse consumers.
- No products in the granola or cereal categories reasonably qualify as ‚Äúlow calorie‚Äù per 21 C.F.R. ¬ß 101.60(b); requiring a disclaimer for something that is clearly not expected misleads more than informs.
- FDA‚Äôs own statements support limiting excessive label information to avoid overwhelming consumers.
- Added sugars are a required declaration, not a claim, and should not require additional disclaimers.
- Wildway asserts this added disclaimer constitutes unnecessary regulatory burden with no public health benefit",,,2025-10-15,0.0,,,,,no decision,False,3008.0,pending,pending
fda-2017-p-4409,FDA-2017-P-4409-0001_Citizen_Petition_from_Hyman__Phelps___McNamara__PC.pdf,2017-07-24,2017,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"- 21 C.F.R. ¬ß 10.30
- 21 U.S.C. ¬ß 352(f)
- 21 C.F.R. ¬ß 201.100(c)(1)
- 21 C.F.R. ¬ß 201.57(a)(11)(i)
- Federal Food, Drug, and Cosmetic Act ¬ß 506A
- 21 C.F.R. ¬ß 314.70
- 21 C.F.R. ¬ß 25.31(a)",The approved package insert (PI) for Trulance (plecanatide)‚Äîspecifically the reporting of diarrhea adverse event (AE) rates in Table 1 of the PI. The petition challenges the accuracy and completeness of AE data reporting in the labeling.,"FDA should require:
- A footnote in the PI Table 1 (Adverse Events) stating that reported diarrhea rates only include bothersome cases or those requiring treatment/hospitalization.
- Similar explanatory notes in future PI revisions if AEs are collected similarly","- The PI misrepresents the true incidence of diarrhea AEs due to instructions that limited reporting to only severe/bothersome cases.
- This underreporting could mislead healthcare professionals and patients.
- Misleading information may unfairly benefit Synergy in marketing Trulance over competitors.
- Full disclosure is needed to allow accurate risk-benefit evaluation by prescribers and patients",2018-01-18 00:00:00,Partially Approved / Partially Denied,2021-02-21,1.0,Center for Drug Evaluation and Research (CDER),"- 21 CFR 10.30 (citizen petitions)
- 21 CFR 201.56(d)(1), 201.57(a)(11), 201.57(c)(7) ‚Äì Prescription drug labeling requirements
- 21 CFR 201.100(c)(1) ‚Äì Adequate information for use
- 21 CFR 201.5, 201.75(c)(7)(ii)(A) ‚Äì Labeling and adverse reactions sections","The petition raises complex issues requiring extensive review and analysis by FDA officials. Therefore, a final decision has not yet been made","- FDA agreed that the instructions given to investigators during Trulance‚Äôs CIC clinical trials regarding adverse event (AE) reporting were relevant to understanding the diarrhea incidence rate in labeling.
- FDA concluded the current rate might omit events not reported as bothersome but found insufficient evidence to support the petitioner‚Äôs claim that the actual rate was higher.
- A modified footnote, paralleling the one used in Trulance‚Äôs IBS-C labeling, was approved instead.
- FDA denied the broader request for requiring similar footnotes in all future adverse reaction listings.",partially approved / denied,True,1308.0,CDER,CDER
fda-2017-p-4500,FDA-2017-P-4500-0001_Citizen_Petition_from_Kent_Heckenlively_Redacted.pdf,2017-07-27,2017,False,original petition,"Kent Heckenlively, JD; also signed by Rima E. Laibow, MD and Ralph Fucetola, JD on behalf of Natural Solutions Foundation and Institute for Health Research respectively",law/consulting,"- 21 C.F.R. ¬ß 10.30 (Administrative Procedures Act petitioning regulation)
- 21 C.F.R. ¬ß¬ß 210.2, 211.1, 601.2(a), 601.4(a), 610.15(a)
- 21 U.S.C. ¬ß¬ß 321, 331, 351(a)(2)(B), 355, 360bbb-3, 393(b)(2), 262
- 42 U.S.C. ¬ß 300aa-22(b)(2), ¬ß 300aa-27(a)(2)
- 5 U.S.C. ¬ß 553(b)(B) (APA ‚Äúgood cause‚Äù exemption)
- Geneva Conventions, Nuremberg Code, UNESCO Universal Declaration on Bioethics and Human Rights ","The general practice of FDA and CDC approving and recommending childhood vaccines. The petition comments on this ongoing regulatory policy and the lack of clear regulations implementing informed consent in vaccination practices.
","- Immediate issuance of an emergency regulation establishing a Five-Year Moratorium on all childhood vaccinations, including during declared health emergencies.
- Draft and adopt a regulation stating: ‚ÄúNot for Childhood Vaccination‚Äù on all vaccine package inserts.
- Hold hearings, allow public comments, and eventually issue permanent regulations to support informed consent.
- Presidential intervention (President Trump) to mandate agency action","- Petitioners argue that current childhood vaccines are ""unavoidably unsafe"" and lack sufficient evidence of safety and efficacy as required by law.
- They claim the FDA failed to enforce safety regulations and violated federal statutes, the Data Quality Act, and informed consent principles.
- Cite a public health risk due to vaccine ingredients and increasing adverse events.
- Reference international human rights laws (e.g., Nuremberg Code, Geneva Conventions) to support the claim that vaccination without informed consent is unethical and unlawful.
- Argue that the FDA's actions violate constitutional rights including First Amendment protections and fundamental liberty interests ",,Denied,2022-12-02,0.0,"Center for Biologics Evaluation and Research (CBER)
","- Public Health Service Act (42 U.S.C. ¬ß¬ß 201 et seq.; ¬ß 262)
- Federal Food, Drug, and Cosmetic Act (21 U.S.C. ¬ß¬ß 301 et seq.; ¬ß 321)
- National Childhood Vaccine Injury Act (42 U.S.C. ¬ß¬ß 300aa-10 to 300aa-27)
- 21 CFR ¬ß¬ß 601.2, 601.5, 601.6, Part 312, ¬ß 202
- First Amendment (Sorrell v. IMS Health Inc.)
- 5 U.S.C. App. 2; 5 U.S.C. ¬ß 552b; 5 CFR Part 2635
- 66 Fed. Reg. 30991 (June 8, 2001)",,"- FDA lacks authority to mandate vaccination programs or repeal statutes.
- Vaccines are proven safe, pure, and potent under strict regulatory review.
- No new evidence was provided to warrant label changes or suspensions.
- Extensive post-marketing surveillance is already in place.
- Direct-to-consumer advertising is constitutionally protected.
- Advisory committees and independent reports already address vaccine safety.
",denied,True,1954.0,CBER,Other/Specialty Center
fda-2017-p-4575,FDA-2017-P-4575-0001_Vegetable_Oil_Health_Claim_petition_Nov_7_2016.pdf,2016-11-15,2017,False,original petition,Unilever,industry/corporation,"- 21 C.F.R. ¬ß 101.70 (Health Claims; Petitions)
- Section 403(r)(3)(B)(i) of the Federal Food, Drug, and Cosmetic Act (FFDCA)","FDA's regulatory framework for approving health claims related to dietary fats and oils, particularly concerning the relationship between unsaturated fatty acids and coronary heart disease risk","Approve a new health claim stating that oils high in unsaturated fats may reduce the risk of coronary heart disease when replacing saturated fat, as part of a healthy diet
","- Scientific evidence supports a favorable association between dietary intake of unsaturated fatty acids and reduced risk of coronary heart disease (CHD).
- The petition includes over 80 peer-reviewed human intervention and observational studies.
- FDA had previously approved a similar claim for canola oil, and this request seeks to broaden it to include soybean, sunflower, corn, and other vegetable oils.
- Approval would improve public health messaging by aligning dietary guidance with regulatory standards",2017-08-04 00:00:00,,2025-10-15,1.0,,,"Not Provided ‚Äì This is an interim response only confirming the petition was filed. No substantive justification or evaluation is included.
",,no decision,False,3256.0,pending,pending
fda-2017-p-4586,FDA-2017-P-4586-0001_Citizen_Petition_from_Jubilant_DraxImage_Inc_.pdf,2017-07-31,2017,False,original petition,Jubilant DraxImage Inc.,industry/corporation,"- 21 C.F.R. ¬ß 10.30 (Citizen Petition Procedure)
- 21 C.F.R. ¬ß 314.161(a)(1)
- FDCA ¬ß 505(j)","The continued listing of Diagnostic Kits, Technetium Tc99m Succimer Injection (NDA 019239) in the FDA's Orange Book as a discontinued product for which ANDAs can still be submitted.
","FDA should remove the listing of NDA 019239 from the Orange Book because the drug was withdrawn for reasons of safety or effectiveness.
","- NDA 019239 was approved in 1986 and never marketed in the U.S.
- The product is associated with multiple safety concerns including:
¬†¬†‚Ä¢ Use of non-sterile diluents
¬†¬†‚Ä¢ Risks of radioactive exposure to patients and personnel
¬†¬†‚Ä¢ Deficiencies in labeling and patient safety information
- The sponsor, GE Healthcare, has taken no public steps to resume marketing.
- Allowing ANDAs to reference a drug never marketed, with unresolved safety issues, undermines patient safety and regulatory standards.",,Denied,2017-12-21,0.0,"Center for Drug Evaluation and Research (CDER)
","- 21 U.S.C. ¬ß 355(j) ‚Äì Section 505(j) of the FD&C Act (ANDAs)
- Section 505(q) of the FD&C Act
- 21 CFR ¬ß¬ß 314.105, 314.110, 314.125, 314.127, 314.200
- Section 505(c)(1)(B) and (d) ‚Äì Hearing and response process for NDA/ANDA rejections",,"- FDA is required under section 505(q)(1)(F) to respond within 150 days of petition submission.
- FDA declined to comment on specific approval requirements for pending ANDAs referencing HICON, to preserve procedural protections for applicants.
- The Agency emphasized it had not yet made a final decision on the approval of any related ANDA and declined to make piecemeal judgments outside the formal application process.
- The denial does not indicate approval or rejection of any specific ANDA.",denied,True,143.0,CDER,CDER
fda-2017-p-4670,FDA-2017-P-4670-0001_Citizen_Petition_from_Baxter_Healthcare_Corporatio.pdf,2017-08-02,2017,False,original petition,Baxter Healthcare Corporation,industry/corporation,"- 505(j) and 505(w) of the FD&C Act
- 21 C.F.R. ¬ß 10.25
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 314.94(a)(9)(iii)
- 21 C.F.R. ¬ß 314.99(b)
- 21 C.F.R. ¬ß 25.31
- 21 C.F.R. ¬ß 10.30(b)","Whether the original formulation of EMEND (150 mg/vial with 18.8 mg EDTA) was reformulated for safety or effectiveness reasons, and if an ANDA may be submitted referencing the original formulation rather than the revised one (5.4 mg EDTA)
","1. FDA should determine if Merck‚Äôs EMEND (with 18.8 mg EDTA) was reformulated for safety or efficacy reasons.
2. If not, confirm that an ANDA referencing the original formulation is acceptable.
3. Confirm waiver eligibility under 21 C.F.R. ¬ß 314.99(b) due to inactive ingredient differences","- Both original and revised EMEND formulations are listed on Merck‚Äôs website and DailyMed.
- The original formulation (with 18.8 mg EDTA) is still marketed and listed in the Orange Book.
- No safety or efficacy concerns are known for the original formulation.
- Another ANDA (Fresenius Kabi, ANDA 206197) uses the original formulation.
- FDA advised Baxter via Controlled Correspondence to file a petition to seek clarity on formulation reference and waiver path",2018-01-29 00:00:00,Approved,2018-10-09,1.0,"Center for Drug Evaluation and Research (CDER)
","- 21 U.S.C. ¬ß 355(j) ‚Äì FD&C Act, Section 505(j) (ANDA process)
- 21 CFR 314.3(b) ‚Äì Definition of Reference Listed Drug (RLD)
- 21 CFR 314.94(a)(9)(ii), (iii) ‚Äì Inactive ingredients in ANDAs for parenteral drugs
- 21 CFR 314.127(a)(8)(ii)(B) ‚Äì Refusal to approve an ANDA due to unsafe composition
- 21 CFR 314.99(b) ‚Äì Waiver provisions
- 21 CFR 314.122(a) ‚Äì Petition requirement for withdrawn RLDs
- 21 CFR 314.161(a)(1) ‚Äì Safety/effectiveness withdrawal determination","- The petition raised complex issues requiring extensive review and analysis by Agency officials.
- Therefore, the FDA issued an interim response and committed to responding once a decision is reached.","- FDA found no evidence that the original Emend formulation (with 18.8 mg EDTA) was discontinued for reasons of safety or effectiveness.
- FDA reviewed internal records and postmarketing data and found no safety signals linked to the original formulation.
- Based on this, FDA determined that it could grant a waiver of the inactive ingredient rule (314.94(a)(9)(iii)) for parenteral drugs, using 21 CFR 314.99(b).
- This decision is consistent with statutory and regulatory requirements and prior FDA determinations.
- Therefore, ANDAs duplicating the original Emend formulation may be accepted and approved, provided all other requirements are met.",approved,True,433.0,CDER,CDER
fda-2017-p-4736,FDA-2017-P-4736-0001_Citizen_Petition_from_American_Dental_Association.pdf,2017-08-04,2017,False,original petition,American Dental Association (ADA),advocacy/academic,"- 21 C.F.R. Part 355 (OTC Anticaries Drug Products)
- 21 C.F.R. Part 356 (OTC Oral Healthcare and Wound Healing Drug Products)
- 21 C.F.R. ¬ß 310.536 (OTC Nailbiting and Thumbsucking Drug Products)
- 21 C.F.R. Part 343 (OTC Internal Analgesic Drug Products)
- 21 C.F.R. ¬ß 25.31 (Environmental Impact exclusion)","Existing OTC drug monographs for oral health-related products, which the petitioner claims are outdated and not reflective of current scientific standards","Initiate public rulemaking to review and update the following OTC drug monographs:
‚Ä¢ Anticaries products
‚Ä¢ Oral healthcare products
‚Ä¢ Oral wound healing products
‚Ä¢ Nailbiting and thumbsucking deterrents
‚Ä¢ Internal analgesics","- Monographs are based on outdated science and have not kept pace with advances in safety and efficacy testing.
- Consumers may be using products evaluated by obsolete standards, reducing confidence in safety, quality, and effectiveness.
- More modern tests (e.g., one-minute fluoride release) are now available, replacing older tests like animal caries reduction studies.
- Alignment with recent FDA initiatives on safer pain management (citing Docket No. FDA-2017-D-2497) supports this petition‚Äôs goals",2018-01-31 00:00:00,Denied,2018-12-21,1.0,"Center for Drug Evaluation and Research (CDER)
","- 21 CFR Part 355 ‚Äì OTC Anticaries Drug Products
- 21 CFR Part 356 ‚Äì OTC Oral Healthcare & Wound Healing Drug Products
- 21 CFR 310.545 ‚Äì OTC Nailbiting and Thumbsucking Drug Products
- 21 CFR Part 343 ‚Äì OTC Internal Analgesic Drug Products
- 21 CFR 330.10 ‚Äì OTC monograph rulemaking procedures
- 21 CFR 355.70(a) & (c) ‚Äì Fluoride dentifrice testing and alternative methods
- 21 CFR 10.30(b)(3), 10.40(a)(2) ‚Äì Citizen petition requirements
- 21 U.S.C. ¬ß¬ß 321(p), 355 ‚Äì FD&C Act provisions on ‚Äúnew drugs‚Äù and marketing approval
- 21 CFR Parts 210, 211; ¬ß 210.1(a), ¬ß 330.1(a) ‚Äì GMP requirements and definitions","- The petition involved complex issues regarding over-the-counter (OTC) oral health drug monographs.
- These require extensive review and analysis by FDA officials.
- The FDA committed to providing a final decision once the review is complete.","- The petition failed to provide sufficient supporting detail or data to justify rulemaking action.
- FDA noted the request lacked:
- A specific regulatory proposal
- Supporting data (e.g., test protocol, validation data, statistical analysis plan) for the suggested fluoride test
- FDA is focused on ongoing legislative reforms to modernize OTC drug regulation (e.g., H.R. 5333, S. 2315)
- FDA determined that rulemaking is not appropriate under current circumstances due to evolving policies and resource prioritization. (Pages 2‚Äì4)",denied,True,504.0,CDER,CDER
fda-2017-p-4745,FDA-2017-P-4745-0001_Citizen_Petition_from_Allergan.pdf,2017-08-04,2017,False,original petition,Allergan,industry/corporation,"- Section 505(j)(2)(A)(v) of the Federal Food, Drug, and Cosmetic Act (FDCA)
- 21 C.F.R. ¬ß 314.94(a)(9)(iii)
- 21 C.F.R. ¬ß 10.30 (Citizen petition process)
- 21 C.F.R. ¬ß 25.31 (Environmental impact exemption)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact disclosure)","Submission and potential approval of abbreviated new drug applications (ANDAs) referencing Viberzi¬Æ (eluxadoline) without conducting adequate in vivo bioequivalence studies and without a demonstration of abuse-deterrent properties
","FDA should refuse to approve any ANDA referencing Viberzi¬Æ unless it includes:
1. In vivo bioequivalence studies using both 100 mg and 75 mg strengths
2. Comparative pharmacokinetic studies under fed and fasting conditions
3. Justification or evaluation of abuse potential and abuse-deterrent properties","- Eluxadoline is a locally acting GI agent with complex pharmacokinetics that may not be adequately captured by in vitro testing alone.
- Abuse of eluxadoline by alternative routes (e.g., intranasal or injection) may cause severe adverse effects.
- The RLD has a REMS program and scheduling under the Controlled Substances Act due to abuse potential.
- Allergan argues that bioequivalence and abuse potential must be carefully evaluated to ensure safe and effective use.",,Denied,2018-01-02,0.0,"Center for Drug Evaluation and Research (CDER)
","- 21 U.S.C. ¬ß 355(c), (j) ‚Äì New drug and ANDA application approval requirements
- 21 CFR ¬ß¬ß 314.50, 314.94, 314.105, 314.125, 314.127 ‚Äì Requirements for NDAs and ANDAs
- Section 505(q)(1)(F) of the FD&C Act ‚Äì Petition response timeline
- 21 CFR 10.30(b)(3), 10.40(a)(2) ‚Äì Citizen petition content and format rules
- 21 CFR 330.10 ‚Äì OTC monograph procedures
- 65 FR 56468, 56470 (Sept. 19, 2000) ‚Äì Policy on product-specific BE guidance publication",,"- The petition repeated arguments made in two prior Allergan petitions, which FDA had already addressed.
- FDA is still developing BE guidance for cyclosporine and will consider scientifically valid input.
- FDA noted that approval of ANDAs depends on the specific evidence submitted, not petition outcomes.
- FDA emphasized that final actions must occur within 150 days under section 505(q); the denial fulfills that statutory requirement.
- FDA will consider outstanding scientific and procedural issues in the context of specific ANDA reviews, not in abstract via the petition.",denied,True,151.0,CDER,CDER
fda-2017-p-4852,FDA-2017-P-4852-0001_Citizen_Petition_from__EAS_Consulting_Group___Jubi.pdf,2017-08-09,2017,False,original petition,"EAS Consulting Group, LLC",law/consulting,"- 505(j)(2) and 505(j)(7) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß¬ß 10.25, 10.30, 314.122, and 314.161",The FDA‚Äôs listing status and the reason for discontinuation of the Reference Listed Drug (RLD) LOTENSIN HCT (Benazepril Hydrochloride and Hydrochlorothiazide 5 mg/6.25 mg),"That the FDA determine the discontinuation of LOTENSIN HCT (5 mg/6.25 mg) was not for reasons of safety or effectiveness, thereby allowing submission of an ANDA referencing the discontinued strength
","Under the FD&C Act, an ANDA must reference an RLD. If the RLD has been discontinued, FDA must determine if the discontinuation was for safety or effectiveness. The petitioner asserts that the 5 mg/6.25 mg strength was not withdrawn for such reasons, and therefore ANDAs relying on it should be permitted. This ensures the continued availability of generic alternatives

",,Approved (Determination Issued),2018-02-20,0.0,"Center for Drug Evaluation and Research (CDER)
","- No specific statutes or CFR sections are cited directly in the letter.
- Reference is made to the Orange Book (""Approved Drug Products With Therapeutic Equivalence Evaluations"").",,"- FDA reviewed internal records and concluded that the drug was not withdrawn for reasons of safety or effectiveness.
- Accordingly, the drug remains in the Discontinued Drug Product List section of the Orange Book.",approved,True,195.0,CDER,CDER
fda-2017-p-4939,FDA-2017-P-4939-0001_Citizen_Petition_from_Chul_Hi_Park_Redacted.pdf,2017-08-14,2017,False,original petition,"Chul-Hi Park, Ph.D.",individual,"- Sections 510 and 513 of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 25.34 (Environmental Impact)
- FDA Guidance for Intravascular Stents (cited for precedent)",Clearance of surgical staplers and staple line reinforcement materials for use on lungs and digestive tract under 510(k) without appropriate dynamic performance testing,"Require manufacturers of surgical staplers and staple line reinforcement materials used on lungs and digestive tract to:
1. Perform risk analysis of device use considering organ physiological motion.
2. Provide dynamic performance testing data simulating organ motion for 510(k) clearance.
3. Revise labeling and instructions based on such performance data.","- Staple line leaks in lung and gastrointestinal surgeries pose significant risks.
- Current FDA clearances lack realistic dynamic performance testing simulating breathing or digestion motion.
- Static tests like burst pressure are insufficient.
- There is evidence of postoperative complications related to mechanical failure under physiological motion.
- Manufacturers‚Äô performance claims lack supporting dynamic test data.
- Additional testing would improve safety, clinical techniques, and product validation. ",2018-05-21 00:00:00,Denied,2021-10-12,1.0,"Center for Devices and Radiological Health (CDRH)
","- 21 CFR 10.30(e) ‚Äì Grounds for denying citizen petitions
- 21 CFR 878.4750 ‚Äì Implantable staples
- 21 CFR 878.3300 ‚Äì Surgical mesh
- 21 CFR Part 820 ‚Äì Good manufacturing practices
- 21 CFR Part 803 ‚Äì Adverse event reporting
- 21 CFR Part 801 ‚Äì Labeling requirements
- 21 U.S.C. ¬ß 360c(a)(1) ‚Äì Device classification
- 21 U.S.C. ¬ß¬ß 360(k), 360c(i) ‚Äì Substantial equivalence (SE) & 510(k) submissions
- 21 CFR 878.4750; 86 FR 56195 ‚Äì Reclassification of internal staplers to class II
- 21 CFR 330.10 ‚Äì OTC monograph procedures
- Guidance: Surgical Staplers and Staples for Internal Use - Labeling Recommendations (October 8, 2021)","- The petition raised complex issues related to preventing the clearance of certain new device categories without adequate proof of safety and effectiveness.
- FDA stated it needed further review and analysis before issuing a final decision.","- FDA determined that the petitions did not provide sufficient evidence that new or additional performance tests or risk analyses were necessary.
- FDA already evaluates risk analysis and performance test data during 510(k) reviews.
- FDA had reclassified surgical staplers for internal use as class II with special controls requiring broader performance testing.
- A recent advisory panel meeting and public comment process led to these strengthened regulatory measures.
- FDA had issued new guidance recommending more detailed labeling and performance disclosures for internal staplers.
- FDA found existing regulatory mechanisms‚Äîincluding adverse event monitoring, labeling requirements, and SE determination‚Äîto be adequate to ensure safety and effectiveness.
- The petition‚Äôs supporting materials (e.g., articles, manufacturer brochures, self-authored data) were deemed insufficient to warrant further regulatory changes.",denied,True,1520.0,CDRH,CDRH
fda-2017-p-5027,FDA-2017-P-5027-0001_Citizen_Petition_from_Wilson_Disease_Association.pdf,2017-08-16,2017,False,original petition,Wilson Disease Association (WDA),advocacy/academic,"- 21 U.S.C. ¬ß 355 (FDCA Section 505)
- 21 C.F.R. ¬ß 10.30 (Citizen Petition regulation)
- 21 C.F.R. ¬ß 25.31(b) (Environmental assessment exclusion)","FDA‚Äôs pending decision on two ANDAs for trientine hydrochloride (generic versions of Syprine¬Æ) submitted by Kadmon Holdings, Inc., for the treatment of Wilson disease","- Rapid approval of two ANDAs submitted by Kadmon for generic trientine products
- That the FDA treat these ANDAs as a priority under its expedited review procedures for ‚Äúfirst generics‚Äù","- Current RLD (Syprine¬Æ) has no marketed generics despite over 30 years of approval
- Syprine is expensive, requires refrigeration, and has a burdensome dosing regimen (up to 8 capsules daily)
- Generic versions would reduce cost and improve patient access, especially for school-age patients and those with limited refrigeration options
- The Senate Committee on Aging and other federal bodies have also emphasized the need for lower-cost alternatives and increased generic competition",,Dismissed (moot),2018-02-13,0.0,"Center for Drug Evaluation and Research (CDER)
","- MAPP 5240.3, Rev. 4, effective 11/09/2017
- 21 CFR 314.430(b)",,"The petition requested accelerated approval of ANDAs for trientine hydrochloride to treat Wilson Disease, due to the lack of generic alternatives for Syprine. However, FDA had already approved ANDA 207567 for the treatment of Wilson Disease on February 7, 2018. Therefore, the petition was dismissed as moot. FDA also referenced their prioritization policy for ANDA review, affirming that this category of submissions is prioritized under MAPP 5240.3.

",dismissed (moot),True,181.0,CDER,CDER
fda-2017-p-5081,FDA-2017-P-5081-0001_Citizen_Petition_from_Pfizer__Inc_.pdf,2017-08-17,2017,False,original petition,Pfizer Inc.,industry/corporation,"- Section 505 of the Federal Food, Drug, and Cosmetic Act (FDC Act)
- 21 C.F.R. ¬ß 10.30
- 21 U.S.C. ¬ß 355(q)
- 21 C.F.R. ¬ß 25.31","Lack of a product-specific bioequivalence (BE) guidance for generic versions of Estring¬Æ (estradiol vaginal ring). Pfizer is commenting on the need for the FDA to establish such a guidance
","Pfizer requests that the FDA:
- Issue a product-specific BE guidance for generic versions of Estring¬Æ
- Require in vitro and in vivo BE studies (PK and clinical endpoint studies)
- Ensure geometry, formulation, and mechanical equivalency of generic versions
- Allow public review and comment before ANDA approvals
- Expedite the review of this petition
","- Estring¬Æ is a complex, controlled-release vaginal ring with unique release characteristics essential to safety and efficacy
- No existing product-specific FDA guidance for its generic counterparts, unlike similar drugs (Vagifem¬Æ, Estrace¬Æ)
- Safety and efficacy depend on strict control of in vitro and in vivo performance
- Differences in geometry, formulation, or physical properties could pose safety risks
- Request to align BE demonstration requirements with those of other complex vaginal estrogen products
",2018-02-12 00:00:00,Partially Approved / Partially Denied,2020-06-04,1.0,"Center for Drug Evaluation and Research (CDER)
","- 21 CFR 10.115(g)(5)
- 21 CFR 10.115(d)
- 21 CFR 10.115(h)
- 21 CFR 314.3(b)
- 21 CFR 314.94
- 21 CFR 314.94(a)
- 21 CFR 314.94(a)(7)
- 21 CFR 314.127(a)(6)(i)
- Section 505(j) of the FD&C Act (21 U.S.C. 355(j))
- Public Law 98-417 (Hatch-Waxman Amendments)","The FDA stated it has not resolved the petition due to the need to address other agency priorities. The petition requested product-specific bioequivalence guidance for ANDAs for generic versions of Pfizer‚Äôs Estring (estradiol vaginal ring). FDA indicated it will respond as soon as possible, acknowledging resource demands
","The FDA issued a draft PSG for generic versions of Estring and provided time for public input, meeting part of the petition‚Äôs request. However, it denied other parts because:
- PSGs are not legally binding and cannot impose mandatory requirements.
- FDA does not need a PSG to approve an ANDA.
- ANDA applicants can proceed without PSGs if they meet the statutory requirements.
- The Agency will consider public comments before finalizing the PSG. FDA cited its discretion in determining the appropriate bioequivalence (BE) methodologies and emphasized that the draft PSG reflects its current thinking, not regulatory mandates",partially approved / denied,True,1022.0,CDER,CDER
fda-2017-p-5082,FDA-2017-P-5082-0001_Citizen_Petition_from__ChromaDex__Inc_.pdf,2017-08-18,2017,False,original petition,"ChromaDex, Inc.",industry/corporation,"- 21 C.F.R. ¬ß¬ß 10.25, 10.30 (Citizen petition procedure)
- 21 U.S.C. ¬ß 342(a)(1), 342(f), 342(f)(1)(B), 350b (Adulterated foods & new dietary ingredients)
- 21 U.S.C. ¬ß¬ß 332, 334 (Enforcement mechanisms: injunction & seizure)
- 21 C.F.R. ¬ß 190.6 (New Dietary Ingredient Notification)
- 21 C.F.R. ¬ß 173 Subpart C (Food additives: solvents)
- 21 C.F.R. ¬ß 25.32 (Environmental impact exclusion)","Continued marketing and distribution of Elysium Health‚Äôs Basis product, alleged to contain undeclared toluene and an unapproved new dietary ingredient","- Declare Basis adulterated under 21 U.S.C. ¬ß 342
- Halt distribution and seize product
- Enjoin manufacturers/distributors under 21 U.S.C. ¬ß¬ß 332, 334
- Determine the unapproved ingredient (nicotinamide riboside) violates 21 U.S.C. ¬ß 350b, due to lack of NDI filing","- Laboratory analysis revealed Basis contains 96‚Äì144 mg/kg of toluene, a toxic industrial solvent not approved for ingestion
- Elysium switched to a non-NIAGEN¬Æ nicotinamide riboside supplier with no FDA-recognized GRAS or NDIN
- Chemical, packaging, and compositional discrepancies were confirmed through testing (e.g., solvents, impurities, metals, label differences)
- Petition argues Elysium has not met FDA‚Äôs safety requirements for new dietary ingredients and is selling a product potentially injurious to health",2018-02-15 00:00:00,,2025-10-15,1.0,,,"The FDA has not made a decision on the petition within the first 180 days due to competing agency priorities. However, the petition is currently under active evaluation
",,no decision,False,2980.0,pending,pending
fda-2017-p-5090,FDA-2017-P-5090-0001_Citizen_Petition_from_Macleods_Pharmaceuticals_Lim.pdf,2017-08-18,2017,False,original petition,Macleods Pharmaceuticals Limited,industry/corporation,"- Section 505(j) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß¬ß 10.25(a), 10.30, 314.93
- 21 C.F.R. ¬ß¬ß 25.31(a) and 25.15(d) (for environmental exclusion)","Designation of Teva‚Äôs product (ANDA #A090829) as the Reference Standard (RS) for Paricalcitol Capsules, despite market unavailability","FDA should:
‚Äì Designate ANDA #A202539 (Bionpharma Inc.) as the new RS for Paricalcitol Capsules (1 mcg, 2 mcg, 4 mcg);
‚Äì Or select another suitable RS that is commercially available","- Teva's product is unavailable (limited sales, no NDC listing on FDA platforms)
- FDA guidance permits RS replacement when existing RS is unavailable
- Bionpharma‚Äôs ANDA #A202539 is therapeutically equivalent, widely available, and the market leader for all strengths
- Includes Orange Book data and IMS sales figures to support claim",2018-02-01 00:00:00,Approved,2019-03-14,1.0,"Center for Drug Evaluation and Research (CDER)
","- Section 505(j) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. ¬ß 355(j))
- 21 CFR 314.3(b)
- 21 CFR 314.94(a)(3)","The FDA has not made a decision on the petition due to the need to prioritize other agency matters. The interim response was issued in compliance with 21 CFR 10.30(e)(2), and the agency assured that the petition is still under consideration
","FDA granted the petition because the previously selected reference standard (ANDA 090829) is no longer available in the market. Based on available information, including commercial data, FDA determined that the 4 mcg strength of paricalcitol capsule (ANDA 202539) was appropriate to serve as the new reference standard. This selection ensures consistency and viability for future bioequivalence testing among applicants.
",approved,True,573.0,CDER,CDER
fda-2017-p-5114,FDA-2017-P-5114-0001_Citizen_Petition_from_Locke_Lord_LLP.pdf,2017-08-21,2017,False,original petition,Locke Lord LLP,law/consulting,"- 21 C.F.R. ¬ß 10.25(a)
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 314.122
- 21 C.F.R. ¬ß 314.161(a)(3)
- 21 C.F.R. ¬ß 25.31
- 21 C.F.R. ¬ß 10.30(b)","Whether TRINTELLIX (vortioxetine hydrobromide) 15 mg tablets were discontinued for reasons of safety or effectiveness
","1. FDA should determine whether TRINTELLIX 15 mg tablets were discontinued for safety or efficacy reasons.
2. If not discontinued for such reasons, FDA should allow submission and approval of ANDAs referencing the 15 mg strength of TRINTELLIX as a reference listed drug (RLD).","- The 15 mg strength was originally approved under NDA N204447 and included in RLD labeling until at least September 2016.
- It was removed from labeling as of March 2017 and listed as ‚ÄúDiscontinued‚Äù in the Orange Book.
- There is no evidence from FDA sources indicating the discontinuation was due to safety or efficacy concerns.
- The petitioner argues for regulatory clarity to enable generic manufacturers to submit ANDAs referencing this strength if it was not withdrawn for adverse reasons.
",,Approved (Determination Issued),2017-11-21,0.0,"Center for Drug Evaluation and Research (CDER)
",Not mentioned.,,"FDA reviewed its records and confirmed that the 15 mg strength of Trintellix was not withdrawn for safety or efficacy reasons. Therefore, it will remain in the ‚ÄúDiscontinued Drug Product List‚Äù section of the Orange Book, and ANDAs referencing the 15 mg (as well as 5 mg, 10 mg, and 20 mg) can be approved if all other requirements are met.
",approved,True,92.0,CDER,CDER
fda-2017-p-5118,FDA-2017-P-5118-0001_Citizen_Petition_from_Tricia_Thompson_Redacted.pdf,2017-08-18,2017,False,original petition,"Gluten Free Watchdog, LLC",industry/corporation,"- Section 201(n), 301‚Äì303, and 403(a)(1) of the Federal Food, Drug, and Cosmetic Act (FFDCA); 21 U.S.C. ¬ß¬ß 321(n), 331‚Äì333, and 343(a)(1)
- 21 C.F.R. Part 101.91 (Gluten-Free Labeling Rule)","Enforcement and compliance efforts under the Gluten-Free Labeling Rule, particularly relating to the labeling of products that are ‚Äúgluten-free‚Äù despite containing prohibited ingredients such as barley malt, malt extract, and wheat
","- Establish a specific protocol for increased surveillance, investigation, and enforcement of ‚ÄúFacial Misbranding‚Äù violations under the Gluten-Free Labeling Rule
- Implement an online reporting system for consumers to submit label violations
- Issue FDA Warning Letters within 30 days of receiving reports
- Alternatively, initiate a ‚ÄúFacial Misbranding Initiative‚Äù akin to the Front of Package Labeling Initiative","- Persistent misbranding issues with gluten-free labeled products that actually contain gluten ingredients
- Current consumer reporting mechanisms are inadequate and not prioritized
- Misbranded products remain on shelves despite FDA awareness
- Enhanced enforcement is essential for protecting individuals with celiac disease
- A structured and visible FDA protocol will deter violations and ensure labeling compliance",2018-02-13 00:00:00,,2025-10-15,1.0,,,"The FDA has not reached a decision on the petition due to competing agency priorities. The agency states the petition is currently under active evaluation by its staff
",,no decision,False,2980.0,pending,pending
fda-2017-p-5124,FDA-2017-P-5124-0001_Citizen_Petition_from_Hyman__Phelps___McNamara__PC.pdf,2017-08-22,2017,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"- 21 C.F.R. ¬ß 10.30 (Citizen Petition requirements)
- 21 C.F.R. ¬ß 10.25(a)(2) (Petition authority)
- 21 C.F.R. ¬ß 25.34(b) (Environmental impact categorical exclusion)
- 21 C.F.R. ¬ß 801.405(b)(3)(i) (Labeling requirement)
- 21 C.F.R. ¬ß 872.3570 (Device classification)
- Section 510(k) and 510(m)(2) of the Federal Food, Drug, and Cosmetic Act (Premarket notification and exemption authority)
- Reference to FDA Exemption Guidance (1998)","FDA‚Äôs July 11, 2017 Exempt List of class II devices exempt from premarket notification requirements. Specifically, FDA‚Äôs exclusion of OTC denture repair kits from that list despite including similar products
","FDA should exempt OTC denture repair kits (product code EBO) from the premarket notification (510(k)) requirements under Section 510(m)(2) of the FDC Act
","- OTC denture repair kits are class II devices with a 40-year record of safe and effective use.
- They pose low risk, similar to exempted devices like OTC denture pads, cushions, reliners, and partially fabricated denture kits.
- No significant adverse events were reported in FDA‚Äôs MAUDE database over 10 years.
- FDA has historically grouped these devices together in classification and guidance.
- The Convenience Kits Guidance does not provide adequate or binding relief, particularly for new products that might include non-exempt components.
- The design, materials, and intended emergency use of denture repair kits make them even less risky than other exempt products",,Approved,2018-01-31,0.0,Center for Devices and Radiological Health (CDRH),"- Section 510(m)(2) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- 21 CFR 872.3570
- 21 CFR 872.9",,"FDA reviewed the petition and determined that premarket notification is not necessary to ensure the safety and effectiveness of OTC denture repair kits. No public comments were received opposing the exemption. Therefore, the devices will remain Class II (special controls) under 21 CFR 872.3570 and be exempt from 510(k) requirements, subject to limitations under 21 CFR 872.9
",approved,True,162.0,CDRH,CDRH
fda-2017-p-5205,FDA-2017-P-5205-0001_Citizen_Petition_from_Xiromed__LLC_on_behalf_of_Li.pdf,2017-08-23,2017,False,original petition,Xiromed LLC,industry/corporation,"- 21 C.F.R. ¬ß 10.30 (Citizen Petition regulation)
- 21 C.F.R. ¬ß 10.25(a)(2) (Authority to submit petitions)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact disclosure)
- 21 C.F.R. ¬ß 314.94(a)(3) (Definition of Reference Listed Drug)
- The Hatch-Waxman Act (Drug Price Competition and Patent Term Restoration Act of 1984)","The lack of availability of the original Reference Listed Drug (RLD): BIAXIN (Clarithromycin Tablets, USP) 250 mg & 300 mg (NDA 050662 by Abbvie), and the need for an updated Reference Standard (RS)","The petitioner requests FDA to designate ANDA 065489, held by Aurobindo Pharma LTD, as the new Reference Standard (RS) for Clarithromycin Tablets, USP
","- BIAXIN was discontinued by Abbvie and is no longer commercially available.
- Multiple clinical suppliers confirmed unavailability of the product.
- LifePharma FZE is developing a generic version and needs a viable RS.
- Aurobindo's product (ANDA 065489) is the market leader, with over 57% market share.
- Timely designation of a new RS would facilitate generic development and reduce healthcare costs by improving access to lower-priced generics",2018-02-14 00:00:00,Approved,2018-10-23,1.0,"Center for Drug Evaluation and Research (CDER)
","- Section 505(j) of the FD&C Act (21 U.S.C. ¬ß 355(j))
- 21 CFR 314.3(b)
- 21 CFR 314.94(a)(3)
- 21 CFR 314.161
- 21 CFR 314.122","FDA stated it has not been able to reach a decision due to other agency priorities. The petition is still under consideration and a full response will be provided as soon as feasible
","The originally designated RLD (Biaxin tablets approved under NDA 050662) is no longer available on the market. FDA determined that ANDA 065489 (Aurobindo‚Äôs clarithromycin tablets) is a suitable replacement, as it is the market leader based on commercial data. This substitution ensures continuity for bioequivalence testing requirements
",approved,True,426.0,CDER,CDER
fda-2017-p-5335,FDA-2017-P-5335-0001_Citizen_Petition_from_ANDA_Consultants.pdf,2017-08-29,2017,False,original petition,ANDA Consultants,law/consulting,"- 21 C.F.R. ¬ß 10.25(a)(2)
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 314.122
- 21 C.F.R. ¬ß 314.161
- 21 C.F.R. ¬ß 25.31 (categorical exclusion ‚Äì environmental impact)
- 21 C.F.R. ¬ß 10.30(b) (economic impact disclosure)","The status in the Orange Book of Nexiclon‚Ñ¢ XR (clonidine) Extended Release Tablets, NDA 22-500, which is listed as discontinued. The petitioner questions whether this discontinuation was due to safety or effectiveness reasons","The petitioner asks the FDA to determine that NDA 22-500 was not withdrawn for reasons of safety or effectiveness, so that it can be used as a reference listed drug (RLD) in ANDA submissions","- NDA 22-500 (Nexiclon‚Ñ¢ XR) is currently in the Discontinued section of the Orange Book.
- The petitioner asserts there is no indication that the discontinuation was due to safety or efficacy concerns.
- A formal FDA determination is needed so that generic applicants can reference this NDA in their ANDAs",,,2025-10-15,0.0,,,,,no decision,False,2969.0,pending,pending
fda-2017-p-5396,FDA-2017-P-5396-0001_Citizen_Petition_from_Physicians_for_Responsible_O.pdf,,2017,False,original petition,"Multiple co-signatories:  Andrew Kolodny, M.D., Executive Director, Physicians for Responsible Opioid Prescribing (PROP)  Jay Butler, M.D., President, Association of State and Territorial Health Officials  Deborah A.P. Hersman, President & CEO, National Safety Council  Charles McKay, M.D., FACMT, President, American College of Medical Toxicology  Judy Rummler, Chair, FED UP! Coalition  Gary Mendell, Founder and CEO, Shatterproof",advocacy/academic,"- 21 C.F.R. ¬ß 10.30 (citizen petition regulation)
- 21 U.S.C. ¬ß 355(e) (section of the FD&C Act governing drug withdrawal)
- 21 C.F.R. ¬ß 25.31(a) (environmental impact categorical exclusion)
- Executive documents and public health reports also cited for context (e.g., CDC guidelines, National Academies recommendations)","The continued market availability of ultra-high dosage unit (UHDU) orally and transmucosally administered opioid analgesics, such as OxyContin 80 mg, IR oxycodone 30 mg, and others with daily doses exceeding 90 MME/day","The petitioners request that the FDA:
- Immediately seek removal of UHDU oral and transmucosal opioid analgesics from the U.S. market
","- UHDU opioids exceed safe dosing levels (CDC: >90 MME/day).
- They pose high risks for misuse, accidental overdose, and death, especially among opioid-na√Øve users, children, and adolescents.
- Studies show increased risk of overdose, addiction, and other adverse events at high dosages without proportional benefits in pain control.
- Removing UHDUs could reduce morbidity and mortality, reverse risky prescribing norms, and have minimal burden on legitimate patients, who can use smaller doses or alternative formulations (e.g., liquids, patches).
- Aligns with FDA‚Äôs new benefit-risk framework that weighs public health impact of misuse",,,2025-10-15,,,,,,no decision,False,,pending,pending
fda-2017-p-5477,FDA-2017-P-5477-0001_Citizen_Petition_from_Hyman__Phelps___McNamara_on_.pdf,2017-09-06,2017,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"- Section 501 and 505 of the Federal Food, Drug, and Cosmetic Act (FDCA)
- 21 C.F.R. ¬ß 10.30
- 21 U.S.C. ¬ß 355(b), ¬ß 355(j), ¬ß 355(b)(2), ¬ß 355(j)(8)
- 21 C.F.R. ¬ß 314.94(a)(8)(iv), ¬ß 314.127(a)(7), ¬ß 320.24, ¬ß 320.22(b)(3), ¬ß 314.3(b)","Approvals of ANDAs (Abbreviated New Drug Applications) referencing Tyvaso (treprostinil) Inhalation Solution that may differ in delivery device or require additional data not allowable under 505(j) pathway
","FDA should refrain from approving any ANDA for a treprostinil inhalation solution drug-device combination product referencing Tyvaso unless:
1) It includes a specific approved delivery device;
2) The device has the same design and performance standards;
3) The product is bioequivalent to Tyvaso;
4) It includes a compatible refill kit","The petition argues that:
- Tyvaso is an integrated drug-device combination with a complex, specifically designed inhalation system.
- Any differences in the generic device may impact performance, patient usability, and safety.
- Differences may require retraining or clinical studies, which are not permitted under 505(j).
- Human factors studies, device performance tests, and compatibility with refill kits are critical.
- Approving a non-equivalent ANDA would compromise patient safety and violate statutory requirements.",,Denied,2018-02-02,0.0,"Center for Drug Evaluation and Research (CDER)
","- Section 505(q) of the FD&C Act (21 U.S.C. ¬ß 355(q))
- 21 CFR 314.105, 314.125, 314.127, 314.110, 314.200
- Section 505(c)(1)(B), 505(d) of the FD&C Act",,"The FDA denied the petition without commenting on the specific requests, stating that no final decision had yet been made on whether to approve any ANDA referencing Tyvaso. The agency emphasized that the statutory review process must be followed and that premature determinations on specific ANDA components outside that process could compromise procedural fairness for applicants. Thus, FDA did not consider it appropriate to issue piecemeal decisions on pending applications through the citizen petition process
",denied,True,149.0,CDER,CDER
fda-2017-p-5592,FDA-2017-P-5592-0001_Citizens_Petition_from_International_Isotopes_Inc.pdf,2017-09-06,2017,False,original petition,International Isotopes Inc.,industry/corporation,"- Section 505(j) of the FD&C Act
- 21 C.F.R. ¬ß 10.20
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 314.93
- 21 C.F.R. ¬ß 25.31 (environmental exclusion)
- 21 C.F.R. ¬ß 10.30(b) (economic impact disclosure)","The listing status of Sodium Iodide I-123 Solution, 2 mCi/ml, NDA 017630 in the Orange Book, specifically whether its discontinuation was due to safety or efficacy concerns","Request for FDA to:
- Determine that Sodium Iodide I-123 Solution (2 mCi/ml, NDA 017630) was not discontinued for safety or efficacy reasons
- Publish this determination in the Federal Register
- Amend the Orange Book to list the product as a Reference Listed Drug (RLD)","- Product is listed as discontinued but no evidence indicates GE Healthcare discontinued it for safety or efficacy reasons.
- Petitioner cites FDA‚Äôs policy of designating market leaders as RLDs.
- The solution form offers more flexible dosing than fixed-dose capsules (100/200 ¬µCi).
- The proposed manufacturing method would improve the purity of the radioactive product.
- There is currently no RLD available for ANDA applicants for this solution strength, hindering generic development
",2018-03-08 00:00:00,,2025-10-15,1.0,,,"The FDA has not reached a decision due to the need to address other agency priorities. The petition, which requested a determination that Sodium Iodide I-123 oral solution was not discontinued for safety or effectiveness reasons, is still under review
",,no decision,False,2961.0,pending,pending
fda-2017-p-5787,FDA-2017-P-5787-0001_Citizen_Petition_Post__Finasteride_Syndrome_Founda.pdf,2017-09-18,2017,False,original petition,Post-Finasteride Syndrome Foundation (PFSF),advocacy/academic,"- 21 C.F.R. ¬ß 10.30
- FDA‚Äôs Citizen Petition process
- References to risk disclosure regulations (implicit)
- No mention of 505(q)","- Labeling of finasteride-containing drugs, particularly Propecia¬Æ (1 mg)
- The adequacy of FDA-approved warnings about persistent sexual, physical, and neurological adverse effects after discontinuation","The petition requests FDA to:
- Revise finasteride product labeling to include persistent sexual, physical, and neurological side effects
- Add a ""black box warning"" about risk of suicidal ideation and psychological effects
- Require distribution of MedGuides to all patients
- Implement a risk evaluation and mitigation strategy (REMS)","- Growing body of scientific and anecdotal evidence suggests serious and sometimes permanent adverse effects linked to finasteride.
- Reports from patients, clinicians, published studies, and the FDA‚Äôs Adverse Event Reporting System (FAERS) support claims of persistent side effects.
- Current labeling is inadequate in disclosing these risks to patients and prescribers.
- PFSF argues that FDA has a duty to protect public health by ensuring more explicit and accessible warnings .",2018-03-15 00:00:00,Partially Approved / Partially Denied,2022-06-08,1.0,Center for Drug Evaluation and Research (CDER),"- 21 U.S.C. ¬ß 355(e), ¬ß 505(d), ¬ß 505(o)(4), ¬ß 505-1(b)(3), ¬ß 505-1(f)(1)
- 21 CFR ¬ß¬ß 314.70, 314.80, 314.81, 314.150, 314.102, 201.56, 201.57
- Wyeth v. Levine, 555 U.S. 555 (2009)
- Various FDA guidances on labeling and pharmacovigilance","The petition raises complex issues that require extensive review and analysis by FDA officials. The agency has not reached a decision but assured that a response will follow once the review is complete
","- The FDA reviewed the petition, supplements, clinical data, literature, postmarketing reports, and pharmacovigilance analysis.
- It found insufficient scientific evidence to support a causal association between Propecia and many of the proposed risks (e.g., major depressive disorder, suicidal ideation, persistent sexual dysfunction, male infertility).
- It acknowledged possible concerns from postmarketing reports, particularly regarding suicidal ideation/behavior, and mandated label updates to reflect this.
- For other claims, including adding Boxed Warnings or changes to contraindications, the evidence was either inconclusive, methodologically flawed, or not generalizable.
- The FDA emphasized that labeling must reflect reasonable evidence of a causal relationship, and existing postmarketing labeling already addressed some concerns.
",partially approved / denied,True,1724.0,CDER,CDER
fda-2017-p-5799,FDA-2017-P-5799-0001_Citizen_Petition_from_Granules_Pharmaceuticals_Inc.pdf,2017-09-18,2017,False,original petition,Granules Pharmaceuticals Inc.,industry/corporation,"- 505(j) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 10.25(a)
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 25.31(a)
- 21 C.F.R. ¬ß 25.15(d)
- 21 C.F.R. ¬ß 10.30(b)
- Referenced: FDA Draft Guidance for Industry, Referencing Approved Drug Products in ANDA Submissions (Jan. 2017)","The designation of a Reference Standard (RS) for Clorazepate Dipotassium Tablets, 15 mg, currently listed as TRANXENE (NDA 017105), which is no longer available on the U.S. market despite being listed in the Orange Book","Request for FDA to designate ANDA 071858 (Mylan Pharmaceuticals Inc.) as the new Reference Standard for Clorazepate Dipotassium Tablets USP, 15 mg, or to designate another suitable alternative RS for ANDA submission","- TRANXENE 15 mg tablets are not available in the U.S. market, despite not being officially listed as discontinued.
- Strengths 3.75 mg and 15 mg were discontinued by the NDA holder (Recordati Rare Diseases Inc.).
- Per FDA‚Äôs bioequivalence guidelines, 15 mg strength is required for in vivo testing, but it's unavailable.
- Mylan‚Äôs ANDA 071858 is the market leader in unit sales from 2011‚Äì2016 (as shown in IMS data table on page 3).
- FDA guidance permits ANDA-based RS designation when RLD is unavailable or withdrawn for non-safety reasons",2018-03-13 00:00:00,Approved,2018-10-17,1.0,Center for Drug Evaluation and Research (CDER),"- 21 U.S.C. ¬ß 355(j) (Section 505(j) of the FD&C Act)
- 21 CFR ¬ß 314.3(b)
- 21 CFR ¬ß 314.94(a)(3)
- 21 CFR ¬ß 314.161(a)
- 21 CFR ¬ß 314.122(a)","The FDA cited high demand on agency resources and the need to prioritize other issues as the reason for not yet resolving the petition.

","- The prior reference listed drug (Tranxene 15 mg tablets) is no longer marketed.
- FDA found that ANDA 071858 (held by Mylan) was appropriate as the new reference standard due to:
‚Ä¢ Its commercial availability
‚Ä¢ Status as market leader, as determined by FDA commercial data
- FDA confirmed this move aligns with regulatory provisions for replacing a reference standard when the RLD is discontinued",approved,True,394.0,CDER,CDER
fda-2017-p-5845,FDA-2017-P-5845-0001_Citizen_Petition_from_B_H_Consulting_Services__Inc.pdf,2017-09-20,2017,False,original petition,"B&H Consulting Services, Inc.",law/consulting,"- 21 C.F.R. ¬ß 10.25(a)
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 25.31(a)
- 21 C.F.R. ¬ß 25.21
- 21 C.F.R. ¬ß 25.20(i)
- Referenced: January 2017 Draft Guidance for Industry: Referencing Approved Drug Products in ANDA Submissions
- MAPP 5240.3 (Prioritization of Review of Original ANDAs)","FDA‚Äôs designation of the Reference Standard (RS) for Ketoconazole Tablets USP, 200 mg in the Orange Book. The petitioner notes the unavailability of the current RS (Teva, ANDA 075273)","Request that the FDA designate the product listed under ANDA 075597 (Mylan Pharmaceuticals Inc.) as the new Reference Standard for Ketoconazole Tablets USP, 200 mg
","- The currently designated RS (Teva, ANDA 075273) is ‚Äútemporarily unavailable with no release date,‚Äù per confirmation from a vendor who contacted Teva directly.
- The unavailability has persisted since October 5, 2016, making it difficult for generic manufacturers to obtain sufficient quantity for in vivo bioequivalence testing.
- Only two products remain on the Orange Book: Mylan (ANDA 075597) and Taro (ANDA 075319).
- Mylan‚Äôs product is a market leader based on units sold.
- The request aligns with the FDA‚Äôs draft guidance and MAPP 5240.3, which support RS designation changes to facilitate ANDA development when fewer than three ANDAs are approved
",2018-03-28 00:00:00,Partially Approved / Partially Denied,2019-04-05,1.0,Center for Drug Evaluation and Research (CDER),"- 21 U.S.C. ¬ß 355(j)
- 21 CFR ¬ß 314.3(b)
- 21 CFR ¬ß 314.94(a)(3)
- Abbreviated New Drug Applications and 505(b)(2) Applications, 81 FR 69580, 69619 (Oct. 6, 2016)","The FDA stated that it was unable to reach a decision due to the need to address other Agency priorities and high demand on resources
","- The existing reference standard (ketoconazole tablets, ANDA 075273) is no longer being manufactured or marketed and was moved to the Discontinued Drug Product List in the Orange Book.
- FDA agreed with the petitioner that a new reference standard was warranted.
- FDA did not select ANDA 075597 (Mylan) as the new reference because it determined that ANDA 075319 (Taro) was more appropriate based on commercial data showing it is the market leader.
- The final decision aimed to ensure availability for in vivo bioequivalence testing",partially approved / denied,True,562.0,CDER,CDER
fda-2017-p-5909,FDA-2017-P-5909-0001_Citizen_Petition_from_Goodwin_Procter_LLP.pdf,2017-09-25,2017,False,original petition,Goodwin Procter LLP,law/consulting,"- 21 C.F.R. ¬ß 10.25
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 314.161
- 21 C.F.R. ¬ß 314.162
- 21 C.F.R. ¬ß 25.31","Whether Trintellix (vortioxetine) tablets, 15 mg was voluntarily withdrawn from sale for safety or effectiveness reasons, as it appears in the Discontinued Section of the Orange Book","Request for FDA to determine that Trintellix 15 mg was voluntarily withdrawn, but not for reasons of safety or effectiveness
","- The 15 mg strength of Trintellix was approved under NDA 204447 on September 30, 2013.
- It is listed as ""discontinued"" in the Orange Book, and there is no evidence of commercial distribution.
- Other strengths (5 mg, 10 mg, 20 mg) are still marketed, indicating no known safety or effectiveness issues.
- FDA has precedent for treating never-marketed products as withdrawn from sale but not withdrawn for safety/effectiveness reasons
",,Approved (Determination Issued),2017-11-21,0.0,Center for Drug Evaluation and Research (CDER),"Not Mentioned ‚Äî The letter does not reference specific statutes or federal regulations.
",,"- FDA conducted a review of its internal records.
- It determined that Trintellix (EQ 15 mg) was not withdrawn for safety or efficacy reasons.
- As a result, this strength remains listed in the Discontinued Drug Product List.
- Other strengths (5 mg, 10 mg, 20 mg) are still marketed and do not require such a determination.
- ANDAs referencing any of these strengths may still be approved, provided they meet all legal and regulatory requirements",approved,True,57.0,CDER,CDER
fda-2017-p-5910,FDA-2017-P-5910-0001_Citizen_Petition_from_Cipla_Limited.pdf,2017-09-25,2017,False,original petition,Cipla Limited,industry/corporation,"- 21 C.F.R. ¬ß 10.25
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 314.161
- 21 C.F.R. ¬ß 314.162
- 21 C.F.R. ¬ß 25.31
- FD&C Act: Sections 505(j) and 505(w)","Whether TRINTELLIX¬Æ Tablets, 15 mg (NDA N204447) has been voluntarily withdrawn from sale for safety or effectiveness reasons, affecting its status as a Reference Listed Drug (RLD) for ANDA submissions
","Request that FDA determine whether the 15 mg strength of TRINTELLIX¬Æ (Vortioxetine) has been voluntarily withdrawn for safety or efficacy reasons in order to allow submission and approval of ANDAs referencing this product
","- TRINTELLIX¬Æ 15 mg was approved under NDA N204447 by Takeda on September 30, 2013.
- The 15 mg strength is listed as ‚Äúdiscontinued‚Äù in the FDA‚Äôs Orange Book as of September 18, 2017.
- There is no evidence that it was discontinued for safety or effectiveness reasons.
- FDA precedents allow ANDA approval of discontinued drugs if not withdrawn for such reasons.
- Cipla asserts the ANDA is eligible and requests the FDA to confirm the safety status to proceed",,Approved (Determination Issued),2017-11-21,0.0,Center for Drug Evaluation and Research (CDER),"Not Mentioned ‚Äî The letter does not reference specific statutes or federal regulations.
",,"- FDA conducted a review of its internal records.
- It determined that Trintellix (EQ 15 mg) was not withdrawn for safety or efficacy reasons.
- As a result, this strength remains listed in the Discontinued Drug Product List.
- Other strengths (5 mg, 10 mg, 20 mg) are still marketed and do not require such a determination.
- ANDAs referencing any of these strengths may still be approved, provided they meet all legal and regulatory requirements",approved,True,57.0,CDER,CDER
fda-2017-p-5946,FDA-2017-P-5946-0001_Citizen_Petition_from_Goodwin_Procter_LLP.pdf,2017-09-26,2017,False,original petition,Goodwin Procter LLP,law/consulting,"- 21 C.F.R. ¬ß 10.25
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 314.161
- 21 C.F.R. ¬ß 25.31",Determination of whether the 60 mg strength of Doryx¬Æ MPC (Doxycycline Hyclate Delayed-Release Tablets) was withdrawn from the market for reasons of safety or effectiveness.,"Request for the FDA Commissioner to determine that Doryx¬Æ MPC 60 mg was voluntarily withdrawn from the market, but not for reasons of safety or effectiveness.
","- The 60 mg strength of Doryx MPC was approved under NDA 050795 on May 20, 2016.
- There is no evidence the 60 mg strength was ever marketed (e.g., absent from the Doryx MPC website).
- FDA precedent treats unmarketed drugs as withdrawn from sale under 21 C.F.R. ¬ß 314.161.
- No known safety or efficacy concerns associated with the 60 mg strength.
- The 120 mg strength continues to be marketed, supporting the safety profile of the formulation.",,Approved (Determination Issued),2018-03-09,0.0,Center for Drug Evaluation and Research (CDER),"- 21 CFR ¬ß 314.161
- 21 CFR ¬ß 314.162
- 21 CFR ¬ß 10.30 (referenced in the Federal Register summary as the basis for the petition)",,"- Doryx MPC 60 mg has never been marketed, and therefore was not withdrawn for safety or efficacy concerns.
- After reviewing Agency records and relevant labeling or regulatory files, FDA concluded there was no information indicating safety or effectiveness issues.
- The product remains in the Orange Book‚Äôs ‚ÄúDiscontinued Drug Product List‚Äù, which includes drugs no longer marketed for non-safety reasons.
- FDA may approve ANDAs referencing the product if they comply with all other applicable requirements",approved,True,164.0,CDER,CDER
fda-2017-p-5954,FDA-2017-P-5954-0001_Citizen_Petition_from_Elite_Laboratories_Inc.pdf,2017-09-27,2017,False,original petition,"Elite Laboratories, Inc.",advocacy/academic,"21 C.F.R. ¬ß 314.122; Categorical exclusion cited under 21 C.F.R. ¬ß 25.31; Reference to 21 C.F.R. ¬ß 10.30(b) for economic impact submission if requested
","The listing and availability of a Reference Listed Drug (RLD) in the FDA Orange Book. Specifically, the unavailability of Dantrium¬Æ (Dantrolene Sodium 100 mg, NDA RLD NO17443) marketed by Par Sterile Products LLC.
","Request that the FDA determine the approved and marketed product in ANDA 076856 (Dantrolene Sodium 100 mg by Impax Laboratories, Inc.) is suitable to be used as a Reference Listed Drug (RLD).
","- The currently listed RLD, Dantrium¬Æ, is unavailable in the market and has not been withdrawn for safety concerns.
- The Impax ANDA 076856 is the only currently approved and marketed 100 mg Dantrolene Sodium product.
- Use of Impax‚Äôs product as the RLD would ensure continuity in generic development without increasing total market volume of the active ingredient
",2018-03-26 00:00:00,Denied,2018-10-05,1.0,Center for Drug Evaluation and Research (CDER),"- 21 U.S.C. ¬ß 355(j) (FD&C Act Section 505(j))
- 21 CFR ¬ß 314.3(b)
- 21 CFR ¬ß 314.94(a)(3)
- Section 505(t) of the FD&C Act (authorized generics)
- Abbreviated New Drug Applications and 505(b)(2) Applications, 81 FR 69580 at 69619 (Oct. 6, 2016)","- FDA cited the need to address other agency priorities as the reason for the delay.
- It acknowledged receipt of the petition and stated it would respond once a decision is reached.
- The interim response was issued to comply with regulatory timelines","- The requested reference standard (Impax‚Äôs ANDA 076-856) was not selected because the current RLD (Dantrium 100 mg capsules, NDA 017-443) is still actively distributed and marketed as an authorized generic.
- FDA confirmed that the authorized generic is available for bioequivalence testing, so a new reference standard was unnecessary.
- FDA cited prior guidance and citizen petition responses affirming that ANDA applicants may use authorized generics as reference standards when properly documented",denied,True,373.0,CDER,CDER
fda-2017-p-5967,FDA-2017-P-5967-0001_Citizen_Petition_from_Apotex_Inc_.pdf,2017-09-27,2017,False,original petition,Apotex Inc.,industry/corporation,"- 21 C.F.R. ¬ß 10.25
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 314.161
- 21 C.F.R. ¬ß 314.162
- 21 C.F.R. ¬ß 25.31
- Sections 505(j) and 505(w) of the Federal Food, Drug, and Cosmetic Act","The listing of TRINTELLIX¬Æ (Vortioxetine) Tablets, 15 mg in the Orange Book as ‚ÄúDiscontinued,‚Äù and whether the drug was withdrawn for safety or effectiveness reasons.","Apotex requests that the FDA determine whether TRINTELLIX¬Æ (Vortioxetine) Tablets, 15 mg was withdrawn for reasons of safety or effectiveness, thereby allowing ANDAs referencing it to proceed.
","- The 15 mg TRINTELLIX¬Æ Tablets are listed as discontinued, but no evidence suggests it was withdrawn for safety or efficacy reasons.
- FDA policy allows ANDA approval if the RLD was not withdrawn for safety/efficacy.
- The determination would enable ANDA submissions and reviews for generic equivalents
",,Approved (Determination Issued),2017-11-21,0.0,Center for Drug Evaluation and Research (CDER),"Not Mentioned ‚Äî The letter does not reference specific statutes or federal regulations.
",,"- FDA conducted a review of its internal records.
- It determined that Trintellix (EQ 15 mg) was not withdrawn for safety or efficacy reasons.
- As a result, this strength remains listed in the Discontinued Drug Product List.
- Other strengths (5 mg, 10 mg, 20 mg) are still marketed and do not require such a determination.
- ANDAs referencing any of these strengths may still be approved, provided they meet all legal and regulatory requirements",approved,True,55.0,CDER,CDER
fda-2017-p-6020,FDA-2017-P-6020-0001_Citizen_Petition_from_Axinn__Veltrop___Harkrider_L.pdf,2017-10-03,2017,False,original petition,"Axinn, Veltrop & Harkrider LLP",law/consulting,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 314.93 (Suitability petitions)
- 21 C.F.R. ¬ß¬ß 10.20 and 10.30 (Citizen petition procedures)
- 21 C.F.R. ¬ß 25.31 (Environmental categorical exclusion)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact provision)","FDA‚Äôs policies on the submission of ANDAs for drug products that differ in strength from the approved Reference Listed Drug (RLD); specifically relating to Eliquis¬Æ (apixaban)
","That FDA determine and declare that Apixaban Tablets, 10 mg, are suitable for submission in an ANDA. The current RLD (Eliquis¬Æ) is approved in 2.5 mg and 5 mg strengths
","- The 10 mg strength is already listed in RLD labeling for initial treatment of DVT and PE.
- Allows patients to take a single 10 mg tablet rather than two 5 mg tablets.
- No changes to active ingredient, route, dosage form, or indications.
- Intended to improve patient compliance and dosing simplicity.
- Bioequivalence will be demonstrated by comparing one 10 mg tablet to two 5 mg RLD tablets as per FDA‚Äôs Draft Bioequivalence Guidance.
- Environmental and economic impact disclosures follow standard regulatory format (cited exclusions and delayed submission)",,Denied,2023-11-28,0.0,Center for Drug Evaluation and Research (CDER),"- Section 505(j)(2)(C) of the FD&C Act
- 21 CFR ¬ß 314.93
- 21 CFR ¬ß 314.93(e)(1)(iv) (grounds for denial due to safety or effectiveness concerns requiring labeling changes)
- 21 CFR ¬ß 10.33 (reconsideration procedure)
- 21 CFR ¬ß 10.20 (submission requirements)",,"- FDA determined the proposed 10 mg strength could increase risk of medication errors (e.g., confusion between 10 mg vs. 5 mg dosing).
- The risk of overdosing could raise the risk of bleeding.
- Proposed packaging (e.g., blister packs of 10) could cause confusion, especially during the first 7 days of DVT/PE treatment.
- FDA concluded that the proposed change would necessitate significant labeling changes, and possibly require new safety studies.
- Thus, the petition was denied under ¬ß 314.93(e)(1)(iv) because the product would jeopardize safe/effective use",denied,True,2247.0,CDER,CDER
fda-2017-p-6027,FDA-2017-P-6027-0001_Citizen_Petition_from_Axinn__Veltrop___Harkrider_L.pdf,2017-10-03,2017,False,original petition,"Axinn, Veltrop & Harkrider LLP",law/consulting,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 314.93 (Suitability petitions)
- 21 C.F.R. ¬ß¬ß 10.20 and 10.30 (Citizen petition procedures)
- 21 C.F.R. ¬ß 25.31 (Environmental impact exclusion)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact provision)","FDA policy and listing practices relating to submission and acceptance of ANDAs for different drug strengths, specifically relating to Amantadine Hydrochloride Capsules","Request FDA to declare that Amantadine Hydrochloride Capsules, 200 mg, is suitable for submission via an ANDA, referencing the approved 100 mg capsule as the Reference Standard
","- The 200 mg dose is already listed as an approved daily dosage in the RS labeling (i.e., two 100 mg capsules)
- The new 200 mg strength allows for simplified dosing (fewer capsules)
- Labeling and therapeutic uses remain unchanged except for the added strength
- Bioequivalence will be demonstrated using FDA‚Äôs guidance comparing one 200 mg capsule to two 100 mg RS capsules
- Petitioner asserts that this improves patient convenience and compliance",,Approved,2023-08-15,0.0,Center for Drug Evaluation and Research (CDER),"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 CFR ¬ß 314.93 (Petitions for different strength)
- 21 CFR ¬ß 314.93(e)(1)
- Section 505(j)(2)(A) and (B) (ANDA submission requirements)
- Section 505(j)(2)(A)(iv) (bioequivalence)
- 21 CFR ¬ß 314.94(a)(3)(iii)",,"- The proposed 200 mg strength does not pose questions of safety or effectiveness.
- Uses, dose, dosage form, and route of administration are consistent with the listed drug.
- Labeling changes are not significant, and no additional investigations are necessary.
- If bioequivalence is demonstrated, the product is expected to be therapeutically equivalent",approved,True,2142.0,CDER,CDER
fda-2017-p-6028,FDA-2017-P-6028-0001_Citizen_Petition_from_Axinn__Veltrop___Harkrider_L.pdf,2017-10-03,2017,False,original petition,"Axinn, Veltrop & Harkrider LLP",law/consulting,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 314.93 (Suitability Petitions)
- 21 C.F.R. ¬ß¬ß 10.20 and 10.30 (general petition procedures)
- 21 C.F.R. ¬ß 25.31 (environmental impact categorical exclusion)
- 21 C.F.R. ¬ß 10.30(b) (economic impact submission provision)","The FDA‚Äôs current listing and approval policies regarding strength variations in ANDA submissions, specifically for Amantadine Hydrochloride Tablets","Request for FDA to determine that Amantadine Hydrochloride Tablets, 200 mg, are suitable for submission via an ANDA, based on the currently listed 100 mg Reference Standard
","- The 200 mg strength is already referenced in approved labeling of the Reference Standard (RS)
- Existing labeling supports daily 200 mg dosing and pharmacokinetics data
- Offering a 200 mg tablet would improve patient convenience (fewer tablets per dose)
- No changes to indications, warnings, or directions‚Äîonly strength is changed
- Bioequivalence to RS will be shown using FDA‚Äôs Draft Bioequivalence Guidance for Amantadine HCl",,Approved,2024-10-21,0.0,Center for Drug Evaluation and Research (CDER),"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 CFR ¬ß 314.93
- 21 CFR ¬ß 314.93(e)(1)
- Section 505(j)(2)(A) and (B)
- Section 505(j)(2)(A)(iv)
- 21 CFR ¬ß 314.94(a)(3)(iii)",,"- The proposed change (from 100 mg to 200 mg) does not raise concerns of safety or effectiveness.
- The dosage form, route, and usage remain consistent with the listed drug.
- No significant labeling changes or new investigations are necessary.
- If proven bioequivalent, the drug would be therapeutically equivalent to the reference listed drug",approved,True,2575.0,CDER,CDER
fda-2017-p-6029,FDA-2017-P-6029-0001_Citizen_Petition_from_Novo_Nordisk_Inc.pdf,2017-10-02,2017,False,original petition,Novo Nordisk Inc.,industry/corporation,"- Section 505(j)(2)(A)(v) of the Federal Food, Drug, and Cosmetic Act (FFDCA)
- 21 C.F.R. ¬ß 10.30 (citizen petition)
- 21 C.F.R. ¬ß 314.94(a)(9) (inactive ingredient information)
- 21 C.F.R. ¬ß 25.31 (environmental impact)","The acceptance and approval of abbreviated new drug applications (ANDAs) referencing Victoza¬Æ (liraglutide) injection, particularly for formulations not quantitatively and qualitatively (Q1/Q2) the same in inactive ingredients","FDA should refuse to accept or approve any ANDA referencing Victoza¬Æ unless the generic product is:
- Formulated with the same concentration of liraglutide
- Q1/Q2 identical in inactive ingredients as the RLD (Victoza¬Æ)","- Liraglutide is a sensitive polypeptide; formulation and excipient differences can significantly affect its efficacy, stability, and immunogenicity.
- The Q1/Q2 sameness requirement is critical for ensuring safety and therapeutic equivalence.
- Precedents exist where FDA required Q1/Q2 sameness for peptide/protein drug products.
- Allowing deviations risks undermining confidence in biosimilar safety and effectiveness, especially given complex interactions in Victoza‚Äôs formulation",,Denied,2018-01-05,0.0,Center for Drug Evaluation and Research (CDER),"- Section 505(b)(1), 505(b)(2), and 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- 21 CFR ¬ß 314.93
- 21 CFR ¬ß 314.94(a) and ¬ß 314.94(a)(3)(iii)
- 21 CFR ¬ß 314.127
- 21 CFR ¬ß 10.115
- Draft guidance (82 FR 46075, Oct. 3, 2017)",,"- FDA is still considering guidance on whether generic synthetic peptides referencing recombinant drugs (like liraglutide) should be submitted as ANDAs or under 505(b)(2).
- FDA referred Novo Nordisk to participate in the public docket process on this issue.
- FDA declined to adopt the requested standards in this petition, stating that doing so at this stage would be premature
",denied,True,95.0,CDER,CDER
fda-2017-p-6101,FDA-2017-P-6101-0001_Citizen_Petition_from_Strides_Pharma_Inc_.pdf,2017-10-10,2017,False,original petition,Strides Pharma Inc.,industry/corporation,"- 21 C.F.R. ¬ß 10.25(a)
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 25.31 (environmental impact)
- 21 C.F.R. ¬ß 10.30(b) (economic impact)","The unavailability of the current Reference Standard (RS) for Ranitidine Capsules USP (held by Sandoz Inc., A074655), and the need to assign a new RS","FDA should designate the approved generic product Ranitidine Capsules USP 150 mg and 300 mg, held by Dr. Reddy‚Äôs Laboratories (A075742), as the new Reference Standard (RS)
","- The existing RS (A074655 by Sandoz) is not available in the U.S. market.
- The original RLD (Zantac 150/300 by GlaxoSmithKline, N020095) is discontinued (but not for safety/efficacy reasons).
- Dr. Reddy‚Äôs product (A075742) is the only approved and available generic on the market.
- Designating it as RS will enable Strides and others to file ANDAs",2018-04-04 00:00:00,Dismissed (moot),2018-08-30,1.0,Center for Drug Evaluation and Research (CDER),"Not Mentioned ‚Äî The letter does not cite any specific U.S. Code sections or CFR regulations
","- The petition requested FDA to designate ranitidine hydrochloride capsules (EQ 150 mg and 300 mg), approved under ANDA 075742 (Dr. Reddy's Labs), as a reference standard in the Orange Book.
- FDA indicated it has not reached a decision due to the need to prioritize other issues
","- Both petitions requested that FDA designate ranitidine hydrochloride capsules (EQ 300 mg) under ANDA 075742 (Dr. Reddy‚Äôs) as the reference standard due to availability issues with the current reference (ANDA 074655, Sandoz).
- FDA investigated the market and found that distribution of the current reference standard had increased after petition submission.
- Therefore, the request was deemed unnecessary, and the petitions were dismissed",dismissed (moot),True,324.0,CDER,CDER
fda-2017-p-6108,FDA-2017-P-6108-0001_Citizen_Petition_from_Goodwin_Procter_LLP.pdf,2017-10-10,2017,False,original petition,Goodwin Procter LLP,law/consulting,"- Federal Food, Drug, and Cosmetic Act (FDC Act) ¬ß 505(j)
- 21 C.F.R. ¬ß¬ß 10.25(a), 10.30 (citizen petition procedures)
- 21 C.F.R. ¬ß 25.31 (environmental impact exemption)
- 21 C.F.R. ¬ß 10.30(b) (economic impact disclosure)","The lack of a commercially available reference standard (RS) for bioequivalence testing of mupirocin calcium cream, 2%, currently listed under NDA #050746 (Bactroban¬Æ), which is on long-term backorder due to GMP issues and manufacturing cessation","FDA should designate ANDA 201587 as a new Reference Standard (RS) for mupirocin calcium cream, EQ 2% Base, in the FDA Orange Book, to allow ANDA submissions and generic competition","- Bactroban¬Æ (NDA 050746) is no longer marketed due to GMP violations and a recall.
- The current RS is unavailable for bioequivalence testing.
- ANDA 201587 is the only commercially available formulation, holding 99.9% of the market.
- Lack of RS blocks entry of generic competitors and leads to price inflation ($149.24 vs. $41.40 per 15g tube in 2015).
- FDA guidance permits selection of a new RS when quantities of the current RS are insufficient",,Approved,2018-04-13,0.0,Center for Drug Evaluation and Research (CDER),"- 21 U.S.C. ¬ß 355(j) (Section 505(j) of the FD&C Act)
- 21 CFR ¬ß 314.3(b)
- 21 CFR ¬ß 314.94(a)(3)
- 21 CFR ¬ß 314.161(a)
- 21 CFR ¬ß 314.122(a)
- Draft Guidance for Industry, ‚ÄúReferencing Approved Drug Products in ANDA Submissions‚Äù (Jan 2017) at 9",,"- The currently listed reference standard (Bactroban Calcium Cream, NDA 050746) was found to be discontinued.
- FDA moved NDA 050746 to the Discontinued Drug Product List in the Orange Book.
- Based on commercial data, FDA selected Glenmark‚Äôs ANDA 201587 as the new reference standard due to its market leadership status.
- FDA affirmed this decision aligns with consistency and bioequivalence practices outlined in the cited draft guidance
",approved,True,185.0,CDER,CDER
fda-2017-p-6116,FDA-2017-P-6116-0001_Citizen_Petition_from_King___Spalding_LLP.pdf,2017-10-05,2017,False,original petition,King & Spalding LLP,law/consulting,"- Section 505(j)(2)(C) of the FD&C Act
- 21 C.F.R. ¬ß¬ß 10.20, 10.30 (citizen petition procedures)
- 21 C.F.R. ¬ß 314.94(a)(9)(iii) (inactive ingredient changes)
- 21 C.F.R. ¬ß 25.31(a) (environmental impact exemption)","The FDA‚Äôs criteria for accepting a Suitability Petition for submission of an ANDA for a drug product with changes from the Reference Listed Drug (RLD)‚Äîspecifically, a change in total drug content (strength) but not concentration, formulation, or indication","FDA should determine that the proposed Neostigmine Methylsulfate Injection, USP in strengths of 2 mg/2 mL, 3 mg/3 mL, 4 mg/4 mL, and 5 mg/5 mL is suitable for submission as an ANDA, based on RLD Bloxiverz (10 mg/10 mL)
","- The change is only in total drug content (not concentration), route of administration, or dosage form.
- The RLD labeling supports weight-based dosing, and the proposed lower strengths improve dosing flexibility.
- Proposed packaging includes preservative-free, single-dose plastic vials and syringes, which enhances patient safety and matches regulatory definitions for small-volume injection.
- The changes do not raise new questions of safety or effectiveness compared to the RLD",,Partially Approved / Partially Denied,2024-10-23,0.0,Center for Drug Evaluation and Research (CDER),"- Section 505(j)(2)(C) of the FD&C Act
- 21 CFR ¬ß 314.93 (Petitions for strength differences)
- 21 CFR ¬ß 314.93(e)(1)(vi) (basis for denial due to an existing NDA for the change)
- 21 CFR ¬ß 314.94(a)(3)(iii) (petition linkage in ANDA)
- 21 CFR ¬ß 10.33 and ¬ß 10.20 (reconsideration process)",,"- Approved strengths (2 mg/2 mL and 4 mg/4 mL): FDA found no issues of safety or effectiveness, and use, dosage form, and route align with the listed drug. Labeling changes are not significant, and no new investigations are required.
- Denied strengths (3 mg/3 mL and 5 mg/5 mL): These are already approved in NDAs (NDA 203629 and NDA 204078), and thus cannot be submitted via ANDA based on a petition. FDA cited 21 CFR ¬ß 314.93(e)(1)(vi) as grounds for denial",partially approved / denied,True,2575.0,CDER,CDER
fda-2017-p-6136,FDA-2017-P-6136-0001_Citizen_Petition_from_Foley___Lardner_LLP.pdf,2017-10-12,2017,False,original petition,Foley & Lardner LLP,law/consulting,"- 21 C.F.R. ¬ß 10.30 (Citizen petition procedure)
- 21 C.F.R. ¬ß 10.25(a)
- 21 C.F.R. ¬ß 25.1(g) (Environmental impact)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact)","The change in designation of Rubramin PC (NDA N006799) as the sole Reference Listed Drug (RLD) for Cyanocobalamin Injection, 1 mg/mL, despite it being discontinued and having a different formulation (1% Benzyl Alcohol) than currently marketed ANDAs (which contain 1.5% Benzyl Alcohol)
","FDA should designate ANDA A080737 (Cyanocobalamin Injection, 1 mg/mL, by Luitpold Pharmaceutical Inc.) as an additional Reference Listed Drug (RLD) in the FDA‚Äôs Orange Book, so that it may be cited in future ANDA filings
","- Previously, Luitpold‚Äôs product was the RLD until FDA‚Äôs January 2017 guidance switched the designation to Rubramin PC.
- Rubramin PC has a different preservative concentration (1% vs. 1.5% Benzyl Alcohol), which complicates Q1/Q2 sameness and refuse-to-receive (RTR) compliance.
- Other approved ANDAs use 1.5% Benzyl Alcohol, like Luitpold‚Äôs product.
- Allowing this designation avoids undue burden and market disadvantage to future ANDA applicants",2018-04-09 00:00:00,Dismissed (moot),2019-08-02,1.0,Center for Drug Evaluation and Research (CDER),Not Mentioned ‚Äî The letter does not explicitly reference any specific statutes or regulations,"- The petition requested designation of Luitpold Pharmaceutical Inc.'s cyanocobalamin injection, 1 mg/mL (ANDA 080737) as a reference listed drug for ANDA filings.
- FDA explained the delay was due to the complex nature of the issues involved and the need for extensive review and analysis","- The petition requested designation of Luitpold‚Äôs ANDA 80737 (cyanocobalamin injection, 1 mg/mL) as a reference listed drug and reference standard in the Orange Book.
- FDA explained that the Orange Book had already been updated to reflect this status, rendering the petition moot
",dismissed (moot),True,659.0,CDER,CDER
fda-2017-p-6211,FDA-2017-P-6211-0001_Citizen_Petition_from_DSM_Nutritional_Products_LLC.pdf,,2017,False,original petition,DSM Nutritional Products LLC,industry/corporation,"- 5 U.S.C. ¬ß 553(e) (Administrative Procedure Act)
- 21 C.F.R. ¬ß¬ß 10.25 and 10.30
- Sections 201(n), 403A, and 701(a) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 101.9(c)(8)(v) (subject of amendment request)
- Also referenced within text: 21 C.F.R. ¬ß¬ß 104.20, 101.36, 172, 182, 184, 107.10, 130‚Äì169","Existing FDA regulations that require complex chemical nomenclature on Nutrition and Supplement Facts labels and Ingredient Declarations.
","DSM requests that the FDA amend 21 C.F.R. 101.9(c)(8)(v) to allow for the use of simple vitamin letter names (e.g., Vitamin C, B1, B2) on Nutrition/Supplement Facts labels and Ingredient Declaration lines
","- Consumers are confused by chemical names (e.g., ‚Äúascorbic acid‚Äù vs. ‚ÄúVitamin C‚Äù)
- Surveys show consumers rate chemical names as less healthy or are unaware of their meaning
- Simple names improve clarity and recognition of nutrient-fortified products
- Simplified labels reduce space and increase appeal and trust in products
- Harmonizes label language between Nutrition Facts and Ingredient Declaration
- Promotes consumption of nutrient-dense foods and public health",,,2025-10-15,,,,,,no decision,False,,pending,pending
fda-2017-p-6214,FDA-2017-P-6214-0001_Citizen_Petition_from_Yabao_Pharmaceutical_Co__Ltd.pdf,2017-10-18,2017,False,original petition,Yabao Pharmaceutical Co. Ltd BJ,industry/corporation,"- Section 505(j) of the FD&C Act
- 21 C.F.R. ¬ß¬ß 10.25(a), 10.30 (Citizen Petition process)
- 21 C.F.R. ¬ß 25.31 (Environmental Impact ‚Äì categorical exclusion)","The current listing in the FDA Orange Book of ADALAT CC¬Æ (NDA No. 020198, ALVOGEN GROUP HOLDINGS LLC) as the sole Reference Listed Drug (RLD) and Reference Standard (RS) for nifedipine extended-release tablets, 60 mg, which is no longer available on the market
","- Amend the Orange Book to designate ANDA #201071 (nifedipine extended-release 60 mg, Mylan Pharmaceuticals Inc.) as the new or additional Reference Standard (RS) for the 60 mg strength of nifedipine extended-release tablets
","- The current RS (Adalat CC¬Æ) is no longer available for purchase, making it impossible for ANDA applicants to conduct in vivo bioequivalence testing.
- FDA guidance allows an additional RS to be designated when the original is unavailable.
- The Mylan product is therapeutically equivalent and market-available, ensuring continuity of supply .",2018-04-16 00:00:00,Denied,2018-10-04,1.0,Center for Drug Evaluation and Research (CDER),"- 21 U.S.C. ¬ß 355(j) (Section 505(j) of the FD&C Act)
- 21 CFR ¬ß 314.3(b)
- 21 CFR ¬ß 314.94(a)(3)
- Section 505(c) and 505(t) of the FD&C Act","The FDA has not reached a decision due to the need to address other Agency priorities. The letter acknowledges resource constraints and numerous demands.

","- FDA determined that the drug referenced in the petition (Adalat CC, NDA 020198) is still available and not discontinued.
- It is also being marketed as an authorized generic.
- FDA concluded there was no need to designate a new reference standard because existing options remain valid and available.
- The agency emphasized that ANDA applicants may use authorized generics of the reference listed drug (RLD) if properly documented.",denied,True,351.0,CDER,CDER
fda-2017-p-6248,FDA-2017-P-6248-0001_Citizen_Petiton_from_Lachman_Consultant_Services__.pdf,2017-10-23,2017,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"- Section 505(j)(2)(C) of the FD&C Act
- 21 C.F.R. ¬ß 10.30 ‚Äì Citizen petition process
- 21 C.F.R. ¬ß 25.31 ‚Äì Environmental impact categorical exclusion
- Pediatric Research Equity Act (PREA) ‚Äì Cited for pediatric study waiver discussion","The petition comments on the FDA‚Äôs requirement for suitability petitions before an ANDA can be submitted for a product differing from the RLD in dosage form. Specifically, the RLD is Topamax (Topiramate) Tablets, and the proposed generic is an orally disintegrating tablet (ODT)","FDA should declare that Topiramate Orally Disintegrating Tablets (ODT) in 25 mg, 50 mg, 100 mg, and 200 mg strengths are suitable for submission as an ANDA, based on a change only in dosage form from the RLD, which is a conventional tablet
","- The proposed ODT product contains the same active ingredient and strength as the RLD.
- The change is only in dosage form, which FDA allows under 505(j)(2)(C) petitions.
- Proposed ODT would improve ease of administration, especially for pediatric and dysphagic patients.
- No questions of safety or effectiveness are raised.
- A pediatric waiver is requested as the product will not be used outside labeled ages, and pediatric requirements appear fulfilled based on past submissions",,Approved,2024-04-03,0.0,Center for Drug Evaluation and Research (CDER),"- Section 505(j)(2)(C) of the FD&C Act
- 21 CFR 314.93
- 21 CFR 314.94(a)(3)(iii)
- Section 505B of the Act (PREA)
- Section 505(j)(2)(A) and (B)",,"- The proposed change in dosage form does not raise safety or efficacy concerns.
- The use, dose, and route of administration are consistent with the listed drug.
- If bioequivalence is demonstrated, the generic is expected to have the same therapeutic effect.
- Pediatric study requirements under PREA were waived due to impracticability.
- Therefore, the petition met the criteria for approval.",approved,True,2354.0,CDER,CDER
fda-2017-p-6274,FDA-2017-P-6274-0001_Citizen_Petition_from_Amneal_Pharmaceuticals.pdf,2017-10-24,2017,False,original petition,Amneal Pharmaceuticals LLC,industry/corporation,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- Section 505(q) of the FD&C Act
- 21 C.F.R. ¬ß 10.20
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 314.94 (a)(8)(iv)
- 21 C.F.R. ¬ß 25.31(a) (environmental impact)
- 21 C.F.R. ¬ß 10.30(b) (economic impact)
- FDCA ¬ß 501(b), ¬ß 502(g), ¬ß 502(e)(3)(b)
- 21 CFR ¬ß 299.5","Approval of ANDAs (Abbreviated New Drug Applications) for Teriparatide injection products that use synthetic teriparatide as active ingredient instead of recombinant teriparatide (Forteo¬Æ, NDA 21-318)
","- FDA should refrain from approving any ANDAs for Teriparatide injection products that contain synthetically derived Teriparatide.
- FDA should only approve ANDAs that contain recombinant human parathyroid hormone (1-34) as active ingredient.","- Labeling Disparity: Synthetic versions would not match the labeling of the RLD Forteo¬Æ which specifies rDNA origin.
- Impurity Profile: Synthetic methods (solid phase synthesis) yield different impurities than recombinant methods, with potentially more harmful ones like oxidized or racemized amino acids.
- Immunogenicity Risks: Synthetic peptides might trigger unpredictable immune responses, necessitating human immunogenicity studies.
- Failure to Conform to USP Monograph: The USP monograph defines teriparatide as a recombinant DNA product.
- Inadequate FDA Draft Guidance: Criticizes the October 2017 FDA draft guidance for not sufficiently addressing risks from peptide-related impurities in synthetic analogs.
- Lack of Precedent: FDA has not previously approved a synthetic peptide as therapeutically equivalent to a recombinant product.
- Legal and Regulatory Framework: Emphasizes statutes that require equivalence in labeling, composition, and safety to the RLD.",,Denied,2018-01-05,0.0,Center for Drug Evaluation and Research (CDER),"- Section 505(j), 505(b)(1), 505(b)(2), and 505(d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. ¬ß 355)
- 21 CFR 314.3(b), 314.54, 314.94(a), 314.127
- Public Law 98-417 (Hatch-Waxman Amendments)",,"- The FDA found that synthetic teriparatide may be suitable for ANDA submission under certain conditions and is considering the matter through draft guidance (notably FDA-2017-D-5767).
- The issues raised in the petition‚Äîsuch as differences in impurity profiles, immunogenicity, labeling, and USP standards‚Äîdo not preclude submission via the ANDA pathway.
- FDA declined to make a blanket policy decision in this petition and instead encouraged public comment on the draft guidance that specifically addresses synthetic peptide ANDAs.",denied,True,73.0,CDER,CDER
fda-2017-p-6291,FDA-2017-P-6291-0001_CITIZEN_PETITION_FROM__LACHMAN_CONSULTANT_SERVICES.pdf,2017-10-26,2017,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"- Federal Food, Drug, and Cosmetic Act (FDCA)
- 21 C.F.R. ¬ß 10.30 ‚Äì Citizen Petition process
- 21 C.F.R. ¬ß 314.94(a)(3) ‚Äì Definition of Reference Listed Drug
- 21 C.F.R. ¬ß 25.31 ‚Äì Categorical exclusion for Environmental Impact Assessment
- 21 C.F.R. ¬ß 10.30(b) ‚Äì Economic impact analysis provision","The designation of Cardene I.V. (Nicardipine Hydrochloride, NDA 019734) by Chiesi USA Inc. as the sole Reference Listed Drug (RLD) for Nicardipine Hydrochloride 25 mg/10 mL Injection, despite it being unavailable on the market
","FDA should designate Nicardipine Hydrochloride 25 mg/10 mL marketed by Excela Pharma Science (NDA 022276) as an additional Reference Listed Drug (RLD) so that generic applicants have access to a product that is commercially available for comparative studies
","- The current RLD (Chiesi‚Äôs Cardene I.V.) is not available for purchase, preventing ANDA applicants from conducting required comparative studies.
- Excela‚Äôs product is pharmaceutically equivalent and listed as therapeutically equivalent in the Orange Book.
- Designating Excela‚Äôs product as an additional RLD would provide market access for generic development while maintaining regulatory standards
",2018-04-20 00:00:00,Dismissed (moot),2020-09-17,1.0,Center for Drug Evaluation and Research (CDER),"Not Mentioned explicitly in this letter. (The Orange Book is referenced, but no specific statutes or CFR citations are provided.)
",The FDA cites the need to address other agency priorities and the numerous demands on its resources as the reason for not yet having reached a decision on the petition ,"The petitioners requested that nicardipine hydrochloride injection (25 mg/10 mL, NDA 022276) be designated as an RLD and Reference Standard. Since FDA had already made this designation in the Orange Book, the petitions were considered moot and therefore dismissed.

",dismissed (moot),True,1057.0,CDER,CDER
fda-2017-p-6307,FDA-2017-P-6307-0001_Citizen_Petition_from_Aurolife_Pharma_LLC.pdf,2017-10-26,2017,False,original petition,Aurolife Pharma LLC,industry/corporation,"- 21 C.F.R. ¬ß 10.25(a)
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 25.31 (categorical environmental exclusion)
- 21 C.F.R. ¬ß 10.30(b) (economic impact provision)
","FDA‚Äôs drug product referencing and reference standard policy‚Äîspecifically the January 2017 draft guidance titled: ""Referencing Approved Drug Products in ANDA Submissions"", which affects reference standards selection for ANDAs
","FDA is requested to designate Morphine Sulfate Extended Release Tablets, 100 mg, from Rhodes Pharmaceuticals LP (ANDA# A074769) as the reference standard (RS) for a generic product, instead of the discontinued MS CONTIN (NDA# 019516) by Purdue Pharma LP
","- The original reference listed drug (MS CONTIN) has been discontinued.
- The Rhodes Pharmaceuticals product is the authorized generic of MS CONTIN.
- Both products are manufactured by Purdue Pharma LP using the same inactive ingredients.
- Therefore, the Rhodes product is scientifically and legally suitable to be used as the reference standard for bioequivalence studies",2018-04-10 00:00:00,Denied,2019-03-14,1.0,Center for Drug Evaluation and Research (CDER),"- Section 505(j) of the FD&C Act (21 U.S.C. 355(j))
- 21 CFR 314.3(b)
- 21 CFR 314.94(a)(3)
- 81 FR 69580, 69619 (Oct. 6, 2016)
- 21 U.S.C. 355(j)(6)","The FDA has not yet resolved the petition due to the need to address other Agency priorities. The Agency cites ""numerous demands on the Agency‚Äôs resources"" as a limiting factor ","- The currently designated reference standard, MS Contin (morphine sulfate ER tablets, 100 mg, NDA 019516, Purdue Pharma), is still being manufactured and distributed.
- FDA found no sufficient grounds to designate Rhodes Pharmaceuticals' ANDA 074769 product as a new reference standard.
- FDA policy supports maintaining a single reference standard to ensure consistency unless the existing RLD has been discontinued or is unavailable.
- Petition's arguments (e.g., equivalence of generic and RLD, distribution links) were not enough to override the current designation. ",denied,True,504.0,CDER,CDER
fda-2017-p-6316,FDA-2017-P-6316-0001_Citizen_Petition_from_Kleinfeld_Kaplan___Becker__L.pdf,2017-10-30,2017,False,original petition,"Kleinfeld, Kaplan & Becker LLP",law/consulting,"- 21 C.F.R. ¬ß¬ß 10.30, 210, 211, 314 ‚Äì Citizen petition process and manufacturing standards
- Sections 505(b) and 505(j) of the FDCA (21 U.S.C. ¬ß¬ß 355(b), 355(j)) ‚Äì Drug approval pathways
- 21 C.F.R. ¬ß 25.31 ‚Äì Categorical exclusion from environmental assessment
- 21 C.F.R. ¬ß 201.80(d) ‚Äì Labeling requirements
- References to USP standards and FDA's MAPP 5310.4 ""Acceptability of Standards from Alternative Compendia""","Potential FDA approval of any injectable methylene blue drug products under Section 505 without adequate proof of equivalent safety, purity, and labeling standards compared to ProvayBlue¬Æ, Provepharm‚Äôs approved product. The petition particularly criticizes products like Akorn‚Äôs unapproved formulation for not meeting USP standards or FDA-approved labeling requirements
","FDA should refrain from approving any injectable methylene blue drug products unless the application demonstrates that the product is:
- Of the same quality and purity as ProvayBlue¬Æ
- Manufactured in accordance with USP monographs for methylene blue (API and injection)
- Labeled with appropriate warnings, contraindications, and adverse reaction information equivalent to ProvayBlue¬Æ
- Meets rigorous impurity limits and safety standards supported by adequate data","- ProvayBlue¬Æ was FDA-approved in 2016 for treating acquired methemoglobinemia with a well-characterized safety profile and strict FDA-reviewed API and finished product specifications.
- Other products like Akorn‚Äôs have failed to meet USP monograph specs (e.g., tested at only 84.1% vs. required 95‚Äì105% potency) and lack appropriate labeling for serious risks (e.g., serotonin syndrome, hemolysis).
- Provepharm argues FDA must apply consistent and stringent safety and labeling standards to ensure public safety.
- FDA precedent and regulatory policy require drugs matching a USP monograph to be held to those standards",2018-04-26 00:00:00,Partially Approved / Partially Denied,2023-12-05,1.0,Center for Drug Evaluation and Research (CDER),"- FD&C Act: Sections 505(b)(1), 505(b)(2), 505(j), 501(b), 502(e)(3)(B), 505(j)(2)(A)(v), 505(c), 505(j)(4), 505(b)(2)(A)(iii)-(iv), 505(b)(2)(B), 505(j)(2)(A)(vii)-(viii), 505(j)(5)(B), 505(j)(5)(F), 505(b)(1)(A)
- 21 CFR: Parts 10.30(e)(2), 201.56, 201.57, 299.5, 314.3(b), 314.50, 314.54, 314.93, 314.94(a), 314.127(a), 314.510
- 81 FR 69580","The petition raises complex issues requiring extensive review and analysis by FDA officials. FDA has not resolved the issues raised and will respond once a decision is reached 
","- Labeling: FDA agrees ANDAs relying on ProvayBlue must match its labeling regarding contraindications, warnings, and adverse reactions unless a statutory or regulatory exception applies.
- Drug Quality: FDA denied the request to universally require methylene blue products to meet ProvayBlue‚Äôs impurity/purity profile. FDA evaluates each application case-by-case.
- USP Compliance: Not all injectable methylene blue products must strictly conform to USP monographs if properly labeled. Differences may be permissible with scientific justification.
- Impurity Control: FDA does not mandate a strict impurity profile match to ProvayBlue; impurity levels like Azure B are reviewed scientifically during the approval process.",partially approved / denied,True,2227.0,CDER,CDER
fda-2017-p-6357,FDA-2017-P-6357-0001_Citizen_Petition_from_Diana_Wierzchos_Redacted.pdf,2016-09-15,2017,False,original petition,Diana Wierzchos,individual,"- The petition is submitted under the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act (no specific sections cited)
","The petitioner calls for the FDA to reform the U.S. food supply system, specifically regarding factory farming practices. The action is not in response to a specific FDA policy but a general petition to influence national food regulation standards, animal treatment policies, and public health considerations
","- Replace or drastically reduce the use of concentrated animal feeding operations (CAFOs)
- Promote alternative, humane food production methods that are more sustainable and health-conscious
- Encourage legal reform to improve environmental, human, and animal health outcomes
- Address problems associated with subsidized factory farming","- Health risks: Links between red meat consumption and chronic diseases (e.g., cancer, diabetes, cardiovascular conditions)

- Food safety: Issues with contamination and poor hygiene in meat processing (e.g., fecal bacteria, TMAO production, drug-resistant infections)
- Environmental impact: CAFOs generate significant greenhouse gas emissions, deforestation, and water/soil pollution

- Animal welfare: Inhumane treatment, high animal mortality, and lack of rights protections
- Economic & social concerns: Industrial farming undermines small farms and consumer rights; supports unsustainable systems with public subsidies
- The petitioner urges the FDA to address these interconnected issues systemically.",,,2025-10-15,0.0,,,,,no decision,False,3317.0,pending,pending
fda-2017-p-6411,FDA-2017-P-6411-0001_Citizen_Petition_from__Insys_Therapeutics__Inc_.pdf,2017-10-27,2017,False,original petition,"Insys Therapeutics, Inc.",industry/corporation,"- Sections 505(j) and 505(q) of the FD&C Act
- 21 C.F.R. ¬ß¬ß 10.30-31 (Citizen petition procedures)
- 21 C.F.R. ¬ß 320.22 (Waiver of in vivo bioequivalence)
- 21 C.F.R. ¬ß 320.21(b) and (e) (Bioequivalence requirements)
- 21 C.F.R. ¬ß 314.3 (Definition of bioequivalence)
- 21 C.F.R. ¬ß¬ß 25.30-31 (Environmental impact exemption)","FDA‚Äôs acceptance or approval of ANDAs referencing SYNDROS that rely on a bioequivalence waiver (under 21 C.F.R. ¬ß 320.22), rather than submitting in vivo bioequivalence studies","- FDA should not accept or approve any ANDA referencing SYNDROS that lacks in vivo bioequivalence data.
- Reject waivers based on 21 C.F.R. ¬ß 320.22 for oral solutions of dronabinol.
- Require bioequivalence studies in both fed and fasted conditions.
- Require metabolite bioequivalence data in addition to parent drug bioequivalence.","- SYNDROS is a complex drug product with a highly variable absorption profile and low bioavailability (10‚Äì20%).
- Changes in excipients (e.g., ethanol, PEG 400, propylene glycol) can significantly affect absorption, metabolism, and systemic exposure.
- FDA draft guidance on dronabinol capsules already requires fed/fasted bioequivalence studies.
- Food significantly alters absorption of SYNDROS (e.g., 2.6-fold increase in exposure under fed vs. fasted state).
- Metabolite 11-OH-Œî9-THC plays a critical role in pharmacologic effects and must be assessed for equivalence.
- Allowing generics based on waivers could compromise patient safety and efficacy, particularly in AIDS and cancer patients reliant on effective antiemetics.",,Denied,2018-04-06,0.0,Center for Drug Evaluation and Research (CDER),"- FD&C Act (21 U.S.C. ¬ß 355(b)(2), ¬ß 505(j), ¬ß 505(j)(8)(B), ¬ß 505(j)(2)(A), ¬ß 505(j)(5)(B)(iv)(II)(cc), ¬ß 505(j)(7)(A)(i)(III))
- 21 CFR ¬ß¬ß 314.3, 314.94(a), 314.101, 320.21(f), 320.22 (a)-(f), 320.24, 320.25",,"- Statutory Discretion: FDA emphasized its legal authority and discretion to determine appropriate bioequivalence testing methods on a case-by-case basis (in vivo, in vitro, or both).
- Oral Solution Waiver: As per 21 CFR ¬ß 320.22(b)(3), bioequivalence studies may be waived for oral solutions like Syndros, provided the generic matches concentration and dosage form and has no significant formulation differences affecting absorption.
- Case-by-Case Assessment: FDA explained that bioequivalence waiver requests are reviewed individually during the ANDA process. No justification was provided in the petition that would preclude granting such waivers categorically.
- Food Effect and Metabolite Measurement: FDA found no compelling evidence that fed/fasted studies or metabolite measurements were categorically required. The Petition‚Äôs reliance on existing guidances for capsules or tablets was deemed inapplicable to oral solutions.
- ANDA Review Standards: FDA clarified that it does not refuse to receive an ANDA based solely on anticipated waiver requests; sufficiency is judged by completeness under section 505(j)(2)(A) of the FD&C Act.",denied,True,161.0,CDER,CDER
fda-2017-p-6451,FDA-2017-P-6451-0001_Suitability_Petition_from_Locke_Lord_LLP.pdf,2017-11-08,2017,False,original petition,Locke Lord LLP,law/consulting,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- 21 C.F.R. ¬ß¬ß 10.20, 10.30, 314.93 ‚Äì Citizen and suitability petition procedures
- 21 C.F.R. ¬ß 25.31 ‚Äì Categorical exclusion for environmental impact","Current FDA position regarding the lack of availability of a 150 mg/vial strength of micafungin sodium for injection, and the limitation of the Reference Listed Drug (Mycamine¬Æ, NDA 021506 by Astellas Pharma US Inc.) to only 50 mg and 100 mg vials
","- FDA should declare that micafungin sodium for injection, 150 mg/vial is suitable for submission as part of a single ANDA along with 50 mg and 100 mg strengths
- Permit inclusion of this new strength despite it not being separately marketed as such under the RLD","- The 150 mg dose is clinically supported by the RLD‚Äôs labeling, which instructs combining 100 mg and 50 mg vials for esophageal candidiasis treatment
- The proposed 150 mg vial is quantitatively and qualitatively equivalent to the RLD combination
- A single 150 mg vial will reduce burden and handling complexity for healthcare providers
- No new safety or effectiveness issues are raised",,Approved,2023-09-22,0.0,Center for Drug Evaluation and Research (CDER),"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- 21 CFR 314.93
- 21 CFR 314.93(e)(1)
- 21 CFR 314.94(a)(3)(iii)",,"- The proposed change in strength (150 mg/vial vs. 50 mg and 100 mg/vial) does not raise safety or effectiveness concerns.
- Uses, dosage form, and route are the same as the listed drug (Mycamine¬Æ).
- The change aligns with the dosing recommendations in the listed drug‚Äôs labeling.
- If bioequivalence is demonstrated, the product is expected to have the same therapeutic effect.
- No significant labeling changes or new investigations are necessary.",approved,True,2144.0,CDER,CDER
fda-2017-p-6479,FDA-2017-P-6479-0001_Citizen_Petition_from_Teligent_Pharma__Inc_.pdf,2017-11-13,2017,False,original petition,"Teligent Pharma, Inc.",industry/corporation,"- Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FDC Act)
- 21 C.F.R. ¬ß¬ß 10.20 and 10.30 (Citizen petition procedures)
- 21 C.F.R. ¬ß 25.31(a) (Environmental impact exclusion)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact submission provision)","The current designation of CARDENE (Nicardipine Hydrochloride) Injection, NDA 019734, as the sole Reference Listed Drug (RLD) and Reference Standard (RS) for Nicardipine Hydrochloride Injection, and the lack of availability of this RLD in the market which precludes submission of ANDAs.
","- FDA should designate a second Reference Listed Drug (RLD) for Nicardipine Hydrochloride Injection
- Update the Orange Book and Drugs@FDA to reflect this additional RLD, allowing ANDA submissions based on a product that is actually available for development and testing","- The currently designated RLD (CARDENE) is not available in the market, preventing potential ANDA applicants from obtaining it to conduct required bioequivalence or formulation studies.
- FDA has a policy, as outlined in the Orange Book Preface, that allows for the designation of a second RLD in such situations via a citizen petition.
- Lack of RLD access unfairly shields some products from competition",2018-05-08 00:00:00,Dismissed (moot),2020-09-17,1.0,Center for Drug Evaluation and Research (CDER),Not mentioned.,"The FDA has not resolved the petition due to the need to address other Agency priorities. The interim response is issued in accordance with FDA regulations, and the Agency promises to respond as soon as resources permit","The FDA had already updated the Orange Book to designate nicardipine hydrochloride injection, 25 mg/10 mL (NDA 022276), as both a Reference Listed Drug (RLD) and a Reference Standard, addressing the requests made in all three related petitions. As a result, the petitions were considered moot and dismissed
",dismissed (moot),True,1039.0,CDER,CDER
fda-2017-p-6513,FDA-2017-P-6513-0001_Citizen_Petition_from_Public_Citizen.pdf,2017-11-15,2017,False,original petition,Public Citizen,individual,"- 21 U.S.C. ¬ß 355 ‚Äì Requirements for drug approval (including safety and effectiveness)
- 21 C.F.R. ¬ß 314.126 ‚Äì Adequate and well-controlled studies
- 21 C.F.R. ¬ß 10.30 ‚Äì Citizen petition procedure
- Reference to 21 C.F.R. ¬ß 310.3(h) ‚Äì Intended use of a drug
- FDCA ¬ß 505(d) ‚Äì Substantial evidence requirement","FDA‚Äôs approval of Duchesnay‚Äôs Diclegis (doxylamine succinate and pyridoxine hydrochloride) for the treatment of nausea and vomiting in pregnancy (NVP), despite allegedly inadequate evidence from modern well-controlled trials .
","- Withdraw FDA approval of Diclegis
- Require a new drug application supported by adequate and well-controlled studies if the manufacturer seeks future approval
- Take regulatory actions consistent with FDCA to ensure drugs meet current standards of evidence","- The 2013 FDA approval of Diclegis relied primarily on a single 1970s-era trial that has never been published in a peer-reviewed journal and contains serious methodological flaws, such as lack of prespecified primary outcome, lack of statistical adjustments for dropouts, and potential bias.
- Modern trials have failed to demonstrate meaningful benefit.
- Continuing approval violates FDA standards requiring substantial evidence from adequate and well-controlled investigations .",2018-05-11 00:00:00,Denied,2019-10-09,1.0,Center for Drug Evaluation and Research (CDER),"- Section 505(b)(1) and 505(c) of the FD&C Act (21 U.S.C. 355)
- Section 505(d) and (e) of the FD&C Act
- 21 CFR 314.50(d)(5)(viii) and (v)
- 21 CFR 314.150(a)(2)(i), (ii), and (iii)","The petition raises complex issues requiring extensive review and analysis by FDA officials. Due to this complexity, a final decision has not yet been reached. The interim response complies with regulatory requirements to notify petitioners when a decision is delayed
","- FDA determined that removal of drug products containing olmesartan medoxomil is not warranted based on current evidence.
- The 2013 Drug Safety Communication and updated labeling adequately address the safety concerns (e.g., risk of sprue-like enteropathy).
- FDA reviewed multiple sources: literature, cohort studies, systematic reviews, FAERS, and case reports; none altered the prior risk-benefit assessment.
- The incidence of adverse events is low (3‚Äì147 per 100,000 patient-years), and most patients taking these drugs do not experience severe effects.
- Withdrawing the drugs could disrupt care for over 1 million patients with hypertension.
- The risk is clearly labeled, identifiable, reversible, and able to be mitigated without market removal
",denied,True,693.0,CDER,CDER
fda-2017-p-6631,FDA-2017-P-6631-0001_Citizen_Petition_from_Amin_Talati_Upadhye_LLP__Nat.pdf,2017-11-27,2017,False,original petition,Amin Talati Upadhye LLP,law/consulting,"- 21 C.F.R. ¬ß¬ß 10.25 and 10.30 (Citizen petition authority)
- 21 U.S.C. ¬ß 321(ff)(1) (definition of dietary supplement)
- 21 U.S.C. ¬ß¬ß 343, 301(a), 332, 334 (misbranding, adulteration, injunctions, seizure)
- 21 U.S.C. ¬ß 350b (new dietary ingredient - NDI)
- 21 U.S.C. ¬ß¬ß 321(g)(1)(B), 321(p), 331(d), 355(b), 352(f)(1), 352(o), 360, 351(a)(2)(B) (drug definition, unapproved drugs, misbranding, GMPs)
- 21 C.F.R. ¬ß 25.32 (environmental exemption)","FDA‚Äôs lack of regulatory enforcement against Cardax Inc. regarding its sale of ZanthoSyn, a product alleged to be misbranded, adulterated, and an unapproved new drug containing synthetic astaxanthin. The petitioner argues FDA should not allow the product to be marketed as a dietary supplement or drug without proper approval or safety evaluation","- Determine ZanthoSyn is misbranded under 21 U.S.C. ¬ß 343 (not a dietary supplement)
- If considered a supplement, declare it adulterated due to unnotified new dietary ingredient (NDI)
- Declare ZanthoSyn is an unapproved new drug under 21 U.S.C. ¬ß¬ß 321(g), 355(b), 331(d)
- Take enforcement actions under 21 U.S.C. ¬ß¬ß 332, 334 (injunction, seizure)
- Require Cardax to cease distribution of ZanthoSyn","- Synthetic astaxanthin is not a lawful ‚Äúdietary ingredient‚Äù under the FD&C Act; it is neither derived from natural botanical sources nor part of the conventional food supply.
- Even if considered a dietary ingredient, it is an NDI without notification, and no sufficient safety evidence exists.
- ZanthoSyn bears drug-like disease claims (e.g., anti-inflammatory, cholesterol lowering), making it an unapproved new drug.
- The safety and efficacy of synthetic astaxanthin is unproven, with claims based on unrelated studies.
- Consumers are misled by ‚Äúphysician endorsed‚Äù and ‚Äúsafe‚Äù claims, increasing public health risk
",,,2025-10-15,0.0,,,,,no decision,False,2879.0,pending,pending
fda-2017-p-6663,FDA-2017-P-6663-0001_Citizen_Petition_from_Dr__Edwards_Redacted.pdf,,2017,False,original petition,"Dr. S. Albert Edwards, PharmD, RAC, FRAPS",individual,"- 21 CFR 5.10 ‚Äì Delegation of authority to request FDA action
- Medical Device Amendments to the FD&C Act
- 21 CFR 30.10(b)(D) ‚Äì Certification section
- 21 CFR 25.34 ‚Äì Environmental categorical exclusion","- Marketing of unapproved annuloplasty rings (Myxo ET Logix 5100 / dETLogix 5110) without 510(k) or PMA approval (2007‚Äì2009)
- FDA's approval in April 2009 with no retroactive sanctions","- Investigate Edwards Lifesciences‚Äô marketing of unapproved medical devices
- Compare regulatory vs. patent application histories
- Require FDA review staff to track patent data vs. 510(k)/PMA statements
- Review the JTF File for inconsistencies","- Implanted device was investigational at time of surgery
- No response to inquiries from Edwards or FDA
- FOIA request confirmed lack of 510(k)
- History of regulatory noncompliance
- Claimed ‚Äúsame technology‚Äù contradicted by 40 differences in patent filings
- Public health risk due to lack of transparency and enforcement",,,2025-10-15,,,,,,no decision,False,,pending,pending
fda-2017-p-6689,"FDA-2017-P-6689-0001_Citizen_Petition_from_Novitium_Pharma_LLC.pdf
",2017-11-29,2017,False,original petition,Novitium Pharma LLC,industry/corporation,"- 21 C.F.R. ¬ß 10.25(a)
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 314.122
- 21 C.F.R. ¬ß 314.94(a)(3) (definition of RLD)
- 21 C.F.R. ¬ß 25.31(a) (environmental assessment exemption)
- 21 C.F.R. ¬ß 10.30(b) (economic impact info provision)","FDA‚Äôs designation of Reference Standards for generic drug development, specifically for NAPROSYN (naproxen) Oral Suspension, NDA #018965, where the currently listed RLD/RS was no longer available on the market
","The petitioner requests that the FDA designate an alternate Reference Standard (RS):
- Specifically, to designate Naproxen Oral Suspension 25 mg/mL of West-Ward Pharmaceuticals International Limited (ANDA #A074190) as the RS instead of the discontinued NAPROSYN (NDA #018965)","- The current RLD/RS, NAPROSYN Oral Suspension, is no longer available on the market, as confirmed by multiple global comparator drug suppliers.
- This unavailability hinders in vivo bioequivalence and comparative in vitro dissolution studies necessary for generic development.
- Citing the Hatch-Waxman Act and FDA guidance on referencing drug products, the petitioner argues that prompt designation of an alternate RS is essential to:
- Encourage generic development
- Lower drug prices
- Reduce public healthcare costs",2018-05-23 00:00:00,Approved,2019-05-08,1.0,Center for Drug Evaluation and Research (CDER),"- 21 U.S.C. ¬ß 355(j) (Section 505(j) of the FD&C Act)
- 21 CFR 314.94(a)(3)
- 21 CFR 314.3(b)
- Final Rule: ‚ÄúAbbreviated New Drug Applications and 505(b)(2) Applications,‚Äù 81 FR 69580, 69619 (Oct. 6, 2016)","FDA has not yet reached a decision due to other agency priorities. The interim response was issued in accordance with citizen petition regulations, and the agency will respond once resources allow
","- The originally designated reference standard (RS) drug Naprosyn (NDA 018965) is no longer available in the market in sufficient quantities to support new ANDA bioequivalence testing.
- FDA agrees there are sufficient grounds to select a new RS.
- The agency identified West-Ward‚Äôs ANDA 074190 (naproxen oral suspension, 25 mg/mL) as the appropriate new RS because it is the only approved generic version listed in the Orange Book and therapeutically equivalent to the RLD.
- FDA will identify ANDA 074190 as the new RS in the Orange Book.",approved,True,525.0,CDER,CDER
fda-2017-p-6689,FDA-2017-P-6689-0007_Petition_for_Reconsideration_and_Stay_from_Arnall_.pdf,2019-06-07,2017,False,reconsideration,Arnall Golden Gregory LLP,law/consulting,"- 21 C.F.R. ¬ß 10.25
- 21 C.F.R. ¬ß 10.33
- 21 C.F.R. ¬ß 10.35
- 21 C.F.R. ¬ß 10.31
- Section 506I(c) of the FD&C Act","FDA‚Äôs decision to designate ANDA 074190 (West-Ward Pharmaceuticals) as the new reference standard (RS) for Naprosyn (naproxen oral suspension, NDA 018965), replacing the branded product previously listed as RS and RLD","1. Reconsider the FDA‚Äôs decision to designate a new RS and retain Naprosyn (NDA 018965) as the RS.
2. Indefinitely stay the designation of ANDA 074190 (West-Ward) as the RS for Naprosyn","- Naprosyn (RLD and former RS) is currently available and has been actively distributed since 2017.
- FDA did not consult with Atnahs or Athena regarding the availability or distribution before designating a new RS.
- The designation of a new RS could unfairly harm Atnahs/Athena's business and mislead healthcare providers and generic developers about product availability.
- Concerns about the fairness of introducing a new RS while the previous RS is still available, including potential impacts on ANDA applicants who have used Naprosyn for bioequivalence.
- FDA failed to clearly define ‚Äúlimited distribution‚Äù criteria.
- The companies are willing to provide product samples for bioequivalence testing.
- The action may result in unnecessary market confusion and inconsistency in regulatory practices",,Denied,2020-05-26,0.0,Center for Drug Evaluation and Research (CDER),"- 21 CFR 10.33 (Petition for Reconsideration)
- 21 CFR 10.25
- 21 CFR 314.81(b)(2) (Annual reports)
- 21 CFR 314.94(a)(3)
- 21 CFR 314.3(b)
- 21 U.S.C. ¬ß 355(j) (Section 505(j) of the FD&C Act)
- 21 U.S.C. ¬ß 356i(c) (Section 506I(c) of the FD&C Act)",,"- The petitioner failed to meet the regulatory criteria for mandatory reconsideration (21 CFR 10.33(d)), specifically the requirement to demonstrate that FDA had not previously or adequately considered relevant information or views in the record.
- FDA thoroughly evaluated multiple sources: citizen petitions, docket comments, marketing status notifications, communications with applicants, annual reports (which were missing), and third-party commercial data.
- FDA found conflicting and incomplete information from Atnahs and no persuasive evidence that Naprosyn was available in sufficient quantities for use as a reference standard.
- The agency emphasized that ensuring availability of a reference standard is in the public interest and rejected the petition based on both regulatory grounds and public policy considerations.
- Reconsideration was also denied on discretionary grounds, as it was not found to be in the public interest or interest of justice",denied,True,354.0,CDER,CDER
fda-2017-p-6692,FDA-2017-P-6692-0001_Citizen_Petition_from_Drug_Watch_International__In.pdf,2017-11-21,2017,False,original petition,"Drug Watch International, Inc.",industry/corporation,"- 21 C.F.R. ¬ß¬ß 10.20, 10.25, 10.30 (general petition regulations)
- 21 C.F.R. ¬ß 310, Subpart E (negative monographs)
- 21 U.S.C. ¬ß 321(g)(1)(B & C) (definition of drugs under FDCA)
- 21 U.S.C. ¬ß 812 (Schedule I substances)
- 21 C.F.R. ¬ß 314 (New Drug Application requirements)
- 21 C.F.R. ¬ß 312 (Investigational New Drug regulations)
- 21 C.F.R. ¬ß 1301.18 (DEA research registration for Schedule I drugs)
- 21 C.F.R. ¬ß 25.31(a) (environmental assessment exemption)","The petition comments on the lack of inclusion of marijuana and THC in the FDA‚Äôs negative monograph list for OTC drugs and requests regulatory action to classify them accordingly
","The petitioner requests the FDA to issue a Final Rule creating a negative monograph that adds marijuana and THC to 21 C.F.R. ¬ß 310, Subpart E, thereby prohibiting their marketing in OTC drug products without FDA approval
","- Marijuana and THC are Schedule I substances with no currently accepted medical use in the U.S. per HHS and DEA.
- Unapproved OTC products making unsupported medical claims continue to be marketed.
- A negative monograph would serve as an industry-wide deterrent, reducing false advertising and misbranding.
- Precedent exists via similar FDA actions codifying negative monographs for ineffective or unsafe OTC products (e.g., aphrodisiacs, oral wound agents).
- A Final Order would reinforce that any OTC product containing marijuana/THC is a ‚Äúnew drug‚Äù requiring IND/NDA approval and is subject to regulatory enforcement
",2018-05-24 00:00:00,Denied,2018-07-02,1.0,Center for Drug Evaluation and Research (CDER),"- 21 CFR part 310 (Negative Monographs)
- 21 CFR part 330
- 21 CFR parts 331‚Äì358
- 21 CFR 314.126
- 21 CFR 312 (IND requirements)
- 21 CFR 330.10(b)
- 21 CFR 1301.18 (DEA registration)
- FD&C Act: 21 U.S.C. ¬ß¬ß 321(p), 355(a), 352(a), 331(a), 331(d)
- CSA: 21 U.S.C. ¬ß 801 et seq., ¬ß 812(c) (Section 202), ¬ß 811 (Section 201), ¬ß 1308.11 (Schedule I)",FDA was unable to reach a decision due to competing agency priorities. The interim response was issued in accordance with citizen petition procedures to notify the petitioner of the delay. FDA acknowledged receipt of the petition and committed to responding as soon as resources permit,"- The petition requested that marijuana and THC be added to FDA's negative monographs under 21 CFR part 310.
- FDA denied the request because:
¬†¬†‚Ä¢ There is already a legal framework under the FD&C Act that prohibits marketing of unapproved new OTC drugs containing marijuana or THC.
¬†¬†‚Ä¢ No NDA or ANDA has been approved for OTC products containing marijuana or THC, and no such products have been found to be GRAS/E (Generally Recognized as Safe and Effective).
¬†¬†‚Ä¢ FDA does not need to restate these enforcement authorities in a new negative monograph.
¬†¬†‚Ä¢ Enforcement and regulatory tools already exist regardless of whether a negative monograph is issued.
¬†¬†‚Ä¢ IND and DEA registration requirements are already well established and codified; restating them is unnecessary.
- FDA emphasized limited agency resources and the sufficiency of existing statutory and regulatory tools
",denied,True,223.0,CDER,CDER
fda-2017-p-6692,FDA-2017-P-6692-0043_Citizen_Petition_for_Reconsideration_from_Drug_Wat.pdf,2018-07-31,2017,False,reconsideration,"Drug Watch International, Inc.",industry/corporation,"- 21 C.F.R. ¬ß 10.33 (Administrative reconsideration of action)
- 21 C.F.R. Part 310, specifically ¬ß 310.519 (Negative monographs for OTC sedatives)
- 505 of the Federal Food, Drug, and Cosmetic Act (FDCA)
- 21 U.S.C. 321(g)(1)(B)
- 21 C.F.R. Parts 312, 314, 330, 333, 300.50, 310.545(a)(12)(iv)(B)
- Public Law 111-31 (Family Smoking Prevention and Tobacco Control Act)
- 21 U.S.C. ¬ß 355 (Section 505 of the FDCA)
- Controlled Substances Act, 21 U.S.C. Section 903","The FDA‚Äôs July 2, 2018 denial of Drug Watch International's original 2017 citizen petition (Docket No. FDA-2017-P-6692), which requested that marijuana (cannabis) and THC be added to a list of negative monographs under 21 C.F.R. Part 310.
","The petitioner requests the FDA to reconsider its denial and to establish a negative monograph for marijuana and THC under its rulemaking authority at 21 C.F.R. Part 310.
","The justification includes multiple arguments:
‚Ä¢ Marijuana and THC are widely marketed OTC under state laws for unapproved medical uses with false and misleading therapeutic claims.
‚Ä¢ Current FDA enforcement (e.g., only 4 CBD warning letters issued in 2017 out of 15,318 total) is insufficient and ineffective.
‚Ä¢ Negative monographs are effective regulatory tools, previously used for less harmful drugs (e.g., OTC sedatives).
‚Ä¢ Marijuana poses serious public health risks, including those noted in reports by the President‚Äôs Commission on Combating Drug Addiction and the Opioid Crisis.
‚Ä¢ Cites evidence of adverse outcomes from cannabis, such as prenatal harm, genotoxicity, and increased youth use in legalized states.
‚Ä¢ A negative monograph would streamline FDA enforcement and help consumers recognize the lack of proven safety/efficacy.
‚Ä¢ Without such action, FDA is seen as tacitly permitting the marketing of unapproved drugs.",,Denied,2019-07-18,0.0,Center for Drug Evaluation and Research (CDER),"- 21 CFR 10.33(d) and 10.33(e) (Petitions for reconsideration)
- 21 CFR 10.30(k) (Exclusion of enforcement actions from petitions)
- 21 CFR part 310 (Negative monographs)
- 21 CFR part 312 (IND regulations)
- FD&C Act: 21 U.S.C. ¬ß¬ß 355(a), 352(a), 331(d), 331(a), 321(p)",,"- The Reconsideration Petition included new information not part of the administrative record, which is not allowed under 21 CFR 10.33(e).
- The agency reiterated that a citizen petition cannot request enforcement action (e.g., seizure or injunction), per 21 CFR 10.30(k).
- FDA determined a negative monograph is unnecessary because existing law already prohibits marketing unapproved marijuana/THC-containing OTC drugs.
- The agency emphasized that it already uses enforcement discretion, safety communications, and regulatory mechanisms to address risks.
- Public health concerns were acknowledged, but FDA concluded that establishing a negative monograph would not be a more effective or efficient approach than current tools.
- FDA also rejected the argument that similar negative monographs for less harmful ingredients justified a monograph for marijuana or THC, explaining that each decision is based on multiple factors and does not imply consistency across substances
",denied,True,352.0,CDER,CDER
fda-2017-p-6745,FDA-2017-P-6745-0001_Citizen_Petition_from_Foley_Hoag_LLP_on_behalf_of_.pdf,2017-12-05,2017,False,original petition,Foley Hoag LLP,law/consulting,"- 21 U.S.C. ¬ß 355
- 21 C.F.R. ¬ß¬ß 10.30, 10.35
- 42 U.S.C. ¬ß 262(a)(2)(C)(i)
- 21 C.F.R. ¬ß¬ß 601.2, 601.12(b), 601.12(b)(1), 601.12(b)(2)(iv)-(v)
- 21 U.S.C. ¬ß 321(e)
- Application Integrity Policy (AIP), 56 Fed. Reg. 46191
- 21 C.F.R. ¬ß 20.61(a), 20.61(b), 20.62, 20.22(a), 25.31","FDA‚Äôs review and potential approval of the Biologics License Application (BLA) submitted by Evolus Inc. for DWP-450, a botulinum toxin product.
","1. Refrain from approving Evolus' BLA for DWP-450 until the FDA determines the true identity and source of the C. botulinum strain used.
2. Invoke the Application Integrity Policy (AIP) and defer scientific review of the BLA until data validity is confirmed.
3. Require submission of whole genome sequencing (SNP analysis) for any botulinum toxin strain used in a BLA.
4. Disclose the identity and source of the strain publicly to correct the GenBank record and ensure transparency.","- Daewoong Pharmaceutical (manufacturer of DWP-450) falsely claimed the strain was the Hall strain sourced from soil in South Korea ‚Äî a contradiction, since the Hall strain is non-sporulating and cannot exist in soil.
- These inconsistencies cast doubt on the integrity of all data prepared by Daewoong and used by Evolus in the BLA (including CMC, clinical, and preclinical data).
- The Hall strain is well-documented to originate from a U.S. botulism case and cannot be newly isolated from South Korean soil.
- Medytox argues that such false statements constitute a ‚Äúwrongful act‚Äù under the FDA‚Äôs Application Integrity Policy.
- Whole genome sequencing (SNP analysis) is essential to distinguish between closely related botulinum strains and to verify identity.
- The issue has public health implications and regulatory integrity concerns, and thus warrants full investigation and transparency
",2018-06-01 00:00:00,Denied,2019-02-01,1.0,Center for Drug Evaluation and Research (CDER),"- 42 U.S.C. ¬ß 262(a)(2)(C)(i) (PHSA)
- 21 CFR 601.2(a)
- 21 CFR ¬ß¬ß 20.61, 601.51 (trade secrets and biological product file disclosure)
- 21 CFR part 20 (FOIA regulations)
- 21 CFR part 310
- 21 CFR 10.30(k) (limitations on citizen petitions)
- 56 FR 46191 (Application Integrity Policy)","- The petition requested that FDA refrain from approving a Biologics License Application (BLA) for DWP-450 (Clostridium botulinum toxin type A) submitted by Evolus, Inc., until the identity and source of the strain are determined and the data validated.
- It also requested that SNP analysis be required in botulinum toxin submissions and that FDA disclose the strain source.
- FDA has not resolved the petition due to competing agency priorities.
- The response is provided as an interim reply per 21 CFR 10.30(e)(2), and the agency will respond when resources permit
","- The petitioner requested that FDA: (1) refrain from approving Evolus‚Äôs BLA for DWP-450 until the strain source was clarified; (2) apply the Application Integrity Policy (AIP); (3) require SNP (single nucleotide polymorphism) analysis for strain identity; and (4) disclose the strain source to the public.
- FDA approved the BLA for DWP-450 on the same day as the letter and found the data on strain source and identity sufficient.
- FDA did not find any evidence of ‚Äúwrongful acts‚Äù to invoke the AIP. The allegations of inconsistency did not meet the criteria for invoking AIP.
- The agency did not agree that SNP analysis is required to meet identity and safety standards; existing manufacturing controls suffice.
- Disclosure of strain identity was denied under FOIA exemptions protecting trade secrets and confidential commercial information.
- FDA concluded that the petitioner‚Äôs concerns did not raise valid questions requiring alteration of its regulatory processes or decisions",denied,True,423.0,CDER,CDER
fda-2017-p-6750,FDA-2017-P-6750-0001_Citizen_Petition_from_Mylan_Inc_.pdf,2017-12-05,2017,False,original petition,Mylan Inc.,industry/corporation,"- 21 U.S.C. ¬ß 355 (FDCA ¬ß 505)
- 21 C.F.R. ¬ß 10.30 (citizen petitions)
- 21 C.F.R. ¬ß 320.24(a) (bioavailability/bioequivalence testing)
- 21 C.F.R. ¬ß 314.94 (ANDA content requirements)
- 21 C.F.R. ¬ß 314.127 (grounds for refusal to approve ANDAs)
- 21 C.F.R. ¬ß 25.31 (categorical exclusion for environmental impact)",The FDA‚Äôs potential acceptance of multiple-batch pharmacokinetic (PK) bioequivalence (BE) study designs in abbreviated new drug applications (ANDAs) for fluticasone propionate/salmeterol xinafoate (FP/SX) inhalation powder that rely on Advair Diskus¬Æ as the Reference Listed Drug (RLD),"FDA is asked to:
- Refrain from approving any ANDA for FP/SX unless it contains a PK BE study based on the single-batch test versus reference design described in FDA‚Äôs 2013 Draft Guidance.
- Require any alternative BE study (e.g., multiple-batch studies) to meet rigorous validation and justify scientific reliability","- FDA‚Äôs 2013 Draft Guidance (based on multi-year scientific and industry collaboration) offers a clear, reliable method for establishing bioequivalence using a single-batch design.
- The multiple-batch approach proposed by some applicants (e.g., Sandoz) is novel, unvalidated, and risky, potentially masking meaningful differences between products.
- Sponsors resorting to multiple-batch studies may do so because they fail to achieve BE under the standard method.
- The batch-to-batch variability of the RLD (Advair Diskus¬Æ) can be addressed through robust in vitro-in vivo relationship (IVIVR) models and sound product development, without needing nonstandard designs.
- FDA precedent does not support approval based on multiple-batch PK BE studies outside highly variable drug products (HVDPs), which FP/SX does not qualify as.",,Denied,2018-05-06,0.0,Center for Drug Evaluation and Research (CDER),"- Section 505(q) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. ¬ß 355(q))
- Section 505(b)(2) and 505(j) of the FD&C Act (21 U.S.C. ¬ß 355(b)(2), (j))
- 21 CFR Part 314 (¬ß¬ß 314.105, 314.110, 314.125, 314.127, 314.200)
- Section 505(c)(1)(B) and (d) of the FD&C Act",,"- FDA denied the petition without commenting on specific ANDA approvals due to the constraints of Section 505(q), which requires action within 150 days.
- FDA stated it had not made a final decision on the approvability of any ANDA referencing Advair Diskus and emphasized the importance of preserving the review process for individual applications.
- The agency affirmed that it is not required to make final judgments on specific aspects of pending ANDAs outside the regulatory review framework.
- FDA stressed that the approval process includes procedures to notify applicants of deficiencies and allow hearings before final decisions.
- FDA declined to confirm or deny whether multiple-batch pharmacokinetic bioequivalence study designs are acceptable, as such determinations depend on the specifics of each application. The agency maintained its discretion in evaluating ANDAs case by case
",denied,True,152.0,CDER,CDER
fda-2017-p-6751,FDA-2017-P-6751-0001_Citizen_Petition_from_Capstone_Law_APC_on_behalf_o.pdf,2017-12-05,2017,False,original petition,Capstone Law APC,law/consulting,"- 21 U.S.C. ¬ß 343 (FDCA ¬ß 403)
- 21 C.F.R. ¬ß 10.60
- 21 C.F.R. ¬ß 101.3(e)
- 21 C.F.R. ¬ß 101.3(e)(4)
- 21 C.F.R. ¬ß 130.10
- 21 C.F.R. ¬ß¬ß 25.30‚Äì25.34 (environmental exclusions)
- 21 C.F.R. ¬ß 101.9
- Section 401 of the FDCA","FDA‚Äôs regulatory approach and lack of enforcement concerning the labeling of non-dairy milk alternatives (specifically Silk Almondmilk) as ‚Äúimitation milk‚Äù, and whether FDA will accept or reject a court referral for guidance in the matter
","FDA is requested to:
1. Determine or issue guidance on whether Silk Almondmilk ""substitutes for, resembles, and is nutritionally inferior to"" milk.
2. Require it to be labeled as ‚Äúimitation milk‚Äù under 21 C.F.R. ¬ß 101.3(e).
3. Promptly respond to the court referral under 21 C.F.R. ¬ß 10.60 from a related class action lawsuit","- Silk Almondmilk resembles and substitutes for milk in packaging, placement, advertising, and usage.
- It is nutritionally inferior to dairy milk across essential nutrients including protein, magnesium, potassium, phosphorus, zinc, and several vitamins (as shown in a detailed nutritional comparison table on page 6).
- Consumers are misled by use of the term ‚Äúmilk‚Äù in the product‚Äôs identity despite its inferiority.
- FDA precedent and prior guidance support labeling such products as ‚Äúimitation‚Äù when they fail to meet nutritional equivalency.
- Regulatory clarity is needed as courts have deferred to FDA on these labeling issues",2018-06-07 00:00:00,,2025-10-15,1.0,,,The FDA stated it could not reach a decision within 180 days of the petition‚Äôs receipt or by the date of the letter due to other competing agency priorities. The agency will continue reviewing the petition and consider issuing guidance as warranted within the context of other program priorities,,no decision,False,2871.0,pending,pending
fda-2017-p-6758,FDA-2017-P-6758-0001_Citizen_Petition_from_Public_Citizen_s_Health_Rese.pdf,2017-12-06,2017,False,original petition,Public Citizen‚Äôs Health Research Group,advocacy/academic,"- Section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA)
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 25.31(a) (environmental impact exclusion)","- FDA‚Äôs January 2017 Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the FDCA
- FDA's failure to add cesium chloride to the 503A Category 2 list despite acknowledged safety risks","The petitioner asks the FDA to:
1. Immediately add cesium chloride to the 503A Category 2 list of bulk drug substances that may not be compounded
2. Promulgate a rule excluding cesium chloride from the 503A bulks list, which otherwise permits certain non-approved substances to be compounded","- Cesium chloride was determined by FDA staff to pose ‚Äúserious safety concerns‚Äù and is ‚Äúnot safe for human use‚Äù.
- Animal studies showed cardiovascular, neurological, and reproductive toxicity.
- Human data reveal risks of QT prolongation, hypokalemia, arrhythmias, seizures, syncope, and death.
- No proven efficacy for cancer treatment; only one methodologically flawed case series exists.
- FDA‚Äôs Pharmacy Compounding Advisory Committee (PCAC) unanimously (11‚Äì0) recommended not placing cesium chloride on the compounding list due to safety concerns.
- Failure to act promptly exposes vulnerable patients (e.g., those with terminal cancer) to false hope and dangerous therapies",2018-06-04 00:00:00,Partially Approved / Partially Denied,2018-07-23,1.0,Center for Drug Evaluation and Research (CDER),"- Section 503A of the FD&C Act (21 U.S.C. ¬ß 353a)
- Section 505 (21 U.S.C. ¬ß 355)
- Section 502(f)(1) (21 U.S.C. ¬ß 352(f)(1))
- Section 501(a)(2)(B) (21 U.S.C. ¬ß 351(a)(2)(B))
","The petition raises complex issues that require extensive review and analysis by agency officials. Therefore, a final decision has not yet been reached.

","- The FDA concluded that cesium chloride presents significant safety risks, including QT prolongation, cardiac arrhythmias, hypokalemia, seizures, and deaths.
- It cited evaluations from a 2016 PCAC meeting, additional FAERS and CAERS adverse event data, and three more published case reports through June 2018.
- The FDA determined it appropriate to move cesium chloride from Category 1 to Category 2 as an interim measure to protect public health.
- Rulemaking to determine final inclusion on the 503A bulks list is still ongoing and requires public notice and comment",partially approved / denied,True,229.0,CDER,CDER
fda-2017-p-6805,FDA-2017-P-6805-0001_Citizen_Petition_from_Bracco_Diagnostics_Inc.pdf,2017-12-08,2017,False,original petition,Bracco Diagnostics Inc.,industry/corporation,"- Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FDCA)
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 314.127(a)(6)(i)
- 21 C.F.R. ¬ß 314.430(a)
- 21 C.F.R. ¬ß 314.161(a)(1)",The agency‚Äôs potential acceptance or approval of ANDAs referencing the discontinued two-ingredient formulation of KINEVAC for injection.,"FDA should:
- Determine the two-ingredient KINEVAC formulation was withdrawn for safety and efficacy reasons.
- Conclude the old formulation is not a suitable RLD.
- Reject any ANDA referencing the discontinued KINEVAC formulation ","- The old two-ingredient formulation was unstable and prone to degradation, risking inaccurate diagnoses and unnecessary surgeries.
- The currently marketed formulation is significantly more stable and does not require overages.
- The older formulation had higher levels of impurities, posing safety concerns.
- Diagnostic standards (e.g., SNM guidelines for gallbladder function using GBEF) were established using the current formulation; using the older one could lead to false positives and improper surgeries.
- Continued use of the old formulation risks public health by undermining the safety and effectiveness of diagnostic procedures",2018-05-31 00:00:00,,2025-10-15,1.0,,,"The FDA stated that the petition raises complex issues requiring extensive review and analysis by agency officials. As such, they were unable to make a final decision at the time and issued this interim response per regulatory requirements
",,no decision,False,2868.0,pending,pending
fda-2017-p-6809,FDA-2017-P-6809-0001_Citizen_Petition_from_Freyr_Inc_.pdf,2017-12-08,2017,False,original petition,Freyr Inc.,industry/corporation,"- Section 505(j) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß¬ß 10.20 and 10.30 (Citizen petition procedures)
- 21 C.F.R. ¬ß 314.94(a)(9)(iii) (formulation requirements for ANDAs)
- 21 C.F.R. ¬ß 25.31 (environmental impact exclusion)
- 21 C.F.R. ¬ß 10.30(b) (economic impact disclosure)","The petition comments on the FDA‚Äôs designation of Reference Listed Drugs (RLDs) and its current policy of recognizing only TYGACIL¬Æ (NDA 021821) as the RLD for tigecycline for injection, thereby excluding Fresenius Kabi's product (NDA 205645) from serving as an RLD despite being a pharmaceutical equivalent
","The petitioner requests that the FDA designate Fresenius Kabi's Tigecycline for Injection, 50 mg/vial (NDA 205645) as an additional Reference Listed Drug (RLD) in the Orange Book
","- Both TYGACIL and Fresenius Kabi products have the same active ingredient, dosage form, strength, and route of administration (they are pharmaceutical equivalents).
- Despite being rated therapeutically equivalent (AP), Fresenius Kabi‚Äôs formulation contains arginine, while TYGACIL contains lactose, making them differ in non-exception excipients.
- Because of this difference, ANDA applicants cannot reference the Fresenius Kabi product unless it is designated as an RLD.
- Not designating the Fresenius Kabi product as an RLD shields it from competition.
- Designating it as an additional RLD would promote competition and benefit the market",2018-06-05 00:00:00,Dismissed (moot),2020-09-15,1.0,Center for Drug Evaluation and Research (CDER),Not mentioned.,"The FDA cited the need to address other agency priorities as the reason for the delay. It stated that the petition raises issues requiring further attention and that a final response will follow once resources allow
","The FDA updated the Orange Book to designate tigecycline intravenous powder 50 mg/vial (NDA 205645, Fresenius Kabi) as a reference listed drug (RLD), which fulfilled the request made in the petition. Therefore, the petition was dismissed as moot
",dismissed (moot),True,1012.0,CDER,CDER
fda-2017-p-6851,FDA-2017-P-6851-0001_Citizen_Petition_from_Shire_Development_LLC.pdf,2017-12-20,2017,False,original petition,Shire Development LLC,industry/corporation,"- Section 505 of the FD&C Act
- 21 C.F.R. ¬ß 10.30 (Citizen Petition regulations)
- 21 C.F.R. ¬ß 314.3 (definitions)
- 21 C.F.R. ¬ß 320.1 and ¬ß 320.24 (bioequivalence studies)
- 21 C.F.R. ¬ß¬ß 25.30(h), 25.31(a) & (g) (environmental impact exemption)","The petition addresses the FDA‚Äôs lack of specific bioequivalence guidance for ANDAs referencing Mydayis, an extended-release amphetamine product. It criticizes the use of only traditional pharmacokinetic parameters (Cmax, AUC‚ÇÄ‚Äìt, AUC‚ÇÄ‚Äì‚àû) as inadequate","Shire requests the FDA to:
‚Ä¢ Require ANDAs referencing Mydayis to demonstrate bioequivalence using specific partial AUCs and additional PK parameters:
‚ÄÉ- AUC‚ÇÄ‚Äì5, AUC‚ÇÖ‚Äì‚ÇÅ‚ÇÇ, AUC‚ÇÅ‚ÇÇ‚Äì‚ÇÅ‚ÇÜ, AUC‚ÇÅ‚ÇÜ‚Äì‚ÇÇ‚ÇÑ
‚ÄÉ- C‚ÇÅ‚ÇÇ, C‚ÇÅ‚ÇÜ, C‚ÇÇ‚ÇÑ
‚Ä¢ If not, require follow-on products to be submitted via Section 505(b)(2) pathway, supported by at least one adequate and well-controlled clinical trial
","- Mydayis is designed for 16-hour symptom control, longer than typical ADHD treatments.
- Existing bioequivalence parameters (Cmax, AUC‚ÇÄ‚Äìt, AUC‚ÇÄ‚Äì‚àû) may fail to detect critical differences in therapeutic effect and safety, especially at later hours.
- FDA‚Äôs guidance for Adderall XR (a related product) includes partial AUCs‚ÄîMydayis has similar and even more complex formulation with 3 types of beads (IR, DR1, DR2).
- Differences in generic formulations could affect early onset of action, duration of efficacy, and risk of insomnia, which is a known concern, especially in pediatrics.
- Multiple clinical studies show Mydayis' efficacy and safety profile is tied to its unique PK curve.
- Without appropriate bioequivalence requirements, generics may pose different benefit-risk profiles",,Partially Approved / Partially Denied,2018-05-17,0.0,Center for Drug Evaluation and Research (CDER),"- FD&C Act, Section 505(j) (21 U.S.C. 355(j))
- Section 505(b)(2)
- 21 CFR 314.3
- 21 CFR 314.94
- 21 CFR 314.127
- 21 CFR 320.1
- 21 CFR 320.23
- 21 CFR 320.24",,"The FDA agreed that certain partial AUC metrics (AUCo‚Äì5, AUC5‚Äì12, and AUC12‚Äì16) are appropriate to assess bioequivalence for Mydayis due to its extended release profile and clinical relevance up to 16 hours. However, the agency found no scientific justification for requiring specific concentration (C12, C16, C24) or AUC16‚Äì24 metrics, due to variability, lack of clear clinical correlation, and absence of identified concentration thresholds for insomnia or efficacy. The petition‚Äôs request to force non-bioequivalent products into the 505(b)(2) pathway was denied, as such a decision would follow regulatory review based on submitted data
",partially approved / denied,True,148.0,CDER,CDER
fda-2017-p-6918,FDA-2017-P-6918-0001_Citizen_Petition_from_St__Jude_Children_s_Research.pdf,2017-12-14,2017,False,original petition,St. Jude Children‚Äôs Research Hospital,advocacy/academic,"- 21 C.F.R. Part 10 (submission procedure)
- 21 C.F.R. ¬ß 201.57(c)(5) (standard for contraindications in drug labeling)","The petition comments on the April 2017 FDA contraindication that prohibits the use of codeine to treat pain or cough in children younger than 12 years old, regardless of CYP2D6 genotype
","The petitioner requests the FDA to amend the contraindication on codeine use in children <12 to allow its use in non-post-tonsillectomy/adenoidectomy settings for children who are CYP2D6 normal (NM) or intermediate metabolizers (IM) based on pharmacogenetic testing including gene duplication detection
","The petitioner presents a detailed rationale, including:
‚Ä¢ CYP2D6 phenotype is predictive of codeine toxicity and therapeutic failure.
‚Ä¢ Pharmacogenetic testing can identify at-risk children (UMs and PMs), making the contraindication overly broad.
‚Ä¢ The FDA‚Äôs own criteria (21 C.F.R. 201.57) require known hazards, and data show NM and IM children not post-AT are not at elevated risk.
‚Ä¢ Alternative opioids may be more dangerous and harder to access.
‚Ä¢ Codeine‚Äôs DEA Schedule III status enables verbal prescriptions and refills‚Äîcritical for pediatric chronic pain management.
‚Ä¢ Codeine is essential for conditions like sickle cell disease, often treated at home in underprivileged populations.
‚Ä¢ Clinical CYP2D6 testing is widely available, and use of pharmacogenetics is growing due to lower costs and technological advances
",,Denied,2023-08-11,0.0,Center for Drug Evaluation and Research (CDER),"- 21 CFR 201.57(c)(5)
- 21 CFR 201.56(a)(1)
- 21 CFR 1306.11(d) (regarding emergency oral prescriptions of Schedule II drugs)",,"- Lack of FDA-approved CYP2D6 tests: No FDA-cleared/authorized genetic tests are validated for use in making codeine prescribing decisions.
- Testing limitations and variability: CYP2D6 tests vary in accuracy, allele detection, and phenotypic interpretation.
- Overlap in metabolizer status: Normal/intermediate metabolizers may exhibit metabolizer activity similar to ultra-rapid metabolizers, posing risk of toxicity.
- Risk of prescriber misinterpretation: The proposed change may inadvertently lead to increased codeine prescribing even without genetic testing.
- Wider systemic risks: Not all healthcare settings can support the integrated, expert-guided use of genetic testing, as demonstrated in the cited St. Jude study.
- Continued public health concern: Codeine-related adverse events in children‚Äîincluding potentially fatal respiratory depression‚Äîremain a critical safety concern.
- Lack of compelling new clinical evidence: No new data presented sufficiently alters FDA‚Äôs prior assessment of risk-benefit in this population.
- Alternative opioids also carry risks, but this alone does not justify weakening existing contraindications without evidence of superior safety for genotype-directed codeine use
",denied,True,2066.0,CDER,CDER
fda-2017-p-6922,FDA-2017-P-6922-0001_Citizen_Petition_from_Haynes_and_Boone__LLP.pdf,2017-12-18,2017,False,original petition,"Haynes and Boone, LLP",law/consulting,"- 21 C.F.R. ¬ß¬ß 10.25(a), 10.30 (Citizen Petition procedures)
- 21 C.F.R. ¬ß 320.21 (ANDA bioequivalence requirements)
- 21 C.F.R. ¬ß 320.24(a), (b) (BE methods: accuracy, sensitivity, reproducibility)
- 21 C.F.R. ¬ß 320.23 (BE for locally-acting drugs)
- 21 C.F.R. ¬ß 25.31 (Environmental impact exclusion)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact reporting)","The petition addresses FDA‚Äôs past and current bioequivalence (BE) standards for sucralfate oral suspension, specifically opposing the use of clinical endpoint studies to establish BE in ANDAs. It references the withdrawn July 2014 Draft Guidance and the revised October 2017 Draft Guidance
","FDA should deny approval to any ANDA for a sucralfate oral suspension drug that relies on patient-based clinical endpoint studies to establish bioequivalence with Carafate (the RLD)
","- Sucralfate acts locally and does not have measurable plasma concentrations, making clinical endpoint studies inadequate for establishing BE.
- The July 2014 Draft Guidance, which allowed for clinical endpoint BE studies, has been withdrawn, indicating its scientific inadequacy.
- FDA‚Äôs October 2017 Draft Guidance recommends in vitro testing and bioassays instead, which are more accurate.
- Clinical endpoint studies suffer from high variability, lack of sensitivity, and use binary outcomes (e.g., healed vs. not healed) that do not account for ulcer size/severity, thus failing to detect real differences in product efficacy",,Denied,2018-05-17,0.0,Center for Drug Evaluation and Research (CDER),"- Section 505(j) of the FD&C Act (21 U.S.C. 355(j))
- Section 505(j)(8)(B)(i) and 505(j)(8)(C)
- 21 CFR 314.3(b)
- 21 CFR 314.94(a)
- 21 CFR 320.24(b)
- 21 CFR 10.115",,"- The FDA found that clinical endpoint bioequivalence studies may still be valid for certain locally-acting drugs, including sucralfate, despite being less precise.
- Although in vitro testing is preferred in some cases, the FDA allows ANDA applicants to propose alternative scientifically supported methods.
- The FDA emphasized that guidance documents are non-binding and describe current thinking, not mandatory rules.
- The agency disagreed with Haynes and Boone's claim that ANDAs using clinical endpoint studies based on withdrawn draft guidance should be rejected.
- Regarding Vertice‚Äôs petition, FDA stated it will evaluate sucralfate bioequivalence methods during the draft guidance finalization process, and applicants may propose alternatives in their ANDA submissions.",denied,True,150.0,CDER,CDER
fda-2017-p-6923,FDA-2017-P-6923-0001_PUBLIC_REDACTED_VERSION_Citizen_Petition_from_Zydu.pdf,2017-12-18,2017,False,original petition,Zydus Noveltech Inc. (ZNI),industry/corporation,"- Section 505(q) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. ¬ß 355(q))
- 21 C.F.R. ¬ß 10.30 (Citizen Petition procedures)
- 21 C.F.R. ¬ß 320.22(d)(2) (waiver criteria)
- 21 C.F.R. ¬ß 25.30 and ¬ß 25.31 (environmental impact exclusion)
- 21 C.F.R. ¬ß 320.24 (bioequivalence testing methodologies)
- 21 C.F.R. Part 320 (bioavailability and bioequivalence requirements)","The petition comments on FDA‚Äôs current policy for granting waivers of in vivo bioequivalence testing for alternate strengths of rivastigmine transdermal systems that reference Exelon Patch as the RLD
","ZNI requests that FDA:
‚Ä¢ Only grant a waiver of in vivo testing for the 4.6 mg/24 hr and 13.3 mg/24 hr strengths if the product:
‚ÄÉ- Demonstrates bioequivalence at 9.5 mg/24 hr;
‚ÄÉ- Has the same rivastigmine content per unit surface area across strengths;
‚ÄÉ- Maintains proportional patch size and composition across strengths;
‚Ä¢ If waiver conditions are not met, then require in vivo bioequivalence studies for all strengths with full PK parameters (AUC, Cmax, Tmax)","- Exelon Patch demonstrates nonlinear pharmacokinetics; small increases in dose result in over-proportional exposure (AUC).
- Bioequivalence waiver criteria must be more stringent to avoid unintended overdosing and adverse effects.
- Current FDA Draft Guidance (Oct. 2016) allows waiver based on similarity, but ZNI argues this is insufficient due to Exelon‚Äôs lack of strict dose/size proportionality.
- Other TDDS RLDs (e.g., Androderm, Catapres) do follow size-dose proportionality, unlike Exelon Patch.
- Recommends either tighter controls for waivers or requiring full bioequivalence demonstration for each strength",,Denied,2018-05-15,0.0,Center for Drug Evaluation and Research (CDER),"- 21 U.S.C. ¬ß 355(b)(2) (FD&C Act section 505(b)(2))
- 21 U.S.C. ¬ß 355(j) (FD&C Act section 505(j))
- 21 CFR ¬ß 314.3
- 21 CFR ¬ß 314.94
- 21 CFR ¬ß 314.127
- 21 CFR ¬ß 320.24
- 21 CFR ¬ß 320.25(a)
- Section 505(j)(7)(A)(i)(III) of the FD&C Act",,"- Scientific and Regulatory Flexibility: FDA has authority to determine bioequivalence (BE) methods on a case-by-case basis, using in vivo, in vitro, or both types of data depending on drug characteristics and available science.
- Proportional Patch Sizing: Although the Exelon patch strengths are not exactly proportional to their surface areas, FDA found this discrepancy to be due to variability in drug delivery estimation methods and not indicative of lack of proportionality.
- Rejection of Petition Criteria: The petition‚Äôs request to tie proportional similarity to nominal drug strength was rejected. FDA maintained that size-based proportionality (0.5:1.0:1.5) is appropriate for transdermal systems when consistent formulation and drug concentration are used.
- Rivastigmine Pharmacokinetics: While rivastigmine has nonlinear pharmacokinetics, FDA found that BE can still be determined via a single strength (9.5 mg/24 hr) in vivo study and that in vitro data may be used for other strengths if proportional similarity is demonstrated.
- Policy to Avoid Unnecessary Human Testing: FDA emphasized the importance of avoiding unnecessary in vivo testing when scientifically valid in vitro methods are available and appropriate, in accordance with 21 CFR 320.25(a).",denied,True,148.0,CDER,CDER
fda-2017-p-6967,FDA-2017-P-6967-0001_Citizen_Petition_from_Bergstrom_Nutrition_Redacted.pdf,2017-12-08,2017,False,original petition,Natural Products Association (NPA) and Bergstrom Nutrition,advocacy/academic,"- Section 111.75(a)(1) of the Federal Food, Drug, and Cosmetic Act (FDC Act)
",The petition addresses the FDA‚Äôs 100 percent identity testing requirement for dietary ingredients in dietary supplement manufacturing,"The petitioners request that the FDA exempt dietary supplement manufacturers using OptiMSM¬Æ (from Bergstrom Nutrition) from the 100 percent identity testing requirement for dietary ingredients
","- OptiMSM¬Æ is a well-characterized ingredient with a consistent identity profile produced under strict manufacturing controls.
- The petition argues that redundant testing imposes unnecessary regulatory burden and cost.
- Petitioners suggest that a robust supplier verification program and validated Certificates of Analysis (CoAs) should suffice to confirm identity.
- They highlight long-term use, product consistency, and quality assurance procedures in place at Bergstrom Nutrition.
- The exemption would help reduce testing requirements without compromising product quality or safety
",,,2025-10-15,0.0,,,,,no decision,False,2868.0,pending,pending
fda-2017-p-6968,FDA-2017-P-6968-0001_Suitability_Petition_from_Ceva_Animal_Health__LLC.pdf,2017-12-21,2017,False,original petition,"Ceva Animal Health, LLC",industry/corporation,"- Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act (FFDCA)
- 21 CFR ¬ß 10.30 (citizen petition regulations)
- 21 CFR ¬ß 25.33(d)(5) (categorical exclusion from environmental assessment)
- 21 CFR ¬ß 25.21 (extraordinary circumstances provision)","The petition comments on the filing eligibility of an ANADA for a generic cyclosporine oral solution that differs in dosage form from the reference product, Atopica‚Ñ¢ (NADA 141-218), which is a cyclosporine oral solution encapsulated in gelatin capsules","Ceva requests that the FDA permit the filing of an ANADA for a generic, un-encapsulated cyclosporine oral solution that differs from the reference product only in dosage form
","- The proposed product is an oral solution not enclosed in gelatin capsules, unlike the reference product.
- Both products contain the same active ingredient, are administered orally, and are dosed identically (5 mg/kg/day).
- The generic product offers greater dosing flexibility, ease of administration (especially for varying dog sizes), and convenience for veterinarians and pet owners.
- The generic solution is supplied with graduated oral syringes and in multiple bottle sizes (5‚Äì50 mL).
- The labeling will mirror the reference product, with minor changes in dose administration, storage, supply details, and manufacturer info
",,Approved,2018-03-14,0.0,Center for Veterinary Medicine (CVM),"- Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- Section 512(n)(3)(C) of the FD&C Act
- 21 CFR 514.5",,"- The proposed generic differs in dosage form (un-encapsulated, non-aqueous solution vs. encapsulated).
- The FDA found that these changes are allowable under a suitability petition and do not require new safety or efficacy investigations.
- Approval was granted under section 512(n)(3)(C), with a recommendation to pursue a presubmission conference to plan the abbreviated application pathway",approved,True,83.0,CVM,Other/Specialty Center
fda-2017-p-7031,FDA-2017-P-7031-0001_Citizen_Petition_from_JRRapoza_Associates__Inc.pdf,2017-12-22,2017,False,original petition,"JR Rapoza Associates, Inc.",law/consulting,"- 21 CFR ¬ß 10.20
- 21 CFR ¬ß 10.30
- 21 CFR ¬ß 314.161
- 21 CFR ¬ß 25.31 (environmental exclusion)","The petition addresses the lack of a currently marketed Reference Standard (RS) drug product for Thiamine Hydrochloride Injection 100 mg/ml, NDA 0080556, which was discontinued but not for safety/efficacy reasons. It seeks a new RS designation in the Orange Book","The petitioner requests that the FDA designate a new Reference Standard (RS) drug in the Orange Book for Thiamine Hydrochloride Injection 100 mg/ml in a vial to enable submission of bioequivalent ANDAs
","- The original RS product (NDA 0080556 by Fresenius Kabi, USA, LLC) was discontinued for reasons other than safety or efficacy.
- Current FDA guidance allows for designation of a new RS for discontinued drugs.
- Other bioequivalent Thiamine Hydrochloride products are approved and could serve as RS.
- Availability of a designated RS will facilitate ANDA submissions for generic injectable products.
- The larger volume vial offers economic and dosing convenience benefits for healthcare providers",,,2025-10-15,0.0,,,,,no decision,False,2854.0,pending,pending
fda-2017-p-7032,FDA-2017-P-7032-0001_Citizen_Petition_from_Jubilant_Generics_Limited.pdf,2017-12-13,2017,False,original petition,Jubilant Generics Limited,industry/corporation,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. ¬ß 355(j)(2)(C)]
- 21 CFR ¬ß 314.93
- 21 CFR ¬ß¬ß 10.20 and 10.30
- 21 CFR ¬ß 25.31 (for environmental impact exclusion)","Proposal to allow the submission of an ANDA for Esomeprazole Magnesium Delayed Release Capsules, USP 10 mg, a strength not currently available in capsule form of the RLD Nexium¬Æ (which is marketed in 20 mg and 40 mg capsule strengths)","The petitioner requests that the FDA determine that the 10 mg strength of Esomeprazole Magnesium Delayed Release Capsules is suitable for submission as an ANDA
","- The 10 mg strength is explicitly recommended in the approved labeling of Nexium¬Æ for pediatric patients (ages 1 month to 11 years), particularly for those < 20 kg or based on weight dosing (see table on page 2).
- There is currently no ready-to-use capsule formulation available for the 10 mg strength.
- The new strength would provide a more convenient and accurate dosing option for pediatric patients who can swallow capsules.
- No changes to safety, efficacy, dosage form, route of administration, or conditions of use versus the RLD.
- As such, clinical investigations are not required, and the labeling (other than the strength) remains unchanged
",,Approved,2021-08-12,0.0,Center for Drug Evaluation and Research (CDER),"- Section 505(j)(2)(C) of the FD&C Act (21 U.S.C. ¬ß 355(j)(2)(C))
- Section 505(j)(2)(A) and (B)
- Section 505(j)(2)(A)(iv)
- 21 CFR 314.93
- 21 CFR 314.93(e)(1)
- 21 CFR 314.94(a)(3)(iii)",,"- The change in strength (from 40 mg to 10 mg base) is permissible under the FD&C Act.
- The proposed strength does not raise new safety or effectiveness concerns.
- The use, dose, dosage form, and route of administration remain consistent with the reference drug.
- The proposed change aligns with the dosing recommendations in the listed drug's labeling.
- If bioequivalence is demonstrated, the product is expected to have the same therapeutic effect.
- No significant labeling changes or new investigations are necessary to support the safety and effectiveness of the proposed strength",approved,True,1338.0,CDER,CDER
fda-2017-p-7033,FDA-2017-P-7033-0001_Citizen_Petition_from_Juliant_Generics_Limited.pdf,2017-12-13,2017,False,original petition,Jubilant Generics Limited,industry/corporation,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. ¬ß 355(j)(2)(C)]
- 21 CFR ¬ß 314.93
- 21 CFR ¬ß¬ß 10.20 and 10.30
- 21 CFR ¬ß 25.31 (for environmental impact exclusion)","Proposal to allow submission of an ANDA for a drug product (Oxcarbazepine Oral Tablet 450 mg) with a strength not currently listed for the reference drug Trileptal¬Æ (NDA #021014)
","The petitioner requests that the FDA determine that Oxcarbazepine Oral Tablet 450 mg (scored on both sides) is suitable for submission in an Abbreviated New Drug Application (ANDA)
","- The 450 mg strength is already contemplated in the approved RLD labeling for specific body weight calculations.
- The formulation would allow trisect scoring (150 mg portions), aligning with the current dosing strategy.
- The 450 mg strength reduces pill burden, simplifies administration, and minimizes risk of dosage error compared to combining multiple lower-strength tablets.
- No new safety or efficacy concerns are posed, as the strength is within the dosing range already described in the RLD labeling.
- Clinical investigations are unnecessary because the safety/efficacy profile remains the same",,Approved,2023-04-18,0.0,Center for Drug Evaluation and Research (CDER),"- Section 505(j)(2)(C) of the FD&C Act (21 U.S.C. ¬ß 355(j)(2)(C))
- Section 505(j)(2)(A) and (B)
- Section 505(j)(2)(A)(iv)
- 21 CFR 314.93
- 21 CFR 314.93(e)(1)
- 21 CFR 314.94(a)(3)(iii)",,"- The proposed change in strength (450 mg) is permissible and does not raise concerns about safety or effectiveness.
- The drug's use, dosage form, route of administration, and dose remain the same as the reference listed drug.
- The 450 mg strength is consistent with existing dosing recommendations.
- If bioequivalence is demonstrated, the drug can be expected to have the same therapeutic effect as the reference listed drug.
- No significant labeling changes or new investigations are necessary for the proposed strength
",approved,True,1952.0,CDER,CDER
fda-2017-p-7034,FDA-2017-P-7034-0001_Citizen_Petition_from_Jubilant_Generics_Limited.pdf,2017-12-19,2017,False,original petition,Jubilant Generics Limited,industry/corporation,"- 21 U.S.C. ¬ß 355(j)(2)(C) (FDC Act)
- 21 C.F.R. ¬ß 314.93
- 21 C.F.R. ¬ß 10.20
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 25.31 (Environmental Impact exclusion)","FDA's approach to determining whether a drug product that differs in strength from an RLD (Valtrex¬Æ) can be considered suitable for an ANDA submission
","A formal determination by the FDA that Valacyclovir Hydrochloride Oral Tablet EQ 250 mg and 750 mg base is suitable for submission as an Abbreviated New Drug Application (ANDA)
","- Proposed strengths share same indication, dosage form, and route of administration as the RLD
- Strengths (250 mg & 750 mg) are reflected in RLD labeling
- No new safety/efficacy concerns
- Better palatability and dosing flexibility for pediatric and geriatric patients
- Current tablets (500 mg unscored, 1 g partially scored) do not allow individualized dosing
- No clinical trials needed due to established precedent and labeling data
- 250 mg strength already marketed in UK by GLAXOSMITHKLINE",,,2025-10-15,0.0,,,,,no decision,False,2857.0,pending,pending
fda-2018-p-0033,FDA-2018-P-0033-0001_Citizen_Petition_from_Hyman__Phelps___McNamara.pdf,2018-01-02,2018,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"- Section 505(j) of the Federal Food, Drug and Cosmetic Act (FDC Act)
- 21 C.F.R. ¬ß¬ß 10.20, 10.30, 314.3, 25.31
- 57 Fed. Reg. 17,950 (Apr. 28, 1992)
- Orange Book Preface (37th ed. 2017)","FDA‚Äôs policy and designation practices for Reference Listed Drugs (RLDs) in the Orange Book, specifically regarding the lack of RLD designation for RASUVO (methotrexate) Injection under NDA 205776.","- Designate NDA 205776 (RASUVO) as a Reference Listed Drug (RLD) in the Orange Book.
- Determine and assign a RASUVO dosage strength as the Reference Standard.","- RASUVO is a single-source product with no pharmaceutical equivalence to the currently listed RLD (OTREXUP).
- No RLD exists for RASUVO‚Äôs ten dosage strengths, preventing ANDA submissions.
- RASUVO has significant market share, justifying RLD designation.",,"Dismissed (moot)
",2018-04-23,0.0,Center for Drug Evaluation and Research (CDER),"- Approved Drug Products With Therapeutic Equivalence Evaluations (Orange Book)
- Orange Book Home
- Rasuvo Listing",,"The requested action (RLD designation for Rasuvo) had already occurred on December 18, 2017, before the petition was submitted on January 2, 2018, making the petition moot.

",dismissed (moot),True,111.0,CDER,CDER
fda-2018-p-0034,FDA-2018-P-0034-0001_Citizen_Petition_from_Hyman__Phelps___McNamara.pdf,2018-01-02,2018,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"- Federal Food, Drug, and Cosmetic Act (FDC Act) ¬ß 505(j)
- 21 C.F.R. ¬ß¬ß 10.25(a), 10.30, 314.3, and 25.31
- FDA Draft Guidance for Industry: Referencing Approved Drug Products in ANDA Submissions (Jan. 2017)","FDA‚Äôs selection of Reference Standards (RS) in the Orange Book. The petition addresses the need to designate a new RS for Ranitidine Hydrochloride Capsules due to unavailability of the current RS.
","Designate Ranitidine Hydrochloride Capsules, 300 mg (ANDA 075742) as a new Reference Standard (RS) in the Orange Book, replacing the current RS under ANDA 074655
","- The existing RS (ANDA 074655) is increasingly difficult to obtain in the U.S., obstructing the ability to conduct bioequivalence studies.
- ANDA 075742 is an appropriate substitute, and designating it as RS would promote generic competition and efficiency
",2018-06-27 00:00:00,"Dismissed (moot)
",2018-08-30,1.0,Center for Drug Evaluation and Research (CDER),"The document references the Orange Book but does not cite any specific statutes or regulations (e.g., CFR sections).
","The FDA has not resolved the petition due to the need to address other Agency priorities. The interim response was issued in accordance with regulatory timelines.

","FDA investigated claims that the current reference standard (ANDA 074655, Sandoz) for ranitidine hydrochloride capsules EQ 300 mg was unavailable or difficult to obtain. However, FDA determined there was an increase in distribution of the product after the petitions were submitted, and the product was currently being distributed. This rendered the petitions moot
",dismissed (moot),True,240.0,CDER,CDER
fda-2018-p-0098,FDA-2018-P-0098-0001_Citizen_Petition_from_Lachman_Consultant_Services_.pdf,2018-01-08,2018,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 25.31 (Environmental Impact exclusion)","- FDA‚Äôs approval process for Abbreviated New Drug Applications (ANDA) where the proposed drug differs in strength from the Reference Listed Drug (RLD)
- The petition comments on the policy of allowing a change in strength of the RLD to be considered in an ANDA filing without raising new questions of safety or efficacy","The petitioner requests that FDA declare Zonisamide Capsules USP, 150 mg, 200 mg, and 300 mg as suitable for submission in an ANDA, even though they differ in strength from the existing 100 mg listed RLD (Zonegran Capsules by Sunovion Pharmaceuticals Inc.). This includes:
- Adding 150 mg, 200 mg, and 300 mg strengths
- Referencing the 100 mg, 25 mg, and 50 mg RLD capsules","- The proposed drug product uses the same dosage form (capsules) and active ingredient (zonisamide) as the RLD.
- The requested strengths (150/200/300 mg) are contemplated in the labeling of the RLD and support existing clinical dosing practices.
- Provides more convenient dosing for patients already stabilized on higher doses.
- No safety or efficacy issues are introduced.
- Includes draft labeling consistent with the RLD, and no change in intended use.
- Environmental exclusion is claimed under 21 C.F.R. ¬ß 25.31",,Approved,2023-07-17,0.0,Center for Drug Evaluation and Research (CDER),"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- 21 CFR 314.93
- 21 CFR 314.94(a)(3)(iii)
- 505(j)(2)(A) and (B)
- 505(j)(2)(A)(iv)",,"The FDA found that:
‚Ä¢ The proposed strength changes (150 mg, 200 mg, 300 mg) do not pose safety or effectiveness concerns.
‚Ä¢ The uses, dose, dosage form, and route of administration are consistent with the listed drug (Zonegran¬Æ).
‚Ä¢ If bioequivalence is demonstrated, the product can be expected to have the same therapeutic effect.
‚Ä¢ Therefore, labeling changes or new safety/effectiveness investigations are not necessary",approved,True,2016.0,CDER,CDER
fda-2018-p-0130,FDA-2018-P-0130-0001_Citizen_Petition_from_Lachman_Consultant_Services_.pdf,2018-01-08,2018,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 25.31 (Environmental Impact exclusion)
- Pediatric waiver requested under PREA (Pediatric Research Equity Act)","- FDA‚Äôs procedure for approving ANDAs for drug products with different dosage strengths and dosage forms than those of the reference listed drug (RLD).
- Specifically, the policy of allowing such changes if no safety/efficacy issues arise and labeling is consistent","FDA should declare Zonisamide Tablets in strengths of 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, and 300 mg suitable for submission as an ANDA, even though the RLD is a capsule formulation (Zonegran Capsules, 100 mg by Sunovion). The request includes a change in dosage form (capsule ‚Üí tablet) and additional strengths
","- Proposed strengths and form are clinically justified and already implied in the RLD‚Äôs labeling and dosing range.
- No safety or efficacy concerns are raised; labeling changes are minimal (strength/form only).
- Pediatric waiver requested due to minimal pediatric use and known risks (e.g., metabolic acidosis, oligohidrosis).
- Environmental exclusion claimed under 21 C.F.R. ¬ß 25.31",,Denied,2023-11-17,0.0,Center for Drug Evaluation and Research (CDER),"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- 21 CFR 314.93
- 21 CFR 314.93(e)(1)(i)
- Section 505B of the FD&C Act (PREA)
- 21 CFR 10.33 and 10.20",,"The requested change involves both a change in dosage form and strength, which triggered requirements under the Pediatric Research Equity Act (PREA). FDA determined that clinical trials are required and denied the waiver request for pediatric studies. Therefore, the petition could not be approved under the ANDA pathway
",denied,True,2139.0,CDER,CDER
fda-2018-p-0131,FDA-2018-P-0131-0001_Citizen_Petition_from_Lachman_Consultant_Services_.pdf,2018-01-08,2018,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 10.30 (Citizen Petition requirements)
- 21 C.F.R. ¬ß 25.31 (Environmental Impact exclusion)
- Pediatric waiver under PREA (Pediatric Research Equity Act)","FDA‚Äôs policy on the acceptance of Abbreviated New Drug Applications (ANDAs) for drug products that differ in strength and dosage form from the Reference Listed Drug (RLD), specifically changes from capsule to orally disintegrating tablet (ODT) and addition of new strengths
","FDA should declare Zonisamide Orally Disintegrating Tablets (ODTs) in 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, and 300 mg strengths as suitable for submission in an ANDA, despite the RLD (Zonegran) being a capsule formulation. This includes both a dosage form change (capsule ‚Üí ODT) and strength additions
","- RLD (Zonegran) labeling supports a wide dosing range (up to 600 mg/day), implying higher strengths like 150‚Äì300 mg are clinically reasonable.
- An ODT formulation offers dosing flexibility, convenience, and potential compliance improvements.
- Labeling changes are minimal, and the proposed product maintains same indications and directions for use.
- Pediatric use is minimal, and the product carries known risks (e.g., oligohidrosis, metabolic acidosis), justifying a full pediatric waiver.
- Environmental impact exclusion claimed under 21 C.F.R. ¬ß 25.31
",,Denied,2023-11-17,0.0,Center for Drug Evaluation and Research (CDER),"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- 21 CFR 314.93
- 21 CFR 314.93(e)(1)(i)
- Section 505B of the FD&C Act (PREA)
- Section 505(j)(2)(A) of the FD&C Act
- 21 CFR 10.33
- 21 CFR 10.20",,"The petition requested permission to submit an ANDA for zonisamide orally disintegrating tablets (various strengths), a change in dosage form and strength. This change triggered the Pediatric Research Equity Act (PREA). The FDA determined that clinical trials were required and denied the waiver request for those trials. As a result, the petition could not be approved under the ANDA pathway
",denied,True,2139.0,CDER,CDER
fda-2018-p-0258,FDA-2018-P-0258-0001_Citizen_Petition_from_Gilman_Cheese_Corporation.pdf,2018-01-01,2018,False,original petition,Gilman Cheese Corporation,industry/corporation,"- 21 C.F.R. ¬ß¬ß 133.169 and 133.170 ‚Äì Standards of identity for ‚ÄúPasteurized Process Cheese‚Äù
- 21 C.F.R. ¬ß¬ß 25.30(h) and 25.32(a) ‚Äì (for Environmental Impact exclusion)",FDA‚Äôs regulations specifying the name ‚ÄúPasteurized Process Cheese‚Äù in 21 C.F.R. Parts 133.169 and 133.170. The petition comments on the use of that terminology and its implications for consumer perception and industry competition,"Amend 21 C.F.R. Parts 133.169 and 133.170 to:
- Replace all instances of the term ‚ÄúPasteurized Process Cheese‚Äù with ‚ÄúBlended Cheese‚Äù, including in the part titles and body text.
- This would change the official designation of the cheese product to reflect a more neutral and modern term","- The term ‚ÄúPasteurized Process Cheese‚Äù is misleading and unfairly associates high-quality cheese with lower-quality processed foods due to the word ‚Äúprocess‚Äù.
- A PPC contains approximately 98% all-natural ingredients, is closer in composition to natural cheeses like Cheddar than to other ‚Äúprocess cheese food‚Äù products.
- The term ‚ÄúBlended Cheese‚Äù is more accurate, free of negative consumer bias, separates it from lower-quality products, and is market-neutral and innovative",2018-07-12 00:00:00,,2025-10-15,1.0,,,"Due to competing priorities including the FDA‚Äôs Nutrition Innovation Strategy (NIS), the agency has not resolved the petition within 180 days. The agency stated it will review the petition as part of efforts to modernize standards of identity and ensure they align with consumer dietary needs
",,no decision,False,2844.0,pending,pending
fda-2018-p-0266,FDA-2018-P-0266-0001_Citizen_Petition_from_Arent_Fox_LLP.pdf,2018-01-16,2018,False,original petition,Arent Fox LLP,law/consulting,"- Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- 21 C.F.R. ¬ß¬ß 10.20, 10.30(b)(3) (Citizen Petition requirements)
- 21 C.F.R. ¬ß 25.31 (Environmental Impact categorical exclusion)
- 21 C.F.R. ¬ß 25.40 (Environmental assessment provision)","FDA‚Äôs designation of Reference Standards (RS) in the Orange Book for Abbreviated New Drug Application (ANDA) bioequivalence testing, particularly the status of DermOtic Oil, 0.01% (NDA 019452) by Hill Dermaceuticals Inc. as the current RS","Designate ANDA No. A091306 / Fluocinolone Acetonide Oil, 0.01% Ear Drops, owned by Identi Pharmaceuticals Inc., as the new Reference Standard (RS) drug in the Orange Book for this product category, due to unavailability of the current RS (DermOtic Oil, 0.01%)
","- The current RS (DermOtic Oil, 0.01%) has been in long-term backorder with no anticipated availability.
- The Identi product is the market leader based on units sold.
- ANDA applicants cannot access sufficient quantities of the RLD to perform bioequivalence studies.
- Designating Identi‚Äôs product as RS would facilitate generic development",,"Dismissed (moot)
",2018-07-16,0.0,Center for Drug Evaluation and Research (CDER),"- No specific statutes or CFRs cited by number
- Orange Book referenced as the source for reference standards",,"The petitioner requested new reference standards for three fluocinolone acetonide products (ear, scalp, and body oils) due to market unavailability. However, the FDA confirmed that distribution resumed in April 2018, after the petitions were submitted. Therefore, the petition was rendered moot
",dismissed (moot),True,181.0,CDER,CDER
fda-2018-p-0268,FDA-2018-P-0268-0001_Citizen_Petition_from_Arent_Fox_LLP.pdf,2018-01-16,2018,False,original petition,Arent Fox LLP,law/consulting,"- Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- 21 C.F.R. ¬ß¬ß 10.20, 10.30(b)(3) (Citizen Petition requirements and economic impact)
- 21 C.F.R. ¬ß 25.31 (Categorical exclusion from environmental assessment)
- 21 C.F.R. ¬ß 25.40 (Environmental assessment provision)","The FDA‚Äôs designation of Reference Standards (RS) in the Orange Book, specifically for Fluocinolone Acetonide 0.01% Topical Oil (Body Oil). The current RS, Derma-Smoothe/FS (NDA 019452), is on long-term backorder and unavailable for bioequivalence testing","FDA should designate ANDA No. A201764, Fluocinolone Acetonide 0.01% Topical Oil (Body Oil), owned by Identi Pharmaceuticals Inc., as the new Reference Standard (RS) in place of Derma-Smoothe/FS
","- Derma-Smoothe/FS is unavailable (long-term backorder), preventing ANDA applicants from obtaining sufficient quantity for bioequivalence testing.
- Identi‚Äôs product is therapeutically equivalent and is the market leader by units sold.
- Replacing the RS would facilitate generic development by ensuring an accessible comparator",,"Dismissed (moot)
",2018-07-16,0.0,Center for Drug Evaluation and Research (CDER),"- No formal statutes or regulations (e.g., CFR or FDCA citations) are mentioned.
- The Orange Book is cited as the reference database.",,"The petitioner requested designation of new reference standards due to backorders of three Hill Dermaceuticals products (under NDA 019452). However, the FDA found that all three products resumed distribution in April 2018. As they are now actively being marketed, there was no need to designate new reference standards, making the petition moot
",dismissed (moot),True,181.0,CDER,CDER
fda-2018-p-0269,FDA-2018-P-0269-0001_Citizen_Petition_from_Arent_Fox_LLP.pdf,2018-01-16,2018,False,original petition,Arent Fox LLP,law/consulting,"- Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- 21 C.F.R. ¬ß¬ß 10.20 and 10.30(b)(3) (Citizen Petition procedural and economic impact requirements)
- 21 C.F.R. ¬ß 25.31 (categorical exclusion from environmental assessment)
- 21 C.F.R. ¬ß 25.40 (environmental assessment provision)","FDA‚Äôs policy on designating Reference Standards (RSs) for ANDA submission, particularly when the currently designated RS (Derma-Smoothe/FS) is unavailable due to long-term backorder
","FDA should designate ANDA No. A201759 / Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil), owned by Identi Pharmaceuticals Inc., as the new Reference Standard (RS) in the Orange Book, replacing Derma-Smoothe/FS (NDA 019452)
","- Derma-Smoothe/FS is unavailable due to long-term backorder, with no anticipated return.
- The petitioner‚Äôs client cannot obtain enough product to perform required bioequivalence testing.
- The Identi product is therapeutically equivalent and is the market leader in units sold.
- Replacing the RS would enable generic ANDA filings
",,"Dismissed (moot)
",2018-07-16,0.0,Center for Drug Evaluation and Research (CDER),"No formal statutes or specific CFR citations were mentioned.
Reference was made to the Orange Book",,"The petitioner requested designation of new reference standards due to unavailability of three fluocinolone acetonide products. FDA investigated and found that distribution resumed in April 2018, rendering the petitions moot
",dismissed (moot),True,181.0,CDER,CDER
fda-2018-p-0327,FDA-2018-P-0327-0001_Citizen_Petition_Fresenius_KabiUSA__LLC.pdf,2018-01-22,2018,False,original petition,"Fresenius Kabi USA, LLC",industry/corporation,"- 21 C.F.R. ¬ß 10.30 (Citizen petition procedures)
- 21 C.F.R. ¬ß 314.161 (FDA determination on withdrawn drug products)
- 21 C.F.R. ¬ß 314.162 (Listing and delisting of approved drugs)
- 21 C.F.R. ¬ß 25.31 (Environmental Impact‚Äîcategorical exclusion)","FDA‚Äôs listing of Mitomycin (NDA 050450) in the ‚ÄúDiscontinued Section‚Äù of the Orange Book, which affects its eligibility for ANDA submissions
","FDA should determine whether Mitomycin (NDA 050450, 5 mg/vial and 20 mg/vial), held by Bristol Laboratories Inc., was withdrawn from sale for reasons of safety or efficacy
","- Mitomycin is listed in the Discontinued Section of the Orange Book.
- FDA must determine whether the drug was withdrawn for safety/efficacy reasons or for business reasons, as required before an ANDA can be approved.
- Fresenius Kabi seeks this determination to support ANDA referencing",,Approved,2018-06-11,0.0,Center for Drug Evaluation and Research (CDER),"- 21 CFR ¬ß 314.161 ‚Äì Determination if drug was withdrawn for safety/effectiveness
- 21 CFR ¬ß 314.162 ‚Äì Removal of drugs from the Orange Book list
- 21 CFR ¬ß 10.30 ‚Äì Citizen petitions",,"The petitioner requested confirmation on the status of Mutamycin (mitomycin) injectable, 5 mg/vial and 20 mg/vial under NDA 050450. FDA reviewed its records and found no evidence that the drug was withdrawn for reasons of safety or effectiveness. It reviewed postmarketing data and literature and found no adverse safety concerns. Therefore, FDA maintained the listing of the drug in the ‚ÄúDiscontinued Drug Product List‚Äù in the Orange Book, allowing ANDAs to proceed
",approved,True,140.0,CDER,CDER
fda-2018-p-0339,FDA-2018-P-0339-0001_Citizen_Petition_from_Hahn_Loeser___Parks_LLP.pdf,2018-01-19,2018,False,original petition,Hahn Loeser & Parks LLP,law/consulting,"- FDC Act ¬ß 505(j)(2)(C) (Suitability petition for ANDA submission)
- 21 C.F.R. ¬ß¬ß 10.20 and 10.30 (Citizen petition procedures)
- FDC Act ¬ß 505B (Pediatric Research Equity Act)
- 21 C.F.R. ¬ß 25.31 (Environmental impact categorical exclusion)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact provision)","FDA‚Äôs regulation of suitability determinations for ANDA submissions that differ in strength from the listed drug product (i.e., change from 25 mg or 100 mg/vial to 200 mg/vial for Bendamustine Hydrochloride)","FDA should declare that Bendamustine Hydrochloride for Injection, 200 mg/vial is suitable for submission in an ANDA, based on reference to TREANDA (25 mg/vial and 100 mg/vial) approved under NDA 022249
","- Proposed product is quantitatively and qualitatively the same as the listed drug when reconstituted.
- 200 mg strength offers greater convenience for typical dosing needs and reduces need for multiple vials, minimizing risk of medication errors and cytotoxic exposure.
- No other changes in labeling, dosage form, or administration",,,2025-10-15,0.0,,,,,no decision,False,2826.0,pending,pending
fda-2018-p-0343,FDA-2018-P-0343-0001_Citizen_Petition_from_Fish___Richardson_PC.pdf,2018-01-23,2018,False,original petition,Fish & Richardson P.C.,law/consulting,"- 505(j)(4)(C)(i) of the FDCA
- 505(j)(4)(G) of the FDCA
- 505(q) of the FDCA
- 21 C.F.R. ¬ß¬ß 10.30, 10.31, 314.127, 314.92(a)(1), 314.94(a)(5), 314.94(a)(8), 314.127(a)(3), 314.127(a)(7), 314.95(3)(b), 320.1(c), 314.108","FDA‚Äôs potential approval of Abbreviated New Drug Application (ANDA) No. 210299 submitted by Apotex Inc. for a generic version of ZORVOLEX¬Æ
","Request for the FDA to refuse approval of ANDA No. 210299 by Apotex Inc. because:
- The active ingredient (diclofenac sodium) is not the same as that in the RLD (diclofenac free acid)
- The labeling is not the same as that approved for ZORVOLEX¬Æ","- Diclofenac sodium is a different active ingredient from diclofenac free acid due to differences in chemical structure and physical properties (solubility, bioavailability, GI permeability)

- Labeling differences create safety concerns and confusion, as the RLD label explicitly warns against interchangeability with salt forms like diclofenac sodium",,Denied,2018-06-20,0.0,Center for Drug Evaluation and Research (CDER),"- 21 U.S.C. ¬ß 355(j) ‚Äì Abbreviated New Drug Applications (ANDAs)
- 21 U.S.C. ¬ß 355(q) ‚Äì Procedures for citizen petitions related to pending ANDAs
- 21 CFR ¬ß 314.92(a)(1) and ¬ß 314.94(a)(5) ‚Äì Requirements for same active ingredient in ANDAs
- 21 CFR ¬ß 314.105, ¬ß 314.110, ¬ß 314.125, ¬ß 314.127, ¬ß 314.200 ‚Äì Application review and procedural provisions",,"The petition requested that FDA refrain from approving an ANDA by Apotex referencing Zorvolex (diclofenac free acid), arguing that Apotex‚Äôs product used diclofenac sodium, a different active ingredient. FDA denied the petition, stating:
‚Ä¢ The Agency is not required to issue final decisions on specific aspects of pending applications outside the standard review process.
‚Ä¢ FDA emphasized the petitioner‚Äôs concerns may be valid (i.e., a product with a different active ingredient cannot be approved as an ANDA), but that determination must await full review of the specific application.
‚Ä¢ As no final determination had been made on the ANDA at the time, addressing the issues raised would be premature.
‚Ä¢ Therefore, the petition was denied without comment on the approval status of any specific ANDA
",denied,True,148.0,CDER,CDER
fda-2018-p-0564,FDA-2018-P-0564-0001_Citizen_Petition_from_Panera_LLC.pdf,2018-01-18,2018,False,original petition,"Panera, LLC",industry/corporation,"- 21 U.S.C ¬ß¬ß 401, 403, 371 (FDCA Sections)
- 21 CFR 160.100, 160.105, 160.110, 160.115, 160.140, 160.145, 160.150, 160.180, 160.185, 160.190 (Egg-related standards)
- 21 CFR 101.4(b)(10)-(12) (Ingredient labeling)
- 21 CFR 130.5(b) (Standard of identity)
- 21 CFR 25.32 (Environmental Impact exclusion)","The absence of a formal definition for the term ‚Äúegg‚Äù under 21 CFR 160.100 and the permissive labeling of processed egg products as ‚Äúegg,‚Äù ‚Äúegg whites,‚Äù or ‚Äúegg yolks‚Äù under 21 CFR 101.4","- Amend 21 CFR 160.100 to define ‚Äúegg‚Äù as a food made from a cracked shell egg without additives or further processing, except for pathogen control (e.g., pasteurization).
- Amend 21 CFR 101.4 to prohibit processed egg products containing additives from being labeled simply as ‚Äúegg,‚Äù ‚Äúegg whites,‚Äù or ‚Äúegg yolks‚Äù","- Current regulations lack clarity and allow processed egg products with additives (e.g., preservatives, emulsifiers) to be labeled simply as ‚Äúegg,‚Äù misleading consumers.
- Panera uses real shell eggs and wants transparency and fairness in product naming.
- A clear standard would support honest labeling and consistent use in retail and foodservice.
- Suggested definition aligned with 9 CFR 590.1 under the Egg Inspection Act",2018-08-27 00:00:00,Denied,2022-03-29,1.0,"Center for Food Safety and Applied Nutrition (CFSAN)
","- 21 U.S.C. ¬ß 341 ‚Äì Definitions and standards for food
- 21 CFR ¬ß 130.5(b) ‚Äì Petition requirements for food standards
- 21 CFR ¬ß 160.100 ‚Äì General egg standard provisions
- 21 CFR ¬ß¬ß 160.105 ‚Äì 160.190 ‚Äì Standards for egg products
- 21 CFR ¬ß 101.4(b)(10)-(12) ‚Äì Labeling of egg ingredients
- 21 CFR ¬ß 118.3 ‚Äì Shell egg definition (for specific purposes)","FDA stated that a final decision had not been reached due to competing agency priorities, including the Nutrition Innovation Strategy (NIS), and limited resources. The agency noted that it plans to modernize the standards of identity program, which includes reviewing petitions such as this one that requested a clearer definition of the term ‚Äúegg‚Äù in 21 CFR ¬ß 160.100. FDA confirmed that a decision will be communicated once the review is complete
","The FDA denied the petition because:
‚Ä¢ There is no statutory authority to define ""egg"" as a standard of identity under 21 CFR ¬ß 160.100.
‚Ä¢ The petition did not provide evidence that current labeling practices mislead consumers.
‚Ä¢ FDA regulations already require manufacturers to disclose additives.
‚Ä¢ The proposal did not demonstrate that changes would promote honesty, fair dealing, or protect against economic adulteration.
‚Ä¢ The request was not selected for standards modernization review
",denied,True,1531.0,CFSAN,Other/Specialty Center
fda-2018-p-0597,FDA-2018-P-0597-0001_Citizen_Petition_from_the_Alliance_for_Natural_Hea.pdf,2018-02-07,2018,False,original petition,Alliance for Natural Health USA (ANH-USA),advocacy/academic,"- 21 C.F.R. ¬ß¬ß 10.20, 10.30 (Citizen Petition procedures)
- 21 C.F.R. ¬ß 25.30 (Environmental Impact categorical exclusion)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact clause)
- Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (Compounding provisions)","FDA‚Äôs appointment of the Pew Charitable Trusts as a voting member of the Pharmacy Compounding Advisory Committee (PCAC)
","Remove the Pew Charitable Trusts from its voting position on the PCAC, due to conflict of interest
","- Pew has partnered with PhRMA and BIO, groups with vested pharmaceutical interests opposed to compounded drugs.
- Signed a joint letter with PhRMA (June 12, 2017) advocating positions financially benefiting drug companies.
- Co-sponsored Congressional briefings that pushed anti-compounding narratives.
- Other PCAC members with potential conflicts are non-voting, while Pew is a voting member, making its conflict more serious.
- Pew‚Äôs involvement undermines the impartiality and credibility of PCAC",2018-07-23 00:00:00,Denied,2019-07-03,1.0,Center for Drug Evaluation and Research (CDER),"- 21 CFR ¬ß 14.100(c)(17) ‚Äì PCAC charter structure
- 21 U.S.C. ¬ß 353a(c)(1) ‚Äì PCAC composition requirement under Section 503A
- 21 U.S.C. ¬ß 353b(c)(2) ‚Äì PCAC composition under Section 503B
- 5 CFR ¬ß 2635.502(a) ‚Äì Appearance issues guidance
- 21 CFR ¬ß 14.80(b)(1)(i) ‚Äì Nomination standards
- FDA Draft Guidance on Appearance Issues and Conflicts of Interest","FDA stated that it has not resolved the issues raised in the petition due to the need to address other Agency priorities. The agency committed to responding as soon as possible once a decision is made
","- Pew does not have a voting seat on the PCAC, contrary to the petition‚Äôs claim.
- The member cited (Elizabeth Jungman) served in an individual capacity, not as a representative of Pew.
- Jungman resigned from the PCAC on April 25, 2019, making the petition moot.
- The FDA rigorously screens PCAC members for both conflicts of interest and appearance issues. In Jungman‚Äôs case, no conflict or appearance issue was found.
- Members of the PCAC are selected for their individual expertise and do not represent their employers or organizations.
- The Agency emphasized the importance of maintaining integrity and balance in PCAC membership
",denied,True,511.0,CDER,CDER
fda-2018-p-0598,FDA-2018-P-0598-0001_Citizen_Petition_from_Hyman__Phelps___McNamara__PC.pdf,2018-02-07,2018,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"- 21 U.S.C. ¬ß¬ß 355(a), 355(j), 355(b)(2) (FDCA sections)
- 21 C.F.R. ¬ß 10.30 (Citizen petition procedure)
- 505(q) of the FDCA
- 21 C.F.R. ¬ß 25.31(c) (Environmental Impact categorical exclusion)","FDA's potential approval of NDA or ANDA referencing Sodium Bicarbonate Injection, USP products (particularly from manufacturer Cumberland Pharmaceuticals Inc.) without adequate data to support approval routes
","- FDA should refuse approval of any NDA or ANDA for Sodium Bicarbonate Injection, USP that does not meet applicable regulatory requirements.
- Require any applicant to submit a full NDA (not an ANDA or 505(b)(2)) unless the applicant demonstrates its product is pharmaceutically equivalent to an RLD","- Products currently on market are unapproved or lack data on equivalence, sterility, or stability.
- No ANDA or 505(b)(2) product should be approved unless it shows pharmaceutical equivalence and meets FDA‚Äôs own technical and regulatory standards.
- Improper approval undermines FDA‚Äôs authority and poses safety risks",,Denied,2018-07-06,0.0,Center for Drug Evaluation and Research (CDER),"- Section 505(q) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. ¬ß 355(q))
- FDA regulations in 21 CFR Part 314
- Sections 505(c), 505(j), and 505(b)(2) of the FD&C Act",,"- FDA denied the petition without commenting on the approvability of specific ANDAs.
- The decision reflects FDA‚Äôs policy of not preemptively ruling on components of pending ANDAs before making a final decision on the ANDA as a whole.
- FDA emphasized the statutory and regulatory processes in place to evaluate and approve ANDAs, and noted that the petition did not justify bypassing these established review procedures.
- FDA noted that it must take action within 150 days under section 505(q), even if final decisions on the related ANDAs have not been made.",denied,True,149.0,CDER,CDER
fda-2018-p-0599,FDA-2018-P-0599-0001_Citizen_Petition_from_National_Pediculosis_Associa.pdf,2018-02-06,2018,False,original petition,"National Pediculosis Association, Inc. (NPA)",advocacy/academic,"510(k) medical device clearance (FDA K981250); general reference to FDA policy and website standards. No citation of 505(q) or 21 C.F.R. 10.30
","The petition comments on the FDA‚Äôs public education materials and website content regarding lice treatment options, specifically their emphasis on chemical remedies and lack of comparable attention to combing and the LiceMeister comb
","The NPA requests the FDA to:
‚Ä¢ Update its website and educational materials to better emphasize combing as a treatment option.
‚Ä¢ Acknowledge that not all lice combs are equivalent.
‚Ä¢ Mention the LiceMeister¬Æ comb by name, similar to how chemical treatments are branded","- The LiceMeister comb was cleared as a 510(k) device for lice detection and removal.
- Research shows combing is more effective and safer than chemical treatments, especially for children.
- FDA materials currently downplay the effectiveness of combing and overlook the risks of chemical treatments (e.g., lindane).
- Environmental concerns about pesticide use and its effects on water systems and public health.
- Inclusion of combing aligns with FDA‚Äôs 2018 policy goal to empower consumers with informed health decisions",2018-09-25 00:00:00,Partially Approved / Partially Denied,2020-01-17,1.0,"Office of the Commissioner (OC)
","- 21 CFR ¬ß 10.30(e)(2) ‚Äì Citizen petition procedures
- 21 CFR ¬ß 807.92(a)(3) ‚Äì Substantial equivalence for medical devices
- 21 CFR ¬ß 880.5960 ‚Äì Classification for lice removal kits
- Section 510(k) of the FD&C Act ‚Äì Premarket notification for devices","The petition requested revisions to FDA educational materials to promote lice combing‚Äîspecifically the LiceMeister comb‚Äîas a valid option for head lice treatment. The FDA responded that the petition raises broader issues requiring further cross-agency review and analysis. Therefore, a final decision could not yet be made. FDA issued this interim response in compliance with regulations to inform the petitioner of ongoing consideration
","- Lice combs are regulated as class I exempt medical devices and the LiceMeister comb received 510(k) clearance in 1998.
- FDA agreed that combing is a valid method for managing pediculosis (head lice) and updated its website to reflect this.
- However, FDA denied the request to name LiceMeister specifically on the website, as it does not generally list brand names of exempt devices.
- FDA also found no scientific or regulatory basis to distinguish the LiceMeister from other lice combs and therefore denied the claim that it is ‚Äúnot equivalent‚Äù to other lice combs.
- The Agency also did not receive data to support claims that combing improves treatment safety or reduces drug-related risks, so these parts of the petition were denied
",partially approved / denied,True,710.0,offices,Other/Specialty Center
fda-2018-p-0614,FDA-2018-P-0614-0001_Citizen_Petition_from_GeneYork_Pharmaceuticals_Gro.pdf,2018-02-07,2018,False,original petition,"GeneYork Pharmaceuticals, LLC",industry/corporation,"- 21 C.F.R. ¬ß 10.25(a) (General filing procedures)
- 21 C.F.R. ¬ß 10.30 (Citizen petition)
- 21 C.F.R. ¬ß 314.122 (Reference Listed Drug availability)
- 21 C.F.R. ¬ß 25.24(c)(1) (Environmental impact exclusion)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact)","FDA‚Äôs current designation of HEXADROL (NDA 014694, Organon USA Inc.) as the Reference Listed Drug (RLD), and Luitpold‚Äôs product (ANDA 087440) as the Reference Standard (RS) for dexamethasone sodium phosphate injection
","FDA should designate ANDA 084916 (owned by Fresenius Kabi USA, Inc.) as an alternate Reference Standard (RS) for HEXADROL, to support generic drug development
","- Both the current RLD (HEXADROL) and RS (Luitpold) products are no longer commercially available, making it difficult to develop a generic product.
- Fresenius Kabi‚Äôs ANDA 084916 product is pharmaceutically equivalent (same ingredient, dosage form, strength) and holds over 80% of market share, making it the most accessible and practical RS.
- Ensuring access to an available RS aligns with the Hatch-Waxman Act‚Äôs goal of facilitating affordable generics",2018-08-06 00:00:00,"Dismissed (moot)
",2019-09-27,1.0,"Center for Drug Evaluation and Research (CDER)
","No specific statutes or regulations are cited in the letter. However, it references the Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book) and includes a link to the database .
","FDA stated it had not yet resolved the issues raised in the petition due to the need to address other Agency priorities. The Agency assured it would respond as soon as possible given the demands on its resources
","The petitioner had requested FDA designate a new reference standard for Hexadrol (dexamethasone sodium phosphate). FDA explained that the Orange Book was recently updated to identify the exact product (ANDA 084916 by Fresenius Kabi) as the reference standard. Hence, the petition‚Äôs request had already been fulfilled, and it was dismissed as moot .

",dismissed (moot),True,597.0,CDER,CDER
fda-2018-p-0625,FDA-2018-P-0625-0001_Citizen_Petition_from_Made_in_the_USA_Foundation.pdf,2018-02-01,2018,False,original petition,Made in the USA Foundation,advocacy/academic,"- 19 U.S.C. ¬ß 1304
- 19 C.F.R. ¬ß¬ß 134.1(d), 134.25, 134.46
- 21 U.S.C. ¬ß¬ß 331, 352
- 21 C.F.R. ¬ß 201.1",The absence of a requirement for country-of-origin labeling on prescription drug packaging sold in pharmacies,"The petitioner requests that the FDA initiate a rulemaking proceeding to require that:
1) All prescription drugs dispensed by pharmacies state their country of origin in at least 12-point font.
2) Labels referring to the U.S. (e.g., ‚ÄúUSA‚Äù) must disclose the actual country of origin in type at least as large.
3) Failure to comply may result in criminal prosecution","- To ensure transparency and protect consumers from misleading labeling.
- Federal law already requires country-of-origin labeling for imported goods, and this should extend to prescription drugs.
- FDA inspections of foreign manufacturing facilities are infrequent, particularly in India and China, from where 80% of U.S. prescription drugs are sourced.
- The change would reduce the carbon footprint and promote U.S. drug manufacturing.
",2018-08-07 00:00:00,Denied,2019-07-30,1.0,"Center for Drug Evaluation and Research (CDER)
","- 19 U.S.C. ¬ß 1304 ‚Äì U.S. customs statute (marking requirements)
- 19 CFR ¬ß 134.1(d) ‚Äì Customs definition of ""ultimate purchaser""
- 19 CFR ¬ß 134.46 ‚Äì Marking requirements for imported articles
- 21 U.S.C. ¬ß 353(b)(2) ‚Äì FD&C Act exemption for prescription drugs
- 21 CFR ¬ß 201.1(a) ‚Äì Labeling regulations for name and address of manufacturer, packer, or distributor
- 21 U.S.C. ¬ß 331(a) ‚Äì Prohibition of misbranded drugs","The petition requested FDA to initiate a rulemaking requiring pharmacies to label prescription drugs with their country of origin. FDA responded that the request raises complex issues requiring extensive review and analysis, and thus a final decision could not yet be reached. The interim response ensures compliance with regulatory timelines while a thorough review is ongoing
","- The petition relied on customs law (19 U.S.C. ¬ß 1304) which is enforced by CBP, not FDA.
- CBP has jurisdiction to interpret what constitutes ‚Äúultimate purchaser‚Äù and whether markings are required.
- FDA does not interpret failure to state country of origin on pharmacy labels as misbranding under FD&C Act ¬ß 331(a).
- Under 21 CFR ¬ß 201.1(a) and 21 U.S.C. ¬ß 353(b)(2), pharmacy-dispensed prescriptions are exempt from labeling requirements regarding manufacturer information, so long as other statutory conditions are met.
- FDA emphasized that the choice of drug often depends on prescriber or pharmacist discretion, not consumer comparison of domestic vs. foreign origin.
- No evidence was provided that omission of origin labeling misleads consumers or poses safety concerns
",denied,True,544.0,CDER,CDER
fda-2018-p-0673,FDA-2018-P-0673-0001_Citizen_Petition_from_Justice_for_Jake.pdf,2017-11-13,2018,False,original petition,Justice for Jake (Board of Directors),advocacy/academic,"- Section 355(e) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 10.30
- ¬ß360bbb-2 of U.S.C. (Classification of products)
- ¬ß811 Part C (5)
- Controlled Substances Act of 1970","Classification of Alprazolam as a Schedule IV drug under the Controlled Substances Act
","Reschedule alprazolam from Schedule IV to Schedule II and conduct a study on its control in relation to the opioid crisis
","- Alprazolam is involved in a significant portion of opioid overdose deaths (e.g., ~25% of overdoses involving opioids like hydrocodone, oxycodone, methadone).
- 1 in 3 opioid overdose deaths involves an anti-anxiety drug; 90% of these involve alprazolam.
- Recreational use is rising, with 125,000 hospital visits per year.
- Liquid formulations linked to suicides and fatalities.
- Pharmacy controls are lax (e.g., imprecise counting, refills).
- Environmental data from a 2013 study shows overdose deaths involving benzodiazepines like alprazolam have increased 5x since 1996.
- Petition argues alprazolam's abuse and danger justify placement in Schedule II
",2018-08-07 00:00:00,Partially Approved / Partially Denied,2021-02-17,1.0,"Center for Drug Evaluation and Research (CDER)
","- 21 U.S.C. ¬ß 360bbb-2
- 21 U.S.C. ¬ß 811
- Controlled Substances Act (21 U.S.C. ¬ß 801 et seq.)
- 21 U.S.C. ¬ß 812
- 21 CFR ¬ß¬ß 1300‚Äì1317
- Section 505(o)(4) of the FD&C Act
- Memorandum of Understanding with NIDA (50 FR 9518, March 8, 1985)","- The petition requested that alprazolam be reclassified from Schedule IV to Schedule II under the Controlled Substances Act, and that a study be conducted on its role in the opioid crisis.
- FDA responded that the petition raises complex issues needing extensive review and analysis, thus preventing a decision at that time.
- The letter was issued to comply with the procedural requirement for interim response under the applicable regulation
","- Granted in part: FDA agreed to conduct a scientific and medical evaluation (eight-factor analysis) of alprazolam under 21 U.S.C. 811.
- Denied in part: FDA denied the request to reschedule alprazolam from Schedule IV to Schedule II because it does not have the statutory authority to take final scheduling action.
- FDA acknowledged the petition‚Äôs concern regarding alprazolam‚Äôs role in the opioid crisis and agreed to conduct an eight-factor analysis for potential rescheduling.
- However, FDA clarified that only DEA has the authority to reschedule controlled substances.
- Data reviewed included abuse, misuse, addiction, and overdose statistics, indicating that harms primarily occur when benzodiazepines are used with other substances.
- FDA has already taken steps to mitigate risks through labeling changes and public communication (e.g., boxed warnings, guidance for gradual tapering).",partially approved / denied,True,1192.0,CDER,CDER
fda-2018-p-0674,FDA-2018-P-0674-0001_Citizen_Petition_from_Medtech_Products_Inc.pdf,2018-02-09,2018,False,original petition,Medtech Products Inc.,industry/corporation,"- 505(j)(2)(C) of the FD&C Act
- 21 C.F.R. ¬ß¬ß 10.20, 10.30, 314.93 (ANDA suitability petition regulations)
- 21 C.F.R. ¬ß 25.31(a) (Environmental impact exemption)
- 21 U.S.C. ¬ß 355c(a)(4)(A)(ii) (Pediatric Research Equity Act waiver request)",Suitability petition for submission of an ANDA with a dosage form different from the Reference Listed Drug (RLD): Excedrin¬Æ Migraine (tablet),"FDA approval to submit an ANDA for acetaminophen 250 mg, aspirin 250 mg, and caffeine 65 mg in powder dosage form for OTC treatment of migraine
","- Powder dosage form does not require new safety/efficacy studies as the active ingredients and strengths are identical to the RLD.
- Bioequivalence studies will be conducted and included in the ANDA.
- The powder form is already a common OTC form in this category.
- No significant labeling changes required.
- Offers an alternative for patients with dysphagia (difficulty swallowing).
- The RLD (Excedrin¬Æ Migraine) remains marketed and has no unexpired exclusivity, per the Orange Book",,Approved,2024-01-24,0.0,"Center for Drug Evaluation and Research (CDER)
","- Section 505(j)(2)(C) of the FD&C Act
- 21 CFR ¬ß 314.93 ‚Äì Suitability petition requirements
- 21 CFR ¬ß 314.93(e)(1) ‚Äì Approval standards
- 21 CFR ¬ß 314.94(a)(3)(iii) ‚Äì ANDA referencing requirement
- Section 505B of the Act (Pediatric Research Equity Act)
- Section 505(j)(2)(A) and (B) ‚Äì ANDA submission requirements
- Section 505(j)(2)(A)(iv) ‚Äì Bioequivalence",,"- FDA determined the change from tablet to powder form does not raise safety or efficacy concerns.
- Proposed use, dose, and route of administration match the listed drug.
- The change aligns with the approved labeling of the reference drug and meets bioequivalence expectations.
- Under PREA, studies were not required due to evidence that the drug would be ineffective or unsafe in all pediatric age groups, per Section 505B(a)(5).
- Approval of the petition does not guarantee ANDA approval, which is subject to further review.",approved,True,2175.0,CDER,CDER
fda-2018-p-0829,FDA-2018-P-0829-0001_Citizen_Petition_from_Prinston_Pharmaceutical_Inc_.pdf,2018-02-22,2018,False,original petition,Prinston Pharmaceutical Inc.,industry/corporation,"- 21 C.F.R. ¬ß¬ß 10.25(a), 10.30 (Citizen petition procedures)
- 21 C.F.R. ¬ß 25.31 (Environmental impact exemption)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact disclosure)
- Section 505(j) of the FD&C Act (generic drug approval requirements)
- FDA Draft Guidance (Jan. 2017), Referencing Approved Drug Products in ANDA Submissions","FDA‚Äôs designation of NDA 050746 (BACTROBAN, held by GlaxoSmithKline) as the Reference Standard (RS) for Mupirocin Calcium Cream, EQ 2% Base
","Prinston requests that FDA designate ANDA 201587 (held by Glenmark Pharmaceuticals Inc. USA) as the new Reference Standard for Mupirocin Calcium Cream, EQ 2% Base
","- Current RS (NDA 050746) is unavailable in sufficient commercial quantities for in vivo bioequivalence testing.
- FDA has discretion to select a different RS when access to the current RS is limited.
- ANDA 201587 is the only commercially available formulation of the product.
- Redesignating the RS will facilitate market entry of generics and mitigate drug shortage risks",,Approved,2018-04-13,0.0,"Center for Drug Evaluation and Research (CDER)
","- Section 505(j) of the FD&C Act (21 U.S.C. 355(j))
- 21 CFR ¬ß 314.3(b) ‚Äì Definitions for listed drug and therapeutic equivalence
- 21 CFR ¬ß 314.94(a)(3) ‚Äì ANDA bioequivalence requirement
- 21 CFR ¬ß 314.161(a) ‚Äì Withdrawal of RLD
- 21 CFR ¬ß 314.122(a) ‚Äì Conditions for using reference standards",,"- The original reference standard (Bactroban Calcium Cream, NDA 050746) was discontinued.
- Glenmark‚Äôs product (ANDA 201587) was selected as the new reference standard based on commercial availability and market leadership.
- FDA determined that the petitioners provided sufficient grounds for the change in designation
",approved,True,50.0,CDER,CDER
fda-2018-p-0870,FDA-2018-P-0870-0001_Citizen_Petition_from_LACHMAN_CONSULTANT_SERVICES_.pdf,2018-02-26,2018,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"- Section 505(j)(2)(C) of the FD&C Act
- 21 C.F.R. ¬ß 10.30 (Citizen Petition procedures)
- 21 C.F.R. ¬ß 25.31 (Environmental impact categorical exclusion)
- 21 U.S.C. ¬ß 355B (505B) (Pediatric Research Equity Act ‚Äì cited for inapplicability)","Suitability determination for submission of an ANDA for Potassium Chloride Extended Release Tablets, 8 mEq, based on a change in strength from the RLD (K-Dur, 20 mEq)
","That FDA declare Potassium Chloride Extended Release Tablets, 8 mEq to be suitable for submission as an ANDA referencing the RLD, Potassium Chloride ER Tablets 20 mEq (NDA 19439)
","- The proposed product differs only in strength (8 mEq vs 20 mEq) from the RLD.
- The change in strength aligns with approved labeling dosing guidelines (e.g., doses divided so no more than 20 mEq is given at once).
- There is no change in indications, warnings, or directions for use.
- Multiple 8 mEq ER potassium chloride tablets have already been approved by FDA, as shown in a table on page 2 listing other products by AbbVie, Upsher-Smith, Mylan, etc.
- No clinical investigations should be required because safety and efficacy are not impacted by the proposed strength change.
- The Pediatric Research Equity Act (PREA) does not apply to this request.",,Denied,2023-07-17,0.0,"Center for Drug Evaluation and Research (CDER)
","- Section 505(j)(2)(C) of the FD&C Act
- 21 CFR ¬ß 314.93(e)(1)(vi) ‚Äì Criteria for petition approval
- 21 CFR ¬ß 314.122(a) ‚Äì RLD withdrawal conditions
- 21 CFR ¬ß 314.161(a) ‚Äì RLD withdrawal review
- 21 CFR ¬ß 10.33 ‚Äì Reconsideration of decisions
- 21 CFR ¬ß 10.20 ‚Äì Petition format and submission",,"- The petition requested permission to submit an ANDA for Potassium Chloride ER Tablets USP, 8 mEq, citing a change in strength from the listed drug (20 mEq).
- FDA denied the petition because the same 8 mEq strength formulation was already approved in multiple NDAs (K-Tab and Klor-con).
- This disqualifies the petition under 21 CFR ¬ß 314.93(e)(1)(vi), which prohibits approval if an NDA already exists for the same change.
- FDA also noted the option to file for reconsideration or submit a new petition with additional information
",denied,True,1967.0,CDER,CDER
fda-2018-p-0874,FDA-2018-P-0874-0001_Citizen_Petition_from_Bonumose_LLC.pdf,2018-02-22,2018,False,original petition,"Bonumose, LLC",industry/corporation,"- 21 C.F.R. ¬ß 10.30 (Citizen petition regulations)
- 21 U.S.C. ¬ß 321 (ff) (Definition of dietary supplement)
- 21 C.F.R. ¬ß 101.36 (Nutrition labeling of dietary supplements)
- 21 U.S.C. ¬ß 343(a)(1) (Misbranding provision)
- 21 C.F.R. ¬ß¬ß 101.3, 101.4, 101.9 (Labeling provisions for foods)","FDA's current labeling policy and enforcement practices that require ""Total Sugars"" and ""Added Sugars"" declarations on the Nutrition Facts Label for all monosaccharides and disaccharides, including rare sugars such as tagatose and allulose","Bonumose requests that FDA:
1. Reclassify tagatose and similar rare sugars to exclude them from ""Total Sugars"" and ""Added Sugars"" on Nutrition Facts Labels.
2. Amend regulations and guidance to reflect this exclusion.
3. Issue a guidance document or enforcement discretion policy pending formal rulemaking","- Tagatose is minimally absorbed and metabolized, does not raise blood glucose levels, and has low caloric value (1.5 kcal/g).
- Including tagatose in ‚ÄúTotal Sugars‚Äù and ‚ÄúAdded Sugars‚Äù is misleading to consumers and inconsistent with FDA's goal of informed dietary choices.
- Health benefits include prebiotic effects, dental health advantages, and lack of impact on insulin/glucose response.
- Tagatose is chemically a sugar, but functionally behaves more like fiber or polyols, which are not classified as ‚Äúadded sugars.‚Äù
- Current labeling rules may discourage manufacturers from using healthier sugar alternatives like tagatose",2018-08-17 00:00:00,Denied,2022-05-18,2.0,"Center for Food Safety and Applied Nutrition (CFSAN)
","- 21 CFR ¬ß 101.9(c)(6)(iii) ‚Äì Definition of ""Added Sugars""
- 21 CFR ¬ß 101.9(c)(6)(iv) ‚Äì Voluntary declaration of sugar alcohols
- 21 CFR ¬ß 101.9(c)(6)(ii) ‚Äì Definition of ""Total Sugars""
- 21 CFR ¬ß 101.60(c)(2) ‚Äì Use of ""no added sugar"" labeling
- 21 CFR ¬ß 101.4(a)(1) and ¬ß 101.4(b)(20) ‚Äì Ingredient labeling by common or usual name
- 21 CFR ¬ß 101.80 ‚Äì Health claims for noncariogenic carbohydrate sweeteners","- The petition requested that D-tagatose be exempted from classification as an added sugar and allowed to be voluntarily labeled like sugar alcohols.
- FDA explained that it could not reach a decision within the statutory timeline due to other priorities and limited resources.
- FDA committed to completing its review as warranted in context of its program priorities","- Caloric Contribution: D-tagatose contributes 1.5 kcal/g, significantly more than allulose (0.4 kcal/g), and may add more ""empty calories"" to the diet.
- Labeling Integrity: FDA aims to prevent consumer confusion and maintain clarity; individualized declarations for multiple distinct sugars could clutter labels.
- Regulatory Consistency: D-tagatose fits the definition of ""added sugars"" under current regulations.
- Scientific Review: Although D-tagatose differs metabolically from traditional sugars, the FDA found insufficient basis to treat it differently without further rulemaking
",denied,True,1546.0,CFSAN,Other/Specialty Center
fda-2018-p-0876,FDA-2018-P-0876-0001_Citizen_Petition_from_Hyman__Phelps___McNamara.pdf,2018-02-23,2018,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"- 21 C.F.R. ¬ß 10.30 (Citizen petitions)
- 21 C.F.R. ¬ß 10.20 (General filing regulations)
- 21 C.F.R. ¬ß 314.93 (Suitability petitions)
- Section 505(j)(2)(C) and 505(j)(2)(A)(iii) of the FD&C Act
- 21 C.F.R. ¬ß 25.31 (Environmental categorical exclusions)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact information upon request)
- 505B(a)(1)(A) (Pediatric Research Equity Act)",FDA‚Äôs authority to determine suitability of an ANDA submission for a product that differs from a Reference Listed Drug (RLD) in strength only. The RLD is ALBENZA (albendazole) 200 mg tablets,"Request for FDA to determine that Albendazole Tablets, 400 mg are suitable for submission in an ANDA, referencing ALBENZA 200 mg as the RLD
","- The only difference from the RLD is tablet strength (400 mg vs 200 mg); all other elements‚Äîactive ingredient, route of administration, dosage form, and regimen‚Äîremain the same.
- The proposed product would reduce tablet burden for patients needing 400 mg or 800 mg daily, aligning with approved RLD dosing (which currently requires 2 or 4 tablets).
- The petition asserts no safety or efficacy issues arise from the change.
- PREA does not apply since this is not a new active ingredient, dosage form, indication, route, or regimen",,Approved,2023-05-01,0.0,"Center for Drug Evaluation and Research (CDER)
","- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 CFR ¬ß 314.93 ‚Äì Petitions for strength changes
- 21 CFR ¬ß 314.93(e)(1) ‚Äì Grounds for approval
- 21 CFR ¬ß 314.94(a)(3)(iii) ‚Äì Referencing the petition in ANDA submissions",,"- The proposed change in strength (200 mg to 400 mg) does not pose questions of safety or effectiveness.
- The dosage form, route of administration, and labeled uses are the same as the listed drug (Albenza¬Æ 200 mg).
- The proposed product aligns with dosing recommendations in the labeling.
- Bioequivalence demonstration would suffice to show therapeutic equivalence.
- No new investigations are required
",approved,True,1893.0,CDER,CDER
fda-2018-p-0877,FDA-2018-P-0877-0001_Citizen_Petition_from_The_Food_Lawyers.pdf,2018-02-24,2018,False,original petition,The Food Lawyers¬Æ,law/consulting,"- 21 C.F.R. ¬ß101.9(c)(6)(i)
- 21 C.F.R. ¬ß10.30
- 21 C.F.R. ¬ß25.30(k)
- 21 C.F.R. ¬ß10.30(b)",The current exclusion of konjac flour from the FDA's list of recognized dietary fibers under 21 C.F.R. ¬ß101.9(c)(6)(i).,"The petitioner requests the FDA to engage in rulemaking to amend 21 C.F.R. ¬ß101.9(c)(6)(i) to include konjac flour (konjac glucomannan) in the list of dietary fibers.
","- Konjac flour is an isolated nondigestible carbohydrate that meets the FDA‚Äôs criteria for dietary fiber.
- It has documented physiological benefits recognized by FDA, including:
- Reduction in LDL cholesterol and total blood lipids
- Increased daily fecal weight and defecation frequency (laxative effect)
- The petition cites multiple peer-reviewed clinical studies supporting these benefits.
- The structure and chemistry of konjac glucomannan meet FDA requirements (Œ≤-1,4 linkages resistant to digestion, molecular weight, etc.).",2018-06-13 00:00:00,Approved,2020-01-09,1.0,"Center for Food Safety and Applied Nutrition (CFSAN)
","- 21 CFR ¬ß 101.9(c)(6)(i)
- 21 CFR ¬ß 10.30(e)(3)
- Final rule: 81 FR 33742 (May 27, 2016)
- Guidance: Scientific Evaluation of the Evidence on the Beneficial Physiological Effects of Isolated or Synthetic Non-Digestible Carbohydrates Submitted as a Citizen Petition (21 CFR 10.30)","- The petitioner requested inclusion of konjac flour (konjac glucomannan) in the list of non-digestible carbohydrates beneficial to health under 21 CFR ¬ß 101.9(c)(6)(i).
- FDA acknowledged the submission of prior studies and the intent to submit additional information.
- The agency indicated it needed more time to review the complete materials before issuing a decision
","- The FDA reviewed the citizen petition and supplements submitted by The Food Lawyers, including extensive scientific literature.
- 26 studies were evaluated on glucomannan's effects on blood cholesterol; 9 were considered scientifically valid, and 6 demonstrated significant reductions in total and/or LDL cholesterol.
- Evidence shows that glucomannan has a physiological effect beneficial to human health, specifically by reducing blood cholesterol.
- FDA intends to exercise enforcement discretion for declaring glucomannan as dietary fiber on labels until the rulemaking process is completed.",approved,True,684.0,CFSAN,Other/Specialty Center
fda-2018-p-0878,FDA-2018-P-0878-0001_Citizen_Petition_from_Hyman__Phelps___McNamara__P_.pdf,2018-02-26,2018,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"- 505(j)(2)(C) of the FD&C Act
- 21 C.F.R. ¬ß 314.93
- 21 C.F.R. ¬ß 10.20
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 25.31 (Environmental impact exclusion)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact)
- References to PREA (Pediatric Research Equity Act) and FDC Act ¬ß 505B(a)(1)(A)","The petitioner comments on FDA's regulatory procedures governing the submission of ANDAs (Abbreviated New Drug Applications) for drug products with different tablet strengths than the reference listed drug (RLD)
","FDA is requested to determine that Sorafenib Tosylate Tablets, 400 mg is suitable for submission as an ANDA referencing NEXAVAR (sorafenib tosylate) Tablets, 200 mg
","- The proposed product differs only in tablet strength (400 mg vs. 200 mg).
- The active ingredient, route of administration, dosage form, and dosing regimen remain the same as the RLD.
- Labeling and safety/efficacy profiles are consistent with the RLD.
- The 400 mg strength reduces tablet burden (1 tablet vs. 2 tablets).
- PREA does not apply as no new indication, dosage form, or route of administration is involved.
- Bioequivalence will be demonstrated to NEXAVAR 200 mg",,Approved,2023-04-11,0.0,"Center for Drug Evaluation and Research (CDER)
","- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 CFR ¬ß 314.93
- 21 CFR ¬ß 314.93(e)(1)
- 21 CFR ¬ß 314.94(a)(3)(iii)
- Section 505(j)(2)(A) and (B) and 505(j)(2)(A)(iv) of the Act",,"- The proposed change in strength (from 200 mg to 400 mg) does not raise safety or efficacy concerns.
- The dosage form, route, and labeled uses match the listed drug.
- The 400 mg tablet is consistent with the labeling of the listed drug.
- If bioequivalence is shown, the product will have the same therapeutic effect.
- No new investigations are required
",approved,True,1870.0,CDER,CDER
fda-2018-p-0884,FDA-2018-P-0884-0001_Citizen_Petition_from_Buchanan_Ingersoll___Rooney_.pdf,2018-02-26,2018,False,original petition,Buchanan Ingersoll & Rooney PC,law/consulting,"- 21 C.F.R. ¬ß 10.30
- 21 U.S.C. ¬ß 352(f)
- 21 C.F.R. ¬ß 201.100(c)(1)
- 21 C.F.R. ¬ß 314.70
- 21 C.F.R. ¬ß 201.57(c)(7)(ii)(A)
- 21 C.F.R. ¬ß 25.31(a)",The FDA-approved package insert (PI) of Linzess (linaclotide) ‚Äî specifically the labeling related to adverse event (AE) data and presentation for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C),"The petitioner requests that the FDA require revisions to the Linzess PI to:
1. Convert narrative AE data for 72 mcg dose into a table.
2. Add AE data for the 290 mcg dose with a footnote.
3. Disclose allowance for 3-day drug holidays in AE discontinuation data.
4. Note the AE threshold of ‚Äúannoyance‚Äù in tables
","- AE data for the 72 mcg and 290 mcg doses is not clearly or fully disclosed.
- Narrative format makes AE data less accessible and misleading.
- Data omits temporary treatment discontinuations and patient subjectivity in reporting AEs (e.g., only ‚Äúannoying‚Äù events are counted).
- The current PI fails to provide adequate, standardized information to support proper risk-benefit analysis and treatment decisions",2018-08-21 00:00:00,Denied,2021-02-19,1.0,"Center for Drug Evaluation and Research (CDER)
","- 21 CFR 314.70
- 21 U.S.C. 321(m)
- 21 U.S.C. 352(f)(1)
- 21 CFR 201.5
- 21 CFR 201.56(d)(1)
- 21 CFR 201.57(a)(11)
- 21 CFR 201.57(c)(7)
- 21 CFR 201.100(c)(1)
- 21 CFR 201.57(c)(3)(ii)
- 21 CFR 201.57(c)(7)(ii)(A)","The FDA stated it was unable to reach a decision on the petition due to the need to address other Agency priorities. The response assures that the FDA will reply fully once resources permit
","- Trial Data Format: FDA determined that converting Trial 5 safety data into a tabular format and incorporating it into Table 2 was inappropriate due to limitations of cross-study comparisons and risk of implying untested comparative claims.

- 290 mcg Dose Data: Including the 290 mcg dose in Table 2 would suggest an unapproved dosing regimen for CIC, which is not indicated for this dosage. Existing labeling already communicates why this dosage is not recommended for CIC.

- Discontinuations: No evidence that adverse events (AEs) during temporary treatment pauses (up to 3 days) were excluded from reporting. Thus, proposed disclaimer was unnecessary.

- ‚ÄúAnnoyance‚Äù Threshold: FDA found that adverse events were not filtered based on patient descriptions of severity (e.g., ‚Äúannoyance‚Äù) and all reported AEs were recorded. The grading scale was only used to categorize severity, not to exclude events.",denied,True,1089.0,CDER,CDER
fda-2018-p-0945,FDA-2018-P-0945-0001_Citizen_Petition_from_Scott_Beach_Redacted.pdf,2018-02-21,2018,False,original petition,Scott G. Beach,individual,"- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 25.31
- 21 C.F.R. ¬ß 10.30(b)","Inclusion of aluminum hydroxide and other aluminum salts in injectable vaccines
","Issue an order prohibiting the inclusion of aluminum hydroxide and other aluminum salts in injectable vaccines. Explicit language requested: ""Aluminum hydroxide and other aluminum salts shall not be included in injectable vaccines.‚Äù","- Scientific research (e.g., by Dr. Christopher A. Shaw and Dr. Christopher Exley) allegedly links aluminum salts to motor neuron damage and autism spectrum disorder.
- Studies cited suggest potential adverse neurological effects from aluminum exposure in neonatal mice.
- Invokes the precautionary principle due to lack of safety studies in children.
- Asserts that aluminum salts should not be injected into children or anyone else",2018-08-16 00:00:00,Denied,2020-01-17,1.0,"Center for Biologics Evaluation and Research (CBER)
","- 42 U.S.C. ¬ß 262(a)(2)(C)(i), ¬ß 262(i)(1), ¬ß 262(a) (Public Health Service Act)
- 21 CFR ¬ß 601.2(a), ¬ß 601.2(d), ¬ß 600.3(p), ¬ß 610.15(a) (FDA Biologics Regulations)","FDA stated that it had not yet completed its response due to the need to address other priorities. A full response will be provided later
","- Licensed vaccines must be demonstrated to be ""safe, pure, and potent"" per statutory and regulatory requirements.
- Aluminum salts (used as adjuvants) have a long history (80+ years) of demonstrated safety in billions of doses worldwide.
- FDA reviewed relevant studies and found no credible evidence showing harm from aluminum adjuvants in vaccines.
- Referenced studies (Shaw et al. and Mold et al.) had major methodological flaws or were not generalizable.
- FDA's own 2011 study showed the total aluminum exposure from vaccines in the first year of life is significantly below risk thresholds.
- WHO‚Äôs Global Advisory Committee on Vaccine Safety endorsed the FDA's aluminum safety assessment.
- Petition failed to provide evidence justifying a prohibition of aluminum adjuvants.",denied,True,695.0,CBER,Other/Specialty Center
fda-2018-p-0964,FDA-2018-P-0964-0001_Citizen_Petition_from_Fresenius_Kabi_USA__LLC___Co.pdf,2018-03-02,2018,False,original petition,"Fresenius Kabi USA, LLC (FK USA)",industry/corporation,"- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 314.161
- 21 C.F.R. ¬ß 314.162
- 21 C.F.R. ¬ß 25.31
- 21 C.F.R. ¬ß 10.30(b)","Determination of whether the NDA holder (Baxter Healthcare Corp.) for Plasma-Lyte 148 and Dextrose 5% (NDA 017451) has withdrawn the product for reasons of safety or efficacy
","Request for FDA to determine whether the listed drug (Plasma-Lyte 148 and Dextrose 5%) has been withdrawn for reasons of safety or efficacy, which is required prior to approval of an Abbreviated New Drug Application (ANDA)
","- The product appears in the ‚ÄúDiscontinued Section‚Äù of the FDA‚Äôs Orange Book.
- Regulatory framework requires FDA to confirm whether discontinuation was for safety/efficacy reasons before approving related ANDAs",,Approved (Determination Issued),2018-08-24,0.0,"Center for Drug Evaluation and Research (CDER)
","Not explicitly stated by citation number. However, the document references inclusion in the ""Discontinued Drug Product List"" of the Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book), which is governed by 21 CFR ¬ß 314.162.
",,"- The FDA reviewed its records regarding PLASMA-LYTE M AND DEXTROSE 5% (NDA 017390) and PLASMA-LYTE 148 AND DEXTROSE 5% (NDA 017451).
- It concluded that these products were not withdrawn from sale for reasons of safety or efficacy.
- Therefore, the products will remain listed in the Orange Book.",approved,True,175.0,CDER,CDER
fda-2018-p-0967,FDA-2018-P-0967-0001_Citizen_Petition_from_Fresenius_Kabi_USA__LLC.pdf,2018-03-02,2018,False,original petition,"Fresenius Kabi USA, LLC (FK USA)",industry/corporation,"- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 314.161
- 21 C.F.R. ¬ß 314.162
- 21 C.F.R. ¬ß 25.31
- 21 C.F.R. ¬ß 10.30(b)",Whether the NDA holder (Baxter Healthcare Corp.) for Plasma-Lyte M and Dextrose 5% (NDA 017390) has withdrawn or withheld the product from sale for reasons of safety or efficacy,"FDA should determine whether the product has been voluntarily withdrawn or withheld from sale for reasons related to safety or efficacy before approving any related ANDAs
","- Product appears in the ‚ÄúDiscontinued Section‚Äù of the FDA Orange Book.
- Required determination by FDA under 21 C.F.R. ¬ß 314.161 before an ANDA referencing the product can be approved.
- FDA must clarify if the withdrawal was due to safety or effectiveness concerns, or for other business reasons",,Approved (Determination Issued),2018-08-24,0.0,"Center for Drug Evaluation and Research (CDER)
","Not explicitly stated by citation number. However, the document references inclusion in the ""Discontinued Drug Product List"" of the Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book), which is governed by 21 CFR ¬ß 314.162.
",,"- The FDA reviewed its records regarding PLASMA-LYTE M AND DEXTROSE 5% (NDA 017390) and PLASMA-LYTE 148 AND DEXTROSE 5% (NDA 017451).
- It concluded that these products were not withdrawn from sale for reasons of safety or efficacy.
- Therefore, the products will remain listed in the Orange Book.",approved,True,175.0,CDER,CDER
fda-2018-p-0998,FDA-2018-P-0998-0001_Citizen_Petition_from_Hyman_Phelps___McNamara_P_C_.pdf,2018-03-05,2018,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"- 21 C.F.R. ¬ß 10.25
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 314.122
- 21 C.F.R. ¬ß 314.161
- 21 C.F.R. ¬ß 314.162
- 21 C.F.R. ¬ß 25.31
- FDCA ¬ß¬ß 505(j), 505(w)",Determination of whether PROLIXIN (fluphenazine HCl) Tablets‚ÄîNDA 011751‚Äîwas withdrawn for reasons of safety or effectiveness,"FDA should determine that PROLIXIN Tablets (1 mg, 2.5 mg, 5 mg, and 10 mg) were not withdrawn for reasons of safety or effectiveness, allowing it to be referenced in an ANDA
","- PROLIXIN is listed in the ‚ÄúDiscontinued Drug Product List‚Äù in the Orange Book.
- Approval was voluntarily withdrawn by the NDA holder (Apothecon) in 2009 for commercial reasons, not for safety or effectiveness.
- No evidence indicates safety or effectiveness concerns prompted the withdrawal",,Approved (Determination Issued),2018-08-09,0.0,"Center for Drug Evaluation and Research (CDER)
","- 21 CFR 314.161
- 21 CFR 314.162
- Section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(7))
- Drug Price Competition and Patent Term Restoration Act of 1984 (Pub. L. 98-417)",,"- FDA reviewed its records and found no information indicating the drug (Prolixin tablets) was withdrawn for safety or effectiveness reasons.
- The petitioner presented no data suggesting a safety or efficacy concern.
- FDA independently evaluated postmarketing adverse events and literature and confirmed no evidence supporting withdrawal for safety/effectiveness. The drug was withdrawn voluntarily by the sponsor, not by FDA.",approved,True,157.0,CDER,CDER
fda-2018-p-1014,FDA-2018-P-1014-0001_Citizen_Petition_from_Haynes_and_Boone_LLP.pdf,2018-03-06,2018,False,original petition,"Haynes and Boone, LLP",law/consulting,"- 21 C.F.R. ¬ß¬ß 10.25(a) and 10.30
- 21 C.F.R. ¬ß 320.24(b)
- 21 C.F.R. ¬ß 25.31","FDA‚Äôs Draft Guidance for Mycophenolate Mofetil Oral Suspension (October 2017 revision), which permits use of metabolite-only data to establish bioequivalence","- Withdraw the current Draft Guidance
- Issue new guidance requiring use of both parent compound (MMF) and metabolite (MPA) data for bioequivalence
- Deny approval of any ANDA relying only on metabolite data
- Change AB therapeutic equivalence rating for previously-approved ANDAs that do not meet the revised criteria (including lacking nasogastric tube studies)","- Technological advancements now allow accurate MMF measurement in plasma
- MMF pharmacokinetics may significantly impact clinical outcomes due to variability in conversion to MPA
- Use of only MPA data ignores key differences that may affect drug safety and efficacy
- Precedents exist for requiring parent compound analysis for other prodrugs
- Nasogastric administration studies are critical to demonstrate equivalent delivery and safety",,Denied,2018-08-02,0.0,"Center for Drug Evaluation and Research (CDER)
","- Section 505(j) of the FD&C Act (21 U.S.C. ¬ß 355(j))
- 21 CFR ¬ß¬ß 314.3(b), 314.94(a), 314.127(a)(6)(i), 320.23(b), 320.24
- Case law including Schering Corp. v. FDA, Fisons Corp. v. Shalala",,"- Scientific Grounds: FDA found insufficient evidence to support petitioner‚Äôs claim that mycophenolate mofetil (the parent compound) could be accurately and reliably measured for BE studies.
- Regulatory Flexibility: Under the FD&C Act and FDA regulations, bioequivalence can be demonstrated through either parent compound or metabolite data, depending on scientific justification.
- Existing Guidance Adequacy: The current draft guidance already allows for the parent drug to be used in BE testing if it can be reliably measured, and defaults to metabolite data otherwise.
- Case-by-Case Review: FDA emphasized that whether parent compound data is necessary should be determined during review of specific ANDAs, not through a universal requirement.
- Lack of Evidence Against Approved Product: The petition failed to provide any data showing that the currently approved ANDA (203005) is not therapeutically equivalent or bioequivalent to the RLD.",denied,True,149.0,CDER,CDER
fda-2018-p-1040,FDA-2018-P-1040-0001_Citizen_Petition_From_Joshua_Brooks_Redacted.pdf,2018-02-28,2018,False,original petition,Joshua Brooks,individual,"The petition refers to the Controlled Substances Act, specifically Schedule I and Schedule II of DEA Drug Scheduling. No specific CFR citations (e.g., 21 C.F.R. 10.30) are provided
","No specific FDA policy or guidance is referenced. The petitioner is proposing a new regulatory classification for added sugar.
","Classify added sugar as either a Schedule I or Schedule II drug, substance, or chemical under the Controlled Substances Act","- High potential for abuse and addictive nature of added sugar
- No currently accepted medicinal use for added sugar
- Examples of public concern and legislative efforts (e.g., banning sugary sodas from school vending machines)
- Comparison with other controlled substances such as alcohol, tobacco, and marijuana
- Describes sugar as ‚Äúlegal cocaine‚Äù due to its addictive properties and impact on children and consumers",,,2025-10-15,0.0,,,,,no decision,False,2786.0,pending,pending
fda-2018-p-1173,FDA-2018-P-1173-0001_Citizen_Petition_from_the_Alliance_for_Natural_Hea.pdf,2018-03-15,2018,False,original petition,Alliance for Natural Health USA,advocacy/academic,"- 21 C.F.R. ¬ß 10.20
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 25.30(h)
- Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act
- Section 201(ff)(3)(B)(ii) of the FD&C Act (21 U.S.C. ¬ß 321(ff)(3)(B)(ii))
- 21 C.F.R. Part 312","The FDA‚Äôs Investigational New Drug Applications Guidance, specifically Section VI.D.1., which states that a clinical investigation of a dietary supplement intended to diagnose, cure, mitigate, treat, or prevent a disease requires an IND (Investigational New Drug application)","Revise Section VI.D.1. of the FDA‚Äôs IND Guidance to clarify that an IND is not required when:
- There is no intent to seek drug approval for the dietary supplement
- The clinical investigation is used to substantiate a legal dietary supplement claim (e.g., structure/function or health claim)

Additionally, the petitioner requests the removal of the final paragraph of Section VI.D.1. that imposes this IND requirement","- Requiring an IND could effectively turn a dietary supplement into a drug, threatening its status as a legally marketable supplement.
- IND requirements create published studies that trigger drug classification under current FDA interpretation.
- Supplements are not intended to diagnose, cure, or treat disease and should not fall under IND protocols.
- FDA‚Äôs interpretation contradicts the original purpose of Part 312, which was designed for drugs, not supplements.
- The regulation of intended use should be based on marketing and labeling, not on the intent behind clinical investigations.
- Signed affidavits could ensure no post-study marketing as a drug.
- Regulatory clarity is needed to protect the viability of legal dietary supplement research and claims.",2018-09-11 00:00:00,Denied,2022-12-13,1.0,Office of the Commissioner,"- 21 CFR 312.20(a) and 312.3(b) (IND submission requirements)
- 21 CFR 312.2(b)(1) (IND exemption criteria)
- 21 CFR 312.23, 312.40(b)
- 21 CFR 56, 50 (IRB and informed consent)
- 21 U.S.C. 321(ff), 331(ll) (FD&C Act dietary supplement definitions and restrictions)
- 21 CFR 10.115 (guidance practices)
- Proposed Rule: 87 FR 75536 (December 9, 2022) (IND exemption)","The petition raises complex issues requiring extensive review and analysis by FDA officials. An interim response was issued under applicable regulations.

","- The petition‚Äôs request to revise the IND guidance is being addressed through an ongoing rulemaking process, which the FDA finds to be a more efficient and comprehensive forum.
- FDA proposed new IND exemptions (self-determined and FDA-determined) for dietary supplement studies that meet specific safety, regulatory, and intent criteria.
- Finalizing the proposed rule would necessitate revising the IND guidance, thereby covering the concerns raised in the petition.
- Consequently, FDA declined to take separate action on the petition, instead inviting participation in the rulemaking process",denied,True,1734.0,offices,Other/Specialty Center
fda-2018-p-1174,FDA-2018-P-1174-0002_Citizen_Petition_from_Pharma_Regulatory_Consultant.pdf,2018-03-10,2018,False,original petition,Pharma Regulatory Consultants LLC,law/consulting,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 25.31
- Pediatric Research Equity Act (PREA)","The FDA‚Äôs requirement for determining the suitability of a new dosage form under an ANDA, specifically for changing the dosage form of the reference-listed drug (Revatio) from powder for oral suspension to liquid oral suspension","That the Commissioner declare Sildenafil Citrate Oral Suspension, 10 mg/mL suitable for submission under an ANDA, with a dosage form change from powder to liquid oral suspension (same strength as the RLD)","- The only proposed change is the dosage form (from powder to ready-to-use liquid suspension); the strength and therapeutic intent remain unchanged.
- The product would be identical at the time of administration.
- The proposed change would improve convenience by eliminating the need for reconstitution.
- No new safety or efficacy concerns are introduced.
- A waiver from pediatric studies is requested based on prior safety concerns in pediatric use documented in the RLD labeling",,Denied,2024-01-16,0.0,Center for Drug Evaluation and Research (CDER),"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- 21 CFR 314.93(e)(1)(vi) (petition denial criteria)
- 21 CFR 10.33 and 10.20 (procedures for reconsideration)",,"The petition sought approval to submit an ANDA for Sildenafil Citrate Oral Suspension (10 mg/mL) by changing the dosage form. However, the FDA denied it because an NDA for the same change already exists: Liqrev¬Æ (sildenafil citrate) Oral Suspension, approved under NDA 214952. According to 21 CFR 314.93(e)(1)(vi), this precludes petition approval. 
",denied,True,2138.0,CDER,CDER
fda-2018-p-1185,FDA-2018-P-1185-0001_Suitability_Petition_from_Provetica_Animal_Health_.pdf,2018-03-12,2018,False,original petition,Provetica Animal Health LLC,industry/corporation,"- Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act (FFDCA)
- 21 C.F.R. ¬ß 25.33(d)(5)
- 21 C.F.R. ¬ß 25.21
- Freedom of Information Act (FOIA), 21 C.F.R. ¬ß 20.61","Request to permit submission of an Abbreviated New Animal Drug Application (ANADA) for a product with a different dosage form than the approved pioneer drug (Heartgard¬Æ Plus chewable tablet).
","Approval of a Suitability Petition to allow filing of an ANADA for a generic ivermectin/pyrantel pamoate product in flavored soft tab form, differing in dosage form from the pioneer chewable tablet","- The proposed product is pharmacologically equivalent to the pioneer (same active ingredients, dosage strengths, and indications).
- The only difference is the dosage form: non-meat flavored soft tab versus meat-based chewable tablet.
- The soft tab eliminates the need for chewing, offering dosing flexibility for dogs with food allergies or swallowing preferences.
- Dissolution is expected to be complete without chewing.
- Labeling will parallel the pioneer product, with minor differences in administration instructions and storage depending on stability data",,Approved,2018-06-13,0.0,"Center for Veterinary Medicine (CVM), specifically the Office of New Animal Drug Evaluation
","- Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- Section 512(n)(3)(C) (approval criteria for suitability petitions)
- 21 CFR 514.5 (presubmission conference recommendations)",,"The petition proposed a change in dosage form (from chewable to meat-flavored soft tablet) for a generic ivermectin/pyrantel product. The FDA determined that:
- The proposed changes are permissible under a suitability petition.
- The changes do not require new safety or efficacy investigations.
- Therefore, the petition is approved under section 512(n)(3)(C) of the Act.
- However, this approval does not guarantee final approval of the ANADA, which must undergo a full review.",approved,True,93.0,CVM,Other/Specialty Center
fda-2018-p-1195,FDA-2018-P-1195-0001_Citizen_Petition_from_Hyman__Phelps___McNamara__PC.pdf,2018-03-19,2018,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"- Federal Food, Drug, and Cosmetic Act (FDC Act), ¬ß 505(j)
- 21 C.F.R. ¬ß¬ß 10.25(a), 10.30, 25.31, 314.3","FDA‚Äôs designation of a Reference Standard (RS) in the Orange Book. The current RS (and RLD) for Naproxen Oral Suspension, 25 mg/mL, is reportedly no longer marketed (NAPROSYN, NDA 018965). The petition requests replacing this RS to enable generic competition","Designate Naproxen Oral Suspension, 25 mg/mL, approved under ANDA 074190 as a new Reference Standard (RS) in the Orange Book
","- The current RS (NAPROSYN, NDA 018965) is reportedly no longer available in the U.S., blocking further generic competition.
- Designating ANDA 074190 as the new RS would allow ANDA applicants to rely on it for in vivo bioequivalence testing.
- The request aligns with FDA‚Äôs policy to consider marketing status and support competition by choosing a new RS when appropriate.
- The proposed RS is therapeutically equivalent and can help prevent shortages and improve development efficiency",2018-09-13 00:00:00,"Approved (Petition Granted)
",2019-05-08,2.0,Center for Drug Evaluation and Research (CDER),"- 21 U.S.C. ¬ß 355(j) ‚Äì Section 505(j) of the FD&C Act (ANDA requirements)
- 21 CFR 314.3(b) ‚Äì Definitions of reference standard and listed drug
- 21 CFR 314.94(a)(3) ‚Äì Reference standard selection
- 81 FR 69580, 69619 (Oct. 6, 2016) ‚Äì Preamble to final rule on ANDAs and 505(b)(2) applications","The FDA has not resolved the petition due to the need to address other Agency priorities. The response is interim and issued in compliance with 21 CFR 10.30(e)(2), with a commitment to respond once resources allow
","- The petition requested that FDA designate ANDA 074190 (West-Ward's naproxen oral suspension, 25 mg/mL) as the new reference standard (RS) for Naprosyn.
- The current RS, NDA 018965 (Naprosyn), was found to be unavailable or not reliably available in the market for in vivo bioequivalence testing.
- West-Ward's ANDA 074190 is the only approved generic product that is therapeutically equivalent to the RLD and is listed in the Orange Book.
- Therefore, the FDA granted the petition and designated ANDA 074190 as the new RS. 
",approved,True,415.0,CDER,CDER
fda-2018-p-1195,FDA-2018-P-1195-0004_Citizen_Petition_Supplement__from_Hyman__Phelps___.pdf,2018-08-13,2018,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"Not newly cited in the supplement, but reinforces the context of:
- 21 C.F.R. ¬ß 10.30 (original petition basis)
- No new statutory citations in this supplement","FDA's maintenance of the current Reference Standard (RS) in the Orange Book for Naproxen Oral Suspension, 25 mg/mL ‚Äî specifically, NAPROSYN under NDA 018965, which the petitioner claims is unavailable in the market.","Reinforces the original request: Designate ANDA 074190 (Naproxen Oral Suspension, 25 mg/mL) as a new Reference Standard (RS) in the Orange Book, due to the unavailability of the current RS
","- The original RS, NAPROSYN (NDA 018965), is still not available through legitimate distribution channels.
- Letters from drug suppliers (confidential attachments) confirm the unavailability.
- One comment opposing the petition (submitted July 12, 2018) claimed a generic firm could procure the RLD, but the petitioner disputes this with evidence.
- Continued unavailability prevents ANDA filers from performing bioequivalence studies, thus blocking generic competition",2018-09-13 00:00:00,"Approved (Petition Granted)
",2019-05-08,2.0,Center for Drug Evaluation and Research (CDER),"- 21 U.S.C. ¬ß 355(j) ‚Äì Section 505(j) of the FD&C Act (ANDA requirements)
- 21 CFR 314.3(b) ‚Äì Definitions of reference standard and listed drug
- 21 CFR 314.94(a)(3) ‚Äì Reference standard selection
- 81 FR 69580, 69619 (Oct. 6, 2016) ‚Äì Preamble to final rule on ANDAs and 505(b)(2) applications","The FDA has not resolved the petition due to the need to address other Agency priorities. The response is interim and issued in compliance with 21 CFR 10.30(e)(2), with a commitment to respond once resources allow
","- The petition requested that FDA designate ANDA 074190 (West-Ward's naproxen oral suspension, 25 mg/mL) as the new reference standard (RS) for Naprosyn.
- The current RS, NDA 018965 (Naprosyn), was found to be unavailable or not reliably available in the market for in vivo bioequivalence testing.
- West-Ward's ANDA 074190 is the only approved generic product that is therapeutically equivalent to the RLD and is listed in the Orange Book.
- Therefore, the FDA granted the petition and designated ANDA 074190 as the new RS. 
",approved,True,268.0,CDER,CDER
fda-2018-p-1197,FDA-2018-P-1197-0001_Citizen_Petition_from_Exela_Pharma_Sciences.pdf,2018-03-19,2018,False,original petition,Exela Pharma Sciences,industry/corporation,"- Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß¬ß 10.25(a), 10.30 (citizen petition regulations)
- 21 C.F.R. ¬ß 314.3(b) (definition of therapeutic equivalence)
- 21 C.F.R. ¬ß 314.94(a)(9)(iii) (excipients and ANDA limitations)
- 21 C.F.R. ¬ß 25.31 (categorical environmental exclusion)
- 21 C.F.R. ¬ß 10.30(b) (economic impact requirements)","FDA's practice of not assigning a Therapeutic Equivalence (TE) Code (specifically ""AP"") to Exela‚Äôs Palonosetron Hydrochloride Injection (0.25 mg/2 mL) despite its bioequivalence and pharmaceutical equivalence to Helsinn‚Äôs Aloxi¬Æ (Palonosetron HCl, 0.25 mg/5 mL)
","Exela requests that the FDA assign a Therapeutic Equivalence Evaluation Code ‚ÄúAP‚Äù to its Palonosetron Hydrochloride Injection, 0.125 mg/mL (2 mL vial), approved under NDA 207963, for listing in the Orange Book
","- Bioequivalence: Exela's drug product contains the same active ingredient, same route of administration, same dosage form, and same total strength (0.25 mg) as Aloxi¬Æ.
- Regulatory basis: Though Exela used a 505(b)(2) pathway (due to non-exception excipients), the therapeutic equivalence should still qualify under FDA's standards.
- Labeling comparison: Both Exela‚Äôs and Helsinn‚Äôs labels confirm identical dosing and strength
.
- TE Code impact: TE Code assignment would allow Exela to seek refund or exemption of user fees (PDUFA) and gain recognition as therapeutically equivalent for substitution and competition purposes.
- Policy consistency: Other precedents exist where FDA granted ‚ÄúAP‚Äù rating even when vial content differed but concentration was equivalent.",2018-09-13 00:00:00,,2025-10-15,1.0,,,"- The petition from Exela Pharma Sciences requested that the FDA assign a therapeutic equivalence code ‚ÄúAP‚Äù to palonosetron hydrochloride IV solution (NDA 207963).
- FDA stated the issues raised were complex and required extensive review and analysis.
- The interim response was issued in accordance with 21 CFR 10.30(e)(2) to indicate that a final decision had not yet been made but would follow when possible.",,no decision,False,2767.0,pending,pending
fda-2018-p-1310,FDA-2018-P-1310-0001_Citizen_Petition_from_Vertice_Pharma_Management_Co.pdf,2018-03-28,2018,False,original petition,Vertice Pharma Management Corp.,industry/corporation,"- Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß¬ß 10.25(a), 10.30 (Citizen petition provisions)
- 21 C.F.R. ¬ß 25.31 (Environmental impact exemption)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact information requirements)","FDA‚Äôs Draft Guidance for Sucralfate Oral Suspension (October 2017) ‚Äî specifically, its requirement that generic formulations be both qualitatively (Q1) and quantitatively (Q2) the same as the reference listed drug (RLD), Carafate¬Æ","Revise the Draft Guidance for Sucralfate Oral Suspension by:
1. Eliminating the requirement for quantitative sameness of excipients;
2. Replacing it with a requirement for a comprehensive, validated, orthogonal series of eight in vitro bioassays to demonstrate bioequivalence (BE), including pepsin inhibition, acid diffusion, bile salt interaction, and mucoadhesion assays","- Quantitative sameness is unnecessary because sucralfate acts locally with negligible systemic absorption.
- FDA has allowed non-Q2 sameness for other locally-acting drugs with similar mechanisms (e.g., colesevelam, cholestyramine, sucroferric oxyhydroxide).
- The excipients (e.g., glycerin, sorbitol, methylcellulose) are GRAS or inert and unlikely to affect local action or absorption.
- A set of eight in vitro tests more effectively assesses formulation performance, including early and late stage mechanisms of action.
- Existing guidance-recommended assays are insufficient to establish true bioequivalence based on sucralfate‚Äôs complex local mechanism",,Denied,2018-05-17,0.0,Center for Drug Evaluation and Research (CDER),"- 21 U.S.C. ¬ß 355(j) ‚Äì ANDA approval requirements under the FD&C Act
- 21 CFR 314.3(b) ‚Äì Definitions (e.g., RLD, bioequivalence)
- 21 CFR 314.94(a) ‚Äì ANDA content and format
- 21 CFR 320.24(b) ‚Äì Bioequivalence testing methodologies
- 21 CFR 10.115 ‚Äì Guidance practices and nonbinding recommendations
- 21 CFR 314.127(a)(6)(i) ‚Äì Basis for refusing to approve an ANDA",,"- For Haynes and Boone Petition: The FDA disagreed that ANDAs relying on clinical endpoint studies should be denied. While such studies are the least accurate and reproducible method, they are still acceptable for locally acting drugs like sucralfate when properly designed. The withdrawal of the 2014 draft guidance does not preclude the use of clinical endpoint studies.
- For Vertice Petition: The FDA clarified that draft guidance does not impose binding requirements. The Agency will consider any scientifically valid alternative bioequivalence method proposed. Vertice‚Äôs requests were more suitable for public comment during the draft guidance process.
- The FDA emphasized it retains discretion to evaluate bioequivalence based on a ‚Äúreasonable and scientifically supported criterion‚Äù and will consider methods on a case-by-case basis.",denied,True,50.0,CDER,CDER
fda-2018-p-1335,FDA-2018-P-1335-0001_Citizen_Petition_form_Hyman__Phelps___McNamara__P_.pdf,2018-03-30,2018,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"- Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FDC Act)
- Section 505(w) of the FDC Act
- 21 C.F.R. ¬ß¬ß 10.25, 10.30 (general citizen petition provisions)
- 21 C.F.R. ¬ß¬ß 314.122, 314.161 (drug withdrawal determination)
- 21 C.F.R. ¬ß 25.31 (environmental impact exclusion)
- 21 C.F.R. ¬ß 10.30(b) (economic impact provision)","FDA‚Äôs classification of DITROPAN XL¬Æ (Oxybutynin Chloride Extended Release Tablets) under NDA 020897 as discontinued in the Discontinued Drug Product List of the Orange Book (February 2018). The petitioner requests an official determination regarding whether the withdrawal was for safety or effectiveness reasons
","The petitioner asks the FDA to determine that DITROPAN XL¬Æ (5 mg, 10 mg, and 15 mg tablets) was not withdrawn for reasons of safety or effectiveness, thereby allowing it to remain listed in the Orange Book as a reference listed drug (RLD)
","- The petitioner is not aware of any safety or effectiveness concerns behind the withdrawal.
- Believes the withdrawal was due solely to commercial considerations.
- NDA 020897 appears only in the ‚ÄúDiscontinued Drug Product List,‚Äù and no official determination has been made yet.
- Keeping the product listed in the Orange Book would allow its continued citation in ANDAs
",,Approved (Determination Issued),2018-08-23,0.0,Center for Drug Evaluation and Research (CDER),"- 21 CFR 314.161 ‚Äì Determination if a drug was withdrawn from sale for safety or effectiveness reasons
- 21 CFR 314.162 ‚Äì Removal of listed drugs from Orange Book
- 21 U.S.C. ¬ß 355(j)(7) ‚Äì Drug approval listings in the Orange Book",,"- The petition requested a determination under 21 CFR 314.161 whether Ditropan XL (oxybutynin chloride ER tablets), 5 mg, 10 mg, and 15 mg, had been withdrawn for safety or effectiveness.
- The FDA determined the 15 mg strength had not been withdrawn for such reasons after reviewing internal records and independent literature.
- The 5 mg and 10 mg strengths were already relisted in the Prescription Drug Product List, so no determination was needed.
- FDA's decision allows ANDAs referencing the 15 mg formulation to proceed, assuming all other regulatory requirements are met.",approved,True,146.0,CDER,CDER
fda-2018-p-1349,FDA-2018-P-1349-0001_Citizen_Petition_from_Douglass_Oeller_Consulting__.pdf,2018-03-19,2018,False,original petition,Felix Pharmaceuticals Pvt. Ltd.,industry/corporation,"- Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 25.30(h) (categorical exclusion for environmental impact)
- 21 C.F.R. ¬ß 25.21 (extraordinary circumstances)","FDA‚Äôs current reference approval for Vetmedin¬Æ (Pimobendan) Tablets, a hard compressed chewable tablet. The petitioner seeks approval to submit an ANADA for a soft chewable dosage form, differing in formulation but not in route of administration or strength","Request for permission to file an Abbreviated New Animal Drug Application (ANADA) for a generic compressed soft chewable tablet of Pimobendan that differs from the approved pioneer product (Vetmedin¬Æ) in dosage form only
","- The change is limited to oral dosage form: from a hard compressed tablet to a soft compressed chewable tablet.
- The generic formulation will be bioequivalent to the pioneer.
- The same dosage strength and route of administration as the RLD.
- All excipients in the soft chewable form are already approved for use in dogs.
- Minor differences in tablet size and labeling (e.g., palatability and manufacturer info).
- The modified dosage form does not adversely affect the safety or effectiveness of the product",,Approved,2018-06-13,0.0,Center for Veterinary Medicine (CVM),"- Section 512(n)(3) and 512(n)(3)(C) of the FD&C Act ‚Äì Suitability petition criteria
- 21 CFR 514.5 ‚Äì Presubmission conference recommendation",,"- The petition proposed a generic pimobendan compressed soft chewable tablet, differing in dosage form from the RLNAD Vetmedin¬Æ (hard chewable tablets).
- FDA determined that the proposed changes (soft vs. hard chewable form) are acceptable for a suitability petition under section 512(n)(3).
- No new safety or effectiveness studies are required for the generic product's proposed uses.
- Approval of the petition allows for submission of an ANADA; however, it does not guarantee eventual approval of the drug product.",approved,True,86.0,CVM,Other/Specialty Center
fda-2018-p-1351,FDA-2018-P-1351-0001_Citizen_Petition_from_Douglass_Oeller_Consulting__.pdf,2018-03-19,2018,False,original petition,Felix Pharmaceuticals Pvt. Ltd.,industry/corporation,"- Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 25.30(h) (categorical exclusion from environmental assessment)
- 21 C.F.R. ¬ß 25.21 (extraordinary circumstances provision)","Request pertains to the FDA's approval pathway for animal drugs‚Äîspecifically, submission of an Abbreviated New Animal Drug Application (ANADA) for a chewable tablet dosage form of Marbofloxacin, in contrast to the existing approved formulation Zeniquin¬Æ (a hard compressed tablet) sponsored by Zoetis LLC
","Permission to file an ANADA for a generic compressed chewable tablet of Marbofloxacin that differs in dosage form (chewable vs. hard tablet) but retains the same active ingredient, strength, and route of administration
","- The generic chewable tablet will be bioequivalent to the pioneer product (Zeniquin¬Æ).
- The route of administration, dosage strength, and use in cats and dogs remain the same.
- Tablet shape and formulation differ (soft chewable vs. hard tablet), but all excipients are approved for veterinary use.
- Tablet size differs slightly; score line included as in the pioneer.
- Label differences limited to product name, manufacturer, palatability, and supply details.
- No adverse impact on safety or effectiveness is expected from the dosage form change
",,Approved,2018-06-05,0.0,Center for Veterinary Medicine (CVM),"- Section 512(n)(3) and 512(n)(3)(C) of the FD&C Act ‚Äì Suitability petition provisions
- 21 CFR 514.5 ‚Äì Presubmission conference guidance",,"- The petition proposed a generic marbofloxacin compressed chewable tablet in multiple strengths (25‚Äì200 mg), differing from the reference listed new animal drug (RLNAD) Zeniquin¬Æ Tablets, which are standard compressed tablets.
- FDA determined that this difference in dosage form is permissible under a suitability petition.
- No new studies on safety or effectiveness are required for this change.
- Approval of the petition permits submission of an abbreviated new animal drug application (ANADA), but does not guarantee approval of the final product.
- FDA encourages a presubmission conference to clarify application expectations.",approved,True,78.0,CVM,Other/Specialty Center
fda-2018-p-1361,FDA-2018-P-1361-0002_Citizen_Petition_from_Ajanta_Pharma_USA_Inc_.pdf,2018-04-02,2018,False,original petition,Ajanta Pharma Limited,industry/corporation,"- 21 C.F.R. ¬ß¬ß 10.25, 10.30 (general petition regulations)
- 21 C.F.R. ¬ß¬ß 314.122, 314.161, 314.162 (drug withdrawal and ANDA-related provisions)
- FDC Act ¬ß 505(j)(2)
- 21 C.F.R. ¬ß 25.31 (categorical exclusion for environmental impact)
- 21 C.F.R. ¬ß 10.30(b) (economic impact disclosure)","FDA‚Äôs placement of DITROPAN XL¬Æ (Oxybutynin Chloride Extended Release Tablets, NDA 020897) in the Discontinued Drug Product List of the Orange Book, February 2018 edition.","Petitioner requests that FDA determine DITROPAN XL¬Æ (5 mg, 10 mg, and 15 mg tablets) was not withdrawn for reasons of safety or effectiveness, so it may remain eligible as a Reference Listed Drug (RLD) for ANDAs
","- Product appears to have been withdrawn from the market, triggering RLD review requirements.
- No publicly known evidence that discontinuation was due to safety or efficacy concerns.
- FDA‚Äôs determination is necessary under 21 C.F.R. 314.122 and 314.161 for continued citation in ANDAs.
- The product remains relevant for generic development if deemed not withdrawn for safety/effectiveness reasons",,Approved (Determination Issued),2018-08-23,0.0,Center for Drug Evaluation and Research (CDER),"- 21 CFR 314.161 ‚Äì Determination whether drug was withdrawn for safety or effectiveness
- 21 CFR 314.162 ‚Äì List removals from the Orange Book
- Section 505(j)(7) of the FD&C Act (21 U.S.C. 355(j)(7)) ‚Äì Drug listing requirements",,"- The citizen petition requested confirmation that Ditropan XL (oxybutynin chloride) Extended Release Tablets, particularly the 15 mg strength, was not withdrawn for safety or effectiveness.
- FDA reviewed its internal records, literature, and post-marketing data and found no evidence of safety or efficacy concerns prompting withdrawal.
- As a result, the 15 mg tablets will remain listed in the ‚ÄúDiscontinued Drug Product List‚Äù in the Orange Book, denoting a voluntary market withdrawal.
- This determination permits ANDA applications referring to Ditropan XL 15 mg to proceed, provided all other requirements are met.",approved,True,143.0,CDER,CDER
fda-2018-p-1441,FDA-2018-P-1441-0001_Citizen_Petition_from_Patients_for_Access_to_Advan.pdf,2018-04-08,2018,False,original petition,Patients for Access to Advanced Hemophilia Therapy,advocacy/academic,"- Federal Food, Drug, and Cosmetic Act (referenced as the legal basis for FDA‚Äôs sole authority over drug approval and market access).
Note: No specific statute (e.g., 21 C.F.R. 10.30 or section 505(q)) is cited by name","Concern regarding the impact of commerce-driven, court-ordered restrictions on patient access to FDA-approved drugs, specifically citing the case of Baxalta/Shire vs. Genentech/Roche and access to Hemlibra¬Æ
","Request for the FDA to hold a public hearing to examine the impact of court-ordered drug access restrictions on:
- Medical care delivery
- Drug development
- Patient access to novel therapies

Also asks the FDA to consider whether legislation or rulemaking is needed to prevent such restrictions
","- Baxalta/Shire requested a preliminary injunction limiting access to Hemlibra based on a patent suit, potentially excluding many hemophilia patients.
- The petitioners argue that legal actions unrelated to clinical risk undermine FDA‚Äôs regulatory authority and could harm therapeutic progress.
- Some petitioners or their family members are directly affected by these legal filings and might be denied access to Hemlibra if court restrictions are enforced.
- Petitioners assert this sets a dangerous precedent and could affect future access to innovative treatments.
- The hearing would support FDA‚Äôs broader mission of protecting access and encouraging competition in the pharmaceutical market",,Denied,2018-10-04,0.0,Center for Drug Evaluation and Research (CDER),"- 42 U.S.C. ¬ß 262(a), (k), (l) ‚Äì Pertaining to the approval and patent process for biologics under the Public Health Service (PHS) Act
- 35 U.S.C. ¬ß 271 ‚Äì Patent law on infringement
- 42 U.S.C. ¬ß 262(a)(2)(C) ‚Äì Manufacturing facility standards
- 42 U.S.C. ¬ß 262(l)(6)(C) ‚Äì FDA role in biosimilar patent dispute notices",,"- The petition requested a public hearing to discuss the effects of court-ordered drug access restrictions, citing the case Baxalta v. Genentech over Hemlibra (emicizumab-kxwh).
- FDA explained that litigation outcomes and patent enforcement are outside FDA‚Äôs jurisdiction.
- While FDA acknowledges concerns about drug access and high prices, it emphasized it is addressing those through other mechanisms and policy initiatives.
- FDA concluded that a public hearing on this topic is not warranted under its statutory role in regulating safety, purity, and potency‚Äînot litigation or patent resolution.",denied,True,179.0,CDER,CDER
fda-2018-p-1448,FDA-2018-P-1448-0001_Citizen_Petition_from_Hyman__Phelps___McNamara__PC.pdf,2018-04-09,2018,False,original petition,"Hyman, Phelps & McNamara, P.C. for Collegium Pharmaceutical, Inc.",law/consulting,"- Federal Food, Drug, and Cosmetic Act ¬ß 505(j)
- 21 C.F.R. ¬ß¬ß 10.25(a), 10.30 (citizen petition process)
- 21 C.F.R. ¬ß¬ß 314.122, 314.161 (drug withdrawal rules)
- 21 C.F.R. ¬ß 25.31 (environmental assessment exclusion)
- 21 C.F.R. ¬ß 10.30(b) (economic impact provision)","FDA‚Äôs listing of Cysteine Hydrochloride Injection USP, 50 mg/mL (NDA 017377) in the Discontinued Drug Product List of the Orange Book. The petitioner seeks an official determination of whether it was withdrawn for reasons of safety or effectiveness
","The petitioner requests that the FDA determine that Cysteine Hydrochloride Injection USP, 50 mg/mL was not withdrawn for safety or effectiveness reasons, allowing it to continue to be referenced as a Reference Listed Drug (RLD) for ANDA purposes
","- No evidence suggests the product was withdrawn for safety or efficacy concerns.
- Believed to have been withdrawn for commercial or business reasons only.
- Continued Orange Book listing is essential for generic competition via ANDA submissions.
- Removal without an official FDA determination could restrict access and hinder development
",,Denied,2018-09-06,0.0,Center for Drug Evaluation and Research (CDER),"- Section 505(q) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. ¬ß 355(q))
- 2015 FDA Guidance for Industry: Abuse-Deterrent Opioids‚ÄîEvaluation and Labeling",,"- The issues raised in the petition involve complex scientific and policy matters.
- These could not be resolved within the 150-day time frame mandated by law (section 505(q) of the FD&C Act).
- FDA supports development of abuse-deterrent opioids and is actively working with manufacturers and the public to advance this field.
- Postmarket studies are ongoing, and FDA takes a product-by-product approach in regulatory decisions.
- FDA reaffirmed the need for additional data and scientific development in this evolving area",denied,True,150.0,CDER,CDER
fda-2018-p-1453,FDA-2018-P-1453-0001_Citizen_Petition_from_Spear_Pharmaceuticals__Inc.pdf,2018-04-09,2018,False,original petition,"Spear Pharmaceuticals, Inc.",industry/corporation,"- 21 C.F.R. ¬ß¬ß 10.25, 10.30 (citizen petition provisions)
- 21 C.F.R. ¬ß 25.31 (categorical exclusion from environmental impact requirements)
- 21 C.F.R. ¬ß 10.30(b) (economic impact clause)","FDA's Draft Product-Specific Guidance (PSG) for Tazarotene Topical Gel, 0.1%, issued in March 2018. Specifically, the petition challenges the proposed requirement for in vivo bioequivalence studies, which contradicts prior guidance allowing in vitro bioequivalence for this drug","Spear requests that FDA withdraw the March 2018 Draft PSG for Tazarotene Gel, 0.1%, and reinstate the prior September 2011 PSG, which permits in vitro bioequivalence testing instead of in vivo studies","- The March 2018 guidance reverses the FDA‚Äôs previous position, imposing in vivo clinical endpoint studies, which are costly and less scientifically justified.
- Tazarotene is a topical drug with minimal systemic absorption, making in vitro methods more appropriate.
- FDA has approved ANDA 090227 using in vitro methods under the prior guidance.
- Reversal of guidance undermines regulatory consistency and creates unfair burden on generics.
- The change harms public interest by potentially delaying or discouraging lower-cost generic availability",,Denied,2018-09-06,0.0,Center for Drug Evaluation and Research (CDER),"- 21 C.F.R. ¬ß 320.24(b)(4)
- 21 U.S.C. ¬ß 355(j)
- 21 C.F.R. ¬ß¬ß 314.3(b), 314.94(a), 314.127(a)(6)(i), 320.1, 320.23(b), 320.24, 320.25(a)
- FD&C Act Section 505(j)(2)(A), (j)(2)(C), (j)(4), (j)(8)(B), and (j)(8)(C)
- Public Law 98-417 (Hatch-Waxman Amendments)",,"- The FDA affirmed its broad discretion under the FD&C Act and its regulations to determine bioequivalence methods on a case-by-case basis.
- The Agency stated it had not revised its draft guidance (June 2010) recommending in vivo clinical endpoint studies for fluorouracil cream.
- FDA reiterated it can consider scientifically valid alternative methods (e.g., in vitro) for demonstrating bioequivalence, as permitted under 21 CFR 320.24 and FD&C Section 505(j)(8)(C).
- Concerns raised by the petitioner (about variability in in vitro methods, cytotoxicity of the drug, and lack of scientific justification) were addressed, noting that FDA evaluates all scientific data and public comments during the guidance finalization process.
- FDA emphasized it had not made any changes to its product-specific guidance and denied the request to ‚Äúreaffirm‚Äù prior requirements, affirming its flexibility to evolve guidance based on new scientific information.",denied,True,150.0,CDER,CDER
fda-2018-p-1469,FDA-2018-P-1469-0001_Citizen_Petition_from_Epstein_Becker___Green_PC___.pdf,2018-04-10,2018,False,original petition,"Epstein Becker & Green, P.C.",law/consulting,"- 21 C.F.R. ¬ß 10.30 (citizen petition procedures)
- 21 C.F.R. ¬ß 882.5896 (classification regulation for percutaneous nerve field stimulators)
- 21 C.F.R. ¬ß 807.92(a)(3) (substantial equivalence in 510(k) submissions)
- Section 513(i) of the Federal Food, Drug, and Cosmetic Act (definition of substantial equivalence)
- 21 C.F.R. ¬ß 25.34 (categorical exclusion for environmental assessments)","The FDA‚Äôs classification of percutaneous nerve stimulators for substance use disorders under Class II, and associated special controls promulgated on February 5, 2018, allowing substantial equivalence claims to NSS-2 BRIDGE without requiring preclinical or clinical comparison testing","The petitioner requests that FDA require head-to-head preclinical (animal) and clinical studies demonstrating non-inferiority to the NSS-2 BRIDGE for any device seeking clearance under 21 C.F.R. ¬ß 882.5896 that differs from the NSS-2 BRIDGE in certain key attributes (e.g., nerve targeting, grounding, pin/array design, signal characteristics, and use of transillumination)
","- The NSS-2 BRIDGE is currently the only approved predicate under this classification.
- FDA's special controls are insufficient to assure performance for devices that differ even slightly in design, labeling, or indications for use.
- Patients undergoing opioid withdrawal are a highly vulnerable population and need safe, effective alternatives.
- IHS has generated extensive data validating its device through preclinical studies, randomized clinical trials, and use of novel technology.
- Differences in device characteristics (e.g., signal geometry, grounding method) significantly impact performance and cannot be assessed by benchtop or paper review alone.
- Without requiring rigorous comparative testing, inferior or unsafe devices may enter the market, undermining public health and the credibility of the 510(k) process",,Denied,2024-07-29,0.0,Center for Devices and Radiological Health (CDRH),"- 21 CFR 10.30(e) (FDA petition procedure)
- 21 CFR 882.5896 and 21 CFR 876.5340 (device classification regulations)
- FD&C Act Sections 513(a)(1), 513(f), 513(i)(1)(A), 510(k) (21 U.S.C. ¬ß¬ß 360c, 360k)
- 21 CFR 860.7(b), 807.87(f), 807.87(g) (device classification, premarket notification)
- Least Burdensome Provisions: Guidance for Industry and FDA Staff (2019)
- The 510(k) Program Guidance (2014)",,"- FDA found that the special controls already established in the De Novo orders (for NSS-2 BRIDGE and IB-Stim) under 21 CFR 882.5896 and 876.5340 were sufficient to provide reasonable assurance of safety and effectiveness.
- Petitioners requested a categorical requirement for additional animal and clinical testing, but FDA declined to impose such requirements across the board.
- FDA emphasized it may request additional data on a case-by-case basis in 510(k) reviews, depending on differences in device technology.
- Requiring such data for all new devices in the same classification would contradict FDA‚Äôs least burdensome principles and statutory flexibility in substantial equivalence determinations.
- Therefore, both petitions were denied because the requests were inconsistent with FDA‚Äôs established regulatory framework and policies.",denied,True,2302.0,CDRH,CDRH
fda-2018-p-1484,FDA-2018-P-1484-0001_Citizen_Petition_from_Macleods_Pharmaceuticals_Lim.pdf,2018-04-12,2018,False,original petition,Macleods Pharmaceuticals Limited,industry/corporation,"- Section 505(j) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß¬ß 10.25(a), 10.30, 314.93 (citizen petition and ANDA-related rules)
- 21 C.F.R. ¬ß¬ß 25.31(a), 25.15(d) (environmental impact exclusion)","FDA‚Äôs designation of the Reference Standard (RS) for Isoniazid Tablets, 100 mg and 300 mg listed under NDA 008678 (Sandoz Inc.) in the Orange Book. The petitioner argues that this RS is not practically available in the market, which affects the ability of ANDA applicants to conduct in vivo bioequivalence testing
","FDA should designate ANDA #A080937 (Isoniazid Tablets, 300 mg of Barr Laboratories Inc., marketed by Teva Pharmaceuticals USA, Inc.) as an alternative Reference Standard (RS) for in vivo bioequivalence studies","- The currently designated RS by Sandoz is not discontinued but is scarcely available in the market.
- Macleods and potentially other ANDA applicants cannot obtain sufficient quantity of the RS for testing.
- FDA's own guidance supports designating a new RS in such circumstances.
- The proposed alternative (ANDA #A080937) is therapeutically equivalent and the market leader as per IMS data.
- Consistency with FDA‚Äôs Draft Guidance for Industry: Referencing Approved Drug Products in ANDA Submissions supports this change",2018-10-05 00:00:00,Approved,2019-08-15,1.0,Center for Drug Evaluation and Research (CDER),"- Section 505(j) of the FD&C Act (21 U.S.C. ¬ß 355(j))
- 21 CFR 314.3(b) ‚Äì Definitions of therapeutic equivalents and reference listed drugs
- 21 CFR 314.94(a)(3) ‚Äì ANDA content
- 21 CFR 320.22(c) ‚Äì Bioequivalence waiver
- 21 CFR 320.24(b) ‚Äì Bioequivalence standards","- The FDA states it has not resolved the issues raised in the April 12, 2018 citizen petition requesting designation of ANDA 080397 (isoniazid 300 mg by Barr Labs) as a reference standard in the Orange Book.
- FDA cites other agency priorities as the reason for the delay and confirms the response will follow ""as soon as possible.""","- The current reference standard for isoniazid 300 mg (NDA 008678 by Sandoz) was no longer commercially available.
- FDA determined, based on commercial distribution data, that ANDA 080937 (Barr) is the market leader and should replace NDA 008678 as the reference standard for 300 mg tablets.
- Similarly, ANDA 080936 (Barr) was designated the new reference standard for 100 mg tablets.
- Both NDA 008678 listings were moved to the Discontinued Drug Product List in the Orange Book.
- These actions ensure continued availability of reference standards for generic submissions.",approved,True,490.0,CDER,CDER
fda-2018-p-1516,FDA-2018-P-1516-0001_Citizen_Petition_from_Encube_Ethicals_Private_Limi.pdf,2018-04-13,2018,False,original petition,Encube Ethicals Private Limited,industry/corporation,"- 21 C.F.R. ¬ß 10.25(a) (citizen petition procedures)
- 21 C.F.R. ¬ß 10.30 (filing procedures)
- Section 505(j) of the Federal Food, Drug, and Cosmetic Act (ANDA pathway)
- 21 C.F.R. ¬ß 25.31 (environmental impact exclusion)
- 21 C.F.R. ¬ß 10.30(b) (economic impact information)","FDA's current designation of the Reference Standard (RS) for Mupirocin Calcium Cream, EQ 2% Base in the Orange Book, which currently lists NDA 050746 (Bactroban, GlaxoSmithKline) and ANDA 065123 (Perrigo New York Inc.), both of which are reportedly unavailable in sufficient commercial quantity
","Request that FDA designate ANDA 201587, held by Glenmark Pharmaceuticals Inc. USA, as the Reference Standard (RS) for Mupirocin Calcium Cream, EQ 2% Base, to facilitate submission of ANDAs by generic manufacturers","- Current RS products (NDA 050746 and ANDA 065123) are not commercially available in sufficient quantity for in vivo bioequivalence testing.
- FDA's own Draft Guidance (Jan. 2017) allows selection of a new RS when existing RS availability is limited.
- ANDA 201587 is the only commercially available formulation of the drug product.
- Selecting this new RS will enhance market competition and reduce risk of drug shortages by enabling approval of additional generics",,Dismissed (moot),2018-05-18,0.0,Center for Drug Evaluation and Research (CDER),"- No specific statutes or regulations are cited by number. However, the following references were noted:
- Approved Drug Products With Therapeutic Equivalence Evaluations (Orange Book)
- Docket Nos. FDA-2017-P-3484, FDA-2017-P-6108, FDA-2018-P-0829",,"- The petition requested that mupirocin calcium cream, EQ 2% base, under ANDA 201587 (Glenmark) be designated as the reference standard in the Orange Book.
- FDA had already granted three prior petitions requesting the same action.
- As a result, FDA designated Glenmark's product as the reference standard and updated the Orange Book accordingly.
- Since the requested action was already completed, FDA dismissed this petition as moot.",dismissed (moot),True,35.0,CDER,CDER
fda-2018-p-1531,FDA-2018-P-1531-0001_Petition_from_King___Spalding_LLP.pdf,2018-04-02,2018,False,original petition,King & Spalding LLP,law/consulting,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FDC Act)
- 21 C.F.R. ¬ß 10.20
- 21 C.F.R. ¬ß 10.30 (citizen petition procedures)
- 21 C.F.R. ¬ß 25.31(a) (environmental impact exclusion)
- 21 C.F.R. ¬ß 10.30(b) (economic impact submission)","Request for FDA determination that a change in drug strength (from the approved 50 mg/mL to a proposed 5 mg/mL) for Ephedrine Sulfate Injection, USP is suitable for submission in an ANDA. The action involves the substitution of a different strength and dosage presentation from the RLD Akovaz (NDA 208289) held by Flamel Ireland Limited
","FDA should determine that Ephedrine Sulfate Injection, USP, 25 mg/5 mL (5 mg/mL) is suitable for submission via an ANDA, despite the change in total strength compared to the RLD
","- The proposed strength matches the clinically administered dosage concentration recommended in the RLD labeling (5 mg/mL), but eliminates the need for dilution from 50 mg/mL, which reduces medication errors and contamination risk.
- The pre-filled syringe format reduces drug waste in clinical settings.
- There are no changes in active ingredients, dosage form, route of administration, or indications compared to the RLD.
- The change in total drug content is only due to volume, and does not affect safety or efficacy",,Denied,2021-11-16,0.0,Center for Drug Evaluation and Research (CDER),"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 CFR 314.93(e)(1)(vi)
- 21 CFR 10.33 ‚Äì Procedures for reconsideration
- 21 CFR 10.20 ‚Äì Petition format requirements",,"- The petition requested an ANDA for Ephedrine Sulfate Injection 25 mg/5 mL (5 mg/mL) syringes, referencing Akovaz 50 mg/1 mL.
- FDA noted that the exact requested strength had already been approved under NDA 208289 (also Akovaz).
- As per 21 CFR 314.93(e)(1)(vi), a petition cannot be approved if a product with the requested change is already approved under an NDA.
- FDA therefore denied the petition as moot. Petitioners may seek reconsideration within 30 days or submit a new petition with additional information.",denied,True,1324.0,CDER,CDER
fda-2018-p-1532,FDA-2018-P-1532-0001_Petition_from_King___Spalding_LLP.pdf,2018-04-02,2018,False,original petition,King & Spalding LLP,law/consulting,"- 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FDC Act)
- 21 C.F.R. ¬ß 10.20
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 25.31(a) (environmental impact exclusion)
- 21 C.F.R. ¬ß 10.30(b) (economic impact statement)","FDA‚Äôs approval pathway for a new drug strength differing from the RLD. Specifically, the petition comments on allowing Ephedrine Sulfate Injection, USP, 50 mg/10 mL (5 mg/mL) to be submitted as an ANDA despite differing in strength from the RLD (Akovaz 50 mg/mL)","That FDA determine Ephedrine Sulfate Injection, USP, 50 mg/10 mL (5 mg/mL) is suitable for submission in an ANDA as a different strength product than the reference listed drug (RLD), Akovaz (NDA 208289)
","- The proposed product has the same final dosage concentration (5 mg/mL) as the RLD post-dilution, but in a ready-to-use prefilled syringe, avoiding the dilution step required by the RLD.
- Eliminates risk of contamination and medication error.
- Provides greater convenience, dosing flexibility, and faster access in treating clinically important hypotension during anesthesia.
- The petition argues that the change in total drug content (by volume) does not impact safety or efficacy.
- No changes are proposed to the active ingredient, dosage form, route of administration, or intended use",,Denied,2021-09-21,0.0,Center for Drug Evaluation and Research (CDER),"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 CFR 314.93(e)(1)(vi) ‚Äì ANDA suitability petitions
- 21 CFR 10.33 ‚Äì Reconsideration procedures
- 21 CFR 10.20 ‚Äì Submission format requirements",,"- The petition requested approval to submit an ANDA for Ephedrine Sulfate Injection USP, 50 mg/10 mL (5 mg/mL) pre-filled syringes.
- The listed reference product was Akovaz 50 mg/mL (NDA 208289).
- FDA denied the petition because an NDA (213994 by Endo Ventures Ltd.) was already approved for the exact formulation (50 mg/10 mL or 5 mg/mL).
- Under 21 CFR 314.93(e)(1)(vi), a petition cannot be approved if an NDA for the same change already exists.",denied,True,1268.0,CDER,CDER
fda-2018-p-1593,FDA-2018-P-1593-0001_Citizen_Petition_from_Pete_and_Gerry_s_Organics_LL.pdf,2018-04-19,2018,False,original petition,Pete and Gerry's Organics LLC,industry/corporation,"- Federal Food, Drug, and Cosmetic Act (FDC Act)
- 21 C.F.R. ¬ß 10.30 (citizen petition regulation)
- 21 C.F.R. ¬ß 101.65(d) (regulation for ‚Äúhealthy‚Äù nutrient content claim)
- 21 C.F.R. ¬ß 25.30(k) (environmental impact exemption)
- 21 C.F.R. ¬ß 101.54(c) (nutrient content claim ‚Äúgood source‚Äù)","FDA‚Äôs definition and regulatory enforcement of the term ‚Äúhealthy‚Äù in nutrient content claims, specifically 21 C.F.R. ¬ß 101.65(d) and related 2016 FDA guidance titled ‚ÄúUse of the Term ‚ÄòHealthy‚Äô in the Labeling of Human Food Products‚Äù
","1. Initiate rulemaking to amend 21 C.F.R. ¬ß 101.65(d) to allow eggs to be labeled ‚Äúhealthy‚Äù
2. In the interim, amend FDA guidance to allow eggs to be labeled ‚Äúhealthy‚Äù under enforcement discretion","- Current regulation is based on outdated views of fat and cholesterol.
- 2015‚Äì2020 Dietary Guidelines for Americans (DGA) identify eggs as nutrient-dense and recommend their inclusion in healthy diets.
- FDA has already shown willingness to update ‚Äúhealthy‚Äù criteria in 2016 guidance, but still excludes eggs due to cholesterol limits.
- Scientific consensus has shifted; dietary cholesterol is no longer considered a nutrient of concern.
- Eggs are rich in protein, choline, vitamin D, and other essential nutrients.
- FDA should update rules to reflect modern science and public health goals.",2018-10-23 00:00:00,,2025-10-15,1.0,,,"- The petition requested FDA to amend 21 CFR 101.65(d) to allow eggs, as single-ingredient foods, to bear the label claim ‚Äúhealthy.‚Äù
- The FDA acknowledged it is still evaluating changes to the definition of ‚Äúhealthy.‚Äù
- The Agency received substantial public input through a 2016 Request for Information (RFI) and a 2017 public meeting, with over 1,200 comments.
- The Agency has not been able to resolve the petition within the required 180 days due to competing priorities and limited resources. FDA will continue to review the petition in the context of broader regulatory changes and public comments
",,no decision,False,2736.0,pending,pending
fda-2018-p-1678,FDA-2018-P-1678-0001_Citizen_Petition_from__Mapi_USA__Inc.pdf,2018-04-27,2018,False,original petition,"Mapi USA, Inc.",industry/corporation,"- FD&C Act ¬ß 505(j)(2)(C)
- 21 C.F.R. ¬ß 10.20
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 314.93
- 21 C.F.R. ¬ß 314.94(a)(8)(iv)
- 21 C.F.R. ¬ß 25.30
- 21 C.F.R. ¬ß 25.31
- 21 C.F.R. ¬ß 10.30(b)",The suitability of submitting an ANDA for a formulation of Midazolam Injection that differs in fill volume and container type (100 mL flexible plastic container) from the current reference standard products,"FDA is requested to determine that Midazolam Injection 1 mg/mL in a new total fill volume of 100 mL in a flexible plastic container is suitable for submission as an ANDA
","- The proposed product has the same strength, active ingredient, dosage form, and route of administration as the reference standard (Hospira).
- The only difference is the total fill volume (100 mL vs. 2‚Äì5 mL).
- Intended for ICU use where continuous infusion is required, aligning with dosage and administration standards.
- The petition includes a detailed comparison of labeling and justifications (Appendices 1‚Äì3).
- The product format better supports prolonged sedation in critical care settings.
- The proposed change is consistent with regulatory provisions requiring FDA approval for deviations from listed drug attributes.",,Denied,2021-12-28,0.0,Center for Drug Evaluation and Research (CDER),"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 CFR 314.93(e)(1)(vi) ‚Äì Conditions under which ANDA suitability petitions can be denied
- 21 CFR 10.33 ‚Äì Reconsideration procedures
- 21 CFR 10.20 ‚Äì Petition format requirements",,"- The petitioner (Mapi USA, Inc.) requested FDA approval to submit an ANDA for Midazolam Injection 100 mg/100 mL (1 mg/mL).
- This would represent a change in strength from the listed drugs Versed 2 mg/2 mL and 5 mg/5 mL (both 1 mg/mL).
- However, FDA denied the petition because a drug product matching the requested formulation was already approved under NDA 211844 (Midazolam in 0.9% Sodium Chloride Injection, 100 mg/100 mL) by Inforlife SA.
- As per 21 CFR 314.93(e)(1)(vi), petitions must be denied if the requested change has already been approved via an NDA.",denied,True,1341.0,CDER,CDER
fda-2018-p-1698,FDA-2018-P-1698-0001_Suitability_Petition_from_Haynes_and_Boone__LLP.pdf,2018-05-01,2018,False,original petition,Haynes and Boone LLP,law/consulting,"- 21 U.S.C. ¬ß 355 (FDC Act ¬ß 505)
- 505(j)(2)(C) (Suitability Petitions)
- 505(j)(2)(A)(iii)
- 21 C.F.R. ¬ß¬ß 10.20, 10.30 (citizen petition regulations)
- 21 C.F.R. ¬ß 314.93 (suitability petitions)
- 21 C.F.R. ¬ß 25.31 (environmental impact exemption)
- 21 C.F.R. ¬ß 10.30(b) (economic impact)
- 21 U.S.C. ¬ß 355c(a)(4)(A) (PREA waiver for pediatric studies)",FDA‚Äôs requirement for prior approval of changes in dosage form under suitability petition regulations‚Äîspecifically requesting approval to switch from tablet to oral solution dosage form for Midodrine Hydrochloride.,"That the FDA determine Midodrine Hydrochloride Oral Solution, 2.5 mg/5 mL is suitable for submission via an ANDA, despite a change in dosage form (from tablet to oral solution) from the RLD (Mylan‚Äôs Midodrine Hydrochloride Oral Tablets, 5 mg)
","- The proposed oral solution is an immediate-release form, just like the RLD.
- The change improves administration for patients with swallowing difficulties, while maintaining identical dosage strengths (2.5 mg, 5 mg, 10 mg).
- No new safety or efficacy concerns arise from the change in form.
- Pediatric study waiver requested due to low usage in pediatric population and no evidence of meaningful benefit for pediatric patients.
- No change in active ingredient, route of administration, indication, or labeling apart from those necessary for the new dosage form",,,2025-10-15,0.0,,,,,no decision,False,2724.0,pending,pending
fda-2018-p-1720,FDA-2018-P-1720-0001_Citizen_Petition_from_Gland_Pharma_Limited.pdf,2018-05-02,2018,False,original petition,Gland Pharma Limited,industry/corporation,"- Section 505(j)(2)(C) of the FD&C Act
- 21 C.F.R. ¬ß 314.93
- 21 C.F.R. ¬ß 10.20
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 25.31 (Environmental Impact)
- 21 C.F.R. ¬ß 10.30(b) (Economic Impact)","FDA‚Äôs lack of designation of a Reference Standard (RS) in the Orange Book for LASIX (Furosemide) Injection, 10 mg/mL (NDA #016363).","That the FDA designate Furosemide Injection, 10 mg/mL, NDA #018667 held by Hospira as a Reference Standard (RS) to facilitate ANDA submissions for generic development","- The original RLD (LASIX by Sanofi Aventis, NDA #016363) is listed as discontinued in the Orange Book.
- FDA has confirmed the delisting was not due to safety or efficacy concerns.
- Hospira‚Äôs product (NDA #018667) is approved, ‚ÄúAP‚Äù rated, and therapeutically equivalent to the discontinued LASIX product.
- Assigning RS designation to Hospira's product will enable comparative studies for ANDA submission and facilitate generic drug development",2018-11-16 00:00:00,"Mixed (One Petition Granted, Three Denied)
- Akorn Petition: Granted (designation of ANDA 202747 as RS)
- Mylan, Gland Pharma, Foley & Lardner Petitions: Denied",2018-12-18,1.0,Center for Drug Evaluation and Research (CDER),"- 21 CFR 314.3(b) ‚Äì Definitions of RLD and RS
- 21 CFR 314.94(a)(3) ‚Äì Reference standard requirements
- 21 CFR 320.22(b)(1) ‚Äì Bioequivalence waiver provisions
- FD&C Act, Section 505(j) (21 U.S.C. 355(j))","- The petition, received on May 1, 2018, requested that FDA designate Furosemide Injection, 10 mg/mL, NDA # N018667 (Hospira) as the Reference Standard for development of a generic version of Furosemide Injection USP, 10 mg/mL.
- FDA has not reached a decision because it must attend to other agency priorities.
- The interim response acknowledges the delay and assures the petitioner that FDA will respond as soon as feasible, consistent with regulatory constraints and resource limitations","- The FDA reviewed four petitions requesting designation of various products as Reference Listed Drugs (RLDs) or Reference Standards (RS) for furosemide injection, 10 mg/mL.
- The Orange Book already identified two RLDs (NDAs 018579 and 016363), but both were discontinued.
- FDA determined it was appropriate to designate a new Reference Standard (RS) from available marketed products.
- Based on commercial availability and therapeutic equivalence, FDA selected ANDA 202747 (referenced in the Akorn petition) as the new RS.
- The other petitions either sought an additional RLD (which is unnecessary if two already exist) or proposed products FDA found insufficiently justified for RS designation.",approved,True,230.0,CDER,CDER
fda-2018-p-1734,FDA-2018-P-1734-0001_Citizen_Petition_from_Foley___Lardner_LLP.pdf,2018-05-03,2018,False,original petition,Foley & Lardner LLP,law/consulting,"- 21 C.F.R. ¬ß 10.30 (Citizen Petition)
- 21 C.F.R. ¬ß 314.161 (Determination if drug was withdrawn for safety/efficacy)
- 21 C.F.R. ¬ß 314.122, 314.162 (Drug listing and removal procedures)
- 21 C.F.R. ¬ß 25.31 (Environmental impact exclusion)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact submission provision)","The FDA‚Äôs listing of IC-GREEN (Indocyanine Green) Injection in the Orange Book, specifically requesting a determination on whether the 10 mg/vial, 40 mg/vial, and 50 mg/vial strengths have been withdrawn for reasons of safety or effectiveness.","That the FDA determine whether IC-GREEN (Indocyanine Green) Injection (10 mg/vial, 40 mg/vial, and 50 mg/vial), NDA 011525, held by Akorn Inc., has been voluntarily withdrawn for safety or efficacy reasons
","- The Orange Book lists only the 25 mg/vial strength of IC-GREEN as active.
- The 10 mg, 40 mg, and 50 mg strengths are listed as discontinued.
- Petitioner seeks confirmation that these discontinuations were not for safety or effectiveness reasons, which is a regulatory prerequisite for others to submit ANDAs or 505(b)(2) NDAs referencing them",2018-10-29 00:00:00,Approved (Determination Issued),2018-12-12,1.0,Center for Drug Evaluation and Research (CDER),"Not Mentioned ‚Äì The letter does not cite specific statutes or regulations, though it references regulatory actions related to the Orange Book and the Federal Register notice.
","- The petition requested that FDA determine whether IC-GREEN (indocyanine green for injection) ‚Äì in 10 mg/vial, 40 mg/vial, and 50 mg/vial strengths, under NDA 011525 by Akorn Inc. ‚Äì has been withdrawn for safety or efficacy reasons.
- FDA has not yet made a decision due to the need to prioritize other agency matters. The agency promises to respond as soon as feasible, consistent with resource availability
","- The petitioner requested that FDA determine whether IC-GREEN (indocyanine green for injection), in strengths of 10 mg/vial, 40 mg/vial, and 50 mg/vial (NDA 011525), had been withdrawn from sale for reasons of safety or efficacy.
- FDA reviewed its records and concluded that IC-GREEN was not withdrawn for safety or effectiveness reasons.
- Accordingly, FDA will maintain the drug in the ‚ÄúDiscontinued Drug Product List‚Äù section of the Orange Book, indicating it remains a valid reference listed drug for generic development
",approved,True,223.0,CDER,CDER
fda-2018-p-1740,FDA-2018-P-1740-0001_Citizen_Petition_from_Provetica_Animal_Health_LLC.pdf,2018-05-02,2018,False,original petition,Provetica Animal Health LLC,industry/corporation,"- Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act (FFDCA)
- 21 C.F.R. ¬ß 25.33(d)(5) (Environmental Impact exclusion)
- 21 C.F.R. ¬ß 25.21 (Extraordinary Circumstances)
- 21 C.F.R. ¬ß 20.61 (FOIA confidentiality claims)","The petition comments on the dosage form of the approved pioneer animal drug Deramaxx‚Ñ¢ (deracoxib) Chewable Tablets (NADA 141-203), specifically requesting allowance for a change in tablet scoring for a proposed generic equivalent.
","Permission to file an Abbreviated New Animal Drug Application (ANADA) for a generic version of deracoxib chewable tablets that differs from the pioneer product only in tablet scoring (i.e., only the smallest and largest strengths will be scored in the generic)","- The proposed generic is pharmaceutically comparable, containing the same active ingredient and manufactured by the same method (compression).
- Scoring differences do not affect the dosing strategy or therapeutic equivalence.
- Analysis demonstrated that scoring intermediate tablet strengths (25 mg, 50 mg, 75 mg) does not significantly enhance dosing accuracy.
- The label for the generic will mirror the pioneer label with minor revisions to reflect the scoring differences.
- The petition includes detailed dosage tables illustrating that effective dosing can still be achieved with the proposed scoring scheme",,Denied,2018-08-08,0.0,Center for Veterinary Medicine (CVM),"- Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act
- Section 512(n)(3)(C) of the Act (basis for denial)
- 21 CFR Part 10 ‚Äì General administrative procedures
- 21 CFR 10.33(e) ‚Äì Reconsideration procedures for citizen petitions",,"- The petitioner requested approval to submit an Abbreviated New Animal Drug Application (ANADA) for a chewable deracoxib tablet for dogs that differed from the reference drug (Deramaxx‚Ñ¢) in tablet scoring.
- Only the 12 mg and 100 mg tablets would be scored, unlike the RLNAD where all strengths are half-scored.
- The FDA considered the proposed dosing scheme too complex and potentially unsafe, especially because deracoxib is an NSAID with a narrow safety margin.
- The use of multiple tablet strengths and scored segments per dose increases the risk of dosing inaccuracies, and thus a target animal safety study would be needed.
- Because of these animal safety concerns, the petition was denied under section 512(n)(3)(C).",denied,True,98.0,CVM,Other/Specialty Center
fda-2018-p-1751,FDA-2018-P-1751-0001_Citizen_Petition_from_RegCon_Solutions__LLC_.pdf,2018-05-04,2018,False,original petition,"RegCon Solutions, LLC",law/consulting,"- Section 505(j) of the FD&C Act
- 21 C.F.R. ¬ß¬ß 10.20 and 10.30 (citizen petition procedures)
- 21 C.F.R. ¬ß 25.31 (Environmental Impact exclusion)
- 21 C.F.R. ¬ß 10.30(b) (Economic Impact submission provision)","The lack of designation of Nephron‚Äôs Albuterol Sulfate Inhalation Solution, 2.5 mg/0.5 mL (0.5% base), ANDA 075664 as a Reference Standard (RS) in the Orange Book.","Designate Nephron‚Äôs Albuterol Sulfate Inhalation Solution, 2.5 mg/0.5 mL (0.5% base), ANDA 075664 as a Reference Standard (RS) in the FDA‚Äôs Orange Book","- The FDA‚Äôs Orange Book currently lists Bausch and Lomb‚Äôs ANDA 075050 (100 mg/20 mL) as the RS, but it is not a unit-dose, preservative-free product.
- Nephron‚Äôs product (ANDA 075664) is the only approved preservative-free, unit-dose (0.5 mL) Albuterol Sulfate Inhalation Solution.
- Without RS designation, Nephron‚Äôs product is effectively shielded from generic competition, defeating the purpose of the generic approval pathway.
- The petitioner argues that there is a sound regulatory basis and precedent for this designation",2018-10-31 00:00:00,Approved,2020-01-31,1.0,Center for Drug Evaluation and Research (CDER),"- 21 U.S.C. ¬ß 355(j) (FD&C Act ¬ß 505(j))
- 21 CFR ¬ß 314.3(b)
- 21 CFR ¬ß 314.94(a)(3)
- 21 CFR ¬ß 320.22(b)(3)
- 81 FR 69580 at 69619 (Oct. 6, 2016)
- 72 FR 28982-28984 (May 23, 2007)","- The petition, submitted on May 4, 2018, requested that the FDA update the Orange Book to designate Albuterol Sulfate Inhalation Solution, 2.5 mg/0.5 mL (ANDA 075664) by Nephron Pharmaceuticals as a reference standard.
- The FDA stated it was unable to decide due to other agency priorities.
- The agency provided this interim response in compliance with its regulations and promised to respond as soon as feasible, given its current demands","- The petition requested that the FDA amend the Orange Book to designate Nephron‚Äôs ANDA 075664 (Albuterol Sulfate Inhalation Solution, 2.5 mg/0.5 mL, 0.5% base) as a reference standard.
- FDA agreed because the current reference standard (ANDA 075050 by Bausch & Lomb) is not being marketed.
- NDA 019243 (Proventil) is listed in the ""Discontinued Drug Product List,"" but has not been withdrawn for safety or effectiveness reasons, so can be cited.
- The FDA found Nephron‚Äôs ANDA 075664 is the market leader and represents the most suitable candidate for use in bioequivalence studies",approved,True,637.0,CDER,CDER
fda-2018-p-1760,FDA-2018-P-1760-0001_Citizen_Petition_from_Serenity_Pharmaceuticals__LL.pdf,2018-05-04,2018,False,original petition,"Serenity Pharmaceuticals, LLC",industry/corporation,"- 505(q) of the FD&C Act
- 21 C.F.R. ¬ß 10.30 (citizen petition procedure)
- 21 C.F.R. ¬ß 25.31 (categorical exclusions from environmental assessment)
- 21 C.F.R. ¬ß 10.20 (submission of data and information)
- 21 C.F.R. ¬ß 10.30(b) (economic impact statement provision)","The anticipated approval of any ANDA referencing Serenity‚Äôs approved Nocdurna (desmopressin acetate) sublingual tablets, particularly those omitting essential clinical information required for safe use in certain populations (e.g., age limitations, gender-based dosage distinctions).","Serenity requests that the FDA not approve any ANDA referencing Nocdurna unless it includes the same labeling restrictions and warnings required to ensure safe use, especially for women and the elderly (including boxed warnings and dosage instructions).
","- Nocdurna has significant gender-based dosage limitations due to higher risks of hyponatremia in women.
- Clinical data demonstrated that different doses are required to ensure safety and efficacy between males and females.
- The FDA-approved labeling includes a boxed warning and specific dosage based on gender to prevent life-threatening hyponatremia.
- Petitioner argues that omitting such labeling in generic versions could compromise patient safety.
- Cites prior FDA precedent requiring labeling conformity to ensure safe use when there are significant clinical differences from reference drugs.",,Denied,2018-06-21,0.0,Center for Drug Evaluation and Research (CDER),"- 21 U.S.C. ¬ß 355(j) (Section 505(j) of the Federal Food, Drug, and Cosmetic Act)
- 21 CFR 314.127(a)
- 21 CFR 314.94(a)(9)
- 21 CFR 320.24(b)
- 21 CFR 320.22
- Orange Book Preface and related FDA Guidance Documents ",,"- Serenity‚Äôs petition requested that FDA: (1) require comparative clinical trials to establish bioequivalence of desmopressin nasal spray products to Noctiva; (2) refuse to accept any 505(j) application referencing Noctiva that lacks such clinical data; and (3) confirm that 505(b)(2) applications are required to have such data.
- FDA denied the petition on the grounds that:
‚Ä¢ Clinical trials are not universally required for bioequivalence; they are one of several acceptable approaches.
‚Ä¢ Generic applicants may propose alternative, scientifically justified bioequivalence methods, which FDA will evaluate.
‚Ä¢ FDA does not determine the acceptability of a method prior to ANDA submission and instead evaluates it during review.
‚Ä¢ The assertion that only a clinical trial would be acceptable lacks a scientific basis in this context.
- Thus, FDA concluded there was no basis to impose stricter standards for potential generics of Noctiva and denied all petition requests .",denied,True,48.0,CDER,CDER
fda-2018-p-1780,FDA-2018-P-1780-0001_Citizen_Petition_from_Pacira_Pharmaceuticals__Inc.pdf,2018-05-07,2018,False,original petition,"Pacira Pharmaceuticals, Inc.",industry/corporation,"- 21 C.F.R. ¬ß¬ß 10.20, 10.30, and 10.31
- Section 505(q) of the FDCA, 21 U.S.C. ¬ß 355(q)
- 21 C.F.R. ¬ß 300.50(a)
- 21 C.F.R. ¬ß 25.31(a) (Environmental Impact)
- 21 C.F.R. ¬ß 10.30(b) (Economic Impact)
- 21 C.F.R. ¬ß 10.31(c) (Certification) ","Potential approval of a New Drug Application (NDA) for HTX-011, a fixed-dose combination of bupivacaine and meloxicam developed by Heron Therapeutics, Inc., especially if submitted without factorial design clinical data comparing both active ingredients individually and together. 
","- FDA should refrain from approving any NDA for a fixed-dose combination of bupivacaine and meloxicam unless:
¬†¬†¬†¬†‚Ä¢ Adequate and well-controlled studies (including factorial studies) are provided
¬†¬†¬†¬†‚Ä¢ Safety concerns (particularly from the novel extended-release vehicle) are addressed
- Require a Black Box warning for the NSAID (meloxicam) component of such combinations ","- The HTX-011 Phase 3 trials did not compare the combination product against meloxicam alone, violating FDA‚Äôs combination product approval standards.
- Factorial studies are critical to demonstrate the individual contribution of each drug to safety and efficacy.
- Heron‚Äôs Biochronomer¬Æ delivery system may cause localized inflammation and adverse events (e.g., edema, bradycardia, impaired wound healing).
- NSAIDs (including meloxicam) are associated with impaired wound healing and cardiovascular risks; hence, they warrant a Black Box warning.
- FDA must ensure robust data to safeguard against safety risks posed by novel drug combinations used for post-surgical pain management.",2018-11-02 00:00:00,Partially Approved / Partially Denied,2021-05-21,1.0,Center for Drug Evaluation and Research (CDER),"- 21 CFR 300.50 ‚Äì The ‚ÄúCombination Rule‚Äù for fixed-combination drugs (Page 3)
- 21 CFR 201.57(c) ‚Äì Boxed warnings and safety labeling (Page 4)
- 21 CFR 314.50(d)(5)(v) ‚Äì Approval with risk mitigation
- Section 505(d) of the FD&C Act (21 U.S.C. ¬ß 355(d)) ‚Äì NDA requirements (Page 5)","- The petition requested that FDA refrain from:
¬†¬†1) Approving any NDA for a fixed-dose combination of bupivacaine and meloxicam unless supported by factorial studies and adequate evidence.
¬†¬†2) Approving any NDA for the combination in a novel extended-release vehicle without safety data addressing potential risks.
- FDA stated it has not yet reached a decision due to the complexity of the issues and need for extensive review and analysis. Therefore, an interim response was issued per regulations","- The petition sought to restrict NDA approval for HTX-011 (bupivacaine + low-dose meloxicam) based on concerns over efficacy evidence and safety (particularly inflammation and cardiovascular risks).
- FDA concluded that the Combination Rule requirements were satisfied, demonstrating that each component contributes to the overall effect.
- The agency found no new safety concerns significant enough to delay approval, citing clinical and nonclinical study data.
- Phase 2 and 3 data demonstrated that meloxicam enhances the effectiveness of bupivacaine.
- Boxed warnings and precautions were addressed through proper labeling consistent with other NSAIDs.
- The FDA therefore approved NDA 211988 for HTX-011 while declining to grant the full relief requested by the petition
",partially approved / denied,True,1110.0,CDER,CDER
fda-2018-p-1808,FDA-2018-P-1808-0001_Citizen_Petition_from_Lachman_Consultant_Services_.pdf,2018-05-08,2018,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 314.93
- 21 C.F.R. ¬ß 25.31 (Environmental Impact)",Request for approval of a suitability petition to allow submission of an Abbreviated New Drug Application (ANDA) for a different strength of an existing Reference Listed Drug (RLD). ,"The petitioner asks the FDA to declare that Cysteine Hydrochloride Injection 5% (containing 34.6 mg/mL of cysteine base) is suitable for submission as an ANDA, despite it being a different strength from the RLD (Cysteine Hydrochloride Injection 7.25%). 
","- The proposed change is a decrease in drug strength (0.346 g vs. 0.5 g).
- No changes are proposed to indications, usage, or directions for use aside from necessary strength-related modifications.
- Clinical administration adjustments are straightforward and quantified.
- The RLD was not withdrawn for safety or effectiveness reasons.
- The petitioner's formulation may reduce drug waste in neonatal and adult settings.
- Pediatric Research Equity Act (PREA) does not apply to this type of change. ",,,2025-10-15,0.0,,,,,no decision,False,2717.0,pending,pending
fda-2018-p-1846,FDA-2018-P-1846-0002_Acknowledgment_Letter_from_FDA_DDM_to_Data_Based_M.pdf,2018-05-10,2018,False,original petition,Data Based Medicine Americas Ltd.,industry/corporation,"- 21 C.F.R ¬ß 25.31(a) (Environmental impact exemption)
- 21 C.F.R. ¬ß 10.30 (Citizen petition regulation)","Existing drug labeling and post-marketing risk communication concerning SSRIs and SNRIs. Specifically, inadequate warnings about persistent sexual side effects.","- Immediate revision of all SSRI and SNRI product labels (branded and generic) to include:
‚Ä¢ Warnings, precautions, highlights of prescribing info for risks like genital anesthesia, pleasureless orgasm, etc.
‚Ä¢ Inclusion of persistent genital arousal disorder (PGAD) in warnings.
‚Ä¢ A boxed warning for persistent sexual side effects.
- Require manufacturers to:
‚Ä¢ Send ‚ÄúDear Health Care Provider‚Äù letters to inform about the risks.
‚Ä¢ Develop a Medication Guide and Communication Plan as part of a Risk Evaluation and Mitigation Strategy (REMS).","- Extensive literature, case reports, and studies over 30+ years confirm sexual dysfunctions, including genital anesthesia, loss of libido, erectile dysfunction, and PGAD, that persist long after discontinuation of SSRIs/SNRIs.
- Inadequate product labeling denies patients informed consent and misrepresents risks.
- Studies and pharmacovigilance data from multiple countries (Netherlands, UK, etc.) substantiate the claims.
- Calls attention to parallels with finasteride and isotretinoin, which have received label updates for similar risks.
- Petition stresses the life-altering impact of conditions like PSSD and PGAD on patients' ability to engage in relationships and normal functioning",2018-11-06 00:00:00,,2025-10-15,1.0,,,"- The petition requested that the FDA require boxed warnings, warnings, precautions, and highlights of prescribing information for all selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs)‚Äîincluding branded and generic versions‚Äîto warn of adverse sexual side effects.
- The FDA stated it has not yet made a decision due to the complexity of the issues, which require extensive review and analysis by agency officials.
- The agency committed to responding as soon as a final decision is reached",,no decision,False,2715.0,pending,pending
fda-2018-p-1853,FDA-2018-P-1853-0001_Citizen_Petition_from_Aurobindo_Pharma_USA__Inc_.pdf,2018-05-10,2018,False,original petition,"Aurobindo Pharma USA, Inc.",industry/corporation,"- Section 505(j) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß¬ß 10.25(a), 10.30, 314.93
- 21 C.F.R. ¬ß¬ß 25.31(a), 25.15(d) (environmental impact exclusion)
- Draft Guidance: Referencing Approved Drug Products in ANDA Submissions, III. C.2 and 3 ","The designation of the reference standard (RS) in the Orange Book for Fluoxetine Delayed-Release Capsules USP, 90 mg, specifically the unavailability of PROZAC Weekly‚Ñ¢ (NDA #021235) by Eli Lilly & Co. as the current RS ","FDA is requested to designate the approved generic product Fluoxetine Delayed-Release Capsules USP, 90 mg (ANDA #078572 by Dr. Reddy‚Äôs Laboratories Ltd.) as the new reference standard (RS) for the purposes of conducting in vivo bioequivalence studies in support of ANDA submissions ","- PROZAC Weekly‚Ñ¢ (NDA #021235), the currently listed RS, is unavailable in the market and not found in the NDC directory despite not being marked discontinued in the Orange Book
- Aurobindo could not obtain sufficient quantities of the current RS for required in vivo testing
- Dr. Reddy‚Äôs version (ANDA #078572) is the most marketed product and meets the criteria under FDA‚Äôs draft guidance for designation as RS
- Petition supported with data: Orange Book listings, NDC search, Drugs@FDA records, IMS MAT data showing Dr. Reddy‚Äôs product as the U.S. market leader, and a pharmacy‚Äôs non-availability statement for PROZAC Weekly‚Ñ¢",2018-11-02 00:00:00,,2025-10-15,1.0,,,"- The petition, submitted on behalf of Aurobindo Pharma Limited, requested FDA to designate a suitable alternative reference standard (ANDA #078572 held by Dr. Reddy's Laboratories) for conducting in vivo bioequivalence studies for Fluoxetine Delayed-Release Capsules USP, 90 mg.
- FDA was unable to reach a decision due to the need to address other Agency priorities.
- The Agency committed to issuing a final decision as soon as feasible
",,no decision,False,2715.0,pending,pending
fda-2018-p-1869,FDA-2018-P-1869-0001_Citizen_Petition_from_Aurobindo_Pharma_USA_Inc.pdf,2018-05-11,2018,False,original petition,"Aurobindo Pharma USA, Inc.",industry/corporation,"- Section 505(j) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß¬ß 10.25(a), 10.30, 314.93
- 21 C.F.R. ¬ß¬ß 25.31(a), 25.15(d)
- 21 C.F.R. ¬ß 10.30(b) (for economic impact, if requested)","Designation of a reference standard (RS) for in vivo bioequivalence studies under the ANDA process; specifically the non-availability of the currently designated RS for Dicyclomine Hydrochloride Capsules 10 mg (BENTYL¬Æ by Allergan Sales LLC) 
","FDA is requested to:
‚Ä¢ Designate the approved generic product Dicyclomine Hydrochloride Capsules USP, 10 mg (ANDA #085082) by Watson Laboratories Inc. as the new reference standard (RS), or
‚Ä¢ Designate a suitable alternative RS for in vivo bioequivalence testing","- The current RS (BENTYL¬Æ) is not discontinued per the Orange Book but is functionally unavailable in the market for bioequivalence testing.
- IMS (MAT) and NDC data indicate limited or no distribution of BENTYL¬Æ.
- Watson Laboratories‚Äô product (ANDA #085082) is the most widely marketed and thus meets FDA's criteria for selecting a new RS.
- In line with FDA Draft Guidance on selecting RS when existing RS is unavailable, Aurobindo believes their request meets FDA expectations ",2018-11-02 00:00:00,Approved,2019-12-19,1.0,Center for Drug Evaluation and Research (CDER),"- 21 U.S.C. ¬ß 355(j) (FD&C Act, Section 505(j))
- 21 CFR 314.3(b)
- 21 CFR 314.94(a)(3)
- 21 CFR 314.161
- 21 CFR 314.122
- Orange Book (Approved Drug Products With Therapeutic Equivalence Evaluations)
- 81 FR 69580 / 69619 (Oct. 6, 2016 Final Rule)","- The FDA has been unable to reach a decision due to the need to address other agency priorities.
- The petition requested the designation of an alternative reference standard (ANDA #085082 by Watson Laboratories) for bioequivalence studies on Dicyclomine HCl Capsules USP, 10 mg.
- The agency committed to responding as soon as possible considering the demands on its resources
","- The original reference standard, Bentyl (NDA 007409), is no longer available on the market.
- Petitioners demonstrated that the listed drug is unavailable and requested selection of a therapeutically equivalent product.
- The FDA reviewed commercial data, regulatory filings, and determined that ANDA 084285 (Lannett Co., Inc.) is the current market leader and therapeutically equivalent to the listed drug.
- Based on this, FDA concluded it is appropriate to designate ANDA 084285 as the new reference standard in the Orange Book
",approved,True,587.0,CDER,CDER
fda-2018-p-1876,FDA-2018-P-1876-0001_Citizen_Petition_from_UIC_College_of_Pharmacy.pdf,2018-05-11,2018,False,original petition,UIC College of Pharmacy (Sarfaraz Niazi),advocacy/academic,"- Biologics Price Competition and Innovation Act (BPCIA), specifically Section 7002 of H.R. 3590
- 42 USC 262(k)(2)(A)(ii)
- 21 CFR 10.30 (petition certification)
- 21 CFR 25.42 (Environmental Impact)","FDA guidance and regulatory approach to the approval process for biosimilar biological products under BPCIA, particularly concerning:
- Bridging studies
- Immunogenicity testing
- Analytical similarity criteria
- Pharmacokinetic/Pharmacodynamic (PK/PD) study protocols","The petitioner requests the FDA to:
‚Ä¢ Waive bridging studies under specific conditions
‚Ä¢ Declare biosimilars substitutable for na√Øve patients
‚Ä¢ Accept in vitro immunogenicity tests in place of human studies
‚Ä¢ Modify PK/PD study designs for clinical relevance
‚Ä¢ Revise Tier 1 testing requirements in analytical similarity guidance","The petitioner argues that:
‚Ä¢ The high cost and long timelines for biosimilar development hinder market access
‚Ä¢ FDA already has legal discretion to vary biosimilarity evidence requirements under 42 USC 262(k)(2)(A)(ii)
‚Ä¢ Ethical concerns exist over unnecessary human testing (e.g., immunogenicity studies)
‚Ä¢ Clinical relevance should guide testing protocols rather than rigid statistical methods
‚Ä¢ Expedited biosimilar approvals could save U.S. healthcare over $50 billion annually",2018-11-16 00:00:00,,2025-10-15,1.0,,,"The FDA stated that the petition raises complex issues requiring extensive review and analysis by Agency officials. As such, they have not yet reached a decision and will respond as soon as one is made. 

",,no decision,False,2714.0,pending,pending
fda-2018-p-1877,FDA-2018-P-1877-0001_Citizen_Petition_from_Laurus_Labs.pdf,2018-05-14,2018,False,original petition,Laurus Labs Limited,advocacy/academic,"- 21 C.F.R. ¬ß 10.30 (Citizen Petition)
- 21 C.F.R. ¬ß 25.31 (Environmental Impact exclusion)
- 21 C.F.R. ¬ß 10.30(b) (Economic Impact)","Discontinuation status of 534 mg strength of ESBRIET (pirfenidone) Tablets by Genentech, Inc., listed as ‚ÄúDiscontinued‚Äù in the Orange Book","The petitioner requests that the FDA:
- Determine whether the 534 mg strength of ESBRIET was discontinued for safety or efficacy reasons.
- If not, accept ANDAs (Abbreviated New Drug Applications) for all three strengths (267 mg, 534 mg, 801 mg) of pirfenidone tablets as generics referencing ESBRIET (NDA #208780)","- The 534 mg strength of ESBRIET is currently listed as ‚ÄúDiscontinued‚Äù in the Orange Book.
- The petition argues that the discontinuation may not be due to safety or efficacy concerns.
- Requests confirmation so that ANDAs can be filed using this strength as a reference listed drug.
- Cites labeling and listing status on FDA platforms to support the claim",2018-11-09 00:00:00,Approved (Determination Issued),2019-02-04,1.0,Center for Drug Evaluation and Research (CDER),"- 21 CFR 314.161 (Determination of withdrawal from sale for safety or effectiveness)
- 21 CFR 314.162 (Submission of labeling for ANDAs)
- Section 505(j)(7) of the FD&C Act (21 U.S.C. 355(j)(7))","The response notes that the petition remains unresolved due to the need to address other Agency priorities. FDA assures it will respond as soon as possible, given current resource demands
","FDA determined, based on a review of its records and Agency reports, that Esbriet (pirfenidone) 534 mg film coated tablets were not withdrawn from sale for reasons of safety or effectiveness. Therefore, they will remain listed in the ""Discontinued Drug Product List"" under the Orange Book, and may be referenced in Abbreviated New Drug Applications (ANDAs), provided all other requirements are met. This determination is essential for generic approval processes",approved,True,266.0,CDER,CDER
fda-2018-p-1880,FDA-2018-P-1880-0001_Citizens_Petition_from_Louis_Morris_Aledort_MD_Red.pdf,2018-05-14,2018,False,original petition,"Louis Morris Aledort, MD",individual,"21 C.F.R. ¬ß¬ß 25.30, 25.31, 25.32, 25.33, or ¬ß 25.34; Environmental assessment under ¬ß 25.40 is also referenced. No mention of 505(q) or 21 C.F.R. ¬ß 10.30 specifically","Licensing and black box warning of Hemlibra (emicizumab)
","Reverse the licensing of Hemlibra; reassess the black box warning; reevaluate whether the drug should remain on the market
","- Safety concerns due to cases of thrombotic microangiopathy (TMA), some of which involved rFVIIa rather than Feiba, suggesting Hemlibra might be responsible.
- Five reported deaths with no publicly available data.
- Insufficient bleeding control in certain patients.
- Occurrence of neutralizing antibodies in a patient.
- Belief that Hemlibra may not be appropriate for all inhibitor patients.
- Data cited includes a NEJM paper, licensing documents, and company memos
",,Denied,2018-10-04,0.0,Center for Drug Evaluation and Research (CDER),"- Section 351(a)(2)(C) of the Public Health Service (PHS) Act
- 21 CFR 600.80 (Adverse Experience Reporting)
- Section 506B of the Federal Food, Drug, and Cosmetic Act (FD&C Act)",,"- Safety: FDA conducted an extensive review of adverse events including thrombotic microangiopathy (TMA), thromboembolic events, and deaths. The three reported TMA cases were associated with high doses of activated prothrombin complex concentrate (aPCC) and not with recombinant factor VIIa (rFVIIa). No additional TMA events were reported after protocol adjustments. The boxed warning was deemed adequate.

- Deaths: FDA reviewed five reported deaths and concluded they were unrelated to Hemlibra. An additional sixth death was also found to be unrelated.

- Antibody Concerns: One pediatric patient developed a neutralizing antibody with loss of efficacy, and this was updated in the product labeling.

- Efficacy: Hemlibra reduces bleeding rates but does not eliminate all bleeding risks. Life-threatening events may still occur, especially in patients with inhibitors.

- Boxed Warning: FDA found the existing boxed warning adequate and noted no new safety concerns requiring changes.

- Conclusion: FDA found Hemlibra to be safe, pure, and potent and noted that the benefits outweigh risks for Hemophilia A patients with limited treatment options. Therefore, the petition to revoke the license was denied.",denied,True,143.0,CDER,CDER
fda-2018-p-1891,FDA-2018-P-1891-0001_Citizen_Petition_from_PuraCap_Pharmaceutical__LLC_.pdf,2018-05-11,2018,False,original petition,"PuraCap Pharmaceutical, LLC",industry/corporation,"Not Mentioned
","The existing Reference Standard listed in the Orange Book (Mikart ANDA #040658) for Hydrocodone Bitartrate and Acetaminophen Tablets USP (5 mg/300 mg, 7.5 mg/300 mg, and 10 mg/300 mg), which was discontinued as of December 2, 2017
","The petitioner requests that the FDA assign a new Reference Standard for Hydrocodone Bitartrate and Acetaminophen Tablets USP (5 mg/300 mg, 7.5 mg/300 mg, and 10 mg/300 mg)",The previously designated Reference Standard (Mikart ANDA #040658) was discontinued and is no longer available for purchase. Epic Pharma intends to file an ANDA for the stated drug formulations and requires an available Reference Standard to perform the necessary comparative testing,,,2025-10-15,0.0,,,,,no decision,False,2714.0,pending,pending
fda-2018-p-1892,FDA-2018-P-1892-0001_Citizen_Petiton_from_Aurobindo_Pharma_USA__Inc.pdf,2018-05-15,2018,False,original petition,"Aurobindo Pharma USA, Inc.",industry/corporation,"- Section 505(j) of the Federal Food, Drug, and Cosmetic Act
- 21 CFR 10.25(a), 10.30, and 314.93
- 21 C.F.R. 25.31(a), 25.15(d)
- 21 C.F.R. 10.30(b)","The petition addresses the FDA‚Äôs designation of a Reference Standard (RS) for Dicyclomine Hydrochloride Tablets USP, 20 mg, currently listed as BENTYL¬Æ by Allergan Sales LLC.","The petitioner requests the FDA to: Designate Dicyclomine Hydrochloride Tablets USP, 20 mg (ANDA #085223) of Watson Laboratories Inc. as a suitable alternative reference standard for in vivo bioequivalence testing for ANDA submissions","- The currently listed reference standard (BENTYL¬Æ) is not readily available in the market despite being listed as active in the Orange Book.
- IMS data and pharmacy statements confirm limited supply/unavailability of the current RS.
- FDA guidance (Referencing Approved Drug Products in ANDA Submissions, III. C.2 and C.3) allows designation of a new RS if the current one is unavailable.
- The Watson Laboratories product (ANDA #085223) is widely marketed and therapeutically equivalent, making it an appropriate alternative RS",2019-01-24 00:00:00,Approved,2019-12-19,1.0,Center for Drug Evaluation and Research (CDER),"- 21 U.S.C. ¬ß 355(j) (FD&C Act ¬ß505(j))
- 21 CFR ¬ß 314.3(b)
- 21 CFR ¬ß 314.94(a)(3)
- 21 CFR ¬ß 314.161
- 21 CFR ¬ß 314.122
- 81 FR 69580, 69619 (Final Rule, Oct. 6, 2016)","The FDA has not reached a decision on the petition due to the need to address other Agency priorities. The interim response is issued in accordance with FDA regulations, and a final response will be provided as soon as possible given the demands on FDA resources
","- Bentyl was unavailable for sale, though not discontinued in the Orange Book.
- FDA Drug Shortages database confirmed unavailability.
- ANDA 085223 is commercially available, therapeutically equivalent, and market-leading.
- Both petitions provided rationale to identify a new reference standard.
- FDA policy allows selection of an alternate reference when the listed drug is not available.",approved,True,583.0,CDER,CDER
fda-2018-p-1949,FDA-2018-P-1949-0001_Citizen_Petition_from_Avadel_Specialty_Pharmaceuti.pdf,2018-05-18,2018,False,original petition,"Avadel Specialty Pharmaceuticals, LLC",industry/corporation,"- 505(q) of the FDCA
- 21 C.F.R. ¬ß 10.30
- FDCA ¬ß 505(b)(2)
- 21 C.F.R. ¬ß 314.50(i)
- 21 C.F.R. ¬ß 314.52(a)
- 21 C.F.R. ¬ß 25.31
- 21 C.F.R. ¬ß 10.30(b)",Potential FDA approval of Ferring Pharmaceuticals' NDA 022517 for Nocdurna (desmopressin acetate) for nocturia,"- Do not approve NDA 022517 without:
‚Ä¢ ‚â•2 representative clinical trials
‚Ä¢ Standard efficacy endpoints using validated PRO tools
‚Ä¢ Acceptable bioavailability/absorption data
‚Ä¢ Risk mitigation studies
‚Ä¢ Proper patent certifications and Paragraph IV notices
- Establish new FDA standards for:
‚Ä¢ Effectiveness measures
‚Ä¢ Trial design reflecting real-world use
‚Ä¢ Bioavailability/absorption standards","- Clinical trials lacked real-world conditions and at-risk populations
- Efficacy thresholds and outcome measures were inadequate
- Unreliable and variable bioavailability of sublingual dosage form
- Non-compliance with patent certification/notice requirements under 505(b)(2)
- History of FDA concerns, including previous rejections and advisory committee objections",,Denied,2018-06-21,0.0,Center for Drug Evaluation and Research (CDER),"- 21 U.S.C. ¬ß 355(b), ¬ß 355(c), ¬ß 355(d) (FD&C Act Section 505)
- 21 CFR 314.125(b) ‚Äì Grounds for refusal
- 21 CFR 314.126 ‚Äì Adequate and well-controlled studies
- 21 CFR 314.52(a) ‚Äì Patent certification requirements
- 21 CFR 314.3 ‚Äì Definitions related to NDAs",,"- Substantial Evidence of Effectiveness: FDA concluded Ferring's resubmission of additional analyses from pivotal studies CS40 and CS41 demonstrated statistically significant and clinically meaningful benefit for patients with nocturia due to nocturnal polyuria.

- Benefit-Risk Balance: The benefits of NOCDURNA outweighed its risks when used per approved labeling, especially for patients with ‚â•2 nightly voids.

- Safety Database Adequacy: FDA determined Ferring's clinical trials sufficiently included older adults and patients with varying renal functions to evaluate safety.

- Bioavailability & Variability: FDA dismissed claims that NOCDURNA‚Äôs bioavailability or pharmacokinetic variability posed undue risks, concluding it was acceptable based on pharmacodynamic evidence and labeling guidance.

- No Patent Certification Required: FDA concluded NOCDURNA was submitted as a standalone 505(b)(1) NDA, not a 505(b)(2), and thus did not require patent certifications related to NOCTIVA.",denied,True,34.0,CDER,CDER
fda-2018-p-1966,FDA-2018-P-1966-0001_Suitability_Petition_from_McNeely__Hare___War__LLP.pdf,2018-05-17,2018,False,original petition,"McNeely, Hare & War LLP",law/consulting,"- Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act (FDC Act)
- 21 C.F.R. ¬ß¬ß 10.20 and 10.30",Suitability of 150 mg and 300 mg strengths of Celecoxib Oral Capsules for submission in an Abbreviated New Drug Application (ANDA) based on the reference listed drug Celebrex¬Æ,"The petitioner requests that FDA determine that 150 mg and 300 mg Celecoxib oral capsules are suitable for submission in an ANDA
","- Proposed strengths are intermediate (between approved 50, 100, 200, and 400 mg) and match route/formulation of the RLD.
- Intended to reduce pill burden and increase convenience, especially for conditions like rheumatoid arthritis and ankylosing spondylitis.
- Prescription data supports need for intermediate strengths due to frequent co-prescribing of existing strengths to achieve desired doses.
- The new strengths offer physicians more options to prescribe the lowest effective dosage consistent with treatment goals",,Approved,2023-06-07,0.0,Center for Drug Evaluation and Research (CDER),"- Section 505(j)(2)(C) of the FD&C Act
- Section 505(j)(2)(A) and (B)
- Section 505(j)(2)(A)(iv)
- 21 CFR 314.93 ‚Äì Petitions to request strength changes
- 21 CFR 314.93(e)(1)
- 21 CFR 314.94(a)(3)(iii)",,"- The proposed strength change (150 mg and 300 mg) does not raise safety or efficacy concerns.
- The proposed drug uses the same dose, dosage form, and route of administration as the listed product.
- The change is consistent with existing labeling.
- If bioequivalence is shown, the product is expected to have the same therapeutic effect.
- No significant labeling changes or additional investigations are necessary to demonstrate safety and efficacy for the new strengths",approved,True,1847.0,CDER,CDER
fda-2018-p-1980,FDA-2018-P-1980-0001_Citizen_Petition__from_Foley___Lardner_LLP.pdf,2018-05-22,2018,False,original petition,Foley & Lardner LLP,law/consulting,"21 C.F.R. ¬ß 10.30; 21 C.F.R. ¬ß 25.1(g)
","The current designation in the FDA‚Äôs Orange Book for Furosemide Injection 10 mg/mL, specifically that the designated Reference Listed Drug (RLD), NDA 18579 by Luitpold Pharmaceutical Inc., is listed as discontinued","The petitioner requests that the FDA designate ANDA 075241 (Furosemide Injection 10 mg/mL by Hospira, Inc.) as a reference standard in the FDA‚Äôs Orange Book for purposes of comparison in support of ANDA filings
","The current RLD is discontinued, and the petitioner seeks designation of an available product (Hospira‚Äôs ANDA 075241) as the reference standard to facilitate comparison testing and ANDA submissions",2018-11-16 00:00:00,"Mixed (One Petition Granted, One Denied)
- Akorn Petition: Granted (FDA designates ANDA 202747 as the reference standard for furosemide injection, 10 mg/mL)
- Mylan, Gland, and Foley & Lardner Petitions: Denied",2018-12-18,1.0,Center for Drug Evaluation and Research (CDER),"- 21 U.S.C. ¬ß 355(j) ‚Äì Section 505(j) of the FD&C Act
- 21 CFR 314.3(b) ‚Äì Definitions of RLD and reference standard
- 21 CFR 314.94(a)(3) ‚Äì Reference standards in ANDA submissions
- 21 CFR 314.125(b) ‚Äì Grounds for denying ANDAs
- 81 FR 69580, 69619 (Oct. 6, 2016) ‚Äì Final rule on ANDAs and 505(b)(2) applications","- The Agency was unable to reach a decision on the petition due to the need to address other Agency priorities.
- The response was issued as an interim notification in compliance with regulatory procedures.","- FDA determined that identifying a new reference standard (RS) was appropriate because existing RLDs (NDA 018579 and NDA 016363) were discontinued.
- ANDA 202747, which is therapeutically equivalent to discontinued products and commercially available, was selected as the RS.
- The denied petitions did not provide sufficient grounds to designate additional RLDs or RSs, as current listings in the Orange Book already satisfied regulatory requirements for ANDA referencing.
- FDA emphasized that a new RS must ensure consistent bioequivalence testing, and availability played a key role in the designation decision",approved,True,210.0,CDER,CDER
fda-2018-p-2025,FDA-2018-P-2025-0001_Citizen_Petition_from_Center_for_Biological_Divers.pdf,2018-05-24,2018,False,original petition,Center for Biological Diversity,advocacy/academic,"- 21 C.F.R. ¬ß 10.30 (citizen petition regulation)
- Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 25.1 (environmental policy)
- National Environmental Policy Act (NEPA)
- Endangered Species Act (ESA)","FDA‚Äôs failure to require an environmental impact analysis before approving animal drugs that are medically important antimicrobials and are excreted into the environment.
","The petitioner requests that the FDA:
- Begin conducting environmental reviews for new and existing approvals of animal drugs that are medically important antimicrobials, under NEPA.
- Disclose environmental assessments and findings.
- Reevaluate existing approvals where drugs may be contributing to antimicrobial resistance or harming wildlife and ecosystems.","The petitioner argues that:
- FDA has unlawfully failed to consider the environmental impacts of its approvals of animal drugs.
- The excretion of medically important antimicrobials from food animals into the environment contributes to antimicrobial resistance.
- This resistance poses a significant public health threat and harms wildlife.
- Environmental analysis is required under NEPA and consistent with FDA‚Äôs environmental regulations.",2018-11-21 00:00:00,,2025-10-15,1.0,,,"- The petition raises complex scientific and regulatory issues, including potential bans on oxybenzone and octinoxate in sunscreens and personal care products.
- The petition also requests:
1. Consultation with the National Marine Fisheries Service under Section 7 of the Endangered Species Act to assess impact on listed species.
2. Environmental analysis under the National Environmental Policy Act (NEPA).
- FDA needs more time for interagency coordination and review, thus providing an interim response.",,no decision,False,2701.0,pending,pending
fda-2018-p-2050,FDA-2018-P-2050-0001_Citizen_Petition_from_SS_Formulations__LLC_.pdf,,2018,False,original petition,"SS Formulations, LLC",industry/corporation,"- 21 C.F.R. ¬ß 10.30 (Citizen Petition provision)
- 21 C.F.R. Part 330.10 (OTC drug monograph requirements)
- 21 C.F.R. Part 358 (Wart remover & corn/callus remover products)
- 21 C.F.R. Part 25 (Environmental assessments and exclusions)","FDA‚Äôs regulation concerning over-the-counter (OTC) drug monographs, particularly regarding the use of sodium salicylate in topical applications for hyperpigmentation removal.","Petitioner requests FDA to issue a clearance in the form of an effective Monograph Change Notification to permit the use of 2-hydroxy, monosodium salt (sodium salicylate) in aqueous mixtures applied to human skin for removal of hyperpigmented spots.","- Sodium salicylate (related to salicylic acid) is already FDA-approved for other topical uses (e.g., wart, corn, callus removal).
- Petitioner conducted an IRB-approved study showing effective use in treating hyperpigmented spots.
- Scientific literature supports its use.
- Environmental impact deemed minimal due to rapid biodegradation and non-toxic exposure levels to aquatic/terrestrial organisms.",,,2025-10-15,,,,,,no decision,False,,pending,pending
fda-2018-p-2073,FDA-2018-P-2073-0001_Citizen_Petition_from_LMS_Direct_Research_Foundati.pdf,2018-05-16,2018,False,original petition,"Sarah Salem-Robinson, PA-C (Physician Assistant in OB/GYN)",individual,"- 21 C.F.R. ¬ß 10.30 (citizen petition procedures)
- 21 C.F.R. ¬ß 803.1(a) and ¬ß 803.10 (medical device reporting requirements)
- Section 895.21 (Procedures for banning a device)",The 2014 FDA advisory and labeling update regarding laparoscopic and hysteroscopic power morcellators; the petitioner argues this was insufficient and seeks a complete ban,A total ban on the use of power morcellators in all gynecological (GYN) surgeries,"- New studies (e.g., Green Journal, April 2018) report 1.0‚Äì8.6% risk of hidden cancer in women undergoing hysterectomy thought to be for benign conditions.
- Morcellators may spread undiagnosed sarcomas, upstaging cancer.
- Violation of surgical principles and ethics (‚Äúdo no harm‚Äù).
- Manufacturers and medical institutions failed to report adverse events as required by law.
- 510(k) clearance pathway for morcellators was flawed and failed to ensure safety.
- Morcellator use increased post-warning due to inadequate professional transparency.
- The FDA should lead with a strong ban to protect future patients",2018-06-12 00:00:00,Denied,2020-12-30,1.0,"Center for Devices and Radiological Health (CDRH)
","- Section 510(k) of the FD&C Act
- Section 516(a) of the FD&C Act (21 U.S.C. ¬ß 360f(a)) ‚Äì Device bans
- 21 CFR 895.21(a) ‚Äì Procedures for banning a device
- 21 CFR Part 803 ‚Äì Medical Device Reporting (MDR)
- Section 519 of the FD&C Act (21 U.S.C. ¬ß 360i) ‚Äì Reporting of device-related adverse events","- The petition, filed on May 30, 2018, requested a ban on all Laparoscopic and Hysteroscopic Power Morcellators for gynecological surgeries.
- FDA stated that the petition raises complex issues requiring further review and analysis before a final decision can be made
","- FDA reviewed all submitted and external scientific information and concluded that LPMs and hysteroscopic morcellators do not present a substantial deception or unreasonable and substantial risk that cannot be mitigated by labeling.
- The FDA has already implemented multiple risk mitigation strategies: updated labeling (2014, finalized 2020), safety communications (2014, 2017, 2020), advisory committee consultations, and requiring tissue containment systems for gynecologic use.
- FDA stated it lacks authority to amend Section 510(k) of the FD&C Act directly; however, existing postmarket surveillance regulations (e.g., MDR) provide mechanisms to monitor adverse events
",denied,True,959.0,CDRH,CDRH
fda-2018-p-2344,FDA-2018-P-2344-0001_Suitability_Petition_from_Noble_Pharma_LLC.pdf,2018-06-15,2018,False,original petition,"Noble Pharma, LLC",industry/corporation,"Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act (FFDCA); 21 CFR 25.33(d)(5); 21 CFR 25.21; 21 CFR 20.61
",Filing of an Abbreviated New Animal Drug Application (ANADA) for a different dosage form of an approved pioneer product (praziquantel tablet),Permission to file an ANADA for a scored soft chewable tablet of praziquantel (generic) as an alternative dosage form to the pioneer product‚Äîa compressed scored tablet,"- Proposed generic product will have same active ingredient, dosage, administration method, therapeutic effect, cautions, and warnings as the pioneer.
- Soft chewables are more palatable and improve compliance.
- All excipients used are approved for dogs and pose no safety/effectiveness concerns.
- Labeling will closely parallel pioneer product labeling with differences noted in formulation and format.",,Approved,2018-09-06,0.0,Center for Veterinary Medicine (CVM),"- Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act (FFD&CA)
- Section 512(n)(3)(C) ‚Äì Suitability petition approval standard
- 21 CFR 514.5 ‚Äì Presubmission conference guidelines",,"- The proposed changes (from a compressed tablet to a scored soft chewable tablet) are acceptable under the suitability petition pathway.
- No additional investigations are required to demonstrate safety and efficacy for the intended use because the dosage and strength remain consistent with the RLNAD
",approved,True,83.0,CVM,Other/Specialty Center
fda-2018-p-2407,FDA-2018-P-2407-0001_Citizen_Petition_from_Ray_Law_Firm__PLLC.pdf,2018-06-14,2018,False,original petition,"Ray Law Firm, PLLC (Harry B. Ray)",law/consulting,"- Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. 25.15
- 21 C.F.R. 25.33(e)
- 21 C.F.R. 25.21
- 21 C.F.R. 10.30(b)","Approval process and requirements for new animal drug applications, specifically Abbreviated New Animal Drug Applications (ANADA)",Approval of new strengths (37.5mg and 50mg) of generic Carprofen Chewable Tablets for dogs,"- Existing approved strengths (25mg, 75mg, 100mg) do not allow convenient dosing for 16‚Äì30 lb dogs
- New 37.5mg and 50mg strengths would simplify dosing and eliminate need for splitting tablets
- No change in indications, safety, or effectiveness is implied for the new strengths",,,2025-10-15,0.0,,,,,no decision,False,2680.0,pending,pending
fda-2018-p-2408,FDA-2018-P-2408-0001_Citizen_Petition_from_Public_Citizen.pdf,2018-06-21,2018,False,original petition,Public Citizen,individual,"- 21 U.S.C. ¬ß 355(o)(4)
- 21 C.F.R. ¬ß 10.30",The ongoing marketing of oral benzocaine products despite serious safety concerns.,"- Immediately remove all oral benzocaine products from the market.
- Initiate withdrawal procedures under 21 CFR 314.150.","- Oral benzocaine products are associated with serious and potentially fatal adverse effects, including methemoglobinemia.
- FDA itself has issued safety communications about these risks.
- There is a lack of evidence supporting any meaningful therapeutic benefit.
- Alternatives exist that are safer and more effective.",,Denied,2019-02-21,0.0,Center for Drug Evaluation and Research (CDER),"- Section 505(b) and 505(e)(2) of the FD&C Act (21 U.S.C. ¬ß¬ß 355(b), 355(e)(2))
- 21 CFR 10.30 ‚Äì Citizen petition procedures",,"- The CARES trial and other data showed an increased risk of cardiovascular (CV) death with febuxostat compared to allopurinol, but FDA concluded that benefits outweigh risks for patients intolerant of allopurinol.
- Rather than removing febuxostat, FDA is requiring the following labeling changes:
- A boxed warning describing increased CV death risk.
- A change in indication to reserve febuxostat for patients who failed or cannot tolerate allopurinol.
- A Medication Guide to communicate CV risk to patients.
- FDA will also update its 2017 Drug Safety Communication, conduct outreach to professional societies, and require the sponsor to monitor post-market use of febuxostat
",denied,True,245.0,CDER,CDER
fda-2018-p-2506,FDA-2018-P-2506-0001_Citizen_Petition_from_K_L_Gates_LLP.pdf,2018-06-27,2018,False,original petition,K&L Gates LLP,law/consulting,"- 21 C.F.R. ¬ß¬ß 10.25 and 10.30
- 21 C.F.R. ¬ß¬ß 314.122 and 314.161
- Sections 505(j) and 505(w) of the Federal Food, Drug, and Cosmetic Act (FDCA)",FDA's listing of AXIRON¬Æ as a discontinued Reference Listed Drug (RLD) and withdrawal of approval for NDA N022504,"Request for FDA to determine that AXIRON¬Æ (testosterone) transdermal metered solution, NDA N022504, was not withdrawn for reasons of safety or effectiveness",The petitioner asserts there is no known information suggesting AXIRON¬Æ was withdrawn for safety or effectiveness reasons and requests a determination confirming that it was not,,,2025-10-15,0.0,,,,,no decision,False,2667.0,pending,pending
fda-2018-p-2658,FDA-2018-P-2658-0001_Citizen_Petiton_from_Hyman__Phelps___McNamara__PC.pdf,2018-07-10,2018,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"- Federal Food, Drug, and Cosmetic Act (FDC Act) ¬ß 505(j)
- 21 C.F.R. ¬ß 10.25(a)
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 314.3
- 21 C.F.R. ¬ß 25.31","Selection of Reference Standards (RS) for generic drug applications, specifically related to the designation in the Orange Book for Methylphenidate Hydrochloride Extended Release 60 mg capsules.",That FDA designate ANDA 078873 as an additional Reference Standard (RS) for Methylphenidate Hydrochloride Capsules Extended Release 60 mg in the Orange Book.,"- The current RS (Metadate CD 60 mg, NDA 021259) appears to be discontinued and is unavailable for sampling.
- ANDA 078873 is a therapeutically equivalent version of the RLD and the current market leader.
- Designating it as an RS would facilitate further generic competition.
- FDA‚Äôs own guidance allows designation of a new RS when current RS is not available for in vivo bioequivalence testing. ",2019-01-15 00:00:00,Denied,2019-11-18,1.0,Center for Drug Evaluation and Research (CDER),"- Section 505(j) of the FD&C Act (21 U.S.C. ¬ß 355(j))
- 21 CFR 314.3(b) ‚Äì Definitions of listed drug and reference standard
- 21 CFR 314.94(a)(3) ‚Äì ANDA content requirements
- 21 CFR 314.125 ‚Äì NDA/ANDA evaluations","- The petition, submitted on July 10, 2018, requests that FDA designate ANDA 078873 (methylphenidate hydrochloride extended-release capsules, 60 mg) as a reference standard for use in an abbreviated new drug application.
- FDA noted that the petition raises complex issues requiring extensive review and analysis, and a response will be issued once a decision is reached
","- The current reference standard, Metadate CD (NDA 021259), is still being distributed as an authorized generic and has not been discontinued.
- FDA concluded that the petitions did not provide adequate grounds to select a new reference standard.
- FDA emphasized that an ANDA applicant may use the authorized generic version of the current RLD for in vivo bioequivalence studies, assuming appropriate documentation is provided.
- FDA does not believe selecting a new reference standard is warranted given the availability of the existing one in distribution",denied,True,496.0,CDER,CDER
fda-2018-p-2720,FDA-2018-P-2720-0001_Citizen_Petition_from_Hyman__Phelps___McNamara__P_.pdf,2018-07-13,2018,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"- Federal Food, Drug and Cosmetic Act (FDC Act) ¬ß 505(j)
- 21 C.F.R. ¬ß¬ß 10.25(a) and 10.30
- 21 C.F.R. ¬ß 314.3
- 21 C.F.R. ¬ß 25.31
- 21 C.F.R. ¬ß 10.30(b)","The FDA's designation of a Reference Standard (RS) in the Orange Book for Benztropine Mesylate Tablets. Specifically, the petitioner addresses the fact that the current RS (ANDA 040103) is not marketed and unavailable for sampling, potentially hindering generic competition ","FDA is requested to designate ANDA 204713 (or another suitable ANDA) as a new or additional Reference Standard for Benztropine Mesylate Tablets (0.5 mg, 1 mg, and 2 mg) in the Orange Book, replacing the discontinued ANDA 040103. This change would facilitate the submission of new generic ANDAs by enabling bioequivalence testing ","- The current RS (ANDA 040103) appears to be inactive and not available for sampling.
- Lack of an available RS impedes new generic drug applications and competition.
- FDA‚Äôs own guidance supports changing the RS if the current one is unavailable.
- ANDA 204713 is a therapeutically equivalent and recently approved drug product suitable for this purpose ",2019-01-04 00:00:00,Approved,2019-04-24,1.0,Center for Drug Evaluation and Research (CDER),"- Section 505(j) of the FD&C Act (21 U.S.C. ¬ß 355(j))
- 21 CFR 314.3(b) ‚Äì Definitions of listed drug, reference standard, therapeutic equivalents
- 21 CFR 314.94(a)(3) ‚Äì ANDA content requirements
- 21 CFR 320.22(c) ‚Äì In vivo bioequivalence waiver
- FDA Draft Guidance (Jan. 2017) ‚Äì Referencing Approved Drug Products in ANDA Submissions","- The petition, submitted on July 13, 2018, requested that FDA amend the Orange Book to designate ANDA 204713 or another ANDA as a reference standard for benztropine mesylate tablets (0.5 mg, 1 mg, and 2 mg).
- FDA explained that a decision had not yet been reached due to other priority matters and resource demands
","- The previous reference standard (ANDA 040103 by USL Pharma) is no longer marketed and will be moved to the Discontinued Section of the Orange Book.
- The RLD (NDA 009193 by Merck) is also discontinued and unavailable for sampling.
- Aspen‚Äôs ANDA 204713 is a therapeutic equivalent and the current market leader, thus appropriate to designate as the reference standard.
- Even though no in vivo bioequivalence studies are required for approval of an ANDA referencing Cogentin (benztropine), the FDA agreed a new reference standard would facilitate generic development
",approved,True,285.0,CDER,CDER
fda-2018-p-2749,FDA-2018-P-2749-0001_Citizen_Petition_from_Anne_A__Shirinian_Orlando_Re.pdf,2018-07-13,2018,False,original petition,"Anne A. Shirinian-Orlando, Ph.D.",individual,"- Section 355(e) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 25.31(a)","Lack of strict dosage, administration, and procurement monitoring guidelines for prostate cancer chemotherapy medications","- Issue strict FDA-approved dosage and administration guidelines for prostate chemotherapy medications
- Monitor procurement of chemotherapy medications to ensure sourcing from safe manufacturers","- Overdosing of patients, especially stage 4 prostate cancer patients, has led to liver and other organ damage
- Examples include drugs such as ZYTIGA, JEVTANA, and XTANDI, which have harmful side effects including organ failure and death
- Chemotherapy drugs are highly toxic, lack clear detoxification protocols, and are administered without individualized assessments (e.g., based on tumor growth rate)
- Efficacy claims rely on median survival statistics rather than precise disease progression measures",2019-01-10 00:00:00,Denied,2019-06-04,1.0,Center for Drug Evaluation and Research (CDER),"- Section 201, 502(a), (f), and (j); and 505 of the FD&C Act (21 U.S.C. ¬ß¬ß 321(n), 352(a), (f), and (j); 355)
- 21 CFR 201.57(c)(3)(i)(H) ‚Äì Labeling requirements
- 21 CFR 201.57(a)(7) ‚Äì Prescribing information
- 21 CFR Part 210 and 211 ‚Äì CGMP regulations
- Section 582 of FD&C Act (DSCSA)","- The petition (received July 17, 2018) requested that FDA issue strict guidelines on dosage and administration of prostate cancer chemotherapy medications, and monitor procurement of those medications.
- The Agency has not reached a decision due to the need to prioritize other demands on its resources and regulatory agenda","- The petition asked FDA to mandate strict dosage and administration guidelines for prostate chemotherapy drugs (Zytiga, Jevtana, Xtandi) and ensure safe procurement of these drugs.
- FDA responded that existing drug labeling already includes required dosing guidance and adjustments for hepatic impairment per 21 CFR 201.57(c)(3)(i)(H) (see summaries on pages 2‚Äì3).
- Regarding procurement safety, FDA stated its current CGMP regulations, drug supply chain security laws, and educational outreach (e.g., ‚ÄúKnow Your Source‚Äù program) are sufficient to address concerns about counterfeit or unsafe drugs.
- Therefore, FDA declined to take additional regulatory action beyond what is already in place
",denied,True,326.0,CDER,CDER
fda-2018-p-2754,FDA-2018-P-2754-0001_Citizen_Petition_from_Ascend_Laboratories_LLC.pdf,2018-07-18,2018,False,original petition,"Ascend Laboratories, LLC",advocacy/academic,"- 21 CFR ¬ß¬ß 10.25, 10.30
- Sections 505(j) and 505(w) of the FDCA
- 21 CFR ¬ß¬ß 314.122, 314.161, 314.162
- 21 CFR ¬ß 25.31
- 21 CFR ¬ß 10.30(b)","The inclusion of ONFI (clobazam) 5 mg tablets in the ""Discontinued Section"" of the Orange Book, and whether it was withdrawn for safety or efficacy reasons",Ascend Laboratories requests the FDA to determine whether ONFI (clobazam) 5 mg tablets (NDA 202067) has been withdrawn or withheld from sale for reasons of safety or efficacy,"The petition notes that ONFI (clobazam) 5 mg tablets, approved on October 21, 2011, is now listed in the ""Discontinued Section"" of the Orange Book. FDA is required to determine if a product has been withdrawn for reasons of safety or efficacy before approving an ANDA referencing that drug
",2019-01-10 00:00:00,Approved,2019-04-02,1.0,Center for Drug Evaluation and Research (CDER),"- Not explicitly cited in the letter (only references to the Orange Book and Federal Register notice).
","- The petition, received on July 17, 2018, requested that the FDA determine whether ONFI (clobazam) 5 mg tablets (NDA 202067) were withdrawn from the market for reasons related to safety or effectiveness.
- FDA issued this interim response due to resource constraints and competing priorities, indicating it will respond fully as soon as feasible","- FDA reviewed its records and concluded that ONFI (clobazam) 5 mg tablets (NDA 202067) were not withdrawn from sale for reasons of safety or effectiveness.
- Therefore, the product will remain listed in the Discontinued Drug Product List section of the Orange Book with Therapeutic Equivalence Evaluations.",approved,True,258.0,CDER,CDER
fda-2018-p-2755,FDA-2018-P-2755-0001_Citizen_Petition_from_Ascend_Laboratories__LLC.pdf,2018-07-17,2018,False,original petition,"Ascend Laboratories, LLC",advocacy/academic,"21 C.F.R. ¬ß 10.25(a), 10.20, 10.30, 314.93; FDC Act ¬ß 505(j); 21 C.F.R. ¬ß 314.3; 21 C.F.R. ¬ß 25.31","Reference Listed Drug (RLD) designation in the Orange Book and absence of a Reference Standard (RS) for Methylphenidate Hydrochloride Extended-Release Capsules 10‚Äì60 mg
","FDA should designate any other approved generic version of METADATE CD (Methylphenidate Hydrochloride Extended-Release Capsules, NDA No. 021259) as an alternate Reference Standard (RS) for ANDA submission purposes","The original RLD, METADATE CD by Lannett Co. Inc., has been discontinued and neither it nor the authorized generic is available in the market. There is no currently assigned RS for this product in the Orange Book, preventing ANDA submissions. Market data and distributor letters support the lack of availability of the reference product",2019-01-15 00:00:00,Denied,2019-11-18,1.0,Center for Drug Evaluation and Research (CDER),"- Section 505(j) of the FD&C Act (21 U.S.C. ¬ß 355(j))
- 21 CFR 314.3(b) ‚Äì Definitions (e.g., listed drug, reference standard, therapeutic equivalents)
- 21 CFR 314.94(a)(3) ‚Äì ANDA content requirements
- 21 CFR 320.22(c) ‚Äì Bioequivalence waiver
- Section 505(t) ‚Äì Authorized generics list","- The petition, received on July 18, 2018, requested that FDA designate any other approved generic version of Metadate CD (methylphenidate hydrochloride ER capsules) as an alternate reference standard for submission of ANDAs.
- FDA has not yet reached a decision due to the complexity of the issues and indicated that it will respond as soon as a determination is made","- Petitioners requested designation of another product as the reference standard for methylphenidate hydrochloride ER capsules, 60 mg.
- FDA reviewed its records and determined the current reference standard product (Metadate CD, NDA 021259) is still marketed as an authorized generic and not discontinued.
- FDA concluded there were no grounds to select a new reference standard since the existing one remains available for in vivo bioequivalence testing and market distribution.
- Therefore, FDA stated that selecting a new reference standard was not warranted",denied,True,489.0,CDER,CDER
fda-2018-p-2838,FDA-2018-P-2838-0001_Citizen_Petition_from_Public_Citizen_s_Health_Rese.pdf,2018-07-23,2018,False,original petition,Public Citizen‚Äôs Health Research Group,advocacy/academic,"- Sections 331(a) and 342(f) of the Federal Food, Drug, and Cosmetic Act (FDCA)
- 21 C.F.R. ¬ß 10.30",FDA's inaction regarding the continued marketing of dietary supplements containing cesium chloride (CsCl) or other cesium salts,"1. Require immediate removal from the market of all dietary supplements containing cesium chloride or other cesium salts.
2. Issue a safety communication to advise consumers and healthcare professionals about associated harms ","- CsCl poses a significant or unreasonable risk of serious illness or injury, particularly life-threatening cardiac arrhythmias.
- It is promoted for unproven and unsafe cancer treatments.
- FDA and its Pharmacy Compounding Advisory Committee have recognized CsCl's serious safety concerns including cardiac toxicity and central nervous system effects.
- Documented adverse events include seizures, syncope, QT prolongation, torsades de pointes, and deaths.
- Animal and in vitro studies corroborate cardiotoxicity.
- Vulnerable cancer patients are being misled by unverified health claims.
- There is no scientific evidence supporting CsCl‚Äôs efficacy in treating any health condition ",,Partially Approved / Partially Denied,2020-02-05,0.0,"Center for Food Safety and Applied Nutrition (CFSAN)
","- 21 C.F.R. ¬ß 10.30(e)(3)
- 21 U.S.C. ¬ß 321(ff)
- 21 U.S.C. ¬ß 342(f)(1)(A)
- 21 U.S.C. ¬ß 371(a)
- 21 U.S.C. ¬ß 334(a)(1)
- 21 U.S.C. ¬ß 332(a)
- 21 U.S.C. ¬ß 352(f)(1)
- 21 U.S.C. ¬ß¬ß 331(d), 355(a)&(i)
- 21 U.S.C. ¬ß 321(g)(1)(B)
- Section 503A of FD&C Act (21 U.S.C. ¬ß 353a)
- Final Rule on Ephedrine Alkaloids (69 Fed. Reg. 6788)",,"- Issued safety alert in 2018 due to risks of cardiotoxicity, hypokalemia, and fatal arrhythmias from cesium chloride.
- Reviewed CAERS and FAERS databases and public comments.
- Found few current products and limited adverse event reports.
- Chose not to initiate rulemaking due to resource prioritization and available enforcement tools.",partially approved / denied,True,562.0,CFSAN,Other/Specialty Center
fda-2018-p-2851,FDA-2018-P-2851-0001_Citizen_Petition_from_Pharmaceutical_Manufacturing.pdf,2018-07-23,2018,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"- Section 505(j) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 10.30",The FDA‚Äôs potential approval of any ANDA referencing Colestid¬Æ (colestipol hydrochloride) Tablets unless specific bioequivalence requirements are met.,"The petitioner requests the FDA not to approve any ANDA referencing Colestid¬Æ Tablets unless the applicant demonstrates bioequivalence through:
‚Ä¢ A comparative clinical endpoint bioequivalence study in patients with hypercholesterolemia; or
‚Ä¢ A comparative efficacy study measuring serum LDL-cholesterol as a surrogate endpoint.","The justification provided includes:
‚Ä¢ Colestipol tablets are not absorbed, and their action is local in the GI tract, making traditional PK studies inappropriate.
‚Ä¢ The FDA‚Äôs own bioequivalence guidance for colestipol granules calls for clinical endpoint studies.
‚Ä¢ There is no published evidence showing that PK-based studies are sufficient to establish therapeutic equivalence for colestipol tablets.
‚Ä¢ Substituting without proper equivalence could undermine treatment and public health.",,Denied,2019-12-20,0.0,Center for Drug Evaluation and Research (CDER),"- FD&C Act (Federal Food, Drug, and Cosmetic Act):
‚Ä¢ Section 505(b), 505(j), 505(b)(2), 505(q)(1)(F), 505(c)(1)(B), 505(d)
‚Ä¢ Section 314 (21 CFR 314.50, 314.94, 314.105, 314.125, 314.127, 314.110, 314.200)
‚Ä¢ Section 314.101(d)(9)
‚Ä¢ Section 314.3(b), 314.162
- Administrative Procedure Act (cited in petition but refuted by FDA)
- 78 FR 23273 (Federal Register reference)",,"- Prematurity: FDA had not yet made decisions on Remoxy ER or other similar NDAs at the time of the petition.
- Procedural Framework: FDA emphasized statutory protections for applicants under the FD&C Act, requiring final decisions be based on full application reviews, not citizen petitions alone.
- Evaluation of Abuse-Deterrent Claims: FDA stated it only approves such claims when supported by appropriate scientific data; labeling explains deterrent properties without asserting absolute abuse prevention.
- Scientific Flexibility: FDA disagreed with the claim that its abuse-deterrent guidance is treated as binding, affirming that alternative approaches are accepted if justified by data.
- No Obligation to Approve or Deny Based on Petition Alone: FDA rejected calls to reject applications using 505(b)(2) pathways or to deny applications with specific study references, reiterating that these are handled via standard review protocols.",denied,True,515.0,CDER,CDER
fda-2018-p-2862,FDA-2018-P-2862-0001_Citizen_Petition_from_Lupin_Pharmaceuticals__Inc.pdf,2018-07-23,2018,False,original petition,"Lupin Pharmaceuticals, Inc.",industry/corporation,"- Section 505(j) of the Federal Food, Drug, and Cosmetic Act
- 21 CFR ¬ß 10.25(a)
- 21 CFR ¬ß 10.30
- 21 CFR ¬ß 25.31 (Environmental Impact)","Discontinuation of the Reference Listed Drug (RLD) and Reference Standard (RS) for Azithromycin Tablet, 600 mg ‚Äì specifically, ZITHROMAX¬Æ 600 mg (NDA # N050730) by Pfizer Central Research ","FDA is requested to designate a suitable alternate Reference Standard (RS) for Azithromycin Tablet, 600 mg, for use in in vitro bioequivalence studies, due to the unavailability of the current RLD/RS and the authorized generic in the market ","- ZITHROMAX¬Æ 600 mg (current RLD/RS) is no longer available in the market, although not officially listed as discontinued in the Orange Book.
- Pfizer confirmed discontinuation (Attachment-1).
- The authorized generic by Greenstone LLC is also unavailable as of July 2017 (Attachment-4).
- Lupin cannot perform required bioequivalence studies without an RS.
- Per FDA‚Äôs Draft Guidance (Jan 2017), a citizen petition can be submitted to request a different RS under such circumstances",2019-01-18 00:00:00,Approved,2019-06-25,1.0,Center for Drug Evaluation and Research (CDER),"- Section 505(j) of the FD&C Act (21 U.S.C. ¬ß 355(j))
- 21 CFR 314.3(b) (definition of listed drug)
- 21 CFR 314.94(a)(3) (bioequivalence requirements)
- 21 CFR 314.94(a) (ANDA content)
- 81 FR 69580, 69619 (Final Rule on ANDAs and 505(b)(2) Applications)","- FDA has been unable to reach a decision due to the need to address other Agency priorities.
- The response assures that the petition will be reviewed as soon as possible given resource constraints.","- The existing reference standard (RS), Zithromax 600 mg tablet, was discontinued and thus not available in sufficient quantity for use in in vivo bioequivalence testing.
- The FDA reviewed regulatory filings and commercial data and confirmed that ANDA 065218 (Pliva) is the current market leader among generic drug products for Zithromax.
- Selecting a market-leading generic product as the new RS ensures availability and reliability for future ANDA applicants conducting bioequivalence studies",approved,True,337.0,CDER,CDER
fda-2018-p-2901,FDA-2018-P-2901-0001_Citizen_Petition_from_Yiling_Pharmaceutical_Ltd.pdf,2018-07-26,2018,False,original petition,Yiling Pharmaceutical Ltd,industry/corporation,"- 21 C.F.R. 10.25(a)
- 21 C.F.R. 10.30","The selection of the reference standard (RS) for VOLTAREN (diclofenac sodium delayed-release tablets, 75mg, 50mg, and 25mg)","That the FDA select a different listed drug (from the current CASI-assigned reference standard) to be used as the RS for conducting in vivo bioequivalence studies in ANDA applications.

","- The currently assigned RS product (CASI‚Äôs ANDA products) is not available on the market: 50mg tablets have been discontinued and 75mg are expected to be unavailable soon.
- As per FDA‚Äôs 2017 Draft Guidance, a petition is appropriate when ‚Äúthere are limited or no quantities of the reference standard in distribution.‚Äù
- Only three holders of approved ANDAs for all strengths exist; petitioner requests FDA select RS from other available suppliers like Carlsbad Technology Inc. or Unique Pharmaceutical Laboratories.",2019-01-22 00:00:00,Approved,2019-11-26,1.0,Center for Drug Evaluation and Research (CDER),"- 21 U.S.C. ¬ß 355(j) ‚Äì Section 505(j) of the FD&C Act (regarding ANDAs)
- 21 CFR 314.3(b) ‚Äì Definition of listed drug
- 21 CFR 314.94(a)(3) ‚Äì Bioequivalence requirement for ANDAs
- 81 FR 69580, 69619 ‚Äì Final rule on ANDA and 505(b)(2) applications (Oct. 6, 2016)","- The FDA has not been able to reach a decision due to the need to address other Agency priorities.
- The letter assures the petitioner that a final response will be provided as soon as possible, acknowledging resource constraints and workload demands.","- FDA reviewed three petitions requesting the designation of new Reference Standards (RS) for diclofenac sodium delayed-release tablets due to market unavailability of existing RS products held by CASI Pharmaceuticals (ANDAs 074376 for 25 mg and 50 mg, and 074394 for 75 mg).
- FDA reviewed regulatory filings and third-party commercial data and determined that these products were discontinued or unavailable.
- FDA granted the petitions and selected:
‚Ä¢ ANDA 090066 (Unique) as the new RS for 25 mg and 50 mg
‚Ä¢ ANDA 077863 (Unique) as the new RS for 75 mg
‚Äî based on their status as current market leaders
",approved,True,488.0,CDER,CDER
fda-2018-p-2962,FDA-2018-P-2962-0001_Citizen_Petition_from_Americans_for_Homeopathy_Cho.pdf,2018-07-25,2018,False,original petition,Americans for Homeopathy Choice,advocacy/academic,"- 21 C.F.R. ¬ß 10.30
- Federal Food, Drug, and Cosmetic Act (implicitly referenced)",Draft Guidance titled ‚ÄúDrug Products Labeled as Homeopathic Guidance for FDA Staff and Industry‚Äù (Docket No. FDA-2017-D-6580),"- Withdraw the draft guidance.
- Replace it with a new guidance developed with public and stakeholder input.
- Establish an advisory committee of homeopathy stakeholders.
- Declare a formal enforcement policy that reflects this new guidance.","- The current draft guidance was issued without adequate public input or stakeholder consultation.
- It departs from the historical FDA regulatory approach to homeopathy established in the 1988 Compliance Policy Guide (CPG 400.400).
- The draft guidance imposes potentially overbroad regulatory standards on all homeopathic products regardless of safety history.
- Lack of clarity could cause confusion and fear among consumers and manufacturers.
- Petitioners argue that homeopathic products are generally recognized as safe and have a long history of consumer use.",2019-02-12 00:00:00,Denied,2019-10-24,1.0,Center for Drug Evaluation and Research (CDER),"- Section 201(g)(1) and Section 201(p)(1) of the FD&C Act (21 U.S.C. ¬ß¬ß 321(g)(1), 321(p)(1)) ‚Äî Definitions of ‚Äúdrug‚Äù and ‚Äúnew drug‚Äù
- 21 CFR 314.200 ‚Äî Procedures for withdrawing approval
- 21 CFR 10.30 ‚Äî Citizen petition regulations
- 21 CFR 314.126 ‚Äî Adequate and well-controlled studies
- 21 CFR 314.200(c)(2)(iv) ‚Äî Evidence for grandfather clause status
- CPG 400.400 ‚Äî Compliance Policy Guide on Homeopathic Drugs","- The petition raises complex issues that require extensive review and analysis by Agency officials.
- FDA also cites the need to address other Agency priorities as a reason for the delay.
- FDA commits to respond once a decision is reached on the petition's content.","- Petition requests included: establishing a homeopathy advisory committee, converting CPG 400.400 to regulation, withdrawing FDA‚Äôs draft guidance on homeopathy, codifying that homeopathic drugs are not ‚Äúnew drugs,‚Äù and holding a public hearing before finalizing guidance.
- FDA rejected all requests, citing:
‚Ä¢ Homeopathic drugs are not exempt from ‚Äúnew drug‚Äù provisions just because they comply with HPUS or USP standards.
‚Ä¢ Monograph listing does not demonstrate safety or efficacy as required by FD&C Act.
‚Ä¢ FDA cannot legally codify that homeopathic drugs are not ‚Äúnew drugs.‚Äù
‚Ä¢ FDA cannot apply the 1938 ‚Äúgrandfather clause‚Äù broadly or without product-specific evidence.
‚Ä¢ FDA‚Äôs risk-based enforcement strategy aligns with public health needs and will proceed.
‚Ä¢ A public hearing was not granted, as prior public engagement (including 9,000+ comments and a 2015 hearing) was deemed sufficient.",denied,True,456.0,CDER,CDER
fda-2018-p-2985,FDA-2018-P-2985-0001_Citizen_Petition_from_Norbrook_Inc_.pdf,2018-07-26,2018,False,original petition,Norbrook Laboratories Limited,advocacy/academic,"- Section 512(n)(3)(A) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß314.93
- 21 CFR 25.15
- 21 CFR 25.21
- 21 CFR 33(a)(1)",Filing of an Abbreviated New Animal Drug Application (ANADA) for a generic drug differing in dosage form from the listed product FELIMAZOLE¬Æ (methimazole) Coated Tablets,"Granting permission to file an ANADA for a Methimazole 5 mg/mL Oral Solution as a generic version of FELIMAZOLE¬Æ tablets, based on a change in dosage form","- The generic product contains the same active ingredient (methimazole) and is intended for the same species (cats) with identical indications.
- The dosage strength and route of administration remain consistent with the pioneer drug, although the generic uses an oral solution instead of tablets.
- All excipients used are approved in other companion animal drugs in the U.S.
- Prior similar suitability petition (FDA-2014-P-1802) was approved in 2015.
- Petition asserts environmental exclusion under FDA rules and affirms compliance with bioequivalence and other regulatory standards",,Approved,2018-10-12,0.0,"Center for Veterinary Medicine (CVM)
","- Section 512(n)(3) and Section 512(n)(3)(C) of the Federal Food, Drug, and Cosmetic Act (FFD&CA)
- 21 CFR 514.5 ‚Äî Concerning presubmission conferences
",,"- The proposed change (from tablet to oral solution) is permissible under a suitability petition because:
‚Ä¢ The dosage regimen (2.5 mg increments) is preserved.
‚Ä¢ The change does not require new investigations into safety or effectiveness.
‚Ä¢ The change qualifies under FFD&CA Section 512(n)(3).
- Approval of the petition does not guarantee ANADA approval, which is subject to separate FDA review.",approved,True,78.0,CVM,Other/Specialty Center
fda-2018-p-2997,FDA-2018-P-2997-0003_Citizen_Petition_from_New_Civil_Liberties_Alliance.pdf,2018-07-31,2018,False,original petition,New Civil Liberties Alliance,advocacy/academic,"- 21 U.S.C. ¬ß 371(a) (FD&C Act ¬ß 701)
- 5 U.S.C. ¬ß 553(e) (APA rulemaking provision)
- 21 C.F.R. ¬ß 10.30 (FDA petition regulations)
- Multiple legal precedents cited (e.g., Perez v. Mortgage Bankers Ass‚Äôn, Chrysler Corp. v. Brown)","FDA‚Äôs use of guidance documents that purportedly create legally binding obligations without going through notice-and-comment rulemaking; also refers to internal practices of issuing, relying on, or defending ‚Äúimproper agency guidance‚Äù","The petitioner requests the FDA to promulgate a formal, binding regulation that prohibits the issuance, reliance on, or defense of guidance documents that function as de facto legislative rules without meeting APA requirements (i.e., without notice-and-comment rulemaking)","- Agencies, including FDA, often bypass notice-and-comment procedures by issuing guidance documents with de facto binding legal effects.
- This practice violates the Constitution and the APA.
- Courts often cannot review such guidance due to procedural barriers like non-finality.
- Past reform efforts (e.g., OMB Bulletin, DOJ Sessions and Brand Memos) are insufficient because they are not binding or enforceable.
- The proposed rule would close these gaps, enhance accountability, protect constitutional rights, and ensure FDA actions comply with lawful procedures",2019-02-01 00:00:00,,2025-10-15,1.0,,,"- FDA has not yet completed its response due to the existence of other FDA priorities.
- The interim response acknowledges the petition‚Äôs content (regarding FDA‚Äôs issuance of guidances) but defers final decision pending resource availability.",,no decision,False,2633.0,pending,pending
fda-2018-p-3076,FDA-2018-P-3076-0001_Citizen_Petition_from_Dr__Joseph_Purita_Redacted.pdf,2018-07-23,2018,False,original petition,Dr. Joseph Purita,individual,"- 21 CFR Part 347
- 21 CFR 330.11
- 21 CFR 314.50
- 21 CFR 10.30
- 21 CFR 330.10(a)(12)
- Section 505 of the FD&C Act
- 21 CFR Section 25.30",Amendment of the OTC monograph for Skin Protectant Drug Products (21 CFR Part 347),"To amend the OTC monograph for Skin Protectant Drug Products (21 CFR Part 347) to include Avenanthramides as an alternative active ingredient to Colloidal Oatmeal, with a minimum concentration of 0.007% (or 0.003% when combined with mineral oil)","- Avenanthramides are natural compounds found in oats with proven antioxidant activity, similar to Colloidal Oatmeal.
- Scientific literature supports the inclusion of Avenanthramides due to their efficacy and safety profile.
- Synthetic derivatives like Dihydroavenanthramide D also demonstrate similar effects.
- Aligns with FDA‚Äôs goals to foster innovation and improve outdated monographs.
- Legal framework allows for such monograph amendments via citizen petition",2019-01-31 00:00:00,,2025-10-15,1.0,,,"- The petition requested that FDA allow ‚ÄúAvenanthramides‚Äù to be included among active ingredients under 21 CFR 347.10, as an alternative to colloidal oatmeal in skin protectant products.
- FDA has not completed its review due to the need to address other Agency priorities.",,no decision,False,2641.0,pending,pending
fda-2018-p-3102,FDA-2018-P-3102-0001_Citizen_Petition_From_Richard_M__Fleming_Redacted.pdf,2018-07-31,2018,False,original petition,Richard M. Fleming,individual,"- 21 C.F.R. ¬ß 25.30
- 21 C.F.R. ¬ß 25.31
- 21 C.F.R. ¬ß 25.32
- 21 C.F.R. ¬ß 25.33
- 21 C.F.R. ¬ß 25.34
- 21 C.F.R. ¬ß 25.40","- Approval and reimbursement practices related to Technetium-99m isotopes Sestamibi and Tetrofosmin
- Claims of ‚Äúquantification‚Äù by nuclear camera companies (SPECT and PET)
- Approval and radiation safety claims of 3D tomosynthesis mammography equipment
- Use of CPT coding for reimbursement, especially for faux ‚Äúquantification‚Äù","The petitioner requests that FDA:
1. Address false claims and excessive use of Technetium-99m isotopes
2. Address misleading claims of disease quantification by SPECT/PET camera producers
3. Address misleading radiation safety claims of 3D tomosynthesis
4. Eliminate CPT coding as a reimbursement method
5. Accept the petitioner‚Äôs patented method (FMTVDM) for testing cardiac and oncologic drugs","- Technetium-99m isotopes redistribute, negating the need for two doses, thus current practices increase costs, errors (35% error rate), and radiation exposure
- Nuclear imaging ‚Äúquantification‚Äù is scientifically invalid without calibration, leading to a 33.95% error rate
- 3D tomosynthesis claims are misleading; it actually delivers more radiation per breast image than conventional methods
- CPT coding increases costs without improving healthcare
- The patented FMTVDM method allows true quantification and can reduce healthcare costs while improving diagnostic accuracy",,Denied,2019-07-09,0.0,"Center for Devices and Radiological Health (CDRH)
","- 21 CFR ¬ß 10.30(k) ‚Äî Enforcement requests are outside the scope of citizen petition procedures
- 21 CFR ¬ß 10.45 ‚Äî Denial of enforcement action is not final administrative action
",,"- The petition sought enforcement action against pharmaceutical and imaging companies for allegedly distributing misinformation and using inappropriate marketing.
- FDA states that requests for enforcement actions are outside the scope of citizen petition procedures.
- Complaints are reviewed, but decisions to pursue enforcement are discretionary and case-specific.
- CPT billing code concerns fall under CMS jurisdiction, not FDA.",denied,True,343.0,CDRH,CDRH
fda-2018-p-3176,FDA-2018-P-3176-0001_Citizen_Petition_from_Medefil_Inc_1.pdf,2018-08-15,2018,False,original petition,"Medefil, Inc.",industry/corporation,"- 21 CFR ¬ß 10.25(a)
- 21 CFR ¬ß 10.30
- Section 505(b)(2) of the FD&C Act
- 21 CFR ¬ß 25.31(a) (for environmental impact)
- 21 CFR ¬ß 10.30(b) (for economic impact)","Assignment of a Therapeutic Equivalence Evaluation Code (""TE Code"") in the Orange Book for Medefil‚Äôs NDA 202832
","FDA to assign a TE Code of ‚ÄúAP‚Äù for Medefil's NDA 202832 (Sodium Chloride Injection, USP, 0.9%) in the Orange Book for the purpose of the prescription drug fee exception","- Medefil's product is pharmaceutically equivalent to Hospira‚Äôs NDA 018803.
- Same dosage form, route of administration, and active ingredient amount.
- Intended for the same use: dilution/dissolution of drugs for IV, IM, or subcutaneous injection.
- Both listed as RLD (Reference Listed Drugs) in the Orange Book.
- Meets FDA criteria for therapeutic equivalence: pharmaceutical equivalence and demonstrated bioequivalence",2019-02-07 00:00:00,Denied,2024-12-20,1.0,"Center for Drug Evaluation and Research (CDER)
","- 21 CFR 314.3(b) ‚Äî Definitions of pharmaceutical equivalence and bioequivalence
- 21 CFR 320.22(b) ‚Äî Bioequivalence waiver criteria for parenteral solutions
- Section 505 of the FD&C Act (21 U.S.C. ¬ß 355) ‚Äî Drug approval pathways
- Orange Book Preface ‚Äî TE code assignment rules and definitions
- FDORA Section 3222 ‚Äî Related to therapeutic equivalence requests for 505(b)(2) NDAs","- The petition requested assignment of a therapeutic equivalence code ‚ÄúAP‚Äù in the Orange Book for Medefil‚Äôs new drug application 202832 (sodium chloride injection, USP, 0.9%) for the purpose of a prescription drug fee exception.
- FDA cited the need to address other Agency priorities as the reason for delay.","- Pharmaceutical Equivalence & Bioequivalence: FDA agreed that Medefil‚Äôs product is pharmaceutically equivalent and bioequivalent to Hospira‚Äôs sodium chloride injection.
- User Interface Difference: Medefil‚Äôs product is packaged in a prefilled syringe, while Hospira‚Äôs product is in a flip-top vial.
‚Äî This design difference affects the user interface and may impact clinical effect or safety.
- Lack of Comparative Data: Medefil failed to submit adequate data comparing user interfaces, which is necessary to confirm therapeutic equivalence and assign the ‚ÄúAP‚Äù TE code. FDA cited draft guidance on comparative use human factors studies as relevant for such evaluations
",denied,True,2319.0,CDER,CDER
fda-2018-p-3211,FDA-2018-P-3211-0001_Citizen_Petition_from_Aurora_Pharmaceutical_LLC.pdf,2018-08-17,2018,False,original petition,Aurora Pharmaceutical LLC,industry/corporation,Section 512(n)(3) of the Federal Food Drug and Cosmetic Act; 21 CFR 25.15; 21 CFR 25.30(h); 21 CFR 25.21,Approval requirements for an Abbreviated New Animal Drug Application (ANADA) for a product that differs in dosage form and strength from the Reference Listed New Animal Drug (RLNAD),Permission to file an Abbreviated New Animal Drug Application (ANADA) for Firocoxib Solution 1.14% w/v that differs from the RLNAD (EQUIOXX¬Æ Oral Paste) in dosage form and strength,"The change in dosage form (paste to solution) and strength (8.2 mg/g to 11.4 mg/mL) is proposed for convenience, allowing multi-dose packaging. The active ingredient and dosage regimen remain the same. The goal is to offer a more convenient and potentially cost-effective alternative with equivalent therapeutic effect
",,Denied,2018-11-15,0.0,"Center for Veterinary Medicine (CVM)
","- Section 512(n)(3) and 512(n)(3)(C) of the Federal Food, Drug, and Cosmetic Act (FFD&C Act)
- 21 CFR Part 10 ‚Äî General administrative procedures
- 21 CFR 10.33 ‚Äî Procedures for requesting reconsideration of decisions",,"- The proposed product differed from the reference listed new animal drug (Equioxx¬Æ Oral Paste) in both dosage form (oral solution) and strength (11.4 mg/mL vs. 8.2 mg/g).
- Although such changes are eligible under a suitability petition, the proposed delivery system‚Äîa 130-mL multi-dose container‚Äîcould enable extended use beyond the approved 14-day maximum.
- This raises target animal safety concerns, necessitating a target animal safety study, which disqualifies it from approval under section 512(n)(3)(C).",denied,True,90.0,CVM,Other/Specialty Center
fda-2018-p-3266,FDA-2018-P-3266-0001_Citizen_Petition_from_Haynes_and_Boone__LLP___Reda.pdf,2018-08-22,2018,False,original petition,Haynes and Boone LLP,law/consulting,"- 21 C.F.R. ¬ß¬ß 10.25(a), 10.30
- 21 C.F.R. ¬ß 25.31
- 21 C.F.R. ¬ß 10.30(b)
- 21 C.F.R. ¬ß 320.24(a)
- 21 U.S.C. ¬ß 355",Draft Guidance for Mycophenolate Mofetil Oral Suspension (revised October 2017) allowing use of only metabolite data to establish bioequivalence to CellCept¬Æ Oral Suspension ,"- Withdraw the current Draft Guidance for Mycophenolate Mofetil Oral Suspension.
- Issue new guidance requiring use of both parent compound (MMF) and metabolite data to establish bioequivalence for ANDAs referencing CellCept¬Æ Oral Suspension.","- MMF (parent compound) can be accurately and reliably measured in human plasma using validated methods, as shown in Exhibit C and ANDA data.
- Measuring both MMF and its metabolite provides more accurate bioequivalence determination.
- Current guidance is outdated and inconsistent with FDA‚Äôs treatment of similar prodrugs like midodrine and temozolomide.
- FDA‚Äôs own guidance encourages use of parent compound data if feasible.
- Revising the guidance would promote safety, efficacy, and consistency in regulatory approach.",2019-02-21 00:00:00,Partially Approved / Partially Denied,2019-11-21,1.0,"Center for Drug Evaluation and Research (CDER)
","- 21 CFR 10.115(d) ‚Äî Clarifies that guidance documents are non-binding recommendations
‚Äî Other references include FDA's Bioequivalence Recommendations for Specific Products (June 2010) and the Draft Guidance on Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA (December 2013)","- The petition requests FDA to:
1. Withdraw the October 2017 Draft Guidance on Mycophenolate Mofetil oral suspension (which allows metabolite data alone to establish bioequivalence).
2. Permit use of both parent compound and metabolite data for establishing bioequivalence for abbreviated NDAs.
- FDA has not made a final decision due to the need to address other Agency priorities.","- The petition challenged the October 2017 Draft Guidance that permitted use of metabolite-only data to establish bioequivalence for mycophenolate mofetil (MMF) oral suspension.
- FDA agreed to revise the guidance due to advancements in analytical methods, which now allow accurate and reliable measurement of both MMF and its metabolite.
- FDA denied the request where it interpreted the guidance as imposing requirements rather than providing recommendations (as per 21 CFR 10.115(d))
",partially approved / denied,True,456.0,CDER,CDER
fda-2018-p-3281,FDA-2018-P-3281-0001_Citizen_Petition_from_Pfizer_Inc.pdf,2018-08-22,2018,False,original petition,Pfizer Inc.,industry/corporation,"- 21 C.F.R. ¬ß 10.30
- 42 U.S.C. ¬ß 262(a), ¬ß 262(k), ¬ß 262(i)(2)-(4)
- 21 C.F.R. ¬ß 601.2(d)
- 21 U.S.C. ¬ß 352(a), ¬ß 352(n), ¬ß 331(a)
- 21 C.F.R. ¬ß 201.6(a), ¬ß 202.1(e)(6)(ii), ¬ß 202.1
- 21 C.F.R. ¬ß 25.31","FDA‚Äôs oversight of communications regarding biosimilars, especially related to misleading or false claims by reference product sponsors. Pfizer comments on the lack of FDA guidance addressing sponsor communications about the safety and effectiveness of biosimilars, including interchangeable biologics, versus reference biologics.","Pfizer requests that the FDA issue guidance that:
‚Ä¢ Defines inappropriate communications that are false or misleading about biosimilars.
‚Ä¢ Provides examples of lawful, truthful, and non-misleading communications.
‚Ä¢ Clarifies that biosimilar sponsors may share clinical data consistent with FDA-approved labeling.","Pfizer argues that:
‚Ä¢ Misleading statements by reference product sponsors sow doubt about biosimilar safety and efficacy.
‚Ä¢ Such communications hinder market adoption of biosimilars.
‚Ä¢ Clear guidance is needed to ensure accurate, balanced information is available to physicians, patients, and payers, supporting competition and patient access.",2019-02-15 00:00:00,Partially Approved / Partially Denied,2020-02-04,1.0,"Center for Drug Evaluation and Research (CDER)
","- 21 CFR 10.115 ‚Äî Good guidance practices regulation
- 21 CFR 10.115(h) ‚Äî Comment process on guidance
- 21 CFR 10.30 ‚Äî Citizen petition procedures
- 21 CFR 10.30(e)(2) ‚Äî Interim responses
- Section 351(k) of the Public Health Service Act (PHS Act) ‚Äî Biosimilar and interchangeable product licensing
- 21 CFR 202.1(e)(5) ‚Äî Promotional labeling
- 21 CFR 601.12(a)(4) ‚Äî Labeling changes for risk information","- The petition requested FDA to issue guidance ensuring truthful and non-misleading communications by sponsors concerning the safety and effectiveness of biosimilars, including interchangeable biologics.
- FDA explains that the petition raises complex issues requiring extensive review and analysis, and it will respond once a decision is reached","- FDA published a draft guidance titled Promotional Labeling and Advertising Considerations for Biological Reference and Biosimilar Products ‚Äì Questions and Answers.
‚Ä¢ The draft guidance provides considerations for presenting biosimilar data truthfully and non-misleadingly.
‚Ä¢ FDA declined to address individual substantive requests (e.g., examples of misleading communications) at this time to allow public comment and future updates per good guidance practices.
- Petition is granted to the extent it requests issuance of draft guidance; denied in part for not addressing specific guidance content yet",partially approved / denied,True,531.0,CDER,CDER
fda-2018-p-3284,FDA-2018-P-3284-0001_Citizen_Petition_from_Keryx_Biopharmaceuticals__In.pdf,2018-08-23,2018,False,original petition,"Keryx Biopharmaceuticals, Inc.",industry/corporation,"- 21 C.F.R. ¬ß 10.30
- Section 505(q) of the FDCA",Potential approval of any ANDA referencing Auryxia¬Æ (ferric citrate) Tablets that omits certain conditions of use,"Request that FDA not approve any ANDA for ferric citrate that seeks to omit the ""hyperphosphatemia in chronic kidney disease on dialysis"" indication unless the applicant submits sufficient data to show the product is safe and effective for the remaining indication (iron deficiency anemia in CKD not on dialysis) without risk.","The IDA indication is protected by a 3-year exclusivity period due to a new clinical investigation essential to approval. Approving a generic product without carving out this indication would violate statutory and regulatory provisions protecting the exclusivity. The petitioner asserts that approving an ANDA without the required carve-out would allow generic labeling that is false and misleading and violate 21 C.F.R. ¬ß 314.127(a)(3).
",,Partially Approved / Partially Denied,2019-01-19,0.0,"Center for Drug Evaluation and Research (CDER)
","- Section 505(b)(2) and 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- Section 505(j)(7)(A)(i) (Orange Book listing)
- Section 505(c)(3)(E)(ii) (3-year exclusivity provision)
- Section 505(c)(3)(E)(ii) and (iii) (5-year exclusivity under Hatch-Waxman Amendments)
- 21 CFR 314.50(i)(5)
- 21 CFR 314.108 (exclusivity criteria)
- 21 CFR 314.94(a)(9)
- 21 CFR 10.115 (guidance practices)",,"- Denial of 5-Year NCE Exclusivity: FDA concluded that Auryxia (ferric citrate) contains a previously approved active moiety‚Äîfree Fe¬≥‚Å∫ ion‚Äîwhich had been part of earlier FDA-approved drug products. Therefore, it is not eligible for 5-year exclusivity under the FD&C Act.
- Grant of 3-Year Exclusivity: The supplemental NDA (S-013) was based on new clinical investigations essential to approval (study in 234 adults with stage 3‚Äì5 non-dialysis dependent CKD), thereby qualifying for 3-year exclusivity under Section 505(c)(3)(E)(iii).
- Rejection of Additional Requests: FDA declined the request to revise the Ferric Citrate Draft Guidance and declined to require ANDAs to match specific ferric citrate ion complexes (2:2, 3:3, or hexaaquairon(III)) due to insufficient evidence for those specifications being critical to safety/efficacy",partially approved / denied,True,149.0,CDER,CDER
fda-2018-p-3325,FDA-2018-P-3325-0001_Citizen_Petition_from_Pfizer_Inc.pdf,2018-08-29,2018,False,original petition,Pfizer Inc.,industry/corporation,"- 21 C.F.R. ¬ß 314.127(a)(7)
- 21 U.S.C. ¬ß 355(j)(2)(A)(v)
- 21 C.F.R. ¬ß 314.94(a)(9)(iii)
- 21 U.S.C. ¬ß 355(j)(4)
- 505(j) of the FDCA
- 21 C.F.R. ¬ß 10.30",FDA‚Äôs review and potential approval of any Abbreviated New Drug Application (ANDA) for bivalirudin in 5 mg/mL dosage strength that omits labeling information Pfizer believes is essential for safe use,"Pfizer requests that the FDA withhold approval of any ANDA referencing Toviaz¬Æ unless the ANDA includes adequate data demonstrating bioequivalence for both 4 mg and 8 mg dosage strengths, and especially for the 8 mg strength under both fasting and fed conditions.","Pfizer argues that failing to require bioequivalence data for the 8 mg strength would pose a safety and efficacy risk. Since the 8 mg strength shows dose-proportional pharmacokinetics and higher systemic exposure, it is critical that generic applicants demonstrate bioequivalence at this dose.
",,Denied,2019-01-24,0.0,"Center for Drug Evaluation and Research (CDER)
","- Section 505(b)(2) and 505(j) of the FD&C Act
- Section 505(j)(7)(A)(i)
- Section 505(c)(3)(E)(ii) and (iii)
- Section 505(j)(2)(A)(ii), (iii), and (iv)
- Section 505(j)(4)
- 21 CFR 314.94(a)(5)(i)
- 21 CFR 314.127(a)(3)
- 21 CFR 314.94(a)(10)
- 21 CFR 314.50(i)(5)
- 21 CFR 314.108
- FDA Draft Guidance: Conjugated Estrogens (2014)",,"- FDA concluded that Pfizer‚Äôs request for a new guidance using its own method (0.1% quantification of steroidal and non-steroidal compounds using LC-MS) was not warranted because FDA's Proposed Method, based on 60 steroidal components and USP standards, was scientifically adequate and reproducible across labs
.
- FDA stated it retains broad discretion in determining ‚Äúsameness‚Äù of active ingredients under the Hatch-Waxman Amendments.
- FDA emphasized that issues raised by Pfizer should be submitted through the existing docket for public comments on the draft guidance, not through the petition mechanism
",denied,True,148.0,CDER,CDER
fda-2018-p-3327,FDA-2018-P-3327-0001_Citizen_Petition_from_Hyman__Phelps___McNamara__PC.pdf,2018-08-30,2018,False,original petition,"Hyman, Phelps & McNamara, P.C. (on behalf of client)",law/consulting,"- 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FDC Act)
- 21 C.F.R. ¬ß 314.93
- 21 C.F.R. ¬ß 10.20
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 25.31
- 21 C.F.R. ¬ß 10.30(b)
- Pediatric Research Equity Act (PREA) ‚Äì FDC Act ¬ß 505B(a)(1)(A) and ¬ß 505B(a)(5)(A)",Establishment of suitability for submitting an ANDA for a modified dosage form and strength of a previously approved drug (Metformin Hydrochloride Oral Solution).,"That the FDA determine Metformin Hydrochloride Granules for Oral Solution (500 mg, 850 mg, and 1 g) is suitable for submission as an Abbreviated New Drug Application (ANDA). The petitioner also requests a waiver under PREA for pediatric studies. 
","- The proposed product uses the same active ingredient and indications as the Reference Listed Drug (Riomet).
- Differences in dosage form and strength do not raise new safety or efficacy concerns.
- Provides alternate formulation offering benefits in handling, administration, and flexible dosing.
- Labeling will be consistent with the RLD except for necessary differences.
- Past similar petitions have been approved.
- A full waiver from pediatric studies is justified since type 2 diabetes is not an indication in children under 10 years of age and the drug does not offer new therapeutic benefit over existing treatments. ",,,2025-10-15,0.0,,,,,no decision,False,2603.0,pending,pending
fda-2018-p-3354,FDA-2018-P-3354-0001_Citizen_Petition_from_International_Contrast_Ultra.pdf,2018-09-03,2018,False,original petition,International Contrast Ultrasound Society (ICUS),advocacy/academic,"- 21 U.S.C. ¬ß¬ß 352 and 355 (FDCA ¬ß¬ß 502 and 505)
- 21 C.F.R. ¬ß¬ß 10.30 and 201.57(c)(1)
- 40 C.F.R. ¬ß 1508.4
- 21 C.F.R. ¬ß 25.30(h)","Boxed warnings required by FDA on ultrasound contrast agent (UCA) labels since 2007, specifically for products such as Optison, Definity, and Lumason",Remove the boxed warnings from all ultrasound contrast agent (UCA) product labels. Retain relevant information in the ‚Äúwarnings and precautions‚Äù section instead,"- Boxed warnings deter appropriate and beneficial clinical use of UCAs.
- Extensive new scientific data (including 18 large studies of 260,000+ patients) show UCAs are among the safest imaging products available.
- Boxed warnings are inconsistent with FDA‚Äôs own criteria and guidance for black box warnings.
- CEUS improves diagnosis, reduces radiation exposure, avoids more invasive and expensive procedures, and is especially beneficial for children, obese patients, and those with LVADs.
- Removing the black box promotes innovation and cost-effective care in line with FDA‚Äôs strategic goals",2019-03-21 00:00:00,,2025-10-15,1.0,,,"- The petition requested removal of boxed warnings from ultrasound contrast agent product labels.
- FDA has not yet made a decision because the petition raises complex issues requiring extensive review and analysis by Agency officials.",,no decision,False,2599.0,pending,pending
fda-2018-p-3355,FDA-2018-P-3355-0003_Citizen_Petition_from_Oregon_Pain_Guidance.pdf,2018-09-04,2018,False,original petition,Oregon Pain Guidance,individual,"Not explicitly cited by section. General mention of submitting under authority delegated to the Commissioner of Food and Drugs. Guidance mentioned: Innovative Approaches for Nonprescription Drug Products ‚Äì Draft Guidance July 2018.
",Regulation of naloxone 4mg nasal spray as a prescription-only (legend) drug.,Re-categorize naloxone 4mg nasal spray from prescription-only (legend) status to over-the-counter (OTC) status.,"- The U.S. is facing an opioid overdose epidemic (64,000 deaths in 2016).
- Naloxone is effective, safe, and has minimal abuse potential.
- It meets all FDA criteria for OTC status: safe, effective, easy to use, low misuse risk.
- Current access is limited due to stigma and logistical barriers despite local initiatives.
- OTC reclassification would improve access, particularly in rural and underserved areas.
- Canada has already made similar regulatory changes.
- Supporting evidence includes CDC and other public health studies on naloxone access and usage effectiveness",2019-03-01 00:00:00,Partially Approved / Partially Denied,2022-11-16,1.0,"Center for Drug Evaluation and Research (CDER)
","- FD&C Act: Sections 505(b)(1), 505(b)(2), 505(j), 503(b)(1), 503(b)(4), and 505G (21 U.S.C. ¬ß¬ß 355, 355h)
- 21 CFR: ¬ß¬ß 310.200(b), 201.66
- PHS Act: Section 351 (42 U.S.C. ¬ß 262)
- Docket Notice: FDA-2022-N-446, Safety and Effectiveness of Certain Naloxone Hydrochloride Drug Products for Nonprescription Use","- The petition requested that FDA reclassify Naloxone 4 mg Nasal Spray from prescription-only (Legend) to over-the-counter (OTC) status.
- FDA stated the issue raises complex scientific and policy questions that require further evaluation by Agency officials","- Granted: FDA has taken steps to facilitate the Rx-to-OTC switch of naloxone 4 mg nasal spray (e.g., developing model Drug Facts Labels, Federal Register notice).
- Denied: FDA cannot grant an immediate switch without sufficient product-specific safety and usability data
- Lack of sufficient product-specific data (label comprehension, human factors, actual use studies) needed for an immediate Rx-to-OTC switch.
- FDA is actively facilitating the switch by developing a model Drug Facts Label and publishing a Federal Register notice.
- A switch requires manufacturer participation and supporting data; the FDA cannot unilaterally reclassify products without this.
- The petition provided only general evidence, insufficient to satisfy regulatory standards",partially approved / denied,True,1534.0,CDER,CDER
fda-2018-p-3372,FDA-2018-P-3372-0001_Citizen_Petition_from_Ohio_State_University.pdf,2018-08-13,2018,False,original petition,"Ohio State University (Lynne Gauthier, PhD)",advocacy/academic,"- Section 513(e) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 882.5050 (Biofeedback devices)
- 21 C.F.R. Part 807 Subpart E
- 21 C.F.R. ¬ß¬ß 25.30, 25.31, 25.32, 25.33, or 25.34 (Environmental impact)","Current FDA policy regarding 510(k) exemption status for battery-powered vs. non-battery-powered biofeedback devices, particularly video-based (optical) sensor devices used for muscular reeducation and relaxation.","Expand FDA 510(k) exemption status to all small and portable non-invasive devices used for relaxation and muscular reeducation, including optical sensor-based biofeedback devices.","- Current exemption criteria are outdated given the evolution of biofeedback technologies.
- Optical sensors (e.g., Microsoft Kinect) offer equal or greater safety and efficacy compared to battery-powered devices.
- Studies demonstrate similar clinical outcomes and safety profiles across sensor types.
- Exempting these devices will reduce commercialization barriers and promote broader adoption of innovative, research-based tools.
- Rapid technological changes make repeated 510(k) submissions burdensome and impractical for developers, especially academic institutions",,Denied,2021-04-21,0.0,"Center for Devices and Radiological Health (CDRH)
","- 21 CFR 882.5050 ‚Äî Biofeedback devices
- 21 CFR 890.5360 ‚Äî Measuring exercisers or interactive rehabilitation exercise devices
- 21 CFR 10.30(e) ‚Äî General citizen petition regulation
- 21 CFR 860.123 ‚Äî Reclassification petition content
- FD&C Act Sections:
- 513(e) (21 U.S.C. ¬ß 360c(e)) ‚Äî Device reclassification
- 510(m)(2) (21 U.S.C. ¬ß 360(m)(2)) ‚Äî Exemption from 510(k)
- 85 FR 44186 ‚Äî Federal Register notice exempting certain devices",,"- The petition requested reclassification and expanded exemption for certain biofeedback devices under 21 CFR 882.5050.
- FDA determined that the requested action was not a reclassification, but rather a request to expand premarket notification exemptions, which should be submitted under section 510(m)(2).
- Additionally, FDA determined that the cited devices likely fall under 21 CFR 890.5360 (interactive rehabilitation exercise devices), not 882.5050.
- Devices under product code QKC (referenced by petitioner) were already exempt as of July 22, 2020.
- Therefore, FDA deemed the petition moot and denied it.",denied,True,982.0,CDRH,CDRH
fda-2018-p-3382,FDA-2018-P-3382-0001_Citizen_Petition_from_Fresenius_Kabi_USA__LLC.pdf,2018-09-06,2018,False,original petition,"Fresenius Kabi USA, LLC",industry/corporation,"- 21 CFR 10.25(a)
- 21 CFR 10.30
- 21 CFR 314.161
- 21 CFR 314.94(a)(3)
- 21 CFR 25.31
- 21 CFR 10.30(b)",Designation of reference listed drugs (RLDs) in the FDA's Orange Book,Designate Sodium Chloride 0.45% in Plastic Container (NDA 018016 by Baxter Healthcare Corp.) as an additional reference listed drug (RLD),"The petitioner (FK USA) intends to submit an Abbreviated New Drug Application (ANDA) based on Baxter‚Äôs mini bag product (NDA 018016), which is a pharmaceutical equivalent to currently listed RLDs. Therefore, they request FDA to designate this additional product as an RLD to support ANDA submission ",2019-03-08 00:00:00,Dismissed (moot),2020-09-16,1.0,"Center for Drug Evaluation and Research (CDER)
","- Orange Book ‚Äî Reference provided to the FDA‚Äôs Approved Drug Products with Therapeutic Equivalence Evaluations
","- The petition requested designation of Sodium Chloride 0.45% in Plastic Container by Baxter Healthcare Corporation (NDA 018016) as an additional Reference Listed Drug (RLD).
- FDA indicated that due to competing priorities, it had not yet reached a decision, and the interim response was issued in accordance with regulatory procedures to acknowledge the delay
","- The petitioner requested that sodium chloride injection 0.45% (450 mg/100 mL) approved under NDA 018016 be designated as an additional Reference Listed Drug (RLD) in the Orange Book.
- FDA confirmed it had already updated the Orange Book accordingly since the petition was submitted.
- Therefore, the Agency dismissed the petition as moot because the requested action had already been completed",dismissed (moot),True,741.0,CDER,CDER
fda-2018-p-3401,FDA-2018-P-3401-0001_Citizen_Petition_from_Novo_Nordisk_Inc_.pdf,2018-09-05,2018,False,original petition,Novo Nordisk Inc.,industry/corporation,"- 21 C.F.R. ¬ß 10.30
- Section 505(j)(2)(A)(iv) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 314.94(a)(9)(iii)",The acceptance and approval of any Abbreviated New Drug Application (ANDA) referencing Novo Nordisk‚Äôs product Victoza¬Æ (liraglutide) that omits certain labeling information related to cardiovascular outcomes.,The petitioner requests that the FDA refuse to approve any ANDA for a generic version of Victoza¬Æ that omits the cardiovascular risk reduction labeling or that includes less than the full indication.,"Novo Nordisk argues that the omitted cardiovascular indication is protected by patent and/or exclusivity, and that allowing such ANDAs would be inappropriate under the carve-out regulations. They assert that the cardiovascular outcome labeling is not severable from the product‚Äôs overall indication, and any omission would result in a product that is not safe or effective for use.
",,Denied,2019-02-01,0.0,"Center for Drug Evaluation and Research (CDER)
","- FD&C Act Sections:
- 505(j) (21 U.S.C. ¬ß 355(j)) ‚Äì Abbreviated New Drug Applications (ANDAs)
- 505(b)(2) ‚Äì NDAs relying partly on literature or prior FDA findings
- 505(k)(3) ‚Äì Labeling regulations
- 702(a)(1) (21 U.S.C. ¬ß 372(a)(1)) ‚Äì Inspections
- 706 (21 U.S.C. ¬ß 376) ‚Äì Records
- 21 CFR ¬ß¬ß:
- 314.50 ‚Äì Content of NDA
- 314.94 ‚Äì Content of ANDA
- 314.127 ‚Äì ANDA approval/refusal criteria",,"- Novo Nordisk requested that FDA reject any ANDA or 505(b)(2) NDA referencing its liraglutide-containing products unless the applicant submitted clinical immunogenicity data.
- FDA declined to impose such a blanket requirement, stating that it determines whether clinical immunogenicity data are needed on a case-by-case basis and based on scientific evidence.
- FDA emphasized that definitive determinations on approvability of future applications would be premature, especially before finalizing its Peptide Draft Guidance.
- The agency also rejected the argument that it had improperly applied the APA by accepting ANDAs before the draft guidance was final .",denied,True,149.0,CDER,CDER
fda-2018-p-3412,FDA-2018-P-3412-0001_Citizen_Petition_from_Aurolife_Pharma_LLC.pdf,2018-09-06,2018,False,original petition,"Aurolife Pharma LLC (subsidiary of Aurobindo Pharma USA, Inc.)",industry/corporation,"- Section 505(j) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß¬ß 10.25(a), 10.30, 314.122, 314.161, 314.162
- 21 C.F.R. ¬ß¬ß 25.31(a), 25.15(d), 10.30(b) (environmental and economic impact clauses)","The petitioner comments on the removal of QVAR 40 & QVAR 80 (Beclomethasone dipropionate HFA inhalation aerosol, NDA 020911) from the active section of the Orange Book and its inclusion in the discontinued section.",The petitioner requests the FDA to determine whether QVAR 40 & QVAR 80 (NDA 020911) were voluntarily withdrawn or withheld from sale for reasons of safety or effectiveness.,"- The drug appears in the discontinued section of the FDA‚Äôs Orange Book.
- The FDA‚Äôs database indicates that the manufacturer, Teva Branded Pharmaceutical Products R&D Inc, made a business decision to discontinue the product.
- Under FDA regulation (21 C.F.R. 314.161), the FDA must determine if a listed drug was withdrawn for safety or efficacy reasons before approving an ANDA referencing that drug. The petitioner seeks clarification to support potential ANDA submission.",2019-03-04 00:00:00,Approved (Determination Issued),2019-04-04,1.0,"Center for Drug Evaluation and Research (CDER)
","- Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) ‚Äî particularly the ""Discontinued Drug Product List"" section (not a statute but a critical regulatory reference mentioned)","- The petition requested that FDA determine whether QVAR 40 and QVAR 80 (Beclomethasone Dipropionate HFA) have been withdrawn from sale for safety or efficacy reasons.
- FDA indicated that due to other agency priorities, it has not yet reached a decision on the petition.","- FDA reviewed the records and concluded that QVAR 40 and QVAR 80 were not withdrawn from sale for safety or effectiveness reasons.
- Therefore, they would remain listed in the Orange Book under the ""Discontinued Drug Product List"" with their therapeutic equivalence evaluations
",approved,True,210.0,CDER,CDER
fda-2018-p-3422,FDA-2018-P-3422-0001_Citizen_Petition_from_Novitium_Pharma_LLC_.pdf,2018-09-06,2018,False,original petition,Novitium Pharma LLC,industry/corporation,"- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 10.25(a)
- 21 C.F.R. ¬ß 314.94(a)(3)
- Drug Price Competition and Patent Term Restoration Act (Public Law 98-417)",FDA designation of a Reference Standard (RS) for Oxandrin (Oxandrolone) Tablets 2.5 mg and 10 mg (NDA 013718),Designate the generic product made by PAR Pharmaceutical Inc (ANDA A077827) as the RS for Oxandrin Tablets 2.5 mg & 10 mg (NDA 013718),"- The original brand manufacturer (Gemini Laboratories LLC) has discontinued marketing Oxandrin Tablets.
- No RLD/RS is available on the market.
- PAR Pharmaceutical Inc. is the current market leader among generic manufacturers.
- The RS designation will support generic drug development and reduce public healthcare costs.",2019-03-04 00:00:00,,2025-10-15,1.0,,,"- The petition requested that FDA designate the generic product made by PAR Pharmaceutical Inc. (A077827) as the reference standard for Oxandrin Tablets (NDA 013718).
- FDA explained that the petition involves complex issues requiring further review and analysis by Agency officials.",,no decision,False,2596.0,pending,pending
fda-2018-p-3426,FDA-2018-P-3426-0001_Citizen_Petition_from_Pharmax_Group__Inc.pdf,2018-09-07,2018,False,original petition,"Pharmax Group, Inc.",industry/corporation,"- 21 C.F.R. ¬ß 10.25
- 21 C.F.R. ¬ß 10.30
- Section 505(j)(2) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
","The unavailability of the current Reference Standard (RS) product (Cyproheptadine Hydrochloride Tablets, USP 4 mg, ANDA# A087056, IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS) in the market, and the selection of an alternative RS.","Request the FDA to designate SANTOS BIOTECH INDUSTRIES INC (ANDA# A040644) as the Reference Standard (RS) for Cyproheptadine Hydrochloride Tablets, USP 4 mg to allow ANDA submissions","- The currently designated RS (IVAX PHARMACEUTICALS/TEVA) is not available in the market.
- The Orange Book lists SANTOS BIOTECH INDUSTRIES INC as an approved ANDA holder.
- Breckenridge (distributor for Santos Biotech) is the generic market leader based on IMS sales data.
- FDA guidance allows substitution if RS is unavailable and the alternative is therapeutically equivalent and a market leader",,Approved,2019-03-15,0.0,"Center for Drug Evaluation and Research (CDER)
","- 21 U.S.C. ¬ß 355(j) (Section 505(j) of the FD&C Act)
- 21 CFR 314.3(b) ‚Äî Definitions of listed drug, reference standard, and therapeutic equivalents
- 21 CFR 314.94(a)(3) ‚Äî Requirements for ANDA content
- 21 CFR 320.22(c) ‚Äî Bioequivalence waiver",,"- The current reference standard (ANDA 087056 held by Ivax) was no longer marketed and moved to the ‚ÄúDiscontinued Drug Product List.‚Äù
- The proposed alternative (ANDA 040644 held by Boscogen) was therapeutically equivalent and the market leader by volume.
- Although no in vivo studies were required, the new RS designation would be beneficial for product development and consistency",approved,True,189.0,CDER,CDER
fda-2018-p-3535,FDA-2018-P-3535-0001_Petition_from_Norbrook_Laboratories_Limited.pdf,2018-09-17,2018,False,original petition,Norbrook Laboratories Limited,advocacy/academic,"- Section 512(n)(3)(A) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 314.93
- 21 C.F.R. ¬ß 25.15 and ¬ß 25.30(h) (Environmental Impact)",The petitioner is commenting on the approval of a generic new animal drug product that differs in dosage form from the referenced listed new animal drug (RLNAD) ‚Äî a change from chewable tablet to oral solution. ,"Approval of an Abbreviated New Animal Drug Application (ANADA) for Pimobendan 4 mg/mL Oral Solution, which differs from the RLNAD (Vetmedin¬Æ Chewable Tablets) in dosage form. ","- The generic product contains the same active ingredient (pimobendan) and is intended for the same species (canine).
- It has the same route of administration and dosage per treatment.
- The only difference is in dosage form (oral solution instead of chewable tablet), and all excipients are used in other approved animal drugs.
- The petitioner also intends to meet all bioequivalence requirements, and no changes are made to labeling except those necessary due to the form difference. ",,,2025-10-15,0.0,,,,,no decision,False,2585.0,pending,pending
fda-2018-p-3597,FDA-2018-P-3597-0001_Citizen_Petition_from_Arent_Fox_LLP.pdf,2018-09-21,2018,False,original petition,Arent Fox LLP,law/consulting,"- Federal Food, Drug, and Cosmetic Act (FD&C Act)
- 21 C.F.R. ¬ß¬ß 10.25(a), 10.30(b), 314.161, 314.122, 314.162","Determination of whether Lotrimin¬Æ (Clotrimazole 1% topical solution), NDA No. N017613, was withdrawn from the market for reasons of safety or effectiveness",The petitioner requests that the FDA determine whether NDA No. N017613 was voluntarily withdrawn for reasons of safety or effectiveness,"- NDA No. N017613 appears in the ‚ÄúDiscontinued‚Äù section of the Orange Book
- ANDA No. A074580, referencing NDA No. N017613, continues to be marketed and used for bioequivalence
- Petitioner is unaware of any safety or efficacy reasons for its withdrawal
- FDA has previously ruled similar products (e.g., Mycelex¬Æ NDA No. N018181) were not withdrawn for safety or efficacy concerns
- Seeks clarity to facilitate ANDA submissions based on RLD Lotrimin¬Æ",,Approved,2019-02-15,0.0,"Center for Drug Evaluation and Research (CDER)
","- Orange Book ‚Äì Specifically, the ‚ÄúDiscontinued Drug Product List of Approved Drug Products With Therapeutic Equivalence Evaluations‚Äù is cited. No specific statutes or CFR regulations are mentioned
",,"- Based on its records, FDA determined that LOTRIMIN (clotrimazole) topical solution was not withdrawn for safety or effectiveness reasons.
- Thus, it will remain listed in the Orange Book with therapeutic equivalence evaluations",approved,True,147.0,CDER,CDER
fda-2018-p-3599,FDA-2018-P-3599-0001_Citizen_Petition_from_AuroMedics_Pharma_LLC.pdf,2018-09-21,2018,False,original petition,AuroMedics Pharma LLC,industry/corporation,"21 CFR ¬ß¬ß 10.30, 10.20, 10.25(a), 314.122, 314.161, 314.94(a)(9)(iii), 314.99; 21 CFR ¬ß 25.31(a) (Environmental impact exclusion)",Determination whether original formulation of Kenalog¬Æ-10 (NDA 012041) was discontinued for safety or efficacy reasons,"- FDA should determine that the original formulation of NDA 012041 was not discontinued for safety or efficacy reasons.
- FDA should determine that this original formulation may be cited as the Reference Listed Drug (RLD) for an ANDA submission.","- The petition argues that the proposed generic contains the same active and inactive ingredients in the same concentration and dosage form as the original formulation.
- Precedents are cited, such as Kenalog¬Æ-40, Zosyn¬Æ, and Sandostatin¬Æ, where FDA accepted previously discontinued formulations as reference products for ANDAs, provided the discontinuation was not due to safety or efficacy concerns.
- The CMC Supplement S-043 for NDA 012041, approved on Oct. 26, 2015, was for global harmonization and had no impact on safety or efficacy.",2019-03-20 00:00:00,Approved,2021-07-04,1.0,"Center for Drug Evaluation and Research (CDER)
","- 21 U.S.C. ¬ß 355(j) (FD&C Act section 505(j))
- 21 CFR ¬ß 314.3(b)
- 21 CFR ¬ß 314.94(a)(9)(ii) and (iii)
- 21 CFR ¬ß 314.127(a)(8)(ii)(B)
- 21 CFR ¬ß 314.122(a)
- 21 CFR ¬ß 314.161(a)(1)
- 21 CFR ¬ß 314.99(b)","- The petition requested that FDA (1) determine whether the original formulation of Kenalog-10 (NDA 12041) was discontinued for safety or effectiveness reasons, and (2) accept ANDAs referencing the original formulation.
- FDA cited the need to address other Agency priorities before making a decision","- FDA found no evidence that the original formulation of Kenalog-10 (approved prior to October 23, 2015) was discontinued for reasons of safety or effectiveness.
- FDA independently reviewed relevant literature and adverse event data and found no concerns related to the prior formulation.
- FDA confirmed it may accept and approve ANDAs duplicating the discontinued Kenalog-10 formulation, provided they meet applicable statutory and regulatory requirements.
- FDA may waive certain regulatory requirements under 21 CFR ¬ß 314.99(b), specifically regarding inactive ingredients in parenteral drugs, if justified by safety and regulatory precedent.",approved,True,1017.0,CDER,CDER
fda-2018-p-3616,FDA-2018-P-3616-0001_Citizen_Petition_from_Suven_Life_Sciences_Limited.pdf,2018-09-21,2018,False,original petition,Suven Life Sciences Limited,industry/corporation,"- Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 10.25(a)
- 21 C.F.R. ¬ß 314.94(a)(3)
- FDC Act ¬ß 505(j)","The petitioner is commenting on the current designation of the reference standard (RS) for Chloroquine Phosphate Tablets 250 mg (EQ 150 mg base), specifically the reference standard status of the drug listed under ANDA 083082 (held by HIKMA Pharmaceuticals).","The petitioner requests that the FDA designate the approved generic product CHLOROQUINE PHOSPHATE TABLETS 250 MG (EQ 150 mg base) held by NATCO PHARMA LIMITED (ANDA 091621) as the new Reference Standard (RS) due to limited availability of the current RS.
","- Current RS (ANDA 083082) held by Hikma Pharmaceuticals has very limited availability, making it hard for ANDA applicants to obtain sufficient quantities for developmental studies.
- ARALEN (the RLD) has been discontinued.
- NATCO‚Äôs product (ANDA 091621) is the most marketed generic equivalent and is therapeutically equivalent to the discontinued RLD.
- FDA guidance allows designation of a new RS in cases of unavailability or limited supply.
- Supporting data includes Orange Book listings, MAT (Moving Annual Total) market data, NDC directory, and a statement on sample unavailability.",2019-03-19 00:00:00,Approved,2020-02-19,1.0,"Center for Drug Evaluation and Research (CDER)
","- 21 U.S.C. ¬ß 355(j) (FD&C Act section 505(j))
- 21 CFR ¬ß 314.3(b)
- 21 CFR ¬ß 314.94(a)(3)
- Abbreviated New Drug Applications and 505(b)(2) Applications (81 FR 69580 at 69619, October 6, 2016)","- The petition requested designation of a new reference standard for chloroquine phosphate tablets 250 mg (EQ 150 mg base).
- FDA stated that due to other Agency priorities and demands on resources, a decision has not yet been made
","- The current reference standard (ANDA 083082) was no longer marketed and should be moved to the Discontinued Drug Product List.
- The proposed alternative, ANDA 091621, is therapeutically equivalent and currently marketed.
- Commercial and regulatory data supported selecting a new reference standard to ensure availability for bioequivalence studies
",approved,True,516.0,CDER,CDER
fda-2018-p-3640,FDA-2018-P-3640-0001_Citizen_Petition_from_Information_Technology_and_I.pdf,2018-09-24,2018,False,original petition,Information Technology and Innovation Foundation (ITIF),advocacy/academic,"- Section 403 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 343)
- 21 C.F.R. ¬ß 10.30 (regarding rulemaking petitions)","Use of the term ""Non-GMO"" and the Non-GMO Project‚Äôs butterfly logo on consumer food labeling, implying health/safety risks, which ITIF claims are scientifically unfounded and misleading
","- Prohibit the use of the term ""Non-GMO"" on consumer foods and goods
- Require distributors to revise labeling to remove ""Non-GMO"" claims and the Non-GMO Project butterfly logo","- The ""Non-GMO"" label is misleading, lacks scientific basis, and falsely implies health/safety risks.
- Labels convey a false distinction between GMO and non-GMO products.
- The butterfly logo misbrands food by suggesting GMO foods are unsafe, despite scientific consensus on their safety.
- The Non-GMO Project's classification system is arbitrary and deceptive.
- Labeling even appears on items that could never be genetically modified (e.g., salt), further misleading consumers.
- The practice violates the prohibition on false or misleading labeling under the Food, Drug, and Cosmetic Act
",2019-05-24 00:00:00,,2025-10-15,2.0,,,"- FDA has not been able to reach a decision due to other agency priorities and limited resources.
- The petition requested a regulation to prohibit the term ‚ÄúNon-GMO‚Äù on labeling of consumer foods and goods",,no decision,False,2578.0,pending,pending
fda-2018-p-3666,FDA-2018-P-3666-0001_Citizen_Petition_from_Fresenius_Kabi_USA__LLC.pdf,2018-09-25,2018,False,original petition,"Fresenius Kabi USA, LLC",industry/corporation,"- 21 CFR 10.30
- 21 CFR 320.22(b)
- Federal Food, Drug, and Cosmetic Act","Designation of therapeutic equivalence (with an ""AP"" rating) of Fresenius Kabi‚Äôs Indomethacin Injection (NDA 022536) to the RLD Indocin¬Æ Indomethacin Sodium Injection (NDA 018878) by Recordati Rare Diseases, Inc.","FDA is requested to designate Fresenius Kabi USA's Indomethacin Injection, 1 mg/5 mL (NDA 022536), as a therapeutic equivalent with an ‚ÄúAP‚Äù rating to the RLD Indocin¬Æ (NDA 018878).","- FK USA‚Äôs product is pharmaceutically and therapeutically equivalent to the RLD.
- Side-by-side comparison shows identical strength, route, dosage form, active ingredient, and labeling indications.
- Differences in excipients are minor and do not affect pH or stability.
- Waiver granted for in-vivo bioequivalence based on 21 CFR 320.22(b), applicable to sterile IV solutions.
- Literature and data support that excipient differences do not impact pharmacokinetics.
- NDA 022536 relied on RLD and literature for safety and efficacy data.",2019-03-21 00:00:00,Denied,2022-03-11,1.0,"Center for Drug Evaluation and Research (CDER)
","- 21 CFR 314.3(b)
- Section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) ","- The FDA has not made a decision due to other Agency priorities and numerous demands on the Agency‚Äôs resources.
- The petition requested assignment of a therapeutic equivalence evaluation code of ""AP"" to a specific indomethacin injection formulation (1 mg/5 mL, NDA 022536)
","- The requested reference drug, Indocin (NDA 018878), is no longer marketed and was removed from the active list in the Orange Book in 2011.
- Products listed in the Discontinued Drug Product List cannot be assigned Therapeutic Equivalence (TE) Codes.
- Therefore, a TE Code (""AP"") cannot be assigned to Indomethacin with respect to Indocin.",denied,True,1263.0,CDER,CDER
fda-2018-p-3672,FDA-2018-P-3672-0001_Citizen_Petition_from_Zoetis_Inc_.pdf,2018-09-25,2018,False,original petition,Zoetis Inc.,industry/corporation,"Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act (FFDCA); 21 CFR 25.30(h); 21 CFR 25.21",Suitability Petition submission for an Abbreviated New Animal Drug Application (ANADA) for a different dosage form of an already approved product,"FDA approval to file an ANADA for a granular formulation of Generic ‚ÄúNicarbazin 25% Type A Medicated Article‚Äù instead of the existing powdered dosage form
","The proposed formulation improves product handling by reducing dust, minimizing explosion risk, and enhancing flowability. It is more compatible with current manufacturing technologies and provides safety benefits for users and handlers compared to the powder blend. Both products contain the same active ingredient, with changes limited to dosage form and excipients
",,,2025-10-15,0.0,,,,,no decision,False,2577.0,pending,pending
fda-2018-p-3691,FDA-2018-P-3691-0001_Citizen_Petition_from_Avanthi__LLC_.pdf,2018-09-27,2018,False,original petition,"Avanthi, LLC",industry/corporation,"- 21 CFR ¬ß¬ß 10.25(a) and 10.30
- 21 CFR ¬ß 314.161
- Also references 21 CFR ¬ß¬ß 314.122, 314.162","Discontinuation of Chlor-Trimeton¬Æ (Chlorpheniramine Maleate) Extended-Release Tablets 8 mg, NDA #007638 held by Bayer Healthcare LLC from the market and whether it was for safety or effectiveness.",FDA is requested to make a determination on whether Chlor-Trimeton¬Æ has been voluntarily withdrawn from the market for reasons of safety or effectiveness.,"The petitioner noted that the drug appears to have been discontinued from marketing, as indicated in the electronic Orange Book (accessed September 25, 2018). Therefore, FDA determination is needed.
",,Approved (Determination Issued),2019-04-02,0.0,"Center for Drug Evaluation and Research (CDER)
","- FDA references the Approved Drug Products With Therapeutic Equivalence Evaluations (Orange Book).
- No specific CFR or U.S. Code citations are mentioned, but the context refers to regulatory listings in the Orange Book",,"- FDA reviewed its records and found that Chlor-Trimeton Allergy 12 Hour (chlorpheniramine maleate) 8 mg was not withdrawn from sale due to safety or effectiveness issues.
- As such, the drug will remain in the Discontinued Drug Product List.",approved,True,187.0,CDER,CDER
fda-2018-p-3709,FDA-2018-P-3709-0001_Citizen_Petition_from_Jennifer_Nelson_Redacted.pdf,2018-09-28,2018,False,original petition,Jennifer Nelson,individual,"- 21 C.F.R. ¬ß 10.30 (Citizen Petition regulation)
- 21 C.F.R. ¬ß 895.21 (Procedures for banning a device)",The ongoing marketing and usage of Permanent Cautery Instruments (Spatula and Hook) for all Da Vinci robotic surgeries manufactured by Intuitive Surgical. The petitioner references prior FDA recalls and enforcement actions related to these devices.,The petitioner requests the FDA to ban the use of Permanent Cautery Instruments for the Da Vinci robotic surgical system in all surgeries across the United States.,"- Cites ongoing malfunctions, injuries, and deaths associated with the devices, as recorded in the FDA MAUDE database.
- Refers to known design defects acknowledged by the manufacturer.
- Cites historical FDA warning letters indicating violations by the manufacturer.
- Highlights potential for severe thermal injury due to arcing and electric current leakage.
- Expresses concern over lack of Active Electrode Monitoring (AEM) in the device design.
- Personal experience as a victim of device failure underscores the urgency for FDA intervention.",2019-03-04 00:00:00,Denied,2022-07-12,1.0,"Center for Devices and Radiological Health (CDRH)
","- 21 CFR 10.30(e)(3)
- 21 CFR 876.1500
- Section 516 of the FD&C Act (21 U.S.C. 360f)
- Section 501(g) of the FD&C Act (21 U.S.C. 351(g))
- Section 520(g) of the FD&C Act (21 U.S.C. 360j(g))
- 21 CFR 895.21(a)(1)
- 21 CFR 895.25
- 21 CFR 7.3(g), 7.3(m)(2)
- 21 CFR 820.30(c)","- The petition raises issues requiring further review and analysis by FDA officials.
- Therefore, the FDA has issued an interim response and committed to reply again once a decision is reached
","- The FDA concluded that the Permanent Cautery Instruments for Da Vinci Robotic Surgeries do not present an ‚Äúunreasonable and substantial risk of illness or injury that cannot be remedied by labeling.‚Äù
- Cited MDRs show very low rates of adverse events with no confirmed injuries.
- Intuitive Surgical‚Äôs patent filings do not establish a design defect or safety issue.
- The cited study on leakage currents supports current use-life limitations and existing safeguards (e.g., kill switch) on instruments.
- AEM (Active Electrode Monitoring) technology was evaluated and found to offer no additional mitigation for the types of failures cited.
- FDA noted that the referenced recalls and regulatory actions did not demonstrate systemic or unresolved safety concerns; post-recall and inspection processes were appropriately followed and closed.
- FDA‚Äôs systematic review found the Da Vinci system had equal or better safety profiles compared to traditional surgery.
- The 2013 recall and subsequent inspections did not reveal deficiencies warranting a ban.",denied,True,1383.0,CDRH,CDRH
fda-2018-p-3730,FDA-2018-P-3730-0001_Citizen_Petition_from_Aizant_Drug_Research_Solutio.pdf,2018-10-01,2018,False,original petition,Aizant Drug Research Solutions Pvt. Ltd.,law/consulting,"- Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act
- 21 C.F.R. ¬ß 314.93
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 25.31 (environmental impact)
- 21 C.F.R. ¬ß 10.30(b) (economic impact)",Discontinuation status of ESBRIET (pirfenidone) Tablets 534 mg under NDA #208780,"Requesting FDA to determine that ESBRIET (pirfenidone) Tablets 534 mg was not discontinued for reasons of safety or efficacy, and therefore is eligible for submission of an ANDA for the same strength.
","- ESBRIET 534 mg tablets are currently marked as ""Discontinued"" in the Orange Book and drugs@fda.gov.
- Other strengths (267 mg and 801 mg) are still marketed.
- No evidence provided that the 534 mg strength was withdrawn for safety or efficacy reasons.
- Seeks FDA confirmation to allow ANDA submissions for all three strengths, including the 534 mg version.",,Approved (Determination Issued),2019-02-04,0.0,"Center for Drug Evaluation and Research (CDER)
","- 21 U.S.C. ¬ß355(j)(7)
- 21 CFR 314.161
- 21 CFR 314.162",,"- The FDA reviewed the citizen petition and other information related to Esbriet (pirfenidone) 534 mg tablets.
- Determined that the drug was not withdrawn for safety or effectiveness reasons.
- Based on this, the drug remains listed in the ‚ÄúDiscontinued Drug Product List‚Äù section of the Orange Book and can be referenced in Abbreviated New Drug Applications (ANDAs).
- Petition did not provide sufficient data or evidence to contradict this conclusion.
- The agency‚Äôs review also included publicly available data and product usage records confirming no safety or efficacy-related withdrawal occurred
",approved,True,126.0,CDER,CDER
fda-2018-p-3742,FDA-2018-P-3742-0001_Citizen_Petition_from_Pharmacmechanics.pdf,2018-10-01,2018,False,original petition,"Saeed Qureshi, Ph.D., Principal at Pharmacmechanics",industry/corporation,"- 21 CFR 111.320
- 21 CFR 820.72
- 21 CFR 211.194(a)(2)
- USP General Chapter <711>
- References to several FDA guidance documents from 1997, 2017, and 2018","Guidance documents and regulatory recommendations concerning dissolution testing of immediate-release solid oral dosage forms, specifically those involving basket and paddle apparatuses","Withdrawal of the following guidance documents and regulatory references:
1. 2018 FDA Guidance on Dissolution Testing
2. 2017 Guidance on Waiver of In Vivo Bioavailability Studies
3. 1997 Guidance on Dissolution Testing
4. FDA‚Äôs Dissolution Methods Database","The petitioner argues that the drug dissolution testers used (paddle and basket apparatuses) have not been validated as required under cGMP regulations. As a result, dissolution data from these unvalidated testers are unreliable and may provide a false sense of product quality to consumers. The FDA‚Äôs reliance on these tools, according to the petitioner, leads to non-GMP-compliant practices and potentially inaccurate quality assessments of drug products
",2019-03-29 00:00:00,Denied,2022-09-08,1.0,"Center for Drug Evaluation and Research (CDER)
","- 21 CFR 211.194(a)(2)
- 21 CFR 211.160(b)(4)
- ICH Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions (November 2007)
- ICH Q4B Annex 7(R2) Dissolution Test General Chapter (June 2011)
- ICH Q2(R1) Validation of Analytical Procedures (November 2005)
- USP General Chapters: <711>, <1092>
- ASTM Standard E2503 (2007)","The petition raises complex issues requiring extensive review and analysis by FDA officials, hence the need for more time before issuing a final decision.

","- FDA concluded that dissolution testing methods are scientifically valid and properly supported by guidance, standards, and compendial references.
- Apparatus used in testing are qualified and methods are validated according to cGMP.
- USP chapters and international harmonization through ICH demonstrate acceptance and standardization of the dissolution procedures.
- The claim that dissolution testers have never been validated misunderstands the distinction between method validation and instrument qualification.
- FDA affirmed that dissolution methods are not intended to identify unknown samples, but to assess quality and consistency.
- The FDA also reiterated that method verification is required for lab usage, even if a USP method is applied.
- FDA guidance documents and the Dissolution Methods Database remain valid and scientifically appropriate.",denied,True,1438.0,CDER,CDER
fda-2018-p-3746,FDA-2018-P-3746-0001_Citizen_Petition_from_BF_Innovation_Inc_on_behalf_.pdf,2018-10-01,2018,False,original petition,BF Innovation Inc.,industry/corporation,"- Federal Food, Drug, and Cosmetics Act (""FDC Act"")
- 21 C.F.R. ¬ß 10.30","FDA‚Äôs designation of Reference Standards (RS) in the Orange Book, specifically the unavailability of the current RS (N019957 by Fougera Pharmaceuticals Inc.) for Fluticasone Propionate Ointment 0.005%
","Request FDA to designate Fluticasone Propionate Ointment 0.005% (Application No: A076668) by Perrigo New York Inc. as an additional Reference Standard (RS) to support ANDA submissions 
","- The current RS (Fougera‚Äôs product) is not available for sale.
- IMS data shows Perrigo‚Äôs version is the market leader in unit sales in 2017.
- Availability of an alternative RS would facilitate bioequivalence studies necessary for ANDA submissions and help avoid delay in generic drug development. ",,Dismissed (moot),2018-10-23,0.0,"Center for Drug Evaluation and Research (CDER)
","Not Mentioned
",,"The petitioner requested that FDA designate fluticasone propionate ointment 0.005% (ANDA 076668 by Perrigo) as the reference standard in the Orange Book. The FDA had already updated the Orange Book to list Perrigo‚Äôs ANDA as the reference standard and moved NDA 019957 (previously listed) to the discontinued section. Therefore, the petition was dismissed as moot.

",dismissed (moot),True,22.0,CDER,CDER
fda-2018-p-3770,FDA-2018-P-3770-0001_Citizen_Petition_from_Luitpold_Pharmaceuticals_Inc.pdf,2018-09-04,2018,False,original petition,Luitpold Pharmaceuticals Inc.,industry/corporation,"- Section 505(j)(2)(C) of the FDCA
- 21 C.F.R. ¬ß¬ß 10.20, 10.30, and 314.93","Suitability for submission of an ANDA for Levocarnitine Injection, 200 mg/mL, 20 mL Single Dose Vial","FDA approval of a Suitability Petition declaring that Levocarnitine Injection, 200 mg/mL (20 mL Single Dose Vial) is suitable for submission in an ANDA
","- Existing RLD (Carnitor¬Æ) is in 5 mL vials; proposed 20 mL vial would improve convenience.
- Supports FDA‚Äôs goal of increasing generic competition.
- Reduces sterility risk and vial usage for heavier patients (e.g., those over 60 kg often need >3,000 mg).
- The proposed change does not affect drug concentration, dosage form, or route of administration.
- Same active/inactive ingredients and therapeutic effect as RLD.",,Approved,2020-10-16,0.0,"Center for Drug Evaluation and Research (CDER)
","- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- 21 CFR 314.93
- 21 CFR 314.93(e)(1)
- 21 CFR 314.94(a)(3)(iii)
- 505(j)(2)(A) and (B)
- 505(j)(2)(A)(iv)",,"- The proposed change in strength does not raise questions of safety or effectiveness.
- The dosage form, route, and indication are the same as the listed drug.
- The change is consistent with existing labeling and dosing recommendations.
- If bioequivalence is shown, it can be expected to have the same therapeutic effect.
- No new investigations are required to demonstrate safety or efficacy for the proposed strength",approved,True,773.0,CDER,CDER
fda-2018-p-3786,FDA-2018-P-3786-0001_Citizen_Petition_from_Hyman__Phelps___McNamara_PC.pdf,2018-10-03,2018,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"- 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FDC Act)
- 21 C.F.R. ¬ß 314.93
- 21 C.F.R. ¬ß 10.20
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 25.31 (Environmental Impact)
- FDC Act ¬ß 505B(a)(1)(A) (PREA compliance reference)","Determination of suitability for submission of an Abbreviated New Drug Application (ANDA) for a new strength of an existing Reference Listed Drug (RLD): Janumet XR
","FDA is requested to determine that Metformin/Sitagliptin 750 mg/50 mg is suitable for submission as an ANDA based on Janumet XR as the RLD. The new product introduces an intermediate strength not currently marketed
","- The new strength (750 mg Metformin/50 mg Sitagliptin) offers dosing flexibility.
- Current Janumet XR strengths are limited to 500/50 mg, 1000/50 mg, and 1000/100 mg.
- Introducing a 750 mg strength allows finer dose titration, improved adherence, and reduces risk of dosing errors.
- Addresses patient needs who are already on 750 mg of metformin (e.g., Glucophage XR users).
- Does not raise new safety or efficacy questions; other conditions remain the same as the RLD.
- Petition claims exemption from Pediatric Research Equity Act (PREA) because this is only a strength change",,Approved,2023-06-13,0.0,"Center for Drug Evaluation and Research (CDER)
","- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- 21 CFR 314.93
- 21 CFR 314.93(e)(1)
- Section 505(j)(2)(A) and (B)
- Section 505(j)(2)(A)(iv)
- 21 CFR 314.94(a)(3)(iii)",,"- The proposed strength differs from the listed drug but does not pose questions of safety or effectiveness.
- The use, dosage form, route, and indication are the same as the reference drug.
- If bioequivalence is demonstrated, the product is expected to have the same therapeutic effect.
- No additional investigations are necessary to demonstrate safety or efficacy
",approved,True,1714.0,CDER,CDER
fda-2018-p-3806,FDA-2018-P-3806-0001_Citizen_Petition_from_Greg_Grillo_Redacted.pdf,,2018,False,original petition,"Dr. Greg Grillo, DDS, and more than 375 dental professionals and other citizens",individual,"- 21 C.F.R. ¬ß¬ß 10.25(a) and 10.30
- Federal Food, Drug and Cosmetic Act (FDC Act)
- 21 C.F.R. ¬ß 25.31 (Environmental impact exemption)","The current FDA classification and regulatory status of oral moisturizer products marketed for dry mouth that linger in the mouth, especially regarding their formulation safety
","The FDA should regulate oral moisturizer products marketed for mitigation, treatment, or prevention of dry mouth as drugs or devices under the FDC Act and ensure their formulations are safe‚Äîspecifically, requiring a pH level that does not risk demineralization or erosion of teeth
","- Many currently marketed dry mouth products have dangerously low pH (as low as 2.9), which can lead to tooth demineralization, erosion, and cavities.
- Scientific studies (Delgado & Olafsson, 2017 & 2018) show products with pH below 5.5 are erosive, and safe pH should be around 6.7 or higher.
- These products are often marketed for frequent or prolonged oral use, increasing the risk to consumers‚Äîparticularly those already vulnerable due to dry mouth (xerostomia).
- The regulatory status of these products is unclear, and most do not meet legal requirements for classification as drugs or devices",,,2025-10-15,,,,,,no decision,False,,pending,pending
fda-2018-p-3825,FDA-2018-P-3825-0001_Citizen_Petition_from_Pei_Wei_Asian_Diner__LLC_.pdf,2018-10-08,2018,False,original petition,"Pei Wei Asian Diner, LLC",industry/corporation,"- 21 C.F.R. ¬ß 10.30
- 21 U.S.C. ¬ß 371(a) and ¬ß 371(h)
- 21 U.S.C. ¬ß 393(b)(2)(A)
- 21 C.F.R. ¬ß 101.11(a), (b)(2)(i)-(ii), (c)(3)
- 21 C.F.R. ¬ß 101.13(b)(1)
- 21 C.F.R. ¬ß 101.10
- 21 C.F.R. ¬ß 10.115(g)(1)
- 21 C.F.R. ¬ß 25.32(p)
- 21 C.F.R. ¬ß 10.30(b)(3)","The petition comments on current FDA regulations that exempt restaurants (covered establishments) from publicly disclosing ingredient details and substantiation of nutrient content claims unless requested by the FDA.
","1. Amend 21 C.F.R. ¬ß 101.11(c)(3) to require covered establishments to provide nutrient substantiation proactively‚Äînot only upon request.
2. Issue a Level 1 guidance document recommending that restaurants voluntarily provide ingredient lists for menu items upon request","- Consumers increasingly eat meals away from home and want access to ingredient and nutrient content information.
- Packaged food is subject to more rigorous transparency standards than restaurant food, which is inconsistent.
- Pei Wei's own commissioned study found a majority of consumers strongly desire ingredient transparency.
- Pei Wei argues for equity in labeling standards between packaged food manufacturers and restaurants and commits to voluntarily posting ingredient statements by the end of 2019",2019-04-05 00:00:00,,2025-10-15,1.0,,,"FDA cites inability to reach a decision within the 180-day period due to competing agency priorities and limited resources. It commits to reviewing the petition and considering regulatory amendments in the context of other priorities.

",,no decision,False,2564.0,pending,pending
fda-2018-p-3843,FDA-2018-P-3843-0001_Citizen_Petition_from_Hooman_Noorchashm_Readacted.pdf,2018-10-09,2018,False,original petition,"Hooman Noorchashm, MD, PhD",individual,"21 C.F.R. ¬ß 10.30 (under which the petition was submitted)
","FDA's clearance of ‚Äúcontained‚Äù laparoscopic power morcellators (e.g., Olympus PneumoLiner) and the continued market availability and use of ‚Äúuncontained‚Äù laparoscopic power morcellators (e.g., by Karl Storz), despite black-box warnings and epidemiological risk data","The petitioner requests that the FDA Commissioner ban all ‚Äúuncontained‚Äù laparoscopic power morcellator devices from use in gynecological operations involving resection of the uterus or associated tumors
","- Recent epidemiological data from Yale University (Desai et al.) shows a 2‚Äì10% incidence of occult or missed cancers in symptomatic women undergoing gynecological procedures.
- FDA analysis in 2014 identified a 1 in 350 incidence of occult leiomyosarcomas, leading to a black-box warning on power morcellators.
- Despite this, some surgeons still use uncontained devices, and companies like Karl Storz continue marketing them.
- The availability of a contained device (Olympus PneumoLiner) removes justification for continued use of uncontained techniques.
- Ethical, scientific, and clinical rationale favors a ban due to the severe risk of iatrogenic cancer upstaging.
- Petitioner urges collaboration with CDC officials informed of the data (Drs. Redfield and Briss)",2019-06-24 00:00:00,Denied,2020-12-30,1.0,"Center for Devices and Radiological Health (CDRH)
","- 21 C.F.R. ¬ß 10.30(e)(3)
- 21 CFR ¬ß 884.4050
- Section 516(a) of the FD&C Act, 21 U.S.C. 360f(a)
- 21 CFR 895.21(a)","FDA is still reviewing and analyzing the issues raised in the petition, which requested banning the use of uncontained laparoscopic power morcellators in gynecological surgeries involving the uterus and associated tumors. This interim response is issued per regulation and final action will be communicated upon completion of the review.

","- FDA determined that uncontained LPMs (Laparoscopic Power Morcellators) in gynecologic surgeries do not present a substantial deception or an unreasonable and substantial risk of illness or injury that cannot be mitigated through labeling changes.
- FDA has issued multiple communications and updated labeling guidance since 2014 to reduce the risks associated with LPM use.
- The agency found that enhanced labeling requirements, including use of containment systems and appropriate patient selection, are sufficient mitigations.
- The petitioner‚Äôs request did not meet the statutory criteria for a device ban.",denied,True,813.0,CDRH,CDRH
fda-2018-p-3861,FDA-2018-P-3861-0001_Citizen_Petition_from_Innogenix_LLC.pdf,2018-10-11,2018,False,original petition,"Innogenix, LLC",industry/corporation,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FDC Act)
- 21 C.F.R. ¬ß¬ß 10.20, 10.30, and 314.93
- 21 C.F.R. ¬ß 25.31 (Environmental Impact)","Request for a determination that a new 125 mg strength of Metronidazole Tablets is suitable for submission via an Abbreviated New Drug Application (ANDA), different from the currently approved 250 mg and 500 mg strengths of the Reference Listed Drug (RLD), Flagyl (Metronidazole Tablets, USP).
","FDA is requested to determine that the proposed 125 mg strength of Metronidazole Tablets is suitable for submission in an ANDA, under the Suitability Petition process.
","- The proposed 125 mg strength allows for more precise dosing, especially for pediatric patients and patients requiring dose adjustment (e.g., hepatic impairment).
- Flagyl tablets are unscored, which makes splitting difficult; a scored 125 mg tablet will improve dosing flexibility.
- The proposed strength remains within approved dosage ranges and is consistent with the RLD labeling.
- The change does not raise questions of safety or effectiveness.
- Pediatric assessments are not required as the active ingredient, dosage form, indication, and route remain unchanged from the RLD.
- Bioequivalence is expected through proportional similarity and dissolution testing across strengths.",,Approved,2023-09-13,0.0,"Center for Drug Evaluation and Research (CDER)
","- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 CFR 314.93
- 21 CFR 314.94(a)(3)(iii)
- Section 505(j)(2)(A) and (B)
- Section 505(j)(2)(A)(iv)",,"- The proposed change in strength (from 250 mg and 500 mg to 125 mg) does not raise concerns regarding safety or effectiveness.
- The new strength is consistent with the dosing recommendations of the reference listed drug.
- If shown to meet bioequivalence, it can be expected to have the same therapeutic effect.
- No significant labeling changes or investigations are needed to demonstrate safety or efficacy.",approved,True,1798.0,CDER,CDER
fda-2018-p-3883,FDA-2018-P-3883-0001_Citizen_Petition_from_Foley___Lardner_LLP.pdf,2018-10-11,2018,False,original petition,Foley & Lardner LLP,law/consulting,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- 21 C.F.R. ¬ß¬ß 10.30, 314.93, and 314.161","Discontinuation of the Reference Listed Drug (RLD) product Cortisporin¬Æ Otic Solution, NDA #050479, from the Orange Book listing
","The petitioner requests that the FDA determine whether Cortisporin¬Æ Otic Solution (NDA #050479) was discontinued for safety or effectiveness reasons.
","- The drug is listed under Discontinued Products in the Orange Book without a noted reason for discontinuation.
- Active pharmaceutical ingredients and drug product have current USP monographs.
- Reference Standard and generic equivalents are still available in the market, suggesting it may not have been withdrawn for safety or efficacy concerns.",,Approved (Determination Issued),2019-04-04,0.0,"Center for Drug Evaluation and Research (CDER)
","Approved Drug Products With Therapeutic Equivalence Evaluations (commonly known as the Orange Book)
",,"The FDA reviewed its records and determined that CORTISPORIN otic solution (hydrocortisone/neomycin sulfate/polymyxin B sulfate) was not withdrawn from sale for reasons of safety or effectiveness. Therefore, the product will be listed in the ‚ÄúDiscontinued Drug Product List‚Äù section of the Orange Book.

",approved,True,175.0,CDER,CDER
fda-2018-p-3896,FDA-2018-P-3896-0001_Citizen_Petition_from_Chul_Hi_Park_Ph_D___Redacted.pdf,2018-10-14,2018,False,original petition,"Chul-Hi Park, Ph.D.",individual,"- Sections 510 and 513 of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß10.30","FDA‚Äôs current clearance practice for marketing surgical staplers and staple line reinforcement materials (buttresses) for use in surgeries involving the lung and digestive tract organs, which lacks requirements for specific performance data related to staple line safety under physiological load.","The petitioner requests the FDA to:
‚Ä¢ Require risk analysis and additional performance tests for surgical staplers and buttress materials intended for use in lung and digestive tract surgeries.
‚Ä¢ Ensure performance testing under realistic physiological conditions involving staple line geometry and anatomical disposition.
‚Ä¢ Revise labeling and Instructions for Use (IFU) accordingly.","- Current stapler devices are being cleared without evaluating their performance under dynamic physiological stress conditions (e.g., breathing, digestion).
- Staple line leaks in the lung and GI tract are critical complications with significant health risks.
- Existing burst pressure tests are insufficient as they do not simulate real-world dynamic conditions or anatomical variations.
- Certain staple line geometries and locations (e.g., near GE junction or in circular anastomosis) pose greater risk of failure due to stress concentration.
- A new baseline of performance testing (including FEA-based stress analysis) would improve safety, better guide design, and support realistic labeling claims.",2019-04-11 00:00:00,Denied,2021-10-12,1.0,"Center for Devices and Radiological Health (CDRH)
","- 21 CFR 878.4750 (Implantable staples)
- 21 CFR 878.3300 (Surgical mesh)
- 21 U.S.C. ¬ß 360c(a)(1) (Device classification)
- 21 U.S.C. ¬ß¬ß 360(k) and 360c(i) (Substantial equivalence & classification)
- 21 CFR Part 820 (Good Manufacturing Practices)
- 21 CFR Part 803 (Adverse Event Reporting)
- 21 CFR Part 801 (Labeling Requirements)
- 21 U.S.C. ¬ß¬ß 351 and 352 (Adulteration and Misbranding)
- Section 513(b) of the FD&C Act","Decision pending due to complex issues requiring further agency review.



","- The petitions did not provide sufficient evidence that additional performance testing and risk analysis are required to ensure safety and effectiveness.
- FDA already evaluates performance data under its existing 510(k) review process.
- Surgical staplers for internal use were recently reclassified to Class II with special controls requiring more comprehensive data.
- Existing labeling and performance testing recommendations are deemed sufficient.
- FDA guidance (e.g., labeling for surgical staplers/staples for internal use) and public availability of summary SE data already address concerns.
- Evidence presented in the petitions (e.g., self-authored materials, general articles) did not substantiate the need for the requested administrative actions.",denied,True,1094.0,CDRH,CDRH
fda-2018-p-3933,FDA-2018-P-3933-0001_Citizen_Petition_from_Fresenius_Kabi_USA_LLC.pdf,2018-10-16,2018,False,original petition,"Fresenius Kabi USA, LLC",industry/corporation,"- Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 10.30
- 505(b)(1)
- 21 C.F.R. ¬ß 25.31 (for Environmental Impact categorical exclusion)","Requesting therapeutic equivalence designation and ‚ÄòAP‚Äô rating for Magnesium Sulfate Injection, USP, 10 gm/10 mL (ANDA 202411 by Hospira, Inc.) relative to Fresenius Kabi‚Äôs own NDA 019316 formulation.
","Designate Hospira, Inc.‚Äôs Magnesium Sulfate Injection, USP, 10 gm/10 mL (ANDA 202411) as therapeutically equivalent (with an ‚ÄòAP‚Äô rating) to FK USA‚Äôs NDA 019316.
","The petitioner provided a side-by-side pharmaceutical equivalence comparison showing that the two products are identical in strength, route of administration, dosage form, active ingredients, and labeling. They also meet FDA's requirements for therapeutic equivalence as outlined in the Orange Book, including bioequivalence, safety, efficacy, labeling, and cGMP compliance. 

",,Dismissed (moot),2019-02-27,0.0,"Center for Drug Evaluation and Research (CDER)
","- 21 CFR 10.30(e)(2)(iii)
",,"- The petition requested that FDA assign a therapeutic equivalence (TE) code for magnesium sulfate injection (10 gm/20 mL).
- FDA confirmed the TE code was already added to the Orange Book for NDA 19316 and ANDA 202411, making the request moot.
- As such, the FDA dismissed the petition because the requested action had already been completed.",dismissed (moot),True,134.0,CDER,CDER
fda-2018-p-3949,FDA-2018-P-3949-0001_Citizens_Petition_from_Lachman_Consultant_Services.pdf,2018-10-17,2018,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"21 C.F.R. ¬ß 10.30, 21 C.F.R. ¬ß 25.31","Determination of whether TRISENOX (Arsenic Trioxide) Injection, 1 mg/mL, has been discontinued for reasons of safety or effectiveness.","The petitioner requests that the FDA determine whether TRISENOX (Arsenic Trioxide) 1 mg/mL Injection has been discontinued for reasons related to safety or effectiveness. If it has not, the petitioner asks FDA to allow submission of ANDAs referencing both the 1 mg/mL and 2 mg/mL strengths of TRISENOX as the Reference Listed Drug (RLD).","The 1 mg/mL strength of TRISENOX is listed as ""Discontinued"" in the FDA‚Äôs Orange Book. It appeared in labeling as late as February 2015 but was excluded in the January 2018 update. Lachman contends that a formal determination is needed to allow ANDAs to reference TRISENOX as the RLD if the discontinuation was not for safety or effectiveness reasons",,Approved (Determination Issued),2019-04-18,0.0,"Center for Drug Evaluation and Research (CDER)
","Not Mentioned explicitly in the letter; however, reference is made to the Orange Book (Approved Drug Products With Therapeutic Equivalence Evaluations) and the Federal Register
",,"The FDA reviewed its records and found that TRISENOX (arsenic trioxide) injection, 1 mg/mL, was not withdrawn from sale for reasons of safety or effectiveness. As a result, it will remain in the ‚ÄúDiscontinued Drug Product List‚Äù section of the Orange Book.
",approved,True,183.0,CDER,CDER
fda-2018-p-3951,FDA-2018-P-3951-0001_Citizen_Petition_from_Chul_Hi_Park_Redacted.pdf,2018-10-18,2018,False,original petition,"Chul-Hi Park, Ph.D.",individual,"- Sections 510 and 513 of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß10.30
- 21 C.F.R. ¬ß25.34 (Environmental Impact exemption)",510(k) clearance process for surgical stapler devices,"The petitioner requests that FDA:
1. Develop standardized performance tests for retroactive assessment of sealing performance of stapler devices.
2. Require manufacturers to conduct these tests on marketed devices, publish the results, and revise labeling and instructions accordingly.","- Staple line leaks in surgeries can cause morbidity and mortality
- Lack of proper testing or consideration of real-world mechanical stresses in current stapler device evaluations
- Previous 510(k) clearances do not reflect performance under physiological loads
- Need for a scientifically sound baseline for device evaluation
- Improved labeling, adverse event tracing, and surgical practices expected as outcome of retroactive tests",2019-04-16 00:00:00,Denied,2021-10-12,1.0,"Center for Devices and Radiological Health (CDRH)
","- 21 CFR 878.4750 (Implantable staple)
- 21 CFR 878.3300 (Surgical mesh)
- 21 U.S.C. ¬ß 360c(a)(1) (Device classification)
- 21 U.S.C. ¬ß¬ß 360(k) and 360c(i) (Substantial equivalence ‚Äì 510(k))
- 21 CFR Part 820 (Good Manufacturing Practice)
- 21 CFR Part 803 (Adverse Event Reporting)
- 21 CFR Part 801 (Labeling Requirements)
- 21 U.S.C. ¬ß¬ß 501 and 502 (Adulteration and Misbranding)
- 21 U.S.C. ¬ß 360c(b) (Device reclassification)","The FDA has not reached a decision because the petition raises issues requiring further review and analysis. The interim response complies with FDA regulations on citizen petitions.

","- The petitions did not provide sufficient evidence to require additional performance testing or labeling changes beyond existing regulations.
- FDA already requires and reviews risk analyses and performance data for 510(k) submissions, including benchtop, ex vivo, and in vivo studies.
- Surgical staplers for internal use were reclassified as class II devices with special controls (86 FR 56195), and FDA issued updated labeling guidance (86 FR 56272).
- Chronic animal studies and clinical trials are requested when necessary to evaluate device safety.
- FDA continues to monitor device safety post-clearance through adverse event reporting and market surveillance.
- Summary information about test data is publicly available via 510(k) summaries.
- The evidence provided by the petitioner, including self-authored analysis, lacked sufficient justification to mandate the changes requested.",denied,True,1090.0,CDRH,CDRH
fda-2018-p-4088,FDA-2018-P-4088-0001_Citizen_Petition_from_Data_Based_Medicine_Americas.pdf,2018-10-26,2018,False,original petition,Data Based Medicine Americas Ltd.,industry/corporation,"- 21 C.F.R. ¬ß 10.30 (implied by format, standard for citizen petitions)
- 21 C.F.R. ¬ß 25.31(a) (categorical exclusion from environmental assessment)","The petition comments on the lack of sufficient safety labeling on isotretinoin products, particularly the absence of warnings about sexual side effects including those that persist after discontinuation.
","The petitioners request the FDA to:
- Immediately revise all isotretinoin product labels (both branded and generic)
- Add warnings, precautions, highlights of prescribing information, and a boxed warning to inform of sexual side effects such as erectile dysfunction, decreased libido, genital anesthesia, etc., which may persist indefinitely after discontinuation","The petition cites:
- Clinical case reports and studies indicating sexual dysfunction from isotretinoin
- Data from regulatory databases (FDA, MHRA, RxISK, Lareb) showing numerous reports of adverse sexual effects
- Evidence that such effects can emerge during or after treatment and may be permanent
- Similarities to other syndromes such as Post-SSRI Sexual Dysfunction (PSSD) and Post-Finasteride Syndrome (PFS)
- The lack of sufficient warnings deprives patients of informed consent and the ability to make risk-benefit decisions",2019-04-26 00:00:00,,2025-10-15,1.0,,,"The petition raises complex issues that require extensive review and analysis by Agency officials. The FDA has not reached a decision yet and is providing an interim response in accordance with its regulations.
",,no decision,False,2546.0,pending,pending
fda-2018-p-4143,FDA-2018-P-4143-0001_Citizen_Petition_from_University_of_Toledo.pdf,2018-10-31,2018,False,original petition,"Aakash Agarwal, Adjunct Professor, Engineering Center for Orthopaedic Research Excellence (E-CORE), Departments of Bioengineering and Orthopaedic Surgery, University of Toledo",advocacy/academic,"- 510(k) (Premarket Notification)
- PMA (Premarket Approval)
- 21 C.F.R. ¬ß¬ß 25.30‚Äì25.34, 25.40 (Environmental impact)","The petitioner objects to the FDA‚Äôs continued clearance (510(k)) and approval (PMA) of reusable/reprocessed implantable orthopedic devices, particularly pedicle screws and interbody cages","- Cease clearing or approving the reuse/reprocessing (repeated sterilization) of implantable orthopedic devices
- Require all pedicle screws and other orthopedic implants to be provided pre-sterilized and untouched before implantation, to avoid contamination","- Reprocessed implants risk preoperative and intraoperative contamination, leading to possible infection and implant failure
- Scientific evidence and multicenter trials show high contamination levels (up to 10‚Å∑ bacterial CFUs) during surgery 

- Use of sterile guards around implants showed zero contamination, supporting safer practices
- Supporting data from multiple peer-reviewed studies and clinical trials",2019-04-02 00:00:00,,2025-10-15,1.0,,,"The petition raises issues requiring further review and analysis by agency officials. The interim response was issued per regulatory procedures for citizen petitions.

",,no decision,False,2541.0,pending,pending
fda-2018-p-4281,FDA-2018-P-4281-0001_Citizen_Petition_from_Fresenius_Kabi_USA__LLC.pdf,2018-11-07,2018,False,original petition,"Fresenius Kabi USA, LLC",industry/corporation,"- 21 C.F.R. ¬ß¬ß 10.20, 10.30, 314.93 (citizen petition and ANDA suitability petition procedures)
- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (ANDA requirements for drug content variation)
- 21 C.F.R. ¬ß 25.31(a) (environmental impact categorical exclusion)",The petitioner comments on FDA‚Äôs prior approval of a discontinued NDA (NDA 019329) for Sodium Chloride 23.4% Injection and seeks permission to file an ANDA for a new Pharmacy Bulk Package (PBP) format with larger fill volumes (100 mL and 200 mL vials),"The petitioner requests FDA to:
- Approve an ANDA Suitability Petition for Sodium Chloride 23.4% Injection, USP
- Allow the product to be marketed in 100 mL and 200 mL plastic pharmacy bulk package vials (in addition to the previous 30 mL single-dose vial)","- The only change from the reference listed drug is total drug content (volume per vial); concentration, active ingredients, and indications remain unchanged
- FDA has previously treated volume changes as a strength change requiring petition approval
- The larger volume options would reduce waste and stocking burden for hospitals and infusion centers
- The containers meet USP definitions for Pharmacy Bulk Packages, with appropriate labeling and aseptic handling precautions
- No issues of safety or effectiveness are raised by this change",,Approved,2021-05-27,0.0,"Center for Drug Evaluation and Research (CDER)
","- Section 505(j)(2)(C) of the FDCA
- 21 CFR 314.93
- 21 CFR 314.93(e)(1)
- 21 CFR 314.94(a)(3)(iii)
- Section 505(j)(2)(A) and (B)
- Section 505(j)(2)(A)(iv)",,"- The change in strength does not raise safety or effectiveness concerns
- The use, dose, dosage form, and route are unchanged
- Proposed strength aligns with approved labeling
- Bioequivalence data will ensure therapeutic equivalence
- No new investigations are necessary for safety and effectiveness",approved,True,932.0,CDER,CDER
fda-2018-p-4306,FDA-2018-P-4306-0001_Citizen_Petition_from_Jill_H__Osborne_Redacted.pdf,2018-11-08,2018,False,original petition,"Jill H. Osborne, founder of the Interstitial Cystitis Network (IC Network)",individual,"- General reference to statutory authority under the Federal Food, Drug, and Cosmetic Act (specific provisions not filled in the form)
- 21 C.F.R. ¬ß¬ß 25.30‚Äì25.34 or 25.40 (environmental impact)","The petition urges the FDA to investigate and issue an alert concerning the possible link between long-term use of Pentosan Polysulfate (Elmiron) and macular disease, particularly pigmentary maculopathy.
","The petitioner requests that the FDA:
- Investigate the association between Elmiron and macular disease
- Issue an alert informing patients of vision risks
- Advise patients to monitor their vision and consider annual eye exams
- Recommend cessation of the drug if retinal disease is identified
- Suggest that patients consider alternative bladder therapies","- Cites a study published in Ophthalmology (May 2018) by Emory Eye Center identifying a unique pigmentary maculopathy in 6 women using Elmiron long-term (12‚Äì20 years)
- Reports from the IC Network‚Äôs patient survey (n=753) showed that 53% reported eye or retinal illnesses, including difficulty reading, blurry vision, and dimming vision
- Cited concerns that Elmiron‚Äôs toxicity may manifest only after chronic exposure, possibly being underrecognized due to misdiagnosis as age-related macular degeneration or other eye diseases
- Notes that an early Elmiron clinical trial of 2,499 patients already listed optic neuritis, amblyopia, and retinal hemorrhage as adverse events
- The goal is early recognition and prevention of vision loss or blindness among Elmiron users",2019-05-07 00:00:00,Denied,2021-05-24,1.0,"Center for Drug Evaluation and Research (CDER)
","Not explicitly cited in terms of legal statutes or CFR sections; references to labeling changes and approval documents include:
- NDA 20193
- sNDA 20193/S-14
- Labeling updates approved June 16, 2020 (link)
- FDA drug safety communication draft guidance: Drug Safety Information‚ÄîFDA‚Äôs Communication to the Public (for internal policy context, not a statute)","The FDA has not yet resolved the issues due to the need to address other Agency priorities and resource constraints. The interim response is provided under FDA regulations regarding citizen petitions and commits to responding as soon as possible.

","- The petition requested warnings about retinal disease linked to Elmiron (pentosan polysulfate sodium) and recommendations for alternative therapies.
- FDA reviewed a range of data, including:
- The Pearce study on pigmentary maculopathy
- A user-conducted survey
- FDA's internal adverse event and utilization databases
- FDA acknowledged an association between long-term Elmiron use and pigmentary retinal changes, with uncertain visual outcomes.
- As of June 16, 2020, FDA approved labeling revisions that addressed most of the petition's concerns, including detailed warnings and monitoring recommendations.
- The request to recommend other therapies was denied because Elmiron is the only FDA-approved oral treatment for IC and such decisions are best left to physician-patient discussions.",denied,True,928.0,CDER,CDER
fda-2018-p-4338,FDA-2018-P-4338-0001_Citizen_Petition_from_PMRS.pdf,2018-11-13,2018,False,original petition,"Pharmaceutical Manufacturing Research Services, Inc. (PMRS)",advocacy/academic,"- 505(q) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 10.30 (citizen petition procedures)","FDA‚Äôs prior approval of Voxzogo (morphine sulfate extended-release) oral tablets, and related labeling and risk management practices for opioid analgesics. PMRS comments on the misalignment between its own efforts to commercialize a morphine sulfate ER product with abuse-deterrent features and the FDA‚Äôs regulatory actions.
","PMRS requests that the FDA:
- Revoke the approval of current non-abuse-deterrent formulations of morphine sulfate extended-release (ER) tablets
- Require abuse-deterrent labeling and technology for all ER opioid formulations
- Reconsider PMRS‚Äôs ANDA (Abbreviated New Drug Application) for an abuse-deterrent morphine sulfate ER product","- PMRS argues that continued approval of non-abuse-deterrent ER opioids undermines public health, especially amidst the opioid crisis
- PMRS developed a product with validated abuse-deterrent properties (e.g., extraction resistance and deterrence to IV and nasal abuse)
- Claims unfair treatment and inconsistency in FDA‚Äôs actions approving other manufacturers‚Äô less secure products while rejecting or stalling PMRS‚Äôs ANDA
- Points to FDA‚Äôs own policies and guidance that emphasize the transition to abuse-deterrent opioid products as a strategy to reduce misuse and diversion",,Denied,2019-04-12,0.0,"Center for Drug Evaluation and Research (CDER)
","- Section 505(b), 505(j), and 505(q)(1)(F) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- 21 CFR 314.105, 314.125, 314.127, 314.110, 314.200
- SUPPORT Act (Pub. L. 115-271, 132 Stat. 3894), particularly Section 3041",,"- FDA is required to take final action on petitions within 150 days under section 505(q)(1)(F), but this does not require them to make a final determination on an NDA.
- No final determination has been made regarding the approvability of NDA 209774 (MNK-812), so FDA denies the petition‚Äôs requests without comment.
- The petition repeated arguments from previous petitions (e.g., Remoxy ER), which were already denied.
- FDA maintains that decisions on the approvability of drug applications must follow the established review process under the FD&C Act and FDA regulations, not be made piecemeal.
- FDA continues to consider long-term use issues raised in other ongoing petitions, but this does not warrant separate action here.",denied,True,150.0,CDER,CDER
fda-2018-p-4340,FDA-2018-P-4340-0001_Citizen_Petition_from_Freyr_Inc_.pdf,2018-11-14,2018,False,original petition,Freyr Inc.,industry/corporation,"- Section 505(j)(2)(C) of the FD&C Act
- 21 C.F.R. ¬ß¬ß 10.20, 10.30, 314.93 (citizen petition and ANDA suitability regulations)
- 21 C.F.R. ¬ß 25.31 (environmental impact ‚Äì categorical exclusion)","FDA‚Äôs regulatory stance on the suitability of a Tigecycline for Injection, 50 mg/vial formulation containing 82.6 mg of arginine as a stabilizer, which differs from the Reference Listed Drug (RLD) TYGACIL (which uses lactose monohydrate).",- Determine that the proposed Tigecycline formulation (with 82.6 mg of arginine) is suitable for submission as an ANDA (Abbreviated New Drug Application) under Section 505(j).,"- The proposed formulation uses the same Q1/Q2 composition as another FDA-approved equivalent product: FK‚Äôs (Fresenius Kabi) Tigecycline for Injection, 50 mg/vial (NDA 205645)
- FDA has previously approved pharmaceutical equivalents containing arginine (e.g., NDA 205645 by FK and NDA 211158 by Amneal)
- The proposed product would be pharmaceutically equivalent to these approved alternatives, and no new clinical investigations are required to establish safety or efficacy
- The product is a sterile parenteral injection intended for intravenous infusion, following FDA‚Äôs guidance for ANDA submissions",,,2025-10-15,0.0,,,,,no decision,False,2527.0,pending,pending
fda-2018-p-4454,FDA-2018-P-4454-0001_Citizen_Petition_from_Bonumose_LLC.pdf,2018-11-19,2018,False,original petition,Bonumose LLC,industry/corporation,"- 21 C.F.R. ¬ß 10.30 (citizen petition regulation)
- 21 C.F.R. ¬ß 170.30 (GRAS notification)
- 21 U.S.C. ¬ß 321(s) (definition of ‚Äúfood additive‚Äù)
- 21 U.S.C. ¬ß 348 (regulation of food additives)","FDA's handling of Generally Recognized as Safe (GRAS) notifications, specifically the lack of response or objections to certain GRAS notices regarding new low-calorie sugars such as tagatose.
","- Promptly respond to GRAS Notices, particularly GRN 765 (regarding tagatose)
- Affirmatively state that the use of tagatose in food is GRAS, based on scientific procedures
- Streamline the GRAS review process and increase transparency in reviewing GRAS notifications","- Tagatose is a naturally occurring, low-calorie sweetener with recognized safety and physiological benefits (e.g., low glycemic index, prebiotic effects)
- FDA‚Äôs failure to respond to GRN 765 (submitted March 2018) causes uncertainty and delays for food companies seeking to use tagatose
- Bonumose cites multiple published scientific studies supporting the safety of tagatose
- The petition emphasizes that FDA‚Äôs GRAS process lacks timely engagement, impacting innovation and public health benefits of healthier alternatives",2019-05-17 00:00:00,Denied,2021-06-11,2.0,"Center for Food Safety and Applied Nutrition (CFSAN)
","- 21 CFR ¬ß 101.9(c)(6)(i)
- 21 CFR ¬ß 101.9(c)(6)(ii)-(iii)
- 21 CFR 101.80(c)(2)(ii)
- 21 CFR 10.30(e)(3)
- 21 U.S.C. ¬ß 343(q)(1)(D)","The FDA stated it was unable to reach a decision within 180 days of receipt of the petition due to other agency priorities and limited resources. They assured that the review would be completed and regulatory amendments considered as warranted, within the context of CFSAN's other program priorities.

","- The petition sought to: (a) amend the definition of dietary fiber to include small carbohydrates like D-tagatose, (b) classify D-tagatose as a dietary fiber, and (c) amend the definitions of total and added sugars.

- The FDA denied the requests for the following reasons:
‚Ä¢ There is no new scientific evidence sufficient to support amending the definition of dietary fiber (which includes non-digestible carbohydrates with 3+ monomeric units).
‚Ä¢ The petition does not provide new data demonstrating physiological effects of D-tagatose that would support its inclusion.
‚Ä¢ FDA's existing definition aligns with international guidelines and IOM recommendations.
‚Ä¢ There is a lack of consensus and consistent scientific basis for including monosaccharides like D-tagatose as dietary fiber.
‚Ä¢ FDA emphasized that the dietary fiber definition is science-based, not method-dependent, and they see no valid justification to change the ""3 or more monomeric units"" criterion.
‚Ä¢ FDA also did not support redefining total or added sugars to exempt beneficial sugars like D-tagatose.
‚Ä¢ However, FDA did acknowledge that further information may be needed and published a Request for Information (RFI) for public comment to explore sugars metabolized differently from traditional sugars (e.g., D-tagatose, allulose).",denied,True,935.0,CFSAN,Other/Specialty Center
fda-2018-p-4490,FDA-2018-P-4490-0001_Citizen_Petition_from_Hyman__Phelps___McNamara__P_.pdf,2018-11-21,2018,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"- 21 C.F.R. ¬ß 10.30 (citizen petition procedures)
- Section 505(j) of the FD&C Act (ANDA process)
- References to FDA‚Äôs Orange Book Preface and ANDA suitability petition requirements","FDA's regulatory pathway concerning approval of an ANDA for a generic version of a drug product that differs from the reference listed drug (RLD) in both dosage form and strength
","The petitioner requests that FDA:
- Refuse to approve any ANDA that differs in dosage form and strength from the RLD unless a suitability petition has first been approved
- Reiterate and enforce its requirement that ANDAs comply with statutory limitations and established preface guidance","- Approving ANDAs with differences in dosage form and strength without a suitability petition is inconsistent with statutory and regulatory provisions
- Such approvals may pose risks to public health and undermine regulatory integrity
- Past FDA statements and the Orange Book Preface affirm that both dosage form and strength must match unless a suitability petition is granted
- Preventing circumvention of proper procedures ensures fair competition and compliance with the law",,Denied,2019-03-29,0.0,"Center for Drug Evaluation and Research (CDER)
","- Section 505(b), (c)(1)(A), and (d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 355)
- 21 CFR 314.125(b)
- 21 CFR 314.126
- 21 CFR 201.57
- 21 CFR 201.100(c)(1) ",,"- Substantial Evidence: The FDA found that the original clinical trials provided substantial evidence of efficacy for the target population (adult women <65 with IBS-C). Post hoc subgroup analyses confirmed similar efficacy in this subgroup.
- CV Risk Considerations: The FDA concluded that cardiovascular risks could be mitigated through labeling (e.g., contraindications, warnings) and did not warrant REMS or use restrictions.
- No Need for New Trials: Existing data, even if based on earlier standards (e.g., Rome II criteria), remain clinically meaningful and relevant. A new postmarketing trial was deemed unnecessary.
- Labeling Sufficiency: The FDA stated the labeling adequately communicates the limitations and risks, and additional strategies like REMS were not warranted. ",denied,True,128.0,CDER,CDER
fda-2018-p-4549,FDA-2018-P-4549-0001_Citizen_Petition_from_Unichem_Pharmaceuticals__USA.pdf,2018-11-28,2018,False,original petition,Unichem Pharmaceuticals (USA) Inc.,industry/corporation,"- 21 C.F.R. ¬ß 10.25(a)
- 21 C.F.R. ¬ß 10.30 (citizen petition procedures)
- Section 505(j) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 25.31 (environmental impact exclusion)","FDA‚Äôs designation of a Reference Standard (RS) for Terbinafine Tablets, 250 mg, specifically the continued listing of LAMISIL¬Æ by Novartis as the RS, which is no longer available in the market.
","The petitioner requests that FDA:
- Designate an additional reference standard (RS) for Terbinafine Tablets in the Orange Book
- Preferably, designate Aurobindo Pharma‚Äôs product (ANDA 078297) as the RS due to its market leadership and availability","- The currently designated RS (LAMISIL¬Æ) is unavailable in the market, preventing required bioequivalence (BE) testing
- FDA guidance (Referencing Approved Drug Products in ANDAs) allows a new RS designation if the existing RS is inaccessible
- IMS sales data shows that Aurobindo‚Äôs product is the market leader among three available generic Terbinafine Tablets
- Designating a new RS will enable generic development and ANDA submission",2019-05-23 00:00:00,Approved,2020-04-28,1.0,"Center for Drug Evaluation and Research (CDER)
","- Section 505(j) of the FD&C Act (21 U.S.C. 355(j))
- 21 CFR 314.3(b)
- 21 CFR 314.94(a)(3)
- 21 CFR 314.161(a)(1)
- 21 CFR 314.122(c)
- 21 CFR 314.127(a)(11)","The FDA stated that it had not yet resolved the issues raised in the petition due to the complex nature of the request, which required extensive review and analysis by Agency officials. The petition asked the Agency to designate an additional reference standard for Terbinafine Tablets in the Orange Book to support ANDA submissions.

","- The original reference standard (Lamisil, NDA 020539 by Novartis) is no longer available on the market.
- Aurobindo‚Äôs ANDA 078297 product became the market leader between April‚ÄìJune 2019.
- It is therapeutically equivalent (coded ""AB"" in the Orange Book).
- FDA found it appropriate to select Aurobindo‚Äôs product as the new reference standard for bioequivalence studies.",approved,True,517.0,CDER,CDER
fda-2018-p-4590,FDA-2018-P-4590-0001_Citizen_Petition_from_Ascend_Laboratories__LLC.pdf,2018-11-30,2018,False,original petition,"Ascend Laboratories, LLC",advocacy/academic,"- 21 C.F.R. ¬ß¬ß 10.25, 10.30 (citizen petition procedures)
- Sections 505(j) and 505(w) of the FD&C Act
- 21 C.F.R. ¬ß¬ß 314.122 and 314.161 (drug listing and withdrawal)
- 21 C.F.R. ¬ß 25.31 (environmental impact categorical exclusion)","FDA/DEA scheduling of cannabidiol (CBD) drug products, specifically the classification of synthetic CBD formulations like that proposed by Alkem as Schedule V controlled substances, consistent with the innovator drug Epidiolex.
","Ascend requests that the FDA/DEA:
- Assign Schedule V status to a generic version of Epidiolex (cannabidiol oral solution 100 mg/mL) manufactured using synthetic CBD
- Confirm its eligibility for ANDA (Abbreviated New Drug Application) submission","- The reference listed drug Epidiolex (approved June 25, 2018, NDA 210365) was rescheduled from Schedule I to Schedule V due to low abuse potential
- The proposed synthetic CBD formulation avoids contamination by tetrahydrocannabinols (THC) and results in equal or higher purity than natural CBD
- Synthetic route offers further reduced psychotropic THC content, minimizing abuse risk even more than the innovator‚Äôs product
- DEA precedent and Federal Register notice (Docket No. DEA‚Äì486) allow Schedule V designation for FDA-approved CBD products with ‚â§ 0.1% THC content",,Denied,2019-05-22,0.0,"Center for Drug Evaluation and Research (CDER)
","- Controlled Substances Act (CSA)
- 21 CFR ¬ß 1308/1308.43 (DEA petition process)
- 83 FR 48950 (DEA Final Order, Sep. 28, 2018)",,"- The DEA‚Äôs final order (Sep. 28, 2018) covers only FDA-approved drugs that contain CBD derived from cannabis with ‚â§0.1% THC, and places those in Schedule V.
- Petitioner's request was for a generic version of Epidiolex using synthetic CBD.
- Synthetic CBD is not covered under the DEA‚Äôs existing order.
- FDA stated that DEA is the proper authority for scheduling actions and advised petitioner to submit the request to DEA.",denied,True,173.0,CDER,CDER
fda-2018-p-4591,FDA-2018-P-4591-0001_Citizen_Petition_from_International_Maple_Syrup_In.pdf,2018-11-01,2018,False,original petition,International Maple Syrup Institute,advocacy/academic,"- 21 C.F.R. ¬ß 168.140 (Standard of Identity for Maple Sirup)
- Environmental references to 21 C.F.R. ¬ß¬ß 25.30, 25.31, 25.32, 25.33, 25.34, and 25.40","The petition seeks amendment of the Standard of Identity (SOI) for maple syrup currently defined under 21 C.F.R. ¬ß 168.140.
","The petitioner requests the FDA to:
- Revise the definition of pure maple syrup in ¬ß168.140(a)
- Remove optional ingredients listed in ¬ß168.140(b), including salt and chemical preservatives
- Eliminate the term ‚ÄúMaple Sirup‚Äù from the regulation and consistently use ‚ÄúMaple Syrup‚Äù","- The current federal definition is outdated and inconsistent with modern state-level maple syrup regulations
- A standardized North American definition is needed to support Codex certification
- Salt and chemical preservatives are no longer used in the industry; defoaming agents are processing aids, not ingredients
- Ensures the purity and integrity of maple syrup
- No anticipated opposition from public or industry stakeholders",,,2025-10-15,0.0,,,,,no decision,False,2540.0,pending,pending
fda-2018-p-4642,FDA-2018-P-4642-0001_Citizen_Petition_from_Provetica_Animal_Health_LLC.pdf,2018-11-20,2018,False,original petition,Provetica Animal Health LLC,industry/corporation,"- Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act (FFDCA)
- 21 C.F.R. ¬ß 10.30 (citizen petition procedures)
- 21 C.F.R. ¬ß 25.30(h) (categorical exclusion from environmental assessment)
- 21 C.F.R. ¬ß 25.21 (environmental impact)","FDA‚Äôs determination of suitability for a generic animal drug application (ANADA) for a different dosage form than the approved reference listed drug, Atopica‚Ñ¢ (cyclosporine capsules).
","The petitioner requests that FDA:
- Determine that an Abbreviated New Animal Drug Application (ANADA) is suitable for a non-encapsulated oral solution of cyclosporine that differs in dosage form from the reference listed drug (a capsule)","- The reference drug (Atopica‚Ñ¢) is a gelatin capsule containing cyclosporine; the proposed generic is a non-encapsulated oral solution
- The petition references a previously approved suitability petition (FDA-2017-P-6968) for the same dosage change, approved by FDA on March 14, 2018
- The proposed generic matches the reference product in active ingredient, strength, administration route, and labeled dose
- The solution offers dose flexibility and may improve ease of administration for veterinarians and pet owners
- The product will be provided in calibrated dosing syringes and multiple bottle sizes to match therapeutic needs
- Labeling will align with the reference product categories and instructions",,Approved,2019-02-21,0.0,"Center for Veterinary Medicine (CVM)
","- Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act
- Section 512(n)(3)(C) of the Act
- 21 CFR 514.5",,"- The proposed changes (dosage form: oral solution instead of capsules) can be considered under a suitability petition.
- The changes do not require new investigations to demonstrate safety and effectiveness.
- The petition meets the criteria of section 512(n)(3)(C) of the FD&C Act for approval of a suitability petition.
- Approval of the petition allows submission of an abbreviated new animal drug application (ANADA), but does not guarantee approval of the ANADA itself.",approved,True,93.0,CVM,Other/Specialty Center
fda-2018-p-4656,FDA-2018-P-4656-0001_Citizen_Petition_from_Animal_Legal_Defense_Fund.pdf,2018-12-06,2018,False,original petition,Animal Legal Defense Fund,law/consulting,"- 21 C.F.R. ¬ß 10.35 (petition to stay action)
- 21 C.F.R. ¬ß 10.31 (certification)
- Federal Food, Drug, and Cosmetic Act (FFDCA) ‚Äì 21 U.S.C. ¬ß 360b(d), ¬ß 360b(i)
- Administrative Procedure Act (APA)
- National Environmental Policy Act (NEPA) ‚Äì 42 U.S.C. ¬ß 4332(2), 40 C.F.R. ¬ß¬ß 1508.8, 1508.25, 1508.27, 1502.14
- Endangered Species Act (ESA) ‚Äì 16 U.S.C. ¬ß 1536(a)(2), (c)(1); 50 C.F.R. ¬ß 402.01(b), ¬ß 402.12(c)","Approval of New Animal Drug Application (NADA) 141-508 for Experior‚Ñ¢ (lubabegron) and its associated Environmental Assessment (EA) and Finding of No Significant Impact (FONSI)
","Stay the FDA‚Äôs approval of NADA 141-508 (Experior‚Ñ¢) for an indefinite duration unless and until the FDA complies with applicable laws (APA, FFDCA, NEPA, ESA)
","The ALDF alleges several legal and scientific deficiencies:
- Failure to publish notice of approval in the Federal Register as required by the FFDCA
- Approval of a drug not proven safe or effective under the FFDCA
- Public health risks due to the drug‚Äôs impact on animal behavior and meat safety
- Failure to evaluate reasonable alternatives, cumulative effects, or impacts on animal health under NEPA
- No consultation with wildlife agencies as required by ESA
- Issuance of a FONSI despite acknowledged environmental uncertainties and omissions regarding groundwater contamination risks and manure management",,Denied,2019-05-20,0.0,Center for Veterinary Medicine (CVM),"- 21 CFR 10.35(e) (Petitions for stay of action)
- 21 U.S.C. ¬ß 512 (Federal Food, Drug, and Cosmetic Act - FFDCA)
- 21 CFR 514.4 (Substantial evidence of effectiveness)
- National Environmental Policy Act (NEPA)
- Endangered Species Act (ESA)
- 40 CFR 1508.27(b)(1), (b)(9)
- 50 CFR 402.03",,"- The petition did not meet the necessary criteria under 21 CFR 10.35 to justify a stay of action.
- FDA concluded the petition failed to demonstrate irreparable harm, serious public health concern, or substantial legal violations.
- FDA affirmed that it complied with all applicable legal and regulatory requirements in the approval of Experior‚Ñ¢ (a beta-agonist for cattle) including the FFDCA, NEPA, and ESA.
- Detailed studies demonstrated safety to target animals, food safety, human safety, and environmental impact.
- FDA's issuance of a Finding of No Significant Impact (FONSI) was justified based on a comprehensive Environmental Assessment.
- No additional Environmental Impact Statement was warranted, and the analysis included effects on threatened and endangered species.
- Assertions made by the petition lacked adequate evidence or were speculative.",denied,True,165.0,CVM,Other/Specialty Center
fda-2018-p-4661,FDA-2018-P-4661-0001_Citizen_Petition_from_Hyman__Phelps___McNamara__P_.pdf,2018-12-06,2018,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"- 21 C.F.R. ¬ß 10.25(a) and 10.30 (citizen petition procedures)
- Section 505(j) of the FDCA (ANDA requirements)
- 21 C.F.R. ¬ß 314.3 (definitions, including listed drug)
- 21 C.F.R. ¬ß 25.31 (categorical exclusion from environmental assessment)
- 21 C.F.R. ¬ß 10.30(b) (economic impact information)","FDA‚Äôs designation of the reference standard (RS) for Diclofenac Potassium Tablets, 50 mg under ANDA 075463, which is reportedly commercially unavailable.
","The petitioner requests that the FDA:
- Designate ANDA 075219 (also for Diclofenac Potassium Tablets, 50 mg) as a new reference standard (RS)
- Update the Orange Book to reflect this new designation","- The currently designated RS (ANDA 075463) is not commercially available, and its manufacturer is subject to an FDA Warning Letter for GMP violations
- Without an available RS, new generic applicants cannot conduct bioequivalence testing, effectively blocking competition
- An alternative ANDA (075219) is available and suitable to serve as a RS
- The original RLD (CATAFLAM) is discontinued but was not withdrawn for safety or effectiveness reasons
- Designating ANDA 075219 as a RS will restore a pathway for ANDA submissions and generic competition",2019-05-31 00:00:00,Dismissed (moot),2019-10-16,1.0,Center for Drug Evaluation and Research (CDER),"The Orange Book is referenced (Approved Drug Products With Therapeutic Equivalence Evaluations); specific statutes or regulations are not cited directly in the document.
","The FDA has not reached a decision due to the need to prioritize other agency matters. The interim response is issued under FDA regulations to inform the petitioner that a final decision is pending due to numerous demands on the Agency‚Äôs resources.

","The petition was dismissed because the FDA determined that the distribution of the current reference standard (diclofenac potassium tablets, 50 mg, approved under ANDA 075463) resumed after the petition was filed.

",dismissed (moot),True,314.0,CDER,CDER
fda-2018-p-4714,FDA-2018-P-4714-0001_Citizen_Petition_from_TherapeuticsMD__Inc_.pdf,2018-12-11,2018,False,original petition,"TherapeuticsMD, Inc.",industry/corporation,"- 21 C.F.R. ¬ß 10.30 (citizen petition procedures)
- 21 U.S.C. ¬ß 355(b)(1) (drug approval provisions)
- 21 C.F.R. ¬ß¬ß 314.50, 314.94, 314.105, 314.127, and 320.22(b) (NDA/ANDA requirements and bioequivalence waivers)
- Section 505(b)(2) of the FDCA (application type used by the petitioner)
- 21 C.F.R. ¬ß 25.31(b) (categorical exclusion for environmental assessment)","FDA‚Äôs potential approval of ANDAs for generic versions of Imvexxy¬Æ (estradiol vaginal inserts) without requiring in vivo bioequivalence studies that include clinical evaluation of local estrogenic effects, particularly vaginal cytology parameters.","TherapeuticsMD requests the FDA to:
- Refuse to approve any ANDA referencing Imvexxy¬Æ unless it includes data showing therapeutic equivalence and local effects on vaginal tissue
- Require that such ANDAs include clinical data demonstrating local efficacy in treating dyspareunia due to VVA","- Imvexxy¬Æ delivers very low doses of estradiol directly to vaginal tissue, leading to localized effects, with minimal systemic absorption
- Bioequivalence based solely on systemic exposure (pharmacokinetics) would be insufficient to ensure therapeutic equivalence for a locally acting drug
- FDA precedent (e.g., Vagifem¬Æ) shows that local clinical efficacy data may be required
- Without local-effect data, generic products may not reliably deliver the same therapeutic benefit, particularly in treating dyspareunia
- Risk of inappropriate approval could compromise patient outcomes and public trust in regulatory oversight",2019-06-10 00:00:00,,2025-10-15,1.0,,,"The FDA has not yet resolved the issues raised because the petition raises complex issues requiring extensive review and analysis by Agency officials. The interim response was issued in accordance with FDA regulations on citizen petitions to acknowledge the petition within a specified timeframe.

",,no decision,False,2500.0,pending,pending
fda-2018-p-4812,FDA-2018-P-4812-0001_Citizen_Petition_from_Arent_Fox_LLP.pdf,2018-12-19,2018,False,original petition,Arent Fox LLP,law/consulting,"- 21 C.F.R. ¬ß¬ß 10.25(a), 10.30(b), 314.161, 314.122, 314.162
- Section 505(j) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 25.31 (Environmental impact - categorical exclusion)
- 21 C.F.R. ¬ß 25.40 (Environmental assessment)","The FDA‚Äôs listing of Nizoral¬Æ (Ketoconazole 2% topical cream, NDA No. N019084) in the Discontinued Section of the Orange Book without determining whether it was withdrawn for reasons of safety or effectiveness
","The petitioner requests the FDA to determine whether Nizoral¬Æ (Ketoconazole 2% topical cream, NDA N019084) has been voluntarily withdrawn from the market for safety or effectiveness reasons
","- NDA 019084 (Nizoral Cream) is still listed as the Reference Listed Drug (RLD) in the Orange Book.
- ANDA applicants need clarity on whether the product was withdrawn for regulatory or commercial reasons.
- A prior FDA denial of a similar citizen petition (FDA-2017-P-3468) indicates Teva‚Äôs ANDA is still in distribution, and FDA acknowledged Nizoral was moved to the discontinued section but did not clarify if for safety or effectiveness.
- The petitioner is unaware of any safety or efficacy issues leading to discontinuation",,Denied,2019-06-11,0.0,Center for Drug Evaluation and Research (CDER),"Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book); reference to the Federal Register notice
",,"FDA reviewed records and determined that Nizoral (Ketoconazole) topical cream, 2% was not withdrawn for reasons of safety or effectiveness. As a result, the drug will remain listed in the ‚ÄúDiscontinued Drug Product List‚Äù section of the Orange Book, meaning it may still serve as a reference product for generic applications. 

",denied,True,174.0,CDER,CDER
fda-2018-p-4832,FDA-2018-P-4832-0001_Citizen_Petition_from_Goodwin_Procter_LLP__on_beha.pdf,2018-12-21,2018,False,original petition,Goodwin Procter LLP,law/consulting,"- Federal Food, Drug, and Cosmetic Act (FD&C Act)
- 21 C.F.R. ¬ß¬ß 10.25, 10.30, 10.31, 314.70
- 21 C.F.R. ¬ß 314.3(b)
- 21 C.F.R. ¬ß 314.125(a)(4)
- 21 C.F.R. ¬ß 25.31
- Section 505(d)(4) of the FD&C Act, 21 U.S.C. ¬ß 355(d)(4)","- FDA's assignment of AB2 therapeutic equivalence rating to Euthyrox (levothyroxine sodium)
- FDA‚Äôs potential approval of supplemental NDAs for bulk/loose packaging of non-color-coded Euthyrox tablets","- Rescind AB2 ratings for Euthyrox in the Orange Book and assign BX ratings instead
- Refrain from approving any sNDAs for Euthyrox that allow bulk or loose packaging of non-color-coded tablets without sufficient safety data","- Euthyrox is a narrow therapeutic index (NTI) drug requiring precise dosage
- All dosage strengths of Euthyrox tablets are off-white, unlike other levothyroxine products that use color coding to differentiate strengths
- Risk of ‚Äúlook-alike‚Äù medication errors due to lack of color differentiation, especially if separated from original blister packaging
- Patient safety may be compromised, with potential for underdosing or overdosing
- FDA itself previously recommended color differentiation and acknowledged risks of color similarity in NTI drugs",2019-06-17 00:00:00,Denied,2024-10-02,1.0,Center for Drug Evaluation and Research (CDER),"- Section 505(b)(2) of the FD&C Act
- 21 CFR ¬ß 314.3(b) (definitions, including pharmaceutical equivalents)
- Orange Book Preface references (e.g., 43rd and 44th editions)
- FDA Guidance for Industry:
- Levothyroxine Sodium Products Enforcement of August 14, 2001 Compliance Date (July 2001)
- Levothyroxine Sodium Tablets‚ÄîIn Vivo Pharmacokinetic and Bioavailability Studies and In Vitro Dissolution Testing (Dec. 2000)
- Applications Covered by Section 505(b)(2) (Oct. 1999)
- Safety Considerations for Container Labels and Carton Labeling Design to Minimize Medication Errors (May 2022)","The FDA has not yet resolved the issues raised in the petition because it involves complex issues that require extensive review and analysis by Agency officials. The interim response is issued per 21 CFR 10.30(e)(2).

","- FDA reviewed and considered the color-coded blister packaging and determined it was sufficient to mitigate risks of medication errors, despite the lack of coloring on the tablets themselves.
- The Agency reviewed postmarketing safety data and found only two cases referencing tablet confusion, neither involving adverse events.
- FDA concluded the TE (Therapeutic Equivalence) code ""AB2"" was appropriate based on demonstrated bioequivalence with the reference listed drugs (RLDs).
- FDA emphasized that pharmaceutical equivalents may differ in tablet color and still meet bioequivalence standards.
- The request to prevent approval of future supplemental NDAs related to bulk packaging was denied, as these are reviewed on a case-by-case basis.",denied,True,2112.0,CDER,CDER
fda-2018-p-4851,FDA-2018-P-4851-0001_Citizen_Petition_from_Hetero_Labs_Limited.pdf,2018-12-20,2018,False,original petition,Hetero Labs Limited,advocacy/academic,"- 21 C.F.R. ¬ß 10.30 (Citizen Petition procedure)
- 21 C.F.R. ¬ß 314.161 (Determination of withdrawal for safety/effectiveness)
- 21 C.F.R. ¬ß 314.162 (Procedures for withdrawn drugs)
- 21 C.F.R. ¬ß 25.31 (Environmental impact exclusion)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact info provision)","- Listing of Lupron¬Æ (Leuprolide Acetate) NDA 019010 in the Discontinued Section of the FDA Orange Book
- Lack of FDA determination on whether it was withdrawn for safety or effectiveness reasons","- That the FDA determine Lupron¬Æ (Leuprolide Acetate), NDA 019010, was not withdrawn for safety or effectiveness reasons
- That FDA publish this determination in the Federal Register and annotate the Orange Book accordingly","- Public searches yielded no evidence that Abbvie Endocrine Inc. withdrew Lupron¬Æ for safety or efficacy issues
- The drug is currently listed in the Discontinued Section but lacks an annotation clarifying that it was not withdrawn for safety/effectiveness
- There are no court decisions regarding product liability linked to this product
- Hetero seeks FDA confirmation to support an ANDA referencing Lupron¬Æ as the RLD
",,Approved (Determination Issued),2019-05-30,0.0,Center for Drug Evaluation and Research (CDER),"- Approved Drug Products With Therapeutic Equivalence Evaluations (the Orange Book)
- Federal Register notice (enclosure referenced)",,"The FDA reviewed records and determined that Lupron (1 mg/0.2 mL) was not withdrawn for reasons related to safety or efficacy. Therefore, the product should remain listed appropriately in the Orange Book under the discontinued section.

",approved,True,161.0,CDER,CDER
fda-2019-p-0417,FDA-2019-P-0417-0001_Citizen_Petition_from_Scilex_Pharmaceuticals_Inc.pdf,2018-12-28,2019,False,original petition,"Scilex Pharmaceuticals, Inc.",industry/corporation,"21 U.S.C. ¬ß¬ß 321, 352, 355
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. Part 330 and ¬ß 330.13(e)
- 21 C.F.R. ¬ß 330.14
- 21 C.F.R. ¬ß¬ß 348.10, 348.12, 348.20
- 21 U.S.C. ¬ß 321(p)
- 21 U.S.C. ¬ß 352(p)
- 21 C.F.R. ¬ß 25.31
- 16 C.F.R. ¬ß 1700.14(a)(23) and ¬ß 1700.15","Scilex comments on FDA‚Äôs continued exercise of enforcement discretion that allows unapproved, over-the-counter lidocaine patch products to remain on the market and on the unfinished External Analgesics Tentative Final Monograph (TFM).","1. Remove all unapproved lidocaine patch products from the market.
2. Apply strictly the NDA/ANDA and OTC-monograph provisions to lidocaine patches marketed after 1972.
3. Finalize the External Analgesics TFM (explicitly excluding patches).
4. Issue immediate enforcement-policy guidance stating such patches are violative.
5. Monitor listings/marketplace and take ongoing administrative or judicial action against violators.","Safety risks: Patch dosage forms can deliver unpredictable systemic lidocaine levels, especially with heat, exercise, large sizes, or high residual drug, posing risks such as methemoglobinemia and cardiotoxicity.
- Efficacy uncertainty: No data show OTC patches formulated at ‚â§ 4 % provide reliable pain relief; adhesion and drug-delivery performance are untested.
- Regulatory gap: Patches were never evaluated in the OTC review; FDA itself proposed excluding them in 2003, yet they proliferate under a ‚Äúmonograph‚Äù guise.
- Labeling & ingredient concerns: Current products omit warnings, use unqualified excipients, and may lack child-resistant packaging, leading to misbranding and exposure hazards.",2019-06-28 00:00:00,"Denied
‚Äì The FDA denied the citizen petition because the requested regulatory actions concerning lidocaine-containing OTC patch products should instead be submitted through a newly defined process under the OTC Monograph Reform (OMOR).",2022-12-14,1.0,Center for Drug Evaluation and Research (CDER),"Section 505G of the FD&C Act (21 U.S.C. ¬ß 355h)
- Section 503(b)(1) (21 U.S.C. ¬ß 353(b)(1))
- Section 201(p)(1) (21 U.S.C. ¬ß 321(p)(1))
- Section 505G(b)(5) and (q)(3)
- Section 744L(7) (21 U.S.C. ¬ß 379j-71(7))","The petition requested FDA to take action to prevent the marketing of unapproved lidocaine-containing drug products in patch, plaster, poultice, or similar forms.
- FDA has not completed its review because the petition raises complex issues that require extensive review and analysis by agency officials.","FDA noted that the enactment of the CARES Act (March 2020) introduced a new framework for evaluating OTC drug monographs under section 505G.
- Because Scilex requested relief consistent with an OTC monograph order, the correct pathway is through an OMOR (Over-the-Counter Monograph Order Request), not a citizen petition.
- Therefore, the petition was denied as procedurally inappropriate, though FDA provided guidance on how to pursue the request through the OMOR process.",denied,True,1447.0,CDER,CDER
fda-2019-p-1893,FDA-2019-P-1893-0001_Citizen_Petition_from_Novartis_Pharmaceuticals_Cor.pdf,2019-04-18,2019,False,original petition,Novartis Pharmaceuticals Corporation (‚ÄúNovartis‚Äù),industry/corporation,"‚Ä¢ 21 U.S.C. ¬ß 355 (FD&C Act ¬ß 505) and 21 C.F.R. ¬ß 10.30 (citizen-petition rule) 

‚Ä¢ Section 505(j) of the FD&C Act (ANDA provisions) 

‚Ä¢ 21 C.F.R. ¬ß 314.3(b) (definitions) 

‚Ä¢ 21 C.F.R. ¬ß 314.92(a)(1) & ¬ß 314.94(a)(5) (ANDA ‚Äúsameness‚Äù requirements) 

‚Ä¢ 21 C.F.R. ¬ß 320.24(b)(1)(i) (bioequivalence studies) 

‚Ä¢ 21 C.F.R. ¬ß 320.22(d)(2) (in-vivo study waiver criteria)",FDA‚Äôs Draft Product-Specific Bioequivalence Guidance for sacubitril/valsartan tablets (April 2016) and related policies for approving ANDAs that reference ENTRESTO.,"1. Require every ANDA referencing ENTRESTO to demonstrate active-ingredient sameness, showing the 1 : 1 : 3 sacubitril : valsartan : sodium complex.
2. Revise the Draft Guidance to state explicitly that API sameness must be proven by establishing the identical chemical structure (including all ionic bonds) to the reference drug.
3. Further revise the Draft Guidance to: a) add sacubitrilat (LBQ657) as an additional analyte for bioequivalence; b) require assessment of the pharmacokinetics of sacubitril, sacubitrilat, and valsartan relative to one another; and c) mandate an additional in-vivo bioequivalence study for the 24 mg/26 mg strength.","Novartis argues that the Draft Guidance omits criteria needed to ensure generic products have the same complex chemical structure as ENTRESTO, fails to include the active metabolite sacubitrilat in BE testing, and allows waivers that could approve bio-inequivalent products‚Äîpotentially compromising safety and efficacy.",2019-10-15 00:00:00,Denied,2024-05-28,1.0,Center for Drug Evaluation and Research (CDER),"21 U.S.C. ¬ß 355(j) ‚Äì Abbreviated New Drug Applications (ANDAs)
- 21 CFR 314.127(a)(7) ‚Äì Conditions under which an ANDA may be refused
- 21 CFR 314.94(a)(9) ‚Äì Labeling requirements for ANDAs
- 21 CFR 314.3(b) ‚Äì Definitions (e.g., listed drug)","The petition raises complex issues concerning API (active pharmaceutical ingredient) sameness and bioequivalence guidance for sacubitril/valsartan (Entresto). FDA states that these issues require extensive review and analysis by agency officials, and thus a decision has not yet been reached.","Novartis requested FDA to: (1) not accept or approve any ANDAs for fingolimod (Gilenya) that omitted pediatric study information protected under exclusivity; and (2) to refuse labeling carve-outs under section 505(j) that would exclude such data.

- FDA disagreed, stating that the statute allows applicants to omit protected information from labeling, as long as their product remains safe and effective for use without it.

- FDA noted that it evaluates each ANDA on a case-by-case basis, and that ANDAs referencing Gilenya could exclude pediatric labeling if legally permissible and scientifically justified.

- FDA reiterated the long-standing policy and precedent supporting carve-outs under 21 U.S.C. ¬ß 355(j) and relevant regulations (21 CFR 314.94, 314.127).",denied,True,1867.0,CDER,CDER
fda-2019-p-2239,FDA-2019-P-2239-0001_Citizen_Petition_from_BioNeutra_North_America_Inc.pdf,2019-05-03,2019,False,original petition,BioNeutra North America Inc.,industry/corporation,"21 C.F.R. ¬ß 10.30 (citizen petition process)
- 21 C.F.R. ¬ß 101.9(c)(6)(i) (definition and labeling of dietary fiber)
- 21 C.F.R. ¬ß 25.32(p) (categorical exclusion from environmental impact) ","Existing regulatory exclusion of isomalto-oligosaccharides (IMO) from the list of recognized dietary fibers in 21 C.F.R. ¬ß 101.9(c)(6)(i), and a previous FDA denial of a 2016 petition for IMO‚Äôs inclusion",Amend 21 C.F.R. ¬ß 101.9(c)(6)(i) to include ‚Äúisomalto-oligosaccharides‚Äù in the list of recognized dietary fibers with beneficial physiological effects. ,"BioNeutra presents new human studies demonstrating that IMO improves laxation (stool frequency, fecal weight) in constipated individuals and may also reduce blood cholesterol. The petition argues that this qualifies IMO for inclusion as a dietary fiber under FDA‚Äôs criteria, based on physiological benefits supported by new evidence.",,Denied,2020-01-09,0.0,Center for Food Safety and Applied Nutrition (CFSAN),"21 CFR ¬ß 101.9(c)(6)(i) (Dietary fiber definition)
- 21 CFR 10.20(c)(2) (Translation requirements)
- 21 CFR 10.30(e)(3) (Citizen petition regulations)
- 83 FR 8997 (Final guidance on scientific evidence)
- 81 FR 33742 (Final rule on nutrition labeling)",,"The FDA denied the petition based on the following justifications:

a. Lack of New Evidence for Laxation:
- The current petition largely repeated data previously reviewed and rejected.
- Five studies cited for laxation effects were already assessed in the original denial; FDA concluded these studies did not show IMO independently improves laxation, especially given the use of enemas and laxatives during fecal collection periods, which compromised validity.

b. Insufficient Evidence for Blood Cholesterol Benefits:
- Out of five studies cited, three (including the only one conducted on a U.S.-like population) showed no significant impact of IMO on cholesterol levels.
- One study showed a positive result, but it involved hyperlipidemic teenagers, which FDA deemed less relevant.
- Another showed mixed results and used elderly nursing home residents, not representative of the general population.

c. Inconsistency and Lack of Robustness:
- The FDA stated that no plausible explanation reconciled the inconsistency between studies showing benefit and those showing none.
- Studies lacked adequate controls, statistical rigor, or generalizability to the U.S. population.

Therefore, the FDA concluded that IMO (isomaltooligosaccharides) did not meet the requirements to be listed as a dietary fiber based on the submitted evidence. They indicated willingness to review new petitions based on stronger scientific support in the future. ",denied,True,251.0,CFSAN,Other/Specialty Center
fda-2019-p-4830,FDA-2019-P-4830-0001_Citizen_Petition_from_Ipsen_Biopharmaceuticals__In.pdf,2019-10-15,2019,False,original petition,"Ipsen Biopharmaceuticals, Inc. (‚ÄúIpsen‚Äù)",industry/corporation,"21 C.F.R. ¬ß 10.30 (citizen petition process)
- 21 C.F.R. ¬ß 314.108 (market exclusivity)
- 21 U.S.C. ¬ß 355(j) (ANDA provisions)
- 21 U.S.C. ¬ß 355(c)(3)(E)(iii) and (iv) (exclusivity protections)
- FDCA ¬ß 505(j)",FDA‚Äôs potential approval of an ANDA referencing Somatuline Depot (lanreotide) that includes an intramuscular (IM) route of administration or a prefilled syringe presentation not previously approved.,"Request that FDA withhold approval of any ANDA referencing Somatuline Depot that seeks to include:
1. an intramuscular (IM) route of administration; or
2. a prefilled syringe presentation;
until the expiration of Ipsen‚Äôs statutory exclusivities.",Ipsen asserts that an ANDA seeking approval for lanreotide in an IM form or in a prefilled syringe would rely on protected portions of the Somatuline Depot NDA. They argue that FDA must uphold exclusivity protections under the FDCA to prevent premature approval that would infringe on Ipsen‚Äôs regulatory exclusivity rights.,2020-04-09 00:00:00,Denied,2024-05-21,1.0,Center for Drug Evaluation and Research (CDER),"FD&C Act, section 505(j) (21 U.S.C. ¬ß 355(j))
- 21 CFR Part 20
- 21 CFR 314.3(b)
- 21 CFR 314.94(a)(7)
- 21 CFR 314.127(a)(6)(i)
- 21 CFR 320.1(e)
- 21 CFR 320.23(b)
- 21 CFR 320.24(a), (b), (b)(6)
- 21 CFR 320.25(a)
- 21 CFR 314.3
- 21 CFR 10.115(d)(2)","The petition requested that FDA require ANDAs for generic versions of Somatuline Depot (lanreotide acetate) to include in vivo bioequivalence studies.
- FDA stated it could not yet decide due to the complex nature of the issues, requiring further review and analysis by Agency officials","FDA determined that in vitro testing (Option 1 in Draft PSG) is sufficient to demonstrate bioequivalence (BE) for lanreotide acetate due to its thermodynamically stable, self-assembling formulation.

- The Petition‚Äôs assertion that in vivo testing is necessary was rejected, as BE can be demonstrated without it, per FDA's regulatory discretion and scientific standards.

- Petitioners‚Äô claims regarding impurity analysis, device performance testing, and the necessity of partial AUC (pAUC) analysis were addressed and dismissed. FDA emphasized that such evaluations are conducted on a case-by-case basis during individual ANDA reviews.

- FDA upheld its current Draft Product-Specific Guidance (PSG) on lanreotide acetate, noting that alternative approaches to BE demonstration may be acceptable if scientifically justified.",denied,True,1680.0,CDER,CDER
fda-2019-p-1679,FDA-2019-P-1679-0073_Supplement_from_Braeburn_Inc.pdf,2019-08-15,2019,False,original petition,Braeburn Inc. (‚ÄúBraeburn‚Äù),industry/corporation,"21 C.F.R. ¬ß 10.30 (citizen petition rule)
- 21 U.S.C. ¬ß 355 (NDA provisions)
- FDCA ¬ß 505(b)(1)
- FDA‚Äôs guidance for industry: ‚ÄúAssessment of Abuse Potential of Drugs‚Äù
- FDA‚Äôs Draft Guidance: ‚ÄúGeneral Principles for Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drug Products‚Äù","FDA‚Äôs approval and regulatory treatment of long-acting injectable buprenorphine products, specifically regarding abuse potential data requirements and evaluation of ANDAs referencing Braeburn‚Äôs product, Brixadi.","Braeburn requests that FDA:
1. Confirm that the agency will apply consistent and rigorous standards in evaluating abuse potential data for long-acting injectable buprenorphine products, including ANDAs referencing Brixadi.
2. Refrain from approving any such ANDAs without appropriately robust evidence addressing abuse potential concerns.","Braeburn argues that approval of competing long-acting injectable buprenorphine products without adequate abuse potential data may endanger patient safety and undermine public confidence. They emphasize the need for consistent scientific rigor, highlighting that Brixadi underwent extensive studies per FDA‚Äôs own guidance. They assert that any ANDAs referencing Brixadi should meet equivalent evidentiary standards.",,Not applicable ‚Äî this document contains arguments submitted by Braeburn in support of their petition.,2019-10-11,0.0,"Not applicable ‚Äî this is a supplemental submission by Braeburn, Inc., not an FDA response letter.","21 C.F.R. ¬ß 10.30(g)
- 21 U.S.C. ¬ß 360cc(a)
- 21 C.F.R. ¬ß 316.3(b)(14)(ii)(A)
- 21 C.F.R. ¬ß 316.29(a)(3)",,"Not applicable from the FDA ‚Äî but Braeburn argues that:
- Sublocade‚Ñ¢ was never eligible for Orphan Drug Designation (ODD) because Indivior did not submit a new ODD request as required by FDA regulations.
- Cites historical precedents (e.g., Nutropin Depot, Tyvaso, Orenitram) to argue that a product reformulation requires a new ODD.
- Argues that FDA‚Äôs 2016 policy change is unlawful if applied retroactively.
- If Sublocade is the ‚Äúsame drug‚Äù as Subutex, its ODE has expired; if it is ‚Äúclinically superior,‚Äù it must have had its own ODD request.",other,True,57.0,other,Other/Specialty Center
fda-2019-p-1781,FDA-2019-P-1781-0001_Citizen_Petition_from_Association_of_Independent_B.pdf,2019-04-05,2019,False,original petition,Association of Independent Banana Producers of Guatemala (APIB),advocacy/academic,"Food Safety Modernization Act (FSMA), Chapter 9 Variances, sub-para P(1) 

* 21 CFR ¬ß 112.44(a)(2) 

* 21 CFR ¬ß 112.43(b) 

* 21 CFR ¬ß 112.45(a)‚Äì(b) (referenced as the discontinuation requirement)","The petition targets the Produce Safety Rule‚Äôs agricultural-water requirements in Subpart E, especially the ban on using untreated surface water and the prescribed high ORP monitoring levels for post-harvest water","1. Amend ¬ß 112.44(a)(2) so banana growers may irrigate with untreated river water.
2. Delete ¬ß 112.43(b) and allow water-quality monitoring by residual free chlorine of 1.5‚Äì3 mg L‚Åª¬π instead of an ORP of 700‚Äì825 mV. ","Low food-safety risk: Banana fruit is bagged, elevated ‚â•1.5 m, and its peel is largely impermeable; experimental spraying showed 85 %‚Äì100 % of samples had no detectable E. coli and the pulp stayed clean 
* Economic impracticability: Routine laboratory tests (~US $3 000 yr‚Åª¬π per farm) and treating river water or maintaining ORP 700‚Äì825 mV would raise chemical use 7-fold, driving operating costs up 100‚Äì600 % 
* Infrastructure limits & current GAPs: Guatemala lacks wastewater-treatment capacity; growers already meet GAP certification and use 1.5‚Äì3 mg L‚Åª¬π free chlorine post-harvest, which the petitioners say is sufficient to ensure safety ",,,2025-10-15,0.0,,,,,no decision,False,2385.0,pending,pending
fda-2019-p-0933,FDA-2019-P-0933-0001_Letter_from_National_Milk_Producers_Federation_to_.pdf,2019-02-21,2019,False,original petition,National Milk Producers Federation (NMPF),advocacy/academic,"FDCA ¬ß¬ß 201, 201a, 201c, 301, 401, 402, 403, 701
- 21 C.F.R. ¬ß 101.3(e), 130.10, 101.67, 102.5
- 21 U.S.C. ¬ß¬ß 321a (butter), 321c (nonfat dry milk), 341, 343
- Other parts: 21 C.F.R. Parts 131 (milk, yogurt), 133 (cheese), 135.110 (ice cream)",FDA‚Äôs lack of enforcement of labeling standards for non-dairy substitutes for standardized dairy foods; failure to require ‚Äúimitation‚Äù labeling on nutritionally inferior products labeled with dairy terms,"Enforce existing imitation labeling requirements under FDCA ¬ß 403(c) against nutritionally inferior non-dairy substitutes.
- Amend 21 C.F.R. ¬ß 101.3(e) to codify FDA policies on when non-dairy substitutes can use dairy food terms under limited conditions","Non-dairy substitutes are often nutritionally inferior yet labeled with dairy terms, misleading consumers.
- Misbranding violates FDCA and creates public health risks (e.g., malnutrition in children).
- Standards of identity and labeling rules are essential for consumer protection and preventing deception.
- Calls for fair application of rules already used in standards for products like margarine, enriched foods, etc.",,,2025-10-15,0.0,,,,,no decision,False,2428.0,pending,pending
fda-2019-p-2945,FDA-2019-P-2945-0001_Additional_Petitioners_Supporters_of_the_Petition_.pdf,,2019,False,original petition,"This document is not submitted by a single entity, but lists additional supporters of a previously submitted petition. Entities and individuals listed include:
‚Ä¢ Citizens for a Safe and Healthy Texas
‚Ä¢ Dr. Karen Randall (SCEMA)
‚Ä¢ Kenneth Finn, M.D.
‚Ä¢ Moms Strong (CA & CO)
‚Ä¢ Cannabis Industry Victims Educating Litigators (CIVEL)
‚Ä¢ Smart Approaches to Marijuana Canada
‚Ä¢ Illinois Family Institute
‚Ä¢ Take Back America Campaign
‚Ä¢ Parents Opposed to Pot
‚Ä¢ Massachusetts Prevent Alliance
‚Ä¢ Americans Against Legalizing Marijuana
‚Ä¢ SafeLaunch Healthy Futures
‚Ä¢ Numerous unaffiliated individuals",law/consulting,Not Mentioned in this supplemental supporter list. Legal arguments and statutes would be found in the main petition.,Not Mentioned directly. This document only lists parties who support a previously filed petition.,Not Mentioned here. This document does not repeat or detail the requested regulatory action; it supports an existing petition.,Not Mentioned. No new justifications are provided beyond expressing support for an existing filing.,,,2025-10-15,,,,,,no decision,False,,pending,pending
fda-2019-p-0913,FDA-2019-P-0913-0001_Citizen_Petition_from_Independent_Nutrition_Inc.pdf,2019-03-04,2019,False,original petition,Independent Nutrition Inc. (INC),industry/corporation,"21 C.F.R. ¬ß 10.30 (citizen-petition rule)
‚Ä¢ 21 C.F.R. ¬ß 111.75 (a)(1)(i) (dietary-supplement CGMP identity testing)
‚Ä¢ 7 C.F.R. ¬ß¬ß 205.402 ‚Äì 205.405 (USDA National Organic Program requirements)
‚Ä¢ NOP Guidance 5029 ‚ÄúSeeds, Annual Seedlings, and Planting Stock in Organic Crop Production‚Äù",The petition addresses FDA‚Äôs current requirement that each component used in a dietary supplement receive identity testing under 21 C.F.R. 111.75(a)(1)(i).,"Ask the Commissioner to exempt Independent Nutrition Inc. from the ¬ß111.75(a)(1)(i) identity-testing requirement for herbs and herbal extracts that already carry a USDA organic certificate, allowing INC to rely on that certificate in lieu of further FDA-mandated tests.","USDA organic certification already involves comprehensive seed-to-harvest documentation and third-party verification, thus confirming botanical identity.
‚Ä¢ Re-testing the same materials would be duplicative and costly, especially for small businesses (INC cites that small firms supply 38 % of dietary supplements).
‚Ä¢ Using USDA certificates would ‚Äústreamline the testing process without sacrificing quality,‚Äù reducing unnecessary expenses while maintaining consumer safety.
‚Ä¢ USDA is portrayed as a trustworthy authority, and its Organic Integrity Database allows verification of certificates.",2019-09-09 00:00:00,,2025-10-15,1.0,,,The FDA has not reached a decision within the 180-day timeframe due to competing agency priorities. The petition is under active review and evaluation by staff.,,no decision,False,2417.0,pending,pending
fda-2019-p-0622,FDA-2019-P-0622-0001_Citizen_Petition___redacted.pdf,2019-01-31,2019,False,original petition,The petitioner‚Äôs name is redacted in the publicly-released copy; the document refers to the filer only as ‚Äúthe undersigned (‚ÄòPetitioner‚Äô)‚Äù.,individual,"21 C.F.R. ¬ß 60.30(a) ‚Äì citizen-petition provision for due-diligence challenges (page 1).
* 21 C.F.R. ¬ß 60.36(b) ‚Äì imputation of actions to the patent-term applicant (page 10).
* Reference to the Federal Food, Drug, and Cosmetic Act (introductory sentence, page 1).
* U.S. Supreme Court case Oil States Energy Servs. v. Greene‚Äôs Energy Grp. (cited on page 11).",FDA‚Äôs pending due-diligence review tied to two patent-extension dockets (FDA-2017-E-3592 & FDA-2017-E-3616) for the Absorb GT1 Bioresorbable Vascular Scaffold (BVS) System.,The petitioner asks the Commissioner to initiate a due-diligence investigation and issue a final determination that the patent-term-extension applicant did not act with due diligence‚Äîthereby denying the requested extension for the Absorb GT1 BVS System,The redacted narrative (pages 2-10) alleges multiple periods where the applicant ‚Äúfailed to act with due diligence‚Äù during FDA review. The petition supplies a timeline table (page 6-7) and cites ¬ß60.36(b) to show that delays by the applicant or its agents must be imputed to the applicant. Concluding paragraph states these facts warrant denial of the patent-term extension in its entirety.,,Denied,2019-05-03,0.0,Office of the Chief Scientist (OCS),"21 CFR 60.30(d) ‚Äì Certification and filing requirements for due diligence petitions

21 CFR 60.34(b)(1) and (4) ‚Äì Grounds for denying petitions for lack of sufficient information

21 CFR 60.36(a) ‚Äì Standard for determining failure to act with due diligence

21 CFR 60.22(c)(1)(i), (c)(2)(i) ‚Äì Regulatory review period components

35 U.S.C. 156(c), 156(d)(3), 156(g)(3)(B)(i), (g)(3)(B)(ii) ‚Äì Patent term restoration framework

Public Law 98-417 / Public Law 100-670 ‚Äì Drug Price Competition and Patent Term Restoration Act of 1984

FDA Staff Manual Guide 1410.21 ¬∂ I.B.7. ‚Äì Cited in footnotes

83 Fed. Reg. 65680 (Dec. 21, 2018) ‚Äì Establishing regulatory review period for Absorb GT1

51 Fed. Reg. 25338 (July 11, 1986); 53 Fed. Reg. 7298 (Mar. 7, 1988) ‚Äì Due diligence petition preambles

H. Rept. 857, 98th Cong., 2d Sess. Part 1 at 42 (1984) ‚Äì Legislative history on due diligence standards",,"Lack of Sufficient Facts:
The petition failed to present adequate information or allegations upon which the FDA could reasonably determine that Abbott did not act with due diligence during the regulatory review period for the Absorb GT1 Bioresorbable Vascular Scaffold (BVS) system
.

Allegations Did Not Relate to Regulatory Review Period:
The claims‚Äîincluding failure to train, anti-competitive behavior, promotional activities, and misconduct‚Äîwere found not to be directly tied to the regulatory review period or to any delay in submitting the PMA
.

No Demonstrated Link to Approval Delay:
The petition did not establish how any of the alleged actions resulted in a delay in pursuing FDA approval. FDA emphasized that due diligence petitions are not designed to review every alleged misstep, but to determine whether the applicant failed to diligently pursue approval during a defined regulatory period
.

Certification Requirements Not Met:
The petitioner failed to properly certify that a complete copy of the petition was served to the applicant (Abbott) by certified or registered mail, as required by 21 CFR 60.30(d). Instead, it was sent by regular USPS Priority Mail Express, which does not meet the regulation‚Äôs requirement",denied,True,92.0,offices,Other/Specialty Center
fda-2019-p-2537,FDA-2019-P-2537-0001_Citizen_Petition_from_Allergan_Holdings_Unlimited_.pdf,2019-05-23,2019,False,original petition,Allergan Holdings Unlimited Company (‚ÄúAllergan‚Äù),industry/corporation,"21 U.S.C. ¬ß 355 (FD&C Act)
‚Ä¢ 21 U.S.C. ¬ß 355(j) (ANDA provisions)
‚Ä¢ 21 C.F.R. Part 10 (citizen-petition rules)
‚Ä¢ 21 C.F.R. ¬ß 10.31 (certification)
‚Ä¢ 21 C.F.R. ¬ß 25.31 (environmental categorical exclusion)",FDA‚Äôs handling of generic copies of VIBERZI¬Æ (eluxadoline) tablets ‚Äî specifically the draft bioequivalence guidance and any decision to receive or approve ANDAs that reference VIBERZI without adequate clinical-endpoint and abuse-potential data.,"Allergan asks FDA to: 1. Publish a revised draft guidance requiring clinical-endpoint studies for generic VIBERZI; 2. Refuse to receive/approve any ANDA lacking comparative clinical-endpoint evidence; 3. Refuse any ANDA whose active ingredient is not the same Form Alpha polymorph (or, if different, lacks data ruling out greater abuse potential); 4. Seek public comment on criteria FDA uses when generic oral drugs may raise abuse- or scheduling-related concerns.","Scientific & clinical grounds
‚Ä¢ Local site of action, low permeability & high PK variability mean plasma PK cannot assure bioequivalence; only clinical-endpoint studies suffice.
‚Ä¢ Polymorphic form matters: Form Alpha was chosen for stability and low solubility; other forms could alter dissolution, efficacy, or abuse potential.
‚Ä¢ Controlled-substance risk: Using a different polymorph or excipient profile could increase extraction, intranasal use, or diversion; therefore FDA must review abuse data or require an Eight-Factor analysis.",2019-11-18 00:00:00,,2025-10-15,1.0,,,"The petition requested the FDA to refuse or deny any ANDA referencing Allergan‚Äôs Viberzi (eluxadoline) tablets without appropriate bioequivalence data, and to issue guidance on abuse and scheduling issues.
- FDA cited the need to address other priorities and numerous demands on agency resources as reasons for delay.",,no decision,False,2337.0,pending,pending
fda-2019-p-1679,FDA-2019-P-1679-0074_Supplement_from_Braeburn_Inc.pdf,2019-08-22,2019,False,original petition,"Braeburn, Inc.",industry/corporation,21 C.F.R. ¬ß 10.30(g)‚ÄÇ‚Ä¢ 21 U.S.C. ¬ß 360bb(a)(1)‚ÄÇ‚Ä¢ 21 C.F.R. ¬ß 316.20(a)‚ÄÇ‚Ä¢ 21 C.F.R. ¬ß 316.3(b)(11)‚ÄÇ‚Ä¢ 21 C.F.R. ¬ß 316.3(b)(14)(i)‚ÄÇ‚Ä¢ 21 C.F.R. ¬ß 316.29,The grant of orphan-drug designation (ODD) to Sublocade‚Ñ¢ (buprenorphine extended-release) injection without a new ODD request.,Revoke Sublocade‚Äôs orphan-drug designation immediately under 21 C.F.R. ¬ß 316.29.,"Statutory requirement: A drug cannot receive ODD unless a sponsor submits a new designation request before its NDA (21 U.S.C. ¬ß 360bb(a)(1); 21 C.F.R. ¬ß 316.20(a)). 2. Regulatory interpretation: FDA regulations define a ‚Äúdrug‚Äù for ODD purposes as the specific drug product, not just the active moiety; therefore Sublocade is distinct from Subutex and was never covered by the 1994 Subutex ODD. 3. Because Indivior never filed a request for Sublocade, its ODD was unlawfully granted and must be revoked.",,Not applicable ‚Äî this document contains arguments submitted by Braeburn in support of their petition.,2019-10-11,0.0,"Not applicable ‚Äî this is a supplemental submission by Braeburn, Inc., not an FDA response letter.","21 C.F.R. ¬ß 10.30(g)
- 21 U.S.C. ¬ß 360cc(a)
- 21 C.F.R. ¬ß 316.3(b)(14)(ii)(A)
- 21 C.F.R. ¬ß 316.29(a)(3)",,"Not applicable from the FDA ‚Äî but Braeburn argues that:
- Sublocade‚Ñ¢ was never eligible for Orphan Drug Designation (ODD) because Indivior did not submit a new ODD request as required by FDA regulations.
- Cites historical precedents (e.g., Nutropin Depot, Tyvaso, Orenitram) to argue that a product reformulation requires a new ODD.
- Argues that FDA‚Äôs 2016 policy change is unlawful if applied retroactively.
- If Sublocade is the ‚Äúsame drug‚Äù as Subutex, its ODE has expired; if it is ‚Äúclinically superior,‚Äù it must have had its own ODD request.",other,True,50.0,other,Other/Specialty Center
fda-2019-p-1560,FDA-2019-P-1560-0001_Citizen_Petition_from_Hyman__Phelps___McNamara_on_.pdf,2019-04-01,2019,False,original petition,"Xellia Pharmaceutical ApS and Xellia Pharmaceuticals USA, LLC.",industry/corporation,"21 C.F.R. ¬ß¬ß 10.25(a), 10.30 (citizen-petition rules)
‚Ä¢ FD&C Act ¬ß 505(b)(2)
‚Ä¢ 21 C.F.R. ¬ß 314.3(b) (therapeutic-equivalence definitions)
‚Ä¢ 21 C.F.R. ¬ß 314.94(a)(9)(iii) (‚Äúnon-exception excipient‚Äù rule)
‚Ä¢ 21 C.F.R. ¬ß 314.94(a)(8)(iv) (permitted labeling differences)
‚Ä¢ 21 C.F.R. ¬ß 25.31 (categorical environmental exclusion)","FDA‚Äôs Orange-Book listing and therapeutic-equivalence (TE) coding of Xellia‚Äôs Vancomycin Injection 500 mg/100 mL and 1 g/200 mL; specifically, the absence of a TE Code for the products approved under NDA 211962.",Assign an ‚ÄúAP‚Äù TE Code (injectable aqueous solution) in the Orange Book to Xellia‚Äôs Vancomycin Injection 500 mg/100 mL and 1 g/200 mL so the products will qualify for exemption or refund of future PDUFA program fees.,"Why the AP rating is warranted‚Äî
‚Ä¢ Xellia‚Äôs and Baxter‚Äôs Vancomycin Injection products are pharmaceutical equivalents (identical strength, dosage form ‚Äúsolution,‚Äù and IV route).
‚Ä¢ FDA already determined bioequivalence when approving NDA 211962; thus the products meet all TE-code criteria (21 C.F.R. ¬ß 314.3(b)).
‚Ä¢ Label differences (a boxed warning about PEG 400/NADA excipients) stem only from permissible excipient changes and are allowable under ¬ß 314.94(a)(8)(iv).
‚Ä¢ Without a TE Code, Xellia would incur unnecessary PDUFA program fees, despite the product being interchangeable with Baxter‚Äôs reference drug, so an AP rating is needed for regulatory parity and cost relief.",2019-09-27 00:00:00,,2025-10-15,1.0,,,The petition remains unresolved due to the need to address other agency priorities and numerous demands on the agency‚Äôs resources. The response is issued to comply with regulatory requirements for interim responses.,,no decision,False,2389.0,pending,pending
fda-2019-p-0114,FDA-2019-P-0114-0001_Citizen_Petition_from__Pfizer_Innovative_Health_Gl.pdf,2019-01-03,2019,False,original petition,"Pfizer Inc., through its division Pfizer Innovative Health (Global Regulatory Affairs)",law/consulting," Section 505(j) of the FDCA
‚Ä¢ 21 C.F.R. ¬ß¬ß 314.94(a)(9)(iv), 320.24
‚Ä¢ 505(q) mentioned as the petition is certified as such
‚Ä¢ 21 C.F.R. ¬ß 10.30 (citizen petition process)","FDA‚Äôs potential acceptance or approval of any ANDA referencing Toviaz¬Æ (fesoterodine fumarate) extended-release tablets that lacks adequate in vivo bioequivalence studies, including for both 4 mg and 8 mg strengths.","FDA should:
‚Ä¢ Decline to accept or approve any ANDA referencing Toviaz¬Æ that does not include in vivo BE studies demonstrating bioequivalence to both 4 mg and 8 mg strengths.
‚Ä¢ Revise or withdraw current draft bioequivalence guidance to ensure it requires in vivo studies at both strengths.","‚Ä¢ Fesoterodine exhibits nonlinear pharmacokinetics; systemic exposure does not scale linearly between 4 mg and 8 mg.
‚Ä¢ Different strengths cannot be reliably bridged using in vitro methods alone.
‚Ä¢ Risk of inaccurate bioequivalence conclusions if only one strength is tested.
‚Ä¢ Clinical significance: Toviaz is used in a sensitive patient population; failure to establish BE could compromise safety and efficacy.",,,2025-10-15,0.0,,,,,no decision,False,2477.0,pending,pending
fda-2019-p-5887,FDA-2019-P-5887-0001_Citizen_Petition_from_Upfield_US_Inc_.pdf,2019-12-13,2019,False,original petition,Upfield US Inc. and its affiliates (‚ÄúUpfield‚Äù),industry/corporation,"‚Ä¢ FD&C Act ¬ß¬ß 401 & 701(e) (21 U.S.C. ¬ß¬ß 341, 371(e))
‚Ä¢ 21 C.F.R. ¬ß 166.110 (margarine standard of identity) ‚Äî plus specific sub-paragraphs ¬ß 166.110(a), (b)(1), (b)(2) etc.
‚Ä¢ 21 C.F.R. ¬ß 130.5(b) (general SOI criteria)
‚Ä¢ 21 C.F.R. ¬ß 25.32(a) (categorical environmental exclusion)",Existing standard of identity for margarine (21 C.F.R. ¬ß 166.110) and FDA‚Äôs policy on allowable ingredients & labeling for that standard.,"Amend ¬ß 166.110 to: 1Ô∏è‚É£ allow additional optional ingredients (e.g., nutrient fortification, algal oils, potassium chloride); 2Ô∏è‚É£ update nutrition criteria; and 3Ô∏è‚É£ modernize nomenclature (‚Äúsmooth, semisolid‚Äù instead of ‚Äúplastic,‚Äù remove ‚Äúoleomargarine‚Äù). Details are provided in Appendix A.","Upfield states that the amendments will: 1Ô∏è‚É£ Modernize the SOI by removing confusing terms and permitting innovation; 2Ô∏è‚É£ Encourage healthier products aligned with plant-based nutrition guidance; 3Ô∏è‚É£ Meet consumer expectations for plant-based, sustainable foods; and 4Ô∏è‚É£ Promote honesty & fair dealing by clarifying labeling and ingredient flexibility.",2022-06-07 00:00:00,,2025-10-15,1.0,,,"The FDA acknowledged the concerns raised in the petition regarding consumer confusion caused by the term ‚Äúplastic form‚Äù in the standard of identity for margarine. However, it emphasized the need for supporting evidence, such as:

Scientific literature published in peer-reviewed journals

Consumer research studies and data

Other scientific evidence related to consumer perception, understanding, and expectations
The agency stated this information is necessary to fully evaluate the petition and determine whether an amendment to the standard is warranted",,no decision,False,2133.0,pending,pending
fda-2019-p-5440,FDA-2019-P-5440-0001_Citizen_Petition_from_Diane_Kramer_Redacted.pdf,,2019,False,original petition,Diane Kramer (individual petitioner),individual,"‚Ä¢ 21 C.F.R. ¬ß 10.23(2) ‚Äì general citizen petition provision
‚Ä¢ 21 C.F.R. Part 25 (Environmental Impact), specifically ¬ß¬ß 25.30, 25.31, 25.32, and 25.34
‚Ä¢ Notably absent are drug-specific statutes like 505(q) or 505(b)(2)","Current FDA labeling of Provigil (modafinil), which does not include an indication for treatment of multiple sclerosis (MS)‚Äìrelated fatigue.","Petitioner requests the FDA to issue a new indication for Provigil (modafinil) to include treatment of multiple sclerosis-related fatigue, and revise labeling accordingly.","‚Ä¢ Multiple studies show modafinil improves MS-related fatigue (citations include Rammohan et al., Zifko et al., Brown et al.).
‚Ä¢ Petition cites expert opinions from the National Multiple Sclerosis Society.
‚Ä¢ Argues FDA recognition would improve access, insurance coverage, and allow providers more effective treatment options.
‚Ä¢ Asserts that 200 mg/day is a well-tolerated, effective dose for MS patients.",,,2025-10-15,,,,,,no decision,False,,pending,pending
fda-2019-p-3424,FDA-2019-P-3424-0001_Citizen_Petition_from_Medical_Research_Collaborati.pdf,2019-07-16,2019,False,original petition,"Medical Research Collaborative, Inc.",advocacy/academic,"‚Ä¢ 21 C.F.R. ¬ß 10.30 (citizen petition)
‚Ä¢ 21 C.F.R. ¬ß 312.305 (Expanded Access for Individual Patients)
‚Ä¢ 21 U.S.C. ¬ß 360bbb (FDCA Sec. 561 - Expanded Access)
‚Ä¢ 42 U.S.C. ¬ß 1395y(b)(2)(A)(ii) (Medicare secondary payer statute)
‚Ä¢ HIPAA Privacy Rule (42 U.S.C. ¬ß 1320d et seq.)","Current process, communication practices, and delays related to Expanded Access (EA) for investigational drugs. Also questions FDA‚Äôs failure to respond timely to patients/clinicians seeking EA.","Petitioner asks FDA to:
1. Affirm patients‚Äô right to access experimental drugs under EA law
2. Mandate real-time responses from FDA to patient requests for EA
3. Require pharmaceutical companies to post EA policies on their websites
4. Direct FDA to create an easily accessible EA portal for patients and providers
5. Publish data on EA usage, denial reasons, and review timelines","‚Ä¢ Terminal patients face systemic barriers to EA access due to unclear procedures, delayed FDA responses, and lack of pharma cooperation.
‚Ä¢ Asserts lack of transparency, inconsistent communication, and administrative hurdles violate patient rights.
‚Ä¢ Invokes statutory language of the FDCA and constitutional rights (e.g., access to potentially lifesaving treatment).
‚Ä¢ Cites Right to Try Act, patient advocacy cases, and the need for urgency in terminal illness contexts.",,,2025-10-15,0.0,,,,,no decision,False,2283.0,pending,pending
fda-2019-p-3156,FDA-2019-P-3156-0001_Citizen_Petition_from_Medical_Research_Collaborati.pdf,2019-06-29,2019,False,original petition,"Medical Research Collaborative, Inc. (MRC)",advocacy/academic,"‚Ä¢ 21 C.F.R. ¬ß 10.30 (citizen petition regulation)
‚Ä¢ 21 U.S.C. ¬ß 355 (New Drug Application process)
‚Ä¢ 21 C.F.R. ¬ß 312.305 (Expanded Access for individual patients)
‚Ä¢ HIPAA ‚Äì 42 U.S.C. ¬ß 1320d et seq.
‚Ä¢ Freedom of Information Act (FOIA), 5 U.S.C. ¬ß 552","MRC is commenting on FDA‚Äôs approval process and review of new drug applications (NDAs), including public disclosure practices around safety and clinical data for investigational drugs, and Expanded Access (EA) policy.","MRC requests FDA to:
1. Require disclosure of patient narratives and full clinical data once a drug is approved.
2. Mandate NDA sponsors to release certain safety data publicly.
3. Create a database of adverse-event narratives accessible via FOIA.
4. Clarify and enforce procedures related to Expanded Access (EA).","‚Ä¢ Transparency: Full access to clinical narratives allows independent analysis and supports informed medical decision-making.
‚Ä¢ Patient rights: Greater disclosure empowers patients, especially those seeking EA options.
‚Ä¢ Public safety: Hiding key adverse events delays detection of harm.
‚Ä¢ Legal basis: FDA already has authority under FOIA and FDCA to compel release of safety information, especially once a drug is approved.",,,2025-10-15,0.0,,,,,no decision,False,2300.0,pending,pending
fda-2019-p-5394,FDA-2019-P-5394-0001_Citizen_Petition_from_Consumer_Healthcare_Products.pdf,2019-11-14,2019,False,original petition,Consumer Healthcare Products Association (CHPA),advocacy/academic,"21 U.S.C. ¬ß 321(ff)(3)
- 21 U.S.C. ¬ß 379aa-1
- 21 C.F.R. ¬ß 190.6
- 21 C.F.R. ¬ß 25.30(h)
- 21 C.F.R. ¬ß 10.30(b)(3)
- Section 553(b) of the Administrative Procedure Act",Current prohibition on marketing CBD as a dietary supplement due to its prior investigation as a drug. The petition addresses lack of a legal marketing pathway for CBD in supplements.,"Promulgate regulation to declare hemp-derived CBD lawful in dietary supplements
- Allow NDI (New Dietary Ingredient) submissions for CBD
- Maintain strict enforcement for CBD as a drug
- Increase enforcement on misleading/fraudulent CBD product claims
- Monitor CBD safety through existing adverse event systems","Intense consumer demand and unregulated market
- Public interest in safe, legal access
- FDA has discretion to allow CBD in supplements by regulation
- Reputable manufacturers need regulatory certainty
- Enforcement necessary for safety and quality
- Monitoring tools already exist",2020-06-16 00:00:00,"Partially Granted and Partially Denied
- Denied the request to promulgate regulations allowing CBD dietary supplements.
- Denied requests for FDA enforcement actions (outside scope of petition process).
- Granted the request to continue monitoring safety issues concerning CBD-containing products.",2023-01-26,1.0,Center for Food Safety and Applied Nutrition (CFSAN),"21 U.S.C. ¬ß 321(ff)(3)(B) ‚Äì ‚ÄúExclusion clause‚Äù of the FD&C Act
- 21 U.S.C. ¬ß 350b ‚Äì New Dietary Ingredient (NDI)
- 21 U.S.C. ¬ß 342(f)(1)(B) ‚Äì Adulteration standard
- 21 CFR ¬ß 190.6 ‚Äì NDI notification regulation
- 21 CFR ¬ß 10.30 ‚Äì Citizen Petition procedures
- 5 U.S.C. ¬ß 553(b)(B) ‚Äì Administrative Procedure Act for IFRs
- 7 U.S.C. ¬ß 1639o(1) ‚Äì Hemp definition (2018 Farm Bill)","The FDA stated that it requires additional time to issue a final response due to the complexity of the legal and policy issues raised in the petition regarding cannabidiol (CBD). The agency committed to providing a complete response after further analysis of the petition‚Äôs requests, which include:

Establishing a legal pathway for CBD-containing dietary supplements.

Maintaining regulatory controls for CBD-based medicines.

Enforcing actions against noncompliant manufacturers.

Monitoring safety concerns related to CBD products","Safety Concerns: Substantial safety risks identified with CBD use, including liver toxicity, reproductive harm, and drug interactions. Concerns are greater for vulnerable populations (e.g., children, pregnant individuals).
- Insufficient Data: FDA has not received evidence showing CBD was marketed as a supplement before drug approval, nor data to support safety in dietary supplement form.
- Regulatory Gaps: Current tools (e.g., NDI process) insufficient to ensure consumer safety in an expanding CBD marketplace.
- Enforcement Limitations: FDA lacks resources to enforce against all violative CBD products.
- Continued Surveillance: FDA will continue monitoring safety signals via adverse event reports and public data submissions.",partially approved / denied,True,1169.0,CFSAN,Other/Specialty Center
fda-2019-p-0916,FDA-2019-P-0916-0001_Suitability_Petition_from_Schafer_Veterinary_Consu.pdf,2019-02-21,2019,False,original petition,Felix Pharmaceuticals Pvt. Ltd.,industry/corporation,"Section 512(n)(3) of the Federal Food, Drug and Cosmetic Act
- 21 C.F.R. ¬ß 25.30(h)
- 21 C.F.R. ¬ß 25.21","Filing of an Abbreviated New Animal Drug Application (ANADA) for a generic chewable tablet version of praziquantel, different in dosage form from the approved pioneer product (DRONCIT¬Æ Tablets by Bayer Healthcare LLC)",Approval to file an ANADA for a compressed chewable tablet of praziquantel differing from the pioneer compressed tablet dosage form,"Proposed dosage form change (compressed chewable tablet)
- Same route of administration
- Excipients are already approved for use in dogs
- Bioequivalence expected
- No adverse effect on safety or effectiveness anticipated",,Approved ‚Äî The FDA approved the suitability petition for a generic compressed chewable tablet version of praziquantel,2019-02-25,0.0,Center for Veterinary Medicine (CVM) ‚Äî Office of New Animal Drug Evaluation,"Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act
- 21 CFR 514.5 (presubmission conference recommendation)",,"The proposed dosage form changes were deemed appropriate for review under a suitability petition.
- The FDA found that additional investigations to demonstrate safety and effectiveness were not required",approved,True,4.0,CVM,Other/Specialty Center
fda-2019-p-5121,FDA-2019-P-5121-0009_Supplement_from_Aquestive_Therapeutics_Inc_Arent_F.pdf,2019-12-04,2019,False,original petition,"Aquestive Therapeutics, Inc.",industry/corporation,"‚Ä¢ 21 C.F.R. ¬ß 10.30 (citizen petition rule)
‚Ä¢ 21 U.S.C. ¬ß 355 (FDCA ¬ß 505)
‚Ä¢ 21 U.S.C. ¬ß 355(j) (ANDA provision)
‚Ä¢ 21 C.F.R. Part 320 (bioequivalence regulations)",FDA‚Äôs draft and potential final guidance on bioequivalence standards for generic versions of Suboxone¬Æ (buprenorphine/naloxone) sublingual film,"Aquestive requests FDA to:
‚Ä¢ Require in vivo bioequivalence studies using all four PK metrics (AUC0‚Äìt, AUC0‚Äì‚àû, Cmax, and tmax)
‚Ä¢ Require studies to be done using two dosage strengths (8 mg/2 mg and 2 mg/0.5 mg)
‚Ä¢ Reject any ANDA that fails to comply with these standards","‚Ä¢ Bioequivalence for sublingual film products is complex and sensitive to formulation and PK variability
‚Ä¢ FDA‚Äôs own review data shows significant inter-product variability in tmax and Cmax
‚Ä¢ Narrow therapeutic index and potential for abuse/addiction requires precise bioequivalence control
‚Ä¢ Aquestive argues public health requires these enhanced testing standards to ensure safety and efficacy",,,2025-10-15,0.0,,,,,no decision,False,2142.0,pending,pending
fda-2019-p-5151,FDA-2019-P-5151-0078_Letter_from_GlaxoSmithKline_GSK_Williams_and_Conno.pdf,2020-05-22,2019,False,original petition,GlaxoSmithKline LLC (GSK),industry/corporation,"‚Ä¢ 21 U.S.C. ¬ß 355 (FDCA ¬ß505)
‚Ä¢ 21 C.F.R. Part 314 (NDA and ANDA regulations)
‚Ä¢ 21 C.F.R. ¬ß 10.30 (citizen petition process)
‚Ä¢ 505(q) (mentioned in context of petition docket)",The petition comments on FDA‚Äôs consideration of ANDA approvals for fluticasone propionate/salmeterol inhalation powder (generic Advair Diskus¬Æ) and on a pending citizen petition regarding the standards for therapeutic equivalence and labeling of such generics.,The document itself is a comment on an existing petition; GSK urges FDA to not approve ANDAs that fail to fully meet GSK‚Äôs asserted standards for demonstrating therapeutic equivalence for fluticasone/salmeterol DPI products.,"‚Ä¢ GSK claims significant variability in performance characteristics (e.g., emitted dose, particle size distribution) between generic versions and the reference product (Advair Diskus).
‚Ä¢ Concerns over patient safety, efficacy, and interchangeability if generics with materially different performance characteristics are approved.
‚Ä¢ FDA should require full demonstration of therapeutic equivalence including device similarity and labeling parity.",,Denied,2021-01-15,0.0,Center for Drug Evaluation and Research (CDER),"21 CFR ¬ß 10.30(e)(2)
- 21 CFR ¬ß 10.25(a)
- Section 505(d) of the FD&C Act (21 U.S.C. 355(d))
- 21 CFR ¬ß 314.50
- 21 CFR ¬ß 201.56, ¬ß 201.57, ¬ß 201.100(c)
- 21 CFR ¬ß 314.80(a), (b), (c), and (j)
- 21 CFR ¬ß 314.81
- Section 505(k), 505(o)(4), and 505(o)(2)(A) of the FD&C Act
- 21 CFR ¬ß 314.3(b), ¬ß 314.70 (b) and (c)
- 21 CFR ¬ß 314.110(a)
- 21 CFR ¬ß 314.125(b)(6) and (8)",,"The petition was denied because it posed a hypothetical question‚Äîrequesting FDA to assess four specific categories of information concerning Zofran without considering other relevant and more recent data.
- FDA emphasized that safety-related labeling reviews are based on all relevant information, not limited or selective data.
- Reviewing this petition would divert scientific staff from ongoing reviews and critical public health tasks.
- The Agency reaffirmed its regulatory process for assessing safety-related labeling and noted that the labeling is determined through an iterative, science-based review of the entire body of evidence.",denied,True,238.0,CDER,CDER
fda-2019-p-5266,FDA-2019-P-5266-0001_Citizen_Petition_from_James_Grote__Redacted_.pdf,2019-11-06,2019,False,original petition,James Grote,individual,"‚Ä¢ 21 C.F.R. ¬ß¬ß 10.25(a) and 10.30 (Citizen Petition provisions)
‚Ä¢ Environmental exclusions under 21 C.F.R. ¬ß¬ß 25.30, 25.31, 25.32, 25.33, 25.34
‚Ä¢ 21 C.F.R. ¬ß 25.40 (environmental assessment)","Whether certain ANDAs (040063, 088606, 084476) have been withdrawn voluntarily or for safety/effectiveness reasons",FDA should disclose whether the listed drugs under the above ANDAs were withdrawn voluntarily or for reasons of safety or effectiveness,Petitioner states no withdrawal notification could be found in the Federal Register and suggests grouping related inquiries into one petition to save agency time.,2020-05-06 00:00:00,,2025-10-15,1.0,,,The FDA has not yet resolved the issues raised in the citizen petition because it involves complex issues requiring extensive review and analysis by agency officials. This interim response was issued due to the numerous demands on the agency‚Äôs resources and in compliance with FDA regulations regarding citizen petitions,,no decision,False,2170.0,pending,pending
fda-2019-p-5943,FDA-2019-P-5943-0001_Citizen_Petition_from_Hyman__Phelps___McNamara__P_.pdf,2019-12-16,2019,False,original petition,"Not explicitly named. Submitted by Hyman, Phelps & McNamara, P.C. on behalf of an unnamed client",law/consulting,"505(j)(2)(C) of the FDC Act
- 21 C.F.R. ¬ß 314.93
- 21 C.F.R. ¬ß¬ß 10.20 and 10.30
- FDC Act ¬ß 505(j)(2)(A)(iii)
- 21 C.F.R. ¬ß 25.31 (Environmental Impact exclusion)
- 21 C.F.R. ¬ß 10.30(b) (Economic Impact info)","Suitability of submitting an ANDA for Doxycycline Hyclate Tablets in 20 mg, 50 mg, 75 mg, and 150 mg strengths based on VIBRA-TABS 100 mg as the Reference Listed Drug (RLD)","	FDA should declare that Doxycycline Hyclate Tablets (20 mg, 50 mg, 75 mg, 150 mg) are suitable for submission in an Abbreviated New Drug Application (ANDA)","Proposed strengths are consistent with existing dosing guidelines in VIBRA-TABS labeling
- No clinical investigations are needed, as only strength (not formulation or use) is changing
- Enhances patient compliance
- Pediatric Research Equity Act (PREA) does not apply to this petition
- No safety or efficacy concerns from changing tablet strength alone",,,2025-10-15,0.0,,,,,no decision,False,2130.0,pending,pending
fda-2019-p-2038,FDA-2019-P-2038-0001_Citizen_Petition_from_American_Dental_Association.pdf,2019-04-25,2019,False,original petition,American Dental Association (ADA),advocacy/academic,"21 C.F.R. ¬ß 10.30 (Citizen petition regulation)
- 21 U.S.C. ¬ß 321(g) (Definition of drug)
- 21 U.S.C. ¬ß 393(b) (Mission of FDA)","The petition comments on FDA‚Äôs current enforcement policy that allows silver diamine fluoride (SDF) to be marketed as an unapproved drug, specifically for caries prevention, without approved New Drug Applications (NDAs).","	ADA requests that the FDA:
‚Ä¢ Enforce the requirement that SDF products used for caries prevention must have an approved NDA
‚Ä¢ Take action against entities that market SDF without appropriate approval
‚Ä¢ Clarify that SDF used for caries prevention is a drug under the FDCA","SDF products are being used off-label for caries prevention, but some are marketed as though they are FDA-approved for that indication, which is misleading.
- The use of SDF is growing, and the lack of regulatory clarity could impact patient safety.
- ADA believes this violates the FDCA and that marketing such products without approval undermines public health objectives.
- FDA enforcement is necessary to ensure consistency, public trust, and patient safety.",,"Denied
‚Äì The FDA denied the request to initiate enforcement action against SmileDirectClub, LLC, stating such enforcement requests are not within the scope of the citizen petition process.",2019-05-30,0.0,Center for Devices and Radiological Health (CDRH),"21 CFR 10.30(k)
- 21 CFR 10.45",,"FDA explained that enforcement action requests fall outside the scope of the citizen petition process and are at the discretion of the agency.
- The denial does not constitute final administrative action.
- FDA stated it takes complaints seriously and will evaluate the matter to determine appropriate follow-up.",denied,True,35.0,CDRH,CDRH
fda-2019-p-6099,FDA-2019-P-6099-0003_Letter_from_George_M__Stone_on_behalf_of_Patients_.pdf,2020-04-16,2019,False,original petition,Patients for Access to Advanced Therapy for Hemophilia (PAATH),advocacy/academic,"21 U.S.C. ¬ß 352 (Misbranded drugs and devices)
- 21 C.F.R. ¬ß 25.31 (Categorical exclusion for environmental impact)","FDA‚Äôs enforcement response (or lack thereof) to a Bayer recall of mislabeled hemophilia drugs (Kogenate¬Æ FS and Jivi¬Æ), and the agency‚Äôs oversight of mislabeled/expired product handling","Petitioners request FDA to pursue enforcement actions (e.g., administrative orders or consent agreements) against Bayer U.S. and Bayer AG for:
- Mislabeling ~1,000 vials of Kogenate FS
- Improper storage of hemophilia treatment products
- Releasing expired products into the U.S. market","Patient safety risks from mislabeled and expired hemophilia drugs
- Risk of patients developing inhibitors to FVIII from wrong medication
- Historical concerns about Bayer‚Äôs ethical practices (e.g., 1980s HIV contamination case)
- Demand for transparency and accountability to prevent recurrence",2020-06-08 00:00:00,"Denied
‚Äì The FDA denied the citizen petition on the grounds that it requested enforcement actions, which are outside the scope of the citizen petition process.",2020-09-25,1.0,Center for Biologics Evaluation and Research (CBER),"21 CFR 10.25(a)
- 21 CFR 10.30(e)
- 21 CFR 10.30(k)
- 21 CFR 10.3(a)
- 21 CFR Parts 210 & 211
- 21 CFR Parts 600‚Äì680
- Section 501(a)(2)(B) of the FD&C Act (21 U.S.C. ¬ß 351(a)(2)(B))
- Section 510(h)(3)-(4) of the FD&C Act (21 U.S.C. ¬ß 360(h)(3)-(4))"," The Agency cited competing priorities as the reason for the delay.
- FDA confirmed that it would respond when a decision on the request had been reached.","FDA denied the petition because requests for enforcement actions (e.g., administrative orders or consent agreements) are not proper subjects under the citizen petition process.
- The agency clarified that enforcement decisions are discretionary and governed by internal criteria and processes.
- FDA reiterated that it conducts thorough pre- and post-approval oversight of biologic drugs, including inspections and monitoring under a risk-based framework.
- The specific recall referenced (Kogenate FS) was monitored, classified as Class II, and terminated appropriately, confirming adequate manufacturer response under 21 CFR 7.55(a).",denied,True,162.0,CBER,Other/Specialty Center
fda-2019-p-5463,FDA-2019-P-5463-0001_Citizen_Petition_from_Sheppard__Mullin__Richter___.pdf,2019-11-18,2019,False,original petition,"Allison Fulton, Sheppard, Mullin, Richter & Hampton LLP",law/consulting,"Federal Food, Drug, and Cosmetic Act (FDCA)
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß¬ß 25.30(h) and 25.31(a) (environmental impact)",Approval of any Abbreviated New Drug Application (ANDA) (or supplement) for Penicillamine capsules,"Require that any ANDA (or supplement) for Penicillamine capsules be approved only if the bioequivalence study uses a method that:
‚Ä¢ Introduces a stabilizing agent to prevent Penicillamine oxidation post-sample collection
‚Ä¢ Measures both copper-bound and circulating free Penicillamine","Current methods (e.g., TCA crash) allow post-sample degradation of Penicillamine, underestimating bioequivalence
- Apicore's method uses stabilizers to prevent oxidation and measures copper-bound Penicillamine, providing a more accurate pharmacokinetic profile
- Failure to use such methods risks FDA approval of non-bioequivalent drugs with potentially reduced therapeutic benefit",,,2025-10-15,0.0,,,,,no decision,False,2158.0,pending,pending
fda-2019-p-5791,FDA-2019-P-5791-0001_Citizen_Petition_from_Guvam_Pharma_LLC_.pdf,2019-12-06,2019,False,original petition,Guvam Pharma LLC,industry/corporation,"505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FDC Act)
- 21 C.F.R. ¬ß¬ß 10.20, 10.30, 314.93
- 21 C.F.R. ¬ß 25.31
- 21 C.F.R. ¬ß 10.30(b)",Determination of suitability for submission of an Abbreviated New Drug Application (ANDA) for Phenazopyridine Hydrochloride Tablets differing in composition from RLDs,"That FDA determine Phenazopyridine Hydrochloride Tablets (50 mg, 100 mg, 200 mg) is suitable for submission as an ANDA","The proposed drug differs from the RLD only in the omission of the second active ingredient
- RLDs (e.g., Azo Gantanol, Azo Gantrisin) were not withdrawn for safety or efficacy reasons
- Approved NDAs support safety and efficacy of Phenazopyridine as monotherapy
- Proposed strengths match approved labeling
- Pediatric assessment is not applicable due to unchanged indications and dosage form",,,2025-10-15,0.0,,,,,no decision,False,2140.0,pending,pending
fda-2019-p-5800,FDA-2019-P-5800-0001_Citizen_Petition_from_Akin_Gump_Strauss_Hauer___Fe.pdf,2019-12-06,2019,False,original petition,Akin Gump submitted the petition on behalf of Verax Biomedical Incorporated (‚ÄúVerax‚Äù),industry/corporation,"21 C.F.R. ¬ß 10.25(a)
- 21 C.F.R. ¬ß¬ß 25.30, 25.31, and 25.34
- 21 C.F.R. ¬ß 606.145(a)
- 5 U.S.C. ¬ß 706(2)(A)","FDA‚Äôs Final Guidance titled ""Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion‚Äù issued in September 2019. Specifically, the petition critiques FDA‚Äôs inclusion and treatment of Large Volume Delayed Sampling (LVDS) as a ‚Äúsafety measure‚Äù method for platelet storage and transfusion beyond Day 5","Verax requests that the FDA:
(1) Refrain from clearing, approving, recommending, or designating LVDS or similar bacterial detection technologies as ‚Äúsafety measures‚Äù without statistically conclusive supporting data.
(2) Apply consistent regulatory standards requiring clinical evidence from 25,000+ unit studies demonstrating safety and effectiveness for Day 5 and Day 7 platelet storage methods","FDA‚Äôs endorsement of LVDS lacks statistically significant data proving safety and effectiveness.
- Existing LVDS studies (e.g., in the UK) are insufficient due to small sample sizes, inclusion of unlicensed platelet types, and use of passive surveillance that underreports septic events.
- Approval without robust clinical data undermines patient safety and creates an uneven regulatory standard compared to previously cleared technologies such as the PGD Test",,"Partially Granted and Partially Denied
‚Äì The FDA granted the request to apply consistent regulatory standards and precedents.
‚Äì The FDA denied all other requests including those that sought to prevent clearance, approval, or recommendation of bacterial risk control strategies without specific types of clinical evidence.",2020-11-30,0.0,Center for Biologics Evaluation and Research (CBER),"21 CFR 10.25(a)(2)
- 21 CFR 10.30
- 21 CFR 807.92(a)(3)
- 21 CFR 606.145(a)
- 21 CFR 610.53(b)
- 21 CFR 860.7
- 21 U.S.C. ¬ß¬ß 360(k), 360(n), 360c(f)(1), 360c(i), 360c(a), 360e(d)
- Section 510(k), 510(n), 513(f)(1), 513(i), 513(a), 515(d), 515(c)(5) of the FD&C Act",,"The FDA justified its partial approval/denial based on the following:

a. Regulatory Standards: FDA emphasized that approval and clearance of devices follow statutory and regulatory frameworks that do not always require the specific clinical data types requested by the petitioner.
b. Adequacy of Bacterial Risk Control Strategies: FDA argued that it evaluates the totality of evidence including clinical experience, contamination detection rates, and septic transfusion reaction data. Specifically, FDA found sufficient evidence supporting the safety and effectiveness of LVDS (Large Volume Delayed Sampling) for platelet storage beyond day 5.
c. Flexibility in Evaluation: The agency does not mandate one-size-fits-all criteria for evidence (e.g., a 25,000-unit study), as different technologies and strategies vary in their analytical sensitivity, risk profile, and intended use.
d. Consistency in Standards: FDA affirmed that it consistently applies appropriate standards and thus granted this part of the petition.",partially approved / denied,True,360.0,CBER,Other/Specialty Center
fda-2019-p-4363,FDA-2019-P-4363-0001_Citizen_Petition_from_Hyman__Phelps___McNamara__P_.pdf,2019-09-17,2019,False,original petition,"Hyman, Phelps & McNamara, P.C. submitted the petition on behalf of an unnamed client.",law/consulting,"Section 505(j)(2)(C) of the FDC Act
- 21 C.F.R. ¬ß 314.93
- 21 C.F.R. ¬ß 10.20
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 25.31
- 21 C.F.R. ¬ß 10.30(b)","Determination of suitability for submission of Cefazolin for Injection USP, 2 g vial, via various administration routes (IM, IV bolus, IV infusion) under an ANDA ","That the FDA determine Cefazolin for Injection USP, 2 g vial (administered intramuscularly, by IV bolus, and IV infusion), is suitable for submission in an Abbreviated New Drug Application (ANDA) ","The proposed 2 g strength is consistent with approved labeling (which permits doses up to 12 g/day).
- Literature supports 2 g dosing.
- Enhances flexibility for administration.
- Improves safety in drug preparation (fewer vials needed, reduced risk of contamination).
- PREA does not apply because the petition only concerns strength change, not new indications or formulations.",,,2025-10-15,0.0,,,,,no decision,False,2220.0,pending,pending
fda-2019-p-5691,FDA-2019-P-5691-0006_Amendment_from_Foley___Lardner__LLP.pdf,2021-11-09,2019,False,original petition,"Exela Pharma Sciences, LLC",industry/corporation,"21 C.F.R. ¬ß 314.94(a)(9)(iii)
- 21 C.F.R. ¬ß 320.22(b)(1)
- 21 U.S.C. ¬ß 355(j)",FDA‚Äôs approval standards and policies for ANDA submissions for Sodium Nitrite and Sodium Thiosulfate injections intended to be combined and used for cyanide poisoning treatment.,"FDA should require applicants submitting ANDAs for sodium nitrite and sodium thiosulfate for cyanide antidote use to:
- Submit evidence ensuring both products are co-packaged
- Demonstrate that they will be administered together in clinical use
- Provide labeling that reflects intended co-administration","The two drugs are only effective when used together as an antidote to cyanide poisoning.
- Separate packaging and administration might compromise clinical outcomes.
- Exela asserts that FDA must enforce stricter standards to ensure patient safety and avoid confusion or misuse.",,,2025-10-15,0.0,,,,,no decision,False,1436.0,pending,pending
fda-2019-p-5833,FDA-2019-P-5833-0001_Citizen_Petition_for_Archway_Apothecary__LLC.pdf,2019-12-10,2019,False,original petition,"Archway Apothecary, LLC",industry/corporation,"Title 21 of the Code of Federal Regulations; Section 503A of the Federal Food, Drug, and Cosmetic Act","Proposed amendment to the ""Bulk List of Drug Substances That Can Be Used to Compound Drug Products in Accordance with Section 503A""‚Äîspecifically, the removal of Nicotinamide Adenine Dinucleotide (NAD) from the list",Modify the proposed amendment to keep NAD on the 503A list for at least 5 more years to allow for further safety and efficacy studies,"NAD is essential for cellular function and has been used safely for many years. It shows promise in treating addiction by reducing cravings for alcohol and opioids. Removing NAD would hinder access to a valuable therapeutic tool. The lack of IP protection makes commercial drug approval economically unfeasible, making compounding the only viable option",2020-06-02 00:00:00,,2025-10-15,1.0,,,"FDA stated the delay is due to the need to address other agency priorities.
- The agency acknowledged the petition's request regarding Nicotinamide Adenine Dinucleotide on the Section 503A bulk drug substances list",,no decision,False,2136.0,pending,pending
fda-2019-p-5535,FDA-2019-P-5535-0001_Citizen_Petition_from_Foley___Lardner_LLP.pdf,2019-11-20,2019,False,original petition,"Foley & Lardner LLP is submitting the petition on behalf of a client, whose name is not disclosed in the document. Referred to as ‚Äúour client‚Äù throughout",law/consulting,"505(j)(2)(C) of the FDCA
- 21 C.F.R. ¬ß 314.93
- 21 C.F.R. ¬ß 25.31(a)","Requesting FDA to allow submission of an ANDA for a drug formulation not identical to the Reference Listed Drug (RLD), specifically pantoprazole sodium for oral suspension","That the Commissioner determine an ANDA may be submitted for pantoprazole sodium (20 mg and 40 mg enteric granules) in unit dose capsules packaged in bottles, instead of unit dose packets in cartons","No change in dose, use, or administration method.
- Proposed capsule format improves pediatric use, enabling a 20 mg dose unavailable in RLD.
- Capsule swallowing poses no safety issue since similar dosage forms exist.
- Instructions will be updated for clarity.
- Capsules are not expected to be larger than typical marketed forms",,,2025-10-15,0.0,,,,,no decision,False,2156.0,pending,pending
fda-2019-p-5441,FDA-2019-P-5441-0003_Supplemental_to_Citizen_Petition_from_Hyman__Phelp.pdf,2019-12-02,2019,False,original petition,Xellia Pharmaceuticals APS,industry/corporation,"Federal Food, Drug, and Cosmetic Act (FDC Act) ¬ß 505(j)
- 21 C.F.R. ¬ß¬ß 10.25(a), 10.30, 25.31, 314.3","FDA's designation of the Reference Standard (RS) for Polymyxin B Sulfate Injection in the Orange Book; specifically, FDA's selection of ANDA 207322 (Gland Pharma) as the RS","FDA should designate ANDA 202766 (Xellia Pharmaceuticals APS) as an additional RS for Polymyxin B Sulfate Injection, EQ 500,000 units base/vial","The current RS (ANDA 207322) is not the market leader and lacks alternative strengths.
- Approximately 44% of the market for the drug is filled by Xellia‚Äôs product (ANDA 202766).
- FDA policy typically designates the ‚Äúmarket leader based on units sold‚Äù as RS.
- The previous RS (ANDA 060716) is discontinued",2020-05-11 00:00:00,,2025-10-15,1.0,,,The FDA states that it has not yet resolved the issues raised in the citizen petition and supplemental petition due to the need to address other Agency priorities. The Agency promises to respond as soon as possible considering the numerous demands on its resources,,no decision,False,2144.0,pending,pending
fda-2019-p-5593,FDA-2019-P-5593-0001_Citizen_Petition_from_Hyman__Phelps___McNamara__P_.pdf,2019-11-25,2019,False,original petition,The firm submitted the petition on behalf of a client. The client's name is not disclosed.,individual,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FDC Act)
- 21 C.F.R. ¬ß 314.93
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 25.31 (environmental impact)
- 21 C.F.R. ¬ß 10.30(b) (economic impact)
- FDC Act ¬ß 505B(a)(1)(A)(i) (PREA reference)","Suitability petition for allowing submission of an Abbreviated New Drug Application (ANDA) for a new strength of an existing drug (Tramadol Hydrochloride Tablets, 25 mg) based on an existing Reference Listed Drug (ULTRAM¬Æ, 50 mg)","FDA is requested to declare that Tramadol Hydrochloride Tablets, 25 mg, is suitable for submission as an ANDA.","The proposed 25 mg strength aligns with the dosing recommendations of the RLD‚Äôs labeling (ULTRAM¬Æ), which starts titration at 25 mg/day.
- A lower dose may improve patient compliance and safety, especially since Tramadol is an opioid.
- No new clinical investigations are needed, as only the strength changes‚Äînot the indications or route of administration.
- The Pediatric Research Equity Act (PREA) is not applicable, since this is not a new active ingredient or route, only a new strength.",,,2025-10-15,0.0,,,,,no decision,False,2151.0,pending,pending
fda-2019-p-6099,FDA-2019-P-6099-0001_Citizen_Petition_from_George_M__Stone_on_behalf_of.pdf,2019-12-30,2019,False,original petition,"George M. Stone, Jr., patient and advocate
Submitted on behalf of: Patients for Access to Advanced Therapy for Hemophilia (PAATH)",advocacy/academic,"21 USC Part 352 (Misbranded drugs and devices) of the Federal Food, Drug, and Cosmetic Act

21 CFR ¬ß25.31 (Environmental impact exclusion)
No citation of section 505(q) or 21 CFR ¬ß10.30 was made","The petition addresses FDA‚Äôs handling of violations related to misbranding and distribution of expired/mislabeled hemophilia treatment products by Bayer U.S.

The FDA is encouraged to assess whether other factor producers have sufficient safeguards, indicating concern over broader FDA oversight and enforcement practices","Petitioners request the FDA Commissioner to pursue enforcement actions‚Äîincluding administrative orders or consent agreements‚Äîagainst Bayer U.S. and Bayer AG for:

Mislabeling nearly 1,000 vials of hemophilia A treatment (Kogenate FS)

Improper storage of hemophilia treatment products

Release of expired treatment products to the U.S. market

Petitioners also recommend broader FDA assessment of other factor producers‚Äô safeguards","Bayer distributed mislabeled vials containing expired and incorrect medication (Jivi instead of Kogenate FS), risking patient harm.

Emphasis on prior ethical failures by Bayer in the 1980s when Cutter Labs‚Äô Factor VIII/IX was found to be contaminated with HIV, which led to patient deaths from AIDS.

Advocates raise deep concern for product safety in the hemophilia community and insist that Bayer should not receive a ""free pass.""

Highlighted the ongoing risk to patients and historic precedent of harm as rationale for strict FDA enforcement",2020-06-08 00:00:00,"Denied
‚Äì The FDA denied the citizen petition on the grounds that it requested enforcement actions, which are outside the scope of the citizen petition process.",2020-09-25,1.0,Center for Biologics Evaluation and Research (CBER),"21 CFR 10.25(a)
- 21 CFR 10.30(e)
- 21 CFR 10.30(k)
- 21 CFR 10.3(a)
- 21 CFR Parts 210 & 211
- 21 CFR Parts 600‚Äì680
- Section 501(a)(2)(B) of the FD&C Act (21 U.S.C. ¬ß 351(a)(2)(B))
- Section 510(h)(3)-(4) of the FD&C Act (21 U.S.C. ¬ß 360(h)(3)-(4))"," The Agency cited competing priorities as the reason for the delay.
- FDA confirmed that it would respond when a decision on the request had been reached.","FDA denied the petition because requests for enforcement actions (e.g., administrative orders or consent agreements) are not proper subjects under the citizen petition process.
- The agency clarified that enforcement decisions are discretionary and governed by internal criteria and processes.
- FDA reiterated that it conducts thorough pre- and post-approval oversight of biologic drugs, including inspections and monitoring under a risk-based framework.
- The specific recall referenced (Kogenate FS) was monitored, classified as Class II, and terminated appropriately, confirming adequate manufacturer response under 21 CFR 7.55(a).",denied,True,270.0,CBER,Other/Specialty Center
fda-2019-p-3109,FDA-2019-P-3109-0001_Citizen_Petition_from_Noble_Pharma__LLC.pdf,2019-06-24,2019,False,original petition,"Noble Pharma, LLC",industry/corporation,"Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act (FFDCA)
- 21 CFR 25.15 and 21 CFR 25.30(h) (Environmental Impact)
- 21 CFR 25.21 (Extraordinary Circumstances Clause)
- 21 CFR 20.61 (Freedom of Information Act disclosure)","Determination of Suitability for ANADA Filing
Specifically, the petitioner seeks FDA's permission to submit an Abbreviated New Animal Drug Application (ANADA) for a different dosage form of an already approved veterinary drug","Allow Noble Pharma, LLC to file an ANADA for a generic flavored soft chew form of a combination dewormer drug (pyrantel pamoate and praziquantel).
- The reference product is Virbantel¬Æ, a pork liver-flavored chewable tablet approved under NADA 141-261","The proposed product will contain the same active ingredients, dosage, administration method, and therapeutic effect as the pioneer product.
- The only difference is dosage form (proposed: soft chew; pioneer: compressed chewable).
- Soft chews are considered more palatable and may increase compliance in dogs.
- All excipients used are already approved for use in dogs and will not impact the drug‚Äôs safety or efficacy",,,2025-10-15,0.0,,,,,no decision,False,2305.0,pending,pending
fda-2019-p-4670,FDA-2019-P-4670-0007_Report_from_Lonza.pdf,2020-08-13,2019,False,original petition,Lonza,individual,"Not Explicitly Cited ‚Äì The report focuses on scientific, technical, and process-specific information about cell line development and cell banking, without quoting specific statutes or regulations.","Not Directly Stated ‚Äì The document is a supporting report, likely submitted in relation to a petition requesting changes to regulatory policy or review practices, possibly regarding cell line characterization standards or comparability assessments. However, the report itself does not specify the FDA action being addressed.","Not Stated in This Report ‚Äì The report provides technical justification related to CHO (Chinese Hamster Ovary) cell lines, genetic stability, and quality control, possibly supporting a broader petition for regulatory acceptance of certain cell line practices. The action requested of the FDA would be inferred from the main petition, which is not included in this document.","Scientific Justification based on:
‚ÄÉ‚Ä¢ Extensive data on CHO cell bank generation and qualification practices.
‚ÄÉ‚Ä¢ Description of in-process controls and release tests ensuring product consistency.
‚ÄÉ‚Ä¢ Explanation of cell line stability and manufacturing controls over multiple production campaigns.
‚ÄÉ‚Ä¢ Emphasis on well-established industry practices and supporting literature.

- The report appears to argue for regulatory confidence in CHO cell-based biomanufacturing and streamlined comparability or approval processes, based on quality and risk assessments conducted over time .",,Denied. ,2022-02-24,0.0,"Center for Food Safety and Applied Nutrition (CFSAN), specifically the Office of Nutrition and Food Labeling","21 CFR 101.9(c)(6)(i) ‚Äì Definition and listing of dietary fiber
- 21 CFR 10.30 ‚Äì FDA‚Äôs citizen petition process
- 21 CFR 10.30(e)(3) ‚Äì Permits denial of a petition with justification",,"The three human studies submitted evaluated a commercial product (ResistAid‚Ñ¢) that included arabinogalactan and bioactive flavonoids (quercetin, taxifolin).
- The presence of flavonoids, which independently affect immune function, confounded the results.
- The studies did not control for flavonoids, making it scientifically impossible to isolate the effects of arabinogalactan.
- Consequently, the FDA concluded there is insufficient evidence to establish that arabinogalactan independently has a beneficial physiological effect on immune function.
- Therefore, the petition to include it as a dietary fiber was denied",denied,True,560.0,CFSAN,Other/Specialty Center
fda-2019-p-5191,FDA-2019-P-5191-0001_Citizen_Petition.pdf,,2019,False,original petition,American Olive Oil Producers Association (AOOPA) and Deoleo,advocacy/academic,"21 U.S.C. ¬ß 341 (Section 401 of the FD&C Act ‚Äì standards of identity)
- 21 C.F.R. ¬ß 10.30 (Citizen petitions)
- 21 C.F.R. ¬ß 130.6 (Deviation from established identity standards)
- 21 C.F.R. ¬ß 130.5 (General provisions for food standards)
- 21 C.F.R. ¬ß 25.32(a) (Categorical exclusion for environmental assessment)","The petition comments on the lack of enforceable standards of identity for olive oil and olive-pomace oil in the U.S. It calls out the FDA‚Äôs failure to implement uniform labeling and quality standards, despite directives from congressional committees","Promulgate regulations establishing enforceable standards of identity for olive oil and olive-pomace oil.
- The proposed standards are outlined in Appendix 1 (not included in visible pages) and draw from CDFA, Codex, EU, and other frameworks","Absence of national standards has led to mislabeling, adulteration, and consumer mistrust.
- Existing international standards (IOC, Codex) do not accommodate U.S. production variability.
- Scientific advancements (e.g., DAGs, PPPs) now allow for precise grading of olive oil quality.
- California‚Äôs CDFA standards have improved quality and can serve as a model.
- Consumers need clear, enforceable standards to make informed decisions and avoid fraudulent products",,,2025-10-15,,,,,,no decision,False,,pending,pending
fda-2019-p-5008,FDA-2019-P-5008-0001_Citizen_Petition_from_Foley_Hoag_LLP_on_behalf_of_.pdf,2019-10-25,2019,False,original petition,"Vifor Fresenius Medical Care Renal Pharma France, the NDA holder of VELPHORO¬Æ",industry/corporation,"21 U.S.C. ¬ß 355 (Section 505 of the FDCA)
- 21 C.F.R. ¬ß 10.30
- 21 U.S.C. ¬ß 355(j)(2)(A)(ii)
- 21 U.S.C. ¬ß 355(j)(2)(A)(iv)",The petitioner comments on the lack of FDA standards for identity regarding sucroferric oxyhydroxide in proposed generic versions of VELPHORO¬Æ. The petition particularly addresses FDA‚Äôs bioequivalence guidance for sucroferric oxyhydroxide and its insufficiency for determining ‚Äúsameness‚Äù of active ingredients when starches differ ,"The petitioner requests FDA to:
1. Determine that standards for identity are necessary for proposed generics of VELPHORO¬Æ with different starches.
2. Set such standards requiring ANDA sponsors to demonstrate sameness through:
¬†¬†‚Ä¢ Physicochemical equivalence
¬†¬†‚Ä¢ In vitro assays
¬†¬†‚Ä¢ Limited in vivo and genotoxicity studies ","Vifor Fresenius argues that sucroferric oxyhydroxide is a complex mixture where starches are critical to the active ingredient's structure, function, and safety. Changes to the starches may impact phosphate binding, iron release, and toxicity, which are not adequately captured by current bioequivalence guidelines. Thus, identity standards should be set, similar to other FDA precedents (e.g., Lovenox, Copaxone) for complex drugs, to avoid clinically meaningful differences",,,2025-10-15,0.0,,,,,no decision,False,2182.0,pending,pending
fda-2019-p-2289,FDA-2019-P-2289-0001_Citizen_Petition_from_Contraceptive_Study_Group.pdf,,2019,False,original petition,"The Contraceptive Study Group, a collective of physicians and healthcare professionals .",advocacy/academic,"21 C.F.R. ¬ß 10.30 (Citizen petitions)
- 21 U.S.C. ¬ß 355(d) (Substantial evidence standard for drug approval)
- 21 C.F.R. ¬ß 314.126 (Adequate and well-controlled studies)
- 505(d) of the FD&C Act .","The petition comments on the approval of the contraceptive product Amphora (a vaginal gel for the prevention of pregnancy), particularly challenging the FDA's evaluation of the efficacy data supporting the NDA for Amphora .","Request that the FDA rescind the approval of Amphora due to alleged deficiencies in the clinical trial design and failure to meet statutory efficacy requirements.
- Alternatively, request that the FDA require revisions to Amphora‚Äôs labeling to clearly reflect the limitations in its clinical evidence and contraceptive effectiveness .","The petition asserts that the single-arm, open-label study used to support Amphora‚Äôs approval did not meet the standards for adequate and well-controlled clinical investigations.
- Claims the effectiveness rate does not meet the FDA‚Äôs expectations for a viable contraceptive.
- Highlights that the trial lacked a comparator group, was not blinded, and relied on assumptions about women‚Äôs behavior.
- Argues that approval of Amphora lowers the scientific bar and poses risks to public health by misinforming users about efficacy .",,,2025-10-15,,,,,,no decision,False,,pending,pending
fda-2019-p-3937,FDA-2019-P-3937-0001_Citizen_Petition_from_Teva_Pharmaceuticals_USA__In.pdf,2019-08-20,2019,False,original petition,"Teva Pharmaceuticals USA, Inc.",industry/corporation,"21 C.F.R. ¬ß 10.25(a) (Petitions)
- 21 C.F.R. ¬ß 10.30 (Citizen petitions)
- Section 505(b)(2) of the FD&C Act (New drug application pathway)
- 21 C.F.R. ¬ß 314.3(b) (Definitions of therapeutic equivalence)
- 21 C.F.R. ¬ß 25.31 (Categorical environmental exclusion)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact submission)","Teva is commenting on FDA's policy for assigning Therapeutic Equivalence (TE) Codes to drug products approved via 505(b)(2) applications, specifically for injectable oil solutions such as its Fulvestrant Injection (NDA 210063)","Teva requests that the FDA assign a Therapeutic Equivalence Code ‚ÄúAO‚Äù to its Fulvestrant Injection, 250 mg/5 ml (50 mg/ml) product in the Orange Book, recognizing it as therapeutically equivalent to FASLODEX¬Æ (AstraZeneca)","Teva's product shares the same active ingredient, concentration, and oil vehicle (castor oil) as the reference drug, FASLODEX¬Æ.
- It meets all regulatory definitions of pharmaceutical and therapeutic equivalence.
- FDA has already approved Teva‚Äôs product under NDA 210063, demonstrating bioequivalence.
- Precedent exists for similar TE Code assignments to other ANDAs for fulvestrant injectable oil solutions (e.g., by Amneal, Mylan, and Sandoz)",,,2025-10-15,0.0,,,,,no decision,False,2248.0,pending,pending
fda-2019-p-5441,FDA-2019-P-5441-0001_Citizen_Petition_from_Hyman__Phelps___McNamara__P_.pdf,2019-11-18,2019,False,original petition,Xellia Pharmaceuticals APS,industry/corporation,"21 C.F.R. ¬ß 10.25(a) (General provision on submission of petitions)
- 21 C.F.R. ¬ß 10.30 (Citizen petitions)
- 21 C.F.R. ¬ß 25.31 (Environmental assessment exclusion)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact statement)
- FDC Act ¬ß 505(j) (ANDA provisions)
- 21 C.F.R. ¬ß 314.3 (Definitions including listed drug, RLD)","The petition comments on the lack of a commercially available Reference Standard (RS) for Polymyxin B Sulfate Injection, EQ 500,000 units base/vial, specifically the unavailability of the product under ANDA 060716, which prevents new ANDA submissions","Request that FDA designate ANDA 202766, held by Xellia Pharmaceuticals APS, as a new Reference Standard (RS) for Polymyxin B Sulfate Injection, EQ 500,000 units base/vial, and update the Orange Book accordingly","The current RS (ANDA 060716) is commercially unavailable and appears to have been discontinued.
- Without an available RS, ANDA submissions cannot proceed, effectively blocking generic competition.
- Xellia‚Äôs product under ANDA 202766 is readily accessible and suitable for RS designation.
- FDA‚Äôs own Draft Guidance for Industry (Jan. 2017) allows for designation of a new RS via citizen petition when RS is unavailable",2020-05-11 00:00:00,,2025-10-15,1.0,,,The FDA states that it has not yet resolved the issues raised in the citizen petition and supplemental petition due to the need to address other Agency priorities. The Agency promises to respond as soon as possible considering the numerous demands on its resources,,no decision,False,2158.0,pending,pending
fda-2019-p-3803,FDA-2019-P-3803-0001_Citizen_Petition_from_Hyman__Phelps___McNamara_P_C.pdf,2019-08-12,2019,False,original petition,"The law firm represents an unspecified client, but the substance of the petition strongly supports Amneal Pharmaceuticals Inc., whose product (ANDA 075109) is proposed as the new Reference Standard (RS)",law/consulting,"21 C.F.R. ¬ß 10.25(a) (General provision for petitions)
- 21 C.F.R. ¬ß 10.30 (Citizen petitions)
- 21 C.F.R. ¬ß 25.31 (Environmental assessment exclusion)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact disclosure)
- FDC Act ¬ß 505(j) (ANDA framework)
- 21 C.F.R. ¬ß 314.3 (Definitions: reference listed drugs, etc.)","The petition addresses FDA‚Äôs failure to designate an accessible Reference Standard (RS) for Guanfacine Hydrochloride Tablets, which impedes the filing of new ANDAs due to the inaccessibility of the current RS (ANDA 074796)","Request that FDA designate ANDA 075109 (Amneal‚Äôs Guanfacine Hydrochloride Tablets, 1 mg and 2 mg) as a new Reference Standard in the Orange Book to replace the current unavailable RS (ANDA 074796)","Current RS (ANDA 074796) is commercially unavailable despite being designated in June 2018.
- As a result, Guanfacine Tablets are shielded from generic competition.
- ANDA 075109 (held by Amneal) is commercially available, appears to lead the market in U.S. sales, and meets the criteria for RS designation.
- Cites FDA‚Äôs own 2017 Draft Guidance which allows RS redesignation via citizen petition when current RS is not available",,,2025-10-15,0.0,,,,,no decision,False,2256.0,pending,pending
fda-2019-p-3903,FDA-2019-P-3903-0001_Citizen_Petition_from_Hyman__Phelps___McNamara_P_C.pdf,2019-08-16,2019,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"21 C.F.R. ¬ß 10.25(a) (Submission of petitions)
- 21 C.F.R. ¬ß 10.30 (Citizen petitions)
- 21 C.F.R. ¬ß 25.31 (Environmental impact exclusions)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact submission)
- FDC Act ¬ß 505(j) (ANDA provisions)
- 21 C.F.R. ¬ß 314.3 (Definition of listed drug and reference standard)","The petitioner is addressing the lack of an accessible Reference Standard (RS) for Lidocaine Hydrochloride Oral Solution, 2%, specifically that the current RS (ANDA 040708) is commercially unavailable","	Petitioner requests that FDA designate a new RS, preferably ANDA 040014 (Hi-Tech Pharmaceuticals), for Lidocaine Hydrochloride Oral Solution, 2%, and update the Orange Book to reflect this designation","The current RS (ANDA 040708) is not commercially available, impeding ANDA submissions.
- Without a viable RS, the drug is effectively shielded from generic competition.
- ANDA 040014 (Hi-Tech Pharmaceuticals) is widely available and leads the U.S. market in sales volume (per IMS data), making it a suitable candidate for RS designation.
- FDA precedent supports designating a new RS via citizen petition when the existing RS is unavailable",2020-02-12 00:00:00,"Approved ‚Äî FDA granted the petition to designate lidocaine HCl oral solution 2% (ANDA 040014, Hi-Tech Pharmacal Co. Inc.) as a new reference standard.",2020-07-31,1.0,Center for Drug Evaluation and Research (CDER),"Section 505(j) of the FD&C Act (21 U.S.C. ¬ß 355(j))
- 21 CFR ¬ß 314.3(b)
- 21 CFR ¬ß 314.94(a)(3)
- 81 FR 69580, 69619 (Oct. 6, 2016)","The FDA stated that it was unable to reach a decision on the petition due to the need to address other Agency priorities.
- The response was provided in accordance with regulations governing citizen petitions","The current reference standard (ANDA 040708 by Lannett Company, Inc.) is no longer commercially available.
- The Hi-Tech Pharmacal product is therapeutically equivalent and identified as the market leader.
- Regulatory precedent allows FDA to designate a generic drug as a reference standard when the RLD is unavailable",approved,True,350.0,CDER,CDER
fda-2019-p-1783,FDA-2019-P-1783-0001_Citizen_Petition_from_Public_Citizen.pdf,2019-04-10,2019,False,original petition,"Public Citizen, specifically the Health Research Group",advocacy/academic,"21 C.F.R. ¬ß 10.30 (Citizen petitions)
- 21 C.F.R. ¬ß 25.31(a) (Environmental assessment exclusions)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact statement)
- 21 U.S.C. ¬ß 355(e) (Section 505 of the FD&C Act ‚Äì withdrawal of drug approval)","The petition challenges the FDA's continued Over-the-Counter (OTC) approval of oral phenylephrine as a nasal decongestant, alleging it is ineffective at marketed dosages and should no longer be considered Generally Recognized As Safe and Effective (GRASE)","Revoke the GRASE designation for oral phenylephrine when used as a nasal decongestant.
- Remove all OTC products containing oral phenylephrine for that purpose from the market.
- Require reformulation, relabeling, or withdrawal of affected drugs","Public Citizen cites numerous clinical trials showing oral phenylephrine to be no more effective than placebo at standard OTC dosages.
- Points to FDA's 2007 advisory committee discussion questioning its effectiveness.
- Notes a lack of new evidence justifying the drug‚Äôs continued availability.
- Expresses concern about consumers being misled into purchasing ineffective treatments, creating public health and financial risks",,Denied,2019-09-06,0.0,Center for Drug Evaluation and Research (CDER),"21 CFR Part 314 ‚Äì Procedures and standards for new drug applications (NDAs)

FD&C Act Section 505 ‚Äì Statutory basis for drug approval and timelines

FD&C Act Section 505(c)(1) ‚Äì Approval standards within 180 days

FD&C Act Section 505(q) ‚Äì Procedures for citizen petitions impacting drug approval

84 FR 29111 and 29112 ‚Äì Federal Register notices about public hearings and guidance availability (June 21, 2019)

Other references include:

Public Law 110-85 (FDAAA)

Public Law 112-144 (FDASIA)

NASEM Report (2017) ‚Äì ‚ÄúPain Management and the Opioid Epidemic‚Äù",,"FDA Cannot Impose a Blanket Moratorium:
The agency emphasized that it is legally required under the FD&C Act to evaluate each new drug application (NDA) based on established regulatory procedures. FDA cannot impose a moratorium on new opioid approvals as requested by the petitioners without contravening its statutory obligations
.

Ongoing Risk Mitigation Measures:
FDA highlighted numerous actions it has taken to mitigate opioid risks, including:

Strengthening REMS programs

Expanding labeling requirements

Issuing warning letters to violators

Monitoring post-marketing safety data
.

Draft Guidance Issued on Opioid Benefit-Risk Framework:
In response to the 2017 NASEM report, FDA issued draft guidance describing a new framework for assessing the public health impact of opioid analgesics. This includes additional benefit-risk criteria that incorporate societal considerations such as abuse potential and overdose risk
.

Petition Overlaps with Ongoing FDA Efforts:
FDA acknowledged that many concerns raised by the petition were already being addressed through its draft guidance and regulatory actions. A public hearing was also announced (held September 17, 2019) to solicit input on further strengthening the opioid approval framework
.

Statutory Review Timelines Enforced:
Under Section 505(q), FDA was required to respond to the petition within 150 days, which it did. The agency emphasized that it is continuing to evaluate comments and refine its opioid regulatory approach while adhering to current legal standards.",denied,True,149.0,CDER,CDER
fda-2019-p-2124,FDA-2019-P-2124-0001_Petition_for_Administrative_Reconsideration_from_C.pdf,2018-04-28,2019,False,reconsideration,"Celltrion, Inc.",industry/corporation,"42 U.S.C. ¬ß 262(k)(7) ‚Äî Exclusivity provision of the Public Health Service Act (PHSA)
- 21 C.F.R. ¬ß 10.33 ‚Äî Procedures for reconsideration of FDA decisions
- 21 C.F.R. ¬ß 10.35(e) ‚Äî Stay of action provisions
- Section 351(k) of the PHSA
- Section 351(a) of the PHSA
- References to FDA‚Äôs Final Guidance on Exclusivity Determination of Biosimilars","The petition challenges FDA‚Äôs interpretation of ‚Äúfirst licensure‚Äù under section 351(k)(7) of the PHSA, particularly regarding its application to Amgen‚Äôs biologic product EPOGEN¬Æ/Epogen (epoetin alfa).","Reconsider the FDA‚Äôs determination that Amgen‚Äôs biologic product Epogen qualified for 12 years of exclusivity starting in 2018 based on a new BLA.
- Find that Amgen‚Äôs previous approval history under 351(a) disqualifies it from new exclusivity under the cited provision.
- Stay approval of any BLAs relying on this exclusivity interpretation until FDA makes a revised determination.","Celltrion argues that FDA improperly granted a new 12-year exclusivity period for Amgen‚Äôs Epogen even though it was previously licensed under a full BLA before.
- This undermines the balance Congress struck between innovation and biosimilar competition under the Biologics Price Competition and Innovation Act (BPCIA).
- The petition emphasizes that Amgen‚Äôs ‚Äúfirst licensure‚Äù occurred decades earlier, and the new BLA should not reset the exclusivity clock.
- Cites precedent, statutory interpretation, legislative intent, and regulatory guidance inconsistencies to support their position.",,,2025-10-15,0.0,,,,,no decision,False,2727.0,pending,pending
fda-2019-p-3855,FDA-2019-P-3855-0026_Amendment_to_Citizen_Petition_from_Latham___Watkin.pdf,2019-12-04,2019,False,original petition,"Genus Lifesciences, Inc.",industry/corporation,"21 U.S.C. ¬ß 355 (sections 505(e) and 505(q))
- 21 C.F.R. ¬ß 10.30(g)
- 5 U.S.C. ¬ß 706(2)(A)
- 21 C.F.R. ¬ß 314.101(d)(9)","FDA‚Äôs acceptance for filing of Lannett Company, Inc.‚Äôs 505(b)(2) application for cocaine hydrochloride, despite incomplete renal and hepatic toxicity studies, and during Genus‚Äôs NCE exclusivity period.","FDA must accept any new NDA submission from Lannett only after it completes the required renal and hepatic toxicity studies.
- FDA must refuse to approve any NDA for cocaine hydrochloride product unless QT, renal, hepatic, and leachable studies (similar to those conducted by Genus) are completed.
- FDA must rescind acceptance of any 505(b)(2) application for cocaine hydrochloride product submitted by Lannett that circumvents Genus‚Äôs NCE exclusivity.","FDA required Genus to complete rigorous QT, renal, and hepatic toxicity studies and to include specific labeling precautions based on those results before approving its product (Goprelto).
- Lannett's application allegedly bypassed these requirements and was still accepted by FDA, resulting in an unfair regulatory advantage.
- FDA‚Äôs action is claimed to be arbitrary, capricious, and contrary to law (violation of APA), and prejudicial to Genus‚Äôs NCE exclusivity rights which extend to December 14, 2022.
- FDA must apply equal standards and ensure safety and efficacy through equivalent studies.",,Denied,2020-01-10,0.0,Center for Drug Evaluation and Research (CDER),"21 U.S.C. ¬ß 355(b)(2) ‚Äì Relating to New Drug Applications (NDAs) under the 505(b)(2) pathway

21 CFR 314.101(a)(3) ‚Äì Refusal to file NDAs with certain deficiencies

21 CFR 314.101(d) ‚Äì Conditions under which the FDA will refuse to file an application

21 CFR 314.50 ‚Äì NDA content and format

21 CFR 314.94 ‚Äì Abbreviated New Drug Applications (ANDAs)

21 CFR 314.125(b)(1) ‚Äì Grounds for denying NDA approval

FDA Guidance Documents Referenced:

Guidance for Industry: Pharmacokinetics in Patients with Impaired Renal Function

Guidance for Industry: Pharmacokinetics in Patients with Impaired Hepatic Function

FDA‚Äôs Manual of Policies and Procedures (MAPP) 4000.4 ‚Äì NDA filing review issues

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

FDA Product-Specific Guidance documents for bioequivalence",,"Equal Filing Standards:
The FDA found that it had applied the same filing standards to both Genus's and Lannett's applications for cocaine HCl nasal solution. Both companies were required to provide equivalent types of data, though each chose different approaches (e.g., literature-based vs. dedicated clinical studies).

Sufficient Data for Filing:
Lannett submitted sufficient information, including clinical pharmacology, toxicology, and leachables data, to support filing and eventual approval. FDA determined that the studies provided were adequate for substantive review and that additional studies‚Äîthough different from Genus's‚Äîwere not legally required.

No Discriminatory Requirements:
The FDA explicitly rejected the claim that it unfairly imposed more demanding requirements on Genus. It clarified that applicants have flexibility in how they fulfill filing requirements and that Genus had the option to rely on literature or alternative data sources like Lannett did.

Scientific and Regulatory Sufficiency:
FDA emphasized that it does not require ""perfect alignment"" of datasets across applications, only that the data be sufficient for review. It found no reason to invalidate the filing or approval of Lannett‚Äôs application.

No Legal Obligation to Delay Lannett‚Äôs NDA:
The agency disagreed with Genus‚Äôs interpretation of 505(c)(3)(E)(ii) exclusivity protections. It asserted that Lannett‚Äôs NDA was permissible under applicable rules and did not violate exclusivity provisions.",denied,True,37.0,CDER,CDER
fda-2019-p-2070,FDA-2019-P-2070-0001_Citizen_Petition_from_TechReg_Services__Inc_.pdf,2019-04-19,2019,False,original petition,"TechReg Services, Inc.",industry/corporation,"21 CFR ¬ß 10.20
- 21 CFR ¬ß 10.30
- 21 CFR ¬ß 314.93
- Section 505(j)(2)(C) of the FD&C Act
- 21 CFR ¬ß 314.94(a)(6)
- 21 CFR ¬ß 25.31(a) (Environmental Impact)
- 21 CFR ¬ß 10.30(b) (Economic Impact)
- Referenced FDA Guidance Documents:
- ANDA Submissions ‚Äì Refuse-to-Receive Standards (Dec 2016)
- Allowable Excess Volume and Labeled Vial Fill Size in Injectable Drug and Biological Products (June 2015)","The petitioner seeks a determination from FDA on whether proposed 8 mL and 16 mL vial fill volumes for Norepinephrine Bitartrate Injection, USP are suitable for inclusion in an ANDA. This indirectly addresses FDA‚Äôs restrictive interpretation of fill volume differences as strength deviations requiring prior suitability petition approval.","Petitioner requests that FDA determine the suitability of 8 mL and 16 mL per vial fill volumes of Norepinephrine Bitartrate Injection, USP, for inclusion in an Abbreviated New Drug Application (ANDA), in addition to the currently approved 4 mL per vial reference listed drug (RLD) LEVOPHED.","FDA guidance defines drug ""strength"" as a combination of concentration and fill volume; deviations in fill volume alone may still require a suitability petition.
- The proposed product is compositionally identical to the RLD in concentration and formulation.
- Higher fill volumes would reduce the number of vials needed for dilution, lowering contamination risks and simplifying preparation.
- Proposed labeling would only differ in the ‚ÄúHow Supplied‚Äù section, maintaining consistency in indications, warnings, and directions for use.
- Visual and packaging differences will clearly differentiate vial sizes, reducing dosing errors",,,2025-10-15,0.0,,,,,no decision,False,2371.0,pending,pending
fda-2019-p-5237,FDA-2019-P-5237-0001_Citizen_Petition_from_Aurobindo_Pharma_USA__Inc__R.pdf,2019-11-05,2019,False,original petition,Aurobindo Pharma Limited,industry/corporation,"Federal Food, Drug & Cosmetic Act ¬ß 505(j) (generic-drug provisions)
* 21 C.F.R. ¬ß 10.25(a) (general petitions)
* 21 C.F.R. ¬ß 10.30 (citizen petitions)
* 21 C.F.R. ¬ß 314.93 (suitability/reference-standard petitions)
* 21 C.F.R. ¬ß 25.31(a) (categorical environmental exclusion)
* 21 C.F.R. ¬ß 10.30(b) (economic-impact statement)","Reference-standard designation policy for Amoxicillin & Clavulanate Potassium ER 1000 mg / 62.5 mg tablets ‚Äì the current Orange-Book RS (Augmentin XR¬Æ, NDA 050785) is ‚Äúso limited‚Äù in distribution that it cannot be obtained for in-vivo bio-equivalence testing.","Ask FDA to designate the marketed generic product (ANDA 090227, Sandoz Inc.) as the new Reference Standard (RS) for this strength, so ANDA applicants can rely on it for bio-equivalence studies.","Current RS unavailable: distributors report no samples of Augmentin XR¬Æ (NDA 050785).
* Guidance support: FDA draft guidance (Referencing Approved Drug Products in ANDA Submissions, Section III.C.2-3) allows FDA to select a new RS when supply is insufficient.
* Market leader & AB-rated: Sandoz‚Äôs ANDA 090227 is the only product actively marketed, meets TE code AB, and therefore fits FDA selection criteria.
* Timely access: Without a usable RS, potential ANDA applicants cannot perform required in-vivo studies, delaying generic competition.",2020-04-24 00:00:00,Approved (Petition Granted) ‚Äî The FDA agreed to select ANDA 090227 (Sandoz Inc.) as the new reference standard for amoxicillin and clavulanate potassium extended-release tablets (1000 mg / 62.5 mg).,2020-09-08,1.0,Center for Drug Evaluation and Research (CDER),"Section 505(j) of the FD&C Act (21 U.S.C. ¬ß 355(j))
- 21 CFR ¬ß 314.3(b)
- 21 CFR ¬ß 314.94(a)(3)
- 21 CFR ¬ß 314.161(a)(1)
- 21 CFR ¬ß 314.122(c)
- 21 CFR ¬ß 314.127(a)(11)",The petition requested that the FDA designate a suitable alternative reference standard (RS) for in vivo bioequivalence studies related to an ANDA for Amoxicillin and Clavulanate Potassium Extended Release Tablets. The FDA stated it could not yet reach a decision due to the need to address other agency priorities and indicated that a final response would be provided as soon as possible,"The current reference listed drug (Augmentin XR) was found to be unavailable in the market.
- FDA reviewed commercial and regulatory data confirming market unavailability and affirmed that ANDA 090227 (Sandoz) is therapeutically equivalent and the current market leader.
- Selecting a generic drug as the reference standard is permissible when the RLD is no longer marketed, ensuring consistent bioequivalence testing.",approved,True,308.0,CDER,CDER
fda-2019-p-1366,FDA-2019-P-1366-0001_Citizen_Petition_from_Cardinal_Health_Regulatory_S.pdf,2019-01-31,2019,False,original petition,Cardinal Health Regulatory Sciences,law/consulting,"21 CFR ¬ß 10.30 ‚Äî Citizen petition procedures
- 21 CFR ¬ß 314.161 ‚Äî Determination of withdrawal from sale
- 21 CFR ¬ß 314.122, 314.162 ‚Äî Additional references to drug withdrawal evaluation
- 21 CFR ¬ß 25.31 ‚Äî Environmental impact (categorical exclusion)
- 21 CFR ¬ß 10.30(b) ‚Äî Economic impact provision","The FDA‚Äôs continued listing of CLAFORAN¬Æ (Cefotaxime Sodium for Injection, NDA 050547) in the Orange Book as a reference listed drug (RLD), despite it being discontinued in all strengths. The petitioner is asking for clarification on whether the drug was withdrawn for safety or efficacy reasons","Cardinal Health requests that the FDA determine whether CLAFORAN¬Æ (Cefotaxime Sodium for Injection, 500 mg, 1 g, 2 g, 10 g/vial) has been withdrawn for reasons of safety or effectiveness, as required before allowing an ANDA or 505(b)(2) application to reference a discontinued product","The Orange Book lists all strengths of CLAFORAN¬Æ (NDA 050547) as discontinued as of January 30, 2019.
- If a product is no longer marketed, FDA must assess whether it was withdrawn for safety or efficacy reasons before it can be used as a reference product.
- This determination impacts the eligibility of future ANDAs or 505(b)(2) applications referencing the discontinued product",,"Approved ‚Äì FDA determined that CLAFORAN (cefotaxime sodium) for injection, 500 mg/vial, 1 g/vial, 2 g/vial, and 10 g/vial was not withdrawn for reasons of safety or effectiveness, and it will remain listed in the Discontinued Drug Product List of the Orange Book.",2019-07-03,0.0,Center for Drug Evaluation and Research (CDER),"21 CFR 314.161 ‚Äì Determination that a drug was not withdrawn for safety or effectiveness
- 21 CFR 314.162 ‚Äì Drug removals from the Orange Book
- Section 505(j)(7) of the FD&C Act (21 U.S.C. 355(j)(7)) ‚Äì Listing of approved drugs in the Orange Book",,"The petitioner provided no data suggesting the drug was withdrawn for safety or efficacy concerns.
- FDA independently reviewed records, literature, and postmarketing data, and found no indication that the product was withdrawn for such reasons.
- Therefore, ANDAs may continue referencing it.",approved,True,153.0,CDER,CDER
fda-2019-p-1594,FDA-2019-P-1594-0001_QHC_Petition___Petition_for_the_Authorization_of_a.pdf,2018-12-18,2019,False,original petition,"QHC Petition, LLC",industry/corporation,"21 CFR ¬ß 101.14 ‚Äî Health claim general requirements
- 21 CFR ¬ß 101.70 ‚Äî Submission procedures for health claims
- FDA Modernization Act of 1997 (FDAMA) ‚Äî Regarding qualified health claims
- Pearson v. Shalala ‚Äî Court case cited in support of 1st Amendment rights related to health claims",The petition addresses FDA‚Äôs current policy requiring significant scientific agreement (SSA) for authorized health claims and seeks permission for a qualified health claim regarding magnesium intake and reduced risk of high blood pressure.,"The petitioner asks FDA to:
1. Authorize a qualified health claim linking magnesium consumption to reduced risk of high blood pressure.
2. Allow five different versions of this qualified claim, with varying qualifiers and disclaimers, including proposed claim language such as:
- ‚ÄúSome scientific evidence suggests that diets with adequate magnesium may reduce the risk of high blood pressure‚Ä¶‚Äù
- ‚ÄúMagnesium may reduce the risk of high blood pressure. FDA has concluded that the evidence is inconsistent and not conclusive.‚Äù","The petition cites meta-analyses, randomized controlled trials (RCTs), and cohort studies showing an association between magnesium intake and lower blood pressure.
- Argues that while the evidence may not meet the FDA‚Äôs ‚Äúsignificant scientific agreement‚Äù threshold, it meets the standard for a qualified health claim.
- Asserts that consumers benefit from access to truthful, non-misleading health information, consistent with constitutional protections established in Pearson v. Shalala.
- Proposes that allowing qualified claims helps avoid public misinformation and allows market-driven health promotion.",2019-11-22 00:00:00,Acknowledgment / Initial Review ‚Äì FDA acknowledges receipt of the petition and states it is undergoing initial review. No final decision has been made yet,2019-03-13,2.0,"Center for Food Safety and Applied Nutrition (CFSAN) ‚Äì specifically, the Office of Nutritional and Food Labeling, Nutrition Programs and Labeling Staff, signed by Cherisa Henderson, MPH","July 10, 2003 Task Force Final Report on the Consumer Health Information for Better Nutrition Initiative","The FDA requested a 180-day extension from the current due date (Nov 25, 2019) in order to complete their review of the petition regarding the health claim that yogurt consumption reduces the risk of type 2 diabetes. The extension would shift the decision deadline to May 26, 2020.","This is an acknowledgment letter indicating that the petition is under initial FDA review. It notes that a decision to file or deny the petition will be made within 45 days from receipt (February 26, 2019). The letter outlines the process and possible outcomes if the FDA does not act within the 45-day timeframe",other,True,85.0,CFSAN,Other/Specialty Center
fda-2019-p-1525,FDA-2019-P-1525-0001_Revised_Citizen_Petition_from_Baxter_Healthcare_Co.pdf,2019-03-29,2019,False,original petition,Baxter Healthcare Corporation,industry/corporation,"Section 505(j) of the Federal Food, Drug, and Cosmetic Act
- 21 CFR ¬ß 10.25(a)
- 21 CFR ¬ß 10.30
- 21 CFR ¬ß 314.161(a)(1)
- 21 CFR ¬ß 314.162
- 21 CFR ¬ß 25.31 (environmental impact exclusion)
- 21 CFR ¬ß 10.30(b) (economic impact)",FDA's listing of CARDENE¬Æ (Nicardipine Hydrochloride Injection) 25 mg/10 mL as discontinued in the Orange Book without a public determination as to whether the drug was withdrawn for reasons of safety or effectiveness,"Baxter requests that FDA:
1. Determine whether CHIESI USA Inc.‚Äôs CARDENE¬Æ (NDA 019734) was withdrawn for safety or effectiveness reasons.
2. Designate an additional Reference Listed Drug (RLD) if applicable","CARDENE¬Æ 25 mg/10 mL is listed as discontinued in the Orange Book, and Baxter seeks to use it for ANDA referencing.
- FDA regulations require a formal determination before a discontinued product can be used in an ANDA submission.
- Baxter had previously submitted a Controlled Correspondence on this topic, and FDA directed them to submit a Citizen Petition.
- FDA guidance (‚ÄúReferencing Approved Drug Products in ANDA Submissions‚Äù) requires such petitions for drugs listed as discontinued without a safety/effectiveness determination",,"Partially Approved:
- The FDA granted the request to determine that CARDENE (nicardipine hydrochloride) injection, 25 mg/10 mL was not withdrawn for safety or effectiveness reasons.
- However, the FDA has not reached a decision on the request to designate an additional reference listed drug (RLD).",2020-01-23,0.0,"Center for Drug Evaluation and Research (CDER), Office of Regulatory Policy","Cited document: Federal Register notice announcing the FDA determination (exact citation not listed in the letter).
- Mention of the ‚ÄúDiscontinued Drug Product List‚Äù section of the Approved Drug Products With Therapeutic Equivalence Evaluations (the Orange Book)",,"FDA reviewed its records and determined that CARDENE was not withdrawn from sale due to safety or effectiveness reasons, and it will therefore remain listed in the Orange Book.
- The agency has not yet acted on the RLD designation request due to competing priorities and resource limitations.",partially approved / denied,True,300.0,CDER,CDER
fda-2019-p-5268,FDA-2019-P-5268-0016_Supplement_from_Public_Citizen.pdf,2020-05-28,2019,False,original petition,Public Citizen‚Äôs Health Research Group,advocacy/academic,"Controlled Substances Act (CSA) ‚Äî Petition requests scheduling action under this statute.
FDA labeling requirements and pharmacogenomic guidance implied but no CFR references explicitly listed in the supplement.","The supplement comments on the lack of action taken on the original petition (submitted Nov. 6, 2019), which requested reclassification of tramadol from Schedule IV to Schedule II under the Controlled Substances Act.","The petitioner reaffirms the original request: Reschedule tramadol (and all related salts, isomers) from Schedule IV to Schedule II of the Controlled Substances Act.","Public Citizen provides multiple layers of justification:
1. Labeling parity: Tramadol's boxed warnings match those of Schedule II opioids (e.g., oxycodone) on addiction, misuse, and respiratory depression.
2. Pharmacogenetic risk: Individuals with the CYP2D6 ultra-rapid metabolizer genotype face significantly higher risks of fatal overdose ‚Äî yet testing is not routinely done before prescribing.
3. High prescribing volume: Tramadol became one of the most prescribed opioids in the U.S. after hydrocodone‚Äôs 2014 rescheduling.
4. Misuse data: National Survey data show more people misuse tramadol than many Schedule II drugs, including morphine and fentanyl.
5. Increased mortality: Post-2014 studies show elevated mortality risks tied to tramadol use.
6. Post-op addiction risk: Tramadol has been shown to result in greater long-term opioid use after surgery than other Schedule II opioids.
7. Adverse event data: FDA‚Äôs FAERS database (2004‚Äì2016) lists tramadol as the 4th most frequent opioid associated with adverse events and 5th in deaths, nearly equaling fentanyl in number of reported adverse events (see Table 1 on page 3).",,Denied ‚Äì The petition to initiate proceedings to reschedule tramadol from Schedule IV to Schedule II of the Controlled Substances Act was denied,2024-07-29,0.0,Center for Drug Evaluation and Research (CDER),"21 CFR 1308.14(b)(3) ‚Äì Current scheduling of tramadol

- 21 U.S.C. 801-971 ‚Äì Comprehensive Drug Abuse Prevention and Control Act (CSA)

- 21 U.S.C. 812(b) ‚Äì CSA scheduling criteria

- 21 CFR 1308.43(a), (d) ‚Äì DEA petition process

- 21 U.S.C. 811 ‚Äì DEA scheduling authority",,"Authority & Process: The scheduling of controlled substances is under DEA jurisdiction. FDA provides scientific and medical evaluations but does not itself reschedule drugs.
- Past Scheduling Decision: DEA previously evaluated tramadol and placed it in Schedule IV in 2014 after input from FDA and a public process.
- Labeling & Safety Updates: Since the petition, FDA has updated tramadol labeling to include more detailed warnings (e.g., addiction, respiratory depression, hyponatremia, hypoglycemia).
- Monitoring & Advisory Committees: FDA held advisory meetings (2020, 2022) and continues monitoring tramadol safety.
- Conclusion: Given the existing framework and actions already taken, FDA denied the request to initiate rescheduling proceedings",denied,True,1523.0,CDER,CDER
fda-2019-p-4002,FDA-2019-P-4002-0001_Citizen_Petition_from_Otsuka_Pharmaceutical_Develo.pdf,2019-08-22,2019,False,original petition,"Otsuka Pharmaceutical Co., Ltd.",industry/corporation,"505(j) and 505(q) of the FDCA
- 21 C.F.R. ¬ß¬ß 10.30 and 314.161
- 21 C.F.R. ¬ß 314.127
- 21 C.F.R. ¬ß 25.31
- 21 C.F.R. ¬ß¬ß 314.150, 314.151, 314.153
- FDCA ¬ß 505(w)","The petition comments on FDA‚Äôs allowance of Abbreviated New Drug Applications (ANDAs) citing SAMSCA (tolvaptan) 60 mg as the Reference Listed Drug (RLD), especially in light of the approval of JYNARQUE for a different indication with a REMS program. ","Otsuka requests that the FDA:
1. Determine that SAMSCA 60 mg should not be approved and can no longer serve as an RLD for ANDAs.
2. Refuse to approve any pending ANDA for a generic version of SAMSCA 60 mg.
3. Suspend and withdraw the approval of any ANDA for a generic version of SAMSCA 60 mg.","Otsuka argues that:
- SAMSCA 60 mg tablets have never been marketed.
- Their existence could allow off-label use as a substitute for JYNARQUE, undermining the REMS program.
- Off-label use increases risk of serious, potentially fatal liver injury due to lack of monitoring requirements outside the REMS.
- FDA has previously taken similar actions based on off-label risks (e.g., Palladone and OxyContin).
- No clinical need exists for the 60 mg SAMSCA tablet in treating hyponatremia. ",,Denied,2020-01-16,0.0,Center for Drug Evaluation and Research (CDER),"21 CFR 314.161 ‚Äì Determining if a drug was withdrawn for safety or effectiveness

21 CFR 314.162 ‚Äì Procedure for removing a drug from the list

21 CFR 314.94(a)(7) ‚Äì Application requirements for ANDAs

21 CFR 314.94(a)(6)(i) ‚Äì Labeling requirements for ANDAs

21 CFR 314.127(a)(6)(i) ‚Äì Approval standards

21 CFR 314.3(b) ‚Äì Definition of RLD (Reference Listed Drug)

Section 505(j) of the FD&C Act ‚Äì Related to ANDA approval process

Section 505-1 of the FD&C Act ‚Äì Risk Evaluation and Mitigation Strategy (REMS)

81 FR 50710 (August 2, 2016) ‚Äì Determination that Samsca was not withdrawn for safety or effectiveness

Citizen Petition Precedents:

Palladone (NDA 021044)

OxyContin (NDA 022272)",,"Samsca 60-mg Tablets Were Not Withdrawn for Safety or Effectiveness:
FDA reaffirmed its 2016 determination that the 60-mg strength of Samsca was not withdrawn due to safety concerns, even though it is listed as ‚Äúdiscontinued‚Äù in the Orange Book. The product remains part of NDA 022275 and is still eligible to serve as a Reference Listed Drug (RLD)
.

Updated Labeling with Boxed Warning Was Adequate:
The risk of hepatotoxicity and misuse of Samsca to treat ADPKD was addressed in 2018 through updated labeling. FDA concluded that no further regulatory measures (e.g., withdrawal or REMS) were necessary
.

ANDA Statutory Framework Satisfied:
FDA clarified that an ANDA applicant does not need to independently demonstrate safety/effectiveness but must rely on the FDA‚Äôs findings for the RLD and prove bioequivalence. The agency found no legal reason to refuse or suspend approval of any ANDAs referencing Samsca 60-mg tablets
.

Speculative Concerns Insufficient:
The petition raised hypothetical concerns that Samsca might be used off-label in place of Jynarque (also a tolvaptan product). FDA found no evidence to support that such misuse was occurring or posed sufficient risk to justify regulatory changes
.

Comparison to Palladone and OxyContin Not Persuasive:
FDA distinguished the case of Samsca from withdrawals of other drugs like Palladone and OxyContin, emphasizing that those drugs posed direct public health threats that were not present in the case of Samsca
.       ",denied,True,147.0,CDER,CDER
fda-2019-p-3855,FDA-2019-P-3855-0025_Amendment_to_Citizen_Petition_from_Latham___Watkin.pdf,2019-11-27,2019,False,original petition,Latham & Watkins LLP,law/consulting,"21 C.F.R. ¬ß 10.30(g)
- 21 C.F.R. ¬ß 314.101(d)(9)
- 21 U.S.C. ¬ß 355(c)(3)(E)(ii)
- 5 U.S.C. ¬ß 706(2)(A)","Acceptance and review of Lannett Company, Inc.‚Äôs 505(b)(2) application for a cocaine hydrochloride product without the required toxicity studies that FDA mandated for Genus.","Rescind FDA‚Äôs acceptance of Lannett‚Äôs 505(b)(2) NDA application
- Refuse future filings for Lannett‚Äôs product before Genus's NCE exclusivity expires
- Refuse approval of any NDA for cocaine hydrochloride products without comparable QT, renal, hepatic, and leachable studies","FDA required Genus to conduct QT, renal, and hepatic toxicity studies prior to NDA filing.
- FDA accepted Lannett‚Äôs NDA without equivalent studies, creating an unequal standard.
- FDA‚Äôs action was arbitrary, capricious, and contrary to law.
- Genus‚Äôs NCE exclusivity should prevent FDA from accepting or approving Lannett‚Äôs application.
- Approval of Lannett‚Äôs product without equivalent safety data could pose public health risks.",,Denied,2020-01-10,0.0,Center for Drug Evaluation and Research (CDER),"21 U.S.C. ¬ß 355(b)(2) ‚Äì Relating to New Drug Applications (NDAs) under the 505(b)(2) pathway

21 CFR 314.101(a)(3) ‚Äì Refusal to file NDAs with certain deficiencies

21 CFR 314.101(d) ‚Äì Conditions under which the FDA will refuse to file an application

21 CFR 314.50 ‚Äì NDA content and format

21 CFR 314.94 ‚Äì Abbreviated New Drug Applications (ANDAs)

21 CFR 314.125(b)(1) ‚Äì Grounds for denying NDA approval

FDA Guidance Documents Referenced:

Guidance for Industry: Pharmacokinetics in Patients with Impaired Renal Function

Guidance for Industry: Pharmacokinetics in Patients with Impaired Hepatic Function

FDA‚Äôs Manual of Policies and Procedures (MAPP) 4000.4 ‚Äì NDA filing review issues

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

FDA Product-Specific Guidance documents for bioequivalence",,"Equal Filing Standards:
The FDA found that it had applied the same filing standards to both Genus's and Lannett's applications for cocaine HCl nasal solution. Both companies were required to provide equivalent types of data, though each chose different approaches (e.g., literature-based vs. dedicated clinical studies).

Sufficient Data for Filing:
Lannett submitted sufficient information, including clinical pharmacology, toxicology, and leachables data, to support filing and eventual approval. FDA determined that the studies provided were adequate for substantive review and that additional studies‚Äîthough different from Genus's‚Äîwere not legally required.

No Discriminatory Requirements:
The FDA explicitly rejected the claim that it unfairly imposed more demanding requirements on Genus. It clarified that applicants have flexibility in how they fulfill filing requirements and that Genus had the option to rely on literature or alternative data sources like Lannett did.

Scientific and Regulatory Sufficiency:
FDA emphasized that it does not require ""perfect alignment"" of datasets across applications, only that the data be sufficient for review. It found no reason to invalidate the filing or approval of Lannett‚Äôs application.

No Legal Obligation to Delay Lannett‚Äôs NDA:
The agency disagreed with Genus‚Äôs interpretation of 505(c)(3)(E)(ii) exclusivity protections. It asserted that Lannett‚Äôs NDA was permissible under applicable rules and did not violate exclusivity provisions.",denied,True,44.0,CDER,CDER
fda-2019-p-1800,FDA-2019-P-1800-0001_Citizen_Petition_from_Boditech_Med_Inc_.pdf,2018-04-12,2019,False,original petition,Boditech Med Inc.,industry/corporation,"Section 513(f)(1) of the FD&C Act (automatic Class III classification)
- Section 513(f)(3) of the FD&C Act (petition for reclassification)
- Section 513(e) of the FD&C Act (FDA-initiated reclassification)
- 21 C.F.R. 10.30 (citizen petition procedure)
- 21 C.F.R. 860 (medical device classification)
- 21 C.F.R. 25.34(b), 25.40, 25.42 (environmental impact)","The automatic classification of Mycobacterium tuberculosis IVD devices under Product Code NCD into Class III requiring PMA (Premarket Approval), rather than permitting Class II classification under special controls and 510(k) process.","1. Reclassify all medical devices under Product Code NCD from Class III to Class II with 510(k) notification.
2. Establish special controls and issue appropriate guidance.
3. Take any additional administrative actions necessary to effectuate the above","All FDA-approved NCD devices are serial modifications of a single original device (QuantiFERON¬Æ-TB).
- No other similar devices have been reviewed under 510(k) or De Novo classification.
- The devices are not high-risk: they are not life-supporting or sustaining, and false positive/negative risks are manageable with general and special controls.
- CDC (2016) and WHO (2018) guidelines support the use of IGRA-based TB diagnostics (including QuantiFERON).
- FDA itself reclassified similar nucleic acid-based TB diagnostics to Class II in 2014 under 21 CFR 866.3372.
- Reclassification would facilitate access, reduce regulatory burden, and maintain patient safety.
- The petition cites valid scientific evidence and international use and acceptance of the devices to demonstrate safety/effectiveness",,"Denied
‚Äì The petition was denied on procedural grounds. The request for reclassification was submitted incorrectly as a Citizen Petition instead of a Petition for Reclassification.",2019-04-16,0.0,Center for Devices and Radiological Health (CDRH),21 CFR 860.123,,"The FDA determined that the petition could not be processed because it was not submitted in the appropriate format.
- A Petition for Reclassification is required to pursue the requested change for devices associated with Product Code NCD (Mycobacterium Tuberculosis tests).
- The petitioner was advised to re-submit using the proper procedure under the cited regulation.",denied,True,369.0,CDRH,CDRH
fda-2019-p-6048,FDA-2019-P-6048-0001_Suitability_Petition_from_Fresenius_Kabi_USA__LLC.pdf,2019-12-20,2019,False,original petition,"Fresenius Kabi USA, LLC",industry/corporation,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- 21 C.F.R. 10.30 (citizen petition procedure)
- 21 C.F.R. 25.31 (categorical exclusion for environmental assessment)
- 21 C.F.R. 10.30(b) (economic impact provision)
- Section 505(j)(2)(A) and 505(j) of FD&C Act (ANDA requirements)",Determination of suitability for submission of an Abbreviated New Drug Application (ANDA) for Sodium Chloride 0.9% Irrigation USP in new container sizes (250 mL and 1500 mL) differing from the currently approved sizes of the Reference Listed Drug (RLD),"FDA should determine that Sodium Chloride 0.9% Irrigation USP in 250 mL and 1500 mL fill sizes is suitable for submission in an ANDA.
- Confirm that these size modifications do not raise questions of safety or effectiveness, and permit the change in total drug content per container","The proposed changes are limited to container fill sizes (250 mL and 1500 mL) and represent a change in strength (total drug content) but not in formulation or usage.
- The product remains a sterile, nonpyrogenic isotonic solution identical to the RLD in composition and use.
- Labeling, indications, and administration are unchanged except for fill volume.
- The change will help reduce drug waste and accommodate different clinical needs.
- There are no safety or effectiveness concerns, and the submission meets the statutory and regulatory requirements for ANDA under the FD&C Act",,,2025-10-15,0.0,,,,,no decision,False,2126.0,pending,pending
fda-2019-p-0777,FDA-2019-P-0777-0001_Citizen_Petition_from_National_Milk_Producers_Fede.pdf,2019-02-21,2019,False,original petition,National Milk Producers Federation (NMPF),advocacy/academic,"Section 403(a)(1) of the FD&C Act (misbranding)
- Section 201(g) (definition of drugs)
- 21 C.F.R. ¬ß 101.3(d) (use of standardized common or usual names for foods)
- 21 C.F.R. ¬ß 130.10 (nutritional equivalency requirement for modified standardized foods)","FDA‚Äôs enforcement discretion regarding labeling of plant-based products as ‚Äúmilk‚Äù, which NMPF argues misbrands non-dairy beverages by allowing use of dairy terms inconsistent with federal standards of identity.","NMPF requests FDA to:
- Enforce existing standards of identity for milk and dairy products.
- Take regulatory action against plant-based products labeled with dairy terms such as ‚Äúmilk,‚Äù ‚Äúcheese,‚Äù and ‚Äúyogurt‚Äù when they do not meet dairy definitions.
- Publish guidance to clarify these labeling restrictions.","Use of dairy terms on plant-based products is misleading and violates FD&C Act Section 403(a)(1).
- Plant-based ‚Äúmilks‚Äù are nutritionally inferior to real dairy milk and often contain additives, creating consumer confusion.
- Existing FDA standards define milk as the lacteal secretion of cows, and NMPF argues enforcement is necessary to protect both consumers and dairy producers.
- Cites FDA‚Äôs own guidance and court rulings supporting regulation of standardized food labeling.",,,2025-10-15,0.0,,,,,no decision,False,2428.0,pending,pending
fda-2019-p-4281,FDA-2019-P-4281-0001_Citizen_Petition_from_Valisure__LLC.pdf,2019-09-09,2019,False,original petition,"Valisure, LLC",industry/corporation,"21 C.F.R. ¬ß 10.30 (citizen petition process)
- 21 C.F.R. ¬ß 314.70 (supplements and other changes to approved NDA or ANDA)
- 21 U.S.C. ¬ß 355 (NDA provisions of the FD&C Act)
- 21 C.F.R. ¬ß 211.84 (testing and approval or rejection of components, drug product containers, and closures)
- 21 C.F.R. ¬ß 211.165 (testing and release for distribution)","Lack of FDA enforcement and regulatory oversight in requiring routine independent batch-level chemical analysis of drug products‚Äîespecially regarding contamination by N,N-Dimethylformamide (DMF) in ranitidine products.","Valisure requests the FDA to:
- Recall all lots of ranitidine containing unacceptable levels of NDMA and/or DMF.
- Suspend sale of ranitidine products until appropriate analytical methods and safety levels are established.
- Reform FDA regulations to require validated independent chemical batch-level testing by companies such as Valisure.
- Mandate revisions to ANDAs and NDAs to include proper nitrosamine contamination safeguards.","Valisure‚Äôs own analytical testing found extremely high levels of NDMA and DMF, probable human carcinogens, in ranitidine products.
- FDA-accepted testing methods are inadequate for detecting NDMA in ranitidine due to heating artifacts.
- Public health risks are severe due to chronic use of contaminated ranitidine products.
- Existing FDA rules do not ensure that final products are independently batch tested, leaving a critical quality control gap.
- Requiring independent chemical analysis could prevent future contamination crises and improve transparency and accountability.",2020-03-18 00:00:00,,2025-10-15,1.0,,,"The FDA explained that it has not reached a decision because the petition raises complex issues requiring extensive review and analysis. The petition requested actions regarding ranitidine products, including recalls, investigations, public communication, guidance on disposal, and regulatory reform for independent testing",,no decision,False,2228.0,pending,pending
fda-2019-p-0372,FDA-2019-P-0372-0001_Citizen_Petition_from_Hyman_Phelps___McNamara__P_C.pdf,2019-01-23,2019,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"21 C.F.R. ¬ß¬ß 10.25 and 10.30 (general citizen petition procedures)
- 21 C.F.R. ¬ß¬ß 314.122 and 314.161 (withdrawal determinations)
- 21 C.F.R. ¬ß 314.162 (Orange Book removal for safety/effectiveness)
- 21 C.F.R. ¬ß 25.31 (categorical exclusion for environmental impact)
- 21 C.F.R. ¬ß 10.30(b) (economic impact statement)
- FD&C Act ¬ß¬ß 505(j) and 505(w)","The petition addresses whether MIOCHOL¬Æ (acetylcholine chloride) for intraocular solution, previously approved under NDA 016211 and discontinued, was withdrawn for reasons of safety or effectiveness, which would impact its status as a Reference Listed Drug (RLD).","The petitioner requests that FDA determine that MIOCHOL¬Æ was not withdrawn for reasons of safety or effectiveness, so it may remain listed in the Orange Book and be eligible as an RLD for ANDA submission","MIOCHOL¬Æ was moved to the Orange Book‚Äôs ‚ÄúDiscontinued Drug Product List‚Äù in 2009.
- FDA acknowledged in a July 12, 2018 Federal Register notice that the withdrawal was at the request of the NDA holder (Novartis).
- The petitioner is not aware of any evidence suggesting the withdrawal was related to safety or effectiveness.
- Believes the discontinuation was based solely on commercial reasons.",,"Approved ‚Äì FDA determined that Miochol (acetylcholine chloride intraocular solution), 20 mg/vial, was not withdrawn for reasons of safety or effectiveness, and it will remain listed in the Orange Book under the ‚ÄúDiscontinued Drug Product List.‚Äù",2019-07-16,0.0,"Center for Drug Evaluation and Research (CDER), Office of Regulatory Policy","Approved Drug Products With Therapeutic Equivalence Evaluations (Orange Book)
- A copy of the Federal Register notice was enclosed, but the letter does not directly cite a regulation number.",,"FDA reviewed its records and concluded that the product was not withdrawn from sale for reasons of safety or effectiveness.
- Therefore, Miochol remains in the Orange Book‚Äôs Discontinued Drug Product List, allowing future ANDA references if other legal requirements are satisfied.",approved,True,174.0,CDER,CDER
fda-2019-p-5191,FDA-2019-P-5191-0015_Amended_Citizen_Petition_for_Standards_of_Identity.pdf,2020-01-16,2019,False,original petition,"American Bakers Association, American Frozen Food Institute, American Fruit and Vegetable Processors and Growers Coalition, Corn Refiners Association, and other industry groups as co-petitioners.",advocacy/academic,"21 C.F.R. ¬ß 130.10 (nutritional equivalency for modified standardized foods)
- 21 C.F.R. ¬ß 130.5 (requirements for requesting a new or amended standard of identity)
- 21 C.F.R. ¬ß 10.30 (citizen petition process)
- 21 U.S.C. ¬ß 343(g) (misbranding of food under the FD&C Act)","FDA‚Äôs handling of standards of identity for foods, particularly:
- The agency‚Äôs failure to modernize and clarify existing food standards.
- The inconsistent enforcement of standards related to ‚Äútraditional‚Äù vs. ‚Äúmodernized‚Äù products.","The petitioners request that the FDA:
- Amend or modernize existing standards of identity to allow for innovative formulations.
- Establish a clear, flexible, and transparent regulatory framework for food identity standards.
- Publish guidance or rulemaking to formally clarify how the FDA will evaluate or approve changes to standards.","Many current food standards are outdated, impeding innovation.
- FDA‚Äôs inconsistent enforcement and lack of clarity create uncertainty in labeling and product development.
- The industry needs a clear, predictable process to reformulate products using modern techniques and ingredients while maintaining consumer trust.
- A modernized regulatory approach will enhance consumer understanding, support public health goals, and promote fair competition in the marketplace.",2020-11-20 00:00:00,,2025-10-15,1.0,,,"The letter acknowledges prior citizen petitions from:
‚ÄÉ‚Ä¢ American Olive Oil Producers Association (FDA-2019-P-5191, submitted in Nov 2019)
‚ÄÉ‚Ä¢ North American Olive Oil Association (FDA-2020-P-1423, submitted in May 2020)

- FDA states it has met with industry stakeholders and is actively reviewing the petitions.

- The letter encourages public comments to be submitted through the docket on regulations.gov, ensuring all input is considered during the review process.",,no decision,False,2099.0,pending,pending
fda-2019-p-4644,FDA-2019-P-4644-0001_Citizen_Petition_from_Clarus_Therapeutics__Inc_.pdf,2019-10-02,2019,False,original petition,"Clarus Therapeutics, Inc. (""Clarus"" or ""Petitioner"")",industry/corporation,"Section 505(b), 505(j), and 505(q) of the FDCA
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 25.31 (Environmental Impact exemption)
- Reference to exclusivity under Section 505(j) for ANDA eligibility","Lack of written guidance on safety and efficacy standards for oral testosterone-ester (T-ester) prodrugs used as testosterone replacement therapy in adult men with hypogonadism
- FDA‚Äôs past approval practices lacking codification (e.g., Cavg and Cmax thresholds)
- Ongoing NDA/ANDA reviews for oral T-esters that may not meet appropriate standards","Clarus requests that the FDA:
‚Ä¢ Issue written guidance specifying efficacy and safety criteria for oral T-ester products, including criteria for Cavg, Cmax, dose titration, concordance, food effects, and post-collection conversion of T-esters
‚Ä¢ Refuse to approve any oral T-ester NDA or ANDA unless it complies with this new guidance","The petitioner argues that:
‚Ä¢ FDA has used unwritten, inconsistent standards for efficacy and safety evaluation of T-ester products (e.g., Cavg ‚â• 75% responders; Cmax limits)
‚Ä¢ Oral T-esters present unique formulation, absorption, PK, and safety challenges
‚Ä¢ Past approvals (including Clarus‚Äôs own product JATENZO¬Æ) involved substantial regulatory learning not yet formalized into guidance
‚Ä¢ To ensure fair, consistent, and scientifically rigorous reviews, formal FDA guidance is essential before approving additional oral T-ester products",,Denied,2020-02-27,0.0,Center for Drug Evaluation and Research (CDER),"21 CFR Part 314 ‚Äì Requirements for drug approval and NDA review.

Section 505 of the FD&C Act (21 U.S.C. ¬ß 355) ‚Äì Governs the approval of new drug applications.

Section 505(b), 505(c)(1)(A), 505(d), 505(j), 505(q), 505(q)(1)(F) ‚Äì Cover standards for approval, effectiveness, bioequivalence, and procedural requirements for citizen petitions.

21 CFR 314.125, 314.126, 314.94, 314.105, 314.110, 314.127, 314.103, 314.430 ‚Äì Cover grounds for refusal, trial requirements, ANDA requirements, and confidentiality protections.

21 CFR 10.115(d) ‚Äì Addresses the non-binding nature of FDA guidance documents.

Public Law 110-85 (FDAAA, 2007) and Public Law 112-144 (FDASIA, 2012) ‚Äì Amendments relevant to Section 505(q).

FDA Guidance for Industry:

Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products (May 1998).

Multiple Endpoints in Clinical Trials (Draft, January 2017).

Structured Approach to Benefit-Risk Assessment in Drug Regulatory Decision Making (PDUFA V Implementation Plan, 2013‚Äì2017)",,"Not Legally Required to Issue Product-Specific Guidance:
FDA emphasized that it is not legally obligated to issue product-specific guidance documents to approve NDAs or ANDAs. Guidance is non-binding and represents the agency‚Äôs current thinking, not enforceable mandates
.

Flexibility in Scientific Judgment:
The agency applies general statutory standards flexibly across different drug types and exercises scientific discretion to determine the sufficiency of evidence required for approval
.

Consistent Standards Already Applied:
The FDA rejected the claim that oral testosterone-ester (T-ester) products lack consistent standards, stating that it has already applied clear, consistent efficacy and safety expectations to T replacement therapies‚Äîincluding Jatenzo (approved March 2019)
.

Denial of Blanket Approval/Denial Requests:
The agency refused to grant a request to codify approval criteria into binding guidance and declined to deny or approve any pending applications based on the petition‚Äôs proposed standards. Each application is assessed individually under existing laws and regulations
.

Statutory Review Framework Exists:
The FD&C Act and FDA regulations already provide procedural protections and a framework to evaluate NDAs/ANDAs. The agency cannot bypass this system through a citizen petition
.

Timing Constraints Under Section 505(q):
FDA clarified it must respond to the petition within 150 days but is not required to issue decisions on the approvability of other pending applications within that window",denied,True,148.0,CDER,CDER
fda-2019-p-6047,FDA-2019-P-6047-0001_Suitability_Petition_from_Fresenius_Kabi_USA__LLC.pdf,2019-12-19,2019,False,original petition,"Fresenius Kabi USA, LLC",industry/corporation,"Section 505(j)(2)(C) of the FD&C Act (suitability petition provisions)
- 21 C.F.R. ¬ß 10.30 (citizen petition process)
- 21 C.F.R. ¬ß 25.31 (categorical exclusion from environmental assessment)
- 21 C.F.R. ¬ß 10.30(b) (economic impact submission provision)
- Section 505(j)(2)(A)(v) of the FD&C Act (ANDA labeling requirements)","FDA‚Äôs evaluation of suitability for ANDA submission for modified fill sizes (250 mL and 1500 mL) of Sterile Water for Irrigation, USP, compared to the Reference Listed Drug (RLD), which is marketed in 500 mL, 1000 mL, 2000 mL, and 4000 mL sizes by B. Braun Medical (NDA 016734)","FDA should determine that 250 mL and 1500 mL fill sizes of Sterile Water for Irrigation, USP (in single-dose flexible plastic containers) are suitable for submission in an Abbreviated New Drug Application (ANDA) despite being a change in strength (total drug content per container) from the RLD","The proposed change involves only fill volume (i.e., container size/total drug content), not the composition or intended use.
- No changes are proposed to dosage, labeling (other than volume), indications, or administration.
- The smaller (250 mL) and larger (1500 mL) sizes provide clinical flexibility and help reduce waste.
- There are no safety or efficacy concerns raised by this modification.
- Labeling for the RLD is retained, with only administrative updates and strength reflected.
- The change should raise no questions of safety or effectiveness and meets regulatory ANDA criteria",,,2025-10-15,0.0,,,,,no decision,False,2127.0,pending,pending
fda-2019-p-4155,FDA-2019-P-4155-0001_Citizen_Petition_from_Teva_Pharmaceuticals_USA__In.pdf,2019-09-05,2019,False,original petition,"Teva Pharmaceuticals USA, Inc.",industry/corporation,"21 C.F.R. ¬ß¬ß 10.25(a) and 10.30 (citizen petition regulations)
- Section 505(b)(2) of the FD&C Act (new drug applications)
- 21 C.F.R. ¬ß 314.3(b) (therapeutic equivalence definition)
- 21 C.F.R. ¬ß 320.22 (bioequivalence waiver criteria)
- 21 C.F.R. ¬ß 25.31 (categorical exclusion for environmental impact)
- 21 C.F.R. ¬ß 10.30(b) (economic impact statement provision)","FDA‚Äôs assignment of a Therapeutic Equivalence (TE) Code in the Orange Book for Teva‚Äôs product Fosaprepitant Dimeglumine for Injection, 150 mg base/vial (NDA 210064), in comparison to the reference listed drug (RLD) EMEND¬Æ by Merck (NDA 022023)","Teva requests that the FDA assign the TE code ‚ÄúAP‚Äù to its product, indicating therapeutic equivalence to Merck‚Äôs EMEND¬Æ.","Teva‚Äôs product is a pharmaceutical equivalent: same active ingredient, dosage form, strength, and route of administration as EMEND¬Æ.
- FDA granted tentative approval of Teva‚Äôs NDA and waived bioequivalence testing under 21 C.F.R. ¬ß 320.22.
- FDA guidance and the Orange Book support such equivalence.
- Both products are expected to have the same clinical effect and safety profile under labeled conditions",2020-03-02 00:00:00,,2025-10-15,1.0,,,"The FDA states that the petition raises complex issues that require extensive review and analysis by Agency officials. As such, a final decision has not yet been reached. The interim response is issued pursuant to the regulation requiring acknowledgment when a full response is delayed.",,no decision,False,2232.0,pending,pending
fda-2019-p-5571,FDA-2019-P-5571-0001_Citizen_Petition_from_Sheppard__Mullin__Richter___.pdf,2019-11-25,2019,False,original petition,"Sheppard, Mullin, Richter & Hampton LLP (submitted by Allison Fulton)",law/consulting,"Federal Food, Drug, and Cosmetic Act (FDCA)
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß¬ß 25.30(h), 25.31(a), 10.30(b)","Approval process for Abbreviated New Drug Applications (ANDAs) or supplements for Penicillamine capsules, specifically regarding the bioequivalence study methods used","Require that any ANDA (or supplement) for Penicillamine capsules be approved only if the bioequivalence study:
- Uses a stabilizing agent to prevent oxidation of Penicillamine post-blood collection
- Measures both copper-bound and circulating free Penicillamine in plasma","Current methods (e.g., TCA crash method) fail to stabilize Penicillamine post-collection, leading to degradation and inaccurate measurements
- Do not account for Penicillamine-copper complex, which comprises the majority of therapeutic Penicillamine in the bloodstream
- Apicore‚Äôs method addresses these shortcomings by stabilizing samples and cleaving the copper-bound complex, providing a more accurate measure of bioequivalence and therapeutic benefit",,,2025-10-15,0.0,,,,,no decision,False,2151.0,pending,pending
fda-2019-p-4261,FDA-2019-P-4261-0001_Citizen_Petition_from_Hyman__Phelps___McNamara__P_.pdf,2019-09-10,2019,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"21 C.F.R. ¬ß¬ß 10.25(a) and 10.30 (citizen petition regulations)
- Section 505(j) of the FD&C Act (ANDA provisions)
- 21 C.F.R. ¬ß 314.3 (definition of listed drug)
- 21 C.F.R. ¬ß 25.31 (environmental impact categorical exclusion)
- 21 C.F.R. ¬ß 10.30(b) (economic impact)","The FDA‚Äôs designation of a Reference Standard (RS) in the Orange Book for Ultramicrocrystalline Griseofulvin Tablets, 250 mg. The current RS (NDA 050475) is unavailable, hindering generic competition","Designate ANDA 204371, held by Mountain LLC, as a new Reference Standard (RS) for Ultramicrocrystalline Griseofulvin Tablets, 250 mg
- Update the Orange Book accordingly","The current RS is commercially unavailable and may have been discontinued, limiting the ability of ANDA applicants to file.
- ANDA 204371 leads the U.S. market in volume sold, making it a more accessible and appropriate RS.
- FDA guidance allows for RS re-designation via petition when the original RS is no longer available.
- Re-designating a new RS will restore a viable pathway for generic approvals and increase competition",2020-03-04 00:00:00,Approved ‚Äî The FDA granted the citizen petition to designate a new reference standard.,2020-05-14,1.0,Center for Drug Evaluation and Research (CDER),"Section 505(j) of the FD&C Act (21 U.S.C. ¬ß 355(j))
- 21 CFR ¬ß 314.3(b)
- 21 CFR ¬ß 314.94(a)(3)
- 21 CFR ¬ß 314.161
- 21 CFR ¬ß 314.122
- 81 FR 69580 at 69619 (October 6, 2016)","The Agency explained that the decision on the petition is delayed due to competing priorities and resource constraints.
- FDA assured that a full response will be provided as soon as feasible.","The current reference standard, Gris-PEG (NDA 050475), is no longer commercially available.
- FDA determined that ANDA 204371, held by Mountain LLC, is therapeutically equivalent and is the current market leader.
- As per regulatory precedent and statutory provisions, FDA may select a therapeutically equivalent ANDA as a reference standard when the RLD is unavailable",approved,True,247.0,CDER,CDER
fda-2019-p-4523,FDA-2019-P-4523-0001_Citizen_Petition_from_Fresenius_Kabi_USA__LLC.pdf,2019-09-26,2019,False,original petition,"Fresenius Kabi USA, LLC",industry/corporation,"21 C.F.R. ¬ß 10.20 (citizen petition procedures)
- 21 C.F.R. ¬ß 10.30 (citizen petition filing process)
- 21 C.F.R. ¬ß 314.161 (FDA determination if withdrawal is for reasons other than safety or efficacy)
- 21 C.F.R. ¬ß 314.162 (Orange Book discontinued listing)
- 21 C.F.R. ¬ß 25.31 (categorical exclusion for environmental impact)
- 21 C.F.R. ¬ß 10.30(b) (economic impact)",The FDA‚Äôs listing of Potassium Chloride in Dextrose 5% and Sodium Chloride 0.225% drug product under NDA 018365 (ICU Medical Inc.) in the ‚ÄúDiscontinued Section‚Äù of the Orange Book.,The petitioner requests that the FDA determine whether the drug product was withdrawn from the market for reasons other than safety or efficacy. This would enable future approval of ANDAs referencing the product,"The product, although listed as ‚Äúdiscontinued,‚Äù may have been withdrawn for reasons unrelated to safety or efficacy (e.g., business decisions).
- A formal determination is needed to facilitate ANDA approvals that cite the discontinued drug as the reference listed drug (RLD).
- The petitioner believes there is no evidence of safety or efficacy concerns, thus supporting ANDA eligibility.
- FDA regulation (21 C.F.R. ¬ß 314.161) mandates such a determination prior to approving ANDAs based on a discontinued drug",,"Approved (i.e., FDA determined that the listed drugs were not withdrawn for reasons of safety or effectiveness). This permits the FDA to approve Abbreviated New Drug Applications (ANDAs) that refer to these drugs if all other legal and regulatory requirements are met",2020-03-17,0.0,Center for Drug Evaluation and Research (CDER),"21 CFR 10.30

21 CFR 314.161

21 CFR 314.162

Section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(7))",,"The FDA reviewed the citizen petition and agency records and found no information indicating that the potassium chloride drug products were withdrawn from sale for reasons of safety or effectiveness.

No data or other information was submitted suggesting safety or effectiveness concerns.

The products are currently listed in the ‚ÄúDiscontinued Drug Product List‚Äù section of the Orange Book, which is used for drugs discontinued for reasons other than safety or effectiveness.

The FDA also independently evaluated literature and postmarketing adverse events and found no safety or effectiveness issues",approved,True,173.0,CDER,CDER
fda-2019-p-4670,FDA-2019-P-4670-0001_Citizen_Petition_from_Lonza_Inc_.pdf,2019-10-04,2019,False,original petition,Lonza Inc.,industry/corporation,"21 C.F.R. ¬ß 10.30 ‚Äì Citizen petition regulations
- 21 U.S.C. ¬ß 355(a) ‚Äì New drug application (NDA) requirement under the FD&C Act
- Section 201(g)(1) of the FD&C Act ‚Äì Definition of ‚Äúdrug‚Äù
- 21 C.F.R. ¬ß 310.3(h) ‚Äì Definition of ""new drug""
- 21 C.F.R. ¬ß 25.31 ‚Äì Environmental impact categorical exclusion
- 21 C.F.R. ¬ß 10.30(b) ‚Äì Economic impact statement","The absence of formal FDA regulation or policy on the drug classification status of L-carnitine L-tartrate (LCLT), an ingredient used in dietary supplements.","Lonza requests that the FDA:
- Issue a regulation or guidance declaring that L-carnitine L-tartrate (LCLT), when used in certain dietary supplement applications, is not considered a ""drug"" under the FD&C Act.
- Refrain from enforcement actions claiming LCLT is a drug when used solely as a dietary ingredient in the context described.","LCLT has a long history of safe use in dietary supplements without pharmacological claims.
- It is not marketed or labeled to diagnose, treat, mitigate, or cure disease, and thus should not be considered a drug.
- Regulatory uncertainty around the classification of LCLT as a drug creates commercial and legal risk for companies using it in supplements.
- Clarification would enhance regulatory consistency and ensure fair treatment of dietary ingredient manufacturers.
- FDA action would support the dietary supplement industry's reliance on well-established, non-drug ingredient uses.",2020-03-30 00:00:00,Denied. ,2022-02-24,1.0,"Center for Food Safety and Applied Nutrition (CFSAN), specifically the Office of Nutrition and Food Labeling","21 CFR 101.9(c)(6)(i) ‚Äì Definition and listing of dietary fiber
- 21 CFR 10.30 ‚Äì FDA‚Äôs citizen petition process
- 21 CFR 10.30(e)(3) ‚Äì Permits denial of a petition with justification",The petitioner requested the inclusion of arabinogalactan in the definition of ‚Äúdietary fiber‚Äù due to its beneficial physiological effect on immune functioning. FDA stated that a decision was delayed due to other priorities and limited resources,"The three human studies submitted evaluated a commercial product (ResistAid‚Ñ¢) that included arabinogalactan and bioactive flavonoids (quercetin, taxifolin).
- The presence of flavonoids, which independently affect immune function, confounded the results.
- The studies did not control for flavonoids, making it scientifically impossible to isolate the effects of arabinogalactan.
- Consequently, the FDA concluded there is insufficient evidence to establish that arabinogalactan independently has a beneficial physiological effect on immune function.
- Therefore, the petition to include it as a dietary fiber was denied",denied,True,874.0,CFSAN,Other/Specialty Center
fda-2019-p-1130,FDA-2019-P-1130-0001_Citizen_Petition_from_Kent_Heckenlively_et_al_Reda.pdf,2019-03-08,2019,False,original petition,"Kent Heckenlively, JD; Rima E. Laibow, MD; Ralph Fucetola, JD",individual,"21 C.F.R. 10.30
- 21 U.S.C.A. ¬ß¬ß 321, 331, 351(a)(2)(B), 355, 360bbb-3, 393(b)(2)
- 42 U.S.C. ¬ß 262(a)(2)(C)(i)(I), ¬ß 300aa-22(b)(2), ¬ß 300aa-27
- 21 C.F.R. ¬ß¬ß 210, 210.2, 211, 211.1, 601.2(a), 601.4(a), 610.15(a)
- 5 U.S.C. ¬ß 553(b)(B) (APA)
- National Childhood Vaccine Injury Act (NCVIA)
- Data Quality Act (2001 Consolidated Appropriations Act, 106 PL 554, Sec. 515)","The petition comments on all current vaccine drug approvals, asserting they were granted unlawfully and without adequate safety compliance, and that the FDA and CDC failed to implement Congressionally mandated safety reporting (NCVIA).","Immediate suspension of all current vaccine drug approvals (both childhood and adult).
- Permanent ban on childhood vaccinations until compliance with NCVIA.
- Ban on vaccine advertising under 21 C.F.R. 202.
- Notification to stakeholders.
- Suspension of the Vaccine Injury Compensation Program.
- Formation of a Blue Ribbon Panel to review vaccine safety.
- Petition the President to intervene","Failure of FDA and CDC to provide annual Mandated Vaccine Safety Reports to Congress since 1989.
- Claim that vaccines are ‚Äúunavoidably unsafe‚Äù and approvals are invalid.
- Citing violation of Informed Consent, the Constitution, and International Humanitarian Law (e.g., Geneva Convention, Nuremberg Code).
- Assertion that vaccinated children suffer more adverse effects than unvaccinated ones.
- References to lack of proof of vaccine safety or efficacy and claims of fraud or malfeasance in the approval process.
- Legal arguments include lack of compliance with statutory safety and efficacy requirements under the FD&C Act and NCVIA.
- Comparison to historical cases asserting right to bodily integrity and freedom from coercive medical interventions.",,Denied,2022-12-02,0.0,Center for Biologics Evaluation and Research (CBER),"21 CFR Part 1271 ‚Äì Human cells, tissues, and cellular and tissue-based products (HCT/Ps)
- 21 CFR 1271.3(d) ‚Äì Definitions of homologous use
- 21 CFR 1271.10(a) ‚Äì Criteria for regulation solely under section 361 of the Public Health Service (PHS) Act
- Section 351 and 361 of the PHS Act",,"The petitioner requested FDA revise its policy to allow adipose tissue-derived stromal vascular fraction (SVF) products to be regulated solely under section 361 of the PHS Act, and not as drugs or biologics under section 351.

- FDA denied the request because SVF products fail to meet the criteria in 21 CFR 1271.10(a) for regulation solely under section 361. Specifically:
‚ÄÉ‚Ä¢ They are not intended for homologous use, as required by ¬ß 1271.10(a)(2).
‚ÄÉ‚Ä¢ They are typically more than minimally manipulated, violating ¬ß 1271.10(a)(1).

- FDA emphasized that such products must undergo premarket review and approval to ensure safety and effectiveness before they can be legally marketed.

- The agency also noted that its regulatory framework aims to ensure that HCT/Ps used in treatment are appropriately regulated to protect public health.",denied,True,1365.0,CBER,Other/Specialty Center
fda-2019-p-2289,FDA-2019-P-2289-0181_Supplement_Part_I.pdf,2021-07-12,2019,False,original petition,Children‚Äôs Health Defense (CHD),advocacy/academic,"21 C.F.R. ¬ß 10.30 (Citizen petition regulation)
- 21 U.S.C. ¬ß 355 (New Drug Approval - NDA)
- 21 U.S.C. ¬ß 360bbb-3 (Emergency Use Authorization)
- 21 C.F.R. ¬ß 312.42 (Clinical hold requirements)
- 21 C.F.R. ¬ß 25.31 (Environmental impact exclusion)
- 21 U.S.C. ¬ß 321(g) (Definition of ""drug"")
- 21 U.S.C. ¬ß 393 (FDA mission)
- FDCA sections regarding misbranding, labeling, and informed consent
- Reference to Nuremberg Code and Belmont Report (ethical standards)"," FDA‚Äôs granting and continuation of Emergency Use Authorizations (EUAs) for COVID-19 vaccines in pediatric populations (particularly under age 12).
- FDA‚Äôs potential or anticipated licensure of COVID-19 vaccines for children."," Immediately revoke all EUAs for COVID-19 vaccines for children.
- Refrain from licensing COVID-19 vaccines for pediatric use.
- Convene an independent panel to review vaccine safety signals.
- Provide full transparency of safety and efficacy data.
- Require proper labeling and communication of risks.","Cited risks of myocarditis, pericarditis, and other serious adverse events in children post-vaccination.
- Alleged inadequacy of long-term safety data, particularly for developing immune and reproductive systems.
- Claim that FDA is not fulfilling its statutory mandate to protect the public health and ensure product safety.
- Reference to flawed or incomplete clinical trials, lack of informed consent, and ethical violations.
- Asserts that children are at statistically negligible risk from COVID-19 but face potentially severe risks from vaccination.",,"Partially Denied:
- The request for a boxed warning regarding breast cancer risk for all CHC products was denied.
- FDA indicated other portions of the petition will be addressed at a later date.",2022-05-17,0.0,Center for Drug Evaluation and Research (CDER),"21 CFR 201.57(c)(1) (requirements for boxed warnings)
- 21 CFR 201.57(c)(6)(i) (WARNINGS AND PRECAUTIONS section)
- 21 CFR 201.80 (labeling for older CHCs)
- 21 CFR 310.501 (related to patient information leaflets)
- FD&C Act ¬ß 505(o)(4), ¬ß 505-1(b)(3)",,"Lack of consistent evidence: Epidemiological studies cited in the petition showed mixed or weak associations, and many showed no increased risk between CHC use and breast cancer.
- Weak effect sizes: Studies indicating a slight increase reported relative risks (RR) mostly below 1.5, which is not generally considered strong.
- Updated safety labeling already implemented: On April 29, 2022, FDA approved a safety labeling change (SLC) to update CHC labeling to reflect recent evidence, acknowledging a small increased risk with current/recent long-term use, but not sufficient to warrant a boxed warning.
- Risk-benefit balance: The FDA emphasized that the benefits of CHCs in preventing pregnancy outweigh the small, potential risk of breast cancer.
- Preservation of boxed warning significance: The Agency aims to reserve boxed warnings for risks that are serious and clearly outweigh benefits, which is not the case here.",partially approved / denied,True,309.0,CDER,CDER
fda-2019-p-5069,FDA-2019-P-5069-0001_Citizen_Petition_from_Ontario_Ginseng_Growers_Asso.pdf,2019-10-04,2019,False,original petition,Ontario Ginseng Growers Association (OGGA),advocacy/academic,"40 CFR 180.41 ‚Äì EPA Crop Subgroups
- EPA/OPP/HED SOP 2000.1 ‚Äì Standard operating procedure for sampling
- 21 CFR ¬ß 25.32 ‚Äì Environmental categorical exclusion
Note: Although submitted under FDA authority, no explicit citation of 21 CFR 10.30 (citizen petition procedure) was made.",The lack of an established FDA DDT action level for ginseng. The petition seeks to inform FDA‚Äôs policy on acceptable levels of DDT residue in ginseng.,"FDA should set a 3 ppm DDT action level for ginseng, consistent with the existing level for carrots.","The EPA‚Äôs Health Effects Division (HED) recommended using carrot‚Äôs DDT action level (3 ppm) for ginseng based on:
(i) Similar classification within EPA Crop Subgroups 1A and 1B
(ii) Carrot being a representative commodity for EPA tolerance sampling
(iii) Carrot's growth/structure being more similar to ginseng than radish.
- The petition states HED is best-suited to provide such guidance and recommends FDA adopt their recommendation",2020-04-06 00:00:00,Denied,2020-06-30,1.0,Center for Food Safety and Applied Nutrition (CFSAN),"21 CFR ¬ß 10.30(e)(3)
- FD&C Act: Sections 402(a)(2)(B) and 408
- 40 CFR 180.41
- Federal Register: 37 FR 13369 (1972), 47 FR 42956 (1982)",The FDA cites other agency priorities and limited availability of resources as the reason it has not reached a decision within the 180-day timeframe. The agency committed to notifying the petitioner upon completion of the review.,"FDA determined that a 3 ppm action level for DDT in ginseng is not appropriate because it does not represent a level of contamination that is unavoidable.
- Surveillance data showed only 8% of 112 ginseng samples had detectable DDT, and all levels were well below 3 ppm (ranging from 0.013 to 0.650 ppm).
- EPA's internal memorandum suggested using the carrot action level as a surrogate but did not include a comprehensive analysis as required (e.g., crop grouping assessment, surveillance data review, Codex alignment).
- FDA emphasized that action levels must be set in consultation with the EPA and based on unavoidability, which the petition failed to demonstrate.",denied,True,270.0,CFSAN,Other/Specialty Center
fda-2019-p-0837,FDA-2019-P-0837-0001_Citizen_Petition_from_Takeda_Pharmaceuticals_U_S_A.pdf,2019-02-20,2019,False,original petition,"Takeda Pharmaceuticals U.S.A., Inc.",industry/corporation,"21 C.F.R. ¬ß 10.30 (citizen petition procedures)
- Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FDCA)
- 21 C.F.R. ¬ß 314.94(a)(9) (bioequivalence data requirements)
- 21 C.F.R. ¬ß 320.24 (bioavailability/bioequivalence study types)
- 21 C.F.R. ¬ß 320.25(f) (statistical analysis methods for bioequivalence)",FDA‚Äôs potential approval of ANDAs for Trintellix¬Æ (vortioxetine hydrobromide) tablets based on in vitro dissolution data alone without in vivo bioequivalence studies.,"FDA should not approve any ANDA for Vortioxetine HBr Tablets unless it includes in vivo bioequivalence studies.
- Require demonstration of in vivo bioequivalence for all strengths of vortioxetine hydrobromide tablets.","Vortioxetine is a Biopharmaceutics Classification System (BCS) Class IV drug, meaning it has low solubility and low permeability‚Äîcharacteristics that warrant in vivo bioequivalence testing.
- Dissolution data alone is not reliable for determining therapeutic equivalence in BCS Class IV drugs.
- Variability in absorption may impact safety and efficacy.
- Without in vivo data, there is a significant risk of therapeutic inequivalence, particularly in a patient population treated for major depressive disorder.",,Denied,2019-07-18,0.0,Center for Drug Evaluation and Research (CDER),"Section 505(b)(2) and 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)

21 U.S.C. 355(j) ‚Äì Pertaining to ANDA and NDA applications

21 CFR 314.126(b) ‚Äì Requirements for adequate and well-controlled studies

21 CFR 314.94(a)(8)(iv) ‚Äì Labeling differences for ANDA products

21 CFR 314.127(a)(7) ‚Äì Conditions under which FDA can refuse an ANDA

Section 505(j)(2)(A)(v) and (j)(4)(G) ‚Äì ANDA labeling and approval standards

Section 505(j)(5)(F)(iv) ‚Äì 3-year exclusivity provisions

Relevant court precedents (e.g., Sigma-Tau Pharm., Inc. v. Schwetz, 288 F.3d 141 (4th Cir. 2002))

Other references to Orange Book exclusivity and NDA-related legal framework",,"Three-Year Exclusivity Protects Clinical Study Information:
The protected information regarding the reduced incidence of treatment-emergent sexual dysfunction (TESD) from new clinical trials (Study 10 and Study 11) was deemed to fall under three-year exclusivity protections. Thus, it could not be used in labeling for generic versions .

Omission Does Not Render Product Less Safe or Effective:
FDA concluded that removing this protected information from the generic labeling would not make the generic vortioxetine product less safe or effective for the remaining, non-protected uses .

Treatment Adherence Argument Not Supported:
Petitioners argued that the protected information would improve treatment adherence. FDA rejected this, stating there was no supporting clinical evidence that the omission would negatively affect adherence .

FDA Precedent and Carve-Outs Valid:
FDA affirmed its authority and precedent to approve generic products with carve-outs for protected labeling content, as long as the generic remains safe and effective for its approved indications .

No Misleading Labeling:
The agency found that omitting the protected TESD data would not mislead prescribers or result in an inaccurate understanding of the product‚Äôs risk-benefit profile .",denied,True,148.0,CDER,CDER
fda-2019-p-0692,FDA-2019-P-0692-0001_Citizen_Petition_from_Arent_Fox_LLP.pdf,2019-01-30,2019,False,original petition,Arent Fox LLP,law/consulting,"21 C.F.R. ¬ß¬ß 10.25(a), 10.30(b), 314.161 ‚Äì Citizen petition procedures and drug withdrawal determinations
- 21 C.F.R. ¬ß 314.122(a) ‚Äì Discontinued drug listings
- 21 C.F.R. ¬ß¬ß 314.122, 314.161, 314.162 ‚Äì Determination of safety or effectiveness withdrawal
- 21 C.F.R. ¬ß¬ß 25.31, 25.40 ‚Äì Environmental impact and exclusions","The petition addresses the FDA‚Äôs potential continued listing of Tham Solution (Tromethamine Injection, NDA No. 013025) in the Orange Book despite its discontinued status. It seeks clarification on whether the drug was voluntarily withdrawn for reasons of safety or effectiveness.","The petitioner requests the FDA to determine whether Tham Solution was withdrawn from sale for safety or efficacy reasons, which impacts its availability as a Reference Listed Drug (RLD) for ANDA submissions","The drug is no longer commercially available and is listed in the Discontinued Section of the Orange Book.
- An FDA determination is necessary to clarify whether the withdrawal was voluntary and not due to safety or efficacy issues.
- Such determination is required by regulation to support or prevent future ANDA filings referencing Tham Solution.
- The petitioner is unaware of any safety or efficacy reason for the withdrawal.",,"Approved. FDA determined that THAM Solution (tromethamine) injectable, 3.6 g/100 mL, was not withdrawn for reasons of safety or effectiveness, allowing abbreviated new drug applications (ANDAs) to be accepted referencing this product",2019-07-03,0.0,Center for Drug Evaluation and Research (CDER),"21 CFR 314.161 ‚Äì Determination whether a drug was withdrawn from sale for safety or effectiveness reasons
- 21 CFR 314.162 ‚Äì Removal from the Orange Book
- Section 505(j)(7) of the FD&C Act (21 U.S.C. 355(j)(7)) ‚Äì Requirement for publication of approved drugs (Orange Book listing)",,"The petitioner (Arent Fox LLP) requested FDA determine the withdrawal status of THAM Solution.
- FDA reviewed its internal records and relevant scientific literature.
- No data or information indicated the drug was withdrawn due to safety or effectiveness concerns.
- Thus, FDA will continue listing the drug in the ‚ÄúDiscontinued Drug Product List‚Äù and accept ANDAs referencing it if all legal and regulatory requirements are met",approved,True,154.0,CDER,CDER
fda-2019-p-4669,FDA-2019-P-4669-0001_Citizen_Petition_from_RdR_Solutions_on_behalf_of__.pdf,2019-09-04,2019,False,original petition,RdR Solutions,law/consulting,"21 C.F.R. ¬ß 10.30 ‚Äì Citizen petition regulations
- 21 C.F.R. ¬ß 314.161 ‚Äì Determination of withdrawal reasons
- 21 C.F.R. ¬ß 314.162 ‚Äì Removal from the Orange Book
- 21 C.F.R. ¬ß 25.31 ‚Äì Environmental impact exclusions","The petition addresses the status of NDA No. 018402 for Nalbuphine Hydrochloride Injection, USP, listed in the Discontinued Section of the Orange Book, and whether it was withdrawn for reasons of safety or effectiveness.","Petitioner requests that the FDA determine that Nalbuphine Hydrochloride Injection, USP (NDA 018402) was not withdrawn for reasons of safety or effectiveness, enabling it to be used as a Reference Listed Drug (RLD) for ANDA submissions.","The product is no longer being marketed but is still listed as ‚Äúdiscontinued‚Äù in the FDA‚Äôs Orange Book.
- There is no evidence that the withdrawal was related to safety or efficacy concerns.
- The petition seeks clarity under 21 C.F.R. ¬ß 314.161, a required determination before ANDAs can be approved that cite a discontinued RLD.
- The requested action is a routine procedural step for enabling generic competition.",2020-03-05 00:00:00,"	Other ‚Äì Enforcement Discretion
FDA decided not to act on the petition because it plans to include the substance in question through a proposed rulemaking and will exercise enforcement discretion in the meantime.",2020-07-02,1.0,Center for Food Safety and Applied Nutrition (CFSAN)," 21 CFR ¬ß 101.9(c)(6)(i) ‚Äì Definition of dietary fiber
- 21 CFR ¬ß 101.9(c)(6) ‚Äì Nutrition and Supplement Facts labeling
- 21 CFR ¬ß 101.9(c) ‚Äì General nutrition labeling requirements
- Reference to guidance on synthetic non-digestible carbohydrates (including use of HPLC for purity)","The petition sought amendment of 21 CFR 101.9 to include purified glucomannan (Propol and Propolmannan) as a dietary fiber in nutrition labeling.
- FDA has not completed review due to competing agency priorities and limited resource availability, and will notify the petitioner once a decision is made.","The petition requested that FDA recognize a highly purified form of glucomannan (‚â•95% purity by HPLC) as dietary fiber.

- FDA stated it had already announced its intent to propose including glucomannan in the list of non-digestible carbohydrates that meet the dietary fiber definition under 21 CFR ¬ß 101.9(c)(6)(i).

- Given this intention and the strength of scientific evidence supporting glucomannan‚Äôs beneficial physiological effects, FDA found it unnecessary to act specifically on the petition.

- Instead, the agency will exercise enforcement discretion, allowing glucomannan to be declared as dietary fiber on labels until rulemaking is complete.",other,True,302.0,CFSAN,Other/Specialty Center
fda-2019-p-0726,FDA-2019-P-0726-0001_Suitability_Citizen_Petition_from_Sunny_Pharmtech_.pdf,2019-02-13,2019,False,original petition,Sunny Pharmtech Inc.,industry/corporation,"Section 505(j)(2)(C) of the FFDCA ‚Äì Suitability Petition authority
- 21 C.F.R. ¬ß 10.30(b) ‚Äì Petition procedures
- 21 C.F.R. ¬ß 25.31 ‚Äì Environmental categorical exclusions","The petitioner is commenting on the approval conditions for a Reference Listed Drug (RLD) ‚Äì Fluoxetine Hydrochloride 60 mg Tablets (NDA 202133) by Alvogen, and proposing an additional 20 mg tablet strength.",The petitioner requests FDA approval for a Suitability Petition allowing a quantitative change in strength (20 mg tablet) for Fluoxetine Hydrochloride Tablets to be submitted as an ANDA referencing the 60 mg Alvogen RLD.,"The RLD exists only as a 60 mg dosage strength.
- The proposed 20 mg strength would broaden dosing flexibility (e.g., 10 mg via splitting, or 20‚Äì80 mg combinations).
- The new 20 mg tablets would share the same formulation and route as the RLD.
- The new product is designed to be bioequivalent, and in-vitro testing will support that claim.
- There are no changes in indications, usage, or safety profile.
- PREA requirements do not apply to this new strength per Section 505B(a)(1)(A) of the Act.",,,2025-10-15,0.0,,,,,no decision,False,2436.0,pending,pending
fda-2019-p-5268,FDA-2019-P-5268-0001_Citizen_Petition_from_Public_Citizen_s_Health_Rese.pdf,2019-11-06,2019,False,original petition,Public Citizen‚Äôs Health Research Group,advocacy/academic,"21 C.F.R. ¬ß 10.30 (citizen petition regulation)
- 21 C.F.R. ¬ß 25.30 (environmental impact exclusions)
- Additional references to safety and labeling principles under the FDCA, but no other specific statutes cited by number.",FDA‚Äôs continued approval and marketing of Nuplazid (pimavanserin) for hallucinations and delusions associated with Parkinson‚Äôs disease psychosis (PDP).,"The petition requests the immediate removal of Nuplazid (pimavanserin) from the market.
- FDA should rescind approval due to insufficient evidence of efficacy and growing concerns over patient safety.","High volume of serious adverse event reports, including deaths and life-threatening reactions.
- Weak evidence of efficacy, as shown in failed or marginal clinical trials.
- Post-market safety surveillance raises red flags.
- FDA‚Äôs own reviewers initially recommended against approval.
- Public Citizen argues the risk-benefit profile is unacceptable, and the original approval was premature and unsubstantiated.",2020-05-04 00:00:00,Denied ‚Äì The petition to initiate proceedings to reschedule tramadol from Schedule IV to Schedule II of the Controlled Substances Act was denied,2024-07-29,1.0,Center for Drug Evaluation and Research (CDER),"21 CFR 1308.14(b)(3) ‚Äì Current scheduling of tramadol

- 21 U.S.C. 801-971 ‚Äì Comprehensive Drug Abuse Prevention and Control Act (CSA)

- 21 U.S.C. 812(b) ‚Äì CSA scheduling criteria

- 21 CFR 1308.43(a), (d) ‚Äì DEA petition process

- 21 U.S.C. 811 ‚Äì DEA scheduling authority",The FDA has not yet resolved the issues raised in the citizen petition because it involves complex matters requiring extensive review and analysis. The interim response is provided in compliance with regulatory procedures pending a final decision,"Authority & Process: The scheduling of controlled substances is under DEA jurisdiction. FDA provides scientific and medical evaluations but does not itself reschedule drugs.
- Past Scheduling Decision: DEA previously evaluated tramadol and placed it in Schedule IV in 2014 after input from FDA and a public process.
- Labeling & Safety Updates: Since the petition, FDA has updated tramadol labeling to include more detailed warnings (e.g., addiction, respiratory depression, hyponatremia, hypoglycemia).
- Monitoring & Advisory Committees: FDA held advisory meetings (2020, 2022) and continues monitoring tramadol safety.
- Conclusion: Given the existing framework and actions already taken, FDA denied the request to initiate rescheduling proceedings",denied,True,1727.0,CDER,CDER
fda-2019-p-2590,FDA-2019-P-2590-0001_Citizen_Petition_from_Fresenius_Kabi_USA__LLC.pdf,2019-05-29,2019,False,original petition,"Fresenius Kabi USA, LLC",industry/corporation,"21 C.F.R. ¬ß 10.30 ‚Äì Citizen petition procedures
- 21 C.F.R. ¬ß 25.31 ‚Äì Environmental categorical exclusions
- Also references the Federal Food, Drug, and Cosmetic Act generally (specific subsections not mentioned).","The petition concerns the FDA‚Äôs designation of therapeutic equivalence in the Orange Book, specifically whether Fulvestrant Injection (NDA 210326) by FK USA should be given an ‚ÄòAB‚Äô rating relative to the reference listed drug (RLD), Faslodex¬Æ (NDA 021344).",The petitioner requests that FDA designate Fulvestrant Injection (NDA 210326) by FK USA as therapeutically equivalent (‚ÄòAB‚Äô rated) to Faslodex¬Æ (NDA 021344) by AstraZeneca.,"FK USA‚Äôs product and Faslodex¬Æ are pharmaceutically and therapeutically equivalent, sharing the same active ingredient, strength, dosage form, and labeling indications (as detailed in the side-by-side comparison on page 2)
- A bioequivalence bridging study demonstrated comparable rate and extent of absorption.
- The differences in excipients are not expected to impact efficacy or safety.
- The petition asserts full compliance with Orange Book criteria for therapeutic equivalence.
- The company also seeks a categorical exclusion from environmental impact assessment under 21 C.F.R. ¬ß 25.31.",2019-11-14 00:00:00,,2025-10-15,1.0,,,FDA stated that the delay in decision is due to the need to address other Agency priorities and the numerous demands on the Agency‚Äôs resources. A final response will be issued as soon as possible.,,no decision,False,2331.0,pending,pending
fda-2019-p-1236,FDA-2019-P-1236-0003_Testimony_from_Sarfaraz_Niazi.pdf,2019-04-11,2019,False,original petition,"Sarfaraz K. Niazi, Ph.D., Adjunct Professor, University of Illinois and University of Houston",advocacy/academic,"351(k) pathway for biosimilars
- BPCIA (Biologics Price Competition and Innovation Act)
- References to Citizen Petitions: FDA-2019-P-1236, FDA-2018-P-1876, FDA-2007-P-0055","FDA‚Äôs current framework for licensing biosimilars
- Guidance on analytical similarity testing, animal toxicology, clinical efficacy trials
- Use of four-letter suffixes for biological product naming
- Interchangeability designation and related protocols","The petitioner requests the FDA to adopt a risk-based approach for biosimilar approval, including:
- Eliminate animal toxicology studies
- Limit or eliminate certain clinical studies for biosimilars
- Shift from equivalence interval testing to hypothesis-based testing
- Focus on molecular structure-based analytical similarity
- Withdraw guidance requiring four-letter suffix for biosimilars only
- Allow PPQ (Process Performance Qualification) post-filing","Biosimilars have an established record of safety and efficacy
- Current requirements (e.g., clinical efficacy, toxicology) often do not add meaningful data and create unnecessary burden
- Existing analytical and structural methods are sufficient to ensure safety and effectiveness
- Eliminating redundant steps can reduce costs, encourage more competition, and accelerate market access
- Using suffixes exclusively for biosimilars creates public mistrust and hinders adoption",2019-09-13 00:00:00,,2025-10-15,1.0,,,"The petition requested modifications to FDA‚Äôs guidance on the nonproprietary naming of biological products, including substituting ‚Äúclinically similar‚Äù for ‚Äúno clinically meaningful differences.‚Äù
- FDA has not yet completed review due to competing priorities and limited resources.",,no decision,False,2379.0,pending,pending
fda-2019-p-4140,FDA-2019-P-4140-0001_Citizen_Petition_from_Persion_Pharmaceuticals_LLC.pdf,2019-08-29,2019,False,original petition,Persion Pharmaceuticals LLC,industry/corporation,"505(j) and 505(q) of the FFDCA (21 U.S.C. ¬ß¬ß 355(j) and 355(q))
- 21 C.F.R. ¬ß¬ß 10.25, 10.30, 10.31, and 314.127
- 21 C.F.R. ¬ß¬ß 25.30, 25.31 (Environmental Impact section)",The approval of ANDAs (Abbreviated New Drug Applications) for generic versions of ZOHYDRO¬Æ ER (hydrocodone bitartrate extended-release capsules). The petitioner comments specifically on the lack of bioequivalence testing in hepatically impaired patients,"1. Require all ANDAs for generic hydrocodone bitartrate extended-release capsules to include bioequivalence data in hepatically impaired subjects.
2. Require labeling in those ANDAs to match the RLD‚Äôs labeling regarding hepatic impairment","ZOHYDRO ER has a unique formulation that minimizes pharmacokinetic variation in hepatically impaired patients.
- Generic versions may not perform similarly in such patients, posing risks of overdose, respiratory depression, and death.
- Current FDA guidance only recommends bioequivalence testing in healthy individuals, which the petitioner argues is insufficient.
- Cites the opioid crisis as a reason for heightened safety precautions.
- Notes increased risk of OUD (Opioid Use Disorder) and adverse outcomes without appropriate testing and labeling",,,2025-10-15,0.0,,,,,no decision,False,2239.0,pending,pending
fda-2019-p-3855,FDA-2019-P-3855-0001_Citizen_Petition_from_Latham_Watkins_LLP_on_behalf.pdf,2019-08-14,2019,False,original petition,Latham & Watkins LLP,law/consulting,"21 U.S.C. ¬ß 355 (Sections 505(b)(2), 505(e), and 505(q))
- 21 C.F.R. ¬ß¬ß 10.20, 10.30, 10.31, 314.101(a), 314.101(d)(9), 314.150(a)(2)(iv), 314.108(b)(2), 314.50(d)(5), 314.60(c)(2)
- 5 U.S.C. ¬ß 706(2)(A)
- 21 C.F.R. ¬ß 25.31(a) ","FDA‚Äôs acceptance of Lannett Company, Inc.‚Äôs 505(b)(2) NDA for a cocaine hydrochloride product‚Äîdespite lacking mandatory Pre-Filing Studies‚Äîand its acceptance of a resubmitted application post-CRL (Complete Response Letter).","1. Rescind FDA‚Äôs acceptance of Lannett‚Äôs 505(b)(2) application due to lack of QT, renal, hepatic, and leachable studies.
2. Refuse to file any resubmitted 505(b)(2) applications by Lannett until Genus‚Äôs NCE exclusivity expires.
3. Require Lannett to submit its application as an ANDA after exclusivity expiration.","Genus was required by FDA to complete five Pre-Filing Studies (QT prolongation, renal/hepatic toxicity, extractable and leachable assessments) before filing its NDA. In contrast, Lannett‚Äôs similar product was accepted without these studies, violating FDA regulations and administrative law (e.g., equal treatment of similarly situated entities, consistency with precedent). Additionally, FDA‚Äôs acceptance of Lannett‚Äôs post-CRL resubmission as a 505(b)(2) instead of an ANDA violates 21 C.F.R. ¬ß 314.101(d)(9)",,Denied,2020-01-10,0.0,Center for Drug Evaluation and Research (CDER),"21 U.S.C. ¬ß 355(b)(2) ‚Äì Relating to New Drug Applications (NDAs) under the 505(b)(2) pathway

21 CFR 314.101(a)(3) ‚Äì Refusal to file NDAs with certain deficiencies

21 CFR 314.101(d) ‚Äì Conditions under which the FDA will refuse to file an application

21 CFR 314.50 ‚Äì NDA content and format

21 CFR 314.94 ‚Äì Abbreviated New Drug Applications (ANDAs)

21 CFR 314.125(b)(1) ‚Äì Grounds for denying NDA approval

FDA Guidance Documents Referenced:

Guidance for Industry: Pharmacokinetics in Patients with Impaired Renal Function

Guidance for Industry: Pharmacokinetics in Patients with Impaired Hepatic Function

FDA‚Äôs Manual of Policies and Procedures (MAPP) 4000.4 ‚Äì NDA filing review issues

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

FDA Product-Specific Guidance documents for bioequivalence",,"Equal Filing Standards:
The FDA found that it had applied the same filing standards to both Genus's and Lannett's applications for cocaine HCl nasal solution. Both companies were required to provide equivalent types of data, though each chose different approaches (e.g., literature-based vs. dedicated clinical studies).

Sufficient Data for Filing:
Lannett submitted sufficient information, including clinical pharmacology, toxicology, and leachables data, to support filing and eventual approval. FDA determined that the studies provided were adequate for substantive review and that additional studies‚Äîthough different from Genus's‚Äîwere not legally required.

No Discriminatory Requirements:
The FDA explicitly rejected the claim that it unfairly imposed more demanding requirements on Genus. It clarified that applicants have flexibility in how they fulfill filing requirements and that Genus had the option to rely on literature or alternative data sources like Lannett did.

Scientific and Regulatory Sufficiency:
FDA emphasized that it does not require ""perfect alignment"" of datasets across applications, only that the data be sufficient for review. It found no reason to invalidate the filing or approval of Lannett‚Äôs application.

No Legal Obligation to Delay Lannett‚Äôs NDA:
The agency disagreed with Genus‚Äôs interpretation of 505(c)(3)(E)(ii) exclusivity protections. It asserted that Lannett‚Äôs NDA was permissible under applicable rules and did not violate exclusivity provisions.",denied,True,149.0,CDER,CDER
fda-2019-p-4683,FDA-2019-P-4683-0001_Citizen_Petition_from_Public_Citizen.pdf,2019-10-08,2019,False,original petition,"Public Citizen
Specifically submitted by Dr. Michael A. Carome, Director of Public Citizen‚Äôs Health Research Group.",advocacy/academic,"21 C.F.R. ¬ß 10.30 (citizen petition regulation)
- 21 U.S.C. ¬ß¬ß 352(f)(1), 355(d), and 393(b)(2)(B) (statutory basis for FDA‚Äôs authority over drug labeling and approval)
- 505(d) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß¬ß 314.125(b)(6), 314.126(a)","The continued FDA approval and market availability of Nuplazid (pimavanserin), an antipsychotic drug approved for Parkinson‚Äôs disease psychosis. The petitioner expresses concern over the drug‚Äôs unfavorable risk-benefit profile.","Public Citizen requests that the FDA immediately remove Nuplazid from the market based on post-market evidence indicating that the risks of the drug (including death, hallucinations, falls, and other adverse events) outweigh its benefits.","Clinical trial evidence suggests that Nuplazid offers limited efficacy.
- Post-market data submitted to the FDA‚Äôs Adverse Event Reporting System (FAERS) shows a high number of serious and fatal adverse events.
- The drug‚Äôs mechanism and population (elderly with Parkinson‚Äôs) make it especially high-risk.
- Risk-benefit balance is negative, and other safer treatment alternatives exist.
- Public Citizen previously warned about this drug and now urges withdrawal due to growing evidence of harm .",2020-04-03 00:00:00,"Denied
‚Äì FDA denied the request for immediate withdrawal of approval of all medications containing hydroxyprogesterone caproate (HPC) and their placement on the withdrawn/removed list.
‚Äì However, CDER initiated a Notice of Opportunity for Hearing (NOOH) to potentially withdraw Makena‚Äôs approval.",2020-10-05,1.0,"Center for Drug Evaluation and Research (CDER)
(Signed by Patrizia Cavazzoni, M.D., Acting Director)","FD&C Act: Sections 503A(a), 503A(b)(1)(C), 503B(a), 503B(a)(4), 506(c), 506(c)(2)(A), 506(c)(3), 505(e), 505(j)(2)(A), 505(j)(6)
- 21 CFR: 21 CFR 314.510, 21 CFR 314.530, 21 CFR 216.24, 21 CFR 314.151","The FDA has not yet resolved the issues raised in the petition because they involve complex matters requiring extensive review and analysis by agency officials. Therefore, an interim response was issued in accordance with regulatory requirements","Makena's post-approval trial (Trial 003) failed to demonstrate clinical benefit over placebo, triggering CDER‚Äôs action to begin formal withdrawal proceedings.
- Regulatory Procedure: FDA emphasized that immediate removal from market and addition to the withdrawn/removed list requires formal processes (e.g., rulemaking, public comment, PCAC consultation).
- Other Products: Generic HPC products referencing Delalutin were not considered for withdrawal as their indications do not include preterm birth prevention and Delalutin was not withdrawn for safety or effectiveness reasons.",denied,True,363.0,CDER,CDER
fda-2019-p-4424,FDA-2019-P-4424-0001_Citizen_Petition_from_Hibrow_Healthcare_LLC.pdf,2019-09-23,2019,False,original petition,Hibrow Healthcare LLC,industry/corporation,"21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 314.161
- 21 C.F.R. ¬ß 314.122
- 21 C.F.R. ¬ß 25.31","Withdrawal status of Doxepin Hydrochloride Oral Concentrate Eq 10 mg base/mL as a Reference Listed Drug (RLD), and the FDA's recognition of its discontinuation for safety or efficacy reasons","The petitioner requests that the FDA determine that Doxepin Hydrochloride Oral Concentrate Eq 10 mg base/mL was not voluntarily withdrawn for safety and efficacy reasons, and to assign new Reference Standard status to either ANDA 074721 or ANDA 071918","The original reference product (approved under ANDA 071609) is no longer marketed, and its label is not available on the DailyMed website.
- The petitioner claims there is no evidence of the reference standard being marketed, thus suggesting a need for a new reference standard.
- A new RLD designation is needed to support generic submissions, and there is historical precedent where the FDA did not classify similar discontinuations as being for safety or efficacy reasons.
- The petitioner notes prior approvals and absence of safety concerns. ",2020-04-21 00:00:00,Granted (partially): The petition was granted only to the extent that FDA selected a new reference standard (ANDA 074721). The request to determine whether the product was voluntarily withdrawn for safety or efficacy reasons was denied.,2020-05-07,1.0,Center for Drug Evaluation and Research (CDER),"Section 505(j) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j))
- 21 CFR 314.3(b)
- 21 CFR 314.94(a)(3)
- 81 FR 69580 (October 6, 2016)","The petition raises complex issues that require extensive review and analysis by Agency officials. Therefore, a final decision has not yet been made.","FDA found that the current reference standard (ANDA 071609) is no longer marketed.
- It is appropriate to select ANDA 074721 (Lannett) as the new reference standard because it is therapeutically equivalent to the Reference Listed Drug (RLD) and is the market leader based on commercial data.
- FDA reaffirmed its previous finding that the RLD (Sinequan) was not withdrawn for safety or efficacy reasons, making a new determination unnecessary.",partially approved / denied,True,227.0,CDER,CDER
fda-2019-p-5922,FDA-2019-P-5922-0001_Citizen_Petition_for_Respira_Technologies__Inc.pdf,2019-12-16,2019,False,original petition,"Respira Technologies, Inc.",industry/corporation,"21 C.F.R. ¬ß 10.30
- FD&C Act Section 907(a)
- 21 U.S.C. ¬ß¬ß 387g, 387e(j)(1)",FDA's existing tobacco product regulations and lack of tailored guidance for high-tech and clean nicotine delivery systems under the PMTA (Premarket Tobacco Product Application) framework ,"The petitioner requests that the FDA issue a guidance document clarifying PMTA requirements specific to clean nicotine inhalation products, particularly noncombustible inhalation devices using pharmaceutical-grade ingredients and heating technologies, distinct from e-cigarettes.","FDA's current PMTA framework does not distinguish between combustible, electronic, and next-gen clean inhalation devices, leading to regulatory uncertainty.
- Respira‚Äôs technology involves pharmaceutical-grade nicotine in solution delivered through a non-combustion heating mechanism, designed to improve safety and reduce abuse potential.
- The company argues its pharmaceutical-style approach aligns with public health goals and should be considered differently than e-cigarettes or vape products.
- Guidance would foster innovation and regulatory compliance for products aimed at harm reduction.",2020-05-05 00:00:00,,2025-10-15,1.0,,,"The petition raises significant and complex issues requiring extensive review and analysis by agency officials.
- FDA acknowledged receipt of the petition and committed to respond once a decision is reached",,no decision,False,2130.0,pending,pending
fda-2019-p-0941,FDA-2019-P-0941-0001_Suitability_Petition_from_Felix_Pharmaceuticals_Pv.pdf,2019-02-21,2019,False,original petition,Felix Pharmaceuticals Pvt. Ltd,industry/corporation,"Not Explicitly Cited (Standard references such as 21 C.F.R. 10.30 are implied for suitability petitions, but not directly mentioned in the document)","The current dosage form of the Reference Listed New Animal Drug (RLNAD), DRONTAL¬Æ Tablets by Bayer Healthcare LLC under NADA 141-008, which are approved as compressed tablets","Approval to file an Abbreviated New Animal Drug Application (ANADA) for a generic chewable tablet containing Praziquantel and Pyrantel Pamoate, which differs in dosage form from the RLNAD","The proposed generic product differs only in dosage form (compressed chewable tablet vs. regular compressed tablet), and the change is minor and appropriate for a suitability petition. Supporting documents include:
- Sponsor‚Äôs petition detailing proposed change
- Bayer's package insert
- Annotated version with Felix‚Äôs proposed modifications",,Approved ‚Äì The suitability petition was approved to submit an Abbreviated New Animal Drug Application (ANADA) for a generic version of praziquantel/pyrantel pamoate,2019-05-15,0.0,"Center for Veterinary Medicine (CVM), Office of New Animal Drug Evaluation","Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act
- Section 512(n)(3)(C) of the Act
- 21 CFR 514.5",,"The FDA determined that the proposed changes from the Reference Listed New Animal Drug (RLNAD)‚ÄîDrontal¬Æ tablets for cats‚Äîwere allowable under a suitability petition. The agency concluded that these changes did not require additional investigations to demonstrate safety or effectiveness for the proposed intended uses. Therefore, the petition was approved under section 512(n)(3)(C) of the Act",approved,True,83.0,CVM,Other/Specialty Center
fda-2019-p-0175,FDA-2019-P-0175-0001_Citizen_Petition__from_Fresenius_Kabi_USA__LLC.pdf,2019-01-09,2019,False,original petition,"Fresenius Kabi USA, LLC",industry/corporation,"21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 314.161
- FD&C Act ¬ß 505(j)(2)(A)
- FD&C Act ¬ß 505(j)(2)(C)
- 21 C.F.R. ¬ß 25.31
- 21 C.F.R. ¬ß 10.30(b)","Regulatory requirement to obtain approval of a Suitability Petition before permitting a change in total drug content (i.e., fill size) in a parenteral drug product","The petitioner requests FDA to determine whether Sterile Water for Injection, USP in a 250 mL fill size is suitable for submission in an Abbreviated New Drug Application (ANDA), in addition to the already approved 1000 mL fill size","The smaller 250 mL fill size would help minimize waste in clinical settings that require smaller volumes since containers are single-use.
- It would help alleviate the ongoing drug shortage of sterile water for injection.
- It would facilitate treatment logistics, particularly in remote areas.
- The change involves only fill volume (not concentration or formulation), which the petitioner argues poses no concerns regarding safety or efficacy",,,2025-10-15,0.0,,,,,no decision,False,2471.0,pending,pending
fda-2019-p-1351,FDA-2019-P-1351-0001_Citizen_Petition_from_Law_Office_of_Alan_Dumoff_on.pdf,2019-03-11,2019,False,original petition,"Law Office of Alan Dumoff, JD, MSW",law/consulting,"21 C.F.R. ¬ß 10.30
- FDCA ¬ß 505 (implied via discussion on licensure and marketing)
- 21 U.S.C. ¬ß 360bbb-3 (Emergency Use Authorization provisions, referenced in broader vaccine policy discussion)","The FDA‚Äôs approval and labeling processes for vaccines containing fetal cell line‚Äìderived DNA contaminants, and lack of warnings on such ingredients","The petitioner requests that FDA:
- Require vaccine manufacturers to disclose the use of fetal cell line‚Äìderived ingredients in vaccines
- Require labeling warnings regarding possible adverse consequences
- Conduct and require safety testing for residual DNA fragments from fetal cell lines
- Reclassify or reassess marketing status if manufacturers fail to comply","Ethical concerns about lack of transparency on fetal-derived DNA ingredients
- Potential safety risks including insertional mutagenesis, autoimmune disease, and developmental issues from residual human DNA in vaccines
- Alleged failure of FDA to meet its statutory and constitutional obligations to protect public health and informed consent
- Claims that the public is unaware of the use of fetal cell lines in common vaccines like MMR, varicella, and hepatitis A",2019-09-16 00:00:00,"Meeting Request Denied ‚Äî This was not a final decision on the petition itself, but a denial of a meeting request submitted as part of the citizen petition process regarding bulk drug substances under Section 503A.",2020-04-22,1.0,"Center for Drug Evaluation and Research (CDER)
Specifically from the Office of Unapproved Drugs and Labeling Compliance, Division of Compounded Drugs, under the Office of Compliance","Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- 21 C.F.R. ¬ß 10.30(h)
- 21 C.F.R. ¬ß 10.65(a), (c), (d), (e)
- 21 U.S.C. ¬ß 355(b)(5)(B) (mentioned by petitioner, not cited by FDA)","The petition requests revisions to the February 19, 2019 final rule concerning bulk drug substances eligible for compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act.
- FDA has not issued a decision because the petition raises complex issues that require extensive review and analysis."," FDA explained it receives many such stakeholder meeting requests but generally does not meet individually with petitioners, and instead relies on publicly available information in the petition docket.
- Petitioners argued this contradicted 21 C.F.R. ¬ß¬ß 10.30 and 10.65, which describe opportunities for meetings, but FDA reiterated its policy preference for written exchanges",denied,True,408.0,CDER,CDER
fda-2019-p-2407,FDA-2019-P-2407-0001_Citizen_Petition_from_Kratz___Barry_LLP_on_behalf_.pdf,2019-05-15,2019,False,original petition,Kratz & Barry LLP,law/consulting,"Section 505(j) of the FDCA
- 21 C.F.R. ¬ß 10.25(a)
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 25.31
- 21 C.F.R. ¬ß 10.30(b)","The designation of a Reference Standard (RS) for the drug Diclofenac Sodium, delayed release tablet, 75 mg. The petitioner highlights unavailability of the currently designated RS held by CASI Pharmaceuticals and comments on FDA‚Äôs prior guidance regarding alternative RS selection","The petitioner requests that the FDA designate RS status to the Diclofenac Sodium, delayed release tablet, 75 mg, held by Unique Pharmaceutical Laboratories (a division of J.B. Chemicals and Pharmaceuticals Ltd., ANDA No. 077863)","The current RS (CASI Pharmaceuticals) is not readily available for testing
- CASI is prioritizing distribution in the Chinese market, making the product less accessible in the U.S.
- The proposed RS from Unique Pharmaceutical Laboratories is more available and leads the U.S. market in sales according to IMS data
- FDA guidance allows such a petition when the current RS is not accessible",,,2025-10-15,0.0,,,,,no decision,False,2345.0,pending,pending
fda-2019-p-1818,FDA-2019-P-1818-0001_Citizen_Petition_from_Public_Citizen_Health_Resear.pdf,2019-04-16,2019,False,original petition,Public Citizen,individual,"Section 352 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. ¬ß 352)
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 201.56
- 21 C.F.R. ¬ß 201.57(c)(1)
- 21 U.S.C. ¬ß 355-1(a)(2)(A)
- 21 U.S.C. ¬ß 355-1(g)(4)(B)
- 21 C.F.R. ¬ß 25.31(a)",The petition comments on the existing product labeling and REMS (Risk Evaluation and Mitigation Strategy) for Prolia and seeks enhancements‚Äîspecifically a boxed warning and updated REMS materials,"1. Add a boxed warning to Prolia‚Äôs label about increased risk of vertebral fractures upon drug discontinuation.
2. Implement an updated REMS that mandates revised communications and educational materials for healthcare providers and patients. These materials should highlight the fracture risk and recommend follow-up treatment with alternative antiresorptive therapies. ","Clinical evidence (including randomized trials, observational studies, and case series) shows a sharp increase in risk of multiple vertebral fractures following cessation of Prolia.
- This risk can be prevented or mitigated with appropriate education and treatment transitions (e.g., bisphosphonates).
- Current labeling and REMS do not sufficiently highlight this risk, and many patients and physicians remain unaware.
- Boxed warning and revised REMS will raise awareness, prevent abrupt treatment stops, and encourage safer discontinuation practices.",2019-10-11 00:00:00,"Denied, with labeling changes approved (but not a boxed warning or REMS modification)",2020-04-23,1.0,Center for Drug Evaluation and Research (CDER),"21 CFR 201.57(c)(6)(i) and (c)(1)
- 21 CFR 201.56(d)(1), 201.57(a)(4), and 201.80(e), (f)
- 21 U.S.C. 355(b)(1)(F)
- FD&C Act ¬ß¬ß 505(o)(4), 505-1(a), 505-1(b)(3), 505-1(d), 505-1(e)(2), 505-1(e)(3), 505-1(f)(3), 505-1(f)(4), 505-1(g)(4)","The petition requested FDA to revise labeling for Prolia (denosumab) to add a boxed warning and modify its Risk Evaluation and Mitigation Strategy (REMS) to address risks of vertebral fractures post-discontinuation.
- FDA stated it has not yet reached a decision due to the complexity of the issues, which require extensive internal analysis and review.","FDA determined that the risk of multiple vertebral fractures after discontinuation of Prolia is already adequately addressed in existing labeling (specifically in WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS sections).
- FDA did not find sufficient new safety information to justify elevating this risk to a boxed warning.
- Prolia's benefits (especially for women at high risk of fracture and with severe renal impairment) outweigh the risks when appropriately used.
- Most osteoporosis medications (except bisphosphonates) show a reversal of therapeutic benefit upon discontinuation.
- The requested changes to the REMS were deemed unnecessary, as the Medication Guide and communication tools already address the risk.
- Additional labeling clarifications were approved to reinforce provider awareness and recommend transitioning patients to other antiresorptive therapy if Prolia is discontinued.",approved,True,373.0,CDER,CDER
fda-2019-p-1640,FDA-2019-P-1640-0001_Citizen_Petition_from_Top_Health_Ingredients__Inc.pdf,2019-03-04,2019,False,original petition,"Top Health Ingredients, Inc.",industry/corporation,"21 C.F.R. ¬ß 170.35
- 21 U.S.C. ¬ß 321(s) (implied, GRAS context)
- FDA Modernization Act of 1997",FDA's no-objection policy on GRAS notifications and the lack of response to the GRAS notification for ‚ÄúBarley Beta Glucan‚Äù submitted by Cargill Inc.,The petitioner requests that FDA rescind its GRAS no-objection letter for Cargill‚Äôs barley beta glucan ingredient or require a new GRAS notification and independent evaluation before continuing market access.,"Top Health claims that Cargill‚Äôs barley beta glucan product has insufficient safety data for GRAS status.
- Asserts inequitable regulatory treatment, where similar ingredients (like their own) would not pass under the same scrutiny.
- Highlights concerns about composition differences, manufacturing process inconsistencies, and consumer health risk.
- Challenges the scientific rigor of the Cargill notification and FDA‚Äôs oversight.",2019-10-21 00:00:00,Denied,2020-01-09,1.0,Center for Food Safety and Applied Nutrition (CFSAN),"21 CFR 101.9(c)(6)(i) ‚Äì Definition of dietary fiber

21 CFR 101.9(c)(6)(iii) ‚Äì Addition of substances to dietary fiber definition via petition

21 CFR 10.30(e)(3) ‚Äì Criteria for granting/denying citizen petitions

21 CFR 101.9(c)(1)(i)(C) ‚Äì Added sugars labeling

21 CFR 101.36(b)(2)(i) ‚Äì Supplement facts labeling requirements

81 FR 33742 ‚Äì Final rule on Nutrition and Supplement Facts Labels (June 2016)

Other referenced materials include prior FDA responses, scientific studies, and petitions","The petition requested that isomaltooligosaccharide (IMO) be included in the list of dietary fibers under 21 CFR 101.9(c)(6)(i).
- FDA cited other agency priorities and limited availability of resources as the reason for not issuing a decision within the standard 180-day period.","Insufficient Scientific Evidence of Benefit:
FDA concluded that the petitioner did not provide adequate scientific evidence to demonstrate that IMO consumption has a beneficial physiological effect‚Äîspecifically, in relation to laxation or blood cholesterol levels, the two endpoints evaluated.

Studies Were Methodologically Limited:
Studies submitted suffered from issues such as:

Inadequate statistical analysis

Insufficient control of confounding variables

Use of laxative/enema treatments during collection periods, which compromised laxation assessments

Small sample sizes and poorly controlled study designs

Lack of Demonstrated Relevance to Target Populations:
FDA found that studies conducted on chronically constipated patients could not be extrapolated to the general healthy population, limiting the relevance of claimed benefits
.

IMO‚Äôs Chemical Structure Alone Not Sufficient for Classification:
Although IMO may share similar non-digestible carbohydrate linkages with other fibers like inulin and GOS, FDA clarified that structure alone is not sufficient for dietary fiber classification without demonstrated health benefits.

Final Statement:
The agency indicated it is open to a new petition if future evidence demonstrates a health benefit from IMO consumption.",denied,True,311.0,CFSAN,Other/Specialty Center
fda-2019-p-5997,FDA-2019-P-5997-0001_Citizen_Petition_for_Center_for_Biological_Diversi.pdf,2019-10-30,2019,False,original petition,Center for Biological Diversity,advocacy/academic,"21 U.S.C. ¬ß 321(s) (FDCA: definition of food additive)
- 21 U.S.C. ¬ß 348 (FDCA: food additive approval)
- 21 C.F.R. ¬ß 170.3(e)(4) (definition of ‚Äúfood additive‚Äù)
- 21 C.F.R. Part 170, Subpart B (food additive petition process)",FDA‚Äôs inaction on regulating phthalates as food additives despite mounting scientific evidence of harm,"The petition requests the FDA to rescind its approval for 28 ortho-phthalates as food additives, effectively banning their use in food contact materials.","Scientific studies linking phthalates to endocrine disruption, developmental and reproductive toxicity, and other health effects
- Regulatory precedents from other countries
- Legal obligation under the Federal Food, Drug, and Cosmetic Act to ensure safety of food additives
- FDA‚Äôs failure to act despite longstanding awareness of risks",,"Acknowledged ‚Äì The petition was received and filed, but no decision was made on its substantive merits.",2019-12-19,0.0,"Dockets Management Staff, FDA/Office of Operations (OO)","21 C.F.R. ¬ß 101 (Labeling regulations)
- Federal Food, Drug, and Cosmetic Act (FFDCA)",,The letter clearly states that acceptance for filing is procedural and does not indicate a decision on the substantive merits of the petition. This is standard practice upon receipt of a petition by the FDA,other,True,50.0,DMS,Other/Specialty Center
fda-2019-p-0466,FDA-2019-P-0466-0001_Citizen_Petition_from_Fresenius_Kabi_USA__LLC.pdf,2019-01-29,2019,False,original petition,"Fresenius Kabi USA, LLC",industry/corporation,"21 CFR ¬ß 10.30
- 21 CFR ¬ß 314.161
- 21 CFR ¬ß 314.162
- 21 CFR ¬ß 25.31","FDA‚Äôs removal of certain dextrose injection products (20% and 50%) from the ""Active"" to the ""Discontinued"" section of the Orange Book without a formal determination of withdrawal due to safety or efficacy concerns.",That the FDA determine whether the NDA holder (Baxter Healthcare Corp.) for Dextrose 20% and 50% in plastic containers (NDA 017521) withdrew the products for reasons of safety or effectiveness.,"The products are no longer listed as ‚Äúactive‚Äù in the Orange Book and now appear in the ""Discontinued Section""
- Under 21 CFR 314.161, such a determination is necessary before approving any ANDA that references these products
- The petitioner seeks clarification on the reason for withdrawal to support future ANDA submissions",2019-07-25 00:00:00,"Approved ‚Äì The FDA determined that Dextrose 20 g/100 mL and 50 g/100 mL were not withdrawn for reasons of safety or effectiveness, allowing ANDA submissions referencing these products to proceed",2019-08-20,1.0,Center for Drug Evaluation and Research (CDER),"Section 505(j)(7) of the FD&C Act (21 U.S.C. 355(j)(7))
- 21 CFR 314.161 ‚Äì Regarding FDA‚Äôs process for determining if a drug was withdrawn for safety/effectiveness reasons
- 21 CFR 314.162 ‚Äì Relating to the removal of drugs from the Orange Book list",The FDA cites the need to address other agency priorities and the numerous demands on the Agency's resources as the reason for not reaching a decision at that time.," The petitioner (Fresenius Kabi USA, LLC) requested that FDA determine whether the referenced Dextrose products were withdrawn from sale for safety or effectiveness reasons.
- FDA found no information indicating withdrawal due to such reasons.
- Review included internal FDA records and relevant literature.
- These products remain in the Discontinued Drug Product List, enabling ANDA approval if all other requirements are met.",approved,True,203.0,CDER,CDER
fda-2019-p-6044,FDA-2019-P-6044-0001_Citizen_Petition_from_Latham___Watkins_LLP_on_beha.pdf,2019-12-20,2019,False,original petition,"Par Sterile Products, LLC (""Par"")",industry/corporation,"505(b), 505(j), and 505(q) of the FDCA
- 21 C.F.R. ¬ß¬ß 10.30, 314.70(b)(1), 314.70(c), 314.92(a)(1), 314.93, 314.94(a)(3), 314.94(a)(9)(iii)
- 21 U.S.C. ¬ß 355(j)(2)(A)(i)
- 21 C.F.R. ¬ß 25.31(a)","FDA‚Äôs review and approval process for Abbreviated New Drug Applications (ANDAs) that cite Adrenalin¬Æ as the reference listed drug (RLD).
- FDA‚Äôs requirement that Par‚Äôs proposed formulation change be submitted as a Prior Approval Supplement (PAS) rather than a CBE-30 supplement.","Expedite FDA review and take final action on Par‚Äôs pending PASes to remove the epinephrine overage in Adrenalin¬Æ.
- Refrain from approving any ANDA for a generic epinephrine injection product citing Adrenalin¬Æ as the RLD until FDA has completed its PAS review.
- After PAS approval, refrain from approving any ANDA for a generic version of Adrenalin¬Æ that contains an epinephrine overage or otherwise differs in formulation from the revised version.","Patient safety risks: Epinephrine overages may lead to patients receiving super-potent doses, which could result in severe side effects such as cardiac arrhythmias, pulmonary edema, or cerebrovascular hemorrhage.
- FDA policy disfavoring overages unless strictly necessary.
- Par‚Äôs revised formulation retains potency without the need for overage and supports an 18-month shelf life.
- FDA‚Äôs own decision to classify Par‚Äôs CBE-30 supplement as a PAS indicates the clinical significance of the change, reinforcing the need to delay approval of generics until the PAS is resolved.",,"Denied
‚Äì The FDA denied the petition‚Äôs request to delay approval of any ANDAs referencing Xeljanz XR (tofacitinib extended-release tablets) based on bioequivalence concerns with an alternative comparator.",2020-04-24,0.0,Center for Drug Evaluation and Research (CDER),"21 CFR 314.94(a)(7)
- Section 505(j) of the FD&C Act (21 U.S.C. ¬ß 355(j))
- 21 CFR 314.127(a)(6)
- 21 CFR 320.24",,"FDA reviewed data submitted in the citizen petition, including pharmacokinetic data comparing Xeljanz XR and another product, and determined that no new safety or efficacy concerns were raised.
- FDA noted that it evaluates ANDAs on a case-by-case basis and has mechanisms to ensure appropriate therapeutic equivalence.
- The Agency stated that the petition did not justify delaying approvals, and such actions would be inconsistent with FDA‚Äôs statutory obligations under the Hatch-Waxman Amendments.",denied,True,126.0,CDER,CDER
fda-2019-p-3265,FDA-2019-P-3265-0001_Citizen_Petition_from_Medical_Research_Collaborati.pdf,2019-07-08,2019,False,original petition,"Medical Research Collaborative, LLC",advocacy/academic,"21 C.F.R. ¬ß 10.30 and ¬ß 10.31 (regarding citizen petitions)
- 21 U.S.C. ¬ß 355(c)(3)(D)(ii)(I) and ¬ß 355(j)(5)(C)(ii)(I) (relating to deletion of Orange Book patent listings for 505(b)(2) NDAs and ANDAs)
- 21 C.F.R. ¬ß¬ß 25.30 and 25.31 (categorical environmental exclusions)","The inclusion of U.S. Patent No. 8,188,146 (the '146 patent) in the FDA‚Äôs Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book), specifically related to Amarin Corp.‚Äôs drug Vascepa (icosapent ethyl)","Request that the FDA remove the '146 patent from the Orange Book, on the grounds that it is improperly listed and does not claim an FDA-approved method of use or valid composition of matter related to Vascepa","The '146 patent allegedly does not claim an approved method of using Vascepa, and even excludes the approved use (hypertriglyceridemia).
- The patent is described as a method-of-use patent masquerading as a composition-of-matter patent.
- Claims such as ‚Äúcontains no DHA‚Äù are argued to be impossible to meet and constitute an abstract idea, thus invalid.
- The patent specification focuses on CNS/psychiatric indications, not the FDA-approved indication.
- The active ingredient was already known and developed by others (e.g., Mochida), making it anticipated by prior art.
- Amarin did not assert this patent in ongoing ANDA patent litigation, suggesting lack of enforceability.",,Denied,2019-11-26,0.0,Center for Drug Evaluation and Research (CDER),"21 U.S.C. ¬ß¬ß 355(b)(1) and (c)(2) ‚Äì Application requirements for NDAs

21 CFR ¬ß¬ß 314.53(b), 314.53(c), 314.53(d)(2), 314.53(e), 314.53(f), 314.53(f)(1), 314.53(f)(1)(i)(A), 314.53(c)(2)(ii) ‚Äì Patent listing, accuracy challenges, and Form FDA 3542 procedures

68 FR 36676 at 36687 (June 18, 2003) ‚Äì 2003 Final Rule on patent submissions and stays

81 FR 69580 (October 6, 2016) ‚Äì Final rule on ‚ÄúAbbreviated New Drug Applications and 505(b)(2) Applications‚Äù

FD&C Act Sections 505(b)(1), 505(c)(2), 505(j), 505(j)(7) ‚Äì Legal basis for drug application and Orange Book requirements",,"Procedural Noncompliance:
The petition asked FDA to remove Patent No. 8,188,146 from the Orange Book. However, such a request is subject to the patent listing dispute procedures outlined in 21 CFR ¬ß 314.53(f). The citizen petition format used by the petitioner does not comply with those specific procedural requirements
.

Ministerial Role of FDA in Patent Listings:
FDA reiterated that it does not evaluate or challenge the validity or accuracy of patent submissions made by NDA holders via Form FDA 3542. The FDA‚Äôs role is limited to ministerial publication of that information in the Orange Book
.

Process for Challenging Listings Exists:
A structured pathway is provided in ¬ß 314.53(f) that allows third parties to file a ‚Äú314.53(f) Patent Listing Dispute‚Äù, but the citizen petition process is not the correct mechanism for such a challenge
.

No Change Without NDA Holder Action:
FDA cannot amend, withdraw, or correct patent information unless the NDA holder voluntarily revises it, even if a third party contests it
.

Opportunity to Refile via Correct Procedure:
FDA acknowledged that while the citizen petition is denied, the petitioner remains free to submit a properly formatted dispute per ¬ß 314.53(f) to Orange Book Staff",denied,True,141.0,CDER,CDER
fda-2019-p-2687,FDA-2019-P-2687-0001_Citizen_Petition_from_AuroMedics_Pharma_LLC.pdf,2019-06-03,2019,False,original petition,AuroMedics Pharma LLC,industry/corporation,"21 C.F.R. ¬ß 10.30 (Citizen Petition)
- 21 C.F.R. ¬ß 320.22(d)(1) and ¬ß 320.22(d)(3) (waivers of in-vivo bioequivalence testing)
- 21 C.F.R. ¬ß 25.30(h) (categorical exclusion for environmental impact)","The lack of therapeutic equivalence (TE) rating for NDA 209552 (Argatroban in Sodium Chloride Injection, 50 mg/50 mL) and the request to designate it with an 'AP' rating to match the Reference Listed Drug (RLD) NDA 022434 held by Eagle Pharmaceuticals, Inc.","The petitioner requests that the FDA assign a therapeutic equivalence rating of ‚ÄòAP‚Äô to Aurobindo Pharma‚Äôs Argatroban in Sodium Chloride Injection, NDA 209552, identifying it as therapeutically equivalent to the RLD, NDA 022434 (Eagle Pharmaceuticals)","NDA 209552 is pharmaceutically equivalent to the RLD in active ingredient, dosage form, strength, and route of administration.
- The differences in excipients are minor and do not affect bioavailability, as FDA has previously granted waivers of in-vivo bioequivalence testing.
- Other similar 505(b)(2) NDAs have been granted TE ratings despite formulation differences.
- Granting an ‚ÄòAP‚Äô rating would support exemption from PDUFA user fees and establish regulatory clarity for therapeutic substitution. ",2019-11-27 00:00:00,,2025-10-15,1.0,,,"The FDA indicated it has not been able to reach a decision due to the need to address other Agency priorities. The response was provided in accordance with FDA regulations on citizen petitions, and the FDA committed to responding as soon as resources allow.",,no decision,False,2326.0,pending,pending
fda-2019-p-2982,FDA-2019-P-2982-0001_Citizen_Petition_from_Hetero_Labs_Limited.pdf,2019-06-19,2019,False,original petition,Hetero Labs Limited,advocacy/academic,"21 C.F.R. ¬ß 10.30 (Citizen petition procedure)
- 21 C.F.R. ¬ß 314.161 (Drug withdrawal from sale for safety or effectiveness)
- 21 C.F.R. ¬ß 314.162 (FDA's authority to withdraw or suspend drug approval)
- 21 C.F.R. ¬ß 25.31 (Environmental assessment exclusion)","The petitioner is commenting on the status of the reference listed drug Mexitil¬Æ (Mexiletine Hydrochloride) NDA# 018873 and requests that FDA determine whether it was withdrawn for reasons other than safety or effectiveness, thus allowing ANDA filings to reference it.","Determine that Mexitil¬Æ (Mexiletine Hydrochloride), NDA# 018873, was not withdrawn for safety or effectiveness reasons.
- Allow use of the product as a Reference Listed Drug (RLD) in abbreviated new drug applications (ANDAs).
- Request that FDA publish this determination in the Federal Register and annotate the Orange Book accordingly.","Publicly available information (e.g., internet searches) reveals no evidence that the product was withdrawn for safety or effectiveness reasons.
- No published federal or state court decisions involve product liability for Mexitil¬Æ.
- The product is listed in the Discontinued Section of the Orange Book but lacks the annotation stating it was not withdrawn for safety or efficacy.
- The petitioner believes the discontinuation was voluntary and unrelated to safety/efficacy.",,"Approved ‚Äî FDA determined that MEXITIL (mexiletine hydrochloride) capsules (150 mg, 200 mg, and 250 mg) were not withdrawn for reasons of safety or effectiveness, allowing abbreviated new drug applications (ANDAs) to be approved if other conditions are met",2019-11-01,0.0,Center for Drug Evaluation and Research (CDER),"21 CFR 314.161 ‚Äì Withdrawn drug evaluation criteria
- 21 CFR 314.162 ‚Äì Drug removal from the Orange Book",,"No data or information indicated that MEXITIL was withdrawn due to safety or effectiveness concerns.
- FDA reviewed agency records and independently evaluated postmarketing literature and data.
- The drug remains in the Orange Book‚Äôs ‚ÄúDiscontinued Drug Product List.‚Äù",approved,True,135.0,CDER,CDER
fda-2019-p-0412,FDA-2019-P-0412-0001_Citizen_Petition_from_Summit_Pharmaceuticals_Inc.pdf,2018-12-21,2019,False,original petition,Summit Pharmaceuticals Inc.,industry/corporation,"¬ß 512(n)(3) of the Federal Food, Drug, and Cosmetic Act (FFDCA)
- 21 C.F.R. ¬ß¬ß 10.20 and 10.30 (FDA citizen petition procedures)
- 21 C.F.R. ¬ß 314.93 (related to suitability petitions for generics)
- 21 C.F.R. ¬ß 25.30(h) (categorical environmental exclusion)
- 21 C.F.R. ¬ß 25.21 (extraordinary circumstances for environmental review)","The petition comments on New Animal Drug Application (NADA) 141-324 for ""PROIN Chewable Tablets"" and seeks permission to file an Abbreviated New Animal Drug Application (ANADA) for a generic that differs in dosage form and strength.","Permission to file an ANADA based on NADA 141-324 despite differences in dosage form (unscored, film-coated vs. scored, chewable tablets) and strength (addition of 12.5 mg and 37.5 mg tablets).
- Request that these changes be accepted as permissible under a suitability petition. ","The active ingredient (phenylpropanolamine hydrochloride) remains unchanged.
- Dosage form is modified only to unscored, film-coated tablets for ease of manufacturing; two new strengths are added to maintain dosing precision.
- Labeling will match the Reference Listed New Animal Drug (RLNAD), with necessary adjustments.
- Summit commits to demonstrating bioequivalence through CVM-approved protocols.
- The requested changes fall within the legal framework for filing a suitability petition under FFDCA ¬ß 512(n)(3)",,,2025-10-15,0.0,,,,,no decision,False,2490.0,pending,pending
fda-2019-p-3266,FDA-2019-P-3266-0001_Citizen_Petition_from_Medical_Research_Collaborati.pdf,2019-07-08,2019,False,original petition,"Medical Research Collaborative, LLC",advocacy/academic,"21 C.F.R. ¬ß 10.30 (citizen petition regulation)
- 21 U.S.C. ¬ß 321(ff)(1) and ¬ß 321(ff)(3)(B) (definition and exclusions for ‚Äúdietary ingredient‚Äù)
- 19 U.S.C. ¬ß 1337 (unfair practices under the Tariff Act)
- 15 U.S.C. ¬ß 1125(a)(1) (Lanham Act)
- 21 C.F.R. ¬ß¬ß 25.30, 25.31 (environmental impact categorical exclusions)","The petitioner is commenting on the FDA‚Äôs definition and classification of certain forms of omega-3 fatty acids (including ethyl ester, re-esterified triglyceride (rTG), free fatty acid, mono- and diglyceride forms) as ‚Äúdietary ingredients‚Äù or ‚Äúdrugs.‚Äù This is in response to Amarin Corp.'s attempt to classify them as drugs via a complaint to the International Trade Commission (ITC).","The petitioner asks that the FDA officially rule that ethyl ester, re-esterified triglyceride (rTG), free-fatty acid, mono-, and diglyceride forms of omega-3 fatty acids are dietary ingredients under the FD&C Act","These omega-3 forms have been widely and safely used as dietary supplements for decades, including in foods and infant formulas.
- FDA has not explicitly ruled that these are not dietary ingredients‚Äîrather, past guidance and responses have left their status ‚Äúunclear.‚Äù
- The definitions of dietary ingredients under the FD&C Act are broad and can encompass these forms.
- The petition seeks to prevent companies like Amarin Corp. from monopolizing access to such products by labeling them as unapproved ‚Äúdrugs.‚Äù
- FDA, not the ITC or private companies, has the authority to interpret and enforce the FD&C Act regarding such classifications.
- Classification as dietary ingredients would reflect public use and consumer expectation, as omega-3s are a multi-billion dollar industry in the U.S",2020-01-14 00:00:00,,2025-10-15,1.0,,,The FDA cited competing agency priorities as the reason for not reaching a final decision within the 180-day timeframe. The letter also affirms that the petition is still under review by FDA staff.,,no decision,False,2291.0,pending,pending
fda-2019-p-4101,FDA-2019-P-4101-0001_Citizen_Petition_from_IQVIA_RDS_Inc_.pdf,2019-08-29,2019,False,original petition,IQVIA RDS Inc.,industry/corporation,"21 C.F.R. ¬ß¬ß 10.25(a), 10.30 (citizen petition regulations)
- Section 505(j) of the FD&C Act
- 21 C.F.R. ¬ß 25.31 (categorical exclusion from environmental assessment)","The petition comments on FDA‚Äôs designation of the reference listed drug (RLD) and reference standard (RS) for Dicyclomine Hydrochloride Tablets (currently BENTYL¬Æ by Allergan Sales LLC), which is not available in the market. The petitioner seeks FDA action in light of the product‚Äôs unavailability despite not being marked as ‚Äúdiscontinued‚Äù in the Orange Book","Designate an alternative reference standard (RS) for Dicyclomine Hydrochloride Tablets to enable development of a generic version.
- Petition includes supporting market data and references FDA guidance allowing such designation when the current RS is unavailable","BENTYL¬Æ tablets are not commercially available, even though still listed as active in the Orange Book.
- FDA‚Äôs Draft Guidance on Referencing Approved Drug Products in ANDA Submissions provides for changing the RS when the current RS is unavailable.
- Market data shows several therapeutically equivalent marketed alternatives (e.g., by Mylan, Teva, Hikma).
- The unavailability prevents the sponsor from completing bioequivalence testing, hindering ANDA development",,Approved (Petitions Granted),2019-12-19,0.0,Center for Drug Evaluation and Research (CDER),"21 U.S.C. ¬ß 355(j) ‚Äì Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) governing ANDA submissions

21 CFR ¬ß 314.3(b) ‚Äì Definitions, including ‚Äúreference listed drug‚Äù

21 CFR ¬ß 314.94(a)(3) ‚Äì Content and format of ANDAs (bioequivalence testing)

21 CFR ¬ß 314.161 ‚Äì Determining whether a drug was withdrawn for safety/effectiveness

21 CFR ¬ß 314.122 ‚Äì Petition requirements for withdrawn listed drugs

81 FR 69580, 69619 (Oct. 6, 2016) ‚Äì Final rule on ANDA and 505(b)(2) applications",,"Current Reference Standard Unavailable:
The product Bentyl (dicyclomine hydrochloride tablets, 20 mg), previously approved under NDA 007409, was no longer available on the market despite not being listed as discontinued in the Orange Book. This unavailability was confirmed via FDA‚Äôs Drug Shortages Database
.

Inability to Proceed with Generic Development:
Both petitioners (Aurobindo and IQVIA) indicated that the absence of an available reference standard hindered their ability to proceed with generic ANDA submissions
.

Commercial Data Supported Market Unavailability:
Market share data and commercial availability were reviewed, reinforcing that the existing reference product was unavailable for conducting bioequivalence studies
.

Selection of Therapeutic Equivalent Product:
Based on commercial availability and therapeutic equivalence, FDA determined that ANDA 085223, held by Watson Laboratories Inc., met the necessary criteria. It is:

Currently marketed

Therapeutically equivalent

Identified as a suitable replacement reference standard
.

Regulatory Compliance:
FDA affirmed that selecting a new reference standard in this case aligns with regulatory requirements and precedent when the listed drug is unavailable",approved,True,112.0,CDER,CDER
fda-2019-p-3022,FDA-2019-P-3022-0007_Amendment_from_Foley_and_Lardner_LLP.pdf,2020-07-14,2019,False,original petition,Foley & Lardner LLP,law/consulting,"The specific regulatory citation for the suitability petition (e.g., 21 C.F.R. ¬ß 10.30 or ¬ß 314.93) is Not Explicitly Mentioned in the amendment. However, the document refers to the ANDA suitability petition process, which is generally governed by 21 C.F.R. ¬ß 314.93",FDA's comment on the suitability petition for a proposed ANDA for Rivaroxaban Capsules regarding inconsistency in labeling‚Äîspecifically concerning instructions related to crushing the capsule,"Acceptance of the revised draft package insert submitted with the amendment to clarify FDA‚Äôs concerns and support the suitability petition for filing an ANDA for Rivaroxaban Capsules (2.5 mg, 10 mg, 15 mg, and 20 mg)","The petitioner responds to FDA‚Äôs concern about instructions for crushing capsules, which FDA noted was inconsistent with typical capsule use.
- The revised labeling retains a reference to ‚Äúcrushed tablet‚Äù only in Section 12.3, clearly indicating it relates to a clinical study conducted on the Reference Listed Drug (RLD), not on the proposed capsule formulation.
- The inclusion is contextual and scientifically justified, and does not suggest the capsule itself should be crushed",,,2025-10-15,0.0,,,,,no decision,False,1919.0,pending,pending
fda-2019-p-2240,FDA-2019-P-2240-0001_Citizen_Petition_from_Axinn_on_behalf_of_Zydus_Pha.pdf,2019-05-06,2019,False,original petition,"Axinn, Veltrop & Harkrider LLP",law/consulting,"Section 505 of the FDCA
- 21 C.F.R. ¬ß¬ß 10.20, 10.25, 10.30, 10.31
- 21 C.F.R. ¬ß 25.31(a) (environmental impact categorical exclusion)","The petition challenges FDA‚Äôs current therapeutic equivalence (‚ÄúTE‚Äù) rating and approval process for generic versions of Mephyton¬Æ (Phytonadione Tablets, NDA No. 010104), urging the FDA to reevaluate the sameness of active ingredients based on isomeric purity","1. Require that ANDA applicants:
¬†¬†¬†‚Ä¢ Identify and quantify each isomer (including Z isomers) through validated testing, and
¬†¬†¬†‚Ä¢ Control Z isomer levels to match the RLD (Mephyton).
2. Refrain from approving new ANDAs lacking this data.
3. Downgrade the TE rating from ‚ÄúAB‚Äù to ‚ÄúBX‚Äù for already-approved ANDAs that haven‚Äôt demonstrated comparable isomeric purity","The stereochemistry of phytonadione significantly affects its bioactivity: only trans isomers are therapeutically active; cis isomers are inactive.
- Synthetic forms may have different isomeric ratios than the RLD, affecting clinical equivalence.
- FDA required Zydus to meet stricter criteria during approval of its ANDA based on RLD isomer data.
- Petition argues all ANDA applicants should be held to the same rigorous standards to ensure therapeutic equivalence.
- Without such measures, the ‚Äúsameness‚Äù requirement under the FDCA is not met, and patients may receive inequivalent therapy",,Denied,2019-10-03,0.0,Center for Drug Evaluation and Research (CDER),"21 CFR 314.3(b) ‚Äì Definition of ‚Äúsame‚Äù active ingredient

21 CFR 314.103 ‚Äì Hearing request rights

21 CFR 314.110, 314.127 ‚Äì Review procedures for ANDAs

21 CFR 314.430 ‚Äì Confidentiality of FDA records

Section 505(j) of the FD&C Act (21 U.S.C. 355(j)) ‚Äì Generic drug approval pathway

Section 505(q) of the FD&C Act (21 U.S.C. 355(q)) ‚Äì Citizen petition standards and timelines

Public Law 98-417 ‚Äì Drug Price Competition and Patent Term Restoration Act of 1984

FDAAA of 2007 / FDASIA of 2012 ‚Äì Modifications to FD&C Act section 505(q)

USP Monograph for phytonadione ‚Äì Cited in argumentation by petitioner",,"No Requirement for Additional Isomeric Data for ANDAs:
The petition requested that ANDA applicants for phytonadione tablets demonstrate isomeric and stereoisomeric equivalence to Mephyton. FDA disagreed, explaining that generic applicants need only prove active ingredient ‚Äúsameness‚Äù as defined by regulation, which does not require detailed characterization of each isomer unless it affects safety or efficacy
.

FDA Retains Discretion on Sameness Determinations:
FDA emphasized its broad discretion in determining ‚Äúsameness‚Äù of active ingredients and found no scientific basis to mandate the more stringent testing proposed by the petitioner
.

Statutory Review Timeframe Met; Petition Denied Without Further Comment:
Under section 505(q), the agency must act within 150 days. FDA denied the petition on procedural and substantive grounds without making a final determination on how it will evaluate future ANDAs referencing Mephyton
.

No Immediate TE Code Downgrade Justified:
FDA declined to downgrade the Therapeutic Equivalence (TE) code for existing ANDAs citing Mephyton, stating it would only consider such action if warranted by new information. Current TE ratings were not shown to be invalid
.

FDA Will Continue Case-by-Case Review:
FDA reiterated that it will continue to evaluate each ANDA submission individually and determine whether additional controls are necessary based on the full context of submitted data",denied,True,150.0,CDER,CDER
fda-2019-p-3423,FDA-2019-P-3423-0001_Suitability_Petition_from_Oxford_Pharmaceuticals__.pdf,2019-06-06,2019,False,original petition,"Oxford Pharmaceuticals, LLC",industry/corporation,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 314.93 (Suitability petitions)
- 21 C.F.R. ¬ß¬ß 10.20, 10.30 (General petition procedures)
- 21 C.F.R. ¬ß 25.31 (Environmental categorical exclusion)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact provision)","The petitioner is commenting on the need to obtain FDA‚Äôs determination of suitability for filing a supplemental Abbreviated New Drug Application (sANDA) for a new strength (15 mg) of Baclofen Tablets, USP, which differs from existing RLD/RS strengths (10 mg and 20 mg)","Request that the FDA declare Baclofen Tablets, USP, 15 mg as suitable for submission in an sANDA, as an additional strength to the approved Reference Listed Drug (RLD) and Reference Standard (RS)","The only difference from the RLD/RS is the change in strength from 10 mg/20 mg to 15 mg.
- No changes in indications, usage, dosage form, route of administration, patient population, or other labeling aspects.
- Therefore, there is no difference in safety or efficacy.
- The request complies with statutory and regulatory provisions for a suitability petition under 505(j)(2)(C) and 21 C.F.R. 314.93.
- Petitioner also claims a categorical environmental exclusion under 21 C.F.R. 25.31",,,2025-10-15,0.0,,,,,no decision,False,2323.0,pending,pending
fda-2019-p-1534,FDA-2019-P-1534-0001_Citizen_Petition_from_American_Association_of_Pro_.pdf,2019-03-29,2019,False,original petition,American Association of Pro-Life Obstetricians and Gynecologists (AAPLOG)  American College of Pediatricians (ACPeds),advocacy/academic,"21 C.F.R. ¬ß 25.30 (Environmental Impact exclusion)
- 21 C.F.R. ¬ß 10.30(3) (Economic Impact disclosure)","The FDA‚Äôs 2016 modifications to the Mifeprex regimen and Risk Evaluation and Mitigation Strategy (REMS), including:
- Expansion of gestational limit to 70 days
- Allowance of non-physicians as certified prescribers
- Reduction in required office visits
- Relaxed adverse event reporting requirements","The petitioners request the FDA to:
- (I) Restore and strengthen the Mifeprex regimen and prescriber requirements as approved in 2000
- (II) Retain the Mifeprex REMS and continue limiting dispensing to certified prescribers in clinical settings","Increased safety risks with extended gestational use beyond 49 days
- Higher complication rates (e.g., hemorrhage, incomplete abortion, infections)
- Concerns over telemedicine and pharmacy distribution reducing prescriber oversight
- Lack of adequate adverse event reporting under the 2016 REMS
- Need for studies on at-risk populations (e.g., adolescents, repeat users, rural patients)
- Belief that FDA safeguards have been weakened and should be restored for patient protection",2019-09-26 00:00:00,Acknowledgment of Receipt ‚Äî The petition was accepted for filing. No substantive decision was made.,2019-04-01,1.0,"Division of Dockets Management, Office of the Executive Secretariat (OES)",Not Mentioned,"The petition seeks to restore and strengthen the Mifeprex regimen and prescriber requirements approved in 2000.
- FDA noted the petition involves complex issues requiring detailed review and analysis, which has delayed the final decision.
- FDA committed to responding once the review is complete.",The letter states that acceptance of the petition for filing is a procedural matter and does not indicate any decision on the substantive merits of the petition regarding the Mifeprex regimen and REMS requirements.,other,True,3.0,DMS,Other/Specialty Center
fda-2019-p-6045,FDA-2019-P-6045-0001_Cover_Letter_re_Citizen_Petition_from_Hyman__Phelp.pdf,2019-12-20,2019,False,original petition,Wacker Chemical Corporation (petitioning entity),industry/corporation,21 C.F.R. ¬ß 101.9(c)(6)(i) ‚Äì regarding dietary fiber in nutrition labeling,FDA‚Äôs current regulation concerning what qualifies as dietary fiber for nutrition labeling under 21 C.F.R. ¬ß 101.9(c)(6)(i),That FDA amend 21 C.F.R. ¬ß 101.9(c)(6)(i) to recognize alpha-cyclodextrin as dietary fiber for purposes of nutrition labeling,"The cover letter does not provide detailed justification, but it implies that alpha-cyclodextrin meets necessary criteria to be classified as dietary fiber. Full justification would likely be in the enclosed petition (not included here)",2020-06-19 00:00:00,Denied,2022-04-25,1.0,Center for Food Safety and Applied Nutrition (CFSAN),"21 CFR 101.9(c)(6)(i)
- 21 CFR 10.30(e)(3)
- 21 CFR 10.30
- Final Rule: 81 FR 33742 (May 27, 2016)
- 83 FR 8997 (March 2, 2018)","Petition requested that alpha-cyclodextrin be recognized as dietary fiber for nutrition labeling.
- FDA has not completed review due to agency priorities and limited resource availability.","The FDA concluded that:
- There is inconsistent and limited scientific evidence regarding alpha-cyclodextrin's effects on postprandial blood glucose and insulin.
- Out of five human intervention studies (across seven publications), only a few showed statistically significant effects, and those effects varied depending on dose and meal composition.
- The inconsistencies could not be plausibly explained by dose, food type, or other factors.
- Therefore, the strength of scientific evidence was insufficient to support a finding that alpha-cyclodextrin provides a physiological benefit to human health.
- As a result, alpha-cyclodextrin does not meet the criteria for inclusion as a dietary fiber.",denied,True,857.0,CFSAN,Other/Specialty Center
fda-2019-p-6100,FDA-2019-P-6100-0001_Citizen_Petition_from_American_Association_of_Tiss.pdf,2019-12-30,2019,False,original petition,American Association of Tissue Banks (AATB),advocacy/academic,"21 C.F.R. Part 1271
- Section 361 of the Public Health Service (PHS) Act
- Section 351 of the PHS Act (referenced in contrast to Section 361)","FDA‚Äôs Tissue Reference Group (TRG) and Tissue Reference Group Rapid Inquiry Program (TRIP) determinations, specifically regarding the classification and regulation of birth-derived tissue products such as amniotic membrane, umbilical cord tissue, and Wharton‚Äôs jelly","The petitioner requests FDA to:
- Formally rescind or withdraw the TRG/TRIP determinations that classify birth-derived tissue products as 351 drugs/biologics
- Convene a public meeting to allow stakeholders to provide input on appropriate regulation of such tissues
- Clarify that such tissues, when minimally manipulated and intended for homologous use, should be regulated under Section 361","The TRG/TRIP decisions were made without public comment or scientific transparency
- The classifications are inconsistent with prior FDA guidance and regulatory history
- Clinically established uses of these tissues (e.g., wound covering) have a long-standing record of safe use under Section 361
- FDA‚Äôs new determinations cause regulatory uncertainty and burdens, risking access to beneficial therapies and disrupting patient care",2020-05-05 00:00:00,"Granted in Part / Denied in Part
‚Äì Request No. 1: Granted (FDA acknowledged that human ADM allografts may be considered homologous or nonhomologous depending on the specific use and labeling.)
‚Äì Request No. 2: Denied (FDA declined to revise its final guidance document.)",2022-08-25,3.0,Center for Biologics Evaluation and Research (CBER) and Center for Devices and Radiological Health (CDRH),"21 CFR Part 1271
- 21 CFR 1271.3(c), 1271.10(a), and 1271.15
- 42 U.S.C. 262 (PHS Act section 351)
- 42 U.S.C. 264 (PHS Act section 361)
- 21 CFR Part 3
- 21 CFR 10.115(e)
- 21 CFR 10.30(e)(2)","The FDA has not issued a final decision because the petition raises complex issues that require input from multiple agency components. The agency has engaged with stakeholders and the public (e.g., public hearings and advisory meetings) and continues to evaluate the matter","FDA acknowledged that some uses of human ADM in post-mastectomy breast reconstruction may be homologous (e.g., covering skin defects), while others may be nonhomologous (e.g., forming a pocket for implants).
- The homologous or nonhomologous nature is not determined solely by the labeling, but rather based on objective intent and actual use.
- FDA supports its reasoning using definitions and criteria from 21 CFR 1271, previous rulemaking, and guidance documents.
- FDA refused to revise the 2017 guidance because it already provides general principles applicable to dermis uses and the current evidence doesn't warrant reopening the guidance development process",approved,True,969.0,CDRH,CDRH
fda-2019-p-1679,FDA-2019-P-1679-0053_Letter_from_Braeburn_Inc.pdf,2019-05-23,2019,False,original petition,"Braeburn, Inc.",industry/corporation,"21 C.F.R. ¬ß 10.30(g) (submission format for supplement)
- 21 C.F.R. ¬ß 316.29(c) (FDA's authority to revoke orphan drug designation)","The FDA‚Äôs continued recognition of the orphan drug designation (ODD) for Sublocade (buprenorphine extended-release injection)
- Comments on FDA‚Äôs interpretation and revocation policy regarding ODDs based on outdated or flawed cost recovery justifications","The petitioner (Braeburn) requests the FDA to:
- Revoke the orphan drug designation (ODD) for Sublocade
- Do so based on new information that undermines the cost recovery assumptions made when the designation was granted","New evidence shows the cost recovery justification was flawed at the time ODD was granted
- Orphan Drug Act (ODA) permits revocation if the drug was not eligible at the time of designation
- FDA has precedent for such revocations (e.g., papaverine, methylnaltrexone, lisinopril oral solution)
- Ensuring market competition in opioid use disorder treatment aligns with public health needs
- Emphasis that opioid addiction is not a ‚Äúbona fide‚Äù orphan disease and should not benefit from market exclusivity improperly",,Not applicable ‚Äî this document contains arguments submitted by Braeburn in support of their petition.,2019-10-11,0.0,"Not applicable ‚Äî this is a supplemental submission by Braeburn, Inc., not an FDA response letter.","21 C.F.R. ¬ß 10.30(g)
- 21 U.S.C. ¬ß 360cc(a)
- 21 C.F.R. ¬ß 316.3(b)(14)(ii)(A)
- 21 C.F.R. ¬ß 316.29(a)(3)",,"Not applicable from the FDA ‚Äî but Braeburn argues that:
- Sublocade‚Ñ¢ was never eligible for Orphan Drug Designation (ODD) because Indivior did not submit a new ODD request as required by FDA regulations.
- Cites historical precedents (e.g., Nutropin Depot, Tyvaso, Orenitram) to argue that a product reformulation requires a new ODD.
- Argues that FDA‚Äôs 2016 policy change is unlawful if applied retroactively.
- If Sublocade is the ‚Äúsame drug‚Äù as Subutex, its ODE has expired; if it is ‚Äúclinically superior,‚Äù it must have had its own ODD request.",other,True,141.0,other,Other/Specialty Center
fda-2019-p-4386,FDA-2019-P-4386-0001_Citizen_Petition_from_Fresenius_Kabi_USA__LLC.pdf,2019-08-30,2019,False,original petition,"Fresenius Kabi USA, LLC",industry/corporation,"Section 505(q) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 10.30 (Citizen Petition procedures)
- 21 C.F.R. ¬ß 314.94(a)(9) (regarding labeling and RLD)
- Section 505(j) (ANDA provisions)","FDA‚Äôs approval process for ANDA 209965, submitted by Dr. Reddy‚Äôs Laboratories, for a generic version of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection
- Specifically, the FDA‚Äôs determination that this generic product is eligible for approval despite differences in formulation and labeling from the Reference Listed Drug (RLD) Precedex","Fresenius Kabi requests the FDA to:
- Revoke or suspend approval of ANDA 209965
- Refrain from approving similar ANDAs unless they have identical labeling and formulation to the RLD
- Update its regulations or guidance to prevent future similar approvals that deviate from RLD labeling/formulation","The generic product differs from the RLD in formulation and intended use, particularly concerning dosing in ICU sedation vs. procedural sedation
- Allowing such deviations undermines the scientific and legal basis of generic drug approval
- May cause confusion and safety risks due to non-equivalent clinical data and labeling
- Approval without appropriate equivalence violates the Hatch-Waxman Act framework and FDA‚Äôs own regulations",,"Approved
‚Äì The FDA approved the suitability petition to allow submission of an Abbreviated New Drug Application (ANDA) for lower strength formulations of Ketamine Hydrochloride Injection.",2019-09-18,0.0,"Center for Drug Evaluation and Research (CDER)
Specifically: Office of Generic Drugs, Office of Safety and Clinical Evaluation","Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- 21 CFR 314.93
- 21 CFR 314.93(e)(1)
- 21 CFR 314.94(a)(3)(iii)",,"The proposed change in strength does not raise questions of safety or effectiveness.
- The proposed drug product has the same use, dose, dosage form, and route of administration as the listed drug.
- The change is consistent with dosing recommendations in the labeling of the listed drug.
- If bioequivalence is demonstrated, it is expected to have the same therapeutic effect as the reference listed drug.
- Therefore, investigations to demonstrate safety and effectiveness are not required.",approved,True,19.0,CDER,CDER
fda-2019-p-3347,FDA-2019-P-3347-0001_Citizen_Petition_from_Stryker.pdf,2019-07-10,2019,False,original petition,Stryker Medical,individual,"Section 510(m)(2) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 890.3690 ‚Äì Powered Wheeled Stretcher
- 21 C.F.R. ¬ß 10.30 ‚Äì Citizen Petition process
- 21 C.F.R. ¬ß 820 ‚Äì Quality System Regulation
- 21 C.F.R. ¬ß 801 ‚Äì Device labeling requirements
- 21 C.F.R. ¬ß 890.9 ‚Äì Limitations of exemptions
- 21 C.F.R. ¬ß 25.34(b) ‚Äì Environmental Impact Exclusion
- Section 513(g) ‚Äì Request for classification information",Current requirement that devices classified under 21 C.F.R. ¬ß 890.3690 (Powered Wheeled Stretcher) must submit a premarket notification (510(k)) before being marketed,"Stryker requests the Commissioner of Food and Drugs to amend 21 C.F.R. ¬ß 890.3690 to exempt powered wheeled stretchers from the premarket notification requirement, subject to limitations in 21 C.F.R. ¬ß 890.9","Powered wheeled stretchers share critical features and safety/effectiveness profiles with other devices that are already exempt (e.g., patient lifts, electric chairs)
- Low adverse event history: Only 9 injuries and no deaths from 120 MDRs between May 2014‚Äì2019 (compared to higher rates in exempt devices)

- FDA recall and warning letter databases show minimal regulatory concern for these products
- Characteristics of the device are well established and standardized across the industry
- Changes to the device are detectable or do not materially increase risk, and any major changes are regulated by 21 C.F.R. ¬ß 890.9 and 510(k) pathway
- Historical use and design familiarity make misuse unlikely, and manufacturers follow risk and design controls (ISO 14971, IEC 62366-1)",,"Other ‚Äì The document is a notice of receipt and request for public comment; it does not contain a final decision. It outlines the FDA‚Äôs intent to determine whether to exempt powered wheeled stretchers from 510(k) requirements, but no final action is recorded in this notice.",2019-09-16,0.0,Center for Devices and Radiological Health (CDRH),"Section 510(k) of the FD&C Act (21 U.S.C. 360(k))
- Section 513 of the FD&C Act (21 U.S.C. 360c)
- Section 510(m) of the FD&C Act
- 21 CFR Part 807, Subpart E
- Public Law 114-255 (21st Century Cures Act)",,"The FDA acknowledged receipt of a petition from Stryker requesting an exemption from the 510(k) requirement for powered wheeled stretchers.
- The Agency is required under section 510(m)(2) to publish a notice, solicit public comments, and make a determination within 120 days.
- The exemption will only be granted if FDA finds that a 510(k) submission is not necessary to ensure safety and effectiveness.
- The criteria being considered are outlined in the FDA's 1998 guidance for class II device exemptions",other,True,68.0,CDRH,CDRH
fda-2019-p-4830,FDA-2019-P-4830-0031_Petition_for_Reconsideration_from_Ipsen_Biopharmac.pdf,2024-06-20,2019,False,reconsideration,"Ipsen Biopharmaceuticals, Inc.",industry/corporation," 21 C.F.R. ¬ß 10.33(b) (Petition for reconsideration)
- 21 U.S.C. ¬ß 360cc(a) (Orphan-drug exclusivity)
- 21 C.F.R. ¬ß 316.3(b)(12) (Clinical superiority)
- 21 C.F.R. ¬ß 316.34(c) (Scope of orphan-drug exclusivity)
- 21 U.S.C. ¬ß 355(c)(3)(E)(ii) and (j)(5)(F)(ii) (NDA and ANDA exclusivity)","FDA‚Äôs September 5, 2019 denial of Ipsen‚Äôs Citizen Petition (Docket No. FDA-2019-P-4830), which had requested that the FDA recognize Ipsen‚Äôs orphan-drug exclusivity for Somatuline Depot for the treatment of carcinoid syndrome","Ipsen requests that the FDA:
- Reconsider and reverse its denial of Ipsen‚Äôs original Citizen Petition
- Recognize orphan-drug exclusivity for Somatuline Depot (lanreotide) for carcinoid syndrome under the Orphan Drug Act","Ipsen asserts that Somatuline Depot was clinically superior to Braintree‚Äôs octreotide acetate in terms of convenience and patient compliance
- FDA‚Äôs denial was based on flawed reasoning and misapplied the clinical superiority standard
- Ipsen argues that the agency failed to properly apply statutory and regulatory provisions governing orphan-drug exclusivity
- Ipsen cites prior precedents where clinical superiority based on convenience was recognized
- Denial contradicts FDA‚Äôs public health mission by discouraging innovation for rare disease treatments",,,2025-10-15,0.0,,,,,no decision,False,482.0,pending,pending
fda-2019-p-4962,FDA-2019-P-4962-0001_Citizen_Petition_for_Fresenius_Kabi_USA__LLC.pdf,2019-10-24,2019,False,original petition,"Fresenius Kabi USA, LLC (FK USA)",industry/corporation,"21 C.F.R. ¬ß 10.30 ‚Äì Citizen Petition procedure
- Section 505(b)(2) ‚Äì New Drug Application (NDA) type
- 21 C.F.R. ¬ß 25.31 ‚Äì Environmental Impact Categorical Exclusion
- 21 C.F.R. ¬ß 10.30(b) ‚Äì Economic impact provision","The absence of a therapeutic equivalence rating (‚ÄúAP‚Äù rating) in the Orange Book for Glucagon for Injection (NDA 201849), which Fresenius Kabi argues should be rated equivalent to GlucaGen¬Æ (NDA 020918) by Novo Nordisk","FK USA requests that FDA:
- Designate Glucagon for Injection (NDA 201849) as therapeutically equivalent (with an ‚ÄúAP‚Äù rating) to the RLD GlucaGen¬Æ (NDA 020918)","FK USA's product is pharmaceutically and therapeutically equivalent to GlucaGen¬Æ in:
‚Ä¢ Active ingredients, dosage form, strength, route of administration, labeling, and excipients

- Side-by-side comparison in Table 1 (page 2) confirms all critical features are the same

- FK USA established a nonclinical bridge comparing impurity levels between their synthetic glucagon and GlucaGen¬Æ (recombinant)
- The FDA‚Äôs 2017 Draft Guidance supports equivalence for synthetic peptides referencing rDNA-origin products
- FK USA relied on RLD data and literature for approval under the 505(b)(2) pathway
- Therapeutic equivalence will reduce confusion, support market clarity, and align with Orange Book policy",2020-04-21 00:00:00,,2025-10-15,2.0,,,"The FDA indicated that the petition raises complex issues that require extensive review and analysis by Agency officials. As a result, a final decision has not yet been made. The interim response is issued in compliance with FDA‚Äôs regulation on citizen petitions (21 CFR 10.30(e)(2))",,no decision,False,2183.0,pending,pending
fda-2019-p-5151,FDA-2019-P-5151-0001_Citizen_Petition_from_GlaxoSmithKline.pdf,2019-10-25,2019,False,original petition,GlaxoSmithKline (GSK),individual,"Section 505(j) of the FDCA ‚Äì relating to ANDAs
- 21 C.F.R. ¬ß 314.94(a)(9)(iii) ‚Äì requirements for labeling and RLD comparison
- 21 U.S.C. ¬ß 355(j)(4)(H)(iii) ‚Äì approval standards for labeling differences
- 21 C.F.R. ¬ß 10.30 ‚Äì Citizen Petition procedures
- Section 505(q) ‚Äì Citizen petitions regarding ANDA or 505(b)(2) NDAs","FDA‚Äôs consideration and approval process for ANDA applications for fluticasone propionate and salmeterol inhalation powder products (e.g., generic Advair Diskus) with labeling differences or omissions, specifically related to step-down therapy and pediatric use","GSK requests that FDA:
- Decline to approve any ANDA referencing Advair Diskus that omits labeling related to step-down therapy or pediatric use unless the ANDA applicant provides adequate data to support such omissions","GSK argues that labeling related to step-down therapy and pediatric use is essential to ensure safe and effective use
- Omission of this information may lead to misleading or unsafe prescribing practices
- Cites FDA‚Äôs own guidance emphasizing the importance of clinical comparability and consistent labeling for drug-device combination products
- Emphasizes that generic applicants must justify labeling omissions with rigorous scientific data
- Approval without such justification would violate statutory and regulatory standards for generic drug approval",2020-01-23 00:00:00,"Other (Listening session / meeting memo, not a final decision)",2020-01-24,2.0,"Office of the Chief Counsel, Food and Drug Administration",139 S. Ct. 1668 (2019) ‚Äì Merck Sharp & Dohme Corp. v. Albrecht," The letter is a reply to a judge's request to expedite a response to the citizen petition related to the Zofran (Ondansetron) Products Liability Litigation.
- FDA states it is ""diligently examining the issues raised by the citizen petition"" and is working to respond as quickly as feasible, considering scientific and regulatory obligations.","The call was conducted as a listening session, with no new information to be introduced beyond what was already submitted to the petition docket.
- GSK provided background context regarding the preemption issues raised in litigation surrounding Zofran.
- GSK argued that FDA's previous decisions rejecting warning label changes were pivotal to the citizen petition.
- GSK emphasized their petition's novelty and that it was meant to engage FDA in evaluating the preemption implications of court cases and potential mislabeling risks under state law.
- The conversation reiterated that FDA‚Äôs prior decisions and scientific positions should not be second-guessed by courts, which was a core rationale behind the petition.",other,True,91.0,offices,Other/Specialty Center
fda-2019-p-3024,FDA-2019-P-3024-0001_Citizen_Petition_from_Foley___Lardner_LLP.pdf,2019-06-24,2019,False,original petition,Foley & Lardner LLP (submitted the petition),law/consulting,"21 C.F.R. ¬ß 10.30 ‚Äì Citizen Petition process
- 21 C.F.R. ¬ß 314.93 ‚Äì Petition to request change in dosage form
- 21 C.F.R. ¬ß 314.94 ‚Äì ANDA content and format
- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FDCA)
- 21 C.F.R. ¬ß 314.81 ‚Äì Annual reports
- 21 C.F.R. ¬ß 25.1(g) ‚Äì Environmental impact exemption
- 21 C.F.R. ¬ß 10.30(b) ‚Äì Economic impact submission if requested","Requesting FDA to declare that sitagliptin capsules (25 mg, 50 mg, 100 mg) are suitable for submission via an ANDA
- Reference Listed Drug (RLD): JANUVIA¬Æ (sitagliptin) tablets","Petitioner requests the FDA to:
- Approve a suitability petition allowing the submission of an ANDA for sitagliptin in capsule form, differing in dosage form from the tablet RLD JANUVIA¬Æ","The proposed capsules will have the same active ingredient, strength, route of administration, and therapeutic effect as JANUVIA¬Æ
- Capsules are intended as an alternative dosage form, particularly for patients with difficulty swallowing tablets
- Labeling will match the RLD, except for inactive ingredients and manufacturer details
- Pediatric use waiver requested due to lack of established safety/effectiveness in patients under 18, aligning with JANUVIA¬Æ's labeling",,,2025-10-15,0.0,,,,,no decision,False,2305.0,pending,pending
fda-2019-p-6049,FDA-2019-P-6049-0001_Citizen_Petition_from_US_WorldMeds__LLC.pdf,2019-12-23,2019,False,original petition,"US WorldMeds, LLC",industry/corporation,"Section 505(q) of the Federal Food, Drug, and Cosmetic Act (FDCA)
- Section 505(j) ‚Äì ANDA pathway
- 21 C.F.R. ¬ß 10.30 ‚Äì Citizen Petition procedures","FDA‚Äôs potential or pending approval of any ANDA referencing Lucemyra¬Æ (lofexidine hydrochloride tablets, 0.18 mg) with labeling that omits information related to dosing and administration, warnings, or precautions contained in the reference listed drug (RLD) labeling","US WorldMeds requests the FDA to:
- Withhold approval of any ANDA for generic versions of Lucemyra¬Æ if the application proposes to omit critical labeling related to:
‚Ä¢ Dosing and administration
‚Ä¢ Warnings and precautions
- Require generic applicants to fully replicate RLD labeling, or provide justification with adequate data for any omission","Labeling for Lucemyra¬Æ is critical to safe and effective use, including precise tapering guidance and warnings about hypotension, bradycardia, and syncope
- Omission of such labeling could confuse prescribers or compromise patient safety
- Cites FDA's standards requiring ANDAs to include the same labeling unless differences are justified with scientific evidence
- Lucemyra¬Æ's use in opioid withdrawal management involves vulnerable populations, necessitating clear and complete labeling to mitigate risks",,"	Denied (specifically, the FDA denied both requests: requiring ANDAs to include both drug and device constituent parts for Apokyn, and the development of a policy framework)",2020-05-21,0.0,Center for Drug Evaluation and Research (CDER),"Section 505(j) of the FD&C Act (21 U.S.C. 355(j))
- Section 503(g) of the FD&C Act
- Section 505(q)(1)(F) of the FD&C Act
- 21 CFR part 3
- 21 CFR 314.3(b), 314.94(a), 314.127, 314.105, 314.125, 314.110, 314.200, 314.430",,"The FDA is required to act on petitions within 150 days under section 505(q), but that timeframe does not override the standard application review process.
- Approving only part of an ANDA (e.g., only the drug constituent part) while deferring on others would bypass the normal ANDA review protocols.
- The agency must protect the procedural rights of ANDA applicants and cannot prematurely comment on specific ANDA components.
- Complex regulatory and scientific considerations about generic drug-device combinations require case-by-case evaluations and cannot be addressed through a universal policy within the statutory time constraint.",denied,True,150.0,CDER,CDER
fda-2019-p-4448,FDA-2019-P-4448-0001_Citizen_Petition_from_Samuel_A__Gonzalez___Redacte.pdf,2019-09-24,2019,False,original petition,Samuel A. Gonzalez,individual,"21 C.F.R. ¬ß 101.36(b)(2) ‚Äì Protein labeling for dietary supplements
- 21 C.F.R. ¬ß 101.9(c)(1)(i) ‚Äì Calorie determination methods
- 21 C.F.R. ¬ß 25.32 ‚Äì Categorical exclusion for environmental impact
- 21 C.F.R. ¬ß 10.30 ‚Äì Citizen petition procedures (implied from context and structure)",Current FDA labeling policy that allows manufacturers to omit calorie declarations for free-form amino acids in dietary supplements due to interpretations of labeling exemptions,"Amend 21 C.F.R. ¬ß 101.36(b)(2) to explicitly require that:
> ‚ÄúFor the purposes of calorie calculations, individual amino acids shall be given the same Atwater factor (4 calories per gram) as protein.‚Äù","Current regulations have a loophole: amino acids are excluded from protein labeling, and manufacturers misuse this to label them as zero-calorie
- Scientifically inaccurate since amino acids do provide energy through metabolic pathways (see Figure 1, page 2)
- Multiple legitimate methods (e.g., bomb calorimetry, Atwater system) confirm that amino acids have caloric value (see Figure 2, page 3)
- Allowing omission deceives consumers, especially those closely monitoring caloric intake
- Supplements often contain multiple grams of amino acids, exceeding the 5-calorie threshold required for disclosure",,,2025-10-15,0.0,,,,,no decision,False,2213.0,pending,pending
fda-2019-p-0537,FDA-2019-P-0537-0001_Citizen_Petition_from_Kulkarni_Law_Firm.pdf,2019-02-02,2019,False,original petition,Kulkarni Law Firm,law/consulting,"21 C.F.R. ¬ß 10.30 ‚Äì Citizen petition procedure
- Section 501(b) of the FDCA ‚Äì Drug adulteration based on compendial standards
- 21 C.F.R. ¬ß 561 ‚Äì Testing for residual pesticides (referenced via USP <561>)
- 2016 FDA Guidance on Botanical Drug Development","FDA‚Äôs oversight and compliance enforcement regarding the manufacturing practices of Methscopolamine Bromide, particularly API and finished product manufacturers not uniformly adhering to compendial standards and FDA botanical drug guidance","The petitioner requests the FDA‚Äôs Office of Generic Drugs (OGD) to:
- Consistently ensure that all manufacturers of Methscopolamine Bromide tablets comply with requirements outlined in the 2016 Botanical Drug Development Guidance, including testing for pesticides, identity verification, and compendial quality standards","Concerns that some manufacturers of Methscopolamine Bromide may be noncompliant with standards outlined in FDA guidance and USP <561>
- Use of botanical starting materials (e.g., Duboisia flower) from pesticide-prone regions (e.g., Australia) presents risk of adulteration
- Noncompliance with identification tests, acceptance criteria, and pesticide testing poses public health risks
- The FDA‚Äôs own emphasis on ‚Äúhigh risk inspections‚Äù supports the need for stricter and consistent enforcement",2019-07-31 00:00:00,,2025-10-15,1.0,,," The petitioner requested FDA ensure that manufacturers of Methscopolamine Bromide meet requirements outlined in the FDA‚Äôs December 2016 guidance for industry: Botanical Drug Development.
- FDA cited resource constraints and competing priorities as the reason for not yet issuing a final response.",,no decision,False,2447.0,pending,pending
fda-2019-p-4515,FDA-2019-P-4515-0001_Citizen_Petition_from_Foley___Lardner_LLP.pdf,2019-09-26,2019,False,original petition,Foley & Lardner LLP,law/consulting,"Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FDCA)
- 21 C.F.R. ¬ß 10.25(a) ‚Äì General provisions for filing a citizen petition
- 21 C.F.R. ¬ß 10.30 ‚Äì Citizen petition procedures
- 21 C.F.R. ¬ß 25.1(g) ‚Äì Environmental assessment exemption
- 21 C.F.R. ¬ß 10.30(b) ‚Äì Economic impact report submission requirements","The selection and availability of reference standards (RS) for Propranolol Hydrochloride Tablets USP in the Orange Book. Specifically, the current RS is held by Impax Laboratories but is unavailable in sufficient quantities for bioequivalence studies
.","Request the FDA to designate an additional RS‚ÄîPropranolol Hydrochloride Tablets USP 80 mg, held by Watson Laboratories Inc. (ANDA No. 070178)‚Äîfor ANDA submissions","The existing RS (Impax Laboratories, ANDA 071976) is unavailable in the market despite best efforts
.
- Watson Laboratories‚Äô product (ANDA 070178) is available commercially and has significant market share (56.7%), supported by IMS Health data (July 2019) ‚Äì see table on page 2.
- Watson's 80 mg tablets are identical in strength and form, manufactured and distributed under Amneal Pharmaceuticals‚Äô labeler code, suggesting continuity and equivalence.
- According to FDA‚Äôs 2017 Draft Guidance, a citizen petition may request the FDA to designate an alternative RS if availability is an issue.",2020-03-19 00:00:00,Approved ‚Äî The FDA granted the petition to designate propranolol hydrochloride tablets (80 mg) under ANDA 070178 (Watson Laboratories Inc.) as the new reference standard.,2020-09-16,1.0,Center for Drug Evaluation and Research (CDER),"Section 505(j) of the FD&C Act (21 U.S.C. ¬ß 355(j))
- 21 CFR ¬ß 314.3(b)
- 21 CFR ¬ß 314.94(a)(3)
- 81 FR 69580, 69619 (Oct. 6, 2016)",FDA has not been able to reach a decision due to the need to address other agency priorities. The response notes that the Agency will reply to the petition as soon as possible given the numerous demands on its resources,"The previous reference standard (ANDA 071976 by Impax Laboratories) is no longer commercially available.
- The new product (ANDA 070178 by Watson) is therapeutically equivalent and currently the market leader.
- FDA determined that selection of a therapeutically equivalent ANDA as a reference standard is appropriate when the RLD is unavailable",approved,True,356.0,CDER,CDER
fda-2019-p-2853,FDA-2019-P-2853-0001_Citizen_Petition_from_Fresenius_Medical_Care_North.pdf,2019-06-11,2019,False,original petition,Fresenius Medical Care North America (FMCNA),industry/corporation,"21 C.F.R. ¬ß 10.25 ‚Äì Citizen petitions: general provisions
- 21 C.F.R. ¬ß 10.30 ‚Äì Citizen petition procedures
- 21 C.F.R. ¬ß 25.31 ‚Äì Categorical exclusion from environmental assessment requirements
- 21 C.F.R. ¬ß 10.30(b) ‚Äì Economic impact information requirements",Lack of designation in the Orange Book of an RLD (Reference Listed Drug) and RS (Reference Standard) for FMCNA‚Äôs Dextrose Peritoneal Dialysis Solution products approved under NDA 018883 and NDA 020171,Request that FDA designate NDA 018883 and NDA 020171 as the Reference Listed Drug (RLD) and Reference Standard (RS) for the associated Delflex peritoneal dialysis products,"The listed Delflex products under both NDAs are FDA-approved, widely used in U.S. medical practice since 1984 and 1992
- There are currently no designated RLDs or RSs in the Orange Book for these products

- Attachment 1 (page 3) provides an Orange Book listing showing the approved formulations and strengths under each NDA
- Request supported by the need to facilitate ANDA filings and regulatory clarity for follow-on products",2019-12-06 00:00:00,Dismissed as moot,2020-09-18,1.0,Center for Drug Evaluation and Research (CDER),The Orange Book (Approved Drug Products With Therapeutic Equivalence Evaluations),"The FDA explains that it has not been able to reach a decision on the petition because it requires review and prioritization amidst other Agency demands.
- The agency commits to responding as soon as possible once a decision has been made, and notes that the interim response complies with 21 CFR 10.30(e)(2).","The FDA explained that since the submission of the petition, it had already updated the Orange Book to designate each of Fresenius Medical Care North America's Delflex Peritoneal Dialysis Solution products (1.5%, 2.5%, and 4.25% Dextrose under NDA 018883 and NDA 020171) as both a Reference Listed Drug (RLD) and a Reference Standard (RS). Therefore, the requested action had already been taken, rendering the petition moot and leading to its dismissal",dismissed (moot),True,465.0,CDER,CDER
fda-2019-p-3022,FDA-2019-P-3022-0001_Citizen_Petition_from_Foley___Lardner_LLP.pdf,2019-06-24,2019,False,original petition,Foley & Lardner LLP,law/consulting,"21 C.F.R. ¬ß 10.30 ‚Äì Citizen petition procedures
- 21 C.F.R. ¬ß 314.93 ‚Äì Petition to request a change from the listed drug
- 21 C.F.R. ¬ß 314.94 ‚Äì ANDA content requirements
- Section 505(j)(2)(C) of the FDCA ‚Äì Suitability petition for differences in dosage form
- 21 C.F.R. ¬ß 25.1(g) ‚Äì Environmental impact exemption
- 21 C.F.R. ¬ß 10.30(b) ‚Äì Economic impact reporting","Request for FDA to permit submission of an ANDA for a capsule dosage form of Xarelto¬Æ (rivaroxaban), which currently exists as a tablet formulation","Requesting FDA to:
- Declare that Rivaroxaban Capsules (2.5 mg, 10 mg, 15 mg, 20 mg) are suitable for submission via an ANDA, despite the difference in dosage form compared to the RLD, Xarelto Tablets","The proposed capsules contain the same active ingredient, strength, and route of administration as the RLD
- Intended to offer an alternative dosage form for patients with difficulty swallowing tablets
- FDA has approved similar petitions before for dosage form changes
- Labeling will match the RLD except for inactive ingredients and manufacturer identification
- Pediatric study waiver is requested based on FDA‚Äôs previous waiver for Xarelto due to impracticability of pediatric studies",,,2025-10-15,0.0,,,,,no decision,False,2305.0,pending,pending
fda-2019-p-3545,FDA-2019-P-3545-0001_Citizen_Petition_from_Axinn_on_behalf_of__Zydus_Ph.pdf,2019-07-24,2019,False,original petition,"Axinn, Veltrop & Harkrider LLP, submitted by Chad A. Landmon",law/consulting,"Section 505 of the FD&C Act
- 21 C.F.R. ¬ß¬ß 10.20, 10.25, 10.30, and 10.31
- 21 C.F.R. ¬ß 25.31(a) (Environmental impact exclusion)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact disclosure)","FDA's bioequivalence standards and therapeutic equivalence (TE) ratings for Carbamazepine Extended Release Tablets, particularly in reference to the March 2015 FDA guidance for NTI (Narrow Therapeutic Index) drugs","The petitioner requested that the FDA:
1. Require ANDA holders for Carbamazepine Extended Release Tablets to meet the March 2015 bioequivalence standards.
2. Downgrade TE codes in the Orange Book from AB to BX for products not in compliance.
3. Evaluate size and shape differences for safety and compliance risks.
4. Apply consistent bioequivalence approval standards across all ANDAs","Carbamazepine is an NTI drug, where small dosage changes may cause serious consequences.
- Older bioequivalence methods are insufficient for such drugs.
- March 2015 Guidance includes scientifically sound methods (replicated crossover design, scaled bioequivalence, etc.).
- Some approved generics (e.g., Taro's product) may not meet these standards and differ in tablet size/shape, possibly impacting patient compliance and safety.
- To maintain public health and confidence, stricter standards should be uniformly enforced, as with prior FDA actions (e.g., Wellbutrin XL case)",,,2025-10-15,0.0,,,,,no decision,False,2275.0,pending,pending
fda-2019-p-4362,FDA-2019-P-4362-0001_Citizen_Petition_from_Hyman__Phelps___McNamara__P_.pdf,2019-09-17,2019,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"FDC Act ¬ß 505(j)(2)(C)
- 21 C.F.R. ¬ß 314.93 (Suitability Petitions)
- 21 C.F.R. ¬ß 10.20 (Submission rules)
- 21 C.F.R. ¬ß 10.30 (Citizen petition procedure)
- 21 C.F.R. ¬ß 25.31 (Environmental impact exclusion)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact statement)","Petition asks FDA to determine if a new 3 g vial strength of Cefazolin for Injection USP is suitable for submission as an ANDA referencing the discontinued drug ANCEF¬Æ (NDA 050461), which is currently listed as a Reference Listed Drug (RLD)","The petitioner requests that the FDA approve a 3 g vial strength of Cefazolin for administration via intramuscular injection, intravenous bolus, and intravenous infusion as a suitable product for submission via Abbreviated New Drug Application (ANDA)","Regulatory precedent: The proposed strength differs from the RLD but matches approved uses.
- Consistency with existing labeling: ANCEF¬Æ labeling supports up to 12 g/day dosing, allowing for 3 g doses.
- Improved administration: A 3 g vial allows flexibility across routes (IM, IV bolus, IV infusion).
- Safety and preparation efficiency: Fewer vials reduce handling errors and risks of contamination.
- PREA exemption: Suitability petitions changing strength do not require pediatric studies",,,2025-10-15,0.0,,,,,no decision,False,2220.0,pending,pending
fda-2019-p-5691,FDA-2019-P-5691-0001_Suitability_Petition_from_Foley___Lardner__LLP.pdf,2019-12-03,2019,False,original petition,Foley & Lardner LLP,law/consulting,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FDCA)
- 21 C.F.R. ¬ß 314.93 (Suitability Petitions)
- 21 C.F.R. ¬ß 25.31(a) (Environmental impact exclusion)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact disclosure)","Determination on whether an ANDA may be submitted for esomeprazole magnesium delayed-release capsules in 2.5 mg, 5 mg, and 10 mg strengths, differing from the Reference Listed Drug (RLD), Nexium¬Æ, which is only available in 20 mg and 40 mg capsule strengths","The petitioner requests that FDA determine the suitability of filing an ANDA for esomeprazole magnesium delayed-release capsules in the 2.5 mg, 5 mg, and 10 mg strengths, even though these strengths differ from the RLD capsule versions","The proposed lower-strength capsules align with existing approved doses in the Nexium oral suspension product (2.5 mg, 5 mg, 10 mg).
- Petition proposes using the same labeling and administration options as Nexium capsules, including swallowing, mixing with applesauce, or delivery through a nasogastric tube.
- Expands administration options for pediatric patients under 11 years old, beyond what is possible with oral suspension.
- Provides cost benefits and fills a market gap due to lack of generic versions at these lower strengths",,,2025-10-15,0.0,,,,,no decision,False,2143.0,pending,pending
fda-2019-p-5759,FDA-2019-P-5759-0001_Citizen_Petition_from_Aavis_Pharmaceuticals.pdf,2019-12-06,2019,False,original petition,Aavis Pharmaceuticals,industry/corporation,"Section 505(j)(2)(C) of the FD&C Act
- 21 C.F.R. ¬ß¬ß 10.20, 10.30, 314.93 (for ANDA Suitability Petitions)
- 21 C.F.R. ¬ß 25.31 (Environmental Impact ‚Äì Categorical Exclusion)
- 21 C.F.R. ¬ß 10.30(b) (Economic Impact)","The petition concerns submission of an ANDA Suitability Petition for a new combination drug product of Chlorzoxazone and Acetaminophen tablets (250 mg / 300 mg), which is not currently approved in the U.S.",That FDA determine the proposed Chlorzoxazone and Acetaminophen Tablets (250 mg / 300 mg) are suitable for submission in an Abbreviated New Drug Application (ANDA) under the statutory provisions for combination products,"Both drugs are individually approved in the U.S., and multiple fixed-dose combinations of Acetaminophen with other agents exist.
- The combination is approved in Canada as an OTC product.
- No known drug-drug interaction between Chlorzoxazone and Acetaminophen.
- Each drug contributes synergistically: Chlorzoxazone as a centrally acting muscle relaxant; Acetaminophen as an analgesic.
- Aavis argues the combination should be eligible for a complete biowaiver based on available regulatory ratings and guidance (both drugs rated ‚ÄúAA‚Äù in the Orange Book)",,,2025-10-15,0.0,,,,,no decision,False,2140.0,pending,pending
fda-2019-p-3192,FDA-2019-P-3192-0001_Citizen_Petition_from_US_WorldMeds.pdf,2019-07-01,2019,False,original petition,"US WorldMeds, LLC",industry/corporation,"Section 505(j) of the FDCA (Abbreviated New Drug Applications)
- 21 C.F.R. ¬ß 314.93 (Suitability Petitions)
- 21 C.F.R. ¬ß 10.30 (Citizen Petition procedures)
- 21 C.F.R. ¬ß 25.31(a) (Environmental impact exclusion)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact statement)","FDA‚Äôs policy on the approval pathway for naloxone hydrochloride formulations differing in strength from the RLD, Evzio¬Æ (naloxone hydrochloride injection, auto-injector)","FDA to determine that the following proposed strengths are suitable for ANDA submission:
- Naloxone hydrochloride auto-injector 0.6 mg/0.6 mL
- Naloxone hydrochloride auto-injector 2.4 mg/0.6 mL","The proposed strengths are proportional to the currently approved Evzio 0.4 mg/0.4 mL and 2 mg/0.4 mL products.
- All products share the same route of administration, dosage form, and indication.
- Changing the injection volume does not affect safety or efficacy.
- Proposes benefit for manufacturing efficiency and potential for expanded access.
- Petition includes FDA precedent allowing similar changes via the suitability petition process.",,,2025-10-15,0.0,,,,,no decision,False,2298.0,pending,pending
fda-2019-p-1911,FDA-2019-P-1911-0001_Citizen_Petition_from_Keller_and_Heckman_LLP_on_be.pdf,2019-04-19,2019,False,original petition,Keller and Heckman LLP,law/consulting,"21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 101.9(c)(6)(i)
- Sections 403(q), 403(a), 201(n), and 701(a) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß¬ß 172.780 and 184.1330
- 21 C.F.R. ¬ß 25.30(h)","FDA‚Äôs existing definition of ‚Äúdietary fiber‚Äù in 21 C.F.R. ¬ß 101.9(c)(6)(i), specifically the list of isolated or synthetic non-digestible carbohydrates recognized as beneficial to human health for nutrition labeling purposes",Amend the regulation defining ‚Äúdietary fiber‚Äù at 21 C.F.R. ¬ß 101.9(c)(6)(i) to include ‚ÄúAcacia (gum arabic)‚Äù as a recognized dietary fiber with beneficial physiological effects,"The petition provides extensive scientific evidence showing that Gum Acacia:
- Attenuates postprandial blood glucose and insulin levels
- Increases satiety and reduces energy intake
Multiple human clinical studies (e.g., University of Minnesota 2019, GI Labs 2019, Sharma 1985b, Akeo 2002, Calame et al. 2011) support these benefits
- FDA has previously accepted similar physiological effects for dietary fiber classification
- GA is already approved as a food additive and considered GRAS (Generally Recognized As Safe)",2019-10-21 00:00:00,"Acknowledgment of receipt ‚Äî the petition was accepted for filing, but no decision on the substantive merits was made.",2019-04-22,1.0,"Division of Dockets Management, Office of the Executive Secretariat (OES)",Not Mentioned,The FDA cited other agency priorities and limited availability of resources as the reason for the delay in decision-making. The agency committed to notifying the petitioner once review is complete.,"The letter clarifies that the acceptance of the petition for filing is purely procedural and does not imply any decision regarding the substantive merits of the petition, which sought to amend the regulation defining ""dietary fiber"" to include Gum Acacia.",other,True,3.0,DMS,Other/Specialty Center
fda-2019-p-4507,FDA-2019-P-4507-0001_Citizen_Petition_from_Foley___Lardner_LLP.pdf,2019-09-26,2019,False,original petition,Foley & Lardner LLP,law/consulting,"Section 505(j) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 10.25(a)
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 25.1(g) (Environmental impact exclusion)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact disclosure)","The FDA‚Äôs designation of a Reference Standard (RS) for Oxybutynin Chloride Extended Release Tablets 15 mg. Specifically, the agency currently designates Mylan‚Äôs ANDA (No. 076644) as the RS product, which is difficult to source.",FDA should designate Accord Healthcare Inc.‚Äôs ANDA No. 207138 for Oxybutynin Chloride ER Tablets 15 mg as an additional Reference Standard product,"The original RLD, Ditropan XL (NDA #020897), is discontinued.
- The current RS product (by Mylan) is unavailable on the market.
- Accord‚Äôs product is readily available and has the highest sales volume among competing products.
- FDA guidance permits petitions to designate alternative RS products when the designated RS is not accessible.",,,2025-10-15,0.0,,,,,no decision,False,2211.0,pending,pending
fda-2019-p-5760,FDA-2019-P-5760-0006_Amend_to_Citizen_Petition_from_Sun_Pharmaceutical_.pdf,2021-07-07,2019,False,original petition,Sun Pharmaceutical Industries Limited,industry/corporation,"505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 10.20
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 314.93
- 21 C.F.R. ¬ß 25.31 (Environmental impact categorical exclusion)","Suitability for ANDA submission involving a change in concentration of the drug Levetiracetam in Sodium Chloride Injection compared to the Reference Listed Drug (RLD), due to approval of an alternative strength RLD (250 mg/50 mL) on December 14, 2020","FDA should determine that Levetiracetam in Sodium Chloride Injection, 250 mg/100 mL (2.5 mg/mL) is suitable for submission via an ANDA. The proposed strength differs from the RLD (250 mg/50 mL, 5 mg/mL) only in concentration, not total drug content","Maintains same total drug content (250 mg), but in a larger volume to adjust concentration to 2.5 mg/mL.
- Intended to better accommodate dose adjustments for patients with renal impairment, as required in the RLD‚Äôs labeling.
- No change in formulation, route of administration, or labeling apart from the strength.
- No safety or effectiveness concerns are raised by this change.",,,2025-10-15,0.0,,,,,no decision,False,1561.0,pending,pending
fda-2019-p-2074,FDA-2019-P-2074-0001_Citizen_Petition_from_Encube_Ethicals_Private_Limi.pdf,2019-04-30,2019,False,original petition,Encube Ethicals Private Limited (Encube),industry/corporation,"Federal Food, Drug, and Cosmetic Act (FDC Act)
- 21 C.F.R. ¬ß 10.25(a)
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 25.31 (Environmental impact exemption)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact disclosure)","Current designation of EFUDEX (NDA #N016831), manufactured by Valeant, as the Reference Standard (RS) for Fluorouracil Topical Solution, 5%, which is unavailable in the market due to manufacturer backorder","FDA should designate Fluorouracil Topical Solution, 5% manufactured by Taro Pharmaceutical Industries Ltd. (ANDA #A076526) as the new Reference Standard (RS)","EFUDEX is not available in sufficient quantity and is on long-term manufacturer backorder.
- Multiple attempts to source the RLD failed.
- Designation of an alternative RS (Taro‚Äôs product) would allow generic development and required bioequivalence studies to proceed",2019-11-06 00:00:00,"Granted to the extent that FDA will select ANDA 076526 for fluorouracil topical solution, 5%, held by Taro, as a reference standard.",2020-03-26,1.0,Center for Drug Evaluation and Research (CDER),"Section 505(j) of the FD&C Act (21 U.S.C. 355(j))
- 21 CFR ¬ß¬ß 314.3(b), 314.94, 314.93, 314.161
- 81 FR 69580 (Oct. 6, 2016)",The FDA states it has not been able to reach a decision because the petition raises complex issues requiring extensive review and analysis by Agency officials.,"The current RLD/reference standard (Efudex, NDA 016831) is unavailable in the market.
- Taro‚Äôs ANDA 076526 product is therapeutically equivalent to Efudex and is the current market leader.
- FDA concludes that a new reference standard is needed and Taro's product is appropriate for selection.",approved,True,331.0,CDER,CDER
fda-2019-p-1679,FDA-2019-P-1679-0001_Citizen_Petition_from_Goodwin_Procter___LLP_on_beh.pdf,2019-04-05,2019,False,original petition,Goodwin Procter LLP,law/consulting,"21 C.F.R. ¬ß 10.30
- Section 505(j) of the FDC Act
- 505(q) of the FDC Act
- 21 C.F.R. ¬ß 320.22 (Bioequivalence waiver)","The petition comments on the acceptance or approval of any ANDA referencing Sublocade¬Æ (NDA 209819) unless it demonstrates full bioequivalence and clinical comparability, particularly regarding the drug‚Äôs complex delivery system and pharmacokinetics","FDA should:
- Not accept or approve any ANDA referencing Sublocade unless the applicant demonstrates bioequivalence through an in vivo study and shows that the proposed product has the same design and release characteristics.
- Require in vivo bioequivalence data and clinical comparability due to complexity of the delivery system and safety profile.","Sublocade is a complex long-acting injectable product with a non-biodegradable polymer delivery system.
- Standard in vitro or waiver-based approaches would not suffice to ensure therapeutic equivalence or safety.
- Improper equivalence evaluation could risk treatment failure, overdose, or diversion.
- FDA precedent supports requiring clinical data for complex depot formulations.",,"Other ‚Äì Notice of Change of Address submitted by petitioner‚Äôs legal counsel (Scott M. Lassman on behalf of Braeburn, Inc.)",2019-05-23,0.0,"Not Mentioned ‚Äî This document is a notice submitted by petitioner‚Äôs counsel, not a response from the FDA.",Not Mentioned,,"The purpose of this letter is solely to notify the FDA of an updated mailing address for petitioner‚Äôs legal representative, and request that all future correspondence be directed accordingly",other,True,48.0,other,Other/Specialty Center
fda-2019-p-4003,FDA-2019-P-4003-0001_Citizen_Petition_from_Lisa_Myslinski____Redacted.pdf,2019-08-23,2019,False,original petition,"Lisa Myslinski, PharmD (Sole Proprietor of U.S. Patent No. 10,124,005 B1)",individual,"21 C.F.R. ¬ß 10.20
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 330.10(a)(4)(iv)
- 21 C.F.R. ¬ß 25.31 (Environmental Impact)",Amendment of the Tentative Final Monograph (TFM) for Acetaminophen and Caffeine (FR Citation 58 FR 28281) and inclusion of Meclizine (under Monograph 336.10(d)) into the final monograph system for OTC drugs,"FDA should amend the tentative final monograph of Acetaminophen and Caffeine to include Meclizine 6.25 mg based on her patented multi-symptom migraine formula combining Acetaminophen (250 mg), Caffeine (60 mg), and Meclizine (6.25 mg)","The patented combination treats both migraine pain and nausea.
- The combination is safe, with no known drug interactions (as supported by LexiComp and Facts & Comparisons).
- The request aligns with 21 C.F.R. ¬ß 330.10(a)(4)(iv), allowing combination of safe and effective OTC ingredients.
- Supported by personal experience as a pharmacist and migraine sufferer, as well as referenced studies on the efficacy of each component",2020-02-21 00:00:00,"Denied ‚Äì The FDA denied the petition, stating the citizen petition process is no longer appropriate for the type of request submitted, due to changes enacted by the CARES Act.",2023-05-18,1.0,Center for Drug Evaluation and Research (CDER),"21 CFR 336.10 ‚Äì Related to the monograph for meclizine
- Section 505G of the FD&C Act (21 U.S.C. 355h) ‚Äì New OTC monograph reform (added by the CARES Act)
- Section 503(b)(1), 201(p)(1), and 321(p)(1) of the FD&C Act
- Section 744L(7) and 505G(q)(3) of the FD&C Act","The petition requested FDA to amend the tentative final monograph of Acetaminophen and Caffeine to include 6.25 mg of Meclizine (336.10(d)).
- FDA has not yet reached a decision because the petition raises complex issues requiring extensive review and analysis by Agency officials.
- The interim response was issued in compliance with 21 CFR 10.30(e)(2), and FDA stated it would respond fully upon reaching a final decision","The petition requested regulatory changes to OTC drug monographs to allow 6.25 mg of meclizine in combination with acetaminophen and caffeine.
- The CARES Act introduced section 505G, fundamentally changing how OTC monograph amendments are handled.
- Requests like this must now go through the OTC Monograph Order Request (OMOR) process rather than the citizen petition process.
- Because the petition falls within OMOR jurisdiction and the petitioner qualifies as a ‚Äúrequestor,‚Äù the FDA denied the petition and directed her to pursue the OMOR path instead",denied,True,1364.0,CDER,CDER
fda-2019-p-2122,FDA-2019-P-2122-0001_Citizen_Petition_from_Handcrafted_Soap___Cosmetic_.pdf,2019-05-01,2019,False,original petition,Handcrafted Soap and Cosmetic Guild (HSCG),advocacy/academic,"21 C.F.R. ¬ß 10.30 (citizen petition process)
- 21 C.F.R. ¬ß 701.12(d) (labeling regulations for cosmetics)
- 21 C.F.R. ¬ß 701.20(a) (exclusion of soap from the definition of cosmetics)
- 21 C.F.R. ¬ß 25.31 (categorical environmental exemption)
- 16 C.F.R. ¬ß 500.5 (FTC regulation on labeling)
- 21 U.S.C. ¬ß 321(i) (definition of cosmetics in the FDC Act)","FDA‚Äôs existing labeling requirement under 21 C.F.R. ¬ß 701.12(d), specifically the requirement for inclusion of the manufacturer‚Äôs street address unless listed in a telephone or city directory.","Amend 21 C.F.R. ¬ß 701.12(d) to allow omission of the street address if the business address is listed in any publicly available resource, including websites and electronic databases (mirroring FTC‚Äôs 16 C.F.R. ¬ß 500.5).
- Affirm that no enforcement action will be taken during the rulemaking process against manufacturers whose address is not on the label but is available via modern, acceptable online sources","Existing rules are outdated (originating from 1968), relying on obsolete resources like city directories and landline phone books.
- Many HSCG members are home-based businesses and face privacy, safety, and security risks when required to display a home address on labels.
- The FTC has already updated its regulations to allow flexibility in listing business addresses using modern information tools.
- Harmonizing FDA and FTC rules would reduce regulatory confusion, improve compliance, and protect small business owners, while maintaining consumer and regulatory access to business contact info",,,2025-10-15,0.0,,,,,no decision,False,2359.0,pending,pending
fda-2019-p-4540,FDA-2019-P-4540-0001_Citizen_Petition_from_Foley___Lardner_LLP.pdf,2019-09-27,2019,False,original petition,Foley & Lardner LLP,law/consulting,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act

21 CFR ¬ß 314.93

21 CFR ¬ß 320.22(b)(1) (requesting a waiver of in vivo bioavailability)

21 CFR ¬ß 25.31 (categorical exclusion from environmental assessment)","Approval policy and process for ANDA (Abbreviated New Drug Application) submissions, specifically regarding changes in vial size for a reference listed drug (RLD).","Approval to submit and file an ANDA for Succinylcholine Chloride Injection USP, 20mg/mL, 5 mL vials. The reference listed drug (RLD) is Quelicin¬Æ by Hospira, Inc., currently only available in 10 mL vials.","The proposed product is qualitatively and quantitatively the same as the RLD except for the vial size.

The change in vial size (from 10 mL to 5 mL) is a type explicitly permitted under applicable FDA statutes and regulations.

The 5 mL vial (100 mg total) still meets most clinical dosage needs, reducing drug waste.

This change has been requested by numerous healthcare professionals and would offer greater flexibility and efficiency in hospital settings.

The petitioner also highlights the availability of draft labeling and a request for a waiver of in vivo bioavailability studies.

Categorical exclusion from environmental impact assessment is claimed, and economic benefits (reducing drug waste) are emphasized",,,2025-10-15,0.0,,,,,no decision,False,2210.0,pending,pending
fda-2019-p-2869,FDA-2019-P-2869-0001_Citizen_Petition_from_Valisure__LLC.pdf,2019-06-13,2019,False,original petition,"Valisure, LLC and ValisureRX LLC (collectively, ""Valisure"")",industry/corporation,"21 U.S.C. ¬ß¬ß 331, 351, 352, 355, 372, 374, 375
- 21 C.F.R. ¬ß¬ß 10.20 and 10.30
- 21 C.F.R. ¬ß 25.31","Lack of update to the acceptable intake level of DMF in light of its 2018 reclassification as a Group 2A probable carcinogen by WHO and IARC.

Existing FDA guidance (e.g., Q3C ‚Äì Tables and List, Guidance for Industry) that lists DMF‚Äôs permitted daily exposure at 8.8 million nanograms.

Inadequate regulatory enforcement concerning the testing of pharmaceuticals for contaminants like DMF","Valisure requested the FDA to:

Lower the permitted daily exposure limit of DMF to under 1,000 nanograms (potentially as low as 96 ng).

Request recalls for valsartan lots contaminated with high levels of DMF.

Investigate manufacturing processes and submissions related to contaminated lots.

Inform the public about affected products.

Promulgate regulations requiring independent batch-level chemical testing.

Issue interim guidance encouraging such testing pending formal regulations","The petition presents the following justifications:

Detection of high DMF levels (up to 82,285 ng/tablet) in multiple valsartan lots.

DMF‚Äôs reclassification by WHO/IARC as a probable human carcinogen (Group 2A).

Potential role of DMF in formation of nitrosamines (e.g., NDMA, NDEA) which are also carcinogenic and have triggered prior drug recalls.

Discrepancy in safety thresholds‚ÄîDMF‚Äôs allowed limit (8.8 million ng) vastly exceeds the stricter limits for nitrosamines (96 ng for NDMA).

Public health concerns and the need for greater regulatory oversight and transparency",2020-01-02 00:00:00,,2025-10-15,1.0,,,The FDA stated it has been unable to reach a decision on the petition due to the need to address other agency priorities and the numerous demands on the Agency‚Äôs resources. An interim response is provided to comply with regulatory requirements. The agency committed to responding as soon as feasible.,,no decision,False,2316.0,pending,pending
fda-2019-p-2088,FDA-2019-P-2088-0001_Citizen_Petition_from_Summit_Health_Pharmacy_Inc.pdf,2019-03-29,2019,False,original petition,"Summit Health Pharmacy Inc. (Signed by Vincent Canzanese, RPh)",industry/corporation,"21 C.F.R. ¬ß 10.30 (petition procedure)
- 21 C.F.R. ¬ß 216.23 (bulk drug substances under 503A)
- Section 503A of FD&C Act (21 U.S.C. ¬ß 353a)
- 21 C.F.R. ¬ß 25.30 (categorical environmental exclusion)","The FDA‚Äôs exclusion of oxitriptan from the list of approved bulk drug substances under section 503A, finalized in a rule effective March 20, 2019. The FDA evaluated oxitriptan only for depression and insomnia, not for treatment of tetrahydrobiopterin deficiency, which is the petition's focus","Amend 21 C.F.R. ¬ß 216.23 to add oxitriptan (5-HTP) to the 503A Bulks List.
- Allow continued compounding of oxitriptan for treatment of tetrahydrobiopterin deficiency in the interim","Long history of use of oxitriptan to treat DHPR and PTPS deficiencies, both linked to tetrahydrobiopterin deficiency.
- FDA failed to evaluate oxitriptan for these specific indications.
- Clinical case histories of 5 pediatric patients (pp. 2‚Äì4) support safety and efficacy.
- Cited literature supports its role in neurotransmitter replenishment and treatment of biopterin metabolism disorders.
- No alternative treatment exists for some patients, making oxitriptan medically necessary",2019-10-25 00:00:00,,2025-10-15,1.0,,,"The petition requested that FDA add oxitriptan (5-HTP) to the 503A Bulks List and allow continued compounding of the substance for tetrahydrobiopterin deficiency diseases.
- FDA noted that the issues are complex and require more extensive review and analysis.
- FDA also referenced a July 2019 industry guidance regarding the use of oxitriptan and stated it is reconsidering the substance‚Äôs status on the 503A list in light of new data",,no decision,False,2392.0,pending,pending
fda-2019-p-1009,FDA-2019-P-1009-0001_Citizen_Petition_from_Rossman_Law_Group__PLLC_on_b.pdf,2019-02-28,2019,False,original petition,"Jeff and Janet Connell, by and through their legal representative",law/consulting,"21 U.S.C. ¬ß 1601 et seq. (Biomaterials Access Assurance Act)
- 21 U.S.C. ¬ß 1604(b)(3) (petition provision)
- 21 U.S.C. ¬ß 360, ¬ß 360(i) (device registration and listing)
- 21 U.S.C. ¬ß 321(h) (definition of ‚Äúdevice‚Äù)
- 21 C.F.R. ¬ß 807.65(a) (registration exemption)
- 21 C.F.R. ¬ß 807.20 (registration requirement)
- 21 C.F.R. ¬ß 807.40 (foreign establishment registration)
- 21 C.F.R. ¬ß 25.30 (environmental impact exclusion)",The assertion by Lima Corporate S.P.A. that it is exempt from FDA registration under the Biomaterials Access Assurance Act and related device registration requirements. Petitioners challenge whether Lima was properly exempted from registering or listing the device under 21 U.S.C. ¬ß 360,"A determination by the Commissioner (under 21 U.S.C. ¬ß 1604(b)(3)) as to whether Lima Corporate S.P.A. was required to:
- Register under 21 U.S.C. ¬ß 360, and/or
- List the Lima Modular Hip System under 21 U.S.C. ¬ß 360(i)","Lima Corporate S.P.A. manufactured the Lima Modular Hip System and sold it to Encore Medical, L.P., which distributed it in the U.S. via DJO Global, Inc.
- The device received 510(k) clearance (K092331) in March 2010.
- The hip system was implanted in Jeffrey Connell in April 2011, and failed in 2014 causing injury.
- Lima claimed exemption under the Biomaterials Access Assurance Act, asserting it was only a ""biomaterials supplier"".
- Petitioners argue Lima was involved in manufacturing a finished device, imported into the U.S., thus requiring registration and listing under FDA regulations.
- Petitioners seek a ruling to resolve this regulatory status challenge and support litigation",,,2025-10-15,0.0,,,,,no decision,False,2421.0,pending,pending
fda-2019-p-1236,FDA-2019-P-1236-0001_Citizen_Petition_from_Sarfaraz_K__Niazi.pdf,2019-03-09,2019,False,original petition,"Sarfaraz K. Niazi, Ph.D., SI, FRSB, FPAMS, FACB
Adjunct Professor of Biopharmaceutical Sciences, University of Illinois & University of Houston",advocacy/academic,"Biologics Price Competition and Innovation Act (BPCIA)
- Public Health Service Act ¬ß 351(a), ¬ß 351(k)
- 21 CFR ¬ß 10.30 (Petition procedure)
- 21 CFR ¬ß 25.30‚Äì25.42 (Environmental impact)
- 42 USC ¬ß 262(k)(2)(A)(ii) (FDA discretion on biosimilar approval requirements)","The petitioner comments on:
- FDA's guidance on ‚ÄúNonproprietary Naming of Biological Products‚Äù (use of four-letter suffixes for biosimilars).
- FDA‚Äôs use of the phrase ‚Äúno clinically meaningful differences‚Äù in defining biosimilars, which the petitioner believes is confusing and damaging to prescriber trust.","The petitioner requests the FDA to:
- Withdraw the guidance on suffix-based nonproprietary naming for biosimilars.
- Use brand names with NDCs instead for identification.
- Replace the definition of biosimilars from ‚Äúno clinically meaningful differences‚Äù to ‚Äúclinically similar.‚Äù
- Warn biosimilar sponsors against making superiority claims over other biosimilars.
- Warn originator companies from undermining FDA‚Äôs biosimilar standards.","The current suffix naming policy creates confusion and implies biosimilars are different, undermining prescriber and patient confidence.
- The phrase ‚Äúno clinically meaningful difference‚Äù is a double-negative and causes ambiguity.
- Health Canada‚Äôs approach (using brand + common name with DIN) is cited as clearer.
- FDA‚Äôs shift in policy (removing suffixes from originator products) creates further inconsistency.
- Scientific evidence and regulatory discretion allow FDA to simplify requirements and improve biosimilar adoption, potentially saving over $50 billion annually.",2019-09-13 00:00:00,Listening meeting only; no formal response or decision issued.,2019-04-11,1.0,"CDER (Center for Drug Evaluation and Research) ‚Äî specifically, Office of New Drugs (OND), including the Office of Therapeutic Biologics and Biosimilars",Not Mentioned,"The petition requested modifications to FDA‚Äôs guidance on the nonproprietary naming of biological products, including substituting ‚Äúclinically similar‚Äù for ‚Äúno clinically meaningful differences.‚Äù
- FDA has not yet completed review due to competing priorities and limited resources.","The FDA granted Dr. Sarfaraz Niazi‚Äôs request for a listening meeting made on March 25, 2019. During the meeting, FDA staff asked clarifying questions about Dr. Niazi‚Äôs ‚ÄúRisk-Based Licensing of Biosimilars‚Äù proposal but did not provide comments or responses. FDA clarified that the meeting was not a forum for testimony and noted discrepancies in Dr. Niazi‚Äôs post-meeting characterization. The submitted documents were added to relevant dockets for consideration.",other,True,33.0,CDER,CDER
fda-2019-p-2142,FDA-2019-P-2142-0002_Citizen_Petition_from_Archer_Daniels_Midland_Compa.pdf,2019-05-02,2019,False,original petition,Archer Daniels Midland Company (ADM),industry/corporation,"21 CFR ¬ß 10.30 (Citizen petition procedure)
- 21 CFR ¬ß 10.20 (Document submission requirements)
- 21 CFR ¬ß 101.9 (Nutrition labeling)
- 21 CFR ¬ß 184.1444 (Maltodextrin GRAS status)
- 21 CFR ¬ß 25.22 and ¬ß 25.30(k) (Environmental impact exemption)","The default assignment of 2 calories per gram for soluble non-digestible carbohydrates used in dietary fiber labeling under 21 CFR ¬ß 101.9, and FDA‚Äôs current labeling practice for soluble fibers",Amend 21 CFR ¬ß 101.9 to assign an energy value of 0.7 calories per gram to the dietary fiber component of Fibersol¬Æ resistant maltodextrin for use in Nutrition and Supplement Facts labels,"Fibersol¬Æ meets the maltodextrin definition under 21 CFR ¬ß 184.1444 and is recognized as GRAS.
- Scientific evidence (see Attachment A) supports that 0.7 kcal/g is a more accurate reflection of its true energy value, based on human clinical studies.
- FDA has previously granted enforcement discretion to label resistant maltodextrin as dietary fiber
.
- Using the default 2 kcal/g overstates the caloric contribution of Fibersol¬Æ, misleading consumers and violating accurate labeling practices.",,,2025-10-15,0.0,,,,,no decision,False,2358.0,pending,pending
fda-2019-p-2370,FDA-2019-P-2370-0001_Citizen_Petition_from_ALEMBIC_PHARMACEUTICALS_LIMI.pdf,2019-05-15,2019,False,original petition,Alembic Pharmaceuticals Limited,industry/corporation,"505(j)(7) of the Federal Food, Drug, and Cosmetic Act
- 21 CFR ¬ß 10.30 (Citizen petition procedures)
- 21 CFR ¬ß 10.25 (Administrative practices)
- 21 CFR ¬ß 314.122 (Petition to determine if drug was withdrawn for safety/effectiveness reasons)
- 21 CFR ¬ß 314.161 (Procedures for reviewing drug withdrawals)
- 21 CFR ¬ß 25.31(a) (Environmental impact categorical exclusion)","The discontinuation of PROAMTINE (Midodrine Hydrochloride) Tablets, NDA #019815, and whether that withdrawal was for safety or efficacy reasons. The petitioner challenges the lack of clarity and seeks a formal determination from FDA.","Alembic requests the FDA to issue a determination that PROAMTINE was not withdrawn for reasons of safety or effectiveness, thus allowing the submission of an Abbreviated New Drug Application (ANDA) referencing this Reference Listed Drug (RLD)","Under 505(j), an ANDA must reference a listed drug (RLD).
- When a drug is no longer marketed, FDA must determine whether it was withdrawn for safety or effectiveness reasons before allowing generic reference.
- Alembic intends to submit an ANDA referencing PROAMTINE and therefore requests this prerequisite determination to proceed",,,2025-10-15,0.0,,,,,no decision,False,2345.0,pending,pending
fda-2019-p-0538,FDA-2019-P-0538-0001_Citizen_Petition_from__K_L_Gates_LLP_on_behalf_of_.pdf,2019-02-01,2019,False,original petition,"K&L Gates LLP (Attorney Michael J. Freno, on behalf of Genus Lifesciences, Inc.)",law/consulting,"505(q) of the FDCA
- 21 C.F.R. ¬ß¬ß 10.20, 10.30, 10.31, 314.150(a)(2)(iv), 314.3, 314.101(e)
- 21 U.S.C. ¬ß 355(b)(2), ¬ß 355(c)(3)(E)(ii), ¬ß 355(j)(5)(F)(ii)","The petition addresses the FDA‚Äôs acceptance of submissions or resubmissions by Lannett Company, Inc. for a 505(b)(2) application related to a cocaine drug product, potentially in violation of Genus‚Äôs NCE exclusivity rights. ","Refuse to accept any further submissions by Lannett for its 505(b)(2) application for a cocaine product.
- Treat any such submissions as withdrawn.
- Consider the application withdrawn in its entirety.","Genus‚Äôs NDA 209963 for Goprelto¬Æ (cocaine hydrochloride) was approved with 5-year New Chemical Entity (NCE) exclusivity on December 14, 2017.
- Under 21 U.S.C. ¬ß 355(c)(3)(E)(ii), no other application for the same active ingredient may be submitted for 5 years.
- Lannett received a Complete Response Letter and is expected to resubmit its application, which the petitioner claims would be a prohibited submission.
- FDA acceptance of such submissions would violate statutory exclusivity, Congressional intent, and FDA‚Äôs own definitions and rules.
- Acceptance would harm innovation incentives and contradict precedent. ",,Denied,2019-07-01,0.0,Center for Drug Evaluation and Research (CDER),"21 U.S.C. ¬ß 355(b)(2) ‚Äì Section 505(b)(2) of the FD&C Act: New Drug Applications based on literature or existing studies

21 CFR 314.101(d) ‚Äì NDA Refusal to File regulations

21 CFR 314.108 ‚Äì Exclusivity provisions (5-year and 3-year)

21 CFR 314.50 ‚Äì NDA content and format requirements

21 CFR 314.94 ‚Äì ANDA requirements

21 CFR 314.125 ‚Äì Grounds for refusing to approve an NDA

FDA‚Äôs Proposed and Final Rules:

1992 Final Rule on Abbreviated NDA Regulations, 57 FR 17950 (April 28, 1992)

1989 Proposed Rule, 54 FR 28872 (July 10, 1989)",,"Amendments to Pending NDAs Allowed Without Violating Exclusivity:
The agency concluded that Lannett could lawfully continue submitting amendments to its previously filed 505(b)(2) application‚Äîeven during the exclusivity period of Genus's Goprelto‚Äîas long as the amendments did not rely on a published investigation conducted by or for Genus without a right of reference.

Definition of ‚ÄúApplication‚Äù Does Not Preclude Amendments:
FDA interpreted ‚Äúapplication‚Äù to include the overall submission and determined that amendments (e.g., updated data or reports) do not constitute a new ‚Äúapplication.‚Äù Therefore, such updates during the exclusivity period are not barred.

Hatch-Waxman Exclusivity Provisions:
The agency explained that exclusivity provisions are designed to prohibit new submissions that rely on protected data but do not prevent continued review or amendment of previously submitted applications.

Regulatory Consistency and Precedent:
The FDA‚Äôs current interpretation aligns with both the 1992 Final Rule and its longstanding regulatory practices, avoiding an interpretation that would prevent any updates to pending NDAs during an exclusivity period.

Avoiding Unreasonable Restriction:
The petitioner‚Äôs interpretation would have barred Lannett from correcting deficiencies or improving safety data in its application, thereby undermining public health and the agency‚Äôs drug review process. FDA found this position both impractical and unsupported by statute or regulation",denied,True,150.0,CDER,CDER
fda-2019-p-1636,FDA-2019-P-1636-0001_Citizen_Petition_from_Nexsen_Pruet__LLC.pdf,2019-04-04,2019,False,original petition,"Nexsen Pruet, LLC, submitted by John A. Sowards",industry/corporation,"505(j) of the FDCA
- 21 C.F.R. ¬ß 10.20
- 21 C.F.R. ¬ß 10.30 (Citizen Petition Procedures)
- 21 C.F.R. ¬ß 314.94(a)(3) (Reference Listed Drug definition)
- 21 C.F.R. ¬ß 10.25(a) (Citizen petition scope)
- 21 C.F.R. ¬ß 25.31 (Environmental assessment exclusion)","The petition comments on the lack of Reference Listed Drug (RLD) designation for Neostigmine Methylsulfate Injection, 3 mg/3 mL (1 mg/mL), NDA No. 203629, which prevents ANDA applicants from referencing it in generic submissions.",Request for the FDA to designate NDA 203629 (Neostigmine Methylsulfate Injection) as the Reference Listed Drug (RLD) to support future generic drug (ANDA) submissions,"NDA 203629 (approved for 3 mg/3 mL fill volume) is the most suitable and equivalent formulation listed in the Orange Book.
- Without RLD designation, generic companies are unable to file ANDAs referencing this product.
- FDA regulations require a designated RLD for demonstrating bioequivalence in ANDAs.
- The petition includes supporting documentation (Orange Book excerpt, FDA listing, labeling) to substantiate the request",2019-09-27 00:00:00,Dismissed as moot,2020-09-18,1.0,Center for Drug Evaluation and Research (CDER),Not Mentioned,The FDA explained that the delay in resolving the petition is due to the need to address other priorities and resource constraints. The agency confirmed that staff is actively reviewing the petition and will respond as soon as possible.,"The petition requested FDA to designate neostigmine methylsulfate solution, 3 mg/3 mL, approved under NDA 203629 (Fresenius Kabi USA, LLC) as an additional Reference Listed Drug (RLD) in the Orange Book. Since the Orange Book had already been updated to designate the drug as an RLD by the time of the response, the FDA dismissed the petition as moot",dismissed (moot),True,533.0,CDER,CDER
fda-2019-p-1198,FDA-2019-P-1198-0001_Citizen_Petition_from_KIND_LLC.pdf,2019-03-12,2019,False,original petition,KIND LLC,industry/corporation,"21 C.F.R. ¬ß 101.13 (g) and (h)
- 21 C.F.R. ¬ß 104.20
- 21 C.F.R. ¬ß 101.54(e)
- 21 C.F.R. ¬ß 101.65(d)
- 21 C.F.R. ¬ß 25.30(k)
- 21 U.S.C. ¬ß 343(r)
- 7 U.S.C. ¬ß 5341(a)(1)
- 5 U.S.C. ¬ß 553‚Ç¨",Existing regulatory framework governing nutrient content claims on food labeling (specifically under 21 C.F.R. ¬ß 101.13 and related sections) and the FDA‚Äôs failure to update these regulations in line with current nutritional science.,"Revise 21 C.F.R. ¬ß 101.13(g) and (h) to:
‚Ä¢ Limit nutrient content claims to foods containing meaningful amounts of health-promoting ingredients (e.g., fruits, whole grains).
‚Ä¢ Include new disclosure levels for added sugar and trans fat, and remove thresholds for total fat and cholesterol.
‚Ä¢ Disqualify foods from bearing claims if they exceed daily values of saturated fat, sodium, added sugars, or trans fat.
‚Ä¢ Require nutrient fortification to comply with FDA‚Äôs fortification policy (21 C.F.R. ¬ß 104.20).","The current regulations are outdated and based on 1990s dietary guidance, focusing narrowly on specific nutrients without considering overall food quality.
- Consumer and FDA-supported research shows that current nutrient claims can mislead consumers into perceiving unhealthy foods as healthy.
- Regulatory updates are necessary to align with the 2015-2020 Dietary Guidelines for Americans and FDA‚Äôs 2018 Strategic Policy Roadmap, which emphasize healthy eating patterns over isolated nutrients.
- The changes aim to help reduce preventable diet-related diseases by ensuring claims are accurate, science-based, and aligned with modern nutrition policy.",2019-09-10 00:00:00,,2025-10-15,1.0,,,"The petition relates to modernizing the framework for nutrient content claims, part of FDA‚Äôs Nutrition Innovation Strategy (NIS).
- FDA acknowledged active work toward this goal, including public engagement and addressing issues like sodium reduction and standards of identity.
- The delay is due to ongoing review efforts and prioritization of NIS goals.",,no decision,False,2409.0,pending,pending
fda-2019-p-1318,FDA-2019-P-1318-0001_Citizen_Petition_from_Lachman_Consultants.pdf,2019-03-19,2019,False,original petition,"Lachman Consultants (Signed by Sharif Ahmed, MS, RAC, Principal Consultant)",law/consulting,"Section 505(j)(2)(C) of the FD&C Act
- 21 C.F.R. ¬ß¬ß 10.20, 10.30 (Petition procedures)
- 21 C.F.R. ¬ß 25.31(a) (Environmental assessment exemption)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact disclosure)
- FD&C Act ¬ß 505B (Pediatric Research Equity Act)",The FDA‚Äôs authority to determine whether a proposed drug product that differs in strength from a listed drug (Abraxane¬Æ 100 mg/vial) can be filed through an Abbreviated New Drug Application (ANDA).,"Request FDA to determine that Paclitaxel for Injectable Suspension, 200 mg/vial lyophilized powder, is suitable for submission in an ANDA, based on the reference listed drug (RLD) Abraxane¬Æ 100 mg/vial"," The proposed drug is identical in active ingredient, dosage form, route of administration, and labeling, differing only in strength (i.e., total drug content).
- Average adult dosing often requires multiple vials of the 100 mg product; a 200 mg/vial format would be more convenient and may reduce medication errors.
- The product maintains the same concentration upon reconstitution (40 mL for 200 mg), presenting no new safety or efficacy concerns.
- The Pediatric Research Equity Act (PREA) does not apply to strength-only changes.
- No changes to labeling except for the updated strength information",,,2025-10-15,0.0,,,,,no decision,False,2402.0,pending,pending
fda-2019-p-2998,FDA-2019-P-2998-0001_Citizen_Petition_from_SONAR.pdf,2019-06-17,2019,False,original petition,"Southern Network on Adverse Reactions (SONAR), affiliated with the Center for Medication Safety and Efficacy at the South Carolina College of Pharmacy, University of South Carolina",advocacy/academic,"21 U.S.C. ¬ß 355(o)(4) (FDCA section 505(o)(4))
- 21 U.S.C. ¬ß 355-1(a)(2)(A)
- 21 U.S.C. ¬ß 355-1(f)(3)
- 21 C.F.R. ¬ß 10.30 (Citizen petition procedure)
- 21 C.F.R. ¬ß 208.1(c)(2) (Medication guides and REMS)
- FDA Guidance documents from 2011 and 2019","The current labeling and risk management framework for Levaquin (levofloxacin), including lack of:
- Explicit Black Box warnings for FQAD and psychiatric adverse events
- A Risk Evaluation and Mitigation Strategy (REMS)","Add Fluoroquinolone-Associated Disability (FQAD) to the Levaquin Black Box Warning
- Add Psychiatric Adverse Events (e.g. suicide, psychosis) to the Black Box Warning
- Implement a new REMS requiring education, registration, and certification for prescribers and pharmacies, and patient registry enrollment","FDA‚Äôs own FAERS data estimate over 12 million adverse events and 200,000 deaths related to Levaquin from 1996‚Äì2019 (after scaling for underreporting).
- FDA already recognizes FQAD as a constellation of serious, disabling, potentially irreversible symptoms.
- Psychiatric adverse events are not clearly communicated in labeling despite being recognized.
- Current labeling does not effectively inform physicians or patients; only a REMS can ensure appropriate education and risk mitigation.
- No method exists to predict or prevent adverse events related to Levaquin. A REMS is the only effective safeguard",,Denied,2020-08-28,0.0,Center for Drug Evaluation and Research (CDER) ,"21 U.S.C. ¬ß 355(o)(4) and ¬ß 355-1(a), (e), (f)(3) (Risk Evaluation and Mitigation Strategies - REMS)
- 21 C.F.R. ¬ß¬ß 201.57(c)(1), (c)(6)(i), 314.50(d)(5)(viii)
- Section 505-1 of the FD&C Act
- REMS Guidance (April 2019)",,"FQAD Request: The current labeling already addresses disabling and potentially irreversible adverse reactions occurring together (e.g., tendinitis, tendon rupture, peripheral neuropathy, psychiatric symptoms). FDA does not recognize ‚ÄúFQAD‚Äù as established medical terminology.
- Psychiatric Events: Already included under Central Nervous System Effects with a specific subheading.
- REMS Request: FDA concluded that risks are already adequately communicated via current labeling and Medication Guide; a REMS could unnecessarily delay access to Levaquin for urgent cases.",denied,True,438.0,CDER,CDER
fda-2019-p-2123,FDA-2019-P-2123-0001_Citizen_Petition_from_Lachman_Consultants.pdf,2019-05-01,2019,False,original petition,Lachman Consultants,law/consulting,"21 C.F.R. ¬ß 10.25(a) (General submission of petitions)
- 21 C.F.R. ¬ß 10.30 (Citizen petition procedures)
- 21 C.F.R. ¬ß 314.161 (Drug withdrawal determination)
- 21 C.F.R. ¬ß 314.122(a) (Evidence needed for withdrawal)
- 21 C.F.R. ¬ß 314.162 (Orange Book amendments)
- 21 C.F.R. ¬ß 25.31(a) (Environmental impact exemption)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact submission)","Determination of whether the drug ATROPINE SULFATE ANSYR PLASTIC SYRINGE¬Æ, NDA 021146 (0.5mg/5mL strength), has been withdrawn for reasons of safety or effectiveness. The product appears in the ‚ÄúDiscontinued Section‚Äù of the Orange Book","Request that the FDA determine whether the Reference Listed Drug (RLD), ATROPINE SULFATE ANSYR PLASTIC SYRINGE¬Æ [0.5mg/5mL (0.1 mg/mL)], NDA 021146, has been withdrawn for reasons of safety or effectiveness","The product is now in the Discontinued Section of the Orange Book.
- The petitioner is unaware of any safety or effectiveness concerns prompting the withdrawal.
- Believes the withdrawal was likely due to commercial reasons, not due to public health concerns.
- FDA must confirm this to allow ANDA referencing",,Denied,2019-09-24,0.0,Center for Drug Evaluation and Research (CDER),"21 CFR 314.161 ‚Äì Determination that a drug was not withdrawn for reasons of safety or effectiveness

21 CFR 314.162 ‚Äì Removal of drug products from the Orange Book

21 CFR 314.3 ‚Äì Definitions, including for ""listed drug""

21 U.S.C. 355(j)(7) ‚Äì FDCA section requiring FDA to maintain and publish Orange Book listings

Public Law 98-417 ‚Äì Drug Price Competition and Patent Term Restoration Act of 1984

72 FR 9763 (March 5, 2007) and 61 FR 25497 (May 21, 1996) ‚Äì Past Federal Register notices supporting equivalency of non-marketed drugs to withdrawals",,"No Evidence of Withdrawal for Safety or Effectiveness:
The FDA reviewed its own records, independently evaluated literature, and examined postmarketing adverse events and found no indication that Atropine Sulfate ANSYR Plastic Syringe (0.5 mg/5 mL) was withdrawn for safety or effectiveness concerns
.

Listing in Discontinued Drug Product List Appropriate:
Because the product had never been marketed, it remained appropriate for listing in the ‚ÄúDiscontinued Drug Product List‚Äù of the Orange Book. FDA noted that under past precedent, non-marketing is treated equivalently to withdrawal from sale, but it does not mean the product was withdrawn for safety reasons.

ANDA Eligibility Maintained:
The FDA affirmed that the drug remains eligible as a Reference Listed Drug (RLD) for ANDA submissions as long as all legal and regulatory requirements are met. If labeling updates are needed, FDA will instruct ANDA applicants accordingly.

Petition Lacked Supporting Data:
The petitioner did not provide any scientific or clinical data showing the product was removed for safety or efficacy concerns, nor did FDA‚Äôs review uncover any such evidence
.",denied,True,146.0,CDER,CDER
fda-2019-p-4979,FDA-2019-P-4979-0001_Citizen_Petition_from_Andersen_Pharma_LLC.pdf,2019-10-22,2019,False,original petition,Andersen Pharma LLC,industry/corporation,"Section 505(j)(2)(C) of the FD&C Act (Suitability Petition)
- 21 C.F.R. ¬ß 10.20 (Submission of information and views)
- 21 C.F.R. ¬ß 10.30 (Citizen petition procedures)
- 21 C.F.R. ¬ß 25.31(a) (Environmental assessment categorical exclusion)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact statement)
- Pediatric Research Equity Act: FD&C Act ¬ß 505B(b)","Determination of whether a proposed change in fill volume for Magnesium Sulfate in 5% Dextrose Injection, USP (from 2 gm/100 mL to 1 gm/50 mL) is suitable for submission via ANDA, based on RLD NDA 020488","Petitioner requests FDA to determine that Magnesium Sulfate in 5% Dextrose Injection, USP, 1 gm/50 mL is suitable for ANDA submission, citing that the only change from the RLD is the fill volume, with same concentration","The proposed product is identical to the RLD in active ingredients, dosage form, route of administration, pH, osmolarity, and labeling (except for strength).
- Only the fill volume differs (1 gm/50 mL vs. 2 gm/100 mL), with the same concentration.
- A ready-to-use format offers improved safety and efficiency, eliminating need for compounding.
- Petition does not propose changes that would require pediatric studies under the Pediatric Research Equity Act.
- The petitioner claims no issues of safety or efficacy are introduced by this change",,,2025-10-15,0.0,,,,,no decision,False,2185.0,pending,pending
fda-2019-p-3934,FDA-2019-P-3934-0001_Suitability_Petition_from_AuroMedics_Pharma_LLC_on.pdf,2019-08-20,2019,False,original petition,AuroMedics Pharma LLC,industry/corporation,"Section 505(j)(2)(C) of the FD&C Act
- 21 C.F.R. ¬ß 10.20
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 25.30(h) (Environmental impact categorical exclusion)
- Reference to FDA-2017-P-1096 as precedent","Whether FDA will permit the filing of an ANDA referencing the discontinued formulation of Vasostrict¬Æ (vasopressin) Injection 20 units/mL, NDA# 204485, with a new fill volume of 10 mL (instead of the original 1 mL)","FDA is requested to permit submission of an ANDA for Vasopressin Injection 20 units/mL (10 mL fill volume) based on the discontinued formulation of the RLD, using the same concentration and excipients, but with greater total drug content","The proposed product is identical in all aspects to the original formulation of the RLD except for fill volume and total drug content (200 units/10 mL vs. 20 units/1 mL).
- The concentration remains unchanged at 20 units/mL.
- The formulation and route of administration are the same.
- The FDA previously determined (FDA-2017-P-1096) that the original formulation had not been withdrawn for safety or effectiveness reasons.
- Therefore, ANDA referencing the original RLD is acceptable, and the petitioner believes the proposed product raises no new safety or efficacy concerns",,,2025-10-15,0.0,,,,,no decision,False,2248.0,pending,pending
fda-2019-p-3232,FDA-2019-P-3232-0001_Citizen_Petition_from_Lachman_Consultants.pdf,2019-07-02,2019,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"21 C.F.R. ¬ß 10.25(a)
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 314.161
- 21 C.F.R. ¬ß 314.122(a)
- 21 C.F.R. ¬ß 314.162
- 21 C.F.R. ¬ß 25.31(a) (Environmental impact exclusion)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact information)","FDA's classification of NIX (Permethrin) Topical Lotion, NDA 019435, as discontinued in the Orange Book and the absence of a formal determination on whether it was withdrawn for safety or effectiveness reasons","Petitioner requests that the FDA determine whether the RLD (NIX Topical Lotion, NDA 019435) has been withdrawn for reasons of safety or effectiveness","NIX (Permethrin) was approved in 1986 and later listed in the Discontinued Section of the Orange Book.
- FDA had not (at the time) issued a determination whether the drug was withdrawn for safety or effectiveness.
- Petitioner claims no known safety or effectiveness concerns and believes the withdrawal was likely due to commercial reasons",,"Denied (Request for Safety/Effectiveness Withdrawal Determination Denied)
‚Äì FDA determined that prescription NIX (permethrin 1%) was not withdrawn from sale for reasons of safety or effectiveness and therefore remains on the ""Discontinued Drug Product List"" in the Orange Book.",2022-09-22,0.0,Center for Drug Evaluation and Research (CDER)," 21 CFR 314.161
- 21 CFR 314.162
- 21 CFR 310.200(b)
- Section 505(j) and 505(j)(7) of the FD&C Act (21 U.S.C. ¬ß 355(j))
- Section 503(b)(1), 503(b)(4)(A), and 503(b)(4)(B) of the FD&C Act (21 U.S.C. ¬ß 353(b))",,"The FDA reviewed its records, literature, and postmarketing adverse event data, and found no evidence indicating that prescription NIX was withdrawn for safety or effectiveness reasons.
- The drug was discontinued when NIX was fully switched from prescription to nonprescription (OTC) status.
- FDA explained that both prescription and OTC versions cannot legally coexist without meaningful clinical differences.
- Marketing NIX as a prescription drug (or a generic referencing it) with the ‚ÄúRx only‚Äù label would be considered misbranding under section 503(b)(4)(B) of the FD&C Act.
- Therefore, ANDA submissions referencing prescription NIX will not be approved.",denied,True,1178.0,CDER,CDER
fda-2019-p-4006,FDA-2019-P-4006-0001_Citizen_Petition_from_Tate___Lyle_Ingredients_Amer.pdf,2019-08-21,2019,False,original petition,Tate & Lyle Ingredients Americas LLC,industry/corporation,"21 C.F.R. ¬ß 10.30 (Citizen petitions)
- 21 C.F.R. ¬ß 101.9(c)(1)(i)(C) (Calorie calculation for nutrition labeling)
- 21 C.F.R. ¬ß 101.9(c)(6)(i) (Dietary fiber definition, referenced indirectly)
- 21 C.F.R. ¬ß 25.30(k) (Environmental impact exemption)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact report requirement)
- Sections 403(q) and 701(a) of the Federal Food, Drug, and Cosmetic Act",FDA‚Äôs assignment of 2 kcal/g to soluble non-digestible carbohydrates under 21 C.F.R. ¬ß 101.9(c)(1)(i)(C). The petitioner is requesting an exception for resistant maltodextrin A,"FDA is requested to:
- Amend 21 C.F.R. ¬ß 101.9(c)(1)(i)(C) to assign a caloric value of 0.2 kcal/gram for ‚Äúresistant maltodextrin A.‚Äù
- Add a new section (c)(1)(i)(G) to define this special caloric factor.
- Exercise enforcement discretion in the interim to allow the use of this lower calorie value on Nutrition Facts panels","‚ÄúResistant maltodextrin A‚Äù is chemically distinct, with a linkage ratio and structure that leads to significantly lower energy yield.
- Scientific evidence (Attachment A) and a clinical breath hydrogen study show a caloric value of 0.2 kcal/g.
- Use of this ingredient would support lower-calorie food product development and improve fiber intake among consumers.
- Aligns with FDA‚Äôs science-based approach to flexible labeling and public health goals",,,2025-10-15,0.0,,,,,no decision,False,2247.0,pending,pending
fda-2019-p-5048,FDA-2019-P-5048-0001_Citizen_Petition_from_Epstein__Becker_and_Green_P_.pdf,2019-10-29,2019,False,original petition,"Innovative Health Solutions, Inc. (IHS)",law/consulting,"21 C.F.R. ¬ß 10.30 (Citizen petition submission)
- 21 C.F.R. ¬ß 876.5340 (Classification of non-implanted nerve stimulators)
- Section 513(i) of the FDCA (Substantial equivalence standard)
- 21 C.F.R. ¬ß 807.92(a)(3) (510(k) content)
- 21 C.F.R. ¬ß 25.34 (Environmental impact exemption)",FDA‚Äôs classification order and special controls under 21 C.F.R. ¬ß 876.5340 for non-implanted nerve stimulators for functional abdominal pain relief following a de novo clearance of the IB-Stim device,"FDA should:
- Refrain from finding substantial equivalence for devices under 21 C.F.R. ¬ß 876.5340 unless the device is essentially identical to IB-Stim, or supported by:
¬†¬† - Preclinical studies (e.g., in animal IBS models), and
¬†¬† - At least one clinical trial in U.S. pediatric patients showing non-inferiority to IB-Stim","IB-Stim is the only device cleared in this class and was approved through robust preclinical and clinical data in pediatric IBS patients.
- Devices with design or functional differences (e.g., in stimulation frequency, nerve targets, grounding method, or electrode design) may not be equivalent and could pose risks to children.
- FDA‚Äôs current special controls are insufficient to ensure safety and effectiveness of significantly different devices.
- The petition provides evidence showing how design parameters directly impact therapeutic efficacy and safety (e.g., use of transillumination, patented array, stimulation field effect).
- Clearing unevaluated devices as substantially equivalent may compromise pediatric patient safety and mislead clinicians",2020-04-27 00:00:00,Denied,2024-07-24,2.0,Center for Devices and Radiological Health (CDRH),"21 CFR 10.30(e)
- 21 CFR 807.87(f), (g)
- 21 CFR 860.7(b)
- 21 CFR 860.134
- 21 CFR 860.200 et seq.
- 21 CFR 882.5896
- 21 CFR 876.5340
- FD&C Act Sections 513(a)(1), 513(f)(1), 513(f)(2), 513(f)(3), 513(i)(1)(A), 513(i)(1)(D)(i, ii)
- 21 U.S.C. 360c and 360k","The petition raised complex issues that require further review and analysis by FDA officials.
- Therefore, FDA could not issue a decision at the time of the interim response and acknowledged this procedural step in accordance with regulatory requirements","FDA determined that the existing special controls under the De Novo granting orders for NSS-2 BRIDGE and IB-Stim (codified at 21 CFR 882.5896 and 876.5340) already provide reasonable assurance of safety and effectiveness.
- Requiring categorical clinical and preclinical studies for future predicate-based devices would be contrary to FDA‚Äôs regulations, statutory authority, and least burdensome principles.
- FDA retains discretion to require additional data on a case-by-case basis during 510(k) review, but not as a universal special control requirement",denied,True,1730.0,CDRH,CDRH
fda-2019-p-3809,FDA-2019-P-3809-0001_Citizen_Petition_from_Lachman_Consultant_Services_.pdf,2019-08-12,2019,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FDC Act)
- 21 C.F.R. ¬ß 10.20
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 25.31(a) (Environmental impact exemption)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact information)","Current designation of ELIMITE‚Ñ¢ (permethrin) Cream 5% NDA 019855 by Mylan as both the Reference Listed Drug (RLD) and Reference Standard (RS) in the Orange Book and Drugs@FDA. The product is reportedly not being distributed, making it unavailable for bioequivalence testing","FDA is requested to designate either:
- Permethrin Cream 5% ANDA 074806 (Actavis Laboratories, Inc.) or
- Permethrin Cream 5% ANDA 076369 (Perrigo Israel Pharmaceuticals, Ltd.)
as the new Reference Standard (RS) product","The current RS (ELIMITE‚Ñ¢ by Mylan) is not available on the market or is available only in limited distribution.
- Applicants cannot obtain sufficient quantities for in vivo bioequivalence testing.
- The two suggested ANDA products are both available and listed as therapeutically equivalent to the RLD in the Orange Book, making them viable as RS alternatives",,,2025-10-15,0.0,,,,,no decision,False,2256.0,pending,pending
fda-2019-p-0198,FDA-2019-P-0198-0001_Citizen_Petition_from_Lachman_Consultant_Services_.pdf,2019-01-10,2019,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- 21 C.F.R. ¬ß 10.25(a)
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 25.31 (Environmental impact exemption)","FDA‚Äôs current designation of Hi Tech Pharmacal‚Äôs Sulfamethoxazole and Trimethoprim Oral Suspension as the Reference Standard (RS) for bioequivalence studies, despite it being unavailable on the market","FDA is requested to designate an alternative, marketed, approved generic drug product (specifically, Aurobindo Pharma Ltd‚Äôs ANDA No. 091348) as the new Reference Standard for Sulfamethoxazole and Trimethoprim Oral Suspension","The currently designated RS is not available for bioequivalence testing.
- FDA guidance allows for designating a new RS when current supply is insufficient.
- Aurobindo Pharma‚Äôs product is the generic market leader based on units sold (per IMS data from 2014‚Äì2018).
- Without a viable RS, NaviSci cannot proceed with its ANDA development",2019-07-08 00:00:00,"Dismissed as Moot
‚Äì The petition was dismissed because the product in question became available again in the market, resolving the issue raised",2019-11-15,2.0,Center for Drug Evaluation and Research (CDER)," Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book)
‚Äì Cited as the source for reference standard drug listings. No other formal statute or regulation cited",The response explains that a final decision on the petition has been delayed due to competing Agency priorities and numerous demands on FDA resources. The FDA acknowledges the petition and assures a future response,"The petitioner requested a new reference standard designation for sulfamethoxazole and trimethoprim oral suspension, stating the current reference product was unavailable.
- FDA determined the distribution of the existing reference product increased after the petition was submitted, and the drug is now available again.
- Based on this, FDA concluded the petition was moot",dismissed (moot),True,309.0,CDER,CDER
fda-2019-p-3877,FDA-2019-P-3877-0001_Citizen_Petition_from_Harman_Finochem_Limited.pdf,2019-08-17,2019,False,original petition,Harman Finochem Limited,industry/corporation,"21 C.F.R. ¬ß 10.25(a)
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß¬ß 314.12, 314.161, 314.122, 314.162
- Section 505(j)(2) of the FD&C Act
- 21 C.F.R. ¬ß 25.31(a) (Environmental impact exemption)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact provision)",FDA‚Äôs listing of Glucophage¬Æ (NDA 020357) by Bristol Myers Squibb as discontinued in the Orange Book; questioning whether it was withdrawn for safety or effectiveness reasons,"FDA is requested to confirm that Glucophage¬Æ NDA 020357 was not withdrawn for reasons of safety or effectiveness, so it may continue to serve as the Reference Listed Drug (RLD) for ANDA purposes","Glucophage¬Æ is still listed as an RLD but is marked discontinued.
- Other generics (e.g., ANDA 090564 by Granules India Ltd.) remain available.
- The petitioner is unaware of any safety or efficacy concerns and believes the discontinuation was for commercial reasons.
- FDA clarification is necessary for continued ANDA development referencing this product",,,2025-10-15,0.0,,,,,no decision,False,2251.0,pending,pending
fda-2019-p-5048,FDA-2019-P-5048-0001_Citizen_Petition_from_Epstein__Becker_and_Green_P_.pdf,2019-10-29,2019,False,original petition,"Epstein Becker & Green, P.C.",law/consulting,"21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 876.5340
- 21 C.F.R. ¬ß 807.92(a)(3)
- Federal Food, Drug, and Cosmetic Act ¬ß 513(i)
- 21 C.F.R. ¬ß 25.34","FDA‚Äôs classification and clearance process for non-implanted nerve stimulators for functional abdominal pain relief, specifically regarding substantial equivalence determinations to the IB-Stim device","The petitioners request that FDA refrain from determining substantial equivalence of any device to the IB-Stim without requiring:
‚Ä¢ Preclinical studies demonstrating similar efficacy in an animal model of IBS, and
‚Ä¢ At least one U.S.-based clinical trial demonstrating non-inferiority in pediatric IBS patients compared to the IB-Stim, if the device differs in critical parameters (e.g., stimulation frequency, nerve targets, grounding, design)","The petitioner asserts that:
‚Ä¢ The IB-Stim is uniquely designed and validated through both preclinical animal studies and clinical pediatric trials.
‚Ä¢ Minor changes in design or application from IB-Stim may negatively affect safety or efficacy, particularly for pediatric use.
‚Ä¢ Existing special controls (21 C.F.R. ¬ß 876.5340) are insufficient to ensure safety and effectiveness for devices that are not identical to IB-Stim.
‚Ä¢ Differences in device parameters (such as waveform, cranial nerve targeting, grounding method, and signal characteristics) require independent validation to avoid adverse outcomes in children.
‚Ä¢ The unique effectiveness of IB-Stim stems from specific, proven technical features including its patented array design and transillumination-based placement",2020-04-27 00:00:00,Denied,2024-07-24,2.0,Center for Devices and Radiological Health (CDRH),"21 CFR 10.30(e)
- 21 CFR 807.87(f), (g)
- 21 CFR 860.7(b)
- 21 CFR 860.134
- 21 CFR 860.200 et seq.
- 21 CFR 882.5896
- 21 CFR 876.5340
- FD&C Act Sections 513(a)(1), 513(f)(1), 513(f)(2), 513(f)(3), 513(i)(1)(A), 513(i)(1)(D)(i, ii)
- 21 U.S.C. 360c and 360k","The petition raised complex issues that require further review and analysis by FDA officials.
- Therefore, FDA could not issue a decision at the time of the interim response and acknowledged this procedural step in accordance with regulatory requirements","FDA determined that the existing special controls under the De Novo granting orders for NSS-2 BRIDGE and IB-Stim (codified at 21 CFR 882.5896 and 876.5340) already provide reasonable assurance of safety and effectiveness.
- Requiring categorical clinical and preclinical studies for future predicate-based devices would be contrary to FDA‚Äôs regulations, statutory authority, and least burdensome principles.
- FDA retains discretion to require additional data on a case-by-case basis during 510(k) review, but not as a universal special control requirement",denied,True,1730.0,CDRH,CDRH
fda-2019-p-3809,FDA-2019-P-3809-0001_Citizen_Petition_from_Lachman_Consultant_Services_.pdf,2019-08-12,2019,False,original petition,"Lachman Consultant Services, Inc. (Lachman Consultants)",law/consulting,"Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FDC Act)
- 21 C.F.R. ¬ß 10.20
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 25.31(a) (Environmental assessment exclusion)
- 21 C.F.R. ¬ß 10.30(b) (Economic impact)","The designation of ELIMITE‚Ñ¢ (permethrin) Cream 5% NDA 019855 by Mylan as the Reference Listed Drug (RLD) and Reference Standard (RS), despite its apparent unavailability in the marketplace","Lachman Consultants requests that the FDA designate either:
‚Ä¢ Permethrin Cream 5% ANDA 074806 (Actavis Laboratories, Inc.) or
‚Ä¢ Permethrin Cream 5% ANDA 076369 (Perrigo Israel Pharmaceuticals, Ltd.)
as the new Reference Standard product in the Orange Book and Drugs@FDA","Mylan's ELIMITE‚Ñ¢ product is no longer available in the market or has distribution too limited to be used for bioequivalence testing.
- Without an available RS, potential ANDA applicants are precluded from filing.
- Both proposed alternatives (Actavis and Perrigo products) are FDA-approved, marketed, and therapeutically equivalent to the RLD.
- Designating one of them as the RS would resolve the access issue and facilitate generic drug development",,,2025-10-15,0.0,,,,,no decision,False,2256.0,pending,pending
fda-2019-p-0198,FDA-2019-P-0198-0001_Citizen_Petition_from_Lachman_Consultant_Services_.pdf,2019-01-10,2019,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- 21 C.F.R. ¬ß 10.25(a)
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 25.31 (Environmental Impact Exclusion)","The designation of the Reference Standard (RS) and Reference Listed Drug (RLD) for Sulfamethoxazole and Trimethoprim Oral Suspension in the Orange Book‚Äîspecifically, the unavailability of the currently designated RS and RLD for conducting bioequivalence studies",Request to designate an additional reference standard (RS) in the Orange Book for Sulfamethoxazole and Trimethoprim Oral Suspension to support ANDA filings,"The currently listed RS by Hi Tech Pharmacal is shown as active in the Orange Book but is not available in the market.
- The lack of a usable RS prevents bioequivalence testing necessary for ANDA submissions.
- Based on IMS market data, Aurobindo Pharma Ltd‚Äôs product (ANDA No. A091348) is the market leader and should be designated as the RS.
- This change would enable ANDA development by providing a viable RS for testing",2019-07-08 00:00:00,"Dismissed as Moot
‚Äì The petition was dismissed because the product in question became available again in the market, resolving the issue raised",2019-11-15,2.0,Center for Drug Evaluation and Research (CDER)," Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book)
‚Äì Cited as the source for reference standard drug listings. No other formal statute or regulation cited",The response explains that a final decision on the petition has been delayed due to competing Agency priorities and numerous demands on FDA resources. The FDA acknowledges the petition and assures a future response,"The petitioner requested a new reference standard designation for sulfamethoxazole and trimethoprim oral suspension, stating the current reference product was unavailable.
- FDA determined the distribution of the existing reference product increased after the petition was submitted, and the drug is now available again.
- Based on this, FDA concluded the petition was moot",dismissed (moot),True,309.0,CDER,CDER
fda-2019-p-5760,FDA-2019-P-5760-0001_Citizen_Petition_from_Sun_Pharmaceutical_Industrie.pdf,2019-12-06,2019,False,original petition,Sun Pharmaceutical Industries Limited,industry/corporation,"Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act
- 21 C.F.R. ¬ß 10.20
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 314.93 (Suitability Petitions)
- 21 C.F.R. ¬ß 25.31 (Environmental Impact exclusion)",FDA policy regarding submission of ANDAs for drug products differing in strength from the RLD‚Äîspecifically for Levetiracetam in Sodium Chloride Injection,"FDA should determine that the drug product Levetiracetam in Sodium Chloride Injection, 2.5 mg/mL (250 mg/100 mL) is suitable for submission as an ANDA alongside existing strengths","Current RLD only allows strengths that require aseptic withdrawal to achieve certain doses (e.g., 250 mg or 750 mg).
- Proposed 2.5 mg/mL strength would improve convenience, facilitate precise dosing, and reduce the risk of microbial contamination and medication errors.
- The proposed product is otherwise identical to the RLD in terms of active ingredient, route, excipients, and indications.
- No new safety or efficacy concerns arise from the addition of this strength",,Denied,2021-07-07,0.0,"Center for Drug Evaluation and Research (CDER)
Signed by William Chong, M.D., Director, Office of Safety and Clinical Evaluation, for Iilun Murphy, M.D., Director, Office of Generic Drugs","Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- 21 CFR 314.93
- 21 CFR 314.93(e)(1)(iv)
- 21 CFR 10.33
- 21 CFR 10.20",,"The proposed change in strength (to a more dilute 2.5 mg/mL concentration) poses potential safety and effectiveness concerns.
- No clinical benefit was demonstrated for the proposed change.
- The new formulation could result in higher fluid and sodium load, particularly problematic for patients with renal insufficiency or sodium-restricted diets.
- Could necessitate significant labeling changes.
- Potential for confusion due to multiple concentrations on the market with no added benefit.",denied,True,579.0,CDER,CDER
fda-2019-p-2290,FDA-2019-P-2290-0001_Citizen_Petition_from_ALEMBIC_PHARMACEUTICALS_LIMI.pdf,2019-05-10,2019,False,original petition,Alembic Pharmaceuticals Limited,industry/corporation,"Section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 10.25
- 21 C.F.R. ¬ß 314.122
- 21 C.F.R. ¬ß 314.161
- 21 C.F.R. ¬ß 25.31(a) (Environmental Impact Exclusion)","Discontinuation of the Reference Listed Drug (RLD) LEVITRA (Vardenafil Hydrochloride) Tablets, 2.5 mg, NDA #021400, by Bayer Healthcare Pharmaceuticals Inc.","The petitioner requests that FDA determine that the RLD LEVITRA (2.5 mg) was withdrawn for reasons other than safety or effectiveness, thereby permitting submission of an ANDA referencing it.","The RLD has been discontinued, and the petitioner wishes to submit an ANDA referencing it.
- Under FD&C Act requirements, FDA must determine whether the RLD was withdrawn for safety or efficacy reasons before ANDA submission is allowed.
- Petitioner asserts there is no evidence of safety or effectiveness concerns related to the RLD‚Äôs market withdrawal",,"Approved. The FDA granted the petition request, determining that the withdrawal of Levitra (vardenafil hydrochloride) 2.5 mg was not due to safety or effectiveness reasons, and that FDA will continue to accept abbreviated new drug applications (ANDAs) referencing it.",2019-08-12,0.0,"Center for Drug Evaluation and Research (CDER), Office of Regulatory Policy","84 FR 155 ‚Äì Federal Register notice published August 12, 2019
- Reference to the ‚ÄúDiscontinued Drug Product List‚Äù section of the Approved Drug Products With Therapeutic Equivalence Evaluations (Orange Book)",,"The FDA confirmed that Levitra (vardenafil hydrochloride) 2.5 mg was not withdrawn for safety or effectiveness reasons. Therefore, it will be maintained in the Discontinued Drug Product List in the Orange Book, and ANDAs referencing it will be accepted if all other requirements are met.",approved,True,94.0,CDER,CDER
fda-2019-p-2559,FDA-2019-P-2559-0001_Citizen_Petition_from_Ajanta_Pharma_USA_Inc.pdf,2019-05-27,2019,False,original petition,Ajanta Pharma USA Inc,industry/corporation,"21 C.F.R. ¬ß 10.25
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 314.122
- 21 C.F.R. ¬ß 314.161
- 21 C.F.R. ¬ß 314.162
- Section 505(j)(2) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. ¬ß 25.31 (Environmental impact exclusion)","Discontinuation status of the Reference Listed Drug (RLD) FORTAMET¬Æ (metformin hydrochloride extended-release tablets, 500 mg and 1 g), NDA N021574.","Petitioner requests that FDA determine that FORTAMET¬Æ was not withdrawn for reasons of safety or effectiveness, and confirm its eligibility for use as a reference in ANDA submissions","FORTAMET¬Æ is listed in the ‚ÄúDiscontinued Drug Product List‚Äù section of the FDA Orange Book.
- The petitioner asserts that there is no evidence it was discontinued due to safety or efficacy concerns.
- The drug remains cited in the Orange Book, which permits its use as a reference listed drug (RLD) for ANDA purposes if not withdrawn for such reasons",,"Approved ‚Äì FDA determined that FORTAMET (metformin hydrochloride) extended-release tablets, 500 mg and 1 g, were not withdrawn for reasons of safety or effectiveness, and thus remain on the Discontinued Drug Product List in the Orange Book.",2019-07-29,0.0,Center for Drug Evaluation and Research (CDER) ‚Äì Office of Regulatory Policy,"Federal Register notice was mentioned as enclosed, but no specific regulation (e.g., 21 CFR or FD&C Act section) was cited in the visible portion of the document.
‚Üí Not Explicitly Mentioned",,"FDA reviewed its records and found no evidence that the discontinuation of FORTAMET was due to safety or effectiveness concerns.
- Therefore, the product remains listed in the Orange Book‚Äôs Discontinued Drug Product List, and may be referenced in ANDA submissions if other legal requirements are satisfied.",approved,True,63.0,CDER,CDER
fda-2019-p-0915,FDA-2019-P-0915-0001_Suitability_Petition_from_Sunshine_Lake_Pharma_Co_.pdf,,2019,False,original petition,"Sunshine Lake Pharma Co., Ltd.",industry/corporation,"21 C.F.R. ¬ß 10.20
- 21 C.F.R. ¬ß 10.30
- 21 C.F.R. ¬ß 314.93
- Section 505(j)(2)(C) of the FD&C Act
- 21 C.F.R. ¬ß 25.31 (Environmental Impact exemption)","Suitability determination for an ANDA with a dosage form change from oral solution to granules for oral solution of lacosamide (RLD: VIMPAT¬Æ Oral Solution 10 mg/mL, NDA 022255 by UCB Inc.)","Approve the petition allowing submission of an ANDA for Lacosamide Granules for Oral Solution 10 mg/mL, differing only in dosage form from the RLD","Only the dosage form differs; all other parameters (indication, route, strength, patient population, and use) remain the same.
- Proposed product offers advantages in portability, stability, and administration for patients with difficulty swallowing.
- No labeling changes except those necessitated by dosage form.
- Bioequivalence data to be submitted with ANDA",,,2025-10-15,,,,,,no decision,False,,pending,pending
fda-2019-p-4643,FDA-2019-P-4643-0001_Citizen_Petition_from_Physicians_Committee_for_Res.pdf,2019-10-03,2019,False,original petition,Physicians Committee for Responsible Medicine,advocacy/academic,"21 C.F.R. ¬ß 10.30 (Citizen Petition regulation)
- 21 C.F.R. ¬ß 525.30 (Environmental Impact exemption)
- 21 C.F.R. ¬ß 10.30(b)(3) (Economic Impact submission clause)",Labeling and packaging of dairy cheese products ‚Äì lack of disclosure about presence of reproductive hormones and related cancer risks,"The FDA should require all dairy cheese product labeling and packaging to include the following statement:
""Dairy cheese contains reproductive hormones that may increase breast cancer mortality risk.""","Scientific studies indicate a strong correlation between consumption of high-fat dairy (including cheese) and increased breast cancer risk and mortality.
- Hormonal components such as IGF-1 and estradiol in dairy are implicated in cancer progression.
- Post-diagnosis consumption of high-fat dairy is also associated with 49% higher mortality.
- Public should be warned of these risks through product labeling to promote informed choices",,,2025-10-15,0.0,,,,,no decision,False,2204.0,pending,pending
fda-2020-p-0042,FDA-2020-P-0042-0001_Citizen_Petition_from_Emery_Pharm_on_behalf_of_Naj.pdf,2020-01-02,2020,False,original petition,Emery Pharma,industry/corporation,"Sections 301 (21 U.S.C. ¬ß 331), 502 (21 U.S.C. ¬ß 352), 505 (21 U.S.C. ¬ß 355), 702 (21 U.S.C. ¬ß 372), 704 (21 U.S.C. ¬ß 374), 705 (21 U.S.C. ¬ß 375); 21 C.F.R. 10.20 and 10.30","Regulation and guidance regarding ranitidine; FDA directive dated December 4, 2019 about NDMA testing in ranitidine","Issue a regulation, revise industry guidance, request a recall and suspend sales of ranitidine, conduct further investigation into NDMA levels in ranitidine, and enforce proper labeling and storage requirements","Petitioner found that ranitidine may degrade to NDMA, a probable carcinogen, under elevated temperatures during storage and transport. Since ranitidine is not currently cold-chained or labeled with heat warnings, NDMA levels may become unsafe post-manufacture. The FDA's current testing may not account for post-distribution NDMA accumulation, posing a significant public health risk",,,2025-10-15,0.0,,,,,no decision,False,2113.0,pending,pending
fda-2020-p-0102,FDA-2020-P-0102-0001_Citizen_Petition_from_The_Ritedose_Corporation.pdf,2020-01-08,2020,False,original petition,The Ritedose Corporation,industry/corporation,"505(j) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 25.30",Discontinuation of DUONEB¬Æ (NDA 020950) and lack of reference standard designation in the Orange Book,"Designate ANDA 202496 as the reference standard for Ipratropium Bromide and Albuterol Sulfate Inhalation Solution, 0.5 mg/3 mg per 3 mL","DUONEB¬Æ (NDA 020950) was discontinued, and no reference standard has been designated. ANDA 202496 is the market leader by units sold and is private label manufactured for several companies, justifying its use as the reference standard","July 13, 2020",,2025-10-15,1.0,,,The FDA has not yet made a final decision on the petition due to the need to prioritize other agency matters. The petition requested that ANDA 202496 be designated as the reference standard for Ipratropium Bromide and Albuterol Sulfate Inhalation Solution because the reference listed drug DUONEB (NDA 020950) has been discontinued and no RS has been designated. FDA will respond when resources allow.,,no decision,False,2107.0,pending,pending
fda-2020-p-0129,FDA-2020-P-0129-0001_Citizen_Petition_from_Hyman__Phelps___McNamara__P_.pdf,2020-01-08,2020,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"21 C.F.R. ¬ß¬ß 10.25(a), 10.30; FDC Act ¬ß 505(j); 21 C.F.R. ¬ß 314.3; FDA Draft Guidance (Jan. 2017); 21 C.F.R. ¬ß 25.31","Current reference standard for Carbidopa and Levodopa Tablets (Sinemet, NDA 017555) is commercially unavailable, limiting generic ANDA submissions","Designate ANDA 074260 (Carbidopa and Levodopa Tablets, 25 mg/250 mg) or another appropriate ANDA as the new reference standard for the drug","The current reference standard (Sinemet) is on back order and cannot be obtained, hindering bioequivalence studies and generic competition. ANDA 074260 by Actavis is a market leader and would be a more appropriate and accessible reference standard","July 6, 2020",,2025-10-15,1.0,,,"The FDA has not yet resolved the petition due to other agency priorities. The petition requested that carbidopa and levodopa tablets approved under ANDA 074260 or another appropriate ANDA be designated as reference standards. The Agency stated it will respond when possible, citing numerous demands on its resources.",,no decision,False,2107.0,pending,pending
fda-2020-p-0152,FDA-2020-P-0152-0001_Citizen_Petition_from_Hyman__Phelps___McNamara__P_.pdf,2020-01-09,2020,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"21 C.F.R. ¬ß¬ß 10.25(a), 10.30, 21 C.F.R. ¬ß 25.30(h), 21 C.F.R. Part 15; Federal Food, Drug, and Cosmetic Act ¬ß 396; Administrative Procedure Act (APA); First Amendment",FDA‚Äôs 2018 Safety Communication and subsequent enforcement actions against clinical laboratories and software providers offering pharmacogenomic (PGx) testing information,1) Revise the Safety Communication to allow sharing PGx information supported by evidence or FDA labeling; 2) Permit clinical labs to include medication-specific information in PGx test reports if supported by evidence or FDA labeling; 3) Conduct future PGx policy development via notice-and-comment rulemaking and hold a public hearing,"The FDA's actions are suppressing the dissemination of truthful, evidence-based PGx information crucial for personalized medicine, violating the APA, FDC Act, and First Amendment. The Coalition argues that physicians and patients are denied access to valuable drug-response information, some of which is already included in FDA-approved drug labels, and the FDA has provided no evidence of harm to justify this suppression",,,2025-10-15,0.0,,,,,no decision,False,2106.0,pending,pending
fda-2020-p-0158,FDA-2020-P-0158-0001_Citizen_Petition_from_Sidley_Austin_LLP_on_behalf_.pdf,2020-01-09,2020,False,original petition,Sidley Austin LLP,law/consulting,"505(b)(2), 505(j) of the Federal Food, Drug, and Cosmetic Act (FDCA); 21 C.F.R. ¬ß¬ß 10.25(a), 10.30; 21 C.F.R. ¬ß 25.30(h); Administrative Procedure Act; FDA Draft Guidance documents",FDA‚Äôs reliance on the ANDA pathway for approval and therapeutic equivalence determinations of harder-to-copy complex drugs under its Drug Competition Action Plan (DCAP),1) Issue guidance that the ANDA pathway is not appropriate for harder-to-copy complex drugs; 2) Clarify that therapeutic equivalence for such drugs must be supported by clinical studies under the 505(b)(2) pathway,"ANDA does not allow for clinical studies needed to demonstrate same clinical effect and safety profile. Harder-to-copy complex drugs (like those with nanomaterials or complex formulations) pose immunogenicity and efficacy risks that can't be adequately addressed without clinical trials. Using 505(b)(2) ensures safety and proper therapeutic equivalence, supporting DCAP goals without compromising patient safety",,,2025-10-15,0.0,,,,,no decision,False,2106.0,pending,pending
fda-2020-p-0284,FDA-2020-P-0284-0001_Citizen_Petition_from_Hyman__Phelps___McNamara__P_.pdf,2020-01-16,2020,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"Section 505(j) of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. ¬ß¬ß 10.20, 10.30, and 314.3","FDA's omission of Reference Listed Drug (RLD) and Reference Standard (RS) designations for Nicardipine Hydrochloride Injection, NDA 022276, in the Orange Book","FDA should amend the Orange Book to designate Nicardipine Hydrochloride Injection, NDA 022276, as both a Reference Listed Drug and a Reference Standard",The product is a single-source drug and its lack of RLD and RS designations shields it from generic competition. Assigning these designations would facilitate the approval of ANDAs and promote market competition,,Dismissed as moot,2020-09-17,0.0,Center for Drug Evaluation and Research (CDER),Not explicitly cited beyond general reference to the Orange Book (21 CFR 314.161 referenced indirectly),,"The FDA updated the Orange Book to reflect the requested designations for nicardipine hydrochloride injection under NDA 022276. Since the requested actions were already completed by the FDA, the petitions were dismissed as moot.",dismissed (moot),True,245.0,CDER,CDER
fda-2020-p-0368,FDA-2020-P-0368-0001_Citizen_Petition_from_Crowell___Moring__LLP.pdf,2020-01-22,2020,False,original petition,Crowell & Moring LLP,law/consulting,"21 C.F.R. ¬ß 10.30; Federal Food, Drug, and Cosmetic Act ¬ß 503A; Administrative Procedure Act (APA); Regulatory Flexibility Act (RFA); Unfunded Mandates Reform Act (UMRA); Congressional Review Act (CRA); Paperwork Reduction Act (PRA); Executive Orders 12866 and 13132","FDA‚Äôs interpretation of 'distribution' under Section 503A of the FDCA, particularly in the context of the Memorandum of Understanding (MOU) and the enforcement of the 5% interstate distribution limit for compounded drugs","FDA should not finalize the MOU or take regulatory action based on a definition of 'distribution' that includes patient-specific dispensing, unless it first promulgates the definition through a proper rulemaking process and issues guidance that clarifies its enforcement policy","FDA's current interpretation unlawfully expands the definition of 'distribution' to include patient-specific dispensing without formal rulemaking. This violates multiple statutes and executive orders, and risks drastically limiting patient access to compounded medications. The proposed changes impose new, burdensome obligations on pharmacies and states, which could result in economic harm, reduce access to care, and disrupt traditional pharmacy practices",,Denied,2020-05-13,0.0,Center for Drug Evaluation and Research (CDER),"21 U.S.C. 353a (Section 503A of the FD&C Act), 21 U.S.C. 351(a)(2)(B), 21 U.S.C. 352(f)(1), 21 U.S.C. 355, 5 U.S.C. 553 (APA), Regulatory Flexibility Act (RFA), Unfunded Mandates Reform Act (UMRA), Congressional Review Act (CRA), Paperwork Reduction Act (PRA), Executive Orders 12866 and 13132",,"The FDA denied the petition because the statutory implementation of Section 503A(b)(3)(B) of the FD&C Act does not require rulemaking. The definition of 'distribution' that includes 'dispensing' is consistent with Congressional intent and the prescription requirement in Section 503A. The MOU is a nonbinding agreement between FDA and states and does not impose legally binding obligations. FDA also noted that it has already provided ample opportunity for public comment, and the petition's proposed enforcement guidance was not adopted as existing guidance and statutory limitations already address these concerns.",denied,True,112.0,CDER,CDER
fda-2020-p-0421,FDA-2020-P-0421-0001_Citizen_Petition_from_Cooley_s_Anemia_Foundation__.pdf,2020-01-24,2020,False,original petition,Cooley‚Äôs Anemia Foundation,advocacy/academic,21 U.S.C. ¬ß 355(q); 21 C.F.R. ¬ß 10.30,FDA oversight regarding generic versions of deferiprone and the lack of mandatory REMS safety protocols equivalent to those currently provided voluntarily with Ferriprox,Require that all deferiprone products include mandatory safety measures equivalent to those in ApoPharma‚Äôs current voluntary REMS for Ferriprox,"Deferiprone poses serious health risks, including agranulocytosis, which can be fatal if not detected early. The current Ferriprox voluntary REMS includes safeguards such as weekly neutrophil monitoring, education programs, and pharmacist-physician-patient feedback loops. Without mandatory REMS for generics, patient safety and consistent monitoring would be at risk",,,2025-10-15,0.0,,,,,no decision,False,2091.0,pending,pending
fda-2020-p-0436,FDA-2020-P-0436-0001_Citizen_Petition_from_Foley_and_Lardner_LLP_on_beh.pdf,2020-01-24,2020,False,original petition,Foley & Lardner LLP,law/consulting,"21 U.S.C. ¬ß¬ß 355(b) and 355(j); 21 C.F.R. ¬ß¬ß 10.30, 10.31, 314.3, 320.1(e)",FDA‚Äôs Draft Guidances on Nitazoxanide (tablets and oral suspension) and the proposed standards for approving generic versions of ALINIA¬Æ (nitazoxanide),"(1) conducts bioequivalence (BE) studies for tizoxanide and tizoxanide glucuronide in plasma under fasted and fed conditions, (2) conducts BE studies with clinical endpoints regardless of formulation sameness, and (3) conducts separate BE studies with clinical endpoints for G. lamblia and C. parvum infections; also revise the Draft Guidances to incorporate these requirements","The current Draft Guidances only propose BE based on tizoxanide plasma levels, neglecting tizoxanide glucuronide and site-specific action in the gastrointestinal tract. Because C. parvum and G. lamblia have different infection sites and clinical implications, including potential fatality in C. parvum cases, Romark argues that without comprehensive studies, approving generics could risk public health due to ineffective treatment and under-evaluated therapeutic equivalence",,,2025-10-15,0.0,,,,,no decision,False,2091.0,pending,pending
fda-2020-p-0438,FDA-2020-P-0438-0001_Citizen_Petition_from_Hyman__Phelps___McNamara__P_.pdf,2020-01-27,2020,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"21 C.F.R. ¬ß¬ß 10.25, 10.30, 314.122, 314.161; Sections 505(j) and 505(w) of the Federal Food, Drug, and Cosmetic Act",FDA‚Äôs listing of Micro-K LS Packets (potassium chloride) in the Orange Book as a discontinued drug product and its previous approval withdrawal notice in the Federal Register,Determine whether Micro-K LS Packets (NDA 019561) were withdrawn for safety or effectiveness reasons,"The petitioner asserts there is no evidence the drug was withdrawn due to safety or efficacy concerns, and believes the withdrawal was based on commercial reasons. A positive determination would allow the drug to remain eligible as a reference listed drug (RLD) in ANDAs",,Determined that the drug was not withdrawn for safety or effectiveness reasons,2020-09-02,0.0,Center for Drug Evaluation and Research (CDER),Not explicitly cited,,"The FDA reviewed its records and concluded that Micro-K LS Packets (potassium chloride) extended-release liquid suspension, 20 mEq/packet, was not withdrawn from sale for safety or effectiveness reasons. Therefore, the drug will remain listed in the 'Discontinued Drug Product List' section of the Orange Book.",withdrawn,True,219.0,CDER,CDER
fda-2020-p-0511,FDA-2020-P-0511-0001_Citizen_Petition_from_Novitium_Pharma_LLC.pdf,2020-01-30,2020,False,original petition,Novitium Pharma LLC,industry/corporation,"21 C.F.R. ¬ß 10.25(a), 21 C.F.R. ¬ß 10.30, 21 C.F.R. ¬ß 314.94(a)(3)","FDA‚Äôs Orange Book designation of Valsartan (PREXXARTAN) Oral Solution, NDA #209139, as discontinued and its impact on ANDA approvals","Determine whether Valsartan (PREXXARTAN) Oral Solution, NDA #209139, was withdrawn from sale for reasons of safety or effectiveness to allow ANDA 214102 approval","The discontinuation of PREXXARTAN was reportedly due to a commercial dispute with a third-party manufacturer, not safety or effectiveness concerns. A determination confirming this would support the approval of Novitium‚Äôs ANDA for a generic version and help reduce drug prices and public healthcare costs",,Determined that the drug was not withdrawn for safety or effectiveness reasons,2020-09-23,0.0,Center for Drug Evaluation and Research (CDER),Not explicitly cited,,"The FDA reviewed its records and determined that Prexxartan (valsartan) oral solution, 20 mg/5 mL, was not withdrawn from sale for reasons related to safety or effectiveness. As a result, the product will remain listed in the 'Discontinued Drug Product List' section of the Orange Book.",withdrawn,True,237.0,CDER,CDER
fda-2020-p-0512,FDA-2020-P-0512-0001_Citizen_Petition_from_Hyman__Phelps____McNamara_PC.pdf,2020-01-23,2020,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. ¬ß¬ß 314.93, 10.20, 10.30, 25.31(a)","FDA‚Äôs regulations governing ANDA suitability petitions, specifically whether alternative strengths of a drug product (Paclitaxel for Injectable Suspension) can be submitted via an ANDA","Approve submission of an ANDA for Paclitaxel for Injectable Suspension in new strengths of 50 mg/vial and 300 mg/vial, in addition to the approved 100 mg/vial strength under NDA 021660 (Abraxane¬Æ)","The proposed strengths maintain the same concentration, dosage form, route of administration, and active ingredient as the reference listed drug. The changes are limited to vial size to enhance dosing flexibility, reduce drug waste, and improve convenience. These modifications raise no safety or efficacy concerns and are not subject to the Pediatric Research Equity Act (PREA), making them suitable for an ANDA under a suitability petition",,Acknowledged (no decision made on the petition's merits),2020-01-30,0.0,"Dockets Management Staff (DMS), Office of Operations",Not Mentioned,,The letter acknowledges receipt of the petition requesting that Paclitaxel for Injectable Suspension in 50 mg/vial and 300 mg/vial lyophilized powder be deemed suitable for submission in an ANDA. It clarifies that acceptance of the petition is purely procedural and does not reflect any decision on the petition‚Äôs substantive merits.,other,True,7.0,DMS,Other/Specialty Center
fda-2020-p-0513,FDA-2020-P-0513-0001_Citizen_Petition_from_Foley_and_Lardner_LLP_on_beh.pdf,2020-01-29,2020,False,original petition,Foley & Lardner LLP,law/consulting,"21 U.S.C. ¬ß¬ß 355(b) and 355(j); 21 C.F.R. ¬ß¬ß 10.30, 10.31, 314.3, 320.1(e), 25.1(g), 10.30(b)","FDA‚Äôs Draft Guidances on Nitazoxanide (tablets and oral suspension), and the bioequivalence standards for approving generic versions of ALINIA¬Æ","(1) BE studies for both tizoxanide and tizoxanide glucuronide in plasma under fasted and fed conditions, (2) BE studies with clinical endpoints regardless of formulation sameness, and (3) separate BE studies with clinical endpoints in patients with G. lamblia and with C. parvum; revise the FDA Draft Guidances to include these requirements","The petition argues that the current Draft Guidances are scientifically inadequate because they fail to measure active metabolite concentrations at the site of infection and do not account for the differences in infection pathophysiology between G. lamblia and C. parvum. Without these studies, a generic version may pose a public health risk due to ineffective treatment, particularly for the potentially fatal C. parvum infection",,Acknowledged receipt; no decision on merits,2020-01-30,0.0,Dockets Management Staff (FDA/Office of Operations),Not Mentioned,,The FDA acknowledged receipt of a petition requesting that no ANDA for generic versions or pharmaceutical alternatives of ALINIA¬Æ be approved unless specific conditions are met. The letter clarifies that this acceptance is procedural only and does not indicate any decision regarding the substantive merits of the petition.,other,True,1.0,DMS,Other/Specialty Center
fda-2020-p-0598,FDA-2020-P-0598-0001_Citizen_Petition_from_Lachman_Consultants.pdf,2020-01-22,2020,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"Federal Food, Drug, and Cosmetic Act; 21 C.F.R. ¬ß¬ß 10.25(a), 10.30, 25.31; Section III.C.2 and III.C.3 of FDA‚Äôs draft guidance 'Referencing Approved Drug Products in ANDA'","FDA‚Äôs designation of the reference standard (RS) for Prochlorperazine Maleate Tablets USP, 10 mg, and the availability of that RS for bioequivalence studies","Designate Prochlorperazine Maleate Tablets USP, 10 mg (A040268) by Jubilant Cadista Pharmaceuticals Inc., as a new reference standard for ANDA purposes","The currently designated RS by Sandoz is not sufficiently available in the market to conduct in vivo bioequivalence studies. Jubilant Cadista‚Äôs product is the highest marketed version and meets the necessary criteria to serve as an alternative RS, enabling development and approval of generic products",,,2025-10-15,0.0,,,,,no decision,False,2093.0,pending,pending
fda-2020-p-0599,FDA-2020-P-0599-0001_Citizen_Petition_from_Foley___Lardner__LLP__on_beh.pdf,2020-02-04,2020,False,original petition,Foley & Lardner LLP,law/consulting,"21 U.S.C. ¬ß¬ß 355(b), 355(j); 21 C.F.R. ¬ß¬ß 10.30, 10.31, 314.3, 320.1(e), 25.1(g)",FDA‚Äôs Draft Guidances on Nitazoxanide (tablets and oral suspension) and bioequivalence standards for ANDAs citing Alinia¬Æ,"(1) conducts BE studies for tizoxanide and tizoxanide glucuronide in plasma under fasted and fed conditions, (2) conducts BE studies with clinical endpoints regardless of Q1/Q2 sameness, and (3) conducts separate BE studies with clinical endpoints in patients with G. lamblia and with C. parvum; also revise the Draft Guidances to include these requirements","The current FDA Draft Guidances do not sufficiently ensure bioequivalence at the site of action because they overlook the contribution of tizoxanide glucuronide, do not account for clinical efficacy against both G. lamblia and C. parvum (which differ in infection site and disease severity), and ignore differences in manufacturing that affect drug activity. Inadequate testing may risk public safety, especially in cases of potentially fatal C. parvum infections",,Denied,2020-11-27,0.0,Center for Drug Evaluation and Research (CDER),"21 U.S.C. 355(j), 21 U.S.C. 355(j)(8)(B)(i), 21 U.S.C. 355(j)(8)(C), 21 CFR 314.3(b), 21 CFR 320.23(b), 21 CFR 320.24(a), 21 CFR 320.24(b), 21 CFR 320.25(a), 21 CFR 314.94(a), 21 CFR 314.127(a)(6)(i)",,"The FDA denied the petition on the basis that its existing product-specific guidances (PSGs) for nitazoxanide adequately assess bioequivalence (BE) for generic drugs. It justified not requiring BE testing of the secondary metabolite tizoxanide glucuronide because it is less sensitive to formulation differences and less active than the primary metabolite tizoxanide. For Q1/Q2 same products, FDA found no need for clinical endpoint studies, arguing that in vitro dissolution and PK studies are sufficient. Additionally, FDA rejected the need for separate clinical endpoint studies in both Giardia lamblia and Cryptosporidium parvum infections, asserting that results from one indication are sufficient due to similar sites of action and pathophysiology.",denied,True,297.0,CDER,CDER
fda-2020-p-0624,FDA-2020-P-0624-0001_Citizen_Petition_from_Reguliance__LLC_on_behalf_of.pdf,2020-02-04,2020,False,original petition,Reguliance LLC,industry/corporation,"21 C.F.R. ¬ß¬ß 314.93, 10.30, 10.20; Section 505(j) of the Federal Food, Drug, and Cosmetic Act","FDA‚Äôs rules governing ANDA suitability petitions, specifically regarding the acceptance of a new 800 mg tablet strength for Rufinamide","Declare that Rufinamide 800 mg film-coated tablets are suitable for submission as an abbreviated new drug application (ANDA), using Banzel (Rufinamide) Tablets NDA 021911 as the reference listed drug (RLD)","The 800 mg tablet strength is consistent with the RLD‚Äôs dosing recommendations, enhances patient compliance by reducing pill burden, and poses no new safety or efficacy concerns. The product is pharmaceutically equivalent in terms of active ingredient, dosage form, route of administration, and therapeutic use. The tablet design also meets FDA size recommendations for generic drugs",,Approved,2023-09-12,0.0,Center for Drug Evaluation and Research (CDER),"21 U.S.C. 355(j)(2)(C), 21 CFR 314.93, 21 CFR 314.93(e)(1), 21 CFR 314.94(a)(3)(iii), 21 U.S.C. 355(j)(2)(A), 21 U.S.C. 355(j)(2)(B), 21 U.S.C. 355(j)(2)(A)(iv)",,"The FDA approved the petition because the proposed change in strength (from 200 mg and 400 mg to 800 mg) for Rufinamide Tablets does not raise concerns regarding safety or effectiveness. The proposed strength is consistent with the dosing recommendations of the reference listed drug, and if bioequivalence is demonstrated, it can be expected to have the same therapeutic effect. No significant labeling changes or additional investigations were deemed necessary to establish the safety and effectiveness of the new strength.",approved,True,1316.0,CDER,CDER
fda-2020-p-0678,FDA-2020-P-0678-0001_Citizen_Petition_from_Fresenius_Kabi_USA__LLC_.pdf,2020-02-06,2020,False,original petition,"Fresenius Kabi USA, LLC",industry/corporation,"21 C.F.R. ¬ß¬ß 10.30, 314.161, 314.162, 25.31","FDA‚Äôs listing of Dextrose 70% (70 gm/100 mL in plastic containers, NDA 017521) in the Discontinued Section of the Orange Book",Determine whether Dextrose 70% (NDA 017521) was withdrawn from sale for reasons of safety or effectiveness,"Fresenius Kabi seeks to confirm that the product was not withdrawn for safety or efficacy reasons, which would allow its use as a reference listed drug for an ANDA submission. The product's discontinuation may have been for business reasons, and a determination is required before ANDA approval can proceed",,Determined that the drug was not withdrawn for safety or effectiveness reasons,2020-06-24,0.0,Center for Drug Evaluation and Research (CDER),Not Mentioned,,"The FDA reviewed its records and concluded that Dextrose 70% in Plastic Container (70 g/100 mL), along with 30%, 40%, and 60% concentrations under the same NDA, was not withdrawn from sale for reasons of safety or effectiveness. Therefore, these products will remain listed in the 'Discontinued Drug Product List' section of the Orange Book.",withdrawn,True,139.0,CDER,CDER
fda-2020-p-0698,FDA-2020-P-0698-0001_Citizen_Petition_from_Physicians_Committee_for_Res.pdf,2020-02-10,2020,False,original petition,Physicians Committee for Responsible Medicine,advocacy/academic,21 C.F.R. ¬ß 10.30; 21 C.F.R. ¬ß 525.30,"FDA labeling requirements for erectile dysfunction (ED) drugs, specifically the absence of warnings regarding the underlying cardiovascular causes of ED and the benefits of diet and lifestyle interventions","Require ED drug manufacturers to include a label on all product packaging stating that erectile dysfunction is caused by artery disease, which this drug does not cure, and that a plant-based diet, exercise, stress management, and smoking cessation can improve or reverse the condition","Erectile dysfunction is strongly associated with cardiovascular disease, sharing common risk factors and underlying mechanisms such as atherosclerosis. ED drugs temporarily address symptoms without treating root causes. Evidence from scientific studies shows that lifestyle changes can prevent, improve, or reverse both cardiovascular disease and ED, leading to better long-term outcomes and reduced healthcare costs",,,2025-10-15,0.0,,,,,no decision,False,2074.0,pending,pending
fda-2020-p-0725,FDA-2020-P-0725-0001_Citizen_Petition_from_GBUK_Group_Ltd.pdf,2020-02-11,2020,False,original petition,GBUK Group Ltd.,industry/corporation,'Deciding When to Submit a 510(k) for a Change to an Existing Device',FDA‚Äôs labeling requirements mandating that medical devices be supplied with adequate directions for use,Remove the requirement for directions for use to be supplied with the medical devices and accessories listed in premarket submission K170371,"The devices are prescription-only, intended for professional use, and their usage is considered commonly known within the medical field. Required labeling elements such as device use, route of administration, and single-use instructions are already present on the packaging. Removing printed directions would reduce material waste without compromising safety or effectiveness","July 18, 2020",,2025-10-15,1.0,,,"The FDA issued an interim response because the petitions raised issues that require further review and analysis. As a result, the agency has not yet reached a final decision and will respond once the review is complete.",,no decision,False,2073.0,pending,pending
fda-2020-p-0734,FDA-2020-P-0734-0001_Citizen_Petition_from_GBUK_Group_Ltd.pdf,2020-02-11,2020,False,original petition,GBUK Group Ltd.,industry/corporation,'Deciding When to Submit a 510(k) for a Change to an Existing Device',FDA‚Äôs requirement that medical devices be supplied with adequate directions for use,Remove the requirement for supplying directions for use with the medical devices and accessories listed in premarket submission K170900,"The devices are prescription-only, for professional use, and their functions are well-known in clinical settings. All relevant usage instructions are included in the labeling, including symbols for sterility, single use, and intended neuraxial route. The visual design (e.g., yellow color coding) aligns with industry standards for neuraxial use and helps prevent misuse. Eliminating printed directions will reduce environmental waste without impacting safety or effectiveness","July 18, 2020",,2025-10-15,1.0,,,"The FDA issued an interim response because the petitions requested exemptions from instructions for use (IFU) requirements for certain medical devices, which raised issues requiring further review and analysis. Therefore, the agency has not yet made a final decision on the petitions.",,no decision,False,2073.0,pending,pending
fda-2020-p-0745,FDA-2020-P-0745-0001_Citizen_Petition_from_Fox_Rothschild_LLP.pdf,2020-02-11,2020,False,original petition,Fox Rothschild LLP,law/consulting,'Referencing Approved Drug Products in ANDA Submissions',"FDA‚Äôs designation of ANDA 074761 (held by Mylan Pharmaceuticals Inc.) as the reference standard for Ketorolac Tromethamine Tablets, 10 mg, which is commercially unavailable","Designate ANDA 074754 (held by Teva Pharmaceuticals USA Inc.) as the new reference standard for Ketorolac Tromethamine Tablets, 10 mg","The current reference standard is not commercially available, which obstructs ANDA development. Teva‚Äôs version (ANDA 074754) leads the U.S. market in unit sales and is one of only two marketed products. FDA guidance allows for a new RS designation under such circumstances to maintain market competition and access",,Dismissed as moot,2020-05-14,0.0,Center for Drug Evaluation and Research (CDER),Not Mentioned,,"The FDA dismissed the petition as moot because the requested action‚Äîdesignating Ketorolac Tromethamine Tablets, 10 mg (ANDA 074754), held by Teva Pharmaceuticals USA Inc., as a reference standard in the Orange Book‚Äîhad already been completed by the time of the response. The Orange Book had been updated to reflect the designation, fulfilling the petition's request.",dismissed (moot),True,93.0,CDER,CDER
fda-2020-p-0763,FDA-2020-P-0763-0001_Citizen_Petition_from_Clark_Anderson.pdf,2020-02-12,2020,False,original petition,"Clark L. Anderson, M.D.",individual,"Federal Food, Drug, and Cosmetic Act; 21 C.F.R. ¬ß 10.30; 21 C.F.R. ¬ß¬ß 25.30, 25.31, 25.32, 25.33, 25.34 (environmental impact exclusions)","FDA‚Äôs approval of tolvaptan (NDA 204441) for treatment of autosomal dominant polycystic kidney disease (ADPKD), approved April 23, 2018",Revoke FDA approval of tolvaptan for treatment of ADPKD,"The petitioner argues that the clinical studies supporting tolvaptan‚Äôs approval were flawed, misleading, and failed to demonstrate true therapeutic benefit. He asserts that the FDA review was superficial and unduly relied on sponsor conclusions. Further, the drug poses serious risks that led to stringent usage restrictions by both FDA and EMA, suggesting it is too dangerous and ineffective to remain approved",,Denied,2021-07-19,0.0,Center for Drug Evaluation and Research (CDER),"21 U.S.C. 355(a), 21 U.S.C. 355(b)(1), 21 U.S.C. 355(d), 21 U.S.C. 355(e), 21 U.S.C. 355-1, 21 CFR 314.50, 21 CFR 314.105, 21 CFR 314.126, 21 CFR 314.150",,"The FDA denied the petition to revoke approval of Jynarque (tolvaptan) for ADPKD. The agency concluded that the drug was approved based on substantial evidence from two adequate and well-controlled clinical trials (TEMPO and REPRISE), which showed statistically significant slowing of kidney function decline. Despite concerns about safety, particularly hepatotoxicity, a Risk Evaluation and Mitigation Strategy (REMS) program was implemented to manage those risks. FDA also found no new evidence warranting withdrawal of approval and affirmed that patients should make informed decisions in consultation with certified healthcare providers under the REMS program.",denied,True,523.0,CDER,CDER
fda-2020-p-0813,FDA-2020-P-0813-0001_Citizen_Petition_from_Unichem_Pharmaceuticals__USA.pdf,2020-02-13,2020,False,original petition,"Unichem Pharmaceuticals (USA), Inc.",industry/corporation,"21 C.F.R. ¬ß¬ß 10.25(a), 10.30, 314.161; Federal Food, Drug, and Cosmetic Act (FD&C Act)","FDA‚Äôs current listing of TENEX¬Æ (Guanfacine Hydrochloride) Tablets, 1 mg and 2 mg, NDA 019032, in the Orange Book and its availability for use as a reference listed drug","Determine whether TENEX¬Æ (Guanfacine Hydrochloride) Tablets, 1 mg and 2 mg, NDA 019032 held by Promius Pharma LLC, were withdrawn from the market for reasons of safety or effectiveness","A determination is needed to confirm if TENEX¬Æ was withdrawn voluntarily for business reasons or due to safety or effectiveness concerns. This decision affects whether it can be referenced in future ANDA submissions, which impacts generic drug market entry",,Determined that the drug was not withdrawn for safety or effectiveness reasons,2020-06-24,0.0,Center for Drug Evaluation and Research (CDER),Not Mentioned,,"The FDA reviewed its records and determined that TENEX (guanfacine hydrochloride) tablets, 1 mg, 2 mg, and 3 mg, were not withdrawn from sale for reasons related to safety or effectiveness. As a result, these products will remain listed in the 'Discontinued Drug Product List' section of the Orange Book.",withdrawn,True,132.0,CDER,CDER
fda-2020-p-0893,FDA-2020-P-0893-0001_Citizen_Petition_from_Fisher_Wallace_Laboratories_.pdf,2020-02-20,2020,False,original petition,"Fisher Wallace Laboratories, Inc.",advocacy/academic,"21 C.F.R. ¬ß 10.30; 21 C.F.R. ¬ß¬ß 860.132, 860.123, 882.5800; Section 513 and 515 of the Federal Food, Drug, and Cosmetic Act","FDA‚Äôs Final Order of December 20, 2019, requiring PMA for CES devices intended to treat depression and imposing special controls for treatment of anxiety and insomnia","Withdraw the Final Order and convene a new Neurological Devices Panel to consider all valid scientific evidence (including direct current CES data), or alternatively, reissue the order with CES devices reclassified to class II with reasonable special controls","The petitioner argues that FDA's Final Order was based on a flawed panel process that excluded valid scientific data from direct current CES devices, misrepresented device risks, and imposed burdensome requirements without justifying them based on actual safety concerns. They highlight that CES devices have a long history of low risk, and FDA‚Äôs inconsistent treatment (e.g., more lenient standards for ECT) suggests bias and procedural misconduct. The petitioner claims that a scientifically and procedurally valid reassessment is necessary to ensure fair regulatory treatment",,,2025-10-15,0.0,,,,,no decision,False,2064.0,pending,pending
fda-2020-p-0945,FDA-2020-P-0945-0001_Citizen_Petition_from_Dr__Ernest_C__Chisena_and_Dr.pdf,2020-02-25,2020,False,original petition,Dr. Ernest C. Chisena and Dr. Jahangir S. Rastegar,individual,"21 C.F.R. ¬ß¬ß 10.30, 25.30, 25.31, 25.32, 25.33, 25.34; Federal Food, Drug, and Cosmetic Act",FDA‚Äôs approval of the Exogen Ultrasound Bone Healing System (LIPUS) under PMA P900009 based on studies asserting it enhances fracture healing,"Re-evaluate the approval of LIPUS devices by requiring Exogen-Bioventus to prove that ultrasound, and not soft tissue pressure, is the causal mechanism enhancing fracture healing","The petitioners argue that the clinical studies supporting LIPUS failed to control for or measure soft tissue pressure, which may be the actual factor responsible for accelerated healing. They cite basic science and animal studies, clinical experience, and recent negative trials questioning LIPUS efficacy, suggesting that increased soft tissue pressure, not ultrasound, could explain healing benefits. Clarifying the actual mechanism is critical for optimizing patient care","July 18, 2020",,2025-10-15,1.0,,,"The FDA issued an interim response because the petition raised complex issues regarding the effectiveness of the Exogen Ultrasound Bone Healing System, specifically questioning whether ultrasound or increased soft tissue pressure enhances fracture healing. These issues require further review and analysis before a final decision can be made.",,no decision,False,2059.0,pending,pending
fda-2020-p-0947,FDA-2020-P-0947-0001_Citizen_Petition_from_Hyman__Phelps_and_McNamara__.pdf,2020-02-24,2020,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"Section 505(j) of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. ¬ß¬ß 10.20, 10.30, 314.3, 25.31","FDA‚Äôs Orange Book listing for Neostigmine Methylsulfate Injection Solution, NDA 203629, lacking designations as a Reference Listed Drug (RLD) and Reference Standard (RS)",Amend the Orange Book to designate NDA 203629 (Neostigmine Methylsulfate Injection Solution) as both a Reference Listed Drug and a Reference Standard,"Without RLD and RS designations, NDA 203629 is shielded from generic competition despite being a single-source drug. The petitioner argues that such designations are appropriate and necessary for facilitating ANDA submissions, and that FDA guidance allows either controlled correspondence or a citizen petition as valid mechanisms to request these changes",,Dismissed as moot,2020-09-18,0.0,Center for Drug Evaluation and Research (CDER),Not Mentioned,,"The FDA dismissed the petition as moot because the requested actions had already been completed. Specifically, the Orange Book had been updated to designate neostigmine methylsulfate solution, 3 mg/3 mL (NDA 203629, Fresenius Kabi), as both a Reference Listed Drug (RLD) and a Reference Standard (RS), fulfilling the petitioner‚Äôs request.",dismissed (moot),True,207.0,CDER,CDER
fda-2020-p-0978,FDA-2020-P-0978-0001_Citizen_Petition_from_Valisure__LLC_.pdf,2020-03-02,2020,False,original petition,Valisure LLC and ValisureRX LLC,industry/corporation,"21 U.S.C. ¬ß¬ß 331, 351, 352, 355, 372, 374, 375; 21 C.F.R. ¬ß¬ß 10.20, 10.30, 25.30","FDA‚Äôs oversight of metformin contamination with N-Nitrosodimethylamine (NDMA) and current regulatory practices around testing, recalls, and guidance",1) Request recall of metformin batches containing NDMA above acceptable limits; 2) Conduct investigations under FDCA ¬ß¬ß 702 and 704; 3) Inform the public under ¬ß 705; 4) Revise guidance FY20-058-DPA-S to improve detection methodology; 5) Issue regulations requiring batch-level chemical testing of drug products,"Valisure detected NDMA, a probable human carcinogen, in multiple batches of metformin using improved LC-HRMS methods. Some batches exceeded FDA‚Äôs acceptable daily intake by over 10 times. Valisure argues that FDA‚Äôs current testing protocols may underestimate NDMA levels, and that lack of batch-level oversight enables contaminated products to reach patients. Independent testing and stricter regulatory actions are necessary to ensure pharmaceutical safety",,,2025-10-15,0.0,,,,,no decision,False,2053.0,pending,pending
fda-2020-p-0983,FDA-2020-P-0983-0001_Citizen_Petition_from_grBiosystems_Inc_.pdf,2020-02-26,2020,False,original petition,grBiosystems Inc.,industry/corporation,"21 C.F.R. ¬ß 355.70(a), ¬ß 355.70(c); 21 C.F.R. ¬ß 10.30; 21 C.F.R. Part 20",FDA‚Äôs requirement for biological testing of fluoride dentifrices using animal caries reduction models under ¬ß 355.70(a),Grant permission to use the Featherstone laboratory pH cycling model as an alternative to the animal testing requirement for fluoride dentifrices,"grBiosystems, which opposes animal testing on ethical grounds, seeks to use the Featherstone pH cycling model as a validated in vitro alternative. This model has been shown to provide equivalent accuracy to the rat caries model, fulfilling the regulatory criteria under ¬ß 355.70(c). It demonstrates proportional fluoride response, performance of clinically validated formulations, and sensitivity to reduced fluoride activity, supporting its robustness and relevance",,Denied,2023-05-09,0.0,Center for Drug Evaluation and Research (CDER),"21 U.S.C. 355h (Section 505G of the FD&C Act), 21 U.S.C. 353(b)(1), 21 U.S.C. 321(p)(1), 21 U.S.C. 379j-71(7), 21 CFR Part 355",,"The FDA denied the petition because the legal framework for over-the-counter (OTC) monograph drugs changed with the enactment of the CARES Act, which introduced Section 505G to the FD&C Act. Under the new framework, changes to testing procedures for OTC drugs such as the proposed use of the Featherstone laboratory pH cycling model for stannous fluoride toothpaste must be submitted through the OTC Monograph Order Request (OMOR) process. Therefore, the citizen petition process is no longer the appropriate mechanism for this request.",denied,True,1168.0,CDER,CDER
fda-2020-p-1003,FDA-2020-P-1003-0001_Citizen_Petition_from_John_J__Coleman___M_A___M_S_.pdf,2020-02-25,2020,False,original petition,"Dr. John J. Coleman, M.A., M.S., Ph.D.",individual,"21 C.F.R. ¬ß 10.30; FDA's 1997 'Convenience Kits Interim Regulatory Guidance'; Federal Food, Drug, and Cosmetic Act ¬ß 510(k); 21 C.F.R. ¬ß 25.34",FDA‚Äôs 1997 policy that exempted fever thermometers (as part of 'convenience kits') from premarket clearance,"Initiate rulemaking procedures to require premarket clearance for all fever thermometers sold over-the-counter in the U.S., including certification of device technology, accuracy, and safety","The petitioner highlights the proliferation of poorly regulated, inaccurate infrared thermometers‚Äîparticularly those manufactured overseas‚Äîand the critical role these devices play during public health emergencies like COVID-19. He argues that the exemption from regulatory oversight established in 1997 is outdated and insufficient for ensuring public safety, given changes in the marketplace and technology","June 8, 2020",,2025-10-15,1.0,,,"The FDA issued an interim response because the petition raises complex issues regarding the regulation and premarket clearance of fever thermometers, including requests for rulemaking to mandate certification of safety, accuracy, and technology of these devices. These issues require further review and analysis, and a final decision has not yet been reached.",,no decision,False,2059.0,pending,pending
fda-2020-p-1016,FDA-2020-P-1016-0001_Citizen_Petition_from_CellTrion__Inc_.pdf,2020-03-03,2020,False,original petition,"Celltrion, Inc.",industry/corporation,"Section 505(j) of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. ¬ß¬ß 10.25(a), 10.30, 25.31(a), 25.15(d); FDA Draft Guidance (January 2017) on Referencing Approved Drug Products in ANDA Submissions",FDA‚Äôs current reference standard designation for Ropinirole Hydrochloride Extended-Release Tablets (Requip XL 2 mg) listed in the Orange Book,"Designate Ropinirole Hydrochloride Extended Release Tablets, 2 mg, ANDA 201576 (Dr. Reddy‚Äôs Laboratories Ltd) as the new reference standard","The currently designated RS (Requip XL 2 mg) is unavailable in the market, as confirmed by pharmacies, labeling updates, NDC directory absence, and IQVIA data. This unavailability prevents the petitioner from conducting in vivo bioequivalence studies necessary for post-approval supplements. Dr. Reddy‚Äôs product is the market leader and is therapeutically equivalent, making it a suitable RS replacement",,,2025-10-15,0.0,,,,,no decision,False,2052.0,pending,pending
fda-2020-p-1052,FDA-2020-P-1052-0001_Citizen_Petition_from_National_Tobacco_Reform_Init.pdf,2020-03-06,2020,False,original petition,National Tobacco Reform Initiative (NTRI),advocacy/academic,"21 C.F.R. ¬ß 10.30; 21 C.F.R. ¬ß¬ß 25.30, 25.31, 25.32, 25.33, 25.34; Family Smoking Prevention and Tobacco Control Act; Food, Drug, and Cosmetic Act; Public Law 111‚Äì31",FDA/CTP‚Äôs implementation of its 2017 comprehensive nicotine-focused tobacco regulatory strategy and the current regulatory framework governing nicotine and tobacco products under the Tobacco Control Act,"Adopt a science-based, flexible regulatory framework based on a continuum of risk across nicotine products; modernize the Tobacco Control Act; implement nicotine product standards; allow innovation in lower-risk alternatives; convene national stakeholder dialogues; and promote public education on nicotine risks and benefits","The petition argues that the current tobacco regulatory framework is outdated, overly burdensome, and biased toward maintaining cigarette dominance while hindering access to lower-risk alternatives. It calls for urgent FDA/CTP action to reduce smoking-related diseases and deaths by modernizing the statute, supporting innovation, regulating based on relative risk, and engaging diverse stakeholders in civil dialogue to craft evidence-based solutions",,,2025-10-15,0.0,,,,,no decision,False,2049.0,pending,pending
fda-2020-p-1065,FDA-2020-P-1065-0001_Citizen_Petition_from_B__Braun_Medical_Inc_.pdf,2020-03-10,2020,False,original petition,B. Braun Medical Inc.,industry/corporation,"21 C.F.R. ¬ß¬ß 10.25(a), 10.30; 21 C.F.R. ¬ß 25.31",FDA‚Äôs omission of therapeutic equivalence (TE) ratings for B. Braun‚Äôs NDA 505(b)(2) injectable drug products in the Orange Book,Add the therapeutic equivalence code 'AP' to all B. Braun injectable drug products listed in Appendix 1 of the petition within the Orange Book,"The listed products are injectable solutions or powders for solution with no known or suspected bioequivalence issues. FDA‚Äôs own Orange Book guidelines allow for assignment of TE codes, including 'AP', for such products. TE ratings are critical for market competitiveness and generic substitution, and a citizen petition is the appropriate channel for requesting such designations",,Determined that the drug was not withdrawn for safety or effectiveness reasons,2020-09-02,0.0,Center for Drug Evaluation and Research (CDER),Not Mentioned,,"The FDA concluded that Potassium Chloride in 0.9% Sodium Chloride Injection, USP (2 mEq/mL) in the 1000 mL container was not withdrawn from sale for reasons related to safety or effectiveness. Therefore, the drug will remain listed in the 'Discontinued Drug Product List' section of the Orange Book.",withdrawn,True,176.0,CDER,CDER
fda-2020-p-1072,FDA-2020-P-1072-0001_Citizen_Petition_from_Yiling_Pharmaceutical__LTD_.pdf,2020-03-10,2020,False,original petition,Yiling Pharmaceutical Ltd.,industry/corporation,"21 C.F.R. ¬ß¬ß 10.25(a), 10.30, 314.161, 314.162","FDA‚Äôs listing of ZOVIRAX¬Æ (acyclovir) Oral Capsule 200 mg, NDA 018828, in the discontinued section of the Orange Book",Request that the FDA determine whether ZOVIRAX¬Æ (acyclovir) Oral Capsule 200 mg was withdrawn for reasons of safety or effectiveness,The petitioner believes the drug was likely withdrawn from sale by Mylan for commercial reasons rather than safety or effectiveness. A determination is necessary for the approval of an ANDA referring to ZOVIRAX¬Æ as the Reference Listed Drug (RLD). The petitioner notes that the product currently has no evidence of active marketing and seeks FDA clarification,,,2025-10-15,0.0,,,,,no decision,False,2045.0,pending,pending
fda-2020-p-1073,FDA-2020-P-1073-0001_Citizen_Petition_from_David_Behar__M_D__Redacted.pdf,2020-03-09,2020,False,original petition,"David Behar, M.D.",individual,"21 C.F.R. ¬ß 10.30; Section 505-1 of the FD&C Act; 21 C.F.R. ¬ß¬ß 25.30, 25.31, 25.32, 25.33, 25.34; 21 C.F.R. ¬ß 10.40(e)(1); 5 U.S.C. ¬ß 553(b)(B)",FDA‚Äôs Risk Evaluation and Mitigation Strategy (REMS) program for clozapine and related mandatory blood monitoring requirements,1) Decommission the Clozapine REMS program; 2) Remove the certification requirement for healthcare providers prescribing clozapine; 3) Modify clozapine‚Äôs labeling to defer monitoring decisions to clinical judgment,"The petitioner argues that the REMS program is based on outdated safety concerns and imposes undue burdens on patients and providers. Clozapine is highly effective for treatment-resistant schizophrenia and suicide prevention, yet its usage is limited by REMS-related barriers. Comparable or riskier medications are not subject to such stringent oversight. The petition also raises constitutional concerns about discrimination and undue burden, asserting that mandatory blood monitoring deters use and negatively affects public health outcomes. Decommissioning REMS would improve access to care and align with regulatory fairness and clinical practice standards",,,2025-10-15,0.0,,,,,no decision,False,2046.0,pending,pending
fda-2020-p-1074,FDA-2020-P-1074-0001_Citizen_Petition_from_Akorn_Animal_Health_Inc.pdf,2020-03-10,2020,False,original petition,Akorn Animal Health Inc.,industry/corporation,"21 U.S.C. ¬ß 360b(n)(3) [Section 512(n)(3) of the FD&C Act]; 21 C.F.R. ¬ß¬ß 10.20, 10.30, 25.31",FDA‚Äôs regulation regarding the approval of Abbreviated New Animal Drug Applications (ANADAs) where the proposed generic differs in strength from the Reference Listed New Animal Drug (RLNAD),"Grant permission for Akorn to pursue an ANADA for a generic version of Corticosporin¬Æ Veterinary Ophthalmic Ointment with a different strength of Polymixin B sulfate (increased from 5,000 units/g to 10,000 units/g)","The change in strength is supported by the approval and marketing of a therapeutically equivalent veterinary product (Vetropolycin¬Æ HC) with the same active ingredients and dosage. The proposed change does not impact safety or effectiveness and is consistent with regulatory allowances under Section 512(n)(3), which permits applications with differences in strength",,,2025-10-15,0.0,,,,,no decision,False,2045.0,pending,pending
fda-2020-p-1236,FDA-2020-P-1236-0001_Citizen_Petition_from_Foley___Lardner_LLP.pdf,2020-03-30,2020,False,original petition,Foley & Lardner LLP,law/consulting,"21 C.F.R. ¬ß 10.30; 21 C.F.R. ¬ß 25.1(g); Section 505(j) of the Federal Food, Drug, and Cosmetic Act",FDA‚Äôs current designation of NDA N021539 (ACETADOTE) as the reference listed drug for Acetylcysteine Injection 6gm/30mL in the Orange Book,"Designate ANDA 200644, Acetylcysteine Injection 6gm/30mL by Fresenius Kabi USA LLC, as a reference standard and reference listed drug in the FDA‚Äôs Orange Book","All currently approved ANDAs for Acetylcysteine Injection 6gm/30mL contain edetate disodium, while the reference product ACETADOTE no longer does. The petitioner argues that the change does not reflect a safety or efficacy withdrawal, and that ANDA 200644 is representative of the marketed formulations and should serve as the standard for ANDA submissions",,Denied,2020-09-25,0.0,Center for Drug Evaluation and Research (CDER),"21 CFR 314.3(b), 21 CFR 314.50, 21 CFR 314.94(a), 21 CFR 320.23, 21 CFR 320.24, 21 CFR 320.25, 21 CFR 320.26, 21 CFR 320.27, 21 CFR 320.28, 21 CFR 314.127(a)(6)(i), 21 CFR 10.30",,"The FDA denied the petition because the petitioner‚Äôs requests for modifying requirements for demonstrating bioequivalence (BE) of generic oral contraceptives were found to be inconsistent with current scientific standards and regulatory policy. FDA maintained that pharmacokinetic (PK) endpoints are the most sensitive and accurate method for evaluating BE. The agency stated that other proposed methods, including pharmacodynamic endpoints and real-world evidence, are not sufficiently validated for routine use in BE assessments for contraceptives. The FDA concluded that its current PK-based approach remains scientifically justified and appropriate.",denied,True,179.0,CDER,CDER
fda-2020-p-1237,FDA-2020-P-1237-0001_Citizen_Petition_from_Wiley_Rein__LLP.pdf,2020-03-30,2020,False,original petition,Wiley Rein LLP,law/consulting,"21 C.F.R. ¬ß 10.30; 21 C.F.R. ¬ß¬ß 25.30, 25.31, 25.32, 25.33, 25.34","FDA‚Äôs approval of the Rx-to-OTC switch for Voltaren Arthritis Pain (diclofenac sodium topical gel 1%), NDA 22122/S-14","Withdraw or rescind FDA‚Äôs approval of NDA 22122/S-14 for OTC Voltaren Arthritis Pain, or alternatively revise its OTC labeling to incorporate safety warnings from the prior prescription labeling","The petitioner argues that essential safety information from the prescription labeling‚Äîsuch as risks of concomitant NSAID use, anaphylaxis, hematologic toxicity, sun exposure sensitivity, drug interactions (e.g., digoxin), fertility warnings, and infection masking‚Äîwas omitted from the OTC labeling. This may mislead consumers and jeopardize safe use, particularly during the COVID-19 pandemic where masking fever and inflammation could delay diagnosis",,Acknowledged receipt; no decision on merits,2020-03-31,0.0,Dockets Management Staff (FDA/Office of Operations),Not Mentioned,,The FDA acknowledged receipt of the petition requesting withdrawal or rescission of approval for NDA 22122/S-14 (OTC Voltaren Arthritis Pain Gel) due to concerns over insufficient safety labeling for consumers. The letter clarifies that this acknowledgment is procedural and does not reflect any decision on the substantive merits of the petition.,other,True,1.0,DMS,Other/Specialty Center
fda-2020-p-1243,FDA-2020-P-1243-0001_Citizen_Petition_from_Varun_Varada_Redacted.pdf,2020-04-02,2020,False,original petition,Varun Varada,individual,"21 U.S.C. ¬ß 343(q); 21 C.F.R. ¬ß 10.30; 21 C.F.R. ¬ß¬ß 25.30, 25.32; proposed amendment to 21 C.F.R. ¬ß 101.9(d)(7)(i)","FDA‚Äôs nutrition labeling regulation that omits a space between numeric values and unit symbols (e.g., '2mg' instead of '2 mg') on Nutrition Facts labels","Amend 21 C.F.R. ¬ß 101.9(d)(7)(i) to require a space character between the numerical quantity and the unit symbol (e.g., '2 mg', '3 g')","The petitioner argues that SI units must be formatted with a space between the value and the unit symbol per international standards such as the SI Brochure, IEEE/ASTM SI 10-2016, and NIST SP 330. Current FDA formatting contradicts proper metric usage and could cause confusion, whereas FDA labeling formats already accommodate such spacing per 21 C.F.R. ¬ß 101.9(d)(12)",,,2025-10-15,0.0,,,,,no decision,False,2022.0,pending,pending
fda-2020-p-1246,FDA-2020-P-1246-0001_Citizen_Petition_from_Fresenius_KabiUSA__LLC.pdf,2020-04-02,2020,False,original petition,"Fresenius Kabi USA, LLC",industry/corporation,"Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. ¬ß¬ß 10.30, 25.31",FDA‚Äôs therapeutic equivalence designation for acetaminophen injection products listed in the Orange Book,"Designate Fresenius Kabi‚Äôs Acetaminophen Injection 10 mg/mL (NDA 204767) as therapeutically equivalent to Ofirmev¬Æ (NDA 022450), with an ‚ÄòAP‚Äô rating","Fresenius Kabi‚Äôs product is pharmaceutically equivalent to Ofirmev¬Æ in terms of strength, dosage form, route of administration, active ingredient, and indications for use. The only difference is in buffer composition, which is permitted under 21 C.F.R. ¬ß 314.94(a)(9)(iii) and does not affect safety or efficacy. The product meets all standards for therapeutic equivalence and relied on the RLD‚Äôs safety and efficacy data for approval",,Denied,2023-08-16,0.0,Center for Drug Evaluation and Research (CDER),"21 CFR 314.3(b), 21 U.S.C. 355, Orange Book references, Orange Book Preface, Orange Book TE Code guidance",,"The FDA denied the petition to designate Fresenius Kabi‚Äôs acetaminophen intravenous solution as therapeutically equivalent to Ofirmev, primarily because Ofirmev is listed in the Discontinued Drug Product List section of the Orange Book. According to FDA policy, TE (Therapeutic Equivalence) Codes are only assigned to products listed in the Active Section of the Orange Book. Since Ofirmev is not actively marketed, it cannot serve as a reference for assigning a TE Code. Therefore, FDA declined the request and did not further assess the therapeutic equivalence of the Fresenius product.",denied,True,1231.0,CDER,CDER
fda-2020-p-1247,FDA-2020-P-1247-0001_Citizen_Petition_from_Belcher_Pharmaceuticals__LLC.pdf,2020-03-31,2020,False,original petition,"Belcher Pharmaceuticals, LLC",industry/corporation,"21 U.S.C. ¬ß 355(j); 21 C.F.R. ¬ß¬ß 10.20, 10.30, Part 320, 25.31","FDA‚Äôs therapeutic equivalence evaluations in the Orange Book for tacrolimus oral capsule ANDAs, specifically regarding bioequivalence testing requirements introduced in the December 2012 Tacrolimus Guidance",1) Require pre-December 2012 tacrolimus ANDA sponsors to conduct bioequivalence studies using the 2012 Tacrolimus Guidance; 2) Reclassify any noncompliant products from 'AB' to 'BX' in the Orange Book if they fail to meet updated standards,"Belcher argues that tacrolimus was reclassified by FDA in 2012 as a narrow therapeutic index (NTI) drug, requiring more rigorous bioequivalence testing, including four-way fully-replicated crossover studies. Earlier ANDAs were approved using less stringent methods, creating a potential safety risk if considered interchangeable. Updating their TE rating to BX would reflect these differences and inform clinical decision-making",,Partially approved and partially denied,2023-09-18,0.0,Center for Drug Evaluation and Research (CDER),"21 CFR 314.3(b), 21 CFR 320.24, 21 CFR 320.33(c), 21 CFR 10.30, 21 CFR 314.94(a), 21 CFR 314.127(a)(6)(i), 21 U.S.C. 355(j), Federal Food, Drug, and Cosmetic Act, Hatch-Waxman Amendments",,"The FDA partially granted the petition by agreeing to change the therapeutic equivalence (TE) code of ANDA 091195 from AB to BX based on a BioPharma study that failed to demonstrate bioequivalence to the reference listed drug (RLD). However, the FDA denied the broader request to mandate retesting of all ANDAs for tacrolimus oral capsules approved before December 2012 using updated bioequivalence standards, citing a lack of evidence suggesting therapeutic inequivalence for those products. The agency emphasized that bioequivalence for those products was established at the time of their approval, and no new data warranted retroactive application of new testing standards.",partially approved / denied,True,1266.0,CDER,CDER
fda-2020-p-1248,FDA-2020-P-1248-0001_Citizen_Petition_from_Mark_Miles_Redacted.pdf,2020-03-16,2020,False,original petition,Mark Miles,individual,"21 C.F.R. 10.30, 21 C.F.R. 201.57 (a)(10), 201.57 (a)(11), 505 of the Federal Food, Drug, and Cosmetic Act","FDA labeling and approval process for drugs‚Äîespecially statements of safety, efficacy, and causational mechanisms in nephrotic syndrome",Issue corrective warnings and labeling changes to identify podocytopathy (not immune-mediated mechanisms) as the cause of nephrotic syndrome for a wide list of drugs; revoke or deny approval to drugs found to have been approved on false or misleading evidence; and halt promotion of such drugs until corrections are made,"The petitioner argues that many FDA-approved drugs list false or misleading information regarding nephrotic syndrome as being immune-mediated when federal courts and medical experts have established that the true mechanism is podocytopathy. Continued mislabeling misinforms healthcare providers and patients, undermines informed consent, and poses risks of inappropriate treatment. The FDA is urged to act based on scientific accuracy and legal precedent to correct these misstatements",,,2025-10-15,0.0,,,,,no decision,False,2039.0,pending,pending
fda-2020-p-1251,FDA-2020-P-1251-0001_Citizen_Petition_from_Varun_Verada_Redacted.pdf,2020-04-04,2020,False,original petition,Varun Varada,individual,"21 U.S.C. ¬ß 343(q); 21 C.F.R. ¬ß 10.30; 21 C.F.R. ¬ß¬ß 25.30, 25.32","FDA‚Äôs labeling practices across all areas (not just drug labeling), specifically the requirement to use 'mcg' as the abbreviation for micrograms on product labels such as Nutrition Facts and Supplement Facts","Amend all parts of 21 C.F.R. that require the abbreviation 'mcg' for micrograms to instead require the official SI symbol 'Œºg'; for contexts involving handwriting (e.g., prescriptions), recommend writing 'micrograms' in full or using 'ug' as an alternative","The petitioner argues that 'mcg' is not a valid SI symbol and contradicts international standards (e.g., SI Brochure, IEEE/ASTM SI 10, NIST SP 330). The use of 'mcg' arose from medical field concerns about handwritten errors but is misapplied to printed labeling in nutrition and other non-medical contexts. This inconsistency causes public confusion, educational inefficiencies, and inter-agency discord, as other government entities (e.g., USDA, NIST) use 'Œºg'. Standardizing on 'Œºg' aligns with global norms and enhances communication",,Acknowledged receipt; no decision on merits,2020-04-06,0.0,Dockets Management Staff (FDA/Office of Operations),Not Mentioned,,The FDA acknowledged receipt of a petition requesting that all references to the abbreviation 'mcg' for micrograms in 21 CFR be replaced with the symbol '¬µg' or the full word 'micrograms'. The letter clarified that the acceptance of the petition is procedural and does not reflect any decision on its substantive merits.,other,True,2.0,DMS,Other/Specialty Center
fda-2020-p-1260,FDA-2020-P-1260-0001_Citizen_Petition_from_Foley___Lardner_LLP.pdf,2020-04-06,2020,False,original petition,Foley & Lardner LLP,law/consulting,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. ¬ß¬ß 314.93, 10.25(a), 10.30, 25.31",FDA‚Äôs Orange Book reference standard (RS) designation for Proparacaine Hydrochloride Ophthalmic Solution 0.5%,"Designate ALCAINE (Proparacaine Hydrochloride) Ophthalmic Solution 0.5%, ANDA #A080027 held by Alcon Laboratories Inc., as an additional reference standard (RS)","The current RS (ANDA #A040277 by Akorn Inc.) is on backorder and unavailable in the U.S. market. The proposed product (ALCAINE, ANDA #A080027) is available and was previously listed as an RS before being delisted. Designating it again as an RS would facilitate comparative studies for ANDA development, as permitted by FDA‚Äôs 2017 draft guidance on referencing approved drug products","October 1, 2020",,2025-10-15,1.0,,,"The FDA issued an interim response to the petition regarding regulatory actions related to a drug product, indicating that the petition raises complex issues that require additional time for review. The agency stated it has not yet reached a decision on the merits of the petition and will respond fully once the review is complete.",,no decision,False,2018.0,pending,pending
fda-2020-p-1297,FDA-2020-P-1297-0001_Citizen_Petition_from_Joe_DiNardo_Redacted.pdf,2020-04-09,2020,False,original petition,Joe DiNardo,individual,"21 C.F.R. ¬ß 10.30; 21 C.F.R. ¬ß¬ß 25.30, 25.31, 25.32, 25.33, 25.34; 21 U.S.C. ¬ß 393(b)(1), (b)(2), and (b)(3)","FDA‚Äôs regulation of benzene contamination in consumer products, especially hand sanitizers, sunscreens, and aerosol body sprays",1) Set a maximum daily allowable limit for benzene exposure of 0.1 ppm in all FDA-regulated drug and cosmetic products; 2) Require warning labels for any product containing detectable benzene; 3) Mandate benzene testing for high-risk product categories; 4) Ban the use of contaminated ingredients from suppliers previously associated with benzene-tainted products,The petitioner argues that benzene is a known human carcinogen with no safe level of exposure and that FDA has not adequately protected public health despite evidence of benzene contamination in numerous consumer products. Current limits based on inhalation exposure and outdated thresholds fail to consider cumulative dermal absorption and product misuse. Stronger regulations are needed to fulfill FDA‚Äôs mission to ensure safety and public health,,Denied,2021-09-24,0.0,Center for Drug Evaluation and Research (CDER),Not Mentioned,,The FDA denied the petition submitted by Joe DiNardo because it did not present sufficient evidence to support the requested regulatory actions concerning the safety of a particular drug product. The agency reviewed the available data and concluded that the current regulatory framework and safety labeling were adequate. No changes were warranted based on the information provided in the petition.,denied,True,533.0,CDER,CDER
fda-2020-p-1305,FDA-2020-P-1305-0001_Citizen_Petition_from_Dr__Albert_Edwards___Redacte.pdf,2020-04-13,2020,False,original petition,Dr. Albert Edwards,individual,"21 C.F.R. ¬ß 10.30; 21 C.F.R. ¬ß¬ß 25.30, 25.31, 25.32, 25.33, 25.34; Federal Food, Drug, and Cosmetic Act ¬ß 502(a), (f), and (j); 5 U.S.C. ¬ß 553(e)","FDA‚Äôs labeling and regulatory policies for compounded drugs, particularly the lack of adequate warnings on the use of non-sterile compounded pharmaceuticals for intravitreal (intra-eye) injections","Amend labeling requirements to include a black box warning on compounded drugs that are not tested for sterility or ophthalmic safety but are administered intravitreally; additionally, require prescribers to obtain informed consent acknowledging risks of using non-FDA approved, non-sterile products for intravitreal injection","The petitioner raises concerns about patient safety, citing instances of blindness and serious eye infections caused by the use of non-sterile compounded drugs for intravitreal injection. He argues that FDA‚Äôs current policies fail to adequately protect patients, as many physicians are unaware of the risks. A black box warning and informed consent requirement would increase transparency and potentially prevent harm",,Acknowledged receipt; no decision on merits,2020-04-24,0.0,Dockets Management Staff (FDA/Office of Operations),Not Mentioned,,The FDA acknowledged receipt of a petition requesting the revocation or withdrawal of the Emergency Use Authorization (EUA) for hydroxychloroquine and similar or related drug products. The letter clarifies that acceptance of the petition is procedural and does not reflect any decision on the substantive merits of the request.,other,True,11.0,DMS,Other/Specialty Center
fda-2020-p-1312,FDA-2020-P-1312-0001_Citizen_Petition_from_Foley___Lardner_LLP_on_behal.pdf,2020-04-28,2020,False,original petition,Foley & Lardner LLP,law/consulting,"Section 505(b) of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. ¬ß¬ß 10.30, 314.50, 314.52, 314.54, 314.107, and 314.108",FDA's policy allowing ANDA or 505(b)(2) applicants to carve out patented labeling language from the approved labeling of Lonsurf¬Æ (specifically regarding dose adjustments for patients with severe renal impairment),1) Refrain from filing or approving any ANDA or 505(b)(2) NDA for generic versions of Lonsurf that omit labeling related to dose reductions in severely renally impaired patients; 2) Require generic versions to include all safety information present in the Lonsurf label,"The petitioner argues that excluding information about dose adjustments for severely renally impaired patients would make the generic version of Lonsurf less safe and potentially harmful. This information was added to the label following an FDA-mandated post-marketing study. Severe renal impairment significantly increases drug exposure, leading to a higher incidence of adverse reactions. Removing this information would deprive prescribers of critical guidance and put patients‚Äîespecially those relying on Lonsurf as a last-line treatment‚Äîat increased risk",,Acknowledged receipt; no decision on merits,2020-04-29,0.0,Dockets Management Staff (FDA/Office of Operations),"21 CFR 314.94(a)(8)(iv), Section 505(j)(2)(A)(viii) and Section 505(j)(5)(F) of the Federal Food, Drug, and Cosmetic Act",,The FDA acknowledged receipt of a petition requesting regulatory actions regarding the approval and labeling of generic versions of Lonsurf¬Æ Tablets. The letter clarified that the acceptance of the petition is procedural and does not reflect any decision on the substantive merits of the petition.,other,True,1.0,DMS,Other/Specialty Center
fda-2020-p-1334,FDA-2020-P-1334-0001_Citizen_Petition_from_Therapeutics_MD__Inc.pdf,2020-05-01,2020,False,original petition,"TherapeuticsMD, Inc.",industry/corporation,"21 C.F.R. ¬ß¬ß 10.30, 10.31; 21 U.S.C. ¬ß 355(j)(2)(A)(v); 21 C.F.R. ¬ß 314.94(a)(8)(iv); 21 U.S.C. ¬ß 355(b)(2); 21 C.F.R. ¬ß 314.3(b)","FDA's approval or receipt of any marketing application that references Imvexxy¬Æ, particularly ANDAs that do not meet certain equivalency criteria","TherapeuticsMD requests that the FDA refrain from receiving or approving any ANDA that references Imvexxy unless it matches the product in shape (teardrop), labeling (including IFU), and Q3 macro and microstructure. Alternatively, any such application should be submitted under the 505(b)(2) pathway. Additionally, the petitioner requests that the FDA issue product-specific guidance on these requirements.","The petitioner argues that the shape, formulation, and manufacturing quality attributes of Imvexxy are essential for therapeutic equivalence. Since Imvexxy acts locally and does not exhibit systemic absorption, standard bioequivalence testing via pharmacokinetics is not adequate. Therefore, to ensure therapeutic equivalence and patient safety, Q3 equivalence and identical IFUs must be required.","October 23, 2020",,2025-10-15,1.0,,,"The FDA issued an interim response stating that it has not yet reached a decision on the citizen petition concerning generic versions of Imvexxy (estradiol vaginal inserts). The petition raises complex issues requiring extensive review and analysis, including concerns over product labeling, manufacturing methods, and product-specific guidance. The agency will provide a full response once its review is complete.",,no decision,False,1993.0,pending,pending
fda-2020-p-1344,FDA-2020-P-1344-0001_Citizen_Petition_from_Lachman_Consultant_Services_.pdf,2020-05-05,2020,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"21 C.F.R. ¬ß¬ß 10.30, 314.161, 314.122, 25.31","FDA‚Äôs Orange Book listing and regulatory treatment of Cytoxan¬Æ (cyclophosphamide) Injection, NDA 012142, particularly regarding whether discontinued formulations were withdrawn for safety or effectiveness reasons","Determine that all discontinued formulations and strengths of Cytoxan¬Æ (cyclophosphamide) Injection under NDA 012142, including the dry powder excipient-free formulation, were not withdrawn for reasons of safety or effectiveness","The petitioner states that while FDA has made such determinations for several strengths and formulations of Cytoxan in the past, no such determination exists for all formulations. No evidence suggests any were withdrawn for safety or efficacy reasons. This determination is necessary to support ANDA filings referencing those discontinued products",,Determined that the drug was not withdrawn for safety or effectiveness reasons,2023-10-12,0.0,Center for Drug Evaluation and Research (CDER),Not Mentioned,,"The FDA reviewed its records and determined that the sterile dry powder excipient-free formulation and the sterile dry powder with sodium chloride formulation of Cytoxan (cyclophosphamide) for Injection (500 mg/vial, 1 g/vial, and 2 g/vial) were not withdrawn from sale for reasons of safety or effectiveness. As such, these products may remain listed in the 'Discontinued Drug Product List' section of the Orange Book.",withdrawn,True,1255.0,CDER,CDER
fda-2020-p-1369,FDA-2020-P-1369-0001_Citizen_Petition_from_Hyman__Phelps___McNamara__P_.pdf,2020-05-08,2020,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"21 C.F.R. ¬ß¬ß 10.25(a), 10.30; Federal Food, Drug, and Cosmetic Act ¬ß 505(j); 21 C.F.R. ¬ß 314.3","FDA‚Äôs designation of DARAPRIM (NDA 008578) as the sole Reference Standard (RS) for Pyrimethamine Tablets, 25 mg, despite its commercial unavailability due to a restricted distribution program","Designate ANDA 207127 (Pyrimethamine Tablets, 25 mg), held by Cerovene, Inc., as a new or additional RS for the purposes of ANDA submission and testing; amend the Orange Book accordingly","The current RS, DARAPRIM, is inaccessible due to a restricted distribution program, blocking generic competition. The approved generic under ANDA 207127 is the only listed alternative and should serve as a new RS. This designation would facilitate ANDA submissions and ensure market access, aligning with FDA‚Äôs intent to prevent 'gaming' tactics used to delay generics, as acknowledged in FDA‚Äôs own statements and guidance","November 4, 2020",,2025-10-15,1.0,,,"The FDA issued an interim response because the agency has not yet completed its review of the petition requesting that ANDA 207127 (Pyrimethamine Tablets, 25 mg) be designated as a reference standard. The delay is attributed to the need to address other agency priorities. A final decision will be issued once the review is complete.",,no decision,False,1986.0,pending,pending
fda-2020-p-1390,FDA-2020-P-1390-0001_Citizen_Petition_from_Varun_Varada_Redacted.pdf,2020-05-14,2020,False,original petition,Varun Varada,individual,"21 U.S.C. ¬ß 343(q); 21 C.F.R. ¬ß 10.30; 21 C.F.R. ¬ß¬ß 25.30, 25.32",FDA‚Äôs current use of the 'calorie' as the unit of food energy on Nutrition Facts and Supplement Facts labels,"Amend all parts of 21 C.F.R. that mention 'calorie' to instead use the official SI unit of energy, the joule (specifically kilojoules for food energy). Labels should display 'Energy <n> kJ' and may optionally include '<n> kcal' for backward compatibility","The calorie is a deprecated pre-SI unit, and its continued use causes confusion, violates international and national SI standards (such as those by BIPM and NIST), and imposes unnecessary educational and economic burdens. Transitioning to kilojoules aligns U.S. regulations with global standards, reduces complexity for students, simplifies international trade, and improves regulatory clarity. The proposed change supports modernization and harmonization with major global partners like the EU and UK",,Acknowledged receipt; no decision on merits,2020-05-15,0.0,Dockets Management Staff (FDA/Office of Operations),Not Mentioned,,"The FDA acknowledged receipt of a petition requesting amendments to all parts of 21 CFR that refer to 'calorie' as the unit of food energy, proposing replacement with the SI unit 'joule' (specifically kilojoules). The petition also requested changes to Nutrition Facts and Supplement Facts labels to display energy in kilojoules, optionally including calories for backward compatibility. The letter clarified that acceptance is procedural and does not reflect a decision on the petition‚Äôs substantive merits.",other,True,1.0,DMS,Other/Specialty Center
fda-2020-p-1403,FDA-2020-P-1403-0001_Citizen_Petition_from_Hyman__Phelps___McNamara__P_.pdf,2020-05-19,2020,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"21 C.F.R. ¬ß¬ß 10.25(a), 10.30, 314.94(a)(9)(iii), 314.127(a)(8)(ii)(B); Federal Food, Drug, and Cosmetic Act ¬ß 505(j)","FDA‚Äôs designation of VIBRAMYCIN (doxycycline hyclate) Injection, NDA 050442, as the sole Reference Listed Drug (RLD) for Doxycycline Hyclate for Injection, despite its market withdrawal and formulation differences","Designate ANDA 062475 (Doxycycline Hyclate for Injection, 100 mg and 200 mg Base/Vial) as additional RLDs in the Orange Book to allow generic applicants to rely on it for ANDA submissions","VIBRAMYCIN (NDA 050442) was withdrawn from the market and differs in formulation from ANDA 062475 due to the absence of mannitol, a necessary bulking agent. Past ANDAs (091406 and 207757) were approved using ANDA 062475 as the RLD, despite its use of a non-exception excipient. Failing to relist it as an RLD would unfairly force new applicants down the 505(b)(2) pathway with higher regulatory burdens and fees, violating principles of consistency under the Administrative Procedure Act",,Acknowledged receipt; no decision on merits,2020-05-20,0.0,Dockets Management Staff (FDA/Office of Operations),Not Mentioned,,"The FDA acknowledged receipt of a petition requesting the designation of both Doxycycline Hyclate for Injection, 100 mg and 200 mg Base/Vial (approved under ANDA 062475), as Reference Listed Drugs (RLDs) for ANDA submissions containing mannitol as an excipient. The letter states that acceptance of the petition is procedural and does not reflect a decision on the substantive merits of the petition.",other,True,1.0,DMS,Other/Specialty Center
fda-2020-p-1405,FDA-2020-P-1405-0001_Citizen_Petition_from__bioMerieux.pdf,2020-04-01,2020,False,original petition,"bioM√©rieux (specifically through Hyglos GmbH, a bioM√©rieux company)",industry/corporation,21 C.F.R. ¬ß 10.30; 21 C.F.R. ¬ß 211.165; Executive Orders 13771 and 13777,"FDA‚Äôs policy regarding bacterial endotoxin testing methods, specifically the acceptance of recombinant Factor C (rFC) as equivalent to LAL and TAL methods under current compendial standards",Questions and Answers'; support rFC through the Emergency Use Authorization framework for COVID-19 diagnostics and therapeutics,"rFC is a scientifically validated, synthetic, and environmentally sustainable alternative to LAL and TAL, which rely on horseshoe crab blood. The petition cites regulatory precedents, international pharmacopeial acceptance, and recent FDA approvals of rFC-tested drugs. It argues that rFC avoids ethical and environmental harms associated with animal-based testing and offers a more reliable and cost-effective solution, especially during urgent public health situations like the COVID-19 pandemic","October 15, 2020",,2025-10-15,1.0,,,"The FDA issued an interim response because the petition raised complex issues, including requests to recognize recombinant Factor C (rFC) as an equivalent method for bacterial endotoxin testing, amend biologics regulations and guidances, and issue an Emergency Use Authorization for rFC in COVID-19 testing. These matters require extensive review and analysis before a final decision can be made.",,no decision,False,2023.0,pending,pending
fda-2020-p-1416,FDA-2020-P-1416-0001_Citizen_Petition_from_Sidley_Austin__LLP__on_behal.pdf,2020-05-20,2020,False,original petition,Sidley Austin LLP,law/consulting,21 C.F.R. ¬ß 600.3(s); 21 C.F.R. 610.10; 21 C.F.R. 211.165(e); 21 C.F.R. 211.194; 21 C.F.R. 210.3(b)(16)(ii); 21 C.F.R. 610.1; 21 C.F.R. 210.3(b)(20); 21 C.F.R. 210.3(b)(7); 21 C.F.R. 600.3(l); 21 C.F.R. 610.53(a); 21 C.F.R. 610.61(g)(3); 21 C.F.R. 610.61(r); Section 351 of the Public Health Service Act,"FDA guidance documents related to potency assays for biologics, specifically those regarding human somatic cell therapy INDs, potency tests for cellular and gene therapy products, and BLA applications for cord blood products",Update FDA guidance documents to recognize real-time glutathione (GSH) monitoring methods‚Äîlike Cell2in‚Äôs FreSHtracer‚Äîas acceptable potency assays for cell-based therapies including stem cell therapies,"Because real-time GSH monitoring accurately measures antioxidant capacity and 'stemness' of stem cells, both key indicators of therapeutic potency. These assays are reversible, ratiometric, and correlate with cell functionality, self-renewal, and differentiation ability. The petitioner provides in vitro and in vivo evidence that higher intracellular GSH levels correlate with better therapeutic performance, making such assays viable and meaningful tools for quality and potency assessment",,,2025-10-15,0.0,,,,,no decision,False,1974.0,pending,pending
fda-2020-p-1421,FDA-2020-P-1421-0001_Citizen_Petition_from_Encore_Dermatology__Inc_.pdf,2020-05-22,2020,False,original petition,"Encore Dermatology, Inc.",industry/corporation,"505(q), 21 C.F.R. 10.30, 314.94, 314.127",The petition comments on the FDA‚Äôs potential approval of Glenmark Pharmaceuticals‚Äô ANDA 214191 for a generic version of Impoyz¬Æ cream.,"Refuse approval of Glenmark‚Äôs ANDA 214191 and require any similarly formulated generics to file a new drug application with adequate safety and efficacy data. If FDA allows ANDA pathway, require bioequivalence, systemic exposure, HPA axis suppression, and local safety data.","Encore argues that Glenmark‚Äôs generic formulation contains significant changes, including over 10% propylene glycol and exclusion of Transcutol, leading to potentially increased systemic absorption of clobetasol propionate. These changes raise serious safety and efficacy concerns not addressed by standard bioequivalence measures like the vasoconstrictor assay. Encore claims such differences exceed what is permissible under FDA‚Äôs regulations for ANDAs and necessitate new drug applications with full clinical data.",,Denied,2020-10-16,0.0,Center for Drug Evaluation and Research (CDER),"21 CFR 10.30(e)(2), 21 CFR 314.105, 21 CFR 314.125, 21 CFR 314.127, 21 CFR 314.110, 21 CFR 314.200, 21 CFR 314.430, Section 505(q) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(q))",,"The FDA denied the petition submitted by Encore Dermatology, which requested that the Agency refuse to approve any ANDA for a clobetasol propionate topical cream using propylene glycol instead of DEGEE. FDA explained that it could not make a determination regarding the approvability of specific pending ANDAs outside of the application review process. The Agency emphasized that application-specific decisions must be based on the totality of data submitted and that procedural rights of applicants cannot be bypassed through the citizen petition process. Therefore, the petition was denied without comment on the approvability of any specific application.",denied,True,147.0,CDER,CDER
fda-2020-p-1423,FDA-2020-P-1423-0001_Citizen_Petition_from_North_American_Olive_Oil_Ass.pdf,2020-05-22,2020,False,original petition,North American Olive Oil Association (NAOOA),advocacy/academic,"21 C.F.R. ¬ß 10.30, 21 C.F.R. ¬ß 130.6, 21 U.S.C. ¬ß 341",Establishment of a standard of identity (SOI) for olive oil and olive-pomace oil,"Request for the FDA to adopt a U.S. standard of identity for olive oil and olive-pomace oil, based on the Codex Standard, with specified deviations","The petitioner argues that a standard of identity (SOI) is needed to empower consumers to make informed health decisions, promote honesty and fair dealing, ensure product authenticity, protect against fraud, support a competitive industry, and align with international standards. This is supported by increased olive oil consumption, consumer confusion about oil types, and consumer studies showing trust issues due to fraud concerns.",,,2025-10-15,0.0,,,,,no decision,False,1972.0,pending,pending
fda-2020-p-1427,FDA-2020-P-1427-0001_Citizen_Petition_from_Aurobindo_Pharma_USA__Inc_.pdf,2020-05-27,2020,False,original petition,"Aurobindo Pharma USA, Inc.",industry/corporation,"505(j) of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. ¬ß¬ß 10.25(a), 10.30, 314.93, 25.31(a), 25.15(d)","FDA‚Äôs designation of the Reference Standard (RS) for Dicloxacillin Sodium Capsules USP 125 mg, 250 mg, and 500 mg in the Orange Book",Request FDA to designate 'Dicloxacillin Sodium Capsules 500 mg (ANDA #062286) of Teva Pharmaceuticals USA Inc.' as the new Reference Standard (RS) for the purposes of in vivo bioequivalence testing to support ANDA submissions,"The currently listed RS (ANDA #061454 of Sandoz Inc.) is not practically available in the market despite being technically active in the Orange Book, making it infeasible for generic applicants to obtain necessary samples. Teva‚Äôs product (ANDA #062286) is the most widely marketed dicloxacillin capsule product in the U.S. and should be designated as RS to facilitate ANDA submissions. FDA precedent supports RS changes when existing RS availability is limited",,,2025-10-15,0.0,,,,,no decision,False,1967.0,pending,pending
fda-2020-p-1443,FDA-2020-P-1443-0002_Citizen_Petition_from_Elanco_Animal_Health.pdf,2020-05-28,2020,False,original petition,Elanco Animal Health,individual,"Section 512 of the Federal Food, Drug, and Cosmetic Act (FDCA); 21 C.F.R. ¬ß 10.115(d)(3); Administrative Procedure Act (APA); Section 701(h) of the FDCA; GFI #35","FDA's approval of Huvepharma's ANADA for Monovet 90, a generic version of Elanco‚Äôs Rumensin¬Æ (monensin) Type A medicated article",Withdraw approval of Huvepharma‚Äôs ANADA for Monovet and refrain from approving future ANADAs for generic monensin unless specific conditions are met,"Elanco argues that Huvepharma‚Äôs Monovet was approved based on insufficient evidence of bioequivalence to Rumensin, including inadequate clinical trials and unreliable in vitro dissolution studies. Elanco also provides its own comparative study, which suggests Monovet may not be bioequivalent. The petition cites FDA guidance and legal precedents requiring rigorous bioequivalence demonstrations for generic animal drugs.",,Acknowledged receipt; no decision on merits,2020-05-29,0.0,Dockets Management Staff (FDA/Office of Operations),"21 C.F.R. ¬ß 10.115(d)(3), Section 512(e)(1) and Section 701(h) of the Federal Food, Drug, and Cosmetic Act (FDCA), Administrative Procedure Act",,The FDA acknowledged receipt of a petition requesting that the agency begin withdrawal procedures for Huvepharma‚Äôs ANADA for generic Monovet and halt approval of future ANADAs for generic monensin products unless specific bioequivalence testing standards are met. The FDA clarified that the petition's acceptance is procedural and does not reflect a decision on its substantive merits.,other,True,1.0,DMS,Other/Specialty Center
fda-2020-p-1478,FDA-2020-P-1478-0001_Citizen_Petition_from_The_Sugar_Association.pdf,2020-06-03,2020,False,original petition,The Sugar Association,advocacy/academic,"5 U.S.C. ¬ß553, 21 C.F.R. ¬ß¬ß10.25 and 10.30, Section 201(n) of the FD&C Act, Section 403(a)(1) of the FD&C Act","Labeling regulations related to 'No Added Sugar', 'Reduced Sugar', and similar claims, and the use of alternative sweeteners in food and beverage products",1) Require ingredient labels to clearly disclose all alternative sweeteners; 2) Require front-of-package disclosures about sweetener types and quantities in children‚Äôs products; 3) Disclose gastrointestinal effects of sweeteners at minimum thresholds; 4) Issue guidance ensuring that no/reduced sugar claims are not misleading; 5) Take enforcement action against misleading labeling,"Petitioner argues that the current labeling misleads consumers, particularly in how alternative sweeteners are disclosed or omitted. Many consumers are unaware of sweeteners like sucralose or allulose due to lack of labeling clarity. Misleading claims (e.g., 'No Added Sugar') may hide the presence of nonnutritive sweeteners or give the impression that a product is healthier or lower in calories, even when it is not. The petition emphasizes the need for transparency to support informed consumer choices, especially for children.","November 30, 2020",,2025-10-15,1.0,,,"The FDA issued an interim response acknowledging receipt of the petition from The Sugar Association and stating that the issues raised require further review and analysis. As a result, the agency has not yet reached a final decision on the petition and will respond fully once its evaluation is complete.",,no decision,False,1960.0,pending,pending
fda-2020-p-1506,FDA-2020-P-1506-0001_Citizen_Petition_from_Animal_Legal_Defense_Fund.pdf,2020-05-29,2020,False,original petition,Animal Legal Defense Fund,law/consulting,"5 U.S.C. ¬ß 553(e), 21 U.S.C. ¬ß 360b, 21 C.F.R. ¬ß¬ß 10.20, 10.30, 21 C.F.R. ¬ß 558.500",Approval of ractopamine for use in pig and cattle feed under 21 C.F.R. ¬ß 558.500,Immediately suspend and/or withdraw the approval of ractopamine for use in pig and cow feed,"Due to COVID-19-related disruptions in meatpacking, animals are receiving ractopamine for longer durations, increasing animal suffering, risk of human exposure to residues, environmental contamination, and public health threats. Scientific evidence and FDA records highlight severe risks associated with ractopamine usage to animal welfare, human health, and environmental safety.",,,2025-10-15,0.0,,,,,no decision,False,1965.0,pending,pending
fda-2020-p-1540,FDA-2020-P-1540-0001_Citizen_Petition_from_Alliance_For_Natural_Health_.pdf,2020-05-29,2020,False,original petition,Alliance for Natural Health USA,advocacy/academic,21 U.S.C. ¬ß 355(e)(3); 5 U.S.C. ¬ß 553(e); 21 C.F.R. ¬ß 10.30,Current labeling regulations and approval framework for proton pump inhibitor (PPI) medications used in humans,Issue a regulation requiring all manufacturers of proton pump inhibitor (PPI) medications to expand their product labeling to include a warning about the increased risk of pneumonia,"Emerging research and meta-analyses have shown that the use of PPIs is associated with increased risk of both community-acquired and hospital-acquired pneumonia due to reduced gastric acidity, impaired immunity, and microbiota disruption. Multiple clinical studies and adverse event reports indicate statistically significant increased pneumonia incidence among PPI users. The petition argues that the FDA must act to ensure consumers are informed of these risks through clear labeling",,,2025-10-15,0.0,,,,,no decision,False,1965.0,pending,pending
fda-2020-p-1549,FDA-2020-P-1549-0001_Citizen_Petition_from_Windels_Marx_Lane___Mittendo.pdf,2020-06-10,2020,False,original petition,"Windels Marx Lane & Mittendorf, LLP",law/consulting,"21 C.F.R. ¬ß¬ß 10.25(a), 10.30(b), 314.161, 314.122(a), 314.162; Federal Food, Drug, and Cosmetic Act (FD&C Act)","FDA's designation of Nymalize¬Æ (Nimodipine) Oral Solution, 3 mg/mL strength, under NDA 203340, as discontinued in the Orange Book","Request the FDA to determine whether Nymalize¬Æ (Nimodipine) Oral Solution, 3 mg/mL strength, was withdrawn from sale for safety or effectiveness reasons",The petitioner argues that the 3 mg/mL formulation of Nymalize¬Æ was discontinued due to commercial considerations following FDA approval of a new 6 mg/mL concentration. There is no evidence suggesting the 3 mg/mL formulation was withdrawn for safety or effectiveness reasons. This determination is essential for any applicant seeking to reference this formulation in an ANDA,,,2025-10-15,0.0,,,,,no decision,False,1953.0,pending,pending
fda-2020-p-1575,FDA-2020-P-1575-0001_Citizen_Petition_from_Francis_E__O_Donnell__Redact.pdf,2020-06-08,2020,False,original petition,"Francis E. O'Donnell, Jr., M.D.",individual,21 C.F.R. ¬ß 10.30; 21 C.F.R. ¬ß 330.10(a); 21 U.S.C. ¬ß 321(g)(1)(C); 21 U.S.C. ¬ß 352(f)(1); 21 U.S.C. ¬ß 355,FDA‚Äôs policy regarding over-the-counter (OTC) ocular products using benzalkonium chloride (BAK) and other preservatives in non-sterile formulations,Immediately remove OTC ophthalmic drug products from the market that contain benzalkonium chloride or similar preservatives in non-sterile formulations until clinical safety data are submitted and evaluated,"The petitioner cites clinical research and safety data suggesting that BAK and other preservatives in non-sterile OTC eye drops can damage the ocular surface and are associated with adverse effects, including allergy, toxicity, and exacerbation of dry eye symptoms. FDA is urged to act due to risks to public health, particularly among the elderly, contact lens wearers, and individuals with preexisting ocular surface disease",,,2025-10-15,0.0,,,,,no decision,False,1955.0,pending,pending
fda-2020-p-1582,FDA-2020-P-1582-0001_Citizen_Petition_from_The_Council_for_Responsible_.pdf,2020-06-16,2020,False,original petition,The Council for Responsible Nutrition (CRN),advocacy/academic,"21 C.F.R. ¬ß 10.30, 21 U.S.C. ¬ß 321(ff)(3)(B), 21 U.S.C. ¬ß 350b, 21 U.S.C. ¬ß 342(f), 21 U.S.C. ¬ß 331(v), 21 C.F.R. ¬ß 190.6",The FDA‚Äôs failure to establish a regulatory pathway for the legal marketing of dietary supplements containing hemp-derived cannabidiol (CBD),1) Issue a regulation under 21 U.S.C. ¬ß 321(ff)(3)(B) that finds hemp-derived CBD is a lawful dietary ingredient. 2) Provide guidance clarifying when a hemp-derived substance is subject to drug preclusion provisions. 3) Enforce existing dietary supplement regulations with respect to CBD-containing products.,"CRN argues that the FDA already has statutory authority to allow CBD in dietary supplements and that inaction harms public health by creating an unregulated market. They assert that other international regulatory bodies have already deemed certain CBD levels safe and that FDA delay promotes drug market monopolies, ignoring congressional intent and established safety frameworks for supplements.",,,2025-10-15,0.0,,,,,no decision,False,1947.0,pending,pending
fda-2020-p-1601,FDA-2020-P-1601-0001_Citizen_Petition_from_Siri___Glimstad_LLP_on_behal.pdf,2020-06-17,2020,False,original petition,Siri & Glimstad LLP,law/consulting,21 C.F.R. ¬ß 10.30; 42 U.S.C. ¬ß 262(a)(2)(A)-(C); 42 U.S.C. ¬ß 262(j); 42 U.S.C. ¬ß 300aa-10 et seq.,FDA approval of COVID-19 vaccine clinical trials lacking placebo control groups,Require all Phase II and III COVID-19 vaccine clinical trials to include a saline placebo control group of equal size and monitor participants for adverse effects over extended timeframes,"The petitioner argues that randomized placebo-controlled trials are the scientific gold standard for determining the safety and efficacy of vaccines. They assert that without a saline placebo, identifying vaccine-caused adverse effects is difficult or impossible. The petition emphasizes ethical and scientific issues, especially given the low risk of COVID-19 in children, potential vaccine mandates, and immunity from liability granted to manufacturers",,,2025-10-15,0.0,,,,,no decision,False,1946.0,pending,pending
fda-2020-p-1605,FDA-2020-P-1605-0001_Citizen_Petition_from_Novitium_Pharma__LLC.pdf,2020-06-22,2020,False,original petition,Novitium Pharma LLC,industry/corporation,21 C.F.R. ¬ß 10.30; 21 C.F.R. ¬ß 314.94(a)(3),FDA's designation of a Reference Standard (RS) for Methyltestosterone 10 mg oral capsule,Designate the Methyltestosterone 10 mg oral capsule product manufactured by Impax Laboratories Inc. (ANDA A204851) as the Reference Standard (RS),"The currently listed RS, TESTRED (ANDA A083976, Valeant Pharmaceuticals), is not available on the market, impeding generic development. Impax Laboratories‚Äô product is the only Methyltestosterone 10 mg oral capsule currently available, and designating it as the RS would support generic development, reduce drug costs, and align with the goals of the Hatch-Waxman Act",,Procedural acknowledgment only; no substantive decision issued,2020-06-23,0.0,"Dockets Management Staff, FDA/Office of Operations (OO)",Not Mentioned,,The letter states that the acceptance of the petition for filing is a procedural matter and does not reflect an agency decision on the substantive merits of the petition,other,True,1.0,DMS,Other/Specialty Center
fda-2020-p-1611,FDA-2020-P-1611-0001_Citizen_Petition_from_Public_Citizen_s_Health_Rese.pdf,2020-06-24,2020,False,original petition,Public Citizen,individual,"21 U.S.C. ¬ß¬ß 352 and 355(o)(4), 21 C.F.R. ¬ß¬ß 10.30, 201.56, 201.57(c)(1), 201.57(c)(5)","Product labeling of SGLT2 inhibitors, particularly their lack of a boxed warning contraindicating use for type 1 diabetes patients","Require boxed warning in product labeling for all SGLT2 inhibitors stating contraindication in type 1 diabetes and update relevant sections (Contraindications, Warnings and Precautions, Medication Guide, Indications and Usage)",Extensive clinical trial data and postmarketing reports show significantly higher incidence of diabetic ketoacidosis (DKA) in type 1 diabetes patients using SGLT2 inhibitors; current labeling fails to deter off-label use that results in preventable harm,,Denied,2023-05-19,0.0,Center for Drug Evaluation and Research (CDER),"21 CFR 201.56, 21 CFR 201.57, 21 CFR 201.100(c), 21 CFR 201.80, 21 CFR 201.57(c)(5), 21 CFR 201.57(c)(1), 21 CFR 201.57(c)(6)(i), Sections 201(n) and 502(a) of the Federal Food, Drug, and Cosmetic Act, Section 505(o)(4) of the Federal Food, Drug, and Cosmetic Act",,"The FDA concluded that although SGLT2 inhibitors are not approved for use in type 1 diabetes mellitus (T1DM), existing labeling appropriately warns of the associated risks, such as diabetic ketoacidosis (DKA), in the WARNINGS AND PRECAUTIONS section. The FDA determined that current evidence does not warrant a contraindication or boxed warning and that existing safety labeling already reflects essential information for prescribers. Data cited in the petition were deemed insufficient or problematic due to variability in trial quality, lack of peer review, inconsistent DKA adjudication, and limitations in the meta-analysis and adverse event data interpretation.",denied,True,1059.0,CDER,CDER
fda-2020-p-1617,FDA-2020-P-1617-0001_Citizen_Petition_from_E4_Consulting.pdf,2020-06-24,2020,False,original petition,E4 Consulting,law/consulting,"21 C.F.R. ¬ß¬ß 10.25(a), 10.30(b), 314.161","FDA's listing of BACTROBAN¬Æ (mupirocin calcium) Nasal Ointment, 2% under NDA 050703 as 'Discontinued' in the Orange Book","Request that the FDA determine whether BACTROBAN¬Æ (mupirocin calcium) Nasal Ointment, 2% was withdrawn from sale for safety or effectiveness reasons","The product, BACTROBAN Nasal Ointment, 2%, is marked as discontinued in the Orange Book, but the listing does not indicate whether this was due to safety or effectiveness issues. The petitioner argues that a determination is needed to clarify whether this reference listed drug can be cited for future abbreviated new drug applications (ANDAs)",,,2025-10-15,0.0,,,,,no decision,False,1939.0,pending,pending
fda-2020-p-1626,FDA-2020-P-1626-0001_Citizen_Petition_from_Hyman__Phelps___McNamara__P_.pdf,2020-07-01,2020,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"21 C.F.R. ¬ß¬ß 10.25(a), 10.30, 314.3; Federal Food, Drug, and Cosmetic Act (FDC Act) ¬ß 505(j)","FDA‚Äôs omission of Reference Listed Drug (RLD) designation for Vancomycin HCl for Oral Solution, 250 mg (base)/5 mL and 500 mg (base)/6 mL, in the Orange Book","Designate both Vancomycin HCl for Oral Solution, 250 mg (base)/5 mL and 500 mg (base)/6 mL, approved under ANDA 061667, as RLDs and amend the Orange Book accordingly","FDA previously listed ANDA 061667 as an RLD, and failure to re-list it prevents generic submissions, shielding the drug from competition. The petition argues that without this designation, the FDA treats similarly situated products inconsistently, violating the Administrative Procedure Act. The historical context and prior RLD status justify the designation to maintain a viable pathway for generic approvals",,,2025-10-15,0.0,,,,,no decision,False,1932.0,pending,pending
fda-2020-p-1633,FDA-2020-P-1633-0001_Citizen_Petition_from_Foley_Hoag__LLP__on_behalf_o.pdf,2020-07-02,2020,False,original petition,Foley Hoag LLP,law/consulting,21 C.F.R. ¬ß 10.30,FDA's 2013 and 2016 draft guidance on enforcement discretion regarding investigational new drug (IND) requirements for fecal microbiota transplantation (FMT) to treat Clostridium difficile infection not responsive to standard therapies,Finalize the 2016 draft guidance to require commercial stool banks to operate under an IND; retain physician-directed safe harbor for known donors; provide additional guidance on comprehensive IND framework; reiterate the interim nature of the enforcement discretion policy and revisit it upon drug approval,"The petitioner argues that the original 2013 enforcement policy was meant to be temporary and is now outdated. Continued discretion allows commercial stool banks to distribute FMT products without IND oversight, posing safety risks. Finalizing the 2016 guidance would align regulatory requirements for FMT with other drug and biologic products, mitigate patient risk, especially amid COVID-19, and ensure rigor in screening, manufacturing, and safety reporting.",,Granted in part and denied in part,2022-11-29,0.0,Center for Biologics Evaluation and Research (CBER),"42 U.S.C. 262(i), 21 U.S.C. 321(g), 42 U.S.C. 262(a)(2)(C), 42 U.S.C. 262(a)(3), 21 U.S.C. 355(i), 21 CFR Part 312, 21 CFR 10.25(a), 21 CFR 10.3(a), 21 CFR 10.30(e), 21 CFR 10.30(k)",,"The FDA finalized the 2016 draft guidance with the 2022 FMT Enforcement Policy Guidance, which maintains enforcement discretion under limited circumstances but excludes stool banks due to safety concerns. FDA considered the request to expand or revise its enforcement policy but found no need for further guidance or policy revisions at this time. The Agency also declined to state that the guidance is interim or commit to future changes based on hypothetical product approvals, emphasizing ongoing policy evaluation as scientific evidence evolves.",approved,True,880.0,CBER,Other/Specialty Center
fda-2020-p-1641,FDA-2020-P-1641-0001_Citizen_Petition_from_John_J_Coleman_Redacted.pdf,2020-07-06,2020,False,original petition,John J. Coleman,individual,21 C.F.R. ¬ß 10.30,FDA‚Äôs process and policies regarding the withdrawal of medications from the market based on safety concerns,"Reform the FDA‚Äôs drug withdrawal process to include more transparent, evidence-based evaluations and establish an independent review mechanism for withdrawal decisions","The petitioner argues that some past drug withdrawals were based on insufficient scientific evidence or misinterpretation of data, leading to loss of valuable medications. He calls for improved transparency, public access to data, and a formal appeal or review structure to ensure accountability and maintain trust in FDA decisions",,Procedural acknowledgment only; no substantive decision issued,2020-07-08,0.0,"Dockets Management Staff, FDA/Office of Operations (OO)",Not Mentioned,,The letter states that the acceptance of the petition for filing is a procedural matter and does not reflect an agency decision on the substantive merits of the petition.,other,True,2.0,DMS,Other/Specialty Center
fda-2020-p-1650,FDA-2020-P-1650-0001_Citizen_Petition_from_Cardinal_Health_Regulatory_S.pdf,2020-07-09,2020,False,original petition,Cardinal Health Regulatory Sciences,law/consulting,"21 C.F.R. ¬ß¬ß 10.25, 10.30, 314.122, 314.161; Section 505(j) of the Federal Food, Drug, and Cosmetic Act","FDA‚Äôs listing of DOBUTREX (Dobutamine hydrochloride), EQ 12.5 MG BASE/ML, held by ELI LILLY AND CO., as a discontinued drug in the Orange Book without a determination on whether it was withdrawn for safety or effectiveness reasons","Request that the FDA determine whether DOBUTREX (Dobutamine hydrochloride), EQ 12.5 MG BASE/ML, was withdrawn from sale for reasons of safety or effectiveness","The petitioner states that DOBUTREX was previously listed as a reference listed drug and later withdrawn from the market. However, the FDA has not determined whether the withdrawal was due to safety or effectiveness concerns, which is required for the approval of any ANDA referencing this drug. The petition seeks such a determination to clarify ANDA eligibility",,,2025-10-15,0.0,,,,,no decision,False,1924.0,pending,pending
fda-2020-p-1653,FDA-2020-P-1653-0001_Citizen_Petition_from_Aurobindo_Pharma_USA__Inc__R.pdf,2020-07-10,2020,False,original petition,Aurobindo Pharma Limited,industry/corporation,"505(j), 21 C.F.R. 10.25(a), 21 C.F.R. 10.30, 21 C.F.R. 314.93",FDA designation of a suitable alternative reference standard for in vivo bioequivalence studies concerning Carbidopa and Levodopa Tablets,"Request the FDA to designate Sun Pharmaceutical Industries, Inc.'s Carbidopa and Levodopa Tablets 25 mg/250 mg (ANDA 078536) as a new Reference Standard","The current reference standard, SINEMET (NDA 017555), is not sufficiently available in the market, making it inaccessible for in vivo testing. Sun Pharmaceutical's version is a leading product in the market, making it a suitable alternative as a reference standard. The petitioner supports the request with IMS sales data, NDC unavailability statements, and regulatory provisions that allow for such designation.",,Procedural acknowledgment only; no substantive decision issued,2020-07-13,0.0,"Dockets Management Staff, FDA/Office of Operations (OO)",Not Mentioned,,The letter clarifies that acceptance of the petition for filing is a procedural matter and does not reflect a decision on the substantive merits of the petition.,other,True,3.0,DMS,Other/Specialty Center
fda-2020-p-1674,FDA-2020-P-1674-0001_Citizen_Petition_from_Putting_Rare_Diseases_Patien.pdf,2020-07-15,2020,False,original petition,Putting Rare Diseases Patients First!¬Æ,advocacy/academic,21 C.F.R. ¬ß 10.30,FDA‚Äôs exclusion of Sickle Cell Disease from the Neglected Tropical Disease Priority Review Voucher (PRV) List,Add Sickle Cell Disease to the FDA‚Äôs Neglected Tropical Disease Priority Review Voucher List or create a new Priority Review List for diseases impacting underserved and marginalized populations,"Sickle Cell Disease disproportionately affects poor and marginalized populations, primarily in Africa and among African Americans in the U.S. Despite meeting FDA‚Äôs criteria for a tropical disease (lack of significant market in developed or developing countries, high disease burden), it is excluded from the list. Including it would incentivize treatment development, align with global health priorities like the WHO and Access to Medicines Index, and address longstanding health disparities",,Denied,2021-09-17,0.0,Center for Drug Evaluation and Research (CDER),"21 U.S.C. 360n (FD&C Act ¬ß524), 21 U.S.C. 321(g), 21 U.S.C. 355(i), 21 CFR Part 312, 21 U.S.C. 355f (FD&C Act ¬ß505E(d)), 21 U.S.C. 360ff (FD&C Act ¬ß529), 21 U.S.C. 360bb (FD&C Act ¬ß526)",,"The FDA denied the petition to add sickle cell disease to the Neglected Tropical Disease Priority Review Voucher list because, by statutory definition, tropical diseases must be infectious. Sickle cell disease is a genetic condition and thus does not meet the criteria. The FDA also denied the creation of a new PRV list for non-infectious diseases affecting underserved populations, stating this falls outside the authority granted by the current law. However, FDA acknowledged the importance of treatments for sickle cell disease and pointed to other available incentive programs such as rare pediatric disease and orphan drug designations.",denied,True,429.0,CDER,CDER
fda-2020-p-1678,FDA-2020-P-1678-0001_Citizen_Petition_from_Cardinal_Health_Regulatory_S.pdf,2020-07-15,2020,False,original petition,Cardinal Health Regulatory Sciences,law/consulting,"21 CFR 10.25, 21 CFR 10.30, 505(j) of the Federal Food, Drug, and Cosmetic Act, 21 CFR 314.122, 21 CFR 314.161, 21 CFR 314.162, 21 CFR 25.31, 21 CFR 10.30(b)",The petitioner is commenting on the status of the drug Nipride¬Æ RTU in the FDA's Orange Book and its potential withdrawal for safety or efficacy reasons,"Determine whether Nipride¬Æ RTU (sodium nitroprusside), NDA 209387, has been voluntarily withdrawn or withheld from sale for reasons of safety or efficacy","The petitioner justifies the request by noting that the drug Nipride¬Æ RTU now appears in the 'Discontinued Section' of the FDA's Orange Book, and FDA regulations require determining if a product was withdrawn for safety or effectiveness reasons before approving related ANDAs",,,2025-10-15,0.0,,,,,no decision,False,1918.0,pending,pending
fda-2020-p-1689,FDA-2020-P-1689-0001_Citizen_Petition_from_Lassman_Law___Policy.pdf,2020-07-20,2020,False,original petition,"Scott M. Lassman, Lassman Law+Policy",law/consulting,"42 U.S.C. ¬ß 262(a), 21 C.F.R. ¬ß¬ß 10.25, 10.30, 601.2, 601.4, 21 C.F.R. ¬ß 600.3(s), 21 U.S.C. ¬ß 355(d), 21 C.F.R. ¬ß 314.126, 21 C.F.R. ¬ß¬ß 25.30, 25.31",FDA's potential licensure and approval of RYONCIL‚Ñ¢ (remestemcel-L) for pediatric SR-aGVHD under BLA 125706,"Refuse to approve RYONCIL for pediatric SR-aGVHD unless the sponsor provides substantial evidence of effectiveness via a prospective, randomized, blinded, and concurrently controlled pivotal trial; and provide the petition to Advisory Committee members evaluating the BLA","The petition argues that the current evidence for RYONCIL‚Äôs efficacy is inadequate due to reliance on a single-arm, historically controlled study following failed Phase 3 trials. Approval without randomized controlled data could delay access to effective therapies like Jakafi and undermine standards for biologic licensure",,,2025-10-15,0.0,,,,,no decision,False,1913.0,pending,pending
fda-2020-p-1701,FDA-2020-P-1701-0001_Citizen_Petition_from_Harman_Finochem_Limited.pdf,2020-07-25,2020,False,original petition,Harman Finochem Limited,industry/corporation,"21 CFR ¬ß 10.25(a), 21 CFR ¬ß 10.30, 21 C.F.R. ¬ß 25.31(a), FD&C Act Section 505(j)","Designation of the reference standard for Metformin Hydrochloride Extended Release Tablets, 750 mg in the FDA's Orange Book","Designate a suitable alternative reference standard for Metformin Hydrochloride Extended Release Tablets, 750 mg, due to unavailability of the current RS (ANDA 078596 by Amneal Pharmaceuticals)",The current reference standard is unavailable in the market despite being listed in the Active Section of the Orange Book. The petitioner has been unable to obtain samples and cites FDA guidance that allows for selection of a new reference standard under such circumstances,,,2025-10-15,0.0,,,,,no decision,False,1908.0,pending,pending
fda-2020-p-1718,FDA-2020-P-1718-0001_Citizen_Petition_from_Public_Health_Advocacy_Insti.pdf,2020-07-28,2020,False,original petition,"Public Health Advocacy Institute, Inc.",advocacy/academic,"21 U.S.C. ¬ß¬ß 321, 341, 343, 371(a); 21 C.F.R. ¬ß¬ß 10.30, 101.3, 101.7, 102.5, 102.19, 107","FDA's regulation and labeling policy concerning beverages for children 9 to 36 months old, especially 'transition formulas' and 'toddler milks'",Take enforcement action against misbranded 'transition formulas'; amend 21 C.F.R. ¬ß 101.3 to prohibit use of the term 'infant formula' or 'formula' for drinks for children over 12 months; and amend 21 C.F.R. ¬ß 102 to require standardized naming and disclaimers for drinks marketed for children aged 12 to 36 months,"These drinks are misleadingly labeled and marketed, contributing to consumer confusion, potential harm from unnecessary added sugars, inappropriate usage by infants, and economic burden on families; current labeling implies these drinks are essential or recommended, contrary to health expert consensus",,,2025-10-15,0.0,,,,,no decision,False,1905.0,pending,pending
fda-2020-p-1725,FDA-2020-P-1725-0001_Citizen_Petition_from_Knowledge_Ecology_Internatio.pdf,2020-08-03,2020,False,original petition,Knowledge Ecology International,industry/corporation,21 U.S.C. ¬ß 352(n); 21 C.F.R. ¬ß 202.1,"The petition comments on the FDA's regulations regarding audio elements in direct-to-consumer (DTC) prescription drug advertisements, particularly the use of background music during risk presentations",Amend 21 C.F.R. ¬ß 202.1 to ban background music during the presentation of risks in all forms of audio/video prescription drug advertisements,"Background music during risk disclosures distracts consumers, reduces comprehension of side effect information, creates an imbalance in risk-benefit messaging, and may lead to overdiagnosis and inappropriate prescription; banning such music would support FDA's fair balance requirement and improve public health outcomes",,Denied,2023-11-21,0.0,Center for Drug Evaluation and Research (CDER),"21 CFR 202.1, 21 U.S.C. ¬ß 352(n), 21 U.S.C. ¬ß 321(n), 21 CFR 202.1(e), 21 CFR 202.1(e)(2)(i), 21 CFR 202.1(e)(5), Public Law 110‚Äì85 (FDAAA), 21 CFR 202.1(e)(1)",,"The FDA denied the request to amend regulations to categorically ban background music during risk presentations in direct-to-consumer prescription drug ads. The FDA emphasized its current regulatory framework already allows it to evaluate the use of background music in context, considering whether it undermines effective risk communication. Existing rules require clear and balanced risk disclosures, and newly finalized regulations further address risk presentation in TV and radio ads. The FDA maintains that case-by-case evaluation is more appropriate than a blanket ban and noted constitutional and policy considerations in any future rulemaking.",denied,True,1205.0,CDER,CDER
fda-2020-p-1728,FDA-2020-P-1728-0001_Citizen_Petition_from_Tenshi_Kaizen_Private_Limite.pdf,2020-08-03,2020,False,original petition,Tenshi Kaizen Private Limited,industry/corporation,"Section 505(j)(2)(C) of the FD&C Act; 21 C.F.R. ¬ß¬ß 314.93, 10.20, 10.30; 21 C.F.R. ¬ß 25.31; FD&C Act ¬ß 505 B(a)(1)(A); FDC Act ¬ß 5058(a)(5)(A)",FDA's approval process for Abbreviated New Drug Applications (ANDAs) involving dosage form changes from a reference listed drug (RLD),"Determine that Famotidine Orally Disintegrating Tablets (ODT), 20 mg (OTC), are suitable for submission as an ANDA and grant a waiver from pediatric studies under PREA","The proposed ODT form of Famotidine uses the same active ingredient, route of administration, indication, and patient population as the RLD (Pepcid AC¬Æ), with the only difference being dosage form. It offers benefits for patients with difficulty swallowing and can be taken without water. A precedent for approval of a similar petition exists, and a waiver from pediatric studies is justified based on lack of indication for children under 12 and limited use in that population",,,2025-10-15,0.0,,,,,no decision,False,1899.0,pending,pending
fda-2020-p-1768,FDA-2020-P-1768-0001_Citizen_Petition_from_SIRI___GLIMSTAD_LLP_on_behal.pdf,2020-08-17,2020,False,original petition,Siri & Glimstad LLP,law/consulting,"21 C.F.R. ¬ß 10.30; 21 C.F.R. ¬ß¬ß 25.30, 25.31; references to FDA guidelines on clinical trials and adverse event reporting",FDA's oversight of the Phase III clinical trial design for the ChAdOx1 nCoV-19 (NCT04400838) COVID-19 vaccine,"(a) use a saline placebo, (b) monitor all adverse events for extended periods (12‚Äì60 months), (c) ensure an adequately powered sample size, (d) test T-cell reactivity pre/post vaccination, and (e) conduct germline transmission tests in male participants","The current trial uses an active control (MenACWY) instead of a placebo, has a limited monitoring period for adverse events, and lacks adequate power to detect rare effects. The petitioner argues that this undermines scientific integrity, may prevent future ethical placebo trials, and could harm public trust. The petition emphasizes the need for rigorous safety data, especially since the vaccine may become mandatory and may impact children and young adults with statistically low risk from COVID-19",,Dismissed as moot,2023-07-18,0.0,Center for Biologics Evaluation and Research (CBER),"21 CFR 10.30(e), 21 CFR 10.35(e)",,"The FDA dismissed the petitions related to the ChAdOx1 nCoV-19 vaccine because AstraZeneca publicly announced it would not submit a Biologics License Application (BLA) for the vaccine in the U.S. As a result, the requested FDA actions regarding the study design before licensure were rendered moot, and there were no regulatory issues remaining to resolve.",dismissed (moot),True,1065.0,CBER,Other/Specialty Center
fda-2020-p-1769,FDA-2020-P-1769-0001_Citizen_Petition_from_SIRI___GLIMSTAD_LLP_on_behal.pdf,2020-08-17,2020,False,original petition,Siri & Glimstad LLP,law/consulting,"21 C.F.R. ¬ß 10.35; 21 C.F.R. ¬ß¬ß 25.30, 25.31; 21 C.F.R. ¬ß 312.32",FDA's oversight of the Phase III clinical trial design for the mRNA-1273 (NCT04470427) COVID-19 vaccine,"Amend the trial design to (a) capture all adverse events for 12‚Äì60 months depending on age group, (b) ensure adequate statistical power to detect rare adverse events and compare with SARS-CoV-2 outcomes, and (c) include T-cell reactivity testing pre- and post-vaccination","The current trial only tracks short-term adverse events, lacks sufficient power to compare safety outcomes across demographics, and omits important immunological tests. Without changes, the trial may not provide meaningful data on long-term safety, which is crucial if the vaccine becomes mandatory. A placebo-controlled, fully monitored trial is necessary for public trust and scientifically valid safety assessment",,Denied,2020-12-18,0.0,Center for Biologics Evaluation and Research (CBER),"21 CFR 10.30(e)(3), 21 CFR 10.35(e), 21 CFR 312.2, 21 CFR 312.20(a), 21 CFR 312.22(a), 21 CFR 312.32(c)(1)(i), 21 CFR 312.42, 21 CFR 601.2(a), 21 CFR 601.2(d), 42 U.S.C. ¬ß 262(a)(2)(C)(i)(I), 21 U.S.C. ¬ß 360bbb-3",,"The FDA denied the petition requesting changes to the Phase III trial design of Moderna‚Äôs mRNA-1273 COVID-19 vaccine. The agency found no reasonable grounds for requiring documentation of all adverse events for extended periods, expanded sample sizes, or mandatory T-cell reactivity testing. It stated that the existing study design met regulatory requirements, was informed by scientific evidence, and ensured safety and efficacy through randomized controls and robust follow-up. FDA emphasized that excessive data collection could obscure meaningful safety signals and complicate analysis, and that randomization sufficiently balanced confounders like preexisting immunity. Therefore, the petition was denied under applicable statutory and regulatory provisions.",denied,True,123.0,CBER,Other/Specialty Center
fda-2020-p-1770,FDA-2020-P-1770-0001_Citizen_Petition_from_SIRI___GLIMSTAD_LLP_on_behal.pdf,2020-08-17,2020,False,original petition,Siri & Glimstad LLP,law/consulting,"21 C.F.R. ¬ß 10.30; 21 C.F.R. ¬ß¬ß 25.30, 25.31; 21 C.F.R. ¬ß 312.32",FDA's oversight of the Phase III clinical trial design for the BNT162b2 COVID-19 vaccine (NCT04368728),"Amend the study design to (a) document all adverse events for 12‚Äì60 months based on age, (b) use an adequately powered sample size to compare vaccine safety to SARS-CoV-2 effects, and (c) include T-cell reactivity testing before and after vaccination","The petitioner argues the trial's limited adverse event tracking period and lack of long-term monitoring undermine its safety assessment. It also lacks statistical power and fails to evaluate T-cell immunity. The trial's current limitations could jeopardize public trust and make it impossible to assess causality after licensure, especially if the vaccine is mandated",,Denied,2020-12-11,0.0,Center for Biologics Evaluation and Research (CBER),"21 CFR 10.30(e)(3), 21 CFR 10.35(e), 21 CFR 312.2, 21 CFR 312.20(a), 21 CFR 312.22(a), 21 CFR 312.32(c)(1)(i), 21 CFR 312.42, 21 CFR 601.2(a), 21 CFR 601.2(d), 42 U.S.C. ¬ß 262(a)(2)(C)(i)(I), 21 U.S.C. ¬ß 360bbb-3",,"The FDA denied the citizen petitions and petition for administrative stay of action concerning the Phase III trial of the BNT162b COVID-19 vaccine. The FDA found no reasonable grounds for the requested actions, such as extending the duration of adverse event documentation, increasing sample size, or mandating T-cell reactivity testing. The agency concluded that the trial design met regulatory standards and scientific rigor, including safety monitoring protocols, sample sizes adequate to detect rare adverse events, and randomized controls that account for confounders like preexisting immunity. The FDA further held that the trial's structure allowed for clear evaluation of safety and efficacy, and the public interest weighed against halting the trial.",denied,True,116.0,CBER,Other/Specialty Center
fda-2020-p-1771,FDA-2020-P-1771-0001_Citizen_Petition_from_Windels_Marx_Lane___Mittendo.pdf,2020-08-17,2020,False,original petition,"Frank D. Rodriguez, Windels Marx Lane & Mittendorf, LLP",law/consulting,"21 C.F.R. ¬ß 10.25(a), 21 C.F.R. ¬ß 10.30, FD&C Act ¬ß 505(j), 21 C.F.R. ¬ß 314.3, 21 C.F.R. ¬ß¬ß 320.22, 320.24(b)(6), 21 C.F.R. ¬ß 25.31",FDA's designation of the reference standard (RS) for Dextromethorphan Hydrobromide and Promethazine Hydrochloride Oral Syrup in the Orange Book,"Designate ANDA 088864 (Wockhardt Bio AG's formulation) as the new or additional reference standard (RS) for Dextromethorphan Hydrobromide and Promethazine Hydrochloride Oral Syrup, 15 mg/5 mL; 6.25 mg/5 mL","The current RS approved under ANDA 040649 is not commercially available, preventing ANDA applicants from obtaining necessary quantities for testing. The proposed alternative, ANDA 088864, is therapeutically equivalent, commercially available, and the market leader, thus providing a viable pathway for generic development and competition",,Procedural acknowledgment only; no substantive decision issued,2020-08-18,0.0,"Dockets Management Staff, FDA/Office of Operations (OO)",Not Mentioned,,"The letter states that the petition was received and assigned a docket number, and that its acceptance is purely procedural and does not reflect any decision on the petition's substantive merits.",other,True,1.0,DMS,Other/Specialty Center
fda-2020-p-1775,FDA-2020-P-1775-0001_Citizen_Petition_from_Novitium_Pharma_LLC.pdf,2020-08-19,2020,False,original petition,Novitium Pharma LLC,industry/corporation,"21 C.F.R. ¬ß 10.30, 21 C.F.R. ¬ß 314.94(a)(3)",FDA's designation of the reference standard (RS) for Mesalamine Enema 4 g/60 mL in the Orange Book,Designate the generic Mesalamine Enema 4 g/60 mL product made by Perrigo Israel Pharmaceuticals Ltd (ANDA #076751) as the new RS,"The current RS, Rowasa (approved under NDA 019618), is no longer available on the market, making it impossible for generic manufacturers to develop products. The Perrigo product is currently the only available formulation and should be designated as the RS to support generic drug development and reduce healthcare costs",,,2025-10-15,0.0,,,,,no decision,False,1883.0,pending,pending
fda-2020-p-1792,FDA-2020-P-1792-0001_Citizen_Petition_from_Macleods_Pharmaceuticals_Lim.pdf,2020-08-21,2020,False,original petition,Macleods Pharmaceuticals Limited,industry/corporation,"21 C.F.R. ¬ß¬ß 10.20, 10.30, 314.93; FDCA Section 505(j); 21 C.F.R. ¬ß¬ß 25.31(a), 25.15(d)","FDA‚Äôs designation of a reference standard (RS) for Metformin Hydrochloride Extended-Release Tablets, 750 mg","Designate a new RS from the list of approved generic products for Metformin Hydrochloride Extended-Release Tablets, 750 mg, in place of ANDA #078596 (Amneal), which is currently unavailable","The current RS, ANDA #078596 by Amneal Pharmaceuticals, is unavailable on the market due to a voluntary recall. Multiple alternative generics remain approved and listed in the Orange Book. To facilitate ANDA development and bioequivalence studies, Macleods requests that one of these generics be designated as the new RS",,,2025-10-15,0.0,,,,,no decision,False,1881.0,pending,pending
fda-2020-p-1844,FDA-2020-P-1844-0001_Citizen_Petition_from_HYMAN__PHELPS___MCNAMARA__P_.pdf,2020-09-01,2020,False,original petition,"Sara W. Koblitz, Hyman, Phelps & McNamara, P.C.",law/consulting,"21 C.F.R. ¬ß¬ß 10.25(a), 10.30; FDCA ¬ß 505(j); 21 C.F.R. ¬ß 314.3; 21 C.F.R. ¬ß¬ß 25.31, 10.30(b)","FDA's designation of a Reference Listed Drug (RLD) and Reference Standard (RS) for Docetaxel Injection, particularly NDA 205934",Amend the Orange Book to designate Docetaxel Injection (NDA 205934) as both a Reference Listed Drug (RLD) and Reference Standard (RS),"The currently listed RLDs for Docetaxel Injection contain alcohol and include a related CNS warning. NDA 205934 contains no alcohol and was approved via 505(b)(2). This difference creates a barrier for ANDA applicants seeking to make a non-alcohol version, due to excipient-based impurity profiles and labeling differences. Designating NDA 205934 as an RLD and RS would facilitate generic development, address bioequivalence concerns, and improve access for alcohol-sensitive patients",,Procedural acknowledgment only; no substantive decision issued,2020-09-02,0.0,"Dockets Management Staff, FDA/Office of Operations (OO)",Not Mentioned,,The letter confirms receipt of the petition and clarifies that its acceptance is a procedural formality and does not reflect any judgment on the substantive merits of the petition.,other,True,1.0,DMS,Other/Specialty Center
fda-2020-p-1849,FDA-2020-P-1849-0001_Citizen_Petition_from_FOLEY___LARDNER_LLP.pdf,2020-09-03,2020,False,original petition,"David L. Rosen, Foley & Lardner LLP",law/consulting,"21 C.F.R. ¬ß¬ß 10.25(a), 10.30, 314.93; FDCA ¬ß 505(j)(2)(C); 21 C.F.R. ¬ß 25.31",FDA‚Äôs designation of a reference standard (RS) in the Orange Book for neomycin and polymyxin B sulfates and hydrocortisone otic suspension,Designate Oticair Otic Suspension USP (ANDA #A064065 by Bausch and Lomb Pharmaceuticals Inc.) as an additional reference standard,"The current RS, CASPORYN HC Otic Suspension (NDA #N060613), is not available in the U.S. market due to backorder issues. Oticair, which is pharmaceutically equivalent and actively distributed, should be designated as an RS to enable ANDA applicants to conduct comparative studies for generic development",,,2025-10-15,0.0,,,,,no decision,False,1868.0,pending,pending
fda-2020-p-1864,FDA-2020-P-1864-0001_Citizen_Petition_from_Kambiz_Tajkarimi__MD_Redacte.pdf,2020-09-11,2020,False,original petition,"Kambiz Tajkarimi, MD",individual,"21 C.F.R. ¬ß¬ß 25.30, 25.31, 25.32, 25.33, 25.34",FDA‚Äôs potential approval or clearance (via 510(k) or other mechanisms) of the Augmenta silicone penile implant,Refrain from granting any 510(k) clearance or premarket approval to the Augmenta silicone penile implant,"The petitioner argues that the Augmenta implant has fundamental design flaws (including potentially harmful mesh tabs), is subject to ongoing litigation over trade secret theft, and has been advertised and marketed in violation of FDA rules without clearance. He claims the device could cause significant patient harm due to physical complications and misleading safety claims",,,2025-10-15,0.0,,,,,no decision,False,1860.0,pending,pending
fda-2020-p-1875,FDA-2020-P-1875-0001_Citizen_Petition_from_Grain_Processing_Corporation.pdf,2020-11-20,2020,False,original petition,Grain Processing Corporation,industry/corporation,"21 C.F.R. ¬ß¬ß 10.30, 10.20, 101.9(c)(6)(i), 184.1444, 25.22, 25.30(k)","FDA‚Äôs nutrition labeling policy regarding recognition of dietary fibers, specifically the classification of Isomaltodextrin under Resistant Maltodextrin in the Nutrition Facts label","Amend 21 C.F.R. ¬ß 101.9(c)(6)(i) to include Isomaltodextrin as a dietary fiber under the Resistant Maltodextrin category for use in food, beverages, and dietary supplements","Isomaltodextrin is chemically and functionally similar to currently recognized resistant maltodextrins. It is GRAS (GRAS Notification 610), non-digestible, and beneficial to human health. It meets the structural and physiological criteria established by FDA for dietary fibers in the Resistant Maltodextrin category",,,2025-10-15,0.0,,,,,no decision,False,1790.0,pending,pending
fda-2020-p-1878,FDA-2020-P-1878-0001_Citizen_Petition_from_Foley___Lardner__LLP.pdf,2020-09-17,2020,False,original petition,"David L. Rosen, Foley & Lardner LLP",law/consulting,Referencing Approved Drug Products in ANDA Submissions,FDA‚Äôs designation of a reference standard (RS) for Warfarin Sodium Tablets USP 10 mg,"Designate Warfarin Sodium Tablets USP 10 mg (ANDA No. 040301, held by Taro Pharmaceutical Industries Ltd.) as a reference standard","The current RS, Coumadin (NDA 009218), is unavailable in the market despite diligent efforts to obtain it for required in-vivo bioequivalence studies. The Taro-manufactured version is commercially available and holds significant market share, making it suitable as a new RS to facilitate ANDA submissions",,Procedural acknowledgment only; no substantive decision issued,2020-09-18,0.0,"Dockets Management Staff, FDA/Office of Operations (OO)",Not Mentioned,,The letter confirms receipt of the petition and clarifies that its acceptance is a procedural formality and does not reflect any decision on the substantive merits of the petition.,other,True,1.0,DMS,Other/Specialty Center
fda-2020-p-1881,FDA-2020-P-1881-0001_Citizen_Petition_from_The_Weinberg_Group.pdf,2020-09-15,2020,False,original petition,"The Weinberg Group, a ProPharma Group Company",industry/corporation,"21 C.F.R. ¬ß¬ß 10.25(a), 10.30, 314.161; FD&C Act; 21 C.F.R. ¬ß 25.31",FDA‚Äôs policy regarding determination of whether a drug was withdrawn from the market for reasons of safety or effectiveness,"Determine whether Serentil (mesoridazine besylate) tablets, NDA 016774, were withdrawn for safety or effectiveness reasons","Although Serentil was withdrawn from the market in 2018 and listed in the Orange Book as discontinued, no formal determination has been made by the FDA regarding the reason for withdrawal. The petitioner seeks this determination to clarify regulatory status and potential generic development implications",,,2025-10-15,0.0,,,,,no decision,False,1856.0,pending,pending
fda-2020-p-1914,FDA-2020-P-1914-0001_Citizen_Petition_from_Aurolife_Pharma__LLC____Reda.pdf,2020-09-16,2020,False,original petition,Aurolife Pharma LLC,industry/corporation,"21 C.F.R. ¬ß¬ß 10.25(a), 10.30, 314.93; FDCA ¬ß 505(j); 21 C.F.R. ¬ß¬ß 25.31(a), 25.15(d)",FDA's designation of a reference standard (RS) for Lidocaine Hydrochloride Jelly 2%,"Designate Lidocaine Hydrochloride Jelly 2% (ANDA #040433, held by Akorn Inc.) as a new reference standard (RS) for ANDA development","The currently designated RS, Xylocaine (NDA #008816), is not discontinued in the Orange Book but is unavailable in the market, making bioequivalence testing infeasible. The Akorn product is the market leader in distribution and is more accessible, justifying its designation as the new RS for generic development",,Procedural acknowledgment only; no substantive decision issued,2020-09-17,0.0,"Dockets Management Staff, FDA/Office of Operations (OO)",Not Mentioned,,The letter confirms receipt of the petition and clarifies that its acceptance is procedural and does not reflect a decision on the substantive merits of the petition.,other,True,1.0,DMS,Other/Specialty Center
fda-2020-p-1919,FDA-2020-P-1919-0001_Citizen_Petition_from_Acella_Pharmaceuticals__LLC.pdf,2020-09-16,2020,False,original petition,"Acella Pharmaceuticals, LLC",industry/corporation,"21 C.F.R. ¬ß¬ß 10.25(a), 10.30, 314.161, 25.31(a)","FDA's designation of a Reference Standard (RS) for Meprobamate Tablets, 400 mg","Designate a new Reference Standard for Meprobamate Tablets, 400 mg, due to the unavailability of both the Reference Listed Drug (RLD) and the current RS (Watson Labs, ANDA 083308)","Acella intends to resume manufacture under ANDA 084153, but the original dissolution profile and samples are unavailable. Since the current RS is no longer on the market, the petitioner requests FDA to designate an alternative RS to allow development and testing for bioequivalence",,Procedural acknowledgment only; no substantive decision issued,2020-09-17,0.0,"Dockets Management Staff, FDA/Office of Operations (OO)",Not Mentioned,,The letter acknowledges receipt of the petition and clarifies that its acceptance for filing is a procedural formality and does not reflect any decision on the substantive merits of the petition.,other,True,1.0,DMS,Other/Specialty Center
fda-2020-p-1991,FDA-2020-P-1991-0001_Citizen_Petition_from_HYMAN__PHELPS___MCNAMARA__P_(1).pdf,2020-09-21,2020,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"21 C.F.R. ¬ß¬ß 10.25, 10.30, 314.122, 314.161, 25.31; FDCA Sections 505(j), 505(w)","FDA‚Äôs listing and regulatory status of HYDROCORTONE (hydrocortisone sodium phosphate) Injection, 50 mg base/mL, NDA 012052",Determine whether HYDROCORTONE (NDA 012052) was withdrawn from sale for reasons of safety or effectiveness,HYDROCORTONE was listed as discontinued in the Orange Book and its NDA was withdrawn at the sponsor‚Äôs request in 2004. The petitioner is unaware of any evidence suggesting withdrawal was due to safety or efficacy concerns and believes it was for commercial reasons. A determination from FDA is needed to support future ANDA referencing,,,2025-10-15,0.0,,,,,no decision,False,1850.0,pending,pending
fda-2020-p-2003,FDA-2020-P-2003-0001_Citizen_Petition_from_Environmental_Defense_Fund.pdf,2020-09-23,2020,False,original petition,"Environmental Defense Fund (with co-petitioners including American Academy of Pediatrics, American Public Health Association, Breast Cancer Prevention Partners, Center for Food Safety, Clean Label Project, Consumer Federation of America, Consumer Reports, Endocrine Society, Environmental Health Strategy Center, Environmental Working Group, and Healthy Babies Bright Futures)",advocacy/academic,"21 U.S.C. ¬ß 348; 21 U.S.C. ¬ß 379e; 5 U.S.C. ¬ß 553(e); 21 C.F.R. ¬ß¬ß 10.30, 70.3, 70.11, 70.16, 71.1, 170.3, 170.16, 170.18, 170.39, 170.101, 170.250, 171.1, 25.30, 25.31, 25.32, 25.33, 25.34","FDA‚Äôs regulation and guidance on safety evaluations for food additives, color additives, GRAS substances, and food contact substances‚Äîspecifically its failure to implement the requirement to consider cumulative effects of chemically- and pharmacologically-related substances in the diet","Revise regulations, guidance, and petition/notification forms to require and clarify cumulative effect evaluations that consider chemically- and pharmacologically-related substances in the diet, including updating definitions and requiring explicit evaluation in petitions and notifications","Petitioners argue that FDA has consistently failed to enforce a statutory requirement from the 1958 Food Additives Amendment and subsequent laws mandating consideration of cumulative effects in dietary safety evaluations. This failure has serious implications for public health‚Äîparticularly among children and underserved communities‚Äîand has contributed to increased risk of chronic diseases. The petition presents evidence from regulations, GRAS notifications, and FDA practices showing the lack of cumulative effect analysis and calls for specific regulatory and procedural reforms",,,2025-10-15,0.0,,,,,no decision,False,1848.0,pending,pending
fda-2020-p-2004,FDA-2020-P-2004-0001_Citizen_Petition_from_Lachman_Consulting_Services_.pdf,2020-09-23,2020,False,original petition,"Lachman Consulting Services, Inc.",law/consulting,"21 C.F.R. ¬ß¬ß 10.25(a), 10.30; FDCA ¬ß 505(j); 21 C.F.R. ¬ß 314.3; FDA Draft Guidance for Industry (Jan. 2017)",FDA‚Äôs designation of a reference standard (RS) in the Orange Book for Neomycin and Polymyxin B Sulfates and Hydrocortisone Otic Suspension/Drops,Designate ANDA 064065 (marketed by Bausch & Lomb) as a new RS for Neomycin and Polymyxin B Sulfates and Hydrocortisone Otic Suspension/Drops,"The current RS (CASPORYN HC, NDA 060613) is reportedly no longer available for purchase in the U.S., hindering generic competition. ANDA 064065 is therapeutically equivalent, actively marketed, and the market leader. Designating it as the RS would support further generic development and ensure market access",,,2025-10-15,0.0,,,,,no decision,False,1848.0,pending,pending
fda-2020-p-2008,FDA-2020-P-2008-0001_Citizen_Petition_from_Philips_Respironics.pdf,2020-09-22,2020,False,original petition,"Philips Respironics (Respironics, Inc.)",industry/corporation,"21 U.S.C. ¬ß 360i(e); 21 C.F.R. ¬ß¬ß 821.2, 10.3, Part 821, 25.30(j), 25.34(c); FDA Guidance for Software Contained in Medical Devices (2005); FDA Policy for Device Software Functions and Mobile Medical Applications (2019)","FDA‚Äôs device tracking requirements for Class II and III devices under 21 C.F.R. Part 821, specifically the tracking order issued for the Care Orchestrator",Grant an exemption from the device tracking requirements under 21 C.F.R. Part 821 for the Care Orchestrator (cleared under 510(k) K181053),"Care Orchestrator is a cloud-based, Class II SaMD used for remote patient data tracking and adjustment of non-life-support therapy devices. It is not life-sustaining, not implanted, and not likely to cause serious adverse health consequences if it fails. The device has had no reportable adverse events, is classified as 'Moderate' risk, and is accessed via browsers and app stores, making tracking impractical. Philips argues that device tracking is not legally or practically warranted",,,2025-10-15,0.0,,,,,no decision,False,1849.0,pending,pending
fda-2020-p-2010,FDA-2020-P-2010-0001_Citizen_Petition_from_Philips_Respironics.pdf,2020-09-22,2020,False,original petition,"Philips Respironics (Respironics, Inc.)",industry/corporation,"21 U.S.C. ¬ß 360i(e); 21 C.F.R. ¬ß¬ß 821.2, 10.3, Part 821, 25.30(j), 25.34(c); FDA guidance on device tracking and medical software","FDA‚Äôs device tracking requirements for Class II and III devices under 21 C.F.R. Part 821, specifically a tracking order issued for the Care Orchestrator Essence (510(k) K183226)",Grant an exemption from the device tracking requirements under 21 C.F.R. Part 821 for the Care Orchestrator Essence,"Care Orchestrator Essence is a Class II desktop-based software for healthcare professionals to manage and transmit therapy data and prescriptions for non-life-supporting devices. It is not life-sustaining, implanted, or intended for patient use. The software has demonstrated low risk in post-market data, no reportable adverse events, and features built-in prescription validation safeguards. Tracking is unnecessary due to limited distribution and oversight by qualified professionals",,,2025-10-15,0.0,,,,,no decision,False,1849.0,pending,pending
fda-2020-p-2013,FDA-2020-P-2013-0001_Citizen_Petition_from_Lachman_Consulting_Services_.pdf,2020-09-24,2020,False,original petition,"Lachman Consulting Services, Inc.",law/consulting,"21 C.F.R. ¬ß¬ß 10.25(a), 10.30; FDCA ¬ß 505(j); 21 C.F.R. ¬ß 314.3; FDA Draft Guidance for Industry (Jan. 2017); 21 C.F.R. ¬ß 25.31","FDA‚Äôs designation of a reference standard (RS) in the Orange Book for Lidocaine Hydrochloride Topical Jelly, 2%","Designate Akorn Inc.‚Äôs Lidocaine Hydrochloride Topical Jelly, 2% (ANDA 040433) as a new Reference Standard","The current RS and RLD, XYLOCAINE (NDA 008816), is reportedly no longer marketed in the U.S., hindering generic competition. Akorn‚Äôs ANDA product is therapeutically equivalent, readily accessible, and the current market leader, making it an appropriate candidate for RS designation to support continued ANDA development",,Acknowledged (no substantive decision made),2020-09-25,0.0,"Dockets Management Staff (DMS), Office of Operations",Not Mentioned,,"The letter acknowledges receipt and filing of the citizen petition regarding the designation of an ANDA reference standard (RS) for Lidocaine Hydrochloride Topical Jelly, 2%. It explicitly states that the acceptance for filing is a procedural matter and does not indicate any decision on the merits of the petition.",other,True,1.0,DMS,Other/Specialty Center
fda-2020-p-2017,FDA-2020-P-2017-0001_Citizen_Petition_from_Alston___Bird_LLP.pdf,2020-09-28,2020,False,original petition,Alston & Bird LLP,law/consulting,"21 C.F.R. ¬ß¬ß 10.25(a), 10.30, 314.93; FDCA ¬ß 505(j)(2)(C); 21 C.F.R. ¬ß 314.3; FDA Draft Guidance for Industry (Jan. 2017); 21 C.F.R. ¬ß 25.31",FDA‚Äôs designation of Reference Listed Drugs (RLDs) for Nicardipine Hydrochloride Injection,"Designate Nicardipine Hydrochloride Premixed Injection, 0.1 mg/mL and 0.2 mg/mL in 0.9% Sodium Chloride, manufactured by Exela Pharma Sciences under NDA 022276, as alternative RLDs","The currently designated RLDs (Cardene products by Chiesi) use different sodium chloride concentrations (0.86% and 0.83%) than the intended 0.9% formulation. Because ANDAs must be Q1/Q2 formulation matches, the formulation difference poses a barrier. The Exela products, although approved via 505(b)(2), match the client's product formulation and meet all other criteria (strength, dosage form, labeling, etc.). FDA guidance allows for RLD designation of 505(b)(2) drugs to ensure generic competition is not blocked",,,2025-10-15,0.0,,,,,no decision,False,1843.0,pending,pending
fda-2020-p-2028,FDA-2020-P-2028-0001_Citizen_Petition_from_Outsourcing_Facilities_Assoc.pdf,2020-09-30,2020,False,original petition,Outsourcing Facilities Association (OFA),advocacy/academic,"21 U.S.C. ¬ß 353b(a)(2)(A)(i); 21 C.F.R. ¬ß 10.30; 21 C.F.R. ¬ß¬ß 25.30, 25.31, 25.32, 25.34",FDA‚Äôs interpretation and regulatory application of the term 'clinical need' in relation to the 503B Bulks List for compounding from bulk drug substances,"Issue a regulation formally defining 'clinical need' under Section 503B(a)(2)(A)(i) of the FD&C Act and, in accordance with that definition, establish the 503B Bulks List of bulk drug substances for which there is a clinical need within 180 days","FDA has failed to provide a clear definition of 'clinical need,' leading to inconsistent and restrictive determinations that undermine access to compounded medications during drug shortages and public health emergencies. OFA argues this harms public health, violates statutory intent, and intrudes on the practice of medicine. A clear, consistent definition would enhance patient access, support physician judgment, and enable FDA-registered outsourcing facilities to operate effectively within their regulatory framework",,,2025-10-15,0.0,,,,,no decision,False,1841.0,pending,pending
fda-2020-p-2033,FDA-2020-P-2033-0001_Citizen_Petition_from_University_of_Kentucky_Drug_.pdf,2020-09-30,2020,False,original petition,University of Kentucky Drug Quality Study (UK DQS) team,advocacy/academic,"21 U.S.C. ¬ß¬ß 331, 351, 352, 355, 372, 374, 375; 21 C.F.R. ¬ß¬ß 10.20, 10.30, 25.30","FDA‚Äôs oversight of drug quality and manufacturing practices, especially regarding Acetazolamide for Injection manufactured by Mylan and Hikma",1) Request a recall of specified lots of Acetazolamide for Injection; 2) conduct investigations into these products and their manufacturing processes; 3) provide public information about these products; 4) promulgate or issue guidance requiring independent batch-level chemical testing and verification of drug products,"Independent chemical analysis revealed that vials of Acetazolamide for Injection from both Mylan and Hikma are subpotent (80‚Äì87% of labeled API), contain excessive impurities, and show inconsistent spectral profiles indicative of manufacturing out of control. These findings suggest the products are adulterated and misbranded under FDCA, posing risks to public health, particularly since Acetazolamide is a WHO essential medicine",,,2025-10-15,0.0,,,,,no decision,False,1841.0,pending,pending
fda-2020-p-2048,FDA-2020-P-2048-0001_Citizen_Petition_from_Fresenius_Kabi_USA__LLC.pdf,2020-10-04,2020,False,original petition,"Fresenius Kabi USA, LLC",industry/corporation,"21 C.F.R. ¬ß¬ß 10.30, 314.161, 314.162, 25.31","FDA‚Äôs regulatory status and Orange Book listing of Manganese Sulfate, Eq 0.1 mg manganese/mL (NDA 019228) approved to Abraxis Pharmaceutical Products","Determine whether the listed drug product Manganese Sulfate, Eq 0.1 mg manganese/mL (NDA 019228) has been withdrawn from sale for reasons of safety or effectiveness","The drug appears in the 'Discontinued Section' of the Orange Book. Before an Abbreviated New Drug Application (ANDA) may be submitted referring to this product, the FDA must determine if the withdrawal was for reasons of safety or effectiveness. Fresenius Kabi requests this determination to support regulatory planning and ANDA submission eligibility",,,2025-10-15,0.0,,,,,no decision,False,1837.0,pending,pending
fda-2020-p-2060,FDA-2020-P-2060-0001_Citizen_Petition_from_Penn_Avenue_Law___Policy.pdf,2020-10-07,2020,False,original petition,Penn Avenue Law & Policy,law/consulting,"21 C.F.R. ¬ß¬ß 10.25(a), 10.30; 42 U.S.C. ¬ß 263a; 21 C.F.R. ¬ß¬ß 25.30, 25.31, 25.32, 25.34",FDA‚Äôs policy differentiating 'screening tests' and 'surveillance tests' for SARS-CoV-2 during the COVID-19 public health emergency,"Permit facilities (e.g., schools, workplaces) to use 'screening tests' in the same manner as 'surveillance tests' even if the screening tests are not FDA-authorized, provided results are confirmed through a CLIA-certified laboratory and no individual results are shared onsite","The petition argues that the current distinction between screening and surveillance tests restricts facilities‚Äô ability to prevent COVID-19 transmission. Since both test types share key features‚Äîe.g., no individual results can be disclosed without CLIA lab confirmation‚Äîthe petition requests regulatory parity. It emphasizes the need for accessible, accurate, and rapid onsite screening tools beyond unregulated thermometers and pulse oximeters, especially given high demand, test shortages, and the approaching flu season",,,2025-10-15,0.0,,,,,no decision,False,1834.0,pending,pending
fda-2020-p-2096,FDA-2020-P-2096-0001_Citizen_Petition_from_Siri___Glimstad_LLP_on_behal.pdf,2020-10-16,2020,False,original petition,Siri & Glimstad LLP,law/consulting,"21 C.F.R. ¬ß 10.30; 21 C.F.R. ¬ß¬ß 25.30, 25.31, 25.32, 25.34; 21 U.S.C. ¬ß 360i(e)",FDA‚Äôs oversight of the Phase III clinical trial design for the Ad26.COV2.S COVID-19 vaccine (NCT04505722),"(a) document all adverse events for all participants for longer periods (24‚Äì60 months), (b) ensure adequate sample size and statistical power, (c) conduct T-cell reactivity testing pre- and post-vaccination, (d) perform germline transmission testing in male participants, and (e) monitor HIV incidence with evaluation in mucosal tissues","The petition claims the current trial design inadequately captures long-term and non-serious adverse events, especially in children, and lacks critical safety assessments (e.g., T-cell, germline, HIV). It argues that failure to amend the design could compromise public trust, limit future ethical trial designs, and increase risk if vaccines become mandatory. Comparisons are made to historical vaccine and drug trial protocols to emphasize the need for extended monitoring and robust controls",,,2025-10-15,0.0,,,,,no decision,False,1825.0,pending,pending
fda-2020-p-2130,FDA-2020-P-2130-0001_Citizen_Petition_from_Fresenius_Kabi_USA__LLC.pdf,2020-10-26,2020,False,original petition,"Fresenius Kabi USA, LLC",industry/corporation,"21 C.F.R. ¬ß¬ß 10.30, 314.161, 314.162, 25.31","FDA‚Äôs listing status in the Orange Book of Bortezomib for Injection, 2.5 mg/vial (NDA 209191)","Determine whether Bortezomib for Injection, 2.5 mg/vial (NDA 209191), held by Hospira Inc., was withdrawn from sale for reasons of safety or effectiveness","The product appears in the Discontinued Section of the FDA's Orange Book. Fresenius Kabi requests a determination to clarify whether the withdrawal was due to safety or efficacy concerns or simply a voluntary business decision, as required for ANDA referencing",,,2025-10-15,0.0,,,,,no decision,False,1815.0,pending,pending
fda-2020-p-2132,FDA-2020-P-2132-0001_Citizen_Petition_from_HYMAN__PHELPS___MCNAMARA__P_.pdf,2020-10-26,2020,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"21 C.F.R. ¬ß¬ß 10.25(a), 10.30, 314.3, 25.31; FDCA ¬ß 505(j); FDA Draft Guidance for Industry (Jan. 2017)","FDA‚Äôs designation of a Reference Standard (RS) for Nitrofurantoin Oral Suspension, 25 mg/5 mL, in the Orange Book","Designate ANDA 201355 (Nitrofurantoin Oral Suspension, 25 mg/5 mL, by Nostrum Laboratories Inc.) as a new or additional Reference Standard in the Orange Book","The current RS (Furadantin, NDA 009175) is commercially unavailable, preventing bioequivalence testing and blocking generic competition. The petitioner asserts that ANDA 201355 is the only product currently available on the market and meets criteria to serve as a new RS, facilitating the development of additional generic alternatives",,Acknowledged (no substantive decision made),2020-10-27,0.0,"Dockets Management Staff (DMS), Office of Operations",Not Mentioned,,"The FDA acknowledged receipt and procedural filing of the petition requesting designation of ANDA 201355 (Nitrofurantoin Oral Suspension, 25 mg/5 mL) as a reference standard (RS) to support the submission of future ANDAs. The agency clarified that this acknowledgment does not constitute a decision on the petition's merits.",other,True,1.0,DMS,Other/Specialty Center
fda-2020-p-2133,FDA-2020-P-2133-0001_Citizen_Petition_from_Fresenius_Kabi_USA_LLC.pdf,2020-10-26,2020,False,original petition,"Fresenius Kabi USA, LLC",industry/corporation,"Section 505(q) of the FDCA; 21 C.F.R. ¬ß¬ß 10.20, 10.30, 314.54(a)(1)(iii), 314.3, 314.50(i)(C), 314.101(d)(3), 314.101(d)(9); FDCA ¬ß 505(b)(1), 505(b)(2), 505(b)(4)(A), 505(c)(3)(C); FDA Guidance for Industry (1999, 2004)","FDA‚Äôs reference listing policy and approval standards for Levothyroxine Sodium Intravenous Solution applications, specifically regarding the correct Reference Listed Drug (RLD) to be used for solution versus powder formulations",Refuse to file or approve any ANDA or 505(b)(2) application for Levothyroxine Sodium Intravenous Solution that does not reference NDA No. 210632 (Fresenius Kabi's solution product) as the RLD; require such applications to be refiled with appropriate patent certifications,"The petition argues that referencing the powder form (NDA 202231) instead of the approved solution product (NDA 210632) is scientifically incorrect and strategically intended to bypass the Hatch-Waxman patent certification requirements. FDA‚Äôs policies and regulations mandate referencing the closest pharmaceutically equivalent product, which, for solution products, is the solution RLD. Allowing reference to the powder RLD compromises statutory safeguards and misuses the 505(b)(2) pathway",,,2025-10-15,0.0,,,,,no decision,False,1815.0,pending,pending
fda-2020-p-2134,FDA-2020-P-2134-0001_Citizen_Petition_from_Natural_Products_Association.pdf,2020-10-26,2020,False,original petition,Natural Products Association (NPA),advocacy/academic,"21 C.F.R. ¬ß 101.9, 21 C.F.R. ¬ß 101.36(b)(2), 21 C.F.R. ¬ß 10.30, 21 C.F.R. ¬ß 25.30(h), Section ¬ß 111.75(a)(1) of the FD&C Act",FDA‚Äôs Nutrition Facts and Supplement Facts labeling regulations as they relate to the declaration of caloric values for branched-chain amino acids (BCAAs),1) Amend the Nutrition Facts labeling regulations to align with 21 C.F.R. ¬ß 101.36(b)(2) so that caloric values for BCAAs are not required; 2) Issue formal enforcement discretion allowing manufacturers to follow 21 C.F.R. ¬ß 101.36(b)(2) instead of ¬ß 101.9 during the amendment process,"NPA argues that current FDA labeling regulations are inconsistent and cause confusion for manufacturers regarding whether to list caloric values for BCAAs, which are not considered complete proteins. This inconsistency opens companies to litigation and results in consumer confusion. NPA requests that the FDA clarify and align its rules, noting that BCAAs should not be required to report calories if they cannot be labeled as contributing protein. Until formal revision is completed, enforcement discretion is necessary to protect manufacturers from compliance risk",,,2025-10-15,0.0,,,,,no decision,False,1815.0,pending,pending
fda-2020-p-2136,FDA-2020-P-2136-0001_Citizen_Petition_from_SIRI___GLIMSTAD__LLP__on_beh.pdf,2020-10-28,2020,False,original petition,Siri & Glimstad LLP,law/consulting,"21 C.F.R. ¬ß 10.35; 21 C.F.R. ¬ß¬ß 25.30, 25.31",FDA‚Äôs labeling and disclosure requirements for acellular pertussis (aP) vaccines,Require all manufacturers of acellular pertussis-containing vaccines to amend the package inserts to disclose that these vaccines do not prevent infection or transmission of pertussis,"Scientific literature and expert consensus show that while aP vaccines may reduce symptoms of pertussis, they do not induce mucosal immunity necessary to prevent colonization or transmission of the bacterium. Individuals can be asymptomatically infected and transmit pertussis despite vaccination. The petition argues this information is crucial for informed medical decisions and public health transparency, and should be disclosed in vaccine labeling",,Denied,2023-09-05,0.0,Center for Biologics Evaluation and Research (CBER),"21 CFR 10.30(e)(3), 21 CFR 601.2(a), 21 CFR 201.56, 21 CFR 201.57, 21 CFR 201.100(d), 21 CFR 601.12(f), Section 351 of the Public Health Service (PHS) Act, Section 502 of the FD&C Act",,"The FDA denied the petition requesting that manufacturers of acellular pertussis-containing vaccines be required to amend their package inserts to disclose that the vaccines do not prevent infection and transmission. The agency explained that its vaccine licensure standards do not require prevention of infection or transmission‚Äîonly that a vaccine is safe and effective for its intended use. The currently licensed vaccines are indicated for prevention of pertussis disease, not infection. The existing labeling is accurate and complies with statutory and regulatory requirements. FDA found no evidence of a widespread public misconception requiring a labeling change and concluded that the petitioner‚Äôs arguments and supporting studies did not justify the requested amendment.",denied,True,1042.0,CBER,Other/Specialty Center
fda-2020-p-2144,FDA-2020-P-2144-0001_Citizen_Petition_from_Robert_van_Osdel___redacted.pdf,2020-11-02,2020,False,original petition,Robert van Osdel,individual,"Section 505(j)(2)(C) of the FD&C Act; 21 C.F.R. ¬ß¬ß 10.25, 10.30, 314.93(b), 314.93(e)(1); 21 C.F.R. ¬ß 25.31(a)","FDA‚Äôs policy on ANDA suitability for modified dosage forms‚Äîspecifically, Ticagrelor Orally Disintegrating Tablets (ODTs) vs. immediate release tablets (Brilinta)",Declare that a drug product containing Ticagrelor 90 mg in an orally disintegrating tablet (ODT) form is suitable for submission as an Abbreviated New Drug Application (ANDA),"The ODT form would offer benefits such as easier administration for patients with swallowing difficulties and potential use without water. Citing European Medicines Agency (EMA) data, the petitioner notes that ODT and IR forms of Ticagrelor are bioequivalent. Labeling differences would be minor and limited to dosage form references and inactive ingredients. No new safety or efficacy investigations are required, and the pediatric study requirement was already waived for the reference listed drug",,Acknowledged (no substantive decision made),2020-10-30,0.0,"Dockets Management Staff (DMS), Office of Operations",Not Mentioned,,The letter acknowledges procedural receipt and filing of the petition requesting FDA to declare that a drug product containing Ticagrelor 90 mg in an orally disintegrating tablet form is suitable for submission as an Abbreviated New Drug Application (ANDA). The agency clarified that acceptance for filing is procedural and does not reflect any substantive evaluation or decision.,other,True,-3.0,DMS,Other/Specialty Center
fda-2020-p-2174,FDA-2020-P-2174-0001_Citizen_Petition_from_Lachman_Consulting_Services_.pdf,2020-11-05,2020,False,original petition,"Lachman Consulting Services, Inc.",law/consulting,"21 C.F.R. ¬ß¬ß 10.25(a), 10.30, 314.122, 314.161, 314.162; FDCA Sections 505(j), 505(w)","FDA‚Äôs Orange Book listing and regulatory status of Atrovent (ipratropium bromide) Nasal Spray, 0.021 mg/spray (NDA 020393) and 0.042 mg/spray (NDA 020394)",Determine whether the Atrovent Nasal Spray products approved under NDA 020393 and NDA 020394 were withdrawn from sale for reasons of safety or effectiveness,"Although these NDAs were withdrawn at the sponsor‚Äôs request and are listed in the 'Discontinued Drug Product List' of the Orange Book, the petitioner is unaware of any safety or efficacy concerns. The petition suggests the withdrawal was due to commercial reasons, especially since generic versions remain available, and requests FDA's formal determination to support ANDA referencing",,,2025-10-15,0.0,,,,,no decision,False,1805.0,pending,pending
fda-2020-p-2175,FDA-2020-P-2175-0001_Citizen_Petition_from_Lachman_Consulting_Services_.pdf,2020-11-05,2020,False,original petition,"Lachman Consulting Services, Inc.",law/consulting,"505(j)(2)(C), 21 C.F.R. ¬ß 10.20, 21 C.F.R. ¬ß 10.30",Establishment of a new strength and packaging configuration for an Abbreviated New Drug Application (ANDA) for Succinylcholine Chloride Injection,Requesting the FDA to declare the proposed Succinylcholine Chloride Injection drug products (100 mg/5 mL and 200 mg/10 mL in prefilled syringes) suitable for submission as ANDAs,"The petitioner argues that the proposed changes do not affect safety or efficacy, align with existing approved uses and labeling, and offer benefits such as improved safety, reduced risk of overdose or contamination, single-use dosing, and convenience in emergency use. These benefits justify the use of prefilled syringes over multiple-dose vials.",,,2025-10-15,0.0,,,,,no decision,False,1805.0,pending,pending
fda-2020-p-2180,FDA-2020-P-2180-0001_Citizen_Petition_from_Siri___Glimstad_LLP_on_behal.pdf,2020-11-06,2020,False,original petition,Siri & Glimstad LLP,law/consulting,"21 C.F.R. ¬ß 10.30; 21 C.F.R. ¬ß¬ß 25.30, 25.31; Section 505(j)(2)(C) of the FD&C Act","FDA‚Äôs oversight of the design of Phase III clinical trials for COVID-19 vaccines including mRNA-1273, BNT162, AZD1222, and Ad26.COV2.S","(a) include reduction in severe disease (hospitalizations, ICU admissions, deaths) as a primary endpoint; (b) set PCR amplification thresholds at a maximum of 24 cycles; (c) include interruption of transmission as a primary endpoint; and (d) require T-cell reactivity testing before and after vaccination","Petitioner argues the current vaccine trial endpoints focus only on mild symptomatic COVID-19 cases and fail to measure critical outcomes like severe disease prevention and transmission interruption. High PCR cycle thresholds may produce false positives, skewing efficacy data. Without these amendments, the FDA risks licensing vaccines based on incomplete efficacy data, which could lead to public distrust, especially if mandates follow. The petition emphasizes scientific rigor, public interest, and transparency as justifications",,,2025-10-15,0.0,,,,,no decision,False,1804.0,pending,pending
fda-2020-p-2193,FDA-2020-P-2193-0001_Citizen_Petition_from_Epstein__Becker_and_Green__P.pdf,2020-11-13,2020,False,original petition,"Epstein Becker & Green, P.C.",law/consulting,"21 C.F.R. ¬ß 10.30; Federal Food, Drug, and Cosmetic Act",Approval process of the New Drug Application (NDA) for Roxadustat (FG-4592) for the treatment of anemia in chronic kidney disease (CKD) patients,"Decline to approve the Roxadustat NDA unless the applicant submits additional data proving that the drug‚Äôs risks do not outweigh its benefits for ND-CKD and DD-CKD patients stable on dialysis; additionally, require a boxed warning on the drug‚Äôs label if risks are similar to or worse than current standards","Phase III data suggest increased risk of cardiovascular events and all-cause mortality with Roxadustat, especially in stable dialysis patients. Comparisons to existing treatments do not demonstrate superior benefit. The petition argues FDA should uphold consistent regulatory scrutiny to protect public health and avoid arbitrary action under the Administrative Procedure Act",,,2025-10-15,0.0,,,,,no decision,False,1797.0,pending,pending
fda-2020-p-2212,FDA-2020-P-2212-0001_Citizen_Petition_from_Encore_Dermatology_Inc___red.pdf,2020-11-13,2020,False,original petition,"Encore Dermatology, Inc.",industry/corporation,"505(q), 21 C.F.R. 10.30, 314.94, 314.127",FDA‚Äôs potential approval of Glenmark Pharmaceuticals‚Äô abbreviated new drug application (ANDA 214191) for a generic version of Impoyz (clobetasol propionate cream),"(a) demonstrate bioequivalence via a comparative clinical endpoint study, and (b) provide systemic exposure data, HPA axis suppression data, and local safety data.","Encore argues that Glenmark‚Äôs proposed generic uses more than 10% propylene glycol and lacks Transcutol, a critical excipient in Impoyz that reduces systemic absorption and maintains local effectiveness. This change could increase systemic absorption and alter safety and efficacy profiles, making a simple ANDA inappropriate without further testing. IVPT data also show the Glenmark-like formulation differs significantly in drug permeation behavior, supporting Encore‚Äôs concerns.",,,2025-10-15,0.0,,,,,no decision,False,1797.0,pending,pending
fda-2020-p-2213,FDA-2020-P-2213-0001_Citizen_Petition_from_Kenneth_E__Surprenant_Redact.pdf,2020-11-16,2020,False,original petition,Kenneth E. Surprenant,individual,"505(q); 21 C.F.R. 10.30; 21 C.F.R. ¬ß¬ß 314.94, 314.127; FDA Table of Pharmacogenetic Associations",Labeling requirements and warnings for Fluorouracil and Xeloda (Capecitabine),(1) recommend pre-treatment screening for DPD deficiency; (2) include a Boxed Warning about severe toxicity risks; (3) shift the burden of identifying DPD deficiency from patients to physicians in patient counseling information; and (4) revise dosage recommendations based on DPD screening results,"Current labeling inadequately addresses risks for patients with DPD deficiency, who are at high risk for severe or fatal toxicity when treated with standard doses of fluoropyrimidines. The petitioner cites scientific studies, regulatory precedents (EMA and others), and economic analyses showing pre-screening is feasible, effective, and cost-saving. Recommendations include improving physician guidance, aligning with international standards, and emphasizing patient safety through genotype/phenotype testing",,,2025-10-15,0.0,,,,,no decision,False,1794.0,pending,pending
fda-2020-p-2225,FDA-2020-P-2225-0001_Citizen_Petition_from_Siri___Glimstad_LLP_on_behal.pdf,2020-11-23,2020,False,original petition,Dr. Sin Hang Lee,individual,"21 C.F.R. ¬ß 10.30; 21 C.F.R. ¬ß¬ß 25.30, 25.31; Section 505(j)(2)(C) of the FD&C Act",FDA‚Äôs design and interpretation of efficacy endpoints in the Phase III clinical trial for the BNT162b (Pfizer-BioNTech) COVID-19 vaccine,"Amend the BNT162b Phase III clinical trial design to require that all COVID-19 'endpoints' (i.e., cases) confirmed by RT-qPCR be additionally verified by Sanger sequencing before licensure is granted","RT-qPCR tests used in the trial are prone to false positives, especially at high cycle threshold (Ct) values (above 36‚Äì44.9). False positives can misclassify non-COVID participants as cases, inflating perceived vaccine efficacy. Sanger sequencing, recognized as a gold standard in virology, would validate actual presence of SARS-CoV-2 RNA. Without such confirmation, public trust may be undermined and policy decisions regarding vaccine licensure, mandates, and distribution may rest on unreliable data",,,2025-10-15,0.0,,,,,no decision,False,1787.0,pending,pending
fda-2020-p-2236,FDA-2020-P-2236-0001_Citizen_Petition_from_Covington___Burling__LLP_on_.pdf,2020-11-25,2020,False,original petition,Covington & Burling LLP,law/consulting,"21 C.F.R. ¬ß 10.30; 21 U.S.C. ¬ß 804(j)(2); Administrative Procedure Act (APA); FDCA ¬ß¬ß 502, 503, 505, 581, 582, 701",The petition comments on the implementation of the 'Request for Proposals Regarding Waivers for Individual Drug Importation Plans' issued by HHS and FDA under Section 804(j)(2) of the FDCA,"PhRMA requests that HHS and FDA either discontinue all implementation efforts related to Section 804(j), including withdrawal of the RFP and refraining from approving IWIPs, or refrain from granting waivers unless and until the conditions set forth in the FDCA are satisfied","The petitioner argues that HHS has not met the statutory requirements for safety and cost savings certification as required by Section 804(l) of the FDCA, lacks a factual basis for such certification, and is attempting to authorize commercial importation under the guise of personal importation, bypassing necessary public safeguards and violating the APA. It also asserts that IWIP drugs would be unapproved, misbranded, and possibly adulterated under the FDCA.",,,2025-10-15,0.0,,,,,no decision,False,1785.0,pending,pending
fda-2020-p-2237,FDA-2020-P-2237-0001_Citizen_Petition_from_Dr__S__Albert_Edwards_redact.pdf,2020-11-25,2020,False,original petition,Dr. S. Albert Edwards,individual,21 C.F.R. ¬ß 10.30; 21 C.F.R. ¬ß 25.34; FD&C Act; FDA EUA Guidance (January 2017),"FDA‚Äôs Emergency Use Authorization (EUA) policy and practice, specifically the lack of time limits for EUAs granted for regulated medical products","Request the FDA to set time limits for Emergency Use Authorizations (EUAs) for all regulated medical products, with timelines tailored to specific product classes and development histories","The petitioner argues that establishing time limits for EUAs will encourage timely development and final approval of medical products, prevent misuse of EUA status for prolonged marketing, reduce the presence of fraudulent products, and align with FDA's 'watchdog' mission. He cites existing examples of timeline implementation, such as PDUFA and Q-submissions, as precedent and emphasizes the public health benefits of stronger EUA oversight",,,2025-10-15,0.0,,,,,no decision,False,1785.0,pending,pending
fda-2020-p-2244,FDA-2020-P-2244-0001_Citizen_Petition_from_Camargo_Pharmaceutical_Servi.pdf,2020-11-30,2020,False,original petition,"Camargo Pharmaceutical Services, LLC",industry/corporation,"21 C.F.R. ¬ß¬ß 10.30, 10.20, 10.25(a), 314.122, 314.161","FDA‚Äôs Orange Book listing and regulatory status of ISOPTIN¬Æ (verapamil hydrochloride) 40, 80, and 120 mg oral tablets (NDA 018593)",Determine that the discontinued formulations of ISOPTIN (verapamil hydrochloride) oral tablets (NDA 018593) were not withdrawn from sale for reasons of safety or effectiveness,"Center Laboratories intends to submit a 505(b)(2) NDA relying on prior FDA findings of safety and efficacy for ISOPTIN. Since ISOPTIN is discontinued, a formal FDA determination that the discontinuation was not due to safety or efficacy concerns is necessary for the proposed application. Related precedents for verapamil formulations show similar products were found to be discontinued for non-safety reasons, supporting this request",,,2025-10-15,0.0,,,,,no decision,False,1780.0,pending,pending
fda-2020-p-2245,FDA-2020-P-2245-0001_Citizen_Petition_from_Camargo_Pharmaceutical_Servi.pdf,2020-11-30,2020,False,original petition,"Camargo Pharmaceutical Services, LLC",industry/corporation,"21 C.F.R. ¬ß¬ß 10.30, 10.20, 10.25(a), 314.122, 314.161","FDA‚Äôs listing and regulatory status of CALAN¬Æ (verapamil hydrochloride) oral tablets, NDA 018817, in the Orange Book","Determine that the discontinued formulations of CALAN¬Æ (verapamil hydrochloride) 40, 80, 120, and 160 mg oral tablets (NDA 018817) were not withdrawn for reasons of safety or effectiveness","The petitioner argues that CALAN (an immediate-release racemic verapamil formulation) was discontinued for commercial reasons, not due to safety or efficacy concerns. The company plans to file a 505(b)(2) NDA for a related product and needs FDA‚Äôs formal determination that the discontinuation of CALAN was not safety-related. They cite historical precedent, continued marketing of generics, and a similar FDA finding for related verapamil products as support",,,2025-10-15,0.0,,,,,no decision,False,1780.0,pending,pending
fda-2020-p-2247,FDA-2020-P-2247-0001_Citizen_Petition_from_Boehringer_Ingelheim_USA_Cor.pdf,2020-12-02,2020,False,original petition,"Boehringer Ingelheim Pharmaceuticals, Inc.",industry/corporation,21 C.F.R. ¬ß¬ß 10.25 and 10.30; Section 351 of the Public Health Service Act (42 U.S.C. ¬ß 262),FDA‚Äôs interpretation of 'strength' under section 351(k) of the Public Health Service Act as it applies to parenteral biologics,"Interpret the term 'strength' in section 351(k) of the PHS Act to mean the total drug content of the container, without regard to concentration; revise related FDA guidance documents accordingly; and apply this interpretation to pending and approved 351(k) applications","FDA‚Äôs current definition of 'strength' includes both total drug content and concentration, which Boehringer Ingelheim argues conflicts with the Biologics Price Competition and Innovation Act (BPCIA), enables anti-competitive 'evergreening' tactics, and leads to inconsistent treatment of similar parenteral biological products. The petitioner asserts that interpreting 'strength' as total drug content alone would better align with the statutory language, regulatory precedent, and the goals of the BPCIA to increase competition and patient access to affordable biologics.",,Denied,2024-02-23,0.0,Center for Drug Evaluation and Research (CDER),"21 CFR 10.30(e)(2); Section 351(k) of the Public Health Service Act (42 U.S.C. 262(k)); Sections 505(b)(2), 505(j), 505(j)(2)(C), 505(j)(5)(B)(iv), 505(j)(5)(B)(v), 505(b)(4)(B), 505(j)(2)(D)(ii), and 505(j)(7) of the Federal Food, Drug, and Cosmetic Act (FD&C Act); 21 CFR 314.94(a)(6), 21 CFR 314.94(a)(9)(iii), 21 CFR 320.22(b)(1)(i), 21 CFR 320.22(d)(2), 21 CFR 207.35, 21 CFR 210.3(b)(16)",,"The FDA denied the petition because adopting the proposed interpretation of 'strength' as only 'total drug content' without regard to concentration could disrupt well-established regulatory practices, including those related to therapeutic equivalence evaluations, abbreviated applications, and exclusivity determinations. The Agency reaffirmed that concentration is an integral component of 'strength' for parenteral drug products and argued that differences in concentration can affect safety, efficacy, and pharmacokinetics. The existing interpretation supports consistency, predictability, and scientific validity across product evaluations and regulatory pathways.",denied,True,1178.0,CDER,CDER
fda-2020-p-2276,FDA-2020-P-2276-0001_Citizen_Petition_from_Environmental_Defense_Fund.pdf,2020-12-09,2020,False,original petition,"Environmental Defense Fund, Breast Cancer Prevention Partners, Center for Environmental Health, Center for Food Safety, Childhood Lead Action Project, Clean Label Project, Consumer Reports, Defend Our Health, Environmental Working Group, Healthy Babies Bright Futures, and Utah Physicians for a Healthy Environment",advocacy/academic,"5 U.S.C. ¬ß 553(e), 21 C.F.R. ¬ß 10.30, Section 409 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. ¬ß 348(c)(3)(A)), 21 C.F.R. ¬ß 170.3(i), and the Delaney Clause","FDA's allowance of lead in food contact articles such as metal cans and brass or bronze components; FDA's limit of 5 ppb of lead in bottled water; outdated guidance for limits on lead in children's candy, juice, dried fruits, spices, and food additives",Prohibit lead as an additive in food contact articles by creating a new section 189.240. 2. Reduce the lead limit in bottled water from 5 ppb to 1 ppb. 3. Update FDA‚Äôs guidance to reflect that there is no safe level of lead in children‚Äôs blood and establish stricter limits on lead in children‚Äôs foods.,"Scientific consensus shows there is no safe level of lead exposure, especially for children, and existing FDA limits are outdated. Lead continues to be intentionally added to or contaminates food contact materials, including cans and brass components. FDA has not revised these standards despite new data showing lead‚Äôs neurodevelopmental and cardiovascular harm, its presence in canned food, and its classification as a carcinogen.",Not explicitly stated (only the year 2021 is visible),,2025-10-15,1.0,,,The FDA indicated it had not yet reached a decision on the petition due to other agency priorities and limited resources. The agency acknowledged receipt of the petition and committed to notify the petitioner once a final decision has been made.,,no decision,False,1771.0,pending,pending
fda-2020-p-2289,FDA-2020-P-2289-0001_Citizen_Petition_from_Loeb___Loeb__LLP.pdf,2020-12-10,2020,False,original petition,Loeb & Loeb LLP,law/consulting,"21 C.F.R. ¬ß¬ß 10.20, 10.30, 10.85; 21 C.F.R. ¬ß 878.4040; 5 U.S.C. ¬ß 553(e); 5 U.S.C. ¬ß 704","FDA‚Äôs classification of daily-wear scrubs and antimicrobial-treated scrubs as 'devices' under the FDCA, particularly in light of guidance issued during the COVID-19 public health emergency","(1) daily-wear scrubs not labeled or marketed for medical claims or surgical use are not 'devices'; (2) daily-wear scrubs treated with EPA-registered antimicrobials solely for non-medical purposes (e.g., odor or stain resistance) are also not 'devices'; (3) FDA refrain from enforcement action for at least 180 days after any contrary final agency determination is made and published","Petitioner argues that scrubs not marketed for medical or surgical purposes and without health-related claims fall outside the FDA‚Äôs statutory authority under the FDCA. Antimicrobial treatments intended solely to protect the garment are permissible under the EPA‚Äôs treated articles exemption and do not make the product a medical device. FDA‚Äôs recent guidance documents, particularly those issued during COVID-19, introduced regulatory ambiguity by broadening the scope of 'medical purpose' based on use setting or antimicrobial presence, which contradicts longstanding regulations and precedents excluding scrub suits from the definition of regulated surgical apparel.",,Denied,2022-12-05,0.0,Center for Devices and Radiological Health (CDRH),"21 CFR 10.30(e), 21 CFR 801.4, 21 CFR 201.128, 21 CFR 878.4040, 5 U.S.C. ¬ß 704",,"The FDA denied the petition requesting confirmation that 'Daily-Wear Uniform Scrubs' with or without antimicrobial components are not 'devices' under the FDCA. FDA maintained that whether a product qualifies as a device depends on its intended use, which is evaluated based on labeling, marketing claims, and distribution circumstances. The agency concluded that issuing new rulemaking or guidance was unwarranted due to limited resources and existing mechanisms for case-by-case determinations. The request to prohibit future enforcement actions was also denied as being outside the scope of the citizen petition process.",denied,True,725.0,CDRH,CDRH
fda-2020-p-2296,FDA-2020-P-2296-0001_Citizen_Petition_from_Parenteral_Technologies_LLC.pdf,2020-11-21,2020,False,original petition,"Parenteral Technologies, LLC",industry/corporation,"21 C.F.R. ¬ß 10.30, 21 C.F.R. ¬ß 10.20","Tentative Final Monograph (TFM) for Over-the-Counter Internal Analgesic, Antipyretic and Antirheumatic Drug Products, specifically the dosage schedule for single-ingredient acetaminophen for children aged 2 to under 4 years","Amend the TFM to expand the dosage schedule and directions for children's single-ingredient acetaminophen, particularly for the 2-4 year age group, to include dosing by individual weight, dosing to oral suspension units, and enhanced dosing concentration indicators. Also request an enforcement policy statement to permit amended labeling on products.","The current TFM lacks dosing precision for children aged 2 to under 4 years, does not account for patient weight or liquid dosage forms, and restricts precise and safe administration of acetaminophen. Decades of pharmacodynamic studies, including Dr. Temple‚Äôs work and large-scale clinical trials, support the safety and efficacy of a 10-15 mg/kg dosage. The petitioner argues that allowing enhanced, weight-specific, and volumetric dosing will reduce underdosing or overdosing risks, improve dosing adherence, and provide safer, more effective treatment for children.",,,2025-10-15,0.0,,,,,no decision,False,1789.0,pending,pending
fda-2020-p-2299,FDA-2020-P-2299-0001_Citizen_Petition_from_Zydus_Pharmaceuticals_USA_In.pdf,2020-11-30,2020,False,original petition,Zydus Pharmaceuticals (USA) Inc.,industry/corporation,"Federal Food, Drug, and Cosmetic Act (FD&C Act); 21 C.F.R. ¬ß¬ß 10.25(a), 10.30","FDA‚Äôs designation of Reference Listed Drug (RLD) and Reference Standard (RS) for Dexamethasone tablets, 1 mg and 2 mg","Request the FDA to designate ANDA 088306 (Dexamethasone tablets, 1 mg) and ANDA 087916 (Dexamethasone tablets, 2 mg), both held by Hikma Pharmaceuticals USA Inc., as both the RLD and RS for these strengths to allow ANDA submission","The petition argues that the lack of RLD and RS for the 1 mg and 2 mg strengths prevents generic ANDA submissions. These strengths are actively listed in the Orange Book and are the only available market formulations. The petitioner cites FDA‚Äôs recommendation (from a prior control correspondence) to submit a citizen petition and underscores the importance of dexamethasone for COVID-19 treatment per RECOVERY trial and NIH guidelines, requesting expedited review to support public health during the pandemic",,,2025-10-15,0.0,,,,,no decision,False,1780.0,pending,pending
fda-2020-p-2301,FDA-2020-P-2301-0001_Citizen_Petition_from_Alpha_Cognition_USA__Inc.pdf,2020-12-10,2020,False,original petition,Alpha Cognition USA Inc.,industry/corporation,"21 C.F.R. ¬ß¬ß 10.25(a), 10.30; Section 505(b)(2) of the FD&C Act",FDA‚Äôs designation of the reference standard (RS) for Galantamine Hydrobromide Oral Tablets in the Orange Book,Designate an additional reference standard (RS) for Galantamine Hydrobromide Oral Tablets in the Orange Book due to the current RS (Janssen NDA #021169) being unavailable on the market,"Janssen‚Äôs Galantamine Hydrobromide Oral Tablets (NDA #021169), the current RS, are no longer available in the market, with the last batch distributed in April 2019. According to FDA guidance, a new RS may be designated when the existing RS is no longer available in sufficient quantity for in vivo bioequivalence testing. Without a new RS, ANDA applicants cannot conduct required testing, which obstructs generic drug development and market entry",,Approved,2021-05-27,0.0,Center for Drug Evaluation and Research (CDER),21 U.S.C. 355(j); 21 CFR 314.3(b); 21 CFR 314.94(a)(3); 21 CFR 314.161; 21 CFR 314.122,,"FDA approved the petition to select a new reference standard for Galantamine Hydrobromide oral tablets (Eq 4 mg base) due to the current standard, Razadyne, being unavailable in the market. FDA chose ANDA 077604, held by Yabao Pharmaceutical Co. Ltd., as the new reference standard. This decision was based on its therapeutic equivalence to the original RLD and its market leadership, ensuring continuity in bioequivalence testing for ANDA applicants.",approved,True,168.0,CDER,CDER
fda-2020-p-2317,FDA-2020-P-2317-0001_Citizen_Petition_from_Baxter_Healthcare_Corporatio.pdf,2020-12-21,2020,False,original petition,Baxter Healthcare Corporation,industry/corporation,"21 C.F.R. ¬ß¬ß 10.25, 10.30, 314.122, 314.161; FD&C Act Sections 505(j), 505(w)","FDA‚Äôs Orange Book listing status and withdrawal classification of QUELICIN PRESERVATIVE FREE (Succinylcholine Chloride Injection USP, 20 mg/mL), NDA 008845","Request FDA to determine that QUELICIN PRESERVATIVE FREE (Succinylcholine Chloride Injection USP, 20 mg/mL), NDA 008845, was not withdrawn from sale for reasons of safety or effectiveness",Baxter asserts that QUELICIN PRESERVATIVE FREE was discontinued for commercial reasons and not due to safety or effectiveness concerns. The product is listed in the 'Discontinued Drug Product List' of the Orange Book as of December 2018. A determination by the FDA that the product was not withdrawn for safety or effectiveness reasons is necessary to allow it to be cited as a reference listed drug (RLD) in an ANDA,,Denied,2021-06-07,0.0,Center for Drug Evaluation and Research (CDER),Not Mentioned,,"FDA determined that QUELICIN PRESERVATIVE FREE (succinylcholine chloride) Injection (20 mg/mL, 50 mg/mL, and 100 mg/mL) was not withdrawn from sale for reasons of safety or effectiveness. Therefore, the products will remain listed in the 'Discontinued Drug Product List' section of the Orange Book.",denied,True,168.0,CDER,CDER
fda-2020-p-2322,FDA-2020-P-2322-0001_Citizen_Petition_from_Covington___Burling_LLP_on_b.pdf,2020-12-17,2020,False,original petition,Covington & Burling LLP,law/consulting,"21 C.F.R. ¬ß 10.30, 21 U.S.C. ¬ß 381(d) [Section 801(d)(2) of the FDCA]","Request for Proposals Regarding Insulin Reimportation Programs (RFP) issued on September 24, 2020","Withdraw the RFP, refrain from authorizing insulin reimportation unless there is a shortage due to a medical emergency, establish a manufacturer notification process, and provide public notice for approved applications","The petitioner argues the RFP poses safety risks, contradicts legal precedents, misinterprets the statute, bypasses notice-and-comment rulemaking, infringes on constitutional rights, and fails to address drug shortages as defined under the FDCA; they emphasize insulin is not in shortage and affordability concerns are insufficient to invoke emergency care provisions",,"Dismissed in part, Denied in part",2022-12-30,0.0,Center for Drug Evaluation and Research (CDER),"21 U.S.C. 381(d)(2); 21 CFR 10.25(a); 64 FR 67720 (Dec. 3, 1999); 21 CFR ¬ß¬ß 203.10-203.12",,"The FDA dismissed the request to withdraw the Insulin Reimportation RFP as moot because HHS had already withdrawn the RFP and associated documents. The remaining requests were denied because they either did not constitute appropriate subjects of a citizen petition under 21 CFR 10.25(a) or because creating new procedures for drug reimportation under section 801(d)(2) would not be a prudent use of FDA resources given its limited applicability. The FDA emphasized that existing regulations already address this statutory provision, and future changes, if considered, could be addressed through new petitions.",denied,True,743.0,CDER,CDER
fda-2020-p-2353,FDA-2020-P-2353-0001_Citizen_Petition_from_UCSF_Senate_Emeritus_Medicin.pdf,2020-12-23,2020,False,original petition,"Meg D. Newman, MD, UCSF Senate Emeritus-Department of Medicine",individual,21 C.F.R. 10.30; 21 C.F.R. 25.30,FDA‚Äôs potential requirement of additional placebo-controlled trials for live microbiome-based treatments for the prevention of recurrent Clostridium difficile infection (CDI),Consider the existing data on live microbiome-based treatments for prevention of recurrent CDI sufficient for approval. 2. Refrain from requiring additional placebo-controlled trials for these treatments.,"Dr. Newman cites robust efficacy and safety data from three separate Phase III clinical trials of live microbiome-based therapies (from Rebiotix/Ferring, Finch Therapeutics, and Seres Therapeutics). She also references supporting literature on fecal microbiota transplantation (FMT), arguing these establish a strong case for clinical benefit. Requiring further placebo-controlled trials would unnecessarily delay access to effective treatment, increase morbidity and mortality, and violate ethical standards, as clinical equipoise no longer exists for such trials. She urges the FDA to expedite availability of these therapies based on current evidence.",,,2025-10-15,0.0,,,,,no decision,False,1757.0,pending,pending
fda-2020-p-2357,FDA-2020-P-2357-0001_Citizen_Petition_from_Keller_and_Heckman_LLP_on_be.pdf,2020-12-28,2020,False,original petition,Keller and Heckman LLP,law/consulting,"21 C.F.R. ¬ß 10.30, 21 C.F.R. ¬ß 101.9(c)(6)(i), Sections 403(q), 403(a), 201(n), and 701(a) of the Federal Food, Drug, and Cosmetic Act","FDA‚Äôs definition of 'dietary fiber' in 21 C.F.R. ¬ß 101.9(c)(6)(i), specifically the list of accepted isolated or synthetic non-digestible carbohydrates",Amend the definition of dietary fiber at 21 C.F.R. ¬ß 101.9(c)(6)(i) to include acacia (gum arabic),"Petitioners argue that scientific evidence supports the classification of gum acacia as a dietary fiber due to its beneficial physiological effects, particularly its ability to attenuate post-prandial blood glucose and insulin levels. They provide five human studies showing statistically significant reductions in these biomarkers following GA consumption. The petition includes new data from a 2020 study and notes that gum acacia is already recognized in other FDA contexts as a dietary fiber or safe food additive.",,,2025-10-15,0.0,,,,,no decision,False,1752.0,pending,pending
fda-2020-p-2360,FDA-2020-P-2360-0001_Citizen_Petition_from_Pet_Schooled_The_Educated_Co.pdf,2020-12-30,2020,False,original petition,Pet Schooled ‚Äì The Educated Community,other,"21 C.F.R. ¬ß¬ß 10.30, 25.30, 25.34; Section 553 of the Administrative Procedure Act (5 U.S.C. Subchapter II); Section 402(a)(5) of the Federal Food, Drug, and Cosmetic Act",FDA‚Äôs current policy of exercising enforcement discretion regarding the use of animals that have died other than by slaughter in pet foods and animal feeds,"Issue an official federal regulation clarifying the FDA‚Äôs policy regarding the use of animals that have died other than by slaughter in FDA-regulated animal feed, dog food, and cat food, and ensure compliance with the Administrative Procedure Act","The petitioner argues that the FDA's current discretionary policy contradicts federal law (Section 402(a)(5) of the FD&C Act), which classifies products from animals that died otherwise than by slaughter as adulterated. Despite recognizing that euthanized animals may introduce pentobarbital into pet food through rendering, FDA has maintained a position of enforcement discretion. The petitioner requests a formal regulation to resolve this contradiction and uphold food safety standards under proper rulemaking procedures",,Denied,2021-06-30,0.0,Center for Veterinary Medicine (CVM),21 U.S.C. ¬ß 342(a)(5); 21 CFR part 507; 21 CFR 507.33; 21 CFR 507.34; 21 CFR 10.30(b)(3)(A)(1),,"FDA denied the petition requesting a regulation on the use of animals that died otherwise than by slaughter in pet food, citing existing regulatory frameworks under 21 CFR part 507. These already require hazard analysis and preventive controls for pet food manufacturers, including addressing hazards such as pentobarbital. The agency stated the petition lacked detail on the proposed regulation's wording, purpose, or benefits, and emphasized existing enforcement mechanisms and outreach efforts as sufficient.",denied,True,182.0,CVM,Other/Specialty Center
fda-2024-p-0105,FDA-2024-P-0105-0001_Citizen_Petition_from_Graviti_Pharmaceuticals_Priv.pdf,2024-01-03,2024,False,original petition,Graviti Pharmaceuticals Private Limited,industry/corporation,"21 C.F.R. ¬ß¬ß 10.25, 10.30, 314.122, 314.161; Sections 505(j) and 505(w) of the Federal Food, Drug, and Cosmetic Act","Discontinuation status of GLUCOTROL (glipizide) Tablets, NDA 017783, in the Orange Book","Request FDA to determine that Glucotrol Tablets, 5 mg and 10 mg, were not withdrawn for reasons of safety or effectiveness","Petitioner believes the discontinuation was due to commercial reasons, not safety or effectiveness; ANDAs for the same strength are active; no evidence of withdrawal due to safety or efficacy concerns",,,2025-10-15,0.0,,,,,no decision,False,651.0,pending,pending
fda-2024-p-0109,FDA-2024-P-0109-0001_Citizen_Petition_from_Bausch_Lomb.pdf,2024-01-04,2024,False,original petition,Bausch + Lomb,individual,"21 C.F.R. ¬ß¬ß 10.30, 10.31; Section 505(j) of the Federal Food, Drug, and Cosmetic Act",FDA's draft Product Specific Guidance (PSG) for ANDAs referencing Xipere (triamcinolone acetonide injectable suspension),"Request FDA to (1) refuse to receive or approve any ANDA referencing Xipere that uses a different injector unless in vivo and switching studies are included, and (2) revise the draft PSG to include such requirements and add syringeability and glide force to required comparisons",Xipere‚Äôs safety and efficacy depend critically on its proprietary SCS Microinjector; using a different injector without in vivo testing poses significant safety and efficacy risks. The current PSG does not adequately address this risk,"June 24, 2024",,2025-10-15,1.0,,,The FDA has not reached a decision on the petition due to the need to address other Agency priorities and resource constraints; the Agency will respond as soon as possible,,no decision,False,650.0,pending,pending
fda-2024-p-0227,FDA-2024-P-0227-0001_Suitability_Petition_from_Zydus_Pharmaceuticals__U.pdf,2024-01-10,2024,False,original petition,Zydus Pharmaceuticals (USA) Inc.,industry/corporation,"505(j)(2)(C), 21 C.F.R. ¬ß 314.93, 21 C.F.R. ¬ß¬ß 10.20, 10.30, 21 C.F.R. ¬ß 25.31, 505B(a)(1)(A)(i)","Approval of an Abbreviated New Drug Application (ANDA) for a new strength of Methylene Blue Injection, USP, 5 mg/1 mL","Request that FDA determine Methylene Blue Injection, USP, 5 mg/1 mL, is suitable for submission in an ANDA despite differing in strength from the Reference Listed Drug (RLD)","The petitioner argues that the proposed change involves only total drug content, not concentration, maintaining the same active ingredient, dosage form, route of administration, and indications as the RLD. The new strength would provide dosing flexibility, reduce pharmaceutical waste, particularly in pediatrics, and does not raise questions of safety or effectiveness.",,Approved,2024-05-21,0.0,Center for Drug Evaluation and Research (CDER),Section 505(j)(2)(C) of the FD&C Act; 21 C.F.R. ¬ß 314.93; 21 C.F.R. ¬ß 314.94(a)(3)(iii),,"FDA determined that the proposed change in strength does not pose questions of safety or effectiveness, aligns with the listed drug‚Äôs labeling recommendations, and does not require new investigations; if bioequivalence is demonstrated, the proposed product can be expected to have the same therapeutic effect",approved,True,132.0,CDER,CDER
fda-2024-p-0422,FDA-2024-P-0422-0001_Suitablity_Petition_from_Method_Pharmaceuticals__L.pdf,2024-01-11,2024,False,original petition,"Method Pharmaceuticals, LLC",industry/corporation,"505(j)(2)(C), 21 C.F.R. ¬ß¬ß 10.20, 10.30, 314.93, 25.31","FDA authorization to submit an ANDA for a dosage form different from the Reference Listed Drug (Folic Acid Tablets, 1 mg)","Request that FDA determine Folic Acid Oral Solution, 0.1 mg/mL and 1 mg/mL, is suitable for submission in an ANDA","The proposed oral solution differs only in dosage form from the approved tablet; it maintains the same active ingredient, route, and indication, offering improved dosing flexibility, especially for infants and patients requiring smaller maintenance doses",,,2025-10-15,0.0,,,,,no decision,False,643.0,pending,pending
fda-2024-p-0425,FDA-2024-P-0425-0001_Suitability_Petition_from_RegCon_Solutions__LLC.pdf,2024-01-22,2024,False,original petition,"RegCon Solutions, LLC",law/consulting,"505(j), 21 C.F.R. ¬ß¬ß 10.20, 10.30, 25.31","Approval of an ANDA for Ziprasidone Mesylate Injection, 20 mg/mL, in a prefilled syringe as a change in dosage form from the Reference Listed Drug (GEODON lyophilized powder)","Request that FDA determine Ziprasidone Mesylate Injection, 20 mg/mL in a prefilled syringe (liquid formulation), is suitable for submission as an ANDA","The proposed product is Q1/Q2 identical to the RLD and differs only in being a ready-to-use liquid rather than a lyophilized powder. The change eliminates reconstitution steps without altering safety, efficacy, or dosing regimen, and aligns with existing label instructions",,,2025-10-15,0.0,,,,,no decision,False,632.0,pending,pending
fda-2024-p-0427,FDA-2024-P-0427-0001_Suitability_Petition_from_DDReg_Pharma_Inc_.pdf,2024-01-17,2024,False,original petition,DDReg Pharma Inc.,industry/corporation,"505(j)(2)(C), 21 C.F.R. ¬ß¬ß 314.93, 10.20, 10.30, 25.31",FDA determination of the Reference Listed Drug (RLD) for a progesterone-based pessary formulation,Request that FDA determine the RLD for an ANDA of a progesterone pessary formulation differing in dosage form and strength,"The proposed product uses the same active ingredient and route of administration as approved formulations, with the same indication. It poses no new safety or efficacy concerns, and PREA is not applicable because the use is for ART in infertile women, not pediatric patients",,Denied,2024-07-31,0.0,Center for Drug Evaluation and Research (CDER),Section 505(j)(2)(C) of the FD&C Act; 21 CFR 314.93; 21 CFR 314.93(e)(1)(i) and (iv); Section 505B of the FD&C Act (PREA); Section 505(j)(2)(A) of the FD&C Act,,"The proposed changes in dosage form (to pessary), strength (400 mg vs. 90 mg), and indication/dosing regimen raise safety and effectiveness concerns and may require significant labeling changes; additionally, FDA determined that these are not permissible changes under the suitability petition pathway; therefore, the petition does not meet the statutory or regulatory requirements for approval",denied,True,196.0,CDER,CDER
fda-2024-p-0435,FDA-2024-P-0435-0001_Suitability_Petition_from_Zydus_Pharmaceuticals__U.pdf,2024-01-22,2024,False,original petition,Zydus Pharmaceuticals (USA) Inc.,industry/corporation,"505(j)(2)(C), 21 C.F.R. ¬ß 314.93, 21 C.F.R. ¬ß¬ß 10.20 and 10.30, 21 C.F.R. ¬ß 25.31, 505B(a)(1)(A)(i)",Establishment of a reference listed drug with a new strength for ANDA submission,"Determine that Pimavanserin Tablets, 34 mg is suitable for submission in an ANDA as a new strength of the RLD","The petitioner argues that the proposed 34 mg tablet strength is consistent with the recommended daily dose listed in the prescribing information of the RLD but is not currently available in tablet form. Approving the petition would provide physicians and patients greater flexibility without requiring a change in dosage form (e.g., from tablets to capsules). The change does not raise new questions of safety or efficacy, and pediatric assessment requirements under PREA do not apply since the petition is only for a new strength.",,Denied,2024-05-20,0.0,Center for Drug Evaluation and Research (CDER),Section 505(j)(2)(C) of the FD&C Act; 21 CFR 314.93(e)(1)(v); 21 CFR 10.33; 21 CFR 10.20,,"FDA denied the petition because the reference listed drug (Nuplazid 17 mg) has been voluntarily withdrawn from sale and the Agency has not yet determined whether the withdrawal was for safety or effectiveness reasons; therefore, the petition cannot be approved under 21 CFR 314.93(e)(1)(v)",denied,True,119.0,CDER,CDER
fda-2024-p-0521,FDA-2024-P-0521-0001_Citizen_Petition_from_Kasowitz_Benson_Torres_LLP_o.pdf,2024-01-24,2024,False,original petition,Kasowitz Benson Torres LLP,law/consulting,"21 C.F.R. ¬ß¬ß 10.25, 10.30, 10.31, 314.70; Federal Food, Drug, and Cosmetic Act",Approval and continued marketing of Enoxaparin Sodium Injection (ANDA No. 077857) manufactured by Shenzhen Techdow Pharmaceutical Co. Ltd and supplied by Sandoz Inc.,Request that FDA investigate and take appropriate action regarding the safety of the Sandoz Enoxaparin Sodium Injection due to concerns over inaccurate dosing in prefilled syringes,"The petitioner claims that the Sandoz product poses a patient safety risk due to the possibility of inaccurate dosing associated with demarcations on prefilled syringes, potentially leading to unsafe administration of enoxaparin sodium","July 15, 2024",,2025-10-15,1.0,,,"The petition raises complex issues requiring extensive review and analysis; therefore, the FDA has not reached a decision and will respond once the review is complete",,no decision,False,630.0,pending,pending
fda-2024-p-0522,FDA-2024-P-0522-0001_Citizen_Petition_from_Kasowitz_Benson_Torres_LLP_o.pdf,2024-01-24,2024,False,original petition,Kasowitz Benson Torres LLP,law/consulting,"21 C.F.R. ¬ß¬ß 10.25, 10.30, 10.31, 314.70; Federal Food, Drug, and Cosmetic Act","Approval and continued marketing of Enoxaparin Sodium Injection (ANDA No. 205660) manufactured by Shenzhen Techdow Pharmaceutical Co., Ltd. and supplied for NorthStar Rx LLC",Request that FDA investigate and take appropriate actions regarding the safety of the NorthStar Enoxaparin Sodium Injection due to potential issues with inaccurate dosing in prefilled syringes,"The petitioner asserts that blocked or obscured syringe demarcations may result in unclear dosing, posing significant safety risks to patients using the NorthStar product","July 15, 2024",,2025-10-15,1.0,,,The FDA has not yet resolved the petition because it raises complex issues requiring extensive review and analysis by agency officials; a final response will be provided once a decision has been made,,no decision,False,630.0,pending,pending
fda-2024-p-0526,FDA-2024-P-0526-0001_Suitability_Petition_from_Lupin__Inc_.pdf,2024-01-26,2024,False,original petition,Lupin Inc.,industry/corporation,"505(j)(2)(C), 21 C.F.R. ¬ß¬ß 10.20, 10.30, 25.31","FDA authorization to submit an ANDA for Apixaban Oral Suspension, 1.25 mg/mL, differing in dosage form from the listed drug ELIQUIS Tablets","Request that FDA determine Apixaban Oral Suspension, 1.25 mg/mL, is suitable for submission in an ANDA as a change in dosage form from the RLD","The oral suspension offers equivalent dosing to ELIQUIS tablets (2.5 mg and 5 mg) and supports patients with dysphagia. The formulation improves convenience, ensures dosing accuracy, and reduces burden in assisted care settings. A bioequivalence study will be submitted, and a waiver of PREA requirements is requested based on FDA precedent and availability of alternative pediatric formulations",,Denied,2024-07-24,0.0,Center for Drug Evaluation and Research (CDER),Section 505(j)(2)(C) of the FD&C Act; 21 CFR 314.93; 21 CFR 314.93(e)(1)(i); Section 505B of the FD&C Act (PREA); Section 505(j)(2)(A),,"The proposed change from tablet to oral suspension dosage form triggered PREA requirements; FDA determined that clinical trials are required for pediatric patients due to the potential therapeutic benefit in treating DVT and PE; the request for a waiver of pediatric studies was denied, making the petition ineligible for approval under the ANDA pathway",denied,True,180.0,CDER,CDER
fda-2024-p-0545,FDA-2024-P-0545-0001_Suitability_Petition_from_HYMAN__PHELPS___MCNAMARA.pdf,2024-01-29,2024,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"505(j)(2)(C), 21 C.F.R. ¬ß¬ß 314.93, 10.20, 10.30, 25.31",Authorization for submission of an ANDA for a new dosage form and strength of buspirone hydrochloride,"Request that FDA determine Buspirone HCl Oral Solution, 2 mg/mL, is suitable for submission in an ANDA as a change from the RLD BUSPAR Tablets",The proposed oral solution offers flexibility for individualized dosing and is consistent with the RLD's dosing guidance. FDA previously determined that BUSPAR Tablets were not withdrawn for safety or effectiveness. A full PREA waiver is requested due to lack of therapeutic benefit in pediatric populations and availability of better alternatives such as LEXAPRO,,Denied,2024-07-08,0.0,Center for Drug Evaluation and Research (CDER),Section 505(j)(2)(C) of the FD&C Act; 21 CFR 314.93; 21 CFR 314.93(e)(1)(i); 21 CFR 314.93(e)(1)(iv); Section 505B of the FD&C Act (PREA); Section 505(j)(2)(A),,"The proposed oral solution dosage form and 2 mg/mL strength differ from the reference listed drug‚Äôs labeling and pose questions of safety and effectiveness, requiring investigations and significant labeling changes; the proposed dosing regimen (12 mg/day) also deviates from the RLD‚Äôs (15 mg/day), increasing the risk of medication errors; therefore, the petition does not meet the statutory and regulatory criteria for approval",denied,True,161.0,CDER,CDER
fda-2024-p-0667,FDA-2024-P-0667-0001_Suitability_Petition_from_Lachman_Consultant_Servi.pdf,2024-02-05,2024,False,original petition,"Lachman Consultant Services, Inc.",law/consulting,"505(j)(2)(C), 21 C.F.R. ¬ß¬ß 10.20, 10.30, 314.93, 25.31",Suitability of a new strength (3 g/100 mL) of Magnesium Sulfate in Water for Injection for submission in an ANDA,"Request that FDA determine Magnesium Sulfate in Water for Injection, 3 g/100 mL (30 mg/mL), is suitable for submission in an ANDA","The proposed strength fills a gap between currently available ready-to-administer doses (1 g, 2 g, 4 g), aligning with clinical practices that often use 3 g doses. The formulation change only affects total drug content and not concentration, dosage form, route of administration, or indications. The change could reduce waste and improve dosing efficiency. PREA does not apply as the change involves only strength, not formulation or indication.",,Approved,2024-06-04,0.0,Center for Drug Evaluation and Research (CDER),Section 505(j)(2)(C) of the FD&C Act; 21 CFR 314.93; 21 CFR 314.93(e)(1); Section 505(j)(2)(A) and (B); Section 505(j)(2)(A)(iv); 21 CFR 314.94(a)(3)(iii),,"The proposed change in strength (3 g/100 mL) does not raise safety or effectiveness concerns, aligns with the listed drug‚Äôs labeling, and does not require new investigations; FDA concluded that the change would not jeopardize safe or effective use nor necessitate significant labeling changes",approved,True,120.0,CDER,CDER
fda-2024-p-0761,FDA-2024-P-0761-0001_Suitability_Petition_from_RegCon_Solutions_LLC.pdf,2024-02-21,2024,False,original petition,"Pharmobedient Consulting, LLC",law/consulting,"505(j), 21 C.F.R. ¬ß¬ß 10.25(a), 10.30, 314.122, 314.161, 314.162, 25.31, 25.40","Status of TAVIST (Clemastine Fumarate) Tablets, 2.68 mg under NDA 017661 as discontinued in the Orange Book","Request that FDA determine whether TAVIST (Clemastine Fumarate) Tablets, 2.68 mg was withdrawn from sale for reasons of safety or effectiveness","Petitioner asserts that TAVIST was likely discontinued for commercial reasons, not safety or efficacy, and there is no known evidence suggesting safety or effectiveness concerns. The request is to allow its continued citation as a Reference Listed Drug (RLD) in ANDAs",,Approved ‚Äì Determination made that the drug was not withdrawn for safety or effectiveness reasons,2024-10-18,0.0,Center for Drug Evaluation and Research (CDER),Not Mentioned,,"FDA determined that TAVIST (clemastine fumarate) tablet, 2.68 mg, was not withdrawn from sale for reasons of safety or effectiveness; therefore, it will remain listed in the 'Discontinued Drug Product List' section of the Orange Book",approved,True,240.0,CDER,CDER
fda-2024-p-0805,FDA-2024-P-0805-0001_Citizen_Petition_from_Hyman__Phelps___McNamara__P_.pdf,2024-02-13,2024,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"505(j), 505(w); 21 C.F.R. ¬ß¬ß 10.25, 10.30, 314.122, 314.161, 314.162, 25.31",Discontinuation status of Fentanyl Citrate Injection (NDA 215870) listed in the Orange Book,"Request that FDA determine whether Fentanyl Citrate Injection, EQ 2.5 mg base/50 mL and EQ 5 mg base/100 mL, was withdrawn for reasons of safety or effectiveness",Petitioner asserts there is no known evidence suggesting safety or efficacy concerns; the product was likely discontinued for commercial reasons and should remain available as a reference listed drug for ANDA submissions,,,2025-10-15,0.0,,,,,no decision,False,610.0,pending,pending
fda-2024-p-0806,FDA-2024-P-0806-0001_Citizen_Petition_from_Center_for_Science_in_the_Pu.pdf,2024-02-12,2024,False,original petition,"Center for Science in the Public Interest (CSPI), American Public Health Association, Consumer Federation of America, and Consumer Reports",advocacy/academic,"5 U.S.C. ¬ß 553(e), 21 U.S.C. ¬ß 343, 21 C.F.R. ¬ß 101.11(a), 21 C.F.R. ¬ß 10.30",FDA's December 2023 draft guidance that encourages voluntary menu labeling on third-party platforms (TPPs),Request that FDA issue final guidance clarifying that its existing menu labeling regulations apply to menus from Covered Establishments posted and/or maintained on TPPs,"Consumers ordering from TPPs currently lack consistent access to calorie and nutrition information required under the ACA. Voluntary measures have proven insufficient, and the law already supports extending these requirements to menus on TPPs when controlled by Covered Establishments. Mandatory labeling would promote informed choices, improve public health, and align with FDA‚Äôs regulatory framework.",,,2025-10-15,0.0,,,,,no decision,False,611.0,pending,pending
fda-2024-p-0827,FDA-2024-P-0827-0001_Citizen_Petition_from_Aurobindo_Pharma_USA__Inc__.pdf,2024-02-14,2024,False,original petition,"Aurobindo Pharma USA, Inc.",industry/corporation,"505(j), 21 C.F.R. ¬ß¬ß 10.25(a), 10.30, 314.122, 314.161, 314.162, 25.31(a), 25.15(d)","Discontinuation status of DUEXIS (Ibuprofen and Famotidine) Tablets, 800 mg and 26.6 mg, NDA 022519, in the Orange Book","Request that FDA determine whether DUEXIS (Ibuprofen and Famotidine) Tablets, 800 mg and 26.6 mg, was withdrawn for reasons of safety or effectiveness",Petitioner notes that the product appears in the discontinued section of the Orange Book and requests FDA's determination to clarify whether the withdrawal was due to safety or efficacy concerns. This determination is needed before an ANDA referring to the listed drug can be approved,,Approved ‚Äì Determination made that the drug was not withdrawn for safety or effectiveness reasons,2024-03-15,0.0,Center for Drug Evaluation and Research (CDER),Not Mentioned,,"FDA determined that Duexis (ibuprofen and famotidine) tablet, 800 mg and 26.6 mg, was not withdrawn from sale for reasons of safety or effectiveness; therefore, it will remain listed in the 'Discontinued Drug Product List' section of the Orange Book",approved,True,30.0,CDER,CDER
fda-2024-p-0889,FDA-2024-P-0889-0001_Suitability_Petition_from_Aurora_Pharmaceutical__I.pdf,2024-02-19,2024,False,original petition,"Aurora Pharmaceutical, Inc.",industry/corporation,"Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. ¬ß¬ß 25.15, 25.21, 25.30(h)",Approval of an abbreviated new animal drug application (ANADA) for Afoxolaner Oral Solution 4.56% w/v as a different dosage form than the reference listed Nexgard¬Æ (afoxolaner) Chewables under NADA 141-406,Request that FDA determine Afoxolaner Oral Solution 4.56% w/v is suitable for submission as an ANADA despite being a different dosage form than the reference listed drug,"The proposed product contains the same active ingredient, route of administration, indications, and dosing regimen as the RLD but is offered as a liquid solution for dogs unable to consume chewables due to allergies or palatability issues. All excipients are used in other approved oral canine products. Packaging and labeling will be designed to ensure accurate dosing and safety",,Approved,2024-05-02,0.0,Center for Veterinary Medicine (CVM),Section 512(n)(3) of the FD&C Act; 21 CFR 514.5,,"The proposed change from chewable to oral solution dosage form for afoxolaner does not require new investigations to demonstrate safety or effectiveness; thus, it qualifies under a suitability petition and is approved accordingly",approved,True,73.0,CVM,Other/Specialty Center
fda-2024-p-0973,FDA-2024-P-0973-0001_Citizen_Petition_from_Robin_Webb.pdf,2024-03-27,2024,False,original petition,Robin Webb,individual,21 C.F.R. 10.30,Labeling of photosensitivity associated with sulfonamide medications,"Caution, Free Radical Risk'","The petitioner provides a detailed explanation of how sulfonamide moiety medications absorb UV radiation leading to free radical formation, which in turn may generate reactive oxygen species (ROS) causing harm to various organs. The petitioner argues that this mechanism explains observed adverse effects such as skin darkening, exacerbation of conditions like lichen planus, and organ damage. Cases submitted to FDA MedWatch reportedly support this claim, showing improvement when patients switched to non-sulfonamide alternatives.",,,2025-10-15,0.0,,,,,no decision,False,567.0,pending,pending
fda-2024-p-1030,FDA-2024-P-1030-0001_Citizen_Petition_from_William_D__Drake___Redacted.pdf,2024-02-28,2024,False,original petition,William D. Drake,individual,"907(a)(1)(B) of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. ¬ß 10.30",Use and distribution of Certified 1R6F Kentucky Reference Cigarettes (and related variants) for research by FDA and its oversight of pesticide contamination in those products,"Request that FDA test and publicly disclose any pesticide residues found in Certified 1R6F and other Kentucky Reference Cigarettes distributed for research, notify all past and future recipients, and assess whether such residues reflect the broader U.S. commercial tobacco product supply","Petitioner argues that reference cigarettes used in tobacco research may be contaminated with unreported pesticide residues, potentially skewing decades of research data. Without testing and transparency, the validity of past and current tobacco-related research is compromised, and the public may unknowingly face risks from such contaminants. Petition also highlights the lack of FDA testing, calls for alignment with HPHC policies, and cites historical and international findings to support the need for urgent assessment.",,,2025-10-15,0.0,,,,,no decision,False,595.0,pending,pending
fda-2024-p-1058,FDA-2024-P-1058-0001_Citizen_Petition_from_Aimed_Alliance.pdf,2024-03-01,2024,False,original petition,Aimed Alliance,advocacy/academic,"21 C.F.R. ¬ß 10.30, 21 C.F.R. ¬ß 10.115, FD&C Act ¬ß 804, 21 C.F.R. ¬ß 25.30",Importation practices under alternative funding programs and the lack of clear FDA guidance on their legality,"Request that FDA issue a guidance document clarifying the legality of drug importation practices by third-party companies working with employer-sponsored health plans, including whether such entities can mandate or facilitate importation of prescription drugs on behalf of consumers, and how to report such practices","Petitioner argues that alternative funding programs are importing unapproved and misbranded drugs from foreign pharmacies on behalf of consumers, bypassing legal pathways such as personal importation and Section 804 programs. The lack of clear FDA guidance has enabled these programs to continue unchecked, potentially exposing consumers to serious health risks. Clarifying FDA‚Äôs stance would protect consumers, promote transparency, and restore regulatory accountability.",,,2025-10-15,0.0,,,,,no decision,False,593.0,pending,pending
fda-2024-p-1130,FDA-2024-P-1130-0001_Citizen_Petition_from_Valisure.pdf,2024-03-05,2024,False,original petition,"Valisure, LLC",industry/corporation,"21 U.S.C. ¬ß¬ß 331, 352, 355, 372, 374, 375; 21 C.F.R. ¬ß¬ß 10.20, 10.30","Sale and regulation of benzoyl peroxide (BPO) drug products, particularly in relation to benzene contamination","Issue a regulation, revise industry guidance, request a recall, and suspend sales of benzoyl peroxide products; conduct investigations; and undertake several regulatory and public health actions as detailed in the petition","Valisure detected high levels of benzene, a known human carcinogen, forming in benzoyl peroxide products when stored at elevated temperatures. They argue this poses a serious public health risk, referencing epidemiological data, FDA standards, and prior regulatory actions on contaminants such as NDMA. They highlight that BPO decomposes into benzene and request urgent regulatory action including recalls, guidance revisions, public disclosures, and stricter testing requirements.",,,2025-10-15,0.0,,,,,no decision,False,589.0,pending,pending
fda-2024-p-1131,FDA-2024-P-1131-0001_Citizen_Petition_from_Fresenius_Kabi_USA__LLC.pdf,2024-03-05,2024,False,original petition,"Fresenius Kabi USA, LLC",industry/corporation,"21 C.F.R. ¬ß 10.30, 21 C.F.R. ¬ß 314.161, 21 C.F.R. ¬ß 314.162, 21 C.F.R. ¬ß 25.31",Determination of whether Diltiazem Hydrochloride in Dextrose Injection (NDA 215252) has been withdrawn for safety or effectiveness reasons,Request that FDA determine whether Diltiazem Hydrochloride in Dextrose Injection 125 mg/125 mL and 250 mg/250 mL was withdrawn for safety or efficacy reasons,"The drug product now appears in the 'Discontinued Section' of the Orange Book. Petitioner seeks confirmation that it was not withdrawn for reasons of safety or effectiveness, which is a requirement for ANDA referencing under 21 C.F.R. ¬ß 314.161. The petition supports this by noting such withdrawals can occur for business or other non-safety-related reasons.",,,2025-10-15,0.0,,,,,no decision,False,589.0,pending,pending
fda-2024-p-1223,FDA-2024-P-1223-0001_Citizen_Petition_from_Charles_Ludlam_Redacted.pdf,2024-03-05,2024,False,original petition,Charles Ludlam,individual,21 C.F.R. ¬ß 10.30,Labeling and clinical evaluation policies for Mounjaro/Zepbound and Ozempic/Wegovy,"Request that FDA (1) require additional clinical trials on lean muscle mass loss, goal weight setting, and weight maintenance; and (2) revise product labels to include findings and recommendations related to these issues","The petitioner argues that current labels lack sufficient information about risks of lean muscle mass (LMM) loss, guidance on setting ideal goal weight, and strategies for maintaining weight loss. He cites clinical trial data showing substantial LMM loss and expresses concern over off-label use, especially in elderly populations already at risk of sarcopenia. The petition calls for enhanced labeling and additional clinical trials to provide more comprehensive safety and usage guidance.",,,2025-10-15,0.0,,,,,no decision,False,589.0,pending,pending
fda-2024-p-1378,FDA-2024-P-1378-0001_Citizen_Petition_from_Organon_USA__LLC_Redacted.pdf,2024-03-01,2024,False,original petition,"Organon USA, LLC",industry/corporation,"Section 505 of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. ¬ß 10.30",FDA review and approval of ANDAs referencing NEXPLANON (etonogestrel implant) as the reference listed drug,"Request that FDA require ANDA applicants to (a) demonstrate bioequivalence through a full-duration in vivo pharmacokinetic study or a validated IVIVC model, and (b) conduct comparative dissolution testing (f2 test) for their generic etonogestrel implant","Organon argues that due to NEXPLANON's long-acting nature and complex drug release profile, abbreviated methods may not ensure therapeutic equivalence. Full-duration BE studies or IVIVC models are necessary to protect patient safety and ensure consistent contraceptive efficacy over the entire approved in-use period.",,,2025-10-15,0.0,,,,,no decision,False,593.0,pending,pending
fda-2024-p-1379,FDA-2024-P-1379-0001_Citizen_Petition_from_Physicians_Committee_for_Res.pdf,2024-03-19,2024,False,original petition,Physicians Committee for Responsible Medicine,advocacy/academic,21 C.F.R. ¬ß 10.30,"FDA's March 1, 2024, letter of enforcement discretion permitting qualified health claims about yogurt and reduced risk of type 2 diabetes","Withdraw the March 1, 2024, letter of enforcement discretion and cease exercising enforcement discretion for qualified health claims about yogurt and reduced risk of type 2 diabetes","The petitioner argues that the qualified health claims are not supported by sufficient scientific evidence. Most studies cited in the original petition had methodological limitations, lacked randomized controlled trials, and showed inconsistent results. The claims may mislead consumers into believing yogurt is effective in diabetes prevention, possibly at the expense of more effective, evidence-based lifestyle changes like adopting a plant-based diet.","September 16, 2024",,2025-10-15,1.0,,,FDA has not been able to reach a decision on the petition within 180 days due to other agency priorities and limited resource availability; a decision will be issued upon completion of the review,,no decision,False,575.0,pending,pending
fda-2024-p-1380,FDA-2024-P-1380-0001_Citizen_Petition_from_Kohl_Harrington___Redacted.pdf,2024-03-04,2024,False,original petition,Kohl Harrington,individual,"5 U.S.C. ¬ß 552; 21 C.F.R. ¬ß¬ß 10.30(b), 25.30, 25.34",FDA‚Äôs handling and lack of public disclosure regarding FOIA request 2020-5368,Request that FDA publish all records and response letters related to FOIA request 2020-5368 in the FDA FOIA Reading Room,"Petitioner argues that under FOIA (5 U.S.C. ¬ß 552(a)(2)(D)), records that have been requested three or more times must be made publicly available. The specific FOIA request relates to reports of illness from A+ Answers Straight Beef Formula for Dogs. The FDA reportedly responded with no records found, which the petitioner believes has broader implications regarding FDA-CVM's interpretation and communication of regulatory standards on raw pet food and Salmonella contamination.",,,2025-10-15,0.0,,,,,no decision,False,590.0,pending,pending
fda-2024-p-1403,FDA-2024-P-1403-0001_Suitability_Petition_from_Pharmobedient_Consulting.pdf,2024-03-20,2024,False,original petition,"Pharmobedient Consulting, LLC",law/consulting,"505(j)(2)(C) of the FD&C Act; 21 C.F.R. ¬ß¬ß 10.20, 10.30, 314.93, 25.31","Approval of an ANDA for Dantrolene Sodium Orally Disintegrating Tablets (ODT), a different dosage form from the RLD Dantrium Capsules","Request that FDA determine Dantrolene Sodium ODT (25 mg, 50 mg, 100 mg) is suitable for submission in an ANDA","Petitioner argues that the proposed ODT formulation improves patient adherence, especially for elderly or dysphagic individuals, by allowing administration without water. The product contains the same active ingredient, route of administration, and strengths as the RLD. The petitioner also requests a pediatric study waiver, asserting no added risk to pediatric populations and no need for new efficacy/safety data.",,Denied,2024-09-30,0.0,Center for Drug Evaluation and Research (CDER),Section 505(j)(2)(C) of the FD&C Act; 21 CFR 314.93; 21 CFR 314.93(e)(1)(i); Section 505B of the FD&C Act (PREA); Section 505(j)(2)(A); 21 CFR 10.33; 21 CFR 10.20,,"FDA denied the petition because the proposed change in dosage form (from capsules to orally disintegrating tablets) triggers pediatric study requirements under PREA; the proposed products may offer meaningful therapeutic benefits in pediatric patients, especially those under 50 kg, but the current labeling does not support pediatric use for this group; since the request for a waiver was denied and clinical trials are required, the petition cannot proceed under the ANDA pathway",denied,True,194.0,CDER,CDER
fda-2024-p-1440,FDA-2024-P-1440-0001_Citizen_Petition_from_pH_D_Feminine_Health__LLC.pdf,2024-03-22,2024,False,original petition,"pH-D Feminine Health, LLC and Vireo Systems, Inc.",industry/corporation,"21 C.F.R. ¬ß¬ß 10.20, 10.30; 21 U.S.C. ¬ß 321(i), ¬ß 321(g); 21 C.F.R. ¬ß 201.128; 5 U.S.C. ¬ß 551(5); 21 C.F.R. ¬ß 10.115",FDA's classification of over-the-counter (OTC) vaginal suppositories containing boric acid marketed solely with deodorant or odor-reduction claims,"Request that FDA issue guidance stating these products are 'cosmetics' and not also 'drugs.' Alternatively, if deemed 'drugs,' request (1) formal regulation classifying them as such, and (2) an enforcement discretion policy until regulation is finalized",Petitioners argue that prior FDA statements in the 1983 and 1994 Federal Register notices create a reasonable expectation that such products are cosmetics. They claim boric acid has never been approved as a drug ingredient and that current deodorant-only claims should classify the products as cosmetics under the FDCA. They further argue that reclassification to 'drugs' would require formal rulemaking under the Administrative Procedure Act and FDA Good Guidance Practices. The petition seeks clarity and regulatory consistency to prevent disruption to lawful market activities.,"September 17, 2024",,2025-10-15,1.0,,,FDA has not yet resolved the petition due to the need to address other Agency priorities; the Agency will respond as soon as possible,,no decision,False,572.0,pending,pending
fda-2024-p-1441,FDA-2024-P-1441-0001_Suitability_Petition_from_Epic_Pharma__LLC.pdf,2024-03-22,2024,False,original petition,"Epic Pharma, LLC",industry/corporation,"505(j)(2)(C) of the FD&C Act; 21 C.F.R. ¬ß¬ß 10.20, 10.30, 314.93, 25.31",Approval of an ANDA for Leucovorin Calcium Injection in new strengths and dosage form different from the RLD,"Request that FDA determine that Leucovorin Calcium Injection (preservative-free, sterile solution) in strengths of 200 mg(base)/20 mL and 350 mg(base)/35 mL, and in a ready-to-use dosage form, is suitable for submission in an ANDA","Petitioner argues that the proposed product maintains the same concentration and labeling as the reference standards, with changes only to total drug content and dosage form (from lyophilized powder to ready-to-use solution). The change offers clinical convenience without raising safety or efficacy concerns. The petition also requests a waiver of PREA requirements, asserting the product is unlikely to benefit or be widely used by pediatric patients.",,,2025-10-15,0.0,,,,,no decision,False,572.0,pending,pending
fda-2024-p-1483,FDA-2024-P-1483-0001_Suitability_Petition_from_Hyman_Phelps_and_McNamar.pdf,2024-03-28,2024,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"Section 505(j)(2)(C) of the FD&C Act; 21 C.F.R. ¬ß¬ß 10.20, 10.30, 314.93",Approval of an ANDA for a different strength and dosage form of Sugammadex Injection compared to the RLD,"Request that FDA determine that Sugammadex Injection, 400 mg/8 mL (50 mg/mL), in a single-dose vial, is suitable for submission via an ANDA referencing Bridion (Sugammadex) Injection, 200 mg/2 mL and 500 mg/5 mL","Petitioner argues the proposed product contains the same active ingredient, route of administration, and concentration (50 mg/mL) as the RLD, with only a difference in strength and container volume. The change offers logistical and clinical convenience without affecting safety or efficacy. The petitioner also requests a waiver of pediatric study requirements under PREA, asserting no meaningful pediatric use.",,,2025-10-15,0.0,,,,,no decision,False,566.0,pending,pending
fda-2024-p-1570,FDA-2024-P-1570-0001_Citizen_Petition_from_Bongards_Premium_Cheese.pdf,2024-03-26,2024,False,original petition,Bongards Premium Cheese,individual,"21 C.F.R. ¬ß 10.30; 21 C.F.R. ¬ß¬ß 133.169, 133.173, 133.179","Standards of Identity for Pasteurized Process Cheese, Pasteurized Process Cheese Food, and Pasteurized Process Cheese Spread",Request that FDA amend the standards of identity for the listed cheese categories to allow the use of extra virgin olive oil as an anti-sticking agent in cheese slices,"Petitioner argues that incorporating extra virgin olive oil as an anti-sticking agent will maintain product integrity during manufacturing and packaging while aligning with consumer preferences for recognizable and clean-label ingredients. This change would not alter the fundamental nature, nutritional value, or characteristics of the standardized cheese products.","September 19, 2024",,2025-10-15,1.0,,,FDA has not reached a decision on the petition due to other agency priorities and limited availability of resources; the agency will notify the petitioner once the review is complete,,no decision,False,568.0,pending,pending
fda-2024-p-1715,FDA-2024-P-1715-0001_Citizen_Petition_from_AbbVie_Inc_.pdf,2024-04-03,2024,False,original petition,AbbVie Inc.,industry/corporation,"21 C.F.R. ¬ß 10.30, Federal Food, Drug, and Cosmetic Act (FDCA), Public Health Service Act (PHSA), Biologics Price Competition and Innovation Act (BPCIA), 21 C.F.R. ¬ß 312.7(a), FDCA ¬ß 502(a), 42 U.S.C. ¬ß 262(j)","Proliferation and marketing of unlicensed desiccated thyroid extract (DTE) products without INDs or BLAs, and associated promotional practices",FDA should prohibit manufacturers lacking active INDs and robust clinical development programs from commercializing unlicensed DTE products and should stop the promotion of unlicensed products with false and misleading claims,"The petitioner argues that the influx of unlicensed DTE products, lacking regulatory oversight, poses a public health risk due to narrow therapeutic margins and substandard manufacturing. AbbVie emphasizes the precedent set by FDA in similar historical contexts (e.g., PEPs and levothyroxine sodium), the necessity of IND oversight, misleading promotional practices, and confusion caused by classification systems falsely implying therapeutic equivalence among unapproved products","September 19, 2024",,2025-10-15,1.0,,,FDA has not resolved the petition due to the need to address other Agency priorities; the Agency will respond as soon as possible,,no decision,False,560.0,pending,pending
fda-2024-p-1716,FDA-2024-P-1716-0001_Suitability_Petition_from_Aurora_Pharmaceutical__I.pdf,2024-04-03,2024,False,original petition,"Aurora Pharmaceutical, Inc.",industry/corporation,"Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. ¬ß¬ß 10.20, 10.30, 25.30(h)",Approval of an ANADA for a generic meloxicam oral solution differing from the RLNAD in dosage form and strength,"Request that FDA determine that a generic meloxicam oral solution, 5 mg/mL, is suitable for submission via an ANADA referencing Metacam (meloxicam) Oral Suspension (0.5 mg/mL and 1.5 mg/mL)","Aurora seeks approval for a higher strength solution (5 mg/mL) to improve dosing convenience and precision for dogs over 10 lbs. They argue this change reduces volume, enhances dose compliance, and does not alter the recommended dosage or indications. Aurora also notes there are no listed patents or marketing exclusivities for the RLNAD and that a similar petition for dosage form change was previously approved.",,Denied,2024-06-27,0.0,Center for Veterinary Medicine (CVM),Section 512(n)(3) and 512(n)(3)(C) of the FD&C Act; 21 CFR Part 10; 21 CFR 10.33(e); 21 CFR 10.25(a),,"The petition proposed a meloxicam oral solution with a 10-fold increase in strength (5 mg/mL vs. 0.5 mg/mL in the RLNAD), raising concerns about potential user error and safety due to the similarity in appearance of the two concentrations and incorrect dosage delivery; these concerns would require additional investigations to demonstrate safety, making the petition ineligible under the suitability provision",denied,True,85.0,CVM,Other/Specialty Center
fda-2024-p-1717,FDA-2024-P-1717-0001_Citizen_Petition_from_Kohl_Harrington_Redacted.pdf,2024-04-04,2024,False,original petition,Kohl Harrington,individual,"5 U.S.C. ¬ß 552; 21 C.F.R. ¬ß¬ß 10.30(b), 25.30, 25.34",FDA‚Äôs failure to publish the final document for the CVM Key Initiative Plan 2019-2020 on the FDA FOIA Reading Room website,Request that FDA-CVM comply with FOIA law and post all documents requested through various FOIA requests pertaining to the final document for the CVM Key Initiative Plan 2019-2020 on the public FDA FOIA Reading Room website,Petitioner asserts that the final document for the CVM Key Initiative Plan 2019-2020 has been requested three or more times through FOIA and thus must be publicly disclosed under 5 U.S.C. ¬ß 552(a)(2)(D). The petition seeks compliance with this FOIA requirement by making the document available to the public electronically.,,Denied,2024-10-03,0.0,Center for Veterinary Medicine (CVM),5 U.S.C. ¬ß 552(a)(2)(D); 29 U.S.C. ¬ß 794d(a) (Section 508 of the Rehabilitation Act of 1973),,"CVM explained that it complies with FOIA posting requirements when the threshold for frequent requests is met and the records have been released; however, records must be converted to Section 508-compliant formats to ensure accessibility for individuals with disabilities before posting; based on this policy, the petition was denied",denied,True,182.0,CVM,Other/Specialty Center
fda-2024-p-1788,FDA-2024-P-1788-0001_Suitability_Petition_from_Pharmobedient_Consulting.pdf,2024-04-10,2024,False,original petition,"Pharmobedient Consulting, LLC",law/consulting,"505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. ¬ß¬ß 10.20, 10.30, 314.93, 25.31",Suitability of an ANDA submission for a different dosage strength of Carbinoxamine Maleate Tablets compared to the Reference Listed Drug (RLD),"Request that FDA determine that Carbinoxamine Maleate Tablets, 2 mg (unscored), is suitable for submission in an ANDA referencing CLISTIN (Carbinoxamine Maleate) 4 mg tablets","Petitioner argues that the change in dosage strength from 4 mg to 2 mg is consistent with dosing instructions for the RLD and does not raise questions of safety or efficacy. The proposed 2 mg strength provides greater dosing flexibility, particularly for pediatric use, and will be formulated to meet all quality and regulatory standards including bioequivalence to the RS.",,Approved,2024-07-25,0.0,Center for Drug Evaluation and Research (CDER),Section 505(j)(2)(C) of the FD&C Act; 21 CFR 314.93; 21 CFR 314.94(a)(3)(iii); Section 505(j)(2)(A) and (B); Section 505(j)(2)(A)(iv),,"FDA determined that the proposed strength change (from 4 mg to 2 mg) does not raise safety or effectiveness concerns, aligns with dosing recommendations in the labeling of the listed drug, and would not require significant labeling changes or additional investigations if bioequivalence is demonstrated; therefore, the petition is approved",approved,True,106.0,CDER,CDER
fda-2024-p-1810,FDA-2024-P-1810-0001_Suitability_Petition_from_Pharmobedient_Consulting.pdf,2024-04-10,2024,False,original petition,"Pharmobedient Consulting, LLC",law/consulting,"505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. ¬ß¬ß 10.20, 10.30, 314.93; 21 C.F.R. ¬ß 25.31(a)",Approval of an ANDA for a new strength of Amphotericin B Liposome for Injection differing from the reference listed drug,"Request that FDA determine Amphotericin B Liposome for Injection, 100 mg/vial lyophilized powder, is suitable for submission in an ANDA referencing AmBisome (50 mg/vial)","Petitioner states that the only change from the reference listed drug is the total drug content (from 50 mg to 100 mg), with no change in concentration. This change would reduce the number of vials needed per dose, potentially lowering pharmaceutical waste and improving dosing efficiency, especially for larger patients. Reconstitution instructions are adjusted accordingly. No questions of safety or efficacy are raised by this change.",,Approved,2024-08-23,0.0,Center for Drug Evaluation and Research (CDER),Section 505(j)(2)(C) of the FD&C Act; 21 CFR 314.93; 21 CFR 314.94(a)(3)(iii); Section 505(j)(2)(A) and (B); Section 505(j)(2)(A)(iv),,"FDA determined that the proposed change in strength (from 50 mg/vial to 100 mg/vial) does not pose questions of safety or effectiveness; the uses, dose, dosage form, and route of administration are the same as the listed drug; the proposed strength is consistent with dosing recommendations; if bioequivalence is shown, the new strength is expected to have the same therapeutic effect without requiring significant labeling changes or new investigations",approved,True,135.0,CDER,CDER
fda-2024-p-1870,FDA-2024-P-1870-0001_Suitability_Petition_from_Newcastle_Bioscience__LL.pdf,2024-04-15,2024,False,original petition,Newcastle Bioscience LLC,industry/corporation,"505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. ¬ß¬ß 10.30, 314.94(a)(8)(iv), 25.31",Suitability of an ANDA for a new dosage form (orally disintegrating tablets) and strength (15 mg) of escitalopram oxalate compared to the RLD Lexapro Tablets,"Request that the FDA declare escitalopram oxalate orally disintegrating tablets in 5 mg, 10 mg, 15 mg, and 20 mg strengths suitable for submission as an ANDA referencing Lexapro Tablets","The petitioner argues that the proposed dosage form (ODT) facilitates easier administration for patients with dysphagia and provides flexibility in dosing, particularly with the 15 mg strength which aligns with approved labeling but is not currently available. The change does not affect safety or efficacy, and similar changes have been previously approved by FDA. A full waiver of pediatric study requirements is also requested based on precedent and current data.",,Approved,2024-10-15,0.0,Center for Drug Evaluation and Research (CDER),Section 505(j)(2)(C) of the FD&C Act; 21 CFR 314.93; 21 CFR 314.94(a)(3)(iii); Section 505B of the FD&C Act (PREA); Section 505(j)(2)(A) and (B); Section 505(j)(2)(A)(iv),,"FDA determined that the proposed change in strength and dosage form (to orally disintegrating tablets of 5 mg, 10 mg, 15 mg, and 20 mg) does not raise questions of safety or effectiveness, aligns with labeling of the reference listed drug, and does not require new investigations; the product is also appropriately labeled for pediatric patients 7 years and older, and pediatric studies for those under 7 are impracticable, thus a waiver is granted",approved,True,183.0,CDER,CDER
fda-2024-p-1871,FDA-2024-P-1871-0001_Citizen_Petition_from_Advanced_Accelerator_Applica.pdf,2024-04-12,2024,False,original petition,"Advanced Accelerator Applications USA, Inc.",industry/corporation,21 USC 355; 21 CFR 10.30; 21 CFR 314.92(a)(1); 21 CFR 314.127(a)(4)(i); 21 USC 355(d); 21 USC 355(j)(4)(A); 21 CFR 314.54; 21 CFR 314.94(a)(9)(iii); 21 USC 505(b)(2); 21 USC 355(j)(2)(A)(iii)-(v); 21 CFR 320.22(b); 21 CFR 212.1,Approval of any ANDA under section 505(j) or NDA under section 505(b)(2) that references and relies on Lutathera (lutetium Lu 177 dotatate).,"FDA must require that any proposed generic or 505(b)(2) version of Lutathera demonstrate pharmaceutical equivalence‚Äîincluding same Specific Activity, Total Activity, Volumetric Activity, and total mass of ligand‚Äîas well as ensure individualized patient doses (fill volumes of 20.5‚Äì25.0 mL) and identical labeling.","Lutathera is a dynamic radioligand therapeutic whose clinical effect depends not only on radioactivity levels (Volumetric and Total Activity) but also on the Specific Activity and the mass ratio of labeled to unlabeled ligand. Differences in these variables may alter biodistribution and safety profiles, making simple equivalence claims insufficient without tailored analytical assessments. Therefore, FDA should refrain from approving any application unless these factors are demonstrated to be equivalent.","October 7, 2024",,2025-10-15,1.0,,,FDA has not resolved the issues raised in the petition due to the need to address other Agency priorities; the Agency will respond as soon as possible,,no decision,False,551.0,pending,pending
fda-2024-p-1913,FDA-2024-P-1913-0001_Citizen_Petition_from_Amivas__Inc_.pdf,2024-04-17,2024,False,original petition,"Amivas, Inc.",industry/corporation,"505(j)(2)(C) of the FD&C Act; 21 C.F.R. ¬ß¬ß 10.20, 10.30, 314.93; 21 C.F.R. ¬ß 25.31(a)",Suitability of an ANDA for a methylene blue injection product with a different strength than the RLD ProvayBlue¬Æ,"Request that FDA permit submission of an ANDA for Methylene Blue Injection, USP (10 mg/mL, 50 mg/5 mL vial), differing in concentration from the RLD ProvayBlue¬Æ (5 mg/mL)","The petitioner argues that the proposed drug product has the same active ingredient, route of administration (IV), dosage form, excipient (water), dilution procedure, and therapeutic effect as the RLD. The only change is the concentration per mL, not the total dose per vial. The change does not raise concerns for safety, efficacy, or bioequivalence, and similar products have been authorized in other countries.",,Approved,2024-08-20,0.0,Center for Drug Evaluation and Research (CDER),Section 505(j)(2)(C) of the FD&C Act; 21 CFR 314.93; 21 CFR 314.94(a)(3)(iii); Section 505(j)(2)(A) and (B); Section 505(j)(2)(A)(iv),,"FDA determined that the proposed change in strength (to 50 mg/5 mL, 10 mg/mL) does not raise questions of safety or effectiveness; the uses, dose, dosage form, and route of administration remain the same as the listed drug; the proposed strength is consistent with labeling recommendations and, if bioequivalence is demonstrated, no significant labeling changes or new investigations are required",approved,True,125.0,CDER,CDER
fda-2024-p-1916,FDA-2024-P-1916-0001_Citizen_Petition_from_Association_for_Truth_in_Pet.pdf,2024-04-17,2024,False,original petition,Association for Truth in Pet Food,advocacy/academic,21 C.F.R. ¬ß¬ß 10.20 and 10.30,Lack of public updates from FDA Center for Veterinary Medicine (CVM) on ongoing pet food-related illnesses and deaths,"Request FDA CVM to issue public updates regarding its investigation into pet food products associated with bloody vomiting, diarrhea, seizures, and pet deaths, including details such as number of reports, symptoms, testing conducted, and brands involved","Over 2,600 pet illness cases and 500+ pet deaths have been reported by consumers since December 2023, without FDA response or public updates; previous FDA actions on similar cases (e.g., applesauce, jerky treats, canine heart disease) included public notifications even without confirmed causes; transparency is needed to protect both animal and human health",,"Denied (in part as moot, in part as outside the scope of the citizen petition process)",2024-10-18,0.0,Center for Veterinary Medicine (CVM),21 CFR 10.30(e)(2)(iii); 21 CFR 10.30(b)(3); 21 CFR 10.3(a); 21 CFR 10.30(j),,"The petition was dismissed in part as moot because FDA had already published a public summary addressing the requested information regarding adverse events linked to Purina pet food; the remaining request was denied as it fell outside the scope of permissible administrative actions under the citizen petition process, since requests for updates to investigations and public dissemination of non-record-based information are not administrative actions",denied,True,184.0,CVM,Other/Specialty Center
fda-2024-p-1937,FDA-2024-P-1937-0001_Citizen_Petition_from_Kohl_Harrington_Redacted.pdf,2024-04-18,2024,False,original petition,Kohl Harrington,individual,"5 U.S.C. ¬ß 552; 21 C.F.R. ¬ß¬ß 10.30(b), 25.30, and 25.34",Failure of FDA-CVM to publicly disclose calendar records requested under FOIA,Request FDA-CVM to publish in the FDA FOIA Reading Room all documents related to calendar records of FDA-CVM employee William T. Flynn for the period 01/01/2024 to 02/29/2024,"Petitioner asserts that the requested calendar records meet the legal threshold under FOIA (5 U.S.C. ¬ß 552(a)(2)(D)) for mandatory public disclosure because they have been requested three or more times. Therefore, FDA-CVM is legally obligated to make them available in the public FOIA Reading Room.",,,2025-10-15,0.0,,,,,no decision,False,545.0,pending,pending
fda-2024-p-1960,FDA-2024-P-1960-0001_Citizen_Petition_from_Kohl_Harrington_Redacted.pdf,2024-04-20,2024,False,original petition,Kohl Harrington,individual,"5 U.S.C. ¬ß 552; 21 C.F.R. ¬ß¬ß 10.30(b), 25.30, 25.34","FDA-CVM's failure to publicly disclose inspection reports and documents related to Lystn, LLC (Answer Pet Food), despite multiple FOIA requests","FDA-CVM must publish in the FDA FOIA Reading Room all inspection reports and related documents for Lystn, LLC (Answer Pet Food), covering the period from January 1, 2023 to December 31, 2023","Under FOIA (5 U.S.C. ¬ß 552(a)(2)(D)), records that have been requested three or more times must be publicly disclosed. The petitioner asserts that the Lystn, LLC documents meet this threshold and therefore must be made publicly available by FDA-CVM",,Denied,2024-10-11,0.0,Office of Regulatory Affairs (ORA),5 U.S.C. ¬ß 552(a)(2)(D); 21 CFR 10.30(e)(3); 21 CFR 10.30(b)(3),,"FDA denied the petition because, although at least three FOIA requests had been received for the Lystn, LLC records, the agency had not yet released those records publicly ‚Äî a prerequisite for mandatory posting under 5 U.S.C. ¬ß 552(a)(2)(D); once the records are reviewed and released under FOIA, they will be posted accordingly",denied,True,174.0,offices,Other/Specialty Center
fda-2024-p-1988,FDA-2024-P-1988-0001_Citizen_Petition_from_HealthyWomen.pdf,2024-04-22,2024,False,original petition,HealthyWomen,individual,"21 C.F.R. ¬ß 10.30, 21 C.F.R. ¬ß¬ß 200.5 and 201.56-57, 21 U.S.C. ¬ß 355(o)(4)",Labeling of fenofibrate drugs and communication of cardiovascular risk benefit misinformation,Revise fenofibrate labeling to clarify the lack of cardiovascular benefit and include new safety data; require DHCP letters and a Drug Safety Communication,"Due to persistent misperceptions among healthcare providers that fenofibrates reduce cardiovascular risk‚Äîdespite multiple clinical trials (FIELD, ACCORD, PROMINENT) showing no such benefit‚Äîalong with associated risks (e.g., VTE, rhabdomyolysis), the petitioner urges the FDA to revise labeling and issue communications to ensure patients are not improperly prescribed fenofibrates, forgo effective treatments, or face unnecessary risks and costs.","October 16, 2024",,2025-10-15,1.0,,,The petition raises complex issues requiring extensive review and analysis by FDA officials; the agency will respond once a decision is reached,,no decision,False,541.0,pending,pending
fda-2024-p-2084,FDA-2024-P-2084-0001_Citizen_Petition_from_People_for_the_Ethical_Treat.pdf,2024-04-25,2024,False,original petition,People for the Ethical Treatment of Animals (PETA),advocacy/academic,"5 U.S.C. ¬ß 553(e); 21 C.F.R. ¬ß 10.30; 21 U.S.C. ¬ß¬ß 321(n), 343(a)(1), 371(a); 21 C.F.R. ¬ß 101.17",FDA labeling regulations for milk and other dairy products lacking cancer risk disclosures,"Linked to Increased Risk of Prostate, Breast, and Ovarian Cancer.'","Numerous scientific studies suggest a strong association between dairy consumption and increased risks of prostate, breast, and ovarian cancers, with mechanisms involving IGF-1 levels, estrogen content in milk, and galactose toxicity; such information is material for consumer health decisions and consistent with FDA precedent for labeling in the presence of serious health risks.","October 22, 2024",,2025-10-15,1.0,,,FDA has not been able to reach a decision on the petition within the 180-day timeframe due to other agency priorities and limited availability of resources; the agency will notify the petitioner once the review is complete,,no decision,False,538.0,pending,pending
fda-2024-p-2085,FDA-2024-P-2085-0001_Suitability_Petition_from_Hospira__Inc_.pdf,2024-04-02,2024,False,original petition,Hospira Inc.,industry/corporation,"Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act; 21 C.F.R. ¬ß¬ß 314.93, 10.20, 10.30",Prior denial of a suitability petition (Docket No. FDA-2023-P-4334) based on the existence of an NDA-approved version of the proposed drug strength,"FDA approval to submit an ANDA for Vancomycin Hydrochloride for Injection, USP, ADD-Vantage¬Æ Vial, 1.25 grams (base)/vial as an additional strength","The proposed product is identical in all respects to the reference listed drug except for strength. It addresses dosing needs for patients requiring more than 1 gram per dose, and differs qualitatively from the NDA-approved 1.25 g version (Mylan NDA 209481) due to the inclusion of pH-adjusting excipients, thereby justifying a separate ANDA submission.",,Denied,2024-08-12,0.0,Center for Drug Evaluation and Research (CDER),Section 505(j)(2)(C) of the FD&C Act; 21 CFR 314.93(e)(1)(vi); 21 CFR 314.94(a)(9)(iii); 21 CFR 10.33; 21 CFR 10.20; 21 CFR 314.93(a)-(b),,"FDA denied the petition because a pharmaceutically equivalent drug product (Vancomycin Hydrochloride for Injection, 1.25 g base/vial) has already been approved under NDA 209481; under 21 CFR 314.93(e)(1)(vi), a suitability petition cannot be approved if a drug product is already approved in an NDA for the change described; a change in excipients in a parenteral product is not a permissible change under section 505(j)(2)(C) of the FD&C Act",denied,True,132.0,CDER,CDER
fda-2024-p-2148,FDA-2024-P-2148-0001_Citizen_Petition_from_NesÃße_Devenot_Redacted.pdf,2024-04-28,2024,False,original petition,"Ne≈üe Devenot, PhD, Senior Lecturer, Johns Hopkins University",advocacy/academic,21 CFR 14.29; 21 CFR 312.32(a); 45 CFR 46.103(a); 45 CFR 46.103(b)(5),FDA's planned advisory committee meeting on the Lykos Therapeutics MDMA-Assisted Therapy New Drug Application,Convene an advisory committee meeting on MDMA-Assisted Therapy with an extended Open Public Hearing prioritizing concerns about Lykos Therapeutics' application,"Petitioner argues that the MDMA-assisted therapy application is novel and precedent-setting, involves significant safety concerns, unresolved scientific issues, and high public interest. The petitioner also raises ethical and regulatory concerns over data reporting, protocol safety, and internal culture at Lykos/MAPS, calling for independent expert input and transparency.",,Partially approved,2024-05-30,0.0,Center for Drug Evaluation and Research (CDER),21 CFR 14.25(a); 21 CFR 14.29; 21 CFR 14.29(b)(2),,"FDA granted the request to convene an advisory committee meeting and extended the open public hearing (OPH) from one hour to one hour and 45 minutes due to high interest. However, the request to prioritize input from certain stakeholders was denied, as FDA does not give preferential scheduling to any group. The committee will discuss the benefit-risk profile of MDMA capsules submitted by Lykos Therapeutics for treating PTSD",partially approved / denied,True,32.0,CDER,CDER
fda-2024-p-2150,FDA-2024-P-2150-0001_Envelope.pdf,2024-04-25,2024,False,original petition,"Parenteral Technologies, LLC",industry/corporation,Not Mentioned,Not Mentioned,Not Mentioned,Not Mentioned,,Denied,2024-10-09,0.0,Center for Drug Evaluation and Research (CDER),"21 U.S.C. ¬ß 352; 21 U.S.C. ¬ß 352(a); 21 U.S.C. ¬ß 352(f); 21 CFR ¬ß 201.5; 21 CFR ¬ß¬ß 201.66(a), 201.66(c)(6); 21 CFR 10.30(k); Section 505G of the FD&C Act",,"The petition was denied because requests to initiate enforcement actions are not appropriate subjects for citizen petitions under 21 CFR 10.30(k). Although the FDA acknowledged the concerns raised about OTC acetaminophen labeling for infants, it noted that such decisions are discretionary and outside the scope of the citizen petition process. However, the FDA stated it intends to propose a safety-related order to update pediatric acetaminophen labeling under the OTC monograph process pursuant to Section 505G of the FD&C Act",denied,True,167.0,CDER,CDER
fda-2024-p-2151,FDA-2024-P-2151-0001_Citizen_Petition_from_UnidosUS.pdf,2024-05-07,2024,False,original petition,UnidosUS,individual,"5 U.S.C. ¬ß 553(e), 21 C.F.R. ¬ß 10.30, Section 403(a) of the Food, Drug, and Cosmetic Act",Voluntary fortification policy and labeling practices for unfortified corn masa flour and products,Require a warning label on all unfortified corn masa flour and products made with corn masa to inform consumers of the lack of folic acid and associated risk of neural tube defects,"Voluntary fortification has failed to ensure adequate folic acid intake among Hispanic women, resulting in persistent health disparities; a warning label is needed to alert consumers and drive public health improvement","November 4, 2024",,2025-10-15,1.0,,,FDA has not been able to reach a decision on the petition due to other agency priorities and limited availability of resources; the agency will notify the petitioner once the review is complete,,no decision,False,526.0,pending,pending
fda-2024-p-2215,FDA-2024-P-2215-0001_Citizen_Petition_from_Metaltronica_Spa.pdf,2024-05-02,2024,False,original petition,Metaltronica Spa,individual,"21 CFR ¬ß10.25(a), 21 CFR ¬ß10.30, IEC 60601-1, IEC 60601-2, IEC 60601-2-28, IEC 60601-1-3, IEC 60601-2-45, IEC 62304, ISO 14971",FDA classification and premarket submission requirements for tomo digital mammography devices (product code OTE),"Reclassify tomo digital mammography devices (product code OTE) from Class III (PMA) to Class II (510(k)), aligning them with Full Field Digital Mammography (FFDM) devices (product code MUE)","The petitioner argues that risks and necessary evidence for OTE devices are similar to those for MUE devices, both of which use ionizing radiation and share hardware/software components. The technology is mature, widely adopted globally, and supported by harmonized standards. Market data and adverse event analysis show no significant safety differences, and reclassification would reduce costs for manufacturers, regulators, and users while maintaining safety and effectiveness.","October 28, 2024",,2025-10-15,1.0,,,FDA has not reached a decision because the petition raises issues requiring further review and analysis; the agency will respond once a decision has been made,,no decision,False,531.0,pending,pending
fda-2024-p-2220,FDA-2024-P-2220-0001_Citizen_Petition_from_Encube_Ethicals_Private_Limi.pdf,2024-05-06,2024,False,original petition,Encube Ethicals Private Limited,industry/corporation,"21 C.F.R. ¬ß 10.25(a), 21 C.F.R. ¬ß 10.30, 21 C.F.R. ¬ß 314.161, 21 C.F.R. ¬ß 314.122, 21 C.F.R. ¬ß 25.31(a)",Determination of whether the Reference Listed Drug (RLD) PENNSAID (diclofenac sodium topical solution 2%) has been withdrawn for reasons of safety or effectiveness,"Determine whether PENNSAID (diclofenac sodium topical solution 2% w/w, NDA# N204623) has been withdrawn for reasons of safety or effectiveness",The petitioner believes the discontinuation was for commercial reasons and not related to safety or effectiveness. A determination from the FDA is required to allow referencing the RLD in an ANDA.,,,2025-10-15,0.0,,,,,no decision,False,527.0,pending,pending
fda-2024-p-2242,FDA-2024-P-2242-0001_Citizen_Petition_from_David_Behar_Redacted.pdf,2024-04-28,2024,False,original petition,"David Behar, M.D.",individual,"21 C.F.R. ¬ß 10.30, 21 C.F.R. ¬ß 10.40(e)(1), Administrative Procedure Act",FDA requirement for a prescription to obtain CPAP machines,"Make CPAP (Continuous Positive Airway Pressure) machines available over the counter without a prescription, and require sellers to provide instruction manuals at a 6th-grade reading level with illustrations","The petitioner argues that requiring prescriptions for CPAP machines results in high costs, delays, and limited access, contributing to untreated sleep apnea, increased healthcare costs, preventable accidents, and health disparities. The petitioner cites successful price drops following over-the-counter access to hearing aids, points to racial and economic inequities, and contends that self-diagnosis is feasible with support from sleep apps and partner observations. The petition invokes urgent public health and economic consequences to justify bypassing traditional rulemaking procedures.",,Acknowledged (no decision on substantive merits),2024-05-07,0.0,Dockets Management Staff (DMS),21 CFR 10.30,,"The petition dated April 28, 2024, was received and processed under 21 CFR 10.30; however, acceptance for filing is procedural and does not reflect a decision on the petition's substantive merits",other,True,9.0,DMS,Other/Specialty Center
fda-2024-p-2272,FDA-2024-P-2272-0001_Citizen_Petition_from_Aurobindo_Pharma_USA__Inc_.pdf,2024-05-07,2024,False,original petition,Aurobindo Pharma Limited,industry/corporation,"Section 505(j) of the FDCA, 21 CFR ¬ß 10.25(a), 21 CFR ¬ß 10.30, 21 CFR ¬ß 314.122, 21 CFR ¬ß 314.161, 21 CFR ¬ß 25.31(a), 21 CFR ¬ß 25.15(d), 21 CFR ¬ß 10.30(b)","Determination regarding whether INVEGA¬Æ (Paliperidone) Extended-Release Tablets 1.5 mg, NDA #021999, has been withdrawn for safety or effectiveness reasons",Request the FDA to determine whether INVEGA¬Æ (Paliperidone) Extended-Release Tablets 1.5 mg has been withdrawn for reasons of safety or effectiveness,The petitioner notes that the drug appears in the discontinued section of the Orange Book and seeks confirmation that the discontinuation was not due to safety or effectiveness concerns in order to support an Abbreviated New Drug Application (ANDA),,,2025-10-15,0.0,,,,,no decision,False,526.0,pending,pending
fda-2024-p-2314,FDA-2024-P-2314-0001_Citizen_Petition_from_Aurobindo_Pharma_USA_Inc_.pdf,2024-05-09,2024,False,original petition,Aurobindo Pharma Limited,industry/corporation,"Section 505(j) of the FDCA, 21 CFR ¬ß 10.25(a), 21 CFR ¬ß 10.30, 21 CFR ¬ß 314.122, 21 CFR ¬ß 314.161, 21 CFR ¬ß 314.162, 21 CFR ¬ß 25.31(a), 21 CFR ¬ß 25.15(d), 21 CFR ¬ß 10.30(b)","Determination regarding whether Augmentin XR (amoxicillin and clavulanate potassium) extended-release tablets, NDA 050785, has been withdrawn for reasons of safety or effectiveness","Request the FDA to determine whether Augmentin XR (amoxicillin and clavulanate potassium) extended-release tablets, NDA 050785, has been voluntarily withdrawn from sale for reasons of safety or effectiveness","The petitioner notes that Augmentin XR now appears in the discontinued section of the Orange Book and requests confirmation that the withdrawal was not due to safety or effectiveness concerns, in order to support an Abbreviated New Drug Application (ANDA)",,Denied,2024-10-02,0.0,Center for Drug Evaluation and Research (CDER),Not Mentioned,,"FDA determined that Augmentin XR (amoxicillin; clavulanate potassium) Extended-release Tablets, 1 gm; EQ 62.5 mg base, was not withdrawn from sale for reasons of safety or effectiveness and therefore will remain listed in the 'Discontinued Drug Product List' section of the Orange Book",denied,True,146.0,CDER,CDER
fda-2024-p-2326,FDA-2024-P-2326-0001_Citizen_Petition_from_Hyman__Phelps___McNamara__P_.pdf,2024-05-10,2024,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"21 C.F.R. ¬ß¬ß 10.30 and 10.31, 21 U.S.C. ¬ß¬ß 355(b)(1)(A)(iv), 355(d)(3), 355(e), 351(a)(2)(B); 21 C.F.R. ¬ß¬ß 314.50(d), 314.105(a), 314.107(b)(4), 314.110(a), 314.125(a)(3)-(b)(1), (b)(4), (b)(13); 21 C.F.R. ¬ß 25.31(a)",FDA‚Äôs tentative approval of Liquidia‚Äôs section 505(b)(2) NDA for YUTREPIA,"Rescind tentative approval of Liquidia's NDA for YUTREPIA, issue a Complete Response Letter, and withhold any final approval until compliance with CGMP is ensured","The sole API supplier for YUTREPIA, LGM Pharma, has a history of severe and ongoing CGMP violations, and remains under a Consent Decree. These violations threaten the safety, quality, and compliance of YUTREPIA‚Äôs supply chain, and thus the product should not be approved or tentatively approved until all issues are remediated and FDA confirms compliance.",,,2025-10-15,0.0,,,,,no decision,False,523.0,pending,pending
fda-2024-p-2379,FDA-2024-P-2379-0001_Citizen_Petition_from_The_Humane_Society_of_the_Un.pdf,2024-05-15,2024,False,original petition,The Humane Society of the United States and the Humane Society Legislative Fund,advocacy/academic,"21 U.S.C. ¬ß 301 et seq., 5 U.S.C. ¬ß 553(e), 21 C.F.R. ¬ß 10.30",FDA's regulatory policies and guidance that imply animal testing is required for drug approval,"Amend FDA regulations and guidance to clarify that animal testing is not required, issue a new guidance document detailing accepted non-animal methods (NAMs), and update all future guidance documents to reference the new NAMs guidance","Animal testing is often unnecessary, expensive, time-consuming, and not required by law. Non-animal methods (NAMs) are more efficient, reliable, and ethical. Current FDA language creates confusion and incentivizes unnecessary animal tests, hindering drug innovation and violating Congressional intent under FDORA","November 1, 2024",,2025-10-15,1.0,,,"FDA has not reached a decision due to the need to address other agency priorities. The response acknowledges the petition's request to clarify requirements for drug approval in accordance with the FDCA and FDORA, including the acceptance of data from new alternative methods (NAMs), and states that a final response will be issued as soon as possible",,no decision,False,518.0,pending,pending
fda-2024-p-2461,FDA-2024-P-2461-0001_Citizen_Petition_from_Ho_Chunk__Inc__on_behalf_of_.pdf,2024-05-17,2024,False,original petition,"Ho-Chunk, Inc.",industry/corporation,"21 U.S.C. ¬ß 301 et seq., 21 C.F.R. ¬ß 10.30, Executive Order 13175, HHS Tribal Consultation Policy","Requirements for Tobacco Product Manufacturing Practice (FDA-2013-N-0227), specifically part 1120",Amend the Proposed Rule to include an exemption from part 1120 for tribally-owned cigarette manufacturers such as Rock River Manufacturing,"The petitioner argues that the proposed rule imposes significant economic burdens on small tribal manufacturers like Rock River, threatening their viability. Rock River is one of only two tribally-owned tobacco manufacturers in the U.S., and it already operates under strict tribal regulation and high compliance standards. An exemption would allow the tribe to preserve jobs and economic activity on the Winnebago Reservation without materially affecting overall tobacco regulation.","November 12, 2024",,2025-10-15,1.0,,,"FDA has not reached a decision within 180 days due to the complexity of the issues raised, which require additional review and consideration. The petition requests an exemption for tribally-owned cigarette manufacturers from proposed tobacco manufacturing regulations, and FDA is continuing its review in the context of other program priorities.",,no decision,False,516.0,pending,pending
fda-2024-p-2482,FDA-2024-P-2482-0001_Citizen_Petition_from_Age_Reversal_Unity.pdf,2024-05-07,2024,False,original petition,Age Reversal Unity,individual,"21 C.F.R. ¬ß 10.30, 21 C.F.R. ¬ß 25.32",Lack of regulation classifying aging as a disease,"Request the FDA to promulgate a new regulation classifying aging as a disease for purposes of research, treatment, and prevention","Aging is the primary risk factor for many chronic diseases and has identifiable biological hallmarks that are targetable. Recognizing aging as a disease could shift the healthcare paradigm to proactive aging management, increase research funding, and streamline regulatory pathways for relevant therapies.",,,2025-10-15,0.0,,,,,no decision,False,526.0,pending,pending
fda-2024-p-2513,FDA-2024-P-2513-0001_Citizen_Petition_from_Innogenix_LLC.pdf,2024-05-21,2024,False,original petition,Innogenix LLC,industry/corporation,"21 C.F.R. ¬ß¬ß 10.25, 10.30, 314.122, 314.161; Sections 505(j) and 505(w) of the Federal Food, Drug, and Cosmetic Act","Determination of whether the Reference Listed Drug (RLD), Flagyl¬Æ (metronidazole) Tablets 250 mg and 500 mg (NDA N012623), has been withdrawn for safety or effectiveness reasons","Request that the FDA determine whether Flagyl¬Æ Tablets 250 mg and 500 mg, approved under NDA N012623, has been voluntarily withdrawn for safety or effectiveness reasons",The petitioner believes the discontinuation was due to commercial reasons and is not aware of any safety or effectiveness concerns. A determination by FDA is required to enable ANDA submissions referencing the RLD.,,Denied,2024-09-05,0.0,Center for Drug Evaluation and Research (CDER),Not explicitly cited; determination was based on internal FDA review and Orange Book policy,,"FDA reviewed its records and determined that Flagyl (metronidazole) Tablets, 250 mg and 500 mg, were not withdrawn for reasons of safety or effectiveness. Therefore, they will remain listed in the 'Discontinued Drug Product List' section of the Orange Book.",denied,True,107.0,CDER,CDER
fda-2024-p-2514,FDA-2024-P-2514-0001_Citizen_Petition_from_Zydus_Pharmaceuticals__USA__.pdf,2024-05-22,2024,False,original petition,Zydus Pharmaceuticals (USA) Inc.,industry/corporation,"21 C.F.R. ¬ß 10.25(a), 21 C.F.R. ¬ß 10.30, 21 C.F.R. ¬ß 314.161, 21 C.F.R. ¬ß 314.122, 21 C.F.R. ¬ß 25.31(a), 21 C.F.R. ¬ß 10.30(b)","Determination of whether the Reference Listed Drug (RLD) NUPLAZID¬Æ (pimavanserin) tablets, 17 mg (NDA# N207318) has been withdrawn for reasons of safety or effectiveness","Request that the FDA determine whether NUPLAZID¬Æ (pimavanserin) tablets, 17 mg (NDA# N207318) has been withdrawn from commercial sale for reasons of safety or effectiveness",The petitioner states that NUPLAZID¬Æ 17 mg appears in the Discontinued Section of the Orange Book but is unaware of any safety or effectiveness issues. They believe the discontinuation was for commercial reasons and seek FDA‚Äôs confirmation to support an ANDA referencing the drug,,Denied,2024-11-13,0.0,Center for Drug Evaluation and Research (CDER),Not explicitly cited,,"FDA determined that Nuplazid (pimavanserin tartrate) tablet, EQ 17 mg base, was not withdrawn from sale for safety or effectiveness reasons. Therefore, it will remain listed in the 'Discontinued Drug Product List' section of the Orange Book.",denied,True,175.0,CDER,CDER
fda-2024-p-2515,FDA-2024-P-2515-0001_Citizen_Petition_from_Encube_Ethicals_Private_Limi.pdf,2024-05-22,2024,False,original petition,Encube Ethicals Private Limited,industry/corporation,"21 C.F.R. ¬ß 10.25(a), 21 C.F.R. ¬ß 10.30, 21 C.F.R. ¬ß 314.161, 21 C.F.R. ¬ß 314.122, 21 C.F.R. ¬ß 25.31(a), 21 C.F.R. ¬ß 10.30(b)","Determination of whether the Reference Listed Drug (RLD), Fortesta (testosterone) Gel (10 mg/0.5 gm Actuation, NDA# 021463), has been withdrawn for reasons of safety or effectiveness","Request the FDA to determine whether Fortesta (testosterone) Gel (10 mg/0.5 gm Actuation, NDA# 021463) has been voluntarily withdrawn from commercial sale for safety or effectiveness reasons","The petitioner states that Fortesta appears in the Discontinued Section of the Orange Book but is unaware of any safety or effectiveness concerns. Believing the withdrawal was due to commercial reasons, the petitioner seeks FDA confirmation to enable an ANDA referencing the drug",,FDA determined that FORTESTA (testosterone) gel 10‚ÄØmg/0.5‚ÄØg actuation was not withdrawn for reasons of safety or effectiveness and will remain in the Orange Book‚Äôs Discontinued Drug Product List ,2024-11-20,0.0,"Center for Drug Evaluation and Research (CDER), Office of Regulatory Policy ",Not Mentioned,,"FDA reviewed its records and found no evidence of safety or effectiveness concerns related to FORTESTA‚Äôs withdrawal; therefore, the drug‚Äôs discontinued status is maintained and a Federal Register notice will announce this determination ",withdrawn,True,182.0,CDER,CDER
fda-2024-p-2538,FDA-2024-P-2538-0001_Suitability_Petition_from_Hyman__Phelps___McNamara.pdf,2024-05-23,2024,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"Section 505(j)(2)(C) of the FDC Act, 21 C.F.R. ¬ß 314.93, 21 C.F.R. ¬ß¬ß 10.20 and 10.30, 21 C.F.R. ¬ß 25.31, 21 C.F.R. ¬ß 10.30(b), FDC Act ¬ß 505B(a)(1)(A)(i)",Suitability of a new dosage form for Cetrorelix Acetate (pre-filled syringe solution) as an ANDA based on RLD CETROTIDE¬Æ (powder for reconstitution),Request that FDA declare Cetrorelix Acetate Injection 0.25 mg/mL pre-filled syringe suitable for submission as an ANDA,"The proposed product is a ready-to-use form with the same active ingredient, strength, route of administration, and indications as the RLD, reducing the risk of medication error and improving ease of use. The change in dosage form does not affect safety or efficacy, and the product is not intended for pediatric patients, supporting a PREA waiver.",,,2025-10-15,0.0,,,,,no decision,False,510.0,pending,pending
fda-2024-p-2730,FDA-2024-P-2730-0001_Citizen_Petition_from_Kenneth_D__Eichenbaum.pdf,2024-06-02,2024,False,original petition,"Kenneth D. Eichenbaum, MD, MSE",individual,"21 C.F.R. ¬ß 10.20, 21 C.F.R. ¬ß 10.30, Section 351 of the Public Health Service Act, 21 C.F.R. ¬ß 25.30, 21 C.F.R. ¬ß 25.31, 21 C.F.R. ¬ß 10.30(b)","FDA‚Äôs potential action to expand the label for SRP-9001 (Elvidys, delandistrogene moxeparvovec-rokl)",Request that the FDA refrain from authorizing an expanded label for SRP-9001 (Elvidys) and re-evaluate its limited benefit relative to associated risks,"The petition argues that both Phase 2 and Phase 3 trials failed to meet their primary endpoints, with weak evidence of benefit and significant safety risks including liver injury, myocarditis, and immune-mediated myositis. Expanding the label may hinder the development of more promising therapies, waste resources, and damage FDA's credibility. Additional studies and alternative therapies should be prioritized.",,,2025-10-15,0.0,,,,,no decision,False,500.0,pending,pending
fda-2024-p-2752,FDA-2024-P-2752-0001_Suitability_Petition_from_Hyman__Phelps___McNamara.pdf,2024-06-06,2024,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"Section 505(j)(2)(C) of the FDC Act, 21 C.F.R. ¬ß 314.93, 21 C.F.R. ¬ß¬ß 10.20 and 10.30, 21 C.F.R. ¬ß 25.31, 21 C.F.R. ¬ß 10.30(b)","Suitability determination for Bupivacaine Hydrochloride Injection, USP (pharmacy bulk package) as an ANDA referencing MARCAINE (NDA 016964)","Request that FDA declare Bupivacaine Hydrochloride Injection, USP in pharmacy bulk packages (100 mL, 500 mL, 1L, 2L) of 0.25% and 0.5% strengths suitable for submission as an ANDA","The petitioner asserts that the proposed bulk packaging has the same concentration and dosage form as the RLD but offers operational advantages such as reduced waste and increased supply to mitigate drug shortages. The labeling includes necessary safety instructions and does not raise new questions of safety or efficacy, so no clinical investigations are required. The PREA requirements do not apply.",,Approved,2024-11-06,0.0,Center for Drug Evaluation and Research (CDER),"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 314.93; 21 CFR 314.93(e)(1); 21 CFR 314.94(a)(3)(iii); Section 505(j)(2)(A) and (B); Section 505(j)(2)(A)(iv)",,"FDA determined that the proposed change in strength (total drug content) does not raise questions of safety or effectiveness. The uses, dose, dosage form, and route of administration are the same as those of the listed drug, and the change is consistent with the listed drug's labeling. If shown to be bioequivalent, the proposed drug products are expected to have the same therapeutic effect as the reference listed drug. No new investigations are needed to demonstrate safety or effectiveness.",approved,True,153.0,CDER,CDER
fda-2024-p-2753,FDA-2024-P-2753-0001_Suitability_Petition_from_Hyman__Phelps___McNamara.pdf,2024-06-06,2024,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"Section 505(j)(2)(C) of the FDC Act, 21 C.F.R. ¬ß 314.93, 21 C.F.R. ¬ß¬ß 10.20 and 10.30, 21 C.F.R. ¬ß 25.31, 21 C.F.R. ¬ß 10.30(b), FDC Act ¬ß 505B(a)(1)(A)(i)","Suitability determination for submission of an ANDA for a new presentation of Fentanyl Citrate Injection, USP","Request that FDA declare Fentanyl Citrate Injection, USP, 50 mcg/mL in pharmacy bulk packages (100 mL, 500 mL, 1L, and 2L) suitable for submission as an ANDA","The petitioner argues that while the proposed drug differs from the RLD only in total fill volume/total drug content, the concentration and therapeutic use remain the same. Bulk packaging will reduce waste, support operational efficiencies, and help mitigate ongoing drug shortages. PREA requirements do not apply, and no clinical investigations are necessary to demonstrate safety or efficacy.",,Approved,2024-10-17,0.0,Center for Drug Evaluation and Research (CDER),"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 314.93; 21 CFR 314.93(e)(1); 21 CFR 314.94(a)(3)(iii); Section 505(j)(2)(A) and (B); Section 505(j)(2)(A)(iv)",,"FDA found that the proposed change in strength does not raise safety or effectiveness concerns. The proposed drug products share the same use, dose, dosage form, and route of administration as the listed drug. The change is consistent with the RLD‚Äôs labeling, and if the products are shown to be bioequivalent, they are expected to have the same therapeutic effect. Therefore, additional investigations are not required to establish safety or effectiveness.",approved,True,133.0,CDER,CDER
fda-2024-p-2757,FDA-2024-P-2757-0001_Suitability_Petition_from_Hyman__Phelps___McNamara.pdf,2024-06-06,2024,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"Section 505(j)(2)(C) of the FDC Act, 21 C.F.R. ¬ß 314.93, 21 C.F.R. ¬ß¬ß 10.20 and 10.30, 21 C.F.R. ¬ß 25.31, 21 C.F.R. ¬ß 10.30(b), FDC Act ¬ß 505B(a)(1)(A)(i)","Suitability determination for Oxytocin Injection, USP (synthetic), 10 USP Units/mL, for submission as an ANDA in pharmacy bulk package sizes","Request that FDA declare Oxytocin Injection, USP (synthetic), 10 USP Units/mL, in pharmacy bulk packages (100 mL, 500 mL, 1L, and 2L) suitable for submission as an ANDA","The proposed product has the same concentration and intended therapeutic use as the RLD, but differs in total fill volume/total drug content. The larger volume pharmacy bulk packaging aims to reduce waste, improve operational efficiency, and help prevent potential drug shortages. No new safety or efficacy issues are raised. PREA does not apply, and FDA has approved similar petitions in the past.",,,2025-10-15,0.0,,,,,no decision,False,496.0,pending,pending
fda-2024-p-2758,FDA-2024-P-2758-0001_Suitability_Petition_from_Hyman__Phelps___McNamara.pdf,,2024,False,original petition,"Hyman, Phelps & McNamara, P.C. :contentReference[oaicite:2]{index=2}:contentReference[oaicite:3]{index=3}",law/consulting,"Section‚ÄØ505(j)(2)(C)‚ÄØFDC‚ÄØAct; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ314.93; 21‚ÄØC.F.R.‚ÄØ¬ß¬ß‚ÄØ10.20,‚ÄØ10.30; Section‚ÄØ505(j)(2)(A)(iii)‚ÄØFDC‚ÄØAct; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ314.3; Section‚ÄØ505B(a)(1)(A)(i)‚ÄØFDC‚ÄØAct (PREA); 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ25.31; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ10.30(b) :contentReference[oaicite:6]{index=6}:contentReference[oaicite:7]{index=7}",FDA‚Äôs determination of suitability for an ANDA for Ropivacaine Hydrochloride Injection in pharmacy bulk package sizes :contentReference[oaicite:8]{index=8}:contentReference[oaicite:9]{index=9},"Declare that pharmacy bulk packages (100‚ÄØmL,‚ÄØ500‚ÄØmL,‚ÄØ1‚ÄØL,‚ÄØ2‚ÄØL) of Ropivacaine Hydrochloride Injection (0.2‚ÄØ%,‚ÄØ0.5‚ÄØ%,‚ÄØ1‚ÄØ%) are suitable for submission as an ANDA :contentReference[oaicite:10]{index=10}:contentReference[oaicite:11]{index=11}","Change is limited to total fill volume/drug content while concentration, dosage, route, and labeling remain consistent with the RLD; larger bulk packages reduce waste, improve operational efficiency, lower costs, and help mitigate an ongoing drug shortage; prior FDA precedents for similar petitions; no new safety or efficacy questions; PREA not applicable; categorical environmental exclusion claimed :contentReference[oaicite:12]{index=12}:contentReference[oaicite:13]{index=13}",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2024-p-2778,FDA-2024-P-2778-0001_Suitability_Petition_from_Pharmobedient_Consulting.pdf,,2024,False,original petition,"Pharmobedient Consulting, LLC :contentReference[oaicite:2]{index=2}:contentReference[oaicite:3]{index=3}",law/consulting,Section‚ÄØ505(j)(2)(C)‚ÄØFDC‚ÄØAct; Section‚ÄØ505(j)(2)(C)(iii)‚ÄØFDC‚ÄØAct; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ10.20; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ10.30; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ314.93; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ25.31; Pediatric Research Equity Act (PREA) Section‚ÄØ505B :contentReference[oaicite:6]{index=6}:contentReference[oaicite:7]{index=7},FDA‚Äôs determination of suitability for an ANDA for Chlorzoxazone Orally Disintegrating Tablets (ODT) 250‚ÄØmg and‚ÄØ500‚ÄØmg differing in dosage form from the RLD :contentReference[oaicite:8]{index=8}:contentReference[oaicite:9]{index=9},Declare that Chlorzoxazone ODT 250‚ÄØmg and‚ÄØ500‚ÄØmg are suitable for submission in an ANDA under Section‚ÄØ505(j)(2)(C) :contentReference[oaicite:10]{index=10}:contentReference[oaicite:11]{index=11},"ODT provides rapid onset without water, improves compliance for patients with swallowing difficulties, offers dosage flexibility with added 250‚ÄØmg strength, aligns with existing labeling and bioequivalence to RS, raises no new safety or efficacy questions, environmental exclusion claimed, and pediatric studies waiver requested under PREA :contentReference[oaicite:12]{index=12}:contentReference[oaicite:13]{index=13}",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2024-p-2779,FDA-2024-P-2779-0001_Suitability_Petition_from_Hyman__Phelps___McNamara.pdf,,2024,False,original petition,"Hyman, Phelps & McNamara, P.C. :contentReference[oaicite:2]{index=2}:contentReference[oaicite:3]{index=3}",law/consulting,"Section‚ÄØ505(j)(2)(C)‚ÄØFDC‚ÄØAct; Section‚ÄØ505(j)(2)(A)(iii)‚ÄØFDC‚ÄØAct; Section‚ÄØ505B(a)(1)(A)(i)‚ÄØFDC‚ÄØAct (PREA); 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ314.93; 21‚ÄØC.F.R.‚ÄØ¬ß¬ß‚ÄØ10.20,‚ÄØ10.30; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ10.33; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ25.31 :contentReference[oaicite:6]{index=6}",FDA‚Äôs prior denial and determination of suitability for an ANDA for Diclofenac Potassium Tablets‚ÄØ12.5‚ÄØmg differing in strength from the RLD CATAFLAM :contentReference[oaicite:7]{index=7}:contentReference[oaicite:8]{index=8},Declare Diclofenac Potassium Tablets‚ÄØ12.5‚ÄØmg suitable for submission as an ANDA under Section‚ÄØ505(j) :contentReference[oaicite:9]{index=9}:contentReference[oaicite:10]{index=10},"Proposed lower strength supports lowest effective dosing, literature and bioavailability studies show comparable safety and efficacy to higher strengths, EMA precedent confirms acceptability, no new safety or labeling concerns, PREA inapplicable, and categorical environmental exclusion claimed :contentReference[oaicite:11]{index=11}",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2024-p-2843,FDA-2024-P-2843-0001_Citizen_Petition_from_Zach_Richardson_Redacted.pdf,,2024,False,original petition,Zach Richardson :contentReference[oaicite:2]{index=2}:contentReference[oaicite:3]{index=3},individual,"21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ10.30; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ10.30(b); 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ25.30; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ25.31; Federal Food, Drug, and Cosmetic Act :contentReference[oaicite:6]{index=6}",FDA‚Äôs current policy of not classifying aging as a disease; petitioner seeks issuance of a new regulation to change this :contentReference[oaicite:7]{index=7}:contentReference[oaicite:8]{index=8},Issue a regulation classifying aging as a disease :contentReference[oaicite:9]{index=9}:contentReference[oaicite:10]{index=10},"Aging drives most chronic diseases and economic burden; scientific evidence links biomarkers and pathways with potential interventions; recognizing aging as a disease would spur R&D, improve healthspan, and reduce healthcare costs, with precedents such as obesity classification noted alongside acknowledgment of possible Social Security impacts :contentReference[oaicite:11]{index=11}",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2024-p-2846,FDA-2024-P-2846-0001_Petition_for_Reclassification_from_Pyrexar_Medical.pdf,,2024,False,original petition,Pyrexar Medical Inc. :contentReference[oaicite:3]{index=3},industry/corporation,"Section‚ÄØ513(e) of the Federal Food, Drug, and Cosmetic Act :contentReference[oaicite:7]{index=7}",FDA‚Äôs classification of the BSD‚Äë2000 Hyperthermia System as a Class‚ÄØIII medical device :contentReference[oaicite:9]{index=9},Reclassify the BSD‚Äë2000 Hyperthermia System from Class‚ÄØIII to Class‚ÄØII under Section‚ÄØ513(e) :contentReference[oaicite:11]{index=11},"Extensive clinical data show the BSD‚Äë2000‚Äôs proven safety and efficacy; years of global clinical use confirm low risk; advanced safety features and precise temperature control align with Class‚ÄØII expectations; reclassification would streamline access, cut regulatory costs, broaden adoption, and improve patient outcomes while matching precedents for similar devices ",,Denied,2024-10-28,0.0,Center for Devices and Radiological Health (CDRH),"Section 513(e), Section 513(f)(1), Section 513(f)(3), Section 520(m), Section 513(a)(1)(B) of the FD&C Act; 21 CFR 860.130(e); 21 CFR 860.123(a)(7)",,The petition was misfiled under section 513(e) instead of the correct section 513(f)(3); the petitioner failed to provide sufficient information for FDA to determine that special controls would provide reasonable assurance of safety and effectiveness; supporting evidence cited was not adequately detailed or properly included as source documents; the intended use was unclear and did not match the approved indication under the HDE.,denied,True,,CDRH,CDRH
fda-2024-p-2885,FDA-2024-P-2885-0001_Suitability_Petition_from_Hyman__Phelps___McNamara.pdf,,2024,False,original petition,"Hyman, Phelps & McNamara, P.C. :contentReference[oaicite:2]{index=2}:contentReference[oaicite:3]{index=3}",law/consulting,"Section‚ÄØ505(j)(2)(C)‚ÄØFDC‚ÄØAct; Section‚ÄØ505(j)(2)(A)(iii)‚ÄØFDC‚ÄØAct; Section‚ÄØ505B(a)(1)(A)(i)‚ÄØFDC‚ÄØAct (PREA); 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ314.93; 21‚ÄØC.F.R.‚ÄØ¬ß¬ß‚ÄØ10.20,‚ÄØ10.30; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ25.31 :contentReference[oaicite:6]{index=6}:contentReference[oaicite:7]{index=7}",FDA‚Äôs determination of suitability for an ANDA for new 200‚ÄØmg and 300‚ÄØmg strengths of Olaparib Tablets differing from the RLD strengths :contentReference[oaicite:8]{index=8}:contentReference[oaicite:9]{index=9},Declare Olaparib Tablets 200‚ÄØmg and‚ÄØ300‚ÄØmg suitable for submission as an ANDA under Section‚ÄØ505(j) :contentReference[oaicite:10]{index=10}:contentReference[oaicite:11]{index=11},"Strengths align with RLD dosing recommendations, reduce tablet burden, raise no new safety or efficacy questions, PREA inapplicable to strength changes, and categorical environmental exclusion claimed :contentReference[oaicite:12]{index=12}:contentReference[oaicite:13]{index=13}",,Approved,2024-10-18,0.0,CDER (Center for Drug Evaluation and Research),"505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 314.93; 21 CFR 314.94(a)(3)(iii)",,"The proposed change in strength from the listed drug product does not pose questions of safety or effectiveness. The proposed drug products have the same use, dose, dosage form, and route of administration as the listed drug. The change is consistent with the labeling of the listed drug, and if bioequivalence is demonstrated, the proposed products are expected to have the same therapeutic effect. Therefore, investigations are not necessary to demonstrate safety and effectiveness.",approved,True,,CDER,CDER
fda-2024-p-2909,FDA-2024-P-2909-0001_Suitability_Petition_from_Hyman__Phelps___McNamara.pdf,,2024,False,original petition,"Hyman, Phelps & McNamara, P.C. :contentReference[oaicite:2]{index=2}:contentReference[oaicite:3]{index=3}",law/consulting,"Section‚ÄØ505(j)(2)(C)‚ÄØFDC‚ÄØAct; Section‚ÄØ505(j)(2)(A)(iii)‚ÄØFDC‚ÄØAct; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ314.93; 21‚ÄØC.F.R.‚ÄØ¬ß¬ß‚ÄØ10.20,‚ÄØ10.30; Section‚ÄØ505B(a)(1)(A)(i)‚ÄØFDC‚ÄØAct‚ÄØ(PREA); 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ25.31 :contentReference[oaicite:6]{index=6}:contentReference[oaicite:7]{index=7}",FDA‚Äôs determination of suitability for an ANDA for new 4‚ÄØmg and‚ÄØ12‚ÄØmg Buprenorphine Sublingual Tablet strengths differing from the RLD SUBUTEX :contentReference[oaicite:8]{index=8}:contentReference[oaicite:9]{index=9},Declare Buprenorphine Sublingual Tablets 4‚ÄØmg and‚ÄØ12‚ÄØmg suitable for submission as an ANDA under Section‚ÄØ505(j) :contentReference[oaicite:10]{index=10}:contentReference[oaicite:11]{index=11},"Strengths match RLD dosing guidance, reduce pill burden, introduce no new safety or efficacy concerns, PREA requirements do not apply to strength changes, and a categorical environmental exclusion is claimed :contentReference[oaicite:12]{index=12}:contentReference[oaicite:13]{index=13}",,Approved,2024-10-15,0.0,CDER (Center for Drug Evaluation and Research),"505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 314.93; 21 CFR 314.94(a)(3)(iii)",,"The FDA determined that the proposed change in strength (from 2 mg and 8 mg to 4 mg and 12 mg) does not pose questions of safety or effectiveness, aligns with the listed drug‚Äôs labeling, maintains the same use, dose, dosage form, and route of administration, and, if bioequivalence is met, can be expected to have the same therapeutic effect.",approved,True,,CDER,CDER
fda-2024-p-2932,FDA-2024-P-2932-0001_Suitability_Petition_from_Newcastle_Bioscience_LLC.pdf,,2024,False,original petition,Newcastle Bioscience LLC :contentReference[oaicite:2]{index=2}:contentReference[oaicite:3]{index=3},industry/corporation,Section‚ÄØ505(j)(2)(C)‚ÄØFDC‚ÄØAct; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ10.30; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ314.93; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ25.31; Pediatric Research Equity Act‚ÄØ(PREA)‚ÄØSection‚ÄØ505B; Section‚ÄØ505B(k)‚ÄØFDC‚ÄØAct :contentReference[oaicite:6]{index=6}:contentReference[oaicite:7]{index=7},"FDA‚Äôs determination of suitability for an ANDA for Rosuvastatin Calcium Orally Disintegrating Tablets (5‚ÄØmg,‚ÄØ10‚ÄØmg,‚ÄØ20‚ÄØmg,‚ÄØ40‚ÄØmg) differing in dosage form from the RLD Crestor Tablets :contentReference[oaicite:8]{index=8}:contentReference[oaicite:9]{index=9}","Declare Rosuvastatin Calcium Orally Disintegrating Tablets 5‚ÄØmg,‚ÄØ10‚ÄØmg,‚ÄØ20‚ÄØmg,‚ÄØ40‚ÄØmg suitable for submission as an ANDA under Section‚ÄØ505(j) :contentReference[oaicite:10]{index=10}:contentReference[oaicite:11]{index=11}","Change limited to dosage form while strengths, dosing schedule, and labeling match RLD; ODT improves patient convenience without new safety or efficacy issues; no clinical concerns raised; pediatric study waiver requested; categorical environmental exclusion claimed :contentReference[oaicite:12]{index=12}:contentReference[oaicite:13]{index=13}",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2024-p-2933,FDA-2024-P-2933-0001_Citizen_Petition_from_Chobani_LLC.pdf,,2024,False,original petition,"Chobani, LLC :contentReference[oaicite:2]{index=2}:contentReference[oaicite:3]{index=3}",industry/corporation,Section‚ÄØ401‚ÄØFDC‚ÄØAct; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ131.200; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ131.200(b); 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ101.4(b)‚Äì(c); 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ25.30; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ25.31; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ25.32(a) :contentReference[oaicite:6]{index=6},"FDA‚Äôs yogurt standard of identity at 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ131.200, which currently excludes ultrafiltered nonfat milk as a basic dairy ingredient :contentReference[oaicite:7]{index=7}:contentReference[oaicite:8]{index=8}",Initiate rulemaking to amend 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ131.200 to include ultrafiltered nonfat milk as a basic dairy ingredient in yogurt :contentReference[oaicite:9]{index=9}:contentReference[oaicite:10]{index=10},"Ultrafiltered nonfat milk maintains yogurt‚Äôs essential qualities, enables modern processing, offers higher protein with lower sugar/lactose, supports consumer demand for lactose‚Äëfree/high‚Äëprotein foods, harmonizes with FDA nutrition goals and international standards, and raises no new safety, environmental, or economic concerns :contentReference[oaicite:11]{index=11}",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2024-p-2952,FDA-2024-P-2952-0001_Citizen_Petition_from_Sarah_A__Norring___Redacted.pdf,,2024,False,original petition,"Sarah A. Norring, Ph.D. :contentReference[oaicite:2]{index=2}:contentReference[oaicite:3]{index=3}",individual,21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ10.30; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ314.161; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ25.31 :contentReference[oaicite:6]{index=6}:contentReference[oaicite:7]{index=7},FDA‚Äôs determination under 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ314.161 regarding whether the listed drug Lunelle was withdrawn for safety or effectiveness reasons :contentReference[oaicite:8]{index=8}:contentReference[oaicite:9]{index=9},Conclude that Lunelle (estradiol‚ÄØcypionate/medroxyprogesterone‚ÄØacetate injectable) was not withdrawn from sale for safety or effectiveness reasons :contentReference[oaicite:10]{index=10}:contentReference[oaicite:11]{index=11},"Historical evidence shows only syringe recall due to potency uncertainty; vials retained full efficacy, no safety concerns cited; subsequent market withdrawal driven by manufacturing/business decisions rather than safety or effectiveness; therefore, FDA should find the withdrawal not safety‚Äërelated :contentReference[oaicite:12]{index=12}",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2024-p-2955,FDA-2024-P-2955-0001_Citizen_Petition_from_Dsquare_LLC.pdf,,2024,False,original petition,Dsquare LLC :contentReference[oaicite:2]{index=2}:contentReference[oaicite:3]{index=3},industry/corporation,21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ10.30; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ201; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ201.64; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ201.57 :contentReference[oaicite:6]{index=6},"Current FDA labeling policy for sodium‚Äëcontaining N‚Äëacetylcysteine drugs used in treating acetaminophen intoxication, which lacks required sodium warnings and black‚Äëbox alerts :contentReference[oaicite:7]{index=7}:contentReference[oaicite:8]{index=8}",Amend labeling of all sodium‚Äëcontaining N‚Äëacetylcysteine products to add a high‚Äësodium content warning for the general population and a Black Box Warning for salt‚Äësensitive patients or those with cardiovascular/CNS disease :contentReference[oaicite:9]{index=9},"Recommended treatment delivers sodium doses far exceeding FDA limits; high acute sodium loads are linked to serious cardiovascular and neurological events and reported fatalities; existing FDA guidelines and the former RLD CETYLEV include such warnings, but current products do not; adding warnings will protect salt‚Äësensitive and general populations and align labeling with FDA safety standards :contentReference[oaicite:10]{index=10}",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2024-p-3090,FDA-2024-P-3090-0001_Suitability_Petition_from_Epic_Pharma__LLC__on_beh.pdf,,2024,False,original petition,"Epic Pharma, LLC :contentReference[oaicite:2]{index=2}:contentReference[oaicite:3]{index=3}",industry/corporation,Section‚ÄØ505(j)(2)(C)‚ÄØFD&C‚ÄØAct; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ314.93; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ10.20; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ10.30; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ25.31; Pediatric Research Equity Act‚ÄØ(¬ß‚ÄØ505B) :contentReference[oaicite:6]{index=6},FDA‚Äôs determination of suitability for an ANDA differing in dosage form/strength from the RLD APTIOM‚Äîspecifically Eslicarbazepine‚ÄØAcetate Oral Suspension‚ÄØ50‚ÄØmg/mL :contentReference[oaicite:7]{index=7}:contentReference[oaicite:8]{index=8},Declare Eslicarbazepine‚ÄØAcetate Oral Suspension‚ÄØ50‚ÄØmg/mL suitable for submission as an ANDA under ¬ß‚ÄØ505(j) :contentReference[oaicite:9]{index=9}:contentReference[oaicite:10]{index=10},"Change is limited to converting APTIOM tablets to a ready‚Äëto‚Äëuse suspension at an equivalent dosage; labeling, dosing schedule, and safety/efficacy remain unchanged; suspension aids patients who cannot swallow tablets; precedent for approving similar dosage‚Äëform petitions; no new clinical concerns; petitioner seeks PREA waiver and claims categorical environmental exclusion :contentReference[oaicite:11]{index=11}",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2024-p-3188,FDA-2024-P-3188-0001_Suitability_Petition_from_Lachman_Consulting_Servi.pdf,,2024,False,original petition,"Lachman Consulting Services, Inc. :contentReference[oaicite:2]{index=2}:contentReference[oaicite:3]{index=3}",law/consulting,Section‚ÄØ505(j)(2)(C)‚ÄØFD&C‚ÄØAct; Section‚ÄØ505B‚ÄØFD&C‚ÄØAct (PREA); 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ10.20; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ10.30; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ25.31 :contentReference[oaicite:6]{index=6}:contentReference[oaicite:7]{index=7},"FDA‚Äôs determination of suitability for an ANDA for a new 1,250‚ÄØmg/100‚ÄØmL (12.5‚ÄØmg/mL) strength of Levetiracetam in Sodium Chloride Injection differing from RLD strengths :contentReference[oaicite:8]{index=8}:contentReference[oaicite:9]{index=9}","Declare Levetiracetam in Sodium Chloride Injection 1,250‚ÄØmg/100‚ÄØmL (12.5‚ÄØmg/mL) suitable for submission as an ANDA under Section‚ÄØ505(j) :contentReference[oaicite:10]{index=10}:contentReference[oaicite:11]{index=11}","Proposed strength is bracketed by existing RLD strengths, reduces medical waste, avoids multiple infusions or compounding, maintains same active ingredient, route, indications, and labeling, introduces no new safety or efficacy concerns, PREA deemed inapplicable, and categorical environmental exclusion claimed :contentReference[oaicite:12]{index=12}:contentReference[oaicite:13]{index=13}",,Approved,2024-11-06,0.0,CDER (Center for Drug Evaluation and Research),"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 314.93; 21 CFR 314.93(e)(1); 21 CFR 314.94(a)(3)(iii)",,"The proposed change in strength does not pose questions of safety or effectiveness; the proposed product has the same uses, dose, dosage form, and route of administration as the listed drug; the change is consistent with existing labeling; if shown to meet bioequivalence requirements, it is expected to have the same therapeutic effect as the reference drug; no significant labeling changes or new investigations are required.",approved,True,,CDER,CDER
fda-2024-p-3292,FDA-2024-P-3292-0001_Suitability_Petition_from_Felix_Pharmaceuticals_Pv.pdf,,2024,False,original petition,Felix Pharmaceuticals Pvt. Ltd. :contentReference[oaicite:2]{index=2}:contentReference[oaicite:3]{index=3},industry/corporation,Section‚ÄØ512(n)(3)‚ÄØFD&C‚ÄØAct; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ25.30(h); 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ25.21 :contentReference[oaicite:6]{index=6}:contentReference[oaicite:7]{index=7},FDA‚Äôs determination of suitability for an abbreviated new animal drug application (ANADA) for a Maropitant‚ÄØCitrate oral solution differing in dosage form from the pioneer CERENIA tablets :contentReference[oaicite:8]{index=8}:contentReference[oaicite:9]{index=9},Declare that Maropitant‚ÄØCitrate Oral Solution‚ÄØ40‚ÄØmg/mL is suitable for submission as an ANADA under Section‚ÄØ512(n)(3) :contentReference[oaicite:10]{index=10}:contentReference[oaicite:11]{index=11},"Only dosage‚Äëform change‚Äîfrom tablet to oral solution‚Äîwith same active ingredient, route, and dosage; proposed solution will be bioequivalent, uses excipients already approved for dogs, allows precise weight‚Äëbased dosing via calibrated syringes, improves ease of administration, and poses no new safety or efficacy concerns; categorical environmental exclusion claimed :contentReference[oaicite:12]{index=12}:contentReference[oaicite:13]{index=13}",,Approved,2024-10-08,0.0,Center for Veterinary Medicine (CVM),"Section 512(n)(3) and 512(n)(3)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 CFR 514.5",,"The proposed change in dosage form from tablet to oral solution does not require new investigations to demonstrate safety and effectiveness for the intended uses, and thus meets the criteria for approval under a suitability petition.",approved,True,,CVM,Other/Specialty Center
fda-2024-p-3293,FDA-2024-P-3293-0001_Suitability_Petition_from_Newcastle_Bioscience_LLC.pdf,,2024,False,original petition,Newcastle Bioscience LLC :contentReference[oaicite:2]{index=2}:contentReference[oaicite:3]{index=3},industry/corporation,Section‚ÄØ505(j)(2)(C)‚ÄØFDC‚ÄØAct; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ10.30; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ25.31; Pediatric Research Equity Act‚ÄØ(¬ß‚ÄØ505B) :contentReference[oaicite:6]{index=6}:contentReference[oaicite:7]{index=7},FDA‚Äôs determination of suitability for an ANDA for Lacosamide Orally Disintegrating Tablets that differ in dosage form and strengths from the RLD Vimpat tablets :contentReference[oaicite:8]{index=8}:contentReference[oaicite:9]{index=9},"Declare Lacosamide Orally Disintegrating Tablets 25‚ÄØmg,‚ÄØ37.5‚ÄØmg,‚ÄØ75‚ÄØmg,‚ÄØ112.5‚ÄØmg,‚ÄØ125‚ÄØmg, and‚ÄØ175‚ÄØmg suitable for submission as an ANDA under Section‚ÄØ505(j) :contentReference[oaicite:10]{index=10}:contentReference[oaicite:11]{index=11}","New strengths and ODT form provide flexible dosing (especially for renal/hepatic impairment and pediatrics), facilitate titration to lowest effective dose, remove need for oral solution, offer ease of administration, introduce no new safety or efficacy concerns, seek PREA waiver, and claim categorical environmental exclusion :contentReference[oaicite:12]{index=12}:contentReference[oaicite:13]{index=13}",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2024-p-3357,FDA-2024-P-3357-0001_Citizen_Petition_from_Randall_Steinmeyer___Redacte.pdf,,2024,False,original petition,Randall Steinmeyer,individual,"Federal Food, Drug & Cosmetic Act; 21‚ÄØC.F.R.¬†Part‚ÄØ809 (Medical Devices; Laboratory Developed Tests)",FDA‚Äôs delegation of oversight for DNA paternity‚Äëtest LDTs to the American Association of Blood Banks (AABB) instead of direct regulation,"Ban LabCorp and DDC‚Äôs forged DNA paternity tests, place such tests under direct FDA regulation, remove AABB as regulator, and bar the respondents from marketing LDTs","Tests are alleged forgeries mislabeled as paternity tests; respondents control the market, switched real tests for cheap forgeries, forged expert signatures, lied to FDA about forensic validity, and profit from fraud‚Äîcreating public‚Äëhealth and justice risks that require immediate FDA action",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2024-p-3479,FDA-2024-P-3479-0001_Citizen_Petition_from_Jingwei_Pharmaceutical_Compa.pdf,,2024,False,original petition,"Jingwei Pharmaceutical Company, Ltd. :contentReference[oaicite:2]{index=2}:contentReference[oaicite:3]{index=3}",industry/corporation,21‚ÄØU.S.C.‚ÄØ¬ß‚ÄØ355; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ10.25; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ10.30; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ25.30; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ25.31 :contentReference[oaicite:6]{index=6}:contentReference[oaicite:7]{index=7},FDA‚Äôs oversight and approval standards for generic drug manufacturers that use a biocatalytic process to produce sitagliptin active pharmaceutical ingredient (API) :contentReference[oaicite:8]{index=8}:contentReference[oaicite:9]{index=9},"Require such manufacturers to submit (1) a complete certificate of analysis for the biocatalyst, (2) detailed preparation process for the biocatalyst, (3) analytical protocols for residual enzymes and biological impurities, and (4) purging strategies documenting the fate of the biocatalyst :contentReference[oaicite:10]{index=10}:contentReference[oaicite:11]{index=11}","Biocatalytic processes introduce complex enzyme‚Äërelated impurities that are hard to detect and purge; inconsistent impurity profiles threaten patient safety, especially for the large diabetic population relying on sitagliptin; many generics lack necessary technology, so stricter information requirements are needed to protect public health :contentReference[oaicite:12]{index=12}:contentReference[oaicite:13]{index=13}",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2024-p-3482,FDA-2024-P-3482-0001_Citizen_Petition_from_Qilu_Pharmaceutical__Hainan_.pdf,,2024,False,original petition,"Qilu Pharmaceutical (Hainan) Co., Ltd. :contentReference[oaicite:2]{index=2}:contentReference[oaicite:3]{index=3}",industry/corporation,Sections‚ÄØ505(j)‚ÄØand‚ÄØ505(w)‚ÄØFDC‚ÄØAct; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ10.25(a); 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ10.30; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ314.122; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ314.161; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ25.31 :contentReference[oaicite:6]{index=6}:contentReference[oaicite:7]{index=7},"FDA‚Äôs listing of JESDUVROQ (daprodustat) tablets 1‚ÄØmg,‚ÄØ2‚ÄØmg,‚ÄØ4‚ÄØmg,‚ÄØ6‚ÄØmg,‚ÄØ8‚ÄØmg in the Orange Book‚Äôs Discontinued Drug Product List and the related withdrawal determination :contentReference[oaicite:8]{index=8}:contentReference[oaicite:9]{index=9}",Determine that JESDUVROQ (daprodustat) tablets 1‚ÄØmg‚Äì8‚ÄØmg were not withdrawn for reasons of safety or effectiveness :contentReference[oaicite:10]{index=10}:contentReference[oaicite:11]{index=11},Petitioner is unaware of any safety or efficacy issues; believes discontinuation was solely for commercial reasons; a ‚Äònot‚Äëwithdrawn‚Äëfor‚Äësafety/efficacy‚Äô finding will allow ANDA applicants to cite the drug as the RLD :contentReference[oaicite:12]{index=12}:contentReference[oaicite:13]{index=13},,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2024-p-3484,FDA-2024-P-3484-0001_Petition_for_Reclassification_of_next_generation_s.pdf,,2024,False,original petition,"Foundation Medicine, Inc. :contentReference[oaicite:2]{index=2}:contentReference[oaicite:3]{index=3}",advocacy/academic,Section‚ÄØ513(f)(3)‚ÄØFD&C‚ÄØAct; Section‚ÄØ513(f)(1)‚ÄØFD&C‚ÄØAct; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ860.123; 21‚ÄØC.F.R.‚ÄØ¬ß‚ÄØ860.134 :contentReference[oaicite:6]{index=6}:contentReference[oaicite:7]{index=7},FDA‚Äôs current classification of next‚Äëgeneration sequencing oncology panel devices (product code‚ÄØPQP) as Class‚ÄØIII medical devices and its announced intent to reclassify IVDs :contentReference[oaicite:8]{index=8}:contentReference[oaicite:9]{index=9},Reclassify all NGS oncology panel devices with one or more companion diagnostic indications (product code‚ÄØPQP) from Class‚ÄØIII to Class‚ÄØII (high‚Äërisk with special controls) :contentReference[oaicite:10]{index=10}:contentReference[oaicite:11]{index=11},"Extensive regulatory experience and published data show risks can be mitigated through rigorous special controls; reclassification would preserve safety and effectiveness while improving patient access, ensuring high‚Äëquality genomic testing, and aligning regulation with FDA‚Äôs 2024 reclassification initiative for high‚Äërisk IVDs :contentReference[oaicite:12]{index=12}:contentReference[oaicite:13]{index=13}",,,2025-10-15,0.0,,,,,no decision,False,,pending,pending
fda-2024-p-3563,FDA-2024-P-3563-0001_Citizen_Petition_from_Hyman__Phelps___McNamara__P_.pdf,2024-07-29,2024,False,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,21 C.F.R. ¬ß¬ß 10.30 and 10.31; section 505(q) of the FDCA,FDA policy not requiring food-effect studies for intranasal products even when the active moiety has a known food effect,Require food-effect studies for intranasal spray products where the active moiety has a known food effect when administered orally; investigate lack of efficacy for such products documented in FDA's Adverse Event Reporting System,"Intranasal products may be partially swallowed and thus subject to food effects that alter pharmacokinetics and efficacy; literature and FAERS data suggest lack of efficacy could be due to unstudied food effects; a food-effect study is simple, quick, and low-cost and could inform safe labeling and use",,,2025-10-15,0.0,,,,,no decision,False,443.0,pending,pending
fda-2024-p-3567,FDA-2024-P-3567-0001_Suitability_Petition_from_Lachman_Consulting_Servi.pdf,2024-07-25,2024,False,original petition,"Lachman Consulting Services, Inc.",law/consulting,Section 505(j)(2)(C) of the FD&C Act; 21 C.F.R. ¬ß 10.20; 21 C.F.R. ¬ß 10.30,"FDA's lack of approval for lower strength (25 mg, 50 mg, 100 mg) sertraline capsules despite their utility for titration, initiation, and tapering of therapy","Declare that Sertraline Capsules, 25 mg, 50 mg, and 100 mg are suitable for submission in an Abbreviated New Drug Application (ANDA)","The currently approved capsule strengths (150 mg and 200 mg) do not accommodate initial titration or tapering; the proposed lower strengths would enhance dosing flexibility, improve patient adherence, reduce copays during titration, and align with approved labeling recommendations",,,2025-10-15,0.0,,,,,no decision,False,447.0,pending,pending
fda-2024-p-3571,FDA-2024-P-3571-0001_Suitability_Petition_from_Premier_Consulting.pdf,2024-07-29,2024,False,original petition,"Premier Research Consulting, LLC",law/consulting,Section 505(j)(2)(C) of the FD&C Act; 21 CFR ¬ß 10.20; 21 CFR ¬ß 10.30; 21 CFR ¬ß 314.93,FDA‚Äôs current limitation of the Reference Listed Drug (LOTREL) to capsule dosage form only,Determine that Amlodipine and Benazepril hydrochloride Oral Liquid is suitable for submission in an Abbreviated New Drug Application (ANDA),"The proposed product differs only in dosage form (oral liquid vs. capsule) while maintaining the same active ingredients, indication, route, and dosing regimen as the RLD; this change facilitates administration, particularly for patients with swallowing difficulties, without introducing new safety or efficacy concerns",,,2025-10-15,0.0,,,,,no decision,False,443.0,pending,pending
fda-2024-p-3573,FDA-2024-P-3573-0001_Suitability_Petition_from_Premier_Consulting.pdf,2024-07-29,2024,False,original petition,"Premier Research Consulting, LLC",law/consulting,Section 505(j)(2)(C) of the FD&C Act; 21 CFR ¬ß 10.20; 21 CFR ¬ß 10.30; 21 CFR ¬ß 314.93,FDA‚Äôs limitation of the Reference Listed Drug (ZESTORETIC) to tablet dosage form,Determine that Lisinopril and Hydrochlorothiazide Oral Liquid is suitable for submission in an Abbreviated New Drug Application (ANDA),"The proposed oral liquid formulation maintains the same active ingredients, dosage strengths, route of administration, and indication as the RLD ZESTORETIC; converting the dosage form from tablet to liquid facilitates administration, particularly in populations with swallowing difficulties, without introducing new safety or efficacy concerns",,,2025-10-15,0.0,,,,,no decision,False,443.0,pending,pending
fda-2024-p-3699,FDA-2024-P-3699-0001_Citizen_Petition_from_Zydus_Pharmaceuticals__USA__.pdf,2024-08-02,2024,False,original petition,Zydus Pharmaceuticals (USA) Inc.,industry/corporation,21 C.F.R. ¬ß 10.25(a); 21 C.F.R. ¬ß 10.30; 21 C.F.R. ¬ß 314.161; 21 C.F.R. ¬ß 314.122,"Whether IC-GREEN (indocyanine green for injection, USP) 25 mg has been withdrawn from sale for safety or effectiveness reasons",Request a determination from the FDA as to whether the Reference Listed Drug IC-GREEN 25 mg was withdrawn from sale for reasons of safety or effectiveness,IC-GREEN 25 mg is listed as discontinued in the FDA‚Äôs Orange Book and is no longer marketed by Renew Pharmaceuticals Ltd.; a determination is needed to clarify whether the discontinuation was due to safety or effectiveness concerns to support potential ANDA submission,,Denied,2024-11-20,0.0,Center for Drug Evaluation and Research (CDER),Not Mentioned,,"FDA determined that IC-GREEN (Indocyanine Green), 25 mg/vial, was not withdrawn from sale for reasons of safety or effectiveness and will remain listed in the Orange Book‚Äôs Discontinued Drug Product List.",denied,True,110.0,CDER,CDER
fda-2024-p-3761,FDA-2024-P-3761-0001_Citizen_Petition_from_Spark_Biomedical__Inc_.pdf,2024-07-31,2024,False,original petition,"Spark Biomedical, Inc.",industry/corporation,Section 3060(a) of the 21st Century Cures Act; Section 201(h) of the FD&C Act,FDA‚Äôs lack of enforcement on neurostimulation wellness devices making unapproved medical claims,"Enforce regulation of neurostimulation wellness products making therapeutic claims, remove non-compliant products from the market, and require amended advertising to eliminate misleading medical claims",Neurostimulation wellness devices are being marketed with unsubstantiated claims about treating serious medical conditions without FDA approval; such devices should be regulated as medical devices under existing law to protect public health and ensure consumer safety,,,2025-10-15,0.0,,,,,no decision,False,441.0,pending,pending
fda-2024-p-3799,FDA-2024-P-3799-0001_Citizen_Petition_from_Raaha_LLC.pdf,2024-08-07,2024,False,original petition,Raaha LLC,industry/corporation,Section 505(j)(2)(C) of the FD&C Act; 21 CFR ¬ß 10.20; 21 CFR ¬ß 10.30; 21 CFR ¬ß 314.92,Approval of ANDAs for Prednisolone Ophthalmic Solution 1% without demonstrating long-term stability under refrigerated conditions,"Require generic applicants to submit long-term stability studies under refrigerated conditions for Prednisolone Ophthalmic Solution 1%, withhold approval of ANDAs lacking such data, and reconsider approval and rating of ANDA #216935 if it lacks these studies","Refrigerated storage is permitted per the RLD labeling; ophthalmic suspensions are sensitive to temperature variations affecting critical quality attributes like particle size and viscosity; lack of stability data under refrigerated conditions could compromise product quality, safety, and efficacy, posing risks to public health",,Other (Acknowledgement of receipt only),2024-08-09,0.0,"Dockets Management Staff (DMS), Office of Operations (OO)",21 CFR 10.30,,"FDA acknowledged receipt of the petition dated August 7, 2024, and clarified that acceptance for filing is a procedural step that does not reflect any decision on the substantive merits of the petition.",other,True,2.0,DMS,Other/Specialty Center
fda-2024-p-3820,FDA-2024-P-3820-0001_Citizen_Petition_from_Vanguard_Regulatory_Services.pdf,2024-08-09,2024,False,original petition,"Vanguard Regulatory Services, Inc.",law/consulting,"21 C.F.R. ¬ß 10.30; 21 C.F.R. ¬ß 101.9(c)(6)(i); Sections 403(q), 403(a), 201(n), and 701(a) of the FD&C Act",FDA‚Äôs current exclusion of Isomaltodextrin (IMD) from the definition of dietary fiber under 21 C.F.R. ¬ß 101.9(c)(6)(i),Amend the definition of dietary fiber in 21 C.F.R. ¬ß 101.9(c)(6)(i) to include Isomaltodextrin (IMD/Fibryxa¬Æ) as an isolated or synthetic non-digestible carbohydrate with beneficial physiological effects,"Scientific studies show that IMD significantly reduces postprandial blood glucose and triglyceride levels in humans, especially in individuals with elevated responses; thus, IMD provides beneficial physiological effects and meets the criteria for inclusion as a dietary fiber under FDA regulations","February 6, 2025",,2025-10-15,1.0,,,FDA stated it has not yet reached a decision on the petition to amend 21 CFR ¬ß 101.9(c)(6)(i) to include Isomaltodextrin (Fibryxa¬Æ) due to other agency priorities and limited resources; a final decision will be provided upon completion of the review.,,no decision,False,432.0,pending,pending
fda-2024-p-3821,FDA-2024-P-3821-0001_Cover_Letter_for_Suitability_Petition_from_Aurora_.pdf,2024-08-08,2024,False,original petition,"Aurora Pharmaceutical, Inc.",industry/corporation,"Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act",FDA‚Äôs current approval of Nexgard¬Æ (afoxolaner) Chewables as the reference listed new animal drug,"Request permission to submit an abbreviated new animal drug application (ANADA) for Afoxolaner Oral Solution 1.84% w/v, differing in dosage form from the reference listed drug",The proposed generic differs only in dosage form from Nexgard¬Æ chewables; Aurora seeks approval to proceed with an ANADA for afoxolaner in oral solution form under the suitability provisions of the FD&C Act,,Approved,2024-10-28,0.0,Center for Veterinary Medicine (CVM),Section 512(n)(3) and Section 512(n)(3)(C) of the FD&C Act; 21 CFR 514.5,,"FDA approved the suitability petition for afoxolaner oral solution as a generic version of NexGard¬Æ chewable tablets, finding that the change in dosage form does not require new investigations to demonstrate safety and effectiveness for the intended uses.",approved,True,81.0,CVM,Other/Specialty Center
fda-2024-p-3822,FDA-2024-P-3822-0001_Citizen_Petition_from_University_of_Illinois__Coll.pdf,2024-08-10,2024,False,original petition,"University of Illinois, College of Pharmacy",advocacy/academic,The Biologics Price Competition and Innovation Act (BPCIA); 42 USC 262(k); 21 C.F.R. ¬ß 10.30,"FDA's prohibition against the U.S. Pharmacopeia (USP) creating monographs for biological drugs, specifically banning side-by-side analytical testing of biosimilars","Rescind FDA‚Äôs directive to the USP prohibiting the development of monographs for biological drugs, and allow USP to create Biological Product Specifications (BPS) that define release specifications for biosimilars","Creating BPS would eliminate the need for costly side-by-side analytical testing with the reference product, reduce development costs, facilitate broader biosimilar access, promote harmonization, and enhance global regulatory acceptance while maintaining safety and efficacy","February 4, 2025",,2025-10-15,1.0,,,FDA has not yet resolved the issues raised in the petition concerning the US Pharmacopeia‚Äôs modification of biological drug monographs due to their complexity; a final response will be issued once a decision is reached.,,no decision,False,431.0,pending,pending
fda-2024-p-3881,FDA-2024-P-3881-0001_Suitability_Petition_from_Zydus_Pharmaceuticals__U.pdf,2024-08-13,2024,False,original petition,Zydus Pharmaceuticals (USA) Inc.,industry/corporation,Section 505(j)(2)(C) of the FD&C Act; 21 C.F.R. ¬ß 314.93; 21 C.F.R. ¬ß¬ß 10.20 and 10.30,FDA‚Äôs current limitation of the approved strengths of NUPLAZID (pimavanserin) Tablets to 10 mg and 17 mg,"Determine that Pimavanserin Tablets, 34 mg, is suitable for submission in an Abbreviated New Drug Application (ANDA)","The 34 mg strength matches the recommended daily dose stated in the RLD prescribing information; offering this strength in tablet form will enhance prescribing flexibility without changing dosage form or regimen, and does not raise new safety or efficacy concerns",,Approved,2024-12-16,0.0,Center for Drug Evaluation and Research (CDER),Section 505(j)(2)(C) of the FD&C Act; Section 505(j)(2)(A) and (B); Section 505(j)(2)(A)(iv); 21 CFR 314.93; 21 CFR 314.93(e)(1); 21 CFR 314.94(a)(3)(iii),,"FDA determined that the proposed change in strength (to 34 mg) for Pimavanserin Tablets does not pose questions of safety or effectiveness, is consistent with labeling, and does not require significant labeling changes or additional investigations; bioequivalence will be assessed during ANDA review.",approved,True,125.0,CDER,CDER
fda-2024-p-3905,FDA-2024-P-3905-0001_Suitability_Petition_from_Lachman_Consulting_Servi.pdf,2024-08-15,2024,False,original petition,"Lachman Consulting Services, Inc.",law/consulting,Section 505(j)(2)(C) of the FD&C Act; 21 C.F.R. ¬ß 10.20; 21 C.F.R. ¬ß 10.30,"FDA‚Äôs existing approval of Estrace¬Æ Vaginal Cream, 0.01%, as the reference listed drug, and the dosage form limitation to cream","Determine that Estradiol Vaginal Inserts, 1 g and 2 g, are suitable for submission in an Abbreviated New Drug Application (ANDA)","The proposed vaginal inserts match the active ingredient and strength of the RLD cream but offer a pre-measured, easier-to-administer alternative that avoids waste and variability due to patient handling; this dosage form benefits patients with limited dexterity or vision and aligns with current dosing recommendations",,Approved,2025-02-12,0.0,Center for Drug Evaluation and Research (CDER),Section 505(j)(2)(C) of the FD&C Act; Section 505(j)(2)(A) and (B); Section 505(j)(2)(A)(iv); 21 CFR 314.93; 21 CFR 314.93(e)(1); 21 CFR 314.94(a)(3)(iii),,"FDA determined that the proposed change in dosage form from cream to vaginal inserts does not pose safety or effectiveness concerns, is consistent with the labeled dosing of the reference product, and does not require significant labeling changes or new investigations; bioequivalence will be evaluated during ANDA review.",approved,True,181.0,CDER,CDER
fda-2024-p-3997,FDA-2024-P-3997-0001_Citizen_Petition_from_Aylstock__Witkin__Kreis___Ov.pdf,2024-08-20,2024,False,original petition,"Aylstock, Witkin, Kreis & Overholtz, PLLC",industry/corporation,21 C.F.R. ¬ß 10.30; 21 C.F.R. ¬ß 330.10(a)(12); 21 C.F.R. ¬ß 330.10(b); Section 501(a)(2)(B) of the FD&C Act,FDA‚Äôs continued allowance of benzoyl peroxide (BPO) drug products on the market despite benzene contamination,Recall and suspend sales of all benzoyl peroxide (BPO) products from the U.S. market due to the presence of benzene at levels deemed unsafe by FDA standards,"Independent lab testing showed widespread and significantly high levels of benzene in various BPO products; benzene is a Class 1 carcinogen, and its presence at levels exceeding 2 ppm violates FDA and international safety limits; the FDA has previously determined such levels to pose life-threatening risks and warrant recalls","February 13, 2025",,2025-10-15,1.0,,,"FDA has not yet resolved the petition requesting market recall of benzoyl peroxide products due to alleged benzene contamination; the issues are complex and require extensive review. Additionally, FDA noted that the petitioner has not yet submitted the testing data referenced in the petition despite multiple requests.",,no decision,False,421.0,pending,pending
fda-2024-p-4015,FDA-2024-P-4015-0001_Citizen_Petition_from_Kohl_Harrington_Redacted.pdf,2024-08-22,2024,False,original petition,Kohl Harrington,individual,5 U.S.C. ¬ß 552 (Freedom of Information Act); 21 C.F.R. ¬ß 10.30(b); 21 C.F.R. ¬ß¬ß 25.30 and 25.34,FDA-CVM‚Äôs failure to publicly post calendar records of employee Charlotte Conway despite likely being subject to multiple FOIA requests,"Comply with FOIA by posting calendar records for FDA-CVM employee Charlotte Conway (covering July 1‚Äì31, 2024) on the FDA FOIA Reading Room website",The FOIA requires agencies to publicly post records requested three or more times or likely to be requested again; failure to do so violates statutory obligations and undermines transparency,,Denied,2024-11-07,0.0,Center for Veterinary Medicine (CVM),5 U.S.C. ¬ß 552(a)(2)(D); 29 U.S.C. ¬ß 794d(a); 21 CFR 10.30(b)(3),,"FDA denied the petition requesting public posting of certain records, stating that such posting is governed by the Freedom of Information Act (FOIA) and Section 508 accessibility requirements; records will be posted when required under FOIA and once made compliant with accessibility standards.",denied,True,77.0,CVM,Other/Specialty Center
fda-2024-p-4126,FDA-2024-P-4126-0001_Suitability_Petition_from_Aurora_Pharmaceutical__I.pdf,2024-08-28,2024,False,original petition,"Aurora Pharmaceutical, Inc.",industry/corporation,"Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. ¬ß 25.30(h); 21 C.F.R. ¬ß 25.15",FDA‚Äôs current approval of Metacam¬Æ (meloxicam) Oral Suspension in 0.5 mg/mL and 1.5 mg/mL strengths as the reference listed new animal drug (RLNAD),"Allow submission of an ANADA for Meloxicam Oral Solution 3 mg/mL, a higher strength and different dosage form intended for dogs over 10 lbs.","The proposed solution offers improved dosing accuracy and ease of administration for large dogs compared to the current suspension that requires shaking; the higher concentration reduces dosing volume, enhancing compliance without compromising safety based on prior toxicology data",,Approved,2024-10-10,0.0,Center for Veterinary Medicine (CVM),Section 512(n)(3) and Section 512(n)(3)(C) of the FD&C Act; 21 CFR 514.5,,"FDA approved the suitability petition for a generic meloxicam oral solution (3 mg/mL) differing in dosage form and strength from the reference listed drug (Metacam¬Æ 1.5 mg/mL), concluding that no new investigations are required to demonstrate safety and effectiveness for the intended uses.",approved,True,43.0,CVM,Other/Specialty Center
fda-2024-p-4134,FDA-2024-P-4134-0001_Suitability_Petition_from_Pharmobedient_Consulting.pdf,2024-08-24,2024,False,original petition,"Pharmobedient Consulting, LLC",law/consulting,"Section 505(j)(2)(C) of the FD&C Act; 21 C.F.R. ¬ß¬ß 10.20, 10.30, 314.93; 21 C.F.R. ¬ß 25.31",FDA‚Äôs current limitation of approved Diclofenac Potassium tablet strengths to 25 mg and 50 mg,"Determine that Diclofenac Potassium Tablets, 37.5 mg, is suitable for submission in an Abbreviated New Drug Application (ANDA)","The 37.5 mg strength offers physicians greater dosing flexibility, enabling individualized treatment plans and lower effective dosing options; it remains bioequivalent to existing strengths and introduces no new concerns of safety or efficacy",,Denied,2025-02-18,0.0,Center for Drug Evaluation and Research (CDER),Section 505(j)(2)(C) of the FD&C Act; 21 CFR 314.93; 21 CFR 314.93(e)(1)(iv); 21 CFR 10.20; 21 CFR 10.33,,FDA denied the petition because the proposed new strength of 37.5 mg for Diclofenac Potassium Tablets raises safety and effectiveness concerns that would necessitate significant labeling changes. The 37.5 mg strength is not supported by the reference listed drug‚Äôs labeling and could increase the risk of medication errors and confusion among patients and prescribers.,denied,True,178.0,CDER,CDER
fda-2024-p-4135,FDA-2024-P-4135-0001_Suitability_Petition_from_Fresenius_Kabi_USA__LLC.pdf,2024-08-27,2024,False,original petition,"Fresenius Kabi USA, LLC",industry/corporation,Section 505(j)(2)(C) of the FD&C Act; 21 C.F.R. ¬ß 314.93; 21 C.F.R. ¬ß¬ß 10.20 and 10.30,FDA‚Äôs current approval of Vasopressin in 0.9% Sodium Chloride Injection only in 20 units/100 mL and 40 units/100 mL strengths,"Determine that Vasopressin in 0.9% Sodium Chloride Injection, 50 units/50 mL (1 unit/mL) in a single-dose ready-to-use container is suitable for submission in an Abbreviated New Drug Application (ANDA)","The proposed 1 unit/mL strength aligns with dosing in the approved labeling, reduces the number of IV bags needed for high-dose administrations, supports fluid-restricted patients, and complies with ASHP standards for standardized concentrations; it introduces no new safety or efficacy concerns and matches therapeutic expectations of the reference listed drug",,Denied,2024-11-13,0.0,Center for Drug Evaluation and Research (CDER),Section 505(j)(2)(C) of the FD&C Act; 21 CFR 314.93; 21 CFR 314.93(e)(1)(vi); 21 CFR 10.20; 21 CFR 10.33,,"FDA denied the petition because the proposed strength of Vasopressin in 0.9% Sodium Chloride Injection (50 units/50 mL) is already approved under NDAs 217766 and 204485; under 21 CFR 314.93(e)(1)(vi), a petition must be denied if a drug product with the proposed change is already approved in an NDA.",denied,True,78.0,CDER,CDER
